PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bahng, S; Mossessova, E; Nurse, P; Marians, KJ				Bahng, S; Mossessova, E; Nurse, P; Marians, KJ			Mutational analysis of Escherichia coli topoisomerase IV. Identification of a region of ParE involved in covalent catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; DNA GYRASE; CRYSTAL-STRUCTURE; MECHANISM; PURIFICATION; DOMAIN; ENZYME	The products of three dominant-negative alleles of parE, encoding the ATP-binding subunit of topoisomerase TV (Topo TV), were purified and their activities characterized when reconstituted with ParC to form Topo IV. The ability of the ParE E418K, ParE G419D, and ParE G442D mutant Topo IVs to bind DNA, hydrolyze ATP, and close their ATP-dependent clamp was relatively unaffected. However, their ability to relax negatively supercoiled DNA was compromised significantly. This could be attributed to severe defects in covalent complex formation between ParC and DNA. Thus, these residues, which are far from the active site Tyr of ParC, contribute to covalent catalysis, This indicates that a dramatic conformational rearrangement of the protein likely occurs subsequent to the binding of the G: segment at the DNA gate and prior to its opening.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mol Biol Grad Program, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University	Bahng, S (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Berger JM, 1998, P NATL ACAD SCI USA, V95, P7876, DOI 10.1073/pnas.95.14.7876; Berger JM, 1998, BBA-GENE STRUCT EXPR, V1400, P3, DOI 10.1016/S0167-4781(98)00124-9; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Caron PR, 1999, METH MOL B, V94, P279; KATO J, 1992, J BIOL CHEM, V267, P25676; Levine C, 1998, BBA-GENE STRUCT EXPR, V1400, P29, DOI 10.1016/S0167-4781(98)00126-2; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; Liu QY, 1999, P NATL ACAD SCI USA, V96, P881, DOI 10.1073/pnas.96.3.881; Marians KJ, 1997, J BIOL CHEM, V272, P9401; Mossessova E, 2000, J BIOL CHEM, V275, P4099, DOI 10.1074/jbc.275.6.4099; Nurse P, 2000, J BIOL CHEM, V275, P4104, DOI 10.1074/jbc.275.6.4104; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; PENG H, 1993, J BIOL CHEM, V268, P24481; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1994, J BIOL CHEM, V269, P20943; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; YONG YQ, 1995, J BIOL CHEM, V270, P24509, DOI 10.1074/jbc.270.41.24509	20	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4112	4117		10.1074/jbc.275.6.4112	http://dx.doi.org/10.1074/jbc.275.6.4112			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660571	hybrid			2022-12-25	WOS:000085288800055
J	Hinke, SA; Pospisilik, JA; Demuth, HU; Mannhart, S; Kuhn-Wache, K; Hoffmannn, T; Nishimura, E; Pederson, RA; McIntosh, CHS				Hinke, SA; Pospisilik, JA; Demuth, HU; Mannhart, S; Kuhn-Wache, K; Hoffmannn, T; Nishimura, E; Pederson, RA; McIntosh, CHS			Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon - Characterization of glucagon degradation products and DPIV-resistant analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT INSULINOTROPIC POLYPEPTIDE; IN-VITRO; BIOLOGICAL-ACTIVITIES; MASS-SPECTROMETRY; RECEPTOR; BINDING; ANTAGONISTS; SPECIFICITY; POSITION-12; METABOLISM	Over the past decade, numerous studies have been targeted at defining structure-activity relationships of glucagon. Recently, we have found that glucagon(1-29) is hydrolyzed by dipeptidyl peptidase IV (DPIV) to produce glucagon(3-29) and glucagon(5-29); in human serum, [pyroglutamyl (pGlu)(3)]glucagon(3-29) is formed from glucagon(3-29) and this prevents further hydrolysis of glucagon by DPIV (H.-U. Demuth, K. Glund, U. Heiser, J. Pospisilik, S. Hinke, T. Hoffmann, F. Rosche, D. Schlenzig, M. Wermann, C. McIntosh, and R. Pederson, manuscript in preparation). In the current study, the biological activity of these peptides was examined in vitro. The amino-terminally truncated peptides all behaved as partial agonists in cyclic AMP stimulation assays, with Chinese hamster ovary K1 cells overexpressing the human glucagon receptor (potency: glucagon(1-29) > [pGlu(3)]glucagon(3-29) > glucagon(3-29) > glucagon(5-29) > [Glu(9)]glucagon(2-29)). In competition binding experiments, [pGlu(3)]glucagon(3-29) and glucagon(5-29) both demonstrated 5-fold lower affinity for the receptor than glucagon(1-29), whereas glucagon(3-29) exhibited 18-fold lower affinity. Of the peptides tested, only glucagon(5-29) showed antagonist activity, and this was weak compared with the classical glucagon antagonist, [Glu(9)]glucagon(2-29). Hence, DPIV hydrolysis of glucagon yields low affinity agonists of the glucagon receptor. As a corollary to evidence indicating that DPIV degrades glucagon (Demuth, ct at, manuscript in preparation), DPIV-resistant analogs were synthesized. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry was used to assess DPIV resistance, and it allowed kinetic analysis of degradation. Of several analogs generated, only [D-Ser(2)] and [Gly(2)]glucagon retained high affinity binding and biological potency, similar to native glucagon in vitro. [D-Ser(2)]Glucagon exhibited enhanced hyperglycemic activity in a bioassay, whereas [Gly(2)]glucagon was not completely resistant to DPIV degradation.	Univ British Columbia, Fac Med, Dept Physiol, Vancouver, BC V6T 1Z3, Canada; Bioctr, D-06120 Halle, Saale, Germany; Novo Nordisk AS, Dept Diabet Biochem & Metab, DK-2760 Malov, Denmark	University of British Columbia; Novo Nordisk	McIntosh, CHS (corresponding author), Univ British Columbia, Fac Med, Dept Physiol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.		Hinke, Simon/R-7120-2019	Nishimura, Erica/0000-0001-5741-3648				ALFORD FP, 1976, J CLIN ENDOCR METAB, V42, P830, DOI 10.1210/jcem-42-5-830; Azizeh BY, 1997, PEPTIDES, V18, P633, DOI 10.1016/S0196-9781(97)00131-9; BUGGY JJ, 1995, J BIOL CHEM, V270, P7474, DOI 10.1074/jbc.270.13.7474; CHIASSON JL, 1983, HDB EXPT PHARM, V66, P361; Dalle S, 1999, J BIOL CHEM, V274, P10869, DOI 10.1074/jbc.274.16.10869; Deacon CF, 1998, DIABETES, V47, P764, DOI 10.2337/diabetes.47.5.764; DEMUTH HU, 1998, 12 INT S REG PEPT AB; DEMUTH HU, 1995, DIPEPTIDYL PEPTIDASE, V4, P1; FRANDSEN EK, 1981, H-S Z PHYSIOL CHEM, V362, P665, DOI 10.1515/bchm2.1981.362.1.665; Gelling RW, 1997, REGUL PEPTIDES, V69, P151, DOI 10.1016/S0167-0115(97)00009-8; Graziano MP, 1996, RECEPTOR CHANNEL, V4, P9; Grondin G, 1999, J HISTOCHEM CYTOCHEM, V47, P489, DOI 10.1177/002215549904700407; Hansen LH, 1996, DIABETES, V45, P725, DOI 10.2337/diabetes.45.6.725; HENDRIKS T, 1981, DIABETOLOGIA, V20, P553; Hjorth SA, 1998, MOL ENDOCRINOL, V12, P78, DOI 10.1210/mend.12.1.0045; Hoist JJ, 1994, GUT PEPTIDES BIOCH P, P305; Holst JJ, 1991, DEGRADATION BIOACTIV, P167; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; HRUBY VJ, 1982, MOL CELL BIOCHEM, V44, P49, DOI 10.1007/BF00573846; JASPAN JB, 1981, AM J PHYSIOL, V240, pE233, DOI 10.1152/ajpendo.1981.240.3.E233; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; LEFEBVRE P, 1983, HDB EXPT PHARM, V66, P389; Li J, 1997, BBA-MOL CELL RES, V1356, P229, DOI 10.1016/S0167-4889(96)00170-X; MARKI F, 1983, HORM METAB RES, V15, P307, DOI 10.1055/s-2007-1018703; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; NIH, 1985, NIH PUBL; Pauly RP, 1999, METABOLISM, V48, P385, DOI 10.1016/S0026-0495(99)90090-2; Pauly RP, 1996, J BIOL CHEM, V271, P23222, DOI 10.1074/jbc.271.38.23222; PAVOINE C, 1991, AM J PHYSIOL, V260, pC993, DOI 10.1152/ajpcell.1991.260.5.C993; Pederson RA, 1998, DIABETES, V47, P1253, DOI 10.2337/diabetes.47.8.1253; Proost P, 1999, J BIOL CHEM, V274, P3988, DOI 10.1074/jbc.274.7.3988; ROBBINS SB, 1988, MEAS EVAL COUNS DEV, V21, P117, DOI 10.1080/07481756.1988.12022893; ROSCHE F, 2000, PROTEIN PEPTIDE ANAL; Schmidt J, 1996, PROTEIN PEPTIDE LETT, V3, P385; SMITH RA, 1993, MOL PHARMACOL, V43, P741; UNSON CG, 1989, PEPTIDES, V10, P1171, DOI 10.1016/0196-9781(89)90010-7; UNSON CG, 1994, P NATL ACAD SCI USA, V91, P454, DOI 10.1073/pnas.91.2.454; Unson CG, 1998, J BIOL CHEM, V273, P10308, DOI 10.1074/jbc.273.17.10308; UNSON CG, 1989, J BIOL CHEM, V264, P789; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; WOLF B, 1978, ACTA BIOL MED GER, V37, P409; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	42	106	127	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3827	3834		10.1074/jbc.275.6.3827	http://dx.doi.org/10.1074/jbc.275.6.3827			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660533	Green Submitted, hybrid			2022-12-25	WOS:000085288800017
J	Petersen, C; Orem, N; Trueheart, J; Thorner, JW; Macara, IG				Petersen, C; Orem, N; Trueheart, J; Thorner, JW; Macara, IG			Random mutagenesis and functional analysis of the Ran-binding protein, RanBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; NUCLEAR EXPORT SIGNAL; IMPORT FACTOR P97; RAN/TC4 GTPASE; KARYOPHERIN-BETA; TRANSPORT FACTORS; PORE COMPLEX; YEAST; RCC1; LOCALIZATION	Ran GTPase is required for nucleocytoplasmic transport of many types of cargo. Several proteins that recognize Ran in its GTP-bound state (Ran GTP) possess a conserved Ran-binding domain (RanBD), Ran-binding protein-1 (RanBP1) has a single RanBD and is required for RanGAP-mediated GTP hydrolysis and release of Ran from nuclear transport receptors (karyopherins), In budding yeast (Saccharomyces cerevisiae), RanBP1 is encoded by the essential YRB1 gene; expression of mouse RanBP1 cDNA rescues the lethality of Yrb1-deficient cells. We generated libraries of mouse RanBP1 mutants and examined 11 mutants in vitro and for their ability to complement a temperature-sensitive yrb1 mutant (yrb1-51(ts)) in vivo, In 9 of the mutants, the alteration was a change in a residue (or 2 residues) that is conserved in all known RanBDs, However, 4 of these 9 mutants displayed biochemical properties indistinguishable from that of wild-type RanBP1. These mutants bound to Ran GTP, stimulated RanGAP, inhibited the exchange activity of RCC1, and rescued growth of the yrb1-51(ts) yeast cells. Two of the 9 mutants altered in residues thought to be essential for interaction with Ran were unable to rescue growth of the yrb1(ts) mutant and did not bind detectably to Ran in vitro. However, one of these 2 mutants (and 2 others that were crippled in other RanBP1 functions) retained some ability to coactivate RanGAP, A truncated form of RanBP1 (lacking its nuclear export signal) was able to complement the yrb1(ts) mutation. When driven from the YRB1 promoter, 4 of the 5 mutants most impaired for Ran binding were unable to rescue growth of the yrb1(ts) cells; remarkably, these mutants could nevertheless form ternary complexes with importin-5 or importin-beta and Ran-GTP, The same mutants stimulated only inefficiently RanGAP-mediated GTP hydrolysis of the Ran GTP-importin-5 complex. Thus, the essential biological activity of RanBP1 in budding yeast correlates not with Ran GTP binding per se or with the ability to form ternary complexes with karyopherins, but with the capacity to potentiate Ran-GAP activity toward GTP-bound Ran in these complexes.	Univ Virginia, Markey Ctr Cell Signalling, Charlottesville, VA 22908 USA; Dartmouth Coll, Hanover, NH 03755 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Virginia; Dartmouth College; University of California System; University of California Berkeley	Macara, IG (corresponding author), Univ Virginia, Markey Ctr Cell Signalling, 7191 Hosp W, Charlottesville, VA 22908 USA.	igm9c@virginia.edu	THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, R01GM021841, R01GM050526] Funding Source: NIH RePORTER; NCI NIH HHS [CA09041] Funding Source: Medline; NIGMS NIH HHS [GM50526, GM21841] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Lounsbury KM, 1996, J BIOL CHEM, V271, P2357, DOI 10.1074/jbc.271.5.2357; Macara LG, 1999, CURR BIOL, V9, pR436, DOI 10.1016/S0960-9822(99)80275-9; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; OUSPENSKI II, 1995, J BIOL CHEM, V270, P1975, DOI 10.1074/jbc.270.5.1975; Ouspenski II, 1998, EXP CELL RES, V244, P171, DOI 10.1006/excr.1998.4174; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Seki T, 1996, J BIOCHEM, V120, P207; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; Turi TG, 1996, J BIOL CHEM, V271, P9166, DOI 10.1074/jbc.271.15.9166; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Zhang CM, 1999, J CELL SCI, V112, P2453; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	57	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4081	4091		10.1074/jbc.275.6.4081	http://dx.doi.org/10.1074/jbc.275.6.4081			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660567	hybrid			2022-12-25	WOS:000085288800051
J	Taylor, GA; Hudson, E; Resau, JH; Vande Woude, GF				Taylor, GA; Hudson, E; Resau, JH; Vande Woude, GF			Regulation of P311 expression by Met-hepatocyte growth factor/scatter factor and the ubiquitin/proteasome system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMORIGENICITY; PROTOONCOGENE; CELLS; PROTEASOME; METASTASIS; RNA	P311 is a mouse cDNA originally identified for its high expression in late-stage embryonic brain and adult cer ebellum, hippocampus, and olfactory bulb. The protein product of P311, however, had not been identified previously, and its function remains unknown. We report here that P311 expression is regulated at multiple levels by pathways that control cellular transformation. P311 mRNA expression was decreased sharply in both neural and smooth muscle cells when the cells were transformed by coexpression of the oncogenic tyrosine kinase receptor Met and its ligand hepatocyte growth factor/scatter factor. The P311 mRNA was found to encode an 8-kDa polypeptide that was subject to rapid degradation by the lactacystin-sensitive ubiquitin/proteasome system and an unidentified metalloprotease, resulting in a protein half-life of about 5 min. These data suggest that P311 expression is dramatically decreased by several pathways that regulate cellular growth.	Adv Biosci Labs, Basic Res Program, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vande Woude, GF (corresponding author), Van Andel Res Inst, 201 Monroe Ave NW,Suite 400, Grand Rapids, MI 49503 USA.				NCI NIH HHS [N01-CO-46000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; Dick LR, 1997, J BIOL CHEM, V272, P182; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Koochekpour S, 1997, CANCER RES, V57, P5391; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Laterra J, 1997, LAB INVEST, V76, P565; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RONNETT GV, 1994, NEUROSCIENCE, V63, P1081, DOI 10.1016/0306-4522(94)90574-6; SAITOH K, 1994, J PATHOL, V174, P191, DOI 10.1002/path.1711740308; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; Taylor GA, 1996, J BIOL CHEM, V271, P20399, DOI 10.1074/jbc.271.34.20399; Taylor GA, 1998, ONCOGENE, V17, P1179, DOI 10.1038/sj.onc.1202004; TSO J, 1986, NUCLEIC ACIDS RES, V13, P2485; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5	23	30	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4215	4219		10.1074/jbc.275.6.4215	http://dx.doi.org/10.1074/jbc.275.6.4215			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660586	hybrid			2022-12-25	WOS:000085288800070
J	Wang, F; Chen, LF; Arcucci, O; Harvey, EV; Bowers, B; Xu, YH; Hammer, JA; Sellers, JR				Wang, F; Chen, LF; Arcucci, O; Harvey, EV; Bowers, B; Xu, YH; Hammer, JA; Sellers, JR			Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOSOME DISTRIBUTION; UNCONVENTIONAL MYOSIN; SMOOTH-MUSCLE; MOTOR PROTEIN; LIGHT-CHAIN; GENE; MELANOCYTES; DOMAIN; ACTIN; TRANSPORT	Mouse myosin V is a two-headed unconventional myosin with an extended neck that binds six calmodulins. Double-headed (heavy meromyosin-like) and single-headed (subfragment 1-like) fragments of mouse myosin V were expressed in Sf9 cells, and intact myosin V was purified from mouse brain. The actin-activated MgATPase of the tissue-purified myosin V, and its expressed fragments had a high V-max and a low K-ATPase. Calcium regulated the MgATPase of intact myosin V but not of the fragments, Both the MgATPase activity and the in vitro motility were remarkably insensitive to ionic strength. Myosin V and its fragments translocated actin at very:low myosin surface densities. ADP markedly inhibited the actin-activated MgATPase activity and the in vitro motility, ADP dissociated from myosin V subfragment 1 at a rate of about 11.5 s(-1) under conditions where the V-max was 3.3 s(-1), indicating that, although not totally rate-limiting, ADP dissociation was close to the Fate-limiting step. The high affinity for actin and the slow rate of ADP release helps the myosin head to re main attached to actin for a large fraction of each ATPase cycle and allows actin filaments to be moved by only a few myosin V molecules in vitro.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Core Microscopy Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sellers, JR (corresponding author), NHLBI, Mol Cardiol Lab, NIH, 10 Ctr Dr,Bldg 10,Rm 8N202, Bethesda, MD 20892 USA.	jsellers@helix.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004229, ZIAHL004229] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benashski SE, 1997, J BIOL CHEM, V272, P20929, DOI 10.1074/jbc.272.33.20929; Bonafe N, 1998, J MUSCLE RES CELL M, V19, P129, DOI 10.1023/A:1005356511634; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; ENGLE LJ, 1994, GENOMICS, V19, P407, DOI 10.1006/geno.1994.1088; ESPINDOLA FS, 1996, MOL BIOL CELL, V7, P372; HAARER BK, 1994, J CELL SCI, V107, P1055; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; LASH JA, 1990, NUCLEIC ACIDS RES, V18, P7176, DOI 10.1093/nar/18.23.7176; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Provance DW, 1996, P NATL ACAD SCI USA, V93, P14554, DOI 10.1073/pnas.93.25.14554; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Sellers J. R., 1999, MYOSINS; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; UBER A, 1980, J ULTRASTRUCT RES, V71, P95; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Wei Q., 1996, Molecular Biology of the Cell, V7, p226A; Wei Q, 1997, J MUSCLE RES CELL M, V18, P517, DOI 10.1023/A:1018659117569; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Wu XF, 1997, J CELL SCI, V110, P847; Zhao LP, 1996, P NATL ACAD SCI USA, V93, P10826, DOI 10.1073/pnas.93.20.10826	34	116	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4329	4335		10.1074/jbc.275.6.4329	http://dx.doi.org/10.1074/jbc.275.6.4329			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660602	hybrid			2022-12-25	WOS:000085288800086
J	Ozaki, M; Deshpande, SS; Angkeow, P; Bellan, J; Lowenstein, CJ; Dinauer, MC; Goldschmidt-Clermont, PJ; Irani, K				Ozaki, M; Deshpande, SS; Angkeow, P; Bellan, J; Lowenstein, CJ; Dinauer, MC; Goldschmidt-Clermont, PJ; Irani, K			Inhibition of the Rac1 GTPase protects against nonlethal ischemia/reperfusion-induced necrosis and apoptosis in vivo	FASEB JOURNAL			English	Article						reactive oxygen species; adenovirus; gene therapy	POSTISCHEMIC TISSUE-INJURY; OXYGEN-FREE-RADICALS; KAPPA-B ACTIVATION; XANTHINE-OXIDASE; REPERFUSION INJURY; NADPH OXIDASE; ARACHIDONATE METABOLISM; SUPEROXIDE PRODUCTION; REOXYGENATION INJURY; MYOCARDIAL-ISCHEMIA	Reperfusion of ischemic tissue results in the generation of reactive oxygen species that contribute to tissue injury. The sources of reactive oxygen species in reperfused tissue are not fully characterized. We hypothesized that the small GTPase Rac1 mediates the oxidative burst in reperfused tissue and thereby contributes to reperfusion injury. Zn an in vivo model of mouse hepatic ischemia/reperfusion injury, recombinant adenoviral expression of a dominant negative Rac1 (Rac1N17) completely suppressed the ischemia/reperfusion-induced production of reactive oxygen species and lipid peroxides, activation of nuclear factor-kappa B, and resulted in a significant reduction of acute liver necrosis, Expression of Rac1N17 also suppressed ischemia/reperfusion-induced acute apoptosis, The protection offered by Rac1N17 was also evident in knockout mice deficient for the gp91phox component of the phagocyte NADPH oxidase. This work demonstrates the crucial role of a Rac1-regulated oxidase in mediating the production of injurious reactive oxygen species, which contribute to acute necrotic and apoptotic cell death induced by ischemia/reperfusion in vivo. Targeted inhibition of this oxidase, which is distinct from the phagocyte NADPH oxidase, should provide a new avenue for in vivo therapy aimed at protecting organs at risk from ischemia/reperfusion injury.	Johns Hopkins Univ, Sch Med, Div Cardiol, Dept Med, Baltimore, MD 21205 USA; Indiana Univ, Sch Med, Indianapolis, IN 46202 USA; Ohio State Univ, Heart & Lung Inst, Columbus, OH 43210 USA	Johns Hopkins University; Indiana University System; Indiana University-Purdue University Indianapolis; University System of Ohio; Ohio State University	Irani, K (corresponding author), Johns Hopkins Univ, Sch Med, Div Cardiol, Dept Med, Ross 1023,720 Rutland Ave, Baltimore, MD 21205 USA.	kirani@jhmi.edu	Ozaki, Michitaka/A-4549-2012	Irani, Kaikobad/0000-0001-9194-7387; Lowenstein, Charles/0000-0003-0485-7514				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ATALLA SL, 1985, TRANSPLANTATION, V40, P584, DOI 10.1097/00007890-198512000-00002; Billadeau DD, 1998, J EXP MED, V188, P549, DOI 10.1084/jem.188.3.549; Burdon RH, 1996, BIOCHEM SOC T, V24, P1028, DOI 10.1042/bst0241028; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; DOCTOR RB, 1991, J AM SOC NEPHROL, V1, P959; DOWNEY JM, 1990, ANNU REV PHYSIOL, V52, P487, DOI 10.1146/annurev.ph.52.030190.002415; Gao GP, 1996, J VIROL, V70, P8934, DOI 10.1128/JVI.70.12.8934-8943.1996; Garcia JH, 1996, STROKE, V27, P761, DOI 10.1161/01.STR.27.4.761; Gersh BJ, 1998, AM J CARDIOL, V82, p3P, DOI 10.1016/S0002-9149(98)00659-6; GOODE HF, 1994, HEPATOLOGY, V19, P354; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GRANGER DN, 1995, ANNU REV PHYSIOL, V57, P311, DOI 10.1146/annurev.ph.57.030195.001523; GRISHAM MB, 1986, AM J PHYSIOL, V251, pG567, DOI 10.1152/ajpgi.1986.251.4.G567; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; HASSELGREN PO, 1984, J SURG RES, V37, P409, DOI 10.1016/0022-4804(84)90207-5; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HEARSE DJ, 1986, ACTA PHYSIOL SCAND, V126, P65; HENSLER T, 1994, INFECT IMMUN, V62, P5281, DOI 10.1128/IAI.62.12.5281-5289.1994; HOTTER G, 1994, J LIPID MEDIAT CELL, V9, P135; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JAESCHKE H, 1988, BIOCHEM BIOPH RES CO, V150, P568, DOI 10.1016/0006-291X(88)90431-7; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARWINSKI W, 1993, RES EXP MED, V193, P275, DOI 10.1007/BF02576235; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; KUZUYA T, 1993, CARDIOVASC RES, V27, P1056, DOI 10.1093/cvr/27.6.1056; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; LINDSAY S, 1991, AM J PHYSIOL, V261, pH2051, DOI 10.1152/ajpheart.1991.261.6.H2051; LUCCHESI BR, 1993, STROKE, V24, pI41; MATHEWS WR, 1994, FREE RADICAL BIO MED, V16, P763, DOI 10.1016/0891-5849(94)90191-0; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; Mohanty PS, 1997, SCI TECHNOL WELD JOI, V2, P133, DOI 10.1179/stw.1997.2.3.133; Muller MJ, 1996, FREE RADICAL BIO MED, V21, P189, DOI 10.1016/0891-5849(96)00028-7; NOHL H, 1993, FREE RADICAL RES COM, V18, P127, DOI 10.3109/10715769309147486; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249, DOI 10.1152/ajpheart.1995.268.3.H1249; ONEILL PG, 1989, AM J PHYSIOL, V256, pH341, DOI 10.1152/ajpheart.1989.256.2.H341; PODZUWEIT T, 1987, BASIC RES CARDIOL, V82, P493, DOI 10.1007/BF01907097; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; REIMER KA, 1985, CIRCULATION, V71, P1069, DOI 10.1161/01.CIR.71.5.1069; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sun JZ, 1996, J CLIN INVEST, V97, P562, DOI 10.1172/JCI118449; SUZUKI S, 1994, TRANSPLANT P, V26, P3695; TADA M, 1988, J MOL CELL CARDIOL, V20, P135, DOI 10.1016/0022-2828(88)90338-0; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; Zhang Z, 1998, FREE RADICAL RES, V28, P151, DOI 10.3109/10715769809065801; Zhou MJ, 1997, ANAL BIOCHEM, V253, P169, DOI 10.1006/abio.1997.2392; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	56	119	131	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					418	429		10.1096/fasebj.14.2.418	http://dx.doi.org/10.1096/fasebj.14.2.418			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657998				2022-12-25	WOS:000085184800021
J	Eckhardt, M; Barth, H; Blocker, D; Aktories, K				Eckhardt, M; Barth, H; Blocker, D; Aktories, K			Binding of Clostridium botulinum C2 toxin to asparagine-linked complex and hybrid carbohydrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFRINGENS-IOTA-TOXIN; GOLGI VESICLE MEMBRANES; HAMSTER OVARY CELLS; BINARY TOXIN; ADP-RIBOSYLTRANSFERASE; GLYCOSYLATION MUTANTS; ESCHERICHIA-COLI; SPIROFORME TOXIN; RHO-PROTEINS; ACTIN	Clostridium botulinum C2 toxin is a binary toxin composed of an enzymatic subunit (C2I) capable of ADP-ribosylating actin and a binding subunit (C2II) that is responsible for interaction with receptors on eukaryotic cells. Here we show that binding of C2 toxin depends on the presence of asparagine-linked carbohydrates. A recently identified Chinese hamster ovary cell mutant (Fritz G., Schroeder, P., and Aktories, K. (1995) Infect. Immun. 63, 2334-2340) was found to be deficient in N-acetylglucosaminyltransferase I. C2 sensitivity of this mutant was restored by transfection of an N-acetylglucosaminyltransferase I cDNA C2 toxin sensitivity was reduced after inhibition of alpha-mannosidase II. In contrast, Chinese hamster ovary cell mutants deficient in sialylated (Lec2) or galactosylated (Lec8) glycoconjugates showed an increase in toxin sensitivity compared with wild-type cells. Our results show that the GlcNAc residue linked beta-1,2 to the alpha-1,3-mannose of the asparagine-linked core structure is essential for C2II binding to Chinese hamster ovary cells.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.	aktories@uni-freiburg.de	Barth, Holger/E-7920-2013; Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; Barth H, 1998, J BIOL CHEM, V273, P29506, DOI 10.1074/jbc.273.45.29506; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Boquet P, 1998, CURR OPIN MICROBIOL, V1, P66, DOI 10.1016/S1369-5274(98)80144-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL C, 1984, J BIOL CHEM, V259, P3370; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FRITZ G, 1995, INFECT IMMUN, V63, P2334, DOI 10.1128/IAI.63.6.2334-2340.1995; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kimura K, 1998, VET MICROBIOL, V62, P27, DOI 10.1016/S0378-1135(98)00195-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUSS S, 1990, EUR J BIOCHEM, V194, P237, DOI 10.1111/j.1432-1033.1990.tb19448.x; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; OHISHI I, 1992, INFECT IMMUN, V60, P4648, DOI 10.1128/IAI.60.11.4648-4655.1992; Perelle S, 1997, FEMS MICROBIOL LETT, V146, P117, DOI [10.1016/S0378-1097(96)00463-6, 10.1111/j.1574-6968.1997.tb10180.x]; Perelle S, 1997, INFECT IMMUN, V65, P1402, DOI 10.1128/IAI.65.4.1402-1407.1997; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; POPOFF MR, 1988, BIOCHEM BIOPH RES CO, V152, P1361, DOI 10.1016/S0006-291X(88)80435-2; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; Sandvig K, 1997, ADV EXP MED BIOL, V412, P225; SIMPSON LI, 1989, J PHARMACOL EXP THER, V251, P1223; SINGH Y, 1991, J BIOL CHEM, V266, P15493; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; SUGII S, 1990, BIOCHIM BIOPHYS ACTA, V1034, P176, DOI 10.1016/0304-4165(90)90073-6; Traving C, 1998, CELL MOL LIFE SCI, V54, P1330, DOI 10.1007/s000180050258; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; WEGNER A, 1988, J BIOL CHEM, V263, P13739; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	36	100	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2328	2334		10.1074/jbc.275.4.2328	http://dx.doi.org/10.1074/jbc.275.4.2328			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644682	hybrid			2022-12-25	WOS:000085128000014
J	Olson, MW; Bernardo, MM; Pietila, M; Gervasi, DC; Toth, M; Kotra, LP; Massova, I; Mobashery, S; Fridman, R				Olson, MW; Bernardo, MM; Pietila, M; Gervasi, DC; Toth, M; Kotra, LP; Massova, I; Mobashery, S; Fridman, R			Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9 - Differential rates for activation by stromelysin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOPEXIN-LIKE DOMAIN; COOH-TERMINAL DOMAIN; HUMAN GELATINASE-A; TISSUE INHIBITOR; IV COLLAGENASE; INTERSTITIAL COLLAGENASE; PROTEOLYTIC ACTIVITY; CRYSTAL-STRUCTURE; EXPRESSION; BINDING	Matrix metalloproteinase-9 (MMP-9) is a member of the MMP family that has been associated with degradation of the extracellular matrix in normal and pathological conditions. A unique characteristic of MMP-9 is its ability to exist in a monomeric and a disulfide-bonded dimeric form. However, there exists a paucity of information on the properties of the latent (pro-MMP-9) and active MMP-9 dimer. Here we report the purification to homogeneity of the monomer and dimer forms of pro-MMP-9 and the characterization of their biochemical properties and interactions with tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. Gel filtration and surface plasmon resonance analyses demonstrated that the pro-MMP-9 monomeric and dimeric forms bind TIMP-1 with similar affinities. In contrast, TIMP-2 binds only to the active forms. After activation, the two enzyme forms exhibited equal catalytic competence in the turnover of a synthetic peptide substrate with comparable kinetic parameters for the onset of inhibition with TIMPs and for dissociation of the inhibited complexes. Kinetic analyses of the activation of monomeric and dimeric pro-MMP-9 by stromelysin 1 revealed K-m values in the nanomolar range and relative low k(cat) values (1.9 x 10(-3) and 4.1 x 10(-4) s(-1), for the monomer and dimer, respectively) consistent with a faster rate (1 order of magnitude) of activation of the monomeric form by stromelysin 1, This suggests that the rate-limiting event in the activation of pro-MMP-9 may be a requisite slow unfolding of pro-MMP-9 near the site of the hydrolytic cleavage by stromelysin 1.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA; Wayne State Univ, Dept Chem, Detroit, MI 48201 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Fridman, R (corresponding author), Wayne State Univ, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.				NCI NIH HHS [CA-61986] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agren MS, 1998, BRIT J SURG, V85, P68; Ahrens D, 1996, ARTHRITIS RHEUM, V39, P1576, DOI 10.1002/art.1780390919; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BROOKS CL, 1988, THEORETICAL PERSPECT; BROWN PD, 1990, CANCER RES, V50, P6184; CANETESOLER R, 1995, DEV DYNAM, V204, P30, DOI 10.1002/aja.1002040105; Esser CK, 1997, J MED CHEM, V40, P1026, DOI 10.1021/jm960465t; Finzel BC, 1998, PROTEIN SCI, V7, P2118, DOI 10.1002/pro.5560071008; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRIDMAN R, 1995, CANCER RES, V55, P2548; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLICK BR, 1978, CAN J BIOCHEM CELL B, V56, P1055, DOI 10.1139/o78-166; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; Gonzalez-Avila G, 1998, PATHOBIOLOGY, V66, P196, DOI 10.1159/000028023; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P18; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YY, 1998, CIRCULATION, V98, P1728, DOI 10.1161/01.CIR.98.17.1728; LIBSON AM, 1995, NAT STRUCT BIOL, V2, P938, DOI 10.1038/nsb1195-938; MANN KG, 1990, BLOOD, V76, P1; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; MOLL UM, 1990, CANCER RES, V50, P6162; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Moses MA, 1996, J CELL BIOCHEM, V60, P379, DOI 10.1002/(SICI)1097-4644(19960301)60:3<379::AID-JCB9>3.0.CO;2-T; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NAGASE H, 1994, J BIOL CHEM, V269, P20952; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OGATA Y, 1992, J BIOL CHEM, V267, P3581; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Pickford AR, 1997, STRUCTURE, V5, P359, DOI 10.1016/S0969-2126(97)00193-7; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Sehgal G, 1998, AM J PATHOL, V152, P591; STRONGIN AY, 1993, KIDNEY INT, V43, P158, DOI 10.1038/ki.1993.26; Tamarina NA, 1997, SURGERY, V122, P264, DOI 10.1016/S0039-6060(97)90017-9; Toth M, 1997, CANCER RES, V57, P3159; TRIEBEL S, 1992, FEBS LETT, V314, P386, DOI 10.1016/0014-5793(92)81511-J; Upadhya AG, 1997, HEPATOLOGY, V26, P922, DOI 10.1002/hep.510260418; VARTIO T, 1989, FEBS LETT, V255, P285, DOI 10.1016/0014-5793(89)81107-X; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; VU TH, 1998, GELATINASE B, P115; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	51	131	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2661	2668		10.1074/jbc.275.4.2661	http://dx.doi.org/10.1074/jbc.275.4.2661			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644727	hybrid			2022-12-25	WOS:000085128000059
J	Marin, EP; Krishna, KG; Zvyaga, TA; Isele, J; Siebert, F; Sakmar, TP				Marin, EP; Krishna, KG; Zvyaga, TA; Isele, J; Siebert, F; Sakmar, TP			The amino terminus of the fourth cytoplasmic loop of rhodopsin modulates rhodopsin-transducin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; PROTEIN-COUPLED RECEPTORS; BOVINE RHODOPSIN; ACTIVATION; PALMITOYLATION; MUTANT; FLUORESCENCE; MUTAGENESIS; INFORMATION; RECOGNITION	Rhodopsin is a seven-transmembrane helix receptor that binds and catalytically activates the heterotrimeric G protein transducin (G(t)). This interaction involves the cytoplasmic surface of rhodopsin, which comprises four putative loops and the carboxyl-terminal tail. The fourth loop connects the carboxyl end of transmembrane helix 7 with Cys(322) and Cys(323), which are both modified by membrane-inserted palmitoyl groups. Published data on the roles of the fourth loop in the binding and activation of G(t) are contradictory. Here, we attempt to reconcile these conflicts and define a role for the fourth loop in rhodopsin-G(t) interactions. Fluorescence experiments demonstrated that a synthetic peptide corresponding to the fourth loop of rhodopsin inhibited the activation of G(t) by rhodopsin and interacted directly with the alpha subunit of G(t). A series of rhodopsin mutants was prepared in which portions of the fourth loop were replaced with analogous sequences from the beta(2)-adrenergic receptor or the mi muscarinic receptor. Chimeric receptors in which residues 310-312 were replaced could not efficiently activate G(t). The defect in G(t) interaction in the fourth loop mutants was not affected by preventing palmitoylation of Cys(322) and CyS323. We suggest that the amino terminus of the fourth loop interacts directly with G(t), particularly with G alpha(t), and with other regions of the intracellular surface of rhodopsin to support G(t) binding.	Rockefeller Univ, Howard Hughes Med Inst, Biochem & Mol Biol Lab, New York, NY 10021 USA; Univ Freiburg, Inst Biophys & Strahlenbiol, D-79104 Freiburg, Germany	Howard Hughes Medical Institute; Rockefeller University; University of Freiburg	Sakmar, TP (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Biochem & Mol Biol Lab, Box 284,1230 York Ave, New York, NY 10021 USA.	sakmar@rockvax.rockefeller.edu	Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953; Aradhyam, Gopala Krishna/0000-0001-8232-3935	NEI NIH HHS [EY07138] Funding Source: Medline; NIGMS NIH HHS [GM07982, GM07739] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007138] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7931, DOI 10.1021/bi9900121; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; BenTal N, 1996, BIOPHYS J, V70, P1803, DOI 10.1016/S0006-3495(96)79744-8; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FUNG BKK, 1983, J BIOL CHEM, V258, P495; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; Han M, 1996, J BIOL CHEM, V271, P32337, DOI 10.1074/jbc.271.50.32337; HAN M, 2000, IN PRESS METHODS ENZ; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; MIN KC, 1993, J BIOL CHEM, V268, P9400; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OSAWA S, 1994, MOL PHARMACOL, V46, P1036; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PAPAC DI, 1992, J BIOL CHEM, V267, P16889; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SHICHI H, 1984, VISION RES, V24, P1523, DOI 10.1016/S0042-6989(84)80001-2; TAKEMOTO DJ, 1986, BIOCHEM J, V235, P309, DOI 10.1042/bj2350309; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yang K, 1996, BIOCHEMISTRY-US, V35, P14040, DOI 10.1021/bi962113u; Yeagle P L, 1996, Mol Vis, V2, P12	45	131	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1930	1936		10.1074/jbc.275.3.1930	http://dx.doi.org/10.1074/jbc.275.3.1930			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636894	hybrid			2022-12-25	WOS:000084940000057
J	Mezghrani, A; Courageot, J; Mani, JC; Pugniere, M; Bastiani, P; Miquelis, R				Mezghrani, A; Courageot, J; Mani, JC; Pugniere, M; Bastiani, P; Miquelis, R			Protein-disulfide isomerase (PDI) in FRTL5 cells - pH-dependent thyroglobulin/PDI interactions determine a novel PDI function in the post-endoplasmic reticulum of thyrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLGLUCOSAMINE-SPECIFIC RECEPTOR; MOLECULAR CHAPERONES; PLASMA-MEMBRANE; PROTEINDISULFIDE ISOMERASE; MULTIFUNCTIONAL PROTEIN; SURFACE EXPRESSION; IODINE CONTENT; GOLGI-COMPLEX; SECRETION; LOCALIZATION	Thyroglobulin (TG)) is secreted by the thyrocytes into the follicular lumen of the thyroid. After maturation and hormone formation, TG is endocytosed and delivered to lysosomes, Quality control mechanisms may occur during this bidirectional traffic since 1) several molecular chaperones are cosecreted with TG in vivo, and 2) lysosomal targeting of immature TG is thought to be prevented via the interaction, in acidic conditions, between the Ser(789)-Met(1172) TG hormonogenic domain (BD) and an unidentified membrane receptor. We investigated the secretion and cell surface expression of PDI and other chaperones in the FRTL5 thyroid cell line, and then studied the characteristics of the interaction between TG and PDI. We demonstrated that PDI, but also other chaperones such as calnexin and KDEL-containing proteins are exposed at the cell surface. We observed on living cells or membrane preparations that PDI specifically binds TG in acidic conditions, and that only ED is involved in binding. Surface plasmon resonance analysis of TG/PDI interactions indicated: 1) that PDI bound TG but only in acidic conditions, and that it preferentially recognized immature molecules, and 2) ED is involved in binding even if cysteine-rich modules are deleted. The notion that PDI acts as an "escort" for immature TG in acidic post-endoplasmic reticulum compartments is discussed.	CNRS, UMR 9921, Fac Pharm, F-34060 Montpellier 2, France; Univ Aix Marseille 2, Lab Biochim Ingn Prot, UMR 6560, Inst Federat Jean Roche,Fac Med Nord, F-13916 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; UDICE-French Research Universities; Aix-Marseille Universite	Miquelis, R (corresponding author), CNRS, UMR 9921, Fac Pharm, 15 Ave Charles Flahault, F-34060 Montpellier 2, France.		Pugniere, Martine/T-1355-2017; PUGNIERE, Martine/AAD-4315-2020	Pugniere, Martine/0000-0002-2049-2909; PUGNIERE, Martine/0000-0002-2049-2909				ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; Arvan P, 1997, THYROID, V7, P89, DOI 10.1089/thy.1997.7.89; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; BASTIANI P, 1980, ACTA ENDOCRINOL-COP, V94, P71, DOI 10.1530/acta.0.0940071; BASTIANI P, 1995, ENDOCRINOLOGY, V136, P4204, DOI 10.1210/en.136.10.4204; Berndorfer U, 1996, J CLIN ENDOCR METAB, V81, P1918, DOI 10.1210/jc.81.5.1918; BJORKMAN U, 1980, BIOCH THYROID HORMON, P88; BLANCK I, 1995, GENOMICS, V27, P561; BLANCK O, 1994, GENOMICS, V21, P18, DOI 10.1006/geno.1994.1219; Bruneau N, 1998, J CELL SCI, V111, P2665; BRUNEAU N, 1995, J BIOL CHEM, V270, P13524, DOI 10.1074/jbc.270.22.13524; CHEN K, 1992, BLOOD, V79, P2226; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONSIGLIO E, 1981, J BIOL CHEM, V256, P592; Couet J, 1996, BIOCHEMISTRY-US, V35, P14800, DOI 10.1021/bi961359w; Delom F, 1999, BIOCHEM BIOPH RES CO, V255, P438, DOI 10.1006/bbrc.1999.0229; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; DUMONT JE, 1989, METABOLIC BASIS INHE, P1843; EDELHOCH H, 1985, THYROGLOBULIN PROTHY, P1; ERICSON LE, 1981, MOL CELL ENDOCRINOL, V22, P1, DOI 10.1016/0303-7207(81)90098-8; ESSEX DW, 1995, BLOOD, V86, P2168, DOI 10.1182/blood.V86.6.2168.bloodjournal8662168; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; Hotchkiss KA, 1996, BIOCHEMISTRY-US, V35, P9761, DOI 10.1021/bi9603938; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KOMFELD R, 1985, ANNU REV BIOCHEM, V54, P631; KRONING H, 1994, SCAND J IMMUNOL, V39, P346, DOI 10.1111/j.1365-3083.1994.tb03384.x; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MANDEL R, 1993, P NATL ACAD SCI USA, V91, P4559; Marino M, 1999, J BIOL CHEM, V274, P12898, DOI 10.1074/jbc.274.18.12898; MAXFIELD FR, 1989, METHOD ENZYMOL, V173, P745; Mezgrhani H, 1997, J BIOL CHEM, V272, P23340, DOI 10.1074/jbc.272.37.23340; MIQUELIS R, 1987, J BIOL CHEM, V262, P15291; MOLINA F, 1996, EUR J BIOCHEM, V240, P225; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Muresan Z, 1997, J BIOL CHEM, V272, P26095, DOI 10.1074/jbc.272.42.26095; MURPHY RF, 1984, J CELL BIOL, V98, P1757, DOI 10.1083/jcb.98.5.1757; Mziaut H, 1996, ENDOCRINOLOGY, V137, P1370, DOI 10.1210/en.137.4.1370; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OKHUMA S, 1978, P NATL ACAD SCI USA, V75, P3327; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PARMA J, 1987, J MOL BIOL, V196, P769, DOI 10.1016/0022-2836(87)90403-7; RAO ASMK, 1993, P NATL ACAD SCI USA, V90, P2950, DOI 10.1073/pnas.90.7.2950; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Tager M, 1997, EXP HEMATOL, V25, P601; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; THIBAULT V, 1993, ENDOCRINOLOGY, V132, P468, DOI 10.1210/en.132.1.468; Thiele C, 1997, CURR BIOL, V7, P496; VANHERLE AJ, 1979, NEW ENGL J MED, V301, P307, DOI 10.1056/NEJM197908093010605; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984; Zheng G, 1998, ENDOCRINOLOGY, V139, P1462, DOI 10.1210/en.139.3.1462	62	38	39	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1920	1929		10.1074/jbc.275.3.1920	http://dx.doi.org/10.1074/jbc.275.3.1920			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636893	hybrid			2022-12-25	WOS:000084940000056
J	Wu, YY; Bradshaw, RA				Wu, YY; Bradshaw, RA			Activation of the Stat3 signaling pathway is required for differentiation by interleukin-6 in PC12-E2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ACUTE-PHASE RESPONSE; LEUKEMIA INHIBITORY FACTOR; CYTOKINE RECEPTOR GP130; NEURONAL DIFFERENTIATION; NEURITE OUTGROWTH; NERVOUS-SYSTEM; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; TERMINAL DIFFERENTIATION	The role of signal transducer and activator of transcription (STAT) signaling pathways in the interleukin-6 (IL-6)-induced morphological differentiation of PC12-E2 cells was assessed using wild type and dominant negative mutants of Stat1 and Stat3, containing Tyr --> Phe (YF), Ser --> Ala (SA), and the double mutations (DM), respectively. FS3-YF or FS3-DM markedly inhibited the IL-6-induced response, but overexpression of FS3-SA caused only a modest inhibition. Expression of all Stat3 mutants had no effect on NGF-induced neurite outgrowth. Overexpression of wild type Stat1 protein inhibited IL-6 activated DNA binding complexes containing Stat3 homodimers, which may explain the partial negative effect of Stat1 on IL-6-induced neurite outgrowth. Specificity of these STAT constructs was confirmed using luciferase reporter gene assays, which showed that IL-6-activated transcription was blocked by expression of FS3-YF and FS3-DM and that FS1 enhanced the interferon gamma-activated transcription. Thus, in PC12-E2 cells, Stat3 homodimers are preferentially activated by IL-6, indicating a role for Stat3 in the regulation of cellular differentiation. Furthermore, IL-6 induced robust neurite outgrowth in PC12-E2 cells expressing dominant negative forms of RAS or SHC or in cells pretreated with the mitogen-activated protein kinase mitogen-activated protein kinase kinase inhibitor, PD98059, Thus, activation of the Stat3 signaling pathway, but not RAS/ERK dependent pathways, is essential for differentiation of PC12-E2 cells by IL-6.	Univ Calif Irvine, Coll Med, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Bradshaw, RA (corresponding author), Univ Calif Irvine, Coll Med, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	rablab@uci.edu	Bradshaw, Ralph A/K-1515-2013		NIA NIH HHS [AG09735] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOLIN LM, 1995, J NEUROCHEM, V64, P850; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Candotti F, 1997, BLOOD, V90, P3996, DOI 10.1182/blood.V90.10.3996; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen EH, 1998, IMMUNOL TODAY, V19, P338, DOI 10.1016/S0167-5699(98)01295-X; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Darnell JE, 1996, P NATL ACAD SCI USA, V93, P6221, DOI 10.1073/pnas.93.13.6221; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Giordano V, 1997, J IMMUNOL, V158, P4097; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Hirano T, 1998, Int Rev Immunol, V16, P249; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Ihara S, 1996, J BIOCHEM, V120, P865; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; Kaplan DR, 1998, PROG BRAIN RES, V117, P35; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSHIMA Y, 1992, NEUROSCI RES, V13, P267, DOI 10.1016/0168-0102(92)90039-F; Lai CF, 1999, J BIOL CHEM, V274, P7793, DOI 10.1074/jbc.274.12.7793; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; Marz P, 1996, BRAIN RES, V706, P71, DOI 10.1016/0006-8993(95)01210-9; Marz P, 1997, EUR J NEUROSCI, V9, P2765, DOI 10.1111/j.1460-9568.1997.tb01705.x; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Murphy PG, 1999, J NEUROSCI, V19, P3791; MURPHY PG, 1995, J NEUROSCI, V15, P5130; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PATTERSON PH, 1994, P NATL ACAD SCI USA, V91, P7833, DOI 10.1073/pnas.91.17.7833; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; Schindler C, 1998, TRENDS CELL BIOL, V8, P97, DOI 10.1016/S0962-8924(98)01233-1; Sterneck E, 1996, J NEUROCHEM, V67, P1365; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Van Wagoner NJ, 1999, J NEUROSCI, V19, P5236; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WILDER RL, 1995, ANNU REV IMMUNOL, V13, P307; WU YY, 1995, J CELL PHYSIOL, V164, P522, DOI 10.1002/jcp.1041640310; Wu YY, 1996, J BIOL CHEM, V271, P13033, DOI 10.1074/jbc.271.22.13033; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhong J, 1999, J NEUROSCI, V19, P4305; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	79	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2147	2156		10.1074/jbc.275.3.2147	http://dx.doi.org/10.1074/jbc.275.3.2147			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636920	hybrid			2022-12-25	WOS:000084940000083
J	Brenner, C; Cadiou, H; Vieira, HLA; Zamzami, N; Marzo, I; Xie, ZH; Leber, B; Andrews, D; Duclohier, H; Reed, JC; Kroemer, G				Brenner, C; Cadiou, H; Vieira, HLA; Zamzami, N; Marzo, I; Xie, ZH; Leber, B; Andrews, D; Duclohier, H; Reed, JC; Kroemer, G			Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator	ONCOGENE			English	Article						anti-oncogene; mitochondrial transmembrane potential; oncogene; permeability transition; planar lipid bilayer	PERMEABILITY TRANSITION PORE; CYTOCHROME-C; ION-CHANNEL; IN-VIVO; APOPTOSIS; MEMBRANES; RELEASE; CYCLOPHILIN; PROTEINS; FORMS	Bcl-2 family protein including anti-apoptotic (Bcl-2) or pro-apoptotic (Bax) members can form ion channels when incorporated into synthetic lipid bilayers. This contrasts with the observation that Bcl-2 stabilizes the mitochondrial membrane barrier function and inhibits the permeability transition pore complex (PTPC). Here we provide experimental data which may explain this apparent paradox. Bax and adenine nucleotide translocator (ANT), the most abundant inner mitochondrial membrane protein, can interact in artificial lipid bilayers to yield an efficient composite channel whose electrophysiological properties differ quantitatively and qualitatively from the channels formed by Bax or ANT alone. The formation of this composite channel can be observed in conditions in which Bax protein alone has no detectable channel activity. Cooperative channel formation by Bax and ANT is stimulated by the ANT ligand atractyloside (Atr) but inhibited by ATP, indicating that it depends on the conformation of ANT. In contrast to the combination of Bax and ANT, ANT does not form active channels when incorporated into membranes with Bcl-2. Rather, ANT and Bcl-2 exhibit mutual inhibition of channel formation. Bcl-2 prevents channel formation by Atr-treated ANT and neutralizes the cooperation between Bax and ANT. Our data are compatible with a menage a trois model of mitochondrial apoptosis regulation in which ANT, the likely pore forming protein within the PTPC, interacts with Bax or Bcl-2 which influence its pore forming potential in opposing manners.	Ctr Natl Rech Sci, UPR420, F-94801 Villejuif, France; Univ Technol Compiegne, Ctr Natl Rech Sci, UPRESA6022, F-60205 Compiegne, France; Univ Rouen, Ctr Natl Rech Sci, UMR6522, IFRMP 23, F-76821 Mont St Aignan, France; Burnham Inst, La Jolla, CA 92037 USA; McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne; Centre National de la Recherche Scientifique (CNRS); Universite de Rouen Normandie; Sanford Burnham Prebys Medical Discovery Institute; McMaster University; McMaster University	Kroemer, G (corresponding author), 19 Rue Guy Moquet,BP 8, F-94801 Villejuif, France.		Vieira, Helena/AAZ-9562-2021; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Marzo, Isabel/E-6918-2016; brenner, catherine/AAE-8632-2020	KROEMER, Guido/0000-0002-9334-4405; Marzo, Isabel/0000-0002-2315-9079; Vieira, Helena/0000-0001-9415-3742; Leber, Brian/0000-0001-5502-1480	NIA NIH HHS [AG 15393] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015393] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BRULLEMANS M, 1994, EUR BIOPHYS J BIOPHY, V23, P39, DOI 10.1007/BF00192204; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; GironCalle J, 1996, BIOCHEMISTRY-US, V35, P15440, DOI 10.1021/bi960840j; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HANKE W, 1984, BIOELECTROCH BIOENER, V12, P329, DOI 10.1016/0302-4598(84)87013-0; HILLE B, 1984, IONIC CHANNELS EXCIT, P226; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SUSIN SA, 1999, IN PRESS METH ENZYMO; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Xie FK, 1998, J PERIPHER NERV SYST, V3, P37; YING XM, 1994, NATURE, V369, P321; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	40	288	317	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					329	336		10.1038/sj.onc.1203298	http://dx.doi.org/10.1038/sj.onc.1203298			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656679				2022-12-25	WOS:000084873700002
J	Chu, W; Pak, BJ; Bani, MR; Kapoor, M; Lu, SJ; Tamir, A; Kerbel, RS; Ben-David, Y				Chu, W; Pak, BJ; Bani, MR; Kapoor, M; Lu, SJ; Tamir, A; Kerbel, RS; Ben-David, Y			Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications	ONCOGENE			English	Article						malignant melanoma; drug resistance; tyrosinase-related protein-2; chemotherapy; cis-diamminedichloroplatinuim(II)	HUMAN OVARIAN-CANCER; DOPACHROME TAUTOMERASE; DNA-REPAIR; CELL-LINES; IN-VITRO; CISPLATIN; GENE; OVEREXPRESSION; CHEMOTHERAPY; GLUTATHIONE	A major obstacle in the systemic treatment of advanced malignant melanoma is its intrinsic resistance to conventionally used chemotherapeutic agents. In order to investigate the mechanisms of this intrinsic resistance, we have previously utilized retroviral insertional mutagenesis on an early-stage, drug sensitive human melanoma cell line (WM35) to establish mutated cell lines that exhibited increased resistance to cis-diamminedichloroplatinum(II) (CDDP), Here, we demonstrate that this increased resistance to CDDP is mediated by the over-expression of tyrosinase-related protein-2 (TYRP2), an enzyme that normally functions in the biosynthesis of the pigment, melanin. Northern and Western blot analyses revealed that the expression of TYRP2 in the virally-derived cell lines as well as in a panel of human melanoma cell lines positively correlated with their levels of resistance to CDDP, Furthermore, enforced expression of TYRP2 in WM35 cells by transfection elevated their resistance to CDDP, The increased CDDP resistance in the virally-derived clones and TYRP2 transfectants was accompanied by a reduction in CDDP-induced apoptosis, Interestingly, the virally-derived CDDP-resistant clones also showed cross resistance to carboplatin and methotrexate, but not taxol, suggesting that TYRP2 over-expression may confer resistance specifically to DNA damaging agents, Overall, these results demonstrate a novel mechanism of drug resistance in human melanoma cells that is mediated by the over-expression of TYRP2, Since TYRP2 is expressed only in cells of melanocytic lineage, this may represent the first report of a lineage-specific mechanism of drug resistance, In summary, these findings suggest a significant role for TYRP2 in the intrinsic drug resistance phenotype of human melanoma cells and may have important implications in the development of chemosensitization strategies for the clinical management of this disease.	Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Ben-David, Y (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, Res Bldg,Room S2-18,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Bani, Maria Rosa/AAB-3397-2020	Bani, Maria Rosa/0000-0001-8178-1432	NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PA, 1985, CANCER RES, V45, P6250; AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; BALCH CM, 1989, CANCER PRINCIPLES PR, V2, P1499; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BATIST G, 1986, J BIOL CHEM, V261, P5544; BERND A, 1994, MELANOMA RES, V4, P287, DOI 10.1097/00008390-199410000-00003; BORCHERS AH, 1990, CANCER RES, V50, P1786; Chan HSL, 1997, CANCER RES, V57, P2325; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; CHU G, 1994, J BIOL CHEM, V269, P787; Citro G, 1998, CANCER RES, V58, P283; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Dolan ME, 1999, CLIN CANCER RES, V5, P2059; Fillpits M, 1997, BRIT J CANCER, V75, P208; HO RCS, 1995, CANCER, V75, P735, DOI 10.1002/1097-0142(19950115)75:2+<735::AID-CNCR2820751418>3.0.CO;2-Q; ISHIKAWA T, 1994, J BIOL CHEM, V269, P29085; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; Kawakami Y, 1998, J IMMUNOTHER, V21, P237, DOI 10.1097/00002371-199807000-00001; Koo HM, 1999, JNCI-J NATL CANCER I, V91, P236, DOI 10.1093/jnci/91.3.236; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; KURODA H, 1991, INT J CANCER, V47, P732, DOI 10.1002/ijc.2910470518; LAI GM, 1988, BIOCHEM PHARMACOL, V37, P4597, DOI 10.1016/0006-2952(88)90325-5; LAI GM, 1989, JNCI-J NATL CANCER I, V81, P535, DOI 10.1093/jnci/81.7.535; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Legrand O, 1998, LEUKEMIA, V12, P1327, DOI 10.1038/sj.leu.2401096; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; LORICO A, 1988, CANCER RES, V48, P2036; LU SJ, 1995, CANCER RES, V55, P1139; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MORIWAKI S-I, 1992, Journal of Dermatological Science, V4, P6, DOI 10.1016/0923-1811(92)90049-H; ORLOW SJ, 1995, P NATL ACAD SCI USA, V92, P10152, DOI 10.1073/pnas.92.22.10152; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Parkhurst MR, 1998, CANCER RES, V58, P4895; PAWELEK JM, 1990, BIOCHEM BIOPH RES CO, V166, P1328, DOI 10.1016/0006-291X(90)91011-G; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; Tief K, 1998, MOL BRAIN RES, V53, P307, DOI 10.1016/S0169-328X(97)00301-X; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Young RC, 1989, DRUG RESISTANCE CANC; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689	41	47	48	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					395	402		10.1038/sj.onc.1203315	http://dx.doi.org/10.1038/sj.onc.1203315			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656687				2022-12-25	WOS:000084873700010
J	Draganescu, A; Hodawadekar, SC; Gee, KR; Brenner, C				Draganescu, A; Hodawadekar, SC; Gee, KR; Brenner, C			Fhit-nucleotide specificity probed with novel fluorescent and fluorogenic substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE TRIAD PROTEIN; TUMOR-SUPPRESSOR; CELL; 5',5'''-P-1,P-3-TRIPHOSPHATE; HYDROLASE; COMPLEXES; CANCER; FORM; ACID	Fhit, a member of the histidine triad superfamily of nucleotide-binding proteins, binds and cleaves diadenosine polyphosphates and functions as a tumor suppressor in human epithelial cancers. Function of Fhit in tumor suppression does not require diadenosine polyphosphate cleavage but correlates with the ability to form substrate complexes. As diadenosine polyphosphates are at lower cellular concentrations than mononucleotides, we sought to quantify interactions between Fhit and competitive inhibitors with the use of diadenosine polyphosphate analogs containing fluorophores in place of one nucleoside. Appp-S-(7-diethylamino-4-methyl-3-(4-succinimidylphenyl)) coumarin (ApppAMC), Appp-S-(4-4-difluoFo-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacine-3-yl) methylaminoacetyl (ApppBODIPY), and GpppBODIPY, synthesized in high yield, are effective Fhit substrates, producing AMP or GIMP plus fluorophore diphosphates. GpppBODIPY cleavage is accompanied by a 5.4-fold increase in fluorescence because BODIPY fluorescence is quenched by stacking with guanine. Titration of unlabeled diadenosine polyphosphates, inorganic pyrophosphate, mononucleotides, and inorganic phosphate into fluorescent assays provided values of K-m and K-I as competitive inhibitors. The data indicate that Fhit discriminates between good substrates via k(cat) and against cellular competitors in equilibrium binding terms. Surprisingly, pyrophosphate competes better than purine mononucleotides.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Mol Probes Inc, Eugene, OR 97402 USA	Jefferson University	Brenner, C (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,Rom 826, Philadelphia, PA 19107 USA.	brenner@dada.jci.tju.edu	Brenner, Charles/D-6339-2014	Brenner, Charles/0000-0002-4955-3226	NATIONAL CANCER INSTITUTE [R01CA075954] Funding Source: NIH RePORTER; NCI NIH HHS [CA75954, R01 CA075954-03, R01 CA075954] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abend A, 1999, BIOCHEMISTRY-US, V38, P3668, DOI 10.1021/bi981895j; Asensio AC, 1999, BBA-PROTEIN STRUCT M, V1432, P396, DOI 10.1016/S0167-4838(99)00102-8; BARNES LD, 1985, ANAL BIOCHEM, V144, P296, DOI 10.1016/0003-2697(85)90120-4; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BARSHOP BA, 1991, ANAL BIOCHEM, V197, P266, DOI 10.1016/0003-2697(91)90387-9; Blackburn GM, 1998, NUCLEOS NUCLEOT, V17, P301, DOI 10.1080/07328319808005178; Brenner C, 1999, PHOSPHORUS SULFUR, V144, P745; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; Brenner C, 1997, PROTEIN ENG, V10, P1461, DOI 10.1093/protein/10.12.1461; Chaudhuri AR, 1999, J BIOL CHEM, V274, P24378, DOI 10.1074/jbc.274.34.24378; Dhar G, 1999, J BIOL CHEM, V274, P14568, DOI 10.1074/jbc.274.21.14568; Geeganage S, 1998, BIOCHEMISTRY-US, V37, P14500, DOI 10.1021/bi9815546; HEUBNER K, 1999, ADV ONCOL, V15, P3; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; Ji L, 1999, ANAL BIOCHEM, V271, P114, DOI 10.1006/abio.1999.4131; Ji L, 1999, CANCER RES, V59, P3333; KAROLIN J, 1994, J AM CHEM SOC, V116, P7801, DOI 10.1021/ja00096a042; KHALFAN H, 1986, HISTOCHEM J, V18, P497, DOI 10.1007/BF01675617; KORNBERG A, 1992, DNA REPLICATION, P54; Lima CD, 1997, STRUCTURE, V5, P763, DOI 10.1016/S0969-2126(97)00231-1; Liu XH, 1999, ANGEW CHEM INT EDIT, V38, P1244, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1244::AID-ANIE1244>3.0.CO;2-0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Pekarsky Y, 1998, P NATL ACAD SCI USA, V95, P8744, DOI 10.1073/pnas.95.15.8744; Ripoll C, 1996, DIABETES, V45, P1431, DOI 10.2337/diabetes.45.10.1431; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1998, CANCER RES, V58, P5032; THOMPSON CB, 1984, J IMMUNOL, V133, P2333; Vartanian A, 1997, FEBS LETT, V415, P160, DOI 10.1016/S0014-5793(97)01086-7; Vartanian A, 1996, FEBS LETT, V381, P32, DOI 10.1016/0014-5793(96)00073-7	33	62	67	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4555	4560		10.1074/jbc.275.7.4555	http://dx.doi.org/10.1074/jbc.275.7.4555			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671479	hybrid, Green Accepted			2022-12-25	WOS:000085378200005
J	Blaxall, BC; Pellett, AC; Wu, SC; Pende, A; Port, JD				Blaxall, BC; Pellett, AC; Wu, SC; Pende, A; Port, JD			Purification and characterization of beta-adrenergic receptor mRNA-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; AU-RICH ELEMENT; AGONIST-INDUCED DESTABILIZATION; SMOOTH-MUSCLE CELLS; C-6 GLIOMA-CELLS; DOWN-REGULATION; GROWTH-FACTOR; MEDIATED DESTABILIZATION; GENE-TRANSCRIPTION; ELAV PROTEIN	beta-Adrenergic receptors (beta-ARs), like other G-protein-coupled receptors, can undergo post-transciptional regulation at the level of mRNA stability. In particular, the human beta(1)- and beta(2)-ARs and the hamster beta(2)-AR mRNA undergo beta-agonist-mediated destabilization. By UV cross-linking, we have previously described an similar to M-r 36,000 mRNA-binding protein, beta ARB, that binds to A/C+U-rich nucleotide regions within 3'-untranslated regions. Further, we have demonstrated previously that beta ARB is immunologically distinct from AUF1/heterogeneous nuclear ribonucleoprotein (hnRNP) D, another mRNA-binding protein associated with destabilization of A+U-rich mRNAs (Pende, A., Tremmel, K. D., De-Maria, C. T., Blaxall, B. C., Minobe, W., Sherman, J. A., Bisognano, J., Bristow, M. R., Brewer, G., and Port, J. D. (1996) J. Biol. Chem. 271, 8493-8501). In this report, we describe the peptide composition of beta ARB. Mass spectrometric analysis of an similar to M-r 36,000 band isolated from ribosomal salt wash proteins revealed the presence of two mRNA-binding proteins, hnRNP Al, and the elav-like protein, HuR, both of which are known to bind to A+U-rich nucleotide regions. By immunoprecipitation, HuR appears to be the biologically dominant RNA binding component of beta ARB. Although hnRNP Al and HuR can both be immunoprecipitated from ribosomal salt wash proteins, the composition of beta ARB (HuR alone versus HuR and hnRNP Al) appears to be dependent on the mRNA probe used. The exact role of HuR and hnRNP Al in the regulation of beta-AR mRNA stability remains to be determined.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Cardiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Port, JD (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Cardiol, 4200 E 9th Ave,B139, Denver, CO 80262 USA.	david.port@uchsc.edu	Blaxall, Burns/ABD-8289-2021	Port, Jonathan D./0000-0001-7048-3544	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051239, R01HL051239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007635] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL051239, HL51239] Funding Source: Medline; NIGMS NIH HHS [GM07635] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ANANT S, 1997, NUCL ACIDS S SER, V36, P115; Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; Atasoy U, 1998, J CELL SCI, V111, P3145; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Belasco J.G., 2012, CONTROL MESSENGER RN; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Dangel V, 1996, BIOCHEM J, V317, P925, DOI 10.1042/bj3170925; Danner S, 1997, EUR J PHARMACOL, V331, P73, DOI 10.1016/S0014-2999(97)01022-4; Danner S, 1998, J BIOL CHEM, V273, P3223, DOI 10.1074/jbc.273.6.3223; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dempsey LA, 1998, GENOMICS, V49, P378, DOI 10.1006/geno.1998.5237; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; DEVEDJIAN JC, 1991, J BIOL CHEM, V266, P14359; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FERRY RC, 1994, J BIOL CHEM, V269, P31850; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gao FB, 1996, J CELL SCI, V109, P579; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; Hamilton BJN, 1997, J BIOL CHEM, V272, P28732, DOI 10.1074/jbc.272.45.28732; HOSODA K, 1995, MOL PHARMACOL, V48, P206; HOUGH C, 1994, J NEUROCHEM, V62, P421; HUANG LY, 1993, J BIOL CHEM, V268, P25769; IZZO NJ, 1994, J BIOL CHEM, V269, P1705; IZZO NJ, 1990, P NATL ACAD SCI USA, V87, P6268, DOI 10.1073/pnas.87.16.6268; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lazou A, 1998, BIOCHEM J, V332, P459, DOI 10.1042/bj3320459; Lee NH, 1998, J BIOL CHEM, V273, P22317, DOI 10.1074/jbc.273.35.22317; LEE NH, 1994, J BIOL CHEM, V269, P4291; LEFKOWITZ RJ, 1993, END SOC 75 ANN M PRO, P204; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mitchusson KD, 1998, BIOCHEM BIOPH RES CO, V252, P357, DOI 10.1006/bbrc.1998.9598; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Nabors LB, 1998, J NEUROIMMUNOL, V92, P152, DOI 10.1016/S0165-5728(98)00196-9; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PLANCK SR, 1988, NUCLEIC ACIDS RES, V16, P11663, DOI 10.1093/nar/16.24.11663; PORT JD, 1992, J BIOL CHEM, V267, P24103; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAKAUE M, 1991, J BIOL CHEM, V266, P5743; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; THOLANIKUNNEL BG, 1995, J BIOL CHEM, V270, P12787, DOI 10.1074/jbc.270.21.12787; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; Tittelbach V, 1998, BIOCHEM PHARMACOL, V56, P967, DOI 10.1016/S0006-2952(98)00231-7; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Williams NG, 1998, J BIOL CHEM, V273, P24624, DOI 10.1074/jbc.273.38.24624; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhong HY, 1999, J NEUROCHEM, V72, P2388, DOI 10.1046/j.1471-4159.1999.0722388.x; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	76	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4290	4297		10.1074/jbc.275.6.4290	http://dx.doi.org/10.1074/jbc.275.6.4290			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660597	hybrid			2022-12-25	WOS:000085288800081
J	Jakymiw, A; Raharjo, E; Rattner, JB; Eystathioy, T; Chan, EKL; Fujita, DJ				Jakymiw, A; Raharjo, E; Rattner, JB; Eystathioy, T; Chan, EKL; Fujita, DJ			Identification and characterization of a novel Golgi protein, golgin-67	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEIN; COILED COILS; TRANSMEMBRANE DOMAINS; FUSION PROTEINS; VESICLE DOCKING; MESSENGER-RNAS; SEQUENCES; MITOSIS; BINDING; GM130	In the course of screening a lambda gt11 human leukemic T-cell cDNA expression library with an antibody specific to the mitotic target of Src, Sam68, we identified and cloned a cDNA encoding a novel protein with a predicted molecular mass of 51.4 kDa. Polyclonal antibodies raised to a His(6)-tagged construct of this protein, detected a -67-kDa protein in immunoprecipitation experiments, and cytological studies showed that this protein localized to the Golgi complex, through colocalization experiments with specific Golgis markers. Therefore, we designated this protein golgin-67, Sequence analysis revealed that golgin-67 is a highly coiled-coil protein, with potential Cdc2 and Src kinase phosphorylation motifs. It has sequence homologies to other Golgi proteins, in eluding the coatamer complex I vesicle docking protein, GM130. Structurally, golgin-67 resembles, golgin-84, an integral membrane Golgi protein with an N-terminal coiled coil domain and a single C-terminal transmembrane domain. The C-terminal region of golgin-67, which contains a predicted transmembrane domain, was demonstrated to be essential for its Golgi localization.	Univ Calgary, Ctr Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Ctr Med, Dept Biochem & Mol Biol, Joint Injury & Arthrit Res Grp, Calgary, AB T2N 4N1, Canada; Scripps Res Inst, Dept Mol & Expt Med, Wm Keck Autoimmune Dis Ctr, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, DNA Core Lab Struct Anal, La Jolla, CA 92037 USA	University of Calgary; University of Calgary; Scripps Research Institute; Scripps Research Institute	Chan, EKL (corresponding author), Univ Calgary, Ctr Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Chan, Edward K. L./B-5671-2009	Chan, Edward K. L./0000-0003-3938-9503; Jakymiw, Andrew/0000-0001-6431-8753	NIAID NIH HHS [AI-39645] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039645] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Bascom RA, 1999, J BIOL CHEM, V274, P2953, DOI 10.1074/jbc.274.5.2953; Bastos R, 1997, J CELL BIOL, V137, P989, DOI 10.1083/jcb.137.5.989; Biscardi JS, 1999, ADV CANCER RES, V76, P61; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOBLET C, 1989, NUCLEIC ACIDS RES, V17, P2144, DOI 10.1093/nar/17.5.2144; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; KOWAL R, 1980, ANAL BIOCHEM, V102, P72, DOI 10.1016/0003-2697(80)90319-X; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Lowe M, 1998, TRENDS CELL BIOL, V8, P40, DOI 10.1016/S0962-8924(97)01189-6; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, BIOCHEM SOC T, V23, P527, DOI 10.1042/bst0230527; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Munro S, 1999, CURR BIOL, V9, P377, DOI 10.1016/S0960-9822(99)80166-3; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VOGEL LB, 1995, J BIOL CHEM, V270, P2506, DOI 10.1074/jbc.270.6.2506; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Zhou Songyang, 1995, Nature (London), V373, P536	44	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4137	4144		10.1074/jbc.275.6.4137	http://dx.doi.org/10.1074/jbc.275.6.4137			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660574	hybrid			2022-12-25	WOS:000085288800058
J	Rowan, BG; Weigel, NL; O'Malley, BW				Rowan, BG; Weigel, NL; O'Malley, BW			Phosphorylation of steroid receptor coactivator-1 - Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTOR; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; HISTONE ACETYLTRANSFERASE; ESTROGEN-RECEPTOR; DNA-BINDING; IN-VITRO; HORMONE; CBP; SEQUENCE	Steroid receptor coactivator-1 (SRC-1) is a member of a coactivator family that enhance the activation of the steroid/nuclear receptor superfamily of ligand-stimulated transcription factors. To study the regulation of SRC-1 by signaling pathways in the cell, the major phosphorylation sites of SRC-1 were identified in COS-1 cells using a combination of in vivo labeling with [P-32]H3PO4, modified manual Edman degradation, phosphoamino acid analysis, endoproteinase digestion, and mutagenesis of the SRC-1 phosphorylation sites. Seven phosphorylation sites were identified in SRC-1: serine 372, serine 395, serine 517, serine 569, serine 1033, threonine 1179, and serine 1185, All the sites contained consensus sequences for the serine/threonine-proline-directed family of protein kinases, and two sites (serine 395 and threonine 1179) contained a perfect consensus sequence for the mitogen-activated protein kinase family (Erk-1 and Erk-2), Furthermore, Erk-2 phosphorylated threonine 1179 and serine 1185 (and to a lesser extent, serine 395) in vitro, suggesting the importance of this pathway for SRC-1 regulation. Treatment of cells expressing SRC-1 with epidermal growth factor enhanced the ligand-dependent, progesterone receptor-mediated activation of a target reporter gene. These results identify phosphorylation as a regulatory modification of SRC-1 and provide a basis upon which to identify signaling pathways that regulate SRC-1 function and, consequently, modify steroid/nuclear receptor action.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Weigel, NL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.							AIT SA, 1998, NATURE, V396, P184; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; AUSTEN BM, 1976, BIOCHEM BIOPH RES CO, V72, P411, DOI 10.1016/S0006-291X(76)80058-7; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DENNER LA, 1989, ENDOCRINOLOGY, V125, P3051, DOI 10.1210/endo-125-6-3051; Fraser RA, 1998, J BIOL CHEM, V273, P16199, DOI 10.1074/jbc.273.26.16199; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268; ZHANG YX, 1994, J BIOL CHEM, V269, P31034	41	223	226	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4475	4483		10.1074/jbc.275.6.4475	http://dx.doi.org/10.1074/jbc.275.6.4475			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660621	hybrid			2022-12-25	WOS:000085288800105
J	Selmer, T; Kahnt, J; Goubeaud, M; Shima, S; Grabarse, W; Ermler, U; Thauer, RK				Selmer, T; Kahnt, J; Goubeaud, M; Shima, S; Grabarse, W; Ermler, U; Thauer, RK			The biosynthesis of methylated amino acids in the active site region of methyl-coenzyme M reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOGENIC BACTERIA; METHANOBACTERIUM-THERMOAUTOTROPHICUM; S-ADENOSYLMETHIONINE; CATALYTIC MECHANISM; METHYLTRANSFERASE; IDENTIFICATION; SEQUENCE; PROTEIN; F430; FACTOR-F430	The global production of the greenhouse gas methane by methanogenic archaea reaches 1 billion tons per annum. The final reaction releasing methane is catalyzed by the enzyme methyl-coenzyme M reductase, The crystal structure of methyl-coenzyme RI reductase from Methanobacterium thermoautotrophicum revealed the presence of five modified amino acids within the alpha-sub-unit and near the active site region. Four of these modifications were C-, N-, and S-methylations, two of which, 2-(S)-methylglutamine and 5-(S)-methylarginine, have never been encountered before. We have now confirmed these modifications by mass spectrometry of chymotryptic peptides, With methyl-coenzyme M reductase purified from cells grown in the presence of L-[methyl-D-3]methionine, it was shown that the methyl groups of the modified amino acids are derived from the methyl group of methionine rather than from methyl-coenzyme RI, an intermediate in methane formation. The D-3 labeling pattern was found to be qualitatively and quantitatively the same as in the two methyl groups of the methanogenic coenzyme F-430, which are known to be introduced via S-adenosylmethionine. From the results, it is concluded that the methyl groups of the modified amino acids in methyl-coenzyme RI reductase are biosynthetically introduced by an S-adenosylmethionine-dependent post-translational modification. A mechanism for the methylation of glutamine at C-2 and of arginine at C-5 is discussed.	Max Planck Inst Terr Mikrobiol, D-35043 Marburg, Germany; Univ Marburg, Fachbereich Biol, Mikrobiol Lab, D-35032 Marburg, Germany; Max Planck Inst Biophys, D-60528 Frankfurt, Germany	Max Planck Society; Philipps University Marburg; Max Planck Society	Thauer, RK (corresponding author), Max Planck Inst Terr Mikrobiol, Karl Von Frisch Str, D-35043 Marburg, Germany.							Appleyard MVCL, 1998, J BIOL CHEM, V273, P14869, DOI 10.1074/jbc.273.24.14869; Atkinson D., 1977, CELLULAR ENERGY META, P75; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; DOOLITTLE LR, 1977, ANAL BIOCHEM, V78, P491, DOI 10.1016/0003-2697(77)90109-9; Ermler U, 1997, SCIENCE, V278, P1457, DOI 10.1126/science.278.5342.1457; FARBER G, 1991, HELV CHIM ACTA, V74, P697, DOI 10.1002/hlca.19910740404; Goubeaud M, 1997, EUR J BIOCHEM, V243, P110, DOI 10.1111/j.1432-1033.1997.00110.x; Gu QM, 1997, J PEPT RES, V49, P484; JAENCHEN R, 1981, FEBS LETT, V130, P133, DOI 10.1016/0014-5793(81)80681-3; JOHNSON AW, 1966, YLID CHEM, P251; KATOH Y, 1990, AGR BIOL CHEM TOKYO, V54, P3117, DOI 10.1080/00021369.1990.10870466; Kim S, 1998, AMINO ACIDS, V15, P291, DOI 10.1007/BF01320895; Kim SD, 1998, J BIOL CHEM, V273, P27374, DOI 10.1074/jbc.273.42.27374; LU RC, 1977, BIOCHEMISTRY-US, V16, P5801, DOI 10.1021/bi00645a025; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Musker W. K., 1970, TOP CURR CHEM, V14, P295; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Nolling J, 1996, INT J SYST BACTERIOL, V46, P1170, DOI 10.1099/00207713-46-4-1170; PAIK WK, 1990, PROTEIN METHYLATION; PATE JS, 1995, AUST J BOT, V543, P73; PFALTZ A, 1985, HELV CHIM ACTA, V68, P1338, DOI 10.1002/hlca.19850680527; PFALTZ A, 1987, EUR J BIOCHEM, V170, P459, DOI 10.1111/j.1432-1033.1987.tb13722.x; PFALTZ A, 1982, HELV CHIM ACTA, V65, P828, DOI 10.1002/hlca.19820650320; Porse BT, 1998, J MOL BIOL, V276, P391, DOI 10.1006/jmbi.1997.1541; Raftery MJ, 1996, BIOCHEM J, V316, P285, DOI 10.1042/bj3160285; Roehm PC, 1998, J AM CHEM SOC, V120, P13083, DOI 10.1021/ja982546f; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; SCHONHEIT P, 1980, ARCH MICROBIOL, V127, P59, DOI 10.1007/BF00414356; Selmer T, 1999, J BIOL CHEM, V274, P20772, DOI 10.1074/jbc.274.30.20772; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SPRINGER E, 1995, INT J SYST BACTERIOL, V45, P554, DOI 10.1099/00207713-45-3-554; TAKUSAGAWA F, 1998, COMPREHENSIVE BIOL C, V1, P1; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; UY R, 1977, SCIENCE, V198, P890, DOI 10.1126/science.337487; WOLFE RS, 1991, ANNU REV MICROBIOL, V45, P1, DOI 10.1146/annurev.mi.45.100191.000245; WU JC, 1987, J BIOL CHEM, V262, P4778; YUN BS, 1995, BIOSCI BIOTECH BIOCH, V59, P876, DOI 10.1271/bbb.59.876; Zobel-Thropp P, 1998, J BIOL CHEM, V273, P29283, DOI 10.1074/jbc.273.45.29283	39	60	68	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3755	3760		10.1074/jbc.275.6.3755	http://dx.doi.org/10.1074/jbc.275.6.3755			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660523	hybrid			2022-12-25	WOS:000085288800007
J	Urquhart, AJ; Kennedy, D; Gould, SJ; Crane, DI				Urquhart, AJ; Kennedy, D; Gould, SJ; Crane, DI			Interaction of Pex5p, the type 1 peroxisome targeting signal receptor, with the peroxisomal membrane proteins Pex14p and Pex13p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PICHIA-PASTORIS; SACCHAROMYCES-CEREVISIAE; PTS1 RECEPTOR; 3-KETOACYL-COA THIOLASE; SH3 DOMAIN; IMPORT; IDENTIFICATION; GENE; SEQUENCE; BINDING	Pexp5p, a receptor for peroxisomal matrix proteins with a type 1 peroxisome targeting signal (PTS1), has been proposed to cycle from the cytoplasm to the peroxisomal membrane where it docks with Pex14p and Pex13p, the latter an SH3 domain-containing protein. Using in vitro binding assays we have demonstrated that binding of Pex5p to Pex14p is enhanced when Pex5p is loaded with a PTS1-containing peptide. In contrast, Pex5p binding to Pex13p, which involves only the SH3 domain, occurs at 20-40-fold lower levels and is reduced when Pex5p is preloaded with a PTS1 peptide, Pex14p was also shown to bind weakly to the Pex13p SH3 domain. Site-directed mutagenesis of the Pex13p SH3 domain attenuated binding to Pex5p and Pex14p, consistent with both of these proteins being binding partners for this domain. The SH3 binding site in Pex5p was determined to lie within a 114-residue peptide (Trp(100)-Glu(213)) in the amino-terminal region of the protein. The interaction between this peptide and the SH3 domain was competitively inhibited by Pex14p, We interpret these data as suggesting that docking of the Pex5p-PTS1 protein complex at the peroxisome membrane occurs at Pex14p and that the Pex13p SH3 domain functions as an associated component possibly involved in sequestering Pex5p after relinquishment of the PTS1 protein cargo to components of the translocation machinery.	Griffith Univ, Sch Biomol & Biomed Sci, Nathan, Qld 4111, Australia; Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Griffith University; University of Queensland; Johns Hopkins University	Crane, DI (corresponding author), Griffith Univ, Sch Biomol & Biomed Sci, Nathan, Qld 4111, Australia.		Crane, Denis I/A-7887-2011; Kennedy, Hendrick/A-7635-2010	Crane, Denis I/0000-0002-5696-1906; Kennedy, Hendrick/0000-0001-7937-3069				ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; CHOTHIA C, 1986, SCIENCE, V233, P755, DOI 10.1126/science.3090684; Colombo P, 1998, J IMMUNOL, V160, P2780; CRANE DI, 1994, J BIOL CHEM, V269, P21835; CRANE DI, 1994, CURR GENET, V26, P443, DOI 10.1007/BF00309932; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; EISENBERG D, 1989, CHEM SCRIPTA, V29A, P217; Elgersma Y, 1998, J CELL BIOL, V140, P807, DOI 10.1083/jcb.140.4.807; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GOULD SJ, 1992, YEAST, V8, P613, DOI 10.1002/yea.320080805; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LUTHY R, 1991, PROTEINS, V10, P229, DOI 10.1002/prot.340100307; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; Matsushita M, 1998, BIOCHEM BIOPH RES CO, V245, P337, DOI 10.1006/bbrc.1998.8420; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; SARASTE M, 1994, NAT STRUCT BIOL, V1, P835, DOI 10.1038/nsb1294-835; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	35	112	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4127	4136		10.1074/jbc.275.6.4127	http://dx.doi.org/10.1074/jbc.275.6.4127			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660573	hybrid			2022-12-25	WOS:000085288800057
J	Winkler, GS; Araujo, SJ; Fiedler, U; Vermeulen, W; Coin, F; Egly, JM; Hoeijmakers, JHJ; Wood, RD; Timmers, HTM; Weeda, G				Winkler, GS; Araujo, SJ; Fiedler, U; Vermeulen, W; Coin, F; Egly, JM; Hoeijmakers, JHJ; Wood, RD; Timmers, HTM; Weeda, G			TFIIH with inactive XPD helicase functions in transcription initiation but is defective in DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; MOLECULAR ANALYSIS; OPEN COMPLEX; FACTOR BTF2; GENE; MUTATIONS; PROTEIN	TFIIH is a multisubunit protein complex involved in RNA polymerase II transcription and nucleotide excision repair, which removes a wide variety of DNA lesions including UV-induced photoproducts. Mutations in the DNA-dependent ATPase/helicase subunits of TFIIH, XPB and XPD, are associated with three inherited syndromes as follows: xeroderma pigmentosum with or without Cockayne syndrome and trichothiodystrophy. By using epitope-tagged XPD we purified mammalian TFIIH carrying a wild type or an active-site mutant XPD subunit. Contrary to XPB, XPD helicase activity was dispensable for in vitro transcription, catalytic formation of trinucleotide transcripts, and promoter opening. Moreover, in contrast to XPB, microinjection of mutant XPD cDNA did not interfere with in vivo transcription. These data show directly that XPD activity is not required for transcription. However, during DNA repair, neither 5' nor 3' incisions in defined positions around a DNA adduct were detected in the presence of TFIIH containing inactive XPD, although substantial damage-dependent DNA synthesis was induced by the presence of mutant XPD both in cells and cell extracts. The aberrant damage-dependent DNA synthesis caused by the mutant XPD does not lead to effective repair, consistent with the discrepancy between repair synthesis and survival in cells from a number of XP-D patients.	Erasmus Univ, Ctr Med Genet, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands; Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Erasmus University Rotterdam; Utrecht University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hoeijmakers, JHJ (corresponding author), Erasmus Univ, Ctr Med Genet, Dept Cell Biol & Genet, POB 1788, NL-3000 DR Rotterdam, Netherlands.	Hoeijmakers@gen.fgg.eur.nl	Araújo, Sofia J/J-5681-2014; Vermeulen, Wim/W-8708-2019; Coin, Frédéric/F-5925-2013; Wood, Richard D/M-6319-2018; Hoeijmakers, Jan/AAX-6972-2021	Araújo, Sofia J/0000-0002-4749-8913; Vermeulen, Wim/0000-0003-3616-734X; Coin, Frédéric/0000-0002-5620-8519; Wood, Richard D/0000-0002-9495-6892; Winkler, Sebastiaan/0000-0002-0476-162X				Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; Constantinou A, 1999, J BIOL CHEM, V274, P5637, DOI 10.1074/jbc.274.9.5637; de Boer J, 1998, MOL CELL, V1, P981, DOI 10.1016/S1097-2765(00)80098-2; de Boer J, 1998, CANCER RES, V58, P89; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GERARD M, 1991, J BIOL CHEM, V266, P20940; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1996, THESIS UTRECHT U UTR; JOHNSON RT, 1985, J CELL SCI, V76, P115; JOHNSON RT, 1992, MUTAT RES, V273, P97, DOI 10.1016/0921-8777(92)90072-B; Kadkhodayan S, 1997, MUTAT RES-DNA REPAIR, V385, P47, DOI 10.1016/S0921-8777(97)00030-X; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; Marinoni JC, 1997, METHODS, V12, P235, DOI 10.1006/meth.1997.0476; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PATERSON MC, 1987, J CELL SCI, P161; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; ROY R, 1994, J BIOL CHEM, V269, P9826; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SHIVJI MKK, 1998, DNA REPAIR PROTOCOLS; Sijbers AM, 1996, NUCLEIC ACIDS RES, V24, P3370, DOI 10.1093/nar/24.17.3370; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TANTIN D, 1994, J BIOL CHEM, V269, P17397; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; WEBER CA, 1994, MUTAT RES LETT, V324, P147, DOI 10.1016/0165-7992(94)90012-4; Winkler GS, 1998, J BIOL CHEM, V273, P1092, DOI 10.1074/jbc.273.2.1092; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	55	136	138	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4258	4266		10.1074/jbc.275.6.4258	http://dx.doi.org/10.1074/jbc.275.6.4258			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660593	hybrid			2022-12-25	WOS:000085288800077
J	Geerlings, A; Ibanez, MML; Memelink, J; van der Heijden, R; Verpoorte, R				Geerlings, A; Ibanez, MML; Memelink, J; van der Heijden, R; Verpoorte, R			Molecular cloning and analysis of strictosidine beta-d-glucosidase, an enzyme in terpenoid indole alkaloid biosynthesis in Catharanthus roseus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSPENSION-CULTURED CELLS; ENDOPLASMIC-RETICULUM; LOCALIZATION; SYNTHASE; PLANTS; EXPRESSION; RETENTION; CINCHONA; PROTEINS; VECTORS	Strictosidine beta-D-glucosidase (SGD) is an enzyme involved in the biosynthesis of terpenoid indole alkaloids (TLAs) by converting strictosidine to cathenamine, The biosynthetic pathway toward strictosidine is thought to be similar in all TIA-producing plants. Somewhere downstream of strictosidine formation, however, the biosynthesis diverges to give rise to the different TIAs found, SGD may play a role in creating this biosynthetic diversity. We have studied SGD at both the molecular and enzymatic levels. Based on the homology between different plant beta-glucosidases, degenerate polymerase chain reaction primers were designed and used to isolate a cDNA clone from a Catharanthus roseus cDNA library. A full-length clone gave rise to SGD activity when expressed in Saccharomyces cerevisiae, SGD shows similar to 60% homology at the amino acid level to other beta-glucosidases from plants and is encoded by a single-copy gene. Sgd expression is induced by methyl jasmonate with kinetics similar to those of two other genes acting prior to Sgd in TLA biosynthesis. These results show that coordinate induction of the biosynthetic genes forms at least part of the mechanism for the methyl jasmonate-induced increase in TIA production. Using a novel in vivo staining method, subcellular localization studies of SGD were performed, This showed that SGD is most likely associated with the endoplasmic reticulum, which is in accordance with the presence of a putative signal sequence, but in contrast to previous localization studies. This new insight in SGD localization has significant implications for our understanding of the complex intracellular trafficking of metabolic intermediates during TIA biosynthesis.	Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Pharmacognosy, NL-2300 RA Leiden, Netherlands; Leiden Univ, Clusius Lab, Inst Mol Plant Sci, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	Verpoorte, R (corresponding author), Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Pharmacognosy, POB 9502, NL-2300 RA Leiden, Netherlands.		van der Heijden, Rob/D-1403-2013; Verpoorte, Robert/Y-4363-2019	Memelink, Johan/0000-0002-4767-506X; Verpoorte, Robert/0000-0001-6180-1424				AERTS RJ, 1994, PLANT J, V5, P635, DOI 10.1111/j.1365-313X.1994.00635.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOLLER T, 1979, PLANT PHYSIOL, V63, P1123, DOI 10.1104/pp.63.6.1123; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDEL V, 1992, P NATL ACAD SCI USA, V89, P2002; BRUNELLI JP, 1993, YEAST, V9, P1309, DOI 10.1002/yea.320091204; Contin A, 1998, FEBS LETT, V434, P413, DOI 10.1016/S0014-5793(98)01022-9; DAVIS LG, 1986, BASIC METHODS MOL BI, P315; Gantet P, 1998, PLANT CELL PHYSIOL, V39, P220, DOI 10.1093/oxfordjournals.pcp.a029360; GEERLINGS A, 1999, IN PRESS PLNAT CELL; Gomord V, 1997, PLANT J, V11, P313, DOI 10.1046/j.1365-313X.1997.11020313.x; HEMSCHEIDT T, 1980, FEBS LETT, V110, P187, DOI 10.1016/0014-5793(80)80069-X; HOLTMAN WL, 1994, PLANT SCI, V99, P43, DOI 10.1016/0168-9452(94)90119-8; HUGHES MA, 1992, ACS SYM SER, V533, P151; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Jones DA, 1998, PHYTOCHEMISTRY, V47, P155, DOI 10.1016/S0031-9422(97)00425-1; Luijendijk TJC, 1996, J CHEM ECOL, V22, P1355, DOI 10.1007/BF02027718; Luijendijk TJC, 1996, PHYTOCHEM ANALYSIS, V7, P16, DOI 10.1002/(SICI)1099-1565(199601)7:1<16::AID-PCA280>3.0.CO;2-H; Luijendijk TJC, 1998, PLANT PHYSIOL BIOCH, V36, P419, DOI 10.1016/S0981-9428(98)80205-2; MCKNIGHT TD, 1991, PLANTA, V185, P148, DOI 10.1007/BF00194055; MEIJER AH, 1993, J PLANT RES, P145; Memelink J, 1994, PLANT MOL BIOL MANUA, pF1; Menke FLH, 1999, EMBO J, V18, P4455, DOI 10.1093/emboj/18.16.4455; Menke FLH, 1999, PLANT PHYSIOL, V119, P1289, DOI 10.1104/pp.119.4.1289; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OLSEN LJ, 1995, ANNU REV PLANT PHYS, V46, P123, DOI 10.1146/annurev.pp.46.060195.001011; PFITZNER U, 1982, PLANTA MED, V46, P10, DOI 10.1055/s-2007-970008; RENAUDIN JP, 1986, PHYSIOL PLANTARUM, V68, P695, DOI 10.1111/j.1399-3054.1986.tb03420.x; Riechmann JL, 1998, BIOL CHEM, V379, P633; Saito T, 1999, PLANT CELL PHYSIOL, V40, P77, DOI 10.1093/oxfordjournals.pcp.a029477; SIKORSKI RS, 1989, GENETICS, V122, P19; St-Pierre B, 1999, PLANT CELL, V11, P887, DOI 10.1105/tpc.11.5.887; STEVENS LH, 1992, PLANT PHYSIOL BIOCH, V30, P675; STEVENS LH, 1993, PLANT CELL REP, V12, P573, DOI 10.1007/BF00233063; Stevens LH, 1994, THESIS LEIDEN U LEID, DOI 10.1007/s11101-006-9047-8; VRPOORTE R, 1998, ALKALOIDS, V50, P453	37	119	143	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3051	3056		10.1074/jbc.275.5.3051	http://dx.doi.org/10.1074/jbc.275.5.3051			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652285	hybrid			2022-12-25	WOS:000085146500007
J	Kimberly, WT; Xia, WM; Rahmati, T; Wolfe, MS; Selkoe, DJ				Kimberly, WT; Xia, WM; Rahmati, T; Wolfe, MS; Selkoe, DJ			The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; FAMILIAL ALZHEIMERS-DISEASE; IN-VIVO; PRECURSOR PROTEIN; MUTANT PRESENILIN-1; TRANSFECTED CELLS; TRANSGENIC MICE; DEGRADATION; DEPOSITION; ENDOPROTEOLYSIS	The discovery that a deficiency of presenilin 1 (PS1) decreases the production of amyloid beta-protein (A beta) identified the presenilins as important mediators of the gamma-secretase cleavage of beta-amyloid precursor protein (APP). Recently, we found that two conserved transmembrane (TM) aspartates in PS1 are critical for AP production, providing evidence that PS1 either functions as a required diaspartyl cofactor for gamma-secretase or is itself gamma-secretase. Presenilin 2 (PS2) shares substantial sequence and possibly functional homology with PS1. Here, we show that the two TM aspartates in PS2 are also critical for gamma-secretase activity, providing further evidence that PS2 is functionally homologous to PS1. Cells stably co-expressing TM Asp -> Ala mutations in both PS1 and PS2 show further accumulation of the APP-derived gamma-secretase substrates, C83 and C99. The production of A beta is reduced to undetectable levels in the conditioned media of these cells. Furthermore, endoproteolysis of the exogenous Asp mutant PS2 is absent, and endogenous PS1 C-terminal fragments are diminished to undetectable levels. Therefore, the co-expression of PS1 and PS2 TM Asp -> Ala mutants suppresses the formation of any detectable PS1 or PS2 heterodimeric fragments and essentially abolishes the production of A beta. These results explain the residual A beta production seen in PS1-deficient cells and demonstrate the absolute requirement of functional presenilins for A beta generation. We conclude that presenilins, and their TM aspartates in particular, are attractive targets for lowering A beta therapeutically to prevent Alzheimer's disease.	Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Selkoe, DJ (corresponding author), Harvard Univ, Inst Med, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.		xia, weiming/E-5465-2016	xia, weiming/0000-0002-7463-3295	NIA NIH HHS [AG06173, AG15379] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [RF1AG006173, P01AG015379, R37AG006173, R01AG006173] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kim TW, 1997, J BIOL CHEM, V272, P11006; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tjernberg LO, 1997, J BIOL CHEM, V272, P1870, DOI 10.1074/jbc.272.3.1870; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; XIA W, 1999, SOC NEUR ABSTR; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096	33	216	234	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3173	3178		10.1074/jbc.275.5.3173	http://dx.doi.org/10.1074/jbc.275.5.3173			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652302	hybrid			2022-12-25	WOS:000085146500024
J	Goldstein, LA; Chen, WT				Goldstein, LA; Chen, WT			Identification of an alternatively spliced seprase mRNA that encodes a novel intracellular isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; S-ADENOSYLMETHIONINE DECARBOXYLASE; FIBROBLAST-ACTIVATION PROTEIN; DIPEPTIDYL-PEPTIDASE-IV; INTEGRAL MEMBRANE PROTEASE; VERTEBRATE MESSENGER-RNAS; MALIGNANT MELANOMA-CELLS; TRANSLATIONAL CONTROL; EPITHELIAL CANCERS; MOLECULAR-CLONING	Seprase is a homodimeric 170-kDa integral membrane gelatinase that is related to the ectoenzyme dipeptidyl peptidase IV. We have identified an alternatively spliced seprase messenger from the human melanoma cell line LOX that encodes a novel truncated isoform, seprase-s. The splice variant mRNA is generated by an out-of-frame deletion of a 1223-base pair exonic region that encodes part of the cytoplasmic tail, transmembrane, and the membrane progimal-central regions of the extracellular domain (Val(5) through Ser(412)) of the seprase 97-kDa subunit (seprase-l). The seprase-s mRNA has an elongated 5' leader (548 nucleotides) that harbors at least two upstream open reading frames that inhibit seprase-s expression from a downstream major open reading frame. Deletion mutagenesis of the wild type splice variant cDNA confirms that initiation of the seprase-s coding sequence begins with an ATG codon that corresponds to Met(522) Of seprase-l, The seprase-s open reading frame encodes a 239-amino acid polypeptide with an M-r similar to 27,000 that precisely overlaps the carboxyl-terminal catalytic region of seprase-l.	SUNY Stony Brook, Dept Med, Div Med Oncol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Chen, WT (corresponding author), SUNY Stony Brook, Dept Med, Div Med Oncol, HSC T-17,Rm 080, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [R01CA039077] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-39077] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ABBOTT CA, 1995, IMMUNOGENETICS, V42, P76; ABBOTT CA, 1994, IMMUNOGENETICS, V40, P331, DOI 10.1007/BF01246674; AOYAMA A, 1990, P NATL ACAD SCI USA, V87, P8296, DOI 10.1073/pnas.87.21.8296; Bergamini G, 1998, J VIROL, V72, P8425, DOI 10.1128/JVI.72.10.8425-8429.1998; BERGENHEM NCH, 1992, P NATL ACAD SCI USA, V89, P8798, DOI 10.1073/pnas.89.18.8798; BERGQUIN IM, 1996, INTRACELLULAR PROTEI, P281; Bermpohl F, 1998, FEBS LETT, V428, P152, DOI 10.1016/S0014-5793(98)00515-8; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; Cao JH, 1996, MOL CELL BIOL, V16, P7109; Chen WT, 1996, ENZYME PROTEIN, V49, P59, DOI 10.1159/000468616; DAMIANI RD, 1993, P NATL ACAD SCI USA, V90, P8244, DOI 10.1073/pnas.90.17.8244; DELBECQ P, 1994, MOL CELL BIOL, V14, P2378, DOI 10.1128/MCB.14.4.2378; Dietrich JM, 1996, J BIOL CHEM, V271, P2271, DOI 10.1074/jbc.271.4.2271; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; DONZE O, 1995, NUCLEIC ACIDS RES, V23, P861, DOI 10.1093/nar/23.5.861; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; GARNIER G, 1995, J IMMUNOL, V154, P3275; Goldstein LA, 1997, BBA-MOL BASIS DIS, V1361, P11, DOI 10.1016/S0925-4439(97)00032-X; HAN ST, 1993, EMBO J, V12, P2449, DOI 10.1002/j.1460-2075.1993.tb05899.x; Harigai M, 1996, ONCOGENE, V12, P1369; HILL JR, 1992, J BIOL CHEM, V267, P21886; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFMANN MA, 1993, P NATL ACAD SCI USA, V90, P11733, DOI 10.1073/pnas.90.24.11733; JASCUR T, 1991, BIOCHEMISTRY-US, V30, P1908, DOI 10.1021/bi00221a025; Kelly T, 1998, MODERN PATHOL, V11, P855; KELLY T, 1994, J CELL PHYSIOL, V158, P299, DOI 10.1002/jcp.1041580212; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; Luo ZL, 1996, J BACTERIOL, V178, P2172, DOI 10.1128/jb.178.8.2172-2177.1996; McGraw DW, 1998, J CLIN INVEST, V102, P1927, DOI 10.1172/JCI4862; Mehtani S, 1998, J BIOL CHEM, V273, P13236, DOI 10.1074/jbc.273.21.13236; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; MONSKY WL, 1994, CANCER RES, V54, P5702; Mori Y, 1996, HYPERTENSION, V28, P810, DOI 10.1161/01.HYP.28.5.810; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Niedermeyer J, 1998, EUR J BIOCHEM, V254, P650, DOI 10.1046/j.1432-1327.1998.2540650.x; Niedermeyer J, 1997, INT J CANCER, V71, P383, DOI 10.1002/(SICI)1097-0215(19970502)71:3<383::AID-IJC14>3.0.CO;2-H; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; PineiroSanchez ML, 1997, J BIOL CHEM, V272, P7595, DOI 10.1074/jbc.272.12.7595; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; Rescheleit DK, 1996, FEBS LETT, V394, P345, DOI 10.1016/0014-5793(96)00986-6; Reynolds K, 1996, J CELL BIOL, V134, P827, DOI 10.1083/jcb.134.4.827; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; Shofuda K, 1997, J BIOL CHEM, V272, P9749; Van den Oord JJ, 1998, BRIT J DERMATOL, V138, P615; WALBORG EF, 1985, EXP CELL RES, V158, P509, DOI 10.1016/0014-4827(85)90474-4; Wang Z, 1997, MOL CELL BIOL, V17, P4904, DOI 10.1128/MCB.17.9.4904; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111	60	28	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2554	2559		10.1074/jbc.275.4.2554	http://dx.doi.org/10.1074/jbc.275.4.2554			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644713	hybrid			2022-12-25	WOS:000085128000045
J	Jeong, W; Cha, MK; Kim, IH				Jeong, W; Cha, MK; Kim, IH			Thioredoxin-dependent hydroperoxide peroxidase activity of bacterioferritin comigratory protein (BCP) as a new member of the thiol-specific antioxidant protein (TSA)/alkyl hydroperoxide peroxidase C (AhpC) family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-CATALYZED OXIDATION; GLUTATHIONE-PEROXIDASE; ESCHERICHIA-COLI; REDUCTASE; PURIFICATION; EXISTENCE; CYSTEINE; YEAST; CELL; ACID	Escherichia coli bacterioferritin comigratory protein (BCP), a putative bacterial member of the TSA/AhpC family, was characterized as a thiol peroxidase, BCP showed a thioredoxin-dependent thiol peroxidase activity, BCP preferentially reduced linoleic: acid hydroperoxide rather than H2O2 and t-butyl hydroperoxide with the use of thioredoxin as an in vivo immediate electron donor. The value of V-max/K-m of BCP for Linoleic acid hydroperoxide was calculated to be 5-fold higher than that for H2O2, implying that ECP has a selective capability to reduce linoleic acid hydroperoxide. Replacement of Cys-45 with serine resulted in the complete loss of thiol peroxidase activity; suggesting that BCP is a new bacterial member of TSA/AhpC family having a conserved cysteine as the primary site of catalysis, BCP exists as a monomer, and its functional Cys-45 appeared to exist as cysteine sulfenic acid. The expression level of BCP gradually elevated during exponential growth until mid-log phase growth, beyond which the expression level was decreased. BCP was induced 3-fold by the oxidative stress given by changing the growth conditions from the anaerobic to aerobic culture. Bcp null mutant grew more slowly than its wild type in aerobic culture and showed the hypersensitivity toward various oxidants such as H2O2, t-butyl hgdroperoxide, and linoleic acid hydroperoxide. The peroxide hypersensitivity of the null mutant could be complemented by the expression of bcp gene. Taken together, these data suggest that BCP is a new member of thioredoxin-dependent TSA/AhpC family, acting as a general hydroperoxide peroxidase.	PaiChai Univ, Dept Biochem, Natl Creat Res Ctr Antioxidant Prot, Taejon 302735, South Korea	Pai Chai University	Kim, IH (corresponding author), PaiChai Univ, Dept Biochem, Natl Creat Res Ctr Antioxidant Prot, Taejon 302735, South Korea.	ihkim@woonam.paichai.ac.kr	Kim, Il-Han/W-1401-2019					Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; Cha MK, 1995, BIOCHEM BIOPH RES CO, V217, P900, DOI 10.1006/bbrc.1995.2856; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, BIOFACTORS, V4, P177; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; FORSTROM JW, 1979, ARCH BIOCHEM BIOPHYS, V193, P51, DOI 10.1016/0003-9861(79)90007-9; HALLIWELL B, 1989, FREE RACICAL BIOL ME; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kim HK, 1996, BIOCHEM BIOPH RES CO, V221, P641, DOI 10.1006/bbrc.1996.0649; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; LADENSTEIN R, 1979, J MOL BIOL, V134, P199, DOI 10.1016/0022-2836(79)90032-9; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V1, P55; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MOSIALOU E, 1993, FEBS LETT, V315, P77, DOI 10.1016/0014-5793(93)81137-O; PARSONAGE D, 1993, J BIOL CHEM, V268, P3161; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182	26	171	182	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2924	2930		10.1074/jbc.275.4.2924	http://dx.doi.org/10.1074/jbc.275.4.2924			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644761	hybrid			2022-12-25	WOS:000085128000093
J	Luongo, CL; Reinisch, KM; Harrison, SC; Nibert, ML				Luongo, CL; Reinisch, KM; Harrison, SC; Nibert, ML			Identification of the guanylyltransferase region and active site in reovirus mRNA capping protein lambda 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA GUANYLYLTRANSFERASE; VACCINIA VIRUS; SACCHAROMYCES-CEREVISIAE; DIRECTED MUTAGENESIS; ENZYME; SUBUNIT; DNA; LOCALIZATION; CORES; GENE	The 144-kDa lambda 2 protein of mammalian reovirus catalyzes a number of enzymatic activities in the capping of reovirus mRNA, including the transfer of GMP from GTP to the 5' end of the 5'-diphosphorylated nascent transcript, This reaction proceeds through a covalently autoguanylylated lambda 2-GMP intermediate. The smaller size of RNA capping guanylyltransferases from other organisms suggested that the lambda 2-associated guanylyltransferase would be only a part of this protein. Limited proteinase K digestion of baculovirus-expressed lambda 2 was used to generate an amino-terminal M-r 42,000 fragment that appears to be both necessary and sufficient for guanylyltransferase activity. Although lysine 226 was identified by previous biochemical studies as the active-site residue that forms a phosphoamide bond with GMP in autoguanylylated lambda 2, mutation of lysine 226 to alanine caused only a partial reduction in guanylyltransferase activity at the autoguanylylation step. Alanine substitution for other lysines within the amino-terminal region of lambda 2 identified lysine 190 as necessary for autoguanylylation and lysine 171 as an important contributor to autoguanylylation. A novel active-site motif is proposed for the RNA guanylyltransferases of mammalian reoviruses and other Reoviridae members.	Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Howard Hughes Medical Institute; Harvard University	Nibert, ML (corresponding author), Univ Wisconsin, Inst Mol Virol, 1525 Linden Dr, Madison, WI 53706 USA.				NATIONAL CANCER INSTITUTE [R01CA013202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI039533] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA13202] Funding Source: Medline; NIAID NIH HHS [R29-AI39533] Funding Source: Medline; NIGMS NIH HHS [GM18409A] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLETT NM, 1974, J VIROL, V167, P315; Bisaillon M, 1997, VIROLOGY, V236, P1, DOI 10.1006/viro.1997.8698; Bisaillon M, 1997, J BIOL CHEM, V272, P18298, DOI 10.1074/jbc.272.29.18298; Bisaillon M, 1997, J BIOL CHEM, V272, P29954, DOI 10.1074/jbc.272.47.29954; BORNSTEIN P, 1977, METHOD ENZYMOL, V11, P189; BRUENN JA, 1991, NUCLEIC ACIDS RES, V19, P217, DOI 10.1093/nar/19.2.217; CASHDOLLAR LW, 1984, VIROLOGY, V133, P191, DOI 10.1016/0042-6822(84)90438-0; CLEVELAND DR, 1986, J VIROL, V60, P307, DOI 10.1128/JVI.60.1.307-311.1986; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONG PJ, 1993, J BIOL CHEM, V268, P7256; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; FAUSNAUGH J, 1990, J BIOL CHEM, V265, P7669; FRESCO LD, 1994, P NATL ACAD SCI USA, V91, P6624, DOI 10.1073/pnas.91.14.6624; FURUICHI Y, 1976, J BIOL CHEM, V251, P5043; Hakansson K, 1998, P NATL ACAD SCI USA, V95, P1505, DOI 10.1073/pnas.95.4.1505; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; Ho CK, 1996, J VIROL, V70, P6658, DOI 10.1128/JVI.70.10.6658-6664.1996; ITOH N, 1987, J BIOL CHEM, V262, P1989; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; Luongo CL, 1998, J BIOL CHEM, V273, P23773, DOI 10.1074/jbc.273.37.23773; Luongo CL, 1997, J VIROL, V71, P8035, DOI 10.1128/JVI.71.10.8035-8040.1997; MAO ZX, 1991, VIROLOGY, V185, P377, DOI 10.1016/0042-6822(91)90785-A; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MORGAN JR, 1984, J VIROL, V52, P206, DOI 10.1128/JVI.52.1.206-214.1984; NIBERT ML, 1992, J VIROL, V66, P6408, DOI 10.1128/JVI.66.11.6408-6418.1992; NILES EG, 1993, J BIOL CHEM, V268, P24986; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; Noble S, 1997, J VIROL, V71, P2182, DOI 10.1128/JVI.71.3.2182-2191.1997; Noble S, 1997, J VIROL, V71, P7728, DOI 10.1128/JVI.71.10.7728-7735.1997; PETT DM, 1973, VIROLOGY, V52, P174, DOI 10.1016/0042-6822(73)90407-8; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; SELIGER LS, 1987, J BIOL CHEM, V262, P16289; SHATKIN AJ, 1983, DOUBLE STRANDED RNA, P43; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; STARNES MC, 1993, VIROLOGY, V193, P356, DOI 10.1006/viro.1993.1132; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; VIRGIN HW, 1991, J VIROL, V65, P6772, DOI 10.1128/JVI.65.12.6772-6781.1991; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; WONG F, 1995, BIOTECHNIQUES, V18, P1034; YEAGER M, 1996, BIOPHYS J, V70, P116	44	55	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2804	2810		10.1074/jbc.275.4.2804	http://dx.doi.org/10.1074/jbc.275.4.2804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644745	hybrid			2022-12-25	WOS:000085128000077
J	Nyitrai, M; Hild, G; Lukacs, A; Bodis, E; Somogyi, B				Nyitrai, M; Hild, G; Lukacs, A; Bodis, E; Somogyi, B			Conformational distributions and proximity relationships in the rigor complex of actin and myosin subfragment-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; RABBIT SKELETAL-MUSCLE; REGULATORY LIGHT-CHAIN; F-ACTIN; TRANSFER SPECTROSCOPY; 3-DIMENSIONAL STRUCTURE; RADIAL COORDINATE; BINDING-SITES; HEAVY-CHAIN; CONTRACTION	Cyclic conformational changes in the myosin head are considered essential for muscle contraction. We hereby show that the extension of the fluorescence resonance energy transfer method described originally by Taylor et al. (Taylor, D, L., Reidler, J., Spudich, J. A, and Stryer, L, (1981) J Cell Biol, 89, 362-367) allows determination of the position of a labeled point outside the actin filament in supramolecular complexes and also characterization of the conformational heterogeneity of an actin-binding protein while considering donor-acceptor distance distributions. Using this method we analyzed proximity relationships between two labeled points of S1 and the actin filament in the acto-S1 rigor complex. The donor (N-[[(iodoacetyl)amino]ethyl]-5-naphthylamine mine-1- sulfonate) was attached to either the catalytic domain (Cys-707) or the essential light chain (Cys-177) of S1, whereas the acceptor (5-(iodoacetamido)fluorescein) was attached to the actin filament (Cys-374), In contrast to the narrow positional distribution (assumed as being Gaussian) of Cys-707 (5 +/- 3 Angstrom), the positional distribution of Cys-177 was found to be broad (102 +/- 4 Angstrom). Such a broad positional distribution of the label on the essential light chain of S1 may be important in accommodating the helically arranged acto-myosin binding relative to the filament axis.	Univ Pecs, Sch Med, Res Grp, Hungarian Acad Sci, H-7601 Pecs, Hungary; Univ Pecs, Sch Med, Dept Biophys, H-7601 Pecs, Hungary	Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; University of Pecs; University of Pecs	Somogyi, B (corresponding author), Univ Pecs, Sch Med, Res Grp, Hungarian Acad Sci, H-7601 Pecs, Hungary.			Nyitrai, Miklos/0000-0002-6229-4337; Lukacs, Andras/0000-0001-8841-9823				Adhikari B, 1997, P NATL ACAD SCI USA, V94, P9643, DOI 10.1073/pnas.94.18.9643; AMIR D, 1986, BIOPOLYMERS, V25, P235, DOI 10.1002/bip.360250205; Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; BAY Z, 1963, P NATL ACAD SCI USA, V50, P1071, DOI 10.1073/pnas.50.6.1071; BHANDARI DG, 1985, FEBS LETT, V187, P160, DOI 10.1016/0014-5793(85)81234-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burghardt TP, 1997, P NATL ACAD SCI USA, V94, P9631, DOI 10.1073/pnas.94.18.9631; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; DOSREMEDIOS CG, 1995, J STRUCT BIOL, V115, P175, DOI 10.1006/jsbi.1995.1042; ELOFSSON A, 1991, BIOCHEMISTRY-US, V30, P9648, DOI 10.1021/bi00104a012; Feuer G., 1948, HUNGARICA ACTA PHYSIOL, V1, P150; FISHE CH, 1925, J BIOL CHEM, V66, P375; GENNIS RB, 1972, BIOCHEMISTRY-US, V11, P2509, DOI 10.1021/bi00763a020; HENRY GD, 1985, BIOCHIM BIOPHYS ACTA, V830, P233, DOI 10.1016/0167-4838(85)90279-1; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOLMES KC, 1997, CURR BIOL, V7, P112; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; Ishiwata S, 1997, BIOPHYS J, V73, P895, DOI 10.1016/S0006-3495(97)78122-0; JONTES JD, 1995, J STRUCT BIOL, V115, P119, DOI 10.1006/jsbi.1995.1037; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KASPRZAK AA, 1988, BIOCHEMISTRY-US, V27, P4512, DOI 10.1021/bi00412a044; KASPRZAK AA, 1989, BIOCHEMISTRY-US, V28, P9230, DOI 10.1021/bi00449a040; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P43; Lillo MP, 1997, BIOCHEMISTRY-US, V36, P11261, DOI 10.1021/bi9707887; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MIKI M, 1986, BIOCHIM BIOPHYS ACTA, V871, P137, DOI 10.1016/0167-4838(86)90166-4; MIKI M, 1986, BIOCHEM INT, V12, P725; MIKI M, 1984, BIOCHIM BIOPHYS ACTA, V790, P275, DOI 10.1016/0167-4838(84)90032-3; MIKI M, 1986, BIOCHIM BIOPHYS ACTA, V872, P76, DOI 10.1016/0167-4838(86)90149-4; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; Moens PDJ, 1997, BIOCHEMISTRY-US, V36, P7353, DOI 10.1021/bi962588l; MOENS PDJ, 1994, BIOCHEMISTRY-US, V33, P13102, DOI 10.1021/bi00248a020; Nyitrai M, 1999, J BIOL CHEM, V274, P12996, DOI 10.1074/jbc.274.19.12996; PARK HS, 1991, BIOCHEMISTRY-US, V30, P3189, DOI 10.1021/bi00227a005; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Roopnarine O, 1998, BIOCHEMISTRY-US, V37, P14428, DOI 10.1021/bi9808363; SELVE N, 1986, J MOL BIOL, V187, P627, DOI 10.1016/0022-2836(86)90341-4; Smyczynski C, 1997, BIOCHEMISTRY-US, V36, P13201, DOI 10.1021/bi970746i; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; TAKASHI R, 1979, BIOCHEMISTRY-US, V18, P5164, DOI 10.1021/bi00590a021; TAKASHI R, 1987, BIOCHEMISTRY-US, V26, P7471, DOI 10.1021/bi00397a041; TAYLOR DL, 1981, J CELL BIOL, V89, P362, DOI 10.1083/jcb.89.2.362; TRAYER HR, 1983, EUR J BIOCHEM, V135, P47, DOI 10.1111/j.1432-1033.1983.tb07616.x; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; XING J, 1995, BIOCHEMISTRY-US, V34, P6475, DOI 10.1021/bi00019a029; YAMAMOTO K, 1983, J BIOCHEM-TOKYO, V94, P2075, DOI 10.1093/oxfordjournals.jbchem.a134565; ZAAGER S, 1988, J BIOL CHEM, V263, P1513	54	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2404	2409		10.1074/jbc.275.4.2404	http://dx.doi.org/10.1074/jbc.275.4.2404			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644692	hybrid			2022-12-25	WOS:000085128000024
J	Andersen, MD; Busk, PK; Svendsen, I; Moller, BL				Andersen, MD; Busk, PK; Svendsen, I; Moller, BL			Cytochromes P-450 from cassava (Manihot esculenta Crantz) catalyzing the first steps in the biosynthesis of the cyanogenic glucosides linamarin and lotaustralin - Cloning, functional expression in Pichia pastoris, and substrate specificity of the isolated recombinant enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BICOLOR L MOENCH; P-HYDROXYPHENYLACETALDEHYDE OXIME; HIGH-LEVEL EXPRESSION; SORGHUM-BICOLOR; IN-VITRO; ESCHERICHIA-COLI; GLUCOSINOLATE BIOSYNTHESIS; METHYLOTROPHIC YEAST; MEMBRANE-PROTEINS; PHASE-SEPARATION	The first committed steps in the biosynthesis of the two cyanogenic glucosides linamarin and lotaustralin in cassava are the conversion of L-valine and L-isoleucine, respectively, to the corresponding oximes, Two full-length cDNA clones that encode cytochromes P-450 catalyzing these reactions have been isolated, The two cassava cytochromes P-450 are 85% identical, share 54% sequence identity to CYP79A1 from sorghum, and have been assigned CYP79D1 and CYP79D2. Functional expression has been achieved using the methylotrophic yeast, Pichia pastoris, The amount of CYP79D1 isolated from 1 liter of P. pastoris culture exceeds the amounts that putatively could be isolated from 22,000 grown-up cassava plants. Each cytochrome P-450 metabolizes L-valine as well as L-isoleucine consistent with the cooccurrence of linamarin and lotaustralin in cassava. CYP79D1 was isolated from P, pastoris, Reconstitution in lipid micelles showed that CYP79D1 has a higher k(c) value with L-valine as substrate than with L-isoleucine, which is consistent with linamarin being the major cyanogenic glucoside in cassava, Both CYP79D1 and CYP79D2 are present in the genome of cassava cultivar MCol22 in agreement with cassava being allotetraploid, CYP79D1 and CYP79D2 are actively transcribed, and production of acyanogenic cassava plants would therefore require down-regulation of both genes.	Royal Vet & Agr Univ, Plant Biochem Lab, Dept Plant Biol, DK-1871 Frederiksberg C, Denmark; Royal Vet & Agr Univ, Ctr Mol Plant Physiol PlaCe, DK-1871 Frederiksberg C, Denmark; Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	Moller, BL (corresponding author), Royal Vet & Agr Univ, Plant Biochem Lab, Dept Plant Biol, 40 Thorvaldsensvej, DK-1871 Frederiksberg C, Denmark.	blm@kvl.dk	Busk, Peter/Q-8145-2016; Møller, Birger Lindberg/H-2657-2014; Møller, Birger Lindberg/GQI-1792-2022	Busk, Peter/0000-0003-1920-636X; Møller, Birger Lindberg/0000-0002-3252-3119; Møller, Birger Lindberg/0000-0002-3252-3119				ANDERSEN MD, 1988, PROTEIN EXPRES PURIF, V13, P355; Bak S, 1998, PLANT MOL BIOL, V38, P725, DOI 10.1023/A:1006064202774; Bak S, 1998, PLANT MOL BIOL, V36, P393, DOI 10.1023/A:1005915507497; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BENNETT R, 1995, PLANTA, V196, P239, DOI 10.1007/BF00201380; Bennett RN, 1996, PLANT CELL ENVIRON, V19, P801, DOI 10.1111/j.1365-3040.1996.tb00417.x; Bennett RN, 1997, PLANT PHYSIOL, V114, P1283, DOI 10.1104/pp.114.4.1283; BENVENISTE I, 1986, BIOCHEM J, V235, P365, DOI 10.1042/bj2350365; BOKANGA M, 1994, ACTA HORTIC, V375, P1; BOKANGA M, 1992, P CBN CALI, P418; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Boyle SM, 1998, MAR ENVIRON RES, V46, P25, DOI 10.1016/S0141-1136(97)00102-5; CHEN J, 1994, MAIZE HDB; CLARE JJ, 1991, BIO-TECHNOL, V9, P455, DOI 10.1038/nbt0591-455; Cliff J, 1997, TROP MED INT HEALTH, V2, P1068, DOI 10.1046/j.1365-3156.1997.d01-178.x; COCK JH, 1982, SCIENCE, V218, P755, DOI 10.1126/science.7134971; COLBY HD, 1995, BIOCHEM PHARMACOL, V49, P1057, DOI 10.1016/0006-2952(95)98501-Y; COLLINGE DB, 1982, J EXP BOT, V33, P154, DOI 10.1093/jxb/33.1.154; COLLINGE DB, 1982, ARCH BIOCHEM BIOPHYS, V218, P38, DOI 10.1016/0003-9861(82)90318-6; CONN EE, 1980, ANNU REV PLANT PHYS, V31, P433, DOI 10.1146/annurev.pp.31.060180.002245; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; CREGG JM, 1987, BIO-TECHNOL, V5, P479, DOI 10.1038/nbt0587-479; Du LC, 1995, P NATL ACAD SCI USA, V92, P12505, DOI 10.1073/pnas.92.26.12505; DU LC, 1995, PHYTOCHEMISTRY, V39, P323, DOI 10.1016/0031-9422(94)00878-W; Durst Francis, 1995, Drug Metabolism and Drug Interactions, V12, P189; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Fregene M, 1997, THEOR APPL GENET, V95, P431, DOI 10.1007/s001220050580; GONZALEZ FJ, 1995, ANNU REV PHARMACOL, V35, P369, DOI 10.1146/annurev.pa.35.040195.002101; GOTOH O, 1992, J BIOL CHEM, V267, P83; GRINNA LS, 1989, YEAST, V5, P107, DOI 10.1002/yea.320050206; HALKIER BA, 1989, PLANT PHYSIOL, V90, P1552, DOI 10.1104/pp.90.4.1552; HALKIER BA, 1995, ARCH BIOCHEM BIOPHYS, V322, P369, DOI 10.1006/abbi.1995.1477; HALKIER BA, 1991, PLANT PHYSIOL, V96, P10, DOI 10.1104/pp.96.1.10; Jefcoate C R, 1978, Methods Enzymol, V52, P258; Jones PR, 1999, J BIOL CHEM, V274, P35483, DOI 10.1074/jbc.274.50.35483; Kahn RA, 1997, PLANT PHYSIOL, V115, P1661, DOI 10.1104/pp.115.4.1661; Kahn RA, 1996, J BIOL CHEM, V271, P32944, DOI 10.1074/jbc.271.51.32944; KOCH B, 1992, ARCH BIOCHEM BIOPHYS, V292, P141, DOI 10.1016/0003-9861(92)90062-2; KOCH BM, 1995, ARCH BIOCHEM BIOPHYS, V323, P177; Li HQ, 1996, NAT BIOTECHNOL, V14, P736, DOI 10.1038/nbt0696-736; MCFARLANE IJ, 1975, J BIOL CHEM, V250, P4708; Moller BL, 1999, BOOK SOIL P, P563; MOLLER BL, 1979, J BIOL CHEM, V254, P8575; NARTEY F, 1968, PHYTOCHEMISTRY, V7, P1307, DOI 10.1016/S0031-9422(00)85629-0; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OMURA T, 1964, J BIOL CHEM, V239, P2370; OSUNTOKUN BO, 1981, WORLD REV NUT DIET, V26, P141; PETROWITZ HF, 1967, DUNNSCHICHT CHROMATO, P626; POULOS TL, 1985, J BIOL CHEM, V260, P6122; ROMANOS MA, 1991, VACCINE, V9, P901, DOI 10.1016/0264-410X(91)90011-T; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SCHUNCK WH, 1987, ARCH MICROBIOL, V147, P245, DOI 10.1007/BF00463483; SHIMOZAWA O, 1993, J BIOL CHEM, V268, P21399; SIBBESEN O, 1995, J BIOL CHEM, V270, P3506, DOI 10.1074/jbc.270.8.3506; SIBBESEN O, 1994, P NATL ACAD SCI USA, V91, P9740, DOI 10.1073/pnas.91.21.9740; Trant JM, 1996, ARCH BIOCHEM BIOPHYS, V326, P8, DOI 10.1006/abbi.1996.0040; TYLLESKAR T, 1995, INT J EPIDEMIOL, V24, P949, DOI 10.1093/ije/24.5.949; TYLLESKAR T, 1992, LANCET, V339, P208, DOI 10.1016/0140-6736(92)90006-O; Wallsgrove RM, 1999, BOOK SOIL P, P523; WERCKREICHHART D, 1993, PLANT PHYSIOL, V102, P1291, DOI 10.1104/pp.102.4.1291; WERCKREICHHART D, 1991, ANAL BIOCHEM, V197, P125, DOI 10.1016/0003-2697(91)90367-3; XU D, 1994, BIOCHEM PHARMACOL, V48, P1421, DOI 10.1016/0006-2952(94)90566-5; FAOSTAT NUTR DATA FO	63	139	156	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1966	1975		10.1074/jbc.275.3.1966	http://dx.doi.org/10.1074/jbc.275.3.1966			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636899	hybrid			2022-12-25	WOS:000084940000062
J	Ramos-Morales, F; Dominguez, A; Romero, F; Luna, R; Multon, MC; Pintor-Toro, JA; Tortolero, M				Ramos-Morales, F; Dominguez, A; Romero, F; Luna, R; Multon, MC; Pintor-Toro, JA; Tortolero, M			Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product	ONCOGENE			English	Article						PTTG; cell cycle; proliferation; phosphorylation; Cdc2	MITOSIS-SPECIFIC PHOSPHORYLATION; TUMOR-TRANSFORMING GENE; DEPENDENT KINASES; MICROTUBULE DYNAMICS; HUMAN HOMOLOG; CDC2 KINASE; M-PHASE; PROTEINS; P34CDC2; IDENTIFICATION	We recently isolated a cDNA for hpttg, the human homolog of rat pituitary tumor transforming gene, Now we have analysed the expression of hpttg as a function of cell proliferation. hPTTG protein level is up-regulated in rapidly proliferating cells, is down-regulated in response to serum starvation or cell confluence, and is regulated in a cell cycle-dependent manner, peaking in mitosis, In addition, we show that hPTTG is phosphorylated during mitosis. Immunodepletion and in vitro phosphorylation experiments, together with the use of a specific inhibitor, indicate that Cdc2 is the kinase that phosphorylates hPTTG. These results suggest that hpttg is induced by, and may have a role in, regulatory pathways involved in the control of cell proliferation.	Univ Seville, Dept Microbiol, Fac Biol, E-41080 Seville, Spain; CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain; Rhone Poulenc Rorer, CRVA, F-94403 Vitry Sur Seine, France	University of Sevilla; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); Sanofi-Aventis; Sanofi France	Ramos-Morales, F (corresponding author), Univ Seville, Dept Microbiol, Fac Biol, Apdo 1095, E-41080 Seville, Spain.		Tortolero, Maria/K-5744-2014; Ramos-Morales, Francisco/C-5734-2008; Romero, Francisco/K-2101-2014; LUNA, ROSA/F-3974-2016; Pintor-Toro, Jose/L-4737-2014	Tortolero, Maria/0000-0003-1797-9940; Ramos-Morales, Francisco/0000-0002-1151-4547; Romero, Francisco/0000-0002-9588-6881; LUNA, ROSA/0000-0002-6131-6610; Pintor-Toro, Jose/0000-0002-9060-5243				BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; BUDAY L, 1995, ONCOGENE, V11, P1327; BUENDIA B, 1991, COLD SPRING HARB SYM, V56, P523; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HERSHKOVITZ M, 1995, P NATL ACAD SCI USA, V92, P2379, DOI 10.1073/pnas.92.6.2379; HIRAMA T, 1995, BLOOD, V86, P841; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; Jackman MR, 1997, CANCER SURV, V29, P47; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Pei L, 1998, J BIOL CHEM, V273, P5219, DOI 10.1074/jbc.273.9.5219; Pei L, 1999, J BIOL CHEM, V274, P3151, DOI 10.1074/jbc.274.5.3151; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; Reed SI, 1997, CANCER SURV, V29, P7; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; YAMASHIRO S, 1991, BIOESSAYS, V13, P563, DOI 10.1002/bies.950131103; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	43	92	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					403	409		10.1038/sj.onc.1203320	http://dx.doi.org/10.1038/sj.onc.1203320			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656688				2022-12-25	WOS:000084873700011
J	Rozovskaia, T; Rozenblatt-Rosen, O; Sedkov, Y; Burakov, D; Yano, T; Nakamura, T; Petruck, S; Ben-Simchon, L; Croce, CM; Mazo, A; Canaani, E				Rozovskaia, T; Rozenblatt-Rosen, O; Sedkov, Y; Burakov, D; Yano, T; Nakamura, T; Petruck, S; Ben-Simchon, L; Croce, CM; Mazo, A; Canaani, E			Self-association of the SET domains of human ALL-1 and of Drosophila TRITHORAX and ASH1 proteins	ONCOGENE			English	Article						SET domain; oligomerization; chromatin alterations	ACUTE LEUKEMIAS; GENE-PRODUCT; COMPLEX; CONTAINS; ENCODES; REGION	The human ALL-1 gene is involved in acute leukemia through gene fusions, partial tandem duplications or a specific deletion, Several sequence motifs within the ALL-1 protein, such as the SET domain, PHD fingers and the region with homology to DNA methyl transferase are shared with other proteins involved in transcription regulation through chromatin alterations. However, the function of these motifs is still not clear. Studying ALL-1 presents an additional challenge because the gene is the human homologue of Drosophila trithorax. The latter is a member of the trithorax-Polycomb gene family which acts to determine the body pattern of Drosophila by maintaining expression or repression of the Antennapedia-bithorax homeotic gene complex. Here we apply yeast two hybrid methodology, in vivo immunoprecipitation and in vitro 'pull down' techniques to show self association of the SET motifs of ALL-I, TRITHORAX and ASH1 proteins (Drosophila ASH1 is encoded by a tr trithorax-group gene). Point mutations in evolutionary conserved residues of TRITHORAX SET, abolish the interaction. SET-SET interactions might act in integrating the activity of ALL-1 (TRX and ASH1) protein molecules, simultaneously positioned at different maintenance elements and directing expression of the same or different target genes.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Weizmann Institute of Science; Jefferson University	Canaani, E (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Young, Richard A/F-6495-2012; Rozenblatt-Rosen, Orit/HDN-4182-2022	Young, Richard A/0000-0001-8855-8647; 	NCI NIH HHS [CA 50507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050507] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; Corda Y, 1999, NAT GENET, V21, P204, DOI 10.1038/5991; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Ekwall K, 1996, J CELL SCI, V109, P2637; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Heim S, 1995, CANC CYTOGENETICS; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Prasad R, 1997, ONCOGENE, V15, P549, DOI 10.1038/sj.onc.1201211; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; RAIMONDI SC, 1993, BLOOD, V81, P2237; Rasio D, 1996, CANCER RES, V56, P1766; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tripoulas N, 1996, GENETICS, V143, P913; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286	24	40	48	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					351	357		10.1038/sj.onc.1203307	http://dx.doi.org/10.1038/sj.onc.1203307			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656681				2022-12-25	WOS:000084873700004
J	Bauvois, B; Djavaheri-Mergny, M; Rouillard, D; Dumont, J; Wietzerbin, J				Bauvois, B; Djavaheri-Mergny, M; Rouillard, D; Dumont, J; Wietzerbin, J			Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells	ONCOGENE			English	Article						CD26 antigen; dipeptidylpeptidase IV; B-CLL; IFN; retinoic acid; STAT	DIPEPTIDYL-PEPTIDASE-IV; CHRONIC LYMPHOCYTIC-LEUKEMIA; PERIPHERAL-BLOOD; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; TYROSINE KINASES; EPITHELIAL-CELLS; ACTIVATION; STAT1; GAMMA	Interferons (IFNs alpha, beta and gamma) and all trans retinoic acid (RA) have the ability to activate genes with GAS sites. We have found that the promoter of CD26/dipeptidylpeptidase IV (DPPIV) contains a consensus GAS site TTCnnnGAA located at bp-35 to -27, and computer analysis confirmed this sequence to be a putative Stat binding site. Consistent with this finding, we show that IFNs and RA rapidly enhanced CD26 gene and protein expression in chronic B lymphocytic leukemia (B-CLL) cells. Immunoblot analyses revealed that unstimulated B-CLL cells expressed detectable levels of serine/tyrosine-phosphorylated Stat1 alpha, and RA and IFN-gamma treatment led to increased levels of tyrosine phosphorylation of Stat1 alpha and its nuclear accumulation. As shown by electrophoretic mobility shift assay, RA and IFN-gamma increased the binding of a nuclear protein to the GAS-CD26 element. Shift-Western blotting identified Stat1 alpha as the GAS-CD26 binding factor. Augmented levels of CD26 protein in malignant B cells cultured with IFNs or RA coincided with the enhancement of DPPIV activity. Taken together, our results are in favor of the IFN-/RA-mediated upregulation of CD26/DPPIV in B-CLL through the signaling pathway involving Stat1 alpha and the GAS response element of CD26 promoter.	Inst Curie, Unite 365 INSERM, F-75231 Paris 05, France; Inst Curie, Sect Rech, F-75231 Paris, France; Serv Hematol Clin, F-75231 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Bauvois, B (corresponding author), Inst Curie, Unite 365 INSERM, F-75231 Paris 05, France.		Bauvois, Brigitte/F-6776-2013; Djavaheri-Mergny, Mojgan/N-6315-2017; Djavaheri-Mergny, Mojgan/L-3890-2019	Bauvois, Brigitte/0000-0002-1751-6922; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505				ABBOTT CA, 1994, IMMUNOGENETICS, V40, P331, DOI 10.1007/BF01246674; BARON S, 1991, JAMA-J AM MED ASSOC, V266, P1375, DOI 10.1001/jama.266.10.1375; Bauvois B, 1999, BRIT J CANCER, V79, P1042, DOI 10.1038/sj.bjc.6690167; BOHM SK, 1995, BIOCHEM J, V311, P835; BUHLING F, 1995, IMMUNOL LETT, V45, P47, DOI 10.1016/0165-2478(94)00230-O; Cordero OJ, 1998, IMMUNOL LETT, V61, P7, DOI 10.1016/S0165-2478(97)00154-5; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; DE LUCA LM, 1991, FASEB J, V5, P2924; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; Djavaheri-Mergny M, 1999, BIOCHEM J, V338, P607, DOI 10.1042/0264-6021:3380607; EGUCHI K, 1989, J IMMUNOL, V142, P4233; EILERS A, 1993, MOL CELL BIOL, V13, P3245, DOI 10.1128/MCB.13.6.3245; EILERS A, 1995, MOL CELL BIOL, V15, P3579; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; Floyd-Smith G, 1999, EXP CELL RES, V246, P138, DOI 10.1006/excr.1998.4296; FOON KA, 1985, AM J MED, V78, P216, DOI 10.1016/0002-9343(85)90429-2; Gaetaniello L, 1998, HEPATOLOGY, V27, P934, DOI 10.1002/hep.510270407; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; HAFLER DA, 1985, NEW ENGL J MED, V312, P1405, DOI 10.1056/NEJM198505303122201; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; Hochhaus A, 1997, LEUKEMIA, V11, P933, DOI 10.1038/sj.leu.2400723; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; Iwata S, 1999, J EXP MED, V190, P301, DOI 10.1084/jem.190.3.301; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Kondo S, 1996, LEUKEMIA RES, V20, P357, DOI 10.1016/0145-2126(95)00159-X; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Lambeir AM, 1996, BBA-GEN SUBJECTS, V1290, P76, DOI 10.1016/0304-4165(96)00012-8; Lehtonen A, 1997, J IMMUNOL, V159, P794; Matikainen S, 1998, LEUKEMIA LYMPHOMA, V30, P63, DOI 10.3109/10428199809050930; Matikainen S, 1996, BLOOD, V88, P114; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; MCSWEENEY EN, 1993, BRIT J HAEMATOL, V85, P77, DOI 10.1111/j.1365-2141.1993.tb08648.x; MORIMOTO C, 1994, P NATL ACAD SCI USA, V91, P9960, DOI 10.1073/pnas.91.21.9960; NAKAO H, 1989, J RHEUMATOL, V16, P7; Osorio LM, 1998, LEUKEMIA LYMPHOMA, V30, P247, DOI 10.3109/10428199809057538; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RIEMANN D, 1995, CLIN EXP IMMUNOL, V100, P277; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; Silvennoinen O, 1997, APMIS, V105, P497, DOI 10.1111/j.1699-0463.1997.tb05047.x; Stecca BA, 1997, J HEPATOL, V27, P337, DOI 10.1016/S0168-8278(97)80180-8; STEFANOVIC V, 1993, IMMUNOLOGY, V80, P465; TANAKA T, 1995, INT J CANCER, V64, P326, DOI 10.1002/ijc.2910640508; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311; Yamabe T, 1997, IMMUNOLOGY, V91, P151, DOI 10.1046/j.1365-2567.1997.00230.x	51	68	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					265	272		10.1038/sj.onc.1203292	http://dx.doi.org/10.1038/sj.onc.1203292			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645005				2022-12-25	WOS:000084844400012
J	Bader, S; Walker, M; Heindrich, B; Bird, A; Bird, C; Hooper, M; Wyllie, A				Bader, S; Walker, M; Heindrich, B; Bird, A; Bird, C; Hooper, M; Wyllie, A			Somatic frameshift mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency	ONCOGENE			English	Article						MBD4; colorectal cancer; RER; mismatch repair	MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; DNA METHYLATION; RECEPTOR; CPG; CARCINOGENESIS	Defects of mismatch repair are thought to be responsible for carcinogenesis in hereditary non-polyposis colorectal cancer and about 15% of sporadic colon cancers. The phenotype is seen as microsatellite instability and is known to be caused either by mutations in mismatch repair genes or by aberrant methylation of these genes stabilizing their downregulation. Lack of repair of microsatellite sequence errors, created during replication, leads to a mutation-prone phenotype, Where mutations occur within mononucleotide tracts within exons they cause translation frameshifts, premature cessation of translation and abnormal protein expression. Such mutations have been observed in the TGF beta RII, BAX, IGFIIR, MSH3 and MSH6 genes in colon and other cancers, We describe here frameshift mutations affecting the gene for the methyl-CpG binding thymine glycosylase, MBD4, in over 40% of microsatellite unstable sporadic colon cancers. The mutations all appear heterozygous but their location would ensure truncation of the protein between the methyl-CpG binding and glycosylase domains, thus potentially generating a dominant negative effect. It is thus possible that such mutations enhance mutation frequency at other sites in these tumours, A suggestion has been made that MBD4 (MED1) mutations may lead to an increased rate of microsatellite instability but this mechanism appears unlikely due to the nature of mutations we have found.	Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie CRC Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Bader, S (corresponding author), Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie CRC Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.		Hendrich, Brian/AAG-5898-2020	Hendrich, Brian/0000-0002-0231-3073; Bird, Adrian/0000-0002-8600-0372	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Bubb VJ, 1996, ONCOGENE, V12, P2641; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 1999, MAMM GENOME, V10, P906, DOI 10.1007/s003359901112; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	19	106	110	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					8044	8047		10.1038/sj.onc.1203229	http://dx.doi.org/10.1038/sj.onc.1203229			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637515				2022-12-25	WOS:000084634600013
J	Cipollo, JF; Trimble, RB				Cipollo, JF; Trimble, RB			The accumulation of Man(6)GlcNAc(2)-PP-dolichol in the Saccharomyces cerevisiae Delta alg9 mutant reveals a regulatory role for the Alg3p alpha 1,3-man middle-arm addition in downstream oligosaccharide-lipid and glycoprotein glycan processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST EXTERNAL INVERTASE; N-LINKED GLYCOSYLATION; ENDOPLASMIC-RETICULUM; PROTEIN GLYCOSYLATION; H-1-NMR SPECTROSCOPY; IN-VIVO; BIOSYNTHESIS; GLUCOSE; GLUCOSYLATION; DEFICIENT	N-Glycans in nearly all eukaryotes are derived by transfer of a precursor Glc(3)Man(9)GlcNAc(2) from dolichol (Dol) to consensus Asn residues in nascent proteins in the endoplasmic reticulum, The Saccharomyces cerevisiae alg (asparagine-linked glycosylation) mutants fail tb synthesize oligosaccharide-lipid properly, and the alg9 mutant, accumulates Man(6)GlcNAc(2)-PP-Dol. Highfield H-1 NMR and methylation analyses of Man(6)GlcNAc(2) released with peptide-N-glycosidase F from invertase secreted by Delta alg9 yeast showed its structure to be Man alpha 1,2Man alpha 1,2Man alpha 1,3(Man alpha 1,3Man alpha 1,6)-Man beta 1, 4GlcNAc beta 1,4GlcNAc alpha/beta, confirming the addition of the alpha 1,3-linked Man to Man(5)GlcNAc(2)-PP-Dol prior to the addition of the final upper-arm al,g-linked Man. This Man(6)GlcNAc(2), is the endoglycosidase H-sensitive product of the Alg3p step. The Delta alg9 Hex7-10GlcNAc(2) elongation intermediates were released from invertase and similarly analyzed. When compared with alg3 sec18 and wild-type core mannans, Delta alg9 N-glycans reveal a regulatory role for the Alg3p-dependent alpha 1,3-linked Man in subsequent oligosaccharide-lipid and glycoprotein glycan maturation. The presence of this Man appears to provide structural information potentiating the downstream action of the endoplasmic reticulum glucosyltransferases Alg6p, Alg8p and Alg10p, glucosidases Gls1p and Gls2p, and the Golgi Och1p outerchain alpha 1,6-Man branch-initiating mannosyltransferase.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Trimble, RB (corresponding author), New York State Dept Hlth, Wadsworth Ctr, C-547, POB 509, Albany, NY 12201 USA.				NIGMS NIH HHS [GM 23900] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aebi M, 1996, GLYCOBIOLOGY, V6, P439, DOI 10.1093/glycob/6.4.439; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; Burda P, 1998, GLYCOBIOLOGY, V8, P455, DOI 10.1093/glycob/8.5.455; Burda P, 1998, J CLIN INVEST, V102, P647, DOI 10.1172/JCI2266; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CHU FK, 1978, J BIOL CHEM, V253, P8691; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GRAHAM TR, 1992, YEAST S, V8, P458; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; Imbach T, 1999, P NATL ACAD SCI USA, V96, P6982, DOI 10.1073/pnas.96.12.6982; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jakob CA, 1998, GLYCOBIOLOGY, V8, P155, DOI 10.1093/glycob/8.2.155; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JARS MU, 1995, J BIOL CHEM, V270, P24810, DOI 10.1074/jbc.270.42.24810; JENSEN JW, 1982, J BIOL CHEM, V257, P9025; Korner C, 1998, P NATL ACAD SCI USA, V95, P13200, DOI 10.1073/pnas.95.22.13200; Nakayama K, 1997, FEBS LETT, V412, P547, DOI 10.1016/S0014-5793(97)00634-0; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Reiss G, 1996, GLYCOBIOLOGY, V6, P493, DOI 10.1093/glycob/6.5.493; Reiss G, 1997, EMBO J, V16, P1164, DOI 10.1093/emboj/16.6.1164; ROMERO PA, 1997, GLYCOBIOLOGY, V7, P1045; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SNIDER MD, 1981, METHOD CELL BIOL, V23, P89, DOI 10.1016/S0091-679X(08)61493-4; STANLEY P, 1988, J BIOL CHEM, V263, P11374; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TANNER W, 1995, GLYCOPROTEINS, P475; Tarentino A L, 1978, Methods Enzymol, V50, P574; TARENTINO AL, 1987, METHOD ENZYMOL, V138, P770; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1980, J BIOL CHEM, V255, P1892; TRIMBLE RB, 1992, GLYCOBIOLOGY, V2, P57, DOI 10.1093/glycob/2.1.57; TRIMBLE RB, 1993, TRENDS GLYCOSCI GLYC, V1, P1; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; TSAI PK, 1984, P NATL ACAD SCI-BIOL, V81, P6340, DOI 10.1073/pnas.81.20.6340; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12104; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12095; VEROSTEK MF, 1991, J BIOL CHEM, V266, P5547; WAECHTER CJ, 1973, J BIOL CHEM, V248, P7570; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605	44	22	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4267	4277		10.1074/jbc.275.6.4267	http://dx.doi.org/10.1074/jbc.275.6.4267			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660594	hybrid			2022-12-25	WOS:000085288800078
J	Contestabile, R; Angelaccio, S; Maytum, R; Bossa, F; John, RA				Contestabile, R; Angelaccio, S; Maytum, R; Bossa, F; John, RA			The contribution of a conformationally mobile, active site loop to the reaction catalyzed by glutamate semialdehyde aminomutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; 1-SEMIALDEHYDE AMINOTRANSFERASE; AMINOLEVULINATE; SYNECHOCOCCUS; INTERMEDIATE	The behavior of glutamate semialdehyde amino-mutase, the enzyme that produces 4-aminolevulinate for tetrapyrrole synthesis in plants and bacteria, is markedly affected by the extent to which the central intermediate in the reaction, 4,5-diaminovalerate, is allowed to dissociate. The kinetic properties of the wild-type enzyme are compared with those of a mutant form in which a flexible loop, that reversibly plugs the entrance to the active site, has been deleted by site-directed mutagenesis. The deletion has three effects. The dissociation constant for diaminovalerate is increased approximately 100-fold. The catalytic efficiency of the enzyme, measured as k(cat)/K-m in the presence of saturating concentrations of diaminovalerate, is lowered 30-fold to 2.1 mM(-1) s(-1). During the course of the reaction, which begins with the enzyme in its pyridoxamine form, the mutant enzyme undergoes absorbance changes not seen with the wild-type enzyme under the same conditions. These are proposed to be due to abortive complex formation between the pyridoxal form of the enzyme (formed by dissociation of diaminovalerate) and glutamate semialdehyde itself.	Univ Wales, Cardiff Sch Biosci, Cardiff CF1 3US, S Glam, Wales; Univ Rome La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Rome La Sapienza, CNR, Ctr Mol Biol, I-00185 Rome, Italy	Cardiff University; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	John, RA (corresponding author), Univ Wales, Cardiff Sch Biosci, POB 911, Cardiff CF1 3US, S Glam, Wales.		Angelaccio, Sebastiana/D-2842-2011; Contestabile, Roberto/J-3467-2019	Contestabile, Roberto/0000-0002-5235-9993; Maytum, Robin/0000-0003-0395-403X				CLARKE AR, 1986, NATURE, V324, P699, DOI 10.1038/324699a0; ECCLESTON JF, 1980, ANAL BIOCHEM, V106, P73, DOI 10.1016/0003-2697(80)90120-7; GRIMM B, 1991, J BIOL CHEM, V266, P12495; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Hennig M, 1997, P NATL ACAD SCI USA, V94, P4866, DOI 10.1073/pnas.94.10.4866; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KALLEN RG, 1985, TRANSAMINASES, P37; KANNANGARA CG, 1988, TRENDS BIOCHEM SCI, V13, P139; PETERSON EA, 1954, J AM CHEM SOC, V76, P169, DOI 10.1021/ja01630a045; POGSON CI, 1972, BIOCHEM BIOPH RES CO, V46, P1043; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; PUGH CE, 1992, J BIOL CHEM, V267, P1584; PUGH CE, 1991, ANAL BIOCHEM, V198, P43, DOI 10.1016/0003-2697(91)90503-L; Shen BW, 1998, J MOL BIOL, V277, P81, DOI 10.1006/jmbi.1997.1583; SMITH MA, 1991, EUR J BIOCHEM, V202, P749, DOI 10.1111/j.1432-1033.1991.tb16429.x; Smith MA, 1998, BIOCHEMISTRY-US, V37, P319, DOI 10.1021/bi9717587; TYACKE RJ, 1993, BIOCHEM J, V293, P697, DOI 10.1042/bj2930697; TYACKE RJ, 1995, BIOCHEM J, V309, P307, DOI 10.1042/bj3090307	18	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3879	3886		10.1074/jbc.275.6.3879	http://dx.doi.org/10.1074/jbc.275.6.3879			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660540	hybrid			2022-12-25	WOS:000085288800024
J	De Cristofaro, R; De Candia, E; Rutella, S; Weitz, JI				De Cristofaro, R; De Candia, E; Rutella, S; Weitz, JI			The Asp(272)-Glu(282) region of platelet glycoprotein Ib alpha interacts with the heparin-binding site of alpha-thrombin and protects the enzyme from the heparin-catalyzed inhibition by antithrombin III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; PROTHROMBIN FRAGMENT-2; VONWILLEBRAND-FACTOR; IX COMPLEX; IDENTIFICATION; RECEPTOR; RESIDUES; DOMAIN; LOCALIZATION; GPIB	Platelet glycoprotein Ib (GpIb) mediates interaction with both von Willebrand factor and thrombin. Thrombin binds to GpIb via its heparin-binding site (HBS) (De Candia, E., De Cristofaro, R., De Marco, L., Mazzucato, M., Picozzi, M., and Landolfi, R. (1997) Thromb. Haemostasis 77,735-740; De Cristofaro, R., De Candia, E., Croce, G., Morosetti, R., and Landolfi, R, (1998) Biochem. J. 332, 643-650). To identify the thrombin-binding domain on GpIb alpha, we examined the effect of GpIb alpha(1-282), a GpIb alpha fragment released by the cobra venom mocarhagin on the heparin-catalyzed rate of thrombin inhibition by antithrombin III (AT). GpIb alpha(1-282) inhibited the reaction in a dose-dependent and competitive fashion. In contrast, the GpIb alpha(1-271) fragment, produced by exposing QpI alpha(1-282) to carboxypeptidase Y, had no effect on thrombin inhibition by the heparin-AT complex. Measurements of the apparent equilibrium constant of the GpIb alpha(1-282) binding to thrombin as a function of different salts (NaCl and tetramethyl-ammonium chloride) concentration (0.1-0.2 M) indicated a large salt dependence (Gamma(+/-) = -4.5), similar to that pertaining to the heparin binding to thrombin. The importance of thrombin HBS in its interaction with GpIb alpha was confirmed using DNA aptamers, which specifically bind to either HBS (HD22) or the fibrinogen recognition site of thrombin (HD1). HD22, but not HD1, inhibited thrombin binding to GpIb alpha(1-282). Furthermore, the proteolytic derivative gamma(T)-thrombin, which lacks the fibrinogen recognition site, binds to GpIb alpha via its intact HBS in a reaction that is inhibited by HD22. Neither alpha- nor gamma(T)-thrombin bound to GpIb alpha(1-271), suggesting that the Asp(272)-Glu(282) region of GpIb alpha may act as a "heparin-like" ligand for the thrombin DBS, thereby inhibiting heparin binding to thrombin. It was also demonstrated that intact platelets may dose-dependently inhibit the heparin-catalyzed thrombin inhibition by AT at enzyme concentrations <5 nM. Altogether, these findings show that thrombin HBS binds to the region of GpIb alpha involving the Asp(272)-GlU(282) segment, protecting the enzyme from the inactivation by the heparin-AT system.	Univ Cattolica Sacro Cuore, Haemostasis Res Ctr, Sch Med, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, Ctr Flow Cytometr Study Blood Cells, Sch Med, I-00168 Rome, Italy; McMaster Univ, Hamilton, ON L8V 1C3, Canada; Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; McMaster University; McMaster University	De Cristofaro, R (corresponding author), Univ Cattolica Sacro Cuore, Ist Semeiot Med, Ctr Ric Fisiopatol Emostasi, Largo F Vito 1, I-00168 Rome, Italy.		Rutella, Sergio/AAF-9187-2020; De Candia, Erica/K-9632-2016; De Cristofaro, Raimondo/K-3942-2018; Rutella, Sergio/AAF-9210-2020; Weitz, Jeffrey/AAD-1929-2019	De Candia, Erica/0000-0003-0942-2819; De Cristofaro, Raimondo/0000-0002-8066-8849; Rutella, Sergio/0000-0003-1970-7375; Weitz, Jeffrey/0000-0002-1092-7550				ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BODE W, 1992, PROTEIN SCI, V1, P426; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHA S, 1976, BIOCHEM PHARMACOL, V25, P2695, DOI 10.1016/0006-2952(76)90259-8; CLEMETSON KJ, 1995, SEMIN THROMB HEMOST, V21, P130, DOI 10.1055/s-2007-1000387; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; De Candia E, 1999, CIRCULATION, V99, P3308, DOI 10.1161/01.CIR.99.25.3308; de Cristofaro R, 1998, BIOCHEM J, V332, P643, DOI 10.1042/bj3320643; DeCandia E, 1997, THROMB HAEMOSTASIS, V77, P735; DECRISTOFARO R, 1993, BIOCHEM J, V289, P475, DOI 10.1042/bj2890475; DECRISTOFARO R, 1995, J MOL BIOL, V245, P447; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; EDSALL JT, 1958, BIOPHYSICAL CHEM, P151; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GRALNICK HR, 1994, P NATL ACAD SCI USA, V91, P6334, DOI 10.1073/pnas.91.14.6334; Greco NJ, 1996, BIOCHEMISTRY-US, V35, P915, DOI 10.1021/bi951504q; Greco NJ, 1996, BIOCHEMISTRY-US, V35, P906, DOI 10.1021/bi951503y; He XH, 1997, BIOCHEMISTRY-US, V36, P8969, DOI 10.1021/bi9704717; HESS D, 1991, EUR J BIOCHEM, V199, P389, DOI 10.1111/j.1432-1033.1991.tb16135.x; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Jandrot-Perrus M, 1999, THROMB HAEMOSTASIS, V81, P316; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; LEVINA NB, 1984, J CHROMATOGR, V286, P207, DOI 10.1016/S0021-9673(01)99187-3; LI CQ, 1997, BLOOD S, V90, P430; Liaw PCY, 1998, J BIOL CHEM, V273, P8932, DOI 10.1074/jbc.273.15.8932; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; NORDENMAN B, 1978, BIOCHEMISTRY-US, V17, P3339, DOI 10.1021/bi00609a026; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1995, BIOPHYS J, V68, P786, DOI 10.1016/S0006-3495(95)80254-7; RYDEL TJ, 1994, J BIOL CHEM, V269, P22000; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SOBEL M, 1991, J CLIN INVEST, V87, P1787, DOI 10.1172/JCI115198; Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; WU QY, 1992, J BIOL CHEM, V267, P24408	50	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3887	3895		10.1074/jbc.275.6.3887	http://dx.doi.org/10.1074/jbc.275.6.3887			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660541	Green Accepted, hybrid			2022-12-25	WOS:000085288800025
J	Nurse, P; Bahng, S; Mossessova, E; Marians, KJ				Nurse, P; Bahng, S; Mossessova, E; Marians, KJ			Mutational analysis of Escherichia coli topoisomerase IV. ATPase negative mutants of ParE induce hyper-DNA cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; DEPENDENT REACTIONS; NALIDIXIC-ACID; GYRASE; MECHANISM; PURIFICATION; REPLICATION; TRANSPORT; RESIDUE; SUBUNIT	ParE is the ATP-binding subunit of topoisomerase TV (Topo TV). During topoisomerization, the ATP-binding and hydrolysis cycle must be coordinated with the cycle of DNA cleavage and religation. We have isolated three dominant-negative mutant alleles of parE that encode ParE proteins that fail to hydrolyze ATP when reconstituted with ParC to form Topo IV. ParE G110S Topo IV and ParE S123L Topo IV failed to bind ATP at all, whereas ParE T201A could bind ATP. All three mutant Topo TV proteins exhibited an elevated level of spontaneous DNA cleavage that could be associated with a decreased rate of DNA resealing. In ParE T201A Topo TV, this defect appeared to result from an increased likelihood that the tetrameric enzyme would fall apart after DNA cleavage. Thus, while ATP is not required for DNA cleavage, the properties of these mutant enzymes suggests that ATP-hydrolysis informs DNA religation.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mol Biol Grad Program, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University	Nurse, P (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benedetti P, 1997, J BIOL CHEM, V272, P12132, DOI 10.1074/jbc.272.18.12132; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Caron PR, 1999, METH MOL B, V94, P279; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine C, 1998, BBA-GENE STRUCT EXPR, V1400, P29, DOI 10.1016/S0167-4781(98)00126-2; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; Marians KJ, 1997, J BIOL CHEM, V272, P9401; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; Mossessova E, 2000, J BIOL CHEM, V275, P4099, DOI 10.1074/jbc.275.6.4099; ODea MH, 1996, J BIOL CHEM, V271, P9723, DOI 10.1074/jbc.271.16.9723; PENG H, 1993, J BIOL CHEM, V268, P24481; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Schultz P, 1996, P NATL ACAD SCI USA, V93, P5936, DOI 10.1073/pnas.93.12.5936; Smith CV, 1998, BIOCHEMISTRY-US, V37, P9658, DOI 10.1021/bi9801309; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	25	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4104	4111		10.1074/jbc.275.6.4104	http://dx.doi.org/10.1074/jbc.275.6.4104			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660570	hybrid			2022-12-25	WOS:000085288800054
J	Roy, R; Biswas, T; Lee, JC; Mitra, S				Roy, R; Biswas, T; Lee, JC; Mitra, S			Mutation of a unique aspartate residue abolishes the catalytic activity but not substrate binding of the mouse N-methylpurine-DNA glycosylase (MPG)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; ESCHERICHIA-COLI; FPG PROTEIN; DIRECT IDENTIFICATION; CRYSTAL-STRUCTURE; ENDONUCLEASE-III; PURIFICATION; MECHANISM; CLONING; SPECIFICITY	N-Methylpurine-DNA glycosylase (MPG) initiates base excision repair in DNA by removing a variety of alkylated purine adducts, Although Asp was identified as the active site residue in various DNA glycosylases based on the crystal structure, Glu-125 in human MPG: (Glu-145 in mouse MPG) was recently proposed to be the catalytic residue. Mutational analysis for all Asp residues in a truncated, fully active MPG protein showed that only Asp-152 (Asp-132 in the human protein), which is located near the active site, is essential for catalytic activity. However, the substrate binding was not affected in the inactive Glu-152, Asn-152, and Ala-152 mutants. Furthermore, mutation of Asp-152 did not significantly affect the intrinsic tryptophan fluorescence of the enzyme and the far UV CD spectra, although a small change in the near UV CD spectra of the mutants suggests localized conformational change in the aromatic residues. We propose that in addition to Glu-145 in mouse MPG, which functions as the activator of a water molecule for nucleophilic attack, Asp-152 plays an essential role either by donating a proton to the substrate base and, thus, facilitating its release or by stabilizing the steric configuration of the active site pocket.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Roy, R (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6136C Med Res Bldg, Galveston, TX 77555 USA.		Lee, James C/A-7849-2009		NATIONAL CANCER INSTITUTE [R01CA053791] Funding Source: NIH RePORTER; NCI NIH HHS [CA53791] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P59; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Krokan HE, 1997, BIOCHEM J, V325, P1; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LARSON K, 1985, MUTAT RES, V233, P211; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Leblanc B, 1994, Methods Mol Biol, V30, P1; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; Mitra S, 1997, MOL CELLS, V7, P305; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; PAIN R, 1996, CURRENT PROTOCOLS PR, V2; Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Sidorkina OM, 1998, NUCLEIC ACIDS RES, V26, P5351, DOI 10.1093/nar/26.23.5351; Singer B, 1997, CHEM RES TOXICOL, V10, P713, DOI 10.1021/tx970011e; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	30	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4278	4282		10.1074/jbc.275.6.4278	http://dx.doi.org/10.1074/jbc.275.6.4278			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660595	hybrid			2022-12-25	WOS:000085288800079
J	Rubino, M; Miaczynska, M; Lippe, R; Zerial, M				Rubino, M; Miaczynska, M; Lippe, R; Zerial, M			Selective membrane recruitment of EEA1 suggests a role in directional transport of clathrin-coated vesicles to early endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; GTP-BINDING PROTEIN; RAB PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOCYTIC VESICLES; AUTOANTIGEN EEA1; FUSION INVITRO; COMPLEX; DOCKING; CELLS	The molecular mechanisms ensuring directionality of endocytic membrane trafficking between transport vesicles and target organelles still remain poorly characterized. We have been investigating the function of the small GTPase Rab5 in early endocytic transport. In vitro studies have demonstrated a role of Rab5 in two membrane fusion events: the heterotypic fusion between plasma membrane-derived clathrin-coated vesicles (CCVs) and early endosomes and in the homotypic fusion between early endosomes. Several Rab5 effecters are required in homotypic endosome fusion, including EEA1, which mediates endosome membrane docking, a's well as Rabaptin-5.Rabex-5 complex and phosphatidylinositol 3-kinase hVPS34. In this study we have examined the localization and function of Rab5 and its effecters in heterotypic fusion in vitro. We report that the presence of active Rab5 is necessary on both CCVs and early endosomes for a heterotypic fusion event to occur. This process requires EEA1 in addition to the Rabaptin-5 complex. However, whereas Rab5 and Rabaptin-5 are symmetrically distributed between CCVs and early endosomes, EEA1 is recruited selectively onto the membrane of early endosomes. Our results suggest that EEA1 is a tethering molecule that provides directionality to vesicular transport from the plasma membrane to the early endosomes.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	European Molecular Biology Laboratory (EMBL); Max Planck Society	Zerial, M (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	zerial@embl-heidelberg.de		Lippe, Roger/0000-0001-5066-3070; Miaczynska, Marta/0000-0003-0031-5267				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ARAKI S, 1990, J BIOL CHEM, V265, P13007; Barbieri MA, 1998, J BIOL CHEM, V273, P25850, DOI 10.1074/jbc.273.40.25850; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; DEHOOP MJ, 1994, NEURON, V13, P11, DOI 10.1016/0896-6273(94)90456-1; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Tang BL, 1998, J BIOL CHEM, V273, P6944, DOI 10.1074/jbc.273.12.6944; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; ULLRICH O, 1995, METHOD ENZYMOL, V257, P243; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	48	125	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3745	3748		10.1074/jbc.275.6.3745	http://dx.doi.org/10.1074/jbc.275.6.3745			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660521	hybrid			2022-12-25	WOS:000085288800005
J	Svergun, DI; Malfois, M; Koch, MHJ; Wigneshweraraj, SR; Buck, M				Svergun, DI; Malfois, M; Koch, MHJ; Wigneshweraraj, SR; Buck, M			Low resolution structure of the sigma 54 transcription factor revealed by x-ray solution scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE-SCATTERING; DIRECT SHAPE DETERMINATION; COLI RNA-POLYMERASE; SYNCHROTRON RADIATION; SIGMA(N) SIGMA(54); PROMOTER DNA; DOMAINS; BIOPOLYMERS; BINDING	The sigma 54 RNA polymerase holoenzyme functions in enhancer-dependent transcription. The structural organization of the sigma 54 subunit of bacterial RNA polymerase in solution is analyzed by synchrotron x-ray scattering. Scattering patterns are collected from the full-length protein and from a large fragment able to bind the core RNA polymerase, and their low resolution shapes are restored using two ab initio shape determination techniques. The sigma 54 subunit is a highly elongated particle, and the core binding fragment can be unambiguously positioned inside the full-length protein. The boomerang-like shape of the core binding fragment is similar to that of the atomic model of a fragment of the Escherichia coli sigma 70 protein, indicating that, although the sigma 54 and sigma 70 factors are unrelated by primary sequence, they may share some structural similarity. Potential DNA binding surfaces of sigma 54 are also predicted by comparison with the sigma 54 core binding fragment.	DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Cristallog, Moscow 117333, Russia; Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2BB, England	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; Imperial College London	Svergun, DI (corresponding author), DESY, European Mol Biol Lab, Hamburg Outstn, Notkestr 85, D-22603 Hamburg, Germany.		Malfois, Marc/L-2974-2014	Malfois, Marc/0000-0001-5231-1896; Svergun, Dmitri/0000-0003-0830-5696				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; CANNON W, 1994, MOL MICROBIOL, V11, P227, DOI 10.1111/j.1365-2958.1994.tb00303.x; Cannon WV, 1997, P NATL ACAD SCI USA, V94, P5006, DOI 10.1073/pnas.94.10.5006; Casaz P, 1997, P NATL ACAD SCI USA, V94, P12145, DOI 10.1073/pnas.94.22.12145; Feigin L. A., 1987, STRUCTURE ANAL SMALL, P839; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; Missailidis S, 1997, MOL MICROBIOL, V24, P653, DOI 10.1046/j.1365-2958.1997.3691738.x; Mooney RA, 1999, CELL, V98, P687, DOI 10.1016/S0092-8674(00)81483-X; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Shannon C., 1964, MATH THEORY COMMUNIC; STUHRMANN HB, 1970, Z PHYS CHEM NEUE FOL, V72, P177, DOI 10.1524/zpch.1970.72.4_6.177; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1997, J APPL CRYSTALLOGR, V30, P798, DOI 10.1107/S0021889897001714; SVERGUN DI, 1991, ACTA CRYSTALLOGR A, V47, P736, DOI 10.1107/S0108767391006414; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120	32	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4210	4214		10.1074/jbc.275.6.4210	http://dx.doi.org/10.1074/jbc.275.6.4210			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660585	hybrid			2022-12-25	WOS:000085288800069
J	Xu, AD; Narayanan, N				Xu, AD; Narayanan, N			Reversible inhibition of the calcium-pumping ATPase in native cardiac sarcoplasmic reticulum by a calmodulin-binding protein - Evidence for calmodulin-dependent regulation of the V-max of calcium transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RYANODINE RECEPTOR; SKELETAL-MUSCLE; CA-ATPASE; VENTRICULAR MYOCYTES; RELEASE CHANNEL; HEART-MUSCLE; KINASE-II; PHOSPHORYLATION; PHOSPHOLAMBAN; MECHANISM	Calmodulin (CaM) and Ca2+/CaM-dependent protein kinase II (CaM kinase) are tightly associated with cardiac sarcoplasmic reticulum (SR) and are implicated in the regulation of transmembrane Ca2+ cycling. In order to assess the importance of membrane-associated CaM in modulating the Ca2+ pump (Ca2+-ATPase) function of BR, the present study investigated the effects of a synthetic, high affinity CaM-binding peptide (CaM BP; amino acid sequence, LKWKKLLKLLKKLLKLG) on the ATP-energized Ca2+ uptake, Ca2+-stimulated ATP hydrolysis, and CaM kinase-mediated protein phosphorylation in rabbit cardiac SR vesicles. The results revealed a strong concentration-dependent inhibitory action of CaM: BP on Ca2+ uptake and Ca2+-ATPase activities of SR (50% inhibition at similar to 2-3 mu M CaM BP), The inhibition, which followed the association of CaM BP with its SR target(s), was of rapid onset (manifested within 30 s) and was accompanied by a decrease in V-max of Ca2+ uptake, unaltered K-0.5 for Ca2+ activation of Ca2+ transport, and a 10-fold decrease in the apparent affinity of the Ca2+ ATPase for its substrate, ATP, Thus, the mechanism of inhibition involved alterations at the catalytic site but not the Ca2+-binding sites of the Ca2+-ATPase. Endogenous CaM kinase-mediated phosphorylation of Ca2+ ATPase, phospholamban, and ryanodine receptor-Ca2+ release channel was also strongly inhibited by CaM BP, The inhibitory action of CaM BP on SR Ca2+ pump function and protein phosphorylation was fully reversed by exogenous CaM (1-3 mu M). A peptide inhibitor of CaM kinase markedly attenuated the ability of CaM to reverse CAM BP-mediated inhibition of Ca2+ transport. These findings suggest a critical role for membrane-bound CaM in controlling the velocity of Ca2+ pumping in native cardiac SR. Consistent with its ability to inhibit SR Ca2+ pump function, CaM BP (1-2.5 mu M) caused marked depression of contractility and diastolic dysfunction in isolated perfused, spontaneously beating rabbit heart preparations. Full or partial recovery of contractile function occurred gradually following withdrawal of CaM BP from the perfusate, presumably due to slow dissociation of CaM BP from its target sites promoted by endogenous cytosolic CaM.	Univ Western Ontario, Dept Physiol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Narayanan, N (corresponding author), Univ Western Ontario, Dept Physiol, Med Sci Bldg, London, ON N6A 5C1, Canada.	nnarayan@physiology.uwo.ca						Alkayed NJ, 1996, FASEB J, V10, P1734; Allen BG, 1996, MOL CELL BIOCHEM, V155, P91; BAKER KJ, 1995, BIOCHEMISTRY-US, V34, P3596, DOI 10.1021/bi00011a014; BERS DM, 1991, EXCITATION CONTRACTI; BRUAN AP, 1995, ANNU REV PHYSIOL, V57, P417; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; COLYER J, 1993, CARDIOVASC RES, V27, P1766, DOI 10.1093/cvr/27.10.1766; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; DEMEIS L, 1981, SARCOPLASMIC RETICUL; duBell WH, 1996, J PHYSIOL-LONDON, V493, P793, DOI 10.1113/jphysiol.1996.sp021423; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FEHER JJ, 1990, CALCIUM HEART, P199; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; Jones DL, 1998, AM J PHYSIOL-HEART C, V274, pH98, DOI 10.1152/ajpheart.1998.274.1.H98; Kadambi VJ, 1997, BIOCHEM BIOPH RES CO, V239, P1, DOI 10.1006/bbrc.1997.7340; Li L, 1997, J PHYSIOL-LONDON, V501, P17, DOI 10.1111/j.1469-7793.1997.017bo.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON LJ, 1991, HEART CARDIOVASCULAR, P1203; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAHANEY JE, 1991, BIOCHEMISTRY-US, V30, P7171, DOI 10.1021/bi00243a019; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; NARAYANAN N, 1981, BIOCHIM BIOPHYS ACTA, V678, P442, DOI 10.1016/0304-4165(81)90126-4; NARAYANAN N, 1991, BIOCHIM BIOPHYS ACTA, V1070, P83, DOI 10.1016/0005-2736(91)90149-3; Netticadan T, 1996, ARCH BIOCHEM BIOPHYS, V333, P368, DOI 10.1006/abbi.1996.0403; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; Osada M, 1998, AM J PHYSIOL-HEART C, V274, pH2025, DOI 10.1152/ajpheart.1998.274.6.H2025; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; Reddy LG, 1999, BIOPHYS J, V76, P3058, DOI 10.1016/S0006-3495(99)77458-8; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Shorina EA, 1997, BIOCHEMISTRY-US, V36, P13455, DOI 10.1021/bi9709349; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Snajdrova L, 1998, J BIOL CHEM, V273, P28032, DOI 10.1074/jbc.273.43.28032; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; TUANA BS, 1984, J BIOL CHEM, V259, P6979; VOSS JC, 1995, BIOCHEMISTRY-US, V34, P930, DOI 10.1021/bi00003a027; Waxham MN, 1998, J BIOL CHEM, V273, P17579, DOI 10.1074/jbc.273.28.17579; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Xu A, 1998, AM J PHYSIOL-HEART C, V275, pH2087, DOI 10.1152/ajpheart.1998.275.6.H2087; Xu A, 1997, J MOL CELL CARDIOL, V29, P405, DOI 10.1006/jmcc.1996.0284; XU A, 1993, J BIOL CHEM, V268, P8394; Xu AD, 1999, BIOCHEM BIOPH RES CO, V258, P66, DOI 10.1006/bbrc.1999.0579	50	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4407	4416		10.1074/jbc.275.6.4407	http://dx.doi.org/10.1074/jbc.275.6.4407			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660612	hybrid			2022-12-25	WOS:000085288800096
J	Lawe, DC; Patki, V; Heller-Harrison, R; Lambright, D; Corvera, S				Lawe, DC; Patki, V; Heller-Harrison, R; Lambright, D; Corvera, S			The FYVE domain of early endosome antigen 1 is required for both phosphatidylinositol 3-phosphate and Rab5 binding - Critical role of this dual interaction for endosomal localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCYTIC PATHWAY; PHOSPHOINOSITIDE 3-KINASE; AUTOANTIGEN EEA1; MEMBRANE-FUSION; WORTMANNIN; TRAFFICKING; INHIBITOR; RECEPTOR; FINGERS; PROTEIN	Early endosome antigen 1 (EEA1) is 170-kDa polypeptide required for endosome fusion. EEA1 binds to both phosphtidylinositol 3-phosphate (PtdIns3P) and to Rab5-GTP in vitro, but the functional role of this dual interaction at the endosomal membrane is unclear. Here we have determined the structural features in EEA1 required for binding to these ligands, We have found that the FYVE domain is critical for both PtdIns3P and Rab5 binding, Whereas PtdIns3P binding only required the FYVE domain, Rab5 binding additionally required a 30-amino acid region directly adjacent to the FYVE domain. Microinjection of glutathione S-transferase fusion constructs into Cos cells revealed that the FYVE domain alone is insufficient for localization to cellular membranes; the upstream 30-amino acid region required for Rab5 binding must also be present for endosomal binding. The importance of Rab5 in membrane binding of EEA1 is underscored by the finding that the increased expression of wild-type Rab5 increases endosomal binding of EEA1 and decreases its dependence on PtdIns3P, Thus, the levels of Rab5 are rate-limiting for the recruitment of EEA1 to endosome membranes. PtdIns3P may play a role in modulating the Rab5 EEA1 interaction.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Corvera, S (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 373 Plantat St, Worcester, MA 01605 USA.				NIDDK NIH HHS [DK54479] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054479] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Burd CG, 1998, SEMIN CELL DEV BIOL, V9, P527, DOI 10.1006/scdb.1998.0255; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Chao DS, 1999, J CELL BIOL, V144, P869, DOI 10.1083/jcb.144.5.869; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HANSEN SH, 1995, J BIOL CHEM, V270, P28425; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; Kundra A, 1998, J BIOL CHEM, V273, P3848, DOI 10.1074/jbc.273.7.3848; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Li GP, 1996, BIOCELL, V20, P325; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Reaves BJ, 1996, J CELL SCI, V109, P749; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sollner TH, 1996, EXPERIENTIA, V52, P1021; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9	30	163	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3699	3705		10.1074/jbc.275.5.3699	http://dx.doi.org/10.1074/jbc.275.5.3699			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652369	hybrid			2022-12-25	WOS:000085146500091
J	Tani, M; Okino, N; Mitsutake, S; Tanigawa, T; Izu, H; Ito, M				Tani, M; Okino, N; Mitsutake, S; Tanigawa, T; Izu, H; Ito, M			Purification and characterization of a neutral ceramidase from mouse liver - A single protein catalyzes the reversible reaction in which ceramide is both hydrolyzed and synthesized	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ACID CERAMIDASE; ENZYMATIC-SYNTHESIS; N-DEACYLASE; GLYCOSPHINGOLIPIDS; IDENTIFICATION; BIOSYNTHESIS; CLONING; DISEASE; SKIN	report here a novel ceramidase that was purified more than 150,000-fold from the membrane fraction of mouse liver. The enzyme was a monomeric polypeptide having a molecular mass of 94 kDa and was highly glycosylated with N-glycans, The amino acid sequence of a fragment obtained from the purified enzyme was homologous to those deduced from the genes encoding an alkaline ceramidase of Pseudomonas aeruginosa and a hypotheical protein of the slime mold Dictyostelium discoideum. However, no significant sequence similarities were found in other known functional proteins including acid ceramidases of humans and mice. The enzyme hydrolyzed various N-acylsphingosines but not galactosylceramide, sulfatide, GM1a, or sphingomyelin. The enzyme exhibited the highest activity around pH 7.5 and was thus identified as a type of neutral ceramidase, The apparent K-m and V-max values for C12-4-nitrobenzo-2-oxa-1,3-diazole-ceramide and C16-C-14-ceramide were 22.3 mu M and 29.1 mu mol/min/mg and 72.4 mu M and 3.6 mu mol/ min/mg, respectively. This study also clearly demonstrated that the purified 94-kDa ceramidase catalyzed the condensation of fatty acid to sphingosine to generate ceramide, but did not catalyze acyl-CoA-dependent acyl-transfer reaction.	Kyushu Univ, Dept Biosci & Biotechnol, Dept Bioresource & Bioenvironm Sci, Grad Sch,Higashi Ku, Fukuoka 8128581, Japan; Takara Shuzo Co Ltd, Biotechnol Res Labs, Otsu, Shiga 5202134, Japan	Kyushu University; Takara Holdings Inc.	Ito, M (corresponding author), Kyushu Univ, Dept Biosci & Biotechnol, Dept Bioresource & Bioenvironm Sci, Grad Sch,Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.		Okino, Nozomu/AAY-2635-2021; Mitsutake, Susumu/A-4082-2012; Ito, Makoto/Q-6164-2019; Tanigawa, Tetsuya/J-6131-2019	Tanigawa, Tetsuya/0000-0002-9305-1637; ito, Makoto/0000-0003-3159-7818; Tani, Motohiro/0000-0003-4316-8260				AL BJM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P245, DOI 10.1016/0005-2760(89)90274-9; BENDALL DS, 1960, BIOCHEM J, V74, P444, DOI 10.1042/bj0740444; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; CHEN WW, 1981, ARCH BIOCHEM BIOPHYS, V208, P444, DOI 10.1016/0003-9861(81)90531-2; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; GATT S, 1963, J BIOL CHEM, V238, P3131; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HASSLER DF, 1993, ADV LIPID RES, V26, P49; ITO M, 1995, J BIOL CHEM, V270, P24370, DOI 10.1074/jbc.270.41.24370; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; Mitsutake S, 1998, J BIOCHEM-TOKYO, V123, P859; Mitsutake S, 1997, ANAL BIOCHEM, V247, P52, DOI 10.1006/abio.1997.2022; MOORE GL, 1969, ANAL BIOCHEM, V32, P122, DOI 10.1016/0003-2697(69)90111-0; MORELL P, 1972, J LIPID RES, V13, P203; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; NILSSON A, 1969, BIOCHIM BIOPHYS ACTA, V176, P339, DOI 10.1016/0005-2760(69)90192-1; OHSAWA K, 1983, ANAL BIOCHEM, V135, P409, DOI 10.1016/0003-2697(83)90703-0; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; ROSENGREN B, 1987, J NEUROCHEM, V49, P834, DOI 10.1111/j.1471-4159.1987.tb00969.x; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Tani M, 1999, J BIOCHEM-TOKYO, V125, P746; Tani M, 1998, ANAL BIOCHEM, V263, P183, DOI 10.1006/abio.1998.2781; WANG E, 1991, J BIOL CHEM, V266, P14486; YADA Y, 1995, J BIOL CHEM, V270, P12677, DOI 10.1074/jbc.270.21.12677; YAVIN E, 1969, BIOCHEMISTRY-US, V8, P1692, DOI 10.1021/bi00832a052	29	71	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3462	3468		10.1074/jbc.275.5.3462	http://dx.doi.org/10.1074/jbc.275.5.3462			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652340	hybrid			2022-12-25	WOS:000085146500062
J	Aizencang, GI; Bishop, DF; Forrest, D; Astrin, KH; Desnick, RJ				Aizencang, GI; Bishop, DF; Forrest, D; Astrin, KH; Desnick, RJ			Uroporphyrinogen III synthase - An alternative promoter controls erythroid-specific expression in the murine gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; CONGENITAL ERYTHROPOIETIC PORPHYRIA; PORPHOBILINOGEN DEAMINASE GENE; MOUSE ERYTHROLEUKEMIA-CELLS; TRANSCRIPTION FACTOR GATA-1; HUMAN FERROCHELATASE GENE; FULL-LENGTH CDNA; NUCLEOTIDE-SEQUENCE; 5-AMINOLEVULINATE SYNTHASE; COPROPORPHYRINOGEN OXIDASE	Uroporphyrinogen III synthase (URO-synthase, EC 4.2.1.75) is the fourth enzyme of the heme biosynthetic pathway and is the defective enzyme in congenital erythropoietic porphyria. To investigate the erythroid-specific expression of murine URO-synthase, the cDNA and similar to 24-kilobase genomic sequences were isolated and characterized. Three alternative transcripts were identified containing different 5'-untranslated regions (5'-UTRs), but identical coding exons 2B through 10. Transcripts with 5'-UTR exon IA alone or fused to exon 1B were ubiquitously expressed (housekeeping), whereas transcripts with 5'-UTR exon 2A were only present in erythroid cells (erythroid-specific). Analysis of the TATA-less housekeeping promoter upstream of exon 1A revealed binding sites for ubiquitously expressed transcription factors Spl, NF1, AP1, Oct1, and NRF2. The TATA-less erythroid-specific promoter upstream of exon 2A had nine putative GATA1 erythroid enhancer binding sites. Luciferase promoter/reporter constructs transfected into NIH 3T3 and mouse erythroleukemia cells indicated that the housekeeping promoter was active in both cell lines, while the erythroid promoter was active only in erythroid cells. Site-specific mutagenesis of the first GATA1 binding site markedly reduced luciferase activity in K562 cells (<5% of wild type). Thus, housekeeping and erythroid-specific transcripts are expressed from alternative promoters of a single mouse URO-synthase gene.	CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Desnick, RJ (corresponding author), CUNY Mt Sinai Sch Med, Dept Human Genet, 5th Ave & 100th St, New York, NY 10029 USA.	rjdesnick@msvax.mssm.edu	Bishop, David F./X-4102-2019		NCRR NIH HHS [5 MO1 RR00071] Funding Source: Medline; NIDDK NIH HHS [2 RO1 DK40895, 5 RO1 DK26824] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026824, R01DK040895] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aizencang GI, 1999, AM J HUM GENET, V65, pA280; ALWAN AF, 1989, BIOCHEM J, V264, P397, DOI 10.1042/bj2640397; ASTRIN KH, 1991, HUM GENET, V87, P18, DOI 10.1007/BF01213085; BATTERSBY AR, 1982, J CHEM SOC PERK T 1, P2413, DOI 10.1039/p19820002413; BATTERSBY AR, 1982, J CHEM SOC PERK T 1, P2427, DOI 10.1039/p19820002427; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BISHOP DF, 1990, NUCLEIC ACIDS RES, V18, P7187, DOI 10.1093/nar/18.23.7187; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BISHOP TR, 1991, AM J HUM GENET, V49, P425; Bishop TR, 1996, NUCLEIC ACIDS RES, V24, P2511, DOI 10.1093/nar/24.13.2511; BOGORAD L, 1958, J BIOL CHEM, V233, P510; BOULECHFAR S, 1992, HUM GENET, V88, P320, DOI 10.1007/BF00197267; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHAPMAN VM, 1994, MAMM GENOME, V5, P741, DOI 10.1007/BF00426087; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; CONBOY JG, 1992, J BIOL CHEM, V267, P18753; DELFAULARUE MH, 1994, HUM MOL GENET, V3, P1325, DOI 10.1093/hmg/3.8.1325; Desnick RJ, 1998, SEMIN LIVER DIS, V18, P77, DOI 10.1055/s-2007-1007143; DIEKS P, 1990, BIOSYNTHESIS HEME CH, P201; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; Furukawa T, 1997, BIOCHEM MOL BIOL INT, V41, P1161; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Gong QH, 1996, MOL CELL BIOL, V16, P6055; GRANDCHAMP B, 1987, EUR J BIOCHEM, V162, P105, DOI 10.1111/j.1432-1033.1987.tb10548.x; HART GJ, 1985, BIOCHEM J, V232, P151, DOI 10.1042/bj2320151; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Hromas R, 1996, CURR TOP MICROBIOL, V211, P159; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Kappas A., 1995, METABOLIC MOL BASES, V2, P2103; KAYA AH, 1994, GENOMICS, V19, P242, DOI 10.1006/geno.1994.1054; KOHASHI M, 1984, BIOCHEM J, V220, P755, DOI 10.1042/bj2200755; LEVIN EY, 1968, SCIENCE, V161, P907, DOI 10.1126/science.161.3844.907; Lin HH, 1996, CURR TOP MICROBIOL, V211, P79; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Minta JO, 1998, GENE, V208, P17, DOI 10.1016/S0378-1119(97)00632-X; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MoranJimenez MJ, 1996, AM J HUM GENET, V58, P712; Mu WT, 1999, MOL BRAIN RES, V67, P137, DOI 10.1016/S0169-328X(99)00049-2; PEVNY L, 1995, DEVELOPMENT, V121, P163; PORCHER C, 1995, J BIOL CHEM, V270, P17368, DOI 10.1074/jbc.270.29.17368; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RIDDLE RD, 1989, P NATL ACAD SCI USA, V86, P792, DOI 10.1073/pnas.86.3.792; ROMANA M, 1987, NUCLEIC ACIDS RES, V15, P7343, DOI 10.1093/nar/15.18.7343; ROMEO G, 1970, Biochemical Genetics, V4, P659, DOI 10.1007/BF00486379; ROMEO G, 1969, P NATL ACAD SCI USA, V63, P856, DOI 10.1073/pnas.63.3.856; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SHOOLINGINJORDAN PM, 1995, J BIOENERG BIOMEMBR, V27, P181, DOI 10.1007/BF02110033; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SMYTHE E, 1988, BIOCHEM J, V253, P275, DOI 10.1042/bj2530275; Takahashi S, 1998, BLOOD, V92, P3436, DOI 10.1182/blood.V92.9.3436.421k13_3436_3444; TAKETANI S, 1992, EUR J BIOCHEM, V205, P217, DOI 10.1111/j.1432-1033.1992.tb16771.x; TAKETANI S, 1995, GENOMICS, V29, P698, DOI 10.1006/geno.1995.9949; Tanabe A, 1997, BIOCHEM BIOPH RES CO, V233, P729, DOI 10.1006/bbrc.1997.6532; Teerawatanasuk N, 1998, MOL BRAIN RES, V55, P61, DOI 10.1016/S0169-328X(97)00364-1; TSAI SF, 1987, J BIOL CHEM, V262, P1268; TSAI SF, 1988, P NATL ACAD SCI USA, V85, P7049, DOI 10.1073/pnas.85.19.7049; TUGORES A, 1994, J BIOL CHEM, V269, P30789; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARNER CA, 1992, J CLIN INVEST, V89, P693, DOI 10.1172/JCI115637; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; XU WM, 1995, GENOMICS, V26, P556, DOI 10.1016/0888-7543(95)80175-L; XU WM, 1995, J CLIN INVEST, V95, P905, DOI 10.1172/JCI117742; YOO HW, 1993, GENOMICS, V15, P21, DOI 10.1006/geno.1993.1005	67	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2295	2304		10.1074/jbc.275.4.2295	http://dx.doi.org/10.1074/jbc.275.4.2295			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644678	hybrid			2022-12-25	WOS:000085128000010
J	Wynn, RM; Song, JL; Chuang, DT				Wynn, RM; Song, JL; Chuang, DT			GroEL/GroES promote dissociation/reassociation cycles of a heterodimeric intermediate during alpha(2)beta(2) protein assembly - Iterative annealing at the quaternary structure level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KETOACID DEHYDROGENASE COMPLEX; CHAPERONIN ATPASE CYCLE; CRYSTAL-STRUCTURE; FOLDING INTERMEDIATE; ESCHERICHIA-COLI; GROEL; BINDING; MECHANISM; ALPHA-2-BETA-2; IDENTIFICATION	Whereas the mechanism of GroEL/GroES-mediated protein folding has been extensively studied, the role of these chaperonins in oligomeric protein assembly remains poorly understood. In the present study, we investigated the interaction of the chaperonins with an alpha beta heterodimeric intermediate during the alpha(2)beta(2) assembly of human mitochondrial branched-chain alpha-ketoacid dehydrogenase/decarboxylase (BCKD), Incubation of the recombinant His(6)-tagged BCKD in 400 mM KSCN for 45 min at 23 degrees C caused a complete dissociation of the alpha(2)beta(2) heterotetramers into inactive alpha beta heterodimers. Dilution of the denaturant resulted in a rapid recovery of BCKD independent of the chaperonins GroEL/GroES, Prolonged incubation of BCKD in 400 mM KSCN resulted in the generation of nonproductive or "bad" heterodimers, which were unable to undergo spontaneous reactivation but capable of binding to GroEL to form a stable GroEL-alpha beta complex. incubation of this complex with GroES and Mg-ATP led to the slow reactivation of BCKD with a second-order rate constant k = 480 m(-1) s(-1). mixing experiments with radiolabeled and unlabeled protein substrates provided direct evidence that GroEL/GroES promote dissociation and subunit exchange between bad heterodimers. This was accompanied by the transformation of bad heterodimers to their "good" or productive counterparts. The good heterodimers were capable of spontaneous dimerization to initially form an inactive heterotetrameric species, followed by conversion to active heterotetramers, However, a large fraction of bad heterodimers were regenerated and rebound to GroEL, The cycle was perpetuated until tbe reconstitution of active BCKD was complete. Our data support the thesis that chaperonins GroEL/GroES mediate iterative annealing of nonproductive assembly intermediates at the quaternary structure level. This step is essential for an efficient subsequent higher order oligomerization.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	chuang01@utsw.swmed.edu		Wynn, Richard/0000-0002-1879-2136	NIDDK NIH HHS [DK-26758] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHUANG DT, 1995, METABOLIC MOL BASES, P1239; Chuang JL, 1999, J BIOL CHEM, V274, P10395, DOI 10.1074/jbc.274.15.10395; DAVIE JR, 1992, J BIOL CHEM, V267, P16601; Fedorov AN, 1997, J MOL BIOL, V268, P712, DOI 10.1006/jmbi.1997.1007; GEORGOPOULOS CP, 1978, P NATL ACAD SCI USA, V75, P131, DOI 10.1073/pnas.75.1.131; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; Grallert H, 1998, J BIOL CHEM, V273, P33305, DOI 10.1074/jbc.273.50.33305; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Huang YS, 1999, J BIOL CHEM, V274, P10405, DOI 10.1074/jbc.274.15.10405; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAENICKE R, 1981, EUR J BIOCHEM, V114, P525, DOI 10.1111/j.1432-1033.1981.tb05176.x; KOCHAN J, 1983, VIROLOGY, V131, P100, DOI 10.1016/0042-6822(83)90537-8; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LAU KS, 1990, BIOCHIM BIOPHYS ACTA, V1038, P360, DOI 10.1016/0167-4838(90)90249-F; LEBRAS G, 1989, BIOCHEMISTRY-US, V28, P6836, DOI 10.1021/bi00443a009; Li J, 1999, J BIOL CHEM, V274, P10790, DOI 10.1074/jbc.274.16.10790; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; MacColl R, 1998, BIOCHEMISTRY-US, V37, P417, DOI 10.1021/bi971453s; Mande SC, 1996, SCIENCE, V271, P1655; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; NiebaAxmann SE, 1997, J MOL BIOL, V271, P803, DOI 10.1006/jmbi.1997.1192; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Tanford C., 1961, PHYS CHEM MACROMOLEC, P356; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WYNN RM, 1992, J BIOL CHEM, V267, P12400; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	40	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2786	2794		10.1074/jbc.275.4.2786	http://dx.doi.org/10.1074/jbc.275.4.2786			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644743	hybrid			2022-12-25	WOS:000085128000075
J	Bahl, R; Arora, S; Nath, N; Mathur, M; Shukla, NK; Ralhan, R				Bahl, R; Arora, S; Nath, N; Mathur, M; Shukla, NK; Ralhan, R			Novel polymorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer	ONCOGENE			English	Article						p21(waf1/cip1); cyclin-dependent kinase inhibitor; p53; esophageal squamous cell carcinomas	TUMOR-SUPPRESSOR GENE; CELL NUCLEAR ANTIGEN; C-TERMINAL REGION; DNA-REPLICATION; BINDING DOMAINS; P53 GENE; P21; EXPRESSION; PCNA; MUTATIONS	p21(waf1/cip1), an important regulator of the cell cycle, binds to PCNA and acts as a mediator of the growth suppressing and apoptosis promoting functions of p53. We report a hitherto unobserved polymorphism in the carboxy terminal domain (codon 149) of p21(waf1/cip1) gene, the domain encoding the PCNA binding motif, The codon 149 polymorphism (G (A) under bar T-->G (G) under bar T) was observed in 42 of 50 (84%) esophageal squamous cell carcinomas (ESCCs) and eight of 50 (16%) normal individuals, The resultant amino acid substitution from aspartate to glycine may have vital implication in PCNA mediated cell cycle regulation by p21(waf1/cip1). The second polymorphism at codon 31, involving a C-->A transversion at nucleotide 168 (AG (C) under bar-->AG (A) under bar) changing the amino acid from serine to arginine, was observed in 2/50 (4%) ESCCs at a relatively lower frequency in the Indian population than that reported in the West. No significant association was observed between p21(waf1/cip1) polymorphism at codon 149 and p21(waf1/cip1) protein expression in ESCC in this cohort of patients. Interestingly, the frequency of p21(waf1/cip1) variants (codon 149) in ESCCs (18 of 19 cases) with wild-type p53 was significantly higher than in tumors with p53 mutations, suggesting that this polymorphism affects the p53 pathway and may play an important role in esophageal tumorigenesis, Analysis of p21(waf1/cip1) expression in relation to p53 gene and protein status revealed its induction by p53-dependent as well as independent pathways in esophageal tumorigenesis.	All India Inst Med Sci, Dept Biochem, New Delhi 110029, India; All India Inst Med Sci, Dept Pathol, New Delhi 110029, India; Inst Rotary Canc Hosp, All India Inst Med Sci, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; DR. B.R.A. Institute Rotary Cancer Hospital	Ralhan, R (corresponding author), All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.							AGARWAL S, 1998, ORAL ONCO EUR J CANC, V34, P1; Barbareschi M, 1996, BRIT J CANCER, V74, P208, DOI 10.1038/bjc.1996.339; Bukholm IK, 1997, INT J CANCER, V73, P38, DOI 10.1002/(SICI)1097-0215(19970926)73:1<38::AID-IJC7>3.0.CO;2-2; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHEN J, 1995, NATURE, V375, P386; Doglioni C, 1996, J PATHOL, V179, P248, DOI 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6; Elbendary AA, 1996, CLIN CANCER RES, V2, P1571; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Facher EA, 1997, CANCER, V79, P2424, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2424::AID-CNCR19>3.0.CO;2-T; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gaur D, 1997, CLIN CANCER RES, V3, P2129; GOUBIN F, 1995, ONCOGENE, V10, P2281; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Heinzel PA, 1996, INT J CANCER, V68, P420, DOI 10.1002/(SICI)1097-0215(19961115)68:4<420::AID-IJC3>3.0.CO;2-2; HUPPI K, 1994, ONCOGENE, V9, P3017; KOOPMANN J, 1995, BRIT J CANCER, V72, P1230, DOI 10.1038/bjc.1995.491; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Marchetti A, 1996, ONCOGENE, V12, P1319; MARCHETTI A, 1996, INT J ONCOL, V6, P187; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; Munoz N, 1996, CANC EPIDEMIOLOGY PR, P681; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NOTANI PN, 1988, E EPIDEMIOL COMM HLT, V187; RALHAN R, 1999, IN PRESS INT J CANC; SABIN LH, 1997, TNM CLASSIFICATIN MA; Sambrook J., 1989, MOL CLONING; Shimada Y, 1999, BRIT J CANCER, V80, P1281, DOI 10.1038/sj.bjc.6690499; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SIDDIQI MA, 1991, DIETARY SOURCES NNIT, P210; VIDAL MJ, 1995, MELANOMA RES, V5, P243, DOI 10.1097/00008390-199508000-00006; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P707; YU MC, 1988, CANCER RES, V48, P345	36	57	61	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					323	328		10.1038/sj.onc.1203325	http://dx.doi.org/10.1038/sj.onc.1203325			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656678				2022-12-25	WOS:000084873700001
J	Zegerman, P; Bannister, AJ; Kouzarides, T				Zegerman, P; Bannister, AJ; Kouzarides, T			The putative tumour suppressor Fus-2 is an N-acetyltransferase	ONCOGENE			English	Article						Fus-2; acetyltransferase; tumour suppressor	CELL LUNG-CANCER; HISTONE ACETYLTRANSFERASE; DELETION; YEAST; ACETYLATION; SUPERFAMILY; NAT2	Acetyltransferases are essential enzymes for a wide variety of cellular processes and mutations in acetyltransferase genes have been associated with the development of certain cancers. For this reason, we conducted a computerized sequence homology search for novel acetyltransferases. Here, we show that the putative tumour suppressor protein Fus-2 has homology to the catalytic domain of acetyltransferases. We demonstrate that Fus-2 can acetylate the N-terminus of proteins using a ping-pong mechanism and that it has a specificity for substrates. Consistent with other N-acetyltransferases, Fus-2 localizes to the cytoplasm, as shown by GFP-tag experiments, Since the Fus-2 gene maps to the chromosomal region 3p21.3, which contains at least one tumour suppressor gene, the N-acetyltransferase functions of Fus-2 may be relevant to its potential role in cancer.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Bannister, Andrew/0000-0002-6312-4436; Zegerman, Philip/0000-0002-5707-1083; Kouzarides, Tony/0000-0002-8918-4162				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; Cascorbi I, 1996, CANCER RES, V56, P3961; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HIBI K, 1992, ONCOGENE, V7, P445; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; JORNVALL H, 1980, FEBS LETT, V111, P214, DOI 10.1016/0014-5793(80)80796-4; KOK K, 1994, CANCER RES, V54, P4183; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WONG LJ, 1983, BIOCHEMISTRY-US, V42, P4637; Zenser TV, 1996, CANCER RES, V56, P3941	18	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					161	163		10.1038/sj.onc.1203234	http://dx.doi.org/10.1038/sj.onc.1203234			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644992				2022-12-25	WOS:000084844300019
J	Cruz, JC; Sugii, S; Yu, CJ; Chang, TY				Cruz, JC; Sugii, S; Yu, CJ; Chang, TY			Role of Niemann-Pick type C1 protein in intracellular trafficking of low density lipoprotein-derived cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CULTURED FIBROBLASTS; TRANSPORT; DISEASE; PATHWAY; LDL; HOMEOSTASIS; LYSOSOMES	Niemann-Pick type C (NPC) is a disease that affects intracellular cholesterol-trafficking pathways. By cloning the hamster ortholog of NPC1, we identified the molecular lesions in two independently isolated Chinese hamster ovary cell mutants, CT60 and CT43, Both mutants lead to premature translational terminations of the NPC1 protein. Transfecting hamster NPC1 cDNA complemented the defects of the mutants, Investigation of the CT mutants, their parental cells, and an NPC1-stable transfectant allow us to present evidence that NPC1 is involved in a post-plasma membrane cholesterol-trafficking pathway, We found that the initial movement of low density lipoprotein (LDL)-derived cholesterol to the plasma membrane (PM) did not require NPC1. After reaching the PM and subsequent internalization, however, cholesterol trafficking back to the PM did involve NPC1. Both LDL-derived cholesterol and cholesterol originating from the PM accumulated in a dense, intracellular compartment in the CT mutants. Cholesterol movement from this compartment to the PM or endoplasmic reticulum was defective in the CT mutants, Our results functionally distinguish the dense, intracellular compartment from the early endocytic hydrolytic organelle and imply that NPC1 is involved in sorting cholesterol from the intracellular compartment back to the PM or to the endoplasmic reticulum.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Chang, TY (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.		Yu, Chunjiang/E-9419-2012	Chang, Ta-Yuan/0000-0002-3249-0468; Sugii, Shigeki/0000-0002-2537-9534	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036709, R01HL036709] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36709] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHANG TY, 1980, J BIOL CHEM, V255, P7787; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; Christian AE, 1997, J LIPID RES, V38, P2264; COXEY RA, 1993, J LIPID RES, V34, P1165; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Gu JZ, 1997, P NATL ACAD SCI USA, V94, P7378, DOI 10.1073/pnas.94.14.7378; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; Khelef N, 1998, J BIOL CHEM, V273, P11218, DOI 10.1074/jbc.273.18.11218; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Morris JA, 1999, BIOCHEM BIOPH RES CO, V261, P493, DOI 10.1006/bbrc.1999.1070; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SLISKOVIC DR, 1991, TRENDS PHARMACOL SCI, V12, P194, DOI 10.1016/0165-6147(91)90546-5; SPILLANE DM, 1995, BBA-LIPID LIPID MET, V1254, P283, DOI 10.1016/0005-2760(94)00190-A; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805; Watari H, 1999, J BIOL CHEM, V274, P21861, DOI 10.1074/jbc.274.31.21861; Yano T, 1996, P JPN ACAD B-PHYS, V72, P214, DOI 10.2183/pjab.72.214	36	149	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4013	4021		10.1074/jbc.275.6.4013	http://dx.doi.org/10.1074/jbc.275.6.4013			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660558	hybrid			2022-12-25	WOS:000085288800042
J	Di Venere, A; Rossi, A; De Matteis, F; Rosato, N; Agro, AF; Mei, G				Di Venere, A; Rossi, A; De Matteis, F; Rosato, N; Agro, AF; Mei, G			Opposite effects of Ca2+ and GTP binding on tissue transglutaminase tertiary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; CROSS-LINKING ENZYMES; ASCORBATE OXIDASE; PROTEINS; FLUORESCENCE; PRESSURE; INTERMEDIATE; IDENTIFICATION; RESOLUTION; COMPLEXES	Tissue transglutaminase (tTG) belongs to a class of enzymes that catalyze a cross-linking reaction between proteins or peptides, The protein activity is known to be finely tuned by Ca2+ and GTP binding. In this study we report the effects of these ligands on the enzyme structure, as revealed by circular dichroism, and steady-state and dynamic fluorescence measurements, We have found that calcium and GTP induced opposite conformational changes at the level of the protein tertiary structure, In particular the metal ions were responsible for a small widening of the protein molecule, as indicated by anisotropy decay measurements and by the binding of a hydrophobic probe such as 1-anilino-8-naphthalenesulfonic acid (ANS), Unlike Ca2+, the nucleotide binding increased the protein dynamics, reducing its rotational correlation lifetime from 32 to 25 ns, preventing also the binding of ANS into the protein matrix. Unfolding of tTG by guanidinium hydrochloride yielded a three-state denaturation mechanism, involving an intermediate species with the characteristics of the so-called "molten globule" state. The effect of GTP binding (but not that of Ca2+) had an important consequence on the stability of tissue transglutaminase, increasing the free energy change from the native to the intermediate species by at least approximate to 0.7 kcal/mol. Also a greater stability of tTG to high hydrostatic pressure was obtained in presence of GTP, These findings suggest that the molecular mechanism by which tTG activity is inhibited by GTP is essentially due to a protein conformational change which, decreasing the accessibility of the protein matrix to the solvent, renders more difficult the exposure of the active site.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Roma Tor Vergata, INFM, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Phys, I-00133 Rome, Italy; Osped San Giovanni Calibita Fatebenefratelli, AFaR, CRCCS, Div Neurol, I-00100 Rome, Italy	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Rome Tor Vergata; University of Rome Tor Vergata	Mei, G (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Tor Vergata 135, I-00133 Rome, Italy.		De Matteis, Fabio/ABG-1923-2020	De Matteis, Fabio/0000-0001-7860-9754; Di Venere, Almerinda/0000-0002-9493-0270				ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; ACHYUTHAN KE, 1989, MOL CELL BIOCHEM, V85, P57; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BEECHEM JM, 1988, P SPIE INT SOC OPT E, V909, P70; BERGAMINI CM, 1988, FEBS LETT, V239, P255, DOI 10.1016/0014-5793(88)80928-1; BERGAMINI CM, 1993, BIOCHEM J, V291, P37, DOI 10.1042/bj2910037; Bismuto E, 1999, PROTEINS, V35, P163, DOI 10.1002/(SICI)1097-0134(19990501)35:2<163::AID-PROT3>3.0.CO;2-8; Bismuto E, 1997, EUR J BIOCHEM, V244, P53, DOI 10.1111/j.1432-1033.1997.00053.x; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2, P459; CIONI P, 1994, J MOL BIOL, V242, P291, DOI 10.1006/jmbi.1994.1579; Cymes GD, 1996, PROTEIN SCI, V5, P2074, DOI 10.1002/pro.5560051013; Di Venere A, 1998, EUR J BIOCHEM, V257, P337, DOI 10.1046/j.1432-1327.1998.2570337.x; FOLK JE, 1967, J BIOL CHEM, V242, P1838; FOLK JE, 1967, J BIOL CHEM, V242, P2615; GRATTON E, 1983, BIOPHYS J, V44, P315, DOI 10.1016/S0006-3495(83)84305-7; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GROSS M, 1973, J BIOL CHEM, V248, P1301; Hummer G, 1998, P NATL ACAD SCI USA, V95, P1552, DOI 10.1073/pnas.95.4.1552; JOHNSON WC, 1996, CIRCULAR DICHROISM C, P438; KIM SY, 1994, J BIOL CHEM, V269, P27979; Kungl AJ, 1998, BIOCHEMISTRY-US, V37, P2778, DOI 10.1021/bi971654w; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Lai TS, 1998, J BIOL CHEM, V273, P1776, DOI 10.1074/jbc.273.3.1776; Lai TS, 1997, J BIOL CHEM, V272, P16295, DOI 10.1074/jbc.272.26.16295; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P156; Mei G, 1997, BIOCHEMISTRY-US, V36, P10917, DOI 10.1021/bi970614p; Mei G, 1999, EUR J BIOCHEM, V265, P619, DOI 10.1046/j.1432-1327.1999.00751.x; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; NAKANISHI K, 1991, EUR J BIOCHEM, V202, P15, DOI 10.1111/j.1432-1033.1991.tb16338.x; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; TANFANI F, 1993, EUR J BIOCHEM, V218, P499, DOI 10.1111/j.1432-1033.1993.tb18402.x; Wang CQ, 1998, BIOCHEMISTRY-US, V37, P8457, DOI 10.1021/bi9723010; WARE WR, 1992, PHOTOCHEMISTRY ORG C, P563; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; Zhang YN, 1996, J BIOL CHEM, V271, P8015, DOI 10.1074/jbc.271.14.8015; [No title captured]	44	68	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3915	3921		10.1074/jbc.275.6.3915	http://dx.doi.org/10.1074/jbc.275.6.3915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660544	hybrid			2022-12-25	WOS:000085288800028
J	Goldstein, BJ; Bittner-Kowalczyk, A; White, MF; Harbeck, M				Goldstein, BJ; Bittner-Kowalczyk, A; White, MF; Harbeck, M			Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B - Possible facilitation by the formation of a ternary complex with the GRB2 adaptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; HEMATOPOIETIC-CELLS; XENOPUS OOCYTES; INTACT-CELLS; ASSOCIATION; BINDING; INTERACTS; SIGNAL; ALPHA; IRS-1	Regulation of the steady-state tyrosine phosphorylation of the insulin receptor and its postreceptor substrates are essential determinants of insulin signal transduction. However, little is known regarding the molecular interactions that influence the balance of these processes, especially the phosphorylation state of postinsulin receptor substrates, such as insulin receptor substrate-1 (IRS-1). The specific activity of four candidate protein-tyrosine phosphatases (protein-tyrosine phosphatase 1B (PTP1B), SH2 domain-containing PT-Pase-2 (SHP-2), leukocyte common antigen-related (LAR), and leukocyte antigen-related phosphatase) (LRP) toward IRS-1 dephosphorylation was studied using recombinant proteins in vitro, PTP1B exhibited the highest specific activity (percentage dephosphorylated per mu g per min), and the enzyme activities varied over a range of 5.5 x 10(3). When evaluated as a ratio of activity versus IRS-1 to that versus p-nitrophenyl phosphate, PTP1B remained significantly more active by 3.1-293-fold, respectively. Overlay blots with recombinant Src homology 2 domains of IRS-1 adaptor proteins showed that the loss of IRS-1 binding of Crk, GRB2, SHP-2, and the p85 subunit of phosphatidylinositol 3'-kinase paralleled the rate of overall IRS-1 dephosphorylation, Further studies revealed that the adaptor protein GRB2 strongly promoted the formation of a stable protein complex between tyrosine-phosphorylated IRS-1 and catalytically inactive PTP1B, increasing their co-immunoprecipitation from an equimolar solution by 13.5 +/- 3.3-fold (n = 7; p < 0.01), Inclusion of GRB2 in a reaction mixture of IRS-1 and active PTP1B also increased the overall rate of IRS-1 tyrosine dephosphorylation by 2.7-3.9-fold (p < 0.01), These results provide new insight into novel molecular interactions involving PTP1B and GRB2 that may influence the steady-state capacity of IRS-1 to function as a phosphotyrosine scaffold and possibly affect the balance of postreceptor insulin signaling.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Res Labs, Div Endocrinol Diabet & Metab Dis, Philadelphia, PA 19107 USA	Jefferson University	Goldstein, BJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Res Labs, Div Endocrinol Diabet & Metab Dis, 349 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Barry.Goldstein@mail.tju.edu			NIDDK NIH HHS [R01-DK43396] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043396] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad F, 1997, J BIOL CHEM, V272, P448; AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Evans J L, 1999, Expert Opin Investig Drugs, V8, P139, DOI 10.1517/13543784.8.2.139; Goldstein BJ, 1998, VITAM HORM, V54, P67, DOI 10.1016/S0083-6729(08)60922-X; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; KAMPS MP, 1991, METHOD ENZYMOL, V201, P101; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981	38	330	358	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4283	4289		10.1074/jbc.275.6.4283	http://dx.doi.org/10.1074/jbc.275.6.4283			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660596	hybrid			2022-12-25	WOS:000085288800080
J	Tzeng, CM; Kornberg, A				Tzeng, CM; Kornberg, A			The multiple activities of polyphosphate kinase of Escherichia coli and their subunit structure determined by radiation target analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; COMPLETE GENOME SEQUENCE; PROPIONIBACTERIUM-SHERMANII; MYCOBACTERIUM-TUBERCULOSIS; INORGANIC POLYPHOSPHATE; GENE; GLUCOKINASE; PPK; PURIFICATION; MECHANISM	Polyphosphate kinase (PPK), the principal enzyme required for the synthesis of inorganic polyphosphate (polyP) from ATP, also exhibits other enzymatic activities, which differ significantly in their biochemical optima and responses to chemical agents. These several activities include: polyp synthesis (forward reaction), nATP --> polyP(n) + nADP (Equation 1); ATP synthesis from polyP (reverse reaction), ADP + polyp(n) --> ATP + polyp(n - 1) (Equation 2); general nucleoside-diphosphate kinase, GDP + polyP(n) --> GTP + polyP(n - 1) (Equation 3); linear guanosine 5'-tetraphosphate (ppppG) synthesis, GDP + polyP(n) --> ppppG + polyP(n - 2) (Equation 4); and autophosphorylation, PPK + ATP --> PPK-P + ADP (Equation 5), The Mg2+ optima are 5, 2, 1, and 0.2 mM, respectively, for the activities in Equations I, 2, 3, and 4. inorganic pyrophosphate inhibits the activities in Equations 1 and 3 but stimulates that in Equation 4, The kinetics of the activities in Equations 1, 2, and 3 are highly processive, whereas the transfer of a pyrophosphoryl group from polyP to GDP (Equation 4) is distributive and demonstrates a rapid equilibrium, random Bi-Bi catalytic mechanism, Radiation target analysis revealed that the principal functional unit of the homotetrameric PPK is a dimer, Exceptions are a trimer for the synthesis of ppppG (Equation 4) and a tetrameric state for the autophosphorylation of PPK (Equation 5) at low ATP concentrations. Thus, the diverse functions of this enzyme involve different subunit organizations and conformations, The highly conserved homology of PPK among 18 microorganisms was used to determine important residues and conserved regions by alanine substitution, by site-directed mutagenesis, and by deletion mutagenesis, Of 46 single-site mutants, seven exhibit none of the five enzymatic activities; in one mutant, ATP synthesis from polyp is reduced relative to GTP synthesis. Among deletion mutants, some lost all five PPK activities, but others retained partial activity for some reactions but not for others.	Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Kornberg, A (corresponding author), Stanford Univ, Dept Biochem, Stanford, CA 94305 USA.	akornber@cmgm.stanford.edu			NIGMS NIH HHS [GM07581-38] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM007581, R37GM007581] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; Ault-Riche D, 1998, J BACTERIOL, V180, P1841; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; Chakrabarty AM, 1998, MOL MICROBIOL, V28, P875, DOI 10.1046/j.1365-2958.1998.00846.x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DIAZ MG, 1989, BIOCH INT, V19, P1253; Geissdorfer W, 1998, APPL ENVIRON MICROB, V64, P896; Hsieh PC, 1996, BIOCHEMISTRY-US, V35, P9772, DOI 10.1021/bi9528659; IGNARRO LJ, 1978, BIOCHIM BIOPHYS ACTA, V541, P170, DOI 10.1016/0304-4165(78)90390-2; Ishige K, 1998, DNA Res, V5, P157, DOI 10.1093/dnares/5.3.157; Kaneko T, 1996, DNA Res, V3, P109; KATO J, 1993, GENE, V137, P237, DOI 10.1016/0378-1119(93)90013-S; KEMPNER ES, 1993, TRENDS BIOCHEM SCI, V18, P236, DOI 10.1016/0968-0004(93)90169-N; KULAEV IS, 1979, BIOCH INORGANIC POLY, P11; Kulakovskaya TV, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1051; Kumble KD, 1996, P NATL ACAD SCI USA, V93, P14391, DOI 10.1073/pnas.93.25.14391; Kuroda A, 1997, P NATL ACAD SCI USA, V94, P439, DOI 10.1073/pnas.94.2.439; Kuroda A, 1997, J BIOL CHEM, V272, P21240, DOI 10.1074/jbc.272.34.21240; Lu Q, 1996, P NATL ACAD SCI USA, V93, P5720, DOI 10.1073/pnas.93.12.5720; LU Q, 1995, J MOL BIOL, V254, P337, DOI 10.1006/jmbi.1995.0620; PEPIN CA, 1986, J BIOL CHEM, V261, P4476; PHILLIPS NFB, 1993, ARCH BIOCHEM BIOPHYS, V300, P309, DOI 10.1006/abbi.1993.1043; Rao NN, 1996, J BACTERIOL, V178, P1394, DOI 10.1128/jb.178.5.1394-1400.1996; ROBINSON NA, 1986, J BIOL CHEM, V261, P4481; ROBINSON NA, 1987, J BIOL CHEM, V262, P5216; SAEKI T, 1975, J ANTIBIOT, V28, P974, DOI 10.7164/antibiotics.28.974; SEGEL IH, 1975, ENZYME KINETICS, P506; SPIRA B, 1995, J BACTERIOL, V177, P4053, DOI 10.1128/jb.177.14.4053-4058.1995; TINSLEY CR, 1993, INFECT IMMUN, V61, P3703, DOI 10.1128/IAI.61.9.3703-3710.1993; TINSLEY CR, 1995, INFECT IMMUN, V63, P1624, DOI 10.1128/IAI.63.5.1624-1630.1995; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tzeng CM, 1996, BIOCHEM J, V316, P143, DOI 10.1042/bj3160143; Tzeng CM, 1998, MOL MICROBIOL, V29, P381, DOI 10.1046/j.1365-2958.1998.00887.x; VOELZ H, 1966, ARCH MIKROBIOL, V53, P371, DOI 10.1007/BF00409874	37	39	47	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3977	3983		10.1074/jbc.275.6.3977	http://dx.doi.org/10.1074/jbc.275.6.3977			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660553	hybrid			2022-12-25	WOS:000085288800037
J	Fleury, F; Sukhanova, A; Ianoul, A; Devy, J; Kudelina, I; Duval, O; Alix, AJP; Jardillier, JC; Nabiev, I				Fleury, F; Sukhanova, A; Ianoul, A; Devy, J; Kudelina, I; Duval, O; Alix, AJP; Jardillier, JC; Nabiev, I			Molecular determinants of site-specific inhibition of human DNA topoisomerase I by fagaronine and ethoxidine - Relation to DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTILEUKEMIC ALKALOID FAGARONINE; CIRCULAR-DICHROISM; NUCLEIC-ACID; DERIVATIVES; MECHANISM; CELLS; SALTS	DNA topoisomerase (top) I inhibition activity of the natural alkaloid fagaronine (NSC157995) and its new synthetic derivative ethoxidine (12-ethoxy-benzo[c] phenanthridine) has beers correlated with their molecular interactions and sequence specificity within the DNA complexes. Flow linear dichroism shows that ethoxidine exhibits the same inhibition of DNA relaxation as fagaronine at the 10-fold lower concentration. The patterns of DNA cleavage by top I show linear enhancement of CPT-dependent sites at the 0.016-50 mu M concentrations of fagaronine, whereas ethoxidine suppress both top I-specific and CPT-dependent sites. Suppression of top I-mediated cleavage by ethoxidine is found to be specific for the sites, including strand cut between A and T, Fagaronine and ethoxidine are DNA major groove intercalators. Ethoxidine intercalates DNA in A-T sequences and its 12-ethoxy-moiety (absent in fagaronine) extends into the DNA minor groove. These findings may explain specificity of suppression by ethoxidine of the strong top I cleavage sites with the A(+1), T(-l) immediately adjacent to the strand cut. Fagaronine does not show any sequence specificity of DNA intercalation, but its highly electronegative oxygen of hydroxy group (absent in ethoxidine) is shown to be an acceptor of the hydrogen bond with the NH, group of G base of DNA. Ability of fagaronine to stabilize top I-mediated ternary complex is proposed to be determined by interaction of its hydroxy group with the guanine at position (+1) of the DNA cleavage site and of quaternary nitrogen interaction with top I, The model proposed provides a guidance for screening new top I-targeted drugs in terms of identification of molecular determinants responsible for their top I inhibition effects.	Univ Reims, Inst Fed Rech 53 Biomol, UFR Pharm, F-51096 Reims, France	Universite de Reims Champagne-Ardenne	Nabiev, I (corresponding author), Univ Reims, Inst Fed Rech 53 Biomol, UFR Pharm, EA2063,51 Rue Cognacq Jay, F-51096 Reims, France.		Sukhanova, Alyona/P-6540-2014; ianoul, anatoli/H-8918-2013; ianoul, anatoli/C-1247-2015; Nabiev, Igor/A-5077-2014	Sukhanova, Alyona/0000-0003-2796-7898; Nabiev, Igor/0000-0002-8391-040X				Bailly Christian, 1992, Journal of Molecular Recognition, V5, P155, DOI 10.1002/jmr.300050406; BARRET Y, 1992, PHYTOTHER RES, V6, P59, DOI 10.1002/ptr.2650060202; Bronstein IB, 1999, ANTICANCER RES, V19, P317; CAPRANICO G, 1994, J MOL BIOL, V235, P1218, DOI 10.1006/jmbi.1994.1075; COMOE L, 1987, LEUKEMIA RES, V11, P445, DOI 10.1016/0145-2126(87)90076-2; COMOE L, 1988, LEUKEMIA RES, V12, P667, DOI 10.1016/0145-2126(88)90101-4; DOSTAL J, 1990, COLLECT CZECH CHEM C, V55, P2841; DOUROS J, 1981, RECENT RES CANCER, V76, P153; FANG SD, 1993, J ORG CHEM, V58, P5025, DOI 10.1021/jo00071a001; Fleury F, 1998, BIOCHEMISTRY-US, V37, P14630, DOI 10.1021/bi9806495; FLEURY F, 1999, P AACR C MOL DET SEN, P12; Ianoul A, 1999, J PHYS CHEM B, V103, P2008, DOI 10.1021/jp984291y; JANIN YL, 1993, J MED CHEM, V36, P3686, DOI 10.1021/jm00075a025; Kerry MA, 1998, J PHARM PHARMACOL, V50, P1307, DOI 10.1111/j.2042-7158.1998.tb03350.x; LARSEN AK, 1993, BIOCHEM PHARMACOL, V46, P1403, DOI 10.1016/0006-2952(93)90105-6; Mackay SP, 1998, ANTI-CANCER DRUG DES, V13, P797; MATSUOKA Y, 1982, BIOPOLYMERS, V21, P2433, DOI 10.1002/bip.360211208; MESSMER WM, 1972, J PHARM SCI-US, V61, P1858, DOI 10.1002/jps.2600611145; MONNOT M, 1992, EUR J BIOCHEM, V204, P1035, DOI 10.1111/j.1432-1033.1992.tb16725.x; Murrell JN, 1963, THEORY ELECT SPECTRA; NABIEV I, 1994, BIOCHEMISTRY-US, V33, P9013, DOI 10.1021/bi00196a020; NORDEN B, 1992, Q REV BIOPHYS, V25, P151; PEZUTTO JM, 1983, CHEM-BIOL INTERACT, V43, P323; Pilch DS, 1997, P NATL ACAD SCI USA, V94, P13565, DOI 10.1073/pnas.94.25.13565; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; RIOU GF, 1978, BIOCHIMIE, V60, P365, DOI 10.1016/S0300-9084(78)80670-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIPPER PE, 1980, CHEM PHYS LETT, V70, P17, DOI 10.1016/0009-2614(80)80051-0; SETHI ML, 1984, J MED CHEM, V27, P544; SETHI VS, 1976, CANCER RES, V36, P2390; SETHI VS, 1975, BIOCHEM BIOPH RES CO, V63, P1070; Sukhanova A, 1998, BIOCHEM MOL BIOL INT, V44, P997; TORRES CAC, 1986, BIOCHEM PHARMACOL, V35, P679; WANG LK, 1993, CHEM RES TOXICOL, V6, P813, DOI 10.1021/tx00036a010; WELLS R D, 1970, Journal of Molecular Biology, V54, P465, DOI 10.1016/0022-2836(70)90121-X; ZEECHENG RK, 1975, J MED CHEM, V18, P66, DOI 10.1021/jm00235a015	36	56	57	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3501	3509		10.1074/jbc.275.5.3501	http://dx.doi.org/10.1074/jbc.275.5.3501			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652345	Green Published, hybrid			2022-12-25	WOS:000085146500067
J	Ogasawara, M; Kim, SC; Adamik, R; Togawa, A; Ferrans, VJ; Takeda, K; Kirby, M; Moss, J; Vaughan, M				Ogasawara, M; Kim, SC; Adamik, R; Togawa, A; Ferrans, VJ; Takeda, K; Kirby, M; Moss, J; Vaughan, M			Similarities in function and gene structure of cytohesin-4 and cytohesin-1, guanine nucleotide-exchange proteins for ADP-ribosylation factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PLECKSTRIN HOMOLOGY DOMAIN; SEC7 DOMAIN; PHOSPHOLIPASE-D; CRYSTAL-STRUCTURE; BOVINE BRAIN; PH DOMAIN; ARF; YEAST; CELL	Activation of ADP-ribosylation factors (ARFs), similar to 20-kDa GTPases that are inactive in the GDP-bound form, depends on guanine nucleotide-exchange proteins (GEPs) to accelerate GTP binding, A novel ARF GEP, designated cytohesin-4, was cloned from a human brain cDNA library. Deduced amino acid sequence of the 47-kDa protein contains the same structural components present in cytohesin -1, -2, and -3, including an similar to 200-amino acid Sec7 domain with an similar to 100-residue pleckstrin homology domain near the C terminus. The Sec7 domain sequence is 77% identical to those of other cytohesins. Structures of the cytohesin-4 and cytohesin-1 genes were remarkably similar, except for an extra 3-base pair (GAG) exon present in cytohesin-1. Two mRNAs with and without the 3-base pair sequence were found in brain in different ratios for cytohesin-1, -2, and -3 but not cytohesin-4, Recombinant cytohesin-4 stimulated guanosine 5'-3-O-(thio)triphosphate binding by human ARF1 and ARF5 but not ARF6. Like other cytohesins and unlike the similar to 200-kDa ARP GEPs, it was not inhibited by brefeldin A A cytohesin-4 mRNA of similar to 3.7 kilobases, abundant in leukocytes, was not detected in most tissues. Among separated populations of blood cells, similar to 90% of CD33(+) (monocytes), 80% of CD2(+) (NK/T), and 10-20% of CD19(+) (B) cells contained cytohesin-4 mRNA by in situ hybridization, Thus, in gene structure and brefeldin A-insensitive GEP activity, cytohesin-4 resembles other cytohesins, but its tissue distribution differs considerably, consistent with a different specific function.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA; NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Ogasawara, M (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, 10 Ctr Dr,MSC 1434,Bldg 10,Rm 5N307, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000627, ZIAHL000627] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1994; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; DIXON B, 1993, CYTOGENET CELL GENET, V63, P42, DOI 10.1159/000133498; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; HAUN RS, 1993, J BIOL CHEM, V268, P7064; Hayashi T, 1996, AM J PATHOL, V149, P1241; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; HONG JX, 1994, J BIOL CHEM, V269, P9743; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1999, J BIOL CHEM, V274, P17417, DOI 10.1074/jbc.274.25.17417; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; PATTON WA, 1997, BACTERIAL TOXINS TOO, P15; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Sata M, 1998, P NATL ACAD SCI USA, V95, P4204, DOI 10.1073/pnas.95.8.4204; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; Telemenakis I, 1997, EUR J CELL BIOL, V74, P143; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	45	69	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3221	3230		10.1074/jbc.275.5.3221	http://dx.doi.org/10.1074/jbc.275.5.3221			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652308	hybrid			2022-12-25	WOS:000085146500030
J	Patskovsky, YV; Patskovska, LN; Listowsky, I				Patskovsky, YV; Patskovska, LN; Listowsky, I			The enhanced affinity for thiolate anion and activation of enzyme-bound glutathione is governed by an arginine residue of human Mu class glutathione S-transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; ACTIVE-SITE; TRANSITION-STATE; COMPLEX; HETEROGENEITY; ISOENZYMES; SUBSTRATE; A1-1	A series of chimeric human Mu class glutathione S-transferases were designed to determine mechanisms by which they activate enzyme-bound glutathione (GSH) for reaction with electrophilic substrates, In view of evidence that the His(107) residue of hGSTM1a-1a is important for catalysis (Patskovsky, Y. V., Patskovska, L. N., and Listowsky, I. (1999) Biochemistry 38, 1193-1202), the cognate Arg(107) residue of the hGSTM2 subunit was replaced (R107N or R107H) and arginine residues were also incorporated into position 107 of hGSTM1 (H107R) and hGSTM4 (S107R) subunits, The major distinguishing kinetic properties invariably associated with enzymes containing an Arg107 residue include an inverse dependence of k(cat) on viscosity and lower K(m)GSH values relative to enzymes with other residues at that position. Moreover, affinities for GSH thiolate anion binding are greater for enzymes containing Arg(107), With K-d values of 20-50 mu M that are consistent with the K(m)GSH values (10-25 mu M) obtained by steady-state kinetic analyses. Both thermodynamic and kinetic and data indicate that the Arg(107) residue is specifically involved in enhancing the binding affinity of GSH thiolate anion relative to that of the protonated form. These enzymes therefore, can be more effective at lower GSH concentrations. Combined mutations indicate that both Arg(107) and Tyr(6) residues are required for thiolate anion formation and stabilization. The three-dimensional structure of ligand-free hGSTM2-2 determined by x-ray crystallography suggests that Arg(107) maintains an electrostatic interaction with the Asp(161) side chain (3 A apart), but is distant from the GSH-binding site. However, an alternative energetically favorable model places the guanidino group 4 Angstrom from the sulfur atom of bound GSH. It is suggested therefore, that in solution, motion of the positively charged arginine into the catalytic pocket could provide a counter ion to promote ionization of the sulfhydryl group of GSH, thereby accounting for the ob served greater affinity of enzymes containing Arg(107) for binding of thiolate anion.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Listowsky, I (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [R01CA042448] Funding Source: NIH RePORTER; NCI NIH HHS [CA42448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; AWASTHI YC, 1994, INT J BIOCHEM, V26, P195; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; BOARD P, 1990, PHARMACOL THERAPEUT, V48, P357, DOI 10.1016/0163-7258(90)90054-6; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Caccuri AM, 1997, J BIOL CHEM, V272, P29681, DOI 10.1074/jbc.272.47.29681; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; Chelvanayagam G, 1997, PROTEINS, V27, P118, DOI 10.1002/(SICI)1097-0134(199701)27:1<118::AID-PROT12>3.0.CO;2-Q; CHEN WJ, 1988, BIOCHEMISTRY-US, V27, P647, DOI 10.1021/bi00402a023; COMSTOCK KE, 1994, ARCH BIOCHEM BIOPHYS, V311, P487, DOI 10.1006/abbi.1994.1266; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; Dietze EC, 1996, BIOCHEMISTRY-US, V35, P11938, DOI 10.1021/bi961073r; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; JENSSON H, 1985, METHOD ENZYMOL, V113, P504; JI X, 1993, BIOCHEMISTRY-US, V32, P12949, DOI 10.1021/bi00211a001; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; Ketterer B, 1994, Adv Pharmacol, V27, P37, DOI 10.1016/S1054-3589(08)61029-7; Listowsky Irving, 1993, P397; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; McCallum SA, 1999, J MOL BIOL, V285, P2119, DOI 10.1006/jmbi.1998.2428; Parsons JF, 1996, J AM CHEM SOC, V118, P2295, DOI 10.1021/ja960022e; PATSKOVSKA L, 1997, ACTA CRYSTALLOGR D, V54, P458; Patskovsky YV, 1999, BIOCHEMISTRY-US, V38, P1193, DOI 10.1021/bi982164m; PEARSON WR, 1993, AM J HUM GENET, V53, P220; Prade L, 1997, STRUCTURE, V5, P1287, DOI 10.1016/S0969-2126(97)00281-5; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; RAGHUNATHAN S, 1994, J MOL BIOL, V238, P815, DOI 10.1006/jmbi.1994.1336; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; Rowe JD, 1997, BIOCHEM J, V325, P481, DOI 10.1042/bj3250481; Rowe JD, 1998, J BIOL CHEM, V273, P9593, DOI 10.1074/jbc.273.16.9593; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SINGHAL SS, 1994, ARCH BIOCHEM BIOPHYS, V311, P242, DOI 10.1006/abbi.1994.1233; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Thorson JS, 1998, J AM CHEM SOC, V120, P451, DOI 10.1021/ja9731682; TU CPD, 1985, J BIOL CHEM, V260, P9961; WANG RW, 1993, J BIOL CHEM, V268, P23981; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; Xiao GY, 1998, J MOL BIOL, V281, P323, DOI 10.1006/jmbi.1998.1935; Xu SJ, 1998, J BIOL CHEM, V273, P3517, DOI 10.1074/jbc.273.6.3517	47	30	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3296	3304		10.1074/jbc.275.5.3296	http://dx.doi.org/10.1074/jbc.275.5.3296			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652317	hybrid			2022-12-25	WOS:000085146500039
J	Reddy, ST; Wadleigh, DJ; Herschman, HR				Reddy, ST; Wadleigh, DJ; Herschman, HR			Transcriptional regulation of the gyclooxygenase-2 gene in activated mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; FACTOR KAPPA-B; SIGNAL-TRANSDUCTION; NUCLEAR FACTOR; RESPONSE ELEMENT; GRANULOSA-CELLS; PHORBOL ESTER; 3T3 CELLS; EXPRESSION; PHOSPHORYLATION	Activation of mast cells by aggregation of their IgE receptors induces rapid and transient synthesis of cyclooxygenase-2 (COX-2). In this study we investigated (i) the cis-acting response elements and transcription factors active at the COX-2 promoter and (ii) the signal transduction pathways mediating COX-2 induction following aggregation of mast cell IgE receptors. Transient transfection assays with COX-2 promoter/luciferase constructs suggest that a consensus cyclic AMP response element is essential for induced COX-2 expression. Cotransfection studies with plasmids expressing c-Jun, dominant negative Ras, dominant negative c-Jun NH2-terminal kinase, and dominant negative MEKK1 demonstrate that activation of the Ras/MEKK1/c-Jun NH2-terminal kinase/c-Jun pathway is required for COX-2 promoter-mediated luciferase expression. Attenuation of COX-2 promoter activity by dominant negative constructs for Raf-1, ERK1, and ERK2 suggests that the Ras/Raf-1/extracellular signal-regulated kinase pathway is also necessary for COX-2 induction. Although mutating the two NF-IL6 sites individually did not affect COX-2 promoter activity, mutating both NF-IL6 sites substantially inhibits COX-2 promoter activity. Moreover, overexpression of wild type CCAAT/enhancer-binding protein-beta (C/EBP beta) augments COX-2 promoter activity in activated mast cells and cotransfection of a dominant negative C/EBP beta construct completely blocks COX-2 promoter/luciferase expression. Our data suggest that in activated mast cells, a Ras/MEKKl/c-Jun NH,terminal kinase signal transduction pathway activating c-Jun, a Ras/Raf-1/extracellular signal-regulated kinase pathway, and activated C/EBP beta facilitate COX-2 induction via the cyclic AMP response element and NF-IL6 sites of the COX-2 promoter.	Univ Calif Los Angeles, Ctr Hlth Sci, Inst Mol Biol, E Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Biol Chem, E Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Herschman, HR (corresponding author), Univ Calif Los Angeles, Ctr Hlth Sci, Inst Mol Biol, 611 Charles E Young Dr, E Los Angeles, CA 90095 USA.				NIAID NIH HHS [AI34567] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034567, U19AI034567] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CAO Z, 1991, GENE DEV, V5, P1553; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KAWATA R, 1995, J IMMUNOL, V155, P818; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; REDDY ST, 1994, J BIOL CHEM, V269, P15473; ROBERTS LJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P185, DOI 10.1016/0005-2760(79)90020-1; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	33	116	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3107	3113		10.1074/jbc.275.5.3107	http://dx.doi.org/10.1074/jbc.275.5.3107			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652293	hybrid			2022-12-25	WOS:000085146500015
J	Shirotani, K; Takahashi, K; Araki, W; Maruyama, K; Tabira, T				Shirotani, K; Takahashi, K; Araki, W; Maruyama, K; Tabira, T			Mutational analysis of intrinsic regions of presenilin 2 that determine its endoproteolytic cleavage and pathological function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID-BETA-PROTEIN; C-TERMINAL FRAGMENTS; TRANSFECTED CELLS; CAENORHABDITIS-ELEGANS; LINKED PRESENILIN-1; MISSENSE MUTATIONS; WILD-TYPE; IN-VIVO; GENE	To investigate the significance of endoproteolytic processing of presenilin 2 (PS2) on its pathological function, we constructed PS2 cDNAs causing amino acid substitutions or deletions around the cleavage site. We found that a PS2 mutant (Del3) with a 20-amino acid deletion was not endoproteolytically processed, while other PS2s with amino acid substitutions and short deletions were cleaved. Overproduction of all the mutant proteins led to a compensatory decrease of endogenous PS1 fragments, but did not affect the amyloid beta peptide X-42/A beta X-40 ratio without the familial Alzheimer's disease mutation. The Del3 mutant did not exhibit significant deficits in gamma-secretase activity. The turnover rate of the Del3 holoprotein was the same as that of full-length PS2. These data suggest that the determinants of the PS2 cleavage site reside within a large region and that the pathological function of PS2 is exerted by familial Alzheimer's disease mutations not related to the cleavage of holoproteins. We also found that PS2 with an 18-amino acid deletion at the C-terminal end was not processed. Its overexpression led neither to diminished accumulation of endogenous PS1 fragments nor to increased production of amyloid beta peptide X-42. The C-terminal end of PS2 seems to possess the signal for entry into the processing pathway.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Div Demyelinating Dis & Aging, Kodaira, Tokyo 1878502, Japan; Tokyo Inst Psychiat, Dept Mol Biol, Tokyo 1568585, Japan	National Center for Neurology & Psychiatry - Japan; Tokyo Institute of Psychiatry	Shirotani, K (corresponding author), RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	kshiro@brain.riken.go.jp	Araki, Wataru/G-7913-2014	Araki, Wataru/0000-0001-8467-6937				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Baumeister R, 1997, Genes Funct, V1, P149; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chui DH, 1998, J NEUROSCI RES, V53, P99; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Grunberg J, 1998, BIOCHEMISTRY-US, V37, P2263, DOI 10.1021/bi972106l; Honda T, 1999, J NEUROCHEM, V72, P255, DOI 10.1046/j.1471-4159.1999.0720255.x; Iwatsubo T., 1998, Society for Neuroscience Abstracts, V24, P6; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Marambaud P, 1998, MOL MED, V4, P147, DOI 10.1007/BF03401912; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; Mehta ND, 1998, ANN NEUROL, V43, P256, DOI 10.1002/ana.410430217; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sato S, 1998, HUM MUTAT, pS91; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shirotani K, 1999, NEUROSCI LETT, V262, P37, DOI 10.1016/S0304-3940(99)00037-3; Shirotani K, 1997, BIOCHEM BIOPH RES CO, V240, P728, DOI 10.1006/bbrc.1997.7730; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Sudoh S, 1998, J NEUROCHEM, V71, P1535; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	50	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3681	3686		10.1074/jbc.275.5.3681	http://dx.doi.org/10.1074/jbc.275.5.3681			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652366	hybrid			2022-12-25	WOS:000085146500088
J	Sugiyama, T; Wang, JC; Scott, DK; Granner, DK				Sugiyama, T; Wang, JC; Scott, DK; Granner, DK			Transcription activation by the orphan nuclear receptor, chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) - Definition of the domain involved in the glucocorticoid response of the phosphoenolpyruvate carboxykinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE; POSITIVE REGULATION; ACTIVE REPRESSION; VITAMIN-D; GTP GENE; SUPERFAMILY; ELEMENTS; GRIP1; TRANSACTIVATION	Chicken ovalbumin upstream promoter-transcription factors (COUP-TFs), orphan members of the nuclear receptor superfamily, play a key role in the regulation of organogenesis, neurogenesis, and cellular differentiation during embryogenic development. COUP-TFs are also involved in the regulation of several genes that encode metabolic enzymes. Although COUP-TFs function as potent transcription repressors, there are at least three different molecular mechanisms of activation of gene expression by COUP-TFs, First, as we have previously shown, COUP-TF is required as an accessory factor for the complete induction of phosphoenolpyruvate carboxykinase gene transcription by glucocorticoids, This action is mediated by the binding of COUP-TF to the glucocorticoid accessory factor 1 (gAF1) and 3 (gAF3) elements in the phosphoenolpyruvate carboxykinase gene glucocorticoid response unit. In addition, COUP-TF1 binds to DNA elements in certain genes and transactivates directly. Finally, COUP-TF1 serves as a coactivator through DNA-bound hepatic nuclear factor 4, Here we show that the same region of COUP-TFI, located between amino acids 184 and 423, is involved in these three mechanisms of transactivation by COUP-TFI, Furthermore, we show that GRIP1 and SRC-1 potentiate the activity of COUP-TFI and that COUP-TFI associates with these coactivators in vivo using the same region required for transcription activation. Finally, overexpression of GRIP1 or SRC-1 does not convert COUP-TFI from a transcriptional repressor into a transcriptional activator in HeLa cells.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.		Wang, Jen-Chywan/AAX-4445-2020	Wang, Jen-Chywan/0000-0001-6030-6886; Sugiyama, Takashi/0000-0002-3715-0075	NIDDK NIH HHS [DK 20593, DK 35107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035107, P60DK020593, P30DK020593, R37DK035107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Achatz G, 1997, MOL CELL BIOL, V17, P4914, DOI 10.1128/MCB.17.9.4914; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KADOWAKI Y, 1995, P NATL ACAD SCI USA, V92, P4432, DOI 10.1073/pnas.92.10.4432; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KIMURA A, 1993, J BIOL CHEM, V268, P11125; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Lazennec G, 1997, MOL CELL BIOL, V17, P5053, DOI 10.1128/MCB.17.9.5053; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Leng X, 1996, MOL CELL BIOL, V16, P2332; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU JS, 1991, J BIOL CHEM, V266, P19095; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; Power SC, 1996, MOL CELL BIOL, V16, P778; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; Rodriguez JC, 1997, BIOCHEM J, V326, P587, DOI 10.1042/bj3260587; Sawaya BE, 1996, J BIOL CHEM, V271, P23572, DOI 10.1074/jbc.271.38.23572; Scott DK, 1996, J BIOL CHEM, V271, P6260, DOI 10.1074/jbc.271.11.6260; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Stroup D, 1997, J BIOL CHEM, V272, P9833; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; YAMADA K, 1990, J BIOL CHEM, V265, P19885	48	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3446	3454		10.1074/jbc.275.5.3446	http://dx.doi.org/10.1074/jbc.275.5.3446			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652338	hybrid			2022-12-25	WOS:000085146500060
J	Bolz, SS; Fisslthaler, B; Pieperhoff, S; De Wit, C; Fleming, I; Busse, R; Pohl, U				Bolz, SS; Fisslthaler, B; Pieperhoff, S; De Wit, C; Fleming, I; Busse, R; Pohl, U			Antisense oligonucleotides against cytochrome P4502C8 attenuate EDHF-mediated Ca2+ changes and dilation in isolated resistance arteries	FASEB JOURNAL			English	Article						organ culture; cytochrome P450 metabolites; hyperpolarization; endothelium; acetylcholine	EPOXYEICOSATRIENOIC ACIDS; HYPERPOLARIZING FACTOR; ENDOTHELIAL-CELLS; K+ CHANNELS; CORONARY-ARTERIES; SMOOTH-MUSCLE; CALCIUM; MONOOXYGENASE; EXPRESSION; CLONING	Using a novel vessel culture technique in combination with antisense oligonucleotide transfection, we tested whether the endothelium-derived hyperpolarizing factor (EDHF) is a cytochrome P450 (CYP)-related compound. Isolated resistance arteries from hamster gracilis muscle (n = 19) were perfused and exposed to antisense (As), sense (S), or scrambled (Scr) oligonucleotides against the coding region of CYP2C8/9, an isoform expressed in endothelial cells. Thereafter, NO- and prostaglandin-independent, EDHF-mediated vascular responses associated with hyperpolarization [i.e., decrease in smooth muscle calcium (Fura 2) and vasodilation] were studied after the application of acetylcholine (ACh). These EDHF-mediated responses were markedly attenuated (by 70%) by As- but not by S- or Scr-oligonucleotide treatment. However, the responses to norepinephrine (0.3 mu mol/l), the NO donor sodium nitroprusside (1 mu mol/l), and the K-Ca channel activator NS1619 (100 mu mol/l) were unaltered. As treatment, which specifically targeted the endothelial layer (as assessed by confocal microscopy), had no inhibitory effect on increases in endothelial calcium to ACh. It is concluded that a CYP2C8/9-related isoform functions as an EDHF synthase in hamster resistance arteries and that a product of this enzyme is an EDHF, or at least an integral part of the signaling cascade leading to EDHF-mediated responses.	Univ Munich, Inst Physiol, D-80336 Munich, Germany; Goethe Univ Frankfurt, Inst Kardiovasc Physiol, D-6000 Frankfurt, Germany	University of Munich	Bolz, SS (corresponding author), Univ Munich, Inst Physiol, Schillerstr 44, D-80336 Munich, Germany.	bolz@lrz.uni-muenchen.de	de Wit, Cor/A-5560-2009; Fleming, Ingrid/AAB-6123-2022; Fleming, Ingrid/L-1225-2014	de Wit, Cor/0000-0003-4621-0399; Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635				Beach JM, 1996, AM J PHYSIOL-HEART C, V270, pH2216, DOI 10.1152/ajpheart.1996.270.6.H2216; Bolz SS, 1997, CARDIOVASC RES, V36, P437, DOI 10.1016/S0008-6363(97)00197-1; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Chataigneau T, 1998, BRIT J PHARMACOL, V123, P968, DOI 10.1038/sj.bjp.0701690; Clark SG, 1997, J PHARMACOL EXP THER, V282, P1473; De Wit C, 1999, AM J PHYSIOL-HEART C, V276, pH1527, DOI 10.1152/ajpheart.1999.276.5.H1527; Dora KA, 1997, P NATL ACAD SCI USA, V94, P6529, DOI 10.1073/pnas.94.12.6529; Eckman DM, 1998, BRIT J PHARMACOL, V124, P181, DOI 10.1038/sj.bjp.0701778; Edwards G, 1996, BRIT J PHARMACOL, V119, P691, DOI 10.1111/j.1476-5381.1996.tb15728.x; Gebremedhin D, 1998, J VASC RES, V35, P274, DOI 10.1159/000025594; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; Hoebel BG, 1997, BRIT J PHARMACOL, V121, P1579, DOI 10.1038/sj.bjp.0701304; Li PL, 1997, CIRC RES, V80, P877; LIN JHC, 1996, ENDOTHELIUM, V4, P219; LISCHKE V, 1995, BRIT J PHARMACOL, V115, P969, DOI 10.1111/j.1476-5381.1995.tb15905.x; McGahren ED, 1998, AM J PHYSIOL-HEART C, V274, pH60; MEININGER GA, 1991, AM J PHYSIOL, V261, pH950, DOI 10.1152/ajpheart.1991.261.3.H950; Miura H, 1998, CIRC RES, V83, P501, DOI 10.1161/01.RES.83.5.501; MORISHIMA N, 1987, BIOCHEMISTRY-US, V26, P8279, DOI 10.1021/bi00399a039; NAGAO T, 1992, AM J PHYSIOL, V263, pH1090, DOI 10.1152/ajpheart.1992.263.4.H1090; Oltman CL, 1998, CIRC RES, V83, P932; Pieperhoff S, 1998, J VASC RES, V35, P225; Popp R, 1996, J PHYSIOL-LONDON, V497, P699, DOI 10.1113/jphysiol.1996.sp021801; Quilley J, 1997, BIOCHEM PHARMACOL, V54, P1059, DOI 10.1016/S0006-2952(97)00039-7; RITKIND AB, 1995, ARCH BIOCH BOPHYS, V320, P380; SAKUMA T, 1994, MOL PHARMACOL, V45, P228; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551	27	88	90	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					255	260		10.1096/fasebj.14.2.255	http://dx.doi.org/10.1096/fasebj.14.2.255			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657982				2022-12-25	WOS:000085184800004
J	Ason, B; Bertram, JG; Hingorani, MM; Beechem, JM; O'Donnell, M; Goodman, MF; Bloom, LB				Ason, B; Bertram, JG; Hingorani, MM; Beechem, JM; O'Donnell, M; Goodman, MF; Bloom, LB			A model for Escherichia coli DNA polymerase III holoenzyme assembly at primer/template ends - DNA triggers a change in binding specificity of the gamma complex clamp loader	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; SLIDING CLAMPS; ACCESSORY PROTEINS; ATP-BINDING; SUBUNIT; BETA; PURIFICATION; EXONUCLEASE; MECHANISM; PARTICLE	The gamma complex of the Escherichia coli DNA polymerase III holoenzyme assembles the beta sliding clamp onto DNA in an ATP hydrolysis driven reaction. Interactions between gamma complex and primer/template DNA are investigated using fluorescence depolarization to measure binding of gamma complex to different DNA substrates under steady-state and presteady-state conditions. Surprisingly, gamma complex has a much higher affinity for single-stranded DNA (K-d in the nM range) than for a primed template (K-d in the mu M range) under steady-state conditions. However, when examined on a millisecond time scale, we find that gamma complex initially binds very rapidly and with high affinity to primer/template DNA but is converted subsequently to a much lower affinity DNA binding state. Presteady-state data reveals an effective dissociation constant of 1.5 nM for the initial binding of gamma complex to DNA and a dissociation constant of 5.7 mu M for the low affinity DNA binding state. Experiments using nonhydrolyzable ATP gamma S show that ATP binding con verts gamma complex hom a low affinity "inactive" to high affinity "active" DNA binding state while ATP hydrolysis has the reverse effect, thus allowing cycling between active and inactive DNA binding forms at steady-state. We propose that a DNA-triggered switch between active and inactive states of gamma complex provides a two-tiered mechanism enabling gamma complex to recognize primed template sites and load beta, while preventing gamma complex from competing with DNA polymerase III core for binding a newly loaded beta.DNA complex.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Arizona State University; Arizona State University-Tempe; University of Southern California; Vanderbilt University; Rockefeller University; Howard Hughes Medical Institute	Bloom, LB (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.		Bloom, Linda B/F-3684-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055596, R01GM021422, R37GM021422] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM055596, GM55596, GM2554, GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; DIFRANCESCO R, 1984, J BIOL CHEM, V259, P5567; FAY PJ, 1981, J BIOL CHEM, V256, P976; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P145; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x	27	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					3006	3015		10.1074/jbc.275.4.3006	http://dx.doi.org/10.1074/jbc.275.4.3006			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644772	hybrid			2022-12-25	WOS:000085128000104
J	Hallak, H; Seiler, AEM; Green, JS; Ross, BN; Rubin, R				Hallak, H; Seiler, AEM; Green, JS; Ross, BN; Rubin, R			Association of heterotrimeric G(i) with the insulin-like growth factor-I receptor - Release of G(beta gamma) subunits upon receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CEREBELLAR GRANULE NEURONS; SENSITIVE G-PROTEIN; PERMEABLE CATION CHANNEL; PERTUSSIS-TOXIN; PHOSPHOLIPASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; RAT HEPATOCYTES; GTP-BINDING	The insulin-like growth factor-I receptor (IGF-IR) is a key regulator of cell proliferation and survival. Activation of the IGF-IR induces tyrosine autophosphorylation and the binding of a series of adaptor molecules, thereby leading to the activation of MAPK. It has been demonstrated that pertussis toxin, which inactivates the G(i) class of GTP-binding proteins, inhibits IGF-I-mediated activation of MAPK, and a specific role for G(beta gamma) subunits in IGF-I signaling was shown. In the present study, we have investigated the role of heterotrimeric Gi in IG;F-IR signaling in neuronal cells. Pertussis toxin inhibited IGF-I-induced activation of MAPK in rat cerebellar granule neurons and NG-108 neuronal cells. G(alpha i) and Gp subunits were associated with IGF-IR immunoprecipitates. Similarly, in IGF-IR-null mouse embryo fibroblasts transfected with the human IG;F-IR, Gi was complexed with the IGF-IR. G(alpha s) was not associated with the IGF-IR in any cell type. IGF-I induced the release of the Gp subunits from the IGF-IR but had no effect on the association of G(alpha i). These results demonstrate an association of heterotrimeric Gi with the IGF-IR and identify a discrete pool of G(beta gamma) Subunits available for downstream signaling following stimulation with IGF-I.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Rubin, R (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, 1020 Locust St,Rm 233,Alumni Hall, Philadelphia, PA 19107 USA.	raphael.rubin@mail.tju.edu			NIAAA NIH HHS [AA07186, AA09976] Funding Source: Medline; BHP HRSA HHS [AHA9730028N] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009976, P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); BHP HRSA HHS; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Baserga R, 1997, BBA-REV CANCER, V1332, pF105, DOI 10.1016/S0304-419X(97)00007-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butler AP, 1996, CELL SIGNAL, V8, P475, DOI 10.1016/S0898-6568(96)00102-7; CHURCH JG, 1988, J BIOL CHEM, V263, P4242; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Curto M, 1997, INT J BIOCHEM CELL B, V29, P1207, DOI 10.1016/S1357-2725(97)00049-6; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; GAWLER D, 1987, FEBS LETT, V216, P94, DOI 10.1016/0014-5793(87)80763-9; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOREN HJ, 1985, CAN J PHYSIOL PHARM, V63, P1017, DOI 10.1139/y85-167; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HEYWORTH CM, 1986, BIOCHEM J, V235, P145, DOI 10.1042/bj2350145; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JIN GF, 1993, REGUL PEPTIDES, V49, P125, DOI 10.1016/0167-0115(93)90434-A; Kanzaki M, 1997, J BIOL CHEM, V272, P4964, DOI 10.1074/jbc.272.8.4964; KELLERER M, 1991, BIOCHEM J, V276, P103, DOI 10.1042/bj2760103; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANGLOIS D, 1990, ENDOCRINOLOGY, V126, P1867, DOI 10.1210/endo-126-4-1867; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LIANG M, 1991, J BIOL CHEM, V266, P13342; LINDER B, 1994, MOL CELL ENDOCRINOL, V105, P111, DOI 10.1016/0303-7207(94)90042-6; Liu JL, 1997, J BIOL CHEM, V272, P29438, DOI 10.1074/jbc.272.47.29438; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; Nie L, 1998, ENDOCRINOLOGY, V139, P179, DOI 10.1210/en.139.1.179; OKAMOTO T, 1994, FEBS LETT, V340, P292; Piiper A, 1997, AM J PHYSIOL-GASTR L, V272, pG1276, DOI 10.1152/ajpgi.1997.272.5.G1276; Poiraudeau S, 1997, J CELL BIOCHEM, V64, P414; PYNE NJ, 1989, BIOCHEM BIOPH RES CO, V165, P251, DOI 10.1016/0006-291X(89)91062-0; RAMIREZ I, 1995, CELL SIGNAL, V7, P303, DOI 10.1016/0898-6568(95)00001-6; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; RUBIN R, 1995, LAB INVEST, V73, P311; Sanchez-Margalet V, 1999, CELL MOL LIFE SCI, V55, P142, DOI 10.1007/s000180050279; Sarbassov DD, 1997, MOL ENDOCRINOL, V11, P2038, DOI 10.1210/me.11.13.2038; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Siebler T, 1996, REGUL PEPTIDES, V62, P65, DOI 10.1016/0167-0115(95)00159-X; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; TEBAR F, 1993, J BIOL CHEM, V268, P17199; Uehara T, 1999, EUR J BIOCHEM, V259, P801, DOI 10.1046/j.1432-1327.1999.00100.x; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VILA MD, 1990, BIOCHEMISTRY-US, V29, P8735, DOI 10.1021/bi00489a033; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YANG LJ, 1993, J BIOL CHEM, V268, P3739; Zhang FX, 1998, J NEUROCHEM, V71, P196, DOI 10.1046/j.1471-4159.1998.71010196.x; Zhang FX, 1998, J BIOL CHEM, V273, P26596, DOI 10.1074/jbc.273.41.26596	56	82	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2255	2258		10.1074/jbc.275.4.2255	http://dx.doi.org/10.1074/jbc.275.4.2255			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644671	hybrid			2022-12-25	WOS:000085128000003
J	Hui, D; Morden, C; Zhang, F; Ling, V				Hui, D; Morden, C; Zhang, F; Ling, V			Combinatorial analysis of the structural requirements of the Escherichia coli hemolysin signal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SECRETION SIGNAL; AMINO-ACIDS; TRANSPORT SIGNAL; P-GLYCOPROTEIN; HLYA; PROTEIN; MEMBRANE; MUTANTS; SYSTEM; REGION	We have investigated the substrate specificity of the Escherichia coli hemolysin transporter system. Translocation of hemolysin is dependent on a C-terminal signal sequence located within the last 60 amino acids of this protein. Previous comparative studies of the signal sequence have revealed a conserved helix(alpha 1)-linker-helix(alpha 2) motif, suggesting that secondary structure is important for transport. In this study, we generated three random libraries in the alpha 1, linker, and alpha 2 regions, as well as an alpha 1-amphiphilic helical library to identify features buried within the structural motif that contribute to transport, Combinatorial variants were generated by altering the primary sequence of specific regions, and correlation between the genotype and phenotype of the mutant populations allowed us to objectively identify any functional features involved. It was found that the alpha 1-amphiphilic helix and the linker are both important for function. To our surprise, the second helix of the conserved structural motif was not essential for transport. The finding that a predicted amphiphilic helix and hydrophobicity, rather than primary sequence, contribute to transport in the alpha 1 region allows us to speculate on the mechanism of multiple substrate recognition. This may have implications for understanding the broad substrate specificity common among other ATP-binding cassette transporters.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada	University of British Columbia; British Columbia Cancer Agency	Ling, V (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.							CHAN HSL, 1994, HEMATOL ONCOL CLIN N, V8, P383, DOI 10.1016/S0889-8588(18)30178-3; Chervaux C, 1996, J BACTERIOL, V178, P1232, DOI 10.1128/jb.178.4.1232-1236.1996; Childs S, 1994, Important Adv Oncol, P21; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; HESS J, 1990, MOL GEN GENET, V224, P201, DOI 10.1007/BF00271553; JARCHAU T, 1994, MOL GEN GENET, V245, P53, DOI 10.1007/BF00279750; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KENNY B, 1994, MOL MICROBIOL, V11, P99, DOI 10.1111/j.1365-2958.1994.tb00293.x; KENNY B, 1992, MOL MICROBIOL, V6, P1477, DOI 10.1111/j.1365-2958.1992.tb00868.x; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; MACKMAN N, 1987, EMBO J, V6, P2835, DOI 10.1002/j.1460-2075.1987.tb02580.x; MACKMAN N, 1985, MOL GEN GENET, V201, P282, DOI 10.1007/BF00425672; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; Shapiro AB, 1998, EUR J BIOCHEM, V254, P181, DOI 10.1046/j.1432-1327.1998.2540181.x; SHEPS JA, 1995, J BIOL CHEM, V270, P14829, DOI 10.1074/jbc.270.24.14829; SHEPS JA, 1996, MEM PROT TR, V3, P81; STANLEY P, 1991, MOL MICROBIOL, V5, P2391, DOI 10.1111/j.1365-2958.1991.tb02085.x; WOLFF N, 1994, BIOCHEMISTRY-US, V33, P6792, DOI 10.1021/bi00188a007; YIN Y, 1995, FEBS LETT, V366, P1, DOI 10.1016/0014-5793(95)00454-H; ZHANG F, 1995, BIOCHEMISTRY-US, V34, P4193, DOI 10.1021/bi00013a007; ZHANG F, 1993, P NATL ACAD SCI USA, V90, P4211, DOI 10.1073/pnas.90.9.4211; ZHANG F, 1993, J BIOL CHEM, V268, P19889	23	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2713	2720		10.1074/jbc.275.4.2713	http://dx.doi.org/10.1074/jbc.275.4.2713			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644734	hybrid			2022-12-25	WOS:000085128000066
J	Landau, E; Tirosh, R; Pinson, A; Banai, S; Even-Ram, S; Maoz, M; Katzav, S; Bar-Shavit, R				Landau, E; Tirosh, R; Pinson, A; Banai, S; Even-Ram, S; Maoz, M; Katzav, S; Bar-Shavit, R			Protection of thrombin receptor expression under hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY COLLATERAL CIRCULATION; ALPHA-THROMBIN; MYOCARDIAL-ISCHEMIA; MOLECULAR-CLONING; MESSENGER-RNA; DNA-SYNTHESIS; SH2 DOMAIN; ACTIVATION; PROTEIN; GENE	Thrombin receptor (ThR) plays a significant role in myocyte contractility and hypertrophy, Heart myocyte ischemic damage, caused by insufficient blood supply, is the leading cause of heart infarction, Here we demonstrate that when primary myocyte cultures are subjected to hypoxic stress, ThR mRNA levels are reduced markedly. This takes place also in vivo in a model of ischemic pig heart, exhibiting reduced levels of ThR compared with normal heart sections. Prior activation of ThR however, by either thrombin receptor-activating peptide (TRAP) or by alpha-thrombin resulted in full protection of ThR mRNA levels under hypoxia, The effect appeared specific to ThR because the addition of TRAP did not affect the hypoxic damage as shown by the levels of lactic dehydrogenase release and up-regulated GLUT-1, a glucose transporter gene. This protection effect took place not only in primary myocytes but also in NIH3T3 fibroblasts, ThR protection occurs via specific cell signaling events because activation of the receptor by TRAP, following interruption of the signaling cascade by calphostin C, a protein kinase C inhibitor, resulted in loss of ThR mRNA protection. Because Ras and Src are part of the ThR signaling cascade, the introduction of either dominant ras or src oncogenes to NIH3T3 murine fibroblasts gave rise to similar protection of ThR mRNA levels under hypoxic conditions without the exogenous addition of TRAP. Likewise, ThR mRNA protection was obtained after transfection with proto-oncogene vav. The 95-kDa protein Vav undergoes tyrosine phosphorylation after ThR activation, serving thus as part of the receptor machinery cascade. We therefore conclude that the initiation of the signaling cascades either exogenously by TRAP or within the cell via src or ras, as well as via aav oncogene interconnecting G-binding protein to the tyrosine kinase pathway, ultimately results in ThR protection under hypoxia, We present hereby, a novel concept of activated receptors, which under minimal oxygen tension protect their otherwise decaying mRNA Maintaining the level of ThR that plays an active role in normal myocyte function may provide a significant repair mechanism in ischemic tissue, assisting in the regaining of normal myocyte functions.	Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Dept Oncol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Lab Myocardial Res, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Dept Cardiol, Bikur Cholim Hosp, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Dept Expt Med, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Bar-Shavit, R (corresponding author), Hadassah Univ Hosp, Dept Oncol, POB 12000, IL-91120 Jerusalem, Israel.			Even-Ram, Sharona/0000-0002-5540-3822				Albert CJ, 1999, AM J PHYSIOL-HEART C, V276, pH642, DOI 10.1152/ajpheart.1999.276.2.H642; BANAI S, 1994, CARDIOVASC RES, V28, P1176, DOI 10.1093/cvr/28.8.1176; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GLEMBOTSKI CC, 1993, J BIOL CHEM, V268, P20646; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDSTEIN JA, 1994, CIRCULATION, V90, P139, DOI 10.1161/01.CIR.90.1.139; IKMAN WJ, 1992, PHYSIOL REV, V72, P449; IRANI K, 1994, BIOCHEM BIOPH RES CO, V202, P1252, DOI 10.1006/bbrc.1994.2065; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; Jiang TR, 1996, CIRC RES, V78, P553, DOI 10.1161/01.RES.78.4.553; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KATZAV S, 1995, ONCOGENE, V11, P1079; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KONDZIOLKA D, 1988, J NEUROSURG, V69, P494, DOI 10.3171/jns.1988.69.4.0494; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; Li FZ, 1996, J BIOL CHEM, V271, P26320, DOI 10.1074/jbc.271.42.26320; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; PINSON A, 1987, HEART CELL CULTURE, V1, P7; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RUGH BF, 1990, CELL, V61, P1187; RUGH KS, 1987, CARDIOVASC RES, V21, P730, DOI 10.1093/cvr/21.10.730; SABIA PJ, 1992, NEW ENGL J MED, V327, P1825, DOI 10.1056/NEJM199212243272601; SASAYAMA S, 1992, CIRCULATION, V85, P1197, DOI 10.1161/01.CIR.85.3.1197; SCHAPER W, 1971, CIRC RES, V28, P671, DOI 10.1161/01.RES.28.6.671; SHEIKI D, 1992, NATURE, V359, P843; Shock DD, 1997, BIOCHEM J, V321, P525, DOI 10.1042/bj3210525; STEIN I, 1995, MOL CELL BIOL, V15, P5363; STEINBERG SF, 1993, AM J PHYSIOL, V265, pH691, DOI 10.1152/ajpheart.1993.265.2.H691; STENMARK KR, 1988, CHEST, V93, P127; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VEMURI R, 1985, IN VITRO CELL DEV B, V21, P521; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WERTHEIMER E, 1991, P NATL ACAD SCI USA, V88, P2529; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; [No title captured]	46	11	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2281	2287		10.1074/jbc.275.4.2281	http://dx.doi.org/10.1074/jbc.275.4.2281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644676	hybrid			2022-12-25	WOS:000085128000008
J	Yang, BX; Fukuda, N; van Hoek, A; Matthay, MA; Ma, TH; Verkman, AS				Yang, BX; Fukuda, N; van Hoek, A; Matthay, MA; Ma, TH; Verkman, AS			Carbon dioxide permeability of aquaporin-1 measured in erythrocytes and lung of aquaporin-1 null mice and in reconstituted proteoliposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHIP28 WATER CHANNELS; KIDNEY COLLECTING DUCT; ION CONDUCTANCE; XENOPUS OOCYTES; EXPRESSION; GLYCEROL; CLONING; MEMBRANES; CELLS; TRANSPORTER	Measurements of CO2 permeability in oocytes and liposomes containing water channel aquaporin-1 (AQP1) have suggested that AQP1 is able to transport both water and CO2. We studied the physiological consequences of CO2 transport by AQP1 by comparing CO2 permeabilities in erythrocytes and intact lung of wild-type and AQP1 null mice. Erythrocytes from wild-type mice strongly expressed AQP1 protein and had 7-fold greater osmotic water permeability than did erythrocytes from null mice. CO2 permeability was measured from the rate of intracellular acidification in response to addition of CO2/HCO3- in a stopped-flow fluorometer using 2',7'-bis-(2-carboxyethyl)-5-(and -6)-carboxyfluorescein (BCECF) as a cytoplasmic pH indicator, In erythrocytes from wild-type mice, acidification was rapid (t(1/2), 7.3 +/- 0.4 ms, S.E., n = 11 mice) and blocked by acetazolamide and increasing external pH (to decrease CO2/HCO3- ratio). Apparent CO2 permeability (P-CO2) was not different in erythrocytes from wild-type (0.012 +/- 0.0008 cm/s) versus null (0.011 +/- 0.001 cm/s) mice. Lung CO2 transport was measured in anesthetized, ventilated mice subjected to a decrease in inspired CO2 content from 5% to 0%, producing an average decrease in arterial blood pCO(2) from 77 +/- 4 to 39 +/- 3 mm Hg (14 mice) with a t(1/2) of 1.4 min. The pCO(2) values and kinetics of decreasing pCO(2) were not different in wild-type versus null mice. Because AQP1 deletion did not affect CO2 transport in erythrocytes and lung we re-examined CO2 permeability in AQP1-reconstituted liposomes containing carbonic anhydrase (CA) and a fluorescent pH indicator. Whereas osmotic water permeability in AQP1-reconstituted liposomes was >100-fold greater than that in control liposomes, apparent P-CO2 (similar to 10(-3) cm/s) did not differ. Measurements using different CA concentrations and HgCl2 indicated that liposome P-CO2 is unstirred layer-limited and that HgCl2 slows acidification because of inhibition of CA rather than AQP1, These results provide direct evidence against physiologically significant AQP1-mediated CO2 transport and establish an upper limit to the CO2 permeability through single AQP1 water channels.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol, San Francisco, CA 94143 USA; Massachusetts Gen Hosp, Renal Unit, Charlestown, MA 02114 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, 1246 Hlth sci E Tower, San Francisco, CA 94143 USA.			Ma, Tonghui/0000-0001-9338-1030; Van Hoek, Alfred/0000-0003-2724-6855	NHLBI NIH HHS [HL60288, HL59198] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMI L, 1995, PFLUG ARCH EUR J PHY, V430, P447, DOI 10.1007/BF00373921; Agre P, 1997, SCIENCE, V275, P1490, DOI 10.1126/science.275.5305.1490; Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; Carter EP, 1996, J GEN PHYSIOL, V108, P133, DOI 10.1085/jgp.108.3.133; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; Cooper GJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1481, DOI 10.1152/ajpcell.1998.275.6.C1481; Deen PMT, 1997, SCIENCE, V275, P1491; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; FOLKESSON HG, 1994, P NATL ACAD SCI USA, V91, P4970, DOI 10.1073/pnas.91.11.4970; FOSTER RE, 1998, P NATL ACAD SCI USA, V95, P15815; GUTKNECHT J, 1977, J GEN PHYSIOL, V69, P779; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Li HL, 1997, NAT STRUCT BIOL, V4, P263, DOI 10.1038/nsb0497-263; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; MA TH, 1994, J BIOL CHEM, V269, P21845; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Prasad GVR, 1998, J BIOL CHEM, V273, P33123, DOI 10.1074/jbc.273.50.33123; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; SHI LB, 1994, J BIOL CHEM, V269, P10417; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; VANHOEK AN, 1993, BIOCHEMISTRY-US, V32, P11847, DOI 10.1021/bi00095a013; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; Verkman AS, 1997, SCIENCE, V275, P1491; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	34	152	156	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2686	2692		10.1074/jbc.275.4.2686	http://dx.doi.org/10.1074/jbc.275.4.2686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644730	hybrid			2022-12-25	WOS:000085128000062
J	Zisch, AH; Pazzagli, C; Freeman, AL; Schneller, M; Hadman, M; Smith, JW; Ruoslahti, E; Pasquale, EB				Zisch, AH; Pazzagli, C; Freeman, AL; Schneller, M; Hadman, M; Smith, JW; Ruoslahti, E; Pasquale, EB			Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses	ONCOGENE			English	Article						signaling pathways; tyrosine phosphorylation; actin cytoskeleton; cell adhesion; mitogen-activated protein kinases	ACTIN-BUNDLING PROTEIN; MAP KINASE; AUTOPHOSPHORYLATION SITE; INTEGRIN ACTIVATION; NEURAL DEVELOPMENT; LIGAND ACTIVATION; POINT MUTATION; CELL MOTILITY; IN-VITRO; FAMILY	Eph receptor tyrosine kinases play key roles in pattern formation during embryonic development, but little is known about the mechanisms by which they elicit specific biological responses in cells. Here, we investigate the role of tyrosines 605 and 611 in the juxtamembrane region of EphB2, because they are conserved Eph receptor autophosphorylation sites and demonstrated binding sites for the SH2 domains of multiple signaling proteins. Mutation of tyrosines 605 and 611 to phenylalanine impaired EphB2 kinase activity, complicating analysis of their function as SH2 domain binding sites and their contribution to EphB2-mediated signaling. In contrast, mutation to the negatively charged glutamic acid disrupted SH2 domain binding without reducing EphB2 kinase activity. By using a panel of EphB2 mutants, we found that kinase activity is required for the changes in cell-matrix and cell-cell adhesion, cytoskeletal organization, and activation of mitogen-activated protein (MAP) kinases elicited by EphB2 in transiently transfected cells, Instead, the two juxtamembrane SH2 domain binding sites were dispensable for these effects. These results suggest that phosphorylation of tyrosines 605 and 611 is critical for EphB2-mediated cellular responses because it regulates EphB2 kinase activity.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NICHD NIH HHS [HD26351, HD25938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026351, P01HD025938, R01HD026351] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; ADAMS JC, 1995, J CELL SCI, V108, P1977; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Giasson BI, 1997, J NEUROSCI, V17, P9466; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Kalo MS, 1999, BIOCHEMISTRY-US, V38, P14396, DOI 10.1021/bi991628t; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lin XH, 1996, MOL BIOL CELL, V7, P1977, DOI 10.1091/mbc.7.12.1977; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Veeranna, 1998, J NEUROSCI, V18, P4008; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; Zisch AH, 1997, CELL TISSUE RES, V290, P217, DOI 10.1007/s004410050926; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U; ZOU JX, IN PRESS P NAT ACAD	74	98	98	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					177	187		10.1038/sj.onc.1203304	http://dx.doi.org/10.1038/sj.onc.1203304			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644995				2022-12-25	WOS:000084844400002
J	Cruzalegui, FH; Cano, E; Treisman, R				Cruzalegui, FH; Cano, E; Treisman, R			ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry	ONCOGENE			English	Article						TCF; SRE; ERK; MAP kinase; Elk-1; SAP-1	SERUM RESPONSE FACTOR; TERNARY COMPLEX FACTORS; MAP KINASE PATHWAYS; C-FOS EXPRESSION; TRANSCRIPTIONAL ACTIVATION; PROTEIN-KINASE; TRANSACTIVATION DOMAIN; ELEMENT; BINDING; CASCADES	Elk-1, a member of the TCF family of Ets domain proteins, contains a C-terminal transcriptional activation domain with multiple copies of the MAPK core consensus sequence S/T-P. This region is phosphorylated by MAP kinases in vitro and in vivo, but the extent and kinetics of phosphorylation at the different sites have not been investigated in detail. We prepared antisera against the phosphorylated forms of residues T353, T363, T368, S383, S389 and T417. The antisera specifically recognize the phosphorylated Elk-1 C terminus and are specific for their cognate sites, as assessed by peptide competition and mutagenesis experiments. Analysis of cells stably expressing Elk-1 in vivo shows that following serum or TPA stimulation, residues T353, T363, T368, S383, S389 and T417 become phosphorylated with similar kinetics. Mutation of any one site does not prevent phosphorylation of the others. Mutation to alanine of S383, F378 or W379, which virtually abolishes transcriptional activation by Elk-1, does not affect phosphorylation of any sites tested. Analysis of Elk-1 using two-dimensional gel electrophoresis shows that following ERK activation Elk-1 receives at least six phosphates in addition to those present prior to stimulation. We propose that the Elk-1 C-terminal regulatory domain becomes stoichiometrically phosphorylated following growth factor stimulation.	Imperial Canc Res Fund, Transcript Lab, London WC2A 3PX, England	Cancer Research UK	Treisman, R (corresponding author), Imperial Canc Res Fund, Transcript Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Cano, Eva/A-2049-2010	Cano, Eva/0000-0003-2750-6135; Treisman, Richard/0000-0002-9658-0067				Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Shen F, 1996, J BIOL CHEM, V271, P4827; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZINCK R, 1995, MOL CELL BIOL, V15, P4930; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	34	137	140	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7948	7957		10.1038/sj.onc.1203362	http://dx.doi.org/10.1038/sj.onc.1203362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637505				2022-12-25	WOS:000084634600003
J	Miyata, S; Koshikawa, N; Yasumitsu, H; Miyazaki, K				Miyata, S; Koshikawa, N; Yasumitsu, H; Miyazaki, K			Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; THROMBIN RECEPTOR; MOLECULAR-CLONING; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; ENZYMATIC-PROPERTIES; SERINE PROTEINASES; TUMOR-CELLS; EXPRESSION; IDENTIFICATION	Trypsin is widely expressed in various non-pancreatic tissues at low levels and overexpressed in some types of human cancers. In the present study, we found that trypsin stimulates integrin-dependent adhesion and growth of MKN-1 human gastric carcinoma cells. MKN-1 cells expressed both proteinase-activated receptor-1 (PAR-1) and PAR-2, which are activated by thrombin and trypsin, respectively. Both trypsin and the PAR-S ligand SLIGKV promoted integrin alpha(5)beta(1)-mediated adhesion of MKN-1 cells to fibronectin, and less effectively integrin alpha(v)beta(3)-mediated cell adhesion to vitronectin, but not that to type IV collagen or laminin-l at all. Thrombin and the PAR-1 ligand SFLLRN promoted the cell adhesion to vitronectin more strongly than trypsin or the PAR-2 ligand, but not the cell adhesion to fibronectin at all. The cell adhesion-stimulating effect of the PAR-S ligand was significantly reduced by the pre-treatment of cells with trypsin, indicating that the effect of trypsin is mediated by PAR-S activation. The trypsin-stimulated cell adhesion to vitronectin, but not to fibronectin, was effectively inhibited by the Gi protein blocker pertussis toxin, and both cell adhesions were completely inhibited by the Src kinase inhibitor herbimycin A. Furthermore, trypsin and the PAR-2 ligand stimulated growth of MKN-1 cells more strongly than thrombin or the PAR-1 ligand. These results show that trypsin regulates cellular adhesion and proliferation by inducing PAR-BIG protein signalings, and that the integrin alpha(5)beta(1)- and integrin alpha(v)beta(3)-dependent cell adhesions are regulated by different PAR/G protein signalings.Trypsin is widely expressed in various non-pancreatic tissues at low levels and overexpressed in some types of human cancers. In the present study, we found that trypsin stimulates integrin-dependent adhesion and growth of MKN-1 human gastric carcinoma cells. MKN-1 cells expressed both proteinase-activated receptor-1 (PAR-1) and PAR-2, which are activated by thrombin and trypsin, respectively. Both trypsin and the PAR-S ligand SLIGKV promoted integrin alpha(5)beta(1)-mediated adhesion of MXN-1 cells to fibronectin, and less effectively integrin alpha(v)beta(3)-mediated cell adhesion to vitronectin, but not that to type IV collagen or laminin-1 at all. Thrombin and the PAR-1 ligand SFLLRN promoted the cell adhesion to vitronectin more strongly than trypsin or the PAR-2 ligand, but not the cell adhesion to fibronectin at all. The cell adhesion-stimulating effect of the PAR-S ligand was significantly reduced by the pre-treatment of cells with trypsin, indicating that the effect of trypsin is mediated by PAR-S activation. The trypsin-stimulated cell adhesion to vitronectin, but not to fibronectin, was effectively inhibited by the Gi protein blocker pertussis toxin, and both cell adhesions were completely inhibited by the Src kinase inhibitor herbimycin A. Furthermore, trypsin and the PAR-2 ligand stimulated growth of MKN-1 cells more strongly than thrombin or the PAR-1 ligand. These results show that trypsin regulates cellular adhesion and proliferation by inducing PAR-BIG protein signalings, and that the integrin alpha(5)beta(1)- and integrin alpha(v)beta(3)-dependent cell adhesions are regulated by different PAR/G protein signalings.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University; Yokohama City University	Miyazaki, K (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, 641-12 Maioka, Yokohama, Kanagawa 2440813, Japan.	miyazaki@yokohama-cu.ac.jp	Koshikawa, Naohiko/S-7306-2017	Koshikawa, Naohiko/0000-0002-4539-888X				BAFFY G, 1994, J BIOL CHEM, V269, P8483; Belham CL, 1996, BIOCHEM J, V320, P939, DOI 10.1042/bj3200939; BLUMBERG PM, 1975, CELL, V6, P137, DOI 10.1016/0092-8674(75)90004-5; Bohm SK, 1996, BIOCHEM J, V314, P1009; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P581; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Chiang HS, 1996, BRIT J CANCER, V73, P902, DOI 10.1038/bjc.1996.161; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; COUGHLIN SR, 1994, P NATL ACAD SCI USA, V91, P9200, DOI 10.1073/pnas.91.20.9200; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Fox MT, 1997, FEBS LETT, V417, P267, DOI 10.1016/S0014-5793(97)01298-2; FUJIL K, 1995, EXP CELL RES, V220, P201, DOI 10.1006/excr.1995.1307; HIRAHARA F, 1995, INT J CANCER, V63, P176, DOI 10.1002/ijc.2910630205; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kato Y, 1998, EUR J CANCER, V34, P1117, DOI 10.1016/S0959-8049(98)00077-X; Kawano N, 1997, HUM PATHOL, V28, P613, DOI 10.1016/S0046-8177(97)90085-X; KLEPFISH A, 1993, INT J CANCER, V53, P978; KOIVUNEN E, 1989, J BIOL CHEM, V264, P14095; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; Koshikawa N, 1998, AM J PATHOL, V153, P937, DOI 10.1016/S0002-9440(10)65635-0; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597; Miyata S, 1998, CLIN EXP METASTAS, V16, P613, DOI 10.1023/A:1006576313979; Miyata S, 1999, J BIOCHEM, V125, P1067, DOI 10.1093/oxfordjournals.jbchem.a022388; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; NIERODZIK MLR, 1992, CANCER RES, V52, P3267; Nierodzik MLR, 1996, BRIT J HAEMATOL, V92, P452, DOI 10.1046/j.1365-2141.1996.d01-1494.x; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; OKADA Y, 1992, J BIOL CHEM, V267, P21712; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SEFTON BM, 1970, NATURE, V227, P843, DOI 10.1038/227843a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sorsa T, 1997, J BIOL CHEM, V272, P21067, DOI 10.1074/jbc.272.34.21067; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	45	106	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4592	4598		10.1074/jbc.275.7.4592	http://dx.doi.org/10.1074/jbc.275.7.4592			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671485	hybrid			2022-12-25	WOS:000085378200011
J	Yang, XY; Wang, LH; Chen, TS; Hodge, DR; Resau, JH; DaSilva, L; Farrar, WL				Yang, XY; Wang, LH; Chen, TS; Hodge, DR; Resau, JH; DaSilva, L; Farrar, WL			Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPAR gamma) agonists - PPAR gamma co-association with transcription factor NFAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CELLS; IL-2; GENE	T lymphocyte activation is highlighted by the induction of interleukin-2 (IL-2) gene expression, which governs much of the early lymphocyte proliferation responses. Peroxisome proliferator-activated receptor-gamma (PPAR gamma) is a member of the nuclear receptor superfamily of ligand-activated transcription factors. PPAR gamma mRNA expression was found in human peripheral blood T lymphocytes, raising the possibility of PPAR gamma involvement in the regulation of T cell function. Here we show that PPAR gamma ligands, troglitazone and 15-deoxy-Delta(12,14) prostaglandin J(2), but not PPAR alpha agonist Wy14643, inhibited IL-2 production and phytohemagglutinin-inducible proliferation in human peripheral blood T-cells in a dose-dependent manner. This inhibitory effect on IL-2 was restricted to the PPAR gamma 2-expressing, not the PPAR gamma-lacking, subpopulation of transfected Jurkat cells. The activated PPAR gamma physically associates with transcriptional factor NFAT regulating the IL-2 promoter, blocking NFAT DNA binding and transcriptional activity. This interaction with T-cell-specific transcription factors indicates an important immunomodulatory role for PPAR gamma in T lymphocytes and could suggest a previously unrecognized clinical potential for PPAR gamma ligands as immunotherapeutic drugs to treat T-cell-mediated diseases by targeting IL-2 gene expression.	NCI, Frederick Canc Res & Dev Ctr, Intramural Res Support Program, SAIC Frederick,NIH, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Cytokine Mol Mechanisms Sect, Lab Mol Immunoregulat,NIH, Frederick, MD 21702 USA; NCI, ABL Basic Res Program, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Farrar, WL (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Intramural Res Support Program, SAIC Frederick,NIH, POB B,Bldg 560,Rm 31-76, Frederick, MD 21702 USA.		Chen, Taosheng/I-6351-2013	Chen, Taosheng/0000-0001-6420-3809	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010253] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brun RP, 1997, CURR OPIN LIPIDOL, V8, P212, DOI 10.1097/00041433-199708000-00004; Chen RH, 1999, AM J PHYSIOL-RENAL, V276, pF777, DOI 10.1152/ajprenal.1999.276.5.F777; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; Greene M. E., 1995, Gene Expression, V4, P281; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Wang LH, 1999, J IMMUNOL, V162, P3897	18	333	351	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4541	4544		10.1074/jbc.275.7.4541	http://dx.doi.org/10.1074/jbc.275.7.4541			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671476	hybrid			2022-12-25	WOS:000085378200002
J	Chen, SY; Johnson, BA; Li, Y; Aster, S; McKeever, B; Mosley, R; Moller, DE; Zhou, GC				Chen, SY; Johnson, BA; Li, Y; Aster, S; McKeever, B; Mosley, R; Moller, DE; Zhou, GC			Both coactivator LXXLL motif-dependent and -independent interactions are required for peroxisome proliferator-activated receptor gamma (PPAR gamma) function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR; LIGAND-BINDING; ASSIGNMENT; PROTEIN; N-15; HETERODIMERS; SPECIFICITY; C-13; PBP	Nuclear receptor activation is dependent on recruitment of coactivators, including CREB-binding protein (GBP/p300) and steroid receptor coactivator-1 (SRC-1), A three-dimensional NMR approach was used to probe the coactivator binding interface in the peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand binding domain (LBD), In the presence of a CBP peptide, peaks corresponding to 20 residues in helices 3, 4, 5, and 12 of the LED were attenuated. Alanine mutants revealed that M301A, V315A, Y320A, L468A, and E471A were required for binding of both CBP and SRC-1 and for cell-based transcription. Several additional amino acids in helix 4 of the PPAR gamma LBD were defective with respect to CBP recruitment, but retained relatively normal SRC-1 recruitment. Thus these amino acid residues may be important determinants of specificity for nuclear receptor LED interactions with discrete coactivator molecules.	Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA; Merck Res Labs, Dept Endocrinol & Chem Biol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Syst, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company	Zhou, GC (corresponding author), Merck Res Labs, Dept Metab Disorders, RYSON-31C,126 E Lincoln Ave, Rahway, NJ 07065 USA.							Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Jain S, 1998, AM J PATHOL, V153, P349, DOI 10.1016/S0002-9440(10)65577-0; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Maniatis T., 1989, MOL CLONING LAB MANU; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; Mulder FAA, 1996, J BIOMOL NMR, V8, P223, DOI 10.1007/BF00211169; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Shan X, 1996, J AM CHEM SOC, V118, P6570, DOI 10.1021/ja960627a; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; VONLANGEN D, 1999, KEYST S MOL CELL BIO; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YAMAZAKI T, 1995, J AM CHEM SOC, V117, P3556, DOI 10.1021/ja00117a025; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	28	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3733	3736		10.1074/jbc.275.6.3733	http://dx.doi.org/10.1074/jbc.275.6.3733			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660518	hybrid			2022-12-25	WOS:000085288800002
J	Inouye, K; Mizutani, S; Koide, H; Kaziro, Y				Inouye, K; Mizutani, S; Koide, H; Kaziro, Y			Formation of the Ras dimer is essential for Raf-1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HA-RAS; PLASMA-MEMBRANE; IN-VITRO; KINASE; PROTEINS; EXPRESSION; C-RAF-1; CELLS; ACID; P21(RAS)	Although it is well established that Ras requires membrane localization for activation of its target molecule, Raf-1, the reason for this requirement is not fully understood. in this study, we found that modified Ras, which is purified from Sf9 cells, could activate Raf-1 in a cell-free system, when incorporated into liposome. Using a bifunctional cross-linker and a protein-fragmentation complementation assay, we detected dimer formation of Ras in the liposome and in the intact cells, respectively. These results suggest that dimerization of Ras in the lipid membrane is essential for activation of Raf-1. To support this, we found that, when fused to glutathione S-transferase (GST), unprocessed has expressed in Escherichia coli could bypass the requirement for liposome. A Ras-dependent Raf-1 activator, which we previously reported (Mizutani, S., Koide, H., and Kaziro, Y. (1998) Oncogene 16, 2781-2786), was still required for Raf-1 activation by GST-Ras. Furthermore, an enforced dimerization of unmodified oncogenic Ras mutant in human embryonic kidney (HEK) 293 cells, using a portion of gyrase B or estrogen receptor, also resulted in activation of Raf-1. From these results, we conclude that membrane localization allows has to form a dimer, which is essential, although not sufficient, for Raf-1 activation.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Kaziro, Y (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		Koide, Hiroshi/E-9000-2011	Koide, Hiroshi/0000-0001-5916-3179				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOWE PN, 1991, J BIOL CHEM, V266, P1672; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; Mizutani S, 1998, ONCOGENE, V16, P2781, DOI 10.1038/sj.onc.1201806; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; SHIROUZU M, 1994, ONCOGENE, V9, P2153; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	27	115	117	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3737	3740		10.1074/jbc.275.6.3737	http://dx.doi.org/10.1074/jbc.275.6.3737			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660519	hybrid			2022-12-25	WOS:000085288800003
J	Lasley, RD; Narayan, P; Uittenbogaard, A; Smart, EJ				Lasley, RD; Narayan, P; Uittenbogaard, A; Smart, EJ			Activated cardiac adenosine A(1) receptors translocate out of caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; RAT VENTRICULAR MYOCYTES; NITRIC-OXIDE SYNTHASE; ADENYLYL-CYCLASE; ANGIOTENSIN-II; G-PROTEINS; STIMULATION; DESENSITIZATION; CARDIOMYOCYTES; MYOCARDIUM	The cardiac affects of the purine nucleoside, adenosine, are well known. Adenosine increases coronary blood flow, exerts direct negative chronotropic and dromotropic effects, and exerts indirect anti-adrenergic effects. These effects of adenosine are mediated via the activation of specific G protein-coupled receptors, There is increasing evidence that caveolae play a role in the compartmentalization of receptors and second messengers in the vicinity of the plasma membrane. Several reports demonstrate that G protein-coupled receptors redistribute to caveolae in response to receptor occupation. In this study, we tested the hypothesis that adenosine A(1) receptors would translocate to caveolae in the presence of agonists, Surprisingly, in unstimulated rat cardiac ventricular myocytes, 67 +/- 5% of adenosine A(1) receptors were isolated with caveolae. However, incubation with the adenosine A(1) receptor agonist 2-chlorocyclopentyladenosine induced the rapid translocation of the A(1) receptors from caveolae into non-caveolae plasma membrane, an effect that was blocked by the adenosine A(1) receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine. An adenosine A(2a) receptor agonist did not alter the localization of A(1) receptors to caveolae, These data suggest that the translocation of A(1) receptors out of caveolae and away from compartmentalized signaling molecules may explain why activation of ventricular myocyte A(1) receptors are associated with few direct effects.	Univ Kentucky, Dept Physiol, Sch Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Surg, Sch Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Smart, EJ (corresponding author), Univ Kentucky, Dept Physiol, Sch Med, 800 Rose St,MS 508 C, Lexington, KY 40536 USA.	ejsmart@pop.uky.edu						ABDELLATIF MM, 1991, CIRC RES, V69, P800, DOI 10.1161/01.RES.69.3.800; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BARRY WH, 1995, ADV EXP MED BIOL, V382, P31; BELARDINELLI L, 1995, FASEB J, V9, P359, DOI 10.1096/fasebj.9.5.7896004; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; CYR C, 1993, J CARDIOVASC PHARM, V22, pS11, DOI 10.1097/00005344-199322008-00005; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; ENGSTROEM L, 1961, BIOCHIM BIOPHYS ACTA, V52, P36, DOI 10.1016/0006-3002(61)90901-5; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Figler RA, 1996, MOL PHARMACOL, V50, P1587; GRAHAM J, 1993, METHODS MOL BIOL, V19; Haasemann M, 1998, J CELL SCI, V111, P917; Henry P, 1996, CIRC RES, V78, P161, DOI 10.1161/01.RES.78.1.161; HILALDANDAN R, 1994, MOL PHARMACOL, V45, P1183; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; LASLEY RD, 1998, MOL B INT U, V1, P133; LEE HT, 1993, AM J PHYSIOL, V265, pH1916, DOI 10.1152/ajpheart.1993.265.6.H1916; LINDEN J, 1985, CIRC RES, V56, P728, DOI 10.1161/01.RES.56.5.728; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; MAISEL AS, 1985, SCIENCE, V230, P183, DOI 10.1126/science.2994229; MARTENS D, 1988, CIRC RES, V63, P613, DOI 10.1161/01.RES.63.3.613; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MINSHALL RD, 1995, CIRC RES, V76, P773, DOI 10.1161/01.RES.76.5.773; MUSSER B, 1993, EUR J PHARM-MOLEC PH, V246, P105, DOI 10.1016/0922-4106(93)90086-O; Narayan P, 1998, J MOL CELL CARDIOL, V30, P913, DOI 10.1006/jmcc.1998.0648; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1997, CELL MOL BIOL, V43, P293; Song YJ, 1996, AM J PHYSIOL-CELL PH, V271, pC1233; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525	39	107	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4417	4421		10.1074/jbc.275.6.4417	http://dx.doi.org/10.1074/jbc.275.6.4417			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660613	hybrid			2022-12-25	WOS:000085288800097
J	Liao, W; Chan, L				Liao, W; Chan, L			Apolipoprotein B, a paradigm for proteins regulated by intracellular degradation, does not undergo intracellular degradation in CaCo2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; UBIQUITIN-PROTEASOME PATHWAY; MESSENGER-RNA; ENDOPLASMIC-RETICULUM; RAT HEPATOCYTES; OLEIC-ACID; SECRETION; TRANSLOCATION; B100	Studies in different liver-derived cells in culture indicate that apolipoprotein (apo) B-100 production is regulated largely by intracellular degradation and the ubiquitin-proteasome pathway is a major mechanism for the degradation. The proteasomal degradation of apoB-100 was postulated to be an intrinsic property of the protein that occurs even in the presence of optimal amounts of lipids supplied to the cell. We examined apoB-100 and apoB-48 biogenesis in CaCo2, a human colon carcinoma cell line. To our surprise, apoB-100 and apoB-48 were quantitatively secreted by CaCo2 cells; essentially none of the newly synthesized apoB was degraded before secretion in a 2-h period whether the cells were cultured on filter or on plastic. Furthermore, although ubiquitin immunoreactivity was readily detected in the intracellular apoB isolated from HepG2 cells, little or no ubiquitin was detectable in the intracellular apoB from CaCo2 cells. The amounts of free ubiquitin and total and non-apoB ubiquitinated proteins were comparable in HepG2 and CaCo2 cells, indicating that CaCo2 cells have the necessary machinery for tagging ubiquitin chains onto cellular proteins for proteasomal degradation. Incubation in lipoprotein-deficient serum did not induce apoB degradation, but the addition of a microsomal triglyceride transfer protein inhibitor led to apoB degradation in CaCo2 cells. Finally, similar proportions of apoB polypeptide in isolated microsomes from CaCo2 and HepG2 cells were accessible to exogenously added trypsin, indicating that the mere exposure of apoB nascent chains to the cytosolic compartment is insufficient to cause the proteasomal degradation. Therefore, the intracellular degradation of apoB is not an intrinsic property of the protein, and the phenomenon is neither universal nor inevitable. The unconditional use of apoB as a paradigm for intracellular protein degradation is not warranted.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Liao, W (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056668, R37HL016512, R01HL016512] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16512, HL-56668] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1994, J BIOL CHEM, V269, P25879; Cavallo D, 1998, J BIOL CHEM, V273, P33397, DOI 10.1074/jbc.273.50.33397; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHANG BHJ, 1998, MODIFICATION EDITING, P325; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; DASHTI N, 1990, J LIPID RES, V31, P113; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; DU EZ, 1994, J BIOL CHEM, V269, P24169; FIELD FJ, 1994, J LIPID RES, V35, P749; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Hersberger M, 1998, J BIOL CHEM, V273, P9435, DOI 10.1074/jbc.273.16.9435; JIAO S, 1990, J LIPID RES, V31, P695; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; Liang JS, 1998, J BIOL CHEM, V273, P35216, DOI 10.1074/jbc.273.52.35216; Liao W, 1999, BIOCHEMISTRY-US, V38, P7532, DOI 10.1021/bi9904196; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; MURTHY S, 1992, ARTERIOSCLER THROMB, V12, P691, DOI 10.1161/01.ATV.12.6.691; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SATO R, 1990, J BIOL CHEM, V265, P11880; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; Tsai HL, 1996, J BIOL CHEM, V271, P3534; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WHITE AL, 1992, J BIOL CHEM, V267, P15657; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SCJ, 1998, TRENDS CARDIOVAS MED, V8, P8, DOI 10.1016/S1050-1738(97)00120-5; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	42	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3950	3956		10.1074/jbc.275.6.3950	http://dx.doi.org/10.1074/jbc.275.6.3950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660549	hybrid			2022-12-25	WOS:000085288800033
J	Namsaraev, EA; Berg, P				Namsaraev, EA; Berg, P			Rad51 uses one mechanism to drive DNA strand exchange in both directions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; RECA PROTEIN; BRANCH MIGRATION; ATP HYDROLYSIS; SACCHAROMYCES-CEREVISIAE; POLARITY; BINDING; REQUIREMENTS; REPLICATION; SEQUENCE	The Rad51 protein of Saccharomyces cerevisiae, like its bacterial counterpart RecA, promotes strand exchange between circular single-stranded DNA (ssDNA) and linear double-stranded DNA (dsDNA) in vitro, However, the two proteins differ in the requirement for initiating joint molecules and in the polarity of branch migration. Whereas RecA initiates joint molecules from any type of ends on the dsDNA and branch migration proceeds exclusively in the 5'- to 3'-direction with respect to the single strand DNA substrate, initiation mediated by Rad51 requires a complementary 3' or 5' overhanging end of the linear dsDNA and branch migration proceeds in either direction. Here we report that the rates of Rad51-mediated branch migration in either the 5'- to 3'- or 3'- to 5'-directions are affected to the same extent by temperature and MgCl2. Furthermore, branch migration in both directions is equally impeded by in sertions of non-homologous sequences in the dsDNA, inserts of 6 base pairs or more being completely inhibitory. We have also found that the preference of strand exchange in the 5'- to 3'-direction does not change if RPA is replaced by Escherichia coli SSB or T4 gene 32 proteins, suggesting that the preference for the direction of strand exchange is intrinsic to Rad51, Based on these results, we conclude that Rad51-promoted branch migration in either direction occurs fundamentally by the same mechanism, quite probably by stabilizing successively formed heteroduplex base pair.	Stanford Univ, Beckman Ctr Mol & Genet Med, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Berg, P (corresponding author), Stanford Univ, Beckman Ctr Mol & Genet Med, Sch Med, Dept Biochem, B062, Stanford, CA 94305 USA.				NIGMS NIH HHS [GM13235] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM013235, R01GM013235] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; HALL SD, 1994, P NATL ACAD SCI USA, V91, P3205, DOI 10.1073/pnas.91.8.3205; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KIM JI, 1992, J BIOL CHEM, V267, P16438; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; Li Z, 1998, J MOL BIOL, V276, P733, DOI 10.1006/jmbi.1997.1572; MacFarland KJ, 1997, J BIOL CHEM, V272, P17675, DOI 10.1074/jbc.272.28.17675; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Namsaraev EA, 1998, P NATL ACAD SCI USA, V95, P10477, DOI 10.1073/pnas.95.18.10477; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; Namsaraev EA, 1998, BIOCHEMISTRY-US, V37, P11932, DOI 10.1021/bi9810297; Nayak S, 1999, J BIOL CHEM, V274, P25979, DOI 10.1074/jbc.274.37.25979; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149	30	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3970	3976		10.1074/jbc.275.6.3970	http://dx.doi.org/10.1074/jbc.275.6.3970			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660552	hybrid			2022-12-25	WOS:000085288800036
J	Romanowski, P; Marr, JJ; Madine, MA; Rowles, A; Blow, JJ; Gautier, J; Laskey, RA				Romanowski, P; Marr, JJ; Madine, MA; Rowles, A; Blow, JJ; Gautier, J; Laskey, RA			Interaction of Xenopus Cdc2 center dot cyclin A1 with the origin recognition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; CELL-CYCLE; S-PHASE; YEAST ORIGIN; FISSION YEAST; EGG EXTRACTS; PROTEIN; MITOSIS; INITIATION	The initiation of DNA replication in eukaryotes is regulated in a minimum of at least two ways. First, several proteins, including origin recognition complex (ORC), Cdc6 protein, and the minichromosome maintenance (MCM) protein complex, need to be assembled on chromatin before initiation. Second, cyclin-dependent kinases regulate DNA replication in both a positive and a negative way by inducing the initiation of DNA replication at G(1)/S transition and preventing further rounds of origin firing within the same cell cycle. Here we characterize a link between the two levels. Immunoprecipitation of Xenopus origin recognition complex with anti XOrc1 or anti-XOrc2 antibodies specifically co immunoprecipitates a histone H1 kinase activity. The kinase activity is sensitive to several inhibitors of cyelin-dependent kinases including 6-dimethylaminopurine (6-DMAP), olomoucine, and p21(Cip1). This kinase activity also copurifies with ORC over several fractionation steps and was identified as a complex of the Cdc2 catalytic subunit and cyclin Al. Neither Cdk2 nor cyclin E could be detected in ORC immunoprecipitations. Reciprocal immunoprecipitations with anti-Xenopus Cdc2 or anti-Xenopus cyclin Al antibodies specifically eo-precipitate XOrc1 and XOrc2. Our results indicate that Xenopus ORC and Cdc2.cyclin Al physically interact and demonstrate a physical link between an active cyclin-dependent kinase and proteins involved in the initiation of DNA replication.	Wellcome Canc Res Campaign Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Columbia Univ, Dept Dermatol & Genet, New York, NY 10032 USA	University of Cambridge; Columbia University	Laskey, RA (corresponding author), Wellcome Canc Res Campaign Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	ra119@mole.bio.cam.ac.uk	Blow, J. Julian/B-3977-2009; Gautier, jean/A-2774-2008	Blow, J. Julian/0000-0002-9524-5849; 				BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chevalier S, 1996, J CELL SCI, V109, P1173; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coverley D, 1998, EXP CELL RES, V238, P63, DOI 10.1006/excr.1997.3829; Coverley D, 1996, EXP CELL RES, V225, P294, DOI 10.1006/excr.1996.0179; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Goodger NM, 1996, J PATHOL, V178, P422, DOI 10.1002/(SICI)1096-9896(199604)178:4<422::AID-PATH497>3.0.CO;2-2; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KOBAYASHI H, 1994, J BIOL CHEM, V269, P29153; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Romanowski P, 1996, TRENDS CELL BIOL, V6, P184, DOI 10.1016/0962-8924(96)10015-5; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Strausfeld UP, 1996, J CELL SCI, V109, P1555; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617	55	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4239	4243		10.1074/jbc.275.6.4239	http://dx.doi.org/10.1074/jbc.275.6.4239			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660590	hybrid			2022-12-25	WOS:000085288800074
J	Wang, A; Schneider-Broussard, R; Kumar, AP; MacLeod, MC; Johnson, DG				Wang, A; Schneider-Broussard, R; Kumar, AP; MacLeod, MC; Johnson, DG			Regulation of BRCA1 expression by the Rb-E2F pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; MESSENGER-RNA; DNA-SYNTHESIS; HUMAN BREAST; S-PHASE; APOPTOSIS; P53	Inheritance of a mutant allele of the breast cancer susceptibility gene BRCA1 confers increased risk of developing breast and ovarian cancers. Likewise, inheritance of a mutant allele of the retinoblastoma susceptibility gene (RBI) results in the development of retinoblastoma and/or osteosarcoma, and both alleles are often mutated or inactivated in sporadic forms of these and other cancers. We now demonstrate that the product of the RBI gene, Rb, regulates the expression of the murine Brca1 and human BRCA1 genes through its ability to modulate E2F transcriptional activity. The Brca1 gene is identified as an in vivo target of E2F1 in a transgenic mouse model. The Brca1 promoter contains E2F DNA-binding sites that mediate transcriptional activation by E2F1 and repression by Rb, Moreover, ectopic expression of cyclin D1 and Cdk4 can stimulate the Brca1 promoter in an E2F-dependent manner, and this is inhibited by coexpression of the p16(INK4a) cyclin-dependent kinase inhibitor. The human BRCA1 promoter also contains a conserved E2F site and is similarly regulated by E2F1 and Rb. This functional link between the BRCA1 and Rb tumor suppressors may provide insight into the mechanism by which BRCA1 inactivation contributes to cancer development.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.			Johnson, David/0000-0002-6223-1790	NCI NIH HHS [CA16672, CA79648] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA079648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hunt KK, 1997, CANCER RES, V57, P4722; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Shao NS, 1996, ONCOGENE, V13, P1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	49	97	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4532	4536		10.1074/jbc.275.6.4532	http://dx.doi.org/10.1074/jbc.275.6.4532			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660629	hybrid			2022-12-25	WOS:000085288800113
J	Gray, PC; Greenwald, J; Blount, AL; Kunitake, KS; Donaldson, CJ; Choe, S; Vale, W				Gray, PC; Greenwald, J; Blount, AL; Kunitake, KS; Donaldson, CJ; Choe, S; Vale, W			Identification of a binding site on the type II activin receptor for activin and inhibin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PROTEIN; CLONING; RESPONSES; DOMAIN; KINASE; CELLS	Type II activin receptors (ActRII and ActRIIB) are single-transmembrane domain serine/threonine kinase receptors that bind activin to initiate the signaling and cellular responses triggered by this hormone, Inhibin also binds type II activin receptors and antagonizes many activin effects. Here we describe alanine scanning mutagenesis of the ActRII extracellular domain, We identify a cluster of three hydrophobic residues (Phe(42), Trp(60), and phe(83)) that, when individually mutated to alanine in the context of the full-length receptor, cause the disruption of activin and inhibin binding to ActRII, Each of the alanine-substituted ActRII mutants retaining activin binding maintains the ability to form crosslinked complexes with activin and supports activin cross-linking to the type I activin receptor ALK4, Unlike wild-type ActRII, the three mutants unable to bind activin do not cause an increase in activin signaling when transiently expressed in a corticotroph cell line, Together, our results implicate these residues in forming a critical binding surface on ActRII required for functional interactions with both activin and inhibin, This first identification of a transforming growth factor-p family member binding site may provide a general basis for characterizing binding sites for other members of the superfamily.	Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute; Salk Institute	Vale, W (corresponding author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	vale@salk.edu			NICHD NIH HHS [HD-13527] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Attisano L, 1996, MOL CELL BIOL, V16, P1066; BILEZIKJIAN LM, 1991, MOL ENDOCRINOL, V5, P1389, DOI 10.1210/mend-5-10-1389; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Donaldson CJ, 1999, ENDOCRINOLOGY, V140, P1760, DOI 10.1210/en.140.4.1760; Draper LB, 1998, J BIOL CHEM, V273, P398, DOI 10.1074/jbc.273.1.398; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Greenwald J, 1998, BIOCHEMISTRY-US, V37, P16711, DOI 10.1021/bi981939o; Greenwald J, 1999, NAT STRUCT BIOL, V6, P18; Guimond A, 1999, FEBS LETT, V456, P79, DOI 10.1016/S0014-5793(99)00869-8; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; LIU F, 1995, MOL CELL BIOL, V15, P3479; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; Pepin MC, 1996, BIOCHEM BIOPH RES CO, V220, P289, DOI 10.1006/bbrc.1996.0398; REES B, 1993, CHEM RES TOXICOL, V6, P385, DOI 10.1021/tx00034a001; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; TSUCHIDA K, 1995, ENDOCRINOLOGY, V136, P5493, DOI 10.1210/en.136.12.5493; VALE W, 1988, RECENT PROG HORM RES, V44, P1; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VALE W, 1995, PRINCIPLES PHARM BAS, P883; Vale W., 1990, HDB EXPT PHARM, P211; VAUGHAN JM, 1993, ENDOCRINOLOGY, V132, P2038, DOI 10.1210/en.132.5.2038; Wuytens G, 1999, J BIOL CHEM, V274, P9821, DOI 10.1074/jbc.274.14.9821; XU JM, 1995, J BIOL CHEM, V270, P6308, DOI 10.1074/jbc.270.11.6308; YOUNG L, 1994, PROTEIN SCI, V3, P717	35	87	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3206	3212		10.1074/jbc.275.5.3206	http://dx.doi.org/10.1074/jbc.275.5.3206			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652306	hybrid			2022-12-25	WOS:000085146500028
J	Jing, N; De Clercq, E; Rando, RF; Pallansch, L; Lackman-Smith, C; Lee, S; Hogan, ME				Jing, N; De Clercq, E; Rando, RF; Pallansch, L; Lackman-Smith, C; Lee, S; Hogan, ME			Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors - A basis for anti-HIV drug design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; AIDS-RELATED COMPLEX; ANTIRETROVIRAL THERAPY; CATALYTIC DOMAIN; HTLV-III/LAV; DNA APTAMER; PHASE-I; INTEGRASE; REPLICATION; BINDING	Recently, we have demonstrated that T30695, a G-tetrad-forming oligonucleotide, is a potent inhibitor of human immunodeficiency virus, type I (HIV-1) integrase and the K+ induced loop folding of T30695 plays a key role in the inhibition of HIV-1 integrase (Jing, N,, and Hogan, M, E, (1998) J, Biol, Chem. 273, 34992-34999), Here we have modified T30695 by introducing a hydrophobic bulky group, propynyl dU, or a positively charged group, 5-amino dU, into the bases of T residues of the loops, and by substitution of the T-Gr loops by T-T loops. Physical measurements have demonstrated that the substitution of propynyl dU or 5-amino dU for T in the T residues of the loops did not alter the structure of T30695, and these derivatives also formed an intramolecular G-quartet structure, which is an essential requirement for anti-HIV activity. Measured IC50 and EC50 values show that these substitutions did not induce an apparent decrease in the ability to inhibit HIV-1 integrase activity and in the inhibition of HIV-1 replication in cell culture. However, the substitution of T-T loops for T-G loops induced a substantial decrease in both thermal stability and anti-MN activity. The data analysis of T30695 and the 21 derivatives shows a significant, functional correlation between thermal stability of the G-tetrad structure and the capacity to inhibit HIV-1 integrase activity and between thermal stability of the G-tetrad structure and the capacity to inhibit HIV-1 replication, as assessed with the virus strains HIV-1 RF, IIIB, and MN in cell culture. This relationship between thermostability and activity provides a basis for improving the efficacy of these compounds to inhibit HIV-1 integrase activity and HIV-1 replication in cell culture.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Katholieke Univ Leuven, Inst Med Res, B-3000 Louvain, Belgium; Biochem Pharma, Laval, PQ, Canada; So Res Inst, Frederick, MD 21701 USA	Baylor College of Medicine; KU Leuven	Jing, N (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA.			De Clercq, Erik/0000-0002-2985-8890	NATIONAL CANCER INSTITUTE [P01CA074173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060153] Funding Source: NIH RePORTER; NCI NIH HHS [CA74173] Funding Source: Medline; NIGMS NIH HHS [GM60153] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWNE MJ, 1993, J INFECT DIS, V167, P21, DOI 10.1093/infdis/167.1.21; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286; DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Este JA, 1998, MOL PHARMACOL, V53, P340, DOI 10.1124/mol.53.2.340; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992; Jing NJ, 1997, J BIOMOL STRUCT DYN, V15, P573, DOI 10.1080/07391102.1997.10508967; Jing NJ, 1997, BIOCHEMISTRY-US, V36, P12498, DOI 10.1021/bi962798y; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Katzman M, 1999, ADV VIRUS RES, V52, P371, DOI 10.1016/S0065-3527(08)60307-3; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; LONGFELLOW CE, 1990, BIOCHEMISTRY-US, V29, P278, DOI 10.1021/bi00453a038; Mazumder A, 1996, BIOCHEMISTRY-US, V35, P13762, DOI 10.1021/bi960541u; Mazumder A, 1996, MOL PHARMACOL, V49, P621; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754; SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105; WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1988, LANCET, V1, P76	30	60	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3421	3430		10.1074/jbc.275.5.3421	http://dx.doi.org/10.1074/jbc.275.5.3421			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652335	hybrid			2022-12-25	WOS:000085146500057
J	Melia, TJ; Malinski, JA; He, F; Wensel, TG				Melia, TJ; Malinski, JA; He, F; Wensel, TG			Enhancement of phototransduction protein interactions by lipid surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; TRANSDUCIN ALPHA-SUBUNIT; CGMP PHOSPHODIESTERASE ACTIVATION; HETEROTRIMERIC G-PROTEIN; GTP-BINDING PROTEIN; RETINAL RODS; INHIBITORY SUBUNIT; PHOSPHOLIPID-VESICLES; CRYSTAL-STRUCTURE; GAMMA-SUBUNIT	The G protein cascade of vision depends on two peripheral membrane proteins: the Gr protein, transducin (G(t)), and cGMP phosphodiesterase (PDE), Each has covalently attached lipids, and interacts with transduction components on the membrane surface. We have found that their surface interactions are critically dependent on the nature of the lipid. Membranes enhance their protein-protein interactions, especially if electrostatic attraction is introduced with positively charged lipids. These interactions are less enhanced on highly curved surfaces, but are most enhanced by unsaturated or bulky acyl chains. On positively charged membranes, G(t) assembles at a high enough density to form two-dimensional arrays with short-range crystalline order. Cationic membranes also support extremely efficient activation of PDE by the GTP gamma S (guanosine 5'-O-(thio-triphosphate)) form of G alpha(t) (G alpha(t)-GTP gamma S), minimizing functional heterogeneity of transducin and allowing activation with nanomolar G alpha(t)-GTP gamma S. Quantification of PDE activation and of the amount of G alpha(t)-GTP gamma S bound to PDE indicated that G(t) activates PDE maximally when bound in a 1:1 molar ratio. No cooperativity was observed, even at nanomolar concentrations. Thus, under these conditions, the one binding site for G alpha(t)-GTP gamma S on PDE that stimulates catalysis must be of higher affinity than one or more additional sites which are silent with respect to activation of PDE.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine	Wensel, TG (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, 1 Baylor Plaza, Houston, TX 77030 USA.			Wensel, Theodore/0000-0003-3518-9352				Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; ANANT JS, 1992, J BIOL CHEM, V267, P687; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; AvilaSakar AJ, 1996, BIOPHYS J, V70, P57, DOI 10.1016/S0006-3495(96)79597-8; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; Berger AL, 1999, BIOCHEMISTRY-US, V38, P1293, DOI 10.1021/bi981683m; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKERT F, 1994, BIOCHEMISTRY-US, V33, P12625, DOI 10.1021/bi00208a013; CHIRUVOLU S, 1994, SCIENCE, V264, P1753, DOI 10.1126/science.8209255; Chiu W, 1999, TRENDS CELL BIOL, V9, P154, DOI 10.1016/S0962-8924(99)01511-1; CLERC A, 1992, J BIOL CHEM, V267, P19948; CLERC A, 1992, J BIOL CHEM, V267, P6620; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; DeMar JC, 1996, J BIOL CHEM, V271, P5007; DeMar JC, 1999, PROG LIPID RES, V38, P49, DOI 10.1016/S0163-7827(98)00020-4; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; Fukami A, 1965, J Electron Microsc (Tokyo), V14, P112; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; Malinski JA, 1996, J BIOL CHEM, V271, P12919, DOI 10.1074/jbc.271.22.12919; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; Melia TJ, 1999, J STRUCT BIOL, V128, P119, DOI 10.1006/jsbi.1999.4151; MELIA TJ, 1999, THESIS BAYLOR COLL M; MIKI N, 1975, J BIOL CHEM, V250, P6320; MILJANICH GP, 1981, J MEMBRANE BIOL, V60, P249, DOI 10.1007/BF01992562; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; Neubert TA, 1998, FEBS LETT, V422, P343, DOI 10.1016/S0014-5793(98)00037-4; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PLAGER DA, 1994, BIOCHEMISTRY-US, V33, P7005, DOI 10.1021/bi00188a033; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; SILVERSMITH RE, 1986, BIOCHEMISTRY-US, V25, P7717, DOI 10.1021/bi00371a065; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; TSUI FC, 1990, BIOPHYS J, V57, P85, DOI 10.1016/S0006-3495(90)82509-1; TYMINSKI PN, 1984, BIOCHEMISTRY-US, V23, P3986, DOI 10.1021/bi00312a028; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WENSEL TG, 1999, INTRO SIGNAL TRANSDU, P29; WENSEL TG, 1988, ENZYME DYNAMICS REGU, P102; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YANG ZH, 1992, J BIOL CHEM, V267, P23197; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	58	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3535	3542		10.1074/jbc.275.5.3535	http://dx.doi.org/10.1074/jbc.275.5.3535			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652348	hybrid			2022-12-25	WOS:000085146500070
J	Porter, CM; Havens, MA; Clipstone, NA				Porter, CM; Havens, MA; Clipstone, NA			Identification of amino acid residues and protein kinases involved in the regulation of NFATc subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; TRANSCRIPTION FACTOR NFAT1; KEY SIGNALING ENZYME; NF-AT; NUCLEAR FACTOR; CYCLOSPORINE-A; CALCINEURIN; FAMILY; PHOSPHORYLATION; LYMPHOCYTES	The subcellular localization of the transcription factor NFATc is tightly regulated by the calcium-regulated phosphatase calcineurin, which acts to directly dephosphorylate NFATc, causing its rapid translocation from the cytoplasm to the nucleus. The calcineurin-mediated nuclear localization of NFATc is opposed by poorly defined protein kinases that act either to directly antagonize nuclear import or, alternatively, to promote nuclear export, Here, we provide evidence that the cellular protein kinases JNK, ERK, p38, and CK2 (formerly casein kinase II) are involved in the regulation of NFATc subcellular localization. We show that JNK, ERK, and p38 physically associate with the NFATc N-terminal regulatory domain and can directly phosphorylate functionally important residues involved in regulating NFATc subcellular localization, namely Ser(172) and the conserved NFATc Ser-Pro repeats. Moreover, we found that overexpression of JNK, ERK, or p38 is able to block ionomycin-induced NFATc nuclear translocation, whereas treatment of cells with both PD98059 and SB202190, which inhibit MAPK/SAPK signaling pathways, is sufficient to trigger NFATc nuclear localization. Finally, we show that CK2 also binds the N terminus of NFATc and phosphorylates functionally important amino acid residues, including a conserved amino acid motif located downstream of each of the NFATc Ser-Pro repeats that appears to be important for regulating NFATc nuclear export. Collectively, these studies identify functionally important amino acid residues and protein kinases involved in the regulation of NFATc subcellular localization.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University	Clipstone, NA (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	n-clipstone@nwu.edu			NIGMS NIH HHS [GM55292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CASTIGLI E, 1993, J IMMUNOL, V150, P3284; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Loh C, 1996, MOL CELL BIOL, V16, P3945; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; Wang DZ, 1995, ANN NY ACAD SCI, V766, P182, DOI 10.1111/j.1749-6632.1995.tb26661.x; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	54	130	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3543	3551		10.1074/jbc.275.5.3543	http://dx.doi.org/10.1074/jbc.275.5.3543			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652349	hybrid			2022-12-25	WOS:000085146500071
J	Sanders, CM; Stenlund, A				Sanders, CM; Stenlund, A			Transcription factor-dependent loading of the E1 initiator reveals modular assembly of the papillomavirus origin melting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE ACTIVITIES; LARGE TUMOR-ANTIGEN; BOVINE PAPILLOMAVIRUS; T-ANTIGEN; REPLICATION ORIGIN; E2 PROTEINS; SV40 ORIGIN; STRUCTURAL-CHANGES; BINDING; ATP	Replication of bovine papillomavirus type 1 DNA absolutely requires the viral transcription factor E2 as well as the initiator Fl, although Fl alone has all the activities expected of an initiator protein. El assembles on the DNA in a stepwise fashion and undergoes a transition in activities from site-specific DNA-binding protein to mobile helicase. Complex assembly is assisted by the viral transcription factor E2 at two levels. E2 acts generally as a specificity factor, which through cooperative binding with El generates an initial Fl complex containing three Fl dimers bound to ori on one face of the DNA, El-ori. Furthermore, E2 can promote the transition to an ori melting complex by recruiting additional Fl molecules to ori, effectively reducing the Fl concentration required for ori melting. This reaction is dependent on an Ea-binding site positioned distal to the precursor E1-ori complex. The final origin melting complex has two subunits that each encircle the DNA and function independently to melt ori. The assembly pathway we describe has implication for understanding DNA melting and unwinding reactions, which are generally poorly understood.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stenlund, A (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.				NCI NIH HHS [CA 13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Chen G, 1998, J VIROL, V72, P2567, DOI 10.1128/JVI.72.4.2567-2576.1998; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; Fouts ET, 1999, J BIOL CHEM, V274, P4447, DOI 10.1074/jbc.274.7.4447; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GILLETTE TG, 1994, P NATL ACAD SCI USA, V91, P8846, DOI 10.1073/pnas.91.19.8846; Gillette TG, 1998, J VIROL, V72, P5735, DOI 10.1128/JVI.72.7.5735-5744.1998; Ito K, 1996, EMBO J, V15, P5636, DOI 10.1002/j.1460-2075.1996.tb00948.x; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Kodadek T, 1998, TRENDS BIOCHEM SCI, V23, P79, DOI 10.1016/S0968-0004(97)01165-1; KOFF A, 1991, J VIROL, V65, P3284, DOI 10.1128/JVI.65.6.3284-3292.1991; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LUSKY M, 1994, P NATL ACAD SCI USA, V91, P8895, DOI 10.1073/pnas.91.19.8895; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MASTRANGELO IA, 1985, P NATL ACAD SCI USA, V82, P3626, DOI 10.1073/pnas.82.11.3626; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; RAVNAN JB, 1992, J VIROL, V66, P6946, DOI 10.1128/JVI.66.12.6946-6952.1992; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P147; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; Sedman J, 1998, J VIROL, V72, P6893, DOI 10.1128/JVI.72.8.6893-6897.1998; Sedman J, 1996, EMBO J, V15, P5085, DOI 10.1002/j.1460-2075.1996.tb00889.x; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; USTAV E, 1993, P NATL ACAD SCI USA, V90, P898, DOI 10.1073/pnas.90.3.898; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x	36	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3522	3534		10.1074/jbc.275.5.3522	http://dx.doi.org/10.1074/jbc.275.5.3522			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652347	Green Accepted, hybrid			2022-12-25	WOS:000085146500069
J	Sester, M; Feuerbach, D; Frank, R; Preckel, T; Gutermann, A; Burgert, HG				Sester, M; Feuerbach, D; Frank, R; Preckel, T; Gutermann, A; Burgert, HG			The amyloid precursor-like protein 2 associates with the major histocompatibility complex class I molecule K-d	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; ENDOPLASMIC-RETICULUM; ANTIGEN-PRESENTATION; ADENOVIRUS TYPE-2; E3/19K PROTEIN; ALZHEIMERS-DISEASE; CELL-SURFACE; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE PROTEINS; GROWTH-REGULATION	Amyloid precursor-like protein 2 (APLP2) is a member of a protein family related to the amyloid precursor protein, which is implicated in Alzheimer's disease. Little is known about the physiological function of this protein family. The adenovirus E3/19K protein binds to major histocompatibility complex (MHC) class I antigens in the endoplasmic reticulum, thereby preventing their transport to the cell surface. In cells coexpressing E3/19K and the MHC K-d molecule, K-d is associated with E3/19K and two cellular protein species with masses of 100 and 110 kDa, termed p100/110, Interestingly, p100/110 are released from the complex upon the addition of K-d-binding peptides, suggesting a role for these proteins in peptide transfer to MHC molecules. Here we demonstrate by microsequencing, reactivity with APLP2-specific antibodies, and comparison of biochemical parameters that p100/110 is identical to human APLP2, We further show that the APLP2/K-d association does not require the physical presence of E3/19K. Thus, APLP2 exhibits an intrinsic affinity for the MHC K-d molecule. Similar to the binding of MHC molecules to the transporter associated with antigen processing, complex formation between APLP2 and K-d strictly depends upon the presence of beta(2)-microglobulin. Conditions that prolong the residency of K-d in the endoplasmic reticulum lead to a profound increase of the association and a drastic reduction of APLP2 transport. Therefore, this unexpected interplay between these unrelated molecules may have implications for both MHC antigen and APLP2 function.	Max Von Pettenkofer Inst, Dept Virol, Genzentrum, D-81377 Munich, Germany; Ctr Mol Biol, D-69120 Heidelberg, Germany	University of Munich	Burgert, HG (corresponding author), Max Von Pettenkofer Inst, Dept Virol, Genzentrum, Feodor Lynen Str 25, D-81377 Munich, Germany.	burgert@lmb.uni-muenchen.de	Sester, Martina/AAA-3383-2022; Burgert, Hans-Gerhard/AAE-6668-2020	Burgert, Hans-Gerhard/0000-0002-1650-9878; Sester, Martina/0000-0001-5482-0002				ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Bennett EM, 1999, J IMMUNOL, V162, P5049; Burgert HG, 1996, TRENDS MICROBIOL, V4, P107, DOI 10.1016/0966-842X(96)81527-7; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; BURGERT HG, 1987, EMBO J, V6, P2019, DOI 10.1002/j.1460-2075.1987.tb02466.x; BUSH AI, 1994, J BIOL CHEM, V269, P26618; CARRENO BM, 1995, J IMMUNOL, V155, P4726; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; COX JH, 1991, J EXP MED, V174, P1629, DOI 10.1084/jem.174.6.1629; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; DELVAL M, 1992, J EXP MED, V176, P729, DOI 10.1084/jem.176.3.729; Deryckere F, 1996, J VIROL, V70, P2832, DOI 10.1128/JVI.70.5.2832-2841.1996; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; Elsing A, 1998, P NATL ACAD SCI USA, V95, P10072, DOI 10.1073/pnas.95.17.10072; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; FEUERBACH D, 1994, J IMMUNOL, V153, P1626; FEUERBACH D, 1993, EMBO J, V12, P3153, DOI 10.1002/j.1460-2075.1993.tb05984.x; Flomenberg P, 1996, J VIROL, V70, P6314, DOI 10.1128/JVI.70.9.6314-6322.1996; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hengel H, 1997, CURR OPIN IMMUNOL, V9, P470, DOI 10.1016/S0952-7915(97)80097-0; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kleijnen MF, 1997, EMBO J, V16, P685, DOI 10.1093/emboj/16.4.685; Koopmann JO, 1997, CURR OPIN IMMUNOL, V9, P80, DOI 10.1016/S0952-7915(97)80163-X; KORNER H, 1992, P NATL ACAD SCI USA, V89, P11857, DOI 10.1073/pnas.89.24.11857; Lagaudriere-Gesbert C, 1997, J IMMUNOL, V158, P2790; LAPHAM CK, 1993, J EXP MED, V177, P1633, DOI 10.1084/jem.177.6.1633; Lehner PJ, 1998, CURR BIOL, V8, pR605, DOI 10.1016/S0960-9822(98)70387-2; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LO ACY, 1995, J BIOL CHEM, V270, P12641, DOI 10.1074/jbc.270.21.12641; Marusina K, 1997, BIOCHEMISTRY-US, V36, P856, DOI 10.1021/bi9619738; Neisig A, 1996, J IMMUNOL, V156, P3196; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; PAABO S, 1986, EMBO J, V5, P1921, DOI 10.1002/j.1460-2075.1986.tb04445.x; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PANGALOS MN, 1995, J NEUROCHEM, V65, P762; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Popp GM, 1996, ENDOCRINOLOGY, V137, P1975, DOI 10.1210/en.137.5.1975; Rassoulzadegan M, 1998, EMBO J, V17, P4647, DOI 10.1093/emboj/17.16.4647; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SANDBRINK R, 1994, J BIOL CHEM, V269, P14227; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SESTER M, 1994, J VIROL, V68, P5423, DOI 10.1128/JVI.68.9.5423-5432.1994; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Solheim JC, 1997, J IMMUNOL, V158, P2236; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; SRIVASTAVA PK, 1994, CURR OPIN IMMUNOL, V6, P728, DOI 10.1016/0952-7915(94)90076-0; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; THINAKARAN G, 1995, J NEUROSCI, V15, P6314; THINAKARAN G, 1995, J BIOL CHEM, V270, P16522, DOI 10.1074/jbc.270.28.16522; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; van Endert PM, 1999, CURR OPIN IMMUNOL, V11, P82, DOI 10.1016/S0952-7915(99)80015-6; VANNOSTRAND WE, 1994, BBA-PROTEIN STRUCT M, V1209, P165, DOI 10.1016/0167-4838(94)90180-5; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; VONDERKAMMER H, 1994, DNA CELL BIOL, V13, P1137, DOI 10.1089/dna.1994.13.1137; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	70	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3645	3654		10.1074/jbc.275.5.3645	http://dx.doi.org/10.1074/jbc.275.5.3645			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652361	hybrid			2022-12-25	WOS:000085146500083
J	Weyand, NJ; Low, DA				Weyand, NJ; Low, DA			Regulation of pap phase variation - Lrp is sufficient for the establishment of the phase off pap DNA methylation pattern and repression of pap transcription in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYELONEPHRITIS-ASSOCIATED PILI; ESCHERICHIA-COLI; RNA-POLYMERASE; EXPRESSION; PROTEIN; OPERON; SEQUENCES; SIGMA; GENE; PROMOTERS	The pyelonephritis-associated pili (pap) operon in Escherichia coli is regulated by an epigenetic mechanism involving the formation of specific DNA methylation patterns characteristic of transcriptionally active (phase ON) and inactive (phase OFF) cells. The formation of pap DNA methylation patterns in vivo was previously shown to require the leucine-responsive regulatory protein (Lrp) and DNA adenine methylase (Dam). To monitor the binding of Lrp to pap DNA, an in vitro methylation protection assay was developed. Binding of Lrp to a Dam target site proximal to the papBA promoter (designated GATC(prox)) blocked methylation of this site and specifically repressed transcription. The DNA methylation pattern and transcription state are identical to those observed in vivo in phase OFF cells. To determine if binding of Lrp at GATC(prox) was necessary for repression of papBA transcription, we analyzed a pnp mutation (pap-13) that reduced the affinity of Lrp for the GATC(prox) region. Binding of Lrp to pap-13 DNA was shifted to a promoter distal Dam target site (designated GATC(dist)). Lrp blocked methylation of GATC(dist) in the pap-13 mutant, but did not repress papBA transcription. Together, these results show that binding of Lrp to the GATC(prox) region is sufficient for the establishment of the phase OFF DNA methylation pattern and repression of papBA transcription.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Low, DA (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Rm 3129,Biosci II Bldg, Santa Barbara, CA 93106 USA.	low@lifesci.ucsb.edu			NIAID NIH HHS [AI23348] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI023348, R01AI023348] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bearson SMD, 1996, J BACTERIOL, V178, P2572, DOI 10.1128/jb.178.9.2572-2579.1996; Beltrametti F, 1999, J BACTERIOL, V181, P3409, DOI 10.1128/JB.181.11.3409-3418.1999; BLYN LB, 1989, EMBO J, V8, P613, DOI 10.1002/j.1460-2075.1989.tb03416.x; BLYN LB, 1990, EMBO J, V9, P4045, DOI 10.1002/j.1460-2075.1990.tb07626.x; BRAATEN BA, 1994, CELL, V76, P577, DOI 10.1016/0092-8674(94)90120-1; BRAATEN BA, 1991, J BACTERIOL, V173, P1789, DOI 10.1128/jb.173.5.1789-1800.1991; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; ERNSTING BR, 1993, J BACTERIOL, V175, P7160, DOI 10.1128/JB.175.22.7160-7169.1993; GROSS CA, 1984, J MOL BIOL, V172, P283, DOI 10.1016/S0022-2836(84)80027-3; HALE WB, 1994, J BACTERIOL, V176, P3438, DOI 10.1128/jb.176.11.3438-3441.1994; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967; HENGGEARONIS R, 1996, ESCHERICHIA COLI SAL, V1, P1497; HU JC, 1983, MOL GEN GENET, V191, P492, DOI 10.1007/BF00425768; HULSMANN KH, 1991, GENE, V98, P83, DOI 10.1016/0378-1119(91)90107-M; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996; KALTENBACH LS, 1995, J BACTERIOL, V177, P6449, DOI 10.1128/jb.177.22.6449-6455.1995; KARLS R, 1989, NUCLEIC ACIDS RES, V17, P3927, DOI 10.1093/nar/17.10.3927; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LOW D, 1987, MOL MICROBIOL, V1, P335, DOI 10.1111/j.1365-2958.1987.tb01940.x; Marschall C, 1998, J MOL BIOL, V276, P339, DOI 10.1006/jmbi.1997.1533; Mathew E, 1996, J BACTERIOL, V178, P7234, DOI 10.1128/jb.178.24.7234-7240.1996; MULVEY MR, 1988, GENE, V73, P337, DOI 10.1016/0378-1119(88)90498-2; NEWMAN EB, 1992, CELL, V68, P617, DOI 10.1016/0092-8674(92)90135-Y; NOU XW, 1993, MOL MICROBIOL, V7, P545, DOI 10.1111/j.1365-2958.1993.tb01145.x; NOU XW, 1995, EMBO J, V14, P5785, DOI 10.1002/j.1460-2075.1995.tb00267.x; PARKER B, 1988, GENE, V73, P531, DOI 10.1016/0378-1119(88)90517-3; Rhee KY, 1996, J BIOL CHEM, V271, P26499, DOI 10.1074/jbc.271.43.26499; Riggs A.D., 1996, COLD SPRING HARBOR M, V32, P29; SIMONIAN MH, 1995, CURRENT PROTOCOLS PR, V1; Suh SJ, 1999, J BACTERIOL, V181, P3890, DOI 10.1128/JB.181.13.3890-3897.1999; Tavazoie S, 1998, NAT BIOTECHNOL, V16, P566, DOI 10.1038/nbt0698-566; van der Woude M, 1998, J BACTERIOL, V180, P5913, DOI 10.1128/JB.180.22.5913-5920.1998; vanderWoude M, 1996, TRENDS MICROBIOL, V4, P5, DOI 10.1016/0966-842X(96)81498-3; VANDERWOUDE MW, 1995, MOL MICROBIOL, V17, P303, DOI 10.1111/j.1365-2958.1995.mmi_17020303.x; VANDERWOUDE MW, 1992, MOL MICROBIOL, V6, P2429; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHOU YN, 1992, J BACTERIOL, V174, P5005, DOI 10.1128/JB.174.15.5005-5012.1992	45	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3192	3200		10.1074/jbc.275.5.3192	http://dx.doi.org/10.1074/jbc.275.5.3192			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652304	hybrid			2022-12-25	WOS:000085146500026
J	Mayr, M; Li, CH; Zou, YP; Huemer, U; Hu, YH; Xu, QB				Mayr, M; Li, CH; Zou, YP; Huemer, U; Hu, YH; Xu, QB			Biomechanical stress-induced apoptosis in vein grafts involves p38 mitogen-activated protein kinases	FASEB JOURNAL			English	Article						MAPKs; smooth muscle cell; propidium iodide; cytokine	SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; ATHEROSCLEROTIC PLAQUES; MECHANICAL-STRESS; CELLULAR-RESPONSE; NATIVE CORONARY; DISEASE; PDGF; EXPRESSION	The present study was designed to investigate whether apoptosis occurs in early-stage vein grafts and to determine the mechanisms by which mechanical stress contributes to apoptosis in vascular smooth muscle cells (SMCs). Apoptosis in vessel walls of mouse vein grafts was confirmed by morphological changes and by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL). TUNEL+ cells in vein grafts 1, 4, and 8 wk postoperatively was 13%, 29%, and 21%, respectively, and apoptosis occurred mainly in veins grafted to arteries, remaining unchanged in vein-to-vein grafts. When mouse, rat, and human arterial SMCs were cultured on a flexible membrane and subjected to cyclic strain stress, apoptosis was observed in a time- and strength-dependent manner. All three types of SMCs showed apoptotic death as confirmed by TUNEL, propidium iodide, and annexin V staining. To further study the signal pathways leading to apoptosis, activities of p38, a subfamily of mitogen-activated protein kinases (MAPKs), were determined. Mechanical stress resulted in p38 MAPK activation, reaching high levels within 8 min. SE 202190, a specific inhibitor for p38 MAPKs, prevented SMC apoptosis in response to mechanical stress. SMC lines stably transfected with a dominant negative rac, an upstream signal transducer, or overexpressing MAPK phosphatase-l, a negative regulator for MAPKs, completely inhibited mechanical stress stimulated p38 activation and abolished mechanical stress-induced apoptosis. Thus, we provide solid evidence that one of the earliest events in venous bypass grafts is apoptosis, in which mechanical stress-induced p38-MAPK activation is responsible for transducing signals leading to apoptosis.	Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Gen & Expt Pathol, Sch Med, A-6020 Innsbruck, Austria	Austrian Academy of Sciences; University of Innsbruck	Xu, QB (corresponding author), Austrian Acad Sci, Inst Biomed Aging Res, Rennweg 10, A-6020 Innsbruck, Austria.	Qingbo.Xu@oeaw.ac.at		Mayr, Manuel/0000-0002-0597-829X				Abe J, 1997, CIRCULATION, V96, P1906, DOI 10.1161/01.CIR.96.6.1906; BENES AJ, 1985, J CELL SCI, V75, P35; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bennett MR, 1998, ATHEROSCLEROSIS, V138, P3, DOI 10.1016/S0021-9150(98)00013-6; BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; Bennett MR, 1998, CIRC RES, V82, P704, DOI 10.1161/01.RES.82.6.704; Best PJM, 1999, ARTERIOSCL THROM VAS, V19, P14, DOI 10.1161/01.ATV.19.1.14; Bjorkerud S, 1996, AM J PATHOL, V149, P367; Bryant SR, 1999, CIRC RES, V84, P323, DOI 10.1161/01.RES.84.3.323; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Furukawa Y, 1999, CIRC RES, V84, P306, DOI 10.1161/01.RES.84.3.306; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Granville DJ, 1998, LAB INVEST, V78, P893; Horino K, 1998, LAB INVEST, V78, P603; Hu YH, 1999, CIRCULATION, V100, P861, DOI 10.1161/01.CIR.100.8.861; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; KOCKX MM, 1994, HISTOPATHOLOGY, V25, P365, DOI 10.1111/j.1365-2559.1994.tb01355.x; Lehoux S, 1998, HYPERTENSION, V32, P338, DOI 10.1161/01.HYP.32.2.338; LI C, 2000, IN PRESS ARTERIOSCLE; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; MAUTNER SL, 1992, AM J CARDIOL, V70, P1380, DOI 10.1016/0002-9149(92)90285-7; Mehta D, 1998, NAT MED, V4, P235, DOI 10.1038/nm0298-235; Metzler B, 1999, ARTERIOSCL THROM VAS, V19, P1862, DOI 10.1161/01.ATV.19.8.1862; MIYASHITA T, 1995, CELL, V80, P293; Motwani JG, 1998, CIRCULATION, V97, P916, DOI 10.1161/01.CIR.97.9.916; Newby AC, 1996, CURR OPIN CARDIOL, V11, P574, DOI 10.1097/00001573-199611000-00004; Nishiura H, 1998, LAB INVEST, V78, P1615; Okada M, 1998, ARTERIOSCL THROM VAS, V18, P894, DOI 10.1161/01.ATV.18.6.894; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Pollman MJ, 1999, CIRC RES, V84, P113; Ridley A, 1999, CURR BIOL, V9, pR156, DOI 10.1016/S0960-9822(99)80100-6; SCHWARTZ SM, 1995, AM J PATHOL, V147, P229; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Sumpio BE, 1998, ARTERIOSCL THROM VAS, V18, P349, DOI 10.1161/01.ATV.18.3.349; Takahashi E, 1998, ACTA PHYSIOL SCAND, V164, P611, DOI 10.1111/j.1365-201X.1998.tb10705.x; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WILSON APR, 1995, J ANTIMICROB CHEMOTH, V36, P1, DOI 10.1093/jac/36.1.1; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; XU QB, 1995, CIRCULATION, V92, P1223, DOI 10.1161/01.CIR.92.5.1223; Yang ZH, 1998, CIRCULATION, V97, P181, DOI 10.1161/01.CIR.97.2.181; Zou YP, 1998, AM J PATHOL, V153, P1301, DOI 10.1016/S0002-9440(10)65675-1; Zou YP, 1998, INT J MOL MED, V1, P827	52	132	139	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					261	270		10.1096/fasebj.14.2.261	http://dx.doi.org/10.1096/fasebj.14.2.261			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10660448	Green Submitted			2022-12-25	WOS:000085184800005
J	Wattanapitayakul, SK; Weinstein, DM; Holycross, BJ; Bauer, JA				Wattanapitayakul, SK; Weinstein, DM; Holycross, BJ; Bauer, JA			Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders	FASEB JOURNAL			English	Article						nitric oxide; vascular; peroxynitrite; endothelium; angiotensin II; oxidation	MANGANESE-SUPEROXIDE-DISMUTASE; CORONARY-ARTERY DISEASE; NITRIC-OXIDE; TYROSINE NITRATION; NADPH OXIDASE; HYPERTENSION; INACTIVATION; MECHANISM; MYELOPEROXIDASE; QUINAPRIL	Angiotensin II (ANG II) is a well-established participant in many cardiovascular disorders, but the mechanisms involved are not clear. Vascular cell experiments suggest that ANG II is a potent stimulator of free radicals such as superoxide anion, an agent known to inactivate nitric oxide and promote the formation of peroxynitrite. Here we hypothesized that ANG II reduces the efficacy of NO-mediated vascular relaxation and promotes vascular peroxynitrite formation in vivo. ANG II was infused in rats at sub-presser doses for 3 days, Systolic blood pressure and heart rate were unchanged on day 3 despite significant reductions in plasma renin activity, Thoracic aorta was isolated for functional and immunohistochemical evaluations. No difference in isolated vascular contractile responses to KCI (125 mM), phenylephrine, or ANG II was observed between groups. In contrast, relaxant response to acetylcholine (ACh) was decreased sixfold without a change in relaxant response to sodium nitroprusside, Extensive prevalence of 3-nitrotyrosine (3-NT, a stable biomarker of tissue peroxynitrite formation) immunoreactivity was observed in ANG II-treated vascular tissues and Tvas specifically confined to the endothelium, Digital image analysis demonstrated a significant inverse correlation between ACh relaxant response and 3-NT immunoreactivity, These data demonstrate that ANG II selectively modifies vascular NO control at sub-presser exposures in vivo. Thus, endothelial dysfunction apparently precedes other established ANG II-induced vascular pathologies, and this may be mediated by peroxynitrite formation in vivo.	Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Bauer, JA (corresponding author), Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA.	Bauer.140@osu.edu			NHLBI NIH HHS [HL59791, HL63067] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059791, R01HL063067] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUER JA, 1991, CIRCULATION, V84, P35, DOI 10.1161/01.CIR.84.1.35; Bauer JA, 1997, J PHARMACOL EXP THER, V280, P326; BAUER JA, 1995, NITRIC OXIDE BIOCH M, P361; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Brink M, 1996, J CLIN INVEST, V97, P2509, DOI 10.1172/JCI118698; Britten MB, 1999, J INTERN MED, V245, P315, DOI 10.1046/j.1365-2796.1999.00449.x; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; CROUSER ED, 1998, AM J RESP CRIT CARE, V157, pA104; Dowell FJ, 1996, J HYPERTENS, V14, P177, DOI 10.1097/00004872-199602000-00005; Drexler H, 1999, J MOL CELL CARDIOL, V31, P51, DOI 10.1006/jmcc.1998.0843; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FREEMAN B, 1994, CHEST, V105, pS79, DOI 10.1378/chest.105.3_Supplement.79S; Fritz P., 1995, Pathologica (Genoa), V87, P300; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GRIFFIN SA, 1991, HYPERTENSION, V17, P626, DOI 10.1161/01.HYP.17.5.626; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Jaimes EA, 1998, KIDNEY INT, V54, P775, DOI 10.1046/j.1523-1755.1998.00068.x; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KUYATT BL, 1993, ANAL QUANT CYTOL, V15, P83; Laursen JB, 1997, CIRCULATION, V95, P588, DOI 10.1161/01.CIR.95.3.588; LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Mancini GBJ, 1996, CIRCULATION, V94, P258, DOI 10.1161/01.CIR.94.3.258; Marumo T, 1998, HYPERTENSION, V32, P1083, DOI 10.1161/01.HYP.32.6.1083; Mihm MJ, 1998, CIRCULATION, V98, P803; MIHM MJ, 1999, J PHARMACOL EXP THER, V291, P350; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; Pagano PJ, 1998, HYPERTENSION, V32, P331, DOI 10.1161/01.HYP.32.2.331; Panza JA, 1997, CLIN CARDIOL, V20, P26; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Pueyo ME, 1998, AM J PHYSIOL-CELL PH, V274, pC214, DOI 10.1152/ajpcell.1998.274.1.C214; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; RATAJSKA A, 1994, J LAB CLIN MED, V124, P408; RUSS JC, 1998, IMAGE PROCESSING HDB, P371; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Schlaifer JD, 1997, AM J CARDIOL, V80, P1594, DOI 10.1016/S0002-9149(97)00750-9; Stroth U, 1999, J CARDIOVASC PHARM, V33, pS21, DOI 10.1097/00005344-199900001-00005; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; TAN LB, 1991, CIRC RES, V69, P1185, DOI 10.1161/01.RES.69.5.1185; Warnholtz A, 1999, CIRCULATION, V99, P2027, DOI 10.1161/01.CIR.99.15.2027; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; ZAR L, 1985, BIOSTATISTICAL ANAL; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	47	138	141	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					271	278		10.1096/fasebj.14.2.271	http://dx.doi.org/10.1096/fasebj.14.2.271			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657983				2022-12-25	WOS:000085184800006
J	Chen, L; Bateman, E				Chen, L; Bateman, E			Linker scanning analysis of TBP promoter binding factor DNA binding, activation, and repression domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR-TFIIB; BASAL TRANSCRIPTION; MUTATIONAL ANALYSIS; TERMINAL DOMAIN; COILED COILS; PROTEIN TBP; TATA-BOX; GENE; INITIATION	The transcription activator TATA box-binding protein promoter-binding factor (TPBF) is both an activator and repressor of TBP gene expression in Acanthamoeba. TPBF bears little similarity to previously characterized families of factors. In order to identify domains that are involved in DNA binding, activation, and repression, we constructed several alanine linker scanning mutants and tested them for their ability to function in a variety of assays. The DNA binding domain comprises a large 100-amino acid domain within the central third of the protein, suggesting that DNA recognition is accomplished by interactions derived from several structural units within this domain. Surprisingly, transcription activation and repression are impaired by mutations within either of two discrete amino acid sequences located on either side of the DNA binding domain. These data suggest that TPBF activation and repression are accomplished by interactions with the same target. Since TATA elements can function bidirectionally, and in solution TBP can bind to TATA elements in either orientation, we propose that TPBF functions in part by orienting TBP or TFIID correctly on the TATA box.	Univ Vermont, Markey Ctr Mol Genet, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA	University of Vermont	Bateman, E (corresponding author), Univ Vermont, Markey Ctr Mol Genet, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA.			Chen, Li/0000-0001-9303-4047				Bateman E, 1998, PROG NUCLEIC ACID RE, V60, P133, DOI 10.1016/S0079-6603(08)60892-2; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; Cox JM, 1997, P NATL ACAD SCI USA, V94, P13475, DOI 10.1073/pnas.94.25.13475; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; Huang WB, 1996, NUCLEIC ACIDS RES, V24, P1158, DOI 10.1093/nar/24.6.1158; Huang WB, 1997, J BIOL CHEM, V272, P3852, DOI 10.1074/jbc.272.6.3852; HUANG WB, 1995, J BIOL CHEM, V270, P28839, DOI 10.1074/jbc.270.48.28839; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Jackson BM, 1996, MOL CELL BIOL, V16, P5557; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LATCHMAN DS, 1995, EUKARYOTIC TRANSCRIP; LEWIN B, 1994, GENES, V5; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU F, 1994, J BIOL CHEM, V269, P18541; MULLER CW, 1995, FEBS LETT, V369, P113, DOI 10.1016/0014-5793(95)00541-G; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5609, DOI 10.1093/nar/21.24.5609; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Sullivan SM, 1998, NUCLEIC ACIDS RES, V26, P4487, DOI 10.1093/nar/26.19.4487; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WASYLYK B, 1988, CRC CR REV BIOCH MOL, V23, P77, DOI 10.3109/10409238809088317; WOLBERGER C, 1993, CURR OPIN STRUC BIOL, V3, P3, DOI 10.1016/0959-440X(93)90194-P; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	52	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2771	2776		10.1074/jbc.275.4.2771	http://dx.doi.org/10.1074/jbc.275.4.2771			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644741	hybrid			2022-12-25	WOS:000085128000073
J	Garver, K; Guo, PX				Garver, K; Guo, PX			Mapping the inter-RNA interaction of bacterial virus phi29 packaging RNA by site-specific photoaffinity cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-PHI-29 PROHEAD RNA; PERMUTED TRANSFER-RNAS; PHAGE PHI-29; BACILLUS-SUBTILIS; IN-VITRO; RIBOSOMAL-RNA; SECONDARY STRUCTURE; VIRAL-DNA; PRNA; CONNECTOR	During replication, the lengthy genome of double-stranded DNA viruses is translocated with remarkable velocity into a limited space within the procapsid. The question of how this fascinating task is accomplished has long been a puzzle. Our recent investigation suggests that phi29 DNA packaging is accomplished by a mechanism similar to the driving of a bolt with a hex nut and that six packaging RNAs (pRNAs) form a hexagonal complex to gear the DNA-translocating machine (Chen, C., and Guo, P. (1997) J. Virol. 71, 3864-3871; Zhang, F., Lemieux, S., Wu, X., St.-Arnaud, S., McMurray, C. T., Major, F., and Anderson, D. (1998) Mol. Cell 2, 141-147; Guo, P., Zhang, C., Chen, C., Garver, K., and Trottier, RI., (1998) Mol. Cell 2, 149-155). In the current study, circularly permuted pRNAs were used to position an azido-phenacyl photoreactive cross-linking agent specifically at a strategic site that was predicted to be involved in pRNA-pRNA interaction. Cross-linked pRNA dimers were isolated, and the sites of cross-link were mapped by primer extension. The cross-linked pRNA dimer retained full activity in phi29 procapsid binding and genomic DNA translocation, indicating that the crosslink distance constraints identified in dimer formation reflect the native pRNA complex. Both cross-linked dimers either containing or not containing the interlocking loops for programmed hexamer formation bound procapsid equally well; however, only the one containing the interlocking loops programmed for hexamer formation was active in phi29 DNA packaging. The cross-linked pRNA dimers were also identified as the minimum binding unit necessary for procapsid binding. Primer extension of the purified cross-linked pRNA dimers revealed that base G(82) Was cross-linked to bases G(39), G(40), A(41), C-49, G(62), C-63, and C-64, which contribute to the formation of the three-way junction, suggesting that these bases are proximate in the formation of pRNA tertiary structure. Interestingly, the photoaffinity agent in the left interacting loop did not cross-link directly to the right loop as expected but cross-linked to bases adjacent to the right loop. These data provide a background for future modeling of pRNA tertiary structure.	Purdue Univ, Ctr Canc, Dept Pathobiol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Guo, PX (corresponding author), Purdue Univ, Ctr Canc, Dept Pathobiol, B-36 Hansen Life Sci Res Bldg, W Lafayette, IN 47907 USA.		Guo, Peixuan/I-7184-2015; Guo, Peixuan/AAE-2573-2022	Guo, Peixuan/0000-0001-5706-2833	NIGMS NIH HHS [GM59944, GM48159] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059944, R01GM048159, R21GM048159] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1990, J BIOL CHEM, V265, P22365; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CERRITELLI ME, 1996, J MOL BIOL, V285, P29; Chen CP, 1999, RNA, V5, P805, DOI 10.1017/S1355838299990350; Chen CP, 1997, J VIROL, V71, P495, DOI 10.1128/JVI.71.1.495-500.1997; Garver K, 1997, RNA, V3, P1068; GRIMES S, 1989, J MOL BIOL, V209, P91, DOI 10.1016/0022-2836(89)90172-1; Guasch A, 1998, J MOL BIOL, V281, P219, DOI 10.1006/jmbi.1998.1928; GUO PX, 1987, NUCLEIC ACIDS RES, V15, P7081, DOI 10.1093/nar/15.17.7081; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1991, VIROLOGY, V185, P395, DOI 10.1016/0042-6822(91)90787-C; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0; GUO PX, 1991, VIROLOGY, V183, P366, DOI 10.1016/0042-6822(91)90149-6; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; HAGENBUCHLE O, 1978, CELL, V13, P551, DOI 10.1016/0092-8674(78)90328-8; HANNA MM, 1983, BIOCHEMISTRY-US, V22, P3547; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; HERRANZ L, 1986, VIROLOGY, V155, P289, DOI 10.1016/0042-6822(86)90191-1; HIXON SH, 1975, BIOCHEMISTRY-US, V14, P4251; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; KOCHAN J, 1984, J MOL BIOL, V174, P433, DOI 10.1016/0022-2836(84)90330-9; LEE CS, 1995, J VIROL, V69, P5024, DOI 10.1128/JVI.69.8.5024-5032.1995; LEE CS, 1995, J VIROL, V69, P5018, DOI 10.1128/JVI.69.8.5018-5023.1995; LEE CS, 1994, VIROLOGY, V202, P1039, DOI 10.1006/viro.1994.1434; Mohammad T, 1999, BIOORG MED CHEM LETT, V9, P1703, DOI 10.1016/S0960-894X(99)00265-6; NOLAN JM, 1993, SCIENCE, V261, P762, DOI 10.1126/science.7688143; PAN T, 1991, SCIENCE, V254, P1361, DOI 10.1126/science.1720569; REID RJD, 1994, J BIOL CHEM, V269, P18656; REID RJD, 1994, J BIOL CHEM, V269, P9084; REID RJD, 1994, J BIOL CHEM, V269, P5157; Rishovd S, 1998, VIROLOGY, V245, P11, DOI 10.1006/viro.1998.9153; Trottier M, 1997, J VIROL, V71, P487, DOI 10.1128/JVI.71.1.487-494.1997; Trottier M, 1996, J VIROL, V70, P55, DOI 10.1128/JVI.70.1.55-61.1996; TURNQUIST S, 1992, P NATL ACAD SCI USA, V89, P10479, DOI 10.1073/pnas.89.21.10479; VALPUESTA JM, 1992, J MOL BIOL, V224, P103, DOI 10.1016/0022-2836(92)90579-9; WICHITWECHKARN J, 1992, J MOL BIOL, V223, P991, DOI 10.1016/0022-2836(92)90257-K; YEO A, 1995, J MOL BIOL, V245, P141, DOI 10.1006/jmbi.1994.0013; YOUVAN DC, 1982, ANAL BIOCHEM, V119, P86, DOI 10.1016/0003-2697(82)90669-8; Zhang CL, 1995, RNA, V1, P1041; ZHANG CL, 1995, VIROLOGY, V207, P442, DOI 10.1006/viro.1995.1103; ZHANG CL, 1994, VIROLOGY, V201, P77, DOI 10.1006/viro.1994.1267; ZHANG CL, 1995, VIROLOGY, V211, P568, DOI 10.1006/viro.1995.1439; Zhang CL, 1997, RNA, V3, P315; Zhang F, 1998, MOL CELL, V2, P141, DOI 10.1016/S1097-2765(00)80123-9	48	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2817	2824		10.1074/jbc.275.4.2817	http://dx.doi.org/10.1074/jbc.275.4.2817			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644747	hybrid			2022-12-25	WOS:000085128000079
J	Hu, Z; Jin, SK; Scotto, KW				Hu, Z; Jin, SK; Scotto, KW			Transcriptional activation of the MDR1 gene by UV irradiation - Role of NF-Y and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEIN; TRANSPORTING P-GLYCOPROTEINS; MULTIDRUG-RESISTANCE; CLASS-II; DNA-BINDING; PROMOTER ACTIVITY; FACTOR YB-1; EXPRESSION; CELLS; INVOLVEMENT	The MDR1 promoter is subject to control by various internal and external stimuli. We have previously shown that the CCAAT box-binding protein, NF-Y, mediates MDR1 activation by the histone deacetylase inhibitors, trichostatin A and sodium butyrate, through the recruitment of the co-activator, P/CAF. We have now extended our investigation to the activation of MDR1 by genotoxic stress. We show that activation of the MDR1 promoter by UV irradiation is also dependent on the CCAAT box (-82 to -73) as well as on a proximal GC element (-56 to -42). Gel shift and supershift analyses with nuclear extracts prepared from human KB-3-1 cells identified NF-Y as the transcription factor interacting with the CCAAT box, while Spl was the predominant factor binding to the GC element. Mutations that abrogated binding of either of these factors reduced or abolished activation by ultraviolet irradiation; moreover, co-expression of a dominant-negative NF-Y protein (NE-YA29) reduced UV-activated transcription. Interestingly, YB-1, a transcription factor that also recognizes the CCAAT motif and had been reported to mediate induction of the MDR1 promoter by ultraviolet light, was incapable of interacting with the double-stranded MDR1 CCAAT box oligonucleotide in nuclear extracts, although it did interact with a single-stranded oligonucleotide. Furthermore, a mutation that abolished activation of MDR1 by W-irradiation had no effect on YB-1 binding and co-transfection of a YB-1 expression plasmid had a repressive effect on UV-inducible transcription. Taken together, these results indicate a role for both NF-Y and Spl in the transcriptional activation of the MDR1 gene by genotoxic stress, and indicate that YB-1, if involved, is not sufficient to mediate this activation.	Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Scotto, KW (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol, 1275 York Ave, New York, NY 10021 USA.	k-scotto@ski.mskcc.org			NCI NIH HHS [R01-CA-57307, P30-CA-08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057307, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abolhoda A, 1999, CLIN CANCER RES, V5, P3352; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; CHARUK JHM, 1995, AM J PHYSIOL-RENAL, V269, pF31, DOI 10.1152/ajprenal.1995.269.1.F31; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHIN KV, 1990, J BIOL CHEM, V265, P221; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; DELMORAI RG, 1909, EXP NEPRHOL, V6, P89; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Ernest S, 1998, KIDNEY INT, pS11; Fardel O, 1996, GEN PHARMACOL, V27, P1283, DOI 10.1016/S0306-3623(96)00081-X; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; Greiner B, 1999, J CLIN INVEST, V104, P147, DOI 10.1172/JCI6663; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; Hu XF, 1999, BRIT J CANCER, V79, P831, DOI 10.1038/sj.bjc.6690133; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; KERR D, 1994, J VIROL, V68, P7637, DOI 10.1128/JVI.68.11.7637-7643.1994; Knutsen T, 1998, GENE CHROMOSOME CANC, V23, P44, DOI 10.1002/(SICI)1098-2264(199809)23:1<44::AID-GCC7>3.0.CO;2-6; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; McCoy C, 1999, CELL GROWTH DIFFER, V10, P377; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Metherall JE, 1996, J BIOL CHEM, V271, P2634, DOI 10.1074/jbc.271.5.2634; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Pallis M, 1999, LEUKEMIA, V13, P1468, DOI 10.1038/sj.leu.2401498; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Sawaya BE, 1998, J GEN VIROL, V79, P239, DOI 10.1099/0022-1317-79-2-239; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; Scotto KW, 1998, CYTOTECHNOLOGY, V27, P257, DOI 10.1023/A:1008032716628; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; TAFURI SR, 1992, NEW BIOL, V4, P349; Takashima S, 1998, J BIOL CHEM, V273, P7675, DOI 10.1074/jbc.273.13.7675; THAYER S, 1998, THESIS CORNELL U NEW; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; TOFFOLI G, 1995, BIOCHEM PHARMACOL, V50, P1245, DOI 10.1016/0006-2952(95)02003-U; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; UEDA K, 1992, J BIOL CHEM, V267, P24248; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822	65	135	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2979	2985		10.1074/jbc.275.4.2979	http://dx.doi.org/10.1074/jbc.275.4.2979			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644769	hybrid			2022-12-25	WOS:000085128000101
J	Huang, NW; Miller, WL				Huang, NW; Miller, WL			Cloning of factors related to HIV-inducible LBP proteins that regulate steroidogenic factor-1-independent human placental transcription of the cholesterol side-chain cleavage enzyme, P450scc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MOLECULAR-CLONING; GENETIC SELECTION; PROMOTER ACTIVITY; IN-VITRO; EXPRESSION; YEAST; CELLS; BIOSYNTHESIS; ELEMENTS	The cholesterol side-chain cleavage enzyme, cytochrome P450scc, initiates the biosynthesis of all steroid hormones. Adrenal and gonadal strategies for P450scc gene transcription are essentially identical and depend on the orphan nuclear receptor steroidogenic factor-1, but the placental strategy for transcription of P450scc employs cis acting elements different from those used in the adrenal strategy and is independent of steroidogenic factor-1. Because placental expression of P450scc is required for human pregnancy, we sought factors that bind to the -155/-131 region of the human P450scc promoter, which participates in its placental but not adrenal or gonadal transcription. A yeast one-hybrid screen of 2.4 x 10(6) cDNA clones from human placental JEG-3 cells yielded two unique clones; one is the previously described transcription factor LBP-1b, which is induced by HIV type I infection of lymphocytes, and the other is a new factor, termed LBP-9, that shares 83% amino acid sequence identity with LBP-1b. When expressed in transfected yeast, both factors bound specifically to the -155/-131 DNA; antisera to LBP proteins supershifted the LBP-9.DNA complex and inhibited formation of the LBP-1b.DNA complex. Reverse transcriptase-polymerase chain reaction detected LBP-1b in human placental JEG-3, adrenal NCI-H295A, liver HepG2, cervical HeLa, and monkey kidney COS-l cells, but LBP-9 was detected only in JEG-3 cells. When the -155/-131 fragment was linked to a minimal promoter, co-expression of LBP-1b increased transcription 21-fold in a dose-dependent fashion, but addition of LBP-9 suppressed the stimulatory effect of LBP-1b The roles of LBP transcription factors in normal human physiology have been unclear. Their modulation of placental but not adrenal P450scc transcription underscores the distinctiveness of placental strategies for steroidogenic enzyme gene transcription.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Miller, WL (corresponding author), Univ Calif San Francisco, Dept Pediat, Bldg MR-4,Rm 209, San Francisco, CA 94143 USA.		Miller, Walter L/J-3696-2012		NICHD NIH HHS [HD 34449] Funding Source: Medline; NIDDK NIH HHS [DK 42154, DK 37922] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD034449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042154, R01DK037922] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren R, 1999, J BIOL CHEM, V274, P19422, DOI 10.1074/jbc.274.27.19422; Baxter J.D., 1979, GLUCOCORTICOID HORMO; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; COMPAGNONE N, 1999, 80 ANN M END SOC NEW, P118; Csapo A I, 1978, Obstet Gynecol Surv, V33, P69, DOI 10.1097/00006254-197802000-00001; CSAPO AI, 1973, AM J OBSTET GYNECOL, V115, P759, DOI 10.1016/0002-9378(73)90517-6; DUFAU ML, 1988, ANNU REV PHYSIOL, V50, P483, DOI 10.1146/annurev.ph.50.030188.002411; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; FARDELLA CE, 1986, ANNU REV NUTR, V16, P443; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GAZDAR AF, 1990, CANCER RES, V50, P5488; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HONDA S, 1993, J BIOL CHEM, V268, P7494; HUM DW, 1993, CLIN CHEM, V39, P333; HUM DW, 1995, DNA CELL BIOL, V14, P451, DOI 10.1089/dna.1995.14.451; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KEENEY DS, 1995, MOL ENDOCRINOL, V9, P1091, DOI 10.1210/me.9.8.1091; KOHLER PO, 1971, J CLIN ENDOCR METAB, V65, P122; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; LeibMosch C, 1995, VIRUS GENES, V11, P133, DOI 10.1007/BF01728654; LIEBMOSCH C, 1992, LEUKEMIA BALTIMORE S, V6, P72; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; Liu Jingdong, 1993, Methods (Orlando), V5, P125, DOI 10.1006/meth.1993.1017; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; Miller WL, 1998, CLIN PERINATOL, V25, P799, DOI 10.1016/S0095-5108(18)30084-8; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; Morohashi K, 1999, TRENDS ENDOCRIN MET, V10, P169, DOI 10.1016/S1043-2760(98)00142-8; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; Parker KL, 1995, VITAM HORM, V51, P339, DOI 10.1016/S0083-6729(08)61044-4; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; RICHARDS JS, 1988, ANNU REV PHYSIOL, V50, P441; Rodriguez H, 1997, J CLIN ENDOCR METAB, V82, P365, DOI 10.1210/jc.82.2.365; ROSEMD, 1990, METHODS YEAST GENETI; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SIMON HA, 1993, ARTIF INTELL ENG, V8, P1; Sjottem E, 1996, J VIROL, V70, P188; SPARKES RS, 1991, DNA CELL BIOL, V10, P359, DOI 10.1089/dna.1991.10.359; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; STRAUSS JF, 1985, ENDOCRINOLOGY, P2171; VOUTILAINEN R, 1998, J CLIN ENDOCR METAB, V63, P202; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; Zhang PL, 1997, MOL ENDOCRINOL, V11, P891, DOI 10.1210/me.11.7.891; Zhang PL, 1999, DNA CELL BIOL, V18, P197, DOI 10.1089/104454999315411; ZHANG PL, 1995, MOL ENDOCRINOL, V9, P1571, DOI 10.1210/me.9.11.1571	60	69	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2852	2858		10.1074/jbc.275.4.2852	http://dx.doi.org/10.1074/jbc.275.4.2852			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644752	hybrid			2022-12-25	WOS:000085128000084
J	Morris, SK; Baird, CL; Lindsley, JE				Morris, SK; Baird, CL; Lindsley, JE			Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; GYRASE-B PROTEIN; DNA DOUBLE HELIX; SACCHAROMYCES-CEREVISIAE; BIS(2,6-DIOXOPIPERAZINE) DERIVATIVES; DROSOPHILA-MELANOGASTER; CATALYTIC INHIBITORS; ATP HYDROLYSIS; MECHANISM; CLEAVAGE	DNA topoisomerase II uses a complex, sequential mechanism of ATP hydrolysis to catalyze the transport of one DNA duplex through a transient break in another. ICRF-193 is a catalytic inhibitor of topoisomerase II that is known to trap a closed-clamp intermediate form of the enzyme, Using steady-state and rapid kinetic ATPase and DNA transport assays, we have analyzed how trapping this intermediate by the drug perturbs the topoisomerase II mechanism. The drug has no effect on the rate of the first turnover of decatenation but potently inhibits subsequent turnovers with an IC50 of 6.5 +/- 1 mu w for the Saccharomyces cerevisiae enzyme. This drug inhibits the ATPase activity of topoisomerase II by an unusual, mixed-type mechanism; the drug is not a competitive inhibitor of ATP, and even at saturating concentrations of drug, the enzyme continues to hydrolyze ATP, albeit at a reduced rate. Topoisomerase II that was specifically isolated in the drug-bound, closed-clamp form continues to hydrolyze ATP, indicating that the enzyme clamp does not need to re-open to bind and hydrolyze ATP, When rapid-quench ATPase assays were initiated by the addition of ATP, the drug had no effect on the sequential hydrolysis of either the first or second ATP, By contrast, when the drug was prebound, the enzyme hydrolyzed one labeled ATP at the uninhibited rate but did not hydrolyze a second ATP, These results are interpreted in terms of the catalytic mechanism for topoisomerase II and suggest that ICRF-193 interacts with the enzyme bound to one ADP.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Lindsley, JE (corresponding author), Univ Utah, Sch Med, Dept Biochem, 50 N Med Dr, Salt Lake City, UT 84132 USA.		Baird, Cheryl/AGM-0065-2022; Baird, Cheryl L/F-6569-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051194, T32GM008753] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51194, 5T32GM08753] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Chang S, 1998, J BIOL CHEM, V273, P19822, DOI 10.1074/jbc.273.31.19822; Fass D, 1999, NAT STRUCT BIOL, V6, P322; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GOTO T, 1984, J BIOL CHEM, V259, P422; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; HSIEH TS, 1975, BIOCHEMISTRY-US, V14, P527, DOI 10.1021/bi00674a011; ISHIDA R, 1995, CANCER RES, V55, P2299; ISHIDA R, 1991, CANCER RES, V51, P4909; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU L, 1994, DNA TOPOISOMERASES T; LIU LF, 1983, J BIOL CHEM, V258, P5365; Maxwell A, 1999, BIOCHEM SOC T, V27, P48, DOI 10.1042/bst0270048; Morris SK, 1999, J BIOL CHEM, V274, P30690, DOI 10.1074/jbc.274.43.30690; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Olland S, 1999, J BIOL CHEM, V274, P21688, DOI 10.1074/jbc.274.31.21688; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; SANDER M, 1983, J BIOL CHEM, V258, P8421; Sato M, 1997, BIOCHEM PHARMACOL, V54, P545, DOI 10.1016/S0006-2952(97)00201-3; SEGEL IH, 1993, ENZYME KINETICS, P390; Sehested M, 1996, BIOCHEM PHARMACOL, V51, P879, DOI 10.1016/0006-2952(95)02241-4; Sehested M, 1998, CANCER RES, V58, P1460; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SZEDLACSEK SE, 1995, METHOD ENZYMOL, V249, P144; TANABE K, 1991, CANCER RES, V51, P4903; Tennyson RB, 1997, BIOCHEMISTRY-US, V36, P6107, DOI 10.1021/bi970152f; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wessel I, 1999, CANCER RES, V59, P3442	41	47	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2613	2618		10.1074/jbc.275.4.2613	http://dx.doi.org/10.1074/jbc.275.4.2613			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644721	hybrid			2022-12-25	WOS:000085128000053
J	Morrow, JA; Arnold, KS; Dong, J; Balestra, ME; Innerarity, TL; Weisgraber, KH				Morrow, JA; Arnold, KS; Dong, J; Balestra, ME; Innerarity, TL; Weisgraber, KH			Effect of arginine 172 on the binding of apolipoprotein E to the low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PROTEIN SECONDARY STRUCTURE; CELL-SURFACE RECEPTORS; HUMAN-E APOPROTEIN; III HYPERLIPOPROTEINEMIA; PLASMA-LIPOPROTEINS; HUMAN-FIBROBLASTS; AQUEOUS-SOLUTION; DOMAIN; SITE	The region of apolipoprotein E (apoE) that interacts directly with the low density lipoprotein (LDL) receptor lies in the vicinity of residues 136-150, where lysine and arginine residues are crucial for full binding activity However, defective binding of carboxyl-terminal truncations of apoE3 has suggested that residues in the vicinity of 170-183 are also important. To characterize and define the role of this region in LDL receptor binding, we created either mutants of apoE in which this region was deleted or in which arginine residues within this region were sequentially changed to alanine, Deletion of residues 167-185 reduced binding activity (15% of apoE3), and elimination of arginines at positions 167, 172, 178, and 180 revealed that only position 172 affected binding activity (2% of apoE3), Substitution of lysine for Arg(172) reduced binding activity to 6%, indicating a specific requirement for arginine at this position. The higher binding activity of the Delta 167-185 mutant relative to the Arg(172) mutant (15% versus 2%) is explained by the fact that arginine residues at positions 189 and 191 are shifted in the deletion mutant into positions equivalent to 170 and 172 in the intact protein. Mutation of these residues and modeling the region around these residues suggested that the influence of Arg(172) On receptor binding activity may be determined by its orientation at a lipid surface. Thus, the association of apoE with phospholipids allows Arg(172) to interact directly with the LDL receptor or with other residues in apoE to promote its receptor-active conformation.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weisgraber, KH (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BRADLEY WA, 1982, BIOCHEM BIOPH RES CO, V109, P1360, DOI 10.1016/0006-291X(82)91927-1; Clayton AHA, 1999, EUR BIOPHYS J BIOPHY, V28, P133, DOI 10.1007/s002490050192; DAS HK, 1985, J BIOL CHEM, V260, P6240; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1984, J BIOL CHEM, V259, P7261; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LALAZAR A, 1989, J BIOL CHEM, V264, P8447; MAHLEY RW, 1977, J BIOL CHEM, V252, P7279; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; PITAS RE, 1987, J BIOL CHEM, V262, P14352; RALL SC, 1982, J BIOL CHEM, V257, P4171; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; UTERMANN G, 1977, NATURE, V269, P604, DOI 10.1038/269604a0; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1994, STRUCTURE, V2, P713, DOI 10.1016/S0969-2126(00)00072-1; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; ZANNIS VI, 1980, J BIOL CHEM, V255, P1759; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059	40	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2576	2580		10.1074/jbc.275.4.2576	http://dx.doi.org/10.1074/jbc.275.4.2576			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644716	hybrid			2022-12-25	WOS:000085128000048
J	Munoz-Sanjuan, I; Smallwood, PM; Nathans, J				Munoz-Sanjuan, I; Smallwood, PM; Nathans, J			Isoform diversity among fibroblast growth factor homologous factors is generated by alternative promoter usage and differential splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FGF RECEPTORS; NERVOUS-SYSTEM; GENE ENCODES; TRANSLATION; INITIATION; EXPRESSION; ACTIVATION; POLYPEPTIDES; TRANSCRIPTS; REGIONS	Fibroblast growth factor (FGF) homologous factors-1, -2, -3, and -4 (FHF's 1-4; also referred to as FGFs 11-14) comprise a separate branch of the FGF family and have been implicated in the development of the nervous system and limbs. We report here the characterization of multiple isoforms of FHF-1, -2, -3, and -4 which are generated through the use of alternative start sites of transcription and splicing of one or more of a series of alternative 5'-exons. Several isoforms show different subcellular distributions when expressed in transfected tissue culture cells, and the corresponding differentially spliced transcripts show distinct expression patterns in developing and adult mouse tissues, Together with the evolutionary conservation of the FHF isoforms among human, mouse, and chicken, these data indicate that alternative promoter use and differential splicing are important regulatory processes in controlling the activities of this subfamily of FGFs.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 805 PCTB,725 N Wolfe St, Baltimore, MD 21205 USA.	jnathans@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; Borja AZM, 1996, DEV BIOL, V180, P680, DOI 10.1006/dbio.1996.0337; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gecz J, 1999, HUM GENET, V104, P56, DOI 10.1007/s004390050910; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Gospodarowicz D, 1990, Curr Top Dev Biol, V24, P57, DOI 10.1016/S0070-2153(08)60084-8; Hartung H, 1997, MECH DEVELOP, V64, P31, DOI 10.1016/S0925-4773(97)00042-7; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lubs HA, 1996, AM J MED GENET, V64, P147, DOI 10.1002/(SICI)1096-8628(19960712)64:1<147::AID-AJMG25>3.0.CO;2-M; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Munoz-Sanjuan I, 1999, DEVELOPMENT, V126, P409; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; Shin JT, 1996, BBA-MOL CELL RES, V1312, P27, DOI 10.1016/0167-4889(96)00013-4; SHIODA J, 1997, J NEUROSCI RES, V50, P673; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STIEBER A, 1995, EXP CELL RES, V219, P562, DOI 10.1006/excr.1995.1265; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Yamamoto S, 1998, BBA-GENE STRUCT EXPR, V1398, P38, DOI 10.1016/S0167-4781(98)00050-5	33	73	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2589	2597		10.1074/jbc.275.4.2589	http://dx.doi.org/10.1074/jbc.275.4.2589			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644718	hybrid			2022-12-25	WOS:000085128000050
J	Sidobre, S; Nigou, J; Puzo, G; Riviere, M				Sidobre, S; Nigou, J; Puzo, G; Riviere, M			Lipoglycans are putative ligands for the human pulmonary surfactant protein A attachment to mycobacteria - Critical role of the lipids for lectin-carbohydrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MACROPHAGES; ALVEOLAR MACROPHAGES; ATTENUATED STRAINS; BINDING PROTEIN; II CELLS; TUBERCULOSIS; LIPOARABINOMANNAN; VIRULENT; DOMAINS; LIPOPOLYSACCHARIDES	The human pulmonary surfactant protein A (hSP-A) has been implicated in the early capture and phagocytosis of the pathogenic Mycobacterium tuberculosis by alveolar macrophages. In this report, we examined the interaction of alveolar proteinosis patient hSP-A with Mycobacterium bovis EGG, the vaccinating strain, as a model of pathogenic mycobacteria, and Mycobacterium smegmatis, a nonpathogenic strain. me found that hSP-A binds to the surface of M., bovis BCG;, but also to a slightly lesser extent, to M. smegmatis, indicating that hSP-A does not discriminate between virulent and nonpathogenic strains. Among the various glycoconjugates isolated from the mycobacterial envelope, we found that the best ligands are the two major lipoglycans: the mannosylated lipoarabinomannan (ManLAM) and the lipomannan, In contrast, the mannose-capped arabinomannan, structurally close to the ManLAM, as well as the LAMs from the non pathogenic M. smegmatis are poorly recognized by hSP-A, These results clearly show that the presence of both the terminal mannose residues and the phophatidyl-myo-inositol anchor are necessary to achieve the highest binding affinity. Selective removal of either the terminal mannose or the acyl residues esterifying the glycerol moiety of the ManLAM abrogates the interaction with hSP-A, further supporting the notion that the hSP-A recognition of the carbohydrate epitopes of the lipoglycans is dependent of the presence of the fatty acids.	CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Riviere, M (corresponding author), CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.		Nigou, Jérôme/D-6802-2019	Nigou, Jérôme/0000-0002-6233-2487				BARNES PF, 1992, INFECT IMMUN, V60, P1441, DOI 10.1128/IAI.60.4.1441-1446.1992; BARNES PF, 1992, J IMMUNOL, V149, P541; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; Cywes C, 1997, INFECT IMMUN, V65, P4258, DOI 10.1128/IAI.65.10.4258-4266.1997; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; DOWNING JF, 1995, P NATL ACAD SCI USA, V92, P4848, DOI 10.1073/pnas.92.11.4848; Ernst JD, 1998, INFECT IMMUN, V66, P1277, DOI 10.1128/IAI.66.4.1277-1281.1998; Ernst WA, 1998, IMMUNITY, V8, P331, DOI 10.1016/S1074-7613(00)80538-5; Fenton MJ, 1996, INFECT IMMUN, V64, P683, DOI 10.1128/IAI.64.3.683-690.1996; Ferguson JS, 1999, J IMMUNOL, V163, P312; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; Gilleron M, 1997, J BIOL CHEM, V272, P117; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HAURUM JS, 1993, BIOCHEM J, V293, P873, DOI 10.1042/bj2930873; Hoppe HC, 1997, INFECT IMMUN, V65, P3896, DOI 10.1128/IAI.65.9.3896-3905.1997; Kishore U, 1996, BIOCHEM J, V318, P505, DOI 10.1042/bj3180505; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 1999, BIOCHEM J, V337, P453, DOI 10.1042/0264-6021:3370453; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; ORTALOMAGNE A, 1995, MICROBIOL-UK, V141, P1609, DOI 10.1099/13500872-141-7-1609; Pasula R, 1997, AM J RESP CELL MOL, V17, P209, DOI 10.1165/ajrcmb.17.2.2469; Pattanajitvilai S, 1998, J BIOL CHEM, V273, P5702, DOI 10.1074/jbc.273.10.5702; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RISDALE RA, 1999, BIOCHIM BIOPHYS ACTA, V1453, P23; ROSS GF, 1986, J BIOL CHEM, V261, P14283; Schlesinger LS, 1996, J IMMUNOL, V157, P4568; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Snider GL, 1997, ANN INTERN MED, V126, P237, DOI 10.7326/0003-4819-126-3-199702010-00011; VANIWAARDEN JF, 1994, BIOCHEM J, V303, P407, DOI 10.1042/bj3030407; VENISSE A, 1995, EUR J BIOCHEM, V231, P440, DOI 10.1111/j.1432-1033.1995.tb20717.x; Weikert LF, 1997, AM J PHYSIOL-LUNG C, V272, pL989, DOI 10.1152/ajplung.1997.272.5.L989; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	40	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2415	2422		10.1074/jbc.275.4.2415	http://dx.doi.org/10.1074/jbc.275.4.2415			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644694	hybrid			2022-12-25	WOS:000085128000026
J	Torrents, E; Buist, G; Liu, A; Eliasson, R; Kok, J; Gibert, I; Graslund, A; Reichard, P				Torrents, E; Buist, G; Liu, A; Eliasson, R; Kok, J; Gibert, I; Graslund, A; Reichard, P			The anaerobic (Class III) ribonucleotide reductase from Lactococcus lactis - Catalytic properties and allosteric regulation of the pure enzyme system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTER; ESCHERICHIA-COLI; PROTEIN; SEQUENCE; BINDING; TIMES; GENES; SITE	Lactococcus lactis contains an operon with the genes (nrdD and nrdG) for a class III ribonucleotide reductase, Strict anaerobic growth depends on the activity of these genes. Both were sequenced, cloned, and overproduced in Escherichia coli, The corresponding proteins, NrdD and NrdG, were purified close to homogeneity, The amino acid sequences of NrdD (747 residues, 84.1 kDa) and NrdG (199 residues, 23.3 kDa) are 53 and 42% identical with the respective E. coli proteins. Together, they catalyze the reduction of ribonucleoside triphosphates to the corresponding deoxyribonucleotides in the presence of S-adenosylmethionine, reduced flavodoxin or reduced deazaflavin, potassium ions, dithiothreitol, and formate. EPR experiments demonstrated a [4Fe-4S](+) cluster in reduced NrdG and a glycyl radical in activated NrdD, similar to the E, coli NrdD and NrdG proteins. Different from E. coli, the two polypeptides of NrdD and the proteins in the NrdD-NrdG complex were only loosely associated, Also the FeS cluster was easily lost from NrdG, The substrate specificity and overall activity of the L. lactis enzyme was regulated according to the general rules for ribonucleotide reductases. Allosteric effecters bound to two separate sites on NrdD, one binding dATP, dGTP, and dTTP and the other binding dATP and ATP, The two sites showed an unusually high degree of cooperativity with complex interactions between effecters and a fine-tuning of their physiological effects. The results with the L. lactis class III reductase further support the concept of a common origin for all present day ribonucleotide reductases.	Karolinska Inst, Dept Biochem 1, Med Nobel Inst, MBB, S-17177 Stockholm, Sweden; Autonomous Univ Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain; Autonomous Univ Barcelona, Inst Biol Fonamental, Bacterial Mol Genet Grp, E-08193 Barcelona, Spain; Univ Groningen, Dept Genet, NL-9641 NN Haren, Netherlands; Stockholm Univ, Dept Biophys, S-10691 Stockholm, Sweden	Karolinska Institutet; Autonomous University of Barcelona; Autonomous University of Barcelona; University of Groningen; Stockholm University	Reichard, P (corresponding author), Karolinska Inst, Dept Biochem 1, Med Nobel Inst, MBB, S-17177 Stockholm, Sweden.	peter.reichard@mbb.ki.se	Torrents, Eduard/C-7184-2008; Kok, Jan/C-9972-2012; Liu, Aimin/C-1572-2017; Gibert, Isidre/L-9834-2014	Torrents, Eduard/0000-0002-3010-1609; Liu, Aimin/0000-0002-4182-8176; Gibert, Isidre/0000-0003-1442-2258				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUIST G, 1995, J BACTERIOL, V177, P1554, DOI 10.1128/jb.177.6.1554-1563.1995; CHIARUTTINI C, 1993, J MOL BIOL, V230, P57, DOI 10.1006/jmbi.1993.1126; Eliasson R, 1999, J BIOL CHEM, V274, P7182, DOI 10.1074/jbc.274.11.7182; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Garriga X, 1996, BIOCHEM BIOPH RES CO, V229, P189, DOI 10.1006/bbrc.1996.1778; GASSON MJ, 1983, J BACTERIOL, V154, P1; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kessler D., 1996, ESCHERICHIA COLI SAL, P199; KING DS, 1995, BIOCHEM BIOPH RES CO, V206, P731, DOI 10.1006/bbrc.1995.1103; KING TE, 1967, METHOD ENZYMOL, V10, P634; LAW J, 1995, J BACTERIOL, V177, P7011, DOI 10.1128/jb.177.24.7011-7018.1995; Leenhouts K., 1992, Mededelingen van de Faculteit Landbouwwetenschappen Universiteit Gent, V57, P2031; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Liu A, 1998, BIOCHEMISTRY-US, V37, P16369, DOI 10.1021/bi981471p; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; REICHARD P, 1993, J BIOL CHEM, V268, P8383; SAHLIN M, 1986, J MAGN RESON, V67, P135, DOI 10.1016/0022-2364(86)90417-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEEGERS JFML, 1994, MICROBIOL-UK, V140, P1291, DOI 10.1099/00221287-140-6-1291; Sjoberg BM, 1997, STRUCT BOND, V88, P139; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; Teuber M., 1995, GENERA LACTIC ACID B, P173, DOI DOI 10.1007/978-1-4615-5817-0_6; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; Young P, 1996, J BIOL CHEM, V271, P20770, DOI 10.1074/jbc.271.34.20770; YOUNG P, 1994, J BIOL CHEM, V269, P27815	42	40	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2463	2471		10.1074/jbc.275.4.2463	http://dx.doi.org/10.1074/jbc.275.4.2463			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644700	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000085128000032
J	Yu, R; Mandlekar, S; Lei, W; Fahl, WE; Tan, TH; Kong, ANT				Yu, R; Mandlekar, S; Lei, W; Fahl, WE; Tan, TH; Kong, ANT			p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; ANTIOXIDANT RESPONSIVE ELEMENT; NAD(P)H-QUINONE OXIDOREDUCTASE GENE; YA-SUBUNIT GENE; MAP KINASE; PHENOLIC ANTIOXIDANTS; INDUCIBLE EXPRESSION; TRANSCRIPTIONAL REGULATION; INFLAMMATORY CYTOKINES; PROTECTIVE ENZYMES	Phase II drug-metabolizing enzymes, such as glutathione S-transferase and quinone reductase, play an important role in the detoxification of chemical carcinogens. The induction of these detoxifying enzymes by a variety of agents occurs at the transcriptional level and is regulated bg a cis-acting element, called the antioxidant response element (ARE) or electrophile-response element. In this study, we identified a signaling kinase pathway that negatively regulates ARE-mediated gene expression. Treatment of human hepatoma HepG2 and murine hepatoma Hepalclc7 cells with tert-butylhydroquinone (tBHQ) stimulated the activity of p38, a member of mitogen-activated protein kinase family. Inhibition of p38 activation by its inhibitor, SB203580, enhanced the induction of quinone reductase activity and the activation of ARE reporter gene by tBHQ. In contrast, SB202474, a negative analog of SB203580, had little effect. Consistent with this result, interfering with the p38 kinase pathway by overexpression of a dominant-negative mutant of p38 or MKK3, an immediate upstream regulator of p38, potentiated the activation of the ARE reporter gene by tBHQ, whereas the wild types of p38 and MKK3 diminished such activation. In addition, inhibition of p38 activity augmented the induction of ARE reporter gene activity by tert-butylhydroxyanisole, sulforaphane, and p-naphthoflavone. Thus, p38 kinase pathway functions as a negative regulator in the ARE-mediated induction of phase II detoxifying enzymes.	Univ Illinois, Dept Pharmaceut & Phamacodynam, Ctr Pharmaceut Biotechnol, Coll Pharm, Chicago, IL 60612 USA; Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Wisconsin System; University of Wisconsin Madison; Baylor College of Medicine	Kong, ANT (corresponding author), Univ Illinois, Dept Pharmaceut & Phamacodynam, Ctr Pharmaceut Biotechnol, Coll Pharm, MC870,900 S Ashland Ave,MBRB Rm 3102, Chicago, IL 60607 USA.	KongT@uic.edu	Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021; Kong, Ah-Ng Tony/AAX-2828-2020	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; 	NCI NIH HHS [R01-CA73647] Funding Source: Medline; NIAID NIH HHS [R01-AI38649, R01-AI42532] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532, R01AI038649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ainbinder E, 1997, EUR J BIOCHEM, V243, P49, DOI 10.1111/j.1432-1033.1997.0049a.x; BERGELSON S, 1994, ONCOGENE, V9, P565; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Gerhauser C, 1997, CANCER RES, V57, P272; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN JH, 1993, J BIOL CHEM, V268, P25009; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, PHARMACOGENETICS, V4, P1, DOI 10.1097/00008571-199402000-00001; Kensler TW, 1997, ENVIRON HEALTH PERSP, V105, P965, DOI 10.2307/3433311; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LI Y, 1992, J BIOL CHEM, V267, P15097; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; NAGASE T, 1995, DNA RES, V2, P164; PEZZUTO JM, 1995, RECENT ADV PHYTOCHEM, V29, P19; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PROCHASKA HJ, 1988, CANCER RES, V48, P4776; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SPORN MB, 1979, FED PROC, V38, P2528; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WANG B, 1994, BBA-GENE STRUCT EXPR, V1219, P645, DOI 10.1016/0167-4781(94)90223-2; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wasserman WW, 1997, ARCH BIOCHEM BIOPHYS, V344, P387, DOI 10.1006/abbi.1997.0215; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WATTENBERG LW, 1985, CANCER RES, V45, P1; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Young PR, 1998, CYTOKINE GROWTH F R, V9, P239, DOI 10.1016/S1359-6101(98)00011-2; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu R, 1996, CANCER RES, V56, P2954; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 1997, J BIOL CHEM, V272, P28962, DOI 10.1074/jbc.272.46.28962; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399	54	171	174	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2322	2327		10.1074/jbc.275.4.2322	http://dx.doi.org/10.1074/jbc.275.4.2322			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644681	hybrid			2022-12-25	WOS:000085128000013
J	Iyer, RR; Pluciennik, A; Rosche, WA; Sinden, RR; Wells, RD				Iyer, RR; Pluciennik, A; Rosche, WA; Sinden, RR; Wells, RD			DNA polymerase III proofreading mutants enhance the expansion and deletion of triplet repeat sequences in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER-DOT-CAG; HEREDITARY-DISEASE GENES; SYNTHESIS IN-VITRO; MISMATCH REPAIR; TRINUCLEOTIDE REPEATS; CTG REPEATS; MUTATIONAL SPECIFICITY; LEADING-STRAND; MUTATOR MUTD5; REPLICATION	The influence of mutations in the 3' to 5' exonucleolytic proofreading c-subunit of Escherichia coli DNA polymerase III on the genetic instabilities of the CGG.CCG and the CTG.CAG repeats that cause human hereditary neurological diseases was investigated. The dnaQ49(ts) and the mutD5 mutations destabilize the CGG.CCG repeats. The distributions of the deletion products indicate that slipped structures containing a small number of repeats in the loop mediate the deletion process. The CTG.CAG repeats were destabilized by the dnaQ49(ts) mutation by a process mediated by long hairpin loop structures (greater than or equal to 5 repeats). The mutD5 mutator strain stabilized the (CTG.CAG)(175) tract, which contained two interruptions. Since the mutD5 mutator strain has a saturated mismatch repair system, the stabilization is probably an indirect effect of the nonfunctional mismatch repair system in these strains. Shorter uninterrupted tracts expand readily in the mutD5 strain, presumably due to the greater stability of long CTG.CAG tracts (>100 repeats) in this strain. When parallel studies were conducted in minimal medium, where the mutD5 strain is defective in exonucleolytic proofreading but has a functional MMR system, both CTG.CAG and CGG.CCG repeats were destabilized, showing that the proofreading activity is essential for maintaining the integrity of TRS tracts. Thus, we conclude that the expansion and deletion of triplet repeats are enhanced by mutations that reduce the fidelity of replication.	Texas A&M Univ, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res,Dept Biochem & Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System	Wells, RD (corresponding author), Texas A&M Univ, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res,Dept Biochem & Biophys, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Sinden, Richard/AAE-3086-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05508] Funding Source: Medline; NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Bacolla A, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P467; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; Bzymek M, 1999, J BACTERIOL, V181, P477, DOI 10.1128/JB.181.2.477-482.1999; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; COX EC, 1983, P NATL ACAD SCI-BIOL, V80, P2295, DOI 10.1073/pnas.80.8.2295; Cox EC, 1997, GENETICS, V146, P443; DAMAGNEZ V, 1989, J BACTERIOL, V171, P4494, DOI 10.1128/JB.171.8.4494-4497.1989; DEGNEN GE, 1974, J BACTERIOL, V117, P477, DOI 10.1128/JB.117.2.477-487.1974; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; ECHOLS H, 1983, P NATL ACAD SCI-BIOL, V80, P2189, DOI 10.1073/pnas.80.8.2189; FIJALKOWSKA IJ, 1993, GENETICS, V134, P1023; Fijalkowska IJ, 1996, P NATL ACAD SCI USA, V93, P2856, DOI 10.1073/pnas.93.7.2856; Fijalkowska IJ, 1997, J BACTERIOL, V179, P7435, DOI 10.1128/jb.179.23.7435-7445.1997; Fijalkowska IJ, 1998, P NATL ACAD SCI USA, V95, P10020, DOI 10.1073/pnas.95.17.10020; FOWLER RG, 1974, MOL GEN GENET, V133, P179, DOI 10.1007/BF00267667; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gao XL, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P623; Hirst MC, 1998, NUCLEIC ACIDS RES, V26, P2353, DOI 10.1093/nar/26.10.2353; Imbert G, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P27; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Jonczyk P, 1998, J BACTERIOL, V180, P1563, DOI 10.1128/JB.180.6.1563-1566.1998; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Kornberg A., 1992, DNA REPLICATION; Kroutil LC, 1999, NUCLEIC ACIDS RES, V27, P3481, DOI 10.1093/nar/27.17.3481; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; Kunkel TA, 1997, CELL, V88, P155, DOI 10.1016/S0092-8674(00)81832-2; Mariappan SVS, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P647; MARUYAMA M, 1983, J MOL BIOL, V167, P757, DOI 10.1016/S0022-2836(83)80109-0; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Ohshima K, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P717; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; Pearson CE, 1998, NUCLEIC ACIDS RES, V26, P816, DOI 10.1093/nar/26.3.816; Pearson CE, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P585; Petruska J, 1998, J BIOL CHEM, V273, P5204, DOI 10.1074/jbc.273.9.5204; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 2002, MOL CLONING LAB MANU; Sargent RG, 1996, NUCLEIC ACIDS RES, V24, P746; Sarkar PS, 1998, CELL, V95, P531, DOI 10.1016/S0092-8674(00)81620-7; Saveson CJ, 1997, GENETICS, V146, P457; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; SCHAAPER RM, 1989, GENETICS, V121, P205; SCHAAPER RM, 1989, EMBO J, V8, P3511, DOI 10.1002/j.1460-2075.1989.tb08516.x; Schumacher S, 1998, J MOL BIOL, V279, P1101, DOI 10.1006/jmbi.1998.1827; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; SELICK HE, 1987, DNA REPLICATION RECO, P183; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; Strauss BS, 1997, NUCLEIC ACIDS RES, V25, P806, DOI 10.1093/nar/25.4.806; Taft-Benz SA, 1998, NUCLEIC ACIDS RES, V26, P4005, DOI 10.1093/nar/26.17.4005; TAKANO K, 1986, MOL GEN GENET, V205, P9, DOI 10.1007/BF02428026; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1998, J BIOL CHEM, V273, P19532, DOI 10.1074/jbc.273.31.19532; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875	71	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2174	2184		10.1074/jbc.275.3.2174	http://dx.doi.org/10.1074/jbc.275.3.2174			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636923	hybrid			2022-12-25	WOS:000084940000086
J	Zhu, T; Lobie, PE				Zhu, T; Lobie, PE			Janus kinase 2-dependent activation of p38 mitogen-activated protein kinase by growth hormone - Resultant transcriptional, activation of ATF-2 and chop, cytoskeletal re-organization and mitogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SIGNAL-TRANSDUCTION PATHWAY; INSULIN-RECEPTOR SUBSTRATE-1; TERNARY COMPLEX FACTORS; JAK2 TYROSINE KINASE; MAP KINASE; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN REORGANIZATION; DOWNSTREAM MEDIATOR; INDUCED APOPTOSIS	We demonstrate here that p38 mitogen-activated protein (MAP) kinase is activated in response to cellular stimulation by human GH (hGH) in Chinese hamster ovary cells stably transfected with GH receptor cDNA This activation requires the proline-rich box 1 region of the GH receptor required for JAK2 association and is prevented by pretreatment of cells with the JAR2-specific inhibitor AG490. ATF-2 is both phosphorylated and transcriptionally activated by hGH, and its transcriptional activation also requires the proline-rich box 1 region of the GH receptor. Expression of wild type JAK2 can further enhance hGH-induced ATF-2-, CHOP-, and Elk-1-mediated transcriptional activation, whereas pretreatment with AG490 is inhibitory. Use of either specific pharmacological inhibitors or transient transfection of cells with p38 alpha MAP kinase cDNA or a dominant negative variant demonstrated that hGH-stimulated transcriptional activation of ATF-2 and CHOP, but not Elk-1, is regulated by p38 MAP kinase. Both the p38 MAP kinase and p44/42 MAP kinase are critical for hGH-stimulated mitogenesis, whereas only p38 MAP kinase is required for hGH-induced actin cytoskeletal re-organization, p38 MAP kinase is therefore an important regulator in coordinating the pleiotropic effects of GH.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Lobie, PE (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; Carter-Su C, 1998, RECENT PROG HORM RES, V53, P61; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DERIJARD B, 1995, SCIENCE, V267, P683; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; Duyndam MCA, 1999, ONCOGENE, V18, P2311, DOI 10.1038/sj.onc.1202584; EDEN S, 1982, ENDOCRINOLOGY, V111, P1505, DOI 10.1210/endo-111-5-1505; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Friedman AD, 1996, CANCER RES, V56, P3250; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Galbiati F, 1999, J BIOL CHEM, V274, P30315, DOI 10.1074/jbc.274.42.30315; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Goh ELK, 1998, ENDOCRINOLOGY, V139, P4364, DOI 10.1210/en.139.10.4364; Goh ELK, 1997, ENDOCRINOLOGY, V138, P3207, DOI 10.1210/en.138.8.3207; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HARDING PA, 1995, RECEPTOR, V5, P81; Harris KW, 1998, BLOOD, V92, P1219, DOI 10.1182/blood.V92.4.1219.416k07_1219_1224; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Hedges JC, 1998, AM J PHYSIOL-CELL PH, V275, pC527, DOI 10.1152/ajpcell.1998.275.2.C527; Hibi M, 1998, Int Rev Immunol, V17, P75, DOI 10.3109/08830189809084488; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Horman S, 1997, CELL PROLIFERAT, V30, P21, DOI 10.1111/j.1365-2184.1997.tb00913.x; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Kilgour E, 1996, BIOCHEM J, V315, P517, DOI 10.1042/bj3150517; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Kim SO, 1998, J CELL BIOCHEM, V71, P286, DOI 10.1002/(SICI)1097-4644(19981101)71:2<286::AID-JCB13>3.0.CO;2-J; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Larsen JK, 1997, AM J PHYSIOL-LUNG C, V273, pL930, DOI 10.1152/ajplung.1997.273.5.L930; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Lobie PE, 1996, ENDOCRINOLOGY, V137, P4037, DOI 10.1210/en.137.9.4037; LOBIE PE, 1999, GROWTH HORMONE, P17; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nagata Y, 1997, BLOOD, V90, P929, DOI 10.1182/blood.V90.3.929.929_929_934; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; Sambrook J., 2002, MOL CLONING LAB MANU; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; SLOOTWEG MC, 1991, J MOL ENDOCRINOL, V6, P179, DOI 10.1677/jme.0.0060179; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Wood TJJ, 1997, MOL CELL ENDOCRINOL, V130, P69, DOI 10.1016/S0303-7207(97)00075-0; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	106	78	78	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2103	2114		10.1074/jbc.275.3.2103	http://dx.doi.org/10.1074/jbc.275.3.2103			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636915	hybrid			2022-12-25	WOS:000084940000078
J	De Falco, G; Bagella, L; Claudio, PP; De Luca, A; Fu, Y; Calabretta, B; Sala, A; Giordano, A				De Falco, G; Bagella, L; Claudio, PP; De Luca, A; Fu, Y; Calabretta, B; Sala, A; Giordano, A			Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation	ONCOGENE			English	Article						CDK9; B-Myb; oncogenes	CYCLIN-DEPENDENT KINASE-5; C-MYB; V-MYB; TERMINAL DIFFERENTIATION; CDC2-RELATED KINASE; MYELOID-LEUKEMIA; EXPRESSION; ACTIVATION; BINDING; TRANSCRIPTION	B-Myb is a transcription factor belonging to the myb family, whose activity has been associated with augmented DNA synthesis and cell cycle progression, We showed recently that B-Myb autoregulates its own expression through promoter transactivation. We report in this study that CDK9, the cyclin T associated kinase, which phosphorylates and activates RNA-Polymerase II, suppresses B-Myb autoregulation through direct interaction with the carboxyl-terminus of the B-Myb protein, Downregulation of the transactivating ability of B-Myb is independent of the kinase activity of CDK9, because a kinase deficient mutant (dn-CDK9) also represses B-myb gene autoregulation, Overexpression of CDK9 did not result in suppression of p53-dependent transactivation or inhibition of the basal activity of the promoters tested so far, demonstrating that CDK9 is a B-Myb-specific repressor, Rather, transfection of the dominant negative dn-CDK9 construct inhibited the basal activity of the reporter genes, confirming an essential role for CDK9 in gene transcription. In addition, Cyclin T1 restores B-Myb transactivating activity when co-transfected along with CDK9, suggesting that the down-regulatory effect observed on B-Myb is specifically due to CDK9 alone. Thus, our data suggest that CDK9 is involved in the negative regulation of activated transcription mediated by certain transcription factors, such as B-Myb, This may indicate the existence of a feedback loop, mediated by the different activities of CDK9, which links basal with activated transcription.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Jefferson Med Coll, Philadelphia, PA 19107 USA; Univ Naples Federico II, Dept Sci Odontostomatol & Maxillo Facciali, Naples, Italy; Ist Regina Elena, Lab Cell Metab & Pharmacokinet, Ctr Expt Res, I-00158 Rome, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Dept Microbiol, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, CH, Italy	Jefferson University; University of Naples Federico II; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Jefferson University; Consorzio Mario Negri Sud	Giordano, A (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Jefferson Med Coll, Jefferson Alumni Hall,Room 226,1020 Locust St, Philadelphia, PA 19107 USA.		De Luca, Antonio/AAD-9562-2020; sala, arturo/C-4959-2008; Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021	De Luca, Antonio/0000-0002-3905-6154; Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622; BAGELLA, Luigi/0000-0003-2815-037X; Sala, Arturo/0000-0002-2841-7866				Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; Bies J, 1996, ONCOGENE, V12, P355; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; DeLuca A, 1997, J CELL PHYSIOL, V172, P265, DOI 10.1002/(SICI)1097-4652(199708)172:2<265::AID-JCP13>3.3.CO;2-C; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; KALKBRENNER F, 1990, ONCOGENE, V5, P657; Katzen AL, 1996, P NATL ACAD SCI USA, V93, P13955, DOI 10.1073/pnas.93.24.13955; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Napolitano G, 1999, AIDS, V13, P1453, DOI 10.1097/00002030-199908200-00003; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Raschella G, 1997, J CELL BIOCHEM, V67, P297, DOI 10.1002/(SICI)1097-4644(19971201)67:3<297::AID-JCB2>3.0.CO;2-R; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Romano G, 1999, J CELL BIOCHEM, V75, P357, DOI 10.1002/(SICI)1097-4644(19991201)75:3<357::AID-JCB1>3.0.CO;2-K; Sala A, 1996, CANCER RES, V56, P1991; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sala A, 1999, J CELL PHYSIOL, V179, P245; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saville MK, 1998, ADV CANCER RES, V72, P109; Sitzmann J, 1996, ONCOGENE, V12, P1889; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	41	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					373	379		10.1038/sj.onc.1203305	http://dx.doi.org/10.1038/sj.onc.1203305			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656684				2022-12-25	WOS:000084873700007
J	Hutton, FG; Turnell, AS; Gallimore, PH; Grand, RJA				Hutton, FG; Turnell, AS; Gallimore, PH; Grand, RJA			Consequences of disruption of the interaction between p53 and the larger adenovirus early region 1B protein in adenovirus E1 transformed human cells	ONCOGENE			English	Article						p53; adenovirus E1B; penetratin peptides	WILD-TYPE P53; TUMOR-SUPPRESSOR; CELLULAR PROTEIN; APOPTOSIS; EXPRESSION; ONCOGENICITY; LOCALIZATION; ASSOCIATION; FRAGMENTS; BINDING	The adenovirus early region 1B (Ad E1B) genes have no transforming capability of their own but markedly increase the transformation frequency of Ad EIA following co-transfection into mammalian cells, The larger E1B proteins of both Ad2/5 and Ad12 bind to p53 and inhibit its ability to transcriptionally activate other genes. We have previously demonstrated that synthetic peptides identical to the binding sites for p53 on both the Ad2 and Ad12 E1B proteins will disrupt the interaction in vivo and in vitro . in the work presented here we have examined the effects of complex dissociation on Ad El-transformed human cells, If has been shown, using confocal microscopy, that when the peptide identical to the p53 binding site was added to Ad5 E1-transformed cells it initally located in the cytoplasmic dense bodies where it caused disruption of the p53/E1B complex. Peptide and p53 then translocated to the nucleus, In Ad12 El-transformed cells the peptide localized in the nucleus directly and there caused a reorganization of p53 staining from a highly organized, 'flecke' distribution to one in vc which nuclear staining was homogeneous and diffuse. Peptides added to either Ad5 El or Ad12 El transformed cells resulted in the release of transcriptionally active p53, interestingly, the level of p53 then fell presumably as a result of proteasomal action - this was probably a reflection of the short half-life of 'free' (i.e. dissociated) p53 compared to that of the bound protein, Free p53 did not cause apoptosis in target cells probably due to the presence of the smaller (19K) E1B proteins. However, addition of peptide leads to a significant reduction in cell growth rate. We have further demonstrated that a significant proportion of those cells which had taken up peptide had ceased DNA synthesis, probably due to a p53-induced cell cycle arrest. The role of the larger E1B protein during transformation is considered in view of these data.	Univ Birmingham, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Grand, RJA (corresponding author), Univ Birmingham, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.			Hutton, Fiona/0000-0002-9707-2988				BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERNARDS R, 1984, BIOCHIM BIOPHYS ACTA, V783, P187, DOI 10.1016/0167-4781(84)90029-0; Chinnadurai G, 1998, SEMIN VIROL, V8, P399, DOI 10.1006/smvy.1997.0139; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Gabler S, 1998, J VIROL, V72, P7960, DOI 10.1128/JVI.72.10.7960-7971.1998; GALLIMORE PH, 1986, ANTICANCER RES, V6, P499; Gallimore PH, 1997, J VIROL, V71, P6629, DOI 10.1128/JVI.71.9.6629-6640.1997; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GALLIMORE PH, 1985, SOC GEN MICROBIOL S, V37, P125; Grand RJA, 1999, ONCOGENE, V18, P955, DOI 10.1038/sj.onc.1202358; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grand RJA, 1996, VIROLOGY, V218, P23, DOI 10.1006/viro.1996.0162; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HUEN DS, 1995, ONCOGENE, V10, P549; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; MERRICK RM, 1991, J GEN VIROL, V72, P955, DOI 10.1099/0022-1317-72-4-955; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; White E, 1998, SEMIN VIROL, V8, P505, DOI 10.1006/smvy.1998.0155; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	37	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					452	462		10.1038/sj.onc.1203316	http://dx.doi.org/10.1038/sj.onc.1203316			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656694				2022-12-25	WOS:000084873700017
J	Calvo, KR; Knoepfler, P; McGrath, S; Kamps, MP				Calvo, KR; Knoepfler, P; McGrath, S; Kamps, MP			An inhibitory switch derepressed by Pbx, Hox, and Meis/Prep1 partners regulates DNA-binding by Pbx1 and E2a-Pbx1 and is dispensable for myeloid immortalization by E2a-Pbx1	ONCOGENE			English	Article						Pbx; E2a-Pbx1; t(1;19) pre-B ALL; Hox; Meis; Prep1; leukemia	GLUCOCORTICOID RESPONSE ELEMENT; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN PROTOONCOGENE PBX1; ONCOPROTEIN E2A-PBX1; PRE-B; TRANSCRIPTION FACTOR; TRANSLOCATION PROTEIN; CHIMERIC ONCOPROTEIN; HOMEODOMAIN PROTEIN; MAPKAP KINASE-2	The Pbx/Exd family of homeodomain (HD) proteins contribute to the transcriptional and developmental roles of other Hox and Meis/Prep1/Hth HD proteins through heterodimer formation, E2a-Pbx1 is an oncogenic derrivative of Pbx1 produced by the t(1;19) translocation in pediatric pre-B cell acute lymphoblastic leukemia. E2a-Pbx1 heterodimerizes with Hox but not with Meis/ Prep1 proteins, produces acute myeloid leukemia in mice, and blocks differentiation of cultured murine myeloid progenitors, Here, we characterize negative and positive regulatory sequences that flank the Pbx1 HD and determine their importance for myeloid immortalization by E2a-Pbx1. A 25 residue predicted alpha helix preceding the Pbx1 HD bound the HD and prevented both its binding to DNA and its ability to heterodimerize with Hox proteins, Addition of 39 residues N-terminal to this inhibitory helix exposed a Pbs dimerization interface that orchestrated cooperative DNA-binding of E2a-Pbx1 and all Pbx proteins as homodimers and heterdimers, Sequences inhibiting DNA-binding and mediating Pbs dimerization coincided with those reported to have nuclear export function. An additional 103 residues N-terminal to the Pbx dimerization interface restored heterodimerization with Hox and Meis1/Prep1 proteins. This negative switch domain comprised of the inhibitory helix and N-terminal regions required for its partner-mediated derepression - was dispensable for myeloid immortalization by E2a-Pbx1, While stabilizing the heterodimer, the 3(10) helix C-terminal to the Pbx1 HD was also dispensable for the ability of E2a-Pbx1 to heterodimerize with Hox proteins and immortalize myeloblasts. Retention of myeloid immortalization by E2a-Pbx1 proteins lacking all Pbx1 sequences N- or C-terminal to the HD indicates that Has proteins, or a get undefined factor that binds the Pbx1 HD and derepresses DNA-binding by the HD, cooperate with E2a-Pbx1 in myeloid immortalization.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Calvo, KR (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Calvo, Katherine/A-8109-2009	Knoepfler, Paul/0000-0001-5444-334X; Calvo, Katherine/0000-0002-0771-4191	NATIONAL CANCER INSTITUTE [R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; CARROLL AJ, 1984, BLOOD, V63, P721; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; DeCesare D, 1997, J BIOL CHEM, V272, P23921, DOI 10.1074/jbc.272.38.23921; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; Green NC, 1998, J BIOL CHEM, V273, P13273, DOI 10.1074/jbc.273.21.13273; Grieder NC, 1997, EMBO J, V16, P7402, DOI 10.1093/emboj/16.24.7402; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Knoepfler PS, 1997, ONCOGENE, V14, P2521, DOI 10.1038/sj.onc.1201097; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NUMATA SI, 1993, LEUKEMIA, V7, P1441; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; ROBERTS VJ, 1995, MECH DEVELOP, V51, P193, DOI 10.1016/0925-4773(95)00364-9; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Subramaniam N, 1997, DNA CELL BIOL, V16, P153, DOI 10.1089/dna.1997.16.153; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3	65	36	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 23	1999	18	56					8033	8043		10.1038/sj.onc.1203377	http://dx.doi.org/10.1038/sj.onc.1203377			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637514				2022-12-25	WOS:000084634600012
J	Chang, WM; Bohm, RA; Strauss, JC; Kwan, T; Thomas, T; Cowmeadow, RB; Atkinson, NS				Chang, WM; Bohm, RA; Strauss, JC; Kwan, T; Thomas, T; Cowmeadow, RB; Atkinson, NS			Muscle-specific transcriptional regulation of the slowpoke Ca2+-activated K+ channel gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; TISSUE-SPECIFIC EXPRESSION; CALCIUM SPARKS; SMOOTH-MUSCLE; DROSOPHILA; RELAXATION; ELEMENTS; CURRENTS; ISOFORMS; NEURONS	Transcriptional regulation of the Drosophila slowpoke calcium-activated potassium channel gene is complex. To date, five transcriptional promoters have been identified, which are responsible for slowpoke expression in neurons, midgut cells, tracheal cells, and muscle fibers. The slowpoke promoter called Promoter C2 is active in muscles and tracheal cells. To identify sequences that activate Promoter C2 in specific cell types, we introduced small deletions into the slowpoke transcriptional control region. Using transformed flies, we asked how these deletions affected the in situ tissue-specific pattern of expression. Sequence comparisons between evolutionarily divergent species helped guide the placement of these deletions. A section of DNA important for expression in all cell types was subdivided and reintroduced into the mutated control region, a piece at a time, to identify which portion was required for promoter activity. We identified 55-, 214-, and 20-nucleotide sequences that control promoter activity. Different combinations of these elements activate the promoter in adult muscle, larval muscle, and tracheal cells.	Univ Texas, Sch Biol Sci, Neurobiol Sect, Austin, TX 78712 USA; Univ Texas, Sch Biol Sci, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Atkinson, NS (corresponding author), Univ Texas, Sch Biol Sci, Neurobiol Sect, Austin, TX 78712 USA.							Anant S, 1998, DEVELOPMENT, V125, P1361; Atkinson NS, 1998, ANN NY ACAD SCI, V860, P296, DOI 10.1111/j.1749-6632.1998.tb09057.x; Baro DJ, 1997, J NEUROSCI, V17, P6597; BECKER MN, 1995, J NEUROSCI, V15, P6250; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brenner R, 1996, J NEUROSCI, V16, P1827; Brenner R, 1996, DEV BIOL, V177, P536, DOI 10.1006/dbio.1996.0183; CHANG WM, 1998, THESIS U TEXAS AUSTI; Dickinson MH, 1997, COMP BIOCHEM PHYS A, V116, P223, DOI 10.1016/S0300-9629(96)00162-4; ELKINS T, 1988, J NEUROSCI, V8, P428; FAY FS, 1995, SCIENCE, V270, P588, DOI 10.1126/science.270.5236.588; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; Hille B., 1992, IONIC CHANNELS EXCIT; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LUNDELL MJ, 1992, DEV BIOL, V154, P84, DOI 10.1016/0012-1606(92)90050-Q; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Navaratnam DS, 1997, NEURON, V19, P1077, DOI 10.1016/S0896-6273(00)80398-0; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; ONEIL MT, 1992, GENETICS, V131, P113; Patterson J. T., 1952, EVOLUTION GENUS DROS; Phelps CB, 1998, METHODS, V14, P367, DOI 10.1006/meth.1998.0592; Postigo AA, 1999, MOL CELL BIOL, V19, P7255; Rosenblatt KP, 1997, NEURON, V19, P1061, DOI 10.1016/S0896-6273(00)80397-9; Roy S, 1999, BIOESSAYS, V21, P486, DOI 10.1002/(SICI)1521-1878(199906)21:6&lt;486::AID-BIES5&gt;3.0.CO;2-M; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULER GD, 1995, MULTIPLE ALIGNMENT C; SHEPPARD DN, 1988, J MEMBRANE BIOL, V105, P65, DOI 10.1007/BF01871107; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Thomas Tarita, 1997, Invertebrate Neuroscience, V2, P283, DOI 10.1007/BF02211941; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; TURNHEIM K, 1989, J MEMBRANE BIOL, V112, P247, DOI 10.1007/BF01870955; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5	37	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3991	3998		10.1074/jbc.275.6.3991	http://dx.doi.org/10.1074/jbc.275.6.3991			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660555	hybrid			2022-12-25	WOS:000085288800039
J	Gradia, S; Acharya, S; Fishel, R				Gradia, S; Acharya, S; Fishel, R			The role of mismatched nucleotides in activating the hMSH2-hMSH6 Molecular Switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; HMUTS-ALPHA; TRANSLOCATION MECHANISM; HETERODUPLEX REPAIR; TUMOR-CELLS; DNA; ATP; BINDING; HMSH2	We have previously shown that hMSH2-hMSH6 contains an intrinsic ATPase which is activated by mismatch-provoked ADP-->ATP exchange that coordinately induces the formation of a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone (1, 2), These studies suggested that mismatch repair could be propagated by a signaling event transduced via diffusion of ATP-bound hMSH2-hMSH6 molecular switches to the DNA repair machinery. The Molecular Switch model (Fishel, R, (1998) Genes Dev, 12, 2096-2101) is considerably different than the Hydrolysis-Driven Translocation model (Blackwell, L. J., Martik, D., Bjornson, K. P., Bjornson, E. S., and Modrich, P. (1998) J. Biol, Chem. 273, 32055-32062) and makes additional testable predictions beyond the demonstration of hydrolysis-independent diffusion (Gradia, S., Subramanian, D., Wilson, T., Acharya, S., Makhov, A., Griffith, J., and Fishel, R, (1999) Mel. Cell 3, 255-261): (i) individual mismatch-provoked ADP-->ATP exchange should be unique and rate-limiting, and (ii) the k(cat.DNA) for the DNA-stimulated ATPase activity should decrease with increasing chain length. Here we have examined hMSH2-hMSH6 affinity and ATPase stimulatory activity for several DNA substrates containing mispaired nucleotides as well as the chain length dependence of a defined mismatch under physiological conditions. We find that the results are most consistent with the predictions of the Molecular Switch model.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Genet & Mol Biol Program, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Genet & Mol Biol Program, Kimmel Canc Ctr, 233 S 10th St, Philadelphia, PA 19107 USA.	rfishel@hendrix.jci.tju.edu			NATIONAL CANCER INSTITUTE [R01CA056542, R01CA067007] Funding Source: NIH RePORTER; NCI NIH HHS [CA67007, CA56542, R01 CA067007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; ARTHUR PG, 1995, ANAL BIOCHEM, V227, P281, DOI 10.1006/abio.1995.1281; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; BOCKER T, 1999, BIOCHIM BIOPHYS ACTA, V31, P1; CHI NW, 1994, J BIOL CHEM, V269, P29984; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FISHEL RA, 1983, UCLA S MOL CELL BIOL, V11, P309; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MATSON SW, 1987, J BIOL CHEM, V262, P2066; Motulsky H., 1999, ANAL DATA GRAPHPAD P; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Sia EA, 1997, MUTAT RES-DNA REPAIR, V383, P61, DOI 10.1016/S0921-8777(96)00046-8; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; WERNTGES H, 1986, NUCLEIC ACIDS RES, V14, P3773, DOI 10.1093/nar/14.9.3773; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; YOUNG MC, 1994, J MOL BIOL, V235, P1436, DOI 10.1006/jmbi.1994.1099	40	99	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3922	3930		10.1074/jbc.275.6.3922	http://dx.doi.org/10.1074/jbc.275.6.3922			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660545	hybrid			2022-12-25	WOS:000085288800029
J	Tetsuka, T; Uranishi, H; Imai, H; Ono, T; Sonta, S; Takahashi, N; Asamitsu, K; Okamoto, T				Tetsuka, T; Uranishi, H; Imai, H; Ono, T; Sonta, S; Takahashi, N; Asamitsu, K; Okamoto, T			Inhibition of nuclear factor-kappa B-mediated transcription by association with the amino-terminal enhancer of split, a Groucho-related protein lacking WD40 repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; RAT MESANGIAL CELLS; DROSOPHILA-ENHANCER; SACCHAROMYCES-CEREVISIAE; REPRESSION DOMAIN; BINDING PROTEIN; KINASE KINASE-1; GENE-PRODUCT; DNA-BINDING; ACTIVATION	The amino-terminal enhancer of split (AES) encodes a 197-amino acid protein that is homologous to the NH2-terminal domain of the Drosophila Groucho protein but lacks COOH-terminal WD40 repeats. Although the Drosophila Groucho protein and its mammalian homologs, transducin-like enhancer of split proteins, are known to act as non-DNA binding corepressors, the role of the AES protein remains unclarified. Using the yeast two-hybrid system, we have identified the protein-protein interaction between AES and the p65 (Re1A) subunit of the transcription factor nuclear factor kappa B (NF-kappa B), which activates various target genes involved in inflammation, apoptosis, and embryonic development. The interaction between AES and p65 was confirmed by in vitro glutathione S-transferase pull down assay and by in vivo co-immunoprecipitation study. In transient transfection assays, AES repressed p65-driven gene expression. AES also inhibited NF-kappa B-dependent gene expression induced by tumor necrosis factor alpha, interleukin-1 beta, and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1, which is an upstream kinase for NF-kappa B activation. These data indicate that AES acts as a corepressor for NF-kappa B and suggest that AES may play a pivotal role in the regulation of NF-kappa B target genes.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Aichi Human Serv Ctr, Dept Genet, Inst Dev Res, Kasugai, Aichi 4800392, Japan	Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.		Ono, Takao/C-6065-2017	Ono, Takao/0000-0002-0498-8293; Asamitsu, Kaori/0000-0001-5333-8011				Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; COUREY AJ, 1995, BBA-GENE STRUCT EXPR, V1261, P1, DOI 10.1016/0167-4781(94)00234-T; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; MALLO M, 1993, MECH DEVELOP, V42, P67, DOI 10.1016/0925-4773(93)90099-J; Mallo M, 1995, CELL MOL BIOL RES, V41, P435; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MIYASAKA H, 1993, EUR J BIOCHEM, V216, P343, DOI 10.1111/j.1432-1033.1993.tb18151.x; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; OKAMOTO T, 1989, AIDS RES HUM RETROV, V5, P131, DOI 10.1089/aid.1989.5.131; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; Parkhurst SM, 1998, TRENDS GENET, V14, P130, DOI 10.1016/S0168-9525(98)01407-3; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pinto M, 1996, J BIOL CHEM, V271, P33026, DOI 10.1074/jbc.271.51.33026; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Sato T, 1998, AIDS RES HUM RETROV, V14, P293, DOI 10.1089/aid.1998.14.293; SCHMIDT CJ, 1993, J BIOL CHEM, V268, P25681; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Song WJ, 1996, MOL CELL BIOL, V16, P115; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Tetsuka T, 1996, J CLIN INVEST, V97, P2051, DOI 10.1172/JCI118641; Tetsuka T, 1996, J BIOL CHEM, V271, P11689, DOI 10.1074/jbc.271.20.11689; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Valentine SA, 1998, MOL CELL BIOL, V18, P6584, DOI 10.1128/MCB.18.11.6584; WAHI M, 1995, GENETICS, V140, P79; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Yoshida S, 1999, J IMMUNOL, V163, P351; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zandi E, 1999, MOL CELL BIOL, V19, P4547	50	78	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4383	4390		10.1074/jbc.275.6.4383	http://dx.doi.org/10.1074/jbc.275.6.4383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660609	hybrid			2022-12-25	WOS:000085288800093
J	Varoqui, H; Zhu, HM; Yao, DD; Ming, H; Erickson, JD				Varoqui, H; Zhu, HM; Yao, DD; Ming, H; Erickson, JD			Cloning and functional identification of a neuronal glutamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; CEREBELLAR GRANULE CELLS; SYNAPTIC VESICLES; EXPRESSION CLONING; ENERGY-DEPENDENCE; CNS TRANSMITTER; RAT-BRAIN; METABOLISM; ASTROCYTES; GENE	Glutamine is the preferred precursor for the neurotransmitter pool of glutamate, the major excitatory transmitter in the mammalian central nervous system. We have isolated a complementary DNA clone (designated GlnT) encoding a plasma membrane glutamine transporter from glutamatergic neurons in culture, and its properties have been examined using the T7 vaccinia system in fibroblasts. When GlnT is transfected into CV-1 cells, L-glutamine is the preferred substrate. Transport is Na+-dependent and inhibited by alpha-methylamino-isobutyric acid, a specific inhibitor of neutral amino acid transport system A. Kinetic analysis of glutamine uptake by GlnT is saturable, with a Michaelis constant (K-m) of 489 +/- 88 mu M at pH 7.4. Glutamine uptake mediated by GlnT is pH-sensitive with a 5-fold greater efficiency of uptake at pH 8.2 than at pH 6.6. Only the maximal velocity of transport increases without a significant change in K-m. The distribution of GlnT mRNA and protein in the central nervous system is widespread and is expressed on neurons that use glutamate as their neurotransmitter. In cultured cerebellar granule cells, GlnT is expressed only on neurons and is absent from astrocytes. GlnT expression increases concomitantly with the morphologic and functional differentiation of these cells in vitro, consistent with its role of supplying glutamatergic neurons with their neurotransmitter precursor, GlnT is the first member of the system A family of neutral amino acid transporters with 11 putative membrane-spanning domains and is a potential target to modulate presynaptic glutamatergic function.	Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Erickson, JD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, 202 Gravier St,Suite D, New Orleans, LA 70112 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036936] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36936] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BARKER GA, 1990, EXP PHYSIOL, V75, P3, DOI 10.1113/expphysiol.1990.sp003382; Billups B, 1996, NATURE, V379, P171, DOI 10.1038/379171a0; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BRADFORD HF, 1976, BRAIN RES, V110, P115, DOI 10.1016/0006-8993(76)90212-2; BRADFORD HF, 1978, J NEUROCHEM, V30, P1453, DOI 10.1111/j.1471-4159.1978.tb10477.x; Broer A, 1999, J NEUROCHEM, V73, P2184; BROOKES N, 1997, GLIA, V21, P4; CHRISTENSEN HN, 1982, PHYSIOL REV, V62, P1193, DOI 10.1152/physrev.1982.62.4.1193; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1976, TRANSPORT PHENOMENA, P3; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; ERECINSKA M, 1990, PROG NEUROBIOL, V35, P245, DOI 10.1016/0301-0082(90)90013-7; Erickson JD, 1996, PROG BRAIN RES, V109, P69; FEURST TO, 1986, P NATL ACAD SCI USA, V83, P8122; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; FONNUM F, 1993, PROG BIOPHYS MOL BIO, V60, P47, DOI 10.1016/0079-6107(93)90012-9; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; GJESSING LR, 1972, J NEUROCHEM, V19, P1807, DOI 10.1111/j.1471-4159.1972.tb06226.x; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; HAMBERGER A, 1979, BRAIN RES, V168, P531, DOI 10.1016/0006-8993(79)90307-X; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; HELL JW, 1990, J BIOL CHEM, V265, P2111; HERTZ L, 1979, PROG NEUROBIOL, V13, P277, DOI 10.1016/0301-0082(79)90018-2; Hertz L, 1987, MODEL SYSTEMS DEV AG, P19; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LIAO K, 1995, BIOCHEM BIOPH RES CO, V208, P1008, DOI 10.1006/bbrc.1995.1434; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; Nagaraja TN, 1996, J NEUROCHEM, V66, P1665; NAJLERAHIM A, 1990, MOL BRAIN RES, V7, P317, DOI 10.1016/0169-328X(90)90082-O; NICKLAS WJ, 1983, GLUTAMINE GLUTAMATE, P219; Nissim I, 1999, AM J PHYSIOL-RENAL, V277, pF493, DOI 10.1152/ajprenal.1999.277.4.F493; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; OXENDER DL, 1963, NATURE, V197, P765, DOI 10.1038/197765a0; PENG L, 1993, DEV NEUROSCI-BASEL, V15, P367, DOI 10.1159/000111357; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Prasad PD, 1999, BIOCHEM BIOPH RES CO, V255, P283, DOI 10.1006/bbrc.1999.0206; RAMAHAROBANDRO N, 1982, BRAIN RES, V244, P113, DOI 10.1016/0006-8993(82)90909-X; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sagne C, 1997, FEBS LETT, V417, P177, DOI 10.1016/S0014-5793(97)01279-9; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SHANK RP, 1981, LIFE SCI, V28, P837, DOI 10.1016/0024-3205(81)90044-8; Sibson NR, 1997, P NATL ACAD SCI USA, V94, P2699, DOI 10.1073/pnas.94.6.2699; Sonnewald U, 1997, GLIA, V21, P56, DOI 10.1002/(SICI)1098-1136(199709)21:1<56::AID-GLIA6>3.0.CO;2-#; Su TZ, 1997, BRAIN RES, V757, P69, DOI 10.1016/S0006-8993(97)00139-X; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; USDIN TB, 1994, NEUROPROTOCOLS, V5, P144; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; WEILER CT, 1982, J NEUROCHEM, V32, P559; WESTERGAARD N, 1995, DEV NEUROSCI-BASEL, V17, P203, DOI 10.1159/000111288; Young GB, 1999, BBA-BIOMEMBRANES, V1415, P306, DOI 10.1016/S0005-2736(98)00196-5; Young III WS, 1992, IN SITU HYBRIDIZATIO, P33	63	242	255	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4049	4054		10.1074/jbc.275.6.4049	http://dx.doi.org/10.1074/jbc.275.6.4049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660562	hybrid			2022-12-25	WOS:000085288800046
J	Goldstein, S; Czapski, G; Lind, J; Merenyi, G				Goldstein, S; Czapski, G; Lind, J; Merenyi, G			Tyrosine nitration by simultaneous generation of (NO)-N-center dot and O-2(center dot) under physiological conditions - How the radicals do the job	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SOLUTIONS; CARBON-DIOXIDE; BIOLOGICAL-ACTIVITY; HYDROGEN-PEROXIDE; PHENOXYL RADICALS; AQUEOUS-SOLUTIONS; OXIDATIVE DAMAGE; PEROXYNITRITE; MECHANISM; NO	Radiation chemical experiments demonstrate that the reaction of tyrosyl radical (TyrO(.)) with (NO2)-N-. yields 45 +/- 3% 3-nitrotyrosine and that a major product of the reaction of TyrO(.) with (NO)-N-. is 3,3'-dityrosine. Radiolysis was used to generate (NO)-N-. and O-2(-.) in the presence of tyrosine and bicarbonate at pH 7.5 +/- 0.1. The nitration yield was found to be dose rate-dependent, and the yield per radical produced by pulse radiolysis was identical to that obtained with authentic peroxynitrite, The proposed mechanism that accounts for the data is as follows: (i) In the presence of CO2 the reaction of (NO)-N-. with O-2(-.) yields 33% (NO2)-N-. and CO3-. where the latter reacts rapidly with tyrosine to form TyrO; (ii) The formation of 3-nitrotyrosine takes place via the reaction of (NO2)-N-. with TyrO(.), which is the main process at high dose rates; and (iii) Under continuous generation of (NO)-N-. and O-2(-.) the formation of 3-nitrotyrosine is strongly suppressed because of efficient scavenging of NO2, by tyrosine. The proposed model shows that the highest nitration yield is obtained for similar fluxes of (NO)-N-. and O-2(-.) and is completely inhibited upon excess production of O-2(-.) because of efficient scavenging of TyrO(.) by O-2(-.). The biological implications of these findings are discussed.	Hebrew Univ Jerusalem, Dept Phys Chem, IL-91904 Jerusalem, Israel; Royal Inst Technol, Dept Chem Nucl Chem, S-10044 Stockholm 70, Sweden	Hebrew University of Jerusalem; Royal Institute of Technology	Goldstein, S (corresponding author), Hebrew Univ Jerusalem, Dept Phys Chem, IL-91904 Jerusalem, Israel.							Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448; ALBERTY RA, 1995, J PHYS CHEM-US, V99, P11028, DOI 10.1021/j100027a051; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Berho F, 1998, J PHYS CHEM A, V102, P1, DOI 10.1021/jp972576p; Berlett BS, 1998, P NATL ACAD SCI USA, V95, P2784, DOI 10.1073/pnas.95.6.2784; BUXTON GV, 1995, J CHEM SOC FARADAY T, V91, P279, DOI 10.1039/ft9959100279; Caulfield JL, 1996, J BIOL CHEM, V271, P25859, DOI 10.1074/jbc.271.42.25859; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; Goldstein S, 1997, INORG CHEM, V36, P5113, DOI 10.1021/ic970471v; Goldstein S, 1998, INORG CHEM, V37, P3943, DOI 10.1021/ic980051l; Goldstein S, 1998, J AM CHEM SOC, V120, P3458, DOI 10.1021/ja9733043; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; Goldstein S, 1996, INORG CHEM, V35, P7735, DOI 10.1021/ic960233k; Goldstein S, 1999, CHEM RES TOXICOL, V12, P132, DOI 10.1021/tx9802522; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P205; Gonzalez-Mancebo S, 1999, J AGR FOOD CHEM, V47, P2235, DOI 10.1021/jf981094n; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; HADDAD IY, 1993, AM J PHYSIOL, V265, P555; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; JANZEN EG, 1993, J ORG CHEM, V58, P3597, DOI 10.1021/jo00066a001; JIN FM, 1993, J CHEM SOC PERK T 2, P1583, DOI 10.1039/p29930001583; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; MALLARD WG, 1998, NIST STANDARD REFERE, V40; Merenyi G, 1997, CHEM RES TOXICOL, V10, P1216, DOI 10.1021/tx970101j; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; PIRES M, 1994, INT J CHEM KINET, V26, P1207, DOI 10.1002/kin.550261208; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRUTZ WA, 1983, INT J RADIAT BIOL, V44, P183, DOI 10.1080/09553008314550981; Saha A, 1998, FREE RADICAL BIO MED, V24, P653, DOI 10.1016/S0891-5849(97)00365-1; SCHULER RH, 1980, J PHYS CHEM-US, V84, P2088, DOI 10.1021/j100453a020; Szalai VA, 1996, BIOCHEMISTRY-US, V35, P15080, DOI 10.1021/bi961117w; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; VONGRAETZEL M, 1969, BER BUNSEN PHYS CHEM, V73, P646; VONGRATZEL M, 1970, BER BUNSEN PHYS CHEM, V74, P488; Williams D. L. H., 1988, NITROSATION, P58; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007	47	177	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3031	3036		10.1074/jbc.275.5.3031	http://dx.doi.org/10.1074/jbc.275.5.3031			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652282	hybrid			2022-12-25	WOS:000085146500004
J	Navarro-Antolin, J; Rey-Campos, J; Lamas, S				Navarro-Antolin, J; Rey-Campos, J; Lamas, S			Transcriptional induction of endothelial nitric oxide gene by cyclosporine A - A role for activator protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; SYNTHASE MESSENGER-RNA; A-INDUCED HYPERTENSION; C-FOS EXPRESSION; NF-KAPPA-B; MOLECULAR-CLONING; GROWTH-FACTOR; CHROMOSOMAL LOCALIZATION; CELLS; RATS	We have previously shown that the immunosuppressant cyclosporine A (CsA) increases the activity, the protein level, and the steady-state levels of the mRNA of the endothelial nitric oxide synthase (eNOS) gene in bovine aortic endothelial cells (BAEC). We have now investigated the mechanisms responsible for these effects. Preincubation with an inhibitor of RNA polymerase II abolished CsA-induced eNOS up-regulation. Nuclear run-on experiments demonstrated a 1.6-fold increase in the induction of eNOS gene by CsA In agreement with these results, transient transfections showed that CsA augmented the transactivation of the eNOS promoter. Electrophoretic mobility shift assays showed an increase in the activator protein-1 (AP-1) DNA binding activity in BAEC treated with CsA An increase in the level of c-fos mRNA and in the nuclear content of c-Fos protein was detected in BAEC treated with CsA. Site-directed mutagenesis of the AP-1 cis-regulatory element in the context of the human eNOS promoter resulted in the abrogation of the induction mediated by Csk Hence, upregulation of eNOS mRNA by CsA is a transcriptional phenomenon involving the proximal AP-1 site in the 5'-regulatory region of the human eNOS gene. Furthermore, our data exemplify how immunosuppressive drugs may result in the regulation of specific genes involved in the homeostasis of endothelial function, such as eNOS.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; Inst Reina Sofia Invest Nefrol, Madrid 28006, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Lamas, S (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.	slamas@cib.csic.es	Lamas, Santiago/G-7308-2015	Lamas, Santiago/0000-0001-5166-4155				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Alonso J, 1997, MOL CELL BIOL, V17, P5719, DOI 10.1128/MCB.17.10.5719; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; ARNAL JF, 1994, AM J PHYSIOL-CELL PH, V267, pC1381, DOI 10.1152/ajpcell.1994.267.5.C1381; Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; Bartholomeusz B, 1996, HYPERTENSION, V27, P1341, DOI 10.1161/01.HYP.27.6.1341; Bobadilla NA, 1998, AM J PHYSIOL-RENAL, V274, pF791, DOI 10.1152/ajprenal.1998.274.4.F791; Bracht C, 1999, J HYPERTENS, V17, P357, DOI 10.1097/00004872-199917030-00008; BUNCHMAN TE, 1991, J CLIN INVEST, V88, P310, DOI 10.1172/JCI115293; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Cuevas P, 1996, P NATL ACAD SCI USA, V93, P11996, DOI 10.1073/pnas.93.21.11996; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; delArco PG, 1996, J BIOL CHEM, V271, P26335; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DENICOLA L, 1993, J CLIN INVEST, V92, P1859, DOI 10.1172/JCI116777; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Flowers MA, 1995, AM J PHYSIOL-HEART C, V269, pH1988, DOI 10.1152/ajpheart.1995.269.6.H1988; Forstermann U, 1998, FASEB J, V12, P773; GREEMBERG ME, 1997, CURRENT PROTOCOLS MO; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Hutchinson IV, 1998, CURR OPIN NEPHROL HY, V7, P665, DOI 10.1097/00041552-199811000-00007; INOUE N, 1995, ARTERIOSCL THROM VAS, V15, P1255, DOI 10.1161/01.ATV.15.8.1255; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kleinert H, 1998, HYPERTENSION, V31, P582, DOI 10.1161/01.HYP.31.2.582; KON V, 1990, KIDNEY INT, V37, P1487, DOI 10.1038/ki.1990.139; KOSTYK SK, 1995, AM J PHYSIOL-HEART C, V269, pH1583, DOI 10.1152/ajpheart.1995.269.5.H1583; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Li HG, 1998, MOL PHARMACOL, V53, P630, DOI 10.1124/mol.53.4.630; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Lopez-Ongil S, 1998, BRIT J PHARMACOL, V124, P447, DOI 10.1038/sj.bjp.0701847; LopezOngil S, 1996, AM J PHYSIOL-HEART C, V271, pH1072, DOI 10.1152/ajpheart.1996.271.3.H1072; MARSDEN PA, 1990, AM J PHYSIOL, V258, pF1295, DOI 10.1152/ajprenal.1990.258.5.F1295; MARSDEN PA, 1991, AM J PHYSIOL, V261, pF117, DOI 10.1152/ajprenal.1991.261.1.F117; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; McQuillan Lynda P., 1994, American Journal of Physiology, V267, pH1921; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MIYAHARA K, 1994, EUR J BIOCHEM, V223, P719, DOI 10.1111/j.1432-1033.1994.tb19045.x; Mosieniak G, 1997, J NEUROCHEM, V68, P1142; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; Navarro-Antolin J, 1998, KIDNEY INT, V54, pS20, DOI 10.1046/j.1523-1755.1998.06807.x; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; Oriji GK, 1998, HYPERTENSION, V32, P849, DOI 10.1161/01.HYP.32.5.849; RANJAN V, 1995, AM J PHYSIOL-HEART C, V269, pH550, DOI 10.1152/ajpheart.1995.269.2.H550; REGO A, 1991, J PHARMACOL EXP THER, V259, P905; ROBINSON LJ, 1994, GENOMICS, V19, P350, DOI 10.1006/geno.1994.1068; ROULLET JB, 1994, J CLIN INVEST, V93, P2244, DOI 10.1172/JCI117222; Schaefer A, 1998, BIOCHEM J, V335, P505, DOI 10.1042/bj3350505; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; Stroes ESG, 1997, HYPERTENSION, V29, P570, DOI 10.1161/01.HYP.29.2.570; Su QX, 1996, BIOCHEM BIOPH RES CO, V229, P249, DOI 10.1006/bbrc.1996.1788; Uematsu M, 1995, AM J PHYSIOL-CELL PH, V269, pC1371, DOI 10.1152/ajpcell.1995.269.6.C1371; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	63	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3075	3080		10.1074/jbc.275.5.3075	http://dx.doi.org/10.1074/jbc.275.5.3075			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652288	hybrid, Green Published			2022-12-25	WOS:000085146500010
J	Lindner, G; Menrad, A; Gherardi, E; Merlino, G; Welker, P; Handjiski, B; Roloff, B; Paus, R				Lindner, G; Menrad, A; Gherardi, E; Merlino, G; Welker, P; Handjiski, B; Roloff, B; Paus, R			Involvement of hepatocyte growth factor/scatter factor and Met receptor signaling in hair follicle morphogenesis and cycling	FASEB JOURNAL			English	Article						apoptosis; hair growth; HGF/SF; keratinocytes; murine hepatocyte growth factor receptor	FACTOR SCATTER FACTOR; EPITHELIAL-CELLS; REGRESSION CATAGEN; MURINE SKIN; TYROSINE KINASE; CYCLOSPORINE-A; ORGAN-CULTURE; BETA-CATENIN; MOUSE SKIN; IN-VIVO	HGF/SF and its receptor (Met) are principal mediators of mesenchymal-epithelial interactions in several different systems and have recently been implicated in the control of hair follicle (HF) growth, We have studied their expression patterns during HF morphogenesis and cycling in C57BL/6 mice, whereas functional hair growth effects of HGF/SF were assessed in vivo by analysis of transgenic mice and in skin organ culture. In normal mouse skin, follicular expression of HGF/SF and Met was strikingly localized: HGF/SF was found only in the HF mesenchyme (dermal papilla fibroblasts) and Met in the neighboring hair bulb keratinocytes, Both HGF/SF and Met expression peaked during the initial phases of HF morphogenesis, the stage of active hair growth (early and mid anagen), and during the apoptosis-driven HF regression (catagen), Met+ cells in the regressing epithelial strand appeared to be protected from undergoing apoptosis. Compared to wild-type controls, transgenic mice overexpressing HGF/SF under the control of the MT-I promoter had twice as many developing HF and displayed accelerated HF development on postnatal day 3, They also showed significant catagen retardation on P17, In organ culture and in vivo, HGF/SF i.c. resulted in a significant catagen retardation. These results demonstrate an important role of HGF/SF and Met in murine hair growth control and suggest that Met-mediated signaling might be exploited for therapeutic manipulation of human hair growth disorders.-Lindner, G., Menrad, A., Gherardi, E., Merlino, G,, Welker, P., Handjiski, B., Roloff, B,, Paus, R. Involvement of hepatocyte growth factor/scatter factor and Met receptor signaling in hair follicle morphogenesis and cycling.	Univ Hamburg, Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany; Humboldt Univ, Dept Dermatol, D-1086 Berlin, Germany; Schering AG, Res Labs, D-1000 Berlin, Germany; MRC Ctr, Growth Factors Grp, Dept Oncol, Cambridge, England; NCI, Mol Biol Lab, Bethesda, MD 20892 USA	University of Hamburg; Humboldt University of Berlin; Schering AG; MRC Laboratory Molecular Biology; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Paus, R (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Dermatol, Martinistr 52, D-20246 Hamburg, Germany.		Gherardi, Ermanno/AAB-9608-2022	Lindner, Gerd/0000-0003-2336-2058; GHERARDI, ERMANNO/0000-0002-0016-2945				Balkovetz DF, 1997, J BIOL CHEM, V272, P3471, DOI 10.1074/jbc.272.6.3471; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 1997, CIBA F SYMP, V212, P169; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1998, J INVEST DERMATOL, V111, P279, DOI 10.1046/j.1523-1747.1998.00277.x; Botchkarev VA, 1999, FASEB J, V13, P395, DOI 10.1096/fasebj.13.2.395; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; Conner EA, 1997, BIOCHEM BIOPH RES CO, V236, P396, DOI 10.1006/bbrc.1997.6938; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; HANSEN LS, 1984, ANAT REC, V210, P569, DOI 10.1002/ar.1092100404; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; Jahoda CAB, 1996, DERMATOL CLIN, V14, P573, DOI 10.1016/S0733-8635(05)70385-5; Jakubczak JL, 1998, MOL CELL BIOL, V18, P1275, DOI 10.1128/MCB.18.3.1275; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Jiang WG, 1998, INT J MOL MED, V2, P203; Jiang WG, 1997, HISTOL HISTOPATHOL, V12, P537; Jindo T, 1998, J INVEST DERMATOL, V110, P338, DOI 10.1046/j.1523-1747.1998.00144.x; JINDO T, 1994, J INVEST DERMATOL, V103, P306, DOI 10.1111/1523-1747.ep12394731; LI LN, 1992, IN VITRO CELL DEV-AN, V28A, P695; Lindner G, 1997, AM J PATHOL, V151, P1601; Longati P, 1996, CELL DEATH DIFFER, V3, P23; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; Maurer M, 1997, AM J PATHOL, V150, P1433; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Metcalfe A, 1997, BIOESSAYS, V19, P711, DOI 10.1002/bies.950190812; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; Oro AE, 1998, CELL, V95, P575, DOI 10.1016/S0092-8674(00)81624-4; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; Paus R, 1996, CANCER RES, V56, P4438; PAUS R, 1989, LAB INVEST, V60, P365; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; PAUS R, 1994, J INVEST DERMATOL, V103, P143, DOI 10.1111/1523-1747.ep12392542; PAUS R, 1994, BRIT J DERMATOL, V130, P174, DOI 10.1111/j.1365-2133.1994.tb02896.x; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 1999, IN PRESS J INVEST DE; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; Peluso JJ, 1997, BIOCHEM PHARMACOL, V54, P847, DOI 10.1016/S0006-2952(97)00118-4; PethoSchramm A, 1996, ARCH DERMATOL RES, V288, P264, DOI 10.1007/BF02530098; Peus D, 1996, DERMATOL CLIN, V14, P559, DOI 10.1016/S0733-8635(05)70384-3; Philpott M, 1998, MOL BASIS EPITHELIAL, P75; ROSEN EM, 1993, SYM SOC EXP BIOL, V47, P227; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt NO, 1999, INT J CANCER, V84, P10, DOI 10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.3.CO;2-C; SHIMAOKA S, 1995, J CELL PHYSIOL, V165, P333, DOI 10.1002/jcp.1041650214; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; STENN KS, 1988, J INVEST DERMATOL, V90, P409, DOI 10.1111/1523-1747.ep12456517; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STRAILE WE, 1961, J EXP ZOOL, V148, P205, DOI 10.1002/jez.1401480304; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Trusolino L, 1998, FASEB J, V12, P1267, DOI 10.1096/fasebj.12.13.1267; VIELKIND U, 1995, ACTA ANAT, V152, P93; Welker P, 1997, ARCH DERMATOL RES, V289, P554, DOI 10.1007/s004030050239; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; Yo Y, 1998, KIDNEY INT, V54, P1128, DOI 10.1046/j.1523-1755.1998.00092.x; YU DW, 1995, J CELL SCI, V108, P3867	71	107	119	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					319	332		10.1096/fasebj.14.2.319	http://dx.doi.org/10.1096/fasebj.14.2.319			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657988				2022-12-25	WOS:000085184800011
J	Miller, KE; Sheetz, MP				Miller, KE; Sheetz, MP			Characterization of myosin V binding to brain vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; UNCONVENTIONAL MYOSIN; PURKINJE-CELLS; GAMMA-TUBULIN; TRANSPORT; ACTIN; GENE; LOCALIZATION; MEMBRANES; PROTEIN	Myosin II and V are important for the generation and segregation of subcellular compartments. Ne observed that vesicular myosin II and V were associated with the protein scaffolding of a common subset of vesicles by density sedimentation, electron microscopy, and immunofluorescence. Solubilization of either myosin II or V was caused by polyphosphates with the following efficacy at 10 mM: for myosin II ATP-Mg2+ = ATP = AMP-PNP (5'-adenylyl imidodiphosphate) > pyrophosphate = tripolyphosphate much greater than tetrapolyphosphate = ADP > cAMP = Mg2+; and for myosin V pyrophosphate = tripolyphosphate > ATP-Mg2+ = ATP = AMP-PNP much greater than ADP = tetrapolyphosphate > cAMP = Mg2+. Consequently, we suggest solubilization was not an effect of phosphorylation, hydrolysis, or disassociation of myosin from actin filaments. Scatchard analysis of myosin V binding to stripped dense vesicles showed saturable binding with a K-m of 10 nM. Analysis of native vesicles indicates that these sites are fully occupied. Together, these data show there are over 100 myosin Vs/vesicle (100-nm radius). Ne propose that polyphosphate anions bind to myosin Il and V and induce a conformational change that disrupts binding to a receptor.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Sheetz, MP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.			Miller, Kyle/0000-0003-0401-4736	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023345] Funding Source: NIH RePORTER; NIGMS NIH HHS [1F32-GM-19219-01] Funding Source: Medline; NINDS NIH HHS [NS 23345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Catlett NL, 1998, P NATL ACAD SCI USA, V95, P14799, DOI 10.1073/pnas.95.25.14799; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; DekkerOhno K, 1996, BRAIN RES, V714, P226, DOI 10.1016/0006-8993(95)01560-4; Espreafico EM, 1998, P NATL ACAD SCI USA, V95, P8636, DOI 10.1073/pnas.95.15.8636; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; Evans LL, 1997, J CELL SCI, V110, P439; Evans LL, 1998, J CELL SCI, V111, P2055; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; GREENE LE, 1980, J BIOL CHEM, V255, P543; HARRINGTON WF, 1972, BIOCHEMISTRY-US, V11, P2945, DOI 10.1021/bi00766a004; Heimann K, 1999, J BIOL CHEM, V274, P10743, DOI 10.1074/jbc.274.16.10743; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Provance DW, 1996, P NATL ACAD SCI USA, V93, P14554, DOI 10.1073/pnas.93.25.14554; Reck-Peterson SL, 1999, MOL BIOL CELL, V10, P1001, DOI 10.1091/mbc.10.4.1001; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stow JL, 1998, TRENDS CELL BIOL, V8, P138, DOI 10.1016/S0962-8924(98)01238-0; Tabb JS, 1998, J CELL SCI, V111, P3221; Takagishi Y, 1996, NEUROSCI LETT, V215, P169, DOI 10.1016/S0304-3940(96)12967-0; WAGNER JA, 1978, BIOCHEMISTRY-US, V17, P1199, DOI 10.1021/bi00600a010; Wu XF, 1998, CELL MOTIL CYTOSKEL, V40, P286, DOI 10.1002/(SICI)1097-0169(1998)40:3<286::AID-CM7>3.0.CO;2-B; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899	34	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2598	2606		10.1074/jbc.275.4.2598	http://dx.doi.org/10.1074/jbc.275.4.2598			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644719	hybrid			2022-12-25	WOS:000085128000051
J	Zhang, Y; Dufau, ML				Zhang, Y; Dufau, ML			Nuclear orphan receptors regulate transcription of the gene for the human luteinizing hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; COUP-TF; TARGET GENES; SUPERFAMILY; HETERODIMERS; EXPRESSION; PROMOTER; MEMBER; CELLS; IDENTIFICATION	imperfect estrogen receptor half-site response element direct-repeat, located within the TATA-less promoter of the human luteinizing hormone receptor (hLHR), was identified as an inhibitory site for Sp1/Sp3-driven basal transcription. Isolation of proteins recognizing this site by yeast one-hybrid screening of a human placenta cDNA library revealed three nuclear orphan receptors, EARS, EAR3/COUP-TFI, and TR4. Electrophoresis mobility shift assays demonstrated that the in vitro translated nuclear orphan receptors specifically bound the direct-repeat motif of the hLHR promoter. Also, endogenous EARS and EAR3/COUP-TFI from JAR cell and human testis and TR4 from testes bound this motif in electrophoresis mobility shift assays. Functional analyses in CV-1 cells showed that EARS and EAR3/COUP-TFI repressed the hLHR promoter activity by up to 70% in a dose dependent and sequence-specific manner. Conversely, TR4 activated the hLHR promoter activity up to 2.5-fold through binding to the same cis-element. The stimulation was reversed by coexpression of EARS or EARS/COUP-TFI, indicating their competitive binding for this site. Such recognition of a common cognate site by the proteins with antagonistic functions implies that a net regulation of the hLHR gene may result from the relative availability of repressors and activator in a physiological state. This also may contribute to the differential expression of the hLHR gene in gonadal and non-gonadal tissues.	NICHD, Endocrinol & Reprod Res Branch, Sect Mol Endocrinol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dufau, ML (corresponding author), NICHD, Endocrinol & Reprod Res Branch, Sect Mol Endocrinol, NIH, Bldg 49,Rm 6A-36,49 Convent Dr,MSC 4510, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000150] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000150] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; Catt KJ, 1991, REPROD ENDOCRINOLOGY, P105; CHEN F, 1994, MOL ENDOCRINOL, V8, P1434, DOI 10.1210/me.8.10.1434; Dajee M, 1998, MOL ENDOCRINOL, V12, P1393, DOI 10.1210/me.12.9.1393; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Geng Y, 1999, BIOCHEM BIOPH RES CO, V263, P366, DOI 10.1006/bbrc.1999.1374; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; ING NH, 1992, J BIOL CHEM, V267, P17617; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; LEE HJ, 1995, J BIOL CHEM, V270, P30129; Lee YF, 1998, J BIOL CHEM, V273, P13437, DOI 10.1074/jbc.273.22.13437; Lee YF, 1999, J BIOL CHEM, V274, P16198, DOI 10.1074/jbc.274.23.16198; Lee YF, 1997, J BIOL CHEM, V272, P12215, DOI 10.1074/jbc.272.18.12215; Leng X, 1996, MOL CELL BIOL, V16, P2332; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Tsai-Morris C, 1999, HUM HERED, V49, P48, DOI 10.1159/000022840; Tsai-Morris CH, 1998, J CLIN ENDOCR METAB, V83, P288, DOI 10.1210/jc.83.1.288	29	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2763	2770		10.1074/jbc.275.4.2763	http://dx.doi.org/10.1074/jbc.275.4.2763			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644740	hybrid			2022-12-25	WOS:000085128000072
J	Horton, JK; Prasad, R; Hou, E; Wilson, SH				Horton, JK; Prasad, R; Hou, E; Wilson, SH			Protection against methylation-induced cytotoxicity by DNA polymerase beta-dependent long patch base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ABASIC SITES; OXYGEN ALKYLATION; MAMMALIAN-CELLS; BOVINE TESTIS; CHO CELLS; PATHWAY; METHOXYAMINE; GLYCOSYLASE; AGENTS	Using a plasmid-based uracil-containing DNA substrate, we found that the long patch base excision repair (BER) activity of a wild-type mouse fibroblast extract was partially inhibited by an antibody to DNA polymerase beta (beta-pol), This suggests that beta-pol participates in long patch BER, in addition to single-nucleotide BER. In single-nucleotide BER, the deoxyribose phosphate (dRP) in the abasic site is removed by the lyase activity of beta-pol. Methoxyamine (MX) can react with the aldehyde of an abasic site, making it refractory to the beta-elimination step of the dRP lyase mechanism, thus blocking single-nucleotide BER. MX exposure sensitizes wildtype, but not beta-pol null mouse embryonic fibroblasts, to the cytotoxic effects of methyl methanesulfonate (MMS) and methylnitrosourea. Expression of beta-pol in the null cells restores the ability of MX to modulate sensitivity to MMS. The beta-pol null cells are known to be hypersensitive to MMS and methylnitrosourea, and in the presence of MX (i.e. under conditions where single-nucleotide BER is blocked) the null cells are still considerably more sensitive than wild-type. The data are consistent with a role of beta-pol in long patch BER, which helps protect cells against methylation damage-induced cytotoxicity.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.		Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050159, Z01ES050159] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beard WA, 1995, METHOD ENZYMOL, V262, P98; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; Calleja F, 1999, MUTAT RES-FUND MOL M, V425, P185, DOI 10.1016/S0027-5107(99)00034-2; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; deVries A, 1996, SEMIN CANCER BIOL, V7, P229, DOI 10.1006/scbi.1996.0031; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; FORTINI P, 1992, CARCINOGENESIS, V13, P87, DOI 10.1093/carcin/13.1.87; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; FORTINI P, 1990, MUTAT RES, V236, P129, DOI 10.1016/0921-8777(90)90040-C; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FROSINA G, 1994, BIOCHEM J, V304, P699, DOI 10.1042/bj3040699; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Lawley PD, 1996, MUTAT RES-FUND MOL M, V355, P13, DOI 10.1016/0027-5107(96)00020-6; LIUZZI M, 1985, J BIOL CHEM, V260, P5252; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MIRZAYANS R, 1988, CARCINOGENESIS, V9, P2257, DOI 10.1093/carcin/9.12.2257; Nakamura J, 1999, CANCER RES, V59, P2522; Nakamura J, 1998, CANCER RES, V58, P222; Ochs K, 1999, CANCER RES, V59, P1544; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; PRASAD R, 2000, IN PRESS J BIOL CHEM, V275; PRICE A, 1992, FEBS LETT, V300, P101, DOI 10.1016/0014-5793(92)80173-E; ROSA S, 1991, NUCLEIC ACIDS RES, V19, P5569, DOI 10.1093/nar/19.20.5569; Sandigursky M, 1998, NUCLEIC ACIDS RES, V26, P1282, DOI 10.1093/nar/26.5.1282; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; SNOWDEN A, 1990, BIOCHEMISTRY-US, V29, P7251, DOI 10.1021/bi00483a013; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TALPAERTBORLE M, 1983, BIOCHIM BIOPHYS ACTA, V740, P410, DOI 10.1016/0167-4781(83)90089-1; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; TEO IA, 1983, MUTAT RES, V107, P371, DOI 10.1016/0027-5107(83)90177-X; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	44	130	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2211	2218		10.1074/jbc.275.3.2211	http://dx.doi.org/10.1074/jbc.275.3.2211			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636928	hybrid			2022-12-25	WOS:000084940000091
J	Reddy, DE; Keck, CL; Popescu, N; Athwal, RS; Kaur, GP				Reddy, DE; Keck, CL; Popescu, N; Athwal, RS; Kaur, GP			Identification of a YAC from 16q24 carrying a senescence gene for breast cancer cells	ONCOGENE			English	Article						cell senescence; breast cancer; YAC contig; YAC transfer; functional complementation	YEAST ARTIFICIAL CHROMOSOMES; MAMMALIAN-CELLS; MOUSE CELLS; CELLULAR SENESCENCE; ALLELIC IMBALANCE; IN-SITU; CARCINOMA; FUSION; EXPRESSION; COMPLEMENTATION	We have identified a 360 kb YAC that carries a cell senescence gene, SEN16. In our earlier studies, we localized SEN16 within a genetic interval of 3-7 cM at 16q24.3. Six overlapping YACs spanning the chromosomal region of senescence activity, were assembled in a contig. Candidate YACs, identified by the markers located in the vicinity of SEN16, were retrofitted to introduce a neo selectable marker. Retrofitted YACs were first transferred into mouse A9 cells to generate A9/YAC hybrids. YAC DNA present in A9/YAC hybrids was further transferred by microcell fusion into immortal cell lines derived from human and rat mammary tumors. YAC d792t2 restored senescence in both human and rat mammary tumor cell lines, while an unrelated YAC from chromosome 6q had no senescence activity.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaur, GP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St,AHP Room 201, Philadelphia, PA 19140 USA.							ATHWAL RS, 1985, SOMAT CELL MOLEC GEN, V11, P177, DOI 10.1007/BF01534706; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; Davies N P, 1996, Methods Mol Biol, V54, P281; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DOGGETT NA, 1995, NATURE, V377, P335; ELICEIRI B, 1991, P NATL ACAD SCI USA, V88, P2179, DOI 10.1073/pnas.88.6.2179; GNIRKE A, 1991, EMBO J, V10, P1629, DOI 10.1002/j.1460-2075.1991.tb07685.x; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HUXLEY C, 1991, GENOMICS, V9, P742, DOI 10.1016/0888-7543(91)90369-P; Julicher K, 1997, GENOMICS, V43, P95, DOI 10.1006/geno.1997.4787; Koreth J, 1999, ONCOGENE, V18, P1157, DOI 10.1038/sj.onc.1202372; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; MEDINA D, 1996, J MAMMARY GLAND BIOL, V1, P21; MUNROE DJ, 1994, GENOMICS, V19, P506, DOI 10.1006/geno.1994.1100; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; NEGRINI M, 1994, CANCER RES, V54, P1331; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PAVAN WJ, 1990, MOL CELL BIOL, V10, P4163, DOI 10.1128/MCB.10.8.4163; Perou CM, 1996, P NATL ACAD SCI USA, V93, P5905, DOI 10.1073/pnas.93.12.5905; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P11207, DOI 10.1073/pnas.90.23.11207; POPESCU N, 1994, GENOMICS, V20, P333, DOI 10.1006/geno.1994.1182; RADFORD DM, 1995, CANCER RES, V55, P3399; Reddy DE, 1999, ONCOGENE, V18, P5100, DOI 10.1038/sj.onc.1202888; Sandhu AK, 1996, ONCOGENE, V12, P247; SKIRNISDOTTIR S, 1995, INT J CANCER, V64, P112, DOI 10.1002/ijc.2910640207; STRAUSS WM, 1992, EMBO J, V11, P417, DOI 10.1002/j.1460-2075.1992.tb05070.x; TSUDA H, 1994, CANCER RES, V54, P513; WADA M, 1994, BIOCHEM BIOPH RES CO, V200, P1693, DOI 10.1006/bbrc.1994.1647; Whitmore SA, 1998, GENOMICS, V52, P325, DOI 10.1006/geno.1998.5457; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V80, P100, DOI 10.1016/0165-4608(94)00161-4	37	8	8	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					217	222		10.1038/sj.onc.1203264	http://dx.doi.org/10.1038/sj.onc.1203264			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644999				2022-12-25	WOS:000084844400006
J	Inagaki, K; Noguchi, T; Matozaki, T; Horikawa, T; Fukunaga, K; Tsuda, M; Ichihashi, M; Kasuga, M				Inagaki, K; Noguchi, T; Matozaki, T; Horikawa, T; Fukunaga, K; Tsuda, M; Ichihashi, M; Kasuga, M			Roles for the protein tyrosine phosphatase SHP-2 in cytoskeletal organization, cell adhesion and cell migration revealed by overexpression of a dominant negative mutant	ONCOGENE			English	Article						cytoskeletal organization; cell migration; integrin signaling; SHP-2	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; GROWTH-FACTOR; FOCAL ADHESION; SIGNAL-TRANSDUCTION; SYP PHOSPHATASE; RAS ACTIVATION; MAP KINASE; PHOSPHORYLATION; INSULIN	SHP-2, a SRC homology 2 domain-containing protein tyrosine phosphatase, mediates activation of Ras and mitogen-activated protein kinase by various mitogens and cell adhesion, Inhibition of endogenous SHP-2 by overexpression of a catalytically inactive (dominant negative) mutant in Chinese hamster ovary cells or Rat-1 fibroblasts has now been shown to induce a marked change in cell morphology (from elongated to less polarized) that is accompanied by substantial increases in the numbers of actin stress fibers and focal adhesion contacts. Overexpression of the SHP-2 mutant also increased the strength of cell-substratum adhesion and resulted in hyperphosphorylation of SHPS-1, a substrate of SHP-2 that contributes to cell adhesion-induced signaling, Inhibition of SHP-2 also markedly increased the rate of cell attachment to and cell spreading on extracellular matrix proteins such as fibronectin and vitronectin, effects that were accompanied by enhancement of adhesion-induced tyrosine phosphorylation of paxillin and p130Cas. In addition, cell migration mediated by fibronectin or vitronectin, but not that induced by insulin, was impaired by over-expression of the SHP-2 mutant, These results suggest that SHP-2 plays an important role in the control of cell shape by contributing to cytoskeletal organization, and that it is an important regulator of integrin-mediated cell adhesion, spreading, and migration as well as of tyrosine phosphorylation of focal adhesion contact-associated proteins.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Sch Med, Dept Dermatol, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University; Kobe University	Noguchi, T (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.							Adachi M, 1996, CELL, V85, P15; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HORIKAWA T, 1995, J INVEST DERMATOL, V104, P256, DOI 10.1111/1523-1747.ep12612795; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; ILLC D, 1995, NATURE, V377, P539; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; Manes S, 1999, MOL CELL BIOL, V19, P3125; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; Menzel D, 1996, CURR OPIN CELL BIOL, V8, P38, DOI 10.1016/S0955-0674(96)80046-9; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOBES CD, 1995, J CELL SCI, V108, P225; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwarzbauer JE, 1997, CURR BIOL, V7, pR292, DOI 10.1016/S0960-9822(06)00140-0; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	58	74	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2000	19	1					75	84		10.1038/sj.onc.1203204	http://dx.doi.org/10.1038/sj.onc.1203204			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644982				2022-12-25	WOS:000084844300009
J	Bertolotti, A; Bell, B; Tora, L				Bertolotti, A; Bell, B; Tora, L			The N-terminal domain of human TAF(II)68 displays transactivation and oncogenic properties	ONCOGENE			English	Article						oncogene; sarcoma; transcription factors II; histone acetylation; RNA polymerase II; recruitment	RNA-POLYMERASE-II; TATA-BINDING PROTEIN; EWS/FLI-1 FUSION GENE; TRANSCRIPTIONAL ACTIVATION; EWINGS-SARCOMA; DNA-BINDING; CHROMOSOME-TRANSLOCATION; MESSENGER-RNA; IN-VIVO; ESTROGEN-RECEPTOR	In Ewing tumor, the (11;22) chromosomal translocation produces a chimeric molecule composed of the aminoterminal domain of EWS fused to the carboxyl-terminal DNA-binding domain of FLI-1. Previously, we have identified a novel protein TAF(II)68, which is highly similar to EWS and another closely related protein TLS (also called FUS), We demonstrate that the N-terminus of TAF(II)68 efficiently stimulates transcription when fused to two different DNA binding domains and that overexpression of TAF(II)68-FLI-1 chimeras in NIH3T3 cells leads to oncogenic transformation. We have also investigated the molecular mechanisms which account for the transcriptional activation ana the oncogenic transformation potential of the N-termini of TAF(II)68 and EWS, Thus, we have tested whether the artificial recruitment of components of the preinitiation complex (PIC) or a histone acetyltransferase (HAT) could bypass the requirement for the activation domains of either EWS or TAF(II)68. Recruitment of individual components of the transcription machinery or the GCN5 HAT is not sufficient to promote activation from FLI-1 responsive genes either in transfection experiments or in oncogenic transformation assays. These results suggest that the TAF(II)68 or EWS activation domains enhance a step after PIC formation in the transcriptional activation process.	CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tora, L (corresponding author), CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch, France.		Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Barberis A, 1998, BIOL CHEM, V379, P1397; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Blair WS, 1996, EMBO J, V15, P1658, DOI 10.1002/j.1460-2075.1996.tb00511.x; Blau J, 1996, MOL CELL BIOL, V16, P2044; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROWN AD, 1995, ONCOGENE, V10, P1749; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CALVIO C, 1995, RNA, V1, P724; Candau R, 1996, MOL CELL BIOL, V16, P593; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Fujimura Y, 1996, ONCOGENE, V12, P159; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; He S, 1998, MOL CELL BIOL, V18, P2876, DOI 10.1128/MCB.18.5.2876; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Majello B, 1998, J BIOL CHEM, V273, P16509, DOI 10.1074/jbc.273.26.16509; MARSOLIER MC, 1994, P NATL ACAD SCI USA, V91, P138; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Melot T, 1997, HYBRIDOMA, V16, P457, DOI 10.1089/hyb.1997.16.457; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nevado J, 1999, P NATL ACAD SCI USA, V96, P2674, DOI 10.1073/pnas.96.6.2674; OHNO T, 1993, CANCER RES, V53, P5859; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Ranish JA, 1996, CURR OPIN GENET DEV, V6, P151, DOI 10.1016/S0959-437X(96)80044-X; Rauscher FJ, 1997, CURR TOP MICROBIOL, V220, P151; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; Roeder RG, 1996, METHOD ENZYMOL, V273, P165; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5609, DOI 10.1093/nar/21.24.5609; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, J CELL SCI, V110, P1741	87	66	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					8000	8010		10.1038/sj.onc.1203207	http://dx.doi.org/10.1038/sj.onc.1203207			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637511				2022-12-25	WOS:000084634600009
J	Huntsman, DG; Chin, SF; Muleris, M; Batley, SJ; Collins, VP; Wiedemann, LM; Aparicio, S; Caldas, C				Huntsman, DG; Chin, SF; Muleris, M; Batley, SJ; Collins, VP; Wiedemann, LM; Aparicio, S; Caldas, C			MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines	ONCOGENE			English	Article						MLL2; MLL; amplification; tumor; cell lines	BREAKPOINT CLUSTER REGION; ALL-1 GENE; ACUTE-LEUKEMIA; TANDEM DUPLICATION; TRANSLOCATIONS; AMPLIFICATION; EXPRESSION; 11Q23; REARRANGEMENTS; INVOLVEMENT	The Mixed Lineage Leukemia (MLL) gene is commonly involved in translocations in infantile leukemia and is amplified in some cases of adult myeloid leukemia. A homolog of MLL denoted MLL2, which represents the second human homolog of the Drosophila trithorax gene, was characterized by assembling ESTs, the KIAA0304 cDNA clone, RT-PCR fragments and a new clone isolated from a cDNA phage library and compared to the available genomic sequence. The MLL2 gene maps to 19q13.1, a region of frequent rearrangement or amplification in solid tumors. MLL2 consists of an 8.5-9 kb transcript and spans 20 kb of genomic DNA, The predicted MLL2 protein possesses all of the major domains defined in MLL and the two genes have a similar genomic structure. We find that MLL2 is amplified in two of 14 pancreatic carcinoma cell lines and one of five glioblastoma cell lines and is a likely critical gene in 19q13.1 amplifications. It is also a candidate for chromosomal rearrangements involving this chromosome locus, MLL2 is one additional mammalian trithorax-group gene with involvement in human cancer.	Univ Cambridge, Addenbrookes Hosp, CRC Dept Oncol, Cambridge CB2 2XY, England; Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Inst Curie, CNRS, UMR 147, F-75248 Paris, France; Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Histopathol, Cambridge CB2 2QQ, England; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Wellcome CRC Inst Canc Res & Dev Biol, Cambridge CB2 1QR, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Caldas, C (corresponding author), Univ Cambridge, Addenbrookes Hosp, CRC Dept Oncol, Wellcome Trust MRC Bldg, Cambridge CB2 2XY, England.		Caldas, Carlos/U-7250-2019; Caldas, Carlos/A-7543-2008; Huntsman, David/ABE-6082-2020; Wiedemann, Leanne/E-3316-2010	Caldas, Carlos/0000-0003-3547-1489; Aparicio, Samuel/0000-0002-0487-9599; chin, suet-feung/0000-0001-5697-1082; Wiedemann, Leanne/0000-0002-0964-4676	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen RJ, 1998, LEUKEMIA, V12, P1119, DOI 10.1038/sj.leu.2401002; Ariyama Y, 1998, GENE CHROMOSOME CANC, V23, P267, DOI 10.1002/(SICI)1098-2264(199811)23:3<267::AID-GCC10>3.3.CO;2-0; BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BREEN TR, 1993, DEVELOPMENT, V117, P119; BREEN TR, 1995, MECH DEVELOP, V52, P89, DOI 10.1016/0925-4773(95)00393-F; Caldas C, 1998, ONCOGENE, V16, P3233, DOI 10.1038/sj.onc.1201873; CALDAS C, 1999, IN PRESS CANC MET RE; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; DJABALI M, 1992, NAT GENET, V2, P112; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; Felix CA, 1998, BLOOD, V91, P4451; Ferbus D, 1999, INT J CANCER, V80, P369; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; Hoglund M, 1998, GENE CHROMOSOME CANC, V21, P8; Lochner K, 1996, CANCER RES, V56, P2171; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; Michaux L, 1998, BLOOD, V92, p78A; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MULERIS M, 1994, CYTOGENET CELL GENET, V65, P82, DOI 10.1159/000133605; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Rasio D, 1996, CANCER RES, V56, P1766; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Tanaka K, 1997, BLOOD, V89, P596, DOI 10.1182/blood.V89.2.596; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Wiedemann LM, 1999, BRIT J HAEMATOL, V105, P256, DOI 10.1111/j.1365-2141.1999.01291.x; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	44	85	94	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7975	7984		10.1038/sj.onc.1203291	http://dx.doi.org/10.1038/sj.onc.1203291			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637508				2022-12-25	WOS:000084634600006
J	Ibberson, M; Uldry, M; Thorens, B				Ibberson, M; Uldry, M; Thorens, B			GLUTX1, a novel mammalian glucose transporter expressed in the central nervous system and insulin-sensitive tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; HYPERGLYCEMIA; FIBROBLASTS; SEQUENCE; NEURONS; SIGNAL; FAMILY; CELLS; SITE	Based on homology with GLUT1-5, we have isolated a cDNA for a novel glucose transporter, GLUTX1. This cDNA encodes a protein of 478 amino acids that shows between 29 and 32% identity with rat GLUT1-5 and 32-36% identity with plant and bacterial hexose transporters. Unlike GLUT1-5, GLUTX1 has a short extracellular loop between transmembrane domain (TM) 1 and TM2 and a long extracellular loop between TM9 and TM10 that contains the only N-glycosylation site. When expressed in Xenopus oocytes, GLUTX1 showed strong transport activity only after suppression of a dileucine internalization motif present in the amino-terminal region. Transport activity was inhibited by cytochalasin B and partly competed by D-fructose and D-galactose. The Michaelis-Menten constant for glucose was approximately 2 mM, When translated in reticulocytes lysates, GLUTX1 migrates as a 35-kDa protein that becomes glycosylated in the presence of microsomal membranes, Western blot analysis of GLUTX1 transiently expressed in HEK293T cells revealed a diffuse band with a molecular mass of 37-50 kDa that could be converted to a similar to 35-kDa polypeptide following enzymatic deglycosylation. Immunofluorescence microscopy detection of GLUTX1 transfected into HEK293T cells showed an intracellular staining. Mutation of the dileucine internalization motif induced expression of GLUTX1 at the cell surface, GLUTX1 mRNA was detected in testis, hypothalamus, cerebellum, brainstem, hippocampus, and adrenal gland, We hypothesize that, in a similar fashion to GLUT4 in vivo cell surface expression of GLUTX1 may be inducible by a hormonal or other stimulus.	Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland		Thorens, B (corresponding author), Inst Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.			Ibberson, Mark/0000-0003-3152-5670				BURANT CF, 1992, J BIOL CHEM, V267, P14523; Chiou TJ, 1996, PLANT PHYSIOL, V110, P511, DOI 10.1104/pp.110.2.511; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; INUKAI K, 1994, BIOCHEM J, V302, P355, DOI 10.1042/bj3020355; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; OOMURA Y, 1974, NATURE, V247, P284, DOI 10.1038/247284a0; ORSINI JC, 1990, BRAIN RES BULL, V25, P49, DOI 10.1016/0361-9230(90)90251-T; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; RUSSELL RRB, 1992, J BIOL CHEM, V267, P4631; SARAVOLAC EG, 1997, FACILITATIVE GLUCOSE, P39; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; SMITH TF, 1985, NUCLEIC ACIDS RES, V13, P645, DOI 10.1093/nar/13.2.645; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thorens B, 1996, AM J PHYSIOL-GASTR L, V270, pG541, DOI 10.1152/ajpgi.1996.270.4.G541; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; WIDMANN C, 1995, BIOCHEM J, V310, P203, DOI 10.1042/bj3100203; YETTEFTI K, 1995, J AUTONOM NERV SYST, V51, P191, DOI 10.1016/0165-1838(94)00130-C; Younes M, 1997, ANTICANCER RES, V17, P2747	32	192	204	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4607	4612		10.1074/jbc.275.7.4607	http://dx.doi.org/10.1074/jbc.275.7.4607			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671487	hybrid			2022-12-25	WOS:000085378200013
J	Lyon, M; Rushton, G; Askari, JA; Humphries, MJ; Gallagher, JT				Lyon, M; Rushton, G; Askari, JA; Humphries, MJ; Gallagher, JT			Elucidation of the structural features of heparan sulfate important for interaction with the Hep-2 domain of fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HUMAN-PLASMA FIBRONECTIN; FACTOR SCATTER FACTOR; BINDING DOMAIN; INTEGRIN ALPHA-4-BETA-1; DIMETHYL-SULFOXIDE; CELL-ADHESION; MAMMARY CELLS; IDENTIFICATION; AFFINITY	The interaction of fibronectin with cell surface heparan sulfate proteoglycans is important biologically in inducing reorganization of the cytoskeleton and the assembly of focal adhesions. The major heparan sulfate-binding site in fibronectin, which is also implicated in these morphological events, is the COOH-terminal Hep-2 domain. We describe the first extensive study of the structural determinants required for the interaction between heparan sulfate/heparin and Hep-a. It is clear that, in heparan sulfate, there is a very prominent role for N-sulfate groups, as opposed to a relatively small apparent contribution from carboxyl groups. Furthermore, a minimal octasaccharide binding sequence appeared to contain at least two 2-O-sulfated iduronate residues, but no 6-O-sulfate groups. However, affinity was enhanced by the presence of 6-O-sulfates, and the interaction with Hep-a also increased progressively with oligosaccharide size up to a maximum length of a tetradecasaccharide, This overall specificity is compatible with recent information on the structure of Hep-a (Sharma, A., Askari, J, A, Humphries, M, J,, Jones, E, Y,, and Stuart, D, I. (1999) EMBO J. 18, 1468-1479) in which two separate, positively charged clusters, involving up to fl basic amino acid residues (mostly arginines with their preferential ability to co-ordinate sulfate groups), could form a single extended binding site.	Univ Manchester, Dept Med Oncol, Christie Hosp NHS Trust, Canc Res Campaign, Manchester M20 4BX, Lancs, England; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Manchester	Lyon, M (corresponding author), Univ Manchester, Dept Med Oncol, Christie Hosp NHS Trust, Canc Res Campaign, Manchester M20 4BX, Lancs, England.			Lyon, Malcolm/0000-0001-9575-6879; Humphries, Martin/0000-0002-4331-6967				ATKINS EDT, 1976, HEPARIN CHEM CLIN US, P21; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BENECKY MJ, 1988, BIOCHEMISTRY-US, V27, P7565, DOI 10.1021/bi00419a058; BENTLEY KL, 1985, J BIOL CHEM, V260, P7250; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; COUCHMAN JR, 1988, J CELL PHYSIOL, V136, P226, DOI 10.1002/jcp.1041360204; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; EVINGTON JRN, 1985, BIOCHEM SOC T, V13, P243, DOI 10.1042/bst0130243; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; JAIKARIA NS, 1991, BIOCHEMISTRY-US, V30, P1538, DOI 10.1021/bi00220a014; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; KELLER KL, 1980, BIOCHEMISTRY-US, V19, P2529, DOI 10.1021/bi00552a035; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LYON M, 1994, J BIOL CHEM, V269, P11216; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; OGAMO A, 1985, BIOCHIM BIOPHYS ACTA, V841, P30; Rahmoune H, 1998, BIOCHEMISTRY-US, V37, P6003, DOI 10.1021/bi972468t; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; STAMATOGLOU SC, 1983, J CELL BIOL, V96, P1820, DOI 10.1083/jcb.96.6.1820; TAYLOR RL, 1972, BIOCHEMISTRY-US, V11, P1383, DOI 10.1021/bi00758a009; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 1998, MATRIX BIOL, V17, P477, DOI 10.1016/S0945-053X(98)90095-6; YAMADA KM, 1980, J BIOL CHEM, V255, P6055; YONEDA J, 1995, EXP CELL RES, V217, P169, DOI 10.1006/excr.1995.1076	45	74	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4599	4606		10.1074/jbc.275.7.4599	http://dx.doi.org/10.1074/jbc.275.7.4599			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671486	hybrid			2022-12-25	WOS:000085378200012
J	Kasahara, T; Kasahara, M				Kasahara, T; Kasahara, M			Three aromatic amino acid residues critical for galactose transport in yeast Gal2 transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT1 GLUCOSE-TRANSPORTER; PUTATIVE TRANSMEMBRANE SEGMENT-10; SACCHAROMYCES-CEREVISIAE; SUGAR TRANSPORTERS; SUBSTRATE RECOGNITION; COMPLETE GENOME; TRYPTOPHAN-388; FORSKOLIN; BINDING; FAMILY	Tyr(446) in putative transmembrane segment 10 (TM10) of the yeast galactose transporter Ga12 has previously been identified as essential for galactose recognition. In the present study, alignment of the amino acid sequences of 63 sugar transporters or related proteins revealed 14 aromatic sites, including Tyr(446) Of Ga12, that are conserved in >75% of these proteins. The importance of the remaining 13 conserved aromatic amino acids was examined individually by random mutagenesis using degenerate primers. Galactose transport-positive clones were identified by plate selection and subjected to DNA sequencing. For those transport-positive clones corresponding to Tyr(352) and phe(504) mutants, all the amino acid substitutions comprised aromatic residues. The importance of the aromatic residues at these sites was further investigated by replacing them individually with each of the other 19 amino acids and measuring the galactose transport activity of the resulting mutants. Among both Tyr(352) and Phe(504) mutants, the other aromatic amino acids support-ed galactose transport; no other amino acids conferred high affinity transport activity. Thus, at least three aromatic sites are critical for galactose transport: one at the extracellular boundary of putative TM7 (Tyr(352)), One in the middle of putative TM10 (Tyr(446)), and one in the middle of putative TM12 (Phe(504)).	Teikyo Univ, Biophys Lab, Sch Med, Hachioji, Tokyo 1920395, Japan	Teikyo University	Kasahara, M (corresponding author), Teikyo Univ, Biophys Lab, Sch Med, Hachioji, Tokyo 1920395, Japan.							BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BELL GI, 1993, J BIOL CHEM, V268, P19161; BISSON LF, 1993, CRIT REV BIOCHEM MOL, V28, P259, DOI 10.3109/10409239309078437; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Doege H, 1998, BIOCHEM J, V329, P289, DOI 10.1042/bj3290289; Dutzler R, 1996, STRUCTURE, V4, P127, DOI 10.1016/S0969-2126(96)00016-0; Forst D, 1998, NAT STRUCT BIOL, V5, P37, DOI 10.1038/nsb0198-37; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Gracy J, 1998, BIOINFORMATICS, V14, P164, DOI 10.1093/bioinformatics/14.2.164; INUKAI K, 1994, BIOCHEM J, V302, P355, DOI 10.1042/bj3020355; Kasahara M, 1998, J BIOL CHEM, V273, P29106, DOI 10.1074/jbc.273.44.29106; Kasahara M, 1996, FEBS LETT, V389, P174, DOI 10.1016/0014-5793(96)00567-4; Kasahara M, 1997, J BIOL CHEM, V272, P16721, DOI 10.1074/jbc.272.27.16721; Kasahara T, 1996, BIOCHEM J, V315, P177, DOI 10.1042/bj3150177; Kasahara T, 1998, J BIOL CHEM, V273, P29113, DOI 10.1074/jbc.273.44.29113; KATAGIRI H, 1993, BIOCHEM J, V291, P861, DOI 10.1042/bj2910861; Kruckeberg AL, 1999, BIOCHEM J, V339, P299, DOI 10.1042/0264-6021:3390299; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Liang H, 1998, MOL CELL BIOL, V18, P926, DOI 10.1128/MCB.18.2.926; MORI H, 1994, J BIOL CHEM, V269, P11578; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Olsowski A, 1998, BIOCHEMISTRY-US, V37, P10738, DOI 10.1021/bi980440r; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; QUIOCHO FA, 1993, BIOCHEM SOC T, V21, P442, DOI 10.1042/bst0210442; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHURMANN A, 1993, BIOCHEM J, V290, P497, DOI 10.1042/bj2900497; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; SHERMAN F, 1986, LAB COURSE MANUAL ME, P164; Walmsley AR, 1998, TRENDS BIOCHEM SCI, V23, P476, DOI 10.1016/S0968-0004(98)01326-7; WANDEL S, 1994, FEBS LETT, V348, P114, DOI 10.1016/0014-5793(94)00558-3; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301	35	18	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4422	4428		10.1074/jbc.275.6.4422	http://dx.doi.org/10.1074/jbc.275.6.4422			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660614	hybrid			2022-12-25	WOS:000085288800098
J	Taylor, JC; Markham, GD				Taylor, JC; Markham, GD			The bifunctional active site of S-adenosylmethionine synthetase - Roles of the basic residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE ADENOSYLTRANSFERASE; TRANSITION-STATE; METHYLATION; MUTAGENESIS; ACTIVATION; MECHANISM; LOOP	S-Adenosylmethionine (AdoMet) synthetase catalyzes a unique two-step enzymatic reaction leading to formation of the primary biological alkylating agent. The crystal structure of Escherichia coli AdoMet synthetase shows that the active site, which lies between two subunits, contains four lysines and one histidine as basic residues. In order to test the proposed charge and hydrogen bonding roles in catalytic function, each lysine has been changed to an uncharged methionine or alanine, and the histidine has been altered to asparagine. The resultant enzyme variants are all tetramers like the wild type enzyme; however, circular dichroism spectra show reductions in helix content for the K245*M and K269M mutants. (The asterisk denotes that the residue is in the second subunit,) Four mutants have k(cat) reductions of similar to 10(3)-10(4)-fold in AdoMet synthesis; however, the k(cat) of K165*M variant is only reduced 2-fold. In each mutant, there is a smaller catalytic impairment in the partial reaction of tripolyphosphate hydrolysis. The K165*A enzyme has a 100-fold greater k(cat) for tripolyphosphate hydrolysis than the wild type enzyme, but this mutant is not activated by AdoMet in contrast to the wild type enzyme. The properties of these mutants require reassessment of the catalytic roles of these residues.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Markham, GD (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031186] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline; NIGMS NIH HHS [GM31186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Chamberlin ME, 1997, AM J HUM GENET, V60, P540; Chamberlin ME, 1996, J CLIN INVEST, V98, P1021, DOI 10.1172/JCI118862; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; CHIFFLET S, 1986, ANAL BIOCHEM, V168, P1; Cleland W W, 1979, Methods Enzymol, V63, P103; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; Frey PA, 1998, BIOCHEM SOC T, V26, P304, DOI 10.1042/bst0260304; Fu ZJ, 1996, J BIOMOL STRUCT DYN, V13, P727, DOI 10.1080/07391102.1996.10508887; Hazelwood S, 1998, AM J MED GENET, V75, P395, DOI 10.1002/(SICI)1096-8628(19980203)75:4<395::AID-AJMG9>3.0.CO;2-P; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; LETSINGER RL, 1972, J AM CHEM SOC, V94, P292, DOI 10.1021/ja00756a060; Markham GD, 1999, BIOCHEMISTRY-US, V38, P4433, DOI 10.1021/bi9829579; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; MARKHAM GD, 1987, J BIOL CHEM, V262, P5609; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MCQUENEY MS, 1995, J BIOL CHEM, V270, P18277, DOI 10.1074/jbc.270.31.18277; Mudd S. H., 1973, ENZYMES, V8, P121; Reczkowski RS, 1998, BIOCHEMISTRY-US, V37, P13499, DOI 10.1021/bi9811011; Reczkowski RS, 1999, BIOCHEMISTRY-US, V38, P9063, DOI 10.1021/bi990528k; RECZKOWSKI RS, 1995, J BIOL CHEM, V270, P18484, DOI 10.1074/jbc.270.31.18484; SOWA T, 1975, B CHEM SOC JPN, V48, P2084, DOI 10.1246/bcsj.48.2084; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Takusagawa F, 1996, BIOCHEMISTRY-US, V35, P2586, DOI 10.1021/bi952604z; Taylor JC, 1999, J BIOL CHEM, V274, P32909, DOI 10.1074/jbc.274.46.32909; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; TROWBRIDGE DB, 1972, J AM CHEM SOC, V94, P3816, DOI 10.1021/ja00766a026; USDIN E, 1982, BIOCH S ADENOSYLMETH	31	18	19	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4060	4065		10.1074/jbc.275.6.4060	http://dx.doi.org/10.1074/jbc.275.6.4060			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660564	hybrid			2022-12-25	WOS:000085288800048
J	Yang, J; Cheng, ZL; Niu, TQ; Liang, XS; Zhao, ZZJ; Zhou, GW				Yang, J; Cheng, ZL; Niu, TQ; Liang, XS; Zhao, ZZJ; Zhou, GW			Structural basis for substrate specificity of protein-tyrosine phosphatase SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CRYSTAL-STRUCTURE; SH2 DOMAINS; CATALYTIC DOMAIN; PURIFICATION; DETERMINANTS; RECOGNITION; CELLS; PTP1; 1B	The substrate specificity of the catalytic domain of SHP-1, an important regulator in the proliferation and development of hematopoietic cells, is critical for understanding the physiological functions of SHP-1, Here we report the crystal structures of the catalytic domain of SHP-1 complexed with two peptide substrates derived from SIRP alpha, a member of the signal-regulatory proteins. We show that the variable beta 6-loop-beta 6 motif confers SHP-1 substrate specificity at the P-4 and further N-terminal subpockets. We also observe a novel residue shift at P-2, the highly conserved subpocket in protein-tyrosine phosphatases, Our observations provide new insight into the substrate specificity of SHP-1.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	University of Massachusetts System; University of Massachusetts Worcester; Vanderbilt University	Zhou, GW (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.		Cheng, Zhiliang/F-3251-2011	Cheng, Zhiliang/0000-0002-9478-957X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057393] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57393] Funding Source: Medline; PHS HHS [AL45858] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adachi T, 1998, J IMMUNOL, V160, P4662; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; DECHERT U, 1995, EUR J BIOCHEM, V231, P673, DOI 10.1111/j.1432-1033.1995.0673d.x; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HOWARD PK, 1994, MOL CELL BIOL, V14, P5154, DOI 10.1128/MCB.14.8.5154; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; Liang XS, 1997, J STRUCT BIOL, V120, P201, DOI 10.1006/jsbi.1997.3927; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roussel A, 1990, ACTA CRYSTALLOGR A, V46, pC66; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; Zhang ZY, 1996, J BIOL CHEM, V271, P5386, DOI 10.1074/jbc.271.10.5386; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	25	68	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4066	4071		10.1074/jbc.275.6.4066	http://dx.doi.org/10.1074/jbc.275.6.4066			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660565	hybrid			2022-12-25	WOS:000085288800049
J	Yasukawa, T; Suzuki, T; Suzuki, T; Ueda, T; Ohta, S; Watanabe, K				Yasukawa, T; Suzuki, T; Suzuki, T; Ueda, T; Ohta, S; Watanabe, K			Modification defect at anticodon wobble nucleotide of mitochondrial tRNAs(Leu)(UUR) with pathogenic mutations of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNALEU(UUR) GENE; CELLS LACKING MTDNA; TRANSFER-RNA; MYCOPLASMA-CAPRICOLUM; PROTEIN-SYNTHESIS; POINT MUTATION; TRANSCRIPTION TERMINATION; MYOCLONIC EPILEPSY; CODON RECOGNITION; DIABETES-MELLITUS	The mitochondrial tRNA(Leu)(UUR) (R = A or Gr) gene possesses several hot spots for pathogenic mutations. A point:mutation at nucleotide position 3243 or 3271 is associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes and maternally inherited diabetes with deafness. Detailed studies on two tRNAs(Leu)(UUR) with the 3243 or 3271 mutation revealed some common characteristics in cybrid cells: (i) a decreased life span, resulting in a 70% decrease in the amounts of the tRNAs in the steady state, (ii) a slight decrease in the ratios of aminoacyl-tRNAs(Leu)(UUR) versus uncharged tRNAs(Leu)(UUR), and (iii) accurate aminoacylation with leucine without any misacylation. As a marked result, both of the mutant tRNA molecules were deficient in a modification of uridine that occurs in the normal tRNA(Leu)(UUR) at the first position of the anticodon, The lack of this modification may lead to the mistranslation of leucine into non-cognate phenylalanine codons by mutant tRNAsLeU(UUR), according to the mitochondrial wobble rule, and/or a decrease in the rate of mitochondrial protein synthesis. This finding could explain why two different mutations (3243 and 3271) manifest indistinguishable clinical features.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; Nippon Med Sch, Inst Gerontol, Dept Biochem & Cell Biol, Nakahara Ku, Kawasaki, Kanagawa 2110063, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Bunkyo Ku, Tokyo 1138656, Japan	University of Tokyo; Nippon Medical School; University of Tokyo	Ohta, S (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.		Suzuki, Tsutomu/J-1776-2015; Ueda, Takuya/K-5217-2014; Yasukawa, Takehiro/AAP-1335-2020	Suzuki, Tsutomu/0000-0002-9731-1731; Ueda, Takuya/0000-0002-7760-8271; Yasukawa, Takehiro/0000-0001-9531-8780				ANDACHI Y, 1989, J MOL BIOL, V209, P37, DOI 10.1016/0022-2836(89)90168-X; ANDACHI Y, 1987, P NATL ACAD SCI USA, V84, P7398, DOI 10.1073/pnas.84.21.7398; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BANKS JF, 1994, ANAL CHEM, V66, P406, DOI 10.1021/ac00075a015; BARRELL BG, 1980, P NATL ACAD SCI-BIOL, V77, P3164, DOI 10.1073/pnas.77.6.3164; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189; GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAYASHI J, 1990, BIOCHEM BIOPH RES CO, V167, P216, DOI 10.1016/0006-291X(90)91753-F; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584; HECKMAN JE, 1980, P NATL ACAD SCI-BIOL, V77, P3159, DOI 10.1073/pnas.77.6.3159; Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; INAGAKI Y, 1995, J MOL BIOL, V251, P486, DOI 10.1006/jmbi.1995.0450; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; KEITH G, 1995, BIOCHIMIE, V77, P142, DOI 10.1016/0300-9084(96)88118-1; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O; Matsuyama S, 1998, J BIOL CHEM, V273, P3363, DOI 10.1074/jbc.273.6.3363; MICHEAL WM, 1996, FEBS LETT, V433, P93; SAMUELSSON T, 1983, J BIOL CHEM, V258, P3178; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SILVESTRI G, 1992, AM J HUM GENET, V51, P1213; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Suzuki T, 1997, EMBO J, V16, P1122, DOI 10.1093/emboj/16.5.1122; Suzuki T, 1996, FEBS LETT, V381, P195, DOI 10.1016/0014-5793(96)00107-X; SUZUKI T, 1999, J MASS SPECTROM SOC, V47, P168; Suzuki Y, 1996, DIABETES CARE, V19, P1304, DOI 10.2337/diacare.19.11.1304; Tomita K, 1998, BBA-GENE STRUCT EXPR, V1399, P78, DOI 10.1016/S0167-4781(98)00099-2; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347; Watanabe Kimitsuna, 1995, P225	44	209	216	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4251	4257		10.1074/jbc.275.6.4251	http://dx.doi.org/10.1074/jbc.275.6.4251			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660592	hybrid			2022-12-25	WOS:000085288800076
J	Gong, LM; Millas, S; Maul, GG; Yeh, ETH				Gong, LM; Millas, S; Maul, GG; Yeh, ETH			Differential regulation of sentrinized proteins by a novel sentrin-specific protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; GTPASE-ACTIVATING PROTEIN; SUMO-1 MODIFICATION; COVALENT MODIFICATION; PML; RANGAP1; CONJUGATION; FAMILY; SMT3P	Sentrin-1, also called SUMO-1, is a protein of 101 residues that is distantly related to ubiquitin and another ubiquitin-like protein, NEDD8, Here we report the cloning of a novel sentrin-specific protease, SENP1, which has no homology to the known de-ubiquitinating enzymes or ubiquitin C-terminal hydrolases. However, SENP1 is distantly related to the yeast Smt3-specific protease, Ulp1. A COS cell expression system was used to demonstrate the activity of SENP1 in vivo. When HA-tagged sentrin-1 was co-expressed with SENP1, the higher molecular weight sentrin-1 conjugates were completely removed. Surprisingly, the major sentrinized band at 90 kDa remained intact. The disappearance of the high molecular weight sentrin-1 conjugates also coincided with an increase in free sentrin-1 monomers. SENP1 is also active against proteins modified by sentrin-2, but not those modified by ubiquitin or NEDD8. In addition, sentrinized PML, a tumor suppressor protein that resides in the nucleus, was selectively affected by SENP1, whereas sentrinized RanGAP1, which is associated with the cytoplasmic fibrils of the nuclear pore complex, remained intact. The inability of SENP1 to process sentrinized RanGAP1 in vivo is most likely due to its nuclear localization because SENP1 is active against sentrinized RanGAP1 in vitro. The identification of a nuclear-localized, sentrin-specific protease will provide a unique tool to study the role of sentrinization in the biological function of PML and in the pathogenesis of acute promyelocytic leukemia.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Mol Med, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Cardiol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Wistar Inst, Philadelphia, PA 19104 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; The Wistar Institute	Yeh, ETH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Mol Med, 6431 Fannin,Suite 4-200, Houston, TX 77030 USA.				NIGMS NIH HHS [GM-57502] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM057502] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boddy MN, 1996, ONCOGENE, V13, P971; den Dunnen JT, 1999, METHOD ENZYMOL, V303, P100; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Ishov AM, 1997, J CELL BIOL, V138, P5, DOI 10.1083/jcb.138.1.5; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okura T, 1996, J IMMUNOL, V157, P4277; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543	30	234	245	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3355	3359		10.1074/jbc.275.5.3355	http://dx.doi.org/10.1074/jbc.275.5.3355			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652325	hybrid			2022-12-25	WOS:000085146500047
J	Grewal, SS; Horgan, AM; York, RD; Withers, GS; Banker, GA; Stork, PJS				Grewal, SS; Horgan, AM; York, RD; Withers, GS; Banker, GA; Stork, PJS			Neuronal calcium activates a Rap1 and B-Raf signaling pathway via the cyclic adenosine monophosphate-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; NERVE GROWTH-FACTOR; GENE-EXPRESSION; MAP KINASE; MEMBRANE DEPOLARIZATION; NUCLEAR TRANSLOCATION; HIPPOCAMPAL-NEURONS; BINDING PROTEINS; PC12 CELLS; LATE-PHASE	Activity-dependent regulation of neuronal events such as cell survival and synaptic plasticity is controlled by increases in neuronal calcium levels. These actions often involve stimulation of intracellular kinase signaling pathways. For example, the mitogen-activated protein kinase, or extracellular signal-regulated kinase (ERK), signaling cascade has increasingly been shown to be important for the induction of gene expression and long term potentiation. However, the mechanisms leading to ERK activation by neuronal calcium are still unclear. In the present study, we describe a protein kinase A (PKA)-dependent signaling pathway that may link neuronal calcium influx to ERKs via the small G-protein, Rap1, and the neuronal Raf isoform, B-Raf. Thus, in PC12 cells, depolarization-mediated calcium influx led to the activation of B-Raf, but not Raf-1, via PKA, Furthermore, depolarization also induced the PKA-dependent stimulation of Rap1 and led to the formation of a Rap1/B-Raf signaling complex. In contrast, depolarization did not lead to the association of Ras with B-Raf, The major action of PKA-dependent Rap1/B-Raf signaling in neuronal cells is the activation of ERKs, Thus, we further show that, in both PC12 cells and hippocampal neurons, depolarization-induced calcium influx stimulates ERK activity in a PKA-dependent manner. Given the fact that both Rap1 and B-Raf are highly expressed in the central nervous system, we suggest that this signaling pathway may regulate a number of activity-dependent neuronal functions.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Stork, PJS (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474,SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Agnihotri N, 1997, J NEUROSCI RES, V47, P555, DOI 10.1002/(SICI)1097-4547(19970301)47:5<555::AID-JNR11>3.0.CO;2-X; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Berman DE, 1998, J NEUROSCI, V18, P10037; Bhat RV, 1998, J NEUROCHEM, V70, P558; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Bito H, 1998, CELL CALCIUM, V23, P143, DOI 10.1016/S0143-4160(98)90113-0; Blum S, 1999, J NEUROSCI, V19, P3535; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Buonanno A, 1999, CURR OPIN NEUROBIOL, V9, P110, DOI 10.1016/S0959-4388(99)80014-2; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Coogan AN, 1999, J NEUROPHYSIOL, V81, P103, DOI 10.1152/jn.1999.81.1.103; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Crow T, 1998, J NEUROSCI, V18, P3480; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fields RD, 1997, J NEUROSCI, V17, P7252; FIORE RS, 1993, J NEUROCHEM, V61, P1626, DOI 10.1111/j.1471-4159.1993.tb09796.x; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GINTY DD, 1991, J BIOL CHEM, V266, P17454; Goslin K., 1991, CULTURING NERVE CELL, P251; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; HIDAKA H, 1983, METHOD ENZYMOL, V102, P185; Huang YY, 1998, NEURON, V21, P169, DOI 10.1016/S0896-6273(00)80524-3; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kawasaki H, 1999, J BIOL CHEM, V274, P13498, DOI 10.1074/jbc.274.19.13498; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KURINO M, 1995, J NEUROCHEM, V65, P1282; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Nguyen PV, 1996, J NEUROSCI, V16, P3189; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sgambato V, 1998, J NEUROSCI, V18, P8814; THOMAS KL, 1994, NEURON, V13, P737, DOI 10.1016/0896-6273(94)90040-X; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	65	133	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3722	3728		10.1074/jbc.275.5.3722	http://dx.doi.org/10.1074/jbc.275.5.3722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652372	hybrid			2022-12-25	WOS:000085146500094
J	Lozano, MJF; Remsing, LL; Quiros, LM; Brana, AF; Fernandez, E; Sanchez, C; Mendez, C; Rohr, J; Salas, JA				Lozano, MJF; Remsing, LL; Quiros, LM; Brana, AF; Fernandez, E; Sanchez, C; Mendez, C; Rohr, J; Salas, JA			Characterization of two polyketide methyltransferases involved in the biosynthesis of the antitumor drug mithramycin by Streptomyces argillaceus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUREOLIC ACID GROUP; SP STRAIN C5; ESCHERICHIA-COLI; CARMINOMYCIN 4-O-METHYLTRANSFERASE; SACCHAROPOLYSPORA-ERYTHRAEA; NUCLEOTIDE-SEQUENCES; O-METHYLTRANSFERASE; MOLECULAR ANALYSIS; TETRACENOMYCIN-C; GENES	A DNA chromosomal region of Streptomyces argillaceus ATCC 12596, the producer organism of the antitumor polyketide drug mithramycin, was cloned. Sequence analysis of this DNA region, located between four mithramycin glycosyltransferase genes, showed the presence of two genes (mtmMI and mtmMII) whose deduced products resembled S-adenosylmethionine-dependent methyltransferases. By independent insertional inactivation of both genes nonproducing mutants were generated that accumulated different mithramycin biosynthetic intermediates. The M3 Delta MI mutant (mtmMI-minus mutant) accumulated 4-demethylpremithramycinone (4-DPMC) which lacks the methyl groups at carbons 4 and 9, The M3 Delta M2 (mtmMII-minus mutant) accumulated 9-demethylpremithramycin A3 (9-DPMA3), premithramycin Al (PMA1), and 7-demethylmithramycin, all of them containing the O-methyl group at C-4 and C-1', respectively, but lacking the methyl group at the aromatic position. Both genes were expressed in Streptomyces lividans TK21 under the control of the erythromycin resistance promoter (ermEp) of Saccharopolyspora erythraea. Cell-free extracts of these clones were precipitated with ammonium sulfate (90% saturation) and assayed for methylation activity using different mithramycin intermediates as substrates. Extracts of strains MJM1 (expressing the mtmMI gene) and MJM2 (expressing the mtmMII gene) catalyzed efficient transfer of tritium from [H-3]S-adenosylmethionine into 4-DPMC and 9-DPMA3, respectively, being unable to methylate other intermediates at a detectable level. These results demonstrate that the mtmMI and mtmMII genes code for two S-adenosylmethionine-dependent methyltransferases responsible for the 4-O-methylation and 9-C-methylation steps of the biosynthetic precursors 4-DPMC and 9-DPMA3, respectively, of the antitumor drug mithramycin. A pathway is proposed for the last steps in the biosynthesis of mithramycin involving these methylation events.	Univ Oviedo, Dept Biol Func, E-33006 Oviedo, Spain; Univ Oviedo, Inst Univ Oncol, E-33006 Oviedo, Spain; Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA	University of Oviedo; University of Oviedo; Instituto Universitario de Oncologia de Asturias; Medical University of South Carolina	Rohr, J (corresponding author), Univ Oviedo, Dept Biol Func, E-33006 Oviedo, Spain.		Rohr, Jurgen/G-5375-2014; Brana, Alfredo/M-1836-2014; Mendez-Fernandez, Carmen/ABE-5745-2020; Quirós, Luis/T-3822-2017; Sánchez, César/E-5937-2010; Fernandez-Brana, Alfredo/O-1488-2019	Rohr, Jurgen/0000-0001-6447-5951; Brana, Alfredo/0000-0002-3277-9085; Mendez-Fernandez, Carmen/0000-0003-2729-841X; Quirós, Luis/0000-0003-3505-3762; Sánchez, César/0000-0001-9891-0843; Fernandez-Brana, Alfredo/0000-0002-3277-9085				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Blanco G, 1996, CHEM BIOL, V3, P193, DOI 10.1016/S1074-5521(96)90262-8; BLANCO G, 1999, IN PRESS MOL GEN GEN; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CONNORS NC, 1993, J GEN MICROBIOL, V139, P1353, DOI 10.1099/00221287-139-6-1353; CONNORS NC, 1990, J GEN MICROBIOL, V136, P1887, DOI 10.1099/00221287-136-9-1887; DAIRI T, 1995, BIOSCI BIOTECH BIOCH, V59, P1099, DOI 10.1271/bbb.59.1099; DECKER H, 1993, J BACTERIOL, V175, P3876, DOI 10.1128/JB.175.12.3876-3886.1993; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWICK PM, 1997, MED NATURAL PRODUCTS, P85; DICKENS ML, 1995, J BACTERIOL, V177, P536, DOI 10.1128/jb.177.3.536-543.1995; FAWAZ F, 1988, J BIOL CHEM, V263, P4602; Fernandez E, 1998, J BACTERIOL, V180, P4929; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KREUZMAN AJ, 1988, J BIOL CHEM, V263, P15626; KUZUYAMA T, 1992, J ANTIBIOT, V45, P1812, DOI 10.7164/antibiotics.45.1812; LACALLE RA, 1991, GENE, V109, P55, DOI 10.1016/0378-1119(91)90588-3; Lombo F, 1999, J BACTERIOL, V181, P642; Lombo F, 1997, J BACTERIOL, V179, P3354, DOI 10.1128/jb.179.10.3354-3357.1997; Lombo F, 1996, GENE, V172, P87, DOI 10.1016/0378-1119(96)00029-7; MADDURI K, 1993, J BACTERIOL, V175, P3900, DOI 10.1128/JB.175.12.3900-3904.1993; NIEMI J, 1995, J BACTERIOL, V177, P2942, DOI 10.1128/jb.177.10.2942-2945.1995; PAULUS TJ, 1990, J BACTERIOL, V172, P2541, DOI 10.1128/jb.172.5.2541-2546.1990; Prado L, 1999, CHEM BIOL, V6, P19, DOI 10.1016/S1074-5521(99)80017-9; REMERS WA, 1979, CHEM ANTITUMOR ANTIB, V1, P133; Rohr J, 1998, CHEM COMMUN, P437, DOI 10.1039/a707446h; Rohr J, 1999, BIOORG CHEM, V27, P41, DOI 10.1006/bioo.1998.1110; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Skarbek J.D., 1981, ANTITUMOR COMPOUNDS, V1, P191; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; Tercero JA, 1996, J BIOL CHEM, V271, P1579, DOI 10.1074/jbc.271.3.1579; VARA J, 1989, J BACTERIOL, V171, P5872, DOI 10.1128/jb.171.11.5872-5881.1989	37	52	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3065	3074		10.1074/jbc.275.5.3065	http://dx.doi.org/10.1074/jbc.275.5.3065			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652287	hybrid			2022-12-25	WOS:000085146500009
J	Tuynman, A; Spelberg, JL; Kooter, IM; Schoemaker, HE; Wever, R				Tuynman, A; Spelberg, JL; Kooter, IM; Schoemaker, HE; Wever, R			Enantioselective epoxidation and carbon-carbon bond cleavage catalyzed by Coprinus cinereus peroxidase and myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSERADISH-PEROXIDASE; CHLOROPEROXIDASE CATALYSIS; CRYSTAL-STRUCTURE; ACTIVE-SITE; LACTOPEROXIDASE; STYRENE; SULFOXIDATION; OXIDATION; MECHANISM; CHLORIDE	We demonstrate that myeloperoxidase (MPO) and Coprinus cinereus peroxidase (CiP) catalyze the enantioselective epoxidation of styrene and a number of substituted derivatives with a reasonable enantiomeric excess (up to 80%) and in a moderate yield. Three major differences with respect to the chloroperoxidase from Caldariomyces fumago (CPO) are observed in the reactivity of MPO and CiP toward styrene derivatives. First, in contrast to CPO, MPO and CiP produced the (S)-isomers of the epoxides in enantiomeric excess. Second, for MPO and CiP the H2O2 had to be added very slowly (10 eq in 16 h) to prevent accumulation of catalytically inactive enzyme intermediates. Under these conditions, CPO hardly showed any epoxidizing activity; only with a high influx of H2O2 (300 eq in 1.6 h) was epoxidation observed. Third, both MPO and CiP formed significant amounts of (substituted) benzaldehydes as side products as a consequence of C-alpha-C-beta bond cleavage of the styrene derivatives, whereas for CPO and cytochrome c peroxidase this activity is not observed. C-alpha-C-beta cleavage was the most prominent reaction catalyzed by CiP, whereas with MPO the relative amount of epoxide formed was higher. This is the first report of peroxidases catalyzing both epoxidation reactions and carbon-carbon bond cleavage. The results are discussed in terms of mechanisms involving ferryl oxygen transfer and electron transfer, respectively.	Univ Amsterdam, BioCentrum, EC Slater Inst, NL-1018 TV Amsterdam, Netherlands; Univ Groningen, Biomol Sci & Biotechnol Inst, Dept Biochem, NL-9747 AG Groningen, Netherlands; DSM Res, Bioorgan Chem, NL-6160 MD Geleen, Netherlands	University of Amsterdam; University of Groningen; DSM NV	Wever, R (corresponding author), Univ Amsterdam, BioCentrum, EC Slater Inst, Muidergracht 12, NL-1018 TV Amsterdam, Netherlands.		Wever, Ron/AAM-4520-2020					ALLAIN EJ, 1993, J AM CHEM SOC, V115, P4415, DOI 10.1021/ja00063a091; ANDERSEN MB, 1991, ACTA CHEM SCAND, V45, P1080, DOI 10.3891/acta.chem.scand.45-1080; BAKKENIST ARJ, 1978, BIOCHIM BIOPHYS ACTA, V524, P45, DOI 10.1016/0005-2744(78)90101-8; BEERS RF, 1952, J BIOL CHEM, V195, P133; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V788, P1, DOI 10.1016/0167-4838(84)90290-5; Cherry JR, 1999, NAT BIOTECHNOL, V17, P379, DOI 10.1038/7939; COLONNA S, 1993, TETRAHEDRON-ASYMMETR, V4, P1325, DOI 10.1016/S0957-4166(00)80243-8; COLONNA S, 1992, J CHEM SOC CHEM COMM, P357, DOI 10.1039/c39920000357; Colonna S, 1995, GAZZ CHIM ITAL, V125, P479; COLONNA S, 1990, BIOCHEMISTRY-US, V29, P10465, DOI 10.1021/bi00498a006; CORBETT MD, 1979, BIOCHEM J, V183, P269, DOI 10.1042/bj1830269; CORBETT MD, 1980, BIOCHEM J, V187, P893, DOI 10.1042/bj1870893; DEMONTELLANO PRO, 1987, BIOCHEMISTRY-US, V26, P5310, DOI 10.1021/bi00391a014; DEMONTELLANO PRO, 1987, J BIOL CHEM, V262, P11641; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DEXTER AF, 1995, J AM CHEM SOC, V117, P6412, DOI 10.1021/ja00128a053; DEXTER AF, 1995, J AM CHEM SOC, V117, P817, DOI 10.1021/ja00107a026; DUESCHER RJ, 1992, J BIOL CHEM, V267, P19859; Finney NS, 1997, ANGEW CHEM INT EDIT, V36, P1720, DOI 10.1002/anie.199717201; GROSS Z, 1995, J AM CHEM SOC, V117, P8021, DOI 10.1021/ja00135a023; GROVES JT, 1986, J AM CHEM SOC, V108, P207; GUENGERICH FP, 1984, ACCOUNTS CHEM RES, V17, P9, DOI 10.1021/ar00097a002; HARVEY PJ, 1985, FEBS LETT, V183, P13, DOI 10.1016/0014-5793(85)80943-1; HOLLENBERG PE, 1970, METHOD ENZYMOL, V52, P521; HOOGLAND H, 1988, BIOCHIM BIOPHYS ACTA, V955, P337, DOI 10.1016/0167-4838(88)90213-0; Hu SH, 1999, J AM CHEM SOC, V121, P872, DOI 10.1021/ja983612g; Hu SH, 1999, TETRAHEDRON LETT, V40, P1641, DOI 10.1016/S0040-4039(99)00056-8; HUWILER M, 1986, EUR J BIOCHEM, V158, P609, DOI 10.1111/j.1432-1033.1986.tb09798.x; JACOBSEN EN, 1993, CATALYTIC ASYMMETRIC, P159; Lakner FJ, 1996, J ORG CHEM, V61, P3923, DOI 10.1021/jo960074m; Lakner FJ, 1997, J AM CHEM SOC, V119, P443, DOI 10.1021/ja962998x; MILLER VP, 1995, ARCH BIOCHEM BIOPHYS, V319, P333, DOI 10.1006/abbi.1995.1302; MILLER VP, 1992, J BIOL CHEM, V267, P8936; NEIDLEMAN SL, 1986, BIOHALOGENATION PRIN, P105; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; OZAKI S, 1995, J AM CHEM SOC, V117, P7056, DOI 10.1021/ja00132a003; PALUCKI M, 1994, J AM CHEM SOC, V116, P9333, DOI 10.1021/ja00099a062; Palucki M, 1998, J AM CHEM SOC, V120, P948, DOI 10.1021/ja973468j; PALUCKI M, 1994, J AM CHEM SOC, V116, P12135, DOI 10.1021/ja00105a099; PAUL KG, 1980, FEBS LETT, V110, P200, DOI 10.1016/0014-5793(80)80072-X; PETERSEN JFW, 1994, FEBS LETT, V339, P291, DOI 10.1016/0014-5793(94)80433-8; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; Savenkova MI, 1998, BIOCHEMISTRY-US, V37, P10828, DOI 10.1021/bi9725780; Savenkova MI, 1998, ARCH BIOCHEM BIOPHYS, V351, P286, DOI 10.1006/abbi.1997.0559; SCHOEMAKER HE, 1990, RECL TRAV CHIM PAY B, V109, P255; Spelberg JHL, 1998, TETRAHEDRON-ASYMMETR, V9, P459, DOI 10.1016/S0957-4166(98)00003-2; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; Sundaramoorthy M, 1998, CHEM BIOL, V5, P461, DOI 10.1016/S1074-5521(98)90003-5; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9889, DOI 10.1021/bi970906q; TRAYLOR TG, 1986, J AM CHEM SOC, V108, P2782, DOI 10.1021/ja00270a063; Tuynman A, 1998, EUR J BIOCHEM, V258, P906, DOI 10.1046/j.1432-1327.1998.2580906.x; YAMAZAKI I, 1977, FREE RADICALS BIOL, V3, P183; ZAKS A, 1995, J AM CHEM SOC, V117, P10419, DOI 10.1021/ja00147a001	53	48	49	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3025	3030		10.1074/jbc.275.5.3025	http://dx.doi.org/10.1074/jbc.275.5.3025			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652281	hybrid			2022-12-25	WOS:000085146500003
J	Yang, TB; Poovaiah, BW				Yang, TB; Poovaiah, BW			Molecular and biochemical evidence for the involvement of calcium/calmodulin in auxin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; DEPENDENT PROTEIN-KINASE; CYTOSOLIC FREE CALCIUM; GLUTAMATE-DECARBOXYLASE; GENE-EXPRESSION; MESSENGER-RNAS; HIGHER-PLANTS; COLEOPTILES; CLONING; TISSUE	The use of S-35-labeled calmodulin (CaM) to screen a corn root cDNA expression library has led to the isolation of a CaM-binding protein, encoded by a cDNA with sequence similarity to small auxin up RNAs (SAURs), a class of early auxin-responsive genes. The cDNA designated as ZmSAUR1 (Zea mays SAURs) was expressed in Escherichia coli, and the recombinant protein was purified by CaM affinity chromatography. The CaM binding assay revealed that the recombinant protein binds to CaM in a calcium-dependent manner. Deletion analysis revealed that the CaM binding site was located at the NH2-terminal domain. A synthetic peptide of amino acids 20-45, corresponding to the potential CaM binding region, was used for calcium-dependent mobility shift assays. The synthetic peptide formed a stable complex with CaM only in the presence of calcium. The CaM affinity assay indicated that ZmSAUR1 binds to CaM with high affinity (R-d similar to 15 nM) in a calcium-dependent manner, Comparison of the NH,-terminal portions of all of the characterized SAURs revealed that they all contain a stretch of the basic alpha-amphiphilic helix similar to the CaM binding region of ZmSAUR1, CaM binds to the two synthetic peptides from the NH2-terminal regions of Arabidopsis SAUR-AC1 and soybean 10A5, suggesting that this is a general phenomenon for all SAURs, Northern analysis was carried out using the total RNA isolated from auxin-treated corn coleoptile segments, Zm-SAUR1 gene expression began within 10 min, increased rapidly between 10 and 60 min, and peaked around 60 min after 10 mu m alpha-naphthaleneacetic acid treatment. These results indicate that ZmSAUR1 is an early auxin-responsive gene. The CaM antagonist N-(6-aminohexyl) 5-chloro-1-naphthalenesulfonamide hydrochloride inhibited the auxin-induced cell elongation but not the auxin-induced expression of ZmSAUR1. This suggests that calcium/CaM do not regulate ZmSAUR1 at the transcriptional level. CaM binding to ZmSAUR1 in a calcium-dependent manner suggests that calcium/CaM regulate ZmSAUR1 at the post-translational level. Our data provide the first direct evidence for the involvement of calcium/CaM-mediated signaling in auxin-mediated signal transduction.	Washington State Univ, Dept Hort, Lab Plant Mol Biol & Physiol, Pullman, WA 99164 USA	Washington State University	Poovaiah, BW (corresponding author), Washington State Univ, Dept Hort, Lab Plant Mol Biol & Physiol, Pullman, WA 99164 USA.							Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; ARAZI T, 1995, PLANT PHYSIOL, V108, P551, DOI 10.1104/pp.108.2.551; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; BRUMMELL DA, 1987, PLANT CELL ENVIRON, V10, P523, DOI 10.1111/1365-3040.ep11603897; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CLORE GM, 1993, CURR OPIN STRUC BIOL, V3, P838, DOI 10.1016/0959-440X(93)90146-C; COHEN JD, 1976, PLANT PHYSIOL, V57, P347, DOI 10.1104/pp.57.3.347; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DROBAK BK, 1985, BIOCHEM BIOPH RES CO, V145, P1043; ESTRUCH JJ, 1994, P NATL ACAD SCI USA, V91, P8837, DOI 10.1073/pnas.91.19.8837; ETTLINGER C, 1988, NATURE, V331, P176, DOI 10.1038/331176a0; EVANS ML, 1985, CRC CR REV PLANT SCI, V2, P317, DOI 10.1080/07352688509382200; EVANS ML, 1974, ANNU REV PLANT PHYS, V25, P195, DOI 10.1146/annurev.pp.25.060174.001211; FELLE H, 1988, PLANTA, V174, P495, DOI 10.1007/BF00634478; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; GEE MA, 1991, PLANT CELL, V3, P419, DOI 10.1105/tpc.3.4.419; GEHRING CA, 1990, NATURE, V345, P528, DOI 10.1038/345528a0; GEHRING CA, 1990, P NATL ACAD SCI USA, V87, P9645, DOI 10.1073/pnas.87.24.9645; GIL P, 1994, PLANT PHYSIOL, V104, P777, DOI 10.1104/pp.104.2.777; GONZALEZDAROS F, 1993, PHYSIOL PLANTARUM, V87, P68, DOI 10.1111/j.1399-3054.1993.tb08792.x; GUILFOYLE TJ, 1986, CRIT REV PLANT SCI, V4, P247, DOI 10.1080/07352688609382226; GUILFOYLE TJ, 1992, BIOCHEM SOC T, V20, P97, DOI 10.1042/bst0200097; HARDIN JW, 1972, P NATL ACAD SCI USA, V69, P3146, DOI 10.1073/pnas.69.11.3146; HOBBIE L, 1994, PLANT MOL BIOL, V26, P1499, DOI 10.1007/BF00016487; JENA PK, 1989, P NATL ACAD SCI USA, V86, P3644, DOI 10.1073/pnas.86.10.3644; KEY JL, 1989, BIOESSAYS, V11, P52, DOI 10.1002/bies.950110204; KUBOWICZ BD, 1982, PLANT PHYSIOL, V69, P187, DOI 10.1104/pp.69.1.187; KUDA J, 1999, P NATL ACAD SCI USA, V96, P4718; LI Y, 1994, PLANT PHYSIOL, V106, P37, DOI 10.1104/pp.106.1.37; LI Y, 1991, PLANT CELL, V3, P1167, DOI 10.1105/tpc.3.11.1167; LONGEMANN J, 1987, ANAL BIOCHEM, V163, P16; MCCLURE BA, 1989, PLANT CELL, V1, P229, DOI 10.1105/tpc.1.2.229; MCCLURE BA, 1989, SCIENCE, V243, P91, DOI 10.1126/science.11540631; MCCLURE BA, 1987, PLANT MOL BIOL, V9, P611, DOI 10.1007/BF00020537; MIERNYK JA, 1987, J BIOL CHEM, V262, P15338; Okamoto H, 1995, PLANT CELL PHYSIOL, V36, P1531; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATIL S, 1995, P NATL ACAD SCI USA, V92, P4897, DOI 10.1073/pnas.92.11.4897; POOVAIAH BW, 1976, PLANT PHYSIOL, V58, P783, DOI 10.1104/pp.58.6.783; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; POOVAIAH BW, 1987, CRC CR REV PLANT SCI, V6, P47, DOI 10.1080/07352688709382247; RAGHOTHAMA KG, 1985, PLANT PHYSIOL, V79, P28, DOI 10.1104/pp.79.1.28; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; Ramachandiran S, 1997, J BIOCHEM-TOKYO, V121, P984; RAY PM, 1974, RECENT ADV PHYTOCHEM, V7, P93; REDDY ASN, 1988, PLANT CELL PHYSIOL, V29, P1165; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; Snedden WA, 1996, J BIOL CHEM, V271, P4148; Snedden WA, 1998, TRENDS PLANT SCI, V3, P299, DOI 10.1016/S1360-1385(98)01284-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAGAWA T, 1957, PLANT PHYSIOL, V32, P207, DOI 10.1104/pp.32.3.207; TAKEZAWA D, 1995, PLANT MOL BIOL, V27, P693, DOI 10.1007/BF00020223; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; THEOLOGIS A, 1985, J MOL BIOL, V183, P53, DOI 10.1016/0022-2836(85)90280-3; THEOLOGIS A, 1986, ANNU REV PLANT PHYS, V37, P407, DOI 10.1146/annurev.arplant.37.1.407; TIMPTE C, 1994, GENETICS, V138, P1239; TREWAVAS A, 1999, PLANT PHYSIOL, V120, P428; Trewavas AJ, 1997, PLANT CELL, V9, P1181, DOI 10.1105/tpc.9.7.1181; Vanderhoef L. N., 1980, Plant growth substances 1979 [Skoog, F. (Editor)]., P90; VELUTHAMBI K, 1984, SCIENCE, V223, P167, DOI 10.1126/science.223.4632.167; VELUTHAMBI K, 1984, PLANT PHYSIOL, V76, P359, DOI 10.1104/pp.76.2.359; Watillon B, 1998, PLANT MOL BIOL, V36, P909, DOI 10.1023/A:1005914506110; YAMAMOTO KT, 1992, PLANT CELL PHYSIOL, V33, P93; Yang T, 1998, PLANT MOL BIOL, V37, P109, DOI 10.1023/A:1005902905512; Yang TB, 1996, MOL GEN GENET, V252, P684, DOI 10.1007/BF02173974; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	67	127	151	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3137	3143		10.1074/jbc.275.5.3137	http://dx.doi.org/10.1074/jbc.275.5.3137			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652297	hybrid			2022-12-25	WOS:000085146500019
J	Barja, G; Herrero, A				Barja, G; Herrero, A			Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals	FASEB JOURNAL			English	Article						8-hydroxy-deoxyguanosine; longevity; aging; free radical	FREE-RADICAL PRODUCTION; HYDROGEN-PEROXIDE PRODUCTION; CALORIC RESTRICTION; METABOLIC-RATE; NUCLEAR-DNA; LONGEVITY; STRESS; PIGEON; AGE; 8-HYDROXY-2'-DEOXYGUANOSINE	DNA damage is considered of paramount importance in aging, Among causes of this damage, free radical attack, particularly from mitochondrial origin, is receiving special attention. If oxidative damage to DNA is involved in aging, long-lived animals (which age slowly) should show lower levels of markers of this kind of damage than short-lived ones, However, this possibility has not heretofore been investigated. In this study, steady-state levels of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) referred to deoxyguanosine (dG) were measured by high performance liquid chromatography (HPLC) in the mitochondrial (mtDNA) and nuclear (nDNA) DNA from the heart of eight and the brain of six mammalian species ranging in maximum life span (MLSP) from 3.5 to 46 years. Exactly the same digestion of DNA to deoxynucleosides and HPLC protocols was used for mtDNA and nDNA, Significantly higher (three- to ninefold) 8-oxodG/dG values were found in mtDNA than in nDNA in all the species studied in both tissues. 8-oxodG/dG in nDNA did not correlate with MLSP across species either in the heart (r = -0.68; P < 0,06) or brain (r 0.53; P < 0.27). However, 8-oxodG/dG in mtDNA was inversely correlated with MLSP both in heart (r = -0.92; P < 0.001) and brain (r = -0,88; P < 0,016) tissues following the power function y = a(.)x(b), where y is 8-oxodG/dG and x is the MLSP, This agrees with the consistent observation that mitochondrial free radical generation is also lower in long-lived than in short-lived species. The results obtained agree with the notion that oxygen radicals of mitochondrial origin oxidatively damage mtDNA in a way related to the aging rate of each species.	Univ Complutense, Dept Biol Anim & Anim Physiol 2, Fac Biol, E-28040 Madrid, Spain	Complutense University of Madrid	Barja, G (corresponding author), Univ Complutense, Dept Biol Anim & Anim Physiol 2, Fac Biol, E-28040 Madrid, Spain.		Barja, Gustavo/AAA-5903-2019; Gustavo, Barja/B-5591-2012	Barja, Gustavo/0000-0001-5736-4735; 				ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; ALTMAN P, 1972, BIOL DATA BOOK, P229; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; Anson RM, 1998, NUCLEIC ACIDS RES, V26, P662, DOI 10.1093/nar/26.2.662; ASUNCION JG, 1996, FASEB J, V10, P333; Barja G, 1998, J BIOENERG BIOMEMBR, V30, P235, DOI 10.1023/A:1020592719405; Barja G, 1998, ANN NY ACAD SCI, V854, P224, DOI 10.1111/j.1749-6632.1998.tb09905.x; BARJA G, 1994, FREE RADICAL RES, V21, P317, DOI 10.3109/10715769409056584; BARJA G, 1999, IN PRESS J BIOENERG; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212; Cadenas S, 1997, CARCINOGENESIS, V18, P2373, DOI 10.1093/carcin/18.12.2373; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHUNG MH, 1992, FREE RADICAL BIO MED, V12, P523, DOI 10.1016/0891-5849(92)90105-P; CUTLER G, 1991, AM J CLIN NUTR, V53, pS373; CUTLER RG, 1991, ANN NY ACAD SCI, V621, P1; DEGREY ADN, 1998, J ANTI-AGING MED, V1, P53; Driggers WJ, 1997, NUCLEIC ACIDS RES, V25, P4362, DOI 10.1093/nar/25.21.4362; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; Herrero A, 1998, MECH AGEING DEV, V103, P133, DOI 10.1016/S0047-6374(98)00035-9; Herrero A, 1997, MECH AGEING DEV, V98, P95, DOI 10.1016/S0047-6374(97)00076-6; Hirano T, 1996, J GERONTOL A-BIOL, V51, pB303, DOI 10.1093/gerona/51A.5.B303; Kaneko T, 1996, MUTAT RES-DNAGING G, V316, P277, DOI 10.1016/S0921-8734(96)90010-7; Koppele JMT, 1996, NEUROBIOL AGING, V17, P819; Kovalenko SA, 1998, ANN NY ACAD SCI, V854, P171, DOI 10.1111/j.1749-6632.1998.tb09900.x; KU HH, 1993, MECH AGEING DEV, V72, P67, DOI 10.1016/0047-6374(93)90132-B; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649; Lightowlers RH, 1999, TRENDS GENET, V15, P91, DOI 10.1016/S0168-9525(98)01684-9; Loft S, 1999, METHOD ENZYMOL, V300, P166; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; MIQUEL J, 1991, ARCH GERONTOL GERIAT, V12, P99, DOI 10.1016/0167-4943(91)90022-I; Muscari C, 1996, AGING-CLIN EXP RES, V8, P429, DOI 10.1007/BF03339606; OZAWA T, 1995, EXP GERONTOL, V30, P269, DOI 10.1016/0531-5565(94)00057-A; Ozawa T, 1998, ANN NY ACAD SCI, V854, P128, DOI 10.1111/j.1749-6632.1998.tb09898.x; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SAI K, 1992, Journal of Environmental Pathology Toxicology and Oncology, V11, P139; Sastre J, 1998, FREE RADICAL BIO MED, V24, P298, DOI 10.1016/S0891-5849(97)00228-1; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1994, NATURAL ANTIOXIDANTS, P63; SOHAL RS, 1990, MECH AGEING DEV, V53, P209, DOI 10.1016/0047-6374(90)90039-I; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; SOHAL RS, 1995, MECH AGEING DEV, V81, P15, DOI 10.1016/0047-6374(94)01578-A; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164	46	383	404	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					312	318		10.1096/fasebj.14.2.312	http://dx.doi.org/10.1096/fasebj.14.2.312			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657987				2022-12-25	WOS:000085184800010
J	Cau, J; Faure, S; Vigneron, S; Labbe, JC; Delsert, C; Morin, N				Cau, J; Faure, S; Vigneron, S; Labbe, JC; Delsert, C; Morin, N			Regulation of xenopus p21-activated kinase (X-PAK2) by Cdc42 and maturation-promoting factor controls Xenopus oocyte maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED PROTEIN; CELL-CYCLE; MAP KINASE; SACCHAROMYCES-CEREVISIAE; STE20/PAK FAMILY; FOCAL COMPLEXES; MITOTIC EVENTS; ACTIN; RHO; GTPASES	Signal transduction cascades involved in regulation of the cell cycle machinery are poorly understood. In the Xenopus oocyte model, meiotic maturation is triggered by MPF, a complex of p34(cdc2)-cyclin B, which is activated in response to a progesterone signal by largely unknown mechanisms. We have previously shown that the p21-activated kinase (PAK) family negatively regulates the MPF amplification loop. In this study, we identify the endogenous PAK2 as a key enzyme in this regulation and describe the pathways by which PAK2 is regulated. We show that the small GTPase Cdc42 is required for maintenance of active endogenous X-PAK2 in resting stage VI oocytes, whereas Rad is not involved in this regulation. During the process of maturation, X-PAK2 phosphorylation results in its inactivation and allows maturation to proceed to completion Activation of mitogen-activated protein kinase and cyclin B-p34(cdc2) is coincident with X-PAK2 inactivation, and purified active MPF inhibits X-PAK2, demonstrating the existence of a new positive feedback loop. Our results confirm and extend the importance of p21-activated kinases in the control of the G(2)/M transition. We hypothesize that the X-PAK2/Cdc42 pathway could link p34(cdc2) activity to the major cytoskeleton rearrangements leading to spindle migration and anchorage to the animal pole cortex.	CNRS UPR 1086, Ctr Rech Biochim Macromol, F-34293 Montpellier 5, France; IFREMER, F-17390 La Tremblade, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Ifremer	Morin, N (corresponding author), CNRS UPR 1086, Ctr Rech Biochim Macromol, 1919 Route Mende, F-34293 Montpellier 5, France.	morin@crbm.cnrs-mop.fr	labbe, jean-claude/B-2277-2009; FAURE, Sandrine/N-6506-2018	FAURE, Sandrine/0000-0002-8902-8274; Morin, Nathalie/0000-0001-8677-1401; cau, Julien/0000-0001-6045-6737				Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Clayton L, 1999, DEV BIOL, V205, P322, DOI 10.1006/dbio.1998.9117; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Faure S, 1999, J BIOL CHEM, V274, P3573, DOI 10.1074/jbc.274.6.3573; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Fisher DL, 1999, DEVELOPMENT, V126, P567; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; GARD DL, 1995, ZYGOTE, V3, P17, DOI 10.1017/S0967199400002331; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Jessus C, 1998, BIOL CELL, V90, P573, DOI 10.1016/S0248-4900(99)80015-X; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lenormand JL, 1999, EMBO J, V18, P1869, DOI 10.1093/emboj/18.7.1869; MALLER JL, 1977, J BIOL CHEM, V252, P1712; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Richman TJ, 1999, J BIOL CHEM, V274, P16861, DOI 10.1074/jbc.274.24.16861; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rime H, 1998, DEV BIOL, V204, P592, DOI 10.1006/dbio.1998.9069; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Tjandra H, 1998, CURR BIOL, V8, P991, DOI 10.1016/S0960-9822(07)00419-8; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wu CL, 1998, J BIOL CHEM, V273, P28107, DOI 10.1074/jbc.273.43.28107; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	47	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2367	2375		10.1074/jbc.275.4.2367	http://dx.doi.org/10.1074/jbc.275.4.2367			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644687	hybrid			2022-12-25	WOS:000085128000019
J	Hemming, SA; Edwards, AM				Hemming, SA; Edwards, AM			Yeast RNA polymerase II subunit RPB9 - Mapping of domains required for transcription elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TFIIS; SACCHAROMYCES-CEREVISIAE; ZINC RIBBON; GENE; MOTIF; DNA; RESOLUTION; CLEAVAGE; SEQUENCE	The RPB9 subunit of RNA polymerase II regulates transcription elongation activity and is required for the action of the transcription elongation factor, TFIIS. RPB9 comprises two zinc ribbon domains joined by a conserved linker region. The C-terminal zinc ribbon is similar in sequence to that found in TFIIS. To elucidate the relationship between the structure and transcription elongation function of RPB9, we initiated a mutagenesis study on the Saccharomyces cerevisiae homologue. The individual zinc ribbon domains, in isolation or in combination could not stimulate transcription by a polymerase lacking RPB9, pol II Delta 9. Mutations in the N-terminal zinc ribbon had little effect on transcription activity. By contrast, mutations in the acidic loop that connects the second and third beta-strands of the C-terminal zinc ribbon were completely inactive for transcription. Interestingly the analogous residues in TFIIS are also critical for elongation activity. A conserved charged stretch in the linker region (residues 89-95, DPTLPR) mediated the interaction with RNA polymerase II.	Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada	University of Toronto	Edwards, AM (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Rm 402,112 Coll St, Toronto, ON M5G 1L6, Canada.			Edwards, Aled/0000-0002-4782-6016				ACKER J, 1993, NUCLEIC ACIDS RES, V21, P5345, DOI 10.1093/nar/21.23.5345; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; Awrey DE, 1998, J BIOL CHEM, V273, P22595, DOI 10.1074/jbc.273.35.22595; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; EREINES D, 1992, P NATL ACAD SCI USA, V88, P4245; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; GU WG, 1993, J BIOL CHEM, V268, P25604; HARRISON DA, 1992, MOL CELL BIOL, V12, P928, DOI 10.1128/MCB.12.3.928; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; JEON CJ, 1994, P NATL ACAD SCI USA, V91, P9106, DOI 10.1073/pnas.91.19.9106; KAINE BP, 1994, P NATL ACAD SCI USA, V91, P3854, DOI 10.1073/pnas.91.9.3854; LANGER D, 1993, NUCLEIC ACIDS RES, V21, P2251, DOI 10.1093/nar/21.9.2251; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; Olmsted VK, 1998, J BIOL CHEM, V273, P22589, DOI 10.1074/jbc.273.35.22589; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; REINES D, 1992, J BIOL CHEM, V267, P3795; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; Wang B, 1998, STRUCTURE, V6, P555, DOI 10.1016/S0969-2126(98)00058-6; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	27	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2288	2294		10.1074/jbc.275.4.2288	http://dx.doi.org/10.1074/jbc.275.4.2288			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644677	hybrid			2022-12-25	WOS:000085128000009
J	Li, L; Otake, LR; Xu, YX; Michaeli, S				Li, L; Otake, LR; Xu, YX; Michaeli, S			The trans-spliceosomal U4 RNA from the monogenetic trypanosomatid Leptomonas collosoma - Cloning and identification of a transcribed tRNA-like element that controls its expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNAS; SMALL NUCLEAR; MODIFIED NUCLEOTIDES; SPLICED LEADER; U6; BRUCEI; GENES; SNRNA; U2; YEAST	U4 small nuclear RNA is essential for tra ns-splicing. Here we report the cloning of U4 snRNA gene from Leptomonas collosoma and analysis of elements controlling its expression. The trypanosome U4 RNA is the smallest known, it carries an Sm-like site, and has the potential for extensive intermolecular base pairing with the U6 RNA. Sequence analysis of the U4 locus indicates the presence of a tRNA-Iike element 86 base pairs upstream of the gene that is divergently transcribed to yield a stable small tRNA-like RNA. Two additional tRNA genes, tRNA(Pro) and tRNA(Gly), were found upstream of this element. By stable expression of a tagged U4 RNA we demonstrate that the tRNA-like gene, but not the upstream tRNA genes, is essential for U4 expression and that the B box but not the A Box of the tRNA-like gene is crucial for expression in vivo, Mapping the 2'-O-methyl groups on U4 and U6 small nuclear RNAs suggests the presence of modifications in canonical positions. However, the number of modified nucleotides is fewer than in mammalian homologues, The U4 genomic organization including both tRNA-Iike and tRNA genes may represent a relic whereby trypanosomatids "hired" tRNA genes to provide extragenic promoter elements, The close proximity of tRNA genes to the tRNA-like molecule in the U4 locus further suggests that the tRNA-like gene may have evolved from a tRNA member of this cluster.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, Howard Hughes Med Inst, New Haven, CT 06536 USA	Weizmann Institute of Science; Bar Ilan University; Howard Hughes Medical Institute; Yale University	Xu, YX (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Xu, Yu-Xin/G-4041-2010; Michaeli, Shulamit/AAC-8255-2022	Liu, Li/0000-0002-3733-6961; Xu, Yu-Xin/0000-0002-0200-4633	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026154, R01GM026154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BORDONNE R, 1990, GENE DEV, V4, P1185, DOI 10.1101/gad.4.7.1185; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; FANTONI A, 1994, MOL CELL BIOL, V14, P2021, DOI 10.1128/MCB.14.3.2021; Goldring A, 1996, EXP PARASITOL, V84, P28, DOI 10.1006/expr.1996.0087; GOLDRING A, 1995, GENE, V156, P139, DOI 10.1016/0378-1119(95)00048-B; GOLDRING A, 1995, EXPT PARASITOLOGY, V80, P333; Goncharov I, 1999, J BIOL CHEM, V274, P12217, DOI 10.1074/jbc.274.18.12217; Gu J, 1996, RNA, V2, P909; HARTSHORNE T, 1990, GENE DEV, V4, P2121, DOI 10.1101/gad.4.12a.2121; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HU J, 1995, MOL CELL BIOL, V15, P1274; Jakab G, 1997, BIOCHIMIE, V79, P387, DOI 10.1016/S0300-9084(97)86148-2; KROL A, 1981, NUCLEIC ACIDS RES, V9, P2699, DOI 10.1093/nar/9.12.2699; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Levitan A, 1998, NUCLEIC ACIDS RES, V26, P1775, DOI 10.1093/nar/26.7.1775; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; Massenet S., 1998, MODIFICATION EDITING, P201; MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; MOTTRAM JC, 1991, J BIOL CHEM, V266, P18313; MYSLINSKI E, 1991, BIOCHIMIE, V73, P17, DOI 10.1016/0300-9084(91)90069-D; NAKAAR V, 1994, MOL CELL BIOL, V14, P6736, DOI 10.1128/MCB.14.10.6736; NAKAAR V, 1995, PARASITOL TODAY, V11, P225, DOI 10.1016/0169-4758(95)80085-9; PALFI Z, 1992, J BIOL CHEM, V267, P20159; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; PATZELT E, 1989, MOL CELL BIOL, V9, P4291, DOI 10.1128/MCB.9.10.4291; SILICIANO PG, 1987, CELL, V50, P585, DOI 10.1016/0092-8674(87)90031-6; TSCHUDI C, 1990, GENE, V91, P71, DOI 10.1016/0378-1119(90)90164-M; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; Tycowski KT, 1998, MOL CELL, V2, P629, DOI 10.1016/S1097-2765(00)80161-6; XU GL, 1994, MOL CELL BIOL, V14, P4565, DOI 10.1128/MCB.14.7.4565; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473	37	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2259	2264		10.1074/jbc.275.4.2259	http://dx.doi.org/10.1074/jbc.275.4.2259			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644672	hybrid			2022-12-25	WOS:000085128000004
J	Kuhne, MR; Ku, G; Weiss, A				Kuhne, MR; Ku, G; Weiss, A			A guanine nucleotide exchange factor-independent function of Vav1 in transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; ANTIGEN RECEPTOR; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; FAMILY; REQUIREMENT; KINASES; LACKING; DOMAIN; ZAP-70	T cell antigen receptor (TCR) stimulation induces the tyrosine phosphorylation of several intracellular proteins including the protooncogene Vav1, Vav1 expression is necessary for normal T cell development and activation. We previously showed that overexpression of Vav1 in Jurkat T cells potentiates the activity of the transcription factor nuclear factor of activated T cells (NF-AT), The mechanism by which Vav1 participates in TCR signaling events is not clear. Vav1 contains a guanine nucleotide exchange factor (GEF) domain that has specificity for Rac and other Rho GTPases that have been recently implicated in T cell activation events. Significantly, in vitro tyrosine phosphoryation of Vav1 by Lck activates its exchange activity. This Lck-mediated phosphorylation of Vav1 has been reported to depend upon Tyr-174 in Vav1, a site implicated in Vav1 function by other studies as well. In this report, we demonstrated that Tyr-174 is not required for the TCR-induced phosphorylation of Vav1 in vivo. Moreover, mutation of Tyr-174 augmented the ability of Vav1 to up-regulate NF-AT activation as well as the Vav1 GEF function leading to Rac activation. However, we also showed that the GEF activity of Vav1 was neither sufficient nor necessary for potentiation of NF-AT, and thereby we identify a GEF-independent role of Vav1 in potentiating NF-AT-driven transcription. Oncogenic Vav1 in which the amino-terminal 67 amino acids were deleted had elevated GEF activity but did not potentiate NF-AT when overexpressed in Jurkat cells. We also showed that a GEF mutant form of Vav1 that had impaired GEF function could still potentiate NF-AT, These studies reveal a previously unrecognized negative regulatory function of Tyr-174 in Vav1 and suggest that domains other than the Vav1 GEF domain contribute to TCR signals leading to NF-AT activation.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weiss, A (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA072531] Funding Source: NIH RePORTER; NCI NIH HHS [CA72531] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Kadlecek TA, 1998, J IMMUNOL, V161, P4688; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Michel F, 1998, J BIOL CHEM, V273, P31932, DOI 10.1074/jbc.273.48.31932; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Song JS, 1999, J IMMUNOL, V163, P802; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Turner H, 1998, J EXP MED, V188, P527, DOI 10.1084/jem.188.3.527; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	27	95	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2185	2190		10.1074/jbc.275.3.2185	http://dx.doi.org/10.1074/jbc.275.3.2185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636924	hybrid			2022-12-25	WOS:000084940000087
J	Santoso, B; Ortiz, BD; Winoto, A				Santoso, B; Ortiz, BD; Winoto, A			Control of organ-specific demethylation by an element of the T-cell receptor-alpha locus control region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING-PROTEIN; DNA METHYLATION; TRANSGENIC MICE; HISTONE DEACETYLASE; CHROMATIN STRUCTURE; ALPHA/DELTA LOCUS; TARGETED MUTATION; GENE-EXPRESSION; TRANSCRIPTION; BETA	DNA methylation is important for mammalian development and the control of gene expression, Recent data suggest that DNA methylation causes chromatin closure and gene silencing. During development, tissue specifically expressed gene loci become selectively demethylated in the appropriate cell types by poorly understood processes. Locus control regions (LCRs), which are cisacting elements providing stable, tissue-specific expression to linked transgenes in chromatin, may play a role in tissue specific DNA demethylation, We studied the methylation status of the LCR for the mouse T-cell receptor alpha/delta locus using a novel assay for scanning large distances of DNA for methylation sites. Tissue-specific functions of this LCR depend largely on two DNase I-hypersensitive site clusters (HS), HS1 (T-cell receptor cy enhancer) and HS1', We report that these HS induce lymphoid organ-specific DNA demethylation in a region located 3.8 kilobases away with little effect on intervening, methylated DNA. This demethylation is impaired in mice with a germline deletion of the HS1/HS1' clusters. Using 5'-deletion mutants of a transgenic LCR reporter gene construct, we show that HS1' can act in the absence of HS1 to direct this tissue-specific DNA demethylation event. Thus, elements of an LCR can control tissue-specific DNA methylation patterns both in transgenes and inside its native locus.	Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Div Immunol, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley		winoto@uclink4.berkeley.edu			NIAID NIH HHS [AI31558] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031558] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; BEDNARIK DP, 1991, NEW BIOL, V3, P969; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bestor TH, 1998, NATURE, V393, P311, DOI 10.1038/30613; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CHADA K, 1985, NATURE, V314, P377, DOI 10.1038/314377a0; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DIAZ P, 1994, IMMUNITY, V1, P207, DOI 10.1016/1074-7613(94)90099-X; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Engler P, 1998, P NATL ACAD SCI USA, V95, P10763, DOI 10.1073/pnas.95.18.10763; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Fraser P, 1998, CURR OPIN CELL BIOL, V10, P361, DOI 10.1016/S0955-0674(98)80012-4; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Herman JG, 1996, CANCER RES, V56, P722; Hong NA, 1997, MOL CELL BIOL, V17, P2151, DOI 10.1128/MCB.17.4.2151; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Janeway C., 1994, IMMUNOBIOLOGY IMMUNE; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Mostoslavsky R, 1998, GENE DEV, V12, P1801, DOI 10.1101/gad.12.12.1801; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ortiz BD, 1999, MOL CELL BIOL, V19, P1901; Ortiz BD, 1997, EMBO J, V16, P5037, DOI 10.1093/emboj/16.16.5037; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Siegfried Z, 1997, CURR BIOL, V7, pR305, DOI 10.1016/S0960-9822(06)00144-8; Sleckman BP, 1998, J EXP MED, V188, P1465, DOI 10.1084/jem.188.8.1465; Sleckman BP, 1997, IMMUNITY, V7, P505, DOI 10.1016/S1074-7613(00)80372-6; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WENG A, 1995, MOL CELL BIOL, V15, P572, DOI 10.1128/MCB.15.1.572; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; WU C, 1989, METHOD ENZYMOL, V170, P269	48	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1952	1958		10.1074/jbc.275.3.1952	http://dx.doi.org/10.1074/jbc.275.3.1952			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636897	hybrid			2022-12-25	WOS:000084940000060
J	Murthy, SS; Shen, T; De Rienzo, A; Lee, WC; Ferriola, PC; Jhanwar, SC; Mossman, BT; Filmus, J; Testa, JR				Murthy, SS; Shen, T; De Rienzo, A; Lee, WC; Ferriola, PC; Jhanwar, SC; Mossman, BT; Filmus, J; Testa, JR			Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma	ONCOGENE			English	Article						proteoglycan; mesothelioma; differential mRNA display; gene regulation; tumor suppressor gene; promoter methylation	ASBESTOS; GLYPICAN; GROWTH; CELLS; INOCULATION; CARCINOMA; MUTATIONS; RATS; NF2	Gene expression changes in rat asbestos-induced malignant mesothelioma (MM) cells were investigated by differential mRNA display. A mRNA transcript identified by this approach was abundant in normal rat mesothelial cells but not expressed in rat MM cell lines. Northern blot analysis confirmed that this transcript is uniformly silenced in rat MM cell lines and primary tumors. Nucleotide sequence analysis revealed that this transcript is encoded by the rat glypican 3 gene (GPC3), whose human homolog is mutated in the Simpson-Golabi-Behmel overgrowth syndrome. Allelic loss at the GPC3 locus was infrequent (6.9%) in MM cell lines, and no mutations were found. GPC3 transcript levels were markedly decreased in 16 of 18 primary tumors and 17 of 22 human MM cell Lines. Most of the cell lines were shown to have aberrant methylation of the GPC3 promoter region. In two of four human MM cell lines tested, GPC3 expression was restored after 2-deoxy 5-azacytidine (DAC)-mediated demethylation of its promoter region. Ectopic expression of GPC3 inhibited in vitro colony formation of human MM cells, Collectively, these data suggest that down-regulation of GPC3 is a common occurrence in MM and that GPC3, an X-linked recessive overgrowth gene, may encode a negative regulator of mesothelial cell growth.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Chem Ind Inst Toxicol, Res Triangle Pk, NC 27709 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Univ Vermont, Dept Pathol, Burlington, VT 05405 USA; Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; University of Vermont; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45745, CA-06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHENG JQ, 1994, CANCER RES, V54, P5547; CRAIGHEAD JE, 1987, AM J PATHOL, V129, P448; CRAIGHEAD JE, 1987, HUM PATHOL, V18, P544, DOI 10.1016/S0046-8177(87)80354-4; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DAVIS JMG, 1974, J NATL CANCER I, V52, P1823, DOI 10.1093/jnci/52.6.1823; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; FUNAKI K, 1991, CANCER RES, V51, P4059; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HILL RJ, 1990, J EXP PATHOL, V71, P105; Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616; JANSSEN YMW, 1995, CANCER RES, V55, P2085; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIBBUS BL, 1988, CANCER RES, V48, P6455; Lin HC, 1999, CANCER RES, V59, P807; MOSSMAN BT, 1989, NEW ENGL J MED, V320, P1721, DOI 10.1056/NEJM198906293202604; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; SEKIDO Y, 1995, CANCER RES, V55, P1227; Song HH, 1997, J BIOL CHEM, V272, P7574, DOI 10.1074/jbc.272.12.7574; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; TAGUCHI T, 1993, CANCER RES, V53, P4349; WAGNER J C, 1960, Br J Ind Med, V17, P260; WAGNER JC, 1973, BRIT J CANCER, V28, P173, DOI 10.1038/bjc.1973.134; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	29	126	138	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					410	416		10.1038/sj.onc.1203322	http://dx.doi.org/10.1038/sj.onc.1203322			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656689				2022-12-25	WOS:000084873700012
J	Sengupta, S; Ralhan, R; Wasylyk, B				Sengupta, S; Ralhan, R; Wasylyk, B			Tumour regression in a ligand inducible manner mediated by a chimeric tumour suppressor derived from p53	ONCOGENE			English	Article						head and neck cancer; apoptosis; tamoxifen; oestrogen receptor; gene therapy	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; SQUAMOUS-CELL CARCINOMAS; C-TERMINAL DOMAIN; TRANSCRIPTIONAL ACTIVATION; GENE-TRANSFER; IN-VIVO; MUTANT P53; GROWTH SUPPRESSION; ESTROGEN-RECEPTOR	The p53 tumour suppressor induces cell cycle arrest and apoptosis in response to cellular stresses. p53 is inactivated by various cellular and viral factors. We set out to generate regulatable p53 derivatives that are highly inducible by synthetic ligands, escape inactivation and efficiently induce apoptosis. We have generated Ligand Inducible Chimeric Tumour Suppressors (LICTS), that are inactive unless provided with artificial ligands. They are resistant to inactivation, due to the replacement of domains that mediate p53 inhibition by heterologous sequences. LICTS are activated by micromolar concentrations of ligand in a variety of cell lines. Following ligand addition, they translocate to the nucleus, activate p53 inducible genes and induce apoptosis. We have established human head and neck squamous cell carcinoma lines that stably express LICTS, which are inducible. These lines form tumours in nude mice in the absence of ligand. Addition of ligand inhibits tumour formation, and moreover, regresses established tumours by apoptosis. Although regulatable p53 expression has been achieved previously, our study provides the first demonstration of regulatable in vivo regression of tumours in a p53 based approach. Regulated inhibition and regression of tumours with a ligand inducible chimeric tumour suppressor could provide a novel approach to p53 based gene therapy.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; All India Inst Med Sci, New Delhi 110029, India	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; All India Institute of Medical Sciences (AIIMS) New Delhi	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.		Wasylyk, Bohdan/ABG-6778-2020; Sengupta, Sagar/AGR-1063-2022	Wasylyk, Bohdan/0000-0002-1718-1237; Sengupta, Sagar/0000-0002-6365-1770				AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bond J, 1996, ONCOGENE, V13, P2097; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Burcin MM, 1999, P NATL ACAD SCI USA, V96, P355, DOI 10.1073/pnas.96.2.355; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Coll JL, 1998, HUM GENE THER, V9, P2063, DOI 10.1089/hum.1998.9.14-2063; Conseiller E, 1998, J CLIN INVEST, V101, P120, DOI 10.1172/JCI1140; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Ford LG, 1997, PROG CLIN BIOL RES, V396, P271; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gallardo D, 1996, CANCER RES, V56, P4891; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GomezManzano C, 1996, CANCER RES, V56, P694; Gradishar WJ, 1997, J CLIN ONCOL, V15, P840, DOI 10.1200/JCO.1997.15.2.840; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; JIANG D, 1993, ONCOGENE, V8, P2805; JUVEN T, 1993, ONCOGENE, V8, P3411; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LE GLS, 1993, SCIENCE, V259, P988; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; LIU TJ, 1994, CANCER RES, V54, P3662; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; MOMOSE F, 1989, J ORAL PATHOL MED, V18, P391, DOI 10.1111/j.1600-0714.1989.tb01570.x; Mukhopadhyay T, 1998, ONCOGENE, V17, P241, DOI 10.1038/sj.onc.1201909; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Pirollo KF, 1997, ONCOGENE, V14, P1735, DOI 10.1038/sj.onc.1201116; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; ROY C, 1992, EXP CELL RES, V200, P416, DOI 10.1016/0014-4827(92)90190-J; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SAKAI E, 1992, ONCOGENE, V7, P927; Sankaranarayanan R, 1998, ANTICANCER RES, V18, P4779; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schuler M, 1998, HUM GENE THER, V9, P2075, DOI 10.1089/hum.1998.9.14-2075; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; SHAH JP, 1995, CA-CANCER J CLIN, V45, P352, DOI 10.3322/canjclin.45.6.352; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Treinies I, 1999, MOL CELL BIOL, V19, P321; Vater CA, 1996, ONCOGENE, V13, P739; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WAKELING AE, 1995, BIOCHEM PHARMACOL, V49, P1545, DOI 10.1016/0006-2952(94)00528-T; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Xu GW, 1996, HEPATOLOGY, V24, P1264; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YonishRouach E, 1995, ONCOGENE, V11, P2197; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	100	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					337	350		10.1038/sj.onc.1203256	http://dx.doi.org/10.1038/sj.onc.1203256			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656680				2022-12-25	WOS:000084873700003
J	Borriello, A; Della Pietra, V; Criscuolo, M; Oliva, A; Tonini, GP; Iolascon, A; Zappia, V; Della Ragione, F				Borriello, A; Della Pietra, V; Criscuolo, M; Oliva, A; Tonini, GP; Iolascon, A; Zappia, V; Della Ragione, F			p27(Kip1) accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation	ONCOGENE			English	Article						neuroblastoma; differentiation; p27; cyclin; cyclin-dependent kinase	KINASE INHIBITOR P27; CELL-CYCLE; CDK INHIBITOR; GROWTH ARREST; PROTEIN; PHOSPHORYLATION; ACTIVATION; LINES; MYC	Development of human neuroblastoma is due to an arrest in the differentiation program of neural crest sympathoadrenal progenitor cells. However, neuroblastomas, as well as their derived cell lines, maintain the potentiality of terminal differentiation. We investigated the molecular mechanisms by which retinoic acid, a molecule introduced in clinical trials for chemotherapy, induces differentiation in neuroblastoma cell lines. Our findings demonstrate that the retinoic acid-dependent growth arrest of LAN-5 neuroblastoma cell line is associated to a very large accumulation (>tenfold) of p27(Kip1) protein, a cyclin-dependent kinase inhibitor; the protein binds and inhibits cyclin-dependent kinase 2, 4 and 6 activities, thus hampering pRb and p107 phosphorylation, p27(Kip1) build-up was observable as an early phenomenon (12-24 h) after retinoic exposure and resulted in a time-dependent accumulation of high quantities of a free p27(Kip1) form, Furthermore, retinoic treatment causes an increase of cyclin-dependent kinase 5 level and activity; however, immunoprecipitation studies proved the absence of interaction with p27(kip1). No noticeable variation of other components of G1 phase cell cycle engine ws observed. Pulse-chase experiments showed a remarkable elongation of p27(Kip1) half-life in retinoic-treated LAN-5, while no enhancement of p27(Kip1) gene expression and of the translational efficiency of its messenger RNA were demonstrated. In vivo degradation of p27(Kip1) was sensitive to two highly specific proteasome inhibitors, LLnL and lactacystin, while the calpain inhibitor II ALLM and the cysteine protease inhibitor E64 did not modify the level of the protein. LLnL treatment caused a very rapid (2 h) build-up of the Cdk inhibitor content and the accumulation of higher molecular weight anti-p27(Kip1) immunoreactive bands, which probably represent ubiquitinated forms of the protein. Finally, in vitro experiments demonstrated that extracts prepared from retinoic-treated LAN-5 cells degraded recombinant p27(Kip1) at a rate remarkably slower than the untreated cells. Our results indicate that retinoic acid strongly increases p27(Kip1) le, els by down-regulating the ubiquitin-proteasome p27(Kip1) degrading pathway.	Univ Naples 2, Inst Biochem Macromol, Sch Med, I-80138 Naples, Italy; Giannina Gaslini Childrens Hosp, Lab Oncol, Adv Biotechnol Ctr, Genoa, Italy; Univ Bari, Dept Biomed Eta Evolut, Bari, Italy	Universita della Campania Vanvitelli; University of Genoa; IRCCS Istituto Giannina Gaslini; Universita degli Studi di Bari Aldo Moro	Della Ragione, F (corresponding author), Univ Naples 2, Inst Biochem Macromol, Sch Med, Via Constantinopoli 16, I-80138 Naples, Italy.		Borriello, Adriana/K-3464-2018; Iolascon, Achille/A-4461-2014	Della Ragione, Fulvio/0000-0002-0592-4283; BORRIELLO, Adriana/0000-0002-9026-8048				Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; DELLARAGIONE F, 1995, ONCOGENE, V10, P827; DONGMING S, 1996, J BIOL CHEM, V271, P14245; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P815; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Iolascon A, 1998, PEDIATR RES, V43, P139, DOI 10.1203/00006450-199801000-00021; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Khan AA, 1996, CANCER CHEMOTH PHARM, V39, P34, DOI 10.1007/s002800050535; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MURAKAMI T, 1991, PROG CLIN BIOL RES, V366, P65; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Philip T, 1989, NEW DIRECTIONS CANCE, P605; PINKERTON CR, 1993, HUMAN NEUROBLASTOMA, P3; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Zancai P, 1998, ONCOGENE, V17, P1827, DOI 10.1038/sj.onc.1202089	32	66	71	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					51	60		10.1038/sj.onc.1203231	http://dx.doi.org/10.1038/sj.onc.1203231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644979				2022-12-25	WOS:000084844300006
J	Grishin, A; Sinha, S; Roginskaya, V; Boyer, MJ; Gomez-Cambronero, J; Zuo, S; Kurosaki, T; Romero, G; Corey, SJ				Grishin, A; Sinha, S; Roginskaya, V; Boyer, MJ; Gomez-Cambronero, J; Zuo, S; Kurosaki, T; Romero, G; Corey, SJ			Involvement of Shc and Cbl-PI 3-kinase in Lyn-dependent proliferative signaling pathways for G-CSF	ONCOGENE			English	Article						G-CSF; Lyn; PI 3-kinase; Cbl; Shc	COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASES; FACTOR-RECEPTOR; ANTIGEN RECEPTOR; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; P21(RAS) ACTIVATION; DISTINCT REGIONS; GROWTH-FACTOR; B-CELLS	Granulocyte colony-stimulating factor (G-CSF) is the major hematopoietic factor which controls the production and differentiation of granulocytes. The G-CSF receptor (G-CSFR) belongs to the superfamily of the cytokine receptors, which transduce signals via the activation of cytosolic protein tyrosine kinases (PTK), To determine the role of specific PTK in G-CSF signaling we expressed the human G-CSFR in cell lines derived from DT40 B cells, which lack either the Src-related Lyn or Syk, Wild-type (wt) and syk-deficient cells underwent increased DNA synthesis in response to G-CSF; lyn-deficient cells did not. The purpose of these studies is to identify Lyn's downstream effectors in mediating DNA synthesis, While G-CSF stimulated Pas activity in all cell lines, G-CSF failed to induce the tyrosine phosphorylation of Shc in lyn-deficient cells. G-CSF induced a statistically significant activation of Erk1/Erk2 Kinase or p90Rsk only in the wt cells. G-CSF induced the tyrosine phosphorylation of Cbl and increased activity of PI 3-kinase in wild-type and syk-deficient, but non in lyn-deficient, cells. Inhibition of Shc by over-expression of its SH2 or PTB domains or PI 3-kinase by either treatment with wortmannin or expression of the CblY731F mutant decreased G-CSF-induced DNA synthesis, Thus, the Lyn, Cbl-PI 3-kinase, and Shc/non-Pas-dependent pathways correlate with the ability of cells to respond to G-CSF with increased DNA synthesis.	Childrens Hosp Pittsburgh, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Wright State Univ, Sch Med, Dept Physiol & Biophys, Dayton, OH 45401 USA; Kansai Med Univ, Dept Mol Genet, Inst Liver Res, Moriguchi, Osaka 570, Japan; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; Wright State University Dayton; Kansai Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Corey, SJ (corresponding author), Childrens Hosp Pittsburgh, Div Hematol Oncol, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Gomez-Cambronero, Julian/0000-0002-7581-9227				BALDARI CT, 1995, ONCOGENE, V10, P1141; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Corey SJ, 1998, J BIOL CHEM, V273, P3230, DOI 10.1074/jbc.273.6.3230; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Joseph DE, 1996, J BIOL CHEM, V271, P13088, DOI 10.1074/jbc.271.22.13088; KAWAUCHI K, 1994, J IMMUNOL, V152, P3306; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; PAN CX, 1993, J BIOL CHEM, V268, P25818; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	45	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					97	105		10.1038/sj.onc.1203254	http://dx.doi.org/10.1038/sj.onc.1203254			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644984				2022-12-25	WOS:000084844300011
J	Tsuneoka, M; Mekada, E				Tsuneoka, M; Mekada, E			Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras	ONCOGENE			English	Article						apoptosis; MEK; Myc; Ras; transformation	CYCLIN-E; INDUCTION; ONCOGENES; PROTEIN; KINASE; PROLIFERATION; ONCOPROTEIN; FIBROBLASTS; REQUIRES; CANCER	Cooperation of myc and activated ras has been suggested to cause malignant cell transformation but the mechanism is still unknown. Here we isolated a transformed cell line in which activation of c-Mye and Ras are independently controllable, and show that after establishment of the transformed state by c-myc and activated ras, removal of activated Ras initiates apoptosis that is dependent on c-Myc activity. Apoptosis is also initiated by an inhibitor of MEK (MAPK/ERK kinase), a kinase downstream of Ras, and apoptosis is blocked by activated Mek1. These results suggest that one of the conditions required for establishment of the transformed state is a block of apoptosis involving MEK activity. We tested the effect of MEK inhibition on cells transformed by various oncogenes, Suppression of apoptosis by MEK; is not critical in general, but in cells transformed by c-myc plus a gene that activates the MAPK cascade it is necessary to avoid cell death, Activated Ras/MEK did not suppress c-myc-dependent apoptosis due to serum-limitation. Overexpression of chicken bcl-xL suppressed apoptosis under serum-limiting conditions, but not apoptosis initiated by Ras/MEK inhibition in cells transformed by myc and activated ras. Altogether, these results suggest the existence of a novel el regulatory mechanism for myc-dependent apoptosis in certain transformed cells.	Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Kurume University	Tsuneoka, M (corresponding author), Kurume Univ, Inst Life Sci, 2432-3 Aikawa Machi, Kurume, Fukuoka 8390861, Japan.			Mekada, Eisuke/0000-0001-8858-4781				BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BOS JL, 1989, CANCER RES, V49, P4682; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; OKAZAKI K, 1995, ONCOGENE, V10, P1149; PFEIFER AMA, 1989, P NATL ACAD SCI USA, V86, P10075, DOI 10.1073/pnas.86.24.10075; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; Tsuneoka M, 1998, J BIOCHEM-TOKYO, V124, P1013, DOI 10.1093/oxfordjournals.jbchem.a022193; Tsuneoka M, 1997, ONCOGENE, V14, P2301, DOI 10.1038/sj.onc.1201067; YAMASHITA T, 1980, INT J CANCER, V26, P435, DOI 10.1002/ijc.2910260408	29	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2000	19	1					115	123		10.1038/sj.onc.1203232	http://dx.doi.org/10.1038/sj.onc.1203232			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644986				2022-12-25	WOS:000084844300013
J	Kaznacheyeva, E; Zubov, A; Nikolaev, A; Alexeenko, V; Bezprozvanny, I; Mozhayeva, GN				Kaznacheyeva, E; Zubov, A; Nikolaev, A; Alexeenko, V; Bezprozvanny, I; Mozhayeva, GN			Plasma membrane calcium channels in human carcinoma A431 cells are functionally coupled to inositol 1,4,5-trisphosphate receptor-phosphatidylinositol 4,5-bisphosphate complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELEASE; ENTRY; INFLUX; TRANSDUCTION; DEPLETION; MECHANISM; INSP(3); SIGNAL	In most nonexcitable cells, calcium (Ca2+) release from inositol 1,4,5-trisphosphate (InsP(3))-sensitive intracellular Ca2+ stores is coupled to Ca2+ influx (calcium release-activated channels (I-CRAC)) pathway. Despite intense investigation, the molecular identity of I-CRAC and the mechanism of its activation remain poorly understood, InsP(3)-dependent miniature calcium channels (I-min) display functional properties characteristic for I-CRAC. Here we used patch clamp recordings of I-min channels in human carcinoma A431 cells to demonstrate that I-min activity was greatly enchanced in the presence of anti-phosphatidylinositol 4,5-bisphosphate antibody (PIP(2)Ab) and diminished in the presence of PIP2. Anti-PIP2 antibody induced a greater than B-fold increase in I-min,sensitivity for InsP(3) activation and an almost 4-fold change in I-min maximal open probability. The addition of exogenous PIP2 vesicles to the cytosolic surface of inside-out patches inhibited I-min activity. These results lead us to propose an existence of a Ca2+ influx pathway in nonexcitable cells activated via direct conformational coupling with a selected population of InsP(3) receptors, located just underneath the plasma membrane and coupled to PIP2. The described pathway provides for a highly compartmentalized Ca2+ influx and intracellular Ca2+ store refilling mechanism.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mozhayeva, GN (corresponding author), Russian Acad Sci, Inst Cytol, 4 Tikhoretsky Ave, St Petersburg 194064, Russia.		Kaznacheyeva, Elena V/I-7260-2017	Kaznacheyeva, Elena V/0000-0003-1273-1188	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038082] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38082] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; Gregory RB, 1999, BIOCHEM J, V341, P401, DOI 10.1042/0264-6021:3410401; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huser J, 1999, J PHYSIOL-LONDON, V514, P101, DOI 10.1111/j.1469-7793.1999.101af.x; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 1999, PFLUG ARCH EUR J PHY, V437, P305, DOI 10.1007/s004240050784; Kiselyov KI, 1997, FEBS LETT, V407, P309, DOI 10.1016/S0014-5793(97)00366-9; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; Lupu VD, 1998, J BIOL CHEM, V273, P14067, DOI 10.1074/jbc.273.23.14067; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MOZHAYEVA GN, 1990, FEBS LETT, V277, P233, DOI 10.1016/0014-5793(90)80853-B; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; Putney JW, 1999, BIOESSAYS, V21, P38; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RUKNUDIN A, 1991, J CELL BIOL, V112, P125, DOI 10.1083/jcb.112.1.125; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; VACA L, 1995, AM J PHYSIOL-CELL PH, V269, pC733, DOI 10.1152/ajpcell.1995.269.3.C733; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Zubov AI, 1999, J BIOL CHEM, V274, P25983, DOI 10.1074/jbc.274.37.25983	28	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4561	4564		10.1074/jbc.275.7.4561	http://dx.doi.org/10.1074/jbc.275.7.4561			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671480	hybrid			2022-12-25	WOS:000085378200006
J	Yoneyama, H; Maseda, H; Kamiguchi, H; Nakae, T				Yoneyama, H; Maseda, H; Kamiguchi, H; Nakae, T			Function of the membrane fusion protein, MexA, of the MexA, B-OprM efflux pump in Pseudomonas aeruginosa without an anchoring membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; OUTER-MEMBRANE; MOLECULAR-CLONING; DRUG-RESISTANCE; TRANSPORT; EXTRUSION; TOPOLOGY	Resistance of Pseudomonas aeruginosa to multiple species of antibiotics is largely attributable to expression of the MexA, B-OprM efflux pump. The MexA protein is thought to be located at the inner membrane and has been assumed to link the xenobiotics-exporting subunit, MexB, and the outer membrane channel protein, OprM, To verify this assumption, we analyzed membrane anchoring and localization of the MexA protein. n-[9,10-H-3]Palmitic acid incorporation experiments revealed that MexA was radiolabeled with palmitic acid, suggesting that the MexA anchors the inner membrane via the fatty acid moiety, To evaluate the role of lipid modification and inner membrane anchoring, we substituted cysteine 24 with phenylalanine or tyrosine and tested whether or not these mutant MexAs function properly. When the mutant mexAs were expressed in the strain lacking chromosomal mexA in the presence of n-[9,10-H-3]palmitic acid, we found undetectable radiolabeling at the MexA band, These transformants restored antibiotic resistance to the level of the wild-type strain, indicating that lipid modification is not essential for MexA function. These mutant strains contained both processed and unprocessed forms of the MexA proteins. Cellular fractionation experiments revealed that an unprocessed form of MexA anchored the inner membrane probably via an uncleaved signal sequence, whereas the processed form was undetectable in the membrane fraction. To assure that the lipid-free MexA polypeptide could be unbound to the membrane, we analyzed the two-dimensional membrane topology by the gene fusion technique. A total of 78 mexA-blaM fusions covering the entire MexA polypeptide were constructed, and all fusion sites were shown to be located at the periplasm, To answer the question of whether or not membrane anchoring is essential for the MexA function, we replaced the signal sequence of the MexA protein with that of the azurin protein, which contains a cleavable signal sequence but no lipid modification site. The signal sequence of the azurin-MexA hybrid protein was properly processed and bore the mature MexA which was fully recovered in the soluble fraction. The transformant, which expressed azurin-MexA hybrid protein restored the antibiotic resistance to a level indistinguishable from that of the wild-type strain. We concluded from these results that the MexA protein is fully functional as expressed in the periplasmic space without anchoring the inner membrane. This finding questioned the assumption that the membrane fusion proteins connect the inner and outer membranes.	Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Shimokasuya 2591193, Japan	Tokai University	Yoneyama, H (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Shimokasuya 2591193, Japan.	yoneyama@is.icc.u-tokai.ac.jp						BOWLER LD, 1989, MOL MICROBIOL, V3, P1277, DOI 10.1111/j.1365-2958.1989.tb00278.x; BRYAN LE, 1979, PSEUDOMONAS AERUGINO, P219; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Guan L, 1999, J BIOL CHEM, V274, P10517, DOI 10.1074/jbc.274.15.10517; Kohler T, 1997, MOL MICROBIOL, V23, P345, DOI 10.1046/j.1365-2958.1997.2281594.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XZ, 1998, J BACTERIOL, V180, P2987, DOI 10.1128/JB.180.11.2987-2991.1998; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; MASUDA N, 1995, ANTIMICROB AGENTS CH, V39, P645, DOI 10.1128/AAC.39.3.645; MIZUNO T, 1978, J BIOCHEM, V84, P179, DOI 10.1093/oxfordjournals.jbchem.a132106; MORSHED SRM, 1995, BIOCHEM BIOPH RES CO, V210, P356, DOI 10.1006/bbrc.1995.1669; NAKAE T, 1995, MICROBIOL IMMUNOL, V39, P221, DOI 10.1111/j.1348-0421.1995.tb02193.x; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; Poole K, 1996, MOL MICROBIOL, V21, P713, DOI 10.1046/j.1365-2958.1996.281397.x; Rensing C, 1997, J BACTERIOL, V179, P6871, DOI 10.1128/jb.179.22.6871-6879.1997; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; SKVIRSKY RC, 1995, J BACTERIOL, V177, P6153, DOI 10.1128/jb.177.21.6153-6159.1995; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506; Yoneyama H, 1998, BIOCHEM BIOPH RES CO, V244, P898, DOI 10.1006/bbrc.1998.8351; Yoneyama H, 1996, MICROBIOL-UK, V142, P2137, DOI 10.1099/13500872-142-8-2137; Zgurskaya HI, 1999, J MOL BIOL, V285, P409, DOI 10.1006/jmbi.1998.2313; ZHANG YB, 1990, GENE, V96, P51, DOI 10.1016/0378-1119(90)90340-W	31	57	59	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4628	4634		10.1074/jbc.275.7.4628	http://dx.doi.org/10.1074/jbc.275.7.4628			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671490	hybrid			2022-12-25	WOS:000085378200016
J	Duranton, J; Boudier, C; Belorgey, D; Mellet, P; Bieth, JG				Duranton, J; Boudier, C; Belorgey, D; Mellet, P; Bieth, JG			DNA strongly impairs the inhibition of cathepsin G by alpha(1)-antichymotrypsin and alpha(1)-proteinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCUS PROTEINASE-INHIBITOR; NEUTROPHIL ELASTASE; LEUKOCYTE ELASTASE; CRYSTAL-STRUCTURE; HEPARIN; BINDING; MECHANISM; KINETICS; COMPLEX	This paper explores the possibility that neutrophil-derived DNA interferes with the inhibition of neutrophil cathepsin G (cat G) and proteinase 3 by the lung antiproteinases alpha(1)-proteinase inhibitor (alpha(1)PI), alpha(1)-antichy-motrypsin (ACT), and mucus proteinase inhibitor (MPI), A 30-base pair DNA fragment ((30bp)DNA), used as a model of DNA, tightly binds cat G (K-d, 8.5 nm) but does not react with proteinase 3, alpha(1)PI, ACT, and MPI at physiological ionic strength, The polynucleotide is a partial noncompetitive inhibitor of cat G whose Ki is close to K-d. ACT and alpha(1)PI are slow binding inhibitors of the cat G-20(bp)- DNA complex whose second-order rate constants of inhibition are 2300 M-1 s(-1) and 21 M-1 s(-1), respectively, which represents a 195-fold and a 3190-fold rate deceleration. DNA thus renders cat G virtually resistant to inhibition by these irreversible serpins, On the other hand, (30bp)DNA has little or no effect on the reversible inhibition of cat Cf by MPI or chymostatin or on the irreversible inhibition of cat G by carbobenzoxy-Gly-Leu-Phe-chloromethylketone. The polynucleotide neither inhibits proteinase 3 nor affects its rate of inhibition by alpha(1)PI. These findings suggest that cat G may cause lung tissue destruction despite the presence of antiproteinases.	Univ Strasbourg 1, INSERM, U392, Fac Pharm,Lab Enzymol, F-67400 Illkirch, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bieth, JG (corresponding author), Univ Strasbourg 1, INSERM, U392, Fac Pharm,Lab Enzymol, 74 Route Rhin, F-67400 Illkirch, France.		Boudier, Christian/N-3841-2018	Boudier, Christian/0000-0002-5534-6389; Mellet, Philippe/0000-0001-5499-9735				ALBERTY RA, 1958, J PHYS CHEM-US, V62, P154, DOI 10.1021/j150560a005; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Belorgey D, 1998, BIOCHEMISTRY-US, V37, P16416, DOI 10.1021/bi981536o; BELORGEY D, 1995, FEBS LETT, V361, P265, DOI 10.1016/0014-5793(95)00173-7; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BOUDIER C, 1981, J BIOL CHEM, V256, P256; Boudier C, 1999, BIOCHEMISTRY-US, V38, P8451, DOI 10.1021/bi9828526; CADENE M, 1995, J BIOL CHEM, V270, P13204, DOI 10.1074/jbc.270.22.13204; Duranton J, 1998, BIOCHEMISTRY-US, V37, P11239, DOI 10.1021/bi980223q; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; FALLER B, 1993, BIOCHEMISTRY-US, V32, P9230, DOI 10.1021/bi00086a031; Fruh H, 1996, BIOL CHEM, V377, P579, DOI 10.1515/bchm3.1996.377.9.579; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Hof P, 1996, EMBO J, V15, P5481, DOI 10.1002/j.1460-2075.1996.tb00933.x; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NAIDOO N, 1995, J BIOL CHEM, V270, P14548, DOI 10.1074/jbc.270.24.14548; POTTER JL, 1969, AM REV RESPIR DIS, V99, P909; RAO NV, 1991, J BIOL CHEM, V266, P9540; Sambrook J., 2002, MOL CLONING LAB MANU; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P2611, DOI 10.1021/bi00383a030; SZEDLACSEK SE, 1988, BIOCHEM J, V254, P311, DOI 10.1042/bj2540311; TEGNER H, 1978, ACTA OTO-LARYNGOL, V85, P282, DOI 10.3109/00016487809111936; Webb J.L., 1963, ENZYMES METABOL INH, P55	25	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3787	3792		10.1074/jbc.275.6.3787	http://dx.doi.org/10.1074/jbc.275.6.3787			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660528	hybrid			2022-12-25	WOS:000085288800012
J	Smith, C; Estavillo, D; Emsley, J; Bankston, LA; Liddington, RC; Cruz, MA				Smith, C; Estavillo, D; Emsley, J; Bankston, LA; Liddington, RC; Cruz, MA			Mapping the collagen-binding site in the I domain of the glycoprotein Ia/IIa (integrin alpha(2)beta(1))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ADHESION; ALPHA-2-BETA-1 VLA-2; CRYSTAL-STRUCTURE; LAMININ RECEPTOR; FLOW CONDITIONS; IDENTIFICATION; CELLS; CD49B/CD29; GPIA/IIA; PROTEINS	The I domain present within the alpha 2 chain of the integrin alpha(2)beta(1) (GPIa/IIa) contains the principal collagen-binding site. Based on the crystal structure of the alpha 2-I domain, a hypothetical model was proposed in which collagen binds to a groove on the upper surface of the I domain (Emsley, J,, King, S. L,, Bergelson, J, M,, and Liddington, R, C, (1997) J, Biol, Chem, 272, 28512-28517), We have introduced point mutations into 13 residues on the upper surface of the domain. Recombinant mutant proteins were assayed for binding to monoclonal antibodies 6F1 and 12F1, to collagen under static conditions, and for the ability to retain adhesive activity under flow conditions. The mutations to residues surrounding the metal ion-dependent adhesion site that caused the greatest loss of collagen binding under both static and flow conditions are N154S in the beta A-alpha 1 turn, N190D in the PB-PC turn, D219R in the alpha 3-alpha 4 turn, and E256V and H258V in the beta D-alpha 5 turn. Mutation in one of the residues that coordinate the metal binding, S155A, completely lost the adhesive activity under flow but bound normally under static conditions, whereas the mutation Y285F had the converse effect. We conclude that the upper surface of the domain, including the metal ion-dependent adhesion site motif, defines the collagen recognition site.	Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Leicester	Cruz, MA (corresponding author), Brigham & Womens Hosp, Dept Med, Div Hematol, 221 Longwood Ave,LMRC-605, Boston, MA 02115 USA.		emsley, jonas/A-8509-2016	emsley, jonas/0000-0002-8949-8030	NHLBI NIH HHS [R01 HL54876] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054876] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1994, BLOOD, V84, P3734, DOI 10.1182/blood.V84.11.3734.bloodjournal84113734; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; COLLER BS, 1989, BLOOD, V74, P182; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Depraetere H, 1997, THROMB HAEMOSTASIS, V77, P981; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Estavillo D, 1999, J BIOL CHEM, V274, P35921, DOI 10.1074/jbc.274.50.35921; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; PISCHEL KD, 1987, J IMMUNOL, V138, P226; SAELMAN EUM, 1994, BLOOD, V83, P1244; SAELMAN EUM, 1993, BLOOD, V82, P3029; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Verkleij MW, 1998, BLOOD, V91, P3808; ZIJENAH LS, 1990, BIOCHEM J, V268, P481, DOI 10.1042/bj2680481	23	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4205	4209		10.1074/jbc.275.6.4205	http://dx.doi.org/10.1074/jbc.275.6.4205			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660584	hybrid			2022-12-25	WOS:000085288800068
J	Beck, DC; Na, CL; Whitsett, JA; Weaver, TE				Beck, DC; Na, CL; Whitsett, JA; Weaver, TE			Ablation of a critical surfactant protein B intramolecular disulfide bond in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; REGULATED SECRETORY PATHWAY; STRUCTURAL REQUIREMENTS; MESSENGER-RNA; SP-C; GRANULES; CELLS; LUNG; IDENTIFICATION; HOMEOSTASIS	The 79-amino acid, mature SP-B peptide contains three intramolecular disulfide bonds shared by all saposin-like proteins. This study tested the hypothesis that the disulfide bond formed between cysteine residues 35 and 46 (residues 235 and 246 of the SP-B proprotein) is essential for proper function of SP-B, To test the role of this bridge in SP-B function in vivo, a construct was generated in which cysteine residues 235 and 246 of the human SP-B proprotein were mutated to serine and cloned under the control of the 3.7-kilobase hSP-C promoter (hSP-B-C235S/C246). In two transgenic mouse lines, expression of the mutant peptide in the wild-type murine SP-B background was invariably lethal in the neonatal period. In four additional lines, survival was inversely related to the level of transgene expression. To test the ability of the mutant peptide to functionally replace the wild type protein, transgenic mice were crossed into the SP-B null background. No animals that expressed hSP-B-C235S/C246S in the murine SP-B-/- background survived the neonatal period. hSP-B-C235S/C246S proprotein accumulated in the endoplasmic reticulum and was not processed to the mature, biologically active peptide, The results of these studies demonstrate that the intramolecular bridge between residues 235 and 246 is critical for intracellular trafficking of SP-B and suggest that overexpression of mutant SP-B in the wild-type background may be lethal.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Weaver, TE (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038859, R37HL056285, R01HL056285, R01HL036055, R37HL038859] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38859, HL36055, HL56285] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akinbi HT, 1997, J BIOL CHEM, V272, P9640; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; Chi XY, 1998, AM J RESP CELL MOL, V19, P107, DOI 10.1165/ajrcmb.19.1.2900; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; COOL DR, 1994, BIOCHIMIE, V76, P265, DOI 10.1016/0300-9084(94)90156-2; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; JOHANSSON J, 1991, BIOCHEMISTRY-US, V30, P6917, DOI 10.1021/bi00242a015; Kaether C, 1997, EUR J CELL BIOL, V74, P133; Kunze I, 1999, BBA-BIOENERGETICS, V1410, P287, DOI 10.1016/S0005-2728(99)00006-7; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P793, DOI 10.1038/nsb1097-793; Lin S, 1999, J BIOL CHEM, V274, P19168, DOI 10.1074/jbc.274.27.19168; Lin S, 1996, BBA-MOL CELL RES, V1312, P177, DOI 10.1016/0167-4889(95)00201-4; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; Morin A, 1996, MOL CELL ENDOCRINOL, V117, P59, DOI 10.1016/0303-7207(95)03730-6; Nogee LM, 1998, BBA-MOL BASIS DIS, V1408, P323, DOI 10.1016/S0925-4439(98)00078-7; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; Pouli AE, 1998, BIOCHEM J, V331, P669, DOI 10.1042/bj3310669; Pryhuber GS, 1996, AM J PHYSIOL-LUNG C, V270, pL714, DOI 10.1152/ajplung.1996.270.5.L714; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKAHASHI A, 1990, BIOCHIM BIOPHYS ACTA, V1044, P43, DOI 10.1016/0005-2760(90)90216-K; Tokieda K, 1997, AM J PHYSIOL-LUNG C, V273, pL875, DOI 10.1152/ajplung.1997.273.4.L875; VORBROKER DK, 1995, AM J PHYSIOL, V268, P647; Waring AJ, 1996, PEPTIDE RES, V9, P28; Weaver TE, 1998, BBA-MOL BASIS DIS, V1408, P173, DOI 10.1016/S0925-4439(98)00066-0; WIKENHEISER KA, 1992, AM J PHYSIOL, V262, pL32, DOI 10.1152/ajplung.1992.262.1.L32; YEI SP, 1994, AM J RESP CELL MOL, V11, P329, DOI 10.1165/ajrcmb.11.3.8086169; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	29	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3371	3376		10.1074/jbc.275.5.3371	http://dx.doi.org/10.1074/jbc.275.5.3371			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652328	hybrid			2022-12-25	WOS:000085146500050
J	Lee, YH; Gallant, C; Guo, HQ; Li, YH; Wang, CLA; Morgan, KG				Lee, YH; Gallant, C; Guo, HQ; Li, YH; Wang, CLA; Morgan, KG			Regulation of vascular smooth muscle tone by N-terminal region of caldesmon - Possible role of tethering actin to myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD CALDESMON; PROTEIN-KINASE-C; CALMODULIN-BINDING; ATPASE ACTIVITY; CELLS; FERRET; PHOSPHORYLATION; CONTRACTION; PHENYLEPHRINE; TRANSLOCATION	To assess the functional significance of tethering actin to myosin by caldesmon in the regulation of smooth muscle contraction, we investigated the effects of synthetic peptides, containing the myosin-binding sequences in the N-terminal region of caldesmon, on force directly recorded from single permeabilized smooth muscle cells of ferret portal vein. Two peptides were used, IK29C and MY27C, containing residues from Ile(25) to Lys(53) and from Met(1) to Tyr(27) Of the human and chicken caldesmon sequence, respectively, plus an added cysteine at the C terminus. In cells clamped at pCa 6.7, both peptides increased basal tone. Pretreatment of cells at pCa 6.7 with IK29C or MY27C decreased the amplitude of subsequent phenylephrine-induced contractions but not microcystin-racemic mixture-induced contractions. In all cases the effects of the peptides were concentration-dependent, and IK29C was more potent than MY27C, in agreement with their relative affinity toward myosin, The peptides were ineffective after the phenylephrine contraction was established. MY27C did not further increase the magnitude of contraction caused by a maximally effective concentration of IK29C, consistent with the two peptides having the same mechanism of action. Neither polylysine nor two control peptides containing scrambled sequences of IK29C, which do not bind myosin, had any effect on basal or phenylephrine-induced force. Our results suggest that IK29C and MY27C induce contraction by competing with the myosin-binding domain of endogenous caldesmon, Digital imaging of fluoroisothiocyanate-tagged IK29C confirmed the association of the peptide with intracellular filamentous structures. The results are consistent with a model whereby tethering of actin to myosin by caldesmon may play a role in regulating vascular tone by positioning the C-terminal domain of caldesmon so that it is capable of blocking the actomyosin interaction.	Boston Biomed Res Inst, Signal Transduct Grp, Boston, MA 02114 USA; Boston Biomed Res Inst, Muscle Res Grp, Boston, MA 02114 USA; Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Boston Biomedical Research Institute; Boston Biomedical Research Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Morgan, KG (corresponding author), Boston Biomed Res Inst, Signal Transduct Grp, 20 Staniford St, Boston, MA 02114 USA.			Lee, Young-Ho/0000-0002-5749-1045; Morgan, Kathleen/0000-0003-3300-3630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31704] Funding Source: Medline; NIAMS NIH HHS [AR41637] Funding Source: Medline; NICHD NIH HHS [HD42293] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BROZOVICH FV, 1990, PFLUG ARCH EUR J PHY, V416, P742, DOI 10.1007/BF00370624; BRYAN J, 1989, J BIOL CHEM, V264, P13873; COLLINS EM, 1992, AM J PHYSIOL, V262, pH754, DOI 10.1152/ajpheart.1992.262.3.H754; COLLINS J H, 1991, Protein Sequences and Data Analysis, V4, P29; Dessy C, 1998, AM J PHYSIOL-CELL PH, V275, pC1081, DOI 10.1152/ajpcell.1998.275.4.C1081; Earley JJ, 1998, CIRC RES, V83, P661, DOI 10.1161/01.RES.83.6.661; FUJII T, 1987, J BIOL CHEM, V262, P2757; GERTHOFFER WT, 1987, J PHARMACOL EXP THER, V240, P8; GONG MC, 1992, J BIOL CHEM, V267, P14662; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; Horowitz A, 1996, AM J PHYSIOL-CELL PH, V271, pC589, DOI 10.1152/ajpcell.1996.271.2.C589; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; KATSUYAMA H, 1993, CIRC RES, V72, P651, DOI 10.1161/01.RES.72.3.651; KHALIL RA, 1994, AM J PHYSIOL, V266, pC1544, DOI 10.1152/ajpcell.1994.266.6.C1544; KHALIL RA, 1992, J PHYSIOL-LONDON, V455, P585, DOI 10.1113/jphysiol.1992.sp019317; Malmquist U, 1996, PFLUG ARCH EUR J PHY, V432, P241, DOI 10.1007/s004240050130; MARSTON SB, 1984, BIOCHEM SOC T, V12, P945, DOI 10.1042/bst0120945; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; Menice CB, 1997, J BIOL CHEM, V272, P25157, DOI 10.1074/jbc.272.40.25157; MORELAND S, 1987, PFLUG ARCH EUR J PHY, V408, P139, DOI 10.1007/BF00581343; MORGAN JP, 1982, PFLUG ARCH EUR J PHY, V395, P75, DOI 10.1007/BF00584972; NGAI PK, 1984, J BIOL CHEM, V259, P3656; Parker CA, 1998, J PHYSIOL-LONDON, V508, P187, DOI 10.1111/j.1469-7793.1998.187br.x; PFITZER G, 1992, JPN J PHARMACOL, V58, P23; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SZPACENKO A, 1985, FEBS LETT, V192, P9, DOI 10.1016/0014-5793(85)80032-6; SZYMANSKI PT, 1992, AM J PHYSIOL, V262, pC1446, DOI 10.1152/ajpcell.1992.262.6.C1446; VELAZ L, 1990, J BIOL CHEM, V265, P2929; Vorotnikov AV, 1997, BIOCHEM J, V328, P211; WALSH MP, 1994, CAN J PHYSIOL PHARM, V72, P1392, DOI 10.1139/y94-201; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; WANG CLA, 1988, BIOCHEM BIOPH RES CO, V156, P1033, DOI 10.1016/S0006-291X(88)80948-3; Wang EZ, 1996, ARCH BIOCHEM BIOPHYS, V329, P156, DOI 10.1006/abbi.1996.0204; WANG Z, 1997, P NATL ACAD SCI USA, V94, P11898; ZHUANG S, 1997, BIOPHYS J, V72, P281; ZHUANG S, 1997, MOL BIOL CELL, V8, P156	42	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3213	3220		10.1074/jbc.275.5.3213	http://dx.doi.org/10.1074/jbc.275.5.3213			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652307	hybrid, Green Published			2022-12-25	WOS:000085146500029
J	Miyauchi, A; Notoya, K; Mikuni-Takagaki, Y; Takagi, Y; Goto, M; Miki, Y; Takano-Yamamoto, T; Jinnai, K; Takahashi, K; Kumegawa, M; Chihara, K; Fujita, T				Miyauchi, A; Notoya, K; Mikuni-Takagaki, Y; Takagi, Y; Goto, M; Miki, Y; Takano-Yamamoto, T; Jinnai, K; Takahashi, K; Kumegawa, M; Chihara, K; Fujita, T			Parathyroid hormone-activated volume-sensitive calcium influx pathways in mechanically loaded osteocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOSARCOMA CELLS; HIPPOCAMPAL-NEURONS; BONE-RESORPTION; ION CHANNELS; EXPRESSION; RECEPTOR; STRETCH; DIFFERENTIATION; OSTEOBLASTS; FRAGMENTS	This paper documents for the first time a volume-sensitive Ca2+ influx pathway in osteocytes, which transmits loading-induced signals into bone formation. Stretch loading by swelling rat and chicken osteocytes in hypo-osmotic solution induced a rapid and progressive increase of cytosolic calcium concentration, [Ca2+](i). The influx of extracellular Ca2+ explains the increased [Ca2+](i) that paralleled the increase in the mean cell volume. Gadolinium chloride (Gd3+), an inhibitor of stretch- activated cation channels, blocked the [Ca2+](i) increase caused by hypotonic solutions. Also, the expression of alpha 1C subunit of voltage-operated L-type Ca2+ channels (alpha 1C) is required for the hypotonicity-induced [Ca2+](i) increase judging from the effect of alpha 1C antisense oligodeoxynucleotides. Parathyroid hormone (PTH) specifically potentiated the hypotonicity-induced [Ca2+](i) increase in a dose-dependent manner through the activation of adenyl cyclase, The increases induced by both PTH and hypotonicity were observed primarily in the processes of the osteocytes, In cyclically stretched osteocytes on flexible-bottomed plates, PTH also synergistically elevated the insulin-like growth factor-1 mRNA level. Furthermore, Gd3+ and alpha 1C antisense significantly inhibited the stretch-induced insulin-like growth factor-1 mRNA elevation. The volume-sensitive calcium influx pathways of osteocytes represent a mechanism by which PTH potentiates mechanical responsiveness, an important aspect of bone formation.	Natl Sanatorium Hyogo Chuo Hosp, Sanda, Hyogo 6691515, Japan; Takeda Chem Ind Ltd, Div Pharmaceut Res, Yodogawa Ku, Osaka 5328686, Japan; Kanagawa Dent Coll, Dept Oral Biochem, Yokosuka, Kanagawa 2388580, Japan; Univ Tokushima, Sch Dent, Dept Orthodont, Tokushima 7700042, Japan; Okayama Univ, Sch Dent, Dept Orthodont, Okayama 7008525, Japan; Meikai Univ, Sch Dent, Dept Oral Anat 1, Sakado, Saitama 3500248, Japan; Kobe Univ, Sch Med, Dept Med, Kobe, Hyogo 6500017, Japan; Calcium Res Inst, Kishiwada 5960842, Japan	Takeda Chemical Industries; Kanagawa Dental College; Tokushima University; Okayama University; Meikai University; Kobe University	Miyauchi, A (corresponding author), Natl Sanatorium Hyogo Chuo Hosp, 1314 Ohara, Sanda, Hyogo 6691515, Japan.	miyauchi@hyougotyu.hosp.go.jp						ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Ajubi NE, 1996, BIOCHEM BIOPH RES CO, V225, P62, DOI 10.1006/bbrc.1996.1131; BARRY ELR, 1995, P NATL ACAD SCI USA, V92, P10914, DOI 10.1073/pnas.92.24.10914; CARVALHO RS, 1994, J BONE MINER RES, V9, P999; Chow JWM, 1998, AM J PHYSIOL-ENDOC M, V274, pE146, DOI 10.1152/ajpendo.1998.274.1.E146; DUNCAN RL, 1994, AM J PHYSIOL-RENAL, V267, pF909, DOI 10.1152/ajprenal.1994.267.6.F909; Duncan RL, 1996, P NATL ACAD SCI USA, V93, P1864, DOI 10.1073/pnas.93.5.1864; DUNCAN RL, 1992, FEBS LETT, V307, P219, DOI 10.1016/0014-5793(92)80771-8; ERNEUX C, 1986, BIOCHEM J, V234, P193, DOI 10.1042/bj2340193; FERMOR B, 1995, J BONE MINER RES, V10, P1935; FUJIMORI A, 1991, ENDOCRINOLOGY, V128, P3032, DOI 10.1210/endo-128-6-3032; Hamill OP, 1996, PHARMACOL REV, V48, P231; HAZAMA A, 1988, J PHYSIOL-LONDON, V402, P687, DOI 10.1113/jphysiol.1988.sp017229; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V217, P264, DOI 10.1006/bbrc.1995.2773; Kamata A, 1998, BIOCHEM BIOPH RES CO, V246, P404, DOI 10.1006/bbrc.1998.8632; KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45; KUDO Y, 1986, BRIT J PHARMACOL, V89, P191, DOI 10.1111/j.1476-5381.1986.tb11135.x; LANGTON PD, 1993, J PHYSIOL-LONDON, V471, P1; LANYON LE, 1984, CALCIFIED TISSUE INT, V36, pS56, DOI 10.1007/BF02406134; LANYON LE, 1993, CALCIFIED TISSUE INT, V53, pS102, DOI 10.1007/BF01673415; LEAN JM, 1995, AM J PHYSIOL-ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318; Lean JM, 1996, AM J PHYSIOL-ENDOC M, V270, pE937, DOI 10.1152/ajpendo.1996.270.6.E937; Ma YF, 1999, J BONE MINER RES, V14, P439, DOI 10.1359/jbmr.1999.14.3.439; MaejimaIkeda A, 1997, BIOCHEM J, V322, P245, DOI 10.1042/bj3220245; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; Meszaros JG, 1996, J BIOL CHEM, V271, P32981, DOI 10.1074/jbc.271.51.32981; MIKUNITAKAGAKI Y, 1995, J BONE MINER RES, V10, P231, DOI 10.1002/jbmr.5650100209; MikuniTakagaki Y, 1996, ENDOCRINOLOGY, V137, P2028, DOI 10.1210/en.137.5.2028; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; Miyauchi A, 1996, ENDOCRINOLOGY, V137, P3544, DOI 10.1210/en.137.8.3544; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; OGURA A, 1992, NEUROSCI RES, V12, P606, DOI 10.1016/0168-0102(92)90067-M; OKADA Y, 1990, NEUROSCI RES       S, V12, P5; RIXON RH, 1994, J BONE MINER RES, V9, P1179; SCHEINMAN SJ, 1985, MINER ELECTROL METAB, V11, P85; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TANAKA K, 1995, MINER ELECTROL METAB, V21, P189; Tanaka-Kamioka K, 1998, J BONE MINER RES, V13, P1555, DOI 10.1359/jbmr.1998.13.10.1555; VANDERPLAS A, 1992, J BONE MINER RES, V7, P389; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P4383	43	78	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3335	3342		10.1074/jbc.275.5.3335	http://dx.doi.org/10.1074/jbc.275.5.3335			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652322	hybrid			2022-12-25	WOS:000085146500044
J	Murray, D; Precht, P; Balakir, R; Horton, WE				Murray, D; Precht, P; Balakir, R; Horton, WE			The transcription factor delta EF1 is inversely expressed with type II collagen mRNA and can repress Col2a1 promoter activity in transfected chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMB CARTILAGE DIFFERENTIATION; TISSUE-SPECIFIC EXPRESSION; BINDING PROTEIN DELTA-EF1; HELIX-LOOP-HELIX; GENE-EXPRESSION; MESSENGER-RNAS; NUCLEAR FACTOR; ZINC-FINGER; 1ST INTRON; ENHANCER	The regulation of Col2a1, which encodes type II collagen, likely results from a balance of both positive and negative proteins. Here we present evidence that the transcription factor delta EF1 participates in the negative regulation of Col2a1 transcription. A deletion analysis suggested that a region between -100 and -307 of the rat Col2a1 gene was required for activity in differentiating chick limb bud mesenchymal cells; however, mutation of a conserved E2 box site in this region actually increased promoter activity. Supershift analysis demonstrated that delta EF1, a known transcriptional repressor, bound to the E2 box in a sequence-dependent manner. Chick limb bud mesenchymal cells, which do not express type II collagen, expressed abundant delta EF1 mRNA, but, following differentiation in micromass culture, delta EF1 mRNA expression was lost. Primary embryonic chick sternal chondrocytes, which express abundant type II collagen, displayed minimal levels of delta EF1 mRNA The inhibition of Col2a1 transcription following treatment of chick sternal chondrocytes with growth factors was accompanied by increased delta EF1 expression. Overexpression of delta EF1 in differentiated chondrocytes resulted in decreased expression of a reporter construct containing a collagen II promoter/enhancer insert; however, this negative regulation was not dependent on the proximal E2 box. This is the first report of a specific transcription factor involved in the negative regulation of Col2a1.	NE Ohio Univ, Coll Med, Dept Anat, Rootstown, OH 44272 USA; NIA, Gerontol Res Ctr, Biol Chem Lab, NIH, Baltimore, MD 21224 USA	Northeast Ohio Medical University (NEOMED); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Horton, WE (corresponding author), NE Ohio Univ, Coll Med, Dept Anat, 4209 State Route 44, Rootstown, OH 44272 USA.							BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; BRADHAM DM, 1994, J CELL PHYSIOL, V158, P61, DOI 10.1002/jcp.1041580109; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dharmavaram RM, 1997, J BIOL CHEM, V272, P26918, DOI 10.1074/jbc.272.43.26918; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FUNAHASHI J, 1991, NUCLEIC ACIDS RES, V19, P3543, DOI 10.1093/nar/19.13.3543; FUNAHASHI J, 1993, DEVELOPMENT, V119, P433; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON W, 1986, DEV BIOL, V115, P392, DOI 10.1016/0012-1606(86)90258-7; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; KOSHER RA, 1986, J CELL BIOL, V102, P1151, DOI 10.1083/jcb.102.4.1151; KRAVIS D, 1985, DEV BIOL, V108, P164, DOI 10.1016/0012-1606(85)90018-1; KULYK WM, 1989, DEVELOPMENT, V106, P449; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Leung KKH, 1998, J CELL BIOL, V141, P1291, DOI 10.1083/jcb.141.6.1291; LUI VCH, 1995, DEV DYNAM, V203, P198, DOI 10.1002/aja.1002030208; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NG LJ, 1993, DEV BIOL, V159, P403, DOI 10.1006/dbio.1993.1251; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; Sekido R, 1997, GENES CELLS, V2, P771, DOI 10.1046/j.1365-2443.1997.1570355.x; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; Takagi T, 1998, DEVELOPMENT, V125, P21; WANG LQ, 1991, J BIOL CHEM, V266, P19878	32	66	69	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3610	3618		10.1074/jbc.275.5.3610	http://dx.doi.org/10.1074/jbc.275.5.3610			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652357	hybrid			2022-12-25	WOS:000085146500079
J	Welihinda, AK; Tirasophon, W; Kaufman, RJ				Welihinda, AK; Tirasophon, W; Kaufman, RJ			The transcriptional co-activator ADA5 is required for HAC1 mRNA processing in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN-RESPONSE; TRANSFER-RNA LIGASE; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; IRE1P KINASE; YEAST; COMPLEX; GCN5; INDUCTION	Accumulation of unfolded proteins in the endoplasmic reticulum (ER) activates signaling pathways to induce transcription of a number of genes encoding ER protein chaperones and-folding catalysts. In Saccharomyces cerevisiae this transcriptional induction is mediated by an increase in the synthesis of the transcription factor Hac1p, The transmembrane receptor Ire1p/Em1p containing a Ser/Thr protein kinase and endoribonuclease activity transmits the unfolded protein response (UPR) from the ER to the nucleus. Activation of Ire1p kinase induces its endoribonuclease activity to cleave unspliced HAC1 mRNA and generate exon fragments that are subsequently ligated by tRNA ligase (RLG1). Whereas unspliced HAC1 mRNA is poorly translated, spliced HAC1 mRNA is efficiently translated. Subunits of the yeast transcriptional co-activator complex SAGA also play a role in the UPR. Deletion of GCN5, ADA2, or ADA3 reduces, and deletion of ADA5 completely abolishes, the UPR, Although HAC1 mRNA requires only Ire1p and Rlg1p in vitro, we demonstrate that ADA5 is required for the IRE1/RLG1-dependent splicing reaction of HAC1 mRNA in vivo. In addition, Ada5p interacts with Tre1p. These results suggest that subcomponents of transcriptional co-activator complexes may be involved in RNA processing events.	Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Dept Biol Chem, 1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	kaufman@umich.edu	Longo, Kenneth A/A-5631-2010	Welihinda, Ajith/0000-0002-0049-0850				Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Harlow E., 1988, ANTIBODIES LAB MANUA; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara T, 1998, J BIOL CHEM, V273, P1802, DOI 10.1074/jbc.273.3.1802; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sherman F., 1986, METHODS YEAST GENETI; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1998, MOL CELL BIOL, V18, P1967, DOI 10.1128/MCB.18.4.1967; Welihinda AA, 1997, P NATL ACAD SCI USA, V94, P4289, DOI 10.1073/pnas.94.9.4289; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307	33	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3377	3381		10.1074/jbc.275.5.3377	http://dx.doi.org/10.1074/jbc.275.5.3377			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652329	hybrid			2022-12-25	WOS:000085146500051
J	Li, J; Kim, YN; Bertics, PJ				Li, J; Kim, YN; Bertics, PJ			Platelet-derived growth factor-stimulated migration of murine fibroblasts is associated with epidermal growth factor receptor expression and tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; CELL-PROLIFERATION; BINDING PROTEIN; BETA-RECEPTOR; EGF RECEPTOR; FACTOR PDGF; 3T3 CELLS; CHEMOTAXIS	Previous studies have shown that epidermal growth factor (EGF) synergizes with various extracellular matrix components in promoting the migration of B82L fibroblasts expressing wild-type EGF receptors and that functional EGF receptors are critical for the conversion of B82L fibroblasts to a migratory cell type (1). In the present study, we examined the effects of platelet-derived growth factor (PDGF) on the motility of B82L fibroblasts using a microchemotaxis chamber. We found that PDGF can enhance fibronectin-induced migration of B82L fibroblasts expressing wild-type EGF receptors (B82L-clone B3), However, B82L cells that lack the EGF receptor (B82L-parental) or that express an EGF receptor that is kinase-inactive (BS2L-K721M) or C-terminally truncated (B82L-c'973) exhibit little PDGF-stimulated migration. In addition, none of these three cell lines exhibit the capacity to migrate to fibronectin alone. These observations indicate that, similar to cell migration toward fibronectin, PDGF-induced cell migration of B82L fibroblasts is augmented by the expression of an intact EGF receptor kinase. The loss of PDGF-stimulated motility in E82L cells that do not express an intact EGF receptor does not appear to result from a gross dysfunction of PDGF receptors, because ligand-stimulated tyrosine phosphorylation of the PDGP-beta receptor and the activation of mitogen-activated protein kinases are readily detectable in these cells. Moreover, an interaction between EGF and PDGF receptor systems is supported by the observation that the EGF receptor exhibits an increase in phosphotyrosine content in a time-dependent fashion upon the addition of PDGF. Altogether, these studies demonstrate that the expression of EGF receptor is critical for PDGF-stimulated migration of murine B82L fibroblasts and suggest a role for the EGF receptor do downstream of PDGF receptor activation in the signaling events that lead to PDGF-stimulated cell motility.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bertics, PJ (corresponding author), Univ Wisconsin, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.							BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BERTICS PJ, 1985, J CELL BIOCHEM, V29, P195, DOI 10.1002/jcb.240290304; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DEUEL TF, 1982, J CLIN INVEST, V69, P1046, DOI 10.1172/JCI110509; ERIKSSON A, 1992, EMBO J, V11, P545; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GRONOWSKI AM, 1993, ENDOCRINOLOGY, V133, P2838, DOI 10.1210/en.133.6.2838; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P2198, DOI 10.1210/en.136.5.2198; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; HAYASHI N, 1995, ARCH BIOCHEM BIOPHYS, V322, P423, DOI 10.1006/abbi.1995.1484; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; Higaki M, 1996, J BIOL CHEM, V271, P29342, DOI 10.1074/jbc.271.46.29342; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; LIN ML, 1995, J CELL PHYSIOL, V164, P593, DOI 10.1002/jcp.1041640318; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MAY JV, 1992, ENDOCRINOLOGY, V131, P689, DOI 10.1210/en.131.2.689; MAY JV, 1990, ENDOCRINOLOGY, V126, P2896, DOI 10.1210/endo-126-6-2896; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; MIRANTI CK, 1999, FASEB SUMM C PROT KI; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLASHAW N, 1983, CELL BIOL INT REP, V7, P489, DOI 10.1016/0309-1651(83)90143-1; PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; Rani CSS, 1997, J BIOL CHEM, V272, P10777; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SENIOR RM, 1983, J CELL BIOL, V96, P382, DOI 10.1083/jcb.96.2.382; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; SIMONSEN CC, 1983, P NATL ACAD SCI USA, V80, P2485; TIDBALL JG, 1993, J CELL BIOL, V123, P627, DOI 10.1083/jcb.123.3.627; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBERGEN, 1992, EXP CELL RES, V199, P90; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHARTON W, 1982, P NATL ACAD SCI-BIOL, V79, P5567, DOI 10.1073/pnas.79.18.5567; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085	54	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2951	2958		10.1074/jbc.275.4.2951	http://dx.doi.org/10.1074/jbc.275.4.2951			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644765	hybrid			2022-12-25	WOS:000085128000097
J	Li, LW; Ljungmann, M; Dixon, JE				Li, LW; Ljungmann, M; Dixon, JE			The human Cdc14 phosphatases interact with and dephosphorylate the tumor suppressor protein p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; TRANSCRIPTION FACTOR; GAMMA-RADIATION; CELL-CYCLE; PHOSPHORYLATION; YEAST; CHECKPOINTS; DEGRADATION	The yeast Cdc14 phosphatase has been shown to play an important role in cell cycle regulation by dephosphorylating proteins phosphorylated by the cyclin-dependent kinase Cdc28/clb. We recently cloned two human orthologs of the yeast CDC14, termed hCDC14A and -B, the gene products of which share similar to 80% amino acid sequence identity within their N termini and phosphatase domains. Here we report that the hCdc14A and hCdc14B proteins interact with the tumor suppressor protein p53 both in vitro and in vitro. This interaction is dependent on the N termini of the hCdc14 proteins and the C terminus of p53. Furthermore, the hCdc14 phosphatases were found to dephosphorylate p53 specifically at the p34(Cdc2)/clb phosphorylation site (p53-phosphor-Ser(315)). Our findings that hCdc14 is a cyclin-dependent kinase substrate phosphatase suggest that it may play a role in cell cycle control in human cells. Furthermore, the identification of p53 as a substrate for hCdc14 indicates that hCdc14 may regulate the function of p53.	Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27157 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	Wake Forest University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Li, LW (corresponding author), Wake Forest Univ, Sch Med, Dept Med, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	lwli@wfubmc.edu		Li, Liwu/0000-0001-8870-5299	NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NCI NIH HHS [CA09676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; GUILLOUF C, 1995, ONCOGENE, V10, P2263; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; Hengstermann A, 1998, ONCOGENE, V17, P2933, DOI 10.1038/sj.onc.1202282; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Mendenhall MD, 1998, MICROBIOL MOL BIOL R, V62, P1191, DOI 10.1128/MMBR.62.4.1191-1243.1998; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; OConnor PM, 1997, CANCER SURV, V29, P151; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Toyn JH, 1997, GENETICS, V145, P85; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	37	86	91	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2410	2414		10.1074/jbc.275.4.2410	http://dx.doi.org/10.1074/jbc.275.4.2410			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644693	hybrid			2022-12-25	WOS:000085128000025
J	Yuan, JZ; Slice, L; Walsh, JH; Rozengurt, E				Yuan, JZ; Slice, L; Walsh, JH; Rozengurt, E			Activation of protein kinase D by signaling through the alpha subunit of the heterotrimeric G protein G(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PHOSPHOLIPASE-C; TRANSDUCTION PATHWAY; MOLECULAR-CLONING; PEPTIDE RECEPTOR; CATALYTIC DOMAIN; PHORBOL ESTERS; INTACT-CELLS; FAMILY; TRANSFORMATION	Protein kinase D (PKD/PKC mu) immunoprecipitated from COS-7 cells transiently transfected with a constitutively active alpha subunit of G(q) (G alpha(q)Q209L) exhibited a marked increase in basal activity, which was not further enhanced by treatment of the cells with phorbol 12,13-dibutyrate, In contrast, transient transfection of COS-7 cells with activated G alpha(12)Q229L or G alpha(13)Q226L neither promoted PKD activation nor interfered with the increase of PKD activity induced by phorbol 12,13-dibutyrate, The addition of aluminum fluoride to cells cotransfected with PKD and wild type G alpha(q) induced a marked increase in PKD activity, which was comparable with that induced by expression of G alpha(q)Q209L. Treatment with the protein kinase C inhibitor GF I or Ro 31-8220 prevented the increase in PKD activity induced by aluminum fluoride. Expression of a COOH-terminal fragment of G alpha(q) that acts in a dominant negative fashion attenuated PKD activation in response to agonist stimulation of bombesin receptor. PKD activation in response to either G alpha(q) or bombesin was completely prevented by mutation of Ser(744) and Ser(748) to Ala in the kinase activation loop of PKD. Our results show that G alpha(q) activation is sufficient to stimulate sustained PKD activation via protein kinase C and indicate that the endogenous G alpha(q) mediates PKD activation in response to acute bombesin receptor stimulation.	Univ Calif Los Angeles, Sch Med, Dept Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, CURE Digest Dis Res Ctr, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu			NIDDK NIH HHS [DK 55003, T32 DK07180] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007180] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; EXTON JH, 1990, J BIOL CHEM, V265, P1; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Houssa B, 1999, J BIOL CHEM, V274, P6820, DOI 10.1074/jbc.274.11.6820; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Paolucci L, 1999, CANCER RES, V59, P572; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU DQ, 1992, J BIOL CHEM, V267, P1811; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZACHARY I, 1987, J BIOL CHEM, V262, P3947; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	58	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2157	2164		10.1074/jbc.275.3.2157	http://dx.doi.org/10.1074/jbc.275.3.2157			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636921	hybrid			2022-12-25	WOS:000084940000084
J	Lucas, L; del Peso, L; Rodriguez, P; Penalva, V; Lacal, JC				Lucas, L; del Peso, L; Rodriguez, P; Penalva, V; Lacal, JC			Ras protein is involved in the physiological regulation of phospholipase D by platelet derived growth factor	ONCOGENE			English	Article						ras; oncogenes; growth factors; PDGF; phospholipase D	KINASE-C-ALPHA; ADP-RIBOSYLATION FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; XENOPUS-LAEVIS OOCYTES; GTP-BINDING PROTEINS; SMOOTH-MUSCLE CELLS; D ACTIVATION; SIGNAL-TRANSDUCTION; LYSOPHOSPHATIDIC ACID	Lipid-derived metabolites play an important role in the regulation of cell responses to external stimuli, including cell growth control, transformation and apoptosis, Phospholipase D (PLD) is one of the critical elements in the regulation of lipid metabolism and the generation of second messengers, some of them involved in cell growth control. Oncogenic Ras proteins affect the activity of PLD by two alternate mechanisms, involving a positive activation and a feedback negative loop. Here we investigate the involvement of the proto-oncogenic Ras protein in the physiological activation of PLD induced by platelet-derived growth factor (PDGF), Over-expression of the wild type Ras protein or some of its regulatory components, such as Shc or Grb2, induces an amplification of PLD activation by PDGF challenge. Furthermore, blocking the endogenous Ras by expression of the dominant negative mutant, H-Ras-Asn(17) completely eliminated the activation of PLD by PDGF, Thus, PDGF requires a complex system for PLD regulation implying the existence of at least two positive regulatory pathways, a Ras-dependent and a PKC-dependent mechanism. These results imply that PLD is an important element in signaling by Ras proteins that is altered after I as-induced transformation.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		del Peso, Luis/K-9391-2014; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	del Peso, Luis/0000-0003-4014-5688; Lacal, Juan Carlos/0000-0002-1908-2777				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; delPeso L, 1997, BIOCHEM J, V322, P519; delPeso L, 1996, J CELL BIOCHEM, V61, P599, DOI 10.1002/(SICI)1097-4644(19960616)61:4<599::AID-JCB14>3.0.CO;2-B; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; ELDAR H, 1993, J BIOL CHEM, V268, P12560; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FREEMAN EJ, 1994, BIOCHEM J, V304, P543, DOI 10.1042/bj3040543; Frohman MA, 1996, CURR BIOL, V6, P945, DOI 10.1016/S0960-9822(02)00634-6; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOASTIN AS, 1986, CANCER RES, V46, P1015; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HONG C, 1990, MOL CELL BIOL, V10, P5314; HUANG CF, 1990, J BIOL CHEM, V265, P14858; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KISS Z, 1992, BIOCHEM J, V285, P229, DOI 10.1042/bj2850229; KISS Z, 1991, BIOCHEM J, V276, P505, DOI 10.1042/bj2760505; KONDO T, 1992, J BIOL CHEM, V267, P23609; LACAL JC, 1994, ONCOL REP, V1, P677; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; LEE YH, 1994, J BIOL CHEM, V269, P26842; LEWOBITZ PF, 1995, MOL CELL BIOL, V15, P6613; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LIU B, 1995, BIOCHEM BIOPH RES CO, V214, P418, DOI 10.1006/bbrc.1995.2303; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIAN Z, 1989, J BIOL CHEM, V264, P21720; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YEO EJ, 1994, J BIOL CHEM, V269, P27823; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Yuryev A, 1998, Cell Res, V8, P81; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	63	20	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					431	437		10.1038/sj.onc.1203323	http://dx.doi.org/10.1038/sj.onc.1203323			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656691				2022-12-25	WOS:000084873700014
J	Javelaud, D; Wietzerbin, J; Delattre, O; Besancon, F				Javelaud, D; Wietzerbin, J; Delattre, O; Besancon, F			Induction of p21(Waf1/Cip1) by TNF alpha requires NF-kappa B activity and antagonizes apoptosis in Ewing tumor cells	ONCOGENE			English	Article						Ewing tumor; NF-kappa B; TNF alpha; apoptosis; p21(Waf1/Cip1)	COLORECTAL-CARCINOMA CELLS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; IONIZING-RADIATION; FUSION PROTEIN; SARCOMA CELLS; GENE FUSION; TRANSLOCATION; FAMILY; INHIBITION	The Ewing family of tumors is characterized by recurrent reciprocal translocations that generate chimeric proteins, either EWS-FLI-1 or EWS-ERG, These proteins are potent transcriptional activators and are responsible for maintaining the oncogenic properties of tumor cells. Since apoptosis appears to be the main mechanism whereby chemotherapy and radiation kill tumor cells, identification of events that can antagonize apoptosis in Ewing tumors is essential for improving their response to conventional therapies. Here, we report that the transcriptional factor NF-kappa B is a survival factor for Ewing tumor-derived cells. In fact, inhibition of NF-kappa B activation as a consequence of the overexpression of a degradation-resistant form of I kappa B alpha, I kappa-B alpha (A32/36), sensitized these cells to TNF alpha-induced killing. Although treatment with TNF alpha did not modify the cellular expression of Bcl-2, c-IAP1, c-IAP2, D53 and EWS-FLI-1 proteins, it increased p21(Waf1/Cip1) levels. This induction required NF-kappa B activation since it mas not observed in the I kappa B alpha (A32/36) expressing cells. Moreover, overexpression of p21(Waf1/Cip1) in these I kappa B alpha (A32/ 36)-expressing cells, in which NF-kappa B and consequently p21(Waf1/Cip1) are no longer inducible by TNF alpha, decreased their susceptibility to TNF alpha-induced killing. Our results therefore identify p21(Waf1/Cip1) as a mediator of the antiapoptotic effect of TNF alpha-induced NF-kappa B in Ewing tumor cells.	Inst Curie, INSERM, U365, F-75005 Paris, France; Inst Curie, INSERM, U509, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Besancon, F (corresponding author), Inst Curie, INSERM, U365, 26 Rue Ulm, F-75005 Paris, France.		Javelaud, Delphine/B-1129-2019	Javelaud, Delphine/0000-0002-7674-7739; delattre, olivier/0000-0002-8730-2276				Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DeLuca C, 1998, VIROLOGY, V244, P27, DOI 10.1006/viro.1998.9085; FISHER LJ, 1993, CAN J ANIM SCI, V73, P539, DOI 10.4141/cjas93-058; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grilli M, 1999, CELL DEATH DIFFER, V6, P22, DOI 10.1038/sj.cdd.4400463; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Horowitz Marc E., 1997, P831; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jiang YL, 1998, BIOCHEM BIOPH RES CO, V245, P691, DOI 10.1006/bbrc.1998.8390; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LIPINSKI M, 1987, CANCER RES, V47, P183; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Melot T, 1997, HYBRIDOMA, V16, P457, DOI 10.1089/hyb.1997.16.457; MUNOZ E, 1994, J VIROL, V68, P8035; NOGUERA R, 1992, LAB INVEST, V66, P143; OHNO T, 1993, CANCER RES, V53, P5859; OREGAN S, 1995, J NEUROCHEM, V64, P69; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	57	58	58	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					61	68		10.1038/sj.onc.1203246	http://dx.doi.org/10.1038/sj.onc.1203246			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644980				2022-12-25	WOS:000084844300007
J	MacNicol, MC; Muslin, AJ; MacNicol, AM				MacNicol, MC; Muslin, AJ; MacNicol, AM			Disruption of the 14-3-3 binding site within the B-Raf kinase domain uncouples catalytic activity from PC12 cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNALING PROTEINS; MAMMALIAN-CELLS; CYCLE ARREST; IN-VITRO; A-RAF; V-RAF; ACTIVATION; 14-3-3-PROTEINS; IDENTIFICATION	A number of Raf-associated proteins have recently been identified, including members of the 14-3-3 family of phosphoserine-binding proteins. Although both positive and negative regulatory functions have been ascribed for 14-3-3 interactions with Raf-1, the mechanisms by which 14-3-3 binding modulates Raf activity have not been fully established. We report that mutational disruption of 14-3-3 binding to the B-Raf catalytic domain inhibits B-Raf biological activity. Expression of the isolated B-Raf catalytic domain (B-Rafcat) induces PC12 cell differentiation in the absence of nerve growth factor, By contrast, the B-Rafcat 14-3-3 binding mutant, B-Rafcat S728A, was severely compromised for the induction of PC12 cell differentiation. Interestingly, the B-Rafcat 14-3-3 binding mutant retained significant in vitro catalytic activity. In Xenopus oocytes, the analogous full-length B-Raf 14-3-3 binding mutant blocked progesterone-stimulated maturation and the activation of endogenous mitogen-activated protein kinase kinase and mitogen-activated protein kinase. Similarly, the full-length B-Raf 14-3-3 binding mutant inhibited nerve growth factor-stimulated PC12 cell differentiation. We conclude that 14-3-3 interaction with the catalytic domain is not required for kinase activity per se but is essential to couple B-Raf catalytic activity to downstream effector activation.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	University of Chicago; University of Chicago; Washington University (WUSTL)	MacNicol, AM (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.				NCI NIH HHS [CA 70846] Funding Source: Medline; NIGMS NIH HHS [GM 54670] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054670] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FREEMAN RS, 1991, MOL CELL BIOL, V11, P17413; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; Howard EL, 1999, MOL CELL BIOL, V19, P1990; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KAMIYAMA T, 1993, JPN J CANCER RES, V84, P250, DOI 10.1111/j.1349-7006.1993.tb02864.x; Kockel L, 1997, GENE DEV, V11, P1140, DOI 10.1101/gad.11.9.1140; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; MacNicol MC, 1997, GENE, V196, P25, DOI 10.1016/S0378-1119(97)00171-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Papin C, 1996, ONCOGENE, V12, P2213; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Rommel C, 1996, ONCOGENE, V12, P609; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SUEN KL, 1995, ONCOGENE, V11, P825; Tamada M, 1997, ONCOGENE, V15, P2959, DOI 10.1038/sj.onc.1201582; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723	51	37	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3803	3809		10.1074/jbc.275.6.3803	http://dx.doi.org/10.1074/jbc.275.6.3803			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660530	hybrid			2022-12-25	WOS:000085288800014
J	Munsch, D; Watanabe-Fukunaga, R; Bourdon, JC; Nagata, S; May, E; Yonish-Rouach, E; Reisdorf, P				Munsch, D; Watanabe-Fukunaga, R; Bourdon, JC; Nagata, S; May, E; Yonish-Rouach, E; Reisdorf, P			Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; WILD-TYPE P53; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; YEAST GENES; IN-VIVO; BAX; PROTEIN; DAMAGE; CANCER	p53 is a tumor suppressor protein that induces apoptosis at least in part through its ability to act as a sequence-specific transactivator. This work reports that intron 1 of the mouse Fas death receptor gene contains a p53-responsive element (p53RE) that matches the p53 consensus sequence and that is located between nucleotides +1704 and +1723 from the transcription initiation site. This element is specifically bound by p53 and functions as a p53-dependent enhancer in mammalian or in yeast reporter gene assays. Contrary to bax, another known pro-apoptotic p53-target gene, both mouse and human FAS p53REs are still activated by the discriminatory P53 mutants Pro-175 and Ala-143, a class of mutants unable to induce apoptosis. We propose that p53-dependent up-regulation of Fas does not induce apoptosis per se but sensitizes the cell to other pro-apoptotic signal(s). The functional conservation of p53-dependent Fas up-regulation argues strongly in favor of its biological importance and suggests that murine models may be used to study further the in vivo role of Fas in the p53 response.	CEA, Lab Cancerol Mol, Dept Radiobiol & Radiopathol, Direct Sci Vie,CNRS,UMR 217, F-92265 Fontenay Aux Roses, France; Osaka Univ, Sch Med, Dept Genet, Suita, Osaka 5650871, Japan	CEA; Centre National de la Recherche Scientifique (CNRS); Osaka University	Reisdorf, P (corresponding author), CEA Saclay, LREG, DSV, DRR, F-91191 Gif Sur Yvette, France.	reisdorf@davidf.cea.fr	Nagata, Shigekazu/AAG-3203-2019; JC, Bourdon/A-4439-2008	Nagata, Shigekazu/0000-0001-9758-8426; JC, Bourdon/0000-0003-4623-9386				Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fuchs EJ, 1997, CANCER RES, V57, P2550; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MAY E, 1989, ONCOGENE, V4, P1037; MAY E, 1992, J VIROL, V66, P3347, DOI 10.1128/JVI.66.6.3347-3354.1992; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRIVES C, 1994, COLD SPRING HARB SYM, V59, P207, DOI 10.1101/SQB.1994.059.01.025; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; RESNICKSILVERMA.L, 1998, GENES DEV, V15; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; RUBY SW, 1983, METHOD ENZYMOL, V101, P253; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sheikh MS, 1998, CANCER RES, V58, P1593; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TSUCHIYA M, 1987, EUR J BIOCHEM, V165, P7, DOI 10.1111/j.1432-1033.1987.tb11187.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADA N, 1995, J BIOL CHEM, V270, P18007, DOI 10.1074/jbc.270.30.18007; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	52	110	110	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3867	3872		10.1074/jbc.275.6.3867	http://dx.doi.org/10.1074/jbc.275.6.3867			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660538	hybrid			2022-12-25	WOS:000085288800022
J	Baloh, RH; Tansey, MG; Johnson, EM; Milbrandt, J				Baloh, RH; Tansey, MG; Johnson, EM; Milbrandt, J			Functional mapping of receptor specificity domains of glial cell line-derived neurotrophic factor (GDNF) family ligands and production of GFR alpha 1 RET-specific agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIDBRAIN DOPAMINERGIC-NEURONS; GROWTH-FACTOR-BETA; CRYSTAL-STRUCTURE; TRANSFORMING GROWTH-FACTOR-BETA-2; ANGSTROM RESOLUTION; TYROSINE KINASE; BINDING SITE; NEURTURIN; ACTIVATION; PROTEIN	The glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) (GDNF, neurturin, artemin, and persephin) are critical regulators of neurodevelopment and support the survival of midbrain dopaminergic and spinal motor neurons in vitro and in animal disease models making them attractive therapeutic candidates for treatment of neurodegenerative diseases. The GFLs signal through a multicomponent receptor complex comprised of a high affinity binding component (GDNF-family receptor alpha-component (GFR alpha 1-GFR alpha 4)) and the receptor tyrosine kinase RET, To bean characterization of GFL receptor specificity at the molecular level, we performed comprehensive homologue-scanning mutagenesis of GDNF, the prototypical member of the GFLs. Replacing short segments of GDNF with the homologous segments from persephin (PSPN) (which cannot bind or activate GFR alpha 1.RET or GFR alpha 2.RET) identified sites along the second finger of GDNF critical for activating the GFR alpha 1.RET and GFR alpha 2.RET receptor complexes. Furthermore, introduction of these regions from GDNF, neurturin, or artemin into PSPN demonstrated that they are sufficient for activating GFR alpha 1.RET, but additional determinants are required for interaction with the other GFR alpha s, This difference in the molecular basis of GFL-GFR alpha specificity allowed the production of GFR alpha 1.RET-specific agonists and provides a foundation for understanding of GFL-GFR alpha.RET signaling at the molecular level.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Milbrandt, J (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave,Box 8118, St Louis, MO 63110 USA.	jeff@pathbox.wustl.edu		Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL INSTITUTE ON AGING [R01AG013730, R01AG013729] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG13729, R01 AG13730] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Baloh RH, 1998, P NATL ACAD SCI USA, V95, P5801, DOI 10.1073/pnas.95.10.5801; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; Burmester JK, 1998, GROWTH FACTORS, V15, P231, DOI 10.3109/08977199809002119; Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; Eigenbrot C, 1997, NAT STRUCT BIOL, V4, P435, DOI 10.1038/nsb0697-435; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; Grondin R, 1998, J NEUROL, V245, pP35, DOI 10.1007/PL00007744; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Horger BA, 1998, J NEUROSCI, V18, P4929; Ibanez CF, 1998, TRENDS NEUROSCI, V21, P438, DOI 10.1016/S0166-2236(98)01266-1; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Miller TM, 1996, J NEUROSCI, V16, P7487; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Moulder KL, 1999, J NEUROSCI, V19, P705; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Naveilhan P, 1998, P NATL ACAD SCI USA, V95, P1295, DOI 10.1073/pnas.95.3.1295; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; Qian SW, 1996, J BIOL CHEM, V271, P30656, DOI 10.1074/jbc.271.48.30656; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Suvanto P, 1997, HUM MOL GENET, V6, P1267, DOI 10.1093/hmg/6.8.1267; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Worby CA, 1998, J BIOL CHEM, V273, P3502, DOI 10.1074/jbc.273.6.3502; Xu RY, 1998, J NEUROCHEM, V70, P1383, DOI 10.1046/j.1471-4159.1998.70041383.x; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	38	57	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3412	3420		10.1074/jbc.275.5.3412	http://dx.doi.org/10.1074/jbc.275.5.3412			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652334	hybrid			2022-12-25	WOS:000085146500056
J	Blanton, MP; McCardy, EA; Gallagher, MJ				Blanton, MP; McCardy, EA; Gallagher, MJ			Examining the noncompetitive antagonist-binding site in the ion channel of the nicotinic acetylcholine receptor in the resting state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 CHLORPROMAZINE; HYDROPHOBIC PROBE; AMINO-ACIDS; REGIONS; SUBUNIT; M2	3-Trifluoromethyl-3-(m-[I-125]iodophenyl) ([I-125]TID) has been shown to be a potent noncompetitive antagonist (NCA) of the nicotinic acetylcholine receptor (AChR). Amino acids that contribute to the binding site for [I-125]TID in the ion channel have been identified in both the resting and desensitized state of the AChR (White, B. H., and Cohen, J. B. (1992) J. Biol Chem. 267, 15770-15783). To characterize further the structure of the NCA-binding site in the resting state channel, we have employed structural analogs of TLD. The TID analogs were assessed by the following: 1) their ability to inhibit [I-125]TID photoincorporation into the resting state channel; 2) the pattern, agonist sensitivity, and NCA inhibition of [I-125]TID analog photoincorporation into AChR subunits, The addition of a primary alcohol group to TID has no demonstrable effect on the interaction of the compound with the resting state channel. However, conversion of the alcohol function to acetate, isobutyl acetate (TIDBIBA), or to trimethyl acetate leads to rightward shifts in the concentration-response curves for inhibition of [I-125]TID photoincorporation into the AChR channel and a progressive reduction in the agonist sensitivity of [I-125]TID analog photoincorporation into AChR subunits. Inhibition of [I-125]TID analog photoincorporation by NCAs (e.g. tetracaine) as well as identification of the sites of [I-125]TIDBIBA photoincorporation in the delta M2 segment indicate a common binding locus for each TID analog. We conclude that relatively small additions to TID progressively reduce its ability to interact with the NCA site in the resting state channel. A model of the NCA site and resting state channel is presented.	Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Anesthesiol, Lubbock, TX 79430 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Washington University (WUSTL)	Blanton, MP (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol, 3601 4th St, Lubbock, TX 79430 USA.			Gallagher, Martin/0000-0002-3537-4200	NINDS NIH HHS [R29 NS35786] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035786] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arias HR, 1998, BBA-REV BIOMEMBRANES, V1376, P173, DOI 10.1016/S0304-4157(98)00004-5; Blanton MP, 1998, J BIOL CHEM, V273, P8659, DOI 10.1074/jbc.273.15.8659; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; Blanton MP, 1998, BIOCHEMISTRY-US, V37, P14545, DOI 10.1021/bi981435q; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN JB, 1985, EFFECTS ANESTHESIA, P53; Eichler J, 1997, EMBO J, V16, P2188, DOI 10.1093/emboj/16.9.2188; Gallagher MJ, 1999, MOL PHARMACOL, V56, P300, DOI 10.1124/mol.56.2.300; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HUCHO F, 1986, EUR J BIOCHEM, V158, P211, DOI 10.1111/j.1432-1033.1986.tb09740.x; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; Katz EJ, 1997, TOXICOL APPL PHARM, V146, P227, DOI 10.1006/taap.1997.8201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; MOORE MA, 1994, BBA-BIOMEMBRANES, V1190, P457, DOI 10.1016/0005-2736(94)90108-2; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; Smith GR, 1997, BIOPHYS J, V73, P1364, DOI 10.1016/S0006-3495(97)78169-4; Unwin N, 1998, J STRUCT BIOL, V121, P181, DOI 10.1006/jsbi.1997.3949; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1991, J BIOL CHEM, V266, P21595; WHITE BH, 1992, J BIOL CHEM, V267, P15770; WU G, 1994, BIOCHEMISTRY-US, V33, P15375, DOI 10.1021/bi00255a018	28	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3469	3478		10.1074/jbc.275.5.3469	http://dx.doi.org/10.1074/jbc.275.5.3469			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652341	hybrid			2022-12-25	WOS:000085146500063
J	Felts, SJ; Owen, BAL; Nguyen, P; Trepel, J; Donner, DB; Toft, DO				Felts, SJ; Owen, BAL; Nguyen, P; Trepel, J; Donner, DB; Toft, DO			The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGESTERONE-RECEPTOR COMPLEXES; HEAT-SHOCK PROTEINS; ROUS-SARCOMA VIRUS; HSP90 MOLECULAR CHAPERONE; 2 CELLULAR PROTEINS; IN-VIVO; TRANSFORMING PROTEIN; GLUCOCORTICOID RECEPTOR; SIGNALING PATHWAY; TERMINAL DOMAIN	The hsp90 family of molecular chaperones was expanded recently due to the cloning of TRAP1 and hsp75 by yeast two-hybrid screens. Careful analysis of the human TRAP1 and hsp75 sequences revealed that they are identical, and we have cloned a similar protein from Drosophila, Immunofluorescence data show that human TRAP1 is localized to mitochondria. This mitochondrial localization is supported by the existence of mitochondrial localization sequences in the amino termini of both the human and Drosophila proteins. Due to the striking homology of TRAP1 to hsp90, we tested the ability of TRAP1 to function as an hsp90-like chaperone. TRAP1 did not form stable complexes with the classic hsp90 co-chaperones p23 and Hop (p60), Consistent with these observations, TRAP1 had no effect on the hsp90-dependent reconstitution of hormone binding to the progesterone receptor in vitro, nor could it substitute for hsp90 to promote maturation of the receptor to its hormone-binding state. However, TRAP1 is sufficiently conserved with hsp90 such that it bound ATP, and this binding was sensitive to the hsp90 inhibitor geldanamycin, In addition, TRAP1 exhibited ATPase activity that was inhibited by both geldanamycin and radicicol, Thus, TRAP1 has functions that are distinct from those of hsp90.	Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; NCI, Med Branch, NIH, Bethesda, MD 20892 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Felts, SJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St S W, Rochester, MN 55905 USA.	felts.sara@mayo.edu	Owen, Barbara/AAD-2322-2021		NCI NIH HHS [CA67891, CA73023] Funding Source: Medline; NIDDK NIH HHS [DK46249] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073023, R01CA067891, R55CA067891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; BARDWELL JCA, 1987, P NATL ACAD SCI USA, V84, P5177, DOI 10.1073/pnas.84.15.5177; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chen CF, 1996, MOL CELL BIOL, V16, P4691; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Horton P., 1996, P INT SYST MOL BIOL, V4, P109; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Nicchitta CV, 1998, CURR OPIN IMMUNOL, V10, P103, DOI 10.1016/S0952-7915(98)80039-3; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; OPPERMANN H, 1981, VIROLOGY, V113, P736, DOI 10.1016/0042-6822(81)90202-6; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; PERDEW GH, 1993, EXP CELL RES, V209, P350, DOI 10.1006/excr.1993.1320; Pratt WB, 1998, TRENDS ENDOCRIN MET, V9, P244, DOI 10.1016/S1043-2760(98)00059-9; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; SCHUH S, 1985, J BIOL CHEM, V260, P4292; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; Smith DF, 1998, BIOL CHEM, V379, P283; Smith DF, 1998, PHARMACOL REV, V50, P493; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	67	289	304	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3305	3312		10.1074/jbc.275.5.3305	http://dx.doi.org/10.1074/jbc.275.5.3305			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652318	hybrid			2022-12-25	WOS:000085146500040
J	Kimura, A; Ohmichi, M; Tasaka, K; Kanda, Y; Ikegami, H; Hayakawa, J; Hisamoto, K; Morishige, K; Hinuma, S; Kurachi, H; Murata, Y				Kimura, A; Ohmichi, M; Tasaka, K; Kanda, Y; Ikegami, H; Hayakawa, J; Hisamoto, K; Morishige, K; Hinuma, S; Kurachi, H; Murata, Y			Prolactin-releasing peptide activation of the prolactin promoter is differentially mediated by extracellular signal-regulated protein kinase and c-Jun N-terminal protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY-CELLS; EPIDERMAL GROWTH-FACTOR; GENE-EXPRESSION; TRANSCRIPTION FACTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; FUNCTIONAL COMPONENTS; RESPONSE ELEMENT; HORMONE ACTION; GH3 CELLS	Regulation of the mitogen-activated protein kinase (MAPK) family by prolactin-releasing peptide (PrRP) in both GH3 rat pituitary tumor cells and primary cultures of rat anterior pituitary cells was investigated. PrRP rapidly and transiently activated extracellular signal-regulated protein kinase (ERK) in both types of cells. Both pertussis toxin, which inactivates G(i)/G(o), proteins, and exogenous expression of a peptide derived from the carboxyl terminus of the beta-adrenergic receptor kinase I, which specifically blocks signaling mediated by the beta gamma subunits of G proteins, completely blocked the PrRP-induced ERK activation, suggesting the involvement of G(i)/G(o) proteins in the PrRP-induced ERK activation, Down-regulation of cellular protein kinase C did not significantly inhibit the PrRP-induced ERK activation, suggesting that a protein kinase C-independent pathway is mainly involved. PrRP-induced ERK activation was not dependent on either extracellular Ca2+ or intracellular Ca2+. However, the ERK cascade was not the only route by which PrRP communicated with the nucleus, JNK was also shown to be significantly activated in response to PrRP, JNK activation in response to PrRP was slower than ERK activation, Moreover, to determine whether a MAPK family cascade regulates rat prolactin (rPRL) promoter activity, we transfected the intact rPRL promoter ligated to the firefly luciferase reporter gene into GH3 cells. PrRP activated the rPRL promoter activity in a time-dependent manner. Co-transfection with a catalytically inactive form of a MAPK construct or a dominant negative JNK, partially but significantly inhibited the induction of the rPRL promoter by PrRP, Furthermore, co-transfection with a dominant negative Ets completely abolished the response of the rPRL promoter to PrRP, These results suggest that PrRP differentially activates ERK and JNK, and both cascades are necessary to elicit rPRL promoter activity in an Ets-dependent mechanism.	Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan; Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Discovery Res Labs 1, Tsukuba, Ibaraki 3004293, Japan	Osaka University; Takeda Chemical Industries	Ohmichi, M (corresponding author), Osaka Univ, Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Aperlo C, 1996, MOL CELL BIOL, V16, P6851; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; DANNIES PS, 1976, NATURE, V261, P707, DOI 10.1038/261707a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRNTZ AG, 1978, NEW ENGL J MED, V298, P201; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KANDA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1447, DOI 10.1006/bbrc.1994.1393; KEECH CA, 1991, MOL CELL ENDOCRINOL, V78, P55, DOI 10.1016/0303-7207(91)90185-U; Kimura A, 1999, ENDOCRINOLOGY, V140, P722, DOI 10.1210/en.140.2.722; Kimura A, 1999, CANCER RES, V59, P5133; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; LOGIN IS, 1991, AM J PHYSIOL, V260, pE553, DOI 10.1152/ajpendo.1991.260.4.E553; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARCHESE A, 1995, GENOMICS, V29, P335, DOI 10.1006/geno.1995.9996; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OHMICHI M, 1994, BIOCHEM BIOPH RES CO, V201, P642, DOI 10.1006/bbrc.1994.1749; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1995, ENDOCRINOLOGY, V136, P2082, DOI 10.1210/en.136.5.2082; OHMICHI M, 1990, NEUROENDOCRINOLOGY, V52, P75, DOI 10.1159/000125542; OHMICHI M, 1997, ENDOCRINOLOGY, V138, P3130; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; POTAPOVA O, 1996, CANCER RES, V56, P2800; REBECCHI MJ, 1983, J BIOL CHEM, V258, P227; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; Roberson MS, 1999, ENDOCRINOLOGY, V140, P1310, DOI 10.1210/en.140.3.1310; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROUDBARAKI MM, 1995, AM J PHYSIOL-ENDOC M, V268, pE1215, DOI 10.1152/ajpendo.1995.268.6.E1215; Sawada T, 1997, ENDOCRINOLOGY, V138, P5275, DOI 10.1210/en.138.12.5275; Schweppe RE, 1997, J BIOL CHEM, V272, P30852, DOI 10.1074/jbc.272.49.30852; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shimizu Y, 1997, ENDOCRINOLOGY, V138, P248, DOI 10.1210/en.138.1.248; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WELCH SK, 1995, BIOCHEM BIOPH RES CO, V209, P606, DOI 10.1006/bbrc.1995.1543; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; YAN GZ, 1991, MOL ENDOCRINOL, V5, P1488, DOI 10.1210/mend-5-10-1488	71	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3667	3674		10.1074/jbc.275.5.3667	http://dx.doi.org/10.1074/jbc.275.5.3667			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652364	hybrid			2022-12-25	WOS:000085146500086
J	Klein, S; Carroll, JA; Chen, Y; Henry, MF; Henry, PA; Ortonowski, IE; Pintucci, G; Beavis, RC; Burgess, WH; Rifkin, DB				Klein, S; Carroll, JA; Chen, Y; Henry, MF; Henry, PA; Ortonowski, IE; Pintucci, G; Beavis, RC; Burgess, WH; Rifkin, DB			Biochemical analysis of the arginine methylation of high molecular weight fibroblast growth factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II; ENDOTHELIAL-CELLS; PROTEIN; LOCALIZATION; RNA; NUCLEAR; BINDING; FORMS; BFGF; NG,NG-DIMETHYLARGININE	The post-translational methylation of the N-terminally extended or high molecular weight (HMW) forms of fibroblast growth factor-2 (FGF-2) has been shown to affect the nuclear accumulation of the growth factor. In this study, we determined the extent and position of methyl groups in HMW FGF-2. Using mass spectrometry and amino acid sequence analysis, we have shown that the 22- and 22.5-kDa forms of HMW FGF-2 contain five dimethylated arginines located at positions -22, -24, -26, -36, and -38 using the methionine residue normally used to initiate the 18-kDa form as position 0. The 24-kDa form of HMW FGF-2 contains seven to eight dimethylated arginines located at positions -48, -50, and -52, in addition to positions -22, -24, -26, -36, and -38, In vitro methylation reactions demonstrate that the N-terminal extension of HMW FGF-8 acts as a specific substrate for yeast Hmt1p and human HRMT1L2 arginine methyltransferases. These findings indicate that HMW FGF-8, with the presence of five or more dimethylated Gly-Arg-Gly repeats, contains an RGG box-like domain, which may be important for protein-protein and/or protein-RNA interactions.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomed Res, New York, NY 10016 USA; NYU, Dept Chem, New York, NY 10013 USA; Univ Med & Dent New Jersey, Dept Mol Biol, Stratford, NJ 08084 USA; Amer Red Cross, Holland Lab, Dept Tissue Biol, Rockville, MD 20855 USA	New York University; New York University; New York University; New York University; New York University; Rutgers State University New Brunswick; Rutgers State University Medical Center; American Red Cross	Klein, S (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA034282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058433] Funding Source: NIH RePORTER; NCI NIH HHS [CA237853, CA34282] Funding Source: Medline; NIGMS NIH HHS [R01GM58433] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arese M, 1999, MOL BIOL CELL, V10, P1429, DOI 10.1091/mbc.10.5.1429; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1991, CELL REGUL, V2, P87, DOI 10.1091/mbc.2.2.87; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; Dealy CN, 1997, DEV BIOL, V184, P343, DOI 10.1006/dbio.1997.8525; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Henry MF, 1996, MOL CELL BIOL, V16, P3668; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KILEDJIAN M, 1994, RNA PROTEIN INTERACT, P127; Klein S, 1996, GROWTH FACTORS, V13, P219, DOI 10.3109/08977199609003223; KLIEN S, 1996, J BIOL CHEM, V37, P22583; Koga C, 1999, BIOCHEM BIOPH RES CO, V261, P756, DOI 10.1006/bbrc.1999.1039; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LIU Q, 1995, MOL CELL BIOL, V15, P2800; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RAWAL N, 1995, BBA-PROTEIN STRUCT M, V1248, P11, DOI 10.1016/0167-4838(94)00213-Z; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Shen B, 1998, BIOCHEM BIOPH RES CO, V252, P524, DOI 10.1006/bbrc.1998.9677; SOMMER A, 1989, BIOCHEM BIOPH RES CO, V160, P1267, DOI 10.1016/S0006-291X(89)80140-8; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P14001; YU ZX, 1993, EXP CELL RES, V204, P247, DOI 10.1006/excr.1993.1031	43	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3150	3157		10.1074/jbc.275.5.3150	http://dx.doi.org/10.1074/jbc.275.5.3150			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652299	hybrid			2022-12-25	WOS:000085146500021
J	Parra, M; Gascard, P; Walensky, LD; Gimm, JA; Blackshaw, S; Chan, N; Takakuwa, Y; Berger, T; Lee, G; Chasis, JA; Snyder, SH; Mohandas, N; Conboy, JG				Parra, M; Gascard, P; Walensky, LD; Gimm, JA; Blackshaw, S; Chan, N; Takakuwa, Y; Berger, T; Lee, G; Chasis, JA; Snyder, SH; Mohandas, N; Conboy, JG			Molecular and functional characterization of protein 4.1B, a novel member of the protein 4.1 family with high level, focal expression in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; MEMBRANE SKELETAL PROTEIN-4.1; SPECTRIN-ACTIN-BINDING; ERYTHROCYTE PROTEIN-4.1; STRUCTURAL PROTEIN-4.1; 4.1-BINDING SITE; TERNARY COMPLEX; GLYCOPHORIN-C; CELL-BODIES; DOMAIN	Brain-enriched isoforms of skeletal proteins in the spectrin and ankyrin gene families have been described. Here we characterize protein 4.1B, a novel homolog of erythrocyte protein 4.1R that is encoded by a distinct gene. In situ hybridization revealed high level, focal expression of 4.1B mRNA in select neuronal populations within the mouse brain, including Purkinje cells of the cerebellum, pyramidal cells in hippocampal regions CA1-3, thalamic nuclei, and olfactory bulb. Expression was also detected in adrenal gland, kidney, testis, and heart. 4.1B protein exhibits high homology to the membrane binding, spectrin-actin binding, and C-terminal domains of 4.1R, including motifs for interaction with NuMA and FKBP13, cDNA characterization and Western blot analysis revealed multiple spliceoforms of protein 4.1B, with functionally relevant heterogeneity in the spectrin-actin and NuMA binding domains. Regulated alternative splicing events led to expression of unique 4.1B isoforms in brain and muscle; only the latter possessed a functional spectrin-actin binding domain. By immunofluorescence, 4.1B was localized specifically at the plasma membrane in regions of cell-cell contact. Together these results indicate that 4.1B transcription is selectively regulated among neuronal populations and that alternative splicing regulates expression of 4.1B isoforms possessing critical functional domains typical of other protein 4.1 family members.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Tokyo Womens Med Univ, Sch Med, Dept Biochem, Tokyo 162, Japan; Univ Calif Davis, Dept Anim Sci, Davis, CA 95616 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Johns Hopkins University; Tokyo Women's Medical University; University of California System; University of California Davis	Conboy, JG (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, MS 74-174, Berkeley, CA 94720 USA.			Gascard, Philippe/0000-0001-5912-5228	NHLBI NIH HHS [HL45182] Funding Source: Medline; NIDDK NIH HHS [P01 DK032094, DK32094] Funding Source: Medline; NIMH NIH HHS [MH18501] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL045182, R01HL045182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; ANDERSON RA, 1988, J CELL BIOCHEM, V37, P269, DOI 10.1002/jcb.240370303; Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; Baklouti F, 1996, BLOOD, V87, P3934, DOI 10.1182/blood.V87.9.3934.bloodjournal8793934; CHAN W, 1993, J CELL BIOL, V123, P1463, DOI 10.1083/jcb.123.6.1463; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; Chasis JA, 1996, BLOOD, V87, P5324, DOI 10.1182/blood.V87.12.5324.bloodjournal87125324; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CORREAS I, 1991, BIOCHEM J, V279, P581, DOI 10.1042/bj2790581; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; DISCHER D, 1993, J BIOL CHEM, V268, P7186; DISCHER DE, 1995, J CELL BIOL, V130, P897, DOI 10.1083/jcb.130.4.897; FEHON RG, 1994, DEVELOPMENT, V120, P545; FOWLER V, 1980, J CELL BIOL, V85, P361, DOI 10.1083/jcb.85.2.361; Gascard P, 1999, MOL BIOL CELL, V10, P1783, DOI 10.1091/mbc.10.6.1783; Grabowski PJ, 1998, CELL, V92, P709, DOI 10.1016/S0092-8674(00)81399-9; GRANGER BL, 1984, CELL, V37, P595, DOI 10.1016/0092-8674(84)90390-8; HEMMING NJ, 1994, BIOCHEM J, V299, P191, DOI 10.1042/bj2990191; HORNE WC, 1993, BLOOD, V82, P2558; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; KREBS KE, 1987, J NEUROSCI, V7, P3907; KREBS KE, 1987, BRAIN RES BULL, V18, P793, DOI 10.1016/0361-9230(87)90218-8; Lallena MJ, 1998, J CELL SCI, V111, P1963; LETO TL, 1984, J BIOL CHEM, V259, P4603; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; Luque CM, 1998, J BIOL CHEM, V273, P11643, DOI 10.1074/jbc.273.19.11643; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Modafferi EF, 1999, RNA, V5, P687, DOI 10.1017/S1355838299990155; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; Parra M, 1998, GENOMICS, V49, P298, DOI 10.1006/geno.1998.5265; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PETERS LL, 1991, J CELL BIOL, V114, P1233, DOI 10.1083/jcb.114.6.1233; Peters LL, 1998, GENOMICS, V54, P348, DOI 10.1006/geno.1998.5537; RALSTON GB, 1976, BIOCHIM BIOPHYS ACTA, V455, P163, DOI 10.1016/0005-2736(76)90161-9; SCHANUS E, 1985, J BIOL CHEM, V260, P3724; Schischmanoff PO, 1997, J BIOL CHEM, V272, P10254, DOI 10.1074/jbc.272.15.10254; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; TANAKA T, 1991, J BIOL CHEM, V266, P1134; Tang CJC, 1998, BLOOD, V92, P1442, DOI 10.1182/blood.V92.4.1442.416k14_1442_1447; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; Tran YK, 1999, CANCER RES, V59, P35; UNGEWICKELL E, 1978, EUR J BIOCHEM, V88, P379, DOI 10.1111/j.1432-1033.1978.tb12459.x; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; Walensky LD, 1998, CURR BIOL, V8, P1269, DOI 10.1016/S0960-9822(07)00536-2; Walensky LD, 1999, J NEUROSCI, V19, P6457; Ward RE, 1998, J CELL BIOL, V140, P1463, DOI 10.1083/jcb.140.6.1463; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	56	99	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3247	3255		10.1074/jbc.275.5.3247	http://dx.doi.org/10.1074/jbc.275.5.3247			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652311	hybrid			2022-12-25	WOS:000085146500033
J	Tachibanaki, S; Nanda, K; Sasaki, K; Ozaki, K; Kawamura, S				Tachibanaki, S; Nanda, K; Sasaki, K; Ozaki, K; Kawamura, S			Amino acid residues of S-modulin responsible for interaction with rhodopsin kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR LIGHT-ADAPTATION; CYCLIC-GMP PHOSPHODIESTERASE; CALCIUM-BINDING PROTEINS; GUANYLATE-CYCLASE; RETINAL RODS; FROG RODS; RECOVERIN; PHOSPHORYLATION; ACTIVATOR; MECHANISM	S-modulin in frog or its bovine homologue, recoverin, is a 23-kDa EF-hand Ca2+-binding protein found in rod photoreceptors. The Ca2+-bound form of S-modulin binds to rhodopsin kinase (Rk) and inhibits its activity. Through this regulation, S-modulin is thought to modulate the light sensitivity of a rod. In the present study, we tried to identify the interaction site of the Ca2+-bound form of S-modulin to Rk. First, we mapped roughly the interaction regions by using partial peptides of S-modulin, The result suggested that a specific region near the amino terminus is the interaction site of S-modulin. We then identified the essential amino acid residues in this region by using S-modulin mutant proteins: four amino acid residues (Phe(22), Glu(26), Phe(55), and Thr(92)) were suggested to interact with Rk, These residues are located in a small closed pocket in the Ca2+- free, inactive form of S-modulin, but exposed to the surface of the molecule in the Ca2+-bound, active form of S-modulin, Two additional amino acid residues (Tyr(108) and Arg(150)) were found to be crucial for the Ca2+-dependent conformational changes of S-modulin.	Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan	Osaka University	Kawamura, S (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Machikane Yama 1-1, Toyonaka, Osaka 5600043, Japan.		Ozaki, Koichi/O-2798-2015	Ozaki, Koichi/0000-0001-7268-5377				AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GORODOVIKOVA EN, 1993, FEBS LETT, V335, P277, DOI 10.1016/0014-5793(93)80746-H; Hisatomi O, 1997, BIOCHEM BIOPH RES CO, V234, P173, DOI 10.1006/bbrc.1997.6609; Johnson WC, 1997, BBA-PROTEIN STRUCT M, V1342, P164, DOI 10.1016/S0167-4838(97)00091-5; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KAWAMURA S, 1994, NEUROSCI RES, V20, P293, DOI 10.1016/0168-0102(94)90050-7; Kawamura S, 1996, J BIOL CHEM, V271, P21359, DOI 10.1074/jbc.271.35.21359; Kawamura Satoru, 1995, P105; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; Matsuda S, 1998, J BIOL CHEM, V273, P20223, DOI 10.1074/jbc.273.32.20223; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; McCarthy ST, 1996, J NEUROPHYSIOL, V76, P1991, DOI 10.1152/jn.1996.76.3.1991; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; NEF S, 1995, J RECEPT SIGNAL TR R, V15, P365, DOI 10.3109/10799899509045227; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Sampath AP, 1998, J GEN PHYSIOL, V111, P53, DOI 10.1085/jgp.111.1.53; Sato N, 1997, J BIOCHEM-TOKYO, V122, P1139; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Whitlock GG, 1999, NEURON, V23, P337, DOI 10.1016/S0896-6273(00)80784-9	37	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3313	3319		10.1074/jbc.275.5.3313	http://dx.doi.org/10.1074/jbc.275.5.3313			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652319	hybrid			2022-12-25	WOS:000085146500041
J	Cosme, J; Johnson, EF				Cosme, J; Johnson, EF			Engineering microsomal cytochrome P4502C5 to be a soluble, monomeric enzyme - Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RABBIT CYTOCHROME-P-450; ESCHERICHIA-COLI; SUBSTRATE; MODEL; REDUCTASE; P450BM-3; DOMAIN; ACID; 2C3	Deletion of the N-terminal membrane-spanning domain from microsomal P450s 2C5 and 2C3 generates the enzymes, 2C5dH and 2C3dH, that exhibit a salt-dependent association with membranes indicating that they retain a monofacial membrane interaction domain. The two proteins are tetramers and dimers, respectively, in high salt buffers, and only 2C5dh requires phospholipids to reconstitute fully the catalytic activity of the enzyme. Amino acid residues derived from P450 2C3dH between residues 201 and 210 were substituted for the corresponding residues in P450 2C5 to identify those that would diminish the membrane interaction, the phospholipid dependence of catalysis, and aggregation of 2C5dH. Each of four substitutions, N202H, I207L, S209G, and S210T, diminished the aggregation of P450 2C5dH and produced a monomeric enzyme. The N202H and I207L mutations also diminished the stimulation of catalytic activity by phospholipid and reduced the binding of P450 2C5dH to phospholipid vesicles. The modified enzymes exhibit rates of progesterone 21-hydroxylation that are similar to that of P450 2C5dH. These conditionally membrane-bound P450s with improved solubility in high salt buffers are suitable for crystallization and structural determination by x-ray diffraction studies.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Johnson, EF (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 105550 N Torrey Pines Rd,NX-4, La Jolla, CA 92037 USA.	johnson@scripps.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00833] Funding Source: Medline; NIGMS NIH HHS [GM31001] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; Chang YT, 1997, PROTEIN ENG, V10, P119, DOI 10.1093/protein/10.2.119; deGroot MJ, 1996, CHEM RES TOXICOL, V9, P1079, DOI 10.1021/tx960003i; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; FRENCH JS, 1980, J BIOL CHEM, V255, P4112; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GRAHAMLORENCE SE, 1995, PHYSL FUNCTIONS CYTO, P57; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; IKUSHIRO S, 1989, BIOCHIM BIOPHYS ACTA, V984, P50, DOI 10.1016/0005-2736(89)90341-6; INGELMANSUNDBERG M, 1980, BIOCHEMISTRY-US, V19, P4004, DOI 10.1021/bi00558a018; JOHNSON EF, 1979, MOL PHARMACOL, V15, P708; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; Luo Zongshu, 1994, Archives of Biochemistry and Biophysics, V309, P52; Modi S, 1996, BIOCHEMISTRY-US, V35, P4540, DOI 10.1021/bi952742o; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; OMURA T, 1964, J BIOL CHEM, V239, P2379; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RICHARDSON TH, 1993, ARCH BIOCHEM BIOPHYS, V300, P510, DOI 10.1006/abbi.1993.1069; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SZKLARZ GD, 1994, J BIOMOL STRUCT DYN, V12, P61, DOI 10.1080/07391102.1994.10508088; SZKLARZ GD, 1995, BIOCHEMISTRY-US, V34, P14312, DOI 10.1021/bi00044a008; TANIGUCHI H, 1984, ARCH BIOCHEM BIOPHYS, V232, P585, DOI 10.1016/0003-9861(84)90577-0; TRUDELL JR, 1982, MOL PHARMACOL, V21, P710; Von Wachenfeldt Claes, 1995, P183; vonWachenfeldt C, 1997, ARCH BIOCHEM BIOPHYS, V339, P107, DOI 10.1006/abbi.1996.9859; WILLIAMS PA, 2000, IN PRESS MOL CELL; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOSHIDA Y, 1980, J BIOCHEM-TOKYO, V88, P463, DOI 10.1093/oxfordjournals.jbchem.a132993	29	135	142	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2545	2553		10.1074/jbc.275.4.2545	http://dx.doi.org/10.1074/jbc.275.4.2545			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644712	hybrid			2022-12-25	WOS:000085128000044
J	Hu, DL; Crist, M; Duan, XQ; Quiocho, FA; Gimble, FS				Hu, DL; Crist, M; Duan, XQ; Quiocho, FA; Gimble, FS			Probing the structure of the PI-SceI-DNA complex by affinity cleavage and affinity photocross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SPLICING DOMAIN; HOMING ENDONUCLEASE; SACCHAROMYCES-CEREVISIAE; CROSS-LINKING; ADENOSINE-TRIPHOSPHATASE; CRYSTAL-STRUCTURE; RNA-POLYMERASE; I-CREI; BINDING; SITE	The PI-SceI protein is an intein-encoded homing endonuclease that initiates the mobility of its gene by making a double strand break at a single site in the yeast genome. The PI-SceI protein splicing and endonucleolytic active sites are separately located in each of two domains in the PI-SceI structure. To determine the spatial relationship between bases in the PI-SceI recognition sequence and selected PI-SceI amino acids, the PI-SceI-DNA complex was probed by photocross-linking and affinity cleavage methods. Unique solvent-accessible cysteine residues were introduced into the two PI-SceI domains at positions 91, 97, 170, 230, 376, and 378, and the mutant proteins mere modified with either 4-azidophenacyl bromide or iron (S)-1-(p-bromoacetamidobenzyl) -ethylenediaminetetraacetate (FeBABE), The phenyl azide-coupled proteins cross-linked to the PI-SceI target sequence, and the FeBABE-modified proteins cleaved the DNA proximal to the derivatized amino acid. The results suggest that an extended beta-hairpin loop in the endonuclease domain that contains residues 376 and 378 contacts the major groove near the PI-SceI cleavage site. Conversely, residues 91, 97, and 170 in the protein splicing domain are in close proximity to a distant region of the substrate. To interpret our results, we used a new PI-SceI structure that is ordered in regions of the protein that bind DNA. The data strongly support a model of the PI-SceI-DNA complex derived from this structure.	Texas A&M Univ, Ctr Genome Res, Inst Biosci & Technol, Syt Hlth Sci Ctr, Houston, TX 77030 USA; Texas A&M Univ, Dept Med Biochem & Genet, Syst Hlth Sci Ctr, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Verna Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Gimble, FS (corresponding author), Texas A&M Univ, Ctr Genome Res, Inst Biosci & Technol, Syt Hlth Sci Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	fgimble@ibt.tamu.edu	Wood, David W/B-2992-2012; Meares, Claude F/A-8345-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050815] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50815] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal AK, 1998, CURR OPIN STRUC BIOL, V8, P19, DOI 10.1016/S0959-440X(98)80005-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Carter ES, 1996, COMPUT APPL BIOSCI, V12, P25; CHEN Y, 1993, J MOL BIOL, V230, P453, DOI 10.1006/jmbi.1993.1162; CHRISTOPHER JA, 1998, SPOCK SOFTWARE VERSI; Dalgaard JZ, 1997, J COMPUT BIOL, V4, P193, DOI 10.1089/cmb.1997.4.193; Derbyshire V, 1997, P NATL ACAD SCI USA, V94, P11466, DOI 10.1073/pnas.94.21.11466; DERVAN PB, 1991, METHOD ENZYMOL, V208, P497; DUAN X, 1998, THESIS BAYLOR COLL M; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; DUMOULIN P, 1993, P NATL ACAD SCI USA, V90, P2030, DOI 10.1073/pnas.90.5.2030; Dumoulin P, 1996, BIOCHEMISTRY-US, V35, P4279, DOI 10.1021/bi9529162; EBRIGHT YW, 1992, BIOCHEMISTRY-US, V31, P10664, DOI 10.1021/bi00159a004; Gimble FS, 1996, J MOL BIOL, V263, P163, DOI 10.1006/jmbi.1996.0567; Gimble FS, 1998, J BIOL CHEM, V273, P30524, DOI 10.1074/jbc.273.46.30524; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GIMBLE FS, 1993, J BIOL CHEM, V268, P21844; Greiner DP, 1997, BIOCONJUGATE CHEM, V8, P44, DOI 10.1021/bc9600731; Grindl W, 1998, NUCLEIC ACIDS RES, V26, P1857, DOI 10.1093/nar/26.8.1857; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; He ZN, 1998, J BIOL CHEM, V273, P4607, DOI 10.1074/jbc.273.8.4607; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu DL, 1999, BIOCHEMISTRY-US, V38, P12621, DOI 10.1021/bi991192h; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jurica NS, 1998, MOL CELL, V2, P469, DOI 10.1016/S1097-2765(00)80146-X; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; Murakami K, 1997, P NATL ACAD SCI USA, V94, P11274, DOI 10.1073/pnas.94.21.11274; Murakami K, 1997, P NATL ACAD SCI USA, V94, P1709, DOI 10.1073/pnas.94.5.1709; OAKLEY MG, 1990, SCIENCE, V248, P847, DOI 10.1126/science.2111578; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Owens JT, 1998, BIOCHEMISTRY-US, V37, P7670, DOI 10.1021/bi980188n; Papavassiliou A G, 1994, Methods Mol Biol, V30, P43; Pingoud V, 1999, J BIOL CHEM, V274, P10235, DOI 10.1074/jbc.274.15.10235; Silva GH, 1999, J MOL BIOL, V286, P1123, DOI 10.1006/jmbi.1998.2519; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123	42	27	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2705	2712		10.1074/jbc.275.4.2705	http://dx.doi.org/10.1074/jbc.275.4.2705			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644733	hybrid			2022-12-25	WOS:000085128000065
J	Kosalkova, K; Marcos, AT; Fierro, F; Hernando-Rico, V; Gutierrez, S; Martin, JF				Kosalkova, K; Marcos, AT; Fierro, F; Hernando-Rico, V; Gutierrez, S; Martin, JF			A novel heptameric sequence (TTAGTAA) is the binding site for a protein required for high level expression of pcbAB, the first gene of the penicillin biosynthesis in Penicillium chrysogenum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOPENICILLIN-N SYNTHETASE; AMINOADIPYL-CYSTEINYL-VALINE; ASPERGILLUS-NIDULANS; CATABOLITE REPRESSION; MOLECULAR REGULATION; FILAMENTOUS FUNGI; CLUSTER; TRANSCRIPTION; PROMOTER; AMPLIFICATION	The first two genes pcbAB and pcbC of the penicillin biosynthesis pathway are expressed from a 1.01-kilobase bidirectional promoter region. A series of sequential deletions were made in the pcbAB promoter region, and the constructions with the modified promoters coupled to the lacZ reporter gene were introduced as single copies at the pyrG locus in Penicillium chrysogenum npe10, Three regions, boxes A, B, and C, produced a significant decrease in expression of the reporter gene when deleted. Protein-DNA complexes were observed by using the electrophoretic mobility shift assay with boxes A and B (complexes AGI, BG1, BG2, and BL1) but not with box C, Uracil interference assay showed that a protein in P. chrysogenum cell extracts interacts with the thymines in a palindromic heptanucleotide TTAGTAA. Point mutations and deletion of the entire TTAGTAA sequence supported the involvement of this sequence in the binding of a transcriptional activator named penicillin transcriptional activator 1 (PTA1). In vivo studies using constructions carrying point mutations in the TTAGTAA sequence (or a deletion of the complete heptanucleotide) confirmed that this intact sequence is required for high level expression of the pcbAB gene. The TTAGTAA sequence resembles the target sequence of BASS (PHO2), a factor required for expression of several genes in yeasts.	Univ Leon, Fac Biol, Area Microbiol, E-24071 Leon, Spain	Universidad de Leon	Martin, JF (corresponding author), Univ Leon, Fac Biol, Area Microbiol, E-24071 Leon, Spain.		Gutiérrez, Santiago/H-6456-2015	Gutiérrez, Santiago/0000-0001-6659-1390; Kosalkova, Katarina/0000-0002-4792-7239; Marcos, Ana Teresa/0000-0002-0263-7473; Fierro, Francisco/0000-0002-2582-5362				ALVAREZ E, 1993, EUR J BIOCHEM, V215, P323, DOI 10.1111/j.1432-1033.1993.tb18038.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARREDO JL, 1989, CURR GENET, V16, P453, DOI 10.1007/BF00340725; Brakhage AA, 1997, FEMS MICROBIOL LETT, V148, P1; BRAKHAGE AA, 1992, J BACTERIOL, V174, P3789, DOI 10.1128/JB.174.11.3789-3799.1992; Brakhage AA, 1998, MICROBIOL MOL BIOL R, V62, P547, DOI 10.1128/MMBR.62.3.547-585.1998; CANTORAL JM, 1993, J BIOL CHEM, V268, P737; CANTORAL JM, 1987, BIO-TECHNOL, V5, P494, DOI 10.1038/nbt0587-494; CHU YW, 1995, CURR GENET, V28, P184, DOI 10.1007/BF00315786; Chu YW, 1997, APPL MICROBIOL BIOT, V47, P250, DOI 10.1007/s002530050922; CUBERO B, 1994, EMBO J, V13, P407, DOI 10.1002/j.1460-2075.1994.tb06275.x; DHAWALE SS, 1993, NUCLEIC ACIDS RES, V21, P5537, DOI 10.1093/nar/21.24.5537; DIEZ B, 1990, J BIOL CHEM, V265, P16358; Favaloro J, 1980, Methods Enzymol, V65, P718; FENG B, 1994, APPL ENVIRON MICROB, V60, P4432, DOI 10.1128/AEM.60.12.4432-4439.1994; FENG B, 1995, CURR GENET, V27, P351, DOI 10.1007/BF00352104; FIERRO F, 1993, MOL GEN GENET, V241, P573, DOI 10.1007/BF00279899; Fierro F, 1996, CURR GENET, V29, P482; Fierro F, 1996, APPL MICROBIOL BIOT, V44, P597; FIERRO F, 1995, P NATL ACAD SCI USA, V92, P6200, DOI 10.1073/pnas.92.13.6200; GUTIERREZ S, 1999, MICROBIOLOGY READ, V145, P315; HAAS H, 1995, CURR GENET, V28, P177, DOI 10.1007/BF00315785; Laich F, 1999, APPL ENVIRON MICROB, V65, P1236; LOPEZNIETO MJ, 1985, APPL MICROBIOL BIOT, V22, P343, DOI 10.1007/BF00582418; MACCABE AP, 1990, EMBO J, V9, P279, DOI 10.1002/j.1460-2075.1990.tb08106.x; Martin JE, 1999, ANTON LEEUW INT J G, V75, P21, DOI 10.1023/A:1001820109140; MARTIN JF, 1997, FUNGAL BIOTECHNOLOGY, P91; Penalva MA, 1998, TRENDS BIOTECHNOL, V16, P483, DOI 10.1016/S0167-7799(98)01229-3; PEREZESTEBAN B, 1993, MOL MICROBIOL, V9, P881, DOI 10.1111/j.1365-2958.1993.tb01746.x; RAMOS FR, 1985, ANTIMICROB AGENTS CH, V27, P380, DOI 10.1128/AAC.27.3.380; SMITH DJ, 1989, MOL GEN GENET, V216, P492, DOI 10.1007/BF00334395; Suarez T, 1996, MOL MICROBIOL, V20, P529, DOI 10.1046/j.1365-2958.1996.5421065.x; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; Vichitsoonthonkul T, 1996, CURR GENET, V30, P447, DOI 10.1007/s002940050155	34	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2423	2430		10.1074/jbc.275.4.2423	http://dx.doi.org/10.1074/jbc.275.4.2423			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644695	hybrid			2022-12-25	WOS:000085128000027
J	MacLachlan, TK; Somasundaram, K; Sgagias, M; Shifman, Y; Muschel, RJ; Cowan, KH; El-Deiry, WS				MacLachlan, TK; Somasundaram, K; Sgagias, M; Shifman, Y; Muschel, RJ; Cowan, KH; El-Deiry, WS			BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II HOLOENZYME; TRANSCRIPTIONAL ACTIVATION; DEPENDENT KINASES; CDK INHIBITORS; TNF RECEPTOR-1; GROWTH-ARREST; CANCER-CELLS; P53; PROTEIN; BREAST	The breast and ovarian cancer susceptibility gene product BRCA1 has been reported to be expressed in a cell cycle-dependent manner; possess transcriptional activity; associate with several proteins, including the p53 tumor suppressor; and play an integral role in certain types of DNA repair. We show here that ectopic expression of BRCA1 using an adenovirus vector (Ad-BRCA1) leads to dephosphorylation of the retinoblastoma protein accompanied by a decrease in cyclin-dependent kinase activity. Flow cytometric analysis on Ad-BRCA1-infected cells revealed a G(1) or G(2) phase ac cumulation, High density cDNA array screening of colon, lung and breast cancer cells identified several genes affected by BRCA1 expression in a p53-independent manner, including DNA damage response genes and genes involved in cell cycle control, Notable changes included induction of the GADD45 and GADD153 genes and a reduction in cyclin B1 expression. Therefore, BRCA1 has the potential to modulate the expression of genes and function of proteins involved in cell cycle control and DNA damage response pathways.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regual, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA; NCI, Med Branch, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regual, Philadelphia, PA 19104 USA.	weldeir@hhmi.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hengst L, 1998, GENE DEV, V12, P3882, DOI 10.1101/gad.12.24.3882; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HWANG A, 1995, J BIOL CHEM, V270, P28419; Kao GD, 1997, CANCER RES, V57, P753; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu KP, 1996, NATURE, V380, P544; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Patton GW, 1997, TOXICOL APPL PHARM, V147, P126, DOI 10.1006/taap.1997.8227; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; THOMAS T, 1994, CANCER RES, V54, P1077; Tomlinson GE, 1998, CANCER RES, V58, P3237; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wu GS, 1996, CLIN CANCER RES, V2, P623; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1995, INT J ONCOL, V6, P937; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	52	189	200	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2777	2785		10.1074/jbc.275.4.2777	http://dx.doi.org/10.1074/jbc.275.4.2777			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644742	hybrid			2022-12-25	WOS:000085128000074
J	Shainskaya, A; Schneeberger, A; Apell, HJ; Karlish, SJD				Shainskaya, A; Schneeberger, A; Apell, HJ; Karlish, SJD			Entrance port for Na+ and K+ ions on Na+,K+-ATPase in the cytoplasmic loop between trans-membrane segments M6 and M7 of the alpha subunit - Proximity of the cytoplasmic segment of the beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; P-TYPE ATPASES; CATION OCCLUSION; NA/K-ATPASE; TRANSMEMBRANE SEGMENT-6; INTRACELLULAR-TRANSPORT; EXTRACELLULAR SURFACE; RB+ OCCLUSION; NA,K-ATPASE; DOMAIN	Based on the following observations we propose that the cytoplasmic loop between trans-membrane segments M6 and M7 (L6/7) of the a subunit of Na+,K+-ATPase acts as an entrance port for Na+ and K+ ions. 1) In defined conditions chymotrypsin specifically cleaves L6/7 in the M5/M6 fragment of 19-kDa membranes, produced by extensive proteolysis of Na+,K+-ATPase, and in parallel inactivates Rb+ occlusion, 2) Dissociation of the MB/MB fragment from 19-kDa membranes is prevented either by occluded cations or by competitive antagonists such as Ca2+, Mg2+, La3+,p-xylylene bisguanidinium and m-xylylene bisguanidinium, or 1-bromo-2,4,6-tris (methylisothiouronium)benzene and 1,3-dibromo-2,4,6-tris (methylisothiouronium)benzene (Br-2-TITU3+). 3) Ca2+ ions raise electrophoretic mobility of the M5/M6 fragment but not that of the other fragments of the alpha subunit, It appears that negatively charged residues in L6/7 recognize either Na+ or K+ ions or the competitive cation antagonists. Na+ and K+ ions are then occluded within trans-membrane segments and can be transported, whereas the cation antagonists are not occluded and block transport at the entrance port. The cytoplasmic segment of the beta subunit appears to be close to or contributes to the entrance port, as inferred from the following observations. 1) Specific chymotryptic cleavage of the 16-kDa fragment of the beta subunit to 15-kDa at 20 degrees C (Shainskaya, A., and Karlish, S, J, D, (1996) J, Biol, Chem. 271, 10309-10316) markedly reduces affinity for Br-2-TITU3+ and for Na+ ions, detected by Na+ occlusion assays or electrogenic Na+ binding, whereas Rb+ occlusion is unchanged. 2) Na+ ions specifically protect the 16-kDa fragment against this chymotryptic cleavage.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Konstanz, Dept Biol, D-78434 Constance, Germany	Weizmann Institute of Science; University of Konstanz	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P319, DOI 10.1021/bi00001a039; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHOW DC, 1995, J EXP BIOL, V198, P1; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; DAVID P, 1991, J BIOL CHEM, V266, P14896; DAVID P, 1992, J BIOL CHEM, V267, P1141; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; FORBUSH B, 1988, J BIOL CHEM, V263, P7970; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; GROSSMAN Z, 1990, EXP PARASITOL, V70, P62, DOI 10.1016/0014-4894(90)90086-R; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; HEYSE S, 1994, J GEN PHYSIOL, V104, P197, DOI 10.1085/jgp.104.2.197; HOVING S, 1995, J BIOL CHEM, V270, P29788; ISHII T, 1994, P NATL ACAD SCI USA, V91, P6103, DOI 10.1073/pnas.91.13.6103; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Melle-Milovanovic D, 1998, J BIOL CHEM, V273, P11075, DOI 10.1074/jbc.273.18.11075; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Or E, 1999, J BIOL CHEM, V274, P2802, DOI 10.1074/jbc.274.5.2802; Or E, 1998, BIOCHEMISTRY-US, V37, P8197, DOI 10.1021/bi9730442; Or E, 1996, J BIOL CHEM, V271, P2470, DOI 10.1074/jbc.271.5.2470; OR E, 1993, J BIOL CHEM, V268, P16929; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schneeberger A, 1999, J MEMBRANE BIOL, V168, P221, DOI 10.1007/s002329900511; SCHULZ S, 1995, EUR BIOPHYS J BIOPHY, V23, P413, DOI 10.1007/BF00196828; SCHWAPPACH B, 1994, J BIOL CHEM, V269, P21620; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Shainskaya A, 1998, J BIOL CHEM, V273, P7311, DOI 10.1074/jbc.273.13.7311; Shainskaya A, 1996, J BIOL CHEM, V271, P10309, DOI 10.1074/jbc.271.17.10309; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHIN JM, 1994, J BIOL CHEM, V269, P8642; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; VASSALO PM, 1986, J BIOL CHEM, V261, P16957; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	54	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2019	2028		10.1074/jbc.275.3.2019	http://dx.doi.org/10.1074/jbc.275.3.2019			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636905	hybrid, Green Published			2022-12-25	WOS:000084940000068
J	Horstmann, S; Ferrari, S; Klempnauer, KH				Horstmann, S; Ferrari, S; Klempnauer, KH			Regulation of B-Myb activity by cyclin D1	ONCOGENE			English	Article						B-Myb; cell cycle regulation; cyclin D1; phosphorylation; trans-activation	CELL-CYCLE; A-MYB; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; DEPENDENT-KINASE; ESTROGEN-RECEPTOR; GENE ACTIVATION; DNA-BINDING; C-MYB; EXPRESSION	Evidence obtained during recent years suggests that B-Myb, a highly conserved member of the Myb transcription factor family, plays a key role in cell proliferation. We have shown previously that the activity of B-Myb is stimulated by cyclin A/Cdk2-dependent phosphorylation of the carboxyl-terminus of B-Myb, We have now investigated in more detail the effect of other cyclins on B-Myb, Here, we show that cyclin D1, in contrast to cyclin A, strongly inhibits the activity of B-Myb. This inhibitory effect does not involve increased phosphorylation of B-Myb but seems to rely on the formation of a specific complex of B-Myb and cyclin D1, Our work identifies B-Myb as an interacting partner for cyclin D1 and suggest that the activity of B-Myb during the cell cycle is controlled by the antagonistic effects of cyclin D1 and A. The results presented here suggest a more general role of cyclin D1 as regulator of transcription in addition to the known effect on RE phosphorylation.	Univ Munster, Inst Biochem, D-48149 Munster, Germany; Inst Expt Canc Res, Tumor Biol Ctr, D-79011 Freiburg, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.		Buchinger, Sebastian/M-3003-2013; Ferrari, Stefano/I-7357-2016	Buchinger, Sebastian/0000-0003-4859-8972; Ferrari, Stefano/0000-0002-6607-215X				ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Kamano H, 1995, ONCOGENE, V11, P2575; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MASSAGUE J, 1995, CURR OPIN CELL BIOL, V7, P769, DOI 10.1016/0955-0674(95)80059-X; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sitzmann J, 1996, ONCOGENE, V12, P1889; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	49	53	53	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					298	306		10.1038/sj.onc.1203302	http://dx.doi.org/10.1038/sj.onc.1203302			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645009				2022-12-25	WOS:000084844400016
J	Lynch, DK; Ellis, CA; Edwards, PAW; Hiles, ID				Lynch, DK; Ellis, CA; Edwards, PAW; Hiles, ID			Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism	ONCOGENE			English	Article						Akt; ErbB4; integrin-linked kinase; phosphatidylinositol 3-kinase; protein kinase B; site-directed mutagenesis	GLYCOGEN-SYNTHASE KINASE-3; NATRIURETIC-PEPTIDE RECEPTOR; PLECKSTRIN HOMOLOGY DOMAIN; PROMOTES CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; PHOSPHOINOSITIDE 3-KINASE; MOLECULAR-CLONING; SIGNALING PATHWAY; INDUCED APOPTOSIS	The serine threonine kinase protein kinase B regulates cellular activities as diverse as glycogen metabolism and apoptosis, Full activation of protein kinase B requires 3-phosphoinositides and dual phosphorylation on threonine-308 and serine-473, CaM-K kinase and 3-phosphoinositide dependent-kinase-l phosphorylate threonine-308, Integrin-linked kinase reportedly phophorylates serine-473, Consistent,vith this, in a model COS cell system we show that expression of wild-type integrin-linked kinase promotes the wortmannin sensitive phosphorylation of serine-473 of protein kinase B and its downstream substrates, and inhibits C-2-ceramide induced apoptosis, In contrast, integrin-linked kinase mutated in a lysine residue critical for function in protein kinases is inactive in these experiments, and furthermore, acts dominantly to block serine-473 phosphorylation induced by ErbB4, However, alignment of analogous sequences from different species demonstrates that integrin-linked kinase is not a typical protein kinase and identifies a conserved serine residue which potentially regulates kinase activity in a phosphorylation dependent manner, Mutation of this serine to aspartate or glutamate, but not alanine, in combination with the inactivating lysine mutation restores integrin-linked kinase dependent phosphorylation of serine-473 of protein kinase, These data strongly suggest that integrin-linked kinase does not possess serine-473 kinase activity but functions as an adaptor to recruit a serine-473 kinase or phosphatase.	Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Mol Pharmacol Unit, Stevenage SG1 2NY, Herts, England	GlaxoSmithKline	Hiles, ID (corresponding author), Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Mol Pharmacol Unit, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.		Edwards, Paul A/M-8291-2014	Edwards, Paul A/0000-0002-4789-3374				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Coffer PJ, 1998, BIOCHEM J, V335, P1; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Foster DC, 1998, J BIOL CHEM, V273, P16311, DOI 10.1074/jbc.273.26.16311; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; PEARSON RB, 1995, EMBO J, V14, P5278; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; Sambrook J, 1987, MOL CLONING LAB MANU; Sawyer C, 1998, ONCOGENE, V17, P919, DOI 10.1038/sj.onc.1202015; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	57	177	187	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					8024	8032		10.1038/sj.onc.1203258	http://dx.doi.org/10.1038/sj.onc.1203258			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637513				2022-12-25	WOS:000084634600011
J	Kimura, Y; Takaoka, M; Tanaka, S; Sassa, H; Tanaka, K; Polevoda, B; Sherman, F; Hirano, H				Kimura, Y; Takaoka, M; Tanaka, S; Sassa, H; Tanaka, K; Polevoda, B; Sherman, F; Hirano, H			N-alpha-acetylation and proteolytic activity of the yeast 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; EUKARYOTIC CELLS; SITE FORMATION; RAT-LIVER; ACETYLTRANSFERASE; PURIFICATION; IDENTIFICATION; ACIDOPHILUM; COMPLETION	N-alpha-Acetylation, catalyzed co-translationally with N-alpha-acetyltransferase (NAT), is the most common modifications of eukaryotic proteins. In yeast, there are at least three NATs: NAT1, MAK3, and NAT3, The 20 S proteasome subunits were purified from the normal strain and each of the deletion mutants, nat1, mak3, and nat3. The electrophoretic mobility of these subunits was compared by two-dimensional gel electrophoresis. Shifts toward the alkaline side of the gel and unblocking of the N terminus of certain of the subunits in one or another of the mutants indicated that the alpha 1, alpha 2, alpha 3, alpha 4, alpha 7, and beta 3 subunits were acetylated with NAT1, the alpha 5 and alpha 6 subunits were acetylated with MAK3, and the beta 4 subunit was acetylated with NAT3. Furthermore, the Ac-Met-Phe-Leu and Ac-Met-Phe-Arg termini of the alpha 5 and alpha 6 subunits, respectively, extended the known types of MAK3 substrates, Thus, nine subunits were N (alpha)-acetylated, whereas the remaining five were processed, resulting in the loss of the N-terminal region. The 20 S proteasomes derived from either the natl mutant or the normal strain were similar in respect to chymotrypsinlike, trypsin-like, and peptidylglutamyl peptide hydrolyzing activities in vitro, suggesting that N-alpha-acetylation does not play a major functional role in these activities. However, the chymotrypsin-like activity in the absence of sodium dodecyl sulfate was slightly higher in the natl mutant than in the normal strain.	Yokohama City Univ, Kihara Inst Biol Res, Grad Sch Integrated Sci, Yokohama, Kanagawa 2440813, Japan; Kamakura Womens Coll, Kamakura, Kanagawa 2478511, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 1138613, Japan; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	Yokohama City University; Kamakura Women's University; Tokyo Metropolitan Institute of Medical Science; University of Rochester	Hirano, H (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Grad Sch Integrated Sci, Maioka 641-12, Yokohama, Kanagawa 2440813, Japan.		Polevoda, Bogdan/A-4880-2008; Sassa, Hidenori/Q-7561-2018		NIGMS NIH HHS [R01 GM12702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHSTETTER T, 1984, J BIOL CHEM, V259, P3344; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Arendt CS, 1999, EMBO J, V18, P3575, DOI 10.1093/emboj/18.13.3575; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JL, 1979, J BIOL CHEM, V254, P1447; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HIRANO H, 1982, PHYTOCHEMISTRY, V21, P1513, DOI 10.1016/0031-9422(82)85008-5; HIRANO H, 1990, ELECTROPHORESIS, V11, P573, DOI 10.1002/elps.1150110708; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Jager S, 1999, J MOL BIOL, V291, P997, DOI 10.1006/jmbi.1999.2995; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LEE FJS, 1989, FEBS LETT, V256, P139, DOI 10.1016/0014-5793(89)81734-X; LEE FJS, 1988, J BIOL CHEM, V263, P14948; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1998, UBIQUITIN BIOL CELL, P127; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MOLEVODA B, 1999, EMBO J, V18, P6155; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SHERMAN F, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P173; Smith MW, 1997, PLANT PHYSIOL, V113, P281, DOI 10.1104/pp.113.1.281; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; TERCERO JC, 1993, J BACTERIOL, V175, P3192, DOI 10.1128/JB.175.10.3192-3194.1993; TOKUNAGA F, 1990, FEBS LETT, V263, P373, DOI 10.1016/0014-5793(90)81417-M	35	93	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4635	4639		10.1074/jbc.275.7.4635	http://dx.doi.org/10.1074/jbc.275.7.4635			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671491	hybrid			2022-12-25	WOS:000085378200017
J	Mossessova, E; Levine, C; Peng, H; Nurse, P; Bahng, S; Marians, KJ				Mossessova, E; Levine, C; Peng, H; Nurse, P; Bahng, S; Marians, KJ			Mutational analysis of Escherichia coli topoisomerase IV. Selection of dominant-negative parE alleles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA GYRASE; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; PURIFICATION; MECHANISM	In order to define regions of ParE, one of the two subunits of topoisomerase IV, that are involved in catalysis during topoisomerization, we developed a selection procedure to isolate dominant-negative parE alleles. Both wild-type parC and mutagenized parE were expressed from a tightly-regulated lac promoter on a moderate-copy plasmid, Mutated parE alleles were rescued from those plasmids that caused IPTG-dependent cell death, The mutant ParE proteins could be divided into two groups when reconstituted with ParC to form topoisomerase IV, those that elicited hyper-DNA cleavage and those that affected covalent complex formation.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mol Biol Grad Program, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University	Mossessova, E (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bahng S, 2000, J BIOL CHEM, V275, P4112, DOI 10.1074/jbc.275.6.4112; Benedetti P, 1997, J BIOL CHEM, V272, P12132, DOI 10.1074/jbc.272.18.12132; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BIRNBOIM HC, 1970, NUCLEIC ACIDS RES, V24, P1513; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Caron PR, 1999, METH MOL B, V94, P279; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; DIEDERICH L, 1994, BIOTECHNIQUES, V16, P916; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine C, 1998, BBA-GENE STRUCT EXPR, V1400, P29, DOI 10.1016/S0167-4781(98)00126-2; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MANIATAS T, 1982, MOL CLONING LAB MANU; Nurse P, 2000, J BIOL CHEM, V275, P4104, DOI 10.1074/jbc.275.6.4104; PENG H, 1993, J BIOL CHEM, V268, P24481; Schultz P, 1996, P NATL ACAD SCI USA, V93, P5936, DOI 10.1073/pnas.93.12.5936; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	21	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4099	4103		10.1074/jbc.275.6.4099	http://dx.doi.org/10.1074/jbc.275.6.4099			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660569	hybrid			2022-12-25	WOS:000085288800053
J	Prasad, R; Dianov, GL; Bohr, VA; Wilson, SH				Prasad, R; Dianov, GL; Bohr, VA; Wilson, SH			FEN1 stimulation of DNA polymerase beta mediates an excision step in mammalian long patch base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAP ENDONUCLEASE-1; PURIFIED PROTEINS; SUBSTRATE-BINDING; PHOSPHATE LYASE; SITE REPAIR; RECONSTITUTION; PATHWAY; 3'-EXO/ENDONUCLEASE; REQUIREMENT; MECHANISM	In mammalian cells, single-base lesions, such as uracil and abasic sites, appear to be repaired by at least two base excision repair (BER) subpathways: "single-nucleotide BER" requiring DNA synthesis of just one nucleotide and "long patch BER" requiring multi-nucleotide DNA synthesis. In single-nucleotide BER, DNA polymerase beta (beta-pol) accounts for both gap filling DNA synthesis and removal of the 5'-deoxyribose phosphate (dRP) of the abasic site, whereas the involvement of various DNA polymerases in long patch BER is less well understood. Recently, we found that beta-pol plays a role in mammalian cell extract-mediated long patch BER, in that formation of a key excision product, 5'-dRP-trinucleotide (5'-dRP-N-3), is dependent upon beta-pol (Dianov, G. L., Prasad, R., Wilson, S. H., and Bohr, V.A. (1999) J, Biol, Chem. 274, 13741-13743). The structure-specific endonuclease flap endonuclease 1 (FEN1) has also been suggested to be involved in long patch BER excision, Here, we demonstrate by immunodepletion experiments that 5'-dRP-N-3 excision in long patch BER of uracil-DNA in a human lymphoid cell extract is, indeed, dependent upon FEN1, Next, we reconstituted the excision step of long patch BER using purified human proteins and an oligonucleotide substrate with 5'-dRP at the margin of a one-nucleotide gap. Formation of the excision product 5'-dRP-N-3 was dependent upon both strand displacement DNA synthesis by beta-pol and FEN1 excision, FEN1 stimulated strand displacement DNA synthesis of beta-pol, FEN1 acting either alone, or without DNA synthesis by beta-pol, produced a two-nucleotide excision product, 5'-dRP-N-1, but not 5'-dRP-N-3. These results demonstrate that human FEN1 and beta-pol can cooperate in long patch BER excision and specify the predominant excision product seen with a cell extract.	NIEHS, NIH, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; NIA, NIH, Mol Genet Lab, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wilson, SH (corresponding author), NIEHS, NIH, Struct Biol Lab, 111 TW Alexander Dr,Bldg 101,Rm B246, Res Triangle Pk, NC 27709 USA.		Wilson, Samuel H/E-6644-2019; Bohr, Vilhelm/AAP-5931-2020	Wilson, Samuel H/0000-0002-1702-5293; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050158, Z01ES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Forsina G., 1996, J BIOL CHEM, V271, P9573; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; HORTON JK, 2000, IN PRESS J BIOL CHEM, V275; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; MANELY JL, 1980, P NATL ACAD SCI USA, V77, P3855; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; PRICE A, 1992, FEBS LETT, V300, P101, DOI 10.1016/0014-5793(92)80173-E; REIN DC, 1990, EUKARYOTIC NUCLEUS M, V1, P95; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Wilson SH, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P693; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	40	181	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4460	4466		10.1074/jbc.275.6.4460	http://dx.doi.org/10.1074/jbc.275.6.4460			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660619	hybrid			2022-12-25	WOS:000085288800103
J	Vennekens, R; Hoenderop, JGJ; Prenen, J; Stuiver, M; Willems, PHGM; Droogmans, G; Nilius, B; Bindels, RJM				Vennekens, R; Hoenderop, JGJ; Prenen, J; Stuiver, M; Willems, PHGM; Droogmans, G; Nilius, B; Bindels, RJM			Permeation and gating properties of the novel epithelial Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR CALCIUM-TRANSPORT; ENDOTHELIAL-CELLS; STORE DEPLETION; ION CHANNELS	The recently cloned epithelial Ca2+ channel (ECaC) constitutes the Ca2+ influx pathway in 1,25-dihydroxyvitamin Ds-responsive epithelia, We have combined patch-clamp analysis and fura-a fluorescence microscopy to functionally characterize ECaC heterologously expressed in HEK293 cells. The intracellular Ca2+ concentration in ECaC-expressing cells was closely correlated with the applied electrochemical Ca2+ gradient, demonstrating the distinctive Ca2+ permeability and constitutive-activation of ECaC, Cells dialyzed with 10 mn 1,2-bis(2-aminoph- enoxy)ethane-N,N,N',N'-tetraacetic acid displayed large inward currents through ECaC in response to voltage ramps. The corresponding current-voltage relationship showed pronounced inward rectification, Currents evoked by voltage steps to potentials below -40 mV partially inactivated with a biexponential timecourse, This inactivation was less pronounced if Ba2+ or Sr2+ replaced Ca2+ and was absent in Ca2+-free solutions, ECaC showed an anomalous mole fraction behavior. The permeability ratio P-CA:P-NA calculated from the reversal potential at 30 mM [Ca2+], was larger than 100, The divalent cation selectivity profile is Ca2+ > Mn2+ > Ba2+ similar to Sr2+. Repetitive stimulation of ECaC-expressing cells induced a decay of the current response, which was greatly reduced if Ca2+ was replaced by Ba2+ and was virtually abolished if [Ca2+], was lowered to 1 nar. In conclusion, ECaC is a Ca2+ selective channel, exhibiting Ca2+-dependent autoregulatory mechanisms, including fast inactivation and slow down-regulation.	Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, B-3000 Louvain, Belgium; Univ Nijmegen, Inst Cellular Signalling, Dept Cell Physiol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Inst Cellular Signalling, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	KU Leuven; Radboud University Nijmegen; Radboud University Nijmegen	Nilius, B (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Hoenderop, Joost G.J./H-8047-2014; Bindels, René JM/B-9824-2013; Vennekens, Rudi/AAQ-1664-2020; Willems, P.H.G.M./L-4759-2015	Hoenderop, Joost G.J./0000-0002-1816-8544; Bindels, René JM/0000-0003-1167-1339; Vennekens, Rudi/0000-0002-2564-5150; Willems, P.H.G.M./0000-0002-0915-1599; Stuiver, Marchel/0000-0003-3437-4468				BINDELS RJM, 1991, J AM SOC NEPHROL, V2, P1122; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; CHAO AC, 1995, J CLIN INVEST, V96, P1794, DOI 10.1172/JCI118225; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; FEHER JJ, 1992, AM J PHYSIOL, V262, pC517, DOI 10.1152/ajpcell.1992.262.2.C517; FRIEDMAN PA, 1995, PHYSIOL REV, V75, P429, DOI 10.1152/physrev.1995.75.3.429; Friedman PA, 1998, ANNU REV PHYSIOL, V60, P179, DOI 10.1146/annurev.physiol.60.1.179; Hille B., 1992, IONIC CHANNELS EXCIT, P337, DOI 10.1016/0014-5793(92)81020-M; Hoenderop JGJ, 1999, P NATL ACAD SCI USA, V96, P6084, DOI 10.1073/pnas.96.11.6084; Hoenderop JGJ, 1999, KIDNEY INT, V55, P225, DOI 10.1046/j.1523-1755.1999.00228.x; Hoenderop JGJ, 1999, BIOCHEM BIOPH RES CO, V261, P488, DOI 10.1006/bbrc.1999.1059; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; NILIUS B, 1994, J GEN PHYSIOL, V103, P787, DOI 10.1085/jgp.103.5.787; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Price CJ, 1999, J NEUROCHEM, V72, P634, DOI 10.1046/j.1471-4159.1999.0720634.x; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; VANOS CH, 1987, BIOCHIM BIOPHYS ACTA, V906, P195, DOI 10.1016/0304-4157(87)90012-8; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	25	238	249	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3963	3969		10.1074/jbc.275.6.3963	http://dx.doi.org/10.1074/jbc.275.6.3963			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660551	Green Published, hybrid			2022-12-25	WOS:000085288800035
J	Beck, DC; Ikegami, M; Na, CL; Zaltash, S; Johansson, J; Whitsett, JA; Weaver, TE				Beck, DC; Ikegami, M; Na, CL; Zaltash, S; Johansson, J; Whitsett, JA; Weaver, TE			The role of homodimers in surfactant protein B function in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PULMONARY SURFACTANT; NATURAL SURFACTANT; TRANSGENIC MICE; HOMEOSTASIS	Surfactant protein B (SP-B) is detected in the airways as a sulfhydryl-dependent dimer (M-r similar to 16,000). To test the hypothesis that formation of homodimers is critical for SP-B function, the cysteine residue reported to be involved in SP-B dimerization was mutated to serine (Cys(248) --> Ser) and the mutated protein was targeted to the distal respiratory epithelium of transgenic mice. Transgenic lines which demonstrated appropriate processing, sorting, and secretion of human SP-B monomer were crossed with SP-B +/- mice to achieve expression of human monomer in the absence of endogenous SP B dimer (hSP-B-mon, mSP-B-/-). In two of three transgenic lines, hSP-B-mon, mSP-B-/- mice had normal lung structure, complete processing of SP-C proprotein, well formed lamellar bodies, and normal longevity. Pulmonary function studies revealed an altered hysteresis curve for hSP-B-mon, mSP-B-/- mice relative to wild type mice. Large aggregate surfactant fractions from hSP-B-mon, mSP-B-/- mice resulted in higher minimum surface tension in vitro compared with surfactant from wild type mice. Surfactant lipids supplemented with 2% hSP-B monomer resulted in slower adsorption and higher surface tension than surfactant with 2% hSP-B dimer, Taken together, these data indicate a role for SP-B dimer in surface tension reduction in the alveolus.	Childrens Hosp, Med Ctr, Div Pulm Biol, TCHRF, Cincinnati, OH 45229 USA; Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden	Cincinnati Children's Hospital Medical Center; Karolinska Institutet	Weaver, TE (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, TCHRF, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Johansson, Jan/0000-0002-8719-4703	NHLBI NIH HHS [HL56285, HL36055, HL38859] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038859, R01HL056285, R37HL038859, R37HL056285, R01HL036055] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akinbi HT, 1997, J BIOL CHEM, V272, P9640; ALI SA, 1995, BIOTECHNIQUES, V18, P746; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; CURSTEDT T, 1987, EUR J BIOCHEM, V168, P255, DOI 10.1111/j.1432-1033.1987.tb13414.x; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; Hawgood S, 1998, BBA-MOL BASIS DIS, V1408, P150, DOI 10.1016/S0925-4439(98)00064-7; Ikegami M, 1998, AM J PHYSIOL-LUNG C, V275, pL247, DOI 10.1152/ajplung.1998.275.2.L247; Ikegami M, 1996, AM J PHYSIOL-LUNG C, V270, pL650, DOI 10.1152/ajplung.1996.270.4.L650; JOHANSSON J, 1991, BIOCHEMISTRY-US, V30, P6917, DOI 10.1021/bi00242a015; Lin S, 1999, J BIOL CHEM, V274, P19168, DOI 10.1074/jbc.274.27.19168; Lin S, 1996, BBA-MOL CELL RES, V1312, P177, DOI 10.1016/0167-4889(95)00201-4; MIZUNO K, 1995, PEDIATR RES, V37, P271, DOI 10.1203/00006450-199503000-00004; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; Perez-Gil J, 1998, BBA-MOL BASIS DIS, V1408, P203, DOI 10.1016/S0925-4439(98)00068-4; RIDER ED, 1993, AM REV RESPIR DIS, V147, P669, DOI 10.1164/ajrccm/147.3.669; Robertson B, 1998, BBA-MOL BASIS DIS, V1408, P346, DOI 10.1016/S0925-4439(98)00080-5; SCHOEL WM, 1994, BBA-GEN SUBJECTS, V1200, P281, DOI 10.1016/0304-4165(94)90169-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stark M, 1998, ANAL BIOCHEM, V265, P97, DOI 10.1006/abio.1998.2856; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Tokieda K, 1997, AM J PHYSIOL-LUNG C, V273, pL875, DOI 10.1152/ajplung.1997.273.4.L875; Vaccaro AM, 1999, NEUROCHEM RES, V24, P307, DOI 10.1023/A:1022530508763; VORBROKER DK, 1995, AM J PHYSIOL, V268, P647; Weaver TE, 1998, BBA-MOL BASIS DIS, V1408, P173, DOI 10.1016/S0925-4439(98)00066-0; YEI SP, 1994, AM J RESP CELL MOL, V11, P329, DOI 10.1165/ajrcmb.11.3.8086169; Yusen RD, 1999, AM J RESP CRIT CARE, V159, P411, DOI 10.1164/ajrccm.159.2.9806033; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	29	54	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3365	3370		10.1074/jbc.275.5.3365	http://dx.doi.org/10.1074/jbc.275.5.3365			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652327	hybrid			2022-12-25	WOS:000085146500049
J	Jefferies, CA; O'Neill, LAJ				Jefferies, CA; O'Neill, LAJ			Rad regulates interleukin 1-induced nuclear factor kappa B activation in an inhibitory protein kappa B alpha-independent manner by enhancing the ability of the p65 subunit to transactivate gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DEPENDENT TRANSCRIPTION; GTP-BINDING; SIGNAL-TRANSDUCTION; KINASE; PHOSPHORYLATION; RAC1; FAMILY; PATHWAYS; RECEPTOR	We have examined the involvement of Rac1 in nuclear factor kappa B (NF kappa B) activation by interleukin 1 (IL1). IL1 induced a rapid and sustained activation of Rad in the thymoma cell line EL4.NOB-1. Transient transfection with dominant negative RacN17 inhibited IL1-induced kappa B-dependent reporter gene expression but not I kappa B alpha degradation, whereas constitutively active RacV12 po tentiated KB-dependent reporter gene expression in response to IL1 but had no effects on its own. Using porcine aortic endothelial cells stably transfected with RacV12 or RacN17 under the control of an inducible promoter, we confirmed that RacV12 did not affect I kappa B alpha degradation, nor did RacN17 inhibit the nl-induced response. RacV12 was also unable to induce nuclear translocation of NF kappa B. These effects suggested a role for Rad in p65-mediated transactivation of NF kappa B, independent of I kappa B alpha regulation. In support of this we found that IL1 activated a pathway leading to increased p65 transactivation activity and that RacV12 alone could drive this response in both cell systems. Additionally, RacN17 inhibited IL1-driven p65-mediated transactivation. From data using specific inhibitors of p38 and p42/ p44 kinases we propose that both p38 and p42/p44 lie downstream of Rad on the nl pathway leading to enhanced transactivation by p65.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Univ Dublin Trinity Coll, Inst Biotechnol, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin	O'Neill, LAJ (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.	laoneill@tcd.ie	Jefferies, Caroline/AAI-1543-2021	Jefferies, Caroline/0000-0002-8879-6722; O'Neill, Luke/0000-0002-4333-2748				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis W, 1999, BIOCHEM J, V338, P387, DOI 10.1042/0264-6021:3380387; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Fitzgerald KA, 1999, J IMMUNOL, V162, P4920; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOPP TP, 1995, PROTEIN SCI, V4, P1851, DOI 10.1002/pro.5560040920; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Marmiroli S, 1998, FEBS LETT, V438, P49, DOI 10.1016/S0014-5793(98)01270-8; Matthews JS, 1999, CYTOKINE, V11, P643, DOI 10.1006/cyto.1998.0478; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; ONEILL LAJ, 1990, J BIOL CHEM, V265, P3146; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, J CELL SCI, P127; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIMMS JE, 1996, EUR CYTOKINE NETW, V7, P119; Singh R, 1999, J CLIN INVEST, V103, P1561, DOI 10.1172/JCI5754; STRICKER K, 1993, EUR J IMMUNOL, V23, P1475, DOI 10.1002/eji.1830230712; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Tang Y, 1999, MOL CELL BIOL, V19, P1881; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	45	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3114	3120		10.1074/jbc.275.5.3114	http://dx.doi.org/10.1074/jbc.275.5.3114			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652294	Green Published, hybrid			2022-12-25	WOS:000085146500016
J	Lammers, R; Lerch, MM; Ullrich, A				Lammers, R; Lerch, MM; Ullrich, A			The carboxyl-terminal tyrosine residue of protein-tyrosine phosphatase alpha mediates association with focal adhesion plaques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; RPTP-ALPHA; PTP-ALPHA; IN-VIVO; RECEPTOR; PHOSPHORYLATION; FAMILY; ADAPTER; DOMAINS; INSULIN	The receptor protein-tyrosine phosphatase alpha (pTP alpha) is involved in the activation of c-Src kinase as well as in down-regulation of the insulin signal. To investigate the role of PTP alpha in activation of the Src kinase in more detail we tried to overexpress this phosphatase in NIH3T3 fibroblasts. Although PTP alpha has been overexpressed in rat embryonic fibroblasts and in embryonic carcinoma cells and should increase mitogenic responses we were not able to achieve a detectable overexpression, In contrast, expression of partially (C442S) or completely inactive (C442S,C732S) PTP alpha or of phosphatase active PTP alpha containing mutation Y781F or Y798F was possible. The level of expression, however, was reduced to background after several passages of lines expressing PTP alpha YC442S,C732S and PTP alpha Y781F. When employed in a focus formation assay, only infection with virus encoding PTP alpha Y798F induced Src-dependent formation of foci. In immunofluorescence studies, PTP alpha C442S and PTP alpha Y781F but not PTP alpha Y798F colocalized with proteins found in focal adhesion plaques. Treatment of PTP alpha YC442S-overexpressing cells with vanadate abolished this colocalization and led to proteolytic processing of the phosphatase. We conclude that tyrosine 798 in PTP alpha is important for localization at focal adhesion plaques. Inhibition of phosphatases by vanadate treatment releases PTP alpha from focal adhesions.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Lammers, R (corresponding author), Univ Tubingen, Med Klin 4, Otfried Muller Str 10, D-72076 Tubingen, Germany.		Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263				Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BAR SD, 1993, CELL, V74, P83; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; FENDLY BM, 1990, CANCER RES, V50, P1550; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Helmke S, 1998, J CELL SCI, V111, P2465; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lammers R, 1998, BIOCHEM BIOPH RES CO, V242, P32, DOI 10.1006/bbrc.1997.7906; Lim KL, 1997, EUR J BIOCHEM, V245, P693, DOI 10.1111/j.1432-1033.1997.00693.x; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SU J, 1994, J BIOL CHEM, V269, P18731; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; Wang HY, 1996, ONCOGENE, V12, P2555; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	34	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3391	3396		10.1074/jbc.275.5.3391	http://dx.doi.org/10.1074/jbc.275.5.3391			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652331	hybrid			2022-12-25	WOS:000085146500053
J	Liu, YH; Witte, S; Liu, YC; Doyle, M; Elly, C; Altman, A				Liu, YH; Witte, S; Liu, YC; Doyle, M; Elly, C; Altman, A			Regulation of protein kinase C theta function during T cell activation by Lck-mediated tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; SIGNAL-TRANSDUCTION; PKC-THETA; MOLECULAR-CLONING; ANTIGEN RECEPTOR; GENETIC-EVIDENCE; SKELETAL-MUSCLE; FAMILY KINASES; DELTA; SRC	Protein kinase C theta (PKC theta) is a novel Ca2+-independent PKC isoform, which is selectively expressed in skeletal muscle and hematopoietic cells, especially T cells. In T cells, it colocalizes with the T cell antigen receptor (TCR).CD3 complex in antigen-stimulated T cells and is involved in the transcriptional activation of the interleukin-2 gene. In the present study, we report that PKC theta is tyrosine phosphorylated in Jurkat T cells upon TCR.CD3 activation. The Src family protein-tyrosine kinase, Lck, was critical in TCR-induced tyrosine phosphorylation of PKC theta. Lck phosphorylated and was associated with the regulatory domain of PKC theta both in vitro and in intact cells. This association was constitutive, but it was enhanced by T cell activation, with both Src-homology 2 and Src-homology 3 domains of Lck contributing to it. Tyrosine 90 (Tyr-90) in the regulatory domain of PKC theta was identified as the major phosphorylation site by Lck. A constitutively active mutant of PKC theta (A148E) could enhance proliferation of Jurkat T cells and synergized with ionomycin to induce nuclear factor of T cells activity. However, mutation of Tyr-90 into phenylalanine markedly reduced (or abolished) these activities. These results suggest that Lck plays an important role in tyrosine phosphorylation of PKC theta, which may in turn modulate the physiological functions of PKC theta during TCR-induced T cell activation.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Altman, A (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	amnon@liai.org		LIU, YUN-CAI/0000-0002-0996-7109	NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NCI NIH HHS [CA35299] Funding Source: Medline; NIAID NIH HHS [AI09881] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; AMREIN KE, 1993, P NATL ACAD SCI USA, V90, P10285, DOI 10.1073/pnas.90.21.10285; BAIER G, 1993, J BIOL CHEM, V268, P4997; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Bradford MD, 1998, EUR J MORPHOL, V36, P176; CHANG JD, 1993, J BIOL CHEM, V268, P14208; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; LIU F, 1994, BIOCHEM BIOPH RES CO, V200, P1570, DOI 10.1006/bbrc.1994.1630; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Liu YC, 1997, J BIOL CHEM, V272, P168; Meller N, 1996, MOL CELL BIOL, V16, P5782; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Moussazadeh M, 1998, FEBS LETT, V438, P225, DOI 10.1016/S0014-5793(98)01302-7; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	97	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3603	3609		10.1074/jbc.275.5.3603	http://dx.doi.org/10.1074/jbc.275.5.3603			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652356	hybrid			2022-12-25	WOS:000085146500078
J	Segouffin-Cariou, C; Billaud, M				Segouffin-Cariou, C; Billaud, M			Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; NERVE GROWTH-FACTOR; RET PROTOONCOGENE; CELL-SURVIVAL; DOCKING SITE; MEN 2A; PROTEIN; MUTATIONS; DOMAIN; SHC	The RET gene codes for a receptor tyrosine kinase that plays a crucial role during the development of both the enteric nervous system and the kidney. Germ line missense mutations at one of six codons specifying extracytoplasmic cysteines are responsible for two related cancer disorders as follows: multiple endocrine neoplasia type2A (MEN2A) and familial medullary thyroid carcinoma (FMTC).MEN2A and FMTC mutations result in a constitutive catalytic activity and as a consequence convert RET into a dominantly acting transforming gene. Although it has been shown that RET-MEN2 mutants activate several transduction pathways, their respective contribution to the neoplastic phenotype remains poorly understood. Over the past few years, it has become increasingly clear that the transforming ability of several viral and cellular oncoproteins depends on their capacity to activate phosphatidylinositol 3-kinase (PI3K), We now report that RET carrying a representative MEN2A mutation at Cys-634 (termed RET-MENSA) activates PI3K and its downstream effector, the serine/ threonine kinase AKT/protein kinase B. Previous studies have demonstrated that mutation of Tyr-1062, which is the intracellular docking site for Shc and Enigma on RET, abolishes the RET-MENSA transforming activity. We provide evidence that mutation of Tyr-1062 abrogates the binding of the p85 regulatory subunit of PI3K to RET-MENSA and the subsequent stimulation of the PI3K/AKT pathway. Furthermore, infection of rat fibroblasts with a retrovirus expressing a dominant-interfering form of PI3K suppresses RET-MEN2A-dependent transformation, whereas overexpression of AKT enhances the RET-MEN2A oncogenic potential. In summary, these data are consistent with the notion that PET-mediated cell-transforming effect is critically dependent on the activation of the PI3K/AKT pathway.	CNRS, Genet Lab, UMR 5641, F-69373 Lyon 08, France	Centre National de la Recherche Scientifique (CNRS)	Billaud, M (corresponding author), CNRS, Genet Lab, UMR 5641, Domaine Rockefeller,8 Ave Rockefeller, F-69373 Lyon 08, France.	billaud@univ-lyon1.fr	Billaud, Marc N/M-6954-2013					Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 1996, HUM MOL GENET, V5, P1577, DOI 10.1093/hmg/5.10.1577; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Marshall GM, 1997, CANCER RES, V57, P5399; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Melillo RM, 1999, CANCER RES, V59, P1120; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; MOTHE I, 1995, EUR J BIOCHEM, V228, P842, DOI 10.1111/j.1432-1033.1995.0842m.x; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Ozes ON, 1999, NATURE, V401, P82; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Sweetser DA, 1999, ONCOGENE, V18, P877, DOI 10.1038/sj.onc.1202376; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	64	179	182	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3568	3576		10.1074/jbc.275.5.3568	http://dx.doi.org/10.1074/jbc.275.5.3568			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652352	hybrid			2022-12-25	WOS:000085146500074
J	Besset, S; Vincourt, JB; Amalric, F; Girard, JP				Besset, S; Vincourt, JB; Amalric, F; Girard, JP			Nuclear localization of PAPS synthetase 1: a sulfate activation pathway in the nucleus of eukaryotic cells	FASEB JOURNAL			English	Article						sulfation; sulfate activation; PAPS synthesis; subcellular localization	HIGH ENDOTHELIAL VENULES; L-SELECTIN; TYROSINE SULFATION; P-SELECTIN; TYROSYLPROTEIN SULFOTRANSFERASE; CYTOSOLIC SULFOTRANSFERASES; 5'-PHOSPHOSULFATE KINASE; SACCHAROMYCES-CEREVISIAE; HEPARAN-SULFATE; ATP SULFURYLASE	Sulfation is a major modification of many molecules in eukaryotes that is dependent on the enzymatic synthesis of an activated sulfate donor, 3'-phosphoadenosine 5'-phosphosulfate (PAPS). While sulfate activation has long been assumed to occur in the cytosol, we show in this study that human PAPS synthetase 1 (PAPSS1), a bifunctional ATP sulfurylase/adenosine 5'-phosphosulfate (APS) kinase enzyme sufficient for PAPS synthesis, accumulates in the nucleus of mammalian cells, Nuclear targeting of the enzyme is mediated by its APS kinase domain and requires a catalytically dispensable 21 amino acid sequence at the amino terminus. Human PAPSS1 and Drosophila melanogaster PAPSS localize to the nucleus in yeast and relieve the methionine auxotrophy of ATP sulfurylase- or APS kinase-deficient strains, suggesting that PAPSS1 is fully functional in vivo when targeted to the nucleus. A second PAPS synthetase gene, designated PAPSS2, has recently been described, mutations of which are responsible for abnormal skeletal development in human spondyloepimetaphyseal dysplasia and murine brachymorphism. We found that PAPSS2, which localizes to the cytoplasm when ectopically expressed in mammalian cells, is relocated to the nucleus when coexpressed with PAPSS1. Taken together, these results indicate that a sulfation pathway might exist in the nucleus of eukaryotic cells.	CNRS, Inst Pharmacol & Biol Struct, Lab Biol Vasc, F-31077 Toulouse 4, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Girard, JP (corresponding author), CNRS, Inst Pharmacol & Biol Struct, Lab Biol Vasc, 205 Route Narbonne, F-31077 Toulouse 4, France.		GIRARD, Jean-Philippe/F-5229-2010	GIRARD, Jean-Philippe/0000-0002-9154-1691				BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Beisswanger R, 1998, P NATL ACAD SCI USA, V95, P11134, DOI 10.1073/pnas.95.19.11134; BHAVANANDAN VP, 1975, P NATL ACAD SCI USA, V72, P2032, DOI 10.1073/pnas.72.6.2032; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; BRION F, 1987, J NEUROCHEM, V48, P1171, DOI 10.1111/j.1471-4159.1987.tb05643.x; COATES SW, 1980, J BIOL CHEM, V255, P9225; Deyrup AT, 1998, J BIOL CHEM, V273, P9450, DOI 10.1074/jbc.273.16.9450; DONG JF, 1995, BLOOD, V86, P4175, DOI 10.1182/blood.V86.11.4175.bloodjournal86114175; Falany CN, 1997, FASEB J, V11, P1; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; FAROOQUI AA, 1980, INT J BIOCHEM, V12, P529, DOI 10.1016/0020-711X(80)90003-8; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; FERRARO A, 1991, BIOCHEM BIOPH RES CO, V178, P1365, DOI 10.1016/0006-291X(91)91044-D; Franzon VL, 1999, INT J BIOCHEM CELL B, V31, P613, DOI 10.1016/S1357-2725(98)00155-1; Girard JP, 1998, ADV EXP MED BIOL, V435, P55; Girard JP, 1998, FASEB J, V12, P603, DOI 10.1096/fasebj.12.7.603; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HOOPER LV, 1999, CHEM BIOL, V6, pR9; IMAI Y, 1993, NATURE, V361, P555; ISAAC RE, 1982, BIOCHEM J, V204, P127, DOI 10.1042/bj2040127; Jullien D, 1997, MECH DEVELOP, V68, P179, DOI 10.1016/S0925-4773(97)00136-6; Klaassen CD, 1997, FASEB J, V11, P404, DOI 10.1096/fasebj.11.6.9194521; KOIZUMI T, 1969, BIOCHIM BIOPHYS ACTA, V184, P106, DOI 10.1016/0304-4165(69)90104-4; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MARGOLIS RK, 1976, BIOCHIM BIOPHYS ACTA, V451, P465, DOI 10.1016/0304-4165(76)90141-0; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; ORKIN RW, 1976, DEV BIOL, V50, P82, DOI 10.1016/0012-1606(76)90069-5; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3695, DOI 10.1021/bi951303m; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; ROBBINS PW, 1958, J BIOL CHEM, V233, P681; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; ROSENTHAL E, 1995, GENE, V165, P243, DOI 10.1016/0378-1119(95)00450-K; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677	50	45	48	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					345	354		10.1096/fasebj.14.2.345	http://dx.doi.org/10.1096/fasebj.14.2.345			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657990				2022-12-25	WOS:000085184800013
J	Rochard, P; Rodier, A; Casas, F; Cassar-Malek, I; Marchal-Victorion, S; Daury, L; Wrutniak, C; Cabello, G				Rochard, P; Rodier, A; Casas, F; Cassar-Malek, I; Marchal-Victorion, S; Daury, L; Wrutniak, C; Cabello, G			Mitochondrial activity is involved in the regulation of myoblast differentiation through myogenin expression and activity of myogenic factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CHICK-EMBRYO CELLS; RESPIRATION-DEFICIENT; DOWN-REGULATION; DNA EXPRESSION; PROLIFERATION; INHIBITION; RAS; TRIIODOTHYRONINE; CHLORAMPHENICOL	To characterize the regulatory pathways involved in the inhibition of cell differentiation induced by the impairment of mitochondrial activity, me investigated the relationships occurring between organelle activity and myogenesis using an avian myoblast cell line (QM7). The inhibition of mitochondrial translation by chloramphenicol led to a potent block of myoblast differentiation, Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone and oligomycin, which affect the organelle at different levels, exerted a similar influence. In addition, we provided evidence that this phenomenon was not the result of an alteration in cell viability. Conversely, overexpression of the mitochondrial T3 receptor (p43) stimulated organelle activity and strongly potentiated myoblast differentiation. The involvement of mitochondrial activity in an actual regulation of myogenesis is further supported by results demonstrating that the muscle regulatory gene myogenin, in contrast to CMD1 (chicken MyoD) and myf5, is a specific transcriptional target of mitochondrial activity. Whereas myogenin mRNA and protein levels were down-regulated by chloramphenicol treatment, they were up-regulated by p43 overexpression, in a positive relationship with the expression level of the transgene, We also found that myogenin or CMD1 overexpression in chloramphenicol-treated myoblasts did not restore differentiation, thus indicating that an alteration in mitochondrial activity interferes with the ability of myogenic factors to induce terminal differentiation.	INRA, Unite Endocrinol Cellulaire, Lab Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France	INRAE	Cabello, G (corresponding author), INRA, Unite Endocrinol Cellulaire, Lab Differenciat Cellulaire & Croissance, Pl Viala, F-34060 Montpellier 1, France.		, Cassar-Malek/AAW-6386-2020	, Cassar-Malek/0000-0001-7407-1408; Francois, Casas/0000-0002-5535-8195; Daury, Laetitia/0000-0002-1296-7150				ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; BERGMEYER HU, 1963, METHOD ENZYMAT AN, V1, P443; BIGLER J, 1992, MOL CELL BIOL, V12, P2406, DOI 10.1128/MCB.12.5.2406; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; BRUNK CF, 1981, EXP CELL RES, V136, P305, DOI 10.1016/0014-4827(81)90008-2; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Casas F, 1999, MOL CELL BIOL, V19, P7913; CASSARMALEK I, 1994, ONCOGENE, V9, P2197; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GREGOIRE M, 1984, EUR J BIOCHEM, V142, P49, DOI 10.1111/j.1432-1033.1984.tb08249.x; Hamai N, 1997, CELL STRUCT FUNCT, V22, P421, DOI 10.1247/csf.22.421; HERZBERG NH, 1993, BIOCHIM BIOPHYS ACTA, V1181, P63, DOI 10.1016/0925-4439(93)90091-E; HIRAYAMA E, 1995, CELL STRUCT FUNCT, V20, P377, DOI 10.1247/csf.20.377; KANEKO T, 1988, MOL CELL BIOL, V8, P3311, DOI 10.1128/MCB.8.8.3311; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KOROHODA W, 1993, FOLIA HISTOCHEM CYTO, V31, P9; LAENG H, 1988, EXP CELL RES, V179, P222, DOI 10.1016/0014-4827(88)90361-8; LEBLONDLAROUCHE L, 1979, J GEN VIROL, V44, P323, DOI 10.1099/0022-1317-44-2-323; Luo Y, 1997, P NATL ACAD SCI USA, V94, P9705, DOI 10.1073/pnas.94.18.9705; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MORAIS R, 1980, BIOCHEM BIOPH RES CO, V94, P71, DOI 10.1016/S0006-291X(80)80189-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Orrenius S, 1997, CELL DEATH DIFFER, V4, P427, DOI 10.1038/sj.cdd.4400272; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Rochard P, 1996, J CELL PHYSIOL, V168, P239, DOI 10.1002/(SICI)1097-4652(199608)168:2<239::AID-JCP2>3.0.CO;2-Q; Russo S, 1997, ONCOGENE, V14, P63, DOI 10.1038/sj.onc.1200805; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Snedecor G.W., 1961, STAT METHODS; VANDENBOGERT C, 1992, J CELL PHYSIOL, V152, P632, DOI 10.1002/jcp.1041520323; VAYSSIERE JL, 1992, IN VITRO CELL DEV-AN, V28A, P763; Wang H, 1997, BBA-GENE STRUCT EXPR, V1352, P325, DOI 10.1016/S0167-4781(97)00035-3; Wang H, 1997, BIOCHEMISTRY-US, V36, P15371, DOI 10.1021/bi971946x; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Wharton DC., 1967, METHOD ENZYMOL, P245; WRUTNIAK C, 1995, J BIOL CHEM, V270, P16347, DOI 10.1074/jbc.270.27.16347; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	40	149	156	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2733	2744		10.1074/jbc.275.4.2733	http://dx.doi.org/10.1074/jbc.275.4.2733			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644737	hybrid			2022-12-25	WOS:000085128000069
J	Strovel, ET; Wu, DQ; Sussman, DJ				Strovel, ET; Wu, DQ; Sussman, DJ			Protein phosphatase 2C alpha dephosphorylates axin and activates LEF-1-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; BETA-CATENIN; FUNCTIONAL INTERACTION; NEGATIVE REGULATOR; CELL POLARITY; PHOSPHORYLATION; DROSOPHILA; GSK3-BETA; APC; TRANSDUCTION	The Dishevelled (Dvl) gene family encodes cytoplasmic proteins that are necessary for Wnt signal transduction. Utilizing the yeast two-hybrid system, we identified protein phosphatase 2C alpha (PP2C) as a Dvl-PDZ domain-interacting protein. PP2C exists in a complex with Dvl, beta-catenin, and Axin, a negative regulator of Wnt signaling. In a Wnt-responsive LEF-1 reporter gene assay, expression of PP2C activates transcription and also elicits a synergistic response with beta-catenin and Wnt-1. In addition, PP2C expression relieves Axin-mediated repression of LEF-1-dependent transcription. PP2C utilizes Axin as a substrate both in vitro and in vivo and decreases its half-life. These results indicate that PP2C is a positive regulator of Wnt signal transduction and mediates its effects through the dephosphorylation of Axin.	Univ Maryland, Sch Med, Div Human Genet, Baltimore, MD 21201 USA; Univ Rochester, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University System of Maryland; University of Maryland Baltimore; University of Rochester	Sussman, DJ (corresponding author), Univ Maryland, Sch Med, Div Human Genet, 655 W Baltimore St, Baltimore, MD 21201 USA.				NATIONAL CANCER INSTITUTE [R01CA063929] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA63929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; ChinSang ID, 1996, GENE DEV, V10, P2314, DOI 10.1101/gad.10.18.2314; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Dale TC, 1998, BIOCHEM J, V329, P209; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Steitz SA, 1996, IN VITRO CELL DEV-AN, V32, P441, DOI 10.1007/BF02723007; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; Takafuta T, 1998, J BIOL CHEM, V273, P17531, DOI 10.1074/jbc.273.28.17531; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; THEISEN H, 1994, DEVELOPMENT, V120, P347; Wagner U, 1996, J CELL SCI, V109, P1537; Wagner U, 1997, FEBS LETT, V411, P369, DOI 10.1016/S0014-5793(97)00733-3; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	39	92	94	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2399	2403		10.1074/jbc.275.4.2399	http://dx.doi.org/10.1074/jbc.275.4.2399			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644691	hybrid			2022-12-25	WOS:000085128000023
J	Worn, A; der Maur, AA; Escher, D; Honegger, A; Barberis, A; Pluckthun, A				Worn, A; der Maur, AA; Escher, D; Honegger, A; Barberis, A; Pluckthun, A			Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN ANTIBODY; LEUCINE-ZIPPER; ESCHERICHIA-COLI; INTRACELLULAR IMMUNIZATION; SACCHAROMYCES-CEREVISIAE; THERMODYNAMIC STABILITY; BINDING PROTEINS; GENE ACTIVATION; SCFV FRAGMENT; LIGHT-CHAIN	A cellular assay system for measuring the activity of cytoplasmically expressed anti-GCN4 scFv fragments directed against the Gcn4p dimerization domain was established in the budding yeast Saccharomyces cerevisiae. The inhibitory potential of different constitutively expressed anti-GCN4 scFv intrabodies was monitored by measuring the activity of beta-galactosidase expressed from a GCN4-dependent reporter gene. The in vivo performance of these scFv intrabodies in specifically decreasing reporter gene activity was related to their in vitro stability, measured by denaturant induced equilibrium unfolding. A framework-engineered stabilized version showed significantly improved activity, while a destabilized point mutant of the anti-GCN4 wild-type showed decreased effects in vivo. These results indicate that stability engineering can result in improved performance of scFv fragments as intrabodies. Increasing the thermodynamic stability appears to be an essential factor for improving the yield of functional scFv in the reducing environment of the cytoplasm, where the conserved intradomain disulfides of antibody fragments cannot form.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Zurich, ESBATech Inc, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich; University of Zurich	Pluckthun, A (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	plueckthun@biocfebs.unizh.ch	Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306; Honegger, Annemarie/0000-0002-3378-3967				Albrecht G, 1998, J BIOL CHEM, V273, P12696, DOI 10.1074/jbc.273.21.12696; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Berger C, 1998, FEBS LETT, V425, P14, DOI 10.1016/S0014-5793(98)00156-2; Berger C, 1999, FEBS LETT, V450, P149, DOI 10.1016/S0014-5793(99)00458-5; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; BIOCCA S, 1994, BIO-TECHNOL, V12, P396, DOI 10.1038/nbt0494-396; BIOCCA S, 1995, TRENDS CELL BIOL, V5, P248, DOI 10.1016/S0962-8924(00)89019-4; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; Cardinale A, 1998, FEBS LETT, V439, P197, DOI 10.1016/S0014-5793(98)01369-6; CARLSON JR, 1988, MOL CELL BIOL, V8, P2638, DOI 10.1128/MCB.8.6.2638; Cattaneo A, 1999, TRENDS BIOTECHNOL, V17, P115, DOI 10.1016/S0167-7799(98)01268-2; CHRUNYK BA, 1993, PROTEIN ENG, V6, P733, DOI 10.1093/protein/6.7.733; Cohen PA, 1998, ONCOGENE, V17, P2445, DOI 10.1038/sj.onc.1202190; DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075; Escher D, 1997, MOL GEN GENET, V256, P456, DOI 10.1007/s004380050589; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; Frisch C, 1996, FOLD DES, V1, P431, DOI 10.1016/S1359-0278(96)00059-4; Gargano N, 1997, J GEN VIROL, V78, P2591, DOI 10.1099/0022-1317-78-10-2591; Ge L, 1995, ANTIBODY ENG, P229; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOTO Y, 1979, J BIOCHEM-TOKYO, V86, P1433, DOI 10.1093/oxfordjournals.jbchem.a132661; Grim JE, 1998, BIOCHEM BIOPH RES CO, V250, P699, DOI 10.1006/bbrc.1998.9391; Hanes J, 1998, P NATL ACAD SCI USA, V95, P14130, DOI 10.1073/pnas.95.24.14130; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Jung S, 1997, PROTEIN ENG, V10, P959, DOI 10.1093/protein/10.8.959; Kabat E. A., 1991, SEQUENCES PROTEINS I; Kaiser C, 1994, METHODS YEAST GENETI, P169; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Leder L, 1995, BIOCHEMISTRY-US, V34, P16509, DOI 10.1021/bi00050a035; Lindner P, 1997, BIOTECHNIQUES, V22, P140, DOI 10.2144/97221rr01; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; Martineau P, 1998, J MOL BIOL, V280, P117, DOI 10.1006/jmbi.1998.1840; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Nieba L, 1997, PROTEIN ENG, V10, P435, DOI 10.1093/protein/10.4.435; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tewari D, 1998, J IMMUNOL, V161, P2642; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WENDT H, 1994, J AM CHEM SOC, V116, P6973, DOI 10.1021/ja00094a077; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3; Worn A, 1999, BIOCHEMISTRY-US, V38, P8739, DOI 10.1021/bi9902079; Worn A, 1998, BIOCHEMISTRY-US, V37, P13120, DOI 10.1021/bi980712q; ZITZEWITZ JA, 1995, BIOCHEMISTRY-US, V34, P12812, DOI 10.1021/bi00039a042	56	101	126	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2795	2803		10.1074/jbc.275.4.2795	http://dx.doi.org/10.1074/jbc.275.4.2795			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644744	hybrid			2022-12-25	WOS:000085128000076
J	Brooks, CC; Scherer, PE; Cleveland, K; Whittemore, JL; Lodish, HF; Cheatham, B				Brooks, CC; Scherer, PE; Cleveland, K; Whittemore, JL; Lodish, HF; Cheatham, B			Pantophysin is a phosphoprotein component of adipocyte transport vesicles and associates with GLUT4-containing vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED TRANSLOCATION; SYNAPTOPHYSIN GENE FAMILY; SYNAPTIC VESICLE; 3T3-L1 ADIPOCYTES; MEMBRANE-PROTEIN; SUBCELLULAR-LOCALIZATION; POTENTIAL MECHANISM; GLUCOSE-TRANSPORT; PLASMA-MEMBRANE; RAT ADIPOCYTES	Pantophysin, a protein related to the neuroendocrine-specific synaptophysin, recently has been identified in non-neuronal tissues. In the present study, Northern blots showed that pantophysin mRNA was abundant in adipose tissue and increased during adipogenesis of 3T3-L1 cells. Immunoblot analysis of subcellular fractions showed pantophysin present exclusively in membrane fractions and relatively evenly distributed in the plasma membrane and internal membrane fractions. Sucrose gradient ultracentrifugation demonstrated that pantophysin and GLUT4 exhibited overlapping distribution profiles. Furthermore, immunopurified GLUT4 vesicles contained pantophysin, and both GLUT4 and pantophysin were depleted from this vesicle population following treatment with insulin. Additionally, a subpopulation of immunopurified pantophysin vesicles contained insulin-responsive GLUT4, Consistent with the interaction of synaptophysin with vesicle-associated membrane protein 2 in neuroendocrine tissues, pantophysin associated with vesicle-associated membrane protein 2 in adipocytes, Furthermore, in [P-32]orthophosphate-labeled cells, pantophysin was phosphorylated in the basal state. This phosphorylation was unchanged in response to insulin; however, insulin stimulated the phosphorylation of a 77-kDa protein associated with alpha-pantophysin immunoprecipitates. Although the functional role of pantophysin in vesicle trafficking is unclear, its presence on GLUT4 vesicles is consistent with the emerging role of soluble N-ethylmaleimide-sensitive protein receptor (SNARE) factor complex and related proteins in regulated vesicle transport in adipocytes. In addition, pantophysin may provide a marker for the analysis of other vesicles in adipocytes.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Massachusetts Institute of Technology (MIT); Whitehead Institute	Cheatham, B (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.		Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047618, R01DK051668, R01DK047618] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07938] Funding Source: Medline; NIDDK NIH HHS [DK47618, DK51668] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asermely KE, 1996, LIFE SCI, V59, P2113, DOI 10.1016/S0024-3205(96)00568-1; BALDINI G, 1995, P NATL ACAD SCI USA, V92, P4284, DOI 10.1073/pnas.92.10.4284; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BARNEKOW A, 1990, ONCOGENE, V5, P1019; BIXBY JL, 1992, MOL BRAIN RES, V13, P339, DOI 10.1016/0169-328X(92)90217-Y; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; Cormont M, 1996, MOL CELL BIOL, V16, P6879; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ESHKIND LG, 1995, CELL TISSUE RES, V282, P423, DOI 10.1007/s004410050493; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Haass NK, 1996, J CELL BIOL, V134, P731, DOI 10.1083/jcb.134.3.731; HUDSON AW, 1995, P NATL ACAD SCI USA, V92, P5895, DOI 10.1073/pnas.92.13.5895; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KITAGAWA K, 1989, BIOCHIM BIOPHYS ACTA, V1014, P83, DOI 10.1016/0167-4889(89)90244-9; LEUBE RE, 1994, J CELL BIOL, V127, P1589, DOI 10.1083/jcb.127.6.1589; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LEUBE RE, 1994, DIFFERENTIATION, V56, P163, DOI 10.1046/j.1432-0436.1994.5630163.x; LINDSTEDT AD, 1991, J PHYSIOL-LONDON, V85, P90; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; Mastick CC, 1997, ENDOCRINOLOGY, V138, P2391, DOI 10.1210/en.138.6.2391; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; RUBENSTEIN JL, 1993, SYNAPSE, V13, P161, DOI 10.1002/syn.890130207; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1993, CELL, V75, P1; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; Takeshima H, 1998, BIOCHEM J, V331, P317, DOI 10.1042/bj3310317; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Thoidis G, 1998, P NATL ACAD SCI USA, V95, P183, DOI 10.1073/pnas.95.1.183; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; WADHWA R, 1993, FEBS LETT, V315, P193, DOI 10.1016/0014-5793(93)81161-R; Wang GY, 1997, J CELL SCI, V110, P505; WASHBOURNE P, 1995, BIOCHEM J, V305, P721, DOI 10.1042/bj3050721; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHONG CZ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P235, DOI 10.1016/0167-4781(92)90495-L	56	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2029	2036		10.1074/jbc.275.3.2029	http://dx.doi.org/10.1074/jbc.275.3.2029			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636906	hybrid			2022-12-25	WOS:000084940000069
J	Nam, SW; Clair, T; Campo, CK; Lee, HY; Liotta, LA; Stracke, ML				Nam, SW; Clair, T; Campo, CK; Lee, HY; Liotta, LA; Stracke, ML			Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells	ONCOGENE			English	Article						autotaxin; invasion; metastasis; motility; ras	MOTILITY-STIMULATING PROTEIN; SURFACE-ANTIGENS; EXPRESSION; CLONING; GROWTH; BRAIN; SITE	Autotaxin (ATX), an exo-nucleotide pyrophosphatase and phosphodiesterase, was originally isolated as a potent stimulator of tumor cell motility. In order to study whether ATX expression affects motility-dependent processes such as invasion and metastasis, we stably transfected full-length ATX cDNA into two nonexpressing cell lines, parental and ras-transformed NIH3T3 (clone7) cells. The effect of ATX secretion on in vitro cell motility was variable, The ras-transformed, ATX-secreting subclones had enhanced motility to ATX as chemoattractant, but there was little difference in the motility responses of NIH3T3 cells transfected with atx, an inactive mutant gene, or empty vector, In MatrigelTM invasion assays, all subclones, which secreted enzymatically active ATX, demonstrated greater spontaneous and ATX-stimulated invasion than appropriate controls. This difference in invasiveness was not caused by differences in gelatinase production, which was constant within each group of transfectants, In vivo studies with athymic nude mice demonstrated that injection of atx-transfected NIH3T3 cells resulted in a weak tumorigenic capacity with few experimental metastases. Combination of ATX expression with ras transformation produced cells with greatly amplified tumorigenesis and metastatic potential compared to ras-transformed controls, Thus, ATX appears to augment cellular characteristics necessary for tumor aggressiveness.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nam, SW (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Room 2A33, Bethesda, MD 20892 USA.			Alewine, Christine/0000-0003-1661-0957				Aznavoorian S, 1996, J BIOL CHEM, V271, P3247, DOI 10.1074/jbc.271.6.3247; Bachner D, 1998, DEV DYNAM, V213, P398; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Deissler H, 1999, FASEB J, V13, P657, DOI 10.1096/fasebj.13.6.657; Deterre P, 1996, J IMMUNOL, V157, P1381; Fuss B, 1997, J NEUROSCI, V17, P9095; Huang RP, 1998, INT J CANCER, V77, P880, DOI 10.1002/(SICI)1097-0215(19980911)77:6<880::AID-IJC14>3.0.CO;2-5; JU WD, 1991, NEW BIOL, V3, P380; Kawagoe H, 1997, CANCER RES, V57, P2516; KINDLERROHRBORN A, 1985, DIFFERENTIATION, V30, P53, DOI 10.1111/j.1432-0436.1985.tb00513.x; KINDLERROHRBORN A, 1994, DIFFERENTIATION, V57, P215, DOI 10.1007/s002580050057; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; Mulvaney PT, 1998, INT J CANCER, V78, P46, DOI 10.1002/(SICI)1097-0215(19980925)78:1<46::AID-IJC9>3.0.CO;2-X; MURATA J, 1994, J BIOL CHEM, V269, P30479; Stefan C, 1999, BBA-MOL CELL RES, V1450, P45, DOI 10.1016/S0167-4889(99)00031-2; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TAKAHASHI T, 1970, J EXP MED, V132, P1181, DOI 10.1084/jem.132.6.1181; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	23	152	155	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					241	247		10.1038/sj.onc.1203263	http://dx.doi.org/10.1038/sj.onc.1203263			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645002				2022-12-25	WOS:000084844400009
J	Brown, LA; Yang, SH; Hair, A; Galanis, A; Sharrocks, AD				Brown, LA; Yang, SH; Hair, A; Galanis, A; Sharrocks, AD			Molecular characterization of a zebrafish TCF ETS-domain transcription factor	ONCOGENE			English	Article						ETS-domain; ternary complex factor; transcription factors; zebrafish	ACTIVATED PROTEIN-KINASE; TERNARY COMPLEX FACTORS; DNA-BINDING SPECIFICITIES; SERUM RESPONSE ELEMENT; SIGNAL-TRANSDUCTION; FACTORS ELK-1; C-FOS; MAP KINASES; PATHWAYS; P38	The ternary complex factor (TCF) subfamily of ETS-transcription factors represent key nuclear targets of the MAP kinase pathways. Members of this subfamily are classified by the presence of several conserved domains for DNA binding, interaction with SRF, interaction with MAP kinases and transcriptional activation. In this study we have isolated a further member of this subfamily (TCF-1) from zebrafish, The protein product of zebrafish TCF-1 (zTCF-1), shares sequence similarity with the mammalian TCFs in all four conserved domains, with highest overall similarity to SAP-1. Zebrafish TCF-1 is expressed throughout zebrafish embryonic development and exhibits typical TCF DNA binding characteristics, with the B-box being required for interaction with SRF, Of the mammalian TCFs, its DNA binding specificity resembles Elk-1. zTCF-1 is a target for both the growth factor/mitogen-activated and stress-activated MAP kinase cascades in vitro and in vivo. However, differential targeting occurs, with the profile of its activation closely resembling that of mammalian SAP-1, Together, our results demonstrate that the TCFs have been functionally conserved during vertebrate development.	Univ Newcastle Upon Tyne, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Sharrocks, AD (corresponding author), Univ Manchester, Sch Biol Sci, Stoppard Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Galanis, Alex/ABF-4762-2020	Galanis, Alex/0000-0001-9991-3173	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWN AL, 1998, UNPUB MECH DEV; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CANO E, 1995, J CELL SCI, V108, P3599; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GILLE H, 1992, NATURE, V358, P415; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MagnaghiJaulin L, 1996, FEBS LETT, V391, P247, DOI 10.1016/0014-5793(96)00745-4; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Plant KE, 1996, NUCLEIC ACIDS RES, V24, P3514, DOI 10.1093/nar/24.18.3514; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO VN, 1994, ONCOGENE, V9, P1855; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SETH A, 1992, J BIOL CHEM, V267, P24796; Sgambato V, 1998, J NEUROSCI, V18, P214; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; SHARROCKS AD, 1995, FEBS LETT, V368, P77, DOI 10.1016/0014-5793(95)00604-8; Shore P, 1996, MOL CELL BIOL, V16, P3338; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZHAO LJ, 1993, GENE, V137, P345, DOI 10.1016/0378-1119(93)90032-X	43	11	12	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7985	7993		10.1038/sj.onc.1203197	http://dx.doi.org/10.1038/sj.onc.1203197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637509				2022-12-25	WOS:000084634600007
J	Erdman, RA; Shellenberger, KE; Overmeyer, JH; Maltese, WA				Erdman, RA; Shellenberger, KE; Overmeyer, JH; Maltese, WA			Rab24 is an atypical member of the Rab GTPase family - Deficient GTPase activity, GDP dissociation inhibitor interaction, and prenylation of Rab24 expressed in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYL TRANSFERASE; ESCORT PROTEIN; BINDING PROTEIN; ENDOPLASMIC-RETICULUM; MEMBRANE-FUSION; CDNA CLONING; TRANSPORT; MUTANTS; EXOCYTOSIS; COMPLEX	The function of Rab24 is currently unknown, but other members of the Rab GTPase family are known to participate in various protein trafficking pathways. Rab proteins are thought to cycle on and off vesicle membranes in conjunction with changes in their guanine nucleotide state. The present studies indicate that Rab24 possesses several unusual characteristics that distinguish it from other Rab proteins. 1) Based on [P-32]orthophosphate labeling of protein-bound nucleotide, Rab24 exists predominantly in the GTP state when expressed in cultured cells. The low GTPase activity is related to the presence of serine instead of glutamine at the position cognate to Ras Gln-61. 2) Posttranslational geranylgeranylation of Rab24, determined by metabolic labeling or detergent partitioning assays, is inefficient when compared with other Rabs ending with the common CXC and CC carboxyl-terminal motifs. This is partly due to the presence of two histidines distal to the target cysteines, but also involves other unidentified features. 3) Most of the Rab24 in the cytoplasmic compartment of cultured cells is not associated with Rab GDP dissociation inhibitors. These findings indicate that, if Rab24 functions in vesicular transport processes, it may operate through a novel mechanism that does not depend on GTP hydrolysis or GDP dissociation inhibitor-mediated recycling.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA; Penn State Univ, Coll Med, Weis Ctr Res, Danville, PA 17822 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Maltese, WA (corresponding author), Med Coll Ohio, Dept Biochem & Mol Biol, 3035 Arlington Ave, Toledo, OH 43614 USA.				NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER; NCI NIH HHS [CA34569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anant JS, 1998, BIOCHEMISTRY-US, V37, P12559, DOI 10.1021/bi980881a; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1990, J BIOL CHEM, V265, P13007; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; COOK DG, 1994, METHOD CELL BIOL, V43, P289; DER CJ, 1988, ONCOGENE, V3, P105; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; DUGAN JM, 1995, J BIOL CHEM, V270, P10982, DOI 10.1074/jbc.270.18.10982; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; Foster R, 1996, MOL CELL BIOL, V16, P2689; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HOFFENBERG S, 1995, J BIOL CHEM, V270, P5048, DOI 10.1074/jbc.270.10.5048; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MALTESE WA, 1984, ANN NEUROL, V16, P250, DOI 10.1002/ana.410160215; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NEWMAN CMH, 1992, J BIOL CHEM, V267, P11329; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OLKKONEN VM, 1993, J CELL SCI, V106, P249; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; Overmeyer JH, 1998, MOL BIOL CELL, V9, P223, DOI 10.1091/mbc.9.1.223; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Shen F, 1996, J BIOL CHEM, V271, P3692; Sheridan KM, 1998, J MOL NEUROSCI, V10, P121, DOI 10.1007/BF02737123; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Valencia A, 1995, GUIDEBOOK SMALL GTPA, P12; Valentijn JA, 1996, EUR J CELL BIOL, V71, P129; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963; Wilson AL, 1996, J BIOL CHEM, V271, P10932, DOI 10.1074/jbc.271.18.10932; Wilson AL, 1996, BIOCHEM J, V318, P1007, DOI 10.1042/bj3181007; Wilson AL, 1998, BIOCHEM J, V333, P497, DOI 10.1042/bj3330497; Wu WJ, 1997, J BIOL CHEM, V272, P26153, DOI 10.1074/jbc.272.42.26153	60	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3848	3856		10.1074/jbc.275.6.3848	http://dx.doi.org/10.1074/jbc.275.6.3848			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660536	hybrid			2022-12-25	WOS:000085288800020
J	Vanhanen, S; West, M; Kroon, JTM; Lindner, N; Casey, J; Cheng, Q; Elborough, KM; Slabas, AR				Vanhanen, S; West, M; Kroon, JTM; Lindner, N; Casey, J; Cheng, Q; Elborough, KM; Slabas, AR			A consensus sequence for long-chain fatty-acid alcohol oxidases from Candida identifies a family of genes involved in lipid omega-oxidation in yeast with homologues in plants and bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TROPICALIS; PROTEIN; DNA; CDNA; ACYLTRANSFERASE; CYTOCHROMES; ENCODES; MALTOSA	The yeast Candida cloacae is capable of growing on alkanes and fatty acids as sole carbon sources. Transfer of cultures from a glucose medium to one containing oleic acid induced seven proteins of M-r 102,000, 73,000, 61,000, 54,000, and 46,000 and two in the region of M-r 45,000 and repressed a protein of M-x 64,000, The induction of the M-r 73,000 protein reached a 7-fold maximum 24 h after induction. The protein was confirmed by its enzyme: activity to be a long-chain fatty-acid alcohol oxidase (LC-FAO) and purified to homogeneity from microsomes by a rapid procedure involving hydrophobic chromatography, An internal peptide of 30 amino acids was sequenced. A 1100-base pair cDNA fragment containing the LC-FAO peptide coding sequence was used to isolate a single exon genomic clone containing the full-length coding sequence of an LC-FAO (fao1), The fool gene product was expressed in Escherichia coli and was translated as a functional long-chain alcohol oxidase, which was present in the membrane fraction. In addition, full-length coding sequences for a Candida tropicalis LC-FAO (faoT) and a second C. cloacae LC-FAO (fao2) were isolated. The DNA sequences obtained had open reading frames of 2094 (fao1), 2091 (fao2), and 2112 (faoT) base pairs. The derived amino acid sequences of fao2 and faoT showed 89.4 and 76.2% similarities to fool, The fao1 gene is much more highly induced on alkane than is fao2, Although this study describes the first known DNA sequences encoding LC-FAOs from any source, there are unassigned Arabidopsis sequences and an unassigned Mycobacterium sequence in the Gen-Bank(TM) Data Bank that show strong homology to the described LC-FAO sequences. The conservation of sequence between yeast, plants, and bacteria suggests that an as yet undescribed family of long-chain fatty-acid oxidases exists in both eukaryotes and prokaryotes.	Univ Durham, Dept Biol Sci, Lipid Mol Biol Grp, Durham DH1 3LE, England; Uniqema Int, NL-2800 AA Gouda, Netherlands; Unilever Res, Colworth House, Sharnbrook MK44 1LQ, Beds, England	Durham University; Unilever	Slabas, AR (corresponding author), Univ Durham, Dept Biol Sci, Lipid Mol Biol Grp, South Rd, Durham DH1 3LE, England.	A.R.Slabas@Durham.ac.uk	Cheng, Qi/C-9922-2018; Kroon, Johan Theodorus Maria/S-8415-2019	Cheng, Qi/0000-0003-1269-6386; Kroon, Johan Theodorus Maria/0000-0003-2086-6074				AKABORI S, 1972, Patent No. 5502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AP, 1994, PLANT MOL BIOL, V26, P211, DOI 10.1007/BF00039533; BROWN AP, 1995, PLANT MOL BIOL, V29, P267, DOI 10.1007/BF00043651; CASEY J, 1990, J GEN MICROBIOL, V136, P1197, DOI 10.1099/00221287-136-7-1197; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DICKINSON FM, 1992, BIOCHEM J, V282, P325, DOI 10.1042/bj2820325; ELBOROUGH KM, 1994, PLANT MOL BIOL, V24, P21, DOI 10.1007/BF00040571; GEISSLER J, 1981, FEBS LETT, V126, P152, DOI 10.1016/0014-5793(81)80229-3; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HALL TC, 1978, P NATL ACAD SCI USA, V75, P3196, DOI 10.1073/pnas.75.7.3196; IKUTA S, 1977, J BIOCHEM-TOKYO, V82, P1741, DOI 10.1093/oxfordjournals.jbchem.a131872; ILCHENKO AP, 1984, MIKROBIOLOGIYA, V50, P903; KATO N, 1976, EUR J BIOCHEM, V64, P341, DOI 10.1111/j.1432-1033.1976.tb10307.x; KEMP GD, 1988, APPL MICROBIOL BIOT, V29, P370, DOI 10.1007/BF00265821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MAUERSBERGER S, 1992, APPL MICROBIOL BIOT, V37, P66; MOREAU RA, 1979, ARCH BIOCHEM BIOPHYS, V194, P422, DOI 10.1016/0003-9861(79)90636-2; Nishida Y, 1996, Audiol Neurootol, V1, P31; Ohkuma M, 1998, J BIOL CHEM, V273, P3948, DOI 10.1074/jbc.273.7.3948; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; PICATAGGIO S, 1992, BIO-TECHNOL, V10, P894, DOI 10.1038/nbt0892-894; PICATAGGIO S, 1991, Patent No. 9106660; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAHM H, 1982, METHOD ENZYMOL, V89, P424; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGLARD D, 1992, YEAST, V8, P1065, DOI 10.1002/yea.320081209; SAVITHA J, 1991, FEMS MICROBIOL LETT, V80, P221, DOI 10.1111/j.1574-6968.1991.tb04665.x; Schou C, 1998, BIOCHEM J, V330, P565, DOI 10.1042/bj3300565; TYKARSKA E, 1990, J PROTEIN CHEM, V9, P83, DOI 10.1007/BF01024988; VRELINK A, 1991, J MOL BIOL, V219, P533; WERNER W, 1970, FRESEN Z ANAL CHEM, V252, P224; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	35	33	43	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4445	4452		10.1074/jbc.275.6.4445	http://dx.doi.org/10.1074/jbc.275.6.4445			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660617	hybrid			2022-12-25	WOS:000085288800101
J	Begg, GE; Harper, SL; Morris, MB; Speicher, DW				Begg, GE; Harper, SL; Morris, MB; Speicher, DW			Initiation of spectrin dimerization involves complementary electrostatic interactions between paired triple-helical bundles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-ASSOCIATION; ERYTHROCYTE SPECTRIN; BETA-SPECTRIN; CRYSTAL-STRUCTURE; IONIC-STRENGTH; ALPHA-SPECTRIN; PROTEIN; BINDING; DOMAIN; SITE	The spectrin heterodimer is formed by the antiparallel lateral association of an alpha and a beta subunit, each of which comprises largely a series of homologous triple-helical motifs. Initiation of dimer assembly involves strong binding between complementary motifs near the actin-binding end of the dimer, In this study, the mechanism of lateral spectrin association at this dimer nucleation site was investigated using the analytical ultracentrifuge to analyze heterodimers formed from recombinant peptides containing two or four homologous motifs from each subunit (alpha 20-21/beta 1-2; alpha 18-21/beta 1-4). Both the two-motif and four-motif dimer associations were weakened substantially with increasing salt concentration, indicating that electrostatic interactions are important for the dimer initiation process. Modeling of the electrostatic potential on the surface of the alpha 20 and beta 2 motifs showed that the side of the motifs comprising the A and B helices is the most favorable for association, with an area of positive electrostatic potential on the AB face of the beta 2 motif opposite negative potential on the AB face of the alpha 20 motif and vise versa. Protease protection analysis of the alpha 20-21/beta 1-2 dimer showed that multiple trypsin and proteinase K sites in the A helices of the beta 2 and alpha 21 motifs become buried upon dimer formation. Together, these data support a model where complementary long range electrostatic interactions on the AB faces of the triple-helical motifs in the dimer nucleation site initiate the correct pairing of motifs, i.e. alpha 21-beta 1 and alpha 20-beta 2. After initial docking of these complementary triple-helical motifs, this association is probably stabilized by subsequent formation of stronger hydrophobic interactions in a complex involving the A helices of both subunits and possibly most of the AB faces. The beta subunit A helix in particular appears to be buried in the dimer interface.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Sydney, Dept Pharm, Sydney, NSW 2006, Australia	The Wistar Institute; University of Sydney	Speicher, DW (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	speicher@wistar.upenn.edu	Morris, Michael/AAP-6590-2021	Morris, Michael/0000-0002-1286-4784	NCI NIH HHS [CA10815] Funding Source: Medline; NHLBI NIH HHS [HL38794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0; Begg GE, 1997, BIOCHEMISTRY-US, V36, P6977, DOI 10.1021/bi970186n; COLE N, 1992, BIOCHIM BIOPHYS ACTA, V1121, P23, DOI 10.1016/0167-4838(92)90332-8; DeSilva TM, 1997, BIOCHEMISTRY-US, V36, P3991, DOI 10.1021/bi962412j; Fujita T, 1998, BIOCHEMISTRY-US, V37, P264, DOI 10.1021/bi971966z; Gervasoni P, 1998, BIOCHEMISTRY-US, V37, P11660, DOI 10.1021/bi980258q; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; KENNEDY SP, 1994, J BIOL CHEM, V269, P11400; LABRAKE CC, 1993, BIOCHEMISTRY-US, V32, P10296, DOI 10.1021/bi00090a004; Laura RP, 1998, BIOCHEMISTRY-US, V37, P11264, DOI 10.1021/bi9809674; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; Lusitani D, 1998, BIOCHEMISTRY-US, V37, P16546, DOI 10.1021/bi9811462; MAZDZANOWSKI J, 1992, ELECTROPHORESIS, V13, P59, DOI 10.1002/elps.1150130112; McCoy AJ, 1997, J MOL BIOL, V268, P570, DOI 10.1006/jmbi.1997.0987; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Pascual J, 1996, FEBS LETT, V383, P201, DOI 10.1016/0014-5793(96)00251-7; SAHR KE, 1990, J BIOL CHEM, V265, P4434; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; SETO MH, 1995, PROTEIN SCI, V4, P655; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; Ursitti JA, 1996, J BIOL CHEM, V271, P6636, DOI 10.1074/jbc.271.12.6636; VIEL A, 1994, P NATL ACAD SCI USA, V91, P10839, DOI 10.1073/pnas.91.23.10839; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEBER PC, 1980, NATURE, V286, P302, DOI 10.1038/286302a0; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; ZHONG M, 1995, P NATL ACAD SCI USA, V92, P2111, DOI 10.1073/pnas.92.6.2111	40	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3279	3287		10.1074/jbc.275.5.3279	http://dx.doi.org/10.1074/jbc.275.5.3279			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652315	hybrid			2022-12-25	WOS:000085146500037
J	Ferreira, C; Bucchini, D; Martin, ME; Levi, S; Arosio, P; Grandchamp, B; Beaumont, C				Ferreira, C; Bucchini, D; Martin, ME; Levi, S; Arosio, P; Grandchamp, B; Beaumont, C			Early embryonic lethality of H ferritin gene deletion in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; ERYTHROLEUKEMIA-CELLS; IRON-METABOLISM; L-CHAIN; SUBUNIT; MOUSE; IDENTIFICATION; HETEROPOLYMERS; EXPRESSION; BINDING	Ferritin molecules play an important role in the control of intracellular iron distribution and in the constitution of long term iron stores. In vitro studies on recombinant ferritin subunits have shown that the ferroxidase activity associated with the H subunit is necessary for iron uptake by the ferritin molecule, whereas the L subunit facilitates iron core formation inside the protein shell. However, plant and bacterial ferritins have only a single type of subunit which probably fulfills both functions. To assess the biological significance of the ferroxidase activity associated with the H subunit, we disrupted the H ferritin gene (Fth) in mice by homologous recombination. Fth(+/-) mice are healthy, fertile, and do not differ significantly from their control littermates, However, Fth(-/-) embryos die between 3.5 and 9.5 days of development, suggesting that there is no functional redundancy between the two ferritin subunits and that, in the absence of H subunits, L ferritin homopolymers are not able to maintain iron in a bioavailable and nontoxic form. The pattern of expression of the wild type Fth gene in 9.5-day embryos is suggestive of an important function of the H ferritin gene in the heart.	Fac Xavier Bichat, INSERM, U409, F-75018 Paris, France; Fac Cochin Port Royal, INSERM, U257, F-75014 Paris, France; Hosp San Raffaele, DIBIT, Unit Prot Engn, I-20132 Milan, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Beaumont, C (corresponding author), Fac Xavier Bichat, INSERM, U409, 16 Rue Henri Huchard, F-75018 Paris, France.		arosio, paolo/E-6817-2010; arosio, paolo/S-3272-2019; levi, sonia/A-3161-2015	arosio, paolo/0000-0002-5343-8992; levi, sonia/0000-0002-5092-0847; Ferreira, Chrystophe/0000-0002-1990-278X				BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; Bensidhoum M, 1998, TRANSGENICS, V2, P275; COCCIA EM, 1992, MOL CELL BIOL, V12, P3015, DOI 10.1128/MCB.12.7.3015; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; Levi S, 1998, BLOOD, V91, P4180, DOI 10.1182/blood.V91.11.4180.411k38_4180_4187; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1988, J BIOL CHEM, V263, P18086; Levy JE, 1999, NAT GENET, V21, P396, DOI 10.1038/7727; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; MUNRO HN, 1978, PHYSIOL REV, V58, P317, DOI 10.1152/physrev.1978.58.2.317; Picard V, 1996, BLOOD, V87, P2057; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; Ponka P, 1998, SEMIN HEMATOL, V35, P35; RYAN TP, 1992, CRIT REV TOXICOL, V22, P119, DOI 10.3109/10408449209146308; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; Schalinske KL, 1998, J BIOL CHEM, V273, P3740, DOI 10.1074/jbc.273.6.3740; THEIL EC, 1976, BRIT J HAEMATOL, V33, P437, DOI 10.1111/j.1365-2141.1976.tb03561.x; THEIL EC, 1981, DEV BIOL, V84, P481, DOI 10.1016/0012-1606(81)90419-X; Tsuji Y, 1998, J BIOL CHEM, V273, P2984, DOI 10.1074/jbc.273.5.2984; Wai SN, 1996, MOL MICROBIOL, V20, P1127, DOI 10.1111/j.1365-2958.1996.tb02633.x; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676	25	210	220	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3021	3024		10.1074/jbc.275.5.3021	http://dx.doi.org/10.1074/jbc.275.5.3021			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652280	hybrid			2022-12-25	WOS:000085146500002
J	Guy, LG; Delvoye, N; Wall, L				Guy, LG; Delvoye, N; Wall, L			Expression of a human beta-globin transgene in mice with the CACC motif and upstream sequences deleted from the promoter still depends on erythroid Kruppel-like factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; HUMAN GAMMA-GLOBIN; DOMINANT CONTROL REGION; GENE-EXPRESSION; TRANSCRIPTION FACTOR; FACTOR EKLF; CHROMATIN STRUCTURE; BINDING; ELEMENT; THALASSEMIA	Mice in which the erythroid Kruppel-like Factor (EKLF) gene is inactivated die in fetal life due to downregulation of the beta-globin gene. Results have suggested that EKLF functions through the proximal CACC motif of the beta-globin promoter. For example, natural mutations of this element that fail to bind EKLF give reduced gene expression and the ability of EKLF to activate reporter genes in co-transfection assays is dependent on an intact CACC, Here, removal of the CACC motif and upstream promoter sequences from the beta-globin gene resulted in reduced expression in transgenic mice. However, breeding onto an EKLF-/- background demonstrated that a CACC-less beta-globin transgene remains highly dependent on EKLF. Hence, although the beta-globin gene partly depends on the proximal CACC motif for expression, it is unlikely that the major mechanism of gene activation by EKLF is through this element. We also show that a lacZ reporter gene linked to the beta-globin promoter, with or without the CACC box present, is actually expressed higher in EKLF-/- fetuses than in wild type animals, suggesting that EKLF may be able to act as an inhibitor of transcription with certain transgene configurations.	Univ Montreal, Ctr Hosp, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	Wall, L (corresponding author), Univ Montreal, Ctr Hosp, Inst Canc Montreal, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.							ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; Asano H, 1999, MOL CELL BIOL, V19, P3571; Asano H, 1998, MOL CELL BIOL, V18, P102, DOI 10.1128/MCB.18.1.102; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DELVOYE NL, 1993, MOL CELL BIOL, V13, P6969, DOI 10.1128/MCB.13.11.6969; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; Donze D, 1996, BLOOD, V88, P4051, DOI 10.1182/blood.V88.10.4051.bloodjournal88104051; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; FELSENFELD G, 1993, GENE, V135, P119, DOI 10.1016/0378-1119(93)90056-9; FENG WC, 1994, J BIOL CHEM, V269, P1493; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; Gillemans N, 1998, GENE DEV, V12, P2863, DOI 10.1101/gad.12.18.2863; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Guy LG, 1998, BLOOD, V91, P2259, DOI 10.1182/blood.V91.7.2259.2259_2259_2263; Guy LG, 1996, EMBO J, V15, P3713, DOI 10.1002/j.1460-2075.1996.tb00741.x; HANCOMBE O, 1991, GENE DEV, V5, P1387; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; KULOZIK AE, 1991, BLOOD, V77, P2054; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; ORKIN SH, 1984, J BIOL CHEM, V259, P8679; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; PERKINS AC, 1995, NATURE, V375, P318; PETERSON KR, 1993, MOL CELL BIOL, V13, P4836, DOI 10.1128/MCB.13.8.4836; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Stamatoyannopolous G., 1994, MOL BASIS BLOOD DIS, P107; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; Tewari R, 1998, EMBO J, V17, P2334, DOI 10.1093/emboj/17.8.2334; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894	37	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3675	3680		10.1074/jbc.275.5.3675	http://dx.doi.org/10.1074/jbc.275.5.3675			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652365	hybrid			2022-12-25	WOS:000085146500087
J	Pi, M; Garner, SC; Flannery, P; Spurney, RF; Quarles, LD				Pi, M; Garner, SC; Flannery, P; Spurney, RF; Quarles, LD			Sensing of extracellular cations in CasR-deficient osteoblasts - Evidence for a novel cation-sensing mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; CALCIUM (CA-O(2+))-SENSING RECEPTOR; NEONATAL SEVERE HYPERPARATHYROIDISM; CELL-LINE; MC3T3-E1 OSTEOBLASTS; CA2+-SENSING RECEPTOR; EXPRESSION; PROLIFERATION; MUTATIONS; STIMULATION	We isolated osteoblastic cell lines from wild-type (CasR(+/+)) and receptor null (CasR(-/-)) mice to investigate whether CasR is present in osteoblasts and accounts for their responses to extracellular cations, Osteoblasts from both CasR(+/+) and CasR(-/-) mice displayed an initial period of cell replication followed by a culture duration-dependent increase in alkaline phosphatase activity, expression of osteocalcin, and mineralization of extracellular matrix. In addition, a panel of extracellular cations, including aluminum and the CasR agonists gadolinium and calcium, stimulated DNA synthesis, activated a transfected serum response element-luciferase reporter construct, and inhibited agonist-induced cAMP in CasR(-/-) osteoblasts. The functional responses to these cations were identical in CasR(+/+) and CasR(-/-) osteoblasts, Thus, the absence of CasR alters neither the maturational profile of isolated osteoblast cultures nor their in vitro responses to extracellular cations. In addition, CasR transcripts could not be detected by reverse transcription-polymerase chain reaction with mouse specific primers in either CasR(+/+) or CasR(-/-) osteoblasts, and immunoblot analysis with a CasR-specific antibody was negative for CasR protein expression in osteoblasts, The presence of a cation-sensing response in osteoblasts from CasR(-/-) mice indicates the existence of a novel osteoblastic extracellular cation-sensing mechanism.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University	Quarles, LD (corresponding author), Duke Univ, Med Ctr, Dept Med, POB 3036, Durham, NC 27710 USA.			Pi, Min/0000-0002-0319-8003; Quarles, L. Darryl/0000-0002-5082-7896	NIAMS NIH HHS [R01-AR43468, R01-AR37308] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037308, R01AR043468] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bapty BW, 1998, KIDNEY INT, V53, P583, DOI 10.1046/j.1523-1755.1998.00790.x; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Chattopadhyay N, 1997, BIOL CHEM, V378, P759; DEMAREST KT, 1997, J BONE MINER RES  S1, V12, pS413; ECAROTCHARRIER B, 1983, J CELL BIOL, V96, P639, DOI 10.1083/jcb.96.3.639; Emanuel RL, 1996, MOL ENDOCRINOL, V10, P555, DOI 10.1210/me.10.5.555; Goldsmith PK, 1997, J BONE MINER RES, V12, P1780, DOI 10.1359/jbmr.1997.12.11.1780; Hartle JE, 1996, J BONE MINER RES, V11, P789; Hinson TK, 1997, GENOMICS, V45, P279, DOI 10.1006/geno.1997.4943; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; House MG, 1997, J BONE MINER RES, V12, P1959, DOI 10.1359/jbmr.1997.12.12.1959; Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448; KANATANI M, 1991, BIOCHEM BIOPH RES CO, V181, P1425, DOI 10.1016/0006-291X(91)92098-5; Kovacs CS, 1998, J CLIN INVEST, V101, P2812, DOI 10.1172/JCI2940; Mailland M, 1997, ENDOCRINOLOGY, V138, P3601, DOI 10.1210/en.138.9.3601; *NAT RES COUNC, 1985, DHHS PUBL NIH; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; Pi M, 1999, J BONE MINER RES, V14, P1310, DOI 10.1359/jbmr.1999.14.8.1310; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; QUARLES LD, 1992, J BONE MINER RES, V7, P683; QUARLES LD, 1994, J CELL BIOCHEM, V56, P106, DOI 10.1002/jcb.240560115; Quarles LD, 1997, J BONE MINER RES, V12, P393, DOI 10.1359/jbmr.1997.12.3.393; QUARLES LD, 1991, ENDOCRINOLOGY, V128, P3144, DOI 10.1210/endo-128-6-3144; Riccardi D, 1996, AM J PHYSIOL-RENAL, V271, pF951, DOI 10.1152/ajprenal.1996.271.4.F951; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Spurney RF, 1999, KIDNEY INT, V55, P1750, DOI 10.1046/j.1523-1755.1999.00432.x; STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420; SUGIMOTO TJ, 1993, J BONE MINER RES, V12, P1445; Xiao ZS, 1998, AM J PHYSIOL-ENDOC M, V275, pE700, DOI 10.1152/ajpendo.1998.275.4.E700; Yamaguchi T, 1998, J BONE MINER RES, V13, P1530, DOI 10.1359/jbmr.1998.13.10.1530; Yamaguchi T, 1998, ENDOCRINOLOGY, V139, P3561, DOI 10.1210/en.139.8.3561; Yamaguchi T, 1998, BIOCHEM BIOPH RES CO, V243, P753, DOI 10.1006/bbrc.1998.8178; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597	36	77	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3256	3263		10.1074/jbc.275.5.3256	http://dx.doi.org/10.1074/jbc.275.5.3256			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652312	hybrid			2022-12-25	WOS:000085146500034
J	Rajamohan, F; Pugmire, MJ; Kurinov, IV; Uckun, FM				Rajamohan, F; Pugmire, MJ; Kurinov, IV; Uckun, FM			Modeling and alanine scanning mutagenesis studies of recombinant pokeweed antiviral protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN A-CHAIN; RIBOSOME-INACTIVATING PROTEINS; GENERATE SCHEMATIC DIAGRAMS; SUBSTRATE-ANALOGS; BINDING; PROGRAM; RNA; MECHANISM; SITE	Phytolacca americana-derived naturally occurring ribosome inhibitory protein pokeweed antiviral protein (PAP) is an N-glycosidase that catalytically removes a specific adenine residue from the stem loop of ribosomal RNA. We have employed molecular modeling studies using a novel model of PAP-RNA complexes and site-directed mutagenesis combined with bioassays to evaluate the importance of the residues at the catalytic site and a putative RNA binding active center cleft between the catalytic site and C-terminal domain for the enzymatic deadenylation of ribosomal RNA by PAP, As anticipated, alanine substitutions by site-directed mutagenesis of the PAP active site residues Tyr(72), Tyr(123), Glu(176), and Arg(179) that directly participate in the catalytic deadenylation of RNA resulted in greater than 3 logs of loss in depurinating and ribosome inhibitory activity. Similarly, alanine substitution of the conserved active site residue Trp(208), which results in the loss of stabilizing hydrophobic interactions with the ribose as well as a hydrogen bond to the phosphate backbone of the RNA substrate, caused greater than 3 logs of loss in enzymatic activity, By comparison, alanine substitutions of residues (KD29)-K-28, (FE81)-F-80, (SR112)-S-111, (FL167)-F-166 that are distant from the active site did not significantly reduce the enzymatic activity of PAP. Our modeling studies predicted that the residues of the active center cleft could via electrostatic interactions contribute to both the correct orientation and stable binding of the substrate RNA molecule in the active site pocket. Nota bly, alanine substitutions of the highly conserved, charged, and polar residues of the active site cleft including (48)Ky(49), (RR68)-R-67, (VN70)-V-69, and (FND92)-F-90 substantially reduced the depurinating and ribosome inhibitory activity of PAP, These results provide unprecedented evidence that besides the active site residues of PAP, the conserved, charged, and polar side chains located at its active center cleft also play a critical role in the PAP-mediated depurination of ribosomal RNA.	Parker Hughes Inst, Biotherapy Program, Roseville, MN 55113 USA; Parker Hughes Inst, Dept Prod Engn, Roseville, MN 55113 USA; Parker Hughes Inst, Dept Biol Struct, Roseville, MN 55113 USA; Parker Hughes Inst, Dept Biochem, Roseville, MN 55113 USA; Parker Hughes Inst, Dept Virol, Roseville, MN 55113 USA		Rajamohan, F (corresponding author), Parker Hughes Inst, Biotherapy Program, 2657 Patton Rd, Roseville, MN 55113 USA.			Uckun, Fatih M./0000-0001-9334-183X				AGO H, 1994, EUR J BIOCHEM, V225, P369, DOI 10.1111/j.1432-1033.1994.00369.x; BRAVI G, 1995, J MOL GRAPHICS, V13, P83, DOI 10.1016/0263-7855(94)00014-J; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; DALLAL JA, 1978, FEBS LETT, V89, P257, DOI 10.1016/0014-5793(78)80230-0; ENDO Y, 1988, J BIOL CHEM, V263, P8735; ENDO Y, 1987, J BIOL CHEM, V262, P5908; GESSNER SL, 1980, J BIOL CHEM, V255, P3251; HARDESTY WMB, 1979, METHOD ENZYMOL, V33, P316; HARTLEY MR, 1991, FEBS LETT, V290, P65, DOI 10.1016/0014-5793(91)81227-Y; HUANG QC, 1995, BIOCHEM J, V309, P285, DOI 10.1042/bj3090285; IRVIN JD, 1983, PHARMACOL THERAPEUT, V21, P371, DOI 10.1016/0163-7258(83)90061-X; IRVIN JD, 1975, ARCH BIOCHEM BIOPHYS, V169, P522, DOI 10.1016/0003-9861(75)90195-2; IRVIN JD, 1992, PHARMACOL THERAPEUT, V55, P279, DOI 10.1016/0163-7258(92)90053-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurinov IV, 1999, PROTEIN SCI, V8, P1765, DOI 10.1110/ps.8.9.1765; Luscombe NM, 1997, NUCLEIC ACIDS RES, V25, P4940, DOI 10.1093/nar/25.24.4940; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MONTANARO L, 1975, BIOCHEM J, V146, P127, DOI 10.1042/bj1460127; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MONZINGO AF, 1993, J MOL BIOL, V233, P705, DOI 10.1006/jmbi.1993.1547; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; *MSI, 1991, INS US GUID; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olson MA, 1997, PROTEINS, V27, P80, DOI 10.1002/(SICI)1097-0134(199701)27:1<80::AID-PROT9>3.0.CO;2-R; Rajamohan F, 1999, PROTEIN EXPRES PURIF, V16, P359, DOI 10.1006/prep.1999.1084; Rajamohan F, 1999, BIOCHEM BIOPH RES CO, V260, P453, DOI 10.1006/bbrc.1999.0922; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WELLS JA, 1991, METHOD ENZYMOL, V202, P390	29	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3382	3390		10.1074/jbc.275.5.3382	http://dx.doi.org/10.1074/jbc.275.5.3382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652330	hybrid			2022-12-25	WOS:000085146500052
J	Strom, DK; Nipp, J; Westendorf, JJ; Linggi, B; Lutterbach, B; Downing, JR; Lenny, N; Hiebert, SW				Strom, DK; Nipp, J; Westendorf, JJ; Linggi, B; Lutterbach, B; Downing, JR; Lenny, N; Hiebert, SW			Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; GRANULOCYTE DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; FUSION PROTEIN; GENE-PRODUCT; DNA-BINDING; T(8-21); TRANSACTIVATION; PROMOTER	AML-l-encoded transcription factor, AML-1B, regulates numerous hematopoietic-specific genes. Inappropriate expression of AML-1-family proteins is oncogenic in cell culture systems and in mice. To understand the oncogenic functions of AML-1, we established cell lines expressing AML-1B to examine the role of AML-1 in the cell cycle. DNA content analysis and bromodeoxyuridine pulse-chase studies indicated that entry into the S phase of the cell cycle was accelerated by up to 4 h in AML-1B-expressing 32D.3 myeloid progenitor cells as compared with control cells or cells expressing E2F-1. However, AML-1B was not able to induce continued cell cycle progression in the absence of growth factors. The DNA binding and transactivation domains of AML-1B were required for altering the cell cycle. Thus, AML-1B is the first transcription factor that affects the timing of the mammalian cell cycle.	Vanderbilt Univ, Dept Biochem, Ingram Canc Ctr, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Ingram Canc Ctr, Sch Med, Nashville, TN 37232 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	Vanderbilt University; Vanderbilt University; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Hiebert, SW (corresponding author), Vanderbilt Univ, Dept Biochem, Ingram Canc Ctr, Sch Med, Med Res Bldg 2,Rm 512,23rd & Pierce, Nashville, TN 37232 USA.		Downing, James R./N-8102-2018		NCI NIH HHS [R01-CA77274, R01-CA64140] Funding Source: Medline; NIA NIH HHS [R01 AG13726] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064140, R01CA077274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013726] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Jun DY, 1997, MOL CELLS, V7, P537; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kurokawa M, 1996, ONCOGENE, V12, P883; LENNY N, 1995, ONCOGENE, V11, P1761; Lenny N, 1997, MOL BIOL REP, V24, P157, DOI 10.1023/A:1006859700409; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Rubnitz JE, 1997, PEDIATRICS, V100, P101, DOI 10.1542/peds.100.1.101; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Tanaka Y, 1998, ONCOGENE, V17, P699, DOI 10.1038/sj.onc.1201985; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	45	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3438	3445		10.1074/jbc.275.5.3438	http://dx.doi.org/10.1074/jbc.275.5.3438			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652337	hybrid			2022-12-25	WOS:000085146500059
J	Tsai, SC; Pasumarthi, KBS; Pajak, L; Franklin, M; Patton, B; Wang, H; Henzel, WJ; Stults, JT; Field, LJ				Tsai, SC; Pasumarthi, KBS; Pajak, L; Franklin, M; Patton, B; Wang, H; Henzel, WJ; Stults, JT; Field, LJ			Simian virus 40 large T antigen binds a novel Bcl-2 homology domain 3-containing proapoptosis protein in the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVAL-PROMOTING PROTEINS; CARDIAC GENE-TRANSCRIPTION; SIMIAN-VIRUS-40 LARGE-T; PROGRAMMED CELL-DEATH; NECROSIS-FACTOR-ALPHA; TRANSGENIC MICE; DNA-SYNTHESIS; DILATED CARDIOMYOPATHY; VENTRICULAR MYOCYTES; ADULT MYOCARDIUM	A 193-kDa SV40 large T antigen (T-Ag)-binding protein, designated p193, was identified and cloned. Inspection of the deduced amino acid sequence revealed the presence of a short motif similar to the Bcl-2 homology (BH) domain 3, suggesting that p193 may be a member of a family of apoptosis promoting proteins containing only BH3 motifs, In support of this, p193 expression promoted apoptosis in NIH-3T3 cells. Deletion of the BH3 motif abolished p193 apoptosis activity, p193-induced apoptosis was antagonized by co-expression of Bcl-X-L. Immune cytologic analysis indicated that p193 is localized to the cytoplasm of transfected cells. p193-induced apoptosis was also antagonized by co-expression of T-Ag, which resulted in the cytoplasmic localization of both proteins. The p193 binding site was mapped to an N-terminal region of T-Ag previously implicated in transforming activity. These results suggest that T-Ag possesses an antiapoptosis activity, independent of p53 sequestration, which is actuated by T-Ag/p193 binding in the cytoplasm.	Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Roche Holding; Genentech	Field, LJ (corresponding author), James Whitcomb Riley Hosp Children, Ctr Pediat Res, 702 Barnhill Dr,Rm 2666, Indianapolis, IN 46202 USA.	ljfield@iupui.edu		Henzel, William/0000-0003-2940-3797; Pasumarthi, Kishore/0000-0001-9317-076X				Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Anversa P, 1998, LAB INVEST, V78, P767; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bishopric NH, 1997, J BIOL CHEM, V272, P20584, DOI 10.1074/jbc.272.33.20584; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; DAUD AI, 1993, AM J PHYSIOL, V264, pH1693, DOI 10.1152/ajpheart.1993.264.5.H1693; DAVIS D, 1986, EXP CELL RES, V166, P94, DOI 10.1016/0014-4827(86)90510-0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Ellison KE, 1996, J MOL CELL CARDIOL, V28, P1385, DOI 10.1006/jmcc.1996.0130; ESSER C, 1995, CYTOMETRY, V21, P382, DOI 10.1002/cyto.990210411; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; Geng YJ, 1999, CIRC RES, V84, P34; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Henzel William J., 1994, Methods (Orlando), V6, P239, DOI 10.1006/meth.1994.1026; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; KAUFMANN R, 1994, INT J MASS SPECTROM, V131, P355, DOI 10.1016/0168-1176(93)03876-N; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KIM KK, 1994, J BIOL CHEM, V269, P22607; KIM KK, 1995, GENOMICS, V28, P520, DOI 10.1006/geno.1995.1184; Kim KK, 1996, J BIOL CHEM, V271, P29255, DOI 10.1074/jbc.271.46.29255; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOHRMAN DC, 1992, J VIROL, V66, P1752, DOI 10.1128/JVI.66.3.1752-1760.1992; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Liu Y, 1996, J CELL BIOL, V133, P325, DOI 10.1083/jcb.133.2.325; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; MARSILIO E, 1991, J VIROL, V65, P5647, DOI 10.1128/JVI.65.10.5647-5652.1991; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; NEVINS JR, 1992, SCIENCE, V258, P424; Nomura N, 1994, DNA Res, V1, P251, DOI 10.1093/dnares/1.5.251; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEN A, 1988, J BIOL CHEM, V263, P19132; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; STENMAN S, 1975, INT J CANCER, V15, P547, DOI 10.1002/ijc.2910150403; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	72	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3239	3246		10.1074/jbc.275.5.3239	http://dx.doi.org/10.1074/jbc.275.5.3239			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652310	hybrid			2022-12-25	WOS:000085146500032
J	Natochin, M; Muradov, KG; McEntaffer, RL; Artemyev, NO				Natochin, M; Muradov, KG; McEntaffer, RL; Artemyev, NO			Rhodopsin recognition by mutant G(s)alpha containing C-terminal residues of transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT COMPLEX; ALPHA-SUBUNIT; ADP-RIBOSYLATION; BINDING-SITES; RECEPTOR; GTP; ACTIVATION; HYDROLYSIS; MUTATIONS; CHIMERAS	The C-terminal regions of the heterotrimeric Gr protein ru-subunits play key roles in selective activation of G proteins by their cognate receptors, In this study, mutant G(S)alpha proteins with substitutions by C-terminal residues of transducin (G(t)alpha) mere analyzed for their interaction with light-activated rhodopsin (R*) to delineate the critical determinants of the G(t)alpha/R* coupling, In contrast to G(S)alpha, a chimeric G(S)alpha/G(t)alpha protein containing only 11 C-terminal residues from transducin was capable of binding to and being potently activated by R*, Our results suggest that Gys(347) and Gly(348) are absolutely essential, whereas Asp(346) is more modestly involved in the G(t) activation by R*. In addition, the analysis of the intrinsic nucleotide exchange in mutant G(S)alpha indicated an interaction between the C terminus and the switch II region in G(t)alpha.GDP. Mutant G(s)alpha containing the G(t)alpha C terminus and substitutions of Asn(239) and Asp(240) (switch II) by the corresponding C(t)alpha residues, Glu(212) and Gly(213), displayed significant reductions in spontaneous guanosine 5'-O-(3-thiotriphosphate)-binding rates to the levels approaching those in G,cu, Communication between the C terminus and switch II of G(t)alpha does not appear essential for the activational coupling between G, and R*, but may represent one of the mechanisms by which G alpha subunits control intrinsic nucleotide exchange.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.			Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Artemyev NO, 1997, BIOCHEMISTRY-US, V36, P4188, DOI 10.1021/bi963002y; Bae H, 1999, J BIOL CHEM, V274, P14963, DOI 10.1074/jbc.274.21.14963; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Natochin M, 1998, BIOCHEMISTRY-US, V37, P13776, DOI 10.1021/bi981155a; Natochin M, 1999, J BIOL CHEM, V274, P7865, DOI 10.1074/jbc.274.12.7865; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; VANDOP C, 1984, J BIOL CHEM, V259, P23; WEST RE, 1985, J BIOL CHEM, V260, P4428; Yang CS, 1999, J BIOL CHEM, V274, P2379, DOI 10.1074/jbc.274.4.2379	25	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2669	2675		10.1074/jbc.275.4.2669	http://dx.doi.org/10.1074/jbc.275.4.2669			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644728	hybrid			2022-12-25	WOS:000085128000060
J	Prokhorova, TA; Blow, JJ				Prokhorova, TA; Blow, JJ			Sequential MCM/P1 subcomplex assembly is required to form a heterohexamer with replication licensing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME-MAINTENANCE PROTEINS; ORIGIN RECOGNITION COMPLEX; CELL-CYCLE REGULATION; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; FISSION YEAST; XENOPUS; SYSTEM; INITIATION	Replication licensing factor (RLF) is a multiprotein complex involved in ensuring that chromosomal DNA replicates only once in a single cell cycle. It comprises two components, termed RLF-M and RLF-B. Purified RLF-M consists of a mixture of complexes containing all six members of the MCM/P1 family of minichromosome maintenance proteins. The precise composition of these different complexes and their contribution to RLF-M activity has been unclear. Here we show that in Xenopus extracts, MCM/P1 proteins mainly form heterohexamers containing each of the six proteins. This heterohexamer is readily split into subcomplexes, whose interactions and subunit composition we characterize in detail. We show for the first time an ordered multistep assembly pathway by which the heterohexamer can be reformed from the subcomplexes. Importantly, this novel pathway is essential for DNA replication, since only the full heterohexamer can bind productively to chromatin and provide RLF-M activity.	Univ Dundee, Canc Res Campaign Chromosome Replicat Res Grp, Dept Biochem, Dundee DD1 5EH, Scotland	University of Dundee	Blow, JJ (corresponding author), Univ Dundee, Canc Res Campaign Chromosome Replicat Res Grp, Dept Biochem, Dundee DD1 5EH, Scotland.		Blow, J. Julian/B-3977-2009	Blow, J. Julian/0000-0002-9524-5849; Prokhorova, Tatyana/0000-0001-8768-8298	Cancer Research UK [A2335, A2793] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BUCCI E, 1965, J MOL BIOL, V12, P183, DOI 10.1016/S0022-2836(65)80292-3; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Chong JPJ, 1997, METHOD ENZYMOL, V283, P549; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1998, EXP CELL RES, V245, P282, DOI 10.1006/excr.1998.4271; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; ISHIMI Y, 1996, J BIOL CHEM, V271, P24111; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Krude T, 1996, J CELL SCI, V109, P309; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Lei M, 1996, MOL CELL BIOL, V16, P5081; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; MAINE GT, 1984, GENETICS, V106, P365; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; Poddar A, 1999, MOL MICROBIOL, V31, P349, DOI 10.1046/j.1365-2958.1999.01179.x; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Richter A, 1997, EUR J BIOCHEM, V247, P136, DOI 10.1111/j.1432-1033.1997.00136.x; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Rowles A, 1999, J CELL SCI, V112, P2011; Roy N, 1997, CURR GENET, V32, P182, DOI 10.1007/s002940050264; Sanyal K, 1998, MOL GEN GENET, V260, P242, DOI 10.1007/s004380050892; SCHUTZ E, 1996, Z GERMANISTIK, V6, P235; Sherman DA, 1998, NUCLEIC ACIDS RES, V26, P3955, DOI 10.1093/nar/26.17.3955; Sherman DA, 1998, MOL BIOL CELL, V9, P1833, DOI 10.1091/mbc.9.7.1833; Sible JC, 1998, CURR BIOL, V8, P347, DOI 10.1016/S0960-9822(98)70136-8; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Su TT, 1996, MOL BIOL CELL, V7, P319, DOI 10.1091/mbc.7.2.319; Su TT, 1997, J CELL BIOL, V139, P13, DOI 10.1083/jcb.139.1.13; Tada S, 1999, CURR BIOL, V9, P211, DOI 10.1016/S0960-9822(99)80092-X; Tada S, 1998, BIOL CHEM, V379, P941; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	53	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2491	2498		10.1074/jbc.275.4.2491	http://dx.doi.org/10.1074/jbc.275.4.2491			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644704	Green Accepted, hybrid			2022-12-25	WOS:000085128000036
J	Puga, A; Barnes, SJ; Dalton, TP; Chang, CY; Knudsen, ES; Maier, MA				Puga, A; Barnes, SJ; Dalton, TP; Chang, CY; Knudsen, ES; Maier, MA			Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIBENZO-P-DIOXINS; AH-RECEPTOR; LACTATIONAL EXPOSURE; HUMAN KERATINOCYTES; GENE-EXPRESSION; HEPATOMA-CELLS; MALE-RATS; ESTROGEN-RECEPTOR; CANCER MORTALITY; IN-UTERO	Polyhalogenated aromatic hydrocarbons, of which 2,3,7,8-tetrachloro-p-dioxin (TCDD) is the prototype compound, elicit a variety of toxic, teratogenic, and carcinogenic responses in exposed animals and in humans. In cultured cells, TCDD shows marked effects on the regulation of cell cycle progression, including thymocyte apoptosis, induction of keratinocyte proliferation and terminal differentiation, and inhibition of estrogen-dependent proliferation in breast cancer cells, The presence of an LXCXE domain in the dioxin aromatic hydrocarbon receptor (AHR), suggested that the effects of TCDD on cell cycle regulation might be mediated by protein-protein interactions between AHR and the retinoblastoma protein (RB), Using the yeast two-hybrid system, AHR and RE were in fact shown to bind to each other, In vitro pull-down experiments with truncated AHR peptides indicated that at least two separate AHR domains form independent complexes with hypophosphorylated RE. Coimmunoprecipitation of whole cell lysates from human breast carcinoma MCF-7 cells, which express both proteins endogenously, revealed that AHR associates with RE in vivo only after receptor transformation and nuclear translocation. However, the AHR nuclear translocator and transcriptional heterodimerization partner, is not required for (nor is it a part of) the AHR RB complexes detected in vitro. Ectopic expression of AHR and RE in human osteosarcoma SAOS-2 cells, which lack endogenous expression of both proteins, showed that AHR synergizes with RE to repress E2F-dependent transcription and to induce cell cycle arrest. Furthermore, AHR partly blocked T-antigen-mediated reversal of RE-dependent transcriptional repression. These results uncover a potential function for the AHR in cell cycle regulation and suggest that this function may be that of serving as an environmental sensor that signals eel cycle arrest when cells are exposed to certain environmental toxicants.	Univ Cincinnati, Med Ctr, Ctr Environm Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Puga, A (corresponding author), Univ Cincinnati, Med Ctr, Ctr Environm Genet, POB 670056, Cincinnati, OH 45267 USA.	Alvaro.Puga@UC.EDU	Puga, Alvaro/B-7676-2008		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES006273, R01ES006273, P30ES006096] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06273, P30 ES06096] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbott BD, 1995, TOXICOLOGY, V105, P365, DOI 10.1016/0300-483X(95)03234-7; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; BERTAZZI PA, 1991, SCI TOTAL ENVIRON, V106, P5, DOI 10.1016/0048-9697(91)90016-8; BJERKE DL, 1994, TOXICOL APPL PHARM, V127, P241, DOI 10.1006/taap.1994.1158; BJERKE DL, 1994, TOXICOL APPL PHARM, V127, P258, DOI 10.1006/taap.1994.1160; BOWES RC, 1995, ARCH BIOCHEM BIOPHYS, V323, P243, DOI 10.1006/abbi.1995.9968; BROOKS SC, 1973, J BIOL CHEM, V248, P6251; Carver LA, 1997, J BIOL CHEM, V272, P11452; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; CHOI EJ, 1991, J BIOL CHEM, V266, P9591; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; Cummings AM, 1996, TOXICOL APPL PHARM, V138, P131, DOI 10.1006/taap.1996.0106; DEVITO MJ, 1995, TOXICOLOGY, V102, P115, DOI 10.1016/0300-483X(95)03040-M; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; FLESCHJANYS D, 1995, AM J EPIDEMIOL, V142, P1165, DOI 10.1093/oxfordjournals.aje.a117575; FLODSTROM S, 1991, FUND APPL TOXICOL, V16, P375, DOI 10.1016/0272-0590(91)90122-K; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; GAIDO KW, 1992, J BIOL CHEM, V267, P24591; GAIDO KW, 1994, TOXICOL APPL PHARM, V127, P199, DOI 10.1006/taap.1994.1154; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; GOTTLICHER M, 1987, CARCINOGENESIS, V8, P1021, DOI 10.1093/carcin/8.7.1021; Guiney PD, 1997, TOXICOL APPL PHARM, V143, P256, DOI 10.1006/taap.1996.8051; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hornug MW, 1999, TOXICOL SCI, V47, P40, DOI 10.1093/toxsci/47.1.40; JENSEN FC, 1964, P NATL ACAD SCI USA, V52, P53, DOI 10.1073/pnas.52.1.53; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kamath AB, 1997, TOXICOL APPL PHARM, V142, P367, DOI 10.1006/taap.1996.8049; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; KERKVLIET NI, 1990, TOXICOL APPL PHARM, V105, P26, DOI 10.1016/0041-008X(90)90356-Y; Kerkvliet NI, 1995, ENVIRON HEALTH PERSP, V103, P47, DOI 10.2307/3432722; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KNUTSON JC, 1982, CELL, V30, P225, DOI 10.1016/0092-8674(82)90028-9; KOCIBA RJ, 1978, TOXICOL APPL PHARM, V46, P279, DOI 10.1016/0041-008X(78)90075-3; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Ma Q, 1997, J BIOL CHEM, V272, P8878; Ma Q, 1996, MOL CELL BIOL, V16, P2144; MABLY TA, 1992, TOXICOL APPL PHARM, V114, P118, DOI 10.1016/0041-008X(92)90103-Y; Maier A, 1998, ENVIRON HEALTH PERSP, V106, P421, DOI 10.2307/3434070; MANZ A, 1991, LANCET, V338, P959, DOI 10.1016/0140-6736(91)91835-I; MCCONKEY DJ, 1989, BIOCHEM BIOPH RES CO, V160, P1003, DOI 10.1016/S0006-291X(89)80101-9; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MILSTONE LM, 1984, J INVEST DERMATOL, V82, P532, DOI 10.1111/1523-1747.ep12261149; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Moolgavkar SH, 1996, TOXICOL APPL PHARM, V138, P31, DOI 10.1006/taap.1996.0094; NEBERT DW, 1989, CRIT REV TOXICOL, V20, P153, DOI 10.3109/10408448909017908; OUGHTON JA, 1995, FUND APPL TOXICOL, V25, P60, DOI 10.1006/faat.1995.1040; POLAND A, 1982, NATURE, V300, P271, DOI 10.1038/300271a0; Reiners JJ, 1999, J BIOL CHEM, V274, P2502, DOI 10.1074/jbc.274.4.2502; RININGER J, 1995, P 15 INT S CHLOR DIO, V25, P367; Rorke EA, 1998, INT J ONCOL, V13, P557; Rowlands JC, 1996, MOL PHARMACOL, V50, P538; SAFE SH, 1995, PHARMACOL THERAPEUT, V67, P247, DOI 10.1016/0163-7258(95)00017-B; Strober BE, 1996, MOL CELL BIOL, V16, P1576; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; VANDENHEUVEL JP, 1993, ENVIRON HEALTH PERSP, V100, P189, DOI 10.1289/ehp.93100189; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; Wang WL, 1998, ARCH BIOCHEM BIOPHYS, V356, P239, DOI 10.1006/abbi.1998.0782; Weber TJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P227, DOI 10.1006/abbi.1996.0167; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; WIEBEL FJ, 1991, TOXICOL LETT, V55, P161, DOI 10.1016/0378-4274(91)90130-X; WOLFLE D, 1993, CELL BIOL TOXICOL, V9, P15, DOI 10.1007/BF00755137; Worner W, 1996, CANCER RES, V56, P1272	80	243	260	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2943	2950		10.1074/jbc.275.4.2943	http://dx.doi.org/10.1074/jbc.275.4.2943			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644764	hybrid			2022-12-25	WOS:000085128000096
J	van der Does, C; Swaving, J; van Klompenburg, W; Driessen, AJM				van der Does, C; Swaving, J; van Klompenburg, W; Driessen, AJM			Non-bilayer lipids stimulate the activity of the reconstituted bacterial protein translocase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVELY CHARGED PHOSPHOLIPIDS; COLI PREPROTEIN TRANSLOCASE; ESCHERICHIA-COLI; ANIONIC PHOSPHOLIPIDS; PRECURSOR PROTEIN; SECA PROTEIN; BACILLUS-SUBTILIS; SIGNAL SEQUENCE; ACIDIC PHOSPHOLIPIDS; MEMBRANE-VESICLES	To determine the phospholipid requirement of the preprotein translocase in vitro, the Escherichia coli SecYEG complex was purified in a delipidated form using the detergent dodecyl maltoside, SecYEG was reconstituted into liposomes composed of defined synthetic phospholipids, and proteoliposomes were analyzed for their preprotein translocation and SecA translocation ATPase activity. The activity strictly required the presence of anionic phospholipids, whereas the non-bilayer lipid phosphatidylethanolamine was found stimulatory. The latter effect could also be induced by dioleoylglycerol, a lipid that adopts a non-bilayer conformation, Phosphatidylethanolamine derivatives that prefer the bilayer state were unable to stimulate translocation, In the absence of SecG, activity was reduced, but the phospholipid requirement was unaltered. Remarkably, nonbilayer lipids were found essential for the activity of the Bacillus subtilis SecYEG complex. Optimal activity required a mixture of anionic and non-bilayer Lipids at concentrations that correspond to concentrations found in the natural membrane.	Univ Groningen, Dept Microbiol, NL-9751 NN Haren, Netherlands; Univ Groningen, Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Dept Microbiol, Kerklaan 30, NL-9751 NN Haren, Netherlands.	A.J.M.DRIESSEN@BIOL.RUG.NL	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; Bogdanov M, 1999, J BIOL CHEM, V274, P12339, DOI 10.1074/jbc.274.18.12339; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CHEN CC, 1984, J BIOL CHEM, V259, P150; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; DRIESSEN AJM, 1990, P NATL ACAD SCI USA, V87, P3107, DOI 10.1073/pnas.87.8.3107; DRIESSEN AJM, 1992, EMBO J, V11, P847, DOI 10.1002/j.1460-2075.1992.tb05122.x; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Duong F, 1999, EMBO J, V18, P3263, DOI 10.1093/emboj/18.12.3263; Eichler J, 1997, EMBO J, V16, P2188, DOI 10.1093/emboj/16.9.2188; ELLENS H, 1986, BIOCHEMISTRY-US, V25, P4141, DOI 10.1021/bi00362a023; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; KELLER RCA, 1992, BIOCHEMISTRY-US, V31, P1672, DOI 10.1021/bi00121a014; Keller RCA, 1996, BIOCHEMISTRY-US, V35, P3063, DOI 10.1021/bi951870+; KONTINEN VP, 1995, FEBS LETT, V364, P157, DOI 10.1016/0014-5793(95)00378-M; Kontinen VP, 1996, FEBS LETT, V389, P281, DOI 10.1016/0014-5793(96)00602-3; KRULWICH TA, 1987, J BACTERIOL, V169, P4479, DOI 10.1128/jb.169.10.4479-4485.1987; KUSTERS R, 1992, FEBS LETT, V308, P97, DOI 10.1016/0014-5793(92)81060-Y; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LEENHOUTS JM, 1995, FEBS LETT, V370, P189, DOI 10.1016/0014-5793(95)00823-R; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Matlack KES, 1997, SCIENCE, V277, P938, DOI 10.1126/science.277.5328.938; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; MULUKUTLA S, 1984, BIOCHEMISTRY-US, V23, P2514, DOI 10.1021/bi00306a030; PHOENIX DA, 1993, J BIOL CHEM, V268, P17069; RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; RIETVELD AG, 1994, J BIOL CHEM, V269, P28670; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SETOYOUNG D, 1985, J MEMBRANE BIOL, V84, P259, DOI 10.1007/BF01871389; Shimizu H, 1997, MOL MICROBIOL, V26, P1013, DOI 10.1046/j.1365-2958.1997.6392003.x; Suzuki H, 1999, J BIOL CHEM, V274, P31020, DOI 10.1074/jbc.274.43.31020; Swaving J, 1999, J BACTERIOL, V181, P7021, DOI 10.1128/JB.181.22.7021-7027.1999; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; van Klompenburg W, 1998, J MEMBRANE BIOL, V162, P1, DOI 10.1007/s002329900336; van Voorst F, 1998, BIOCHEMISTRY-US, V37, P12261, DOI 10.1021/bi9809021; Van Wely KHM, 1998, EUR J BIOCHEM, V255, P690, DOI 10.1046/j.1432-1327.1998.2550690.x; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; vanRaalte ALJ, 1996, EUR J BIOCHEM, V235, P207; WEIS SJB, 1998, P NATL ACAD SCI USA, V85, P8978; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514	56	94	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2472	2478		10.1074/jbc.275.4.2472	http://dx.doi.org/10.1074/jbc.275.4.2472			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644701	Green Published, hybrid			2022-12-25	WOS:000085128000033
J	Murata, M; Kawanishi, S				Murata, M; Kawanishi, S			Oxidative DNA damage by vitamin A and its derivative via superoxide generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYL RADICAL FORMATION; OXYGEN PARTIAL-PRESSURE; BETA-CAROTENE; ALPHA-TOCOPHEROL; LUNG-CANCER; PROOXIDANT PROPERTIES; HYDROGEN-PEROXIDE; RETINOL; ANTIOXIDANT; ACID	Recent intervention studies revealed that beta-carotene supplement to smokers resulted in a higher incidence of lung cancer. However, the causal mechanisms remain to be clarified. We reported here that vitamin A (retinol) and its derivative (retinal) caused cellular DNA cleavage detected by pulsed field gel electrophoresis. Retinol and retinal significantly induced 8-oxo-7,8-dihydro-2'-deoxyguanosine formation in HL-60 cells but not in H(2)O(2)-resistant HP100 cells, suggesting the involvement of H(2)O(2) in cellular DNA damage. Experiments using (32)P-labeled isolated DNA demonstrated that retinol and retinal caused Cu(II)-mediated DNA damage, which was inhibited by catalase. W-visible spectroscopic and electron spin resonance-trapping studies revealed the generation of superoxide and carbon-centered radicals, respectively. The superoxide generation during autoxidation of retinoids was significantly correlated with the formation of 8-oxo-7,8-dihydro-2'-deoxyguanosine, although the yield of carbon-centered radicals was not necessarily related to the intensity of DNA damage. These findings suggest that superoxide generated by autoxidation of retinoids was dismutated to H(2)O(2), which was responsible for DNA damage in the presence of endogenous metals. Retinol and retinal have prooxidant abilities, which might lead to carcinogenesis of the supplements of beta-carotene.	Mie Univ, Sch Med, Dept Hyg, Tsu, Mie 5148507, Japan	Mie University	Kawanishi, S (corresponding author), Mie Univ, Sch Med, Dept Hyg, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	kawanisi@doc.medic.mie-u.ac.jp						Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560; Badr FM, 1998, MUTAT RES-GEN TOX EN, V414, P157, DOI 10.1016/S1383-5718(98)00038-2; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; Burkitt MJ, 1996, FEBS LETT, V379, P51, DOI 10.1016/0014-5793(95)01481-0; BURKITT MJ, 1994, METHOD ENZYMOL, V234, P66; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; Chen YQ, 1999, CANCER RES, V59, P3985; Collins AR, 1998, CARCINOGENESIS, V19, P2159, DOI 10.1093/carcin/19.12.2159; Duthie SJ, 1997, MUTAT RES-GEN TOX EN, V390, P141, DOI 10.1016/S0165-1218(97)00010-4; Freyaldenhoven MA, 1998, CHEM RES TOXICOL, V11, P102, DOI 10.1021/tx970044u; Giri U, 1996, CARCINOGENESIS, V17, P2023, DOI 10.1093/carcin/17.9.2023; Halliwell B, 1999, MUTAT RES-GEN TOX EN, V443, P37, DOI 10.1016/S1383-5742(99)00009-5; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Herbert V, 1996, J NUTR, V126, pS1197, DOI 10.1093/jn/126.suppl_4.1197S; INOUE S, 1992, CARCINOGENESIS, V13, P1497, DOI 10.1093/carcin/13.9.1497; ITO K, 1992, BIOCHEMISTRY-US, V31, P11606, DOI 10.1021/bi00161a046; ITO K, 1993, J BIOL CHEM, V268, P13221; KASUGAI I, 1992, LEUKEMIA RES, V16, P173, DOI 10.1016/0145-2126(92)90129-U; Kensler T, 1995, Prog Clin Biol Res, V391, P103; KUROKAWA Y, 1985, J NATL CANCER I, V74, P715; Lowe GM, 1999, FREE RADICAL RES, V30, P141, DOI 10.1080/10715769900300151; Maxam A M, 1980, Methods Enzymol, V65, P499; Murata M, 1999, CARCINOGENESIS, V20, P851, DOI 10.1093/carcin/20.5.851; Oikawa S, 1999, CARCINOGENESIS, V20, P1485, DOI 10.1093/carcin/20.8.1485; Olson JA, 1996, J NUTR, V126, pS1208, DOI 10.1093/jn/126.suppl_4.1208S; Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Palozza P, 1997, FREE RADICAL BIO MED, V22, P1065, DOI 10.1016/S0891-5849(96)00498-4; Pappalardo G, 1997, EUR J CLIN NUTR, V51, P661, DOI 10.1038/sj.ejcn.1600457; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; PRYOR WA, 1978, BIOCHEM BIOPH RES CO, V81, P498, DOI 10.1016/0006-291X(78)91562-0; Rehman A, 1998, BIOCHEM BIOPH RES CO, V246, P293, DOI 10.1006/bbrc.1998.8592; REID TM, 1993, P NATL ACAD SCI USA, V90, P3904, DOI 10.1073/pnas.90.9.3904; Rodriguez-Burford C, 1999, CARCINOGENESIS, V20, P71, DOI 10.1093/carcin/20.1.71; SLAGA TJ, 1995, ADV EXP MED BIOL, V369, P167; Tada-Oikawa S, 1999, FEBS LETT, V442, P65, DOI 10.1016/S0014-5793(98)01618-4; Tesoriere L, 1997, ARCH BIOCHEM BIOPHYS, V343, P13, DOI 10.1006/abbi.1997.0128; VILE GF, 1988, FEBS LETT, V238, P353, DOI 10.1016/0014-5793(88)80511-8; WILLETT WC, 1984, NEW ENGL J MED, V310, P633, DOI 10.1056/NEJM198403083101006; YAMAMOTO K, 1989, J BIOL CHEM, V264, P15435; Yamashita N, 1998, CHEM RES TOXICOL, V11, P855, DOI 10.1021/tx970129v; Yamashita N, 1999, MUTAT RES-FUND MOL M, V425, P107, DOI 10.1016/S0027-5107(99)00029-9; Yamashita N, 1998, MUTAT RES-FUND MOL M, V397, P191, DOI 10.1016/S0027-5107(97)00210-8; YOUNG IS, 1995, FREE RADICAL BIO MED, V18, P833, DOI 10.1016/0891-5849(94)00202-U	46	156	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2003	2008		10.1074/jbc.275.3.2003	http://dx.doi.org/10.1074/jbc.275.3.2003			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636903	hybrid			2022-12-25	WOS:000084940000066
J	Cleverley, SC; Costello, PS; Henning, SW; Cantrell, DA				Cleverley, SC; Costello, PS; Henning, SW; Cantrell, DA			Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma	ONCOGENE			English	Article						Rho; lymphoma; thymus; transformation; C3-transferase	RAS TRANSFORMATION; TRANSGENIC MICE; GTPASES; COOPERATION; BOTULINUM; PROTEIN; TUMORS; MYB	In situ studies in model cell lines have implicated the GTPase Rho in the control of diverse cellular responses including the control of the actin cytoskeleton and the regulation of cell cycle progression. It is also reported that the transformation of fibroblasts via oncogenic Ras requires intact Rho signalling. An invaluable tool used to investigate Rho function is the bacterial toxin C3 transferase derived from Clostridium hotulinum. C3 transferase ribosylates Rho in its effector domain thereby abolishing interaction with downstream effecters. We have previously reported the use of C3 transferase under the control of the thymocyte specific Ick promoter to explore the role of Rho in T cell biology. Strikingly, Ick-C3 mice develop aggressive malignant thymic lymphoblastic lymphomas between 4 and 8 months of age. These studies reveal that loss of Rho function is associated with prediposition to lymphoid cell transformation. Inhibition of Rho function has been suggested as a therapeutic strategy for treatment of Ras-transformed tumours, The development of lymphomas in mice devoid of functional Rho in their T cell compartment shows that such a strategy would need to be used with caution.	Imperial Canc Res Fund, Lymphocyte Activat Lab, London WC2A 3PX, England	Cancer Research UK	Cantrell, DA (corresponding author), Imperial Canc Res Fund, Lymphocyte Activat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.							ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Badiani PA, 1996, ONCOGENE, V13, P2205; Bronson R., 1990, GENETIC EFFECTS AGIN, VII, P279; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GALLANDRINI R, 1997, IMMUNITY, V7, P163; Henning SW, 1998, CURR OPIN IMMUNOL, V10, P322, DOI 10.1016/S0952-7915(98)80171-4; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Owen MJ, 1996, CURR OPIN IMMUNOL, V8, P191, DOI 10.1016/S0952-7915(96)80057-4; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	23	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					13	20		10.1038/sj.onc.1203259	http://dx.doi.org/10.1038/sj.onc.1203259			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644975				2022-12-25	WOS:000084844300002
J	Takahashi, T; Suwabe, N; Dai, P; Yamamoto, M; Ishii, S; Nakano, T				Takahashi, T; Suwabe, N; Dai, P; Yamamoto, M; Ishii, S; Nakano, T			Inhibitory interaction of c-Myb and GATA-1 via transcriptional co-activator CBP	ONCOGENE			English	Article						c-Myb; GATA-1; CBP; cell differentiation; hematopoiesis	MURINE HEMATOPOIETIC-CELLS; EMBRYONIC STEM-CELLS; NUCLEAR-PROTEIN CBP; ERYTHROID-DIFFERENTIATION; ONCOGENE PRODUCT; COACTIVATOR CBP; GENE; EXPRESSION; BINDING; PROMOTER	Gene targeting experiments have revealed that transcription factors such as c-Myb and GATA-1 play crucial roles during hematopoietic differentiation. c-Myb is necessary in the immature cells of almost every hematopoietic lineage and GATA-1 is essential for the development of the ervthroid lineage. In addition, CREB-binding protein (CBP) acts as a transcriptional adapter for various transcription factors, including c-Myc and GATA-1. In this paper,,ve show that the transcription factors c-Myb and GATA-1 each inhibit the transcriptional activity of the other and that any possible bipartite complexes c-Myb, GATA-1, and CBP could be formed, but the tripartite complex was hardly formed, The exclusive binding of GATA-1 and c-Myb to CBP is probably the molecular basis for the mutual inhibition of their transcriptional activity. Our data suggest that cross-talk between these three factors might be important for hematopoietic differentiation and that CBP functions as a hey molecule during the process.	Osaka Univ, Dept Mol Cell Biol, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan	Osaka University; University of Tsukuba; University of Tsukuba; RIKEN	Nakano, T (corresponding author), Osaka Univ, Dept Mol Cell Biol, Microbial Dis Res Inst, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.		Yamamoto, Masayuki/A-4873-2010; Ishii, Shunsuke/A-5271-2016	Yamamoto, Masayuki/0000-0002-9073-9436; Ishii, Shunsuke/0000-0002-6530-2478				Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cross MA, 1997, CIBA F SYMP, V204, P3; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; FERRAO P, 1995, ONCOGENE, V11, P1631; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HIGUCHI R, 1990, PCR TECHNOLOGY PRINC; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; Lipsick JS, 1996, ONCOGENE, V13, P223; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V9, P1123; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Orita T, 1997, J BIOL CHEM, V272, P23216, DOI 10.1074/jbc.272.37.23216; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	43	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2000	19	1					134	140		10.1038/sj.onc.1203228	http://dx.doi.org/10.1038/sj.onc.1203228			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644988				2022-12-25	WOS:000084844300015
J	Yoshida, S; Kaneita, Y; Aoki, Y; Seto, M; Mori, S; Moriyama, M				Yoshida, S; Kaneita, Y; Aoki, Y; Seto, M; Mori, S; Moriyama, M			Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5 '-RACE and LA-PCR analyses of biopsy samples	ONCOGENE			English	Article						BCL6; translocation; hypermutation; lymphoma	NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; SOMATIC HYPERMUTATION; BURKITT-LYMPHOMA; CHROMOSOMAL BREAKPOINT; 3Q27 TRANSLOCATION; MOLECULAR-CLONING; ONCOGENE; LOCUS; PROTEIN	In order to elucidate the molecular mechanism(s) for BCL6 translocation, we identified translocational partner genes by subjecting clinical biopsy samples from patients with non-Hodgkin's lymphoma to 5'-rapid amplification of cDNA ends (5'-RACE). Sequence analysis of the 5'-RACE product revealed that the BCL6 gene was fused to the J segment of the immunoglobulin heavy chain (IgH) gene in about half of the cases, but in the other half, it was fused to heterologous partners, including the MHC class II transactivator (CIITA), pim-1, eukaryotic initiation factor 4AII (ejf4AII), transferrin receptor (TFRR) and ikaros genes, Since analyses using genomic long and accurate (LA)-PCR revealed that the breakpoints in the partner gene mere confined to the first intron or the second exon in all cases, the promoter and the first exon of the BCL6 gene mere replaced by the promoter and the first or both the first and second exon of the partner gene, The breakpoint Banking sequences had no recombination signal sequences (RSSs) or chi sequences and were homologous with the switch region only when the BCL6 gene was fused to the IgH gene, suggesting that BCL6 translocation cannot be explained solely by mistakes of V(D)J, or chi-mediated or class-switch recombination, but rather another mechanism may also be required to explain the molecular mechanism for the promiscuous BCL6 translocation.	Univ Tokyo, Inst Med Sci, Dept Pathol, Tokyo, Japan; Aichi Canc Inst, Lab Chemotherapy, Nagoya, Aichi, Japan; Tottori Univ, Fac Med, Sch Life Sci, Dept Mol Biol, Tottori 6838503, Japan	University of Tokyo; Aichi Cancer Center; Tottori University	Moriyama, M (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Mol Biol, 86 Nishimachi, Tottori 6838503, Japan.							Akasaka T, 1997, CANCER RES, V57, P7; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1994, BLOOD, V83, P2423; BENARDIN F, 1997, ONCOGENE, V14, P849; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLAFAVERA R, 1993, CAUSES CONSEQUENCES, P313; DALLERY E, 1995, ONCOGENE, V10, P2171; GAIDANO G, 1998, BIOL HIGH GRADE MALI, P353; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; HARRIS NL, 1994, BLOOD, V84, P1361; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Klein U, 1998, IMMUNOL REV, V162, P261; MIKI T, 1994, BLOOD, V83, P217; MIKI T, 1994, BLOOD, V83, P26; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; SUZUKI K, 1994, JPN J CANCER RES, V85, P911, DOI 10.1111/j.1349-7006.1994.tb02968.x; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1993, HUMAN B CELL NEOPLAS, P333; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZUTTER MM, 1998, BIOL LOW GRADE MALIG, P337	33	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7994	7999		10.1038/sj.onc.1203293	http://dx.doi.org/10.1038/sj.onc.1203293			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637510				2022-12-25	WOS:000084634600008
J	Lando, D; Pongratz, I; Poellingers, L; Whitelaw, ML				Lando, D; Pongratz, I; Poellingers, L; Whitelaw, ML			A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1 alpha and the HIF-like factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; DISULFIDE BOND FORMATION; PAS DOMAIN PROTEIN-1; TRANSCRIPTION FACTOR; DIOXIN RECEPTOR; ALPHA-SUBUNIT; ACTIVATION; REF-1; CELLS; THIOREDOXIN	Hypoxia-inducible factor 1 alpha (HIF-1 alpha) and the HIF-like factor (HLF) are two highly related basic Helix-Loop-Helix/Per-Arnt-Sim (bHLH/PAS) homology transcription factors that undergo dramatically increased function at low oxygen levels. Despite strong similarities in their activation mechanisms (e.g, they both undergo rapid hypoxia-induced protein stabilization, bind identical target DNA sequences, and induce synthetic reporter genes to similar degrees), they are both essential for embryo survival via distinct functions during vascularization (HIF-1 alpha) or catecholamine production (HLF). It is currently unknown how such specificity of action is achieved. We report here that DNA binding by HLF, but not by HIF-1 alpha, is dependent upon reducing redox conditions. In vitro DNA binding and mammalian two-hybrid assays showed that a unique cysteine in the DNA-binding basic region of HLF is a target for the reducing activity of redox factor Ref-1. Although the N-terminal DNA-binding domain of HIF-1 alpha can function in the absence of Ref-1, we found that the C-terminal region containing the transactivation domain requires Ref-1 for fall activity. Our data reveal that the hypoxia-inducible factors are subject to complex redox control mechanisms that can target discrete regions of the proteins and are the first to establish a discriminating control mechanism for differential regulation of RIF-la and HLF activity.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	University of Adelaide; Karolinska Institutet	Whitelaw, ML (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.	murray.whitelaw@adelaide.edu.au	Lando, David/A-2546-2010; Lando, David/AAH-3052-2019	Lando, David/0000-0001-5783-8769				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Asai T, 1997, BIOCHEM BIOPH RES CO, V236, P71, DOI 10.1006/bbrc.1997.6906; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Becker K, 1998, NAT STRUCT BIOL, V5, P267, DOI 10.1038/nsb0498-267; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRESNICK EH, 1988, BIOCHEMISTRY-US, V27, P2866, DOI 10.1021/bi00408a030; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Hunter T, 1998, CELL, V92, P141, DOI 10.1016/S0092-8674(00)80906-X; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; OKUNO H, 1993, ONCOGENE, V8, P695; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1998, J LAB CLIN MED, V131, P207, DOI 10.1016/S0022-2143(98)90091-9; SIMONS SS, 1995, METHOD ENZYMOL, V251, P406; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Tell G, 1998, BIOCHEM BIOPH RES CO, V252, P178, DOI 10.1006/bbrc.1998.9548; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	60	145	155	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4618	4627		10.1074/jbc.275.7.4618	http://dx.doi.org/10.1074/jbc.275.7.4618			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671489	hybrid			2022-12-25	WOS:000085378200015
J	Sherman, DL; Brophy, PJ				Sherman, DL; Brophy, PJ			A tripartite nuclear localization signal in the PDZ-domain protein L-periaxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELINATING SCHWANN-CELLS; BASIC-PROTEIN; GENE; PSD-95/SAP90; EXPRESSION; SEQUENCES; TRANSPORT; COMPLEX; SYNGAP; KINASE	The murine Periaxin gene encodes two PDZ-domain proteins in myelin-forming Schwann cells of the vertebrate peripheral nervous system (Dytrych, L., Sherman, D. L., Gillespie, C. S., and Brophy, P. J. (1998) J. Biol. Chem, 273, 5794-5800), Here we show that L-periaxin is targeted to the nucleus of embryonic Schwann cells. Subsequently, the protein redistributes to the plasma membrane processes of the myelinating Schwann cell where it is believed to function in a signaling complex. In contrast, L-periaxin remains in the nucleus when expressed ectopically in oligodendrocytes, the myelin-forming glia of the central nervous system. The nuclear localization signal (NLS) is basic and tripartite and comprises three signals that act synergistically, Nuclear targeting of L-periaxin is energy-dependent and is inhibited by cell-cell contact. These data show that L-periaxin is a member of a growing family of proteins that can shuttle between the nucleus and cortical signaling/adherence complexes.	Univ Edinburgh, Dept Preclin Vet Sci, Edinburgh EH9 1QH, Midlothian, Scotland	University of Edinburgh	Brophy, PJ (corresponding author), Univ Edinburgh, Dept Preclin Vet Sci, Summerhall, Edinburgh EH9 1QH, Midlothian, Scotland.							ALI SA, 1995, BIOTECHNIQUES, V18, P746; BERRYMAN MA, 1992, J HISTOCHEM CYTOCHEM, V40, P845, DOI 10.1177/40.6.1350287; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; Dytrych L, 1998, J BIOL CHEM, V273, P5794, DOI 10.1074/jbc.273.10.5794; FISCHERFANTUZZI L, 1988, MOL CELL BIOL, V8, P5495, DOI 10.1128/MCB.8.12.5495; GILLESPIE CS, 1994, NEURON, V12, P497, DOI 10.1016/0896-6273(94)90208-9; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; Gumbiner BM, 1998, CURR OPIN GENET DEV, V8, P430, DOI 10.1016/S0959-437X(98)80114-7; HOGAN B, 1994, MANIPULATING MOUSE E, P226; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Mirsky R, 1996, CURR OPIN NEUROBIOL, V6, P89, DOI 10.1016/S0959-4388(96)80013-4; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Pedraza L, 1997, J NEUROSCI RES, V50, P258, DOI 10.1002/(SICI)1097-4547(19971015)50:2<258::AID-JNR14>3.0.CO;2-4; Scherer SS, 1995, DEVELOPMENT, V121, P4265; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHIEH MW, 1993, PLANT PHYSIOL, V101, P353, DOI 10.1104/pp.101.2.353; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793	29	56	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4537	4540		10.1074/jbc.275.7.4537	http://dx.doi.org/10.1074/jbc.275.7.4537			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671475	hybrid			2022-12-25	WOS:000085378200001
J	Baracca, A; Barogi, S; Carelli, V; Lenaz, G; Solaini, G				Baracca, A; Barogi, S; Carelli, V; Lenaz, G; Solaini, G			Catalytic activities of mitochondrial ATP synthase in patients with mitochondrial DNA T8993G mutation in the ATPase 6 gene encoding subunit alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTON TRANSLOCATION; MOLECULAR MACHINE; LEIGHS SYNDROME; DISEASE; MECHANISM; HETEROPLASMY; F1-ATPASE; MTDNA; F1F0-ATPASE	We:investigated the biochemical phenotype of the mtDNA T8993G point mutation in the ATPase 6 gene, associated with neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP), in three patients from two unrelated families. All three carried >80% mutant genome in platelets and were manifesting clinically various degrees of the NARP phenotype, Coupled submitochondrial particles prepared from platelets capable of succinate-sustained ATP synthesis were studied using very sensitive and rapid luminometric and fluorescence methods. A sharp decrease (>95%) in the succinate-sustained ATP synthesis rate of the particles was found, but both the ATP hydrolysis rate and ATP-driven proton translocation (when the protons flow from the matrix to the cytosol) were minimally affected. The T8993G mutation changes the highly conserved residue Leu(156) to Arg in the ATPase 6 subunit (subunit a). This subunit, together with subunit c, is thought to cooperatively catalyze proton translocation and rotate, one with respect to the other, during the catalytic cycle of the F1F0 complex. Our results suggest that the T8993G mutation induces a structural defect in human F1F0-ATPase that causes a severe impairment of ATP synthesis. This is possibly due to a defect in either the vectorial proton transport from the cytosol to the mitochondrial matrix or the coupling of proton flow through F-0, to ATP synthesis in F-1, Whatever mechanism is involved, this leads to impaired ATP synthesis. On the other hand, ATP hydrolysis that involves proton flow from the matrix to the cytosol is essentially unaffected.	Univ Perfezionamento S Anna, Scuola Super Studi, Settore Med, I-56127 Pisa, Italy; Univ Bologna, Dipartimento Biochim, I-48026 Bologna, Italy; Univ So Calif, Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA	Scuola Superiore Sant'Anna; University of Bologna; University of Southern California	Solaini, G (corresponding author), Univ Perfezionamento S Anna, Scuola Super Studi, Settore Med, Via Carducci 40, I-56127 Pisa, Italy.	gsolaini@sssup.it	Lenaz, Giorgio/B-5751-2013	CARELLI, VALERIO/0000-0003-4923-6404; SOLAINI, GIANCARLO/0000-0001-7825-0446	Telethon [1048] Funding Source: Medline	Telethon(Fondazione Telethon)		Baracca A, 1997, BIOCHEM BIOPH RES CO, V235, P469, DOI 10.1006/bbrc.1997.6807; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Buchanan SK, 1996, BIOCHEM J, V318, P343, DOI 10.1042/bj3180343; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1989, J BIOL CHEM, V264, P3292; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; Carelli V, 1997, NEUROLOGY, V48, P1623, DOI 10.1212/WNL.48.6.1623; Casadio R, 1996, J BIOL INORG CHEM, V1, P284, DOI 10.1007/s007750050055; COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4; DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Fillingame RH, 1997, J EXP BIOL, V200, P217; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; HARTZOG PE, 1993, J BIOL CHEM, V268, P12250; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; HOLT IJ, 1990, AM J HUM GENET, V46, P428; HOUSTEK J, 1995, BBA-MOL BASIS DIS, V1271, P349, DOI 10.1016/0925-4439(95)00063-A; Howitt SM, 1996, J BIOENERG BIOMEMBR, V28, P415, DOI 10.1007/BF02113983; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KARRASCH S, 1998, EUR BIOENERG C SHORT, V10, P49; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386; MANN VM, 1992, BRAIN, V115, P333, DOI 10.1093/brain/115.2.333; MATSUNOYAGI A, 1986, J BIOL CHEM, V261, P14031; MATTHEWS PM, 1995, HUM GENET, V96, P261; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Papageorgiou S, 1998, J BIOENERG BIOMEMBR, V30, P533, DOI 10.1023/A:1020528432609; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PUDDU P, 1993, BRIT J OPHTHALMOL, V77, P84, DOI 10.1136/bjo.77.2.84; SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390; TATUCH Y, 1992, AM J HUM GENET, V50, P852; Tatuch Yuriy, 1994, European Journal of Human Genetics, V2, P35; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16; VazquezMemije ME, 1996, J INHERIT METAB DIS, V19, P43, DOI 10.1007/BF01799347; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	46	90	92	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4177	4182		10.1074/jbc.275.6.4177	http://dx.doi.org/10.1074/jbc.275.6.4177			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660580	hybrid			2022-12-25	WOS:000085288800064
J	Kassam, A; Winrow, CJ; Fernandez-Rachubinski, F; Capone, JP; Rachubinski, RA				Kassam, A; Winrow, CJ; Fernandez-Rachubinski, F; Capone, JP; Rachubinski, RA			The peroxisome proliferator response element of the gene encoding the peroxisomal beta-oxidation enzyme enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase is a target for constitutive androstane receptor beta/9-cis-retinoic acid receptor-mediated transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HYDRATASE-DEHYDROGENASE; NUCLEAR FACTOR-IV; ACTIVATED RECEPTOR; RETINOIC ACID; THYROID-HORMONE; FATTY-ACIDS; NGFI-B; ORPHAN; SUPERFAMILY; ALPHA	The genes encoding the first two enzymes of the peroxisomal beta-oxidation pathway, acyl-CoA oxidase (AOx) and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (HD), contain upstream cis-acting regulatory regions termed peroxisome proliferator response elements (PPRE), Transcription of these genes is mediated through the binding of peroxisome proliferator-activated receptor or (PPAR alpha), which binds to a PPRE as a heterodimer with the 9-cis-retinoic acid receptor (RXR alpha). Here we demonstrate that the HD-PPRE is also a target for the constitutive androstane receptor beta (CAR beta) In vitro binding analysis showed that CAR beta bound the HD-PPRE, but not the AOx-PPRE, as a heterodimer with RXR alpha, Binding of CAR beta/RXR alpha to the HD-PPRE occurred via determinants that overlap partially with those required for PPAR alpha/RXR alpha binding. In vivo, CAR beta/RXR alpha activated transcription from an HD-PPRE luciferase reporter construct, Interestingly, CAR beta was shown to also modulate PPAR alpha/RXR alpha-mediated transactivation in a response element-specific manner. In the presence of the peroxisome proliferator, Wy-14,643, CAR beta had no effect on PPAR alpha/RXR alpha-mediated transactivation from the HD-PPRE but antagonized transactivation from the AOx-PPRE in both the presence and the absence of proliferator, Our results illustrate that transcription of the AOx and HD genes is differentially regulated by CAR beta and that the HD gene is a specific target for regulation by CAR beta, Overall, this study proposes a novel role for CAR beta in the regulation of peroxisomal beta-oxidation.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	University of Alberta; University of Alberta; McMaster University	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, Med Sci Bldg 5-14, Edmonton, AB T6G 2H7, Canada.		Winrow, Christopher/K-1864-2014	Winrow, Christopher/0000-0001-8248-4157				BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; CARTER ME, 1993, J BIOL CHEM, V268, P13805; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; CHU RY, 1995, J BIOL CHEM, V270, P29636; DAVIS IJ, 1991, MOL ENDOCRINOL, V5, P854, DOI 10.1210/mend-5-6-854; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Feltkamp D, 1999, J BIOL CHEM, V274, P10421, DOI 10.1074/jbc.274.15.10421; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; Kassam A, 1999, J BIOL CHEM, V274, P22895, DOI 10.1074/jbc.274.32.22895; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; Picard D, 1998, NATURE, V395, P543, DOI 10.1038/26850; Rachubinski RA, 1999, J BIOL CHEM, V274, P18278, DOI 10.1074/jbc.274.26.18278; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Winrow Christopher J., 1994, Gene Expression, V4, P53; Winrow CJ, 1998, J BIOL CHEM, V273, P31442, DOI 10.1074/jbc.273.47.31442; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	41	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4345	4350		10.1074/jbc.275.6.4345	http://dx.doi.org/10.1074/jbc.275.6.4345			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660604	hybrid			2022-12-25	WOS:000085288800088
J	Nakagawa, T; Imanaka, T; Morita, M; Ishiguro, K; Yurimoto, H; Yamashita, A; Kato, N; Sakai, Y				Nakagawa, T; Imanaka, T; Morita, M; Ishiguro, K; Yurimoto, H; Yamashita, A; Kato, N; Sakai, Y			Peroxisomal membrane protein Pmp47 is essential in the metabolism of middle-chain fatty acid in yeast peroxisomes and is associated with peroxisome proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPOROGENOUS METHYLOTROPHIC YEAST; CANDIDA-BOIDINII; SACCHAROMYCES-CEREVISIAE; RAT-LIVER; BETA-OXIDATION; TRANSPORT; COA; EXPRESSION; IMPORT; ENZYME	Pmp47 of the methylotrophic yeast Candida boidinii belongs to a mitochondrial family of solute transporters and is localized in peroxisomal membranes. Its human homolog, Pmp34, is also known. In this study, we characterized the role of Pmp47 in fatty acid metabolism and peroxisome proliferation using the PMP47-deleted strain of C. boidinii (strain pmp47 Delta). The wild-type strain grew well on a middle-chain fatty acid, laureate, as the single carbon source, and mild peroxisome proliferation was observed during its growth. The pmp47 Delta strain could not grow on laureate but could grow on long-chain fatty acids including palmitate, myristate, and oleate, The levels of laureate oxidation activity in intact cells and in semi-permeabilized cells of strain pmp47 Delta were lower than the respective level in the wildtype strain, although the level of laureate oxidation activity in the cell lysate and the level of lauroyl-CoA oxidation in semi-permeabilized cells of strain pmp47 Delta were indistinguishable from the respective level in the wild-type strain. When lauroyl-CoA was provided in the cytosol of strain pmp47 Delta through expression of Saccharomyces cerevisiae Faa2p (lauroyl-CoA synthetase) in which its peroxisome targeting signal was deleted, the growth of strain pmp47 Delta on laureate was recovered to the level of growth of the wild-type strain. Laureate is converted to its CoA form in peroxisomes by the action of lauroyl-CoA synthetase, These results suggested that Pmp47 is involved in the transport of a small molecule (possibly ATP) required in the conversion of laureate to its CoA form in peroxisomes and that the absence of Pmp47 causes impairment of laureate metabolism, which results in the inability of pmp47 Delta cells to grow on laureate. In addition, Pmp47 may be involved in peroxisome proliferation, because the pmp47 Delta strain contained a reduced number of peroxisomes, as judged from the fluorescence analysis of cells expressing green fluorescent protein tagged with the peroxisome targeting signal 1(GFP-AKL).	Kyoto Univ, Div Appl Life Sci, Grad Sch Agr, Sakyo Ku, Kyoto 6068502, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sugitani, Toyama 9300194, Japan; Teikyo Univ, Fac Pharmaceut Sci, Dept Hyg Chem & Nutr, Sagamiko, Kanagawa 1990145, Japan	Kyoto University; University of Toyama; Teikyo University	Sakai, Y (corresponding author), Kyoto Univ, Div Appl Life Sci, Grad Sch Agr, Sakyo Ku, Kyoto 6068502, Japan.		Yurimoto, Hiroya/N-6538-2018	Yurimoto, Hiroya/0000-0001-7506-6184; Yamashita, Atsushi/0000-0002-2544-2134; Imanaka, Tsuneo/0000-0003-4677-1356; Nakagawa, Tomoyuki/0000-0003-0112-0349				Abumrad N, 1998, J LIPID RES, V39, P2309; BERGMEYER HU, 1955, BIOCHEM Z, V327, P255; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; GOODMAN JM, 1984, J BIOL CHEM, V259, P8485; GOODMAN JM, 1990, J CELL SCI, V97, P193; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; ICHIHARA K, 1991, J LIPID RES, V32, P1709; Imanaka T, 1999, J BIOL CHEM, V274, P11968, DOI 10.1074/jbc.274.17.11968; Ito K, 1998, J BIOL CHEM, V273, P1684, DOI 10.1074/jbc.273.3.1684; JANK B, 1993, TRENDS BIOCHEM SCI, V18, P427; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; SAKAI Y, 1992, J BACTERIOL, V174, P5988, DOI 10.1128/jb.174.18.5988-5993.1992; SAKAI Y, 1991, J BACTERIOL, V173, P7458, DOI 10.1128/jb.173.23.7458-7463.1991; SAKAI Y, 1994, BIO-TECHNOL, V12, P291, DOI 10.1038/nbt0394-291; Sakai Y, 1998, YEAST, V14, P1175, DOI 10.1002/(SICI)1097-0061(19980930)14:13<1175::AID-YEA319>3.3.CO;2-Z; Sakai Y, 1996, J CELL BIOL, V134, P37, DOI 10.1083/jcb.134.1.37; SAKAI Y, 1995, J BACTERIOL, V177, P6773, DOI 10.1128/jb.177.23.6773-6781.1995; SAKAI Y, 2000, IN PRESS CELL BIOCH; Sambrook J., 2002, MOL CLONING LAB MANU; Schrader M, 1998, J BIOL CHEM, V273, P29607, DOI 10.1074/jbc.273.45.29607; SHAFFER JE, 1994, CELL, V79, P427; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Tolbert N E, 1974, Methods Enzymol, V31, P734; VANHOOREN JCT, 1994, INT J BIOCHEM, V26, P1095, DOI 10.1016/0020-711X(94)90131-7; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; Wylin T, 1998, EUR J BIOCHEM, V258, P332, DOI 10.1046/j.1432-1327.1998.2580332.x; YAMASHITA A, 1995, BIOCHEM J, V312, P301, DOI 10.1042/bj3120301; ZHOU SL, 1994, BIOCHEM J, V297, P315, DOI 10.1042/bj2970315	36	39	40	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3455	3461		10.1074/jbc.275.5.3455	http://dx.doi.org/10.1074/jbc.275.5.3455			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652339	hybrid			2022-12-25	WOS:000085146500061
J	Oyarce, AM; Eipper, BA				Oyarce, AM; Eipper, BA			Cell type-specific storage of dopamine beta-monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; PEPTIDE-PROCESSING ENZYME; GRANULE MEMBRANE-PROTEIN; UNCLEAVED SIGNAL PEPTIDE; SECRETORY GRANULES; ENDOPLASMIC-RETICULUM; ATT-20 CELLS; CHROMAFFIN GRANULES; MESSENGER-RNA; PHEOCHROMOCYTOMA CELLS	Expression of dopamine P-monooxygenase (DBM), the enzyme that converts dopamine into norepinephrine, is limited to adrenal chromaffin cells and a small population of neurons. We studied DBM trafficking to regulated granules by stably expressing rat DBM in AtT-20 corticotrope tumor cells, which contain regulated granules, and in Chinese hamster ovary (CHO) cells, which lack regulated granules. The behavior of exogenous DBM in both cell lines was compared with endogenous DEM in adrenal chromaffin cells. CHO cells secreted active DBM, indicating that production of active enzyme does not require features unique to neuroendocrine cells. Pulse-chase experiments indicated that early steps in DBM maturation followed a similar time course in AtT-20, CHO, and adrenal chromaffin cells. Use of a conformation-sensitive DBM antiserum indicated that acquisition of a folded structure occurred with a similar time course in all three cell types. Cell type-specific differences in DBM trafficking became apparent only when storage in granules was examined. As expected, DBM was stored in secretory granules in chromaffin cells; CHO cells failed to store DBM. Despite the fact that AtT-20 cells have regulated granules, exogenous DBM was not stored in these granules. Thus storage of DBM in secretory granules requires cell type specific factors.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Eipper, BA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, WBSB 907,725 N Wolfe St, Baltimore, MD 21205 USA.				NIDA NIH HHS [DA-11269, DA-00266] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA011269, P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BAEHR W, 1988, FEBS LETT, V238, P253, DOI 10.1016/0014-5793(88)80490-3; BASTIAENSEN E, 1989, FEBS LETT, V244, P477, DOI 10.1016/0014-5793(89)80587-3; BLACKBOROUGH P, 1981, ARCH BIOCHEM BIOPHYS, V669, P33; Boswell JS, 1996, BIOCHEMISTRY-US, V35, P12241, DOI 10.1021/bi960742y; BRAAS KM, 1989, MOL ENDOCRINOL, V3, P1387, DOI 10.1210/mend-3-9-1387; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; CASTLE AM, 1995, J CELL SCI, V108, P3827; CASTLE AM, 1992, J BIOL CHEM, V267, P13093; COLOMER V, 1994, EMBO J, V13, P3711, DOI 10.1002/j.1460-2075.1994.tb06680.x; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; CORCORAN JJ, 1990, AM J PHYSIOL, V259, pC161, DOI 10.1152/ajpcell.1990.259.1.C161; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1993, PROTEIN SCI, V2, P489; FENG ZH, 1992, J BIOL CHEM, V267, P21808; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GIBSON KR, 1993, J BIOL CHEM, V268, P9490; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1978, J NEUROCHEM, V30, P549, DOI 10.1111/j.1471-4159.1978.tb07808.x; Grimmelikhuijzen CJP, 1996, INT REV CYTOL, V167, P37, DOI 10.1016/S0074-7696(08)61345-5; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; HODGES RS, 1988, J BIOL CHEM, V263, P11768; HOFLE G, 1991, REGUL PEPTIDES, V32, P321, DOI 10.1016/0167-0115(91)90025-C; HOUHOU L, 1995, J BIOL CHEM, V270, P12601, DOI 10.1074/jbc.270.21.12601; HUGHES EN, 1981, J BIOL CHEM, V256, P664; HURTLEY SM, 1993, J CELL SCI, V106, P649; JUNG LJ, 1993, J CELL BIOL, V121, P11, DOI 10.1083/jcb.121.1.11; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; KULATHILA R, 1994, ARCH BIOCHEM BIOPHYS, V311, P191, DOI 10.1006/abbi.1994.1225; LADURON PM, 1975, FEBS LETT, V52, P132, DOI 10.1016/0014-5793(75)80654-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS EJ, 1992, J BIOL CHEM, V267, P494; Li B, 1996, BIOCHEM J, V313, P57, DOI 10.1042/bj3130057; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Mains R E, 1980, Ann N Y Acad Sci, V343, P94, DOI 10.1111/j.1749-6632.1980.tb47245.x; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MAINS RE, 1990, TRENDS ENDOCRIN MET, V1, P388, DOI 10.1016/1043-2760(90)90097-M; MALTESE JY, 1993, ENDOCRINOLOGY, V133, P2579, DOI 10.1210/en.133.6.2579; MARGOLIS RK, 1984, ARCH BIOCHEM BIOPHYS, V228, P443, DOI 10.1016/0003-9861(84)90009-2; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MERKLER DJ, 1995, FEBS LETT, V366, P165, DOI 10.1016/0014-5793(95)00516-C; Milgram SL, 1996, MOL ENDOCRINOL, V10, P837, DOI 10.1210/me.10.7.837; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Milgram SL, 1997, J CELL SCI, V110, P695; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; Muller L, 1999, J BIOL CHEM, V274, P21471, DOI 10.1074/jbc.274.30.21471; Muresan Z, 1997, J BIOL CHEM, V272, P26095, DOI 10.1074/jbc.272.42.26095; OYARCE AM, 1991, ARCH BIOCHEM BIOPHYS, V290, P503, DOI 10.1016/0003-9861(91)90573-2; OYARCE AM, 1989, J MOL NEUROSCI, V1, P171, DOI 10.1007/BF02918903; OYARCE AM, 1995, J CELL SCI, V108, P287; Partoens P, 1998, J CELL SCI, V111, P681; POTTER LT, 1963, J PHARMACOL EXP THER, V142, P291; ROBERTSON JG, 1994, BIOCHEMISTRY-US, V33, P11563, DOI 10.1021/bi00204a019; Rosenberg JB, 1998, J CLIN INVEST, V101, P613, DOI 10.1172/JCI1250; Rowe J, 1999, J CELL SCI, V112, P1865; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SABBAN EL, 1989, BIOCHEM INT, V19, P769; SAXENA A, 1983, J BIOL CHEM, V258, P4147; SAXENA A, 1985, J BIOL CHEM, V260, P3386; Slot JW, 1997, J CELL BIOL, V137, P1243, DOI 10.1083/jcb.137.6.1243; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; TAYLOR CS, 1989, J BIOL CHEM, V264, P15242; THIELE EA, 1990, ENDOCRINOLOGY, V126, P809, DOI 10.1210/endo-126-2-809; VINDROLA O, 1993, NEUROPEPTIDES, V25, P151, DOI 10.1016/0143-4179(93)90096-S; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WIMALASENA K, 1991, ANAL BIOCHEM, V197, P353, DOI 10.1016/0003-2697(91)90404-H; WINKLER H, 1993, J ANAT, V183, P237; WONG DL, 1990, NEUROPSYCHOPHARMACOL, V3, P115; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	83	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3270	3278		10.1074/jbc.275.5.3270	http://dx.doi.org/10.1074/jbc.275.5.3270			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652314	hybrid			2022-12-25	WOS:000085146500036
J	Park, PW; Pier, GB; Preston, MJ; Goldberger, O; Fitzgerald, ML; Bernfield, M				Park, PW; Pier, GB; Preston, MJ; Goldberger, O; Fitzgerald, ML; Bernfield, M			Syndecan-1 shedding is enhanced by LasA, a secreted virulence factor of Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; NECROSIS-FACTOR RECEPTOR; CELL-SURFACE; METALLOPROTEASE INHIBITOR; EPITHELIAL-CELLS; FACTOR-ALPHA; L-SELECTIN; BACTERIAL PROTEINASES; BORDETELLA-PERTUSSIS; MAMMALIAN-CELLS	Microbial pathogens frequently take advantage of host systems for their pathogenesis. Shedding of cell surface molecules as soluble extracellular domains (ectodomains) is one of the host responses activated during tissue injury. In this study, we examined whether pathogenic bacteria can modulate shedding of syndecan-1, the predominant syndecan of host epithelia. Our studies found that overnight culture supernatants of Pseudomonas aeruginosa and Staphylococcus aureus enhanced the shedding of syndecan-1 ectodomains, whereas culture supernatants of several other Gramnegative and Gram-positive bacteria had only low levels of activity. Because supernatants from all tested strains of P, aeruginosa (n = 9) enhanced syndecan-1 shedding by more than 4-fold above control levels, we focused our attention on this Gram-negative bacterium. Culture supernatants of P. aeruginosa increased shedding of syndecan-1 in both a concentration- and time-dependent manner, and augmented shedding by various host cells. A 20-kDa shedding enhancer was partially purified from the supernatant through ammonium sulfate precipitation and gel chromatography, and identified by N-terminal sequencing as LasA, a known P. aeruginosa virulence factor. LasA was subsequently determined to be a syndecan-1 shedding enhancer from the findings that (i) immunodepletion of LasA from the partially purified sample resulted in abrogation of its activity to enhance shedding and (ii) purified LasA increased shedding in a concentration-dependent manner. Our results also indicated that LasA enhances syndecan-1 shedding by activation of the host cell's shedding mechanism and not by direct interaction with syndecan-1 ectodomains, Enhanced syndecan-1 shedding may be a means by which pathogenic bacteria take advantage of a host mechanism to promote their pathogenesis.	Harvard Univ, Childrens Hosp, Sch Med, Dept Med,Div Newborn Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bernfield, M (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Med,Div Newborn Med, 300 Longwood Ave,Enders 9, Boston, MA 02115 USA.	bernfield@a1.tch.harvard.edu	Pier, Gerald/AAO-2692-2021	Pier, Gerald/0000-0002-9112-2331; Park, Pyong Woo/0000-0002-7979-4979	NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER; NCI NIH HHS [CA28735] Funding Source: Medline; NHLBI NIH HHS [HL569398] Funding Source: Medline; NIAID NIH HHS [AI22535] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BAZIL V, 1991, J IMMUNOL, V147, P1567; Bennett TA, 1996, J IMMUNOL, V156, P3093; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BLACKWOOD LL, 1983, INFECT IMMUN, V39, P198, DOI 10.1128/IAI.39.1.198-201.1983; Blum H, 1996, J IMMUNOL, V157, P1846; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Frey M, 1997, J IMMUNOL, V158, P5424; GALLOWAY DR, 1991, MOL MICROBIOL, V5, P2315, DOI 10.1111/j.1365-2958.1991.tb02076.x; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Gustin JK, 1996, J BACTERIOL, V178, P6608, DOI 10.1128/jb.178.22.6608-6617.1996; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hayashi J, 1999, INFECT IMMUN, V67, P417, DOI 10.1128/IAI.67.1.417-420.1999; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kessler E, 1997, J BIOL CHEM, V272, P9884; Kessler E, 1998, J BIOL CHEM, V273, P30225, DOI 10.1074/jbc.273.46.30225; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; LEININGER E, 1991, P NATL ACAD SCI USA, V88, P345, DOI 10.1073/pnas.88.2.345; Manna SK, 1998, J BIOL CHEM, V273, P33333, DOI 10.1074/jbc.273.50.33333; Mattsson E, 1996, INFECT IMMUN, V64, P4351, DOI 10.1128/IAI.64.10.4351-4355.1996; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Munk ME, 1999, INFECT IMMUN, V67, P423, DOI 10.1128/IAI.67.1.423-425.1999; Okamoto T, 1997, J BIOL CHEM, V272, P6059, DOI 10.1074/jbc.272.9.6059; Ott VL, 1998, J BIOL CHEM, V273, P35291, DOI 10.1074/jbc.273.52.35291; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PETERS JE, 1990, J BACTERIOL, V172, P2236, DOI 10.1128/jb.172.5.2236-2240.1990; Preston MJ, 1997, INFECT IMMUN, V65, P3086, DOI 10.1128/IAI.65.8.3086-3090.1997; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Rostand KS, 1997, INFECT IMMUN, V65, P1; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; SUTER S, 1994, AM J RESP CRIT CARE, V150, pS118, DOI 10.1164/ajrccm/150.6_Pt_2.S118; TRAVIS J, 1995, TRENDS MICROBIOL, V3, P405, DOI 10.1016/S0966-842X(00)88988-X; Vollmer P, 1996, INFECT IMMUN, V64, P3646, DOI 10.1128/IAI.64.9.3646-3651.1996; Walev I, 1996, P NATL ACAD SCI USA, V93, P7882, DOI 10.1073/pnas.93.15.7882; WICK MJ, 1991, CELL, V67, P651; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; WOODS DE, 1982, INFECT IMMUN, V36, P1223, DOI 10.1128/IAI.36.3.1223-1228.1982	59	116	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3057	3064		10.1074/jbc.275.5.3057	http://dx.doi.org/10.1074/jbc.275.5.3057			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652286	hybrid			2022-12-25	WOS:000085146500008
J	Huang, DY; Shenoy, A; Cui, JK; Huang, WY; Liu, PK				Huang, DY; Shenoy, A; Cui, JK; Huang, WY; Liu, PK			In situ detection of AP sites and DNA strand breaks bearing 3 '-phosphate termini in ischemic mouse brain	FASEB JOURNAL			English	Article						aging; apoptosis; oxidative DNA damage; DNA repair; stroke	NITRIC-OXIDE SYNTHASE; MITOCHONDRIAL-DNA; OXIDATIVE DAMAGE; FOREBRAIN ISCHEMIA; CELL-DEATH; NUCLEAR; 7-NITROINDAZOLE; REPAIR; EXCITOTOXICITY; MUTAGENESIS	Our aims were to examine whether oxidative DNA damage was elevated in brain cells of male C57BL/6 mice after oxidative stress, and to determine whether neuronal nitric oxide synthase (nNOS) was involved in such damage. Oxidative stress was induced by occluding both common carotid arteries for 90 min, followed by reperfusion, Escherichia coli exonuclease LII (Exo III) removes apyrimidinic or apurinic (AP) sites and 3'-phosphate termini in single-strand breaks, and converts these lesions to 3'OH termini. These ExoIII-sensitive sites (EXOSS) can then be postlabeled using digoxigenin11-dUTP and Klenow DNA polymerase-I, and detected using fluorescein isothiocyanate-IgG against digoxigenin, Compared with the non-ischemia controls, the density of EXOSS-positive cells was elevated at least 20-fold (P < 0.01) at 15 min of reperfusion, and remained elevated for another 30 min. EXOSS mainly occurred in the cell nuclei of the astrocytes and neurons. Signs of cell death were detected at 24 h of reperfusion and occurred mostly in the neurons. Both DNA damage and cell death in the cerebral cortical neurons were abolished by treatment with 3-bromo-7-nitroindazole (30 mg/kg, intraperitoneal), which specifically inhibited nNOS. Our results suggest that nNOS, its activator (calcium), and peroxynitrite exacerbate oxidative DNA damage after brain ischemia.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Baylor College of Medicine	Liu, PK (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Suite 944, Houston, TX 77030 USA.	philipl@bcm.tmc.edu			NINDS NIH HHS [R01 NS034810-04, NS34810, R01 NS034810-04S1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034810] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ayata C, 1997, J NEUROSCI, V17, P6908; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Chen J, 1997, J NEUROCHEM, V69, P232; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Cork RJ, 1998, PROG BRAIN RES, V118, P37; CUI J, 1999, J NEUROCHEM, V73, P1; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gobbel GT, 1998, J NEUROSCI, V18, P147; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HENNER WD, 1982, J BIOL CHEM, V257, P1750; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Iadecola C, 1997, J NEUROSCI, V17, P9157; INOUE S, 1995, FEBS LETT, V371, P86, DOI 10.1016/0014-5793(95)00873-8; KAMII H, 1994, J CEREB BLOOD FLOW M, V16, P153; Kawase M, 1999, STROKE, V30, P441, DOI 10.1161/01.STR.30.2.441; Kisby GE, 1997, NEUROREPORT, V8, P1337, DOI 10.1097/00001756-199704140-00004; KOH JY, 1988, J NEUROSCI, V8, P2153, DOI 10.1523/jneurosci.08-06-02153.1988; KORNBERG A, 1980, EXONUCLEASE, V3, P324; LIN L, 2000, IN PRESS J NEUROCHEM; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu JK, 1996, FASEB J, V10, P1532, DOI 10.1096/fasebj.10.13.8940299; Liu PK, 1999, STROKE THERAPY, P299; LIU PK, 1994, ANN NEUROL, V36, P566, DOI 10.1002/ana.410360405; Liu PK, 1996, J NEUROSCI, V16, P6795; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; Murakami K, 1998, J NEUROSCI, V18, P205; Nanri K, 1998, STROKE, V29, P1248, DOI 10.1161/01.STR.29.6.1248; Nunomura A, 1999, J NEUROSCI, V19, P1959; ONeill MJ, 1996, EUR J PHARMACOL, V310, P115, DOI 10.1016/0014-2999(96)00387-1; Parshad R, 1996, P NATL ACAD SCI USA, V93, P5146, DOI 10.1073/pnas.93.10.5146; READON JT, 1997, P NATL ACAD SCI USA, V94, P9463; Schulz JB, 1995, J NEUROSCI, V15, P8419; SHALL S, 1995, BIOCHIMIE, V77, P313, DOI 10.1016/0300-9084(96)88140-5; Shimizu-Sasamata M, 1998, J NEUROSCI, V18, P9564; Suzuki M, 1997, J BIOL CHEM, V272, P11228; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; Zhuang JC, 1998, P NATL ACAD SCI USA, V95, P8286, DOI 10.1073/pnas.95.14.8286	48	53	59	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					407	417		10.1096/fasebj.14.2.407	http://dx.doi.org/10.1096/fasebj.14.2.407			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657997	Green Accepted			2022-12-25	WOS:000085184800020
J	Lian, JP; Marks, PG; Wang, JY; Falls, DL; Badwey, JA				Lian, JP; Marks, PG; Wang, JY; Falls, DL; Badwey, JA			A protein kinase from neutrophils that specifically recognizes Ser-3 in cofilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-DEPOLYMERIZING FACTOR; NADPH OXIDASE COMPLEX; STIMULATED HUMAN-NEUTROPHILS; RESPIRATORY BURST OXIDASE; P21-ACTIVATED KINASES; RAPID ACTIVATION; PHOSPHORYLATION; DEPHOSPHORYLATION; COMPONENTS; IDENTIFICATION	Cofilin promotes the depolymerization of actin filaments, which is required for a variety of cellular responses such as the formation of lamellipodia and chemotaxis. Phosphorylation of cofilin on serine residue 3 is known to block these activities. We now report that neutrophils contain a protein kinase that selectively catalyzes the phosphorylation of cofilin on serine 3 (greater than or equal to 70%) and a nonspecific kinase that recognizes multiple sites in this protein. The selective serine 3 cofilin kinase binds to a deoxyribonuclease I affinity column, whereas the nonspecific cofilin kinase does not. Deoxyribonuclease I forms a very tight complex with actin, and deoxyribonuclease affinity columns have been utilized to identify a variety of proteins that interact with the cytoskeleton. The serine 3 cofilin kinase did not react with antibodies to LIM kinase 1 or 2, which can catalyze the phosphorylation of cofilin in other cell types. The activity of the serine 3 cofilin kinase was insensitive to a variety of selective antagonists of protein kinases but was blocked by staurosporine. This pattern of inhibition is similar to that observed for the kinase that is active with cofilin in intact neutrophils. Thus, neutrophils contain a protein kinase distinct from LIM kinase-1/2 that selectively recognizes serine 3 in cofilin.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Boston Biomed Res Inst, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Emory University; Boston Biomedical Research Institute	Badwey, JA (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Thorn Bldg,Rm 703,75 Francis St, Boston, MA 02115 USA.				NHLBI NIH HHS [K08 HL-03235] Funding Source: Medline; NIAID NIH HHS [AI 23323] Funding Source: Medline; NIDDK NIH HHS [DK 50015] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050015] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Badwey J A, 1986, Methods Enzymol, V132, P365; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; DING JB, 1993, J BIOL CHEM, V268, P5234; Ding JB, 1996, J BIOL CHEM, V271, P24869, DOI 10.1074/jbc.271.40.24869; Djafarzadeh S, 1997, EXP CELL RES, V236, P427, DOI 10.1006/excr.1997.3731; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heyworth PG, 1997, HISTOCHEM CELL BIOL, V108, P221, DOI 10.1007/s004180050162; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; Huang RY, 1998, MOL CELL BIOL, V18, P7130, DOI 10.1128/MCB.18.12.7130; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOLBE HVJ, 1985, J BIOL CHEM, V260, P5899; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lian JP, 1997, FEBS LETT, V404, P211, DOI 10.1016/S0014-5793(97)00134-8; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, NATURE, V401, P542, DOI 10.1038/44044; MARKEY F, 1981, CELL, V23, P145, DOI 10.1016/0092-8674(81)90279-8; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; OGAWA K, 1990, NUCLEIC ACIDS RES, V18, P7169, DOI 10.1093/nar/18.23.7169; Okada K, 1996, EXP CELL RES, V227, P116, DOI 10.1006/excr.1996.0256; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; PAPPIN DJC, 1990, ANAL BIOCHEM, V187, P10, DOI 10.1016/0003-2697(90)90410-B; *PIERC CHEM CO, 1996, SUP SUBSTR W BLOTT K; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; Ressad F, 1999, J BIOL CHEM, V274, P20970, DOI 10.1074/jbc.274.30.20970; ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021; Rodal AA, 1999, J CELL BIOL, V145, P1251, DOI 10.1083/jcb.145.6.1251; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Smertenko AP, 1998, PLANT J, V14, P187, DOI 10.1046/j.1365-313X.1998.00107.x; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; SUZUKI K, 1995, J BIOL CHEM, V270, P19551, DOI 10.1074/jbc.270.33.19551; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Wang JY, 1998, J BIOL CHEM, V273, P20525, DOI 10.1074/jbc.273.32.20525; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; WYMANN MP, 1989, J BIOL CHEM, V264, P15829; WYMANN MP, 1990, J BIOL CHEM, V265, P619; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; ZIGMOND SH, 1993, CELL MOTIL CYTOSKEL, V25, P309, DOI 10.1002/cm.970250402	51	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2869	2876		10.1074/jbc.275.4.2869	http://dx.doi.org/10.1074/jbc.275.4.2869			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644754	hybrid			2022-12-25	WOS:000085128000086
J	Pari, K; Sundari, CS; Chandani, S; Balasubramanian, D				Pari, K; Sundari, CS; Chandani, S; Balasubramanian, D			beta-Carbolines that accumulate in human tissues may serve a protective role against oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSSIBLE CAUSATIVE SUBSTANCE; CHAPERONE-LIKE ACTIVITY; 1-METHYL-1,2,3,4-TETRAHYDRO-BETA-CARBOLINE-3-CARBOXYLIC ACID; ALPHA-CRYSTALLIN; L-TRYPTOPHAN; EYE LENS; MAILLARD REACTION; ALKALOIDS; IDENTIFICATION; INGESTION	beta-Carbolines are tricyclic nitrogen heterocycles formed in plants and animals as Maillard reaction products between amino acids and reducing sugars or aldehydes. They are being detected increasingly in human tissues, and their physiological roles need to be understood. Two beta-carboline carboxylates have been reported to accumulate in the human eye lens. We report here on the identification of another beta-carboline, namely 1-methyl-1-vinyl -2,3,4 trihydro-beta-caboline-3-carboxylic acid, in the lenses of some cataract patients from India. Analysis of these three lenticular beta-carbolines using photodynamic and antioxidant assays shows all of them to be inert as sensitizers and effective as antioxidants; they quench singlet oxygen, superoxide and hydroxyl radicals and inhibit the oxidative formation of higher molecular weight aggregates of the test protein, eye lens crystallin. Such antioxidative ability of beta-carbolines is of particular relevance to the lens, which faces continual photic and oxidative stress. The beta-carboline diacid TV is also seen to display an unexpected ability of inhibiting the thermal coagulation of gamma-crystallin and the dithiothreitol-induced precipitation of insulin. These results offer experimental support to earlier suggestions that one of the roles that the beta-carbolines have is to offer protection against oxidative stress to the human tissues where they accumulate.	Hyderabad Eye Res Fdn, L V Prasad Eye Inst, Hyderabad 500034, Andhra Pradesh, India; Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	L. V. Prasad Eye Institute; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Balasubramanian, D (corresponding author), Hyderabad Eye Res Fdn, L V Prasad Eye Inst, Rd Number 2, Hyderabad 500034, Andhra Pradesh, India.				NATIONAL EYE INSTITUTE [R01EY010888] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY 10888] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAMOVITCH RA, 1964, ADV HETEROCYCL CHEM, V3, P79, DOI 10.1016/S0065-2725(08)60542-5; ADACHI J, 1991, J NUTR, V121, P646, DOI 10.1093/jn/121.5.646; ADACHI J, 1991, ARCH TOXICOL, V65, P505, DOI 10.1007/BF01977365; AIRAKSINEN MM, 1981, MED BIOL, V59, P21; ALLEN JRF, 1980, PHYTOCHEMISTRY, V19, P1573, DOI 10.1016/S0031-9422(00)83773-5; Balon M, 1998, PHOTOCHEM PHOTOBIOL, V67, P414; BROSSI A, 1973, J MED CHEM, V16, P418, DOI 10.1021/jm00262a027; CHAE KH, 1986, B KOR CHEM SOC, V7, P478; CHAKRABARTI B, 1986, J INDIAN CHEM SOC, V63, P131; CHEN RF, 1965, SCIENCE, V150, P1593, DOI 10.1126/science.150.3703.1593; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; DIAS A, 1992, J PHYS CHEM-US, V96, P10290, DOI 10.1021/j100204a036; DILLON J, 1976, NATURE, V259, P422, DOI 10.1038/259422a0; EICHNER K, 1981, PROG FOOD NUTR SCI, V5, P441; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Hofmann T, 1998, J AGR FOOD CHEM, V46, P932, DOI 10.1021/jf970732j; HOLMSTEDT B, 1982, JBETA CARBOLINES TET, P3; KAWASHIMA Y, 1995, CHEM PHARM BULL, V43, P783; KOPPENOL WH, 1984, ISR J CHEM, V24, P11; KRALJIC I, 1978, PHOTOCHEM PHOTOBIOL, V28, P577, DOI 10.1111/j.1751-1097.1978.tb06972.x; Krebs HC, 1997, J NAT PROD, V60, P1183, DOI 10.1021/np970283h; KRISHNA CM, 1991, PHOTOCHEM PHOTOBIOL, V54, P51, DOI 10.1111/j.1751-1097.1991.tb01984.x; LARSON RA, 1988, PHOTOCHEM PHOTOBIOL, V48, P665, DOI 10.1111/j.1751-1097.1988.tb02879.x; LINGNERT H, 1983, J AGR FOOD CHEM, V31, P27, DOI 10.1021/jf00115a007; LUTHRA M, 1992, EXP EYE RES, V55, P641, DOI 10.1016/S0014-4835(05)80177-0; LUTHRA M, 1994, FEBS LETT, V349, P39, DOI 10.1016/0014-5793(94)00635-0; Manabe S, 1996, EXP EYE RES, V63, P179, DOI 10.1006/exer.1996.0106; MANDAL K, 1988, PHOTOCHEM PHOTOBIOL, V47, P583, DOI 10.1111/j.1751-1097.1988.tb08848.x; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Miller Nicholas J., 1993, Biochemical Society Transactions, V21, p95S; MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407; NAGAHARA A, 1991, FOOD CHEM TOXICOL, V29, P243, DOI 10.1016/0278-6915(91)90021-X; OGAWA Y, 1993, ARCH TOXICOL, V67, P290, DOI 10.1007/BF01974349; PERIASAMY N, 1988, J CHEM PHYS, V88, P1638, DOI 10.1063/1.454143; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; Rommelspacher H, 1985, Prog Drug Res, V29, P415; WAKABAYASHI K, 1983, P NATL ACAD SCI-BIOL, V80, P2912, DOI 10.1073/pnas.80.10.2912; YEN GC, 1995, J AGR FOOD CHEM, V43, P415; ZIGLER JS, 1985, ARCH BIOCHEM BIOPHYS, V241, P163, DOI 10.1016/0003-9861(85)90372-8	40	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2455	2462		10.1074/jbc.275.4.2455	http://dx.doi.org/10.1074/jbc.275.4.2455			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644699	hybrid			2022-12-25	WOS:000085128000031
J	Behrendt, N; Jensen, ON; Engelholm, LH; Mortz, E; Mann, M; Dano, K				Behrendt, N; Jensen, ON; Engelholm, LH; Mortz, E; Mann, M; Dano, K			A urokinase receptor-associated protein with specific collagen binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; SECRETORY PHOSPHOLIPASES A(2); MACROPHAGE MANNOSE RECEPTOR; LINKED IMMUNOSORBENT-ASSAY; MEDIATED CELL-ADHESION; PLASMINOGEN-ACTIVATOR; MEMBRANE-RECEPTOR; V COLLAGEN; STRUCTURAL REQUIREMENTS; CONNECTIVE-TISSUE	The plasminogen activation cascade system, directed by urokinase and the urokinase receptor, plays a key role in extracellular proteolysis during tissue remodeling, To identify molecular interaction partners of these trigger proteins on the cell, we combined covalent protein cross-linking with mass spectrometry based methods for peptide mapping and primary structure analysis of electrophoretically isolated protein conjugates, A specific tri-molecular complex was observed upon addition of pro-urokinase to human U937 cells. This complex included the urokinase receptor, pro-urokinase, and an unknown, high molecular weight urokinase receptor-associated protein. The tryptic peptide mixture derived from a cross-linked complex of pro-urokinase and the latter protein was analyzed by nanoelectrospray tandem mass spectrometric sequencing. This analysis identified the novel protein as the human homologue of a murine membrane-bound lectin with hitherto unknown function, The human cDNA was cloned and sequenced. The protein, designated uPARAP, is a member of the macrophage mannose receptor protein family and contains a putative collagen-binding (fibronectin type II) domain in addition to 8 C-type carbohydrate recognition domains. It proved capable of binding strongly to a single type of collagen, collagen V. This collagen binding reaction at the exact site of plasminogen activation on the cell may lead to adhesive functions as well as a contribution to cellular degradation of collagen matrices.	Rigshosp, Finsen Lab, DK-2100 Copenhagen 0, Denmark; EMBL, Prot & Peptide Grp, Heidelberg, Germany; Odense Univ, Dept Mol Biol, DK-5230 Odense, Denmark	Rigshospitalet; University of Copenhagen; European Molecular Biology Laboratory (EMBL); University of Southern Denmark	Behrendt, N (corresponding author), Rigshosp, Finsen Lab, Strandboulevarden 49,Bldg 7-2, DK-2100 Copenhagen 0, Denmark.		Jensen, Ole N/J-1763-2012; Mann, Matthias/A-3454-2013	Jensen, Ole N/0000-0003-1862-8528; Mann, Matthias/0000-0003-1292-4799; Engelholm, Lars/0000-0002-6616-1232; Behrendt, Niels/0000-0003-1833-3922; Mortz, Ejvind/0000-0002-4381-1546				ADACHI E, 1994, J ELECTRON MICROSC, V43, P264; Adachi E, 1997, INT REV CYTOL, V173, P73; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BANYAI L, 1994, BIOCHEM J, V298, P403, DOI 10.1042/bj2980403; BANYAI L, 1990, EUR J BIOCHEM, V193, P801, DOI 10.1111/j.1432-1033.1990.tb19403.x; BEHRENDT N, 1993, METHOD ENZYMOL, V223, P207; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; Behrendt N, 1998, FIBRINOLYSIS PROTEOL, V12, P191, DOI 10.1016/S0268-9499(98)80013-1; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BEHRENDT N, 1993, FEBS LETT, V336, P394, DOI 10.1016/0014-5793(93)80844-K; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; FICHARD A, 1995, MATRIX BIOL, V14, P515, DOI 10.1016/S0945-053X(05)80001-0; GOLDFARB RH, 1986, SEMIN THROMB HEMOST, V12, P294, DOI 10.1055/s-2007-1003570; GRONDAHLHANSEN J, 1988, J LAB CLIN MED, V111, P42; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; Jensen ON, 1997, ANAL CHEM, V69, P4741, DOI 10.1021/ac970896z; JENSEN ON, 1997, PROTEIN STRUCTURE PR, P29; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; MUMBY SM, 1984, J CELL BIOL, V98, P646, DOI 10.1083/jcb.98.2.646; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; NICOLAS JP, 1995, J BIOL CHEM, V270, P28869, DOI 10.1074/jbc.270.48.28869; NIELSEN LS, 1986, J IMMUNOASSAY, V7, P209, DOI 10.1080/01971528608060467; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; NIYIBIZI C, 1994, BIOCHEM BIOPH RES CO, V202, P328, DOI 10.1006/bbrc.1994.1931; NIYIBIZI C, 1989, CONNECT TISSUE RES, V20, P247, DOI 10.3109/03008208909023894; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; O'Farrell TJ, 1998, ARCH BIOCHEM BIOPHYS, V354, P24, DOI 10.1006/abbi.1998.0662; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; Ruggiero F, 1996, J CELL SCI, V109, P1865; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; SANE DC, 1990, J BIOL CHEM, V265, P3543; Shevchenko A, 1997, J PROTEIN CHEM, V16, P481, DOI 10.1023/A:1026361427575; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; Taylor ME, 1997, GLYCOBIOLOGY, V7, pR5; Todd RF, 1997, J LAB CLIN MED, V129, P492, DOI 10.1016/S0022-2143(97)90003-2; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wu K, 1996, J BIOL CHEM, V271, P21323, DOI 10.1074/jbc.271.35.21323; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	69	124	132	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1993	2002		10.1074/jbc.275.3.1993	http://dx.doi.org/10.1074/jbc.275.3.1993			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636902	hybrid			2022-12-25	WOS:000084940000065
J	Han, S; Takahashi, S; Rousseau, DL				Han, S; Takahashi, S; Rousseau, DL			Time dependence of the catalytic intermediates in cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY OXYGEN INTERMEDIATE; RESONANCE RAMAN-SPECTRA; ELECTRON-TRANSFER; HYDROGEN-PEROXIDE; ROOM-TEMPERATURE; 2.8 ANGSTROM; PARACOCCUS-DENITRIFICANS; RHODOBACTER-SPHAEROIDES; AMBIENT-TEMPERATURE; DIOXYGEN REACTION	Cytochrome c oxidase, the terminal enzyme in the electron transfer chain, catalyzes the reduction of oxygen to water in a multiple step process by utilizing four electrons from cytochrome c, To study the reaction mechanism, the resonance Raman spectra of the intermediate states were measured during single turnover of the enzyme after catalytic initiation by photolysis of CO from the fully reduced GO-bound enzyme. By measuring the change in intensity of lines associated with heme a, the electron transfer steps were determined and found to be biphasic with apparent rate constants of similar to 40 x 10(3) s(-1) and similar to 1 x 10(3) s(-1). The time dependence for the oxidation of heme a and for the measured formation and decay of the oxy, the ferryl ("F"), and the hydroxy intermediates could be simulated by a simple reaction scheme. In this scheme, the presence of the "peroxy" ("P") intermediate does not build up a sufficient population to be detected because its decay rate is too fast in buffered H2O at neutral pH. A comparison of the change in the spin equilibrium with the formation of the hydroxy intermediate demonstrates that this intermediate is high spin. We also confirm the presence of an oxygen isotope-sensitive line at 355 cm(-1), detectable in the spectrum from 130 to 980 mu s, coincident with the presence of the F intermediate.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Kyoto Univ, Kyoto 6068501, Japan	Yeshiva University; Albert Einstein College of Medicine; Kyoto University	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Ullmann 313, Bronx, NY 10461 USA.	rousseau@accom.yu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054806, R01GM054812] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54812, GM54806] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGADE PV, 1986, BIOPHYS J, V50, P613, DOI 10.1016/S0006-3495(86)83500-7; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BABCOCK GT, 1981, BIOCHEMISTRY-US, V20, P959, DOI 10.1021/bi00507a049; BABCOCK GT, 1979, BIOCHEMISTRY-US, V18, P2493, DOI 10.1021/bi00579a009; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; CHING YC, 1985, BIOCHEMISTRY-US, V24, P4938, DOI 10.1021/bi00339a032; Das TK, 1998, BIOCHEMISTRY-US, V37, P14471, DOI 10.1021/bi981500w; FABIAN M, 1995, BIOCHEMISTRY-US, V34, P13802, DOI 10.1021/bi00042a011; Fabian M, 1999, BIOCHEMISTRY-US, V38, P6270, DOI 10.1021/bi982541v; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Ghosh A, 1998, J PHYS CHEM B, V102, P10087, DOI 10.1021/jp982232e; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; GREENWOO.C, 1967, J BIOL CHEM, V242, P1782; HAN S, 1990, P NATL ACAD SCI USA, V87, P8408, DOI 10.1073/pnas.87.21.8408; HAN S, 1989, J BIOL CHEM, V264, P6604; HAN S, 1990, P NATL ACAD SCI USA, V87, P2491, DOI 10.1073/pnas.87.7.2491; HAN SH, 1990, BIOCHEMISTRY-US, V29, P1380, DOI 10.1021/bi00458a006; HAN SH, 1990, J AM CHEM SOC, V112, P9445, DOI 10.1021/ja00182a001; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HILL BC, 1984, BIOCHEM J, V218, P913, DOI 10.1042/bj2180913; HILL BC, 1994, J BIOL CHEM, V269, P2419; HILL BC, 1986, BIOCHIM BIOPHYS ACTA, V853, P91, DOI 10.1016/0304-4173(86)90006-6; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P16782, DOI 10.1021/bi961722z; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P9446, DOI 10.1021/bi960392f; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P6975, DOI 10.1021/bi00443a030; Musser SM, 1995, ADV ENZYMOL RAMB, V71, P79; OGURA T, 1990, J AM CHEM SOC, V112, P5630, DOI 10.1021/ja00170a032; OGURA T, 1989, BIOCHEMISTRY-US, V28, P8022, DOI 10.1021/bi00446a008; OGURA T, 1991, B CHEM SOC JPN, V64, P2901, DOI 10.1246/bcsj.64.2901; Ogura T, 1996, J AM CHEM SOC, V118, P5443, DOI 10.1021/ja951922i; OGURA T, 1993, J AM CHEM SOC, V115, P8527, DOI 10.1021/ja00072a002; OGURA T, 1990, J BIOL CHEM, V265, P14721; ORII Y, 1984, J BIOL CHEM, V259, P7187; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; ORII Y, 1976, J BIOL CHEM, V251, P7487; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P8580, DOI 10.1021/bi952096t; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P76, DOI 10.1021/bi9511705; PROSHLYAKOV DA, 1994, J BIOL CHEM, V269, P29385; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; Rousseau DL, 1999, NATURE, V400, P412, DOI 10.1038/22664; SALMEEN I, 1978, BIOCHEMISTRY-US, V17, P800, DOI 10.1021/bi00598a008; Sucheta A, 1997, BIOCHEMISTRY-US, V36, P554, DOI 10.1021/bi962422k; Sucheta A, 1998, BIOCHEMISTRY-US, V37, P17905, DOI 10.1021/bi981092w; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; VAROTSIS C, 1993, METHOD ENZYMOL, V226, P409; VAROTSIS C, 1995, BBA-BIOENERGETICS, V1231, P111, DOI 10.1016/0005-2728(95)00076-U; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; VAROTSIS C, 1989, J AM CHEM SOC, V111, P6439, DOI 10.1021/ja00198a075; VAROTSIS C, 1990, J AM CHEM SOC, V112, P1297, DOI 10.1021/ja00159a091; VAROTSIS C, 1990, J BIOL CHEM, V265, P11131; Verkhovsky MI, 1999, NATURE, V400, P480, DOI 10.1038/22813; VYGODINA T, 1987, FEBS LETT, V219, P387, DOI 10.1016/0014-5793(87)80258-2; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; WANG JL, 1995, BIOCHEMISTRY-US, V34, P15504, DOI 10.1021/bi00047a016; WIKSTROM M, 1981, P NATL ACAD SCI-BIOL, V78, P4051, DOI 10.1073/pnas.78.7.4051; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; YONETANI T, 1960, J BIOL CHEM, V235, P845; Yoshikawa S, 1998, J BIOENERG BIOMEMBR, V30, P7, DOI 10.1023/A:1020595108560; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	67	97	98	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1910	1919		10.1074/jbc.275.3.1910	http://dx.doi.org/10.1074/jbc.275.3.1910			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636892	hybrid			2022-12-25	WOS:000084940000055
J	Reinhardt, DP; Gambee, JE; Ono, RN; Bachinger, HP; Sakai, LY				Reinhardt, DP; Gambee, JE; Ono, RN; Bachinger, HP; Sakai, LY			Initial steps in assembly of microfibrils - Formation of disulfide-cross-linked multimers containing fibrillin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-BINDING-PROTEIN; MARFAN-SYNDROME; CALCIUM-BINDING; LATENT; MUTATIONS; COMPONENT; GENE; IDENTIFICATION; ORGANIZATION; SEQUENCE	Fibrillins are the major constituents of extracellular microfibrils, How fibrillin molecules assemble into microfibrils is not known. Sequential extractions and pulse-chase labeling of organ cultures of embryonic chick aortae revealed rapid formation of disulfide-cross-linked aggregates containing fibrillin-1. These results demonstrated that intermolecular disulfide bond formation is an initial step in the assembly process. To identify free cysteine residues available for intermolecular cross-linking, small recombinant peptides of fibrillin-1 harboring candidate cysteine residues were analyzed. Results revealed that the first four cysteine residues in the unique N terminus form intramolecular disulfide bonds. One cysteine residue (Cys(204)) in the first hybrid domain of fibrillin-1 was found to occur as a free thiol and is therefore a good candidate for intermolecular disulfide bonding in initial steps of the assembly process, Furthermore, evidence indicated that the comparable cysteine residue in fibrillin-2 (Cys(233)) also occurs as a free thiol. These free cysteine residues in fibrillins are readily available for intermolecular disulfide bond formation, as determined by reaction with Ellman's reagent. In addition to these major results, the cleavage site of the fibrillin-1 signal peptide and the N-terminal sequence of monomeric authentic fibrillin-1 from conditioned fibroblast medium were determined.	Shriners Hosp Crippled Childrens, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Sakai, LY (corresponding author), Shriners Hosp Crippled Childrens, 3101 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	lys@shcc.org	Reinhardt, Dieter P/A-3102-2008	Reinhardt, Dieter P/0000-0001-6535-9872				Collod-Beroud G, 1998, NUCLEIC ACIDS RES, V26, P229, DOI 10.1093/nar/26.1.229; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; Dallas SL, 2000, J BONE MINER RES, V15, P68, DOI 10.1359/jbmr.2000.15.1.68; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Dzamba BJ, 1998, EXTRACELLULAR MATRIX-CELL INTERACTION, P23; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Keene DR, 1997, J HISTOCHEM CYTOCHEM, V45, P1069, DOI 10.1177/002215549704500805; Liu WO, 1997, GENET TEST, V1, P237, DOI 10.1089/gte.1997.1.237; Lonnqvist L, 1998, HUM MOL GENET, V7, P2039, DOI 10.1093/hmg/7.13.2039; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; MOREN A, 1994, J BIOL CHEM, V269, P32469; Nakajima Y, 1997, J CELL BIOL, V136, P193, DOI 10.1083/jcb.136.1.193; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Ritty TM, 1999, J BIOL CHEM, V274, P8933, DOI 10.1074/jbc.274.13.8933; ROSS R, 1969, J CELL BIOL, V40, P366, DOI 10.1083/jcb.40.2.366; Saharinen J, 1998, J BIOL CHEM, V273, P18459, DOI 10.1074/jbc.273.29.18459; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SAKAI LY, 1990, ELASTIN CHEM BIOL AS, P213; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; Yuan XM, 1997, EMBO J, V16, P6659, DOI 10.1093/emboj/16.22.6659	29	65	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2205	2210		10.1074/jbc.275.3.2205	http://dx.doi.org/10.1074/jbc.275.3.2205			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636927	hybrid			2022-12-25	WOS:000084940000090
J	Manganini, M; Maier, JAM				Manganini, M; Maier, JAM			Transforming growth factor beta(2) inhibition of hepatocyte growth factor-induced endothelial proliferation and migration	ONCOGENE			English	Article						Hepatocyte Growth Factor; Met; signal transduction; endothelial cells	BLOOD-VESSEL FORMATION; KINASE IN-VITRO; TYROSINE KINASE; SCATTER FACTOR; MET RECEPTOR; C-MET; CELLS; PROTEIN; PHOSPHORYLATION; ACTIVATION	Angiogenesis is a highly controlled event,which depends on the proper equilibrium of activators and inhibitors present within the microenvironment, Hepatocyte Growth Factor (HGF) activates migration and proliferation of endothelial cells and is angiogenic, acting through the tyrosine kinase receptor encoded by the Met protooncogene. To get insights into the molecular mechanisms involved in HGF-induced angiogenesis, we searched for cDNAs differentially expressed in human endothelial cells exposed to HGF, a potent angiogenic factor. We found that HGF-treated endothelial cells upregulated the expression of Transforming Growth Factor (TGF) beta(2). To understand the significance of this finding, we cultured endothelial cells with HGF and TGF pi simultaneously. We found that TGF beta(2) impairs HGF-dependent proliferative and migratory responses, TGF Pt did not prevent the tyrosine phosphorylation of R-let, but it inhibited some signalling pathways activated by HGF. We show that endothelial proliferation induced by HGF required the activation of the MAPK cascade, while HGF-induced endothelial migration,vas dependent on the tyrosine phosphorylation of Src. Indeed, TGF beta(2), inhibited HGF effects because it prevented HGF-induced MAP kinase activation and tyrosine phosphorylation of Src. We suggest that the induction of TGF beta(2), by HGF in endothelial cells may represent a physiologic mechanism to counterbalance HGF angiogenic activity.	Univ Milan, Dept Biomed Sci & Technol, I-20133 Milan, Italy	University of Milan	Maier, JAM (corresponding author), Univ Milan, Dept Biomed Sci & Technol, Via Olgettina 60, I-20133 Milan, Italy.		Maier, Jeanette AM/H-4820-2012	Maier, Jeanette AM/0000-0002-6326-9221				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ATFI A, 1994, J BIOL CHEM, V269, P30688; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cary LA, 1996, J CELL SCI, V109, P1787; Consalez GG, 1996, TRENDS GENET, V12, P455; Dragoni I, 1998, J BIOL CHEM, V273, P31119, DOI 10.1074/jbc.273.47.31119; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fukuda K, 1998, ONCOGENE, V16, P3349, DOI 10.1038/sj.onc.1201896; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; HUWILER A, 1994, FEBS LETT, V354, P255, DOI 10.1016/0014-5793(94)01132-X; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Maier JAM, 1996, ONCOGENE, V13, P1009; Maniatis T., 1982, MOL CLONING LAB MANU; MCCARTHY SA, 1991, TRENDS PHARMACOL SCI, V12, P462, DOI 10.1016/0165-6147(91)90637-8; MERWIN JR, 1991, AM J PATHOL, V138, P37; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PAZDRAK K, 1995, J IMMUNOL, V155, P4454; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wu ZH, 1998, AM J PATHOL, V152, P1599; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	36	26	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					124	133		10.1038/sj.onc.1203225	http://dx.doi.org/10.1038/sj.onc.1203225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644987				2022-12-25	WOS:000084844300014
J	Cartee, RT; Forsee, WT; Schutzbach, JS; Yother, J				Cartee, RT; Forsee, WT; Schutzbach, JS; Yother, J			Mechanism of type 3 capsular polysaccharide synthesis in Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED TERATOCARCINOMA CELLS; CHITIN SYNTHASE; BIOSYNTHESIS; GENE; HYALURONAN; IDENTIFICATION; SEQUENCE; PROTEIN; LOCUS; SEROTYPE-14	The glycosidic linkages of the type 3 capsular polysaccharide of Streptococcus pneumoniae ([3)-beta-D-GlcUA-(1-->4)-beta-D-Glc-(1-->](n)) are formed by the membrane-associated type 3 synthase (Cps3S), which is capable of synthesizing polymer from UDP sugar precursors. Using membrane preparations of S, pneumoniae in an in vitro assay, we observed type 3 synthase activity in the presence of either Mn2+ or Mg2+ with maximal levels seen with 10-20 mM Mn2+. High molecular weight polymer synthesized in the assay was composed of Glc and glucuronic acid and could be degraded to a low molecular weight product by a type 3-specific depolymerase from Bacillus circulans, Additionally, the polymer bound specifically to an affinity column made with a type 3 polysaccharide-specific monoclonal antibody. The polysaccharide was rapidly synthesized from smaller chains and remained associated with the enzyme-containing membrane fraction throughout its synthesis, indicating a processive mechanism of synthesis. Release of the polysaccharide was observed, however, when the level of one of the substrates became limiting. Finally, addition of sugars to the growing type 3 polysaccharide was shown to occur at the nonreducing end of the polysaccharide chain.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Yother, J (corresponding author), Univ Alabama, Dept Microbiol, BBRB 661-12,845 19th St S, Birmingham, AL 35294 USA.				NHLBI NIH HHS [T32HL07553] Funding Source: Medline; NIGMS NIH HHS [GM53017] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053017] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrecubieta C, 1996, J EXP MED, V184, P449, DOI 10.1084/jem.184.2.449; Arrecubieta C, 1995, GENE, V167, P1, DOI 10.1016/0378-1119(95)00657-5; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; BRILES DE, 1981, NATURE, V294, P88, DOI 10.1038/294088a0; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; Caimano MJ, 1998, MICROB DRUG RESIST, V4, P11, DOI 10.1089/mdr.1998.4.11; CHENWU JL, 1992, MOL MICROBIOL, V6, P497, DOI 10.1111/j.1365-2958.1992.tb01494.x; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DEENLEYSIDE WJ, 1997, J BIOL CHEM, V271, P28581; DILLARD JP, 1994, MOL MICROBIOL, V12, P959, DOI 10.1111/j.1365-2958.1994.tb01084.x; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; GARDNER KH, 1974, BIOPOLYMERS, V13, P1975, DOI 10.1002/bip.1974.360131005; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; GUIDOLIN A, 1994, INFECT IMMUN, V62, P5384, DOI 10.1128/IAI.62.12.5384-5396.1994; HEATLEY F, 1988, BIOCHEM J, V254, P489, DOI 10.1042/bj2540489; HENRICHSEN J, 1995, J CLIN MICROBIOL, V33, P2759, DOI 10.1128/JCM.33.10.2759-2762.1995; HOPWOOD JJ, 1977, BIOCHEM BIOPH RES CO, V75, P472, DOI 10.1016/0006-291X(77)91066-X; Kolkman MAB, 1997, J BIOL CHEM, V272, P19502, DOI 10.1074/jbc.272.31.19502; Kolkman MAB, 1996, J BACTERIOL, V178, P3736, DOI 10.1128/jb.178.13.3736-3741.1996; Koyama M, 1997, P NATL ACAD SCI USA, V94, P9091, DOI 10.1073/pnas.94.17.9091; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; MINKE R, 1978, J MOL BIOL, V120, P167, DOI 10.1016/0022-2836(78)90063-3; Mollerach M, 1998, J EXP MED, V188, P2047, DOI 10.1084/jem.188.11.2047; Munoz R, 1997, MOL MICROBIOL, V25, P79, DOI 10.1046/j.1365-2958.1997.4341801.x; Pigman W.W., 1948, CHEM CARBOHYDRATES; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; Reeves RE, 1941, J BIOL CHEM, V139, P511; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Silakowski B, 1996, J BACTERIOL, V178, P6706, DOI 10.1128/jb.178.23.6706-6713.1996; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SMITH EEB, 1960, J BIOL CHEM, V235, P1876; SPRINGER TA, 1993, CURRENT PROTOCOLS MO; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252; TORRIANI A, 1962, J BIOL CHEM, V237, P3; TURCO SJ, 1977, J BIOL CHEM, V252, P2918; VANDAM JEG, 1990, ANTON LEEUW INT J G, V58, P1; YOTHER J, 1994, J BACTERIOL, V176, P2976, DOI 10.1128/JB.176.10.2976-2985.1994; ZWEIG G, 1967, PAPER CHROMATOGRAPHY	43	50	58	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3907	3914		10.1074/jbc.275.6.3907	http://dx.doi.org/10.1074/jbc.275.6.3907			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660543	hybrid			2022-12-25	WOS:000085288800027
J	Cefaratti, C; Romani, A; Scarpa, A				Cefaratti, C; Romani, A; Scarpa, A			Differential localization and operation of distinct Mg2+ transporters in apical and basolateral sides of rat liver plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED BLOOD-CELLS; MAGNESIUM TRANSPORT; STIMULATION; HEPATOCYTES; EXCHANGE; ANTIPORT; MECHANISMS; AMILORIDE; VESICLES; RELEASE	Upon activation of specific cell signaling, hepatocytes rapidly accumulate or release an amount of Mg2+ equivalent to 10% of their total Mg2+ content. Although it is widely accepted that Mg2+ efflux is Na+-dependent, little is known about transporter identity and the overall regulation. Even less is known about the mechanism of cellular Mg2+ uptake. Using sealed and right-sided rat liver plasma membrane vesicles representing either the basolateral (bLPM) or apical (aLPM) domain, it was possible to dissect three different Mg2+ transport mechanisms based upon specific inhibition, localization within the plasma membrane, and directionality, The bLPM: possesses only one Mg2+ transporter, which is strictly Na+-dependent, bi-directional, and not inhibited by amiloride, The aLPM possesses two separate Mg2+ transporters, One, similar to that in the bLPM because it strictly depends on Na+ transport, and it can be differentiated from that of the bLPM because it is unidirectional and fully inhibited by amiloride. The second is a novel Ca2+/Mg2+ exchanger that is unidirectional and inhibited by amiloride and imipramine. Hence, the bLPM transporter may be responsible for the exchange of Mg2+ between hepatocytes and plasma, and vice versa, shown in livers upon specific metabolic stimulation, whereas the aLPM transporters can only extrude Mg2+ into the biliary tract. The dissection of these three distinct pathways and, therefore, the opportunity to study each individually will greatly facilitate further characterization of these transporters and a better understanding of Mg2+ homeostasis.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Scarpa, A (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	axs15@po.cwru.edu		Romani, Andrea/0000-0001-9864-4848	NHLBI NIH HHS [HL 18708] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018708] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOS DJ, 1982, AM J PHYSIOL, V242, pC131, DOI 10.1152/ajpcell.1982.242.3.C131; BEYENBACH KW, 1990, MAGNESIUM TRACE ELEM, V9, P233; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cefaratti C, 1998, AM J PHYSIOL-CELL PH, V275, pC995, DOI 10.1152/ajpcell.1998.275.4.C995; FERAY JC, 1987, J BIOL CHEM, V262, P5763; FERAY JC, 1988, N-S ARCH PHARMACOL, V338, P332; FLATMAN PW, 1984, J MEMBRANE BIOL, V80, P1, DOI 10.1007/BF01868686; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; FRENKEL EJ, 1989, J PHYSIOL-LONDON, V414, P385, DOI 10.1113/jphysiol.1989.sp017694; GRUBBS RD, 1987, MAGNESIUM, V6, P113; GUNTHER T, 1985, BIOCHEM BIOPH RES CO, V130, P540, DOI 10.1016/0006-291X(85)90450-4; GUNTHER T, 1992, FEBS LETT, V297, P132, DOI 10.1016/0014-5793(92)80343-F; GUNTHER T, 1993, MINER ELECTROL METAB, V19, P259; Gunzel D, 1996, J PHYSIOL-LONDON, V491, P595, DOI 10.1113/jphysiol.1996.sp021242; ISMAILBEIGI F, 1971, J GEN PHYSIOL, V57, P710, DOI 10.1085/jgp.57.6.710; KANT JA, 1972, NATURE-NEW BIOL, V240, P26, DOI 10.1038/newbio240026a0; KEENAN D, 1995, CIRC RES, V77, P973, DOI 10.1161/01.RES.77.5.973; LUDI H, 1987, J PHYSIOL-LONDON, V390, P367; MAGUIRE ME, 1988, ANN NY ACAD SCI, V551, P201, DOI 10.1111/j.1749-6632.1988.tb22338.x; MOORE EW, 1990, HEPATOLOGY, V12, pS206; MOSELEY RH, 1986, AM J PHYSIOL, V250, pG35, DOI 10.1152/ajpgi.1986.250.1.G35; PRPIC V, 1984, J BIOL CHEM, V259, P1382; RESNICK LM, 1992, J AM SOC NEPHROL, V3, pS78; ROMANI A, 1992, FEBS LETT, V296, P135, DOI 10.1016/0014-5793(92)80364-M; ROMANI A, 1991, J BIOL CHEM, V266, P24376; ROMANI A, 1993, J BIOL CHEM, V268, P15489; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; ROMANI A, 1993, CIRC RES, V72, P1139, DOI 10.1161/01.RES.72.6.1139; ROMANI A, 1990, NATURE, V346, P841, DOI 10.1038/346841a0; SCHELL MJ, 1992, J CELL BIOL, V119, P1173, DOI 10.1083/jcb.119.5.1173; SHIFFMAN ML, 1992, J LAB CLIN MED, V120, P875; STECK TL, 1970, SCIENCE, V168, P255, DOI 10.1126/science.168.3928.255; Sun AQ, 1998, AM J PHYSIOL-GASTR L, V275, pG1045, DOI 10.1152/ajpgi.1998.275.5.G1045; Tessman PA, 1998, AM J PHYSIOL-GASTR L, V275, pG1106, DOI 10.1152/ajpgi.1998.275.5.G1106; WALKER GM, 1986, MAGNESIUM, V5, P9; WEBLING DD, 1966, BIOCHEM J, V100, P652, DOI 10.1042/bj1000652; WOLTERS H, 1991, BIOCHIM BIOPHYS ACTA, V1069, P61, DOI 10.1016/0005-2736(91)90104-G	37	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3772	3780		10.1074/jbc.275.6.3772	http://dx.doi.org/10.1074/jbc.275.6.3772			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660526	hybrid			2022-12-25	WOS:000085288800010
J	Persechini, A; Yano, K; Stemmer, PM				Persechini, A; Yano, K; Stemmer, PM			Ca2+ binding and energy coupling in the calmodulin-myosin light chain kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SKELETAL-MUSCLE; QUANTITATIVE-ANALYSIS; NEUTRON-SCATTERING; ENZYME ACTIVATION; STRUCTURAL BASIS; CALCIUM-BINDING; MECHANISM; KINETICS; DOMAINS	We have previously shown that 3 Ca2+ ions are released cooperatively and 1 independently from the complex:between (Ca2+)(4)-calmodulin and skeletal muscle myosin light chain kinase or a peptide containing its core calmodulin-binding sequence. We now have found that three Ca2+-binding sites also function cooperatively in equilibrium Ca-2+ binding to these complexes, Replacement of sites I and II in calmodulin by a copy of sites III and IV abolishes these cooperative effects. Energy coupling-dependent increases in Ca2+-binding affinity in the mutant and native calmodulin complexes with enzyme are considerably less than in the peptide complexes, although the complexes have similar affinities. Ca2+ binding to three sites in the native calmodulin-enzyme complex is enhanced; the affinity of the remaining site is slightly reduced. In the mutant enzyme complex Ca2+ binding to one pair of sites is enhanced; the other pair is unaffected. In this complex reversal of enzyme activation occurs when Ca2+ dissociates from the pair of sites with enhanced affinity; more rapid dissociation from the other pair has no effect, although both pairs participate in activation. Ca2+-independent interactions with calmodulin clearly play a major role in the enzyme complex, and appear to weaken Ca2+ dependent interactions with the core calmodulin-binding sequence.	Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Dept Pediat, Omaha, NE 68198 USA	University of Rochester	Persechini, A (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA.			Stemmer, Paul/0000-0003-3315-9846	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044322] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44322] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; COX JA, 1981, J BIOL CHEM, V256, P3218; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P13997, DOI 10.1021/bi981311d; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MAMARBACHI A, 1987, CELL CALCIUM, V8, P473, DOI 10.1016/0143-4160(87)90030-3; MCCARTHY JJ, 1994, ANAL BIOCHEM, V221, P250, DOI 10.1006/abio.1994.1409; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; OLWIN BB, 1984, J BIOL CHEM, V259, P949; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; Persechini A, 1996, J BIOL CHEM, V271, P62, DOI 10.1074/jbc.271.1.62; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Persechini A, 1996, J BIOL CHEM, V271, P19279, DOI 10.1074/jbc.271.32.19279; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; Persechini A, 1996, J BIOL CHEM, V271, P32217, DOI 10.1074/jbc.271.50.32217; SHENOLIKAR S, 1979, EUR J BIOCHEM, V100, P329, DOI 10.1111/j.1432-1033.1979.tb04175.x; Shoshan-Barmatz V, 1998, INT REV CYTOL, V183, P185, DOI 10.1016/S0074-7696(08)60145-X; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	34	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4199	4204		10.1074/jbc.275.6.4199	http://dx.doi.org/10.1074/jbc.275.6.4199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660583	hybrid			2022-12-25	WOS:000085288800067
J	Yu, QT; Lehrer, RI; Tam, JP				Yu, QT; Lehrer, RI; Tam, JP			Engineered salt-insensitive alpha-defensins with end-to-end circularized structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNPROTECTED PEPTIDE SEGMENTS; HUMAN INTESTINAL DEFENSIN-5; ANTIMICROBIAL PEPTIDE; HUMAN BETA-DEFENSIN-1; SECONDARY STRUCTURE; LIGATION STRATEGY; CRYSTAL-STRUCTURE; CYCLIC-PEPTIDES; GROWTH-FACTOR; HOST-DEFENSE	We designed a retro-isomer and seven circularized "beta-tile" peptide analogs of a typical rabbit cu-defensin, NP-1. The analogs retained defensin-like architecture after the characteristic end-to-end, Cys(3,31) (C I:C VI), alpha-defensin disulfide bond was replaced by a backbone peptide bond. The retro-isomer of NP-1 was as active as the parent compound, suggesting that overall topology and amphipathicity governed its antimicrobial activity. A beta-tile design with or without a single cross-bracing disulfide bond sufficed for antimicrobial activity, and some of the analogs retained activity against Escherichia coli and Salmonella typhimurium in NaCl concentrations that rendered NP-I inactive. The new molecules had clustered positive charges resembling those in protegrins and tachyplesins, but were less cytotoxic. Such simplified alpha-defensin analogs minimize problems encountered during the oxidative folding of three-disulfide defensins, In addition, they are readily accessible to a novel thia zip cyclization procedure applicable to large unprotected peptide precursors of 31 amino acids in aqueous solutions. Collectively, these findings provide new and improved methodology to create salt-insensitive defensin-like peptides for application against bacterial diseases.	Vanderbilt Univ, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA	Vanderbilt University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tam, JP (corresponding author), Vanderbilt Univ, Dept Microbiol & Immunol, A5119 MCN, Nashville, TN 37232 USA.		Tam, James P/A-2176-2011	Tam, James P/0000-0003-4433-198X	NATIONAL CANCER INSTITUTE [R01CA036544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022839, R01AI046164, R01AI022839] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36544] Funding Source: Medline; NIAID NIH HHS [AI 22839, AI 46164] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bals R, 1998, INFECT IMMUN, V66, P1225, DOI 10.1128/IAI.66.3.1225-1232.1998; Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; Botti P, 1996, J AM CHEM SOC, V118, P10018, DOI 10.1021/ja954278g; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; CHO Y, 1966, INFECT IMMUN, V66, P2791; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fahrner RL, 1996, CHEM BIOL, V3, P543, DOI 10.1016/S1074-5521(96)90145-3; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GRAN L, 1973, ACTA PHARMACOL TOX, V32, P400; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOJO H, 1991, B CHEM SOC JPN, V64, P111, DOI 10.1246/bcsj.64.111; Juvvadi P, 1996, J AM CHEM SOC, V118, P8989, DOI 10.1021/ja9542911; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; LIN YZ, 1991, BIOCHEMISTRY-US, V30, P3310, DOI 10.1021/bi00227a020; Liu CF, 1996, J AM CHEM SOC, V118, P307, DOI 10.1021/ja952790w; Liu CF, 1996, TETRAHEDRON LETT, V37, P933, DOI 10.1016/0040-4039(95)02394-1; LIU CF, 1994, P NATL ACAD SCI USA, V91, P6584, DOI 10.1073/pnas.91.14.6584; Meister M, 1997, BIOESSAYS, V19, P1019, DOI 10.1002/bies.950191112; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; MERRIFIELD RB, 1986, SCIENCE, V57, P1619; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; Porter EM, 1997, INFECT IMMUN, V65, P2389, DOI 10.1128/IAI.65.6.2389-2395.1997; Porter EM, 1997, INFECT IMMUN, V65, P2396, DOI 10.1128/IAI.65.6.2396-2401.1997; Roumestand C, 1998, FEBS LETT, V421, P263, DOI 10.1016/S0014-5793(97)01579-2; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SHIMODA M, 1995, INFECT IMMUN, V63, P2886, DOI 10.1128/IAI.63.8.2886-2891.1995; Steinbeg Deborah A., 1997, V78, P169; STEWART SM, 1984, SOLID PHASE PEPTIDE, P113; Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342; Tam JP, 1995, P NATL ACAD SCI USA, V92, P12485, DOI 10.1073/pnas.92.26.12485; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Tam JP, 1998, BIOPOLYMERS, V46, P319, DOI 10.1002/(SICI)1097-0282(19981015)46:5<319::AID-BIP3>3.0.CO;2-S; Tam JP, 1997, TETRAHEDRON LETT, V38, P5599, DOI 10.1016/S0040-4039(97)01271-9; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; TERRAS FRG, 1995, PLANT CELL, V7, P573, DOI 10.1105/tpc.7.5.573; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; YANG Y, 1994, PROTEIN SCI, V3, P1267, DOI 10.1002/pro.5560030813; Yeh Trai-Ming, 1994, Chinese Journal of Microbiology and Immunology (Taipei), V27, P120; Zhang LS, 1997, TETRAHEDRON LETT, V38, P3, DOI 10.1016/S0040-4039(96)02260-5; Zhang LS, 1997, J AM CHEM SOC, V119, P2363, DOI 10.1021/ja9621105; ZHANG XL, 1992, BIOCHEMISTRY-US, V31, P11348, DOI 10.1021/bi00161a012	57	60	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3943	3949		10.1074/jbc.275.6.3943	http://dx.doi.org/10.1074/jbc.275.6.3943			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660548	hybrid			2022-12-25	WOS:000085288800032
J	Zhao, WQ; Meiri, N; Xu, H; Cavallaro, S; Quattrone, A; Zhang, L; Alkon, DL				Zhao, WQ; Meiri, N; Xu, H; Cavallaro, S; Quattrone, A; Zhang, L; Alkon, DL			Spatial learning induced changes in expression of the ryanodine type II receptor in the rat hippocampus	FASEB JOURNAL			English	Article						water maze task; learning and memory; calcium; mRNA; in situ hybridization	CALCIUM RELEASE CHANNEL; LONG-TERM POTENTIATION; DENTATE GYRUS; MEMORY; CA2+; KINASE; BRAIN; IDENTIFICATION; LOCALIZATION; DEPRESSION	Calcium signaling critical to neural functions is mediated through Ca2+ channels localized on both the plasma membrane and intracellular organelles such as endoplasmic reticulum, Whereas Ca2+ influx occurs via the voltage- or/and ligand-sensitive Ca2+ channels, Ca2+ release from intracellular stores that amplifies further the Ca2+ signal is thought to be involved in more profound and lasting changes in neurons, The ryanodine receptor, one of the two major intracellular Ca2+ channels, has been an important target for studying Ca2+ signaling in brain functions, including learning and memory, due to its characteristic Ca2+-induced Ca2+ release, In this study, we report regional and cellular distributions of the type-2 ryanodine receptor (RyR2) mRNA in the rat brain, and effects of spatial learning on RyR2 gene expression at mRNA and protein levels in the rat hippocampus, Using in situ hybridization, reverse transcription polymerase chain reaction, and ribonuclease protection assays, significant increases in RyR2 mRNA were found in the hippocampus of rats trained in an intensive water maze task, With immunoprecipitation and immunoblotting, protein levels of RyR2 were also demonstrated to be increased in the microsomal fractions prepared from hippocampi of trained rats, These results suggest that RyR2, and hence the RyR2-mediated Ca2+ signals, may be involved in memory processing after spatial learning. The increases in RyR2 mRNA and protein at 12 and 24 h after training could contribute to more permanent changes such as structural modifications during long-term memory storage.	NINDS, Lab Adapt Syst, NIH, Bethesda, MD 20892 USA; NIMH, Behav Endocrinol Branch, NIH, Bethesda, MD 20892 USA; Agr Res Org, Volcani Ctr, Inst Anim Sci, IL-50250 Bet Dagan, Israel; CNR, Inst Bioimaging & Pathophysiol Cent Nervous Syst, Catania, Italy; IRCCS, Oasai Inst Res Mental Retardat & Brain Aging, Troina, EN, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Consiglio Nazionale delle Ricerche (CNR)	Zhao, WQ (corresponding author), NINDS, Lab Adapt Syst, NIH, Bldg 36,Room 4A22,36 Convent Dr, Bethesda, MD 20892 USA.		Cavallaro, Sebastiano/F-3104-2010; Cavallaro, Sebastiano/AFM-7125-2022	Cavallaro, Sebastiano/0000-0001-7590-1792; Cavallaro, Sebastiano/0000-0001-7590-1792; Quattrone, Alessandro/0000-0003-3333-7630				ACOSTAURQUIDI J, 1984, SCIENCE, V224, P1254, DOI 10.1126/science.6328653; AIREY JA, 1990, J BIOL CHEM, V265, P14187; Alkon DL, 1998, TRENDS NEUROSCI, V21, P529, DOI 10.1016/S0166-2236(98)01277-6; Amaral David G., 1995, P443; ARAI M, 1992, AM J PHYSIOL, V262, pH614; Cavallaro S, 1997, P NATL ACAD SCI USA, V94, P9669, DOI 10.1073/pnas.94.18.9669; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; FAGNOU DD, 1995, MOL CELL BIOCHEM, V149, P279, DOI 10.1007/BF01076589; Finkbeiner S, 1997, BIOESSAYS, V19, P657, DOI 10.1002/bies.950190803; FREIL DD, 1992, NEURON, V8, P1109; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Gruol DL, 1996, J NEUROPHYSIOL, V76, P3325, DOI 10.1152/jn.1996.76.5.3325; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MEISSNER G, 1988, MOL CELL BIOCHEM, V82, P59; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P484; MOLANDER C, 1995, RAT NERVOUS SYSTEM, P33; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Muller RU, 1996, HIPPOCAMPUS, V6, P709, DOI 10.1002/(SICI)1098-1063(1996)6:6<709::AID-HIPO13>3.0.CO;2-4; MURPHY SN, 1989, MOL PHARMACOL, V35, P671; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OBENAUS A, 1989, NEUROSCI LETT, V98, P172, DOI 10.1016/0304-3940(89)90505-3; OMARA SM, 1995, NEUROSCIENCE, V68, P621, DOI 10.1016/0306-4522(95)00233-9; PADUA RA, 1992, J CHEM NEUROANAT, V5, P63, DOI 10.1016/0891-0618(92)90034-N; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Reyes M, 1996, J NEUROSCI, V16, P5951; ROSENZWEIG MR, 1993, BEHAV BRAIN RES, V57, P193, DOI 10.1016/0166-4328(93)90135-D; SAKAKIBARA M, 1986, BIOPHYS J, V50, P319, DOI 10.1016/S0006-3495(86)83465-8; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKASAGO T, 1991, J BIOLCH TOKYO, V109, P103; Traub R.D., 1991, NEURONAL NETWORKS HI; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; VanderZee EA, 1997, PROG NEURO-PSYCHOPH, V21, P379, DOI 10.1016/S0278-5846(97)00010-9; Wang Y, 1996, J PHYSIOL-LONDON, V495, P755, DOI 10.1113/jphysiol.1996.sp021631; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Zhao WQ, 1999, J BIOL CHEM, V274, P34893, DOI 10.1074/jbc.274.49.34893; ZHAO WQ, 1999, IN PRESS J NEUROSCI	43	73	83	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					290	300		10.1096/fasebj.14.2.290	http://dx.doi.org/10.1096/fasebj.14.2.290			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657985				2022-12-25	WOS:000085184800008
J	Faccio, L; Fusco, C; Chen, A; Martinotti, S; Bonventre, JV; Zervos, AS				Faccio, L; Fusco, C; Chen, A; Martinotti, S; Bonventre, JV; Zervos, AS			Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEINS; GENE; DOMAINS; KINASE; IDENTIFICATION; TEMPERATURES; PRODUCT; GROWTH; DEGP	We report the isolation and characterization of a cDNA encoding the novel mammalian serine protease Omi. Omi protein consists of 458 amino acids and has homology to bacterial HtrA endoprotease, which acts as a chaperone at low temperatures and as a proteolytic enzyme that removes denatured or damaged substrates at elevated temperatures. The carboxyl terminus of Omi has extensive homology to a mammalian protein called L56 (human HtrA), but unlike L56, which is secreted, Omi is localized in the endoplasmic reticulum, Omi has several novel putative protein-protein interaction motifs, as well as a PDZ domain and a Src homology 3-binding domain, Omi mRNA is expressed ubiquitously, and the gene is localized on human chromosome 2p12, Omi interacts with Mxi2, an alternatively spliced form of the p38 stress-activated kinase, Omi protein, when made in a heterologous system, shows proteolytic activity against a nonspecific substrate beta-casein, The proteolytic activity of Omi is markedly up-regulated in the mouse kidney following ischemia/reperfusion.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Boston, MA 02129 USA; Massachusetts Gen Hosp, Renal Unit, Med Serv, Boston, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02129 USA; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of L'Aquila	Zervos, AS (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, 149 13th St, Boston, MA 02129 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055734] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK55734-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bao JX, 1996, ONCOGENE, V12, P2171; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; De Silva H, 1998, BIOCHEM BIOPH RES CO, V250, P647, DOI 10.1006/bbrc.1998.9365; Edelstein CL, 1997, KIDNEY INT, V51, P1341, DOI 10.1038/ki.1997.183; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fusco C, 1999, YEAST, V15, P715, DOI 10.1002/(SICI)1097-0061(19990615)15:8<715::AID-YEA406>3.0.CO;2-K; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Kaushal GP, 1998, AM J PHYSIOL-RENAL, V274, pF587, DOI 10.1152/ajprenal.1998.274.3.F587; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P10053, DOI 10.1093/nar/16.21.10053; LIPINSKA B, 1989, J BACTERIOL, V171, P1574, DOI 10.1128/jb.171.3.1574-1584.1989; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; LOVIS C, 1994, RENAL FAILURE, V16, P179, DOI 10.3109/08860229409044859; Molitoris BA, 1998, CURR OPIN NEPHROL HY, V7, P405, DOI 10.1097/00041552-199807000-00009; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Safirstein R, 1997, Adv Ren Replace Ther, V4, P38; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SHAPIRO DN, 1994, GENOMICS, V23, P282, DOI 10.1006/geno.1994.1496; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SKORKOGLONEK J, 1995, J BIOL CHEM, V270, P11140, DOI 10.1074/jbc.270.19.11140; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yokota M, 1999, BRAIN RES, V819, P8, DOI 10.1016/S0006-8993(98)01334-1; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	33	179	202	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2581	2588		10.1074/jbc.275.4.2581	http://dx.doi.org/10.1074/jbc.275.4.2581			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644717	hybrid			2022-12-25	WOS:000085128000049
J	Garza, LA; Birnbaum, MJ				Garza, LA; Birnbaum, MJ			Insulin-responsive aminopeptidase trafficking in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; RAT ADIPOSE-CELLS; REGULATED MEMBRANE AMINOPEPTIDASE; HAMSTER OVARY CELLS; PLASMA-MEMBRANE; SUBCELLULAR TRAFFICKING; TRANSFERRIN RECEPTOR; HEXOSE-TRANSPORT; TRANSLOCATION; ENDOCYTOSIS	The insulin-responsive aminopeptidase (IRAP/VP165/gp160) was identified originally in GLUT4-containing vesicles and shown to translocate in response to insulin, much like the glucose transporter 4 (GLUT4), This study characterizes the trafficking and kinetics of IRAP in exocytosis, endocytosis, and recycling to the membrane in 3T3-L1 adipocytes. After exposure of 3T3-L1 adipocytes to insulin, IRAP translocated to the plasma membrane as assessed by either cell fractionation, surface biotinylation, or the plasma membrane sheet assay. The rate of exocytosis closely paralleled that of GLUT4. In the continuous presence of insulin, IRAP was endocytosed with a half-time of about 3-5 min. IRAP endocytosis is inhibited by cytosol acidification, a property of clathrin-mediated endocytosis, but not by the expression of a constitutively active Akt/PKB, Arrival in an LDM fraction derived via subcellular fractionation exhibited a slower time course than disappearance from the cell surface, suggesting additional endocytic intermediates. As assayed by membrane "sheets," GLUT4 and IRAP showed similar internalization rates that are wortmannin-insensitive and occur with a half-time of roughly 5 min. IRAP remaining on the cell surface 10 min following insulin removal was both biotin- and avidin-accessible, implying the absence of thin-necked invaginations, Finally, endocytosed IRAP quickly recycled back to the plasma membrane in a wortmannin-sensitive process. These results demonstrate rapid endocytosis and recycling of IRAP in the presence of insulin and trafficking that matches GLUT4 in rate.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cox Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Birnbaum, MJ (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	birnbaum@hhmi.upenn.edu		garza, luis/0000-0002-6547-9695; Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK39615] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM-07170] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007170] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Hasani H, 1998, J BIOL CHEM, V273, P17504, DOI 10.1074/jbc.273.28.17504; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; Filippis A, 1998, BIOCHEM J, V330, P405, DOI 10.1042/bj3300405; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21931; Herbst JJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE600, DOI 10.1152/ajpendo.1997.272.4.E600; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Johnson AO, 1998, J BIOL CHEM, V273, P17968, DOI 10.1074/jbc.273.28.17968; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; Martin S, 1997, J CELL SCI, V110, P2281; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Rogi T, 1996, J BIOL CHEM, V271, P56, DOI 10.1074/jbc.271.1.56; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SATOH S, 1993, J BIOL CHEM, V268, P17820; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Sumitani S, 1997, ENDOCRINOLOGY, V138, P1029, DOI 10.1210/en.138.3.1029; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x; Wei ML, 1998, J CELL BIOL, V140, P565, DOI 10.1083/jcb.140.3.565; YANG J, 1993, J BIOL CHEM, V268, P4600	39	84	85	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2560	2567		10.1074/jbc.275.4.2560	http://dx.doi.org/10.1074/jbc.275.4.2560			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644714	hybrid			2022-12-25	WOS:000085128000046
J	Krieger-Brauer, HI; Medda, PK; Sattel, B; Kather, H				Krieger-Brauer, HI; Medda, PK; Sattel, B; Kather, H			Inhibitory effect of isoproterenol on NADPH-dependent H2O2 generation in human adipocyte plasma membranes is mediated by beta gamma-subunits derived from G(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HETEROTRIMERIC G-PROTEINS; GTP-BINDING PROTEIN; ADENYLYL-CYCLASE; SIGNAL-TRANSDUCTION; OXIDASE COMPONENTS; RECEPTOR SIGNAL; ANGIOTENSIN-II; ALPHA-SUBUNITS; ACTIVATION	Previous studies revealed that human fat cell plasma membranes contain a multireceptor-linked H2O2-generating system that is under antagonistic control by hormones and cytokines and is stimulated by insulin via G alpha(12). In this report, it is shown that the inhibitory action of the beta-adrenergic agonist isoproterenol is mediated by G protein beta gamma-subunits, based on observations that its action was specifically reversed by anti-G beta antibodies or a C-terminal beta-adrenergic receptor kinase-1 fragment containing the G beta gamma-binding site of the enzyme, and was mimicked by exogenously supplied G protein beta gamma-subunits. Isoproterenol signals through a prototypical G(s)-coupled receptor. Consistent with these results, direct activation of G(s) by cholera toxin or by an anti-G alpha(s) antibody exhibiting beta-adrenergic receptor-mimetic properties (K-20) resulted in an isoproterenol-like inhibition of NADPH-dependent H2O2 generation. In addition, a peptide corresponding to the target sequence of K-20 blocked the action of the catecholamine, apparently by competition between the peptide and G(s) for activated beta-adrenergic receptors, indicating that the G protein beta gamma-subunits mediating the inhibitory effects of the catecholamine were in fact derived from G(s).	Heidelberg Univ, Klin Inst Herzinfarktforsch & Med, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Krieger-Brauer, HI (corresponding author), Heidelberg Univ, Klin Inst Herzinfarktforsch & Med, Bergheimer Str 58, D-69115 Heidelberg, Germany.							Barr AJ, 1997, J BIOL CHEM, V272, P2223; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; Bokoch GM, 1996, FASEB J, V10, P1290, DOI 10.1096/fasebj.10.11.8836042; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Degtiar VE, 1997, J PHYSIOL-LONDON, V502, P321, DOI 10.1111/j.1469-7793.1997.321bk.x; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; KATADA T, 1982, J BIOL CHEM, V257, P3739; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Krieger-Brauer HI, 1999, J BIOL CHEM, V274, P28308, DOI 10.1074/jbc.274.40.28308; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; Marumo T, 1997, CIRCULATION, V96, P2361; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; Moulton PJ, 1998, BIOCHEM J, V329, P449; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; MURTHY KS, 1994, J BIOL CHEM, V269, P15977; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nielsen MD, 1996, J BIOL CHEM, V271, P33308, DOI 10.1074/jbc.271.52.33308; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; RADEKE HH, 1991, J BIOL CHEM, V266, P21025; RODBELL M, 1964, J BIOL CHEM, V239, P375; SAKAI H, 1994, J BIOL CHEM, V269, P23426; Schandar M, 1998, J BIOL CHEM, V273, P16669, DOI 10.1074/jbc.273.27.16669; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; VAUGHAN M, 1978, J SUPRAMOL STR CELL, V8, P473; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297	44	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2486	2490		10.1074/jbc.275.4.2486	http://dx.doi.org/10.1074/jbc.275.4.2486			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644703	hybrid			2022-12-25	WOS:000085128000035
J	Terry-Lorenzo, RT; Inoue, M; Connor, JH; Haystead, TAJ; Armbruster, BN; Gupta, RP; Oliver, CJ; Shenolikar, S				Terry-Lorenzo, RT; Inoue, M; Connor, JH; Haystead, TAJ; Armbruster, BN; Gupta, RP; Oliver, CJ; Shenolikar, S			Neurofilament-L is a protein phosphatase-1-binding protein associated with neuronal plasma membrane and post-synaptic density	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-ASSOCIATED KINASE; FILAMENT-BINDING PROTEIN; LIGHT-CHAIN-PHOSPHATASE; ACID-TREATED NEURONS; MYOSIN PHOSPHATASE; POSTSYNAPTIC DENSITY; SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; DENDRITIC SPINES; TRIPLET PROTEINS	Far Westerns with digoxigenin conjugated protein phosphatase-1 (PP1) catalytic subunit identified PP1-binding proteins in extracts from bovine, rat, and human brain. A major 70-kDa PP1-binding protein was purified from bovine brain cortex plasma membranes, using affinity chromatography on the immobilized phosphatase inhibitor, microcystin-LR. Mixed peptide sequencing following cyanogen bromide digestion identified the 70-kDa membrane-bound PP1-binding protein as bovine neurofilament-1 (NF-L). NF-L was the major PP1-binding protein in purified preparations of bovine spinal cord neurofilaments and the cytoskeletal compartment known as post-synaptic density, purified from rat brain cortex. Bovine neurofilaments, at nanomolar concentrations, inhibited the phosphorylase phosphatase activity of rabbit skeletal muscle PP1 catalytic subunit but not the activity of PP2A, another major serine/ threonine phosphatase. PP1 binding to bovine NF-L was mapped to the head region. This was confirmed by both binding and inhibition of PP1 by recombinant human NF-L fragments. Together, these studies indicate that NF-L fulfills many of the biochemical criteria established for a PP1-targeting subunit and suggest that NF-L may target the functions of PP1 in membranes and cytoskeleton of mammalian neurons.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	Duke University; University of Virginia	Shenolikar, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	sheno001@mc.duke.edu		Connor, John/0000-0002-8867-7256	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054, R01DK052378] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19242] Funding Source: Medline; NIDDK NIH HHS [DK52378A, DK52054] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Alphey L, 1997, J CELL BIOL, V138, P395, DOI 10.1083/jcb.138.2.395; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Benson DL, 1996, J NEUROCYTOL, V25, P181, DOI 10.1007/BF02284795; Blank T, 1997, P NATL ACAD SCI USA, V94, P14859, DOI 10.1073/pnas.94.26.14859; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Carpenter DA, 1996, J CELL SCI, V109, P2493; Colbran RJ, 1997, J NEUROCHEM, V69, P920; Damer CK, 1998, J BIOL CHEM, V273, P24396, DOI 10.1074/jbc.273.38.24396; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Ehlers MD, 1998, J NEUROSCI, V18, P720; ENDO S, 1995, J NEUROCHEM, V64, P1833; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Gailly P, 1996, EUR J BIOCHEM, V239, P326, DOI 10.1111/j.1432-1033.1996.0326u.x; Gardoni F, 1998, J NEUROCHEM, V71, P1733; GEORGES E, 1986, J NEUROCHEM, V47, P477; Giasson BI, 1996, J NEUROCHEM, V66, P1207; Gibb BJM, 1998, J NEUROCHEM, V70, P492; Gibb BJM, 1996, J NEUROCHEM, V66, P1306; Hirokawa N, 1998, J CELL BIOL, V143, P1, DOI 10.1083/jcb.143.1.1; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Johnson D, 1997, EUR J BIOCHEM, V244, P931, DOI 10.1111/j.1432-1033.1997.00931.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; Mukai H, 1996, J BIOL CHEM, V271, P9816, DOI 10.1074/jbc.271.16.9816; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nairn A C, 1992, Curr Opin Neurobiol, V2, P296, DOI 10.1016/0959-4388(92)90118-5; Nakai K, 1997, BLOOD, V90, P3936, DOI 10.1182/blood.V90.10.3936; NAKAMURA Y, 1990, BIOCHEM BIOPH RES CO, V169, P744, DOI 10.1016/0006-291X(90)90394-3; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; OZOLS J, 1990, METHOD ENZYMOL, V182, P225; Price NE, 1999, CURR OPIN NEUROBIOL, V9, P336, DOI 10.1016/S0959-4388(99)80049-X; SACHER MG, 1994, J BIOL CHEM, V269, P18480; SAITO T, 1995, BIOCHEMISTRY-US, V34, P7376, DOI 10.1021/bi00022a010; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; SCOTT D, 1985, J BIOL CHEM, V260, P736; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Snyder GL, 1998, J NEUROSCI, V18, P10297; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1997, MOL BRAIN RES, V49, P15, DOI 10.1016/S0169-328X(97)00117-4; Strack S, 1997, J NEUROCHEM, V68, P2119; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Streifel TD, 1996, BIOCHEM BIOPH RES CO, V222, P646, DOI 10.1006/bbrc.1996.0797; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; Tu JL, 1996, MOL CELL BIOL, V16, P4199; TU JL, 1994, MOL CELL BIOL, V14, P6789, DOI 10.1128/MCB.14.10.6789; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; VillaMoruzzi E, 1996, INT J BIOCHEM CELL B, V28, P13, DOI 10.1016/1357-2725(95)00119-0; WALSH MJ, 1992, J NEUROCHEM, V59, P667, DOI 10.1111/j.1471-4159.1992.tb09421.x; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; WIBLE BA, 1989, P NATL ACAD SCI USA, V86, P720, DOI 10.1073/pnas.86.2.720; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; Yoshimura Y, 1999, FEBS LETT, V446, P239, DOI 10.1016/S0014-5793(99)00226-4; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	72	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2439	2446		10.1074/jbc.275.4.2439	http://dx.doi.org/10.1074/jbc.275.4.2439			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644697	hybrid			2022-12-25	WOS:000085128000029
J	Bergsdorf, C; Paliga, K; Kreger, S; Masters, CL; Beyreuther, K				Bergsdorf, C; Paliga, K; Kreger, S; Masters, CL; Beyreuther, K			Identification of cis-elements regulating exon 15 splicing of the amyloid precursor protein pre-mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; RNA SECONDARY STRUCTURE; MESSENGER-RNA; ALZHEIMERS-DISEASE; DEFAULT EXON; GENE; SELECTION; INTRON; EXPRESSION; CELLS	Alternative splicing of exon 15 of the amyloid precursor protein (APP) pre-mRNA generates two APP isoform groups App(ex15) (containing exon 15) and L-APP (without exon 15), which show a cell-specific distribution in non-neuronal cells and neurons of rat. Both APP isoforms differ in regard to functional properties like posttranslational modification, APP secretion, and proteolytic production of A beta peptide from APP molecules. Since A beta generation is an important factor in the development of Alzheimer's disease, one could anticipate that these major APP isoforms might contribute differentially to the mechanisms underlying neurodegeneration in Alzheimer's disease, In this study, we established an APP minigene system in a murine cell system to identify cis-acting elements controlling exon 15 recognition. A 12.5-kilobase pair genomic fragment of the murine APP gene contained all cis-regulatory elements to reproduce the splicing pattern of the endogenous APP transcripts. By using this approach, two intronic cis-elements flanking exon 15 were identified that block the inclusion of exon 15 in APP transcripts of non-neuronal cells. Point mutation analysis of these intronic regions indicated that pyrimidine-rich sequences are involved in the splice repressor function. Finally, grafting experiments demonstrated that these regulatory regions cell-specifically enhance the blockage of a chimeric exon in the non-neuronal splicing system.	Univ Heidelberg, Ctr Biol Mol, ZMBH, D-69120 Heidelberg, Germany; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia	Ruprecht Karls University Heidelberg; University of Melbourne	Bergsdorf, C (corresponding author), Univ Regensburg, Lehrstuhl Biochem I, Univ Str 31, D-93040 Regensburg, Germany.							Bell MV, 1998, MOL CELL BIOL, V18, P5930, DOI 10.1128/MCB.18.10.5930; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; CHAN RC, 1995, MOL CELL BIOL, V15, P6377; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESTES PA, 1992, J BIOL CHEM, V267, P14902; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; Gooding C, 1998, RNA, V4, P85; Hartmann T, 1996, J BIOL CHEM, V271, P13208, DOI 10.1074/jbc.271.22.13208; Hattori M, 1997, NUCLEIC ACIDS RES, V25, P1802, DOI 10.1093/nar/25.9.1802; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kawamoto S, 1996, J BIOL CHEM, V271, P17613; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; Lenkkeri U, 1998, HUM GENET, V102, P192, DOI 10.1007/s004390050676; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LIN CH, 1995, RNA, V1, P234; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; LOU H, 1995, MOL CELL BIOL, V15, P7135; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Modafferi EF, 1997, MOL CELL BIOL, V17, P6537, DOI 10.1128/MCB.17.11.6537; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; OKAMOTO M, 1994, BRAIN RES, V637, P57, DOI 10.1016/0006-8993(94)91217-3; Paliga K, 1997, EUR J BIOCHEM, V250, P354, DOI 10.1111/j.1432-1033.1997.0354a.x; PANGALOS MN, 1995, J NEUROCHEM, V65, P762; PANGALOS MN, 1995, J BIOL CHEM, V270, P10388, DOI 10.1074/jbc.270.18.10388; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; SAMBROOKJ, 1989, MOL CLONING LAB MANU; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; Seraphin B, 1996, NUCLEIC ACIDS RES, V24, P3276, DOI 10.1093/nar/24.16.3276; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SIRANDPUGNET P, 1995, NUCLEIC ACIDS RES, V23, P3501, DOI 10.1093/nar/23.17.3501; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; TACKE R, 1991, GENE DEV, V5, P1416, DOI 10.1101/gad.5.8.1416; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; WASCO W, 1993, GENOMICS, V15, P237, DOI 10.1006/geno.1993.1047; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Wu AF, 1997, J NEUROSCI, V17, P4987; Zhang L, 1996, RNA, V2, P682	50	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2046	2056		10.1074/jbc.275.3.2046	http://dx.doi.org/10.1074/jbc.275.3.2046			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636908	hybrid			2022-12-25	WOS:000084940000071
J	Sato, AK; Zarutskie, JA; Rushe, MM; Lomakin, A; Natarajan, SK; Sadegh-Nasseri, S; Benedek, GB; Stern, LJ				Sato, AK; Zarutskie, JA; Rushe, MM; Lomakin, A; Natarajan, SK; Sadegh-Nasseri, S; Benedek, GB; Stern, LJ			Determinants of the peptide induced conformational change in the human class II major histocompatibility complex protein HLA-DR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-DERIVED PEPTIDE; HIGH-AFFINITY BINDING; T-CELL RECOGNITION; HLA-DR MOLECULES; MHC CLASS-I; CRYSTAL-STRUCTURE; INVARIANT CHAIN; ANTIGENIC PEPTIDES; BOUND PEPTIDES; BETA-CHAINS	The human class II major histocompatibility complex protein HLA-DR1 has been shown previously to undergo a distinct conformational change from an open to a compact form upon binding peptide, To investigate the role of peptide in triggering the conformational change, the minimal requirements for inducing the compact conformation were determined. Peptides as short as two and four residues, which occupy only a small fraction of the peptide-binding cleft, were able to induce the conformational change. A mutant HLA-DR1 protein with a substitution in the beta subunit designed to fill the P1 pocket from within the protein (Gly(86) to Tyr) adopted to a large extent the compact, peptide-bound conformation. Interactions important in stabilizing the compact conformation are shown to be distinct from those responsible for high affinity binding or for stabilization of the complex against thermal denaturation. The results suggest that occupancy of the P1 pocket is responsible for partial conversion to the compact form but that both side chain and main chain interactions contribute to the full conformational change. The implications of the conformational change to intracellular antigen loading and presentation are discussed.	MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Dept Phys, Cambridge, MA 02139 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Johns Hopkins University	Stern, LJ (corresponding author), MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sadegh-Nasseri, Scheherazade/0000-0002-8127-1720	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053549, P01GM056552] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI38996] Funding Source: Medline; NIGMS NIH HHS [P01-GM56552, R01 GM053549, R01-GM53549] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asherie N, 1998, BIOPHYS CHEM, V75, P213, DOI 10.1016/S0301-4622(98)00208-7; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; Boniface JJ, 1996, J EXP MED, V183, P119, DOI 10.1084/jem.183.1.119; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; DORNMAIR K, 1990, P NATL ACAD SCI USA, V87, P4134, DOI 10.1073/pnas.87.11.4134; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; Fremont DH, 1998, IMMUNITY, V9, P385, DOI 10.1016/S1074-7613(00)80621-4; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; Fremont DH, 1998, IMMUNITY, V8, P305, DOI 10.1016/S1074-7613(00)80536-1; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GRIFFITH IJ, 1988, J EXP MED, V167, P541, DOI 10.1084/jem.167.2.541; HAMMER J, 1994, P NATL ACAD SCI USA, V91, P4456, DOI 10.1073/pnas.91.10.4456; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; Harding CV, 1996, CRIT REV IMMUNOL, V16, P13, DOI 10.1615/CritRevImmunol.v16.i1.20; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; Jardetzky TS, 1996, P NATL ACAD SCI USA, V93, P734, DOI 10.1073/pnas.93.2.734; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; Jensen PE, 1998, J IMMUNOL METHODS, V215, P71, DOI 10.1016/S0022-1759(98)00062-3; Katz JF, 1996, J EXP MED, V184, P1747, DOI 10.1084/jem.184.5.1747; Kropshofer H, 1996, EMBO J, V15, P6144, DOI 10.1002/j.1460-2075.1996.tb01002.x; Kropshofer H, 1997, IMMUNITY, V6, P293, DOI 10.1016/S1074-7613(00)80332-5; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LAPAN KE, 1992, HYBRIDOMA, V11, P217, DOI 10.1089/hyb.1992.11.217; LEIGHTON J, 1991, J IMMUNOL, V147, P198; Mosyak L, 1998, IMMUNITY, V9, P377, DOI 10.1016/S1074-7613(00)80620-2; Murthy VL, 1997, STRUCTURE, V5, P1385, DOI 10.1016/S0969-2126(97)00288-8; Natarajan SK, 1999, J IMMUNOL, V162, P4030; Natarajan SK, 1999, J IMMUNOL, V162, P3463; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NEWTONNASH DK, 1993, J IMMUNOL, V150, P1813; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; OSULLIVAN D, 1991, J IMMUNOL, V146, P1240; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P193; Rabinowitz JD, 1998, IMMUNITY, V9, P699, DOI 10.1016/S1074-7613(00)80667-6; Rabinowitz JD, 1997, P NATL ACAD SCI USA, V94, P8702, DOI 10.1073/pnas.94.16.8702; RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6; RAMMENSEE HG, 1997, MHC LIGANDS PEPTIDE; REAY PA, 1992, EMBO J, V11, P2829, DOI 10.1002/j.1460-2075.1992.tb05350.x; Reich Z, 1997, P NATL ACAD SCI USA, V94, P2495, DOI 10.1073/pnas.94.6.2495; ROCHE PA, 1990, J IMMUNOL, V144, P1849; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; Runnels HA, 1996, J EXP MED, V183, P127, DOI 10.1084/jem.183.1.127; SADEGHNASSERI S, 1994, NATURE, V370, P647, DOI 10.1038/370647a0; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; Scott CA, 1998, IMMUNITY, V8, P319, DOI 10.1016/S1074-7613(00)80537-3; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; Smith KJ, 1998, J EXP MED, V188, P1511, DOI 10.1084/jem.188.8.1511; Stebbins CC, 1996, J IMMUNOL, V157, P4892; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555, DOI 10.1038/9858; Tan LJ, 1997, EUR J IMMUNOL, V27, P1479, DOI 10.1002/eji.1830270626; vanHam SM, 1996, J EXP MED, V184, P2019, DOI 10.1084/jem.184.5.2019; Vogt AB, 1996, P NATL ACAD SCI USA, V93, P9724, DOI 10.1073/pnas.93.18.9724; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; Wu SH, 1996, J IMMUNOL, V156, P3815; Zarutskie JA, 1999, BIOCHEMISTRY-US, V38, P5878, DOI 10.1021/bi983048m	70	74	78	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2165	2173		10.1074/jbc.275.3.2165	http://dx.doi.org/10.1074/jbc.275.3.2165			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636922	hybrid			2022-12-25	WOS:000084940000085
J	Gryz, EA; Meakin, SO				Gryz, EA; Meakin, SO			Acidic substitution of the activation loop tyrosines in TrkA supports nerve growth factor-independent cell survival and neuronal differentiation	ONCOGENE			English	Article						nerve growth factor; TrkA; tyrosine kinase receptor; kinase activation; activation loop; neurotrophins	MAP KINASE KINASE; FACTOR-I RECEPTOR; INSULIN-RECEPTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; MAMMALIAN-CELLS; PC12 CELLS; NEURITE OUTGROWTH; CRYSTAL-STRUCTURE; BINDING-SITES	TrkA is the receptor tyrosine kinase (RTK) for nerve growth factor (NGF) and stimulates NGF-dependent cell survival and differentiation in primary neurons. TrkA expression in neuronal tumors also supports NGF-dependent differentiation of neuroblastomas and apoptosis of medulloblastomas. Phosphorylation of the activation loop tyrosines in RTK's are essential to activation as well as allosteric changes that facilitate substrate interaction and phosphorylation. Acidic amino acid substitution of the activation loop tyrosines in TrkA, Tyr(683)Tyr(684), was performed to mimic the negative charges normally induced by ligand activation and receptor phosphorylation. A total of eight independent mutants containing single or double substitutions were generated for comparison. Herein, we demonstrate that acidic substitution of the activation loop tyrosines is sufficient to induce allosteric changes required for constitutive TrkA kinase activity as well as phosphorylation of TrkA signaling proteins such as Shc, PLC gamma-1, FRS-2 and erk1/2. The strongest constitutively active TrkA mutants, GluAsp and AspGlu, support NGF-independent neuritogenesis and cell survival to levels approximately 65 and 80-100%, respectively, of NGF-activated wild type TrkA. Thus, constitutively active TrkA may provide a useful strategy in future therapeutic approaches to limit the development and progression of neuronal tumors.	John P Robarts Res Inst, Neurodegenerat Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Meakin, SO (corresponding author), John P Robarts Res Inst, Neurodegenerat Grp, 100 Perth Dr, London, ON N6A 5K8, Canada.		Meakin, Susan/K-8823-2013	Meakin, Susan/0000-0003-2469-6615				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BRUNET A, 1994, ONCOGENE, V9, P3379; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; Goldsmith BA, 1997, J NEUROCHEM, V69, P1014; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GREEN SH, 1986, J BIOL CHEM, V261, P5316; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LONGATI P, 1994, ONCOGENE, V9, P49; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; McCarty JH, 1998, ONCOGENE, V16, P1691, DOI 10.1038/sj.onc.1201688; Meakin SO, 1997, J NEUROCHEM, V69, P954; Meakin SO, 1998, J NEUROCHEM, V71, P1875; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1991, P NATL ACAD SCI USA, V88, P5862, DOI 10.1073/pnas.88.13.5862; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Muragaki Y, 1997, J NEUROSCI, V17, P530; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; POLUHA W, 1995, ONCOGENE, V10, P185; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Raffioni S, 1998, J BIOL CHEM, V273, P35250, DOI 10.1074/jbc.273.52.35250; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHILLING P, 1991, J HYPERTENS, V9, P3; STANNARD B, 1995, ENDOCRINOLOGY, V136, P4918, DOI 10.1210/en.136.11.4918; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WEINMASTER G, 1986, J BIOL CHEM, V261, P328; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHANG B, 1991, J BIOL CHEM, V266, P990	56	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					417	430		10.1038/sj.onc.1203330	http://dx.doi.org/10.1038/sj.onc.1203330			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656690				2022-12-25	WOS:000084873700013
J	Boisclair, YR; Wang, JR; Shi, JR; Hurst, KR; Ooi, GT				Boisclair, YR; Wang, JR; Shi, JR; Hurst, KR; Ooi, GT			Role of the suppressor of cytokine signaling-3 in mediating the inhibitory effects of interleukin-1 beta on the growth hormone-dependent transcription of the acid-labile subunit gene in liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN COMPLEX; MESSENGER-RNA LEVELS; FACTOR-I GENE; PROMOTER ACTIVITY; RAT-LIVER; INSULIN; CIS; EXPRESSION; STIMULATION; ACTIVATION	During catabolic diseases such as sepsis, inflammation, and infection, a state of growth hormone (GH) resistance develops in liver. This has been attributed in part to increased production of the proinflammatory cytokine interleukin-1 beta (IL-1 beta). To determine how IL-1 beta induces GH resistance, we studied the acid-labile subunit (ALS) gene whose hepatic transcription is increased by GH via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. IL-1 beta reduced the ability of GH to stimulate ALS mRNA in rat primary hepatocytes and ALS promoter activity in H4-II-E rat hepatoma cells. This inhibition was dependent on ALSGAS1, an element resembling a gamma-interferon activated sequence that mediates the transcriptional effects of GH. Inhibition by IL-1 beta was also associated with a reduction of GH-dependent binding of STATE to this element after chronic (8 and 24 h), but not after acute treatment (15 min). Because these results indicated that the inhibition by IL-1 beta was indirect, expression of the recently discovered suppressors of cytokine action (SOCS) was examined in liver cells. IL-1 beta did not alter the expression of SOCS1, SOCS2, and CIS, indicating that they are not involved. In contrast, IL-1 beta increased SOCS3 mRNA by 8-fold after 24 h of treatment, whereas GH had no effect. Forced expression of SOCS3 was just as effective as IL-1 beta in reducing the GH induction of ALS promoter activity in H4-II-E rat hepatoma cells. Similar results were observed in primary rat hepatocytes. We conclude that the induction of SOCS3 by IL-1 beta contributes to the development of GH resistance in liver, and represents a mechanism by which cytokines such as IL-1 beta cross-talk with cytokines using the JAK-STAT pathway.	Cornell Univ, Dept Anim Sci, Ithaca, NY 14853 USA; Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia	Cornell University; Prince Henry's Institute of Medical Research	Boisclair, YR (corresponding author), Cornell Univ, Dept Anim Sci, 259 Morrison Hall, Ithaca, NY 14853 USA.	yrb1@cornell.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051624] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-51624] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; Botfield C, 1997, BAILLIERE CLIN ENDOC, V11, P679, DOI 10.1016/S0950-351X(97)80958-5; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; DAHN MS, 1988, ARCH SURG-CHICAGO, V123, P1409; DAI J, 1992, BIOCHEM BIOPH RES CO, V188, P304, DOI 10.1016/0006-291X(92)92385-B; Defalque D, 1999, AM J PHYSIOL-ENDOC M, V276, pE565, DOI 10.1152/ajpendo.1999.276.3.E565; Delhanty PJD, 1998, BIOCHEM BIOPH RES CO, V243, P269, DOI 10.1006/bbrc.1998.8089; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fan J, 1996, AM J PHYSIOL-REG I, V270, pR621, DOI 10.1152/ajpregu.1996.270.3.R621; FAN J, 1995, AM J PHYSIOL-ENDOC M, V269, pE33, DOI 10.1152/ajpendo.1995.269.1.E33; FAN J, 1995, AM J PHYSIOL-REG I, V269, pR1204, DOI 10.1152/ajpregu.1995.269.5.R1204; Frost R A, 1998, Curr Opin Clin Nutr Metab Care, V1, P195, DOI 10.1097/00075197-199803000-00010; GARGOSKY SE, 1994, ENDOCRINOLOGY, V134, P2267, DOI 10.1210/en.134.5.2267; Helman D, 1998, FEBS LETT, V441, P287, DOI 10.1016/S0014-5793(98)01555-5; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; Jenkins RC, 1998, BAILLIERE CLIN ENDOC, V12, P315, DOI 10.1016/S0950-351X(98)80025-6; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu JL, 1998, MOL ENDOCRINOL, V12, P1452, DOI 10.1210/me.12.9.1452; Losman JA, 1999, J IMMUNOL, V162, P3770; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Ooi GT, 1998, MOL ENDOCRINOL, V12, P675, DOI 10.1210/me.12.5.675; Ooi GT, 1997, MOL ENDOCRINOL, V11, P997, DOI 10.1210/me.11.7.997; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; SUH DS, 1994, MOL ENDOCRINOL, V8, P794, DOI 10.1210/me.8.6.794; THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80; THOMAS MJ, 1995, ENDOCRINOLOGY, V136, P562, DOI 10.1210/en.136.2.562; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; Venkataraman C, 1999, J IMMUNOL, V162, P4053; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; Wolf M, 1996, EUR J ENDOCRINOL, V135, P729, DOI 10.1530/eje.0.1350729; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; ZAPF J, 1986, J CLIN INVEST, V77, P1768, DOI 10.1172/JCI112500; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	55	82	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3841	3847		10.1074/jbc.275.6.3841	http://dx.doi.org/10.1074/jbc.275.6.3841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660535	hybrid			2022-12-25	WOS:000085288800019
J	Close, BE; Tao, K; Colley, KT				Close, BE; Tao, K; Colley, KT			Polysialyltransferase-1 autopolysialylation is not requisite for polysialylation of neural cell adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; GOLGI VESICLE MEMBRANES; POLYSIALIC ACID UNITS; MUTANT DEFICIENT; LUNG-CARCINOMA; SIGNAL ANCHOR; WILMS TUMOR; N-CAM; STX; GLYCOPROTEINS	Polysialyltransferase-1 (PST; ST8Sia TV) is one of the alpha 2,8-polysialyltransferases responsible for the polysialylation of the neural cell adhesion molecule (NCAM), The presence of polysialic acid on NCAM has been shown, to modulate cell-cell and cell-matrix interactions. We previously reported that the PST enzyme itself is modified by alpha 2,8-linked polysialic acid chains in vivo. To understand the role of autopolysialylation in PST enzymatic activity, we employed a mutagenesis approach. We found that PST is modified by five Asn-linked oligosaccharides and that the vast majority of the polysialic acid is found on the oligosaccharide modifying Asn-74. In addition, the presence of the oligosaccharide on Asn 119 appeared to be required for folding of PST into an active enzyme. Co-expression of the PST Asn mutants with NCAM demonstrated that autopolysialylation is not required for PST polysialyltransferase activity. Notably, catalytically active, non-autopolysialylated PST does not polysialylate any endogenous COS-1 cell proteins, highlighting the protein specificity of polysialylation. Immunoblot analyses of NCAM polysialylation by polysialylated and non-autopolysialylated PST suggests that the NCAM is polysialylated to a higher degree by autopolysialylated PST. We conclude that autopolysialylation of PST is not required for, but does enhance, NCAM polysialylation.	Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colley, KT (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Biol, 1819 W Polk St,MC 536, Chicago, IL 60612 USA.	karenc@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048134, R01GM048134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; FINNE J, 1987, J IMMUNOL, V138, P4402; GLICK MC, 1991, PROG CLIN BIOL RES, V366, P267; Horstkorte R, 1999, EXP CELL RES, V246, P122, DOI 10.1006/excr.1998.4255; KIBBELAAR RE, 1989, J PATHOL, V159, P23, DOI 10.1002/path.1711590108; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kudo M, 1998, GLYCOBIOLOGY, V8, P771, DOI 10.1093/glycob/8.8.771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; MICHALIDES R, 1994, INT J CANCER, P34; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; ROTH J, 1988, AM J PATHOL, V133, P596; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1969, DOI 10.1073/pnas.84.7.1969; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TROY FA, 1995, BIOL SIALIC ACIDS, P94; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; ZUBER C, 1992, J BIOL CHEM, V267, P9965	45	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4484	4491		10.1074/jbc.275.6.4484	http://dx.doi.org/10.1074/jbc.275.6.4484			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660622	hybrid			2022-12-25	WOS:000085288800106
J	Hill, K; Welti, S; Yu, JH; Murray, JT; Yip, SC; Condeelis, JS; Segall, JE; Backer, JM				Hill, K; Welti, S; Yu, JH; Murray, JT; Yip, SC; Condeelis, JS; Segall, JE; Backer, JM			Specific requirement for the p85-p110 alpha phosphatidylinositol 3-kinase during epidermal growth factor-stimulated actin nucleation in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P85 REGULATORY SUBUNIT; PHOSPHOINOSITIDE 3-KINASE; MAMMARY ADENOCARCINOMA; ACTIVATION; INSULIN; RAC; 3'-KINASE; RHO	We have studied the role of phosphatidylinositol 3-kinases (PI 3-kinases) in the regulation of the actin cytoskeleton in MTLn3 rat adenocarcinoma cells. Stimulation of MTLn3 cells with epidermal growth factor (EGF) induced a rapid increase in actin polymerization, with production of lamellipodia within 3 min. EGF-stimulated lamellipodia were blocked by 100 naa wortmannin, suggesting the involvement of a class Ia PI 3-kinase, MTLn3 cells contain equal amounts of p110 alpha and p110 beta, and do not contain p110 delta. Injection of specific inhibitory antibodies to p110 alpha induced cell rounding and blocked EGF-stimulated lamellipod extension, whereas control or anti-p110 beta antibodies had no effect. In contrast, both antibodies inhibited EGF-stimulated DNA synthesis. An in situ assay for actin nucleation showed that EGF-stimulated formation of new barbed ends was blocked by injection of anti-p110 alpha antibodies. In summary, the p110 alpha isoform of PI 3-kinase is specifically required for EGF-stimulated actin nucleation during lamellipod extension in breast cancer cells.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Backer, JM (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Murray, James/AAC-6612-2019	Murray, James/0000-0002-6928-2347	NIGMS NIH HHS [GM55692] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen WE, 1997, J CELL SCI, V110, P707; Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; Chan AY, 1998, J CELL SCI, V111, P199; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; NERI A, 1982, J NATL CANCER I, V68, P507; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; REIF K, 1993, J BIOL CHEM, V268, P10780; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	28	73	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3741	3744		10.1074/jbc.275.6.3741	http://dx.doi.org/10.1074/jbc.275.6.3741			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660520	hybrid			2022-12-25	WOS:000085288800004
J	Salvatore, CA; Tilley, SL; Latour, AM; Fletcher, DS; Koller, BH; Jacobson, MA				Salvatore, CA; Tilley, SL; Latour, AM; Fletcher, DS; Koller, BH; Jacobson, MA			Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MAST-CELLS; MOLECULAR-CLONING; PHARMACOLOGICAL CHARACTERIZATION; MEDIATOR RELEASE; A(2B) RECEPTORS; TNF-ALPHA; IN-VITRO; RAT; EXPRESSION; AGONISTS	The A(3) adenosine receptor (A3AR) is one of four receptor subtypes for adenosine and is expressed in a broad spectrum of tissues. In order to study the function of A3AR, a mouse line carrying a mutant A(3) allele was generated. Mice homozygous for targeted disruption of the A3AR gene, A3AR(-/-) are fertile and visually and histologically indistinguishable from wild type mice. The lack of a functional receptor in the A3AR-/- mice was confirmed by molecular and pharmacological analyses. The absence of A3AR protein expression in the A3AR(-/-) mice was demonstrated by lack of N-6-(4-amino-3-[I-125]iodobenzyl)adenosine binding to bone marrow-derived mast cell membranes that were found to express high levels of A3AR in wild type mice. In A3AR(-/-) mice, the density of A(1) and A(2A) adenosine receptor subtypes was the same as in A3AR(+/+) mice as determined by radioligand binding to brain membranes. Additionally, A(2B), receptor transcript expression was not affected by ablation of the A3AR gene. A3AR(-/-) mice have basal heart rates and arterial blood pressures indistinguishable from A3AR(+/+) mice. Functionally, in contrast to wild type mice, adenosine and the A3AR-specific agonist, 2-chloro-N-6-(3-iodobenzyl)-adenosine-5'-N-methyl-carboxamide (S-Cl-IB-MECA), elicit no potentiation of antigen-dependent degranulation of bone marrow-derived mast cells from A3AR(-/-) mice as measured by hexosaminidase release. Also, the ability of 2Cl-IB-MECA to inhibit lipopolysaccharide-induced tumor necrosis factor-alpha production in vivo was decreased in A3AR(-/-) mice in comparison to A3AR(+/+) mice. The A(2A) adenosine receptor agonist, 2-p-(2-carboxyethyl)phenylamino)-5'-N-ethylcarboxamidoadenosine, produced inhibition of lipopolysaccharide-stimulated tumor necrosis factor-alpha production in both A3AR(-/-) and A3AR(+/+) mice. These results show that the inhibition in vivo can be mediated by multiple subtypes, specifically the A(3) and A(2A) adenosine receptors, and A3AR activation plays an important role in both pro- and anti-inflammatory responses.	Merck Res Labs, Dept Pharmacol, W Point, PA 19486 USA; Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Anim Pharmacol, Rahway, NJ 07065 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	Merck & Company; Merck & Company; University of North Carolina; University of North Carolina Chapel Hill	Jacobson, MA (corresponding author), Merck Res Labs, Dept Pharmacol, WP26-265, W Point, PA 19486 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058554] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-58554] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG S, 1995, CARDIOVASC RES, V29, P647, DOI 10.1016/0008-6363(96)88635-4; Auchampach JA, 1997, MOL PHARMACOL, V52, P846, DOI 10.1124/mol.52.5.846; BELLARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73; Bowlin TL, 1997, CELL MOL BIOL, V43, P345; BRUNS RF, 1986, MOL PHARMACOL, V29, P331; CUSHLEY MJ, 1984, AM REV RESPIR DIS, V129, P380; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DOYLE MP, 1994, AM J PHYSIOL, V266, pH2042, DOI 10.1152/ajpheart.1994.266.5.H2042; Feoktistov I, 1998, BIOCHEM PHARMACOL, V55, P627, DOI 10.1016/S0006-2952(97)00512-1; FEOKTISTOV I, 1995, J CLIN INVEST, V96, P1979, DOI 10.1172/JCI118245; FOZARD JR, 1993, BRIT J PHARMACOL, V109, P3, DOI 10.1111/j.1476-5381.1993.tb13522.x; HANNON JP, 1995, BRIT J PHARMACOL, V115, P945, DOI 10.1111/j.1476-5381.1995.tb15902.x; Hasko G, 1996, J IMMUNOL, V157, P4634; Hill RJ, 1997, J PHARMACOL EXP THER, V280, P122; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JACOBSON KA, 1993, FEBS LETT, V336, P57, DOI 10.1016/0014-5793(93)81608-3; JACOBSON KA, 1992, J MED CHEM, V35, P407, DOI 10.1021/jm00081a001; LEVRAUX V, 1993, LIFE SCI, V52, P1917, DOI 10.1016/0024-3205(93)90632-D; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; LINDEN J, 1985, CIRC RES, V56, P279, DOI 10.1161/01.RES.56.2.279; Linden J, 1999, MOL PHARMACOL, V56, P705; LINDEN J, 1994, TRENDS PHARMACOL SCI, V15, P298, DOI 10.1016/0165-6147(94)90011-6; LINDEN J, 1993, MOL PHARMACOL, V44, P524; MARQUARDT DL, 1988, BIOCHEM PHARMACOL, V37, P4019, DOI 10.1016/0006-2952(88)90088-3; MARQUARDT DL, 1994, J IMMUNOL, V152, P4508; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; MEYERHOF W, 1991, FEBS LETT, V284, P155, DOI 10.1016/0014-5793(91)80674-R; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; PEACHELL PT, 1988, AM REV RESPIR DIS, V138, P1143, DOI 10.1164/ajrccm/138.5.1143; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; RAMKUMAR V, 1995, J IMMUNOL, V154, P5436; ROTTEM M, 1992, BLOOD, V79, P972; SAJJADI FG, 1993, BIOCHIM BIOPHYS ACTA, V1179, P105, DOI 10.1016/0167-4889(93)90077-3; Sajjadi FG, 1996, J IMMUNOL, V156, P3435; SALVATORE CA, 1993, P NATL ACAD SCI USA, V90, P10365, DOI 10.1073/pnas.90.21.10365; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P43; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; Sullivan GW, 1998, DRUG DEVELOP RES, V45, P103, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<103::AID-DDR4>3.0.CO;2-W; TERAI T, 1995, EUR J PHARMACOL, V279, P217, DOI 10.1016/0014-2999(95)00165-H; VanSchaick EA, 1996, EUR J PHARMACOL, V308, P311, DOI 10.1016/0014-2999(96)00373-1; VONLUBITZ DKJE, 1994, EUR J PHARMACOL, V263, P59, DOI 10.1016/0014-2999(94)90523-1; Walker BAM, 1997, AM J RESP CELL MOL, V16, P531, DOI 10.1165/ajrcmb.16.5.9160835; Yao Y, 1997, BIOCHEM BIOPH RES CO, V232, P317, DOI 10.1006/bbrc.1997.6290; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	46	258	270	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4429	4434		10.1074/jbc.275.6.4429	http://dx.doi.org/10.1074/jbc.275.6.4429			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660615	hybrid			2022-12-25	WOS:000085288800099
J	Angstrom, J; Backstrom, M; Berntsson, A; Karlsson, N; Holmgren, J; Karlsson, KA; Lebens, M; Teneberg, S				Angstrom, J; Backstrom, M; Berntsson, A; Karlsson, N; Holmgren, J; Karlsson, KA; Lebens, M; Teneberg, S			Novel carbohydrate binding site recognizing blood group A and B determinants in a hybrid of cholera toxin and Escherichia coli heat-labile enterotoxin B-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING; VIBRIO-CHOLERAE; HUMAN ADENOCARCINOMA; SPECIFICITY; IMMUNOGENICITY; GLYCOLIPIDS; SELECTIN; GLYCOSPHINGOLIPIDS; IDENTIFICATION; ANTIGENS	The B-subunits of cholera toxin (CTB) and Escherichia coli heat-labile enterotoxin (LTB) are structurally and functionally related. However, the carbohydrate binding specificities of the two proteins differ. While both CTB and LTB bind to the GM1 ganglioside, LTB also binds to N-acetyllactosamine-terminated glycoconjugates. The structural basis of the differences in carbohydrate recognition has been investigated by a systematic exchange of amino acids between LTB and CTB. Thereby, a CTB/LTB hybrid with a gain-of-function mutation resulting in recognition of blood group A and B determinants was obtained. Glycosphingolipid binding assays showed a specific binding of this hybrid B-subunit, but not CTB or LTB, to slowly migrating nonacid glycosphingolipids of human and animal small intestinal epithelium. A binding-active glycosphingolipid isolated from cat intestinal epithelium was characterized by mass spectrometry and proton NMR as GalNAc alpha 3(Fuc alpha 2)Gal beta 4(Fuc alpha 3)GlcNAc beta 3Gal beta 4Glc NAc beta 3Gal beta 4Glc beta 1Cer. Comparison with reference glycosphingolipids showed that the minimum binding epitope recognized by the CTB/LTB hybrid was Gal alpha 3(Fuc alpha 2)Gal beta 4(Fuc alpha 3)GlcNAc beta. The blood group A and B determinants bind to a novel carbohydrate binding site located at the top of the B-subunit interfaces, distinct from the GM1 binding site, as found by docking and molecular dynamics simulations.	Univ Gothenburg, Inst Med Biochem, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Dept Med Microbiol & Immunol, SE-41346 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Teneberg, S (corresponding author), Univ Gothenburg, Inst Med Biochem, POB 440, SE-40530 Gothenburg, Sweden.		Karlsson, Niclas/G-5235-2013	Karlsson, Niclas/0000-0002-3045-2628; Lebens, Michael/0000-0001-9458-9474; Holmgren, Jan/0000-0003-1784-5918				ANGSTROM J, 1994, P NATL ACAD SCI USA, V91, P11859, DOI 10.1073/pnas.91.25.11859; Backstrom M, 1997, MOL MICROBIOL, V24, P489, DOI 10.1046/j.1365-2958.1997.3541721.x; BLACK RE, 1985, P 11 NOB C, P23; Blanck O, 1996, J BIOL CHEM, V271, P7289, DOI 10.1074/jbc.271.13.7289; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIMER ME, 1980, ADV MASS SPECTROM, V8, P1097; CLAUSEN H, 1985, BIOCHEMISTRY-US, V24, P3578, DOI 10.1021/bi00335a028; De Haan L, 1998, IMMUNOLOGY, V94, P424, DOI 10.1046/j.1365-2567.1998.00535.x; Dickinson Bonny L., 1996, P73, DOI 10.1016/B978-012410580-5/50006-6; DOMENIGHINI M, 1995, MOL MICROBIOL, V15, P1165, DOI 10.1111/j.1365-2958.1995.tb02289.x; Elson Charles O., 1996, P59, DOI 10.1016/B978-012410580-5/50005-4; FUKUTA S, 1988, INFECT IMMUN, V56, P1748, DOI 10.1128/IAI.56.7.1748-1753.1988; Guidry JJ, 1997, INFECT IMMUN, V65, P4943, DOI 10.1128/IAI.65.12.4943-4950.1997; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HANSSON GC, 1983, J BIOL CHEM, V258, P4091; HOLMGREN J, 1973, INFECT IMMUN, V8, P851, DOI 10.1128/IAI.8.6.851-859.1973; IMBERTY A, 1995, GLYCOCONJUGATE J, V12, P331, DOI 10.1007/BF00731336; Karlsson K A, 1978, Prog Chem Fats Other Lipids, V16, P207, DOI 10.1016/0079-6832(78)90045-9; Karlsson KA, 1996, BIOORGAN MED CHEM, V4, P1919, DOI 10.1016/S0968-0896(96)00174-5; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KARLSSON KA, 1979, J BIOL CHEM, V254, P9311; KARLSSON KA, 1974, BIOCHEMISTRY-US, V13, P3643, DOI 10.1021/bi00715a003; KARLSSON KA, 1976, GLYCOLIPID METHODOLO, P97; KOGAN TP, 1995, J BIOL CHEM, V270, P14047, DOI 10.1074/jbc.270.23.14047; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LEBENS M, 1993, BIO-TECHNOL, V11, P1574, DOI 10.1038/nbt1293-1574; Lebens M, 1996, INFECT IMMUN, V64, P2144, DOI 10.1128/IAI.64.6.2144-2150.1996; LEONG J, 1985, INFECT IMMUN, V48, P73, DOI 10.1128/IAI.48.1.73-77.1985; LEVERY SB, 1986, CARBOHYD RES, V151, P311, DOI 10.1016/S0008-6215(00)90351-3; Merritt EA, 1998, J MOL BIOL, V282, P1043, DOI 10.1006/jmbi.1998.2076; MERRITT EA, 1994, PROTEIN SCI, V3, P166; Moreno E, 1997, BIOCHEMISTRY-US, V36, P4429, DOI 10.1021/bi962231h; Nashar TO, 1996, P NATL ACAD SCI USA, V93, P226, DOI 10.1073/pnas.93.1.226; ORLANDI PA, 1994, BIOCHEMISTRY-US, V33, P12886, DOI 10.1021/bi00209a021; Revelle BM, 1996, J BIOL CHEM, V271, P4289; SANCHEZ J, 1989, P NATL ACAD SCI USA, V86, P481, DOI 10.1073/pnas.86.2.481; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; TENEBERG S, 1994, GLYCOCONJUGATE J, V11, P533, DOI 10.1007/BF00731304; WALDI D, 1962, DUNNSCHICHT CHROMATO, P495	40	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3231	3238		10.1074/jbc.275.5.3231	http://dx.doi.org/10.1074/jbc.275.5.3231			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652309	hybrid			2022-12-25	WOS:000085146500031
J	Brodolin, K; Mustaev, A; Severinov, K; Nikiforov, V				Brodolin, K; Mustaev, A; Severinov, K; Nikiforov, V			Identification of RNA polymerase beta ' subunit segment contacting the melted region of the lacUV5 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN COMPLEX-FORMATION; SINGLE-STRANDED-DNA; SIGMA(70) SUBUNIT; CRYSTAL-STRUCTURE; CROSS-LINKING; TEMPERATURE-DEPENDENCE; LAMBDA-EXONUCLEASE; ELONGATION COMPLEX; NONTEMPLATE STRAND; TRANSCRIPTION	Identification of the RNA polymerase functional regions involved in interactions with promoter is a basis for understanding the mechanism of transcription initiation. We have used formaldehyde cross-linking to identify a region of Escherichia coli RNA polymerase beta' subunit contacting lacUV5 promoter in open complex. Treatment of open complex with formaldehyde results in cross-linking of beta' and sigma(70) subunits at positions -5 and -3 on the nontemplate strand of the promoter DNA These cross-links reflect specific interactions between RNA polymerase and promoter established in open complex. The positions of formaldehyde cross-links in the beta' subunit were mapped to the N-terminal segment (Cys(198)-Met(237)), which is contiguous to the evolutionary conserved region B, The proximity of the beta' and sigma crosslinks suggest that the N-terminal region of the beta' subunit, interacting with single-stranded promoter DNA, can cooperate with the sigma subunit in the process of open complex formation.	Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia; Publ Hlth Res Inst, New York, NY 10016 USA; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA	Russian Academy of Sciences; Rutgers State University New Brunswick	Brodolin, K (corresponding author), Russian Acad Sci, Inst Mol Genet, Kurchatov Sq, Moscow 123182, Russia.		Severinov, Konstantin/C-8545-2016; Brodolin, Konstantin/I-2996-2016; Brodolin, Konstantin/S-5499-2019	Brodolin, Konstantin/0000-0003-3124-7586; Brodolin, Konstantin/0000-0003-3124-7586	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059295, R01GM030717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30717, R01 GM59295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR SE, 1994, BIOCHEMISTRY-US, V33, P11501, DOI 10.1021/bi00204a012; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; Bartlett MS, 1998, J MOL BIOL, V279, P331, DOI 10.1006/jmbi.1998.1779; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BRODOLIN KL, 1993, NUCLEIC ACIDS RES, V21, P5748, DOI 10.1093/nar/21.24.5748; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BUCKLE M, 1991, NUCLEIC ACIDS RES, V19, P833, DOI 10.1093/nar/19.4.833; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GRAGEROV AI, 1980, MOL GEN GENET, V180, P399, DOI 10.1007/BF00425854; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Heisler LM, 1996, J BIOL CHEM, V271, P14572, DOI 10.1074/jbc.271.24.14572; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KONTERMANN RE, 1993, PROTEIN SCI, V2, P223; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; KUNKEL GR, 1981, MOL CELL BIOCHEM, V34, P3, DOI 10.1007/BF02354846; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; Li XY, 1998, J BIOL CHEM, V273, P23558, DOI 10.1074/jbc.273.36.23558; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; MCGHEE JD, 1975, BIOCHEMISTRY-US, V14, P1281, DOI 10.1021/bi00677a029; MCGHEE JD, 1975, BIOCHEMISTRY-US, V14, P1297, DOI 10.1021/bi00677a030; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Owens JT, 1998, BIOCHEMISTRY-US, V37, P7670, DOI 10.1021/bi980188n; Owens JT, 1998, P NATL ACAD SCI USA, V95, P6021, DOI 10.1073/pnas.95.11.6021; Roberts CW, 1996, CELL, V86, P495; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; Severinov K, 1996, J BIOL CHEM, V271, P27969, DOI 10.1074/jbc.271.44.27969; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; SRIPRAKASH KS, 1975, J BIOL CHEM, V250, P5438; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6	46	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3661	3666		10.1074/jbc.275.5.3661	http://dx.doi.org/10.1074/jbc.275.5.3661			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652363	hybrid			2022-12-25	WOS:000085146500085
J	Murakami, S; Lefebvre, V; de Crombrugghe, B				Murakami, S; Lefebvre, V; de Crombrugghe, B			Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PRO-ALPHA-1(II) COLLAGEN GENE; CHONDROCYTE-SPECIFIC ENHANCER; HUMAN OSTEOARTHRITIC CARTILAGE; AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; II COLLAGEN; RHEUMATOID-ARTHRITIS; CAMPOMELIC DYSPLASIA; INDUCED APOPTOSIS	The inflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha) strongly inhibit the expression of genes for cartilage extracellular matrix proteins. We have recently obtained genetic evidence indicating that the high mobility group domain containing transcription factor Sox9 is required for cartilage formation and for expression of chondrocyte-specific genes including the gene for type II collagen (Col2a1). We show here that IL-1 and TNF-alpha cause a marked and rapid decrease in the levels of Sox9 mRNA and/or protein in chondrocytes. A role for the transcription factor NF kappa B in Sox9 down-regulation was suggested by the ability of pyrrolidine dithiocarbamate, an inhibitor of the NF kappa B pathway, to block the effects of IL-1 and TNF-alpha. This role was further supported by the ability of a dominant-negative mutant of I kappa B alpha to block the IL-1 and TNF-alpha inhibition of Sox9-dependent Col2a1 enhancer elements. Furthermore, forced expression of the NF kappa B subunits p65 or p50 also inhibited Sox9-dependent Col2a1 enhancer. Because Sox9 is essential for chondrogenesis, the marked down-regulation of the Sox9 gene by IL-1 and TNF-alpha in chondrocytes is sufficient to account for the inhibition of the chondrocyte phenotype by these cytokines. The down-regulation of Sox9 may have a crucial role in inhibiting expression of the cartilage phenotype in inflammatory joint diseases.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	de Crombrugghe, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919, R01AR042909] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01 AR42919-02, R01 AR42909] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bolton MC, 1996, BIOCHEM J, V319, P489, DOI 10.1042/bj3190489; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Cameron FJ, 1996, HUM MOL GENET, V5, P1625, DOI 10.1093/hmg/5.10.1625; CHANDRASEKHAR S, 1990, EXP CELL RES, V191, P105, DOI 10.1016/0014-4827(90)90042-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chubinskaya S, 1996, LAB INVEST, V74, P232; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONTANA A, 1982, RHEUMATOL INT, V2, P49, DOI 10.1007/BF00541245; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; HUSBY G, 1988, J AUTOIMMUN, V1, P363, DOI 10.1016/0896-8411(88)90006-6; IP YT, 1991, CELL, V64, P439; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; KIROV N, 1994, MOL CELL BIOL, V14, P713, DOI 10.1128/MCB.14.1.713; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; Labow M, 1997, J IMMUNOL, V159, P2452; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P366, DOI 10.1016/0167-4889(90)90145-4; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; Lum ZP, 1996, J CELL PHYSIOL, V166, P351, DOI 10.1002/(SICI)1097-4652(199602)166:2<351::AID-JCP13>3.0.CO;2-E; MALLEINGERIN F, 1993, P NATL ACAD SCI USA, V90, P3289, DOI 10.1073/pnas.90.8.3289; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; METSARANTA M, 1991, BIOCHIM BIOPHYS ACTA, V1089, P241, DOI 10.1016/0167-4781(91)90014-D; MIOSSEC P, 1986, ARTHRITIS RHEUM, V29, P461, DOI 10.1002/art.1780290402; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Ohta S, 1998, LAB INVEST, V78, P79; OKADA Y, 1992, LAB INVEST, V66, P680; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Richards AJ, 1996, HUM MOL GENET, V5, P1339, DOI 10.1093/hmg/5.9.1339; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Shornick LP, 1996, J EXP MED, V183, P1427, DOI 10.1084/jem.183.4.1427; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; SPRANGER J, 1994, EUR J PEDIATR, V153, P56, DOI 10.1007/BF01959208; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WOOD DD, 1983, ARTHRITIS RHEUM, V26, P975, DOI 10.1002/art.1780260806; YOCUM DE, 1989, CELL IMMUNOL, V122, P131, DOI 10.1016/0008-8749(89)90154-8; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; ZHOU G, 1995, J CELL SCI, V108, P3677	67	225	244	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3687	3692		10.1074/jbc.275.5.3687	http://dx.doi.org/10.1074/jbc.275.5.3687			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652367	hybrid			2022-12-25	WOS:000085146500089
J	Moffett, S; Brown, DA; Linder, ME				Moffett, S; Brown, DA; Linder, ME			Lipid-dependent targeting of G proteins into rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; GPI-ANCHORED PROTEINS; T-CELL ACTIVATION; SIGNAL-TRANSDUCTION; MEMBRANE-BINDING; ADENYLYL-CYCLASE; TYROSINE KINASES; MODEL MEMBRANES; PLASMA-MEMBRANE; ALPHA-SUBUNITS	Domains rich in sphingolipids and cholesterol, or rafts, may organize signal transduction complexes at the plasma membrane. Raft lipids are believed to exist in a state similar to the liquid-ordered phase. It has been proposed that proteins with a high affinity for an ordered lipid environment will preferentially partition into rafts (Melkonian, K. A., Ostermeyer, A. G., Chen, J. Z., Roth, M. G., and Brown, D. A. (1999) J. Biol. Chem. 274, 3910-3917), We investigated the possibility that lipid-lipid interactions between lipid-modified proteins and raft lipids mediate targeting of proteins to these domains. G protein monomers or trimers were reconstituted in liposomes, engineered to mimic raft domains. Assay for partitioning of G proteins into rafts was based on Triton X-100 insolubility. Myristoylation and palmitoylation of G alpha(i) were necessary and sufficient for association with liposomes and partitioning into rafts. Strikingly, the amount of fatty-acylated G alpha(i) in rafts was significantly reduced when myristoylated G alpha(i) was thioacylated with cis-unsaturated fatty acids instead of saturated fatty acids such as palmitate. Prenylated beta gamma subunits were excluded from rafts, whether reconstituted alone or with fatty-acylated cy subunits, These results suggest that the structural difference between lipids that modify proteins is one basis for the selectivity of protein targeting to rafts.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Washington University (WUSTL); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Linder, ME (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Box 8228, St Louis, MO 63110 USA.		Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051466, R01GM047897] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51466, GM47897] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ANTONNY B, 1993, J BIOL CHEM, V268, P2393; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; ARREAZA G, 1995, J BIOL CHEM, V270, P23641, DOI 10.1074/jbc.270.40.23641; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown RE, 1998, J CELL SCI, V111, P1; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; Cladera J, 1997, EUR J BIOCHEM, V243, P798, DOI 10.1111/j.1432-1033.1997.00798.x; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; FUNG BKK, 1983, J BIOL CHEM, V258, P503; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; Ge MT, 1999, BIOPHYS J, V77, P925, DOI 10.1016/S0006-3495(99)76943-2; GENNIS RB, 1989, BIOMEMBRANES MOL STR, P49; HALLAK H, 1994, J BIOL CHEM, V269, P4713; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MACALA LJ, 1983, J LIPID RES, V24, P1243; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Rehm A, 1997, J CELL BIOL, V137, P305, DOI 10.1083/jcb.137.2.305; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; SCHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; Song KS, 1997, CELL MOL BIOL, V43, P293; STERNWEIS PC, 1979, J BIOL CHEM, V254, P3333; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	58	345	354	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2191	2198		10.1074/jbc.275.3.2191	http://dx.doi.org/10.1074/jbc.275.3.2191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636925	hybrid			2022-12-25	WOS:000084940000088
J	Luders, J; Demand, J; Hohfeld, J				Luders, J; Demand, J; Hohfeld, J			The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp70 and the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC PROTEIN BAG-1; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; 20S PROTEASOME; PIM1 PROTEASE; CANCER-CELLS; DNA-REPAIR; RECEPTOR; HSC70; DEGRADATION	The BAG-1 protein modulates the chaperone activity of Hsc70 and Hsp70 in the mammalian cytosol and nucleus. Remarkably, BAG-1 possesses a ubiquitin-like domain at its amino terminus, suggesting a link to the ubiquitin/proteasome system. Here we show that BAG-1 is indeed associated with the 26 S proteasome in HeLa cells. Binding of the chaperone cofactor to the proteolytic complex is regulated by ATP hydrolysis and is not mediated by Hsc70 and Hsp70. The presented findings reveal a role of BAG-1 as a physical link between the Hsc70/Hsp70 chaperone system and the proteasome. In fact, targeting of BAG-1 to the proteasome promotes an association of the chaperones with the proteolytic complex in vitro and in vivo. A regulatory function of the chaperone cofactor at the interface between protein folding and protein degradation is thus indicated.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Hohfeld, J (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany.		Lüders, Jens/H-2812-2015	Lüders, Jens/0000-0002-9018-7977				Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Gebauer M, 1997, FEBS LETT, V417, P109, DOI 10.1016/S0014-5793(97)01267-2; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hohfeld J, 1998, BIOL CHEM, V379, P269; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Savel'ev AS, 1998, J BIOL CHEM, V273, P20596, DOI 10.1074/jbc.273.32.20596; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; [No title captured]	46	370	378	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4613	4617		10.1074/jbc.275.7.4613	http://dx.doi.org/10.1074/jbc.275.7.4613			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671488	hybrid			2022-12-25	WOS:000085378200014
J	Salmon, AL; Johnsen, AH; Bienert, M; McMurray, G; Nandha, KA; Bloom, SR; Shaw, C				Salmon, AL; Johnsen, AH; Bienert, M; McMurray, G; Nandha, KA; Bloom, SR; Shaw, C			Isolation, structural characterization, and bioactivity of a novel neuromedin U analog from the defensive skin secretion of the Australasian tree frog, Litoria caerulea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SPINAL-CORD; ACTIVE PEPTIDES; PHARMACOLOGICAL ACTIVITY; SMALL-INTESTINE; GUINEA-PIG; RAT; U-8; PURIFICATION; CONSERVATION; EXPRESSION	We report the isolation of a novel bioactive peptide, neuromedin U-23 (NmU-23), from the defensive skin secretion of the Australasian tree frog, Litoria caerulea. The primary structure of the peptide was established by a combination of microsequencing, mass spectroscopy and site-directed antiserum immunoreactivity as SDEEVQVPGGVISNGYFLFRPRN-amide (M-r 2580.6), A synthetic replicate of frog NmU-23 displaced monoradioiodinated rat NmU-23 from uterine membranes in a dose-dependent fashion indistinguishable from nonisotopically labeled rat NmU-23. In a rat uterine smooth muscle strip preparation, synthetic frog NmU-23 produced dose-dependent contractions identical to porcine NmU-25, However, in a preparation of human urinary bladder muscle strip, the synthetic frog peptide was more potent than porcine NmU-25 in eliciting contraction and produced desensitization of the preparation to the latter peptide. This report demonstrates that the defensive skin secretion of a frog contains a novel peptide exhibiting a high degree of primary structural similarity to the endogenous vertebrate peptide, NmU, and that this frog skin analog displays biological activity in mammalian tissues.	Queens Univ Belfast, Dept Med, Nat Drug Discovery Lab, Med Clin, Belfast BT12 6BJ, Antrim, North Ireland; Rigshosp, Dept Clin Chem, DK-2100 Copenhagen, Denmark; Inst Mol Pharmacol, D-10315 Berlin, Germany; Dept Pharmacol, Oxford OX2 3QT, England; Royal Postgrad Med Sch, Dept Med, London W12 0NN, England	Queens University Belfast; Rigshospitalet; University of Copenhagen; Imperial College London	Salmon, AL (corresponding author), Queens Univ Belfast, Dept Med, Nat Drug Discovery Lab, Med Clin, Mulhouse Bldg,Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.							ANASTASI A, 1965, COMP BIOCHEM PHYSIOL, V14, P43; ANASTASI A, 1968, ARCH BIOCHEM BIOPHYS, V125, P57, DOI 10.1016/0003-9861(68)90638-3; ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873; AUSTIN C, 1995, J MOL ENDOCRINOL, V14, P157, DOI 10.1677/jme.0.0140157; BARTHALMUS GT, 1988, PHARMACOL BIOCHEM BE, V30, P957, DOI 10.1016/0091-3057(88)90126-8; BENITOORFILA MA, 1991, EUR J PHARMACOL, V193, P329, DOI 10.1016/0014-2999(91)90147-I; BERTOLINI A, 1986, NEUROPEPTIDES, V8, P25, DOI 10.1016/0143-4179(86)90061-2; BROWN DR, 1988, EUR J PHARMACOL, V155, P159, DOI 10.1016/0014-2999(88)90415-3; CONLON JM, 1988, J NEUROCHEM, V51, P988, DOI 10.1111/j.1471-4159.1988.tb01837.x; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DOMIN J, 1992, REGUL PEPTIDES, V41, P1, DOI 10.1016/0167-0115(92)90508-R; DOMIN J, 1989, J BIOL CHEM, V264, P20881; DOMIN J, 1986, BIOCHEM BIOPH RES CO, V140, P1127, DOI 10.1016/0006-291X(86)90752-7; DOMIN J, 1987, PEPTIDES, V8, P779, DOI 10.1016/0196-9781(87)90058-1; ERSPAMER V, 1984, COMP BIOCHEM PHYS C, V77, P99, DOI 10.1016/0742-8413(84)90137-3; ERSPAMER V, 1981, PEPTIDES, V2, P7, DOI 10.1016/0196-9781(81)90003-6; ERSPAMER V, 1985, PEPTIDES, V6, P7, DOI 10.1016/0196-9781(85)90343-2; ERSPAMER V, 1986, COMP BIOCHEM PHYS C, V85, P125, DOI 10.1016/0742-8413(86)90063-0; ESPARMER V, 1994, AMPHIBIAN BIOL INTEG, P231; GARDINER SM, 1990, AM J PHYSIOL, V258, pE32; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GUARINI S, 1988, NEUROPEPTIDES, V11, P69, DOI 10.1016/0143-4179(88)90012-1; KAGE R, 1991, REGUL PEPTIDES, V33, P191, DOI 10.1016/0167-0115(91)90213-Z; LAZARUS LH, 1993, PROG NEUROBIOL, V41, P473, DOI 10.1016/0301-0082(93)90027-P; LO G, 1992, MOL ENDOCRINOL, V6, P1538, DOI 10.1210/me.6.10.1538; MAGGI CA, 1990, BRIT J PHARMACOL, V99, P186, DOI 10.1111/j.1476-5381.1990.tb14675.x; Malendowicz LK, 1998, HORM METAB RES, V30, P374, DOI 10.1055/s-2007-978901; MALENDOWICZ LK, 1994, NEUROPEPTIDES, V26, P47, DOI 10.1016/0143-4179(94)90092-2; MALENDOWICZ LK, 1994, RES EXP MED, V194, P69, DOI 10.1007/BF02576368; MINAMINO N, 1988, BIOCHEM BIOPH RES CO, V156, P355, DOI 10.1016/S0006-291X(88)80848-9; MINAMINO N, 1985, PEPTIDES, V6, P245, DOI 10.1016/0196-9781(85)90381-X; MINAMINO N, 1985, BIOCHEM BIOPH RES CO, V130, P1078, DOI 10.1016/0006-291X(85)91726-7; MOR A, 1994, P NATL ACAD SCI USA, V91, P10295, DOI 10.1073/pnas.91.22.10295; MURPHY R, 1990, PEPTIDES, V11, P613, DOI 10.1016/0196-9781(90)90066-E; NANDHA KA, 1993, BIOMED RES-TOKYO, V14, P71; NANDHA KA, 1993, ENDOCRINOLOGY, V133, P482, DOI 10.1210/en.133.2.482; OHARTE F, 1991, PEPTIDES, V12, P11, DOI 10.1016/0196-9781(91)90159-M; OHARTE F, 1991, PEPTIDES, V12, P809, DOI 10.1016/0196-9781(91)90138-F; PIERIBONE VA, 1992, J NEUROSCI, V12, P3361; ROSEGHINI M, 1988, COMP BIOCHEM PHYS C, V91, P281, DOI 10.1016/0742-8413(88)90030-8; ROSEGHINI M, 1989, COMP BIOCHEM PHYS C, V94, P455, DOI 10.1016/0742-8413(89)90097-2; STONE DJM, 1992, J CHEM SOC CHEM COMM, P1224, DOI 10.1039/c39920001224; STONE DJM, 1993, J CHEM RES, V4, P138; SUMI S, 1987, LIFE SCI, V41, P1585, DOI 10.1016/0024-3205(87)90725-9; WAUGH RJ, 1993, J CHEM SOC PERK T, V5, P73; ZIELINSKI WJ, 1989, ANIM BEHAV, V38, P1083, DOI 10.1016/S0003-3472(89)80149-6	46	33	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4549	4554		10.1074/jbc.275.7.4549	http://dx.doi.org/10.1074/jbc.275.7.4549			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671478	hybrid			2022-12-25	WOS:000085378200004
J	Collette, Y; Arold, S; Picard, C; Janvier, K; Benichou, S; Benarous, R; Olive, D; Dumas, C				Collette, Y; Arold, S; Picard, C; Janvier, K; Benichou, S; Benarous, R; Olive, D; Dumas, C			HIV-2 and SIV Nef proteins target different Src family SH3 domains than does HIV-1 Nef because of a triple amino acid substitution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY VIRUS NEF; BINDING SURFACE; CRYSTAL-STRUCTURE; RHESUS MACAQUES; DOWN-REGULATION; SERINE KINASE; I MOLECULES; ASSOCIATION; HCK; COMPLEX	The nef gene is required for optimal viral spread of human and simian immunodeficiency viruses. However, the molecular mechanisms underlying the action of the Nef proteins may not be identical for all viral families. Here we investigate the interaction between the Nef protein of human and simian immunodeficiency viruses and SH3 domains from Src family kinases, Using the yeast two-hybrid system and immunoblotting we show that, in contrast to HIV-1 Nef, SN and HIV-2 Nef poorly interact with Hck SH3 but bind to Src and Fyn SH3 domains. The molecular basis of these differences in SH3 targeting was revealed by sequence analysis and homology modeling of the putative SH3-Nef structures. Three amino acids (Trp-113, Thr-117, and Gln-118) that localize in a "hydrophobic pocket" implicated in SH3 binding of HIV-1 Nef, are systematically substituted in SIV/HIV-2 alleles (by Tyr, Glu, and Glu, respectively). We demonstrate that site-directed mutagenesis of these residues in SIVmac239 Nef suffices to restore Hck SH3 binding and co immunoprecipitation with full-length Hck from transfected cells, Our findings identify fundamental mechanistic differences in targeting of Src family kinases by HN and SIV Nef. The herein described mechanism of SH3 selection by Nef via a "pocket" proximal to the canonical proline-rich motif may be a common feature for SH3 recognition by their natural ligands.	Univ Mediterranee, U119 INSERM, F-13009 Marseille, France; Univ Montpellier 1, U414 INSERM, UMR C9955 CNRS, Ctr Biochim Struct,Fac Pharm, F-34060 Montpellier, France; Inst Cochin Genet Mol, EPI INSERM 9923, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Collette, Y (corresponding author), Univ Mediterranee, U119 INSERM, 27 Blvd Lei Roure, F-13009 Marseille, France.		COLLETTE, Yves/F-2270-2013; Janvier, Katy/O-7780-2017; Arold, Stefan/T-2612-2019	COLLETTE, Yves/0000-0001-5359-7099; Janvier, Katy/0000-0002-3105-4736; Benichou, Serge/0000-0003-3602-3530; Arold, Stefan T/0000-0001-5278-0668				Arold S, 1998, BIOCHEMISTRY-US, V37, P14683, DOI 10.1021/bi980989q; Arold S, 1997, STRUCTURE, V5, P1361, DOI 10.1016/S0969-2126(97)00286-4; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; Greenway AL, 1999, J VIROL, V73, P6152, DOI 10.1128/JVI.73.7.6152-6158.1999; Grzesiek S, 1997, PROTEIN SCI, V6, P1248, DOI 10.1002/pro.5560060613; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Karn T, 1998, VIROLOGY, V246, P45, DOI 10.1006/viro.1998.9157; Khan IH, 1998, J VIROL, V72, P5820, DOI 10.1128/JVI.72.7.5820-5830.1998; KORBER B, 1997, HUMAN RETROVIRUS AID; Lang SM, 1997, NAT MED, V3, P860, DOI 10.1038/nm0897-860; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Manninen A, 1998, VIROLOGY, V250, P273, DOI 10.1006/viro.1998.9381; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; TUFFERY P, 1991, J BIOMOL STRUCT DYN, V8, P1267, DOI 10.1080/07391102.1991.10507882; Wiskerchen M, 1996, VIROLOGY, V224, P292, DOI 10.1006/viro.1996.0531	32	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4171	4176		10.1074/jbc.275.6.4171	http://dx.doi.org/10.1074/jbc.275.6.4171			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660579	hybrid			2022-12-25	WOS:000085288800063
J	Dash, PR; Read, ML; Fisher, KD; Howard, KA; Wolfert, M; Oupicky, D; Subr, V; Strohalm, J; Ulbrich, K; Seymour, LW				Dash, PR; Read, ML; Fisher, KD; Howard, KA; Wolfert, M; Oupicky, D; Subr, V; Strohalm, J; Ulbrich, K; Seymour, LW			Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; THERAPY; DNA; FORMULATIONS; COPOLYMERS; COMPLEXES; INJECTION; MELANOMA; LIPOSOME; FUTURE	Binding of serum proteins to polyelectrolyte gene delivery complexes is thought to be an important factor limiting bloodstream circulation and restricting access to target tissues. Protein binding can also inhibit transfection activity in vitro. In this study a multivalent reactive hydrophilic polymer has been used to inhibit protein binding. This polymer is based on poly-[N-(2-hydroxypropyl)methacrylamide] (pHPMA) bearing pendent oligopeptide (Gly-Phe-Leu-Gly) side chains terminated in reactive 4-nitrophenoxy groups (8.6 mol%). The polymer reacts with the primary amino groups of poly(L-lysine) (pLL) and produces a hydrophilic coating on the surface of pLL DNA complexes (as measured by fluorescamine). The resulting pHPMA-coated complexes show a decreased surface charge (from +14 mV for pLL DMA complexes to -25 mV for pHPMA-modified complexes) as measured by zeta potential analysis, The pHPMA-coated complexes also show a slightly increased average diameter (approximately 90 nm compared with 60 nm for pLL DNA complexes) as viewed by atomic force and transmission electron microscopy and around 100 nm as viewed by photon correlation spectroscopy, They are completely resistant to protein interaction, as determined by turbidometry and SDS-polyacrylamide gel electrophoresis analysis of complexes isolated from plasma, and show significantly decreased nonspecific uptake into cells in vitro. Spare reactive ester groups can be used to conjugate targeting ligands (e.g. transferrin) on to the surface of the complex to provide a means of tissue-specific targeting and transfection. The properties of these complexes therefore make them promising candidates for targeted gene delivery, both in vitro and potentially in vivo.	Univ Birmingham, Canc Res Campaign, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Acad Sci Czech Republ, Inst Macromol Chem, Prague 6, Czech Republic	University of Birmingham; Czech Academy of Sciences; Institute of Macromolecular Chemistry of the Czech Academy of Sciences	Seymour, LW (corresponding author), Univ Birmingham, Canc Res Campaign, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.	L.Seymour@bham.ac.uk	Ulbrich, Karel/G-5145-2014; Šubr, Vladimír/G-3488-2014; Read, Martin/A-3505-2012; Wolfert, Margreet A/J-1726-2016; Oupicky, David/AAR-1655-2021	Read, Martin/0000-0001-8918-4333; Wolfert, Margreet A/0000-0003-4864-0026; Oupicky, David/0000-0003-4710-861X; Subr, Vladimir/0000-0002-1614-6595; Dash, Phil/0000-0002-6029-4560; Howard, Kenneth/0000-0002-9407-278X				Allen TM, 1998, DRUGS, V56, P747, DOI 10.2165/00003495-199856050-00001; Anderson WF, 1998, NATURE, V392, P25; Bonadio J, 1998, ADV DRUG DELIVER REV, V33, P53, DOI 10.1016/S0169-409X(98)00020-9; Chao J, 1999, BIODRUGS, V11, P43, DOI 10.2165/00063030-199911010-00005; Dash PR, 1997, J CONTROL RELEASE, V48, P269, DOI 10.1016/S0168-3659(97)00043-6; Dash PR, 1999, GENE THER, V6, P643, DOI 10.1038/sj.gt.3300843; DeMatteo RP, 1999, ANN SURG ONCOL, V6, P88, DOI 10.1007/s10434-999-0088-2; During MJ, 1998, MOL MED TODAY, V4, P485, DOI 10.1016/S1357-4310(98)01370-7; Efrat S, 1998, DIABETOLOGIA, V41, P1401, DOI 10.1007/s001250051085; Gleich LL, 1998, ARCH OTOLARYNGOL, V124, P1097, DOI 10.1001/archotol.124.10.1097; Gottschalk U, 1998, ARZNEIMITTEL-FORSCH, V48, P1111; Hara T, 1997, ADV DRUG DELIVER REV, V24, P265, DOI 10.1016/S0169-409X(96)00467-X; Hara T, 1997, P NATL ACAD SCI USA, V94, P14547, DOI 10.1073/pnas.94.26.14547; Klatzmann D, 1996, HUM GENE THER, V7, P255, DOI 10.1089/hum.1996.7.2-255; Kong HL, 1998, J NATL CANCER I, V90, P273, DOI 10.1093/jnci/90.4.273; Lasic DD, 1995, CHEM REV, V95, P2601, DOI 10.1021/cr00040a001; Li S, 1997, J LIPOS RES, V7, P207, DOI 10.3109/08982109709035496; Mahato RI, 1997, CRIT REV THER DRUG, V14, P133; Mornex JF, 1998, PRESSE MED, V27, P769; Nomura T, 1997, CANCER RES, V57, P2681; Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900; RIHOVA B, 1989, BIOMATERIALS, V10, P335, DOI 10.1016/0142-9612(89)90075-6; Toncheva V, 1998, BBA-GEN SUBJECTS, V1380, P354, DOI 10.1016/S0304-4165(98)00004-X; Waddill W, 1997, AM J ROENTGENOL, V169, P63, DOI 10.2214/ajr.169.1.9207502; Ward CM, 1999, COLLOID SURFACE B, V16, P253, DOI 10.1016/S0927-7765(99)00076-4; Wolfert MA, 1996, HUM GENE THER, V7, P2123, DOI 10.1089/hum.1996.7.17-2123	26	141	158	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3793	3802		10.1074/jbc.275.6.3793	http://dx.doi.org/10.1074/jbc.275.6.3793			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660529	Green Published, hybrid			2022-12-25	WOS:000085288800013
J	Khan, KMF; Falcone, DJ				Khan, KMF; Falcone, DJ			Selective activation of MAPK(erk1/2) by laminin-1 peptide alpha 1 : Ser(2091)-Arg(2108) regulates macrophage degradative phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; PLASMINOGEN-ACTIVATOR; UROKINASE EXPRESSION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; INDUCTION; PROTEOGLYCAN; RELEASE; GROWTH	Components of the extracellular matrix contain cryptic domains, which are exposed by proteolysis and elicit biological responses distinct from intact molecules. The disparate cellular response to extracellular matrix fragments and parent intact molecules suggests differential recognition and signaling pathways. In experiments reported here, we demonstrate that urokinase and matrix metalloproteinase-9 expression by RAW264.7 macrophages is stimulated by a synthetic laminin peptide derived from the alpha 1-chain (SRARKQAASIKVAVSADR), whereas intact laminin-l has no effect on proteinase expression by macrophages. Incubation of macrophages with alpha 1:SRARKQAASIKVAVSADR stimulates tyrosine phosphorylation of several proteins including mitogen-activated protein kinase (MAPK)(erk1/2). In contrast, neither intact laminin-1 nor the alpha 1-chain peptide CDPGY-IGSR stimulated protein tyrosine phosphorylation in these cells. Inhibition of tyrosine kinases or protein kinase C blocked alpha 1-chain peptide-induced phosphorylation of MAPK(erk1/2) and the up-regulation of steady state levels of urokinase mRNA and matrix metalloproteinase-9 activity. A MAPK kinase inhibitor blocked alpha 1-chain-induced phosphorylation of MAPK(erk1/2) and the induction of proteinase expression. Intact laminin-1, which was unable to induce macrophage proteinase expression, failed to stimulate the phosphorylation of MAPK(erk1/2). These data demonstrate that incubation of macrophages with alpha 1:SRARKQAASIKVAVSADR, but not intact laminin-1, triggers protein kinase C-dependent activation of MAPK(erk1/2), leading to the up-regulation of proteinase expression.	Cornell Univ, Joan & Sanford I Weill Med Col, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Col, Dept Cell Biol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Col, Dept Vasc Biol Ctr, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Falcone, DJ (corresponding author), Cornell Univ, Coll Med, Dept Pathol, Rm A678,1300 York Ave, New York, NY 10021 USA.	dfalcone@mail.med.cornell.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040819] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07432, R01-HL40819] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aplin AE, 1998, PHARMACOL REV, V50, P197; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CORCORAN ML, 1995, J BIOL CHEM, V270, P10365, DOI 10.1074/jbc.270.18.10365; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P8270, DOI 10.1021/bi00399a038; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; FALCONE DJ, 1991, J BIOL CHEM, V266, P22726; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; HUNNINGHAKE GW, 1981, SCIENCE, V212, P925, DOI 10.1126/science.7233186; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; ODEKON LE, 1991, IMMUNOLOGY, V74, P114; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SENIOR RM, 1980, J CLIN INVEST, V66, P859, DOI 10.1172/JCI109926; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shattil SJ, 1997, J CLIN INVEST, V100, P1, DOI 10.1172/JCI119500; SHAW LM, 1995, J BIOL CHEM, V270, P23648, DOI 10.1074/jbc.270.40.23648; TURPEENNIEMIHUJANEN T, 1986, J BIOL CHEM, V261, P1883; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	26	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4492	4498		10.1074/jbc.275.6.4492	http://dx.doi.org/10.1074/jbc.275.6.4492			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660623	hybrid			2022-12-25	WOS:000085288800107
J	Ying, GG; Proost, P; van Damme, J; Bruschi, M; Introna, M; Golay, J				Ying, GG; Proost, P; van Damme, J; Bruschi, M; Introna, M; Golay, J			Nucleolin, a novel partner for the Myb transcription factor family that regulates their activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; C-MYB; A-MYB; B-MYB; GENE ENCODES; PROTEIN; CELLS; ACTIVATOR; IDENTIFICATION; DIFFERENTIATION	To unravel the mechanisms of action of transcriptional regulation by the Myb family of transcription factors, we have set out to isolate their protein partners. We identify nucleolin as one of the nuclear polypeptides that interact specifically with the A-Myb and c-Myb, but not B-Myb DNA-binding domains. We show unambiguously that this interaction is direct and takes place in vivo, as demonstrated by co-immunoprecipitation of the endogenously and exogenously expressed proteins. The minimal DNA-binding domain containing only the R2R3 c-Myb repeats is sufficient for nucleolin binding. Computer analysis of the R2R3 three-dimensional structure, as well as extensive mutational analysis within this region, reveals that the Arg(161) residue, present in c-Myb and A-Myb, but not B-Myb, is crucial for this interaction. We show that the interaction of nucleolin with Myb is functional because co-transfection of nucleolin downregulates Myb transcriptional activity. Nucleolin is a multifunctional phosphoprotein present in both nucleoplasm and more abundantly in the nucleolus and shows helicase and chromatin decondensing activities. This is the first demonstration of nucleolin binding to a transcription factor.	Ist Ric Farmacol Mario Negri, Dept Immunol & Cell Biol, Lab Mol Immunohematol, I-20157 Milan, Italy; Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Ist Ric Farmacol Mario Negri, Dept Biochem & Mol Pharmacol, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; KU Leuven; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Golay, J (corresponding author), Ist Ric Farmacol Mario Negri, Dept Immunol & Cell Biol, Lab Mol Immunohematol, Via Eritrea 62, I-20157 Milan, Italy.	Golay@irfmn.mnegri.it	Proost, Paul/V-3052-2017; Golay, Josee/AAA-4085-2022; Introna, Martino/AAA-5823-2019	Proost, Paul/0000-0002-0133-5545; Golay, Josee/0000-0002-7932-909X; Introna, Martino/0000-0001-6216-0892; BRUSCHI, MAURIZIO/0000-0002-5709-818X				BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; BRYS A, 1994, P NATL ACAD SCI USA, V91, P4915, DOI 10.1073/pnas.91.11.4915; CHEN CM, 1991, J BIOL CHEM, V266, P7754; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; DeRocco SE, 1997, P NATL ACAD SCI USA, V94, P3240, DOI 10.1073/pnas.94.7.3240; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GOLAY J, 1994, ONCOGENE, V9, P2469; GOLAY J, 1994, J IMMUNOL, V153, P543; Golay J, 1998, J IMMUNOL, V160, P2786; Golay J, 1997, CELL GROWTH DIFFER, V8, P1305; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KALKBRENNER F, 1990, ONCOGENE, V5, P657; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; MIRANDA GA, 1995, EXP CELL RES, V217, P294, DOI 10.1006/excr.1995.1090; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Saville MK, 1998, ADV CANCER RES, V72, P109; Schwab MS, 1998, EXP CELL RES, V239, P226, DOI 10.1006/excr.1997.3878; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TASHIRO S, 1995, ONCOGENE, V10, P1699; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; Ying GG, 1997, J BIOL CHEM, V272, P24921, DOI 10.1074/jbc.272.40.24921; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	59	49	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4152	4158		10.1074/jbc.275.6.4152	http://dx.doi.org/10.1074/jbc.275.6.4152			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660576	hybrid			2022-12-25	WOS:000085288800060
J	Dockal, M; Carter, DC; Ruker, F				Dockal, M; Carter, DC; Ruker, F			Conformational transitions of the three recombinant domains of human serum albumin depending on pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PLASMA-ALBUMIN; N-F TRANSITION; ACID-INDUCED ISOMERIZATION; DRUG-BINDING PROPERTIES; LARGE FRAGMENTS; CIRCULAR-DICHROISM; SULFHYDRYL ENVIRONMENT; DISTANCE MEASUREMENTS; SECONDARY STRUCTURE; BASE TRANSITION	Human serum albumin (HSA) is a protein of 66.5 kDa that is composed of three homologous domains, each of which displays specific structural and functional characteristics. HSA is known to undergo different pH-dependent structural transitions, the N-F and F-E transitions in the acid pH region and the N-B transition at slightly alkaline pH, In order to elucidate the structural behavior of the recombinant HSA domains as stand-alone proteins and to investigate the molecular and structural origins of the pH-induced conformational changes of the intact molecule, we have employed fluorescence and circular dichroic methods. Here we provide evidence that the loosening of the HSA structure in the N-F transition takes place primarily in HSA-DOM III and that HSA-DOM I undergoes a structural rearrangement with only minor changes in secondary structure, whereas HSA-DOM II transforms to a molten globule-like state as the pH is reduced. In the pH region of the N-B transition of HSA, HSA-DOM I and HSA-DOM II experience a tertiary structural isomerization, whereas with HSA-DOM III no alterations in tertiary structure are observed, as judged from near-UV CD and fluorescence measurements.	Univ Agr Sci, Inst Appl Microbiol, A-1190 Vienna, Austria; New Century Pharmaceut Inc, Huntsville, AL 35824 USA	University of Natural Resources & Life Sciences, Vienna	Ruker, F (corresponding author), Univ Agr Sci, Inst Appl Microbiol, Muthgasse 18, A-1190 Vienna, Austria.			Rueker, Florian/0000-0001-7639-2686				BOS OJM, 1988, BIOCHIM BIOPHYS ACTA, V953, P37, DOI 10.1016/0167-4838(88)90007-6; BOS OJM, 1989, J BIOL CHEM, V264, P953; BOS OJM, 1988, BIOCHEM PHARMACOL, V37, P3905, DOI 10.1016/0006-2952(88)90072-X; BRAAM WGM, 1974, INT J PEPT PROT RES, V6, P21; CANN JR, 1958, J AM CHEM SOC, V80, P4263, DOI 10.1021/ja01549a035; CANN JR, 1971, BIOCHEMISTRY-US, V10, P3713, DOI 10.1021/bi00796a012; CANN JR, 1957, J AM CHEM SOC, V79, P4672, DOI 10.1021/ja01574a025; CANN JR, 1971, BIOCHEMISTRY-US, V10, P3707, DOI 10.1021/bi00796a011; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CHEN RF, 1966, BIOCHIM BIOPHYS ACTA, V120, P169, DOI 10.1016/0926-6585(66)90291-3; CORNELL CN, 1978, BIOCHEMISTRY-US, V17, P1755, DOI 10.1021/bi00602a027; CORNELL CN, 1978, BIOCHEMISTRY-US, V17, P1750, DOI 10.1021/bi00602a026; COWGILL RW, 1968, BIOCHIM BIOPHYS ACTA, V168, P431, DOI 10.1016/0005-2795(68)90176-1; COWGILL RW, 1968, BIOCHIM BIOPHYS ACTA, V168, P417, DOI 10.1016/0005-2795(68)90175-X; COWGILL RW, 1966, BIOCHIM BIOPHYS ACTA, V120, P196, DOI 10.1016/0926-6585(66)90339-6; COWGILL RW, 1976, BIOCH FLUORESCENCE, V2, P442; Creighton TE, 1992, PROTEIN FOLDING; Dockal M, 1999, J BIOL CHEM, V274, P29303, DOI 10.1074/jbc.274.41.29303; EDELHOCH H, 1969, ANN NY ACAD SCI, V158, P391, DOI 10.1111/j.1749-6632.1969.tb56233.x; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; ERA S, 1990, INT J PEPT PROT RES, V35, P1; Era S, 1998, J PEPT RES, V52, P431; ERA S, 1983, INT J PEPT PROT RES, V22, P333; FINK AL, 1994, BIOCHEMISTRY-US, V33, P12504, DOI 10.1021/bi00207a018; GEISOW MJ, 1977, BIOCHEM J, V163, P477, DOI 10.1042/bj1630477; GEISOW MJ, 1977, BIOCHEM J, V161, P619, DOI 10.1042/bj1610619; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; HALFMAN CJ, 1971, BIOCHIM BIOPHYS ACTA, V243, P284, DOI 10.1016/0005-2795(71)90085-7; HALFMAN CJ, 1971, BIOCHIM BIOPHYS ACTA, V243, P294, DOI 10.1016/0005-2795(71)90086-9; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HILAK MC, 1974, INT J PEPT PROT RES, V6, P95; HONORE B, 1989, BIOCHEM J, V258, P199, DOI 10.1042/bj2580199; HORWITZ J, 1970, J AM CHEM SOC, V92, P2119, DOI 10.1021/ja00710a054; HORWITZ J, 1969, J AM CHEM SOC, V91, P184, DOI 10.1021/ja01029a034; KHAN MY, 1984, EUR J BIOCHEM, V141, P473, DOI 10.1111/j.1432-1033.1984.tb08216.x; KHAN MY, 1986, BIOCHEM J, V236, P307, DOI 10.1042/bj2360307; KHAN SM, 1980, BIOCHIM BIOPHYS ACTA, V624, P1, DOI 10.1016/0005-2795(80)90219-6; Kosa T, 1998, PHARMACEUT RES, V15, P449, DOI 10.1023/A:1011932516717; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEE JY, 1992, J BIOL CHEM, V267, P14753; LEONARD WJ, 1961, J BIOL CHEM, V236, P2662; Lund M, 1999, EUR J BIOCHEM, V260, P470, DOI 10.1046/j.1432-1327.1999.00175.x; MOORE WE, 1968, BIOCHEMISTRY-US, V7, P3409, DOI 10.1021/bi00850a015; NOEL JKF, 1972, J BIOL CHEM, V247, P7391; Peters T., 1996, ALL ALBUMIN BIOCH GE; PHELPS RA, 1956, J AM CHEM SOC, V78, P3539, DOI 10.1021/ja01595a075; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; PUNDAK S, 1984, BIOCHEMISTRY-US, V23, P1549, DOI 10.1021/bi00302a032; REED RG, 1975, BIOCHEMISTRY-US, V14, P4578, DOI 10.1021/bi00692a004; SJODIN T, 1977, BIOCHIM BIOPHYS ACTA, V494, P61, DOI 10.1016/0005-2795(77)90135-0; SJOHOLM I, 1973, J BIOL CHEM, V248, P8434; SOGAMI M, 1975, BIOCHIM BIOPHYS ACTA, V393, P446, DOI 10.1016/0005-2795(75)90073-2; SOGAMI M, 1982, INT J PEPT PROT RES, V19, P263; SOGAMI M, 1968, BIOCHEMISTRY-US, V7, P2172, DOI 10.1021/bi00846a020; SOGAMI M, 1969, BIOCHEMISTRY-US, V8, P49, DOI 10.1021/bi00829a008; SOGAMI M, 1971, J BIOCHEM-TOKYO, V69, P819, DOI 10.1093/oxfordjournals.jbchem.a129532; SOGAMI M, 1973, BIOCHIM BIOPHYS ACTA, V310, P118, DOI 10.1016/0005-2795(73)90014-7; STEINER RF, 1963, BIOCHIM BIOPHYS ACTA, V66, P341, DOI 10.1016/0006-3002(63)91203-4; STEINHARDT J, 1971, BIOCHEMISTRY-US, V10, P4005, DOI 10.1021/bi00798a001; STRICKLA.EH, 1969, BIOCHEMISTRY-US, V8, P3205, DOI 10.1021/bi00836a012; Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439; SUZUKIDA M, 1983, BIOCHEMISTRY-US, V22, P2415, DOI 10.1021/bi00279a017; THART BJ, 1986, BIOCHEM PHARMACOL, V35, P1005, DOI 10.1016/0006-2952(86)90091-2; Uversky VN, 1997, BIOCHEMISTRY-US, V36, P13638, DOI 10.1021/bi970332p; Wang CQ, 1998, BIOCHEMISTRY-US, V37, P8457, DOI 10.1021/bi9723010; WILLIAMS EJ, 1959, J AM CHEM SOC, V81, P865, DOI 10.1021/ja01513a030; WILTING J, 1979, BIOCHIM BIOPHYS ACTA, V579, P469, DOI 10.1016/0005-2795(79)90075-8; Woody RW, 1996, CIRCULAR DICHROISM C, P109	69	406	438	3	87	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3042	3050		10.1074/jbc.275.5.3042	http://dx.doi.org/10.1074/jbc.275.5.3042			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652284	hybrid			2022-12-25	WOS:000085146500006
J	Bonazzi, A; Mastyugin, V; Mieyal, PA; Dunn, MW; Laniado-Schwartzman, M				Bonazzi, A; Mastyugin, V; Mieyal, PA; Dunn, MW; Laniado-Schwartzman, M			Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; NF-KAPPA-B; ENDOTHELIAL-CELLS; INFLAMMATION; ACID; EICOSANOIDS; PRODUCTS; EYE; TRANSCRIPTION; GLUTATHIONE	Hypoxic injury provokes inflammation of many tissues including the ocular surface. In rabbit corneal epithelial cells, both peroxisome proliferator-activated receptor (PPAR)-inducible cytochrome P450 4B1 and cyclooxygenase-2 (COX-2) mRNAs were increased by hypoxia, PPAR alpha and beta but not gamma mRNAs were detected in these cells. The PPAR activator, WY-14,643 increased COX-2 expression. Similarly, non-steroidal anti-inflammatory drugs with the ability to activate PPARs induced COX-2 independently of prostaglandin synthesis inhibition. COX-2 protein overexpression by hypoxia and PPAR activation was not associated with a parallel increase in prostaglandin E-2 accumulation. However, the enzyme regained full catalytic activity when: 1) hypoxic cells were re-exposed to normoxic conditions in the presence of heme and arachidonic acid, and 2) WY-14,643-treated cells were depleted of intracellular GSH. Consistent with previous observations showing that the corneal production of cytochrome P450-derived inflammatory eicosanoids is elevated by hypoxia and inflammation, the current data suggest that hypoxic injury is a model of inflammation in which molecules other than COX-derived arachidonic acid metabolites play a major proinflammatory role. This study also suggests that increased cellular GSH may be the mechanism responsible for the characteristic dissociation of PPAR-induced COX-2 expression and activity. Moreover, we provide new insights into the commonly observed lack of efficacy of classical non-steroidal anti-inflammatory drugs in the treatment of hypoxia-related ocular surface inflammation.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	New York Medical College	Laniado-Schwartzman, M (corresponding author), New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.	michal_schwartzman@nymc.edu		Bonazzi, Albino/0000-0002-7857-5352	NEI NIH HHS [EY05613] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLEN KGD, 1990, ANAL BIOCHEM, V186, P108, DOI 10.1016/0003-2697(90)90581-S; ARAKI K, 1993, INVEST OPHTH VIS SCI, V34, P2665; BAZAN HEP, 1985, CURR EYE RES, V4, P175, DOI 10.3109/02713688509000847; Bazan NG, 1997, SURV OPHTHALMOL, V41, pS23, DOI 10.1016/S0039-6257(97)80004-5; BRUCE AS, 1990, SURV OPHTHALMOL, V35, P25, DOI 10.1016/0039-6257(90)90046-X; CAI YN, 1995, J BIOCHEM TOXICOL, V10, P87, DOI 10.1002/jbt.2570100205; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chang MS, 1997, CURR EYE RES, V16, P1147, DOI 10.1076/ceyr.16.11.1147.5107; Chida M, 1996, AM J PHYSIOL-LUNG C, V270, pL872, DOI 10.1152/ajplung.1996.270.5.L872; Conners MS, 1997, INVEST OPHTH VIS SCI, V38, P1963; CONNERS MS, 1995, INVEST OPHTH VIS SCI, V36, P828; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FARBER HW, 1991, CIRC RES, V68, P1446, DOI 10.1161/01.RES.68.5.1446; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GLUUD BS, 1985, ACTA OPHTHALMOL, V63, P375; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF1013, DOI 10.1152/ajprenal.1997.273.6.F1013; HAYNES WL, 1989, INVEST OPHTH VIS SCI, V30, P1588; Hempel SL, 1996, AM J RESP CELL MOL, V14, P170, DOI 10.1165/ajrcmb.14.2.8630267; Ji YS, 1998, CIRC RES, V83, P295, DOI 10.1161/01.RES.83.3.295; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kulmacz RJ, 1998, FEBS LETT, V430, P154, DOI 10.1016/S0014-5793(98)00657-7; Ledwith BJ, 1997, J BIOL CHEM, V272, P3707, DOI 10.1074/jbc.272.6.3707; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; Mastyugin V, 1999, J PHARMACOL EXP THER, V289, P1611; Mates J M, 1999, Front Biosci, V4, pD339; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; MICHELS C, 1993, AM J PHYSIOL, V264, pC866, DOI 10.1152/ajpcell.1993.264.4.C866; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; NAPOLI SA, 1990, ANN OPHTHALMOL, V22, P30; SACK RA, 1992, INVEST OPHTH VIS SCI, V33, P626; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Schwartzman ML, 1997, ADVANCES IN OCULAR TOXICOLOGY, P3; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; SMOLIN G, 1989, EYE, V3, P167, DOI 10.1038/eye.1989.24; SRINIVASAN BD, 1980, INVEST OPHTH VIS SCI, V19, P1087; SRINIVASAN BD, 1989, OCULAR EFFECTS PROST, P229; Vafeas C, 1998, J PHARMACOL EXP THER, V287, P903; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; WILLIAMS KI, 1988, J PATHOL, V156, P101, DOI 10.1002/path.1711560204; WILLIAMS RN, 1985, EXP EYE RES, V41, P733, DOI 10.1016/0014-4835(85)90181-2; Willson TM, 1997, CURR OPIN CHEM BIOL, V1, P235, DOI 10.1016/S1367-5931(97)80015-4; ZELDIN DC, 1995, J CLIN INVEST, V95, P2150, DOI 10.1172/JCI117904	44	109	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2837	2844		10.1074/jbc.275.4.2837	http://dx.doi.org/10.1074/jbc.275.4.2837			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644750	hybrid			2022-12-25	WOS:000085128000082
J	Kas, K; Finger, E; Grall, F; Gu, XS; Akbarali, Y; Boltax, J; Weiss, A; Oettgen, P; Kapeller, R; Libermann, TA				Kas, K; Finger, E; Grall, F; Gu, XS; Akbarali, Y; Boltax, J; Weiss, A; Oettgen, P; Kapeller, R; Libermann, TA			ESE-3, a novel member of an epithelium-specific Ets transcription factor subfamily, demonstrates different target gene specificity from ESE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; GROWTH-FACTOR; SECRETORY PROTEIN; ENDOA ENHANCER; MESSENGER-RNAS; EWINGS-SARCOMA; MAP-KINASE; TEL GENE; EXPRESSION; FAMILY	Most cancers originate as a result of aberrant gene expression in mainly glandular epithelial tissues leading to defects in epithelial cell differentiation. The latter is governed by distinct sets of transcriptional regulators. Here we report the characterization of epithelium-specific Ets factor, family member 3 (ESE-3), a novel member of the ESE subfamily of Ets transcription factors. ESE-3 shows highest homology to two other epithelium restricted Ets factors, ESE-1 and ESE-2. ESE-3, like ESE-1 and ESE-2, is exclusively expressed in a subset of epithelial cells with highest expression in glandular epithelium such as prostate, pancreas, salivary gland, and trachea. A potential role in branching morphogenesis is suggested, since ESE-3 transactivates the c-MET promoter via three high affinity binding sites. Additionally, ESE-3 binding to DNA sequences in the promoters of several glandular epithelium-specific genes suggests a role for ESE-3 in later stages of glandular epithelium differentiation. Although ESE-3 and ESE-1 bind with similar affinity to various Ets binding sites, ESE-3 and ESE-1 differ significantly in their ability to transactivate the promoters containing these sites. Our results support the notion that ESE-1, ESE-2, and ESE-3 represent a unique epithelium-specific subfamily of Ets factors that have critical but distinct functions in epithelial cell differentiation and proliferation.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst,Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Katholieke Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Harvard Medical School; KU Leuven; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Libermann, TA (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst,Dept Med, 4 Blackfan Circle, Boston, MA 02115 USA.	tliberma@caregroup.harvard.edu	Libermann, Towia/F-9866-2010; Oettgen, Peter/AAF-5026-2021	Libermann, Towia/0000-0002-4006-8179	NATIONAL CANCER INSTITUTE [R01CA076323, K08CA071429] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76323, KO8/CA 71429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; BENNICK A, 1987, J DENT RES, V66, P457, DOI 10.1177/00220345870660021201; Bochert MA, 1998, BIOCHEM BIOPH RES CO, V246, P176, DOI 10.1006/bbrc.1998.8560; BORLES JC, 1995, NATURE, V377, P635; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Fischer DF, 1999, GENOMICS, V55, P88, DOI 10.1006/geno.1998.5622; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FLETCHER JC, 1995, DEVELOPMENT, V121, P1411; FUJIMURA Y, 1994, NUCLEIC ACIDS RES, V22, P613, DOI 10.1093/nar/22.4.613; Gambarotta G, 1996, ONCOGENE, V13, P1911; GAWIN B, 1995, GENOMICS, V30, P37, DOI 10.1006/geno.1995.0006; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HART AH, 1995, ONCOGENE, V10, P1423; IDA K, 1995, INT J CANCER, V63, P500, DOI 10.1002/ijc.2910630407; Ishida S, 1998, CYTOGENET CELL GENET, V82, P278, DOI 10.1159/000015119; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KLOBECK HG, 1989, NUCLEIC ACIDS RES, V17, P3981, DOI 10.1093/nar/17.10.3981; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kratzschmar J, 1996, EUR J BIOCHEM, V236, P827, DOI 10.1111/j.1432-1033.1996.t01-1-00827.x; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Liu YH, 1998, GENE, V215, P159, DOI 10.1016/S0378-1119(98)00264-9; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Maffe A, 1998, EUR J MORPHOL, V36, P74; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; McLean TW, 1996, BLOOD, V88, P4252; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MURPHY GP, 1998, CANCER, V83, P2559; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; NOLET S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P247, DOI 10.1016/0167-4781(91)90016-F; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; POULSEN K, 1986, EMBO J, V5, P1891, DOI 10.1002/j.1460-2075.1986.tb04441.x; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHULZ RA, 1993, P NATL ACAD SCI USA, V90, P10076, DOI 10.1073/pnas.90.21.10076; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Seol DW, 1998, BBA-GENE STRUCT EXPR, V1395, P252, DOI 10.1016/S0167-4781(97)00202-9; SETH A, 1994, ONCOGENE, V9, P469; SETH A, 1990, ONCOGENE, V5, P1761; SHIRASUNA K, 1981, CANCER, V48, P745, DOI 10.1002/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WERNERT N, 1992, AM J PATHOL, V140, P119; Zhou J, 1998, ONCOGENE, V17, P2719, DOI 10.1038/sj.onc.1202198; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	66	93	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2986	2998		10.1074/jbc.275.4.2986	http://dx.doi.org/10.1074/jbc.275.4.2986			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644770	hybrid			2022-12-25	WOS:000085128000102
J	Sampson, DA; Arana, ME; Boehmer, PE				Sampson, DA; Arana, ME; Boehmer, PE			Cysteine 111 affects coupling of single-stranded DNA binding to ATP hydrolysis in the herpes simplex virus type-1 origin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UL9 GENE; HELICASE ACTIVITY; INSECT CELLS; VIRAL ORIGIN; I ORIGIN; REPLICATION; DOMAIN; ORIS; COMPLEX; MUTANT	Herpes simplex virus type-1 origin-binding protein (UL9 protein) initiates viral replication by unwinding the origins. It possesses sequence specific DNA-binding activity, single-stranded DNA-binding activity, DNA helicase activity, and ATPase activity that is strongly stimulated by single-stranded DNA. We have examined the role of cysteines in its action as a DNA helicase, The DNA helicase and DNA-dependent ATPase activities of UL9 protein were stimulated by reducing agent and specifically inactivated by the sulfhydryl-specific reagent N-ethyhmaleimide, To identify the cysteine responsible for this phenomenon, a conserved cysteine in the vicinity of the ATP-binding site (cysteine 111) was mutagenized to alanine, UL9C111A. protein exhibits defects in its DNA helicase and DNA-dependent ATPase activities and was unable to support origin-specific DNA replication in vivo. A kinetic analysis indicates that these defects are due to the inability of single-stranded DNA to induce high affinity ATP binding in UL9C111A protein. The DNA-dependent ATPase activity of UL9C111A protein is resistant to N-ethylmaleimide, while its DNA helicase activity remains sensitive. Accordingly, sensitivity of UL9 protein to N-ethylmaleimide is due to at least two cysteines, Cysteine 111 is involved in coupling single-stranded DNA binding to ATP-binding and subsequent hydrolysis, while a second cysteine is involved in coupling ATP hydrolysis to DNA unwinding.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Boehmer, PE (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.			Boehmer, Paul/0000-0003-4479-0529	NIAID NIH HHS [AI38335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038335] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTTS AP, 1995, J GEN VIROL, V76, P3125, DOI 10.1099/0022-1317-76-12-3125; ARBUCKLE MI, 1993, J GEN VIROL, V74, P1349, DOI 10.1099/0022-1317-74-7-1349; Biswas N, 1999, J BIOL CHEM, V274, P8068, DOI 10.1074/jbc.274.12.8068; Boehmer PE, 1998, J BIOL CHEM, V273, P2676, DOI 10.1074/jbc.273.5.2676; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1996, METHOD ENZYMOL, V275, P16; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CARMICHAEL EP, 1988, J VIROL, V62, P91, DOI 10.1128/JVI.62.1.91-99.1988; DEB S, 1991, J VIROL, V65, P2829, DOI 10.1128/JVI.65.6.2829-2838.1991; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1993, J BIOL CHEM, V268, P1213; EARNSHAW DL, 1994, BIOCHEM BIOPH RES CO, V199, P1333, DOI 10.1006/bbrc.1994.1377; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ELIAS P, 1992, J BIOL CHEM, V267, P17424; ELIAS P, 1990, J BIOL CHEM, V265, P17167; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; HAZUDA DJ, 1991, J BIOL CHEM, V266, P24621; HAZUDA DJ, 1992, J BIOL CHEM, V267, P14309; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; MALIK AK, 1992, VIROLOGY, V190, P702, DOI 10.1016/0042-6822(92)90908-8; MARTIN DW, 1994, VIROLOGY, V198, P71, DOI 10.1006/viro.1994.1009; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; MCGEOCH DJ, 1988, J VIROL, V62, P444, DOI 10.1128/JVI.62.2.444-453.1988; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STOW ND, 1992, J GEN VIROL, V73, P313, DOI 10.1099/0022-1317-73-2-313; STOW ND, 1993, VIROLOGY, V196, P413, DOI 10.1006/viro.1993.1496; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WONG SW, 1991, J VIROL, V65, P2601, DOI 10.1128/JVI.65.5.2601-2611.1991; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; [No title captured]	43	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2931	2937		10.1074/jbc.275.4.2931	http://dx.doi.org/10.1074/jbc.275.4.2931			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644762	hybrid			2022-12-25	WOS:000085128000094
J	Schor, NF; Rudin, CM; Hartman, AR; Thompson, CB; Tyurina, YY; Kagan, VE				Schor, NF; Rudin, CM; Hartman, AR; Thompson, CB; Tyurina, YY; Kagan, VE			Cell line dependence of Bcl-2-induced alteration of glutathione handling	ONCOGENE			English	Article						oxidative stress; apoptosis; glutathione	NEOCARZINOSTATIN CYTO-TOXICITY; CHEMOTHERAPY-INDUCED APOPTOSIS; NEUROBLASTOMA-CELLS; NERVOUS-SYSTEM; FREE-RADICALS; CYTOCHROME-C; BCL-2; DEATH; DIFFERENTIATION; POTENTIATION	Bcl-2 has been associated with both oxidative and antioxidative effects in vivo. Moreover, despite evidence that Bcl-2 is antiapoptotic by virtue of its effect on reactive oxygen species and their scavengers, BcI-2 exerts its antiapoptotic effects even under anaerobic conditions. The reasons for the variable relationship between Bcl-2 and reactive oxygen species are not clear. The present studies demonstrate that the impact of Bcl-2 on glutathione (GSH) metabolism is cell line-dependent. Bcl-2 overproduction in PC12 cells is associated with increased functional thiol reserves, increased reductive activation of chemotherapeutic prodrugs, and GSH accumulation after treatment with N-acetlcysteine. In contrast, Bcl-2-overproducing MCF-7 breast cancer cells demonstrate neither altered GSH handling nor potentiation of chemotherapeutic prodrug reduction. These findings indicate that the effects of Bcl-2 on GSH handling are millieu-dependent. This could account for the variable effects of Bcl-2 in in vivo systems. Furthermore, since our previous studies have demonstrated that reduction-dependent prodrugs may be useful chemotherapeutic agents against tumors that demonstrate altered GSH handling, screening in vitro for alteration of GSH handling may predict responsiveness of such tumors to these reduction-dependent agents.	Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA; Dept Environm & Occupat Hlth, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Chicago	Schor, NF (corresponding author), Childrens Hosp Pittsburgh, Div Child Neurol, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; Tyurina, Yulia/0000-0003-0287-2091; Schor, Nina/0000-0002-3817-7376	NCI NIH HHS [CA74289] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074289, R55CA074289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; BEERMAN TA, 1977, BIOCHIM BIOPHYS ACTA, V475, P294, DOI 10.1016/0005-2787(77)90020-X; Beham A. W., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P224; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonetti A., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P192; CAMPOS L, 1993, BLOOD, V81, P3091; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; CHIN DH, 1988, BIOCHEMISTRY-US, V27, P8106, DOI 10.1021/bi00421a020; Cortazzo M, 1996, CANCER RES, V56, P1199; DEGRAFF WG, 1985, CANCER RES, V45, P4760; DEGRAFF WG, 1985, J BIOL CHEM, V260, P8312; DOLE M, 1994, CANCER RES, V54, P3253; DOLE MG, 1995, CANCER RES, V55, P2576; Gelbard HA, 1997, PEDIATR NEUROL, V16, P93, DOI 10.1016/S0887-8994(96)00258-5; HALLIWELL B, 1985, TINS             JAN, P22; Hartsell TL, 1996, J PHARMACOL EXP THER, V277, P1158; HARTSELL TL, 1995, J PHARMACOL EXP THER, V275, P479; HUBEL CA, 1997, FREE RADICAL BIO MED, V23, P596; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Langmuir ME, 1996, FLUORESCENCE MICROSCOPY AND FLUORESCENT PROBES, P229; MAEDA H, 1994, ENEDIYNE ANTIBIOTICS, P363; Narayanan V, 1997, PEDIATR NEUROL, V16, P9, DOI 10.1016/S0887-8994(96)00257-3; Reber U, 1998, BIOCHEM PHARMACOL, V55, P349, DOI 10.1016/S0006-2952(97)00480-2; Schor NF, 1999, BRAIN RES, V831, P125, DOI 10.1016/S0006-8993(99)01414-6; SCHOR NF, 1992, J CLIN INVEST, V89, P774, DOI 10.1172/JCI115655; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; Smith TK, 1998, DEV BRAIN RES, V105, P175, DOI 10.1016/S0165-3806(97)00168-5; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; Stoyanovsky DA, 1996, ARCH BIOCHEM BIOPHYS, V330, P3, DOI 10.1006/abbi.1996.0219; TEIXEIRA C, 1995, CANCER RES, V55, P3902; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TYURINA YY, 1997, ARCH BIOCHEM BIOPHYS, V344, P412; WOOD KA, 1994, ANN NY ACAD SCI, V738, P400; WOOD KA, 1995, J NEUROSCI, V15, P5851; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	37	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					472	476		10.1038/sj.onc.1203324	http://dx.doi.org/10.1038/sj.onc.1203324			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656697				2022-12-25	WOS:000084873700020
J	Todd, MC; Sclafani, RA; Langan, TA				Todd, MC; Sclafani, RA; Langan, TA			Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein	ONCOGENE			English	Article						adenovirus; cell cycle; cyclin D1; ovarian tumors; p16; Rb	RETINOBLASTOMA PROTEIN; P16(INK4A) EXPRESSION; PRODUCT P16(INK4A); MOLECULAR ANALYSIS; HIGH-FREQUENCY; BREAST-CANCER; CYCLE ARREST; GENE-PRODUCT; TUMORS; LINES	Defects of the 'Rb/cyclin D1/p16 pathway' have been shown to play a critical role in the development of virtually all human malignancies assessed. To determine the contribution of G1 phase cell cycle defects to ovarian tumorigenesis, we have examined a panel of normal and tumor ovarian tissues and ovarian cancer cell lines for the expression of Rb, p16 and cyclin D1 proteins. Unlike most types of human cancer whose development involves the loss of either Rb or p16 expression, we observed the coexpression of Rb, p16 and cyclin D1 in 82% of ovarian cancer tissues and cell lines, Furthermore, the growth and cell cycle distribution profiles of three ovarian cancer cell lines (ES-2, PA-1 and NIH OVCAR-3) that coexpressed Rb and p16, were found to be unaffected by adenoviral-mediated overexpression of functional p16 protein, indicating the existence of a defect(s) downstream from p16 in these cells. By contrast overexpression of ectopic p16 in the one ovarian cancer cell line (SK-OV3) that expressed Rb but lacked p16 protein, resulted in a G1 growth arrest. These data suggest that defects of the 'Rb/cyclin D1/p16 pathway', other than the loss of Rb or p16, may play a major role in the development of ovarian cancer.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Todd, MC (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave,Box B121, Denver, CO 80262 USA.			Sclafani, Robert/0000-0002-1100-6489				Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; CAMPBELL IG, 1995, INT J CANCER, V63, P222, DOI 10.1002/ijc.2910630213; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Dong Y, 1997, INT J CANCER, V74, P57, DOI 10.1002/(SICI)1097-0215(19970220)74:1<57::AID-IJC10>3.0.CO;2-F; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; Gemma A, 1996, INT J CANCER, V68, P605, DOI 10.1002/(SICI)1097-0215(19961127)68:5<605::AID-IJC9>3.0.CO;2-2; Geradts J, 1996, AM J PATHOL, V149, P15; GERADTS J, 1995, CANCER RES, V55, P6006; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; HE J, 1995, CANCER RES, V55, P4833; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hung WC, 1996, HUM PATHOL, V27, P1324, DOI 10.1016/S0046-8177(96)90345-7; JIN XM, 1995, CANCER RES, V55, P3250; Kanuma T, 1997, MOL CARCINOGEN, V18, P134, DOI 10.1002/(SICI)1098-2744(199703)18:3<134::AID-MC2>3.0.CO;2-F; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; LIU Y, 1994, INT J CANCER, V58, P663, DOI 10.1002/ijc.2910580508; Marchini S, 1997, BRIT J CANCER, V76, P146, DOI 10.1038/bjc.1997.355; McCluskey LL, 1999, GYNECOL ONCOL, V72, P87, DOI 10.1006/gyno.1998.5235; Milde-Langosch K, 1998, INT J CANCER, V79, P61, DOI 10.1002/(SICI)1097-0215(19980220)79:1<61::AID-IJC12>3.0.CO;2-K; Niemann TH, 1998, GYNECOL ONCOL, V69, P214, DOI 10.1006/gyno.1998.5015; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Palmero I, 1996, CANCER SURV, V27, P351; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; Ryan A, 1998, GYNECOL ONCOL, V68, P14, DOI 10.1006/gyno.1997.4881; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; SCHULTZ DC, 1995, CANCER RES, V55, P2150; Schuyer M, 1996, BRIT J CANCER, V74, P1069, DOI 10.1038/bjc.1996.491; Sclafani RA, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P123; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shih YC, 1997, INT J CANCER, V70, P508, DOI 10.1002/(SICI)1097-0215(19970304)70:5<508::AID-IJC3>3.3.CO;2-6; Sui L, 1999, GYNECOL ONCOL, V73, P202, DOI 10.1006/gyno.1999.5373; TAYLOR RR, 1995, GYNECOL ONCOL, V58, P307, DOI 10.1006/gyno.1995.1235; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wolf JK, 1999, GYNECOL ONCOL, V73, P27, DOI 10.1006/gyno.1998.5259; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Worsley SD, 1997, GYNECOL ONCOL, V64, P189, DOI 10.1006/gyno.1996.4569; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	46	25	27	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					258	264		10.1038/sj.onc.1203289	http://dx.doi.org/10.1038/sj.onc.1203289			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645004				2022-12-25	WOS:000084844400011
J	Esteller, M; Avizienyte, E; Corn, PG; Lothe, RA; Baylin, SB; Aaltonen, LA; Herman, JG				Esteller, M; Avizienyte, E; Corn, PG; Lothe, RA; Baylin, SB; Aaltonen, LA; Herman, JG			Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome	ONCOGENE			English	Article						LKB1; hypermethylation; Peutz-Jeghers; human cancer	PROMOTER HYPERMETHYLATION; SOMATIC MUTATIONS; COLON-CANCER; CELL-LINES; METHYLATION; GENE; NEOPLASIA; KINASE; HMLH1	Germ-Line mutations of the LKB1 gene cause Peutz-Jeghers syndrome (PJS) characterized by mucocutaneous pigmentation, predisposition to benign hamartomas of the gastrointestinal tract and also to several types of tumors. However, somatic mutations of this gene are, very rare. To examine inactivation of LKB1 by epigenetic mechanisms,,ve investigated a series of primary tumors and canter cell lines, for hg permethylation affecting the CpG island located in the 5' region of the LKB1 gene using Methylation-specific PCR (MSP). First, we screened 51 cancer cell lines. Only three colorectal and one cervical carcinoma cell lines were methylated at LKB1, and loss of the LKB1 transcript was demonstrated. Treatment with the demethylating agent 5-aza-2'-deoxycytidine restored LKB1 expression, To address the incidence of LKB1 epigenetic inactivation in primary tumors, we analysed colorectal, breast, gastric, pancreatic, thyroid, bladder and testicular carcinomas (n = 195), Normal tissues from the mentioned organs were unmethylated in this region. Among the described tumors, only one colorectal carcinoma and three testicular tumors displayed LKB1 promoter hypermethylation. Further study of those histological types more commonly associated with PJS, demonstrated that LKB1 promoter hypermethylation was present in five of 11 (45%) papillary breast carcinomas, Finally, in three patients with a strong family story suggestive of PJS disease, abnormal LKB1 methylation was found in four of 22 (18%) hamartomatous polyps lesions. Our findings provide an alternative pathway for inactivation of the LKB1 tumor suppressor gene involving promoter hypermethylation.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway	Johns Hopkins University; Johns Hopkins Medicine; University of Helsinki; University of Oslo	Herman, JG (corresponding author), Johns Hopkins Oncol Ctr, 424 N Bond St, Baltimore, MD 21231 USA.		Esteller, Manel/L-5956-2014; Aaltonen, Lauri/A-5375-2010	Esteller, Manel/0000-0003-4490-6093; Aaltonen, Lauri/0000-0001-6839-4286; Lothe, Ragnhild A./0000-0002-1693-1032				Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bignell GR, 1998, CANCER RES, V58, P1384; Boardman LA, 1998, ANN INTERN MED, V128, P896, DOI 10.7326/0003-4819-128-11-199806010-00004; Dong SM, 1998, CANCER RES, V58, P3787; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 1999, AM J CLIN PATHOL, V111, P336; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gruber SB, 1998, CANCER RES, V58, P5267; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; JONES HW, 1971, OBSTET GYNECOL, V38, P945; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kane MF, 1997, CANCER RES, V57, P808; Lee JY, 1998, CANCER RES, V58, P1140; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Resta N, 1998, CANCER RES, V58, P4799; RILEY E, 1980, CANCER, V46, P815, DOI 10.1002/1097-0142(19800815)46:4<815::AID-CNCR2820460428>3.0.CO;2-V; Tomlinson IPM, 1997, J MED GENET, V34, P1007, DOI 10.1136/jmg.34.12.1007; TOMPKINS WA, 1974, J NATL CANCER I, V52, P1101, DOI 10.1093/jnci/52.4.1101; Vermeulen SJ, 1998, CANCER GENET CYTOGEN, V107, P76, DOI 10.1016/S0165-4608(98)00081-8; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Ylikorkala A, 1999, HUM MOL GENET, V8, P45, DOI 10.1093/hmg/8.1.45	29	146	152	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					164	168		10.1038/sj.onc.1203227	http://dx.doi.org/10.1038/sj.onc.1203227			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644993				2022-12-25	WOS:000084844300020
J	Reddy, GB; Das, KP; Petrash, JM; Surewicz, WK				Reddy, GB; Das, KP; Petrash, JM; Surewicz, WK			Temperature-dependent chaperone activity and structural properties of human alpha A- and alpha B-crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; SECONDARY STRUCTURE; INFRARED-SPECTROSCOPY; HYDROPHOBIC SURFACES; QUATERNARY STRUCTURE; SUBSTRATE; SPECTRA; INSIGHT; BINDS	The chaperone activity and biophysical properties of recombinant human alpha A- and alpha B-crystallins were studied by light scattering and spectroscopic methods. While the chaperone function of alpha A-crystallin markedly improves with an increase in temperature, the activity of alpha B homopolymer appears to change very little upon heating. Compared with alpha B-crystallin, the alpha A-homopolymer is markedly less active at low temperatures, but becomes a more active species at high temperatures. At physiologically relevant temperatures, the alpha B homopolymer appears to be modestly (two times or less) more potent chaperone than alpha A homopolymer, In contrast to very similar thermotropic changes in the secondary structure of both homopolymers, alpha A- and alpha B-crystallins markedly differ with respect to the temperature-dependent surface hydrophobicity profiles, Upon heating, alpha A-crystallin undergoes a conformational transition resulting in the exposure of additional hydrophobic sites, whereas no such transition occurs for alpha B-crystallin, The correlation between temperature-dependent changes in the chaperone activity and hydrophobicity properties of the individual homopolymers supports the view that the chaperone activity of a crystallin is dependent on the presence of surface-exposed hydrophobic patches. However, the present data also show that the surface hydrophobicity is not the sole determinant of the chaperone function of alpha-crystallin.	Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Washington Univ, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Case Western Reserve University; Washington University (WUSTL)	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	wks3@pop.cwru.edu	Reddy, G Bhanuprakash/AAJ-3494-2020	Reddy, G Bhanuprakash/0000-0003-4787-3944; Das, Kali/0000-0001-7686-9077	NEI NIH HHS [EY11694] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011694] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Das BK, 1997, BIOCHEM BIOPH RES CO, V236, P370, DOI 10.1006/bbrc.1997.6950; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DERETIC D, 1994, J BIOL CHEM, V269, P16853; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; HOENDERS HJ, 1981, MOL CELLULAR BIOL EY, P279; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; SAX CM, 1994, ADV ENZYMOL, V69, P153; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; Smulders RHPH, 1997, FEBS LETT, V409, P101, DOI 10.1016/S0014-5793(97)00498-5; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; WANG KY, 1994, J BIOL CHEM, V269, P13601	34	166	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4565	4570		10.1074/jbc.275.7.4565	http://dx.doi.org/10.1074/jbc.275.7.4565			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671481	hybrid			2022-12-25	WOS:000085378200007
J	Braun, KW; Tribley, WA; Griswold, MD; Kim, KH				Braun, KW; Tribley, WA; Griswold, MD; Kim, KH			Follicle-stimulating hormone inhibits all-trans-retinoic acid-induced retinoic acid receptor alpha nuclear localization and transcriptional activation in mouse Sertoli cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; RAT TESTIS; SELECTIVE INHIBITOR; DNA-SYNTHESIS; IN-VIVO; DIFFERENTIATION; EXPRESSION; APOPTOSIS; MICE	The regulation of retinoic acid receptor alpha (RAR alpha) signal transduction has not been well characterized. In this study, we determined whether all-trans-retinoic acid (tRA) and follicle-stimulating hormone (FSH) modulate RAR alpha receptor subcellular localization, leading to changes in its transcriptional activity and protein expression in mouse Sertoli cell lines. We found that tRA induced the nuclear localization of RARa within 30 min and that longer term exposure increased the receptor transcriptional activity and RAR alpha protein expression. Conversely, FSH suppressed the tRA-induced nuclear localization, transcriptional transactivation, and protein expression of RAR alpha, Treatment with two different protein kinase A-selective antagonists reversed the inhibitory actions of FSH on tRA-dependent RAR alpha nuclear localization and transcriptional activity. These results:are consistent with the involvement of protein kinase A in mediating the inhibitory effects of FSH, For the first time, we demonstrate a unique signaling coni vergence between the RAR alpha and the FSH-mediated signaling pathways, which may have significant implications in the testis because both are critical regulators of testis : physiology.	Washington State Univ, Sch Mol Biosci, Ctr Reprod Biol, Pullman, WA 99164 USA	Washington State University	Kim, KH (corresponding author), Washington State Univ, Sch Mol Biosci, Ctr Reprod Biol, Pullman, WA 99164 USA.	khkim@mail.wsu.edu						Akmal KM, 1997, BIOL REPROD, V56, P549, DOI 10.1095/biolreprod56.2.549; Akmal KM, 1998, ENDOCRINOLOGY, V139, P1239, DOI 10.1210/en.139.3.1239; AKNER G, 1995, J STEROID BIOCHEM, V52, P1, DOI 10.1016/0960-0760(94)00155-F; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chilov D, 1999, J CELL SCI, V112, P1203; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DE LUCA LM, 1991, FASEB J, V5, P2924; DeFranco DB, 1997, BIOCHEM SOC T, V25, P592, DOI 10.1042/bst0250592; Dierich A, 1998, P NATL ACAD SCI USA, V95, P13612, DOI 10.1073/pnas.95.23.13612; Dufour JM, 1999, BIOL REPROD, V61, P1300, DOI 10.1095/biolreprod61.5.1300; ESKOLA V, 1993, MOL CELL ENDOCRINOL, V93, P143, DOI 10.1016/0303-7207(93)90117-3; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; GEILEN CC, 1992, FEBS LETT, V309, P381, DOI 10.1016/0014-5793(92)80811-T; GRISWOLD MD, 1976, MOL CELL ENDOCRINOL, V4, P139, DOI 10.1016/0303-7207(76)90033-2; GRISWOLD MD, 1977, MOL CELL ENDOCRINOL, V7, P151, DOI 10.1016/0303-7207(77)90064-8; Gudas Lorraine J., 1994, P443; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; Kumar TR, 1998, ENDOCRINOLOGY, V139, P3289, DOI 10.1210/en.139.7.3289; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Maguire SM, 1997, BIOL REPROD, V56, P1106, DOI 10.1095/biolreprod56.5.1106; MCGUINNESS MP, 1994, BIOL REPROD, V51, P116, DOI 10.1095/biolreprod51.1.116; Mehta K, 1996, CELL GROWTH DIFFER, V7, P179; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; ORTH J, 1997, ENDOCRINOLOGY, V100, P103; PESCHON JJ, 1992, MOL ENDOCRINOL, V6, P1403, DOI 10.1210/me.6.9.1403; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; ROY DY, 1995, MOL CELL BIOL, V15, P6481; RUSSELL LD, 1993, SERTOLI CELL, P493; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; SSOGAWA K, 1997, BIOCHEMISTRY-US, V122, P1075; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; Xiao YH, 1996, J CELL PHYSIOL, V167, P413, DOI 10.1002/(SICI)1097-4652(199606)167:3<413::AID-JCP5>3.0.CO;2-S	40	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4145	4151		10.1074/jbc.275.6.4145	http://dx.doi.org/10.1074/jbc.275.6.4145			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660575	hybrid			2022-12-25	WOS:000085288800059
J	Kuai, J; Boman, AL; Arnold, RS; Zhu, XJ; Kahn, RA				Kuai, J; Boman, AL; Arnold, RS; Zhu, XJ; Kahn, RA			Effects of activated ADP-ribosylation factors on Golgi morphology require neither activation of phospholipase D1 nor recruitment of coatomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; ENDOSOME-ENDOSOME FUSION; COATED VESICLES; ENDOPLASMIC-RETICULUM; MEMBRANES REQUIRES; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE EXCHANGE; ARF GTPASE; TRANSPORT; CISTERNAE	Nine mutations in the switch I and switch II regions of human ADP-ribosylation factor 3 (ARF3) were isolated from loss-of-interaction screens, using two-hybrid assays with three different effecters. We then analyzed the ability of the recombinant proteins to (i) bind guanine nucleotides, (ii) activate phospholipase D1 (PLD1), (iii) recruit coatomer (COP-I) to Golgi-enriched membranes, and (iv) expand and vesiculate Golgis in intact cells. Cor relations of activities in these assays were used as a means of testing specific hypotheses of ARF action, including the role of PLD1 activation in COP-I recruitment, the role of COP-I in Golgis vesiculation caused by expression of the dominant activating mutant [Q71L]ARF3, and the need for PLD1 activation in Golgis vesiculation. Because we were able to find at least one example of a protein that has lost each of these activities with retention of the others, we conclude that activation of PLD1, recruitment of COP-I to Golgi, and vesiculation of Golgis in cells are functionally separable processes. The ability of certain mutants of ARF3 to alter Golgi morphology without changes in PLD1 activity or COP-I binding is interpreted as evidence for at least one additional, currently unidentified, effector for ARF action at the Golgi.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rkahn@bimcore.emory.edu	Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055148, R01GM055823] Funding Source: NIH RePORTER; NCI NIH HHS [CA46508] Funding Source: Medline; NIGMS NIH HHS [GM55148, GM55823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan RB, 1999, SCIENCE, V285, P63, DOI 10.1126/science.285.5424.63; Bai C, 1996, METHOD ENZYMOL, V273, P331; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BECKERS CJM, 1992, METHOD ENZYMOL, V219, P5; Boman AL, 1999, CELL MOTIL CYTOSKEL, V44, P119, DOI 10.1002/(SICI)1097-0169(199910)44:2<119::AID-CM4>3.3.CO;2-3; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Gant TM, 1997, EUR J CELL BIOL, V74, P10; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Happe S, 1998, J CELL BIOL, V140, P511, DOI 10.1083/jcb.140.3.511; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; MOODIE SA, 1995, ONCOGENE, V11, P447; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; RANDAZZO PA, 1995, METHOD ENZYMOL, V250, P394; RANDAZZO PA, 1995, METHOD ENZYMOL, V257, P128; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; Rudge SA, 1998, MOL BIOL CELL, V9, P2025, DOI 10.1091/mbc.9.8.2025; SERAFINI T, 1992, METHOD ENZYMOL, V219, P286; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; SPIRO DJ, 1995, J BIOL CHEM, V270, P13693, DOI 10.1074/jbc.270.23.13693; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Warren G, 1999, CELL, V98, P125, DOI 10.1016/S0092-8674(00)81006-5; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; Zhang CJ, 1998, J BIOL CHEM, V273, P19792, DOI 10.1074/jbc.273.31.19792; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	53	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4022	4032		10.1074/jbc.275.6.4022	http://dx.doi.org/10.1074/jbc.275.6.4022			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660559	hybrid			2022-12-25	WOS:000085288800043
J	Kukol, A; Arkin, IT				Kukol, A; Arkin, IT			Structure of the Influenza C virus CM2 protein transmembrane domain obtained by site-specific infrared dichroism and global molecular dynamics searching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B VIRUS; CONFORMATIONAL-CHANGES; SECONDARY STRUCTURE; RNA SEGMENT-6; ION CHANNELS; NB; BACTERIORHODOPSIN; SELECTIVITY; M-2	The 115-residue protein CM2 from Influenza C virus has been recently characterized as a tetrameric integral membrane glycoprotein. infrared spectroscopy and site-directed infrared dichroism were utilized here to determine its transmembrane structure. The transmembrane domain of CM2 is cy-helical, and the helices are tilted by beta = (14.6 +/- 3.0)degrees from the membrane normal. The rotational pitch angle about the helix axis omega for the 1-C-13-labeled residues Gly(59) and Leu(66) is omega = (218 +/- 17)degrees, where w is defined as zero for a residue pointing in the direction of the helix tilt. A detailed structure was obtained from a global molecular dynamics search utilizing the orientational data as an energy refinement term. The structure consists of a left-handed coiled-coil with a helix crossing angle of Omega = 16 degrees, The putative transmembrane pore is occluded by the residue Met(65). In addition hydrogen/deuterium exchange experiments show that the core is not accessible to water.	Univ Cambridge, Dept Biochem, Cambridge Ctr Mol Recognit, Cambridge CB2 1GA, England	University of Cambridge	Arkin, IT (corresponding author), Univ Cambridge, Dept Biochem, Cambridge Ctr Mol Recognit, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	sa232@cam.ac.uk	Arkin, Isaiah/GQA-4328-2022; Kukol, Andreas/AAR-4569-2020	Kukol, Andreas/0000-0002-8859-010X; Arkin, Isaiah/0000-0002-7659-1746				ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; Arkin IT, 1997, J AM CHEM SOC, V119, P8973, DOI 10.1021/ja964253x; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Cladera J, 1996, BIOPHYS J, V70, P2882, DOI 10.1016/S0006-3495(96)79858-2; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; HONGO S, 1994, J GEN VIROL, V75, P3503, DOI 10.1099/0022-1317-75-12-3503; Hongo S, 1997, J VIROL, V71, P2786, DOI 10.1128/JVI.71.4.2786-2792.1997; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; Kovacs FA, 1997, BIOPHYS J, V73, P2511, DOI 10.1016/S0006-3495(97)78279-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kukol A, 1999, BIOPHYS J, V77, P1594, DOI 10.1016/S0006-3495(99)77007-4; Kukol A, 1999, J MOL BIOL, V286, P951, DOI 10.1006/jmbi.1998.2512; Lamb RA, 1997, VIROLOGY, V229, P1, DOI 10.1006/viro.1997.8451; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; Pekosz A, 1997, VIROLOGY, V237, P439, DOI 10.1006/viro.1997.8788; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; Sansom MSP, 1998, BIOESSAYS, V20, P992, DOI 10.1002/(SICI)1521-1878(199812)20:12<992::AID-BIES5>3.0.CO;2-7; Sansom MSP, 1998, CURR OPIN STRUC BIOL, V8, P237, DOI 10.1016/S0959-440X(98)80045-6; Sansom MSP, 1997, VIROLOGY, V233, P163, DOI 10.1006/viro.1997.8578; Sunstrom NA, 1996, J MEMBRANE BIOL, V150, P127, DOI 10.1007/s002329900037; TADESSE L, 1991, J AM CHEM SOC, V113, P7036, DOI 10.1021/ja00018a052; Tieleman DP, 1999, BIOPHYS J, V76, P1757, DOI 10.1016/S0006-3495(99)77337-6; Torres J, 1995, BIOCHEMISTRY-US, V34, P16320, DOI 10.1021/bi00050a012; TSUBOI M, 1962, J POLYM SCI, V59, P139, DOI 10.1002/pol.1962.1205916712	28	30	32	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4225	4229		10.1074/jbc.275.6.4225	http://dx.doi.org/10.1074/jbc.275.6.4225			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660588	hybrid			2022-12-25	WOS:000085288800072
J	McCready, TL; Islam, BF; Schmitz, FJ; Luu, HA; Dawson, JF; Holmes, CFB				McCready, TL; Islam, BF; Schmitz, FJ; Luu, HA; Dawson, JF; Holmes, CFB			Inhibition of protein phosphatase-1 by clavosines A and B - Novel members of the calyculin family of toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGE DISCODERMIA-CALYX; BIOACTIVE MARINE METABOLITES; NATURAL PRODUCT INHIBITORS; RHAMNOSE-BINDING LECTINS; OKADAIC ACID; CATALYTIC SUBUNIT; STRUCTURAL BASIS; RECOGNITION; MODEL; PROTEIN-PHOSPHATASE-1	Site-directed mutagenesis was used to investigate the mechanism of interaction between the catalytic subunit of human protein phosphatase-l (PP-1c gamma) and members of the calyculin family of toxins. Clavosines A and B are related to calyculins but are glycosylated with a trimethoxy rhamnose group. We provide experimental evidence implicating Tyr-134 as an important residue in PP-1c gamma that mediates interactions with the calyculins. Mutation of Tyr-134 to Phe, to prevent hydrogen bond formation, resulted in a slight increase in sensitivity of PP-1c gamma to clavosines A and B and calyculin A. In contrast, a Y134A mutant was 10-fold less sensitive to inhibition by all three inhibitors. The greatest effect on inhibition was found by substituting an Asp for Tyr-134 in the phosphatase. Clavosine B inhibited PP-1c gamma Y134D with a 310-fold decrease in potency. Clavosine A and calyculin A were also markedly poorer inhibitors of this mutant. These results suggest that a hydrogen bond between Tyr-134 and the calyculins is unlikely to be essential for inhibitor binding to the phosphatase. The clavosines and calyculin A were tested for their ability to inhibit other mutants of PP-1c gamma (including Ile-133, Val-223, and Cys-291). Our mutagenesis studies provide an experimental basis for assessing models of calyculin binding found in the literature (Lindvall, M. K., Pihko, P. M., and Koskinen, A. M. (1997) J. Biol. Chem. 272, 23312-23316; Gupta, V., Ogawa, A. K., Du, X., Houk, K. N., and Armstrong, R. W. (1997) J. Med. Chem. 40, 3199-3206; Gauss, C. M., Sheppeck, I. J., Nairn, A. C., and Chamberlain, R. (1997) Bioorg. Med. Chem. 5, 1751-1773). A new model for clavosine and calyculin A binding to PP-lc is presented that is consistent with previous structure-function experiments and which accommodates key structural features of the clavosines, including the novel rhamnose moiety.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Alberta; University of Oklahoma System; University of Oklahoma - Norman	McCready, TL (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.		Dawson, John/HDM-6702-2022					Bagu JR, 1997, J BIOL CHEM, V272, P5087, DOI 10.1074/jbc.272.8.5087; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203; CHAM BE, 1990, CANCER LETT, V55, P221, DOI 10.1016/0304-3835(90)90122-E; Craig M, 1996, BIOCHEM CELL BIOL, V74, P569, DOI 10.1139/o96-061; DAWSON JF, 1998, THESIS U ALBERTA EDM; Dumdei EJ, 1997, J ORG CHEM, V62, P2636, DOI 10.1021/jo961745j; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Elgavish S, 1997, TRENDS BIOCHEM SCI, V22, P462, DOI 10.1016/S0968-0004(97)01146-8; Fu X, 1998, J ORG CHEM, V63, P7957, DOI 10.1021/jo981249q; GABIUS HJ, 1987, CANCER INVEST, V5, P39, DOI 10.3109/07357908709020305; Gauss CM, 1997, BIOORGAN MED CHEM, V5, P1751, DOI 10.1016/S0968-0896(97)00145-4; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Gupta V, 1997, J MED CHEM, V40, P3199, DOI 10.1021/jm960873x; HOLMES CFB, 1991, TOXICON, V29, P469, DOI 10.1016/0041-0101(91)90021-I; HOSONO M, 1993, BIOL PHARM BULL, V16, P239; Huang HB, 1997, P NATL ACAD SCI USA, V94, P3530, DOI 10.1073/pnas.94.8.3530; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KATO Y, 1988, DRUG EXP CLIN RES, V14, P723; KATO Y, 1986, J AM CHEM SOC, V108, P2780, DOI 10.1021/ja00270a061; KATO Y, 1988, J ORG CHEM, V53, P3930, DOI 10.1021/jo00252a009; Kennelly P.J., 1999, FRONT BIOSCI, V4, pD372, DOI [10.2741/kennelly, DOI 10.2741/KENNELLY]; Lindvall MK, 1997, J BIOL CHEM, V272, P23312, DOI 10.1074/jbc.272.37.23312; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MATSUNAGA S, 1991, TETRAHEDRON, V47, P2999, DOI 10.1016/S0040-4020(01)96031-4; Matsunaga S, 1997, J ORG CHEM, V62, P2640, DOI 10.1021/jo961746b; MATSUNAGA S, 1991, TETRAHEDRON LETT, V32, P5605, DOI 10.1016/0040-4039(91)80096-O; Matsunaga S, 1997, TETRAHEDRON LETT, V38, P3763, DOI 10.1016/S0040-4039(97)00748-X; NORMAN SA, 1994, MAMM GENOME, V5, P41, DOI 10.1007/BF00360567; OKADA A, 1991, AGR BIOL CHEM TOKYO, V55, P2765, DOI 10.1080/00021369.1991.10871036; QUINN RJ, 1993, BIOORG MED CHEM LETT, V3, P1029, DOI 10.1016/S0960-894X(00)80281-4; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; Steube KG, 1998, ANTICANCER RES, V18, P129; SUGANUMA M, 1990, CANCER RES, V50, P3521; Tateno H, 1998, J BIOL CHEM, V273, P19190, DOI 10.1074/jbc.273.30.19190; Volter KE, 1999, BIOORG MED CHEM LETT, V9, P717, DOI 10.1016/S0960-894X(99)00066-9; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Zhang LF, 1996, BIOCHEMISTRY-US, V35, P1606, DOI 10.1021/bi9521396	38	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4192	4198		10.1074/jbc.275.6.4192	http://dx.doi.org/10.1074/jbc.275.6.4192			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660582	hybrid			2022-12-25	WOS:000085288800066
J	Moore, TM; Garg, R; Johnson, C; Coptcoat, MJ; Ridley, AJ; Morris, JDH				Moore, TM; Garg, R; Johnson, C; Coptcoat, MJ; Ridley, AJ; Morris, JDH			PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATINOCYTE GROWTH-FACTOR; GERMINAL CENTER KINASE; TYROSINE KINASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; ANDROGEN RECEPTOR; FOCAL ADHESIONS; STRESS-RESPONSE; CANCER CELLS; IN-VITRO	Degenerate polymerase chain reaction against conserved kinase catalytic subdomains identified 15 tyrosine and serine-threonine kinases expressed in surgically removed prostatic carcinoma tissues, including six receptor kinases (PDGFBR, IGF1-R, VEGFR2, MET, RYK, and EPH-A1), six non-receptor kinases (ABL, JAK1, JAK2, TYK2, PLK-1, and EMK), and three novel kinases, Several of these kinases are oncogenic, and may function in the development of prostate cancer. One of the novel kinases is a new member of the sterile 20 (STE20) family of serine-threonine kinases which we have called prostate-derived STE20-like kinase (PSK) and characterized functionally. PSK encodes an open reading frame of 3705 nucleotides and contains an N-terminal:kinase domain. Immunoprecipitated PSK phosphorylates myelin basic protein and transfected PSK stimulates MKK4 and MKK7 and activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway. Microinjection of PSK into cells results in localization of PSK to a vesicular compartment and causes a marked reduction in actin stress fibers, In contrast, C-terminally truncated PSK (1-349) did not localize to this compartment or induce a decrease in stress fibers demonstrating a requirement for the C terminus. Kinase-defective PSK (K57A) was unable to reduce stress fibers. PSK is the first member of the STE20 family lacking a Cdc42/Rac binding domain that has been shown to regulate both the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and the actin cytoskeleton.	Kings Coll London, Sch Med & Dent, Rayne Inst, Acad Dept Surg,Mol Oncol Lab, London SE5 9NU, England; UCL Branch, Ludwig Inst Canc Res, London W1P 8BT, England; UCL, Dept Biochem & Mol Biol, London W1P 8BT, England	University of London; King's College London; Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Morris, JDH (corresponding author), Kings Coll London, Sch Med & Dent, Rayne Inst, Acad Dept Surg,Mol Oncol Lab, 123 Coldharbour Lane, London SE5 9NU, England.	jonathan.morris@kcl.ac.uk		Morris, Jonathan/0000-0002-3211-1798; Ridley, Anne/0000-0001-8186-5708				Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; CULIG Z, 1994, CANCER RES, V54, P5474; Dawson DM, 1998, J NATL CANCER I, V90, P519, DOI 10.1093/jnci/90.7.519; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Ferrer FA, 1997, J UROLOGY, V157, P2329, DOI 10.1016/S0022-5347(01)64775-X; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Gioeli D, 1999, CANCER RES, V59, P279; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirai S, 1996, ONCOGENE, V12, P641; Hobisch A, 1998, CANCER RES, V58, P4640; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Leav I, 1998, HUM PATHOL, V29, P668, DOI 10.1016/S0046-8177(98)90274-X; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Ligos JM, 1998, BIOCHEM BIOPH RES CO, V249, P380, DOI 10.1006/bbrc.1998.9163; Manes S, 1999, J BIOL CHEM, V274, P6935, DOI 10.1074/jbc.274.11.6935; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MARU Y, 1990, ONCOGENE, V5, P445; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; *NAT I CAN, 1997, CAN CANC STAT, P15; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Okamoto M, 1997, CANCER RES, V57, P141; Osada S, 1997, ONCOGENE, V14, P2047, DOI 10.1038/sj.onc.1201043; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Putz T, 1999, CANCER RES, V59, P227; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROEHRBORN CG, 1991, MECHANISMS OF PROGRESSION TO HORMONE-INDEPENDENT GROWTH OF BREAST AND PROSTATIC CANCER, P97; RUIZPEREZ VL, 1995, CURR GENET, V28, P309, DOI 10.1007/BF00326428; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shi CS, 1999, BLOOD, V93, P1338, DOI 10.1182/blood.V93.4.1338.404k27_1338_1345; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tsuka H, 1998, INT J ONCOL, V13, P927; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; VLAHOS CJ, 1993, J CELL BIOCHEM, V52, P404, DOI 10.1002/jcb.240520405; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	77	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4311	4322		10.1074/jbc.275.6.4311	http://dx.doi.org/10.1074/jbc.275.6.4311			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660600	hybrid			2022-12-25	WOS:000085288800084
J	Spurio, R; Brandi, L; Caserta, E; Pon, CL; Gualerzi, CO; Misselwitz, R; Krafft, C; Welfle, K; Welfle, H				Spurio, R; Brandi, L; Caserta, E; Pon, CL; Gualerzi, CO; Misselwitz, R; Krafft, C; Welfle, K; Welfle, H			The C-terminal subdomain (IF2 C-2) contains the entire fMet-tRNA binding site of initiation factor IF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSLATION; ELONGATION; GENE; TU	Previous protein unfolding studies had suggested that IF2 C, the 24.5-kDa fMet-tRNA binding domain of Bacillus stearothermophilus translation initiation factor IF2, may consist of two subdomains, In the present work, the four Phe residues of IF2 C (positions 531, 599, 657, and 721) were replaced with Trp, yielding four variant proteins having intrinsic fluorescence markers in different positions of the molecule. Comparison of the circular dichroism and Trp fluorescence changes induced by increasing concentrations of guanidine hydrochloride demonstrated that LF2 C indeed consists of two subdomains: the more stable N-terminal (IF2 C-l) subdomain containing Trp-599, and the less stable C-terminal (IF2 C-2) subdomain containing Trp-721. Isolated subdomain LF2 C-2, which consists of just 110 amino acids (from Glu-632 to Ala-741), was found to bind fMet-tRNA with the same specificity and affinity as native IF2 or IF2 C-domain, Trimming IF2 C-2 from both N and C termini demonstrated that the minimal fragment still capable of fMet-binding consists of 90 amino acids. LF2 C-2 was further characterized by circular dichroism; by urea-, guanidine hydrochloride-, and temperature-induced unfolding and by differential scanning calorimetry. The results indicate that IF2 C-2 is a globular molecule containing predominantly beta structures (25% antiparallel and 8% parallel beta strands) and turns (19%) whose structural properties are not grossly affected by the presence or absence of the N-terminal subdomain 1F2 C-1.	Univ Camerino, Dept Biol, Genet Lab, I-62032 Camerino, Italy; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Humboldt Univ, Fac Med Charite, Inst Biochem, D-10117 Berlin, Germany	University of Camerino; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Gualerzi, CO (corresponding author), Univ Camerino, Dept Biol, Genet Lab, I-62032 Camerino, Italy.		Krafft, Christoph/A-4595-2009	Krafft, Christoph/0000-0003-1049-0560; Spurio, Roberto/0000-0002-7611-4341				Brock S, 1998, MOL MICROBIOL, V29, P409, DOI 10.1046/j.1365-2958.1998.00893.x; BROMBACH M, 1986, MOL GEN GENET, V205, P97, DOI 10.1007/BF02428037; CENATIEMPO Y, 1987, BIOCHEMISTRY-US, V26, P5070, DOI 10.1021/bi00390a028; CROWL R, 1985, GENE, V38, P31, DOI 10.1016/0378-1119(85)90200-8; Gualerzi CO, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P477; GUALERZI CO, 1991, J BIOL CHEM, V266, P16356; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Krafft C, 1998, BIOPHYS J, V74, P63, DOI 10.1016/S0006-3495(98)77767-7; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MISSELWITZ R, 1995, BBA-PROTEIN STRUCT M, V1250, P9, DOI 10.1016/0167-4838(95)00041-R; Misselwitz R, 1997, BIOCHEMISTRY-US, V36, P3170, DOI 10.1021/bi962613n; Nissen P, 1999, STRUCTURE, V7, P143, DOI 10.1016/S0969-2126(99)80021-5; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Pace C. N., 1997, PROTEIN STRUCTURE PR, V2, P299; PETERSEN HU, 1979, BIOCHEM BIOPH RES CO, V91, P1068, DOI 10.1016/0006-291X(79)91989-2; PON CL, 1985, J BIOL CHEM, V260, P8918; Rajbhandary Uttam L., 1995, P511; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P245, DOI 10.1016/0968-0004(94)90149-X; SPURIO R, 1993, TRANSLATIONAL APPARATUS, P241	20	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2447	2454		10.1074/jbc.275.4.2447	http://dx.doi.org/10.1074/jbc.275.4.2447			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644698	hybrid			2022-12-25	WOS:000085128000030
J	Toyoda, H; Kinoshita-Toyoda, A; Selleck, SB				Toyoda, H; Kinoshita-Toyoda, A; Selleck, SB			Structural analysis of glycosaminoglycans in Drosophila and Caenorhabditis elegans and demonstration that tout-velu, a Drosophila gene related to EXT tumor suppressors, affects heparan sulfate in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANES; INDIAN HEDGEHOG; PROTEOGLYCAN; BIOSYNTHESIS; EXPRESSION; GROWTH; INHIBITOR; PROTEIN	We have devised a sensitive method for the isolation and structural analysis of glycosaminoglycans from two genetically tractable model organisms, the fruit fly, Drosophila melanogaster, and the nematode, Caenorhabditis elegans. We detected chondroitin/chondroitin sulfate- and heparan sulfate-derived disaccharides in both organisms. Chondroitinase digestion of glycosaminoglycans from adult Drosophila produced both nonsulfated and 4-O-sulfated unsaturated disaccharides, whereas only unsulfated forms were detected in C. elegans. Heparin lyases released disaccharides bearing N-, 2-O-, and 6-O-sulfated species, including mono-, di-, and trisulfated forms, We observed tissue- and stage-specific differences in both chondroitin sulfate and heparan sulfate composition in Drosophila. We have also applied these methods toward the analysis of tout-velu, an EXT-related gene in Drosophila that controls the tissue distribution of the growth factor Hedgehog. The proteins encoded by the vertebrate tumor suppressor genes EXT1 and 2, show heparan sulfate co-polymerase activity, and it has been proposed that tout-velu affects Hedgehog activity via its role in heparan sulfate biosynthesis. Analysis of total glycosaminoglycans from tout-velu mutant larvae show marked reductions in heparan sulfate but not chondroitin sulfate, consistent with its proposed function as a heparan sulfate co-polymerase.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan	University of Arizona; Chiba University	Selleck, SB (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, 1007 E Lowell St, Tucson, AZ 85721 USA.	selleck@u.arizona.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054832, R01GM025243] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-25243, GM-54832] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Binari RC, 1997, DEVELOPMENT, V124, P2623; CAMBIAZO V, 1990, COMP BIOCHEM PHYS B, V97, P307, DOI 10.1016/0305-0491(90)90286-3; CAMPBELL AG, 1987, J BIOL CHEM, V262, P17605; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; GRANER M, 1994, INSECT BIOCHEM MOLEC, V24, P557, DOI 10.1016/0965-1748(94)90091-4; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Hortsch M, 1998, INT J DEV BIOL, V42, P33; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kim YS, 1996, J BIOL CHEM, V271, P11750, DOI 10.1074/jbc.271.20.11750; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl B, 1997, J BIOL CHEM, V272, P26091, DOI 10.1074/jbc.272.42.26091; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MADA A, 1992, ANAL SCI, V8, P793, DOI 10.2116/analsci.8.793; Merrill C, 1999, SCIENCE, V283, P1742, DOI 10.1126/science.283.5408.1742; Moerman DG, 1996, DEV BIOL, V173, P228, DOI 10.1006/dbio.1996.0019; NAKATO H, 1995, DEVELOPMENT, V121, P3687; NELSON GA, 1982, J CELL BIOL, V92, P121, DOI 10.1083/jcb.92.1.121; OCHIAI H, 1988, CHEM PHARM BULL, V36, P3726; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; Roth S, 1998, CURR BIOL, V8, pR906, DOI 10.1016/S0960-9822(98)00006-2; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; Selleck S, 1998, MATRIX BIOL, V17, P473, DOI 10.1016/S0945-053X(98)90094-4; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Toyoda H, 1999, J CHROMATOGR A, V830, P197, DOI 10.1016/S0021-9673(98)00854-1; TOYODA H, 1993, BIOL PHARM BULL, V16, P945; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613	41	226	239	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2269	2275		10.1074/jbc.275.4.2269	http://dx.doi.org/10.1074/jbc.275.4.2269			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644674	hybrid			2022-12-25	WOS:000085128000006
J	McWhinney, C; Wenham, D; Kanwal, S; Kalman, V; Hansen, C; Robishaw, JD				McWhinney, C; Wenham, D; Kanwal, S; Kalman, V; Hansen, C; Robishaw, JD			Constitutively active mutants of the alpha(1a)- and the alpha(1b)-adrenergic receptor subtypes reveal coupling to different signaling pathways and physiological responses in rat cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MYOSIN LIGHT CHAIN-2; SMOOTH-MUSCLE CELLS; GENE-EXPRESSION; ALPHA(1)-ADRENERGIC RECEPTOR; ALPHA-1-ADRENERGIC RECEPTOR; TRANSDUCTION PATHWAYS; PHOSPHOLIPASE-C; ALPHA(1C)-ADRENERGIC RECEPTOR; VENTRICULAR CARDIOMYOCYTES	Activation of alpha(1)-adrenergic receptors influences both the contractile activity and the growth potential of cardiac myocytes, However, the signaling pathways linking activation of specific alpha(1)-adrenerse receptor (AR) subtypes to these physiological responses remain controversial. In the present study, a molecular approach was used to identify conclusively the signaling pathways activated in response to the individual alpha(1A)- and alpha(1B)-AR subtypes in cardiac myocytes. For this purpose, a mutant alpha(1a)-AR subtype (alpha(1a)-S-290/293-AR) was constructed based on analogy to the previously described constitutively active mutant alpha(1b)-AR subtype (alpha(1b)-S288-294-AR). The mutant (alpha(1a)-S-290/293-AR subtype displayed constitutive activity based on four criteria. To introduce the constitutively active alpha(1)-AR subtypes into cardiac myocytes, recombinant Sindbis viruses encoding either the alpha(1a)-S-290/293-AR or alpha(1b)-S288-294-R subtype were used to infect the whole cell population with >90%, efficiency, thereby allowing the biochemical activities of the various signaling pathways to be measured. When expressed at comparable levels, the alpha(1a)-S-290/293-AR subtype exhibited a significantly elevated basal level as well as agonist-stimulated level of inositol phosphate accumulation, coincident with activation of atrial natriuretic factor-luciferase gene expression. By contrast, the alpha(1b)-S288-294-AR subtype displayed a markedly increased serum response element luciferase gene expression but no activation of atrial natriuretic factor-luciferase gene expression. Taken together, this study provides the first molecular evidence for coupling of the alpha(1a)-AR and the alpha(1b)-AR subtypes to different signaling pathways in cardiac myocytes.	Penn State Coll Med, Henry Hood Res Program, Weis Ctr Res, Danville, PA 17822 USA; Oklahoma State Univ, Sch Med, Dept Physiol & Pharmacol, Tulsa, OK 74107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Robishaw, JD (corresponding author), Penn State Coll Med, Henry Hood Res Program, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.				NHLBI NIH HHS [HL 49278] Funding Source: Medline; NIDDK NIH HHS [DK 45417] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045417] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhter SA, 1997, J BIOL CHEM, V272, P21253, DOI 10.1074/jbc.272.34.21253; ARDATI A, 1993, EMBO J, V12, P5151; Autelitano DJ, 1998, J MOL CELL CARDIOL, V30, P1515, DOI 10.1006/jmcc.1998.0717; BARKA T, 1987, ONCOGENE, V1, P439; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cornelius T, 1997, HYPERTENSION, V30, P1348, DOI 10.1161/01.HYP.30.6.1348; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; DECOCK JBJ, 1994, FEBS LETT, V356, P275, DOI 10.1016/0014-5793(94)01283-0; Deng XF, 1998, J PHARMACOL EXP THER, V286, P489; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Garcia-Sainz JA, 1998, EUR J PHARMACOL, V342, P311, DOI 10.1016/S0014-2999(97)01465-9; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Grupp IL, 1998, AM J PHYSIOL-HEART C, V275, pH1338, DOI 10.1152/ajpheart.1998.275.4.H1338; HAN C, 1987, MOL PHARMACOL, V32, P505; HANINGTON EO, 1995, TRENDS CARDIOVAS MED, V5, P193, DOI 10.1016/1050-1738(95)00058-H; HANSEN CA, 1994, BBA-MOL CELL RES, V1224, P517, DOI 10.1016/0167-4889(94)90289-5; HANSEN CA, 1995, J MOL CELL CARDIOL, V27, P471, DOI 10.1016/S0022-2828(08)80043-0; Harris AN, 1997, J MOL CELL CARDIOL, V29, P515, DOI 10.1006/jmcc.1996.0295; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; HIEBLE JP, 1995, PHARMACOL REV, V47, P267; Horban A, 1997, J MOL CELL CARDIOL, V29, P2903, DOI 10.1006/jmcc.1997.0525; Hu ZW, 1999, MOL ENDOCRINOL, V13, P3, DOI 10.1210/me.13.1.3; IKEDA U, 1991, AM J PHYSIOL, V260, pH953, DOI 10.1152/ajpheart.1991.260.3.H953; IWAKI K, 1990, J BIOL CHEM, V265, P13809; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAZ TM, 1994, MOL PHARMACOL, V46, P414; LEE HR, 1988, J BIOL CHEM, V263, P7352; Li HT, 1997, CIRC RES, V81, P396, DOI 10.1161/01.RES.81.3.396; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MICHEL MC, 1994, N-S ARCH PHARMACOL, V350, P136; MICHEL MC, 1993, N-S ARCH PHARMACOL, V348, P385; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MINNEMAN KP, 1994, MOL PHARMACOL, V46, P929; MOALIC JM, 1989, J HYPERTENS, V7, P195; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OKAZAKI M, 1994, J CLIN INVEST, V94, P210, DOI 10.1172/JCI117309; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PEREZ DM, 1993, MOL PHARMACOL, V44, P784; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SEI CA, 1991, J BIOL CHEM, V266, P15910; Seternes OM, 1998, BBA-GENE STRUCT EXPR, V1395, P345, DOI 10.1016/S0167-4781(97)00189-9; SHARROCKS AD, 1995, FEBS LETT, V368, P77, DOI 10.1016/0014-5793(95)00604-8; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Soh JW, 1999, MOL CELL BIOL, V19, P1313; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; STEWART AFR, 1994, CIRC RES, V75, P796, DOI 10.1161/01.RES.75.4.796; SUGDEN PH, 1995, CARDIOVASC RES, V30, P478, DOI 10.1016/S0008-6363(95)00096-8; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORNBERG H, 1994, J BIOL CHEM, V269, P33179; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wang YB, 1997, CIRCULATION, V96, P3106; Wenham D, 1997, EUR J PHARMACOL, V339, P77, DOI 10.1016/S0014-2999(97)01359-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xi XP, 1997, FEBS LETT, V417, P283, DOI 10.1016/S0014-5793(97)01303-3	75	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2087	2097		10.1074/jbc.275.3.2087	http://dx.doi.org/10.1074/jbc.275.3.2087			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636913	hybrid			2022-12-25	WOS:000084940000076
J	Sirard, C; Kim, S; Mirtsos, C; Tadich, P; Hoodless, PA; Itie, A; Maxson, R; Wrana, JL; Mak, TW				Sirard, C; Kim, S; Mirtsos, C; Tadich, P; Hoodless, PA; Itie, A; Maxson, R; Wrana, JL; Mak, TW			Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR SMAD4/DPC4; DNA-BINDING PROTEIN; TGF-BETA; INDUCED TRANSCRIPTION; MAD PROTEINS; GENE; INHIBITION; DEATH; BMP4; DPC4	The tumor suppressor gene Smad4 has been proposed to be a common mediator of transforming growth factor beta (TGF beta)-related signaling pathways. We investigated the role of Smad4 in TGF beta-related pathways by targeted disruption of its locus in murine cell lines. TGF beta responses, including growth arrest, induction of the endogenous PAI-1 gene, and other extracellular matrix components, were normal in Small-deficient fibroblasts. Assembly of a TGF beta-induced DNA-binding complex on one of two regulatory regions in the human plasminogen activator inhibitor (PAI)-1 promoter did not require Smad4 but was, instead, dependent on a TFE-3 binding site. In contrast, Smad4 was required for activation of the Xenopus Mix.2 promoter in response to TGF beta/activin, Smad4 was also involved in the regulation of the Msx homeobox protein family members in response to bone morphogenetic protein (BMP), Interestingly, the expression of the endogenous Msx-2 was reduced, whereas that of Msx-3 was activated in differentiating Smad4(-/-) ES cells relative to wild-type cells. Moreover, reporter assays of the Msx-2 promoter revealed an absolute requirement for Smad4 in fibroblasts and ES cells for activation, Our results indicate that Smad4 is dispensable for critical TGF beta-induced responses but is required for others in murine fibroblasts. We have identified transcriptional targets for Smad4 in the BMP signaling pathway, which may contribute to the genetic defect observed in the Smad4-deficient embryos.	Amgen Inst Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ So Calif, Sch Med, Dept Biochem, Kenneth R Norris Hosp & Inst, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biol Mol, Kenneth R Norris Hosp & Inst, Los Angeles, CA 90033 USA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Southern California; University of Southern California	Mak, TW (corresponding author), Amgen Inst Ontario Canc Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Wrana, Jeffrey/F-8857-2013	Hoodless, Pamela/0000-0003-1371-0725				ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Bei M, 1998, DEVELOPMENT, V125, P4325; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; Datto MB, 1999, MOL CELL BIOL, V19, P2495; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ganan Y, 1996, DEVELOPMENT, V122, P2349; Goumans MJ, 1999, DEVELOPMENT, V126, P3473; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lee KJ, 1999, ANNU REV NEUROSCI, V22, P261, DOI 10.1146/annurev.neuro.22.1.261; LeSuer JA, 1999, DEVELOPMENT, V126, P137; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Marazzi G, 1997, DEV BIOL, V186, P127, DOI 10.1006/dbio.1997.8576; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Rodriguez-Leon J, 1999, NAT CELL BIOL, V1, P125, DOI 10.1038/10098; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; Shimeld SM, 1996, MECH DEVELOP, V55, P201, DOI 10.1016/0925-4773(96)00505-9; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Suzuki A, 1997, DEVELOPMENT, V124, P3037; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wang WD, 1996, MECH DEVELOP, V58, P203, DOI 10.1016/S0925-4773(96)00562-X; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	58	138	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2063	2070		10.1074/jbc.275.3.2063	http://dx.doi.org/10.1074/jbc.275.3.2063			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636910	hybrid			2022-12-25	WOS:000084940000073
J	Mizuno, T; Iwamoto, KS; Kyoizumi, S; Nagamura, H; Shinohara, T; Koyama, K; Seyama, T; Hamatani, K				Mizuno, T; Iwamoto, KS; Kyoizumi, S; Nagamura, H; Shinohara, T; Koyama, K; Seyama, T; Hamatani, K			Preferential induction of RET/PTC1 rearrangement by X-ray irradiation	ONCOGENE			English	Article						thyroid; radiation; RET/PTC; scid mice	PAPILLARY THYROID CARCINOMAS; RET TYROSINE KINASE; EXTERNAL RADIATION; MOLECULAR CHARACTERIZATION; ONCOGENE REARRANGEMENTS; HIGH PREVALENCE; CHERNOBYL; PROTOONCOGENE; CHILDREN; EXPRESSION	Ionizing radiation is a well known risk factor of thyroid cancer development, but the mechanism of radiation induced carcinogenesis is not clear. The RET/PTC oncogene, an activated form of the RET proto-oncogene, is frequently observed in papillary thyroid carcinoma (PTC); RET/PTC1, -2 and -3 are known to be the three major forms, High frequencies of RET/PTC rearrangements have been observed in radiation-associated PTC, such as those appearing post-Chernobyl or post-radiotherapy, but the rearrangement types differ between these two populations. We investigated whether a specific type of RET/PTC rearrangement was induced by X-rays in vivo and in vitro. ln human normal thyroid tissues transplanted in scid mice, the RET/PTC1 rearrangement was predominantly detected throughout the observation period (up to 60 days) after X-ray exposure of 50 Gy, On the other hand, RET/PTC3 was detected only 7 days after X-irradiation, and no transcript of RET/PTC2 was detected. These results are supported by the results of an in vitro study, The RET/PTC1 rearrangement was preferentially induced in a dose-dependent manner by X-rays within a high dose range (10, 50 and 100 Gy) in four cell lines. On the other hand, RET/PTC3 was induced at a much lower frequency, and no induction of RET/PTC2 was observed. These results suggest that the preferential induction of the RET/PTC1 rearrangement may play an important role in the early steps of thyroid carcinogenesis induced by acute X-irradiation.	Radiat Effects Res Fdn, Dept Radiobiol, Hiroshima 7320815, Japan	Radiation Effects Research Foundation - Japan	Mizuno, T (corresponding author), Radiat Effects Res Fdn, Dept Radiobiol, Hiroshima 7320815, Japan.							BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANCOCK SL, 1995, INT J RADIAT ONCOL, V31, P1165, DOI 10.1016/0360-3016(95)00019-U; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P10069, DOI 10.1093/nar/16.21.10069; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ITO T, 1993, JPN J CANCER RES, V84, P105, DOI 10.1111/j.1349-7006.1993.tb02840.x; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P259; Kitamura Y, 1999, J HUM GENET, V44, P96, DOI 10.1007/s100380050117; Klugbauer S, 1995, ONCOGENE, V11, P2459; Learoyd DL, 1998, J CLIN ENDOCR METAB, V83, P3631, DOI 10.1210/jc.83.10.3631; Mayr B, 1998, BRIT J CANCER, V77, P903, DOI 10.1038/bjc.1998.149; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; Mizuno T, 1997, ONCOGENE, V15, P1455, DOI 10.1038/sj.onc.1201313; MORRIS CM, 1991, BLOOD, V78, P1078; Motomura T, 1998, THYROID, V8, P485, DOI 10.1089/thy.1998.8.485; Murnane JP, 1996, MUTAT RES-GENET TOX, V367, P11, DOI 10.1016/S0165-1218(96)90017-8; Nikiforov YE, 1997, CANCER RES, V57, P1690; Pisarchik AV, 1998, THYROID, V8, P1003, DOI 10.1089/thy.1998.8.1003; Preston DL, 1994, RADIAT RES, V137, P68; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SANTORO M, 1994, ONCOGENE, V9, P509; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; Smida J, 1999, INT J CANCER, V80, P32, DOI 10.1002/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.3.CO;2-C; Sugg SL, 1996, J CLIN ENDOCR METAB, V81, P3360, DOI 10.1210/jc.81.9.3360; THOMPSON DE, 1994, RAD RES S, V137, P17; TUCKER MA, 1991, CANCER RES, V51, P2885; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0	34	75	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					438	443		10.1038/sj.onc.1203343	http://dx.doi.org/10.1038/sj.onc.1203343			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656692				2022-12-25	WOS:000084873700015
J	Chang, J; Lee, C; Hahm, KB; Yi, Y; Choi, SG; Kim, SJ				Chang, J; Lee, C; Hahm, KB; Yi, Y; Choi, SG; Kim, SJ			Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells	ONCOGENE			English	Article						transcription factor; cancer; TGF-beta; tumorigenicity	GROWTH-FACTOR-BETA; MICROSATELLITE INSTABILITY; DOMAIN PROTEIN; GENE; FAMILY; INHIBITION; MEMBER; COLON; CDNA	The epithelium-specific transcription factor, ERT/ESX/ ESE-1/ELF3, binds to the TGF-beta RII promoter in a sequence specific manner and regulates its expression, In this study, we investigated whether ERT could regulate endogenous TGF-beta RII expression in Hs578t breast cancer cells. Analyses of the Hs578t parental cell line revealed ion RII mRNA expression and resistance to the growth inhibitory effects of TGF-beta. Infection of this cell Line with a retroviral construct expressing ERT induced higher levels of endogenous RII mRNA expression and protein expression relative to cells infected with chloramphenicol acetyltransferase (CATneo) as a control. Relative to control cells, the ERTneo-expressing Hs578t cells show approximately a 50% reduction in cell growth in the presence of exogenous TGF-beta 1, as well as a fourfold higher induction of activation in transient transfection assays using the 3TP-luciferase reporter construct. When transplanted into athymic mice, ERT-expressing Hs578t cells showed decreased and delayed tumorigenicity compared with control cells. This data strongly suggests that ERT plays an important role as a transcriptional activator of TGF-P RII expression, and that deregulated ERT expression may play a critical role in rendering Hs578t human breast cancer cells insensitive to TGF-beta's growth inhibitory effects.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA.							CAPOCASALE RJ, 1995, P NATL ACAD SCI USA, V92, P5501, DOI 10.1073/pnas.92.12.5501; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 1997, CANCER RES, V57, P2856; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; Kim IY, 1996, CANCER RES, V56, P44; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MYEROFF LL, 1995, CANCER RES, V55, P5545; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	25	44	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					151	154		10.1038/sj.onc.1203252	http://dx.doi.org/10.1038/sj.onc.1203252			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644990				2022-12-25	WOS:000084844300017
J	Rubbi, CP; Milner, J				Rubbi, CP; Milner, J			Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus	ONCOGENE			English	Article						latent p53; transcription sites; nucleolus; confocal microscopy; hdm-2	RNA-POLYMERASE-II; WILD-TYPE P53; NASCENT RNA; INDUCED APOPTOSIS; CONFOCAL IMAGES; NUCLEAR MATRIX; DNA-DAMAGE; CELL-CYCLE; PROTEIN; MICROSCOPY	The p53 tumour suppressor functions as a sensor of genotoxic stress and, once activated, induces cell growth arrest or apoptosis, The precise intranuclear localization of latent p53 protein in non-stressed cells is unknown, Such information is essential in order to understand how relatively few molecules of p53 can detect and respond to DNA damage. Here we present the first detailed supramolecular localization of p53 in the nuclei of cells under normal conditions of growth, We show that soluble, non-bound p53 is released by permeabilization, leaving structurally bound p53 in both the nucleus and nucleolus. ln situ biochemical studies reveal (i) that nuclear-bound p53 is tethered by RNA (directly or indirectly) and (ii) that a sub-population of nuclear-bound p53 co-localizes with sites of RNA synthesis. Transcriptional co-localization appeared to be independent of p53 conformation but dependent upon its quaternary structure. In the nucleolus p53 was observed at sites of rRNA synthesis and also adjacent to such sites. In contrast, nucleolar hdm-2 (shown by others to complex p53 and 5S RNA) was excluded from sites of rRNA synthesis. Our discovery that p53 is physically linked with sites of transcription may explain how relatively few p53 protein molecules can monitor genetic stress and respond preferentially to damage of actively transcribed genes.	Univ York, Dept Biol, YCR P53 Res Grp, York YO1 5DD, N Yorkshire, England	University of York - UK	Milner, J (corresponding author), Univ York, Dept Biol, YCR P53 Res Grp, York YO1 5DD, N Yorkshire, England.							ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BARBARESE E, 1995, J CELL SCI, V108, P2781; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CONCHELLO JA, 1994, APPL OPTICS, V33, P3740, DOI 10.1364/AO.33.003740; Fay FS, 1997, EXP CELL RES, V231, P27, DOI 10.1006/excr.1996.3460; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; GIBSON SF, 1991, J OPT SOC AM A, V8, P1601, DOI 10.1364/JOSAA.8.001601; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Gonzalez R.C., 1993, DIGITAL IMAGE PROCES, P583; Grande MA, 1997, J CELL SCI, V110, P1781; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Katsumoto T, 1995, BIOL CELL, V84, P167, DOI 10.1016/0248-4900(96)89426-3; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lane DP, 1996, ONCOGENE, V12, P2461; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; MILNER J, 1993, ONCOGENE, V8, P2001; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; Pombo A, 1996, EXP CELL RES, V229, P201, DOI 10.1006/excr.1996.0360; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Stenoien D, 1998, J CELL BIOCHEM, V70, P213, DOI 10.1002/(SICI)1097-4644(19980801)70:2<213::AID-JCB7>3.0.CO;2-R; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; TEPOELE RH, 1999, IN PRESS ONCOGENE; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WEBER J, 1977, CELL, V10, P611, DOI 10.1016/0092-8674(77)90093-9; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZERRAHN J, 1992, ONCOGENE, V7, P1371	43	69	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					85	96		10.1038/sj.onc.1203378	http://dx.doi.org/10.1038/sj.onc.1203378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644983				2022-12-25	WOS:000084844300010
J	Georgiades, IB; Curtis, LJ; Morris, RM; Bird, CC; Wyllie, AH				Georgiades, IB; Curtis, LJ; Morris, RM; Bird, CC; Wyllie, AH			Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability	ONCOGENE			English	Article						colorectal cancer; chromosomal instability; genomic instability; microsatellite instability; RER	ANEUPLOID CLONAL DIVERGENCE; NONPOLYPOSIS COLON-CANCER; DNA-REPLICATION ERRORS; MISMATCH REPAIR GENES; GENOMIC INSTABILITY; SOMATIC MUTATIONS; MUTATOR PHENOTYPE; TUMORS; P53; CARCINOGENESIS	Two apparently independent mechanisms of instability are recognized in colorectal cancer, microsatellite instability and chromosomal instability. Evidence from colorectal cancer cell lines indicates the presence of either, or both, types of instability in the vast majority, Here, we sought to determine the prevalence of such instability in primary sporadic colorectal cancers. Microsatellite instability was established by demonstration of ovel clonal, nongerm-line alleles in at least two of four tested loci. Chromosomal abnormalities were identified by comparative genomic hybridization (CGH) and flow cytometric analysis of nuclear DNA content. Tumours harbouring chromosomal instability were distinguished from those with stable but aneuploid karyotypes by comparing chromosomal defects at multiple sites throughout each cancer. This analysis allowed assessment of both the number of chromosomal abnormalities and their heterogeneity throughout the tumour. The results confirm that microsatellite instability is consistently associated with multiple, repeated changes in microsatellites throughout the growth of the affected colorectal carcinomas, There were also several carcinomas in which major structural or numerical abnormalities in chromosomes had clearly continued to arise during tumour growth, However, a substantial subset of tumours shelved neither microsatellite instability nor multiple, major chromosomal abnormalities. We suggest that the development of a proportion of colorectal cancers proceeds via a different pathway of carcinogenesis not associated with either of the currently recognized forms of genomic instability.	Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Sir Alastair Currie CRC Labs, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Curtis, LJ (corresponding author), Gen Infirm Leeds, Dept Histopathol, Great George St, Leeds LS1 3CX, W Yorkshire, England.							AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1997, CANCER RES, V57, P3920; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Bubb VJ, 1996, ONCOGENE, V12, P2641; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARDER P, 1993, ONCOGENE, V8, P1397; CARDER PJ, 1995, BRIT J CANCER, V71, P215, DOI 10.1038/bjc.1995.46; Eshleman JR, 1996, ONCOGENE, V12, P1425; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KIM HG, 1994, AM J PATHOL, V145, P148; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOEB LA, 1991, CANCER RES, V51, P3075; LOTHE RA, 1993, CANCER RES, V53, P5849; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MCQUEEN HA, 1991, BRIT J CANCER, V63, P94, DOI 10.1038/bjc.1991.19; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1994, AM J HUM GENET, V55, P659; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PURDIE CA, 1991, AM J PATHOL, V138, P807; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Senba S, 1998, CANCER, V82, P279, DOI 10.1002/(SICI)1097-0142(19980115)82:2<279::AID-CNCR6>3.3.CO;2-D; Thibodeau SN, 1998, CANCER RES, V58, P1713; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Togo G, 1996, CANCER RES, V56, P5620; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; WU C, 1994, ONCOGENE, V9, P991; Yao J, 1999, INT J CANCER, V80, P667, DOI 10.1002/(SICI)1097-0215(19990301)80:5<667::AID-IJC6>3.0.CO;2-0	43	103	106	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7933	7940		10.1038/sj.onc.1203368	http://dx.doi.org/10.1038/sj.onc.1203368			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637503				2022-12-25	WOS:000084634600001
J	Grantham, J; Llorca, O; Valpuesta, JM; Willison, KR				Grantham, J; Llorca, O; Valpuesta, JM; Willison, KR			Partial occlusion of both cavities of the eukaryotic chaperonin with antibody has no effect upon the rates of beta-actin or alpha-tubulin folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CCT; POLYPEPTIDE; THERMOSOME; SUBUNITS; RELEASE; DOMAIN; GROEL	The eukaryotic chaperonin containing T-complex polypeptide 1 (CCT) is required in vivo for the production of native actin and tubulin. It is a 900-kDa oligomer formed from two back-to back rings, each containing eight different subunits surrounding a central cavity in which interactions with substrates are thought to occur, Here, we show that a monoclonal antibody recognizing the C terminus of the CCT alpha subunit can bind inside, and partially occlude, both cavities of apo-CCT, Rabbit reticulocyte lysate was programmed to synthesize beta-actin and alpha-tubulin in the presence and absence of anti-CCT alpha antibody. The binding of the antibody inside the cavity and its occupancy of a large part of it does not prevent the folding of beta-actin and alpha-tubulin by CCT, despite the fact that all the CCT in the in vitro translation reactions was continuously bound by two antibody molecules. Furthermore, no differences in the protease susceptibility of actin bound to CCT in the presence and absence of the monoclonal antibody were detected, indicating that the antibody molecules do not perturb the conformation of actin folding intermediates substantially. These data indicate that complete sequestration of substrate by CCT may not be required for productive folding, suggesting that there are differences in its folding mechanism compared with the Group I chaperonins.	Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England; CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Willison, KR (corresponding author), Inst Canc Res, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.		Valpuesta, Jose M/AAA-6002-2019; Llorca, Oscar/P-2784-2019; Grantham, Julie/A-5002-2009; Valpuesta, José M/T-1977-2017; Llorca, Oscar/K-1144-2014	Llorca, Oscar/0000-0001-5705-0699; Valpuesta, José M/0000-0001-7468-8053; Llorca, Oscar/0000-0001-5705-0699				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1997, GUIDEBOOK MOL CHAPER, P207; Liou AKF, 1998, BIOL CHEM, V379, P311, DOI 10.1515/bchm.1998.379.3.311; Liou AKF, 1997, EMBO J, V16, P4311, DOI 10.1093/emboj/16.14.4311; Llorca O, 1999, NAT STRUCT BIOL, V6, P639; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; XU X, 1997, NATURE, V388, P741	16	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4587	4591		10.1074/jbc.275.7.4587	http://dx.doi.org/10.1074/jbc.275.7.4587			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671484	hybrid			2022-12-25	WOS:000085378200010
J	Azuma, T; Koths, K; Flanagan, L; Kwiatkowski, D				Azuma, T; Koths, K; Flanagan, L; Kwiatkowski, D			Gelsolin in complex with phosphatidylinositol 4,5-bisphosphate inhibits caspase-3 and-9 to retard apoptotic progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; CELL-DEATH; PROTEASES; EFFECTOR; MOTILITY; PATHWAYS; BCL-2; MICE	Apoptosis, or programmed cell death, occurs because of the activation of a protease cascade amplification circuit that includes the critical effector caspase-3. Previously, we identified the widely expressed actin modulatory protein gelsolin as a prominent substrate of caspase-3 and demonstrated that the N-terminal gelsolin cleavage product promotes apoptosis, Here we show that phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4-bisphosphate in pure micelles or mixed vesicles prevent caspase-3 cleavage of gelsolin. Moreover, phosphatidylinositol 4,5-bisphospfiate-gelsolin strongly inhibits caspase-3 and -9 activity through the formation of a stable phosphatidylinositol 4,6-bisphosphate-gelsolin-caspase complex. In addition, phosphatidylinositol 4,5-bisphosphate-gelsolin prevents apoptotic progression mediated by caspase-3 in a cell-free system, and phosphatidylinositol 4,5-bisphosphategelsolin-caspase-9 and phosphatidylinositol 4,5-bisphosphate-gelsolin-caspase-3 complexes form in mouse embryonic fibroblasts during apoptosis induction when; stimulated with fibronectin, to delay cell death. The results suggest that gelsolin can act as both an effector and an inhibitor of caspase-3, the latter in concert with phosphatidylinositol 4,5-bisphosphate, and other membrane phospholipids to regulate the onset and progression of apoptosis.	Brigham & Womens Hosp, Div Hematol, Genet Lab, Boston, MA 02115 USA; Chiron Corp, Emeryville, CA 94608 USA	Harvard University; Brigham & Women's Hospital; Novartis	Kwiatkowski, D (corresponding author), Brigham & Womens Hosp, Div Hematol, Genet Lab, 221 Longwood Ave,MRC 301, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056949, R01HL054188] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56949, HL54188] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Geng YJ, 1998, EUR J CELL BIOL, V77, P294, DOI 10.1016/S0171-9335(98)80088-5; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Meerschaert K, 1998, EMBO J, V17, P5923, DOI 10.1093/emboj/17.20.5923; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAUZ DL, 1994, CELL, V76, P777; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0	31	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3761	3766		10.1074/jbc.275.6.3761	http://dx.doi.org/10.1074/jbc.275.6.3761			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660524	hybrid			2022-12-25	WOS:000085288800008
J	Murakumo, Y; Roth, T; Ishii, H; Rasio, D; Numata, S; Croce, CM; Fishel, R				Murakumo, Y; Roth, T; Ishii, H; Rasio, D; Numata, S; Croce, CM; Fishel, R			A human REV7 homolog that interacts with the polymerase zeta catalytic subunit hREV3 and the spindle assembly checkpoint protein hMAD2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCRINE NEOPLASIA TYPE-2; DAMAGE-INDUCED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; DNA-POLYMERASE; MITOTIC CHECKPOINT; ESCHERICHIA-COLI; FEEDBACK-CONTROL; BUDDING YEAST; REPAIR; GENE	Widespread alteration of the genomic DNA is a hallmark of tumors, and alteration of genes involved in DNA maintenance have been shown to contribute to the tumorigenic process. The DNA polymerase xi of Saccharomyces cerevisiae is required for error-prone repair following DNA damage and consists of a complex between three proteins, scRev1, scRev3, and scRev7, Here we describe a candidate human homolog of S. cerevisiae Rev7 (hREV7), which was identified in a yeast two-hybrid screen using the human homolog of S. cerevisiae Rev3 (hREV3), The hREV7 gene product displays 23% identity and 53% similarity with scREV7, as well as 23% identity and 54% similarity with the human mitotic checkpoint protein hMAD2. hREV7 is located on human chromosome 1p36 in a region of high loss of heterozygosity in human tumors, although no alterations of hREV3 or hREV7 were found in primary human tumors or human tumor cell lines. The interaction domain between hREV3 and hREV7 was determined and suggests that hREV7 probably functions with hREV3 in the human DNA polymerase xi complex. In addition, we have identified an interaction between hREV7 and hMAD2 but not hMAD1. While overexpression of hREV7 does not lead to cell cycle arrest, we entertain the possibility that it may act as an adapter between DNA repair and the spindle assembly checkpoint.	Thomas Jefferson Univ, Kimmel Canc Ctr BLSB933, Genet & Mol Biol Program, Kimmel Canc Inst,Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr BLSB933, Genet & Mol Biol Program, Kimmel Canc Inst,Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [P01CA021124, R35CA039860, P01CA051083] Funding Source: NIH RePORTER; NCI NIH HHS [CA51083, CA21124, CA39860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allshire RC, 1997, CURR OPIN GENET DEV, V7, P264, DOI 10.1016/S0959-437X(97)80137-2; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P284, DOI 10.1016/S0968-0004(98)01257-2; Baynton K, 1998, MOL CELL BIOL, V18, P960, DOI 10.1128/MCB.18.2.960; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P296, DOI 10.1002/gcc.2870090411; BOVERI T, 1914, FISCHER; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Farr KA, 1998, MOL CELL BIOL, V18, P2738, DOI 10.1128/MCB.18.5.2738; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Hardwick KG, 1999, GENETICS, V152, P509; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Holbeck SL, 1997, GENETICS, V147, P1017; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Kironmai KM, 1998, MOL CELL BIOL, V18, P1424, DOI 10.1128/MCB.18.3.1424; Kuwamoto K, 1999, PHOTODERMATOL PHOTO, V15, P127, DOI 10.1111/j.1600-0781.1999.tb00072.x; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LAWRENCE CW, 1984, MOL GEN GENET, V195, P487, DOI 10.1007/BF00341451; Lawrence CW, 1996, CANCER SURV, V28, P21; LI R, 1993, NATURE, V366, P82, DOI 10.1038/366082a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li XR, 1997, MOL CELL BIOL, V17, P2723, DOI 10.1128/MCB.17.5.2723; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LOEB LA, 1991, CANCER RES, V51, P3075; Maniatis T., 1982, MOL CLONING LAB MANU; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 1997, GENETICS, V147, P1557; MOLEY JF, 1992, CANCER RES, V52, P770; Morelli C, 1998, CYTOGENET CELL GENET, V83, P18, DOI 10.1159/000015157; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SIMON M, 1995, CANCER RES, V55, P4696; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; TORPEY LE, 1994, YEAST, V10, P1503, DOI 10.1002/yea.320101115; Walker GC, 1998, P NATL ACAD SCI USA, V95, P10348, DOI 10.1073/pnas.95.18.10348; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; WILSON TM, 1995, CANCER RES, V55, P5146; Xiao W, 1998, CARCINOGENESIS, V19, P945, DOI 10.1093/carcin/19.5.945	55	155	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4391	4397		10.1074/jbc.275.6.4391	http://dx.doi.org/10.1074/jbc.275.6.4391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660610	hybrid			2022-12-25	WOS:000085288800094
J	Nowling, TK; Johnson, LR; Wiebe, MS; Rizzino, A				Nowling, TK; Johnson, LR; Wiebe, MS; Rizzino, A			Identification of the transactivation domain of the transcription factor Sox-2 and an associated co-activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; FIBROBLAST GROWTH-FACTOR-4 ENHANCER; DNA-BINDING SPECIFICITY; K-FGF PROTOONCOGENE; STEM-CELLS; REGULATORY ELEMENTS; COACTIVATOR P300; GENE-EXPRESSION; GLIAL-CELLS; F9 CELLS	The importance of interactions between Sox and POU transcription factors in the regulation of gene expression is becoming increasingly apparent. Recently, many examples of the involvement of Sox-POU partnerships in transcription have been discovered, including a partnership between Sox-2 and Oct-3, Little is known about the mechanisms by which these factors modulate transcription. To better understand the molecular interactions involved, we mapped the location of the transactivation domain of Sox-2. This was done in the context of its interaction with Oct-3, as well as its ability to trans activate as a fusion protein linked to the DNA-binding domain of Gal4. Both approaches demonstrated that Sox-2 contains a transactivation domain in its C-terminal half, containing a serine-rich region and the C-terminus. We also determined that the viral oncoprotein Ela inhibits the ability of the Ga14/Sox-2 fusion protein to transactivate, as well as the transcriptional activation mediated by the combined action of Sox-a and Oct-3, In contrast, a mutant form of E1a, unable to bind p300, lacks both of these effects. Importantly, we determined that p300 overcomes the inhibitory effects of Ela in both assays. Together, these findings suggest that Sox-2 mediates its effects, at least in part, through the co-activator p300.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Nebraska Med Ctr 986805, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Rizzino, A (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Nebraska Med Ctr 986805, Omaha, NE 68198 USA.	arizzino@unmc.edu	Wiebe, Matthew/X-5007-2019; Wiebe, Matt/AAC-4642-2021	Wiebe, Matthew/0000-0001-6337-6556; 	NCI NIH HHS [CA 09476, CA 74771, CA 36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009476, R01CA074771, P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4503, DOI 10.1093/nar/19.16.4503; Johnson LR, 1998, MOL REPROD DEV, V50, P377; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lamb K, 1996, MOL REPROD DEV, V44, P460; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; NISWANDER L, 1992, DEVELOPMENT, V114, P755; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; SASAKI A, 1991, JPN J CANCER RES, V82, P1191, DOI 10.1111/j.1349-7006.1991.tb01778.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; Scholtz B, 1996, DEV BIOL, V173, P420, DOI 10.1006/dbio.1996.0037; SCHOORLEMMER J, 1991, MECH DEVELOP, V36, P75, DOI 10.1016/0925-4773(91)90074-G; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Smits PHM, 1996, ONCOGENE, V12, P1529; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VELCICH A, 1989, ONCOGENE RES, V5, P31; Vigano MA, 1996, NUCLEIC ACIDS RES, V24, P2112, DOI 10.1093/nar/24.11.2112; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; ZANTEMA A, 1995, CURR TOP MICROBIOL, V199, P1	45	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3810	3818		10.1074/jbc.275.6.3810	http://dx.doi.org/10.1074/jbc.275.6.3810			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660531	Green Published, hybrid			2022-12-25	WOS:000085288800015
J	Salerno, MS; Mordvinov, VA; Sanderson, CJ				Salerno, MS; Mordvinov, VA; Sanderson, CJ			Binding of octamer factors to a novel 3 '-positive regulatory element in the mouse interleukin-5 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELLS; EXPRESSION; PROMOTER; EOSINOPHILS; IL-5; DIFFERENTIATION; LYMPHOKINES; ANTIBODY; PATHWAYS; PROTEINS	The development of eosinophilia is regulated by interleukin (IL)-5, The biological specificity of eosinophilia suggests a tight and independent regulation of IL-5 expression. A number of regulatory regions in the 5'-end of the IL-5 gene have been described; many of them are involved in the regulation of other genes, and it is not clear how the specific expression of IL-5 is regulated. In this study, we report the finding of a novel 3'-regulatory element. Data base analysis of a a-kilobase fragment of the 3'-end of the mouse IL-5 gene revealed the presence of a 40-base pair-long repetitive sequence that consists of four direct repeats of ATGAATGA distributed in a symmetrical manner, This sequence, named mouse downstream regulatory element-1 (mDRE1), was shown to be protected in DNase I footprinting assays in vitro, Electrophoretic mobility shift assays using specific antibodies identified the transcription factors Oct-1 and Oct-2 as responsible for the formation of the specific complexes with mDRE1 and nuclear extracts from both EL4 and primary T-cells. Competition electrophoretic mobility shift assays with oligonucleotides containing different numbers of ATGAATGA repeats showed that Oct-1 and Oct-2 bind to different motifs in the mDRE1 sequence. Deletion of mDRE1 from a 9.5-kilobase IL-5 gene construct significantly decreased the expression of the luciferase reporter gene, suggesting that it plays a positive role in the expression of the IL-5 gene.	Curtin Univ Technol, Mol Immunol Grp, Sch Biomed Sci, Perth, WA 6000, Australia	Curtin University	Sanderson, CJ (corresponding author), Curtin Univ Technol, Mol Immunol Grp, Sch Biomed Sci, Level 5,MRF Bldg, Rear 50 Murray St, Perth, WA 6000, Australia.		Mordvinov, Viatcheslav A/S-8277-2017	Mordvinov, Viatcheslav A/0000-0002-6173-0774				Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Barata LT, 1998, J ALLERGY CLIN IMMUN, V101, P222, DOI 10.1016/S0091-6749(98)70387-2; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; BUTTERWORTH AE, 1975, NATURE, V256, P727, DOI 10.1038/256727a0; BUTTERWORTH AE, 1984, ADV PARASIT, V23, P143, DOI 10.1016/S0065-308X(08)60287-0; CAMPBELL HD, 1988, EUR J BIOCHEM, V174, P345, DOI 10.1111/j.1432-1033.1988.tb14104.x; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; Csonga R, 1998, J IMMUNOL, V160, P273; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; Karlen S, 1996, BLOOD, V88, P211; KARLEN S, 1993, J VIROL, V67, P4296, DOI 10.1128/JVI.67.7.4296-4306.1993; Kubo M, 1997, EMBO J, V16, P4007, DOI 10.1093/emboj/16.13.4007; Kwon J, 1996, J BIOL CHEM, V271, P22383, DOI 10.1074/jbc.271.37.22383; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LECAM A, 1995, EUR J BIOCHEM, V231, P620; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; LEE HJ, 1993, J IMMUNOL, V151, P6135; NAORA H, 1994, BLOOD, V83, P3620; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwenger GTF, 1998, LEUKEMIA LYMPHOMA, V28, P443, DOI 10.3109/10428199809058351; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; Thomas MA, 1999, BBA-GENE STRUCT EXPR, V1444, P61, DOI 10.1016/S0167-4781(98)00268-1; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; WARREN HS, 1995, J IMMUNOL, V154, P5144; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830	31	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4525	4531		10.1074/jbc.275.6.4525	http://dx.doi.org/10.1074/jbc.275.6.4525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660628	hybrid			2022-12-25	WOS:000085288800112
J	Kovoor, A; Chen, CK; He, W; Wensel, TG; Simon, MI; Lester, HA				Kovoor, A; Chen, CK; He, W; Wensel, TG; Simon, MI; Lester, HA			Co-expression of G beta 5 enhances the function of two G gamma subunit-like domain-containing regulators of G protein signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC POTASSIUM CHANNEL; RGS PROTEINS; K+ CHANNELS; XENOPUS-OOCYTES; BETA-SUBUNIT; NUCLEOTIDE EXCHANGE; P115 RHOGEF; ACTIVATION; COMPLEX; G-ALPHA(13)	Regulators of G protein signaling (RGS) stimulate the GTPase activity of G protein G alpha subunits and probably play additional roles. Some RGS proteins contain a G gamma subunit-like (GGL) domain, which mediates a specific interaction with G beta 5, The role of such interactions in RGS function is unclear. RGS proteins can accelerate the kinetics of coupling of G protein-coupled receptors to G-protein-gated inwardly rectifying K+ (GIRK) channels. Therefore, we coupled m2-muscarinic acetylcholine receptors to GIRK channels in Xenopus oocytes to evaluate the effect of G beta 5 on RGS function. Co-expression of either RGS7 or RGS9 modestly accelerated GIRK channel kinetics. When G beta 5 was co-expressed with either RGS7 or RGS9, the acceleration of GIRK channel kinetics was strongly increased over that produced by RGS7 or RGS9 alone. RGS function was not enhanced by co-expression of G beta 1, and co-expression of G beta 5 alone had no effect on GIRK channel kinetics. G beta 5 did not modulate the function either of RGS4, an RGS protein that lacks a GGL domain, or of a functional RGS7 construct in which the GGL domain was omitted. Enhancement of RGS7 function by G beta 5 was not a consequence of an increase in the amount of plasma membrane or cytosolic RGS7 protein.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	California Institute of Technology; Baylor College of Medicine	Lester, HA (corresponding author), CALTECH, Div Biol, MC 156-29, Pasadena, CA 91125 USA.	lester@caltech.edu		Wensel, Theodore/0000-0003-3518-9352				ALBERTS B, 1994, MOL BIOL CELL, P731; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Herlitze X, 1999, J PHYSIOL-LONDON, V517, P341, DOI 10.1111/j.1469-7793.1999.0341t.x; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; Higgins JB, 1996, CELL SIGNAL, V8, P433, DOI 10.1016/S0898-6568(96)00071-X; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Karschin C, 1996, J NEUROSCI, V16, P3559; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Kofuji P, 1996, NEURON, V16, P941, DOI 10.1016/S0896-6273(00)80117-8; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; QUICK MW, 1992, BIOTECHNIQUES, V13, P357; Rahman Z, 1999, J NEUROSCI, V19, P2016; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sodickson DL, 1996, J NEUROSCI, V16, P6374; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Zerangue N, 1998, CURR BIOL, V8, pR313, DOI 10.1016/S0960-9822(98)70196-4	38	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3397	3402		10.1074/jbc.275.5.3397	http://dx.doi.org/10.1074/jbc.275.5.3397			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652332	hybrid			2022-12-25	WOS:000085146500054
J	McBride, AE; Weiss, VH; Kim, HK; Hogle, JM; Silver, PA				McBride, AE; Weiss, VH; Kim, HK; Hogle, JM; Silver, PA			Analysis of the yeast arginine methyltransferase Hmt1p/Rmt1p and its in vivo function - Cofactor binding and substrate interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; SACCHAROMYCES-CEREVISIAE; S-ADENOSYLMETHIONINE; DEPENDENT METHYLTRANSFERASES; N-METHYLTRANSFERASE; RECOGNITION MOTIF; SHUTTLE VECTORS; NUCLEAR EXPORT; RNA; METHYLATION	Many eukaryotic RNA-binding proteins are modified by methylation of arginine residues. The yeast Saccharomyces cerevisiae contains one major arginine methyltransferase, Hmt1p/Rmt1p, which is not essential for normal cell growth, However, cells missing HIMT1 and also bearing mutations in the mRNA-binding proteins Np13p or Cbp80p can no longer survive, providing genetic backgrounds in which to study Hmt1p function. We now demonstrate that the catalytically active form of Hmt1p is required for its activity in vivo. Amino acid changes in the putative Kmt1p S-adenosyl-L-methionine-binding site were generated and shown to be unable to catalyze methylation of Np13p in vitro and in vivo or to restore growth to strains that require HMT1. In addition these mutations affect nucleocytoplasmic transport of Np13p. A cold-sensitive mutant of Hmt1p was generated and showed reduced methylation of Np13p, but not of other substrates, at 14 degrees C. These results define new aspects of Hmt1 and reveal the importance of its activity in vivo.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Silver, PA (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	psilver@fas.harvard.edu	Hogle, James/HIG-9121-2022	Hogle, James/0000-0002-3655-1504	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019236, R01GM057476] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57476, GM19236] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Ahmad I, 1996, J MOL BIOL, V259, P229, DOI 10.1006/jmbi.1996.0315; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CASELLAS P, 1978, BIOCHIM BIOPHYS ACTA, V519, P243, DOI 10.1016/0005-2787(78)90077-1; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; Henry M, 1996, GENETICS, V142, P103; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Izaurralde E, 1998, RNA, V4, P351; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Krebber H, 1999, GENE DEV, V13, P1994, DOI 10.1101/gad.13.15.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Lewis JD, 1997, EUR J BIOCHEM, V247, P461, DOI 10.1111/j.1432-1033.1997.00461.x; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; Lewis JD, 1996, NUCLEIC ACIDS RES, V24, P3332, DOI 10.1093/nar/24.17.3332; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LIU Q, 1995, MOL CELL BIOL, V15, P2800; LOO S, 1995, GENETICS, V141, P889; MIYAKE M, 1975, J NEUROCHEM, V24, P909, DOI 10.1111/j.1471-4159.1975.tb03655.x; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; ORRWEAVER TL, 1983, P NATL ACAD SCI-BIOL, V80, P4417, DOI 10.1073/pnas.80.14.4417; PAIK WK, 1968, J BIOL CHEM, V243, P2108; RAJPUROHIT R, 1992, BIOCHIM BIOPHYS ACTA, V1122, P183, DOI 10.1016/0167-4838(92)90322-5; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; Rose MD., 1990, METHODS YEAST GENETI; RUSSELL ID, 1992, J CELL BIOL, V119, P737, DOI 10.1083/jcb.119.4.737; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGLETON DR, 1995, J CELL SCI, V108, P265; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173	44	80	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3128	3136		10.1074/jbc.275.5.3128	http://dx.doi.org/10.1074/jbc.275.5.3128			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652296	Green Published, hybrid			2022-12-25	WOS:000085146500018
J	Narumi, O; Mori, S; Boku, S; Tsuji, Y; Hashimoto, N; Nishikawa, S; Yokota, Y				Narumi, O; Mori, S; Boku, S; Tsuji, Y; Hashimoto, N; Nishikawa, S; Yokota, Y			OUT, a novel basic helix-loop-helix transcription factor with an Id-like inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING NERVOUS-SYSTEM; E-BOX MOTIF; SKELETAL-MUSCLE; DNA-BINDING; NEGATIVE REGULATOR; MOLECULAR CHARACTERIZATION; MOUSE EMBRYOGENESIS; EXPRESSION PATTERN; CRYSTAL-STRUCTURE; DROSOPHILA-HAIRY	Transcription factors belonging to the basic helix-loop-helix (bHLH) family are involved in various cell differentiation processes. We report the isolation and functional characterization of a novel bHLH factor, termed OUT. OUT, structurally related to capsulin/epicardin/Pod-1 and ABF-1/musculin/MyoR, is expressed mainly in the adult mouse reproductive organs, such as the ovary, uterus, and testis, and is barely detectable in tissues of developing embryos. Physical association of OUT with the E protein was predicted from the primary structure of OUT and confirmed by co-immunoprecipitation, However, unlike other bHLH factors, this novel protein failed to bind E-box or N-box DNA sequences and inhibited DNA binding of homo- and heterodimers consisting of E12 and MyoD in gel mobility shift assays. In luciferase assays, OUT inhibited the induction of E-box-dependent transactivation by MyoD-E12 heterodimers. Deletion studies identified the domain responsible for the inhibitory action of OUT in its bHLH and C-terminal regions. Moreover, terminal differentiation of C2C12 myoblasts was inhibited by exogenous introduction of OUT. These inhibitory functions of OUT closely resemble those of the helix-loop-helix inhibitor Id proteins. Based on these findings, we propose that this novel protein functions as a negative regulator of bHLH factors through the formation of a functionally inactive heterodimeric complex.	Kyoto Univ, Dept Mol Genet, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Neurosurg, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Yokota, Y (corresponding author), Kyoto Univ, Dept Mol Genet, Grad Sch Med, Sakyo Ku, Shogoin Kawahara Cho 53, Kyoto 6068507, Japan.	yyokota@virus.kyoto-u.ac.jp	Boku, Shuken/H-2776-2017					Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; AKIMENKO MA, 1989, NUCLEIC ACIDS RES, V17, P4745, DOI 10.1093/nar/17.12.4745; APONE S, 1995, J BIOL CHEM, V270, P21420, DOI 10.1074/jbc.270.36.21420; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; Braun T, 1996, EMBO J, V15, P310, DOI 10.1002/j.1460-2075.1996.tb00361.x; BRODY JR, 1989, AM J ANAT, V186, P1, DOI 10.1002/aja.1001860102; BROWN L, 1994, MOL CELL BIOL, V14, P1245, DOI 10.1128/MCB.14.2.1245; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; Chen BB, 1997, NUCLEIC ACIDS RES, V25, P423, DOI 10.1093/nar/25.2.423; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Cripps RM, 1998, GENE DEV, V12, P422, DOI 10.1101/gad.12.3.422; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; Elnitski L, 1997, J BIOL CHEM, V272, P369; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Hidai H, 1998, MECH DEVELOP, V73, P33, DOI 10.1016/S0925-4773(98)00031-8; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; IP YT, 1994, EMBO J, V13, P5826, DOI 10.1002/j.1460-2075.1994.tb06926.x; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Lemercier C, 1997, DEV BIOL, V182, P101, DOI 10.1006/dbio.1996.8454; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; Lu JR, 1998, MECH DEVELOP, V73, P23, DOI 10.1016/S0925-4773(98)00030-6; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Massari ME, 1998, MOL CELL BIOL, V18, P3130, DOI 10.1128/MCB.18.6.3130; Mori S, 1999, MOL BRAIN RES, V64, P199, DOI 10.1016/S0169-328X(98)00323-4; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Peyton M, 1996, MOL CELL BIOL, V16, P626; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Quaggin SE, 1998, MECH DEVELOP, V71, P37, DOI 10.1016/S0925-4773(97)00201-3; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Robb L, 1998, MECH DEVELOP, V76, P197, DOI 10.1016/S0925-4773(98)00122-1; Robb L, 1998, DEV DYNAM, V213, P105, DOI 10.1002/(SICI)1097-0177(199809)213:1<105::AID-AJA10>3.0.CO;2-1; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; Schutte BC, 1997, BIOTECHNIQUES, V22, P40, DOI 10.2144/97221bm06; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SIMPSON P, 1983, GENETICS, V105, P615; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; VENUTI JM, 1995, J CELL BIOL, V128, P563, DOI 10.1083/jcb.128.4.563; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Yoshida N, 1998, J CELL SCI, V111, P769; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	88	28	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3510	3521		10.1074/jbc.275.5.3510	http://dx.doi.org/10.1074/jbc.275.5.3510			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652346	Green Submitted, hybrid			2022-12-25	WOS:000085146500068
J	LeGros, HL; Halim, AB; Geller, AM; Kotb, M				LeGros, HL; Halim, AB; Geller, AM; Kotb, M			Cloning, expression, and functional characterization of the beta regulatory subunit of human methionine adenosyltransferase (MAT II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; RAT-LIVER; MOLECULAR MECHANISMS; NUCLEOTIDE-SEQUENCE; HUMAN-ERYTHROCYTES; HUMAN-LYMPHOCYTES; MESSENGER-RNA; ISOZYMES; GENE; FRACTIONATION	MAT II, the extrahepatic form of methionine adeno-syltransferase (MAT), consists of catalytic alpha(2)/alpha(2) subunits and a noncatalytic beta subunit, believed to have a regulatory function. The full-length cDNA that encodes the beta subunit of human MAT II was cloned and found to encode for a 334-amino acid protein with a calculated molecular weight of 37,552. Analysis of sequence homology showed similarity with bacterial enzymes that catalyze the reduction of TDP-linked sugars. The beta subunit cDNA was cloned into the pQE-30 expression vector, and the recombinant His tagged protein, which was expressed in Escherichia cell, was recognized by antibodies to the human MAT II, to synthetic peptides copying the sequence of native beta subunit protein, and to the r beta protein. There is no cross-reactivity between the MAT II alpha(2) or beta subunits. None of the anti-beta subunit antibodies reacted with protein extracts of E. coli host cells, suggesting that these bacteria have no beta subunit protein. Interestingly, the r beta subunit associated with E. coli as well as human MAT a subunits. This association changed the kinetic properties of both enzymes and lowered the K-m of MAT for L-methionine. Together, the data show that we have cloned and expressed the human MAT II beta subunit and confirmed its long suspected regulatory function. This knowledge affords a molecular means by which MAT activity and consequently the levels of AdoMet may be modulated in mammalian cells.	Univ Tennessee, Dept Surg, Memphis, TN 38163 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA; Vet Affairs Med Ctr, Memphis, TN 38104 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Kotb, M (corresponding author), Univ Tennessee, Dept Surg, 956 Court Ave,Suite A-202, Memphis, TN 38163 USA.				NIGMS NIH HHS [GM-54892-09] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054892] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; CANTONI GL, 1953, J BIOL CHEM, V204, P403; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; DELAROSA J, 1992, J BIOL CHEM, V267, P10699; DELAROSA J, 1995, J BIOL CHEM, V270, P21860; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; Gil B, 1996, HEPATOLOGY, V24, P876; HOFFMAN JL, 1983, METHOD ENZYMOL, V94, P223; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; HORIKAWA S, 1991, BIOCHEM INT, V25, P81; KLAPPER MH, 1977, BIOCHEM BIOPH RES CO, V78, P1018, DOI 10.1016/0006-291X(77)90523-X; KOTB M, 1985, J BIOL CHEM, V260, P3923; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1039, P253, DOI 10.1016/0167-4838(90)90193-J; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1040, P137, DOI 10.1016/0167-4838(90)90068-Q; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANGKAMPHENKEN B, 1994, BBA-GEN SUBJECTS, V1201, P397, DOI 10.1016/0304-4165(94)90068-X; LeGros HL, 1997, J BIOL CHEM, V272, P16040, DOI 10.1074/jbc.272.25.16040; LIAU MC, 1979, CANCER RES, V39, P162; Maceratesi P, 1998, MOL GENET METAB, V63, P26, DOI 10.1006/mgme.1997.2645; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MATO JM, 1994, ADV EXP MED BIOL, V368, P113; Mingorance J, 1997, INT J BIOCHEM CELL B, V29, P485, DOI 10.1016/S1357-2725(96)00151-3; MITSUI KI, 1988, J BIOL CHEM, V263, P11211; MUDD SH, 1973, ADENOSYLTRANSFERASES, P121; MUDD SH, 1995, DISORDERS TRANSSULFU, P1279; ODEN KL, 1983, BIOCHEMISTRY-US, V22, P2978, DOI 10.1021/bi00281a030; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; PAJARES MA, 1992, FEBS LETT, V309, P1, DOI 10.1016/0014-5793(92)80726-W; PISSOWOTZKI K, 1991, MOL GEN GENET, V231, P113, DOI 10.1007/BF00293829; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAKATA SF, 1993, J BIOL CHEM, V268, P13978; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; SUMA Y, 1986, J BIOCHEM, V100, P67, DOI 10.1093/oxfordjournals.jbchem.a121707; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; UBAGAI T, 1995, J CLIN INVEST, V96, P1943, DOI 10.1172/JCI118240	38	61	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2359	2366		10.1074/jbc.275.4.2359	http://dx.doi.org/10.1074/jbc.275.4.2359			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644686	hybrid			2022-12-25	WOS:000085128000018
J	Swift, S; Sheridan, PJ; Covic, L; Kuliopulos, A				Swift, S; Sheridan, PJ; Covic, L; Kuliopulos, A			PAR1 thrombin receptor-G protein interactions - Separation of binding and coupling determinants in the G alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-DEPENDENT CARBOXYLASE; PHEROMONE RESPONSE PATHWAY; BETA-GAMMA-SUBUNITS; SACCHAROMYCES-CEREVISIAE; PLATELET ACTIVATION; MOLECULAR-GENETICS; SYNTHETIC PEPTIDES; MATING SIGNAL; YEAST; IDENTIFICATION	Signal transfer between the protease-activated PAR1 thrombin receptor and membrane-associated heterotrimeric G proteins is mediated by protein-protein interactions. We constructed a yeast signaling system that resolves domain-specific functions of binding from coupling in the G alpha subunit, The endogenous yeast G alpha subunit, Gpa1, does not bind to PAR1 and served as a null structural template. N- and C-terminal portions of mammalian G(i2) and G(16) were substituted back into the Gpa1 template and gain-of-function assessed. The C-terminal third of G(16), but not of G(i2), provides sufficient interactions for coupling to occur with PAR1. The N-terminal two-thirds of G(i2) also contains sufficient determinants to bind and couple to PAR1 and overcome the otherwise negative or missing interactions supplied by the C-terminal third of Gpa1, Replacement of the N-terminal alpha-helix of G(i2), residues 1-34, with those of Opal abolishes coupling but not binding to PAR1 or to beta gamma subunits. These data support a model that the N-terminal alpha N helix of the G alpha subunit is physically interposed between PAR1 and the G beta subunit and directly assists in transferring the signal between agonist-activated receptor and G protein.	Tufts Univ, Sch Med, New England Med Ctr, Div Hematol Oncol,Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University; Tufts University	Kuliopulos, A (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Div Hematol Oncol,Mol Cardiol Res Inst, Boston, MA 02111 USA.	akuliopu@opal.tufts.edu		Swift, Steven/0000-0002-3840-4401	NHLBI NIH HHS [R01HL57905] Funding Source: Medline; NIGMS NIH HHS [R29GM52926] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057905] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM052926] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKTORIES K, 1984, EUR J BIOCHEM, V145, P333, DOI 10.1111/j.1432-1033.1984.tb08558.x; Baltensperger H, 1997, J BIOL CHEM, V272, P10151; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Brass Lawrence F., 1995, P1536; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Dean WL, 1997, J BIOL CHEM, V272, P15113, DOI 10.1074/jbc.272.24.15113; DeSimone SM, 1998, MOL GEN GENET, V257, P662, DOI 10.1007/s004380050695; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; FENG DM, 1995, J MED CHEM, V38, P4125, DOI 10.1021/jm00020a029; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kajkowski EM, 1997, J RECEPT SIGNAL TR R, V17, P293, DOI 10.3109/10799899709036610; Kallal L, 1997, MOL CELL BIOL, V17, P2897, DOI 10.1128/MCB.17.5.2897; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Klein C, 1998, NAT BIOTECHNOL, V16, P1334, DOI 10.1038/4310; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; KULIOPULOS A, 1992, BIOCHEMISTRY-US, V31, P9436, DOI 10.1021/bi00154a016; KULIOPULOS A, 1994, J BIOL CHEM, V269, P21364; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Leibel RL, 1997, J BIOL CHEM, V272, P31937, DOI 10.1074/jbc.272.51.31937; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; Milligan G, 1996, TRENDS PHARMACOL SCI, V17, P235, DOI 10.1016/0165-6147(96)10026-2; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Seiler SM, 1996, MOL PHARMACOL, V49, P190; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; Stratton HF, 1996, MOL CELL BIOL, V16, P6325; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WIELAND T, 1994, METHOD ENZYMOL, V237, P3; WILLIAMS AG, 1990, BLOOD, V76, P721; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	58	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2627	2635		10.1074/jbc.275.4.2627	http://dx.doi.org/10.1074/jbc.275.4.2627			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644723	hybrid			2022-12-25	WOS:000085128000055
J	Vaughn, MW; Huang, KT; Kuo, L; Liao, JC				Vaughn, MW; Huang, KT; Kuo, L; Liao, JC			Erythrocytes possess an intrinsic barrier to nitric oxide consumption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; OXYGEN-UPTAKE; DIFFUSION; HEMOGLOBIN	It has been reported that free hemoglobin (Hb) reacts with NO at an extremely high rate (K-Hb similar to 10(7) M-1 s(-1)) and that the red blood cell (RBC) membrane is highly permeable to NO. RBCs, however, react with NO 500-1000 times slower. This reduction of NO reaction rate by RBCs has been attributed to the extracellular diffusion limitation. To test whether additional Limitations are also important, we designed a competition test, which allows the extracellular diffusion limitation to be distinguished from transmembrane or intracellular resistance. This test exploited the competition between free Hb and RBCs for NO generated in a homogenous phase by an NO donor. If the extracellular diffusion resistance is negligible, then the results would follow a kinetic model that assumes homogenous reaction without extracellular diffusion limitation, In this case, the measured effective reaction rate constant, K-RBC, would remain invariant of the hematocrit, extracellular-free Hb concentration, and NO donor concentration. Results show that the K-RBC approaches a constant only when the hematocrit is greater than 10% suggesting that at higher hematocrit, the extracellular diffusion resistance is negligible. Under such a condition, the NO consumption by RBCs is still 500-1000 times slower than that by free Hb. This result suggests that intrinsic RBC factors, such as transmembrane diffusion limitation or intracellular mechanisms, exist to reduce the NO consumption by RBCs.	Univ Calif Los Angeles, Dept Chem Engn, Los Angeles, CA 90095 USA; Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA; Texas A&M Univ, Dept Med Physiol, College Stn, TX 77843 USA	University of California System; University of California Los Angeles; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Liao, JC (corresponding author), Univ Calif Los Angeles, Dept Chem Engn, 5531 Boelter Hall, Los Angeles, CA 90095 USA.	liaoj@ucla.edu	Vaughn, Mark w/I-7150-2015	Vaughn, Mark w/0000-0002-2534-4497; Kuo, Lih/0000-0002-4912-6910; Liao, James/0000-0002-4580-7276				BEUTLER MD, 1984, RED CELL METABOLISM; Butler AR, 1998, BBA-GEN SUBJECTS, V1425, P168, DOI 10.1016/S0304-4165(98)00065-8; CARLSEN E, 1958, J GEN PHYSIOL, V42, P83, DOI 10.1085/jgp.42.1.83; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; COIN JT, 1979, J BIOL CHEM, V254, P1178; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V328, P208, DOI 10.1006/abbi.1996.0162; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Hartridge H, 1927, J PHYSIOL-LONDON, V52, P232, DOI 10.1113/jphysiol.1927.sp002354; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KREUZER F, 1960, J APPL PHYSIOL, V15, P1117, DOI 10.1152/jappl.1960.15.6.1117; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; Lancaster JR, 1996, METHOD ENZYMOL, V268, P31; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; MERCHUK JC, 1983, CHEM ENG SCI, V38, P1315, DOI 10.1016/0009-2509(83)80052-9; MOULINOUX JP, 1984, BIOCHIMIE, V66, P385, DOI 10.1016/0300-9084(84)90022-1; POHL U, 1991, BASIC RES CARDIOL S, V86, P105; RICE SA, 1980, BIOPHYS J, V29, P65, DOI 10.1016/S0006-3495(80)85118-6; Riggs A., 1981, Methods in Enzymology, V76, P5; Schmid-Schonbein H, 1979, QUANTITATIVE CARDIOV, P353; VANDEGRIFF KD, 1984, BIOPHYS J, V45, P825, DOI 10.1016/S0006-3495(84)84226-5; VANDEGRIFF KD, 1984, J BIOL CHEM, V259, P2619; Vaughn MW, 1998, AM J PHYSIOL-HEART C, V274, pH1705, DOI 10.1152/ajpheart.1998.274.5.H1705; Vaughn MW, 1998, AM J PHYSIOL-HEART C, V274, pH2163, DOI 10.1152/ajpheart.1998.274.6.H2163; Yonetani T, 1998, J BIOL CHEM, V273, P20323, DOI 10.1074/jbc.273.32.20323	28	185	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2342	2348		10.1074/jbc.275.4.2342	http://dx.doi.org/10.1074/jbc.275.4.2342			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644684	hybrid			2022-12-25	WOS:000085128000016
J	Lu, WG; Pochampally, R; Chen, LH; Traidej, M; Wang, YL; Chen, JD				Lu, WG; Pochampally, R; Chen, LH; Traidej, M; Wang, YL; Chen, JD			Nuclear exclusion of p53 in a subset of tumors requires MDM2 function	ONCOGENE			English	Article						MDM2; p53; ARF; antisense oligodeoxynucleotide; leptomycin B; tumor suppressor	DNA-DAMAGE; CELL-CYCLE; CYTOPLASMIC SEQUESTRATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; TERMINAL DOMAIN; BREAST-CANCER; FEEDBACK LOOP; PROTEIN	Wild type p53 accumulates in the cytoplasm in a subset of tumors such as neuroblastomas and breast carcinomas through an unknown mechanism. Exclusion of p53 from the nucleus may lead to inactivation of p53 during tumor development. We present evidence that MDM2 plays a significant role in promoting the degradation of nuclear p53 in tumor cells with a cytoplasmic p53 phenotype, Inhibition of MDM2 expression using antisense oligonucleotide, inhibition of MDM2 function by the tumor suppressor ARF or a MDM2 deletion mutant result in the accumulation of nuclear p53, p53 point mutants deficient in MDM2 binding have increased nuclear localization. Inhibition of nuclear export by leptomycin B also results in retention of nascent p53 in the nucleus, suggesting that cytoplasmic distribution of p53 results from efficient export of nuclear p53 in combination with MDM2-mediated degradation, These results suggest that MDM2 is an important determinant of p53 subcellular distribution and may contribute to p53 inactivation without overexpression.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Louisiana State Univ, Med Ctr, Dept Microbiol, New Orleans, LA 70112 USA	H Lee Moffitt Cancer Center & Research Institute; Louisiana State University System	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.			Pochampally, Radhika/0000-0002-4263-0364; Chomnawang, Mullika/0000-0002-3200-9259				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; CORDONCARDO C, 1994, CANCER RES, V54, P794; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GANNON JV, 1991, NATURE, V349, P802; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Isaacs JS, 1998, CELL GROWTH DIFFER, V9, P545; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zariwala M, 1996, ONCOGENE, V13, P2033; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	52	66	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					232	240		10.1038/sj.onc.1203262	http://dx.doi.org/10.1038/sj.onc.1203262			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645001	Bronze			2022-12-25	WOS:000084844400008
J	Clark, SF; Molero, JC; James, DE				Clark, SF; Molero, JC; James, DE			Release of insulin receptor substrate proteins from an intracellular complex coincides with the development of insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PHOSPHOTYROSINE PROTEIN; GLYCOGEN-SYNTHASE; RAT ADIPOCYTES; OKADAIC ACID	Insulin receptor substrate (IRS) proteins are major substrates of the insulin receptor (IR), IRS-1 associates with an insoluble multiprotein complex, possibly the cytoskeleton, in adipocytes. This localization may facilitate interaction with the IR at the cell surface. In the present study, we examined the hypothesis that the release of IRS proteins from this location may be a mechanism for insulin desensitization. We show that a second IRS protein, IRS-2, is associated with a multiprotein complex in adipocytes with similar characteristics to the IRS-1 complex. Insulin treatment (15-60 min) caused the release of IRS-1 and IRS-2 from this complex (high speed pellet; HSP) into the cytosol, whereas the level of tyrpsyl-phosphorylated IRS proteins remained constant. Chronic insulin treatment resulted in a dramatic reduction in IRS-1 and IRS-2 in the HSP, eventually (>2 h) leading to IRS protein degradation and decreased levels of tyrosyl-phosphorylated IRS proteins. Okadaic acid, which rapidly induces insulin resistance in adipocytes independently of TR function, caused an almost quantitative release of IRS-1 into the cytosol commensurate with a significant reduction in tyrosyl-phosphorylated IRS proteins. Platelet-derived growth factor, a factor known to compromise insulin signaling, caused a more moderate release of IRS proteins from the HSP. Collectively, these results suggest that the assembly of IRS-1/IRS-2 into a multiprotein complex facilitates coupling to the IR and that the regulated release from this location may represent a novel mechanism of insulin resistance.	Univ Queensland, Dept Physiol & Pharmacol, Ctr Mol & Cellular Biol, Brisbane, Qld 4072, Australia	University of Queensland	James, DE (corresponding author), Univ Queensland, Dept Physiol & Pharmacol, Ctr Mol & Cellular Biol, Brisbane, Qld 4072, Australia.		Clark, Sharon/B-8057-2009	James, David/0000-0001-5946-5257				Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Craparo A, 1997, J BIOL CHEM, V272, P11663; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; Hill MM, 1997, ELECTROPHORESIS, V18, P2629, DOI 10.1002/elps.1150181419; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; KURCHALIA T, 1992, J CELL BIOL, V118, P1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; OKADA T, 1994, J BIOL CHEM, V269, P3568; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Smith LK, 1996, MOL CELL ENDOCRINOL, V122, P81, DOI 10.1016/0303-7207(96)03875-0; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TANTI JF, 1993, AM J PHYSIOL, V264, pE868, DOI 10.1152/ajpendo.1993.264.6.E868; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829	57	73	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3819	3826		10.1074/jbc.275.6.3819	http://dx.doi.org/10.1074/jbc.275.6.3819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660532	hybrid			2022-12-25	WOS:000085288800016
J	Lasker, JM; Chen, WB; Wolf, I; Bloswick, BP; Wilson, PD; Powell, PK				Lasker, JM; Chen, WB; Wolf, I; Bloswick, BP; Wilson, PD; Powell, PK			Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney - Role of CYP4F2 and CYP4A11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	American-Society-of-Biochemistry-and-Molecular-Biology Annual Meeting	MAY 15-20, 1998	WASHINGTON, D.C.	Amer Soc Biochem & Molec Biol			SPONTANEOUSLY HYPERTENSIVE RATS; HUMAN LIVER-MICROSOMES; ENDOGENOUS EPOXYEICOSATRIENOIC ACIDS; POTENTIAL FUNCTIONAL-SIGNIFICANCE; ARACHIDONIC-ACID; OMEGA-HYDROXYLASE; CYTOCHROME-P450 4A; RENAL-FUNCTION; MOLECULAR-CLONING; CORTEX MICROSOMES	20-Hydroxyeicosatetraenoic acid (20-HETE), an omega-hydroxylated arachidonic acid (AA) metabolite, elicits specific effects on kidney vascular and tubular function that, in turn, influence blood pressure control. The human kidney's capacity to convert AA to SO-METE is unclear, however, as is the underlying P450 catalyst. Microsomes from human kidney cortex were found to convert AA to a single major product, namely 80-HETE, but failed to catalyze AA epoxygenation and midchain hydroxylation. Despite the monophasic nature of renal AA omega-hydroxylation kinetics, immunochemical studies revealed participation of two P450s, CYP4FS and CYP4A11, since antibodies to these enzymes inhibited SO-METE formation by 65.9 +/-17 and 32.5 +/- 14%, respectively. Western blotting confirmed abundant expression of these CYP4 proteins in human kidney and revealed that other AA-oxidizing P450s, including CYP2C8, CYP2C9, and CYP2E1, were not expressed. Immunocytochemistry showed CYP4F2 and CYP4A11 expression in only the S2 and 53 segments of proximal tubules in cortex and outer medulla, Our results demonstrate that CYP4F2 and CYP4A11 underlie conversion of AA to 20-METE, a natriuretic and vasoactive eicosanoid, in human kidney. Considering their proximal tubular localization, these P450 enzymes may partake in pivotal renal functions, including the regulation of salt and water balance, and arterial blood pressure itself.	CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Lasker, JM (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem, Box 1020,1 Gustave L Levy Pl, New York, NY 10029 USA.	lasker@smtplink.mssm.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK092310, R01DK040698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007842] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07842] Funding Source: Medline; NIDDK NIH HHS [N01 DK92310, DK40698] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amet Y, 1997, BIOCHEM PHARMACOL, V53, P765, DOI 10.1016/S0006-2952(96)00821-0; Amet Y, 1997, BIOCHEM PHARMACOL, V54, P947, DOI 10.1016/S0006-2952(97)00257-8; Bylund J, 1998, ANAL BIOCHEM, V265, P55, DOI 10.1006/abio.1998.2897; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; Capdevila Jorge H., 1995, P443; CARROLL MA, 1991, J BIOL CHEM, V266, P12306; Carroll MA, 1997, ADV EXP MED BIOL, V407, P255; CUMMINGS B, 1999, TOXICOL SCI S, V48, pS96; Cummings BS, 1999, DRUG METAB DISPOS, V27, P542; DAIKH BE, 1994, J PHARMACOL EXP THER, V271, P1427; DEWAZIERS I, 1990, J PHARMACOL EXP THER, V253, P387; ESCALANTE B, 1993, EUR J PHARMACOL, V235, P1, DOI 10.1016/0014-2999(93)90812-V; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; FERGUSON NL, 1993, DRUG METAB DISPOS, V21, P745; Gibson GG, 1996, ANN NY ACAD SCI, V804, P328; Goasduff T, 1996, ALCOHOL, V13, P301, DOI 10.1016/0741-8329(95)02111-6; GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193; Haehner BD, 1996, MOL PHARMACOL, V50, P52; Harder DR, 1997, J VASC RES, V34, P237, DOI 10.1159/000159228; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HARDWICK JP, 1991, METHOD ENZYMOL, V206, P273; IMAOKA S, 1991, BIOCHIM BIOPHYS ACTA, V1074, P209, DOI 10.1016/0304-4165(91)90063-M; Imig JD, 1996, AM J PHYSIOL-REG I, V270, pR217, DOI 10.1152/ajpregu.1996.270.1.R217; IMIG JD, 1993, HYPERTENSION, V22, P357, DOI 10.1161/01.HYP.22.3.357; Ito O, 1998, AM J PHYSIOL-RENAL, V274, pF395, DOI 10.1152/ajprenal.1998.274.2.F395; Jin RY, 1998, ARCH BIOCHEM BIOPHYS, V359, P89, DOI 10.1006/abbi.1998.0880; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1990, FEBS LETT, V268, P227, DOI 10.1016/0014-5793(90)81014-F; KARARA A, 1993, J BIOL CHEM, V268, P13565; Kawashima H, 1997, ARCH BIOCHEM BIOPHYS, V347, P148, DOI 10.1006/abbi.1997.0342; LAETHEM RM, 1992, J BIOL CHEM, V267, P5552; LAETHEM RM, 1992, MOL PHARMACOL, V42, P958; Lasker JM, 1998, ARCH BIOCHEM BIOPHYS, V353, P16, DOI 10.1006/abbi.1998.0615; Luo G, 1998, ARCH BIOCHEM BIOPHYS, V357, P45, DOI 10.1006/abbi.1998.0806; MA XL, 1993, HEPATOLOGY, V18, P1247; MA YH, 1993, CIRC RES, V72, P126, DOI 10.1161/01.RES.72.1.126; Makita K, 1996, FASEB J, V10, P1456, DOI 10.1096/fasebj.10.13.8940291; MATSUBARA S, 1987, J BIOL CHEM, V262, P13366; MCGIFF JC, 1993, STEROIDS, V58, P573, DOI 10.1016/0039-128X(93)90098-8; MUERHOFF AS, 1989, J BIOL CHEM, V264, P749; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P902, DOI 10.1111/j.1530-0277.1994.tb00058.x; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Nowicki S, 1997, J CLIN INVEST, V99, P1224, DOI 10.1172/JCI119279; OKITA RT, 1979, BIOCHEM PHARMACOL, V28, P3385, DOI 10.1016/0006-2952(79)90077-7; OMATA K, 1992, AM J PHYSIOL, V262, pF591, DOI 10.1152/ajprenal.1992.262.4.F591; PALMER CNA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P161, DOI 10.1016/0167-4781(93)90285-L; Powell PK, 1996, ARCH BIOCHEM BIOPHYS, V335, P219, DOI 10.1006/abbi.1996.0501; Powell PK, 1998, J PHARMACOL EXP THER, V285, P1327; Powell WS, 1996, J PHARMACOL EXP THER, V276, P728; Rahman M, 1997, AM J HYPERTENS, V10, P356, DOI 10.1016/S0895-7061(96)00381-0; RAUCY JL, 1991, METHOD ENZYMOL, V206, P577; RAUCY JL, 1989, ARCH BIOCHEM BIOPHYS, V271, P270, DOI 10.1016/0003-9861(89)90278-6; RIFKIND AB, 1995, ARCH BIOCHEM BIOPHYS, V320, P380, DOI 10.1016/0003-9861(95)90023-3; ROMAN LJ, 1993, ARCH BIOCHEM BIOPHYS, V307, P57, DOI 10.1006/abbi.1993.1560; Ronis MJJ, 1998, BIOCHEM PHARMACOL, V55, P123, DOI 10.1016/S0006-2952(97)00381-X; SACERDOTI D, 1989, SCIENCE, V243, P388, DOI 10.1126/science.2492116; SACERDOTI D, 1988, BIOCHEM PHARMACOL, V37, P521, DOI 10.1016/0006-2952(88)90223-7; SAWAMURA A, 1993, BIOCHIM BIOPHYS ACTA, V1168, P30; SCHWARTZMAN ML, 1990, KIDNEY INT, V37, P94, DOI 10.1038/ki.1990.13; Schwartzman ML, 1996, NEPHRON, V73, P652; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; SHIMOJO N, 1993, BIOCHEM PHARMACOL, V46, P621, DOI 10.1016/0006-2952(93)90547-A; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stec DE, 1996, HYPERTENSION, V27, P1329, DOI 10.1161/01.HYP.27.6.1329; Stec DE, 1997, HYPERTENSION, V29, P315, DOI 10.1161/01.HYP.29.1.315; STROMSTEDT M, 1990, DNA CELL BIOL, V9, P569, DOI 10.1089/dna.1990.9.569; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3915; TSUTSUMI M, 1993, ARCH BIOCHEM BIOPHYS, V304, P209, DOI 10.1006/abbi.1993.1341; TSUTSUMI M, 1989, HEPATOLOGY, V10, P437, DOI 10.1002/hep.1840100407; Wang MH, 1999, AM J PHYSIOL-RENAL, V276, pF246, DOI 10.1152/ajprenal.1999.276.2.F246; Wang MH, 1996, ARCH BIOCHEM BIOPHYS, V336, P240, DOI 10.1006/abbi.1996.0554; Wang MH, 1998, J PHARMACOL EXP THER, V284, P966; Wu S, 1996, J BIOL CHEM, V271, P3460; YOSHIMURA R, 1990, J BIOCHEM, V108, P544, DOI 10.1093/oxfordjournals.jbchem.a123239; Zeldin DC, 1996, ARCH BIOCHEM BIOPHYS, V330, P87, DOI 10.1006/abbi.1996.0229; Zeldin DC, 1996, MOL PHARMACOL, V50, P1111; Zeldin DC, 1997, MOL PHARMACOL, V51, P931, DOI 10.1124/mol.51.6.931; Zou AP, 1996, HYPERTENSION, V27, P631, DOI 10.1161/01.HYP.27.3.631; ZOU AP, 1994, AM J PHYSIOL, V266, pF275, DOI 10.1152/ajprenal.1994.266.2.F275; ZOU AP, 1994, J PHARMACOL EXP THER, V268, P474; Zou AP, 1996, AM J PHYSIOL-REG I, V270, pR228, DOI 10.1152/ajpregu.1996.270.1.R228; ZOU AP, 1994, AM J PHYSIOL, V266, pF934, DOI 10.1152/ajprenal.1994.266.6.F934	82	243	255	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4118	4126		10.1074/jbc.275.6.4118	http://dx.doi.org/10.1074/jbc.275.6.4118			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	283RJ	10660572	hybrid			2022-12-25	WOS:000085288800056
J	Xiao, GZ; Jiang, D; Thomas, P; Benson, MD; Guan, KL; Karsenty, G; Franceschi, RT				Xiao, GZ; Jiang, D; Thomas, P; Benson, MD; Guan, KL; Karsenty, G; Franceschi, RT			MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBIC-ACID; IN-VIVO; OSTEOCALCIN GENE; MC3T3-E1 CELLS; GROWTH-FACTOR; FACTOR-BETA; EXPRESSION; KINASE; DIFFERENTIATION; MATRIX	The bone-specific transcription factor, Cbfa1, regulates expression of the osteocalcin (OCN) gene and is essential for bone formation. However, little is known about the mechanisms regulating Cbfa1 activity. This work examines the role of the MAPK pathway in regulating Cbfa1-dependent transcription. Stimulation of MAPK by transfecting a constitutively active form of MEK1, MEK(SP), into MC3T3-E1 preosteoblast cells increased endogenous OCN mRNA, while a dominant negative mutant, MEK(DN), was inhibitory. MEK(SP) also stimulated activity of a 147-base pair minimal OCN promoter, and this stimulation required an intact copy of OSE2, the DNA binding site for Cbfa1. Effects of MEK(SP) were specific to Cbfa1-positive osteoblast-like cells. A purified His-tagged Cbfa1 fusion protein was directly, phosphorylated by activated recombinant MAPK in vitro, Furthermore, P-32 metabolic labeling studies demonstrated that MEK(SP) clearly enhanced phosphorylation of Cbfa1 in intact cells, while MEK(DN) decreased phosphorylation. The specific MEK1/MER2 inhibitor, PD98059, inhibited extracellular matrix-dependent up-regulation of the OCN promoter, indicating that the MAPK pathway and, presumably, Cbfa1 phosphorylation are also required for responsiveness of osteoblasts to extracellular matrix signals. This study is the first demonstration that Cbfa1 is controlled by MAPKs and suggests that this pathway has an important role in the control of osteoblast-specific gene expression.	Univ Michigan, Dept Periodont Prevent & Geriatr, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Sch Med, Ann Arbor, MI 48109 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Baylor College of Medicine	Franceschi, RT (corresponding author), Univ Michigan, Dept Periodont Prevent & Geriatr, Sch Dent, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	rennyf@umich.edu	Benson, M. Douglas/L-9125-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011723, R01DE012211] Funding Source: NIH RePORTER; NICHD NIH HHS [T32-HD007505] Funding Source: Medline; NIDCR NIH HHS [DE12211, DE 11723] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; GERSTENFELD LC, 1987, DEV BIOL, V122, P49, DOI 10.1016/0012-1606(87)90331-9; GHOSHCHOUDHURY N, 1998, BONE, V23; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Mahmoodian F, 1996, ARCH BIOCHEM BIOPHYS, V336, P86, DOI 10.1006/abbi.1996.0535; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; RENKAWITZ R, 1979, MOL GEN GENET, V173, P1, DOI 10.1007/BF00267685; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOGARI A, 1995, JPN J PHARMACOL, V68, P255, DOI 10.1254/jjp.68.255; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103	39	468	499	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4453	4459		10.1074/jbc.275.6.4453	http://dx.doi.org/10.1074/jbc.275.6.4453			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660618	hybrid			2022-12-25	WOS:000085288800102
J	Yu, WH; Woessner, JF				Yu, WH; Woessner, JF			Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVOLUTING RAT UTERUS; PROGELATINASE-A; CELL-SURFACE; GLYCOSAMINOGLYCAN INTERACTIONS; TISSUE INHIBITORS; BINDING; COLLAGENASE; ACTIVATION; ENZYME; DEGRADATION	Many matrix metalloproteinases (MMPs) are tightly bound to tissues; matrilysin (MMP-7), although the smallest of the MMPs, is one of the most tightly bound. The most likely docking molecules for MMP-7 are heparan sulfate proteoglycans on or around epithelial cells and in the underlying basement membrane. This is established by extraction experiments and confocal microscopy, The enzyme is extracted from homogenates of postpartum rat uterus by heparin/heparan sulfate and by heparinase III treatment. The enzyme is colocalized with heparan sulfate in the apical region of uterine glandular epithelial cells and can be released by heparinase digestion. Heparan sulfate and MMP-7 are expressed at similar stages of the rat estrous cycle. The strength of heparin binding by recombinant rat proMMP-7 was examined by affinity chromatography, affinity coelectrophoresis, and homogeneous enzyme-based binding assay; the K-D, is 5-10 nM. Zymographic measurement of MMP-7 activity is greatly enhanced by heparin, Two putative heparin-binding peptides have been identified near the C- and N-terminal regions of proMMP-7; however, molecular modeling suggests a more extensive binding track or cradle crossing multiple peptide strands. Evidence is also found for the binding of MMP-2, -9, and -13. Binding of MMP-7 and other MMPs to heparan sulfate in the extracellular space could prevent loss of secreted enzyme, provide a reservoir of latent enzyme, and facilitate cellular sensing and regulation of enzyme levels. Binding to the cell surface could position the enzyme for directed proteolytic attack, for activation of or by other MMPs and for regulation of other cell surface proteins. Dislodging MMPs by treatment with compounds such as heparin might be beneficial in attenuating excessive tissue breakdown such as occurs in cancer metastasis, arthritis, and angiogenesis.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Woessner, JF (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, R-127,POB 106960, Miami, FL 33101 USA.	fwoessne@med.miami.edu	Yu, Wei Hsuan/AAF-7129-2021	YU, WEI-HSUAN/0000-0002-1782-3738	NIAMS NIH HHS [AR-16940] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016940, R37AR016940] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON SR, 1995, J BIOL CHEM, V270, P16016, DOI 10.1074/jbc.270.27.16016; Anees M, 1996, J ENZYM INHIB, V10, P203, DOI 10.3109/14756369609030314; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; BUSIEK DF, 1995, J IMMUNOL, V154, P6484; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; Celentano DC, 1997, J CLIN PHARMACOL, V37, P991, DOI 10.1002/j.1552-4604.1997.tb04278.x; Cha J, 1997, BIOCHEMISTRY-US, V36, P16019, DOI 10.1021/bi972223g; Cha JH, 1996, BIOCHEMISTRY-US, V35, P15831, DOI 10.1021/bi962085f; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chen WT, 1996, ENZYME PROTEIN, V49, P59, DOI 10.1159/000468616; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P14419, DOI 10.1021/bi00252a007; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; DEPREZ PN, 1995, BBA-PROTEIN STRUCT M, V1252, P53, DOI 10.1016/0167-4838(95)00109-8; GADHER SJ, 1990, MATRIX, V10, P154, DOI 10.1016/S0934-8832(11)80164-2; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Guo X, 1996, ANAL BIOCHEM, V235, P153, DOI 10.1006/abio.1996.0107; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Jeffrey JJ, 1998, HDB PROTEOLYTIC ENZY, P1167; KAO WWY, 1986, CURR EYE RES, V5, P801; Kolkenbrock H, 1996, BIOL CHEM, V377, P529, DOI 10.1515/bchm3.1996.377.7-8.529; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; MILSTONE LM, 1994, J CELL SCI, V107, P3183; NAGASE H, 1995, METHOD ENZYMOL, V248, P449; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagase H, 1997, BIOL CHEM, V378, P151; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; POTTER SW, 1992, ANAT REC, V234, P383, DOI 10.1002/ar.1092340308; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Rogachefsky R A, 1993, Osteoarthritis Cartilage, V1, P105, DOI 10.1016/S1063-4584(05)80025-1; ROSWIT WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P285, DOI 10.1016/0003-9861(83)90032-2; RudolphOwen LA, 1997, ENDOCRINOLOGY, V138, P4902, DOI 10.1210/en.138.11.4902; SAKAMOTO S, 1973, CALC TISS RES, V12, P247, DOI 10.1007/BF02013739; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; SELLERS A, 1980, BIOCHEM J, V189, P521, DOI 10.1042/bj1890521; SMITH JW, 1987, ANAL BIOCHEM, V160, P105, DOI 10.1016/0003-2697(87)90619-1; VATER CA, 1978, BIOCHIM BIOPHYS ACTA, V539, P238, DOI 10.1016/0304-4165(78)90010-7; Vyas AA, 1997, J BIOL CHEM, V272, P9661, DOI 10.1074/jbc.272.15.9661; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WEEKS JG, 1976, BIOCHIM BIOPHYS ACTA, V445, P205, DOI 10.1016/0005-2744(76)90173-X; WELGUS HG, 1980, J BIOL CHEM, V255, P6806; Wilson CL, 1998, BIOL EXTRAC, P149; WIRL G, 1977, CONNECT TISSUE RES, V5, P171, DOI 10.3109/03008207709152268; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YANG BH, 1993, J BIOL CHEM, V268, P8617	52	196	205	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4183	4191		10.1074/jbc.275.6.4183	http://dx.doi.org/10.1074/jbc.275.6.4183			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660581	hybrid			2022-12-25	WOS:000085288800065
J	Benmerah, A; Poupon, V; Cerf-Bensussan, N; Dautry-Varsat, A				Benmerah, A; Poupon, V; Cerf-Bensussan, N; Dautry-Varsat, A			Mapping of Eps15 domains involved in its targeting to clathrin-coated pits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; RECEPTOR-MEDIATED ENDOCYTOSIS; NERVE-TERMINALS; PROTEIN COMPLEX; BINDING DOMAIN; ADAPTER AP-2; SH3 DOMAIN; EH-DOMAIN; DYNAMIN; VESICLES	Clathrin-coated pit (CCP) formation occurs as a result of the targeting and assembly of cytosolic coat proteins, mainly the plasma membrane clathrin-associated protein complex (AP-2) and clathrin, to the intracellular face of the plasma membrane. In the present study, the mechanisms by which Eps15, an AP-a-binding protein, is targeted to CCPs was analyzed by following the intracellular localization of Eps15 mutants fused to the green fluorescent protein. Our previous results indicated that the N-terminal Eps15 homology (EH) domains are required for CCP targeting. We now show that EH domains are, however, not sufficient for targeting to CCPs, Similarly, neither the central coiled-coil nor the C-terminal AP-2 binding domains were able to address green fluorescent protein to CCPs, Thus, targeting of Eps15 to CCPs likely results from the collaboration between EM domains and another domain of the protein. An Eps15 mutant lacking the coiled-coil domain localized to CCPs showing that Eps15 dimerization is not strictly required. In contrast, Eps15 mutants lacking all AP-2 binding sites showed a dramatic decrease in plasma membrane staining, showing that AP-2 binding sites, together with EH domains, play an important role in targeting Eps15 into CCPs, Finally, the effect of the Eps15 mutants on clathrin-dependent endocytosis was tested by both immunofluorescence and flow cytometry, The results obtained showed that inhibition of transferrin uptake was observed only with mutants able to interfere with CCP assembly.	Fac Necker Enfants Malad, INSERM E9925, F-75730 Paris, France; Inst Pasteur, URA CNRS 1960, Unite Biol Interact Cellulaires, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Benmerah, A (corresponding author), Fac Necker Enfants Malad, INSERM E9925, 156 Rue de Vaugirard, F-75730 Paris 15, France.		benmerah, alexandre/H-3742-2017; Cerf-Bensussan, nadine/H-9505-2017	benmerah, alexandre/0000-0003-0188-8016; Cerf-Bensussan, nadine/0000-0003-0665-1245				Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Durrbach A, 1996, J CELL SCI, V109, P457; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GAIDAROV I, 1997, MOL BIOL CELL, V8, P92; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Iannolo G, 1997, CANCER RES, V57, P240; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lee A, 1999, CURR BIOL, V9, P261, DOI 10.1016/S0960-9822(99)80115-8; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; ROBINSON MS, 1993, J CELL BIOL, V123, P67, DOI 10.1083/jcb.123.1.67; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SCHRODER S, 1995, EUR J BIOCHEM, V228, P297, DOI 10.1111/j.1432-1033.1995.tb20263.x; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; WONG WT, 1994, ONCOGENE, V9, P1591; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	56	92	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3288	3295		10.1074/jbc.275.5.3288	http://dx.doi.org/10.1074/jbc.275.5.3288			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652316	hybrid			2022-12-25	WOS:000085146500038
J	Bezzine, S; Koduri, RS; Valentin, E; Murakami, M; Kudo, I; Ghomashchi, F; Sadilek, M; Lambeau, G; Gelb, MH				Bezzine, S; Koduri, RS; Valentin, E; Murakami, M; Kudo, I; Ghomashchi, F; Sadilek, M; Lambeau, G; Gelb, MH			Exogenously added human group X secreted phospholipase A(2) but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFACIAL CATALYSIS; ESCHERICHIA-COLI; SCOOTING MODE; VENOM PHOSPHOLIPASE-A2; LYSOPHOSPHATIDIC ACID; BILAYER INTERFACE; PHOSPHATIDIC-ACID; VESICLES; BINDING; EXPRESSION	Mammalian secreted phospholipases A(2) (sPLA2s) comprise a group of at least eight enzymes, including the recently identified group X sPLA2, A bacterial expression system was developed to produce human group X sPLA2 (hGX). Inhibition studies show that the sPLA2 inhibitor LY311727 binds modestly more tightly to human group IIA sPLA2 than to hGX and that a pyrazole-based inhibitor of group IIA sPLA2 is much less active against hGX. The phospholipid head group preference of vesicle-bound hGX was determined, hGX binds tightly to phosphatidylcholine vesicles, which is thought to be required to act efficiently on cells. Tryptophan 67 hGX makes a significant contribution to interfacial binding to zwitterionic vesicles. As little as 10 ng/ml hGX releases arachidonic acid for cyclooxygenase-2-dependent prostaglandin E-2 generation when added exogenously to adherent mammalian cells. In contrast, human group IIA, rat group V, and mouse group IB sPLA2s are virtually inactive at releasing arachidonate when added exogenously to adherent cells. Dislodging cells from the growth surface enhances the ability of all the sPLA2s to release fatty acids. Studies with CHO-K1 cell mutants show that binding of sPLA2s to glycosaminoglycans is not the basis for poor plasma membrane hydrolysis by group IB, IIA, and V sPLA2s.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France; Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Showa University	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.	gelb@chem.washington.edu	Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X; gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036235, R37HL036235, R01HL036235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36235] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atsumi G, 1997, BBA-LIPID LIPID MET, V1349, P43, DOI 10.1016/S0005-2760(97)00082-9; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BAYBURT T, 1996, THESIS U WASHINGTON; Christie W.W., 2003, LIPID ANAL; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DEGEUS P, 1987, NUCLEIC ACIDS RES, V15, P3743, DOI 10.1093/nar/15.9.3743; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; GELB MH, 1994, FASEB J, V8, P916, DOI 10.1096/fasebj.8.12.8088457; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; Goldberg, 1995, Fold Des, V1, P21; Hack CE, 1997, IMMUNOL TODAY, V18, P111, DOI 10.1016/S0167-5699(97)01002-5; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5740; HITE GA, Patent No. 846687; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAIN MK, 1982, BIOCHIM BIOPHYS ACTA, V688, P341, DOI 10.1016/0005-2736(82)90345-5; JAIN MK, 1987, BIOCHIM BIOPHYS ACTA, V905, P1, DOI 10.1016/0005-2736(87)90002-2; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P435, DOI 10.1016/0005-2736(86)90541-9; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JAIN MK, 1995, METHOD ENZYMOL, V249, P567; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V980, P23, DOI 10.1016/0005-2736(89)90195-8; JAIN MK, 1989, BIOCHEMISTRY-US, V28, P4135, DOI 10.1021/bi00436a002; Janssen MJW, 1999, BBA-MOL CELL BIOL L, V1440, P59, DOI 10.1016/S1388-1981(99)00122-5; JUNG L, IN PRESS J AM CHEM S; KACHEL K, 1995, BIOCHEMISTRY-US, V34, P15475, DOI 10.1021/bi00047a012; KIM HY, 1994, ANAL CHEM, V66, P3977, DOI 10.1021/ac00094a020; KINKAID A, 1991, BIOCHEM J, V278, P843, DOI 10.1042/bj2780843; KINKAID AR, 1995, BIOCHEM J, V308, P507, DOI 10.1042/bj3080507; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Othman R, 1996, BBA-LIPID LIPID MET, V1303, P92, DOI 10.1016/0005-2760(96)00083-5; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PETERS AR, 1992, BIOCHEMISTRY-US, V31, P10024, DOI 10.1021/bi00156a023; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; Sartipy P, 1996, J BIOL CHEM, V271, P26307, DOI 10.1074/jbc.271.42.26307; Sartipy P, 1998, ARTERIOSCL THROM VAS, V18, P1934, DOI 10.1161/01.ATV.18.12.1934; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SIHIZAKI J, 1999, J BIOL CHEM, V274, P24973; Snitko Y, 1999, BIOCHEMISTRY-US, V38, P7803, DOI 10.1021/bi990600e; Snitko Y, 1997, BIOCHEM J, V321, P737, DOI 10.1042/bj3210737; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; Wilson HA, 1999, J BIOL CHEM, V274, P11494, DOI 10.1074/jbc.274.17.11494; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; WORRALL AF, 1991, BIOCHEM J, V278, P365, DOI 10.1042/bj2780365	73	193	195	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3179	3191		10.1074/jbc.275.5.3179	http://dx.doi.org/10.1074/jbc.275.5.3179			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652303	hybrid			2022-12-25	WOS:000085146500025
J	Guerini, D; Wang, XQ; Li, L; Genazzani, A; Carafoli, E				Guerini, D; Wang, XQ; Li, L; Genazzani, A; Carafoli, E			Calcineurin controls the expression of isoform 4CII of the plasma membrane Ca2+ pump in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; PROTEIN PHOSPHATASE; GENE-EXPRESSION; CALCIUM-ATPASE; BINDING-PROTEIN; VACCINIA VIRUS; NMDA RECEPTOR; ACTIVATION; DOMAINS; ENZYME	The expression of the CII splice variant of the plasma membrane Ca2+ ATPase 4 (PMCA4) was down-regulated in granule neurons when they were cultured under conditions of partial membrane depolarization (25 mM KCl), which are required for long term in vitro survival of the neurons. These conditions, which cause a chronic increase of the resting free Ca2+ concentration in the neurons, have recently been shown to promote up-regulation of the PMCA2, 3, and 1CII isoforms, Whereas the chronic, i.e. >3 days, Ca2+ increase was necessary for the up-regulation of the PMCA1CII, 2, and 3, the downregulation of the PMCA4CII mRNA was already evident 1-2 h after the start of culturing in 25 mhz KCl, The immunosuppressant calcineurin inhibitor FK506 inhibited the down-regulation of the PMCA4CII at both the protein and the mRNA level but did not affect the changes of the other PMCA pumps, Direct evidence for the involvement of calcineurin in the down-regulation of the PMCA4CII was obtained by overexpressing a truncated, constitutively active, and Ca2+-independent form of calcineurin; under these conditions, depolarization was not required for the down-regulation of the PMCA4CII pump. De novo synthesis of (transcription) factors was required for the down-regulation of the PMCA4CII mRNA Calcineurin, therefore, controls the neuronal transcription of PMCA4CII, a splice variant of the pump isoforms that is found almost exclusively in brain.	Univ Padua, Inst Biochem, Dept Biochem, I-35121 Padua, Italy; Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland	University of Padua; Swiss Federal Institutes of Technology Domain; ETH Zurich	Carafoli, E (corresponding author), Univ Padua, Inst Biochem, Dept Biochem, Via Gabelli 65, I-35121 Padua, Italy.		Carafoli, Ernesto/K-5192-2016; Genazzani, Armando/AAI-8280-2020	Carafoli, Ernesto/0000-0002-7826-0094; Genazzani, Armando/0000-0003-1923-7430				Ashiya M, 1997, RNA, V3, P996; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BOYLE DB, 1988, GENE, V65, P123, DOI 10.1016/0378-1119(88)90424-6; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; CARMICHAEL J, 1987, CANCER RES, V47, P943; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; DRILLIEN R, 1983, VIROLOGY, V131, P385, DOI 10.1016/0042-6822(83)90506-8; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; Filoteo AG, 1997, J BIOL CHEM, V272, P23741, DOI 10.1074/jbc.272.38.23741; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; Fresu L, 1999, GLIA, V28, P150, DOI 10.1002/(SICI)1098-1136(199911)28:2<150::AID-GLIA6>3.3.CO;2-Z; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLO V, 1987, J NEUROSCI, V7, P2203; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; Guerini D, 1999, J BIOL CHEM, V274, P1667, DOI 10.1074/jbc.274.3.1667; Guerini D, 1998, CELL TISSUE RES, V292, P191, DOI 10.1007/s004410051050; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; KEETON TP, 1993, J BIOL CHEM, V268, P2740; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUO TH, 1991, J BIOL CHEM, V266, P2520; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seiz Preiano Brigitta, 1996, Biochemistry, V35, P7946, DOI 10.1021/bi9527404; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	46	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3706	3712		10.1074/jbc.275.5.3706	http://dx.doi.org/10.1074/jbc.275.5.3706			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652370	hybrid			2022-12-25	WOS:000085146500092
J	Mikhailov, MV; Ashcroft, SJH				Mikhailov, MV; Ashcroft, SJH			Interactions of the sulfonylurea receptor 1 subunit in the molecular assembly of beta-cell K-ATP channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; NUCLEOTIDE-BINDING FOLD; INSULIN-SECRETION; ANION TRANSPORT; INSECT CELLS; RECONSTITUTION; PROTEIN; COEXPRESSION; FRAGMENTS; MEMBRANE	We have investigated protein interactions involved in pancreatic beta-cell ATP-sensitive potassium channel assembly. These channels, which are of key importance for control of insulin release, are a hetero-oligomeric complex of pore-forming Kir6.2 subunits and sulfonylurea receptor (SUR1) subunits with two nucleotide-binding domains (NBD1 and NBD2), We divided SUR1 into two halves at Pro-1042, Expression of either the individual N- or C-terminal domain in a baculovirus expression system did not lead to glibenclamide binding activity, although studies with green fluorescent protein fusion proteins showed that both half-molecules were inserted into the plasma membrane, However, significant glibenclamide binding activity was observed when the half-molecules were co-expressed (even when NBD2 was deleted from the C-terminal half-molecule). Simultaneous expression of Kir6.2 resulted in enhanced glibenclamide binding activity. We conclude that the glibenclamide-binding site includes amino acid residues from both halves of the molecule, that there is strong interaction between different regions of SUR1, that NBD2 is not essential for glibenclamide binding, and that interactions between Kir6.2 and SUR1 participate in ATP-sensitive potassium channel assembly. Investigation of NBD1-green fluorescent protein fusion protein distribution inside insect cells expressing C-terminal halves of SUR1 demonstrated strong interaction between NBD1 and NBD2. We also expressed and purified NBD1 from Escherichia coli, Purified NBD1 was found to exist as a tetramer indicating strong homomeric attractions and a possible role for NBD1 in SUR1 assembly.	John Radcliffe Hosp, Nuffield Dept Clin Biochem, Oxford OX3 9DU, England	University of Oxford	Mikhailov, MV (corresponding author), John Radcliffe Hosp, Nuffield Dept Clin Biochem, Oxford OX3 9DU, England.							AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1989, COLLOQ INSE, V198, P99; ASHCROFT SJH, 1993, ADV EXP MED BIOL, V334, P47; Ashfield R, 1999, DIABETES, V48, P1341, DOI 10.2337/diabetes.48.6.1341; Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COPE DL, 1994, BIOCHEM J, V300, P291, DOI 10.1042/bj3000291; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; Giblin JP, 1999, J BIOL CHEM, V274, P22652, DOI 10.1074/jbc.274.32.22652; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; GROVES JD, 1995, J BIOL CHEM, V270, P9097, DOI 10.1074/jbc.270.16.9097; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LOO TW, 1994, J BIOL CHEM, V269, P7750; Lorenz E, 1998, MOL CELL BIOL, V18, P1652, DOI 10.1128/MCB.18.3.1652; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; Makhina EN, 1998, J BIOL CHEM, V273, P3369, DOI 10.1074/jbc.273.6.3369; Mikhailov MV, 1998, FEBS LETT, V429, P390, DOI 10.1016/S0014-5793(98)00640-1; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NIKI I, 1989, PFLUG ARCH EUR J PHY, V415, P47, DOI 10.1007/BF00373140; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; Possee RD., 1992, BACULOVIRUS EXPRESSI; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Thomas PM, 1996, AM J HUM GENET, V59, P510; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang L, 1997, J BIOL CHEM, V272, P10631	35	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3360	3364		10.1074/jbc.275.5.3360	http://dx.doi.org/10.1074/jbc.275.5.3360			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652326	hybrid			2022-12-25	WOS:000085146500048
J	Yam, CH; Siu, WY; Lau, A; Poon, RYC				Yam, CH; Siu, WY; Lau, A; Poon, RYC			Degradation of cyclin a does not require its phosphorylation by CDC2 and cyclin-dependent kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; UBIQUITIN-LIGASE COMPLEX; F-BOX PROTEIN; MAMMALIAN-CELLS; NUCLEAR EXPORT; SACCHAROMYCES-CEREVISIAE; PROTEASOME PATHWAY; RAPID DEGRADATION; REGULATED BINDING; GENE-EXPRESSION	Many cyclins are degraded by the ubiquitination/proteasome pathways involving the anaphase-promoting complex and SCF complexes. These degradations are frequently dependent on phosphorylation by cyclin-dependent kinases (CDKs), providing a self-limiting mechanism for CDK activity, Here we present evidence from in vitro and in vivo assay systems that the degradation of human cyclin A can be inhibited by kinase-inactive mutants of CDK2 and CDC2, One obvious interpretation of these results is that like other cyclins, CDK-dependent phosphorylation of the cyclin A may be involved in cyclin A degradation. Our data indicated that CDK2 can phosphorylate cyclin A on Ser-154. Site-directed mutagenesis of Ser-154 abolished the phosphorylation by recombinant CDK2 in vitro and the majority of cyclin A phosphorylation in the cell. Activation of CDK2 and binding to SKP2 or p27(KIP1) were not affected by the phosphorylation of Ser-154. Surprising, in marked contrast to cyclin E, where phosphorylation of Thr-380 by CDK2 is required for proteolysis, degradation of cyclin A was not affected by Ser-154 phosphorylation. It is likely that the stabilization of cyclin A by the kinase-inactive CDKs was mainly due to a cell cycle effect. These data suggest an important difference between the regulation of cyclin A and cyclin E.	Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Peoples R China.	bcrandy@ust.hk		Poon, Randy/0000-0001-5571-6231				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Funakoshi M, 1999, EMBO J, V18, P5009, DOI 10.1093/emboj/18.18.5009; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Poon RYC, 1997, CANCER RES, V57, P5168; POON RYC, 1996, ENCY CANC, P246; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; VANDERGEER P, 1994, CELL BIOL LAB HDB, P422; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yamano H, 1998, EMBO J, V17, P5670, DOI 10.1093/emboj/17.19.5670; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	55	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3158	3167		10.1074/jbc.275.5.3158	http://dx.doi.org/10.1074/jbc.275.5.3158			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652300	hybrid			2022-12-25	WOS:000085146500022
J	Park, HS; Park, E; Kim, MS; Ahn, K; Kim, IY; Choi, EJ				Park, HS; Park, E; Kim, MS; Ahn, K; Kim, IY; Choi, EJ			Selenite inhibits the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) through a thiol redox mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL-TRANSDUCTION; NITRIC-OXIDE; CYSTEINE RESIDUES; MAMMALIAN-CELLS; DNA-BINDING; STRESS; TRANSCRIPTION; JNK; APOPTOSIS	Selenium, an essential biological trace element, has been shown to modulate functions of many regulatory proteins involved in signal transduction and to affect a variety of cellular activities including cell growth, survival, and death. The molecular mechanism by which selenium exerts its action on the cellular events, however, remains unclear. In our present study, we observed that selenite suppresses both the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and the p38 mitogen-activated protein kinase pathway in 293T cells. In contrast, selenite had little effect on the extracellular signal-regulated kinase pathway. Furthermore, selenite directly inhibited JNK/SAPK activity in vitro but not the p38 activity. The in vitro inhibition of JNK/SAPK by selenite was reversed by the addition of reducing agents such as dithiothreitol and beta-mercapto-ethanol. Replacement of cysteine 116 in JNK1 by serine abolished the inhibitory effect of selenite on JNK1 activity both in vitro and in vivo. Selenite also suppressed a c-Jun-dependent luciferase reporter activity stimulated through the JNK signaling pathway. Taken together, our findings strongly suggest that selenite differentially modulates the mammalian mitogen-activated protein kinase pathways and that it can repress the JNK/SAPK signaling pathway by inhibiting JNK/SAPK through a thiol redox mechanism.	Korea Univ, Grad Sch Biotechnol, Sungbuk Ku, Seoul 136701, South Korea; Korea Univ, Natl Creat Res Initiat Ctr Cell Death, Sungbuk Ku, Seoul 136701, South Korea	Korea University; Korea University	Choi, EJ (corresponding author), Korea Univ, Grad Sch Biotechnol, Sungbuk Ku, Seoul 136701, South Korea.							BERGAD PL, 1986, CURR EYE RES, V5, P919, DOI 10.3109/02713688608995172; BOREK C, 1986, P NATL ACAD SCI USA, V83, P1490, DOI 10.1073/pnas.83.5.1490; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; Duhe RJ, 1998, P NATL ACAD SCI USA, V95, P126, DOI 10.1073/pnas.95.1.126; FAKHRUL I, 1991, ARCH BIOCHEM BIOPHYS, V289, P161; Gather H. E., 1968, BIOCHEMISTRY-US, V7, P2898; GATHER HE, 1969, BIOCHEMISTRY-US, V8, P2557; Gopalakrishna R, 1997, ARCH BIOCHEM BIOPHYS, V348, P37, DOI 10.1006/abbi.1997.0335; GREEDER GA, 1980, SCIENCE, V209, P825, DOI 10.1126/science.7406957; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANDEL ML, 1995, P NATL ACAD SCI USA, V92, P4497, DOI 10.1073/pnas.92.10.4497; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kim H, 1997, BIOCHEMISTRY-US, V36, P13677, DOI 10.1021/bi970837f; Kim IY, 1997, P NATL ACAD SCI USA, V94, P12904, DOI 10.1073/pnas.94.24.12904; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEDINA D, 1984, CANCER RES, V44, P4361; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MORGAN NJ, 1991, ANNU REV NEUROSCI, V14, P421; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; PHELPS DC, 1981, BIOCHEMISTRY-US, V20, P453, DOI 10.1021/bi00506a001; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROTRUCK JT, 1972, J NUTR, V102, P689, DOI 10.1093/jn/102.5.689; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHAMBERGER RJ, 1985, MUTAT RES, V154, P29, DOI 10.1016/0165-1110(85)90008-9; SHARMA S, 1994, CANCER RES, V54, P5848; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SPYROU G, 1995, FEBS LETT, V368, P59, DOI 10.1016/0014-5793(95)00599-5; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Stapleton SR, 1997, BBA-MOL CELL RES, V1355, P259, DOI 10.1016/S0167-4889(96)00140-1; TASHIMA Y, 1989, J BIOCHEM-TOKYO, V105, P358, DOI 10.1093/oxfordjournals.jbchem.a122668; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798	46	99	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2527	2531		10.1074/jbc.275.4.2527	http://dx.doi.org/10.1074/jbc.275.4.2527			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644709	hybrid			2022-12-25	WOS:000085128000041
J	Rui, LY; Archer, SF; Argetsinger, LS; Carter-Su, C				Rui, LY; Archer, SF; Argetsinger, LS; Carter-Su, C			Platelet-derived growth factor and lysophosphatidic acid inhibit growth hormone binding and signaling via a protein kinase C-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTED TYROSYL PHOSPHORYLATION; MESSENGER-RIBONUCLEIC-ACID; ADULT-RAT HEPATOCYTES; GH-BINDING; INSULIN-RECEPTOR; SKELETAL-MUSCLE; TRANSCRIPTION FACTOR; TISSUE DISTRIBUTION; PRIMARY CULTURES; GENE-EXPRESSION	Growth hormone (GH) regulates body growth and metabolism. GH exerts its biological action by stimulating JAK2, a GH receptor (GHR)-associated tyrosine kinase. Activated JAK2 phosphorylates itself and GHR, thus initiating multiple signaling pathways. In this work, we demonstrate that platelet-derived growth factor (PDGF) and lysophosphatidic acid (LPA) down-regulate GH signaling via a protein kinase C (PKC)-dependent pathway. PDGF substantially reduces tyrosyl phosphorylation of JAK2 induced by GH but not interferon-gamma or leukemia inhibitory factor. PDGF, but not epidermal growth factor, decreases tyrosyl phosphorylation of GHR (by approximately 90%) and the amount of both total cellular GHR (by approximately 80%) and GH binding (by approximately 70%). The inhibitory effect of PDGF on GH-induced tyrosyl phosphorylation of JAK2 and GHR is abolished by depletion of 4 beta-phorbol 12-myristate 13-acetate (PMA)-sensitive PKCs with chronic PMA treatment and is severely inhibited by GF109203X, an inhibitor of PKCs. In contrast, extracellular signal-regulated kinases I and 2 and phosphatidylinositol S-kinase appear not to be involved in this inhibitory effect of PDGF. LPA, a known activator of PKC, also inhibits GH-induced tyrosyl phosphorylation of JAK2 and GHR and reduces the number of GHR. We propose that ligands that activate PKC, including PDGF, LPA, and PMA, down-regulate GH signaling by decreasing the number of cell surface GHR through promoting GHR internalization and degradation and/or cleavage of membrane GHR and release of the extracellular domain of GHR.	Univ Michigan, Dept Physiol, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Carter-Su, C (corresponding author), Univ Michigan, Dept Physiol, Sch Med, Ann Arbor, MI 48109 USA.	cartersu@umich.edu			NICHD NIH HHS [P30 HD 18258] Funding Source: Medline; NIDDK NIH HHS [R01 DK034171, DK 34171] Funding Source: Medline; NIGMS NIH HHS [GM07315] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD018258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R37DK034171] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht DE, 1997, J BIOL CHEM, V272, P2236; Alele J, 1998, ENDOCRINOLOGY, V139, P1927, DOI 10.1210/en.139.4.1927; ALPERS CE, 1993, KIDNEY INT, V43, P286, DOI 10.1038/ki.1993.45; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; Barnard R, 1997, J ENDOCRINOL, V153, P1, DOI 10.1677/joe.0.1530001; BAUMANN G, 1994, J ENDOCRINOL, V141, P1, DOI 10.1677/joe.0.1410001; BAUMANN G, 1988, ENDOCRINOLOGY, V122, P976, DOI 10.1210/endo-122-3-976; BURTON KA, 1992, ENDOCRINOLOGY, V131, P958, DOI 10.1210/en.131.2.958; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CARTERSU C, 1997, J ANIM S2, V75, P1; CHIN E, 1992, ENDOCRINOLOGY, V131, P3061, DOI 10.1210/en.131.6.3061; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Clark RG, 1996, ENDOCRINOLOGY, V137, P4308, DOI 10.1210/en.137.10.4308; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; GRONLUND L, 1995, ISSUES SCI TECHNOL, V11, P9; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; GULLER S, 1989, ENDOCRINOLOGY, V125, P2360, DOI 10.1210/endo-125-5-2360; HANSEN BS, 1993, ENDOCRINOLOGY, V133, P2809, DOI 10.1210/en.133.6.2809; HERNDON DN, 1995, ANN SURG, V221, P649, DOI 10.1097/00000658-199506000-00004; HOCK JM, 1994, ENDOCRINOLOGY, V134, P1423, DOI 10.1210/en.134.3.1423; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Hu YH, 1998, MOL BRAIN RES, V53, P251, DOI 10.1016/S0169-328X(97)00306-9; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Kimura M, 1998, JPN J PHARMACOL, V76, P165, DOI 10.1254/jjp.76.165; Kimura M, 1998, BIOL PHARM BULL, V21, P22; King APJ, 1996, J BIOL CHEM, V271, P18088, DOI 10.1074/jbc.271.30.18088; LIM L, 1990, ENDOCRINOLOGY, V127, P1287, DOI 10.1210/endo-127-3-1287; LINDAHL A, 1987, J ENDOCRINOL, V115, P263, DOI 10.1677/joe.0.1150263; MANNOR DA, 1991, J CLIN ENDOCR METAB, V73, P30, DOI 10.1210/jcem-73-1-30; MAOR G, 1989, ENDOCRINOLOGY, V125, P1239, DOI 10.1210/endo-125-3-1239; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MERTANI HC, 1995, MOL CELL ENDOCRINOL, V109, P47, DOI 10.1016/0303-7207(95)03485-P; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NIXON BT, 1984, P NATL ACAD SCI-BIOL, V81, P3429, DOI 10.1073/pnas.81.11.3429; NIXON T, 1983, J CELL PHYSIOL, V115, P291, DOI 10.1002/jcp.1041150312; Ohlsson C, 1998, EUR J CLIN INVEST, V28, P184; Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SADEGHI H, 1990, MOL ENDOCRINOL, V4, P1799, DOI 10.1210/mend-4-12-1799; Seewald S, 1999, AM J HYPERTENS, V12, P532, DOI 10.1016/S0895-7061(98)00269-6; Shoba L, 1999, MOL CELL ENDOCRINOL, V152, P125, DOI 10.1016/S0303-7207(99)00045-3; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; SMITH JC, 1981, P NATL ACAD SCI-BIOL, V78, P4363, DOI 10.1073/pnas.78.7.4363; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; SOTIROPOULOS A, 1993, ENDOCRINOLOGY, V132, P1863, DOI 10.1210/en.132.4.1863; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; STROBL JS, 1994, PHARMACOL REV, V46, P1; SUZUKI K, 1990, J BIOL CHEM, V265, P11320; TIDBALL JG, 1993, J CELL BIOL, V123, P627, DOI 10.1083/jcb.123.3.627; TIONG TS, 1991, ENDOCRINOLOGY, V129, P1628, DOI 10.1210/endo-129-3-1628; TIONG TS, 1989, BIOCHEM BIOPH RES CO, V158, P141, DOI 10.1016/S0006-291X(89)80189-5; Tritos NA, 1998, AM J MED, V105, P44, DOI 10.1016/S0002-9343(98)00135-1; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; VANZOELEN EJJ, 1993, GROWTH FACTORS, V9, P329, DOI 10.3109/08977199308991593; Waters MJ., 1999, HDB PHYSL, P397; Windisch PA, 1998, ANN PHARMACOTHER, V32, P437, DOI 10.1345/aph.17255; YABLONKAREUVENI Z, 1990, J CELL BIOL, V111, P1623, DOI 10.1083/jcb.111.4.1623; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; ZHANG Y, 1999, P 81 ANN M END SOC S, P154	76	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2885	2892		10.1074/jbc.275.4.2885	http://dx.doi.org/10.1074/jbc.275.4.2885			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644756	hybrid			2022-12-25	WOS:000085128000088
J	Glick, E; Leshkowitz, D; Walker, MD				Glick, E; Leshkowitz, D; Walker, MD			Transcription factor BETA2 acts cooperatively with E2A and PDX1 to activate the insulin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; PANCREATIC-ISLET CELLS; BINDING PROTEINS; MAMMALIAN-CELLS; HOMEOBOX FACTOR; FACTOR STF-1; EXPRESSION; DNA; MYOD; HOMEODOMAIN	The insulin gene is efficiently expressed only in pancreatic beta cells. Using reverse transcriptase-polymerase chain reaction analysis, we show that insulin mRNA levels are at least 10(5)-fold higher in beta cells than non-beta cells. To examine the underlying mechanisms, we expressed beta cell transcription factors by transfection of non-beta cells. Separate expression of BETA2, E2A or PDX1 led to modest (<10-fold) activation of the insulin promoter, whereas co-expression of the three proteins produced synergistic, high level activation (160-fold), This level of activity is similar to 25% that observed in transfected beta cell lines. Of the three factors studied, BETA2 appears to play a dominant role. Efficient transcription required a C-terminal activation domain of BETA2 and an N-terminal region, which does not function as an independent activation domain, The myogenic basic helix-loop-helix (bHLH) protein MyoD was unable to bind and activate the promoter, even when its DNA binding region was replaced with that of BETA2. Our results demonstrate the central importance of BETA2 in insulin gene transcription and the importance of sequences outside the canonical DNA binding domain in permitting efficient DNA binding and cell-specific activity of the insulin gene promoter.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Walker, MD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	m.walker@weizmann.ac.il						ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; AUSDUBEL FM, 1988, CURRENT PROTOCOLS MO; BESNARD C, 1991, J CELL PHYSIOL, V146, P349, DOI 10.1002/jcp.1041460303; Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEAN M, 1995, AM J HUM GENET, V57, P1254; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Huang J, 1998, MOL CELL BIOL, V18, P5478, DOI 10.1128/MCB.18.9.5478; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LESHKOWITZ D, 1991, MOL CELL BIOL, V11, P1547, DOI 10.1128/MCB.11.3.1547; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MURRE C, 1994, BIOCHIM BIOPHYS ACTA, V1215, P129; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PARK CW, 1992, J BIOL CHEM, V267, P15642; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Ptashne M, 1998, CURR BIOL, V8, pR812, DOI 10.1016/S0960-9822(07)00508-8; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; Sharma A, 1999, MOL CELL BIOL, V19, P704; St-Onge L, 1999, CURR OPIN GENET DEV, V9, P295, DOI 10.1016/S0959-437X(99)80044-6; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Yin DX, 1996, ANAL BIOCHEM, V235, P195, DOI 10.1006/abio.1996.0112	42	100	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2199	2204		10.1074/jbc.275.3.2199	http://dx.doi.org/10.1074/jbc.275.3.2199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636926	hybrid			2022-12-25	WOS:000084940000089
J	Iaccarino, I; Marra, G; Dufner, P; Jiricny, J				Iaccarino, I; Marra, G; Dufner, P; Jiricny, J			Mutation in the magnesium binding site of hMSH6 disables the hMutS alpha sliding clamp from translocating along DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SECA; MUTS-ENCODED PROTEIN; MISMATCH REPAIR; ATPASE; CELLS; IDENTIFICATION; RECOMBINATION; HETERODIMER; MECHANISM; MOTIF	In human cells, binding of base/base mismatches and small insertion/deletion loops is mediated by hMutS alpha, a heterodimer of hMSH2 and hMSH6, In the presence of ATP and magnesium, hMutS alpha dissociates from the mismatch by following the DNA contour in the form of a sliding clamp. This process is enabled by a conformational change of the heterodimer, which is driven by the binding of ATP and magnesium in the Walker type A and B motifs of the polypeptides, respectively. We show that a purified recombinant hMutS alpha variant, hMuts alpha 6DV, which contains an aspartate to valine substitution in the Walker type B motif of the hMSH6 subunit, fails to undergo the conformational change compatible with trans location. Instead, its direct dissociation from the mismatch-containing DNA substrate in the presence of ATP and magnesium precludes the assembly of a functional mismatch repair complex. The "translocation-prone" conformation of wild type hMutS alpha could be observed solely under conditions that favor hydrolysis of the nucleotide and mismatch repair in vitro. Thus, whereas magnesium could be substituted with manganese, ATP could not be replaced with its slowly or nonhydrolyzable homologues ATP-gamma S or AMPPNP, respectively. The finding that ATP induces different conformational changes in hMutS alpha in the presence and in the absence of magnesium helps explain the functional differences between hMutS alpha variants incapable of binding ATP as compared with those unable to bind the metal ion.	Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland; Paul Scherrer Inst, CH-8008 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Jiricny, J (corresponding author), Univ Zurich, Inst Med Radiobiol, August Forel Str 7, CH-8008 Zurich, Switzerland.		Iaccarino, Ingram/B-9086-2015	Iaccarino, Ingram/0000-0001-7324-993X				Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 1999, J BIOL CHEM, V274, P16115, DOI 10.1074/jbc.274.23.16115; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eisen JA, 1998, NUCLEIC ACIDS RES, V26, P4291, DOI 10.1093/nar/26.18.4291; GORBALENYA AE, 1990, J MOL BIOL, V213, P583, DOI 10.1016/S0022-2836(05)80243-8; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Pal E.F., 1989, NATURE, V341, P209; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Sato K, 1996, J BIOL CHEM, V271, P17439, DOI 10.1074/jbc.271.29.17439; Studamire B, 1998, MOL CELL BIOL, V18, P7590, DOI 10.1128/MCB.18.12.7590; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; VANDERWOLK JPW, 1995, J BIOL CHEM, V270, P18975, DOI 10.1074/jbc.270.32.18975	29	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2080	2086		10.1074/jbc.275.3.2080	http://dx.doi.org/10.1074/jbc.275.3.2080			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636912	hybrid			2022-12-25	WOS:000084940000075
J	Koziak, K; Kaczmarek, E; Kittel, A; Sevigny, J; Blusztajn, JK; Esch, JSA; Imai, M; Guckelberger, O; Goepfert, C; Qawi, I; Robson, SC				Koziak, K; Kaczmarek, E; Kittel, A; Sevigny, J; Blusztajn, JK; Esch, JSA; Imai, M; Guckelberger, O; Goepfert, C; Qawi, I; Robson, SC			Palmitoylation targets CD39/endothelial ATP diphosphohydrolase to caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; FATTY-ACIDS; PLASMALEMMAL CAVEOLAE; SIGNAL-TRANSDUCTION; CELL ACTIVATION; NERVOUS-SYSTEM; CD39; PROTEINS; CLONING; IDENTIFICATION	Ectonucleotidases influence purinergic receptor function by the hydrolysis of extracellular nucleotides, CD39 is an integral membrane protein that is a prototype member of the nucleoside 5'-triphosphate diphosphohydrolase family. The native CD39 protein has two intracytoplasmic and two transmembrane domains. There is a large extracellular domain that undergoes extensive glycosylation and can be post-translationally modified by limited proteolysis, We have identified a potential thioester linkage site for S-acylation within the N-terminal region of CD39 and demonstrate that this region undergoes palmitoylation in a constitutive manner. The covalent lipid modification of this region of the protein appears to be important both in plasma membrane association and in targeting CD39 to caveolae. These specialized plasmalemmal domains are enriched in G protein-coupled receptors and appear to integrate cellular activation events. We suggest that palmitoylation could modulate the function of CD39 in regulating cellular signal transduction pathways.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Ctr Immunobiol, Boston, MA 02215 USA; Hungarian Acad Sci, H-1450 Budapest, Hungary; Boston Univ, Sch Med, Boston, MA 02118 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Hungarian Academy of Sciences; Boston University	Robson, SC (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Ctr Immunobiol, Rm 370 H,Res N,99 Brookline Ave, Boston, MA 02215 USA.	grobson@caregroup.harvard.edu	Esch, Jan Schulte am/AAL-9904-2021; Robson, Simon C./AAA-8537-2021; Sévigny, Jean/AGH-9323-2022; Sevigny, Jean/E-8039-2012; Koziak, Katarzyna/V-2323-2019	Esch, Jan Schulte am/0000-0002-2101-5012; Sévigny, Jean/0000-0003-2922-1600; Sevigny, Jean/0000-0003-2922-1600; /0000-0001-8438-3122	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL57307] Funding Source: Medline; NIA NIH HHS [P01 AG09525] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BIZZOZERO OA, 1994, NEUROCHEM RES, V19, P923, DOI 10.1007/BF00968702; Chadwick BP, 1998, GENOMICS, V50, P357, DOI 10.1006/geno.1998.5317; Chadwick BP, 1997, MAMM GENOME, V8, P668, DOI 10.1007/s003359900534; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Esch JSA, 1999, BIOCHEMISTRY-US, V38, P2248, DOI 10.1021/bi982426k; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Joseph M, 1997, INDIAN J BIOCHEM BIO, V34, P1; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kittel A, 1999, BIOCHEM BIOPH RES CO, V262, P596, DOI 10.1006/bbrc.1999.1254; Koziak K, 1999, THROMB HAEMOSTASIS, V82, P1538; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; MARCUS AJ, 1996, ATHEROSCLEROSIS CORO, V1, P607; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; Mulero JJ, 1999, J BIOL CHEM, V274, P20064, DOI 10.1074/jbc.274.29.20064; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; PATTERSON SI, 1994, J CELL BIOL, V124, P521, DOI 10.1083/jcb.124.4.521; Robson SC, 1997, J EXP MED, V185, P153, DOI 10.1084/jem.185.1.153; Robson SC, 1997, BLOOD COAGUL FIBRIN, V8, P21, DOI 10.1097/00001721-199701000-00005; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Smith TM, 1998, BBA-PROTEIN STRUCT M, V1386, P65, DOI 10.1016/S0167-4838(98)00063-6; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Tao NB, 1996, J BIOL CHEM, V271, P22315, DOI 10.1074/jbc.271.37.22315; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang TF, 1998, J BIOL CHEM, V273, P24814, DOI 10.1074/jbc.273.38.24814; Zimmermann H, 1998, NEUROCHEM INT, V32, P421, DOI 10.1016/S0197-0186(97)00126-5; Zimmermann H, 1999, TRENDS PHARMACOL SCI, V20, P231, DOI 10.1016/S0165-6147(99)01293-6	39	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2057	2062		10.1074/jbc.275.3.2057	http://dx.doi.org/10.1074/jbc.275.3.2057			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636909	hybrid			2022-12-25	WOS:000084940000072
J	Reardon, AJ; Le Goff, M; Briggs, MD; McLeod, D; Sheehan, JK; Thornton, DJ; Bishop, PN				Reardon, AJ; Le Goff, M; Briggs, MD; McLeod, D; Sheehan, JK; Thornton, DJ; Bishop, PN			Identification in vitreous and molecular cloning of opticin, a novel member of the family of leucine-rich repeat proteins of the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; COLLAGEN FIBRILLOGENESIS; MONOCLONAL-ANTIBODIES; SKIN FRAGILITY; DECORIN; CORNEAL; BINDING; LUMICAN; BONE; FIBROMODULIN	A prominent 45-kDa component was identified by protein staining following SDS-polyacrylamide gel electrophoresis of a 4 M guanidine hydrochloride extract from bovine vitreous collagen fibrils, Peptide sequences obtained from this component were used as a basis for the cloning (from human retinal cDNA) and sequencing of a novel member of the leucine-rich repeat extracellular matrix protein family that we have named opticin. Opticin mRNA was found by reverse transcription polymerase chain reaction in ligament and skin as well as in retina. An open reading frame containing 332 amino acids was identified, the first 19 amino acids representing a signal peptide. The deduced amino acid sequence of the mature protein encodes a 35-kDa protein with a calculated isoelectric point of 5.4. The central domain of this protein consists of six B-type leucine-rich repeats. This domain is flanked by cysteine clusters including a C-terminal two-cysteine cluster containing an additional leucine-rich repeat. The N-terminal region contains a cluster of potential O-glycosylation sites, and analysis of bovine vitreous opticin demonstrated the presence of sialylated O-linked oligosaccharides substituting the core protein. Opticin shows highest protein sequence identity to epiphycan (42%) and osteoglycin (35%) and belongs to Class III of the leucine-rich repeat extracellular matrix protein family.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Manchester Royal Eye Hosp, Sch Med, Res Grp Eye & Vis Sci, Manchester M13 9WH, Lancs, England	University of Manchester; Manchester Royal Eye Hospital; University of Manchester	Bishop, PN (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Room 2-14,Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Thornton, David/0000-0001-7148-1970; Bishop, Paul/0000-0001-7937-7932				BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; Bishop P, 1996, EYE, V10, P664, DOI 10.1038/eye.1996.159; BISHOP PN, 1994, BIOCHEM J, V299, P497, DOI 10.1042/bj2990497; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; CATERSON B, 1985, FED PROC, V44, P386; CATERSON B, 1983, J BIOL CHEM, V258, P8848; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FOOS RY, 1982, OPHTHALMOLOGY, V89, P1502; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Johnson HJ, 1997, J BIOL CHEM, V272, P18709, DOI 10.1074/jbc.272.30.18709; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; MCLEOD D, 1977, T OPHTHAL SOC UK, V97, P225; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Reardon A, 1998, MATRIX BIOL, V17, P325, DOI 10.1016/S0945-053X(98)90085-3; SEBAG J, 1989, INVEST OPHTH VIS SCI, V30, P1867; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Snead MP, 1999, J MED GENET, V36, P353; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839; Wilkin DJ, 1998, AM J MED GENET, V80, P121, DOI 10.1002/(SICI)1096-8628(19981102)80:2<121::AID-AJMG6>3.3.CO;2-D	34	83	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2123	2129		10.1074/jbc.275.3.2123	http://dx.doi.org/10.1074/jbc.275.3.2123			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636917	hybrid			2022-12-25	WOS:000084940000080
J	Ishidate, T; Matsumine, A; Toyoshima, K; Akiyama, T				Ishidate, T; Matsumine, A; Toyoshima, K; Akiyama, T			The APC-hDLG complex negatively regulates cell cycle progression from the G0/G1 to S phase	ONCOGENE			English	Article						APC; hDLG; cell cycle; tumor suppressor	TUMOR-SUPPRESSOR PROTEIN; WNT SIGNALING PATHWAY; ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN; HUMAN HOMOLOG; DISCS LARGE; POSTSYNAPTIC DENSITY; GENE-PRODUCT; INTERACTS; AXIN	The adenomatous polyposis coli (APC) gene is mutated in familial adenomatous polyposis and in many sporadic colorectal tumors. The carboxyl-terminal S/TXV motif of the APC gene product interacts with the PDZ domain of hDLG, the human homolog of the Drosophila lethal (I) discs large-1 (dlg) tumor suppressor. In the present study, we found that overexpression of hDLG suppresses cell proliferation by blocking cell cycle progression from the G0/G1 to S phase. This inhibition of cell cycle progression was abolished when the PDZ, SH3 or guanylate kinase-like domain of hDLG was mutated. Moreover, overexpression of these mutant hDLGs partially interfered with the cell cycle blocking activity of APC. Consistent with this result, mutant APC lacking the S/TXV motif exhibited weaker cell cycle blocking activity than the intact APC, These results suggest that APC-hDLG complex formation plays an important role in transducing the APC cell cycle blocking signal.	Univ Tokyo, Dept Mol & Genet Informat, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan; Osaka Univ, Dept Oncogene Res, Inst Microbial Dis, Suita, Osaka 565, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Higashinari Ku, Osaka 537, Japan	University of Tokyo; Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases	Akiyama, T (corresponding author), Univ Tokyo, Dept Mol & Genet Informat, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.							BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Pedemonte S, 1998, GENE CHROMOSOME CANC, V22, P257, DOI 10.1002/(SICI)1098-2264(199808)22:4<257::AID-GCC1>3.0.CO;2-U; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; STEWART M, 1972, DEV BIOL, V27, P71, DOI 10.1016/0012-1606(72)90113-3; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867	36	155	158	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					365	372		10.1038/sj.onc.1203309	http://dx.doi.org/10.1038/sj.onc.1203309			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656683				2022-12-25	WOS:000084873700006
J	Lee, SG; Rho, HM				Lee, SG; Rho, HM			Transcriptional repression of the human p53 gene by hepatitis B viral X protein	ONCOGENE			English	Article						HBx; repression; human p53 promoter; E-box element; c-Myc	HELIX-LOOP-HELIX; TUMOR-SUPPRESSOR GENE; PROMOTER ACTIVITY; VIRUS; BINDING; ELEMENT; LIVER; REPLICATION; EXPRESSION; SEQUENCE	Hepatitis B viral X protein (HBx) and the human p53 protein (p53) have been known as a transactivator and as a tumor suppressor, respectively, These two proteins have also been known to interact with each other to neutralize their authentic functions and the p53 represses the E-IBV enhancer/X promoter activity. Here we report that the promoter activity of the human p53 gene was strongly repressed by the HBx using the chloramphenicol acetyl transferase (CAT) assay, Analyses of serial deletion, site-directed mutagenesis and the heterologous promoter system showed that the site responsible for the repression was the E-box element in the promoter of the p53 gene, In addition, HBx as expected also repressed the activation of the p53 promoter by c-Myc through the E-box element, Northern blot analyses also showed that the expression of the p53 gene in the HepG2-K8 cell line, which expresses HBV genes including HBx, was much more repressed than that of the control cell HepG2. These results with previous data suggest that the shift of the reciprocal inhibitory activities at the levels of protein-protein interaction and transcription between HBx and p53 may play a decisive role in the HBV-related hepatocarcinogenesis.	Seoul Natl Univ, Dept Biol Mol, Seoul 151742, South Korea; Seoul Natl Univ, Res Ctr Cell Differentiat, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Rho, HM (corresponding author), Seoul Natl Univ, Dept Biol Mol, Seoul 151742, South Korea.		Lee, Seok-Geun/B-3408-2011	Lee, Seok-Geun/0000-0002-0060-5777				AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; CASELMANN WH, 1996, ADV VIRUS RES, V47, P303; Choi BH, 1999, J BIOL CHEM, V274, P2858, DOI 10.1074/jbc.274.5.2858; Choi CY, 1997, J BIOL CHEM, V272, P16934, DOI 10.1074/jbc.272.27.16934; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM SH, 1992, J GEN VIROL, V73, P2421, DOI 10.1099/0022-1317-73-9-2421; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Ray RB, 1997, J BIOL CHEM, V272, P10983; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	32	105	122	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					468	471		10.1038/sj.onc.1203312	http://dx.doi.org/10.1038/sj.onc.1203312			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656696				2022-12-25	WOS:000084873700019
J	Micouin, A; Wietzerbin, J; Steunou, V; Martyre, MC				Micouin, A; Wietzerbin, J; Steunou, V; Martyre, MC			p95(vav) associates with the type I interferon (IFN) receptor and contributes to the antiproliferative effect of IFN-alpha in megakaryocytic cell lines	ONCOGENE			English	Article						vav; type IIFN receptor; megakaryocytic cells; IFN antiproliferative effect	VAV PROTOONCOGENE PRODUCT; PROTEIN-TYROSINE KINASE; HEMATOPOIETIC-CELLS; T-CELL; MYELOID METAPLASIA; BETA RECEPTOR; STEEL FACTOR; B-CELLS; PHOSPHORYLATION; EXPRESSION	The vav proto-oncogene product is a 95 kDa protein predominantly expressed in hematopoietic cells. Vav presents a wide range of functional domains, including structural domains known to be involved in signal transduction, Triggering of various cytokine receptors among which type I interferon receptor induces a rapid and transient tyrosine phosphorylation of p95(vav). Nevertheless, the biological functions of p95(vav) are still unclear, This report is the first documentation on the physical association of p95(vav) With both alpha and beta type I interferon receptor chains, as demonstrated by co-immunoprecipitation and Western blot analysis in megakaryocytic cells (Dami and UT7), This interaction is increased by interferon-alpha/beta stimulation, Moreover, p95(vav) phosphorylated subsequently to type I interferon treatment, is translocated in the nucleus; a concomitant increase of its association with the regulatory subunit of the nuclear DNA-dependent protein kinase, KU-70 is observed in the nucleus. To determine whether p95(vav) participates in the biological response to type I interferons, we studied the effects of non modified Vav oligodeoxynucleotides on the antiproliferative effect of interferon-alpha on megakaryocytic cells, By this oligodeoxynucleotide strategy, we show that p95(vav) contributes greatly to the cell proliferation inhibition induced by type I IFN.	Inst Curie, U365 INSERM, Sect Rech, F-75231 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Micouin, A (corresponding author), Inst Curie, U365 INSERM, Sect Rech, 26 Rue Ulm, F-75231 Paris, France.							ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CARLOSTELLA C, 1987, BLOOD, V70, P1014; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; COHEN B, 1995, MOL CELL BIOL, V15, P4208; COLAMONICI OR, 1994, J BIOL CHEM, V269, P5660; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1998, J BIOL CHEM, V273, P3144, DOI 10.1074/jbc.273.6.3144; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; GREENBERG SM, 1988, BLOOD, V72, P1968; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HU P, 1993, BIOESSAYS, V15, P179, DOI 10.1002/bies.950150306; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KATZAV S, 1995, CRIT REV ONCOGEN, V6, P82; KOMATSU N, 1991, CANCER RES, V51, P341; Lewerenz M, 1998, J MOL BIOL, V282, P585, DOI 10.1006/jmbi.1998.2026; Luger SM, 1996, BLOOD, V87, P1326, DOI 10.1182/blood.V87.4.1326.bloodjournal8741326; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MARTYRE MC, 1994, BRIT J HAEMATOL, V86, P244, DOI 10.1111/j.1365-2141.1994.tb04722.x; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; Miyakawa Y, 1997, BLOOD, V89, P2789, DOI 10.1182/blood.V89.8.2789; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; REEVES WH, 1994, MANUAL BIOL MARKERS; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; Romero F, 1996, MOL CELL BIOL, V16, P37; Romero F, 1998, J BIOL CHEM, V273, P5923, DOI 10.1074/jbc.273.10.5923; SACCHI S, 1995, LEUKEMIA LYMPHOMA, V19, P13, DOI 10.3109/10428199509059658; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Uddin S, 1997, FEBS LETT, V403, P31, DOI 10.1016/S0014-5793(97)00023-9; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Williams EA, 1997, J CHEM TECHNOL BIOT, V70, P9; WU J, 1995, MOL CELL BIOL, V15, P4337; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	43	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					387	394		10.1038/sj.onc.1203314	http://dx.doi.org/10.1038/sj.onc.1203314			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656686				2022-12-25	WOS:000084873700009
J	Martinez, LA; Chen, Y; Pavone, A; Fischer, SM; Conti, CJ				Martinez, LA; Chen, Y; Pavone, A; Fischer, SM; Conti, CJ			Deregulated expression of cyclin D1 overrides antimitogenic signals	ONCOGENE			English	Article						cell cycle; cyclin D1; keratinocytes; transforming growth factor beta 1	MOUSE SKIN CARCINOGENESIS; EPITHELIAL-CELL LINE; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; RETINOBLASTOMA PROTEIN; GROWTH-INHIBITION; BREAST-CANCER; ECTOPIC EXPRESSION; P27(KIP1) PROTEIN; DEPENDENT KINASES	Several types of epithelial neoplasms exhibit high expression of transforming growth factor beta 1 (TGF(beta)-1), indicating that they have acquired tolerance to this normally growth inhibitory cytokine, Since cyclin D1 is expressed at high levels in murine skin tumors coincident with high levels of TGF(beta)-1 expression, we hypothesized that cyclin D1 may override TGF(beta)-1 induced growth arrest, We observed that in primary murine keratinocytes treated with TGF(beta)-1, cyclin D1 is quickly suppressed at both the mRNA and protein level. Since changes in other cell cycle proteins occur at a later time during TGF,-1 treatment, the early suppression of cyclin D1 suggests that this gene is a critical target for TGF(beta)-1 growth suppression, Using primary keratinocytes from transgenic mice that overexpress cyclin D1 (K5-D1 mice), we observed partial resistance to TGF(beta)-1 growth inhibition. This resistance involves changes in the cyclin/ cdk/inhibitor complexes rather than differences in expression of the TGF(beta) receptors or signaling. Comparison of cdk associated kinase activity between wild-type and K5-D1 cells shows differential regulation, We conclude that deregulated cyclin D1 and subsequent alterations in cell cycle machinery provides keratinocytes the ability to at least partially override growth inhibitory signals.	Univ Texas, MD Andersn Canc Res Ctr, Pk Res Div, Smithville, TX 78957 USA; Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29425 USA	University of Texas System; UTMD Anderson Cancer Center; Medical University of South Carolina	Conti, CJ (corresponding author), Univ Texas, MD Andersn Canc Res Ctr, Pk Res Div, Pk Rd 1-C, Smithville, TX 78957 USA.				NATIONAL CANCER INSTITUTE [P30CA016672, R01CA042157, R01CA034443] Funding Source: NIH RePORTER; NCI NIH HHS [CA42157, CA34443, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; Arber N, 1996, ONCOGENE, V12, P1903; BIANCHI AB, 1993, ONCOGENE, V8, P1127; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Ciaparrone M, 1998, CANCER RES, V58, P114; Doki Y, 1997, CARCINOGENESIS, V18, P1139, DOI 10.1093/carcin/18.6.1139; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FILMUS J, 1994, ONCOGENE, V9, P3627; Fowlis DJ, 1996, CELL GROWTH DIFFER, V7, P679; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; JIANG W, 1993, ONCOGENE, V8, P3447; KO TC, 1995, ONCOGENE, V10, P177; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PATAMALAI B, 1994, MOL CARCINOGEN, V9, P220, DOI 10.1002/mc.2940090406; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Ravitz MJ, 1997, ADV CANCER RES, V71, P165, DOI 10.1016/S0065-230X(08)60099-8; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rundhaug JE, 1997, MOL CARCINOGEN, V19, P122, DOI 10.1002/(SICI)1098-2744(199707)19:2<122::AID-MC7>3.0.CO;2-H; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; Sgambato A, 1997, CLIN CANCER RES, V3, P1879; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIMON KE, 1995, CELL GROWTH DIFFER, V6, P1261; Weinstein IB, 1997, CLIN CANCER RES, V3, P2696; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572	40	13	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					315	322		10.1038/sj.onc.1203301	http://dx.doi.org/10.1038/sj.onc.1203301			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645011				2022-12-25	WOS:000084844400018
J	Futamura, A; Gettins, PGW				Futamura, A; Gettins, PGW			Serine 380 (P14) -> glutamate mutation activates antithrombin as an inhibitor of factor Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASED STRUCTURAL FLEXIBILITY; HEPARIN-BINDING SITE; ALPHA(1)-PROTEINASE INHIBITOR; CONFORMATIONAL CHANGE; REACTIVE CENTER; SERPIN; PROTEINASE; MECHANISM; SUBSTRATE; ACCELERATION	Heparin regulates the inhibitory activity of antithrombin. It has been proposed that residues P15 and P14 are expelled from beta-sheet A of antithrombin by heparin binding, permitting better interaction of the reactive center loop with factor Xa. We have made a P14 antithrombin variant (S380E) to create an activated inhibitory form of antithrombin in which P14 is already expelled from beta-sheet A. S380E antithrombin fluorescence is enhanced 35 +/- 5% compared with control antithrombin. There is minimal further increase in antithrombin fluorescence upon heparin binding. The variant has a 5 degrees C lower T-m than control antithrombin. The variant is an inhibitor of proteinases and has a nearly 200-fold increased basal rate of inhibition of factor Xa, after correction for an increased stoichiometry of inhibition. This is comparable to that of antithrombin activated by high affinity heparin pentasaccharide. Full-length high affinity heparin causes only a 7-fold additional increase in rate and a large increase in stoichiometry of inhibition. In contrast, the basal rate of inhibition of thrombin is similar to that of control antithrombin but is increased 300-fold by heparin. These findings suggest that the native state of the S380E variant exists in a loop-expelled conformation that is consequently highly reactive toward factor Xa.	Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049234, R01HL049234] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; FAN BQ, 1994, BIOCHEMISTRY-US, V33, P14156, DOI 10.1021/bi00251a026; FAN BQ, 1993, J BIOL CHEM, V268, P17588; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 1998, BIOCHEMISTRY-US, V37, P3272, DOI 10.1021/bi972182o; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; LANCHANTIN GF, 1973, J BIOL CHEM, V248, P5956; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; Olson S.T., 1993, PERSPECT DRUG DISCOV, V1, P479; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Olson ST, 1997, ARCH BIOCHEM BIOPHYS, V341, P212, DOI 10.1006/abbi.1997.9973; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; TURKO IV, 1993, FEBS LETT, V335, P9, DOI 10.1016/0014-5793(93)80429-X; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; Zettlmeissl G, 1988, Behring Inst Mitt, P26	30	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4092	4098		10.1074/jbc.275.6.4092	http://dx.doi.org/10.1074/jbc.275.6.4092			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660568	hybrid			2022-12-25	WOS:000085288800052
J	Uren, A; Reichsman, F; Anest, V; Taylor, WG; Muraiso, K; Bottaro, DP; Cumberledge, S; Rubin, JS				Uren, A; Reichsman, F; Anest, V; Taylor, WG; Muraiso, K; Bottaro, DP; Cumberledge, S; Rubin, JS			Secreted frizzled-related protein-1 binds directly to wingless and is a biphasic modulator of Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; SPEMANN ORGANIZER; XENOPUS EMBRYOS; DROSOPHILA; GENE; FAMILY; ANTAGONIST; RECEPTORS; APOPTOSIS; CANCER	Secreted Frizzled-related protein-1 (sFRP-1) contains a cysteine-rich domain homologous to the putative Wnt-binding site of Frizzleds. To facilitate the biochemical and biological analysis of sFRP-1, we developed a mammalian recombinant expression system that yields similar to 3 mg of purified protein/liter of conditioned medium. Using this recombinant protein, we demonstrated that sFRP-1 and Wg (wingless) interact in enzyme-linked immunosorbent and co-precipitation assays. Surprisingly, a derivative lacking the cysteine-rich domain retained the ability to bind Wg, Cross-linking experiments performed with radioiodinated sFRP-1 provided definitive evidence that sFRP-1 and Wg bind directly to each other. Besides detecting a cross-linked complex consistent in size with 1:1 stoichiometry of sFRP-1 and Wg, we also observed a larger complex whose size suggested the presence of a second sFRP-1 molecule. The formation of both complexes was markedly enhanced by an optimal concentration of exogenous heparin, emphasizing the potential importance of heparan-sulfate proteoglycan in Wnt binding and signaling. sFRP-1 exerted a biphasic effect on Wg activity in an armadillo stabilization assay, increasing armadillo level at low concentrations but reducing it at higher concentrations. These results provide new insights about the Wnt binding and biological activity of sFRPs.	NCI, Cellular & Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01002 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Massachusetts System; University of Massachusetts Amherst	Rubin, JS (corresponding author), NCI, Cellular & Mol Biol Lab, Div Basic Sci, NIH, Bldg 37,Rm 1E24,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.		Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334; Reichsman, Frieda/0000-0003-4522-350X	NATIONAL CANCER INSTITUTE [Z01BC010251, ZIABC010251] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Jawdeh G, 1999, LAB INVEST, V79, P439; Ashe HL, 1999, NATURE, V398, P427, DOI 10.1038/18892; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Binari RC, 1997, DEVELOPMENT, V124, P2623; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575; CUMBERLEDGE S, 1993, NATURE, V363, P549, DOI 10.1038/363549a0; Dale TC, 1998, BIOCHEM J, V329, P209; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kispert A, 1996, DEVELOPMENT, V122, P3627; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Mayr T, 1997, MECH DEVELOP, V63, P109, DOI 10.1016/S0925-4773(97)00035-X; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller HAJ, 1999, DEVELOPMENT, V126, P577; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; Pfeffer PL, 1997, INT J DEV BIOL, V41, P449; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Salic AN, 1997, DEVELOPMENT, V124, P4739; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang YS, 1996, J BIOL CHEM, V271, P4468; Wolf V, 1997, FEBS LETT, V417, P385, DOI 10.1016/S0014-5793(97)01324-0; Xu QH, 1998, DEVELOPMENT, V125, P4767; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zhang J, 1998, DEVELOPMENT, V125, P3075; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	57	312	341	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4374	4382		10.1074/jbc.275.6.4374	http://dx.doi.org/10.1074/jbc.275.6.4374			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660608	hybrid, Green Submitted			2022-12-25	WOS:000085288800092
J	Zauli, G; Secchiero, P; Rodella, L; Gibellini, D; Mirandola, P; Mazzoni, M; Milani, D; Dowd, DR; Capitani, S; Vitale, M				Zauli, G; Secchiero, P; Rodella, L; Gibellini, D; Mirandola, P; Mazzoni, M; Milani, D; Dowd, DR; Capitani, S; Vitale, M			HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSCRIPTIONAL REPRESSOR ICER; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; RESPONSE ELEMENT; BASIC DOMAIN; T-CELLS; PROTEIN; CAMP; AIDS	lTreatment of dopaminergic rat PC12 cells with human immunodeficiency virus, type 1 (HIV-1) Tat protein or tat cDNA inhibited the expression of tyrosine hydroxylase (TR), the rate limiting enzyme for the dopamine biosynthetic pathway, as well as the production and release of dopamine into the culture medium. Moreover, the: Tat addition to PC12 cells up-regulated the expression of the inducible cAMP early repressor (ICER), a specific member of the cAMP-responsive element modulator transcription factor family, in a cAMP-dependent manner. In turn, ICER overexpression abrogated the transcription activity of the TH promoter in PC12 cells, strongly suggesting ICER involvement in Tat-mediated inhibition of TH gene expression. lit vivo injection of synthetic HIV-1 Tat protein into the striatum of healthy rats induced a subclinical Parkinson's-like disease that became manifested only when the animals were treated with amphetamine. As early as one week postinjection, the histochemical examination of the rat substantia nigra showed a reduced staining of neurons expressing TH followed by a loss of TH+ neurons at later time points. As Tat protein can be locally released into the central nervous system by HIV-1-infected microglial cells, our findings may contribute to the explanation of the pathogenesis of the motorial abnormalities often reported in HIV-1 seropositive individuals.	Univ Ferrara, Dept Morphol & Embryol, Anat Sect, I-44100 Ferrara, Italy; Univ Chieti, Inst Human Morphol Gabriel DAnnunzio, I-66100 Chieti, Italy; Univ Brescia, Dept Biomed Sci & Biotechnol, Human Anat Sect, I-25123 Brescia, Italy; Univ Bologna, Dept Clin & Expt Med, Microbiol Sect, I-40138 Bologna, Italy; St Louis Univ, Hlth Sci Ctr, Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; CNR, Inst Res Codivilla Putti, Inst Normal & Pathol Cytomorphol, I-40136 Bologna, Italy	University of Ferrara; G d'Annunzio University of Chieti-Pescara; University of Brescia; University of Bologna; Saint Louis University; Consiglio Nazionale delle Ricerche (CNR)	Zauli, G (corresponding author), Univ Ferrara, Dept Morphol & Embryol, Anat Sect, Via Fossato Mortara 66, I-44100 Ferrara, Italy.		Milani, Daniela/G-5579-2015; Mirandola, Prisco/L-3137-2015; Zauli, Giorgio/ABE-8001-2020; Rodella, Luigi Fabrizio/F-1079-2010; Gibellini, Davide/K-8725-2016; secchiero, paola/G-9689-2015; Vitale, Marco/O-8751-2015	Milani, Daniela/0000-0002-9540-7801; Mirandola, Prisco/0000-0002-5058-3924; Gibellini, Davide/0000-0003-3688-1252; secchiero, paola/0000-0003-4101-7987; Vitale, Marco/0000-0002-3261-6868; Zauli, Giorgio/0000-0002-3750-8698; Rodella, Luigi Fabrizio/0000-0002-9497-4708; CAPITANI, Silvano/0000-0003-2795-6814				BERGER JR, 1994, AIDS, V8, P67, DOI 10.1097/00002030-199401000-00010; BERGER JR, 1992, SEMIN NEUROL, V12, P1, DOI 10.1055/s-2008-1041151; Bodor J, 1996, P NATL ACAD SCI USA, V93, P3536, DOI 10.1073/pnas.93.8.3536; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; Cheng J, 1998, NEUROSCIENCE, V82, P97, DOI 10.1016/S0306-4522(97)00174-7; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gallo RC, 1999, P NATL ACAD SCI USA, V96, P8324, DOI 10.1073/pnas.96.15.8324; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gibellini D, 1998, J IMMUNOL, V160, P3891; GOLDSTEIN G, 1996, NAT MED, V1, P960; Gringeri A, 1998, J Hum Virol, V1, P293; HRISO E, 1991, AM J PSYCHIAT, V148, P1558; JEON BS, 1995, NEURODEGENERATION, V4, P131, DOI 10.1006/neur.1995.0016; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KIM KS, 1993, J BIOL CHEM, V268, P15689; KOLSON DL, 1994, J GEN VIROL, V75, P1927, DOI 10.1099/0022-1317-75-8-1927; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; KURE K, 1990, ACTA NEUROPATHOL, V80, P393, DOI 10.1007/BF00307693; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; Li CJ, 1997, P NATL ACAD SCI USA, V94, P8116, DOI 10.1073/pnas.94.15.8116; LINDNER MD, 1995, EXP NEUROL, V132, P62, DOI 10.1016/0014-4886(95)90059-4; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; Mao DL, 1998, MOL ENDOCRINOL, V12, P492, DOI 10.1210/me.12.4.492; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; MERRILL JE, 1991, FASEB J, V5, P23921; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; Milani D, 1998, AIDS, V12, P1275, DOI 10.1097/00002030-199811000-00008; Mirsattari SM, 1998, MOVEMENT DISORD, V13, P684, DOI 10.1002/mds.870130413; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Monaco L, 1997, ONCOGENE, V15, P2493, DOI 10.1038/sj.onc.1201636; NATH A, 1987, NEUROLOGY, V37, P37, DOI 10.1212/WNL.37.1.37; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852; Orsini MJ, 1996, J NEUROSCI, V16, P2546; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; REYES MG, 1991, ACTA NEUROPATHOL, V82, P39, DOI 10.1007/BF00310921; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Takai N, 1998, J NEUROSCI RES, V54, P214, DOI 10.1002/(SICI)1097-4547(19981015)54:2<214::AID-JNR9>3.0.CO;2-H; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; UDENFRIE.S, 1966, PHARMACOL REV, V18, P43; WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WONG SC, 1994, J NEUROCHEM, V62, P1691; Yamada M, 1999, P NATL ACAD SCI USA, V96, P4078, DOI 10.1073/pnas.96.7.4078; ZAULI G, 1995, J ACQ IMMUN DEF SYND, V10, P306; ZETTERSTROM T, 1986, BRAIN RES, V376, P1, DOI 10.1016/0006-8993(86)90893-0; Zidovetzki R, 1998, AIDS RES HUM RETROV, V14, P825, DOI 10.1089/aid.1998.14.825; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	52	70	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4159	4165		10.1074/jbc.275.6.4159	http://dx.doi.org/10.1074/jbc.275.6.4159			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660577	hybrid			2022-12-25	WOS:000085288800061
J	Barazzoni, R; Short, KR; Nair, KS				Barazzoni, R; Short, KR; Nair, KS			Effects of aging on mitochondrial DNA copy number and cytochrome c oxidase gene expression in rat skeletal muscle, liver, and heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENESCENT RATS; ENCODED GENES; AGE; TRANSCRIPTION; ADAPTATION; PROTEIN; GROWTH; DAMAGE	Mitochondrial DNA (mtDNA) deletions and mutations have been reported to occur with aging in various tissues. To determine the functional impact of these changes, we measured mtDNA copy number, mitochondria-encoded cytochrome c oxidase (COX) subunit I and III transcript levels, and COX enzyme activity in skeletal muscles (medial and lateral gastrocnemius and soleus), liver, and heart in 6- and 27-month-old rats. Substantial age-related reductions of mtDNA copy number occurred in skeletal muscle groups (-23-40%, p < 0.03) and liver (-50%, p < 0.01) but not in the heart. The decline in mtDNA was not associated with reduced COX transcript levels in tissues with high oxidative capacities such as red soleus muscle or liver, while transcript levels were reduced with aging in the less oxidative mixed fiber gastrocnemius muscle (-17-22%, p < 0.06), Consistent with transcript levels, COX activity also remained unchanged in aging liver and heart but declined with age in the lateral gastrocnemius (-32%, p < 0.05). Thus, the effects of aging on mitochondrial gene expression are tissue-specific. A substantial age-related decline in mtDNA copy number proportional to tissue oxidative capacities is demonstrated in skeletal muscle and liver. mtDNA levels are in contrast preserved in the aging heart muscle, presumably due to its incessant aerobic activity. Reduced mtDNA copy number has no major effects on mitochondrial encoded transcript levels and enzyme activities in various tissues under these baseline study conditions. In contrast, maintenance of mitochondrial transcript levels that may be linked to oxidative metabolism and energy demand appears to be the main determinant of mitochondrial oxidative capacity in aging tissues.	Mayo Clin & Mayo Fdn, Endocrine Res Unit, Rochester, MN 55905 USA	Mayo Clinic	Nair, KS (corresponding author), Mayo Clin & Mayo Fdn, Endocrine Res Unit, Joseph 5-194, Rochester, MN 55905 USA.		Short, Kevin R/AAC-2553-2020	Short, Kevin R/0000-0001-6704-9587	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009531] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00585] Funding Source: Medline; NIA NIH HHS [R0 AG 09531] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADLER CP, 1986, J MOL CELL CARDIOL, V18, P39, DOI 10.1016/S0022-2828(86)80981-6; ALONI Y, 1971, P NATL ACAD SCI USA, V68, P1757, DOI 10.1073/pnas.68.8.1757; ANTONETTI DA, 1995, J CLIN INVEST, V95, P1383, DOI 10.1172/JCI117790; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; Barrientos A, 1997, BIOCHEM MOL MED, V62, P165, DOI 10.1006/bmme.1997.2647; BOHMAN R, 1985, J EXP ZOOL, V233, P385, DOI 10.1002/jez.1402330307; CASTELLUCCIO C, 1994, MECH AGEING DEV, V76, P73, DOI 10.1016/0047-6374(94)91583-0; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; Delp MD, 1998, J APPL PHYSIOL, V85, P1813, DOI 10.1152/jappl.1998.85.5.1813; Dutta C, 1997, MUSCLE NERVE       S, V5, pS5; DUTTA C, 1996, J GERONTOL A-BIOL, V50, P1; Fu AZ, 1998, AM J PHYSIOL-ENDOC M, V275, pE1023, DOI 10.1152/ajpendo.1998.275.6.E1023; GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x; GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H; GENOVA ML, 1995, BIOCHEM J, V311, P105, DOI 10.1042/bj3110105; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; HSINCHEN L, 1994, BIOCHIM BIOPHYS ACTA, V1226, P37; JI LL, 1990, AM J PHYSIOL, V258, pR918, DOI 10.1152/ajpregu.1990.258.4.R918; JI LL, 1991, AM J PHYSIOL, V261, pR386, DOI 10.1152/ajpregu.1991.261.2.R386; LAKATTA EG, 1993, PHYSIOL REV, V73, P413, DOI 10.1152/physrev.1993.73.2.413; MARINGARCIA J, 1994, J MOL CELL CARDIOL, V26, P1029, DOI 10.1006/jmcc.1994.1123; MEERSON FZ, 1972, J MOL CELL CARDIOL, V4, P571, DOI 10.1016/0022-2828(72)90113-7; MURAKAMI T, 1994, AM J PHYSIOL, V267, pE388, DOI 10.1152/ajpendo.1994.267.3.E388; Newsholme E. A., 1973, REGULATION METABOLIS; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; RAJAMANICKAM C, 1979, CIRC RES, V45, P505, DOI 10.1161/01.RES.45.4.505; Rooyackers OE, 1996, P NATL ACAD SCI USA, V93, P15364, DOI 10.1073/pnas.93.26.15364; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SCOTTO AW, 1983, ARCH BIOCHEM BIOPHYS, V222, P150, DOI 10.1016/0003-9861(83)90512-X; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; STOCCO DM, 1978, J GERONTOL, V33, P802, DOI 10.1093/geronj/33.6.802; TAKASAWA M, 1993, EXP GERONTOL, V28, P269, DOI 10.1016/0531-5565(93)90034-B; TOMANEK RJ, 1973, J ULTRA MOL STRUCT R, V42, P201, DOI 10.1016/S0022-5320(73)90050-6; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; Welle S, 1996, AM J PHYSIOL-ENDOC M, V270, pE224, DOI 10.1152/ajpendo.1996.270.2.E224; WILLIAMS RS, 1986, J BIOL CHEM, V261, P2390; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; WILSON PD, 1975, BIOCHEM SOC T, V3, P126, DOI 10.1042/bst0030126	40	276	287	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3343	3347		10.1074/jbc.275.5.3343	http://dx.doi.org/10.1074/jbc.275.5.3343			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652323	hybrid			2022-12-25	WOS:000085146500045
J	Liu, XB; Wang, WC; Singh, BB; Lockwich, T; Jadlowiec, J; O'Connell, B; Wellner, R; Zhu, MX; Ambudkar, IS				Liu, XB; Wang, WC; Singh, BB; Lockwich, T; Jadlowiec, J; O'Connell, B; Wellner, R; Zhu, MX; Ambudkar, IS			Trp1, a candidate protein for the store-operated Ca2+ influx mechanism in salivary gland cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; FUNCTIONAL EXPRESSION; DROSOPHILA TRP; HUMAN HOMOLOG; ACINAR-CELLS; RAT HOMOLOG; CHANNEL; DEPLETION; CLONING; MEMBRANE	The trp gene family has been proposed to encode the store operated Ca2+ influx (SOC) channel(s). This study examines the role of Trp1 in the SOC mechanism of salivary gland cells. htrp1, htrp3, and Trp1 were detected in the human submandibular gland cell line (HSG), HSG cells stably transfected with htrp1 alpha cDNA displayed (i) a higher level of Trp1, (ii) a 3-5-fold increase in SOC (thapsigargin-stimulated Ca2+ influx), determined by [Ca2+](i) and Ca2+-activated K+ channel current measurements, and (iii) similar basal Ca2+ permeability, and inhibition of SOC by Gd3+ but not by Zn2+, as compared with control cells. importantly, (i) transfection of HSG cells with antisense trp1 alpha cDNA decreased endogenous Trp1 level and significantly attenuated SOC, and (ii) transfection of HSG cells with htrp3 cDNA did not increase SOC, These data demonstrate an association between Trp1 and SOC and strongly suggest that Trp1 is involved in this mechanism in HSG cells, Consistent with this suggestion, Trp1 was detected in the plasma membrane region, the proposed site of SOC, of acinar and ductal cells in intact rat submandibular glands. Based on these aggregate data, we propose Trp1 as a candidate protein for the SOC mechanism in salivary gland cells.	NIDCR, NIH, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, Bethesda, MD 20892 USA; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University System of Ohio; Ohio State University	Ambudkar, IS (corresponding author), NIDCR, NIH, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, Bldg 10,Rm 1N-113, Bethesda, MD 20892 USA.			Singh, Brij/0000-0003-0535-5997; O'Connell, Brian/0000-0003-4529-7664	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMBUDKAR IS, 2000, IN PRESS CRIT REV OR; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Funayama M, 1996, MOL BRAIN RES, V43, P259, DOI 10.1016/S0169-328X(96)00208-2; He XJ, 1997, PFLUG ARCH EUR J PHY, V433, P260; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 1998, AM J PHYSIOL-CELL PH, V275, pC571, DOI 10.1152/ajpcell.1998.275.2.C571; Lockwich T, 1995, J MEMBRANE BIOL, V148, P277; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; O'Connell AC, 1999, RADIAT RES, V151, P150, DOI 10.2307/3579765; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Sakura H, 1997, DIABETOLOGIA, V40, P528, DOI 10.1007/s001250050711; Sinkins WG, 1998, BIOCHEM J, V331, P331, DOI 10.1042/bj3310331; Tomita Y, 1998, NEUROSCI LETT, V248, P195, DOI 10.1016/S0304-3940(98)00362-0; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	36	233	243	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3403	3411		10.1074/jbc.275.5.3403	http://dx.doi.org/10.1074/jbc.275.5.3403			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652333	hybrid			2022-12-25	WOS:000085146500055
J	Dunder, U; Kaartinen, V; Valtonen, P; Vaananen, E; Kosma, VM; Heisterkamp, N; Groffen, J; Mononen, I				Dunder, U; Kaartinen, V; Valtonen, P; Vaananen, E; Kosma, VM; Heisterkamp, N; Groffen, J; Mononen, I			Enzyme replacement therapy in a mouse model of aspartylglycosaminuria	FASEB JOURNAL			English	Article						aspartylglycosylaminase; recombinant proteins; lysosomal storage diseases; animal disease models; lysosomes	MUCOPOLYSACCHARIDOSIS TYPE-VII; RECOMBINANT BETA-GLUCURONIDASE; HUMAN FIBROBLASTS; LYSOSOMAL ENZYME; GAUCHER-DISEASE; GLYCOSYLASPARAGINASE; MICE; ASSAY; LEADS	Aspartylglycosaminuria (AGU), the most common lysosomal disorder of glycoprotein degradation, is caused by deficient activity of glycosylasparaginase (AGA), AGA-deficient mice share most of the clinical, biochemical and histopathologic characteristics of human AGU disease. In the current study, recombinant human AGA administered i.v. to adult AGU mice disappeared from the systemic circulation of the animals in two phases predominantly into non-neuronal tissues, which were rapidly cleared from storage compound aspartylglucosamine. Even a single AGA injection reduced the amount of aspartylglucosamine in the Liver and spleen of AGU mice by 90% and 80%, respectively. Quantitative biochemical analyses along with histological and immunohistochemical studies demonstrated that the pathophysiologic characteristics of AGU were effectively corrected in non-neuronal tissues of AGU mice during 2 wk of AGA therapy. At the same time, AGA activity increased to 10% of that in normal brain tissue and the accumulation of aspartylglucosamine was reduced by 20% in total brain of the treated animals. Immunohistochemical studies suggested that the corrective enzyme was widely distributed within the brain tissue. These findings suggest that AGU may be correctable by enzyme therapy.	Kuopio Univ Hosp, Dept Clin Chem, FIN-70211 Kuopio, Finland; Univ So Calif, Sch Med, Dept Pathol, Childrens Hosp,Res Inst, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Div Haematol Oncol, Childrens Hosp,Res Inst, Los Angeles, CA 90027 USA; Univ Kuopio, Dept Pathol & Forens Med, FIN-70210 Kuopio, Finland; Turku Univ Hosp, Dept Clin Chem & Hematol, FIN-20521 Turku, Finland	Kuopio University Hospital; Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Eastern Finland; University of Turku	Mononen, I (corresponding author), Kuopio Univ Hosp, Dept Clin Chem, POB 1777, FIN-70211 Kuopio, Finland.		Kaartinen, Vesa/AAU-5396-2021; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X				ARVIO M, 1997, CLIN MANIFESTATIONS, P19; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEAUDET LL, 1989, DISORDERS GLYCOPROTE, P1603; BEUTLER E, 1995, GAUCHER DIS, P2641; BOVE KE, 1995, HUM PATHOL, V26, P1040, DOI 10.1016/0046-8177(95)90097-7; Crawley AC, 1996, J CLIN INVEST, V97, P1864, DOI 10.1172/JCI118617; Gonzalez-Gomez I, 1998, AM J PATHOL, V153, P1293, DOI 10.1016/S0002-9440(10)65674-X; Kaartinen V, 1998, J INHERIT METAB DIS, V21, P207, DOI 10.1023/A:1005387215224; Kaartinen V, 1996, NAT MED, V2, P1375, DOI 10.1038/nm1296-1375; KAARTINEN V, 1990, ANAL BIOCHEM, V190, P98, DOI 10.1016/0003-2697(90)90140-5; KAARTINEN V, 1990, CLIN CHIM ACTA, V191, P15, DOI 10.1016/0009-8981(90)90053-U; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; MONONEN I, 1995, FASEB J, V9, P428, DOI 10.1096/fasebj.9.5.7896015; MONONEN I, 1997, LYSOSOMAL STORAGE DI; MONONEN IT, 1993, ANAL BIOCHEM, V208, P372, DOI 10.1006/abio.1993.1063; O'Connor LH, 1998, J CLIN INVEST, V101, P1394, DOI 10.1172/JCI1773; Prows CA, 1997, AM J MED GENET, V71, P16, DOI 10.1002/(SICI)1096-8628(19970711)71:1<16::AID-AJMG3>3.3.CO;2-U; SANDO GN, 1977, CELL, V12, P619, DOI 10.1016/0092-8674(77)90262-8; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; Sands MS, 1997, J CLIN INVEST, V99, P1596, DOI 10.1172/JCI119322; SHULL RM, 1994, P NATL ACAD SCI USA, V91, P12937, DOI 10.1073/pnas.91.26.12937; VANDERPLOEG AT, 1991, J CLIN INVEST, V87, P513, DOI 10.1172/JCI115025; Vogler C, 1996, PEDIATR RES, V39, P1050, DOI 10.1203/00006450-199606000-00019; VOGLER C, 1993, PEDIATR RES, V34, P837, DOI 10.1203/00006450-199312000-00028	24	60	62	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					361	367		10.1096/fasebj.14.2.361	http://dx.doi.org/10.1096/fasebj.14.2.361			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657992				2022-12-25	WOS:000085184800015
J	Bahner, M; Sander, P; Paulsen, R; Huber, A				Bahner, M; Sander, P; Paulsen, R; Huber, A			The visual G protein of fly photoreceptors interacts with the PDZ domain assembled INAD signaling complex via direct binding of activated G alpha(q) to phospholipase C beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRP CA2+ CHANNEL; PHOTOTRANSDUCTION CASCADE; DROSOPHILA-MELANOGASTER; GENETIC DISSECTION; KINASE-C; MEMBRANES; NORPA; PHOSPHORYLATION; LOCALIZATION; DEACTIVATION	Visual transduction in the compound eye of flies is a well-established model system for the study of G protein-coupled transduction pathways. Pivotal components of this signaling pathway, including the principal light-activated Ca2+ channel transient receptor potential, an eye specific protein kinase C, and the norpA-encoded phospholipase C beta, are assembled into a supramolecular signaling complex by the modular PDZ domain protein INAD. We have used immunoprecipitation assays to study the interaction of the heterotrimeric visual G protein with this INAD signaling complex, Light-activated G alpha(q)- guanosine 5'-O-(thiotriphosphate) and Alf(4)(-)-activated G alpha(q), but not G beta gamma, form a stable complex with the INAD signaling complex. This interaction requires the presence of norpA-encoded phospholipase C beta, indicating that phospholipase C beta is the target of activated G alpha(q). Our data establish that the INAD signaling complex is a light-activated target of the phototransduction pathway, with G alpha(q), forming a molecular on-off switch that shuttles the visual signal from activated rhodopsin to INAD-linked phospholipase C beta.	Univ Karlsruhe, Inst Zool, Dept Cell & Neurobiol, D-76128 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Huber, A (corresponding author), Univ Karlsruhe, Inst Zool, Dept Cell & Neurobiol, Kornblumenstr 13, D-76128 Karlsruhe, Germany.	DC05@rz.uni-karlsruhe.de		Huber, Armin/0000-0003-3977-089X				Adamski FM, 1998, J BIOL CHEM, V273, P17713, DOI 10.1074/jbc.273.28.17713; BENTROP J, 1986, EUR J BIOCHEM, V161, P61, DOI 10.1111/j.1432-1033.1986.tb10124.x; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BLUMENFELD A, 1985, P NATL ACAD SCI USA, V82, P7116, DOI 10.1073/pnas.82.20.7116; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; DOLPH PJ, 1994, NATURE, V370, P59, DOI 10.1038/370059a0; ELGAMMAL S, 1987, CELL TISSUE RES, V248, P511, DOI 10.1007/BF00216477; GOLDSMITH TH, 1977, J GEN PHYSIOL, V70, P453, DOI 10.1085/jgp.70.4.453; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; Huber A, 1998, FEBS LETT, V425, P317, DOI 10.1016/S0014-5793(98)00248-8; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LEE YJ, 1994, NEURON, V13, P1143, DOI 10.1016/0896-6273(94)90052-3; MCKAY RR, 1995, J BIOL CHEM, V270, P13271, DOI 10.1074/jbc.270.22.13271; MINKE B, 1985, J COMP PHYSIOL A, V156, P339, DOI 10.1007/BF00610727; MINKE B, 1991, PROG RETIN RES, V11, P99, DOI 10.1016/0278-4327(91)90026-X; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; PAULSEN R, 1984, J COMP PHYSIOL, V155, P47, DOI 10.1007/BF00610930; Scott K, 1998, NATURE, V395, P805, DOI 10.1038/27448; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Selinger Z., 1987, Progress in Clinical and Biological Research, V249, P169; Shieh BH, 1997, P NATL ACAD SCI USA, V94, P12682, DOI 10.1073/pnas.94.23.12682; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Wes PD, 1999, NAT NEUROSCI, V2, P447, DOI 10.1038/8116; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	35	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2901	2904		10.1074/jbc.275.4.2901	http://dx.doi.org/10.1074/jbc.275.4.2901			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644758	hybrid			2022-12-25	WOS:000085128000090
J	Browning, DD; McShane, MP; Marty, C; Ye, RD				Browning, DD; McShane, MP; Marty, C; Ye, RD			Nitric oxide activation of p38 mitogen-activated protein kinase in 293T fibroblasts requires cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CYCLIC-GMP; ANCHORING PROTEINS; SIGNAL; GROWTH; TRANSCRIPTION; STIMULATION; IDENTIFICATION; LOCALIZATION; INFLAMMATION	An increase in cellular levels of cyclic nucleotides activates serine/threonine-dependent kinases that lead to diverse physiological effects. Recently we reported the activation of the p38 mitogen-activated protein kinase (MAPK) pathway in neutrophils by a cGMP-dependent mechanism. In this study we demonstrated that exogenously supplied nitric oxide leads to activation of p38 MAPK in 293T fibroblasts. Phosphorylation of p38 corresponded with an increase in ATF-alpha-dependent gene expression. The effect of nitric oxide was mimicked by addition of 8-bromo-cGMP, indicating that activation of soluble guanylyl cyclase was involved. The importance of cGMP-dependent protein kinase in the activation of p38 MAPK by nitric oxide in 293T cells was assessed in a transfection based assay. Overexpression of cGMP-dependent protein kinase-1 alpha caused phosphorylation of p38 in these cells and potentiated the effectiveness of cGMP. Overexpression of a catalytically inactive mutant form of this enzyme (T516A) blocked the ability of both nitric oxide and 8-bromo-cGMP to activate p38 as measured by both p38 phosphorylation and ATF-2 driven gene expression. Together, these data demonstrate that nitric oxide stimulates a novel pathway leading to activation of p38 MAPK that requires activation of cGMP-dependent protein kinase.	Univ Illinois, Dept Pharmacol MC868, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ye, RD (corresponding author), Univ Illinois, Dept Pharmacol MC868, 835 S Wolcott Ave, Chicago, IL 60612 USA.		Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016; MARTY, Caroline/I-1721-2017	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; MARTY, Caroline/0000-0003-4350-2302; Browning, Darren/0000-0003-0497-7620	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI040176, R01AI040176, R56AI033503, R01AI033503] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40176, AI33503] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; Bhat NR, 1998, J NEUROSCI, V18, P1633; Bhat NR, 1999, J NEUROCHEM, V72, P472, DOI 10.1046/j.1471-4159.1999.0720472.x; Browning DD, 1999, J BIOL CHEM, V274, P537, DOI 10.1074/jbc.274.1.537; Brune B, 1996, REV PHYSIOL BIOCH P, V127, P1, DOI 10.1007/BFb0048263; BRUNE B, 1994, LIFE SCI, V54, P61, DOI 10.1016/0024-3205(94)00775-6; Callsen D, 1999, BIOCHEMISTRY-US, V38, P2279, DOI 10.1021/bi982292a; Callsen D, 1998, J IMMUNOL, V161, P4852; Chan ED, 1999, J IMMUNOL, V162, P415; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; FEIL R, 1995, BIOCHEMISTRY-US, V34, P13152, DOI 10.1021/bi00040a029; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; Kanterewicz BI, 1998, J NEUROCHEM, V70, P1009; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Lincoln T M, 1995, Adv Pharmacol, V34, P305; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MCDONALD LJ, 1994, MOL CELL BIOCHEM, V138, P201, DOI 10.1007/BF00928462; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOILANEN E, 1995, ANN MED, V27, P359, DOI 10.3109/07853899509002589; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; Sciorati C, 1997, BRIT J PHARMACOL, V122, P687, DOI 10.1038/sj.bjp.0701413; SEGER R, 1992, J BIOL CHEM, V267, P14373; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vo NK, 1998, BIOCHEM BIOPH RES CO, V246, P831, DOI 10.1006/bbrc.1998.8722; Wang X, 1997, J NEUROCHEM, V68, P443; Willmott N, 1996, J BIOL CHEM, V271, P3699; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	44	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2811	2816		10.1074/jbc.275.4.2811	http://dx.doi.org/10.1074/jbc.275.4.2811			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644746	hybrid			2022-12-25	WOS:000085128000078
J	Glading, A; Chang, P; Lauffenburger, DA; Wells, A				Glading, A; Chang, P; Lauffenburger, DA; Wells, A			Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED SCHWANN-CELLS; PHOSPHOLIPASE-C; FOCAL ADHESIONS; PROTEASE CALPAIN; MYELIN MCALPAIN; MIGRATION SPEED; TALIN; IMMUNOLOCALIZATION; PHOSPHORYLATION; ATTACHMENT	To become migratory, cells must reorganize their connections to the substratum, and during locomotion they must break rear attachments. The molecular and biochemical mechanisms underlying these biophysical processes are unknown. Recent studies have implicated both extracellular signal-regulated kinase/mitogen-activated protein (ERK/MAP) kinase and calpain (EC 3.4.22.17) in these processes, but it is uncertain whether these are two distinct pathways acting on different modes of motility. We report that cell deadhesion involved in epidermal growth factor (EGF) receptor-mediated fibroblast motility requires activation of M-calpain downstream of ERK/MAP kinase signaling, NR6 fibroblasts expressing full-length mild type epidermal growth factor receptor required both calpain and ERK activation, as demonstrated by pharmacological inhibitors (calpeptin and calpain inhibitor I and PD98059, respectively) for EGF-induced deadhesion and motility. EGF induced rapid activation of calpain that was preventable by molecular inhibition of the Ras-Raf-MEK but not phospholipase C gamma signaling pathway, and calpain was stimulated by transfection of constitutively active MEK. Enhanced calpain activity was not mirrored by increased calpain protein levels or decreased levels of its endogenous inhibitor calpastatin. The link between ERK/MAP kinase signaling and cell motility required the M-isoform of calpain (calpain II), as determined by specific antisense-mediated down-regulation, These data promote a previously undescribed signaling pathway of ERK/MAP kinases activating calpain to destabilize cell-substratum adhesions in response to EGF stimulation.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alabama System; University of Alabama Birmingham; Massachusetts Institute of Technology (MIT)	Wells, A (corresponding author), Univ Pittsburgh, Dept Pathol, 713 Scaife, Pittsburgh, PA 15261 USA.		Glading, Angela/AAI-3455-2020	Wells, Alan/0000-0002-1637-8150; Glading, Angela/0000-0002-1830-6601	NATIONAL CANCER INSTITUTE [R01CA069213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054739] Funding Source: NIH RePORTER; NCI NIH HHS [CA69213] Funding Source: Medline; NIGMS NIH HHS [GM54739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1986, BIOCHEM BIOPH RES CO, V136, P1090, DOI 10.1016/0006-291X(86)90445-6; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Chakrabarti AK, 1997, J NEUROSCI RES, V47, P609, DOI 10.1002/(SICI)1097-4547(19970315)47:6<609::AID-JNR6>3.0.CO;2-H; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; COUCHMAN JR, 1985, EUR J CELL BIOL, V36, P182; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; Guttmann RP, 1997, J BIOL CHEM, V272, P2005, DOI 10.1074/jbc.272.3.2005; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Johnson GVW, 1997, BIOESSAYS, V19, P1011, DOI 10.1002/bies.950191111; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KUO WN, 1994, MOL CELL BIOCHEM, V136, P157, DOI 10.1007/BF00926076; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Maheshwari G, 1998, MICROSC RES TECHNIQ, V43, P358, DOI 10.1002/(SICI)1097-0029(19981201)43:5<358::AID-JEMT2>3.0.CO;2-D; Maheshwari G, 1999, BIOPHYS J, V76, P2814, DOI 10.1016/S0006-3495(99)77435-7; MUGURUMA M, 1995, J BIOCHEM-TOKYO, V117, P1036, DOI 10.1093/oxfordjournals.jbchem.a124803; Neuberger T, 1997, J NEUROSCI RES, V47, P521, DOI 10.1002/(SICI)1097-4547(19970301)47:5<521::AID-JNR7>3.0.CO;2-J; OSHIMA M, 1989, J BIOL CHEM, V264, P20811; Palecek SP, 1996, J CELL SCI, V109, P941; Palecek SP, 1998, J CELL SCI, V111, P929; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; ROSSER BG, 1993, J BIOL CHEM, V268, P23593; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; Shiraha H, 1999, J CELL BIOL, V146, P243; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; SIEGAL GP, 1993, CANCER LETT, V69, P123, DOI 10.1016/0304-3835(93)90164-5; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TOMPA P, 1995, ANAL BIOCHEM, V228, P287, DOI 10.1006/abio.1995.1352; TRANQUI L, 1995, EXP CELL RES, V217, P149, DOI 10.1006/excr.1995.1074; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; Ware MF, 1998, J CELL SCI, V111, P2423; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; Xie H, 1998, J CELL SCI, V111, P615; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825	45	222	232	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2390	2398		10.1074/jbc.275.4.2390	http://dx.doi.org/10.1074/jbc.275.4.2390			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644690	hybrid			2022-12-25	WOS:000085128000022
J	Noguchi, S; Jianmongkol, S; Bender, AT; Kamada, Y; Demady, DR; Osawa, Y				Noguchi, S; Jianmongkol, S; Bender, AT; Kamada, Y; Demady, DR; Osawa, Y			Guanabenz-mediated inactivation and enhanced proteolytic degradation of neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOCHROMES-P450; L-ARGININE; PROTEIN; HEME; 3,5-DICARBETHOXY-2,6-DIMETHYL-4-ETHYL-1,4-DIHYDROPYRIDINE; MECHANISM; ENZYME; BRAIN; LACTACYSTIN; MACROPHAGE	Guanabenz, a metabolism-based irreversible inactivator of neuronal nitric-oxide synthase (nNOS) in vitro, causes the loss of immunodetectable nNOS in vivo. This process is selective in that the slowly reversible inhibitor NG-nitro-L-arginine did not decrease the levels of nNOS in vivo. To better understand the mechanism for the loss of nNOS protein in vivo we have investigated the effects of guanabenz and N-G-nitro-L-arginine in HEB: 293 cells stably transfected with the enzyme. me show here that guanabenz, but not N-G-nitro-L-arginine, caused the inactivation and loss of nNOS protein in the HER 293 cells. in studies with cycloheximide or in pulse-chase experiments with [S-35]methionine, we demonstrate that the loss of nNOS was due in large part to enhanced proteolysis of the protein with the half-life decreasing by one-half from 20 to 10 h. Other metabolism-based irreversible inactivators to nNOS, N-G-methyl-L-arginine, and N-5-(1-iminoethyl)-L-ornithine, but not the reversible inhibitor 7-nitroindazole (7-NI), caused a similar decrease in the half-life of nNOS, Proteasomal inhibitors, lactacystin, Cbz-leucine-leucine-leucinal, and N-acetyl-leucine-leucine-norleucinal, but not the lysosomal protease inhibitor leupeptin, were found to effectively inhibit the proteolytic degradation of nNOS, Thus Fee have shown for the first time that the irreversible inactivators of nNOS, perhaps through covalent alteration of the enzyme, enhance the proteolytic turnover of the enzyme by a mechanism involving the proteasome.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Osawa, Y (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.		KAMADA, Yasuhiko/B-2175-2011	KAMADA, Yasuhiko/0000-0003-1271-9082	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES08365] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1983, CHEM ENG NEWS, V61, P48, DOI 10.1021/cen-v061n038.p048; Babu BR, 1998, J BIOL CHEM, V273, P8882, DOI 10.1074/jbc.273.15.8882; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; BORNHEIM LM, 1987, MOL PHARMACOL, V32, P299; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; CORREIA MA, 1987, ARCH BIOCHEM BIOPHYS, V258, P436, DOI 10.1016/0003-9861(87)90365-1; CORREIA MA, 1992, ARCH BIOCHEM BIOPHYS, V294, P493, DOI 10.1016/0003-9861(92)90716-A; CORREIA MA, 1992, ARCH BIOCHEM BIOPHYS, V297, P228, DOI 10.1016/0003-9861(92)90666-K; Feelisch M., 1996, METHODS NITRIC OXIDE, P455; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; Hajimohammadreza I, 1997, J NEUROCHEM, V69, P1006; KLATT P, 1994, J BIOL CHEM, V269, P1674; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laine R, 1998, MOL PHARMACOL, V54, P305, DOI 10.1124/mol.54.2.305; LUNETTA JM, 1989, MOL PHARMACOL, V35, P10; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nakatsuka M, 1998, DRUG METAB DISPOS, V26, P497; NOGUCHI T, 1982, BIOCHEM PHARMACOL, V31, P609, DOI 10.1016/0006-2952(82)90439-7; OLKEN NM, 1994, BIOCHEMISTRY-US, V33, P14784, DOI 10.1021/bi00253a017; OSAWA Y, 1989, CHEM RES TOXICOL, V2, P131, DOI 10.1021/tx00009a001; Reif A, 1999, J BIOL CHEM, V274, P24921, DOI 10.1074/jbc.274.35.24921; REIF DW, 1995, ARCH BIOCHEM BIOPHYS, V320, P170, DOI 10.1006/abbi.1995.1356; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; Roberts BJ, 1997, J BIOL CHEM, V272, P9771; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TIERNEY DJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P9, DOI 10.1016/0003-9861(92)90358-4; Walker G, 1997, J BIOL CHEM, V272, P16679, DOI 10.1074/jbc.272.26.16679; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Yang MX, 1997, ARCH BIOCHEM BIOPHYS, V341, P25, DOI 10.1006/abbi.1997.9907	39	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2376	2380		10.1074/jbc.275.4.2376	http://dx.doi.org/10.1074/jbc.275.4.2376			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644688	hybrid			2022-12-25	WOS:000085128000020
J	Oleksiak, MF; Wu, S; Parker, C; Karchner, SI; Stegeman, JJ; Zeldin, DC				Oleksiak, MF; Wu, S; Parker, C; Karchner, SI; Stegeman, JJ; Zeldin, DC			Identification, functional characterization, and regulation of a new cytochrome P450 subfamily, the CYP2Ns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; PROTEIN-KINASE-C; EPOXYEICOSATRIENOIC ACIDS; MOLECULAR-CLONING; 11,12-EPOXYEICOSATRIENOIC ACID; AMINO-ACID; EPOXYGENASE; EXPRESSION; ENZYMES; SEQUENCES	The screening of liver and heart cDNA libraries from the teleost Fundulus heteroclitus with degenerate oligonucleotide probes to conserved alpha-helical regions in mammalian P450s resulted in the identification of two cDNAs that together represent a novel P450 subfamily, the CYP2Ns. Northern analysis demonstrated that CYP2N1 transcripts are most abundant in liver and intestine, whereas CYP2N2 mRNAs are most abundant in heart and brain. CYP2N1 and CYP2N2 proteins were co-expressed with NADPH cytochrome P450 oxidoreductase in Sf9 insect cells, and their ability to metabolize arachidonic acid and xenobiotic substrates was examined. Both CYP2N1. and CYP2N2 metabolize arachidonic acid to epoxyeicosatrienoic acids. Epoxidation is highly regio- and enantioselective with preferential formation of (8R,9S)-epoxyeicosatrienoic acid (optical purities are 91 and 90% for CYP2N1 and CYP2N2, respectively) and (11R,12S)-epoxyeicosatrienoic acid (optical purities are 92 and 70% for CYP2N1 and CYP2N2, respectively). CYP2N1 and CYP2N2 also catalyze the formation of a variety of hydroxyeicosatetraenoic acids. Both P450s have benzphetamine N-demethylase activities but show minimal alkoxyresorufin O-dealkylase activities. To investigate factors affecting CYP2N expression in vivo, CYP2N transcripts were examined following starvation and/or treatment with 12-O-tetradecanoyl phorbol-13-acetate. Intestinal CYP2N1 mRNAs decrease in starved and/or phorbol ester-treated fish, whereas intestinal CYP2N2 transcripts decrease only following phorbol ester treatment. Interestingly, cardiac CYP2N2 expression decreases following phorbol ester treatment but increases following starvation. These results demonstrate that members of this novel P450 subfamily encode early vertebrate forms of arachidonic acid catalysts that are widely expressed and are regulated by environmental factors. Given the wealth of information on the functional role of P450-derived arachidonate metabolites in mammals, we postulate that CYP2N1 and CYP2N2 products have similar biological functions in early vertebrates. The identity of the mammalian orthologue(s) of the CYP2Ns remains unknown.	NIEHS, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Woods Hole Oceanographic Institution	Stegeman, JJ (corresponding author), NIEHS, Pulm Pathobiol Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	jstegeman@whoi.edu	Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Stegeman, John/0000-0001-8204-5357	CSR NIH HHS [NA46RG0470] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025034, Z01ES050106] Funding Source: NIH RePORTER	CSR NIH HHS; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CAPDEVILA J, 1983, ENDOCRINOLOGY, V113, P421; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CAPDEVILA JH, 1986, ARCH BIOCHEM BIOPHYS, V231, P511; CAPDEVILA JH, 1981, P NATL ACAD SCI USA, V78, P7375; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CINTI DL, 1976, BIOCHEM BIOPH RES CO, V73, P171, DOI 10.1016/0006-291X(76)90512-X; CLARE RA, 1991, J CHROMATOGR-BIOMED, V562, P237, DOI 10.1016/0378-4347(91)80581-V; COREY EJ, 1980, J AM CHEM SOC, V102, P1433, DOI 10.1021/ja00524a043; CRAVEN PA, 1992, DIGEST DIS SCI, V37, P1162, DOI 10.1007/BF01296555; DAIKH BE, 1994, J PHARMACOL EXP THER, V271, P1427; DAVANZO C, 1990, ESTUARIES, V13, P20, DOI 10.2307/1351428; FALCK JR, 1990, METHOD ENZYMOL, V187, P357; FALCK JR, 1990, J BIOL CHEM, V265, P10244; FALCK JR, 1982, TETRAHEDRON LETT, V23, P1755, DOI 10.1016/S0040-4039(00)86732-5; Faulkner D. J, 1977, MARINE NATURAL PRODU; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FISCHER SM, 1985, ARACHIDONIC ACID MET; Fitzgerald Lisa M., 1993, Molecular Marine Biology and Biotechnology, V2, P112; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; GEBREMEDHIN D, 1992, AM J PHYSIOL, V263, pH519, DOI 10.1152/ajpheart.1992.263.2.H519; Gilday D, 1996, J BIOL CHEM, V271, P33054, DOI 10.1074/jbc.271.51.33054; GOTOH O, 1992, J BIOL CHEM, V267, P83; GRAVES PE, 1990, ARCH BIOCHEM BIOPHYS, V281, P106, DOI 10.1016/0003-9861(90)90419-Y; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HAHN ME, 1993, AQUAT TOXICOL, V26, P185, DOI 10.1016/0166-445X(93)90030-5; HAMMONDS TD, 1989, ANAL BIOCHEM, V182, P300, DOI 10.1016/0003-2697(89)90598-8; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HOBBS AA, 1986, J BIOL CHEM, V261, P9444; Hoebel BG, 1998, EUR J PHARMACOL, V346, P115, DOI 10.1016/S0014-2999(98)00118-6; JUNIER MP, 1990, ENDOCRINOLOGY, V126, P1534, DOI 10.1210/endo-126-3-1534; KARARA A, 1989, J BIOL CHEM, V264, P19822; Kmiec Z, 1996, J ENDOCRINOL INVEST, V19, P304, DOI 10.1007/BF03347867; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KUTSKY P, 1983, PROSTAGLANDINS, V26, P13, DOI 10.1016/0090-6980(83)90070-9; LAETHEM RM, 1994, BBA-PROTEIN STRUCT M, V1206, P42, DOI 10.1016/0167-4838(94)90070-1; LAETHEM RM, 1992, J PHARMACOL EXP THER, V262, P433; LAETHEM RM, 1993, J BIOL CHEM, V268, P12912; LEE CA, 1995, ARCH BIOCHEM BIOPHYS, V319, P157, DOI 10.1006/abbi.1995.1278; LEE PC, 1993, COMP BIOCHEM PHYS C, V106, P649, DOI 10.1016/0742-8413(93)90222-7; MANNA S, 1983, TETRAHEDRON LETT, V24, P33, DOI 10.1016/S0040-4039(00)81319-2; MAURENTE G, 1994, BIOCHIM BIOPHYS ACTA, V1212, P109; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MOFFAT MP, 1993, AM J PHYSIOL, V264, pH1154, DOI 10.1152/ajpheart.1993.264.4.H1154; MORRISON AR, 1981, P NATL ACAD SCI-BIOL, V78, P7375, DOI 10.1073/pnas.78.12.7375; MOSSET P, 1986, TETRAHEDRON LETT, V27, P6035, DOI 10.1016/S0040-4039(00)85391-5; MOUSTAKIS CA, 1985, J AM CHEM SOC, V107, P5283, DOI 10.1021/ja00304a048; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NAVARRO I, 1992, COMP BIOCHEM PHYS A, V102, P401, DOI 10.1016/0300-9629(92)90154-I; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIMOTO M, 1993, BIOCHEMISTRY-US, V32, P8863, DOI 10.1021/bi00085a018; OLIW EH, 1982, J BIOL CHEM, V257, P3771; OMURA T, 1964, J BIOL CHEM, V239, P2370; PORTER NA, 1979, J ORG CHEM, V44, P3177, DOI 10.1021/jo01332a017; PROCTOR KG, 1989, BLOOD VESSELS, V26, P53; Qu W, 1998, MOL PHARMACOL, V54, P504, DOI 10.1124/mol.54.3.504; RIFKIND AB, 1995, ARCH BIOCHEM BIOPHYS, V320, P380, DOI 10.1016/0003-9861(95)90023-3; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scarborough PE, 1999, DRUG METAB REV, V31, P205, DOI 10.1081/DMR-100101915; Schlezinger JJ, 1998, ARCH BIOCHEM BIOPHYS, V353, P265, DOI 10.1006/abbi.1998.0651; SENGER H, 1997, COMP BIOCH PHYSL, V116, P257; UZUMAKI H, 1986, CARCINOGENESIS, V7, P289, DOI 10.1093/carcin/7.2.289; WAKABAYASHI K, 1961, BIOCHIM BIOPHYS ACTA, V48, P615, DOI 10.1016/0006-3002(61)90069-5; WELLS PG, 1989, TOXICOL APPL PHARM, V97, P398, DOI 10.1016/0041-008X(89)90244-5; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; Wu S, 1996, J BIOL CHEM, V271, P3460; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551; YOSHIDA S, 1990, ARCH BIOCHEM BIOPHYS, V280, P346, DOI 10.1016/0003-9861(90)90340-5; Zacharewski TR, 1996, AM SOC TEST MATER, V1262, P165, DOI 10.1520/STP15581S; ZELDIN DC, 1995, J CLIN INVEST, V95, P2150, DOI 10.1172/JCI117904	76	47	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2312	2321		10.1074/jbc.275.4.2312	http://dx.doi.org/10.1074/jbc.275.4.2312			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644680	hybrid			2022-12-25	WOS:000085128000012
J	Croissant, JD; Carpenter, S; Bader, D				Croissant, JD; Carpenter, S; Bader, D			Identification and genomic cloning of CMHC1 - A unique myosin heavy chain expressed exclusively in the developing chicken heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-I GENE; SKELETAL-MUSCLE; MESSENGER-RNA; CARDIAC-MUSCLE; TRANSCRIPTION; FAMILY	We report the identification and cloning of a unique chick myosin heavy chain (CMHC1) that is expressed exclusively in the heart during embryogenesis. Using primers specific to myosin heavy chains, we used reverse transcriptase-polymerase chain reaction to clone and isolate CMHC1 from embryonic day 10 chicken heart RNA. Sequence analysis indicated that CMHC1 was a novel member of the myosin heavy chain family. Expression of the CMHC1 transcripts was detected in Hamburger Hamilton stage 10 chick embryos in the fusing myocardium, Expression of CMHC1 was maintained at high levels throughout the tubular heart of later stage embryos. Reverse transcriptase-polymerase chain reaction and in situ hybridizations failed to detect CMHC1 transcripts in the developing somites, limb buds, or skeletal musculature at any stage of chick development. Genomic CMHC1 clones have been isolated that contain sequences approximately 5.2 kilobase upstream of the presumptive CMHC1 transcription start site. Portions of the upstream regulatory region induced a al-fold increase in reporter gene expression in primary cardiomyocytes, Because of its unique cardiac-restricted expression, CMHC1 will provide an excellent model system to study the molecular mechanisms required for the early developmental regulation of heart-specific genes.	Vanderbilt Univ, Med Ctr, Gladys P Stahlman Cardiovasc Res Lab, Nashville, TN 37212 USA	Vanderbilt University	Bader, D (corresponding author), Vanderbilt Univ, Med Ctr, Gladys P Stahlman Cardiovasc Res Lab, Nashville, TN 37212 USA.							AUSONI S, 1994, J BIOL CHEM, V269, P339; BISAHA JG, 1991, DEV BIOL, V148, P355, DOI 10.1016/0012-1606(91)90343-2; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Di Lisi R, 1998, J BIOL CHEM, V273, P25371, DOI 10.1074/jbc.273.39.25371; EPP TA, 1993, GENOMICS, V18, P505, DOI 10.1016/S0888-7543(11)80006-6; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HASTINGS KEM, 1991, J BIOL CHEM, V266, P19659; He CZ, 1997, J BIOL CHEM, V272, P28550, DOI 10.1074/jbc.272.45.28550; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; KENDREW J, 1994, ENCY MOL BIOL, P700; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; NAKAYAMA S, 1994, J BIOCHEM-TOKYO, V115, P909, DOI 10.1093/oxfordjournals.jbchem.a124439; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; Nikovits W, 1996, J BIOL CHEM, V271, P17047, DOI 10.1074/jbc.271.29.17047; RADICE GP, 1989, DEV BIOL, V133, P562, DOI 10.1016/0012-1606(89)90058-4; ROBBINS J, 1986, J BIOL CHEM, V261, P6606; RUSHBROOK JI, 1994, J MUSCLE RES CELL M, V15, P505, DOI 10.1007/BF00121157; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; SEIDMAN CE, 1991, MOL BIOL MED, V8, P159; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; STEWART AFR, 1991, J MOL EVOL, V33, P357, DOI 10.1007/BF02102866; Wang GF, 1996, J BIOL CHEM, V271, P19836, DOI 10.1074/jbc.271.33.19836; WANG RX, 1994, J MOL CELL CARDIOL, V26, P1155, DOI 10.1006/jmcc.1994.1134; Weiss A, 1996, ANNU REV CELL DEV BI, V12, P417, DOI 10.1146/annurev.cellbio.12.1.417; Xavier-Neto J, 1999, DEVELOPMENT, V126, P2677; YUTZEY KE, 1994, DEVELOPMENT, V120, P871	30	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1944	1951		10.1074/jbc.275.3.1944	http://dx.doi.org/10.1074/jbc.275.3.1944			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636896	hybrid			2022-12-25	WOS:000084940000059
J	de Caestecker, MP; Yahata, T; Wang, D; Parks, WT; Huang, SX; Hill, CS; Shioda, T; Roberts, AB; Lechleider, RJ				de Caestecker, MP; Yahata, T; Wang, D; Parks, WT; Huang, SX; Hill, CS; Shioda, T; Roberts, AB; Lechleider, RJ			The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; TUMOR-SUPPRESSOR; HETERO-OLIGOMERIZATION; BINDING-PROTEIN; DNA-BINDING; COACTIVATOR; CELLS; PHOSPHORYLATION; DOWNSTREAM; RESPONSES	Transforming growth factor-p (TGF-P) family members signal through a unique set of intracellular proteins called Smads, Smad4, previously identified as the tumor suppressor DPC4, is functionally distinct among the Smad family, and is required for the assembly and transcriptional activation of diverse, Smad-DNA complexes. We previously identified a 48-amino acid proline-rich regulatory element within the middle linker domain of this molecule, the Smad4 activation domain (SAD), which is essential for mediating these signaling activities. We now characterize the functional activity of the SAD. Mutants lacking the SAD are still able to form complexes with other Smad family members and associated transcription factors, but cannot activate transcription in these complexes. Furthermore, the SAD itself is able to activate transcription in heterologous reporter assays, identifying it as a proline-rich transcriptional activation domain, and indicating that the SAD is both necessary and sufficient to activate Smad-dependent transcriptional responses. We show that transcriptional activation by the SAD is p300-dependent, and demonstrate that this activity is associated with a physical interaction of the SAD with the amino terminus of p300, These data identify a novel function of the middle linker region of Smad4, and define the role of the SAD as an important locus determining the transcriptional activation of the Smad complex.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Massachusetts Gen Hosp, Ctr Canc, Lab Tumor Biol, Charlestown, MA 02129 USA; Imperial Canc Res Fund, Dev Signaling Lab, London WC2A 3PX, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Massachusetts General Hospital; Cancer Research UK	Lechleider, RJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA.	Robertsa@dce41.nci.nih.gov		Hill, Caroline/0000-0002-8632-0480; Parks, W. Tony/0000-0001-7341-3277				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Eckner R, 1996, BIOL CHEM, V377, P685; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hudson JB, 1998, DEVELOPMENT, V125, P1407; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LATCHMAN DS, 1993, INT J EXP PATHOL, V74, P417; LEDAI J, 1998, CANCER RES, V58, P4592; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Qin B, 1999, STRUCTURE, V7, P1493, DOI 10.1016/S0969-2126(00)88340-9; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	38	140	145	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2115	2122		10.1074/jbc.275.3.2115	http://dx.doi.org/10.1074/jbc.275.3.2115			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636916	hybrid			2022-12-25	WOS:000084940000079
J	Weisman-Shomer, P; Naot, Y; Fry, M				Weisman-Shomer, P; Naot, Y; Fry, M			Tetrahelical forms of the fragile X syndrome expanded sequence d(CGG)(n) are destabilized by two heterogeneous nuclear ribonucleoprotein-related telomeric DNA-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHESIS IN-VITRO; TRIPLET REPEATS; TRINUCLEOTIDE REPEATS; HAIRPIN STRUCTURES; RAT HEPATOCYTES; METHYLATION; FMR-1; INSTABILITY; EXPRESSION; QUADRUPLEX	Formations of hairpin and tetrahelical structures by the trinucleotide repeat sequence d(CGG)(n) might contribute to its expansion in fragile X syndrome. Here we show that tetraplex structures of d(CGG)(n) are destabilized by two mammalian heterogeneous nuclear ribonucleoprotein-related tetraplex telomeric DNA-binding and -stabilizing proteins, quadruplex telomeric DNA-binding protein 42 (qTBP42) (Sarig, G., Weisman-Shomer, P., Erlitzki, R., and Fry, M. (1997) J. Biol. Chem. 272, 4474-4482) and unimolecular quadruplex telomeric DNA-binding protein 25 (uqTBP25) (Erlitzki, R., and Fry, M. (1997) J. Biol. Chem. 272, 15881-15890). Bluntended and 3'-tailed or 3'- and 8'-tailed bimolecular tetraplex structures of d(CGG)(n) and guanine-sparse 20-/46-mer partial DNA duplex were progressively destabilized by increasing amounts of qTBP42 or uqTBP25 in time-dependent and ATP- or Mg2+-independent reactions. By contrast, tetraplex structures of telomeric and IgG sequences or guanine-rich double-stranded DNA resisted destabilization by qTBP42 or uqTBP25. Increased stability of tetraplex d(CGG)(n) in the presence of K+ or Na+ ions or at lowered reaction temperature diminished the destabilizing activity of uqTBP25. The contrasting stabilization of tetraplex telomeric DNA and destabilization of tetraplex d(CGG)(n) by qTBP42 and uqTBP25 suggested that sequence or structural differences between these tetraplexes might serve as cues for the differential stabilizing/destabilizing activities.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Fry, M (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, POB 9649, IL-31096 Haifa, Israel.							Baran N, 1997, NUCLEIC ACIDS RES, V25, P297, DOI 10.1093/nar/25.2.297; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; CHEN FM, 1995, J BIOL CHEM, V270, P23090, DOI 10.1074/jbc.270.39.23090; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; CVEKI A, 1995, BBA-GENE STRUCT EXPR, V1261, P290, DOI 10.1016/0167-4781(95)00021-8; Darlow JM, 1998, J MOL BIOL, V275, P3, DOI 10.1006/jmbi.1997.1453; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Elliot Brownlee W., 1996, FRAGILE X SYNDROME D, P88; Erlitzki R, 1997, J BIOL CHEM, V272, P15881, DOI 10.1074/jbc.272.25.15881; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GACY AM, 1995, CELL, V81, P533; GRODENIN DA, 1997, NAT GENET, V16, P116; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; Hansen RS, 1997, P NATL ACAD SCI USA, V94, P4587, DOI 10.1073/pnas.94.9.4587; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KETTANI A, 1995, J MOL BIOL, V254, P638, DOI 10.1006/jmbi.1995.0644; KHAN FA, 1991, FEBS LETT, V290, P159, DOI 10.1016/0014-5793(91)81249-8; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUMAR A, 1986, J BIOL CHEM, V261, P1266; LUO S, 1993, SOMAT CELL MOLEC GEN, V9, P393; Mariappan SVS, 1998, J MOL BIOL, V283, P111, DOI 10.1006/jmbi.1998.1990; McMurray CT, 1999, P NATL ACAD SCI USA, V96, P1823, DOI 10.1073/pnas.96.5.1823; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PATEL DJ, 1999, OXFORD HDB NUCL ACID, P389; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J, 1989, MOL CLONING LAB MANU, VII; Sandberg G, 1997, NUCLEIC ACIDS RES, V25, P2883, DOI 10.1093/nar/25.14.2883; Sarig G, 1997, BIOCHEM BIOPH RES CO, V237, P617, DOI 10.1006/bbrc.1997.7198; Sarig G, 1997, J BIOL CHEM, V272, P4474, DOI 10.1074/jbc.272.7.4474; Shafer RH, 1998, PROG NUCLEIC ACID RE, V59, P55; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Sherman S., 1996, FRAGILE X SYNDROME D, P165; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; Smith SS, 1998, INT J MOL MED, V1, P147; Soulez M, 1996, BIOCHEM BIOPH RES CO, V219, P418, DOI 10.1006/bbrc.1996.0248; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666	49	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2231	2238		10.1074/jbc.275.3.2231	http://dx.doi.org/10.1074/jbc.275.3.2231			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636930	hybrid			2022-12-25	WOS:000084940000093
J	Costantini, P; Belzacq, AS; La Vieira, H; Larochette, N; de Pablo, MA; Zamzami, N; Susin, SA; Brenner, C; Kroemer, G				Costantini, P; Belzacq, AS; La Vieira, H; Larochette, N; de Pablo, MA; Zamzami, N; Susin, SA; Brenner, C; Kroemer, G			Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis	ONCOGENE			English	Article						ADP/ATP carrier; Bcl-2; cell death; mitochondria; permeability transition	MITOCHONDRIAL BENZODIAZEPINE RECEPTOR; DEPENDENT ANION CHANNEL; CYTOCHROME-C; ADP/ATP CARRIER; BCL-2; MEMBRANE; RELEASE; INDUCTION; PROTEIN; PHENANTHROLINE	Mitochondrial membrane permeabilization is a critical event in the process leading to physiological or chemotherapy-induced apoptosis. This permeabilization event is at least in part under the control of the permeability transition pore complex (PTPC), which interacts with oncoproteins from the Bcl-2 family as well as with tumor suppressor proteins from the Bar family, which inhibit or facilitate membrane permeabilization, respectively. Here we show that thiol crosslinking agents including diazenedicarboxylic acid bis SN,N-dimethylamide (diamide), dithiodipyridine (DTDP), or bis-maleimido-hexane (BMH) can act on the adenine nucleotide translocator (ANT), one of the proteins within the PTPC. ANT alone reconstituted into artificial lipid bilayers suffices to confer a membrane permeabilization response to thiol crosslinking agents. Diamide, DTDP, and BMH but not tert-butylhydroperoxide or arsenite cause the oxidation of a critical cysteine residue (Cys 56) of ANT. Thiol modification within ANT is observed in intact cells, isolated mitochondria, and purified ANT. Recombinant Bcl-2 fails to prevent thiol modification of ANT. Concomitantly, a series of different thiol crosslinking agents (diamide, DTDP, and BMH, phenylarsine oxide) but not tert-butylhydroperoxide or arsenite induce mitochondrial membrane permeabilization and cell death irrespective of the expression level of Bcl-2. These data indicate that thiol crosslinkers cause a covalent modification of ANT which, beyond any control by Bcl-2, leads to mitochondrial membrane permeabilization and cell death.	CNRS, ERS 1984, F-94801 Villejuif, France; Univ Technol Compiegne, CNRS, UPRES A6022, F-60205 Compiegne, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne	Kroemer, G (corresponding author), CNRS, ERS 1984, 19 Rue Guy Moquet, F-94801 Villejuif, France.		Susin, Santos A/Q-6754-2017; Kroemer, Guido/AAY-9859-2020; LAROCHETTE, Nathanael/R-4298-2017; KROEMER, Guido/B-4263-2013	Susin, Santos A/0000-0002-3366-1628; LAROCHETTE, Nathanael/0000-0002-7936-678X; KROEMER, Guido/0000-0002-9334-4405; Vieira, Helena/0000-0001-9415-3742				Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beyer K, 1996, BIOCHEMISTRY-US, V35, P15784, DOI 10.1021/bi9610055; BRENNER C, 1999, IN PRESS ONCOGENE; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; Costantini P, 1998, BBA-BIOENERGETICS, V1365, P385, DOI 10.1016/S0005-2728(98)00090-5; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; GironCalle J, 1996, BIOCHEMISTRY-US, V35, P15440, DOI 10.1021/bi960840j; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SUSIN SA, 1999, IN PRESS METH ENZYMO; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864	45	236	246	0	13	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					307	314		10.1038/sj.onc.1203299	http://dx.doi.org/10.1038/sj.onc.1203299			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645010				2022-12-25	WOS:000084844400017
J	Namba, K; Abe, M; Saito, S; Satake, M; Ohmoto, T; Watanabe, T; Sato, Y				Namba, K; Abe, M; Saito, S; Satake, M; Ohmoto, T; Watanabe, T; Sato, Y			Indispensable role of the transcription factor PEBP2/CBF in angiogenic activity of a murine endothelial cell MSS31	ONCOGENE			English	Article						PEBP2/CBF; transcription factor; angiogenesis	ACUTE MYELOID-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; RECEPTOR TYROSINE KINASE; MYOSIN HEAVY-CHAIN; DEFINITIVE HEMATOPOIESIS; PLASMINOGEN-ACTIVATOR; GROWTH-FACTOR; DNA-BINDING; PROTOONCOGENE PRODUCT; VASCULAR DEVELOPMENT	Mice lacking the AML1/PEBP2 alpha B/CBFa2 gene or PEBP2 beta/CBFb gene exhibit a defect in definitive hematopoiesis and die in utero because of hemorrhage in the central nervous system. Hematopoiesis in the embryo is considered to be tightly associated with vascular development, Here ive examined whether PEBP2/CBF plays any role in angiogenesis besides that in definitive hematopoiesis, We found that AML1/ PEBP2 alpha B/CBFa2, PEBP2 alpha A/CBFa1, and PEBP2 beta/ CBFb were expressed in a murine endothelial cell Line MISS31, The expression of these molecules as cell as the DNA binding activity of PEBP2/CBF were augmented by angiogenic growth factors such as bFGF and VEGF. Moreover, the expression of PEBP2 alpha/CBFa protein in endothelial tells was confirmed at the site of angiogenesis in vivo, To further clarify the role of PEBP2/CF in angiogenesis, we established permanent transfectants of PEBP2 beta-MYH11 gene, one that interacts with the runt domain of the alpha subunit and deregulates PEBP2/CBF in a dominant interfering manner. Proliferation, migration, and tube formation of the PEBP2 beta-MYH11 transfectants were significantly reduced in comparison with those activities of the mock transfectants. These results suggest that transcription factor PEBP2/CBF plays an important role in angiogenesis.	Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 7008558, Japan	Tohoku University; Tohoku University; Okayama University	Sato, Y (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Vasc Biol, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.							BAE SC, 1993, ONCOGENE, V8, P809; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; CLAXTON DF, 1994, BLOOD, V83, P1850; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DICKSON MC, 1995, DEVELOPMENT, V121, P1945; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nishikawa S, 1998, IMMUNITY, V8, P761, DOI 10.1016/S1074-7613(00)80581-6; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SATO Y, 1993, EXP CELL RES, V204, P223, DOI 10.1006/excr.1993.1028; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Tanaka Y, 1998, ONCOGENE, V17, P699, DOI 10.1038/sj.onc.1201985; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; WOTTON D, 1993, LEUKEMIA S, V2, pS55; YANAI N, 1991, CELL STRUCT FUNCT, V16, P87, DOI 10.1247/csf.16.87; YANG JT, 1993, DEVELOPMENT, V119, P1093	48	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					106	114		10.1038/sj.onc.1203257	http://dx.doi.org/10.1038/sj.onc.1203257			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644985				2022-12-25	WOS:000084844300012
J	Riedel, H; Yousaf, N; Zhao, YY; Dai, HP; Deng, YP; Wang, J				Riedel, H; Yousaf, N; Zhao, YY; Dai, HP; Deng, YP; Wang, J			PSM, a mediator of PDGF-BB-, IGF-I-, and insulin-stimulated mitogenesis	ONCOGENE			English	Article						SH2-B; growth factor; receptor tyrosine kinase; adapter; trojan peptide; malignant cell transformation	GROWTH-FACTOR-I; SH2 DOMAIN; PHOSPHATIDYLINOSITOL-3 KINASE; SIGNAL-TRANSDUCTION; TYROSINE KINASE; TRK RECEPTORS; PROTEINS; SYSTEM; CELLS; PHOSPHORYLATION	PSM/SH2-B has been described as a cellular partner of the Fc epsilon RI receptor, insulin receptor (IR), insulin-like growth factor-I (IGF-I) receptor (IGF-IR), and nerve growth factor receptor (TrkA). A function has been proposed in neuronal differentiation and development but its role in other signaling pathways is still unclear. To further elucidate the physiologic role of PSM we have identified additional mitogenic receptor tyrosine kinases as putative PSM partners including platelet-derived growth factor (PDGF) receptor (PDGFR) beta, hepatocyte growth factor receptor (Met), and fibroblast growth factor receptor. We have mapped Y740 as a site of PDGFR beta that is involved in the association with PSM. We have further investigated the putative role of PSM in mitogenesis with three independent experimental strategies and found that all consistently suggested a role as a positive, stimulatory signaling adapter in normal NIH3T3 and baby hamster kidney fibroblasts, (1) PSM expression from cDNA using an ecdysone-regulated transient expression system stimulated PDGF-BB-, IGF-I-, and insulin- but not EGF-induced DNA synthesis in an ecdysone dose-responsive fashion; (2) Microinjection of the (dominant negative) PSM SH2 domain interfered with PDGF-BB- and insulin-induced DNA synthesis; and (3) A peptide mimetic of the PSM Pro-rich putative SH3 domain-binding region interfered with PDGF-BB-, IGF-I-, and insulin- but not with EGF-induced DNA synthesis in NIH3T3 fibroblasts. This experiment was based on cell-permeable fusion peptides with the Drosophila antennapedia homeodomain which effectively traverse the plasma membrane of cultured cells, These experimental strategies independently suggest that PSM functions as a positive, stimulatory, mitogenic signaling mediator in PDGF-BB, IGF-I, and insulin but not in EGF action. This function appears to involve the PSM SH2 domain as well as the Pro-rich putative SH3 domain binding region. Our findings support the model that PSM participates as an adapter in carious mitogenic signaling mechanisms by linking an activated (receptor) phospho-tyrosine to the SH3 domain of an unknown cellular partner.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Riedel, H (corresponding author), Wayne State Univ, Dept Biol Sci, 2171 BSB, Detroit, MI 48202 USA.			Deng, Youping/0000-0002-5951-8213	NCI NIH HHS [R01 CA77873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed Z, 1999, BIOCHEM J, V341, P665, DOI 10.1042/0264-6021:3410665; BASERGA R, 1995, CANCER RES, V55, P249; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; BROWN SAN, 1993, BIOCHEM BIOPH RES CO, V193, P1116, DOI 10.1006/bbrc.1993.1741; Carter-Su C, 1998, RECENT PROG HORM RES, V53, P61; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; COOPER J, 1993, BIOL PLATELET DERIVE, P44; DeMali KA, 1997, J BIOL CHEM, V272, P9011; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Gotoh N, 1995, ONCOGENE, V11, P2525; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1993, BIOL PLATELET DERIVE, P1; Higaki M, 1996, J BIOL CHEM, V271, P29342, DOI 10.1074/jbc.271.46.29342; Hughes AD, 1996, GEN PHARMACOL-VASC S, V27, P1079, DOI 10.1016/S0306-3623(96)00060-2; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; Kotani K, 1998, BIOCHEM J, V335, P103, DOI 10.1042/bj3350103; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Moodie SA, 1999, J BIOL CHEM, V274, P11186, DOI 10.1074/jbc.274.16.11186; MURAGAKI Y, 1995, J COMP NEUROL, V356, P387, DOI 10.1002/cne.903560306; MYERS MG, 1991, J BIOL CHEM, V266, P10616; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; OOI J, 1995, ONCOGENE, V10, P1621; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Rui LY, 1999, J BIOL CHEM, V274, P10590, DOI 10.1074/jbc.274.15.10590; Rui LY, 1999, J BIOL CHEM, V274, P26485, DOI 10.1074/jbc.274.37.26485; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WENNSTROM S, 1994, ONCOGENE, V9, P651; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; ZVIBEL I, 1985, INT J CANCER, V36, P261, DOI 10.1002/ijc.2910360220	53	35	36	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					39	50		10.1038/sj.onc.1203253	http://dx.doi.org/10.1038/sj.onc.1203253			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644978				2022-12-25	WOS:000084844300005
J	Naya, FJ; Mercer, B; Shelton, J; Richardson, JA; Williams, RS; Olson, EN				Naya, FJ; Mercer, B; Shelton, J; Richardson, JA; Williams, RS; Olson, EN			Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; CYCLOSPORINE; ACTIVATION; PROTEINS; ELEMENTS; FAMILY; MYOD; MICE	Adult skeletal muscle fibers can be categorized into fast and slow twitch subtypes based on specialized contractile and metabolic properties and on distinctive patterns of muscle gene expression. Muscle fiber-type characteristics are dependent on the frequency of motor nerve stimulation and are thought to be controlled by calcium-dependent signaling. The calcium, calmodulin-dependent protein phosphatase, calcineurin, stimulates slow fiber-specific gene promoters in cultured skeletal muscle cells, and the calcineurin inhibitor, cyclosporin A inhibits slow fiber gene expression in vivo, suggesting a key role of calcineurin in activation of the slow muscle fiber phenotype, Calcineurin has also been shown to induce hypertrophy of cardiac muscle and to mediate the hypertrophic effects of insulin-like growth factor-1 on skeletal myocytes in vitro. To determine whether activated calcineurin was sufficient to induce slow fiber gene expression and hypertrophy in adult skeletal muscle in vivo, we created transgenic mice that expressed activated calcineurin under control of the muscle creatine kinase enhancer. These mice exhibited an increase in slow muscle fibers, but no evidence for skeletal muscle hypertrophy, These results demonstrate that calcineurin activation is sufficient to induce the slow fiber gene regulatory program in vivo and suggest that additional signals are required for skeletal muscle hypertrophy.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010; Calvo S, 1999, MOL CELL BIOL, V19, P515; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CHIN ER, 1996, PHYSIOLOGIST, V39, pA75; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dunn SE, 1999, J BIOL CHEM, V274, P21908, DOI 10.1074/jbc.274.31.21908; Esser K, 1999, J BIOL CHEM, V274, P12095, DOI 10.1074/jbc.274.17.12095; GOY JJ, 1989, LANCET, V1, P1446; Hughes SM, 1998, CURR BIOL, V8, pR892, DOI 10.1016/S0960-9822(07)00554-4; HUGHES SM, 1993, DEVELOPMENT, V118, P1137; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rawls A, 1998, DEVELOPMENT, V125, P2349; SALMONS S, 1976, NATURE, V263, P30, DOI 10.1038/263030a0; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; [No title captured]	29	319	334	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4545	4548		10.1074/jbc.275.7.4545	http://dx.doi.org/10.1074/jbc.275.7.4545			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671477	hybrid			2022-12-25	WOS:000085378200003
J	Oda, M; Sakitani, K; Kaibori, M; Inoue, T; Kamiyama, Y; Okumura, T				Oda, M; Sakitani, K; Kaibori, M; Inoue, T; Kamiyama, Y; Okumura, T			Vicinal dithiol-binding agent, phenylarsine oxide, inhibits inducible nitric-oxide synthase gene expression at a step of nuclear factor-kappa B DNA binding in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; HEAT-SHOCK RESPONSE; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; IN-VITRO; T-CELLS; PROTEIN; TRANSCRIPTION; ACTIVATION; INTERLEUKIN-1-BETA	Inflammatory cytokine interleukin 1 beta induces inducible nitric-oxide synthase (iNOS) mRNA and its protein, which are followed by increasing the production of nitric oxide, in primary cultures of rat hepatocytes. Nuclear factor-kappa B (NF-kappa B), an important transcription factor for iNOS gene expression, is also activated and translocated to the nucleus. In the present study, we found that vicinal dithiol-binding agent, phenylarsine oxide (PAO), inhibited the induction of iNOS protein and mRNA as well as the release of nitrite (nitric oxide metabolite) into the culture medium. Simultaneous addition of a vicinal dithiol compound, 2,3-dimercaptopropanol, with PAO completely abolished these inhibitions. PAO could not prevent either degradation of an inhibitory protein, I kappa B, of NF-kappa B or translocation of NF-kappa B to the nucleus, However, electrophoretic mobility shift assay demonstrated that PAO decreased the interaction between NF-kappa B and its binding consensus oligonucleotide. Transfection experiments with iNOS promoter-luciferase construct revealed that PAO inhibited NF-kappa B binding to DNA These results indicate that PAO inhibits iNOS gene expression at a step of NF-kappa B binding to DNA by modifying its vicinal dithiol moiety, which may play a crucial role for the iNOS regulation in hepatocytes.	Kansai Med Univ, Dept Med Chem, Moriguchi, Osaka 5708506, Japan; Kansai Med Univ, Dept Surg 1, Moriguchi, Osaka 5708506, Japan; Kansai Med Univ, Dept Internal Med 3, Moriguchi, Osaka 5708506, Japan	Kansai Medical University; Kansai Medical University; Kansai Medical University	Okumura, T (corresponding author), Kansai Med Univ, Dept Med Chem, 10-15 Fumizonocho, Moriguchi, Osaka 5708506, Japan.							Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; Beck KF, 1996, FEBS LETT, V394, P263, DOI 10.1016/0014-5793(96)00966-0; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; deVera ME, 1996, SURGERY, V120, P144, DOI 10.1016/S0039-6060(96)80281-9; deVera ME, 1996, HEPATOLOGY, V24, P1238; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GELLER DA, 1995, J IMMUNOL, V155, P4890; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HORIUTI Y, 1991, CELL STRUCT FUNCT, V16, P203, DOI 10.1247/csf.16.203; ISLAM F, 1991, ARCH BIOCHEM BIOPHYS, V289, P161, DOI 10.1016/0003-9861(91)90456-S; Kaibori M, 1999, J HEPATOL, V30, P1138, DOI 10.1016/S0168-8278(99)80270-0; KALEF E, 1993, ANAL BIOCHEM, V212, P325, DOI 10.1006/abio.1993.1337; KANEMAKI T, 1993, PROSTAGLANDINS, V45, P459, DOI 10.1016/0090-6980(93)90122-N; Kim IY, 1997, P NATL ACAD SCI USA, V94, P12904, DOI 10.1073/pnas.94.24.12904; Kitade H, 1996, HEPATOLOGY, V23, P797, DOI 10.1002/hep.510230421; Kitade H, 1996, BBA-MOL CELL RES, V1311, P20, DOI 10.1016/0167-4889(95)00188-3; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Nunokawa Y, 1996, BIOCHEM BIOPH RES CO, V223, P347, DOI 10.1006/bbrc.1996.0897; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; NUSSLER AK, 1993, BIOCHEM BIOPH RES CO, V194, P826, DOI 10.1006/bbrc.1993.1896; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sakitani K, 1998, GENES CELLS, V3, P321, DOI 10.1046/j.1365-2443.1998.00193.x; Sakitani K, 1997, HEPATOLOGY, V25, P416; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shumilla JA, 1998, ARCH BIOCHEM BIOPHYS, V349, P356, DOI 10.1006/abbi.1997.0470; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; Spitsin SV, 1997, MOL MED, V3, P315, DOI 10.1007/BF03401810; SPITZER JA, 1994, HEPATOLOGY, V19, P217, DOI 10.1002/hep.1840190132; STADLER J, 1991, AM J PHYSIOL, V260, P910; Tewes F, 1997, EUR J IMMUNOL, V27, P3015, DOI 10.1002/eji.1830271139; Vos TA, 1999, HEPATOLOGY, V29, P421, DOI 10.1002/hep.510290231; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; ZAHLER WL, 1968, J BIOL CHEM, V243, P716	50	59	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4369	4373		10.1074/jbc.275.6.4369	http://dx.doi.org/10.1074/jbc.275.6.4369			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660607	hybrid			2022-12-25	WOS:000085288800091
J	Patel, BN; Dunn, RJ; David, S				Patel, BN; Dunn, RJ; David, S			Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; IRON UPTAKE; GENE-EXPRESSION; PLASMA-PROTEINS; ACERULOPLASMINEMIA; CELLS; PHOSPHATIDYLINOSITOL; METABOLISM; RETINA; ORIGIN	Ceruloplasmin is a copper containing ferroxidase that is essential for normal iron homeostasis. Whereas ceruloplasmin in plasma is produced and secreted by hepatocytes, in the brain a glycosylphosphatidylinositol (GPI)-anchored form of ceruloplasmin is expressed on the surface of astrocytes, By using a cDNA cloning approach, we have now determined that the GPI-anchored form of ceruloplasmin is generated by alternative RNA splicing. The splicing occurs downstream of exon 18 and replaces the C-terminal 5 amino acids of the secreted form with an alternative 30 amino acids that signal GPI anchor addition. RNase protection analysis demonstrates that the GPI-anchored form is the major form in the brain, whereas the secreted form predominates in the liver. Individuals with aceruloplasminemia, a hereditary deficiency of ceruloplasmin, have severe iron deposition in a number of organs, including the brain where it results-in neurodegeneration. Therefore, this novel GPI-anchored form of ceruloplasmin is likely to play an important role in iron metabolism in the central nervous system.	Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; McGill Univ, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University	David, S (corresponding author), Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.							ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BELL JE, 1991, NEUROPATH APPL NEURO, V17, P441, DOI 10.1111/j.1365-2990.1991.tb00748.x; Bothwell TH, 1998, SEMIN HEMATOL, V35, P55; Bottai D, 1997, J COMP NEUROL, V389, P65, DOI 10.1002/(SICI)1096-9861(19971208)389:1<65::AID-CNE5>3.0.CO;2-C; DAIMON M, 1995, BIOCHEM BIOPH RES CO, V208, P1028, DOI 10.1006/bbrc.1995.1437; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; FLEMING RE, 1990, J BIOL CHEM, V265, P7701; GAITSKHOKI V S, 1990, Biokhimiya, V55, P927; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; GUTTERIDGE JMC, 1992, ANN NEUROL S, V32, P16; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Klomp LWJ, 1996, HUM MOL GENET, V5, P1989, DOI 10.1093/hmg/5.12.1989; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; KOSCHINSKY ML, 1986, P NATL ACAD SCI USA, V83, P5086, DOI 10.1073/pnas.83.14.5086; Levin LA, 1998, INVEST OPHTH VIS SCI, V39, P157; Lindley PF, 1997, J BIOL INORG CHEM, V2, P454, DOI 10.1007/s007750050156; LISANTI MP, 1991, J CELL SCI, V99, P637; LOW MG, 1985, NATURE, V318, P62, DOI 10.1038/318062a0; MITTAL B, 1994, MOL CELL NEUROSCI, V5, P63, DOI 10.1006/mcne.1994.1006; Miyajima H, 1997, ANN NEUROL, V41, P404, DOI 10.1002/ana.410410318; Miyajima H, 1998, NEUROLOGY, V51, P1188, DOI 10.1212/WNL.51.4.1188; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; MOLLGARD K, 1988, DEV BIOL, V128, P207, DOI 10.1016/0012-1606(88)90283-7; OSAKI S, 1966, J BIOL CHEM, V241, P2746; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; RICHARDSON DR, 1995, BBA-MOL CELL RES, V1269, P105, DOI 10.1016/0167-4889(95)00096-B; ROSKAMS A, 1990, J NEUROSCI RES, V31, P421; ROYLE NJ, 1987, SOMAT CELL MOLEC GEN, V13, P285, DOI 10.1007/BF01535211; Sambrook J., 2002, MOL CLONING LAB MANU; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; THOMAS T, 1989, DEV BIOL, V134, P38, DOI 10.1016/0012-1606(89)90076-6; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; YANG FM, 1990, J BIOL CHEM, V265, P10780; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Young SP, 1997, FEBS LETT, V411, P93, DOI 10.1016/S0014-5793(97)00478-X; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	38	160	169	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4305	4310		10.1074/jbc.275.6.4305	http://dx.doi.org/10.1074/jbc.275.6.4305			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660599	hybrid			2022-12-25	WOS:000085288800083
J	Kapyla, J; Ivaska, J; Riikonen, R; Nykvist, P; Pentikainen, O; Johnson, M; Heino, J				Kapyla, J; Ivaska, J; Riikonen, R; Nykvist, P; Pentikainen, O; Johnson, M; Heino, J			Integrin alpha I-2 domain recognizes type I and type IV collagens by different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ALPHA-2-BETA-1 VLA-2; CELL-ADHESION; A-DOMAIN; BINDING; FIBRONECTIN; SEQUENCE; SUBUNIT; SITE; INTEGRIN-ALPHA-2-BETA-1	The collagens are recognized by the alpha I domains of the collagen receptor integrins, A common structural feature in the collagen-binding alpha I domains is the presence of an extra helix, named helix alpha C. However, its participation in collagen binding has not been shown. Here, we have deleted the helix alpha C in the alpha(2)I domain and tested the function of the resultant recombinant protein (Delta alpha C alpha(2)I) by using a real-time biosensor, The Delta alpha C alpha(2)I domain had reduced affinity for type I collagen (430 +/- 90 nM) when compared with wild-type alpha(2)I domain (90 +/- 30 nM), indicating both the importance of helix alpha C in type I collagen binding and that the collagen binding surface in alpha(2)I domain is located near the metal ion-dependent adhesion site. Previous studies have suggested that the charged amino acid residues, surrounding the metal ion-dependent adhesion site but not interacting with Mg2+, may play an important role in the recognition of type I collagen, Direct evidence indicating the participation of these residues in collagen recognition has been missing. To test this idea, we produced a set of recombinant alpha(2)I domains with mutations, namely D219A, D219N, D219R, E256Q, D259N, D292N, and E299Q, Mutations in amino acids Asp(219), Asp(259), Asp(292), and Glu(299) resulted in weakened affinity for type I collagen. When alpha(2) D219N and D292N mutations were introduced separately into alpha(2)beta(1) integrin expressed on Chinese hamster ovary cells, no alterations in the cell spreading on type I collagen were detected. However, Chinese hamster ovary cells expressing double mutated alpha(2) D219N/D292N integrin showed remarkably slower spreading on type I collagen, while spreading on type TV collagen was not affected. The data indicate that alpha(2)I domain binds to type I collagen with a different mechanism than to type IV collagen.	Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40351 Jyvaskyla, Finland; Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Abo Akad Univ, Dept Biochem, FIN-20520 Turku, Finland	University of Jyvaskyla; University of Turku; University of Turku; Abo Akademi University; Finland National Institute for Health & Welfare	Kapyla, J (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, POB 35, FIN-40351 Jyvaskyla, Finland.		Pentikäinen, Olli T/E-1980-2012	Pentikäinen, Olli T/0000-0001-7188-4016; Kapyla, Jarmo/0000-0003-3036-713X; Ivaska, Johanna/0000-0002-6295-6556				BERNSTEIN FC, 1977, J MOL BIOL, V233, P716; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Dickeson SK, 1998, BIOCHEMISTRY-US, V37, P11280, DOI 10.1021/bi9727848; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; GERHART J, 1997, CELLS EMBRYOS EVOLUT, P9; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HUGHES AL, 1992, MOL BIOL EVOL, V9, P216; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Ivaska J, 1999, J BIOL CHEM, V274, P3513, DOI 10.1074/jbc.274.6.3513; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; Kern A, 1998, J CELL PHYSIOL, V176, P634, DOI 10.1002/(SICI)1097-4652(199809)176:3<634::AID-JCP20>3.3.CO;2-J; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Messent AJ, 1998, J CELL SCI, V111, P1127; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; Pentikainen O, 1999, J BIOL CHEM, V274, P31493, DOI 10.1074/jbc.274.44.31493; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salminen TA, 1999, ACTA CRYSTALLOGR D, V55, P1365, DOI 10.1107/S0907444999006009; SALTER DM, 1995, J HISTOCHEM CYTOCHEM, V43, P447, DOI 10.1177/43.4.7897185; Setty S, 1998, J BIOL CHEM, V273, P12244, DOI 10.1074/jbc.273.20.12244; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735	36	69	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3348	3354		10.1074/jbc.275.5.3348	http://dx.doi.org/10.1074/jbc.275.5.3348			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652324	hybrid			2022-12-25	WOS:000085146500046
J	Dadgostar, H; Cheng, GH				Dadgostar, H; Cheng, GH			Membrane localization of TRAF 3 enables JNK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE; TERMINAL KINASE; SIGNALING PROTEINS; CELL-DEATH; RECEPTOR; FAMILY; STRESS; CD40; LETHALITY	Members of the tumor necrosis factor receptor family as well as other receptors achieve their diverse biological effects through the activation of intracellular signals including the c-Jun N-terminal kinase (JNK) pathway. Such signals are believed to be delivered through mediators known as TNF receptor-associated factors (TRAFs). Although the N-terminal zinc finger region of TRAFs has been shown to be essential for downstream signaling, there is no indication yet as to the nature of its role or of the factors that distinguish the N terminus of TRAF 3, which does not activate JNK in the systems examined thus far, from those of other TRAFs, which do activate this pathway. In the present study, it is shown that, among the known TRAFs, localization to the insoluble cell pellet fraction consistently correlates with JNK activation and that both characteristics map to the TRAF N terminus. Furthermore, it is demonstrated that forced localization of TRAF 3 to the cell membrane is sufficient to convert this molecule into an activator of JNK. This suggests that one of the roles of the TRAF N terminus may be to participate in interactions that promote the recruitment of TRAFs to the membrane and that this localization effect plays an important role in TRAF-mediated JNK activation.	Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Med Sci Training Program,Grad Program, Los Angeles, CA USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cheng, GH (corresponding author), Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM 08042, R01 GM 57559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057559, T32GM008042] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Chin AID, 1999, MOL CELL BIOL, V19, P6665; Dadgostar H, 1998, J BIOL CHEM, V273, P24775, DOI 10.1074/jbc.273.38.24775; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; Grammer AC, 1998, J IMMUNOL, V161, P1183; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Min W, 1998, J IMMUNOL, V161, P319; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG H, 1997, P NATL ACAD SCI USA, V94, P972; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	34	36	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2539	2544		10.1074/jbc.275.4.2539	http://dx.doi.org/10.1074/jbc.275.4.2539			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644711	hybrid			2022-12-25	WOS:000085128000043
J	Lin, C; Widjaja, J; Joseph, SK				Lin, C; Widjaja, J; Joseph, SK			The interaction of calmodulin with alternatively spliced isoforms of the type-I inositol trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; 1,4,5-TRISPHOSPHATE RECEPTOR; BINDING DOMAIN; CA2+-INDEPENDENT INHIBITION; RAT-LIVER; PHOSPHORYLATION; CA2+; BRAIN; SEQUENCE; CALCIUM	A 592-amino acid segment of the regulatory domain of the neuronal type-I inositol 1,4,5-trisphosphate receptor (IP3R) isoform (type-I long, amino acids1314-1905) and the corresponding 552-amino acid alternatively spliced form present in peripheral tissues (type-I short, amino acids 1693-1733 deleted) were expressed as glutathione S-transferase fusion proteins. These domains encompass a putative calmodulin (CaM) binding domain and two protein kinase A phosphorylation sites. Both long and short fusion proteins retained the ability to bind CaM in a Ca2+-dependent manner as measured by CaM-Sepharose chromatography or a dansyl-CaM fluorescence assay. Both assays indicated that the short fusion protein bound twice the amount of CaM than the long form at saturating concentrations of CaM. In addition, the binding of the short form to CaM-Sepharose was inhibited by phosphorylation with protein kinase A, whereas the binding of the long form was unaffected. Full-length cDNAs encoding type-I long, type-I short, and type-III IP3R isoforms were expressed in COS cells, and the Ca2+ sensitivity of [H-3]IP, binding to permeabilized cells was measured. The type-I long isoform was more sensitive to Ca2+ inhibition (IC50 = 0.55 mu M) than the type-I short (IC50 = 5.7 mu M) Or the type-III isoform (IC50 = 3 mu M). In agreement with studies on the fusion proteins, the full-length type-I short bound more CaM-Sepharose, and this binding was inhibited to a greater extent by protein kinase A phosphorylation than the type-I long IP3R. Although type-III IP(3)Rs did not bind directly to CaM-Sepharose, hetero-oligomers of type-I/III DP,Rs retained the ability to interact with CaM. We conclude that the deletion of the SII splice site in the type-I IP3R results in the differential regulation of the alternatively spliced isoforms by Ca2+, CaM, and protein kinase A.	Thomas Jefferson Univ, Sch Med, Dept Pathol & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Joseph, SK (corresponding author), Thomas Jefferson Univ, Sch Med, Dept Pathol & Cell Biol, Romm 230A JAH,1020 Locust St, Philadelphia, PA 19107 USA.	Suresh.Joseph@mail.tju.edu			NIDDK NIH HHS [R01-DK34804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; Cardy TJA, 1997, BIOCHEM J, V328, P785, DOI 10.1042/bj3280785; Cardy TJA, 1998, BIOCHEM J, V334, P447, DOI 10.1042/bj3340447; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; GUERRINI R, 1995, BIOCHEMISTRY-US, V34, P5120, DOI 10.1021/bi00015a024; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; Islam MO, 1996, BIOCHEM J, V316, P295, DOI 10.1042/bj3160295; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; JOSEPH SK, 1999, METHODS CALCIUM SIGN; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; Missiaen L, 1999, J BIOL CHEM, V274, P13748, DOI 10.1074/jbc.274.20.13748; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; Moyers JS, 1998, BIOCHEM J, V333, P609, DOI 10.1042/bj3330609; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; NUCIFORA FC, 1995, MOL BRAIN RES, V32, P291, DOI 10.1016/0169-328X(95)00089-B; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; Sipma H, 1999, J BIOL CHEM, V274, P12157, DOI 10.1074/jbc.274.17.12157; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591; Zoche M, 1997, BIOL CHEM, V378, P851, DOI 10.1515/bchm.1997.378.8.851; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	49	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2305	2311		10.1074/jbc.275.4.2305	http://dx.doi.org/10.1074/jbc.275.4.2305			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644679	hybrid			2022-12-25	WOS:000085128000011
J	Nemes, Z; Demeny, M; Marekov, LN; Fesus, L; Steiner, PM				Nemes, Z; Demeny, M; Marekov, LN; Fesus, L; Steiner, PM			Cholesterol 3-sulfate interferes with cornified envelope assembly by diverting transglutaminase 1 activity from the formation of cross-links and esters to the hydrolysis of glutamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN STRATUM-CORNEUM; PROTEIN-KINASE-C; CELL-ENVELOPE; KERATINOCYTE TRANSGLUTAMINASE; LAMELLAR ICHTHYOSIS; SUBSTRATE PROPERTIES; STRUCTURAL PROTEINS; ETA-ISOFORM; SULFATE; GENE	The loss of transglutaminase 1 enzyme (TGase 1) activity causes lamellar ichthyosis, Recessive X-linked ichthyosis (XI) results from accumulation of excess cholesterol 3-sulfate (CSO4) in the epidermis but the pathomechanism how elevated epidermal CSO4 causes ichthyosis is largely unknown. Here we provide evidence that III is also a consequence of TGase 1 dysfunction. TGase 1 is a key component of barrier formation in keratinocytes: it participates in the cross-linking of cell envelope (CE) structural proteins, and also forms the lipid bound envelope by esterification of long chain omega-hydroxyceramides onto CE proteins. Using involucrin and an epidermal omega-hydroxyceramide analog as substrates, kinetic analyses revealed that at membrane concentrations above 4 mol %, CSO4 caused a marked and dose-dependent inhibitory effect on isopeptide and ester bond formation. Sequencing of tryptic peptides from TGase 1-reacted involucrin showed a large increase in deamidation of substrate glutamines. me hypothesize that supraphysiological levels of CSO4 in keratinocyte membranes distort the structure of TGase 1 and faoilitate the access of water into its active site causing hydrolysis of substrate glutamine residues. Our findings provide further evidence for the pivotal role of the TGase 1 enzyme in CE formation.	NIAMSD, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Debrecen, Sch Med, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Debrecen	Steiner, PM (corresponding author), NIAMS, NIH, Bldg 6,Rm 425, Bethesda, MD 20892 USA.	pemast@helix.nih.gov						Aeschlimann D, 1998, J BIOL CHEM, V273, P3452, DOI 10.1074/jbc.273.6.3452; ANTONLAMPRECHT I, 1992, DIAGNOSTIC ULTRASTRU, P00459; Candi E, 1998, J BIOL CHEM, V273, P13693, DOI 10.1074/jbc.273.22.13693; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CHIDA K, 1995, CANCER RES, V55, P4865; DeLaurenzi V, 1996, NAT GENET, V12, P52; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ELIAS PM, 1984, J CLIN INVEST, V74, P1414, DOI 10.1172/JCI111552; EPSTEIN EH, 1984, J AM ACAD DERMATOL, V10, P866, DOI 10.1016/S0190-9622(84)80144-9; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1973, ADV ENZYMOL RAMB, V38, P109; GREEN H, 1992, MOL BIOL EVOL, V9, P977; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GROSS M, 1974, J BIOL CHEM, V249, P3021; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; IKUTA T, 1994, CELL GROWTH DIFFER, V5, P943; Ishida-Yamamoto A, 1998, EXP DERMATOL, V7, P1, DOI 10.1111/j.1600-0625.1998.tb00295.x; Jarnik M, 1998, J CELL SCI, V111, P1051; Kawabe S, 1998, J INVEST DERMATOL, V111, P1098, DOI 10.1046/j.1523-1747.1998.00441.x; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG SA, 1985, ARCH DERMATOL RES, V277, P284, DOI 10.1007/BF00509081; LYKKESFELDT G, 1983, LANCET, V2, P1336, DOI 10.1016/S0140-6736(83)91093-0; Marekov LN, 1998, J BIOL CHEM, V273, P17763, DOI 10.1074/jbc.273.28.17763; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Nemes Z, 1999, J BIOL CHEM, V274, P11013, DOI 10.1074/jbc.274.16.11013; Nemes Z, 1999, P NATL ACAD SCI USA, V96, P8402, DOI 10.1073/pnas.96.15.8402; PARAMESWARAN KN, 1981, BIOCHEMISTRY-US, V20, P3703, DOI 10.1021/bi00516a006; Parameswaran KN, 1997, J BIOL CHEM, V272, P10311; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; RANASINGHE AW, 1986, J INVEST DERMATOL, V86, P187, DOI 10.1111/1523-1747.ep12284246; REHFELD SJ, 1988, J INVEST DERMATOL, V91, P499, DOI 10.1111/1523-1747.ep12476654; REHFELD SJ, 1986, ARCH DERMATOL RES, V278, P259, DOI 10.1007/BF00407734; Rice R.H., 1994, KERATINOCYTE HDB, P259; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; Sato J, 1998, J INVEST DERMATOL, V111, P189, DOI 10.1046/j.1523-1747.1998.00244.x; SHAPIRO LJ, 1978, LANCET, V2, P756; Steinberg D., 1978, METABOLIC BASIS INHE, P688; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Tarcsa E, 1998, J BIOL CHEM, V273, P23297, DOI 10.1074/jbc.273.36.23297; TARCSA E, 1990, ANAL BIOCHEM, V186, P135, DOI 10.1016/0003-2697(90)90586-X; Wertz P W, 1997, EXS, V78, P227; Wertz P. W., 1991, PHYSL BIOCH MOL BIOL, V1, P205; WILLIAMS ML, 1992, SEMIN DERMATOL, V11, P169; WILLIAMS ML, 1991, ADV LIPID RES, V24, P211; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Zettersten E, 1998, J INVEST DERMATOL, V111, P784, DOI 10.1046/j.1523-1747.1998.00386.x	55	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2636	2646		10.1074/jbc.275.4.2636	http://dx.doi.org/10.1074/jbc.275.4.2636			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644724	Green Submitted, hybrid			2022-12-25	WOS:000085128000056
J	Rohr, O; Schwartz, C; Hery, C; Aunis, D; Tardieu, M; Schaeffer, E				Rohr, O; Schwartz, C; Hery, C; Aunis, D; Tardieu, M; Schaeffer, E			The nuclear receptor chicken ovalbumin upstream promoter transcription factor interacts with HIV-1 Tat and stimulates viral replication in human microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; CENTRAL-NERVOUS-SYSTEM; NF-KAPPA-B; HUMAN BRAIN-CELLS; GENE-EXPRESSION; TYPE-1 TAT; IN-VITRO; INDEPENDENT ACTIVATION; HORMONE RECEPTOR	Human immunodeficiency virus type 1 (HIV-1) infects the central nervous system and plays a direct role in the pathogenesis of AIDS dementia. However, the molecular mechanisms underlying HIV-1 expression in the central nervous system are poorly understood. We have recently reported that the nuclear receptor chicken ovalbumin upstream promoter transcription factor (COUP-TF), an orphan member of the nuclear receptor superfamily, is an activator of HIV-1 gene transcription. Here, our results show that COUP-TF stimulates HIV-1 transcription in primary cultured human microglial cells, the primary target for HIV-1 infection in brain. Run-on assays indicated that COUP-TF acts on the initiation step of transcription. Results from reverse transcription-polymerase chain reaction and immunocytochemistry analysis further revealed the importance of this factor by demonstrating that overexpression of COUP-TF leads to initiation of viral replication in primary HIV-infected human microglia, In addition, COUP-TF is able to physically interact and cooperate with the viral transactivator Tat, The combination of COUP-TF and Tat leads to NF-kappa B- and Sp1-independent enhanced transcriptional stimulation. In vitro binding studies showed that COUP-TF interacts with Tat through amino acids within the N-terminal DNA-binding domain of COUP-TF. Amino acids 48-72 in the basic and C-terminal regions of Tat are required for the binding of Tat to COUP-TF, These results suggest that COUP-TF is an essential transcription factor involved in HIV-1 expression in microglia and reveal a novel interplay of Tat and COUP-TF during regulation of viral expression.	U338 INSERM, F-67084 Strasbourg, France; Fac Med Paris Sud, Lab Virus Neurone & Immunite, CRI 9612, F-94276 Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Schaeffer, E (corresponding author), Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.		Dominique, Aunis/W-1419-2019	ROHR, Olivier/0000-0001-8992-2025				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; DESAIYAJNIK V, 1995, J VIROL, V69, P5103, DOI 10.1128/JVI.69.8.5103-5112.1995; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GARCIA JA, 1994, PROG NUCLEIC ACID RE, V49, P157; GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51; Ghorpade A, 1998, J VIROL, V72, P3340, DOI 10.1128/JVI.72.4.3340-3350.1998; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HATCH WC, 1994, AIDS RES HUM RETROV, V10, P1597, DOI 10.1089/aid.1994.10.1597; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; ING NH, 1992, J BIOL CHEM, V267, P17617; Janabi N, 1998, GLIA, V23, P304; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KAMINE J, 1992, J VIROL, V66, P3932, DOI 10.1128/JVI.66.6.3932-3936.1992; Kashanchi F, 1996, J VIROL, V70, P5503, DOI 10.1128/JVI.70.8.5503-5510.1996; Kingsman SM, 1996, EUR J BIOCHEM, V240, P491, DOI 10.1111/j.1432-1033.1996.0491h.x; LIU JS, 1992, J VIROL, V66, P3883, DOI 10.1128/JVI.66.6.3883-3887.1992; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; NUOVO GJ, 1994, AM J PATHOL, V144, P659; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PARROTT C, 1991, J VIROL, V65, P1414, DOI 10.1128/JVI.65.3.1414-1419.1991; PERRY VH, 1994, J LEUKOCYTE BIOL, V56, P399, DOI 10.1002/jlb.56.3.399; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; RHIM H, 1994, J ACQ IMMUN DEF SYND, V7, P1116; Rohr O, 1999, J CELL BIOCHEM, V75, P404, DOI 10.1002/(SICI)1097-4644(19991201)75:3<404::AID-JCB6>3.0.CO;2-G; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Sawaya BE, 1996, J BIOL CHEM, V271, P22895, DOI 10.1074/jbc.271.37.22895; Sawaya BE, 1996, J BIOL CHEM, V271, P23572, DOI 10.1074/jbc.271.38.23572; Strizki JM, 1996, J VIROL, V70, P7654, DOI 10.1128/JVI.70.11.7654-7662.1996; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUNE C, 1995, J VIROL, V69, P6572; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1994, ADV NEUROIMMUNOL, V4, P291, DOI 10.1016/S0960-5428(06)80270-6; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089	46	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2654	2660		10.1074/jbc.275.4.2654	http://dx.doi.org/10.1074/jbc.275.4.2654			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644726	Green Published, hybrid			2022-12-25	WOS:000085128000058
J	Saves, I; Ozanne, V; Dietrich, J; Masson, JM				Saves, I; Ozanne, V; Dietrich, J; Masson, JM			Inteins of Thermococcus fumicolans DNA polymerase are endonucleases with distinct enzymatic behaviors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PI-SCEI; ADENOSINE-TRIPHOSPHATASE; GENE; SEQUENCES; CLEAVAGE; MUTATION; DOMAINS; BINDING; SUBUNIT	The DNA polymerase gene of Thermococcus fumicolans harbors two intein genes. Both inteins have been produced in Escherichia coli and purified either as naturally spliced products from the expression of the complete DNA polymerase gene or directly from the cloned inteins genes. Both recombinant inteins exhibit endonuclease activity, with an optimal temperature of 70 degrees C. The Tfu pol-1 intein, which belongs to the Psp KOD pol-1 allelic family, recognizes and cleaves a minimal sequence of 16 base pairs (bp) on supercoiled DNA with either Mn2+ or Mg2+ as cofactor. It cleaves linear DNA only with Mn2+ and requires a 19-bp minimal recognition sequence. The Tfu pol-2 intein, which belongs to the Tli pol-2 allelic family, is a highly active homing endonuclease using Mg2+ as cofactor. Its minimal recognition and cleavage site is 21 bp long either on linear or circular DNA substrate. Its endonuclease activity is strongly inhibited by the 3' digestion product, which remains bound to the enzyme after the cleavage reaction. According to current nomenclature, these endonucleases were named PI-TfuI and PI-TfuII. These two inteins thus exhibit different requirements for metal cofactor and substrate topology as well as different mechanism of action.	CNRS, Inst Pharmacol & Biol Struct, IPBS, F-31077 Toulouse, France; Appligene Oncor, F-67402 Illkirch Graffenstaden, France; IFREMER, Ctr Brest, Biotechnol Lab, F-29280 Plouzane, France; Complexe Sci Rangueil, Inst Natl Sci Appl, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Ifremer; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de Toulouse; Institut National des Sciences Appliquees de Toulouse	Masson, JM (corresponding author), Valigene, Tour Neptune, F-92086 Paris, France.	masson@ipbs.fr						BELFORT M, 1995, J BACTERIOL, V177, P3897, DOI 10.1128/jb.177.14.3897-3903.1995; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; Gimble FS, 1996, J MOL BIOL, V263, P163, DOI 10.1006/jmbi.1996.0567; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; Godfroy A, 1996, INT J SYST BACTERIOL, V46, P1113, DOI 10.1099/00207713-46-4-1113; He ZN, 1998, J BIOL CHEM, V273, P4607, DOI 10.1074/jbc.273.8.4607; HIRATA R, 1990, J BIOL CHEM, V265, P6726; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; MUELLER JE, 1993, NUCLEASES, P111; Nishioka M, 1998, NUCLEIC ACIDS RES, V26, P4409, DOI 10.1093/nar/26.19.4409; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; Pietrokovski S, 1998, CURR BIOL, V8, pR634, DOI 10.1016/S0960-9822(07)00409-5; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shao Y, 1997, CHEM BIOL, V4, P187, DOI 10.1016/S1074-5521(97)90287-8; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1701, DOI 10.1021/bi952391d; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1712, DOI 10.1021/bi9523926; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	24	19	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2335	2341		10.1074/jbc.275.4.2335	http://dx.doi.org/10.1074/jbc.275.4.2335			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644683	hybrid			2022-12-25	WOS:000085128000015
J	Schulz, A; Grosse, R; Schultz, G; Gudermann, T; Schoneberg, T				Schulz, A; Grosse, R; Schultz, G; Gudermann, T; Schoneberg, T			Structural implication for receptor oligomerization from functional reconstitution studies of mutant V2 vasopressin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; HORMONE RECEPTOR; MOLECULAR-BASIS; CELL-SURFACE; COEXPRESSION; RHODOPSIN; CYSTEINES; DIMERIZATION	Previous studies have established that G-protein-coupled receptors (GPCRs) are composed of independent folding domains. Based on this findings we attempted to rescue the function of clinically relevant missense mutations (R137H, S167L, and R181C) within the N-terminal domain of the V2 vasopressin receptor (V2-R), by coexpressing mutated full-length (Y280C) and C-terminally truncated (E242X) receptor constructs in COS-7 cells. Coimmunoprecipitation and enzyme-linked immunosorbent assay studies demonstrated a specific association of E242X with full-length V2 Rs even in the presence of missense mutations. Systematic analysis of the structural requirements for the observed receptor/fragment association showed that N-terminal fragments containing at least transmembrane regions 1-3 interact with the full-length V2-R. Despite this specific interaction, no functional reconstitution was achieved for mutant V2-Rs following coexpression with E242X and Y280C, However, functional activity of R137H and R181C upon coexpression with E242X was regained by mutational disruption of the extracellular disulfide bond, which is highly conserved among GPCRs. OUT data with the V2-R are consistent with a structural model in which class I GPCRs form contact oligomers by lateral interaction rather than by a domain-swapping mechanism.	Free Univ Berlin, Inst Pharmakol, Klinikum Benjamin Franklin, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schoneberg, T (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.	schoberg@zedat.fu-berlin.de	soler, martha maricel m gomez/L-6025-2014	soler, martha maricel m gomez/0000-0002-4412-8108; Grosse, Robert/0000-0002-3380-5273				Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; Cook JVF, 1996, ENDOCRINOLOGY, V137, P2851, DOI 10.1210/en.137.7.2851; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HEBERT TE, 1996, J BIOL CHEM, V271, P18384; Higuchi R., 1989, PCR TECHNOLOGY, P61; HITT M, 1995, VIRAL GENE TECHNIQUE, P13; Jakubik J, 1999, J BIOL CHEM, V274, P1349, DOI 10.1074/jbc.274.3.1349; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOSUGI S, 1992, BIOCHEM BIOPH RES CO, V189, P1754, DOI 10.1016/0006-291X(92)90281-O; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; Marchese A, 1999, TRENDS PHARMACOL SCI, V20, P370, DOI 10.1016/S0165-6147(99)01366-8; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; PERLMAN JH, 1995, J BIOL CHEM, V270, P24682, DOI 10.1074/jbc.270.42.24682; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Sadeghi HM, 1997, MOL ENDOCRINOL, V11, P706, DOI 10.1210/me.11.6.706; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; Schoneberg T, 1997, J CLIN INVEST, V100, P1547, DOI 10.1172/JCI119678; Schulein R, 1996, J BIOL CHEM, V271, P28844, DOI 10.1074/jbc.271.46.28844; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; Wenkert D, 1996, MOL CELL ENDOCRINOL, V124, P43, DOI 10.1016/S0303-7207(96)03926-3; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	40	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2381	2389		10.1074/jbc.275.4.2381	http://dx.doi.org/10.1074/jbc.275.4.2381			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644689	hybrid			2022-12-25	WOS:000085128000021
J	Vetter, SW; Keng, YF; Lawrence, DS; Zhang, ZY				Vetter, SW; Keng, YF; Lawrence, DS; Zhang, ZY			Assessment of protein-tyrosine phosphatase 1B substrate specificity using "inverse alanine scanning"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE COMBINATORIAL LIBRARIES; PHOSPHOTYROSINE; RECOGNITION	An "inverse alanine scanning" peptide library approach has been developed to assess the substrate specificity of protein-tyrosine phosphatases (PTPases). In this method each Ala moiety in the parent peptide, Ac-AAAApYAAAA-NH2, is separately and sequentially replaced by the 19 non-Ala amino acids to generate a library of 158 well defined peptides. The relatively small number of peptides allows the acquisition of explicit kinetic data for all library members, thereby furnishing information about the contribution of individual amino acids with respect to substrate properties. The approach was applied to protein-tyrosine phosphatase 1B (PTP1B) as a first example, and the highly potent peptide substrate Ac-ELEFpYMDYE-NH2 (k(cat)/K-m 2.2 +/- 0.05 x 10(7) m(-1) s(-1)) has been identified. More importantly, several heretofore unknown features of the sub strate specificity of PTP1B were revealed. This includes the ability of PTP1B to accommodate acidic, aromatic, and hydrophobic residues at the -1 position, a strong nonpreference for Lys and Arg residues in any position, and the first evidence that residues well beyond the +1 position contribute to substrate efficacy.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lawrence, DS (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA.	dlawrenc@aecom.yu.edu; zyzhang@aecom.yu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boutin JA, 1997, MOL DIVERS, V3, P43, DOI 10.1023/A:1009602707067; Chen CL, 1996, METHOD ENZYMOL, V267, P211; Cheung YW, 1997, J AM CHEM SOC, V119, P9568, DOI 10.1021/ja971825k; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; Huyer G, 1998, ANAL BIOCHEM, V258, P19, DOI 10.1006/abio.1997.2541; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Montigiani S, 1996, J MOL BIOL, V258, P6, DOI 10.1006/jmbi.1996.0229; Montserat J, 1996, J BIOL CHEM, V271, P7868, DOI 10.1074/jbc.271.13.7868; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Pellegrini MC, 1998, BIOCHEMISTRY-US, V37, P15598, DOI 10.1021/bi981427+; PINILLA C, 1995, BIOPOLYMERS, V37, P221, DOI 10.1002/bip.360370306; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; ZHANG ZY, 1995, J BIOL CHEM, V270, P16052; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	24	66	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2265	2268		10.1074/jbc.275.4.2265	http://dx.doi.org/10.1074/jbc.275.4.2265			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644673	hybrid			2022-12-25	WOS:000085128000005
J	Kim, YS; Han, SJ; Ryu, JH; Choi, KH; Hong, YS; Chung, YH; Perrot, S; Raibaud, A; Brey, PT; Lee, WJ				Kim, YS; Han, SJ; Ryu, JH; Choi, KH; Hong, YS; Chung, YH; Perrot, S; Raibaud, A; Brey, PT; Lee, WJ			Lipopolysaccharide-activated kinase, an essential component for the induction of the antimicrobial peptide genes in Drosophila melanogaster cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IMMUNE-RESPONSE; INSECT IMMUNITY; EMBRYONIC POLARITY; INNATE IMMUNITY; PROTEIN-KINASE; REL PROTEINS; DORSAL; PHOSPHORYLATION; ALPHA	Eukaryotic organisms use a similar Rel/NF-kappa B signaling cascade for the induction of innate immune genes. In Drosophila, lipopolysaccharide (LPS) signal-induced activation of the Rel/NF-kappa B family transcription factors is an essential step in the transcriptional activation of inducible antimicrobial peptide genes. However, the mechanism by which the LPS-induced signaling pathway proceeds remains largely unknown. Here we have cloned a novel Drosophila LPS-activated kinase (DLAK) that is structurally related to mammalian I kappa B kinases, DLAK is expressed and transiently activated in LPS-responsive Drosophila cells following LPS stimulation. Furthermore, DLAK can interact with Cactus, a Drosophila I kappa B and phosphorylate recombinant Cactus, in vitro. Overexpression of dominant-negative mutant DLAK (DLAK(K50A)) blocks LPS induced Cactus degradation. DLAK-bound Cactus can be degraded in a LPS signal-dependent fashion, whereas the DLAK(K50A) mutant-bound Cactus is completely resistant to degradation in the presence of LPS, The DLAK(K50A) mutant also inhibits nuclear kappa B binding activity and kappa B-dependent diptericin reporter gene activity in a dose-dependent manner, but the kappa B-dependent diptericin reporter gene activity can be rescued by overexpression of wild type DLAK. Moreover, mRNA analysis of various kappa B-dependent antimicrobial peptide genes shows that LPS inducibility of these genes is greatly impaired in cells overexpressing DLAK(K50A). These results establish that DLAK is a novel LPS-activated kinase, which is an essential signaling component for the induction of antimicrobial peptide genes following LPS treatment in Drosophila cells.	Yonsei Univ, Coll Med, Immunol Lab, Med Res Ctr, Seoul, South Korea; Hanyang Univ, Dept Microbiol, Coll Med, Seoul 133791, South Korea; Inst Pasteur, Lab Biochim & Biol Mol Insertes, F-75724 Paris, France	Yonsei University; Yonsei University Health System; Hanyang University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Lee, WJ (corresponding author), Yonsei Univ, Coll Med, Immunol Lab, Med Res Ctr, CPO Box 8044,Shinchon Dong 134, Seoul, South Korea.		Han, Sung-Jun/B-9547-2012					ASLING B, 1995, INSECT BIOCHEM MOLEC, V25, P511, DOI 10.1016/0965-1748(94)00091-C; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BECKER S, 1991, J IMMUNOL, V147, P4307; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; Chasan Rebecca, 1993, P387; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIMARCQ JL, 1994, EUR J BIOCHEM, V221, P201, DOI 10.1111/j.1432-1033.1994.tb18730.x; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; Engstrom Ylva, 1998, P211; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; FYRBERG EA, 1981, CELL, V24, P107, DOI 10.1016/0092-8674(81)90506-7; GRANT PA, 1992, NUCLEIC ACIDS RES, V20, P4401, DOI 10.1093/nar/20.17.4401; Gross I, 1996, NUCLEIC ACIDS RES, V24, P1238, DOI 10.1093/nar/24.7.1238; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; Han SJ, 1998, J BIOL CHEM, V273, P369, DOI 10.1074/jbc.273.1.369; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; IP YT, 1994, CURR OPIN GENET DEV, V4, P672, DOI 10.1016/0959-437X(94)90133-N; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nicolas E, 1998, J BIOL CHEM, V273, P10463, DOI 10.1074/jbc.273.17.10463; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; PARDUE ML, 1986, DROSOPHILA PRACTICAL; PETERSEN UM, 1995, EMBO J, V14, P3146, DOI 10.1002/j.1460-2075.1995.tb07317.x; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; Sambrook J., 2002, MOL CLONING LAB MANU; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STJOHNSTON D, 1992, CELL, V68, P201; SUN SC, 1992, EUR J BIOCHEM, V204, P885, DOI 10.1111/j.1432-1033.1992.tb16708.x; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WAHLEN AM, 1993, J CELL BIOL, V123, P523; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; WICKER C, 1990, J BIOL CHEM, V265, P22493; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu LP, 1998, NATURE, V392, P93, DOI 10.1038/32195; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	59	35	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2071	2079		10.1074/jbc.275.3.2071	http://dx.doi.org/10.1074/jbc.275.3.2071			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636911	hybrid			2022-12-25	WOS:000084940000074
J	Rodriguez-Gabriel, MA; Remacha, M; Ballesta, JPG				Rodriguez-Gabriel, MA; Remacha, M; Ballesta, JPG			The RNA interacting domain but not the protein interacting domain is highly conserved in ribosomal protein P0	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE VIABILITY; ESCHERICHIA-COLI; ACIDIC PHOSPHOPROTEINS; GTPASE CENTER; BINDING; STALK; SITE; P1; P2; YEAST	Protein P0 interacts with proteins P1 alpha, P1 beta, P2 alpha, and P2 beta, and forms the Saccharomyces cerevisiae ribosomal stalk. The capacity of RPP0 genes from Aspergillus fumigatus, Dictyostelium discoideum, Rattus norvegicus, Homo sapiens, and Leishmania infantum to complement the absence of the homologous gene has been tested. In S. cerevisiae W303dGP0, a strain containing standard amounts of the four P1/P2 protein types, all heterologous genes were functional except the one from L. infantum, some of them inducing an osmosensitive phenotype at 37 degrees C. The polymerizing activity and the elongation factor-dependent functions but not the peptide bond formation capacity is affected in the heterologous P0 containing ribosomes. The heterologous P0 proteins bind to the yeast ribosomes but the composition of the ribosomal stalk is altered. Only proteins P1 alpha and P2 beta are found in ribosomes carrying the A. fumigatus, R. norvegicus, and H. sapiens proteins. When the heterologous genes are expressed in a conditional null-P0 mutant whose ribosomes are totally deprived of P1/P2 proteins, none of the heterologous P0 proteins complemented the conditional phenotype. In contrast, chimeric P0 proteins made of different amino-terminal fragments from mammalian origin and the complementary carboxyl-terminal fragments from yeast allow W303dGP0 and D67dGP0 growth at restrictive conditions, These results indicate that while the P0 protein RNA-binding domain is functionally conserved in eukaryotes, the regions involved in protein-protein interactions with either the other stalk proteins or the elongation factors have notably evolved.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC)	Ballesta, JPG (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol, Canto Blanco, E-28049 Madrid, Spain.	jpgballesta@cbm.uam.es	Remacha, Miguel/G-1250-2016; Rodriguez-Gabriel, Miguel/L-2425-2013	Rodriguez-Gabriel, Miguel/0000-0002-6855-5286				Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Ballesta JPG, 1996, PROG NUCLEIC ACID RE, V55, P157, DOI 10.1016/S0079-6603(08)60193-2; BALLESTA JPG, 2000, RIBOSOME STRUCTURE F; BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Briones E, 1998, J BIOL CHEM, V273, P31956, DOI 10.1074/jbc.273.48.31956; Dieffenbach C.W., 1995, PCR PRIMER LAB MANUA; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; Gomez-Lorenzo MG, 1998, J BIOL CHEM, V273, P25041, DOI 10.1074/jbc.273.39.25041; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HIGHLAND JH, 1975, J BIOL CHEM, V250, P831; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOSE MP, 1995, BIOCHEMISTRY-US, V34, P7941, DOI 10.1021/bi00024a019; KISCHA K, 1971, NATURE-NEW BIOL, V233, P62, DOI 10.1038/newbio233062a0; LILJAS A, 1991, INT REV CYTOL, V124, P103; MACCONNELL WP, 1980, BIOCHEM BIOPH RES CO, V92, P46, DOI 10.1016/0006-291X(80)91517-X; Moller W., 1986, STRUCTURE FUNCTION G, P309; MONRO RE, 1967, J MOL BIOL, V28, P161, DOI 10.1016/S0022-2836(67)80085-8; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; MUSTERS W, 1991, P NATL ACAD SCI USA, V88, P1469, DOI 10.1073/pnas.88.4.1469; PRIETO J, 1991, NUCLEIC ACIDS RES, V19, P1342, DOI 10.1093/nar/19.6.1342; RAUE HA, 1988, PROG BIOPHYS MOL BIO, V51, P77, DOI 10.1016/0079-6107(88)90011-9; Remacha M, 1995, BIOCHEM CELL BIOL, V73, P959, DOI 10.1139/o95-103; REMACHA M, 1990, MOL CELL BIOL, V10, P2182, DOI 10.1128/MCB.10.5.2182; REMACHA M, 1992, J BIOL CHEM, V267, P12061; REMACHA M, 1995, MOL CELL BIOL, V15, P4754; Rodriguez-Gabriel MA, 1998, BIOCHEMISTRY-US, V37, P16620, DOI 10.1021/bi981396i; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; SANTOS C, 1995, J BIOL CHEM, V270, P20608, DOI 10.1074/jbc.270.35.20608; SANTOS C, 1994, J BIOL CHEM, V269, P15689; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; Szick K, 1998, P NATL ACAD SCI USA, V95, P2378, DOI 10.1073/pnas.95.5.2378; THOMPSON J, 1993, EMBO J, V12, P1499, DOI 10.1002/j.1460-2075.1993.tb05793.x; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; Zambrano R, 1997, BIOCHEMISTRY-US, V36, P14439, DOI 10.1021/bi971494o; Zurdo J, 1997, BIOCHEMISTRY-US, V36, P9625, DOI 10.1021/bi9702400	43	48	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2130	2136		10.1074/jbc.275.3.2130	http://dx.doi.org/10.1074/jbc.275.3.2130			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636918	hybrid			2022-12-25	WOS:000084940000081
J	Ala-aho, R; Johansson, N; Grenman, R; Fusenig, NE; Lopez-Otin, C; Kahari, VM				Ala-aho, R; Johansson, N; Grenman, R; Fusenig, NE; Lopez-Otin, C; Kahari, VM			Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1	ONCOGENE			English	Article						interferon-gamma; collagenase; squamous cell carcinoma; mitogen activated protein kinase; matrix metalloproteinase	NECROSIS-FACTOR-ALPHA; SQUAMOUS-CELL CARCINOMAS; GENE-EXPRESSION; MATRIX METALLOPROTEINASE-13; TISSUE INHIBITOR; MESSENGER-RNA; FIBROBLAST COLLAGENASE; RHEUMATOID-ARTHRITIS; BREAST CARCINOMAS; III PROCOLLAGENS	Collagenase-3 (MMP-13) is characterized by an exceptionally wide substrate specificity and restricted expression, MMP-13 is specifically expressed by transformed human keratinocytes in squamous cell carcinomas in who and its expression correlates with their invasion capacity. Here, we show, that interferon-gamma (IFN-gamma) markedly inhibits expression of MMP-13 by human cutaneous SCC cells (UT-SCC-7) and by ras-transformed human epidermal keratinocytes (A-5 cells) at the transcriptional level. In addition, IFN-gamma inhibits collagenase-1 (MMP-1) expression in these cells, IFN-gamma, abolished the enhancement of MMP-13 and MMP-1 expression by transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha), and inhibited invasion of A-5 cells through type I collagen. IFN-gamma also rapidly and transiently activates extracellular signal-regulated kinase 1,2 (ERK1,2) and blocking ERK1,2 pathway (Raf/MEK1,2/ERK1,2) by specific MEK1,2 inhibitor PD98059 partially (by 50%) prevents Ser-727 phosphorylation of STAT1 and suppression of MMP-13 expression by IFN-gamma, Furthermore, Ser-727 phosphorylation of STAT1 by ERK1,2, or independently of ERK1,2 activation is associated with marked reduction in MMP-13 expression. These observations identify a novel role for IFN-gamma as a potent inhibitor of collagenolytic activity and invasion of transformed squamous epithelial cells, and show that inhibition of MMP-13 expression by IFN-gamma involves activation of ERK1,2 and STAT1.	Univ Turku, Medicity Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Biochem Med, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Dermatol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Turku Univ, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, FIN-20520 Turku, Finland; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	University of Turku; University of Turku; University of Turku; Abo Akademi University; University of Turku; University of Turku; Helmholtz Association; German Cancer Research Center (DKFZ); University of Oviedo	Kahari, VM (corresponding author), Univ Turku, Medicity Res Lab, Tykistokatu 6, FIN-20520 Turku, Finland.		Kahari, Veli-Matti/T-4925-2019; López-Otín, Carlos/AAB-2106-2020; Kähäri, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368; López-Otín, Carlos/0000-0001-6964-1904; Kähäri, Veli-Matti/0000-0003-2421-9368				Ahonen M, 1998, CANCER RES, V58, P2310; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Arany I, 1998, CANCER LETT, V123, P173, DOI 10.1016/S0304-3835(97)00432-1; BOUKAMP P, 1990, CANCER RES, V50, P2840; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Heppner KJ, 1996, AM J PATHOL, V149, P273; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Kauppila S, 1996, AM J PATHOL, V148, P539; KIM J, 1995, J IMMUNOL, V155, P2240; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Krane SM, 1996, J BIOL CHEM, V271, P28509, DOI 10.1074/jbc.271.45.28509; Lee SH, 1998, BRIT J DERMATOL, V139, P186; Lindy O, 1997, ARTHRITIS RHEUM-US, V40, P1391, DOI 10.1002/art.1780400806; Makela M, 1998, BIOCHEM BIOPH RES CO, V253, P325, DOI 10.1006/bbrc.1998.9641; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; Moers C, 1999, INT J CANCER, V80, P564, DOI 10.1002/(SICI)1097-0215(19990209)80:4<564::AID-IJC14>3.0.CO;2-X; OGRADY RL, 1984, ANAL BIOCHEM, V140, P490, DOI 10.1016/0003-2697(84)90199-4; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; PYKE C, 1992, CANCER RES, V52, P1336; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; SCHUGER L, 1990, PATHOBIOLOGY, V58, P279, DOI 10.1159/000163597; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Stancato LF, 1998, J BIOL CHEM, V273, P18701, DOI 10.1074/jbc.273.30.18701; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TAMAI K, 1995, J INVEST DERMATOL, V104, P384, DOI 10.1111/1523-1747.ep12665857; Tartour E, 1998, J NATL CANCER I, V90, P287, DOI 10.1093/jnci/90.4.287; Uitto VJ, 1998, AM J PATHOL, V152, P1489; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Uria JA, 1997, CANCER RES, V57, P4882; Vaalamo M, 1998, AM J PATHOL, V152, P1005; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; VARGA J, 1995, J CLIN INVEST, V96, P475, DOI 10.1172/JCI118058; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wernicke D, 1996, J RHEUMATOL, V23, P590; WESTERMARCK J, 1995, J INVEST DERMATOL, V105, P197, DOI 10.1111/1523-1747.ep12317114; Westermarck J, 1998, MATRIX BIOL, V17, P547, DOI 10.1016/S0945-053X(98)90107-X; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Xu XL, 1998, CANCER RES, V58, P2832; ZHU GG, 1993, CANCER RES, V53, P5028	63	50	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					248	257		10.1038/sj.onc.1203306	http://dx.doi.org/10.1038/sj.onc.1203306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645003				2022-12-25	WOS:000084844400010
J	Shi, YJ; Pin, OY; Sugrue, SP				Shi, YJ; Pin, OY; Sugrue, SP			Characterization of the gene encoding pinin/DRS/memA and evidence for its potential tumor suppressor function	ONCOGENE			English	Article						pinin; tumor suppressor; 14q13; desmosome; DNA methylation; TCC	E-CADHERIN; CELL-LINES; DNA METHYLATION; PROSTATE-CANCER; ADHESION SYSTEM; ALPHA-CATENIN; BREAST-CANCER; LUNG CANCERS; EXPRESSION; CARCINOMA	Several cell adhesion-related proteins have been shown to act as tumor-suppressors (TS) in the neoplastic progression of epithelial-derived tumors. Pinin/DRS/memA was first identified in our laboratory and it was shown to be a cell adhesion-related molecule. Our previous study demonstrated that restoration of pinin expression in transformed cells not only positively influenced cellular adhesive properties but also reversed the transformed phenotype to more epithelial-like. Here, we show by FISH analysis that the gene locus for pinin is within 14q13. The alignment of the pinin gene with STS markers localized the gene to the previously identified TS Locus D14S75-D14S288. Northern analyses revealed diminished pinin mRNA in renal cell carcinomas (RCC) and certain cancer cell lines. Immunohistochemical examination of tumor samples demonstrated absent or greatly reduced pinin in transitional cell carcinoma (TCC) and RCC tumors, TCC-derived J82 cells as well as EcR-293 cells transfected with full-length pinin cDNA demonstrated inhibition of anchorage-independent growth of cells in soft agar. Furthermore, methylation analyses revealed that aberrant methylation of pinin CpG islands was correlated with decreased/absent pinin expression in a subset of tumor tissues. These data lend significant support to the hypothesis that pinin/DRS/memA may act as a tumor suppressor in certain types of cancers.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Chang Gung Univ, Coll Med, Tau Yuan, Taiwan	State University System of Florida; University of Florida; Chang Gung University	Sugrue, SP (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.				NEI NIH HHS [EY07883] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007883] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bandera CA, 1997, CANCER RES, V57, P513; Baylin SB, 1998, ADV CANCER RES, V72, P141; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Beroud C, 1996, GENE CHROMOSOME CANC, V17, P215, DOI 10.1002/(SICI)1098-2264(199612)17:4<215::AID-GCC3>3.0.CO;2-6; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Birchmeier W, 1996, CURR TOP MICROBIOL, V213, P117; BIRCHMEIER W, 1995, BIOESSAYS, V17, P97, DOI 10.1002/bies.950170203; Brandner JM, 1997, DIFFERENTIATION, V62, P119, DOI 10.1046/j.1432-0436.1997.6230119.x; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; CAVENEE WK, 1993, J CLIN INVEST, V91, P3, DOI 10.1172/JCI116185; CHANG WYH, 1995, CANCER RES, V55, P3246; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Clurman B, 1997, NATURE, V389, P122, DOI 10.1038/38116; CONN IG, 1990, BRIT J UROL, V65, P176, DOI 10.1111/j.1464-410X.1990.tb14694.x; Davies G, 1998, ONCOL REP, V5, P1567; Degen WGJ, 1999, BBA-GENE STRUCT EXPR, V1444, P384, DOI 10.1016/S0167-4781(99)00012-3; Doki Y, 1997, CARCINOGENESIS, V18, P1139, DOI 10.1093/carcin/18.6.1139; Emig R, 1998, BRIT J CANCER, V78, P1661, DOI 10.1038/bjc.1998.739; EWING CM, 1995, CANCER RES, V55, P4813; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; GARROD DR, 1995, CANCER SURV, V24, P97; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; HSIEH JT, 1995, CANCER RES, V55, P190; Kane MF, 1997, CANCER RES, V57, P808; Kashiwabara K, 1998, INT J CANCER, V79, P215, DOI 10.1002/(SICI)1097-0215(19980619)79:3<215::AID-IJC1>3.0.CO;2-S; Kaur J, 1998, INT J CANCER, V79, P370, DOI 10.1002/(SICI)1097-0215(19980821)79:4&lt;370::AID-IJC11&gt;3.0.CO;2-9; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LICHTER P, 1992, HUMAN CYTOGENETICS P; MARSHALL CJ, 1977, J NATL CANCER I, V58, P1743, DOI 10.1093/jnci/58.6.1743; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mutirangura A, 1998, INT J CANCER, V78, P153, DOI 10.1002/(SICI)1097-0215(19981005)78:2<153::AID-IJC5>3.0.CO;2-Y; OUYANG P, 1992, J CELL BIOL, V118, P1477, DOI 10.1083/jcb.118.6.1477; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pin OY, 1999, BIOCHEM BIOPH RES CO, V263, P192, DOI 10.1006/bbrc.1999.1353; Pin OY, 1996, J CELL BIOL, V135, P1027, DOI 10.1083/jcb.135.4.1027; SHAPIRO GI, 1995, CANCER RES, V55, P505; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Taverna D, 1998, CANCER RES, V58, P848; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; Weaver DA, 1997, CARCINOGENESIS, V18, P1251, DOI 10.1093/carcin/18.6.1251; Wong MKK, 1997, MOL BIOL CELL, V8, P1441; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474	54	43	48	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					289	297		10.1038/sj.onc.1203328	http://dx.doi.org/10.1038/sj.onc.1203328			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645008				2022-12-25	WOS:000084844400015
J	Zong, S; Hu, P; Ye, TZ; Stan, R; Ellis, NA; Pandolfi, PP				Zong, S; Hu, P; Ye, TZ; Stan, R; Ellis, NA; Pandolfi, PP			A role for PML and the nuclear body in genomic stability	ONCOGENE			English	Article						PML; BLM; APL; Bloom syndrome; nuclear body; sister-chromatid exchange	ACUTE PROMYELOCYTIC LEUKEMIA; RAR-ALPHA; TRANSGENIC MICE; BLOOMS-SYNDROME; GENE; TRANSLOCATION; INTERFERON; T(15-17); PATHWAYS; PROTEIN	The PML gene of acute promyelocytic leukemia (APL) encodes a cell-growth and tumor suppressor. PML to discrete nuclear bodies (NBs) that are disrupted in APL cells. The Bloom syndrome gene BLM encodes a RecQ DNA helicase, whose absence from the cell results in genomic instability epitomized by high levels of sister-chromatid exchange (SCE) and cancer predisposition, We show here that BLM colocalizes with PML to the NB. In cells from persons with Bloom syndrome the localization of PML is unperturbed, whereas in APL cells carrying the PML-RAR alpha oncoprotein, both PML and BLM are delocalized from the NE into microspeckled nuclear regions. Treatment with retinoic acid (RA) induces the relocalization of both proteins to the NE. In primary PML-/- cells, BLM fails to accumulate in the NE. Strikingly, in PML-/- cells the frequency of SCEs is increased relative to PML +/+ cells. These data demonstrate that BLM is a constituent of the NE and that PML is required for its accumulation in these nuclear domains and for the normal function of BLM. Thus, our findings suggest a role for BLM in APL pathogenesis and implicate the PRL NE in the maintenance of genomic stability.	Mem Sloan Kettering Canc Ctr, Dept Human Genet, Mol & Dev Biol Lab, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, Lab Canc Susceptibil, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Human Genet, Mol & Dev Biol Lab, Program Mol Biol, 1275 York Ave,Box 110, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA071692, R37CA071692, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA08748, CA71692] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beresten SF, 1999, PROTEIN EXPRES PURIF, V17, P239, DOI 10.1006/prep.1999.1135; Boddy MN, 1996, ONCOGENE, V13, P971; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; GERMAN J, 1977, AM J HUM GENET, V29, P248; German J, 1998, GENETIC BASIS HUMAN, P301; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1995, ONCOGENE, V11, P871; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463	32	188	194	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7941	7947		10.1038/sj.onc.1203367	http://dx.doi.org/10.1038/sj.onc.1203367			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637504				2022-12-25	WOS:000084634600002
J	Feder, R; Dagan, A; Mor, A				Feder, R; Dagan, A; Mor, A			Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-MEMBRANES; MOLECULAR-BASIS; FROG-SKIN; ANTIBIOTICS; ANALOGS; DESIGN; S3	To understand how peptide organization in aqueous solution might affect the activity of antimicrobial peptides, the potency of various dermaseptin S4 analogs was assessed against human red blood cells (RBC), protozoa, and several Gram-negative bacteria. Dermaseptin 54 had weak antibacterial activity but potent hemolytic or antiprotozoan effects. K4K20-S4 was 2-3 fold more potent against protozoa and RBC, yet K4K20-S4 was more potent by 2 orders of magnitude against bacteria. K-4-S4 had similar behavior as K4K20-S4, but K-20-S4 and analogous negative charge substitutions were as active as dermaseptin 54 or had reduced activity. Binding experiments suggested that potency enhancement was not the result of increased affinity to target cells. In contrast, potency correlated well with aggregation properties. Fluorescence studies indicated that K-20-S4 and all negative charge substitutions were as aggregated as dermaseptin S4, whereas K-4-S4 and K4K20-S4 were clearly less aggregated. Overall, the data indicated that N-terminal domain interaction between dermaseptin 54 monomers is responsible for the peptide's oligomerization in solution and, hence, for its limited spectrum of action. Moreover, bell-shaped dose-response profiles obtained with bacteria but not with protozoa or RBC implied that aggregation can have dramatic consequences on antibacterial activity. Based on these results, we tested the feasibility of selectivity reversal in the activity of dermaseptin 54, Tampering with the composition of the hydrophobic domains by reducing hydrophobicity or by increasing the net positive charge affected dramatically the peptide's activity and resulted in various analogs that displayed potent antibacterial activity but reduced hemolytic activity. Among these, maximal antibacterial activity was displayed by a 15-mer version that was more potent by 2 orders of magnitude compared with native dermaseptin 54, These results emphasize the notion that peptide-based antibiotics represent a highly modular synthetic antimicrobial system and provide indications of how the peptide's physico-chemical properties affect potency and selectivity.	Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, Lab Antimicrobial Peptides Invest, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Mor, A (corresponding author), Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, Lab Antimicrobial Peptides Invest, IL-91904 Jerusalem, Israel.							BESSALLE R, 1993, J MED CHEM, V36, P1203, DOI 10.1021/jm00061a011; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Coote PJ, 1998, ANTIMICROB AGENTS CH, V42, P2160, DOI 10.1128/AAC.42.9.2160; De Lucca AJ, 1998, MED MYCOL, V36, P291, DOI 10.1080/02681219880000461; EPAND RM, 1995, BIOPOLYMERS, V37, P319, DOI 10.1002/bip.360370504; FROHLICH DR, 1991, INT J PEPT PROT RES, V37, P2; Ghosh JK, 1997, J BIOL CHEM, V272, P31609, DOI 10.1074/jbc.272.50.31609; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; HERNANDEZ C, 1992, EUR J CELL BIOL, V59, P414; Jouenne T, 1998, J ANTIMICROB CHEMOTH, V42, P87, DOI 10.1093/jac/42.1.87; KYTE J, 1982, J MOL BIOL, V157, P106; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; MOR A, 1994, BIOCHEMISTRY-US, V33, P6642, DOI 10.1021/bi00187a034; MOR A, 1994, J BIOL CHEM, V269, P1934; MOR A, 1994, J BIOL CHEM, V269, P31635; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; STRAHILEVITZ J, 1994, BIOCHEMISTRY-US, V33, P10951, DOI 10.1021/bi00202a014; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910	23	158	168	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4230	4238		10.1074/jbc.275.6.4230	http://dx.doi.org/10.1074/jbc.275.6.4230			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660589	hybrid			2022-12-25	WOS:000085288800073
J	Fu, J; Kreibich, G				Fu, J; Kreibich, G			Retention of subunits of the oligosaccharyltransferase complex in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; MAMMALIAN OLIGOSACCHARYLTRANSFERASE; TRANSMEMBRANE PROTEINS; RIBOSOME BINDING; GOLGI-APPARATUS; RIBOPHORINS-I; ER MEMBRANE; RAT-LIVER; SIGNAL; ROUGH	Membrane proteins of the endoplasmic reticulum (ER) may be localized to this organelle by mechanisms that involve retention, retrieval, or a combination of both. For luminal ER proteins, which contain a KDEL domain, and for type I transmembrane proteins carrying a dilysine motif, specific retrieval mechanisms have been identified. However, most ER membrane proteins do not contain easily identifiable retrieval motifs, ER localization information has been found in cytoplasmic, transmembrane, or luminal domains. In this study, we have identified ER localization domains within the three type I transmembrane proteins, ribophorin I (RI), ribophorin II (RII), and OST48. Together with DAD1, these membrane proteins form an oligomeric complex that has oligosaccharyltransferase (OST) activity. We have previously shown that ER retention information is independently contained within the transmembrane and the cytoplasmic domain of RII, and in the case of RI, a truncated form consisting of the luminal domain was retained in the ER, To determine whether other domains of RI carry additional retention information, we have generated chimeras by exchanging individual domains of the Tac antigen with the corresponding ones of RI, We demonstrate here that only the luminal domain of RI contains ER retention information. We also show that the dilysine motif in OST48 functions as an ER localization motif because OST48 in which the two lysine residues are replaced by serine (OST48ss) is no longer retained in the ER and is found instead also at the plasma membrane. OST48ss is, however, retained in the ER when coexpressed with RI, RII, or chimeras, which by themselves do not exit from the ER, indicating that they may form partial oligomeric complexes by interacting with the luminal domain of OST48. In the case of the Tac chimera containing only the luminal domain of RII, which by itself exits from the ER and is rapidly degraded, it is retained in the ER and becomes stabilized when coexpressed with OST48.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University	Kreibich, G (corresponding author), NYU, Sch Med, Dept Cell Biol, 550 1st Ave, New York, NY 10016 USA.	kreibg01@mcrcr6.med.nyu.edu						AMARCOSTESEC A, 1984, J CELL BIOL, V99, P2247, DOI 10.1083/jcb.99.6.2247; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DAHLLOF B, 1991, J BIOL CHEM, V266, P1804; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Fu J, 1997, J BIOL CHEM, V272, P29687, DOI 10.1074/jbc.272.47.29687; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORTSCH M, 1985, EUR J BIOCHEM, V150, P559, DOI 10.1111/j.1432-1033.1985.tb09057.x; IVESSA NE, 1992, J CELL BIOL, V117, P949, DOI 10.1083/jcb.117.5.949; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; Kolhekar AS, 1998, J BIOL CHEM, V273, P23012, DOI 10.1074/jbc.273.36.23012; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; LippincottSchwartz J, 1997, CURR OPIN NEUROBIOL, V7, P631, DOI 10.1016/S0959-4388(97)80082-7; MARKS MS, 1995, J BIOL CHEM, V270, P10475, DOI 10.1074/jbc.270.18.10475; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RON D, 1992, BIOTECHNIQUES, V13, P866; ROSENFELD MG, 1984, J CELL BIOL, V99, P1076, DOI 10.1083/jcb.99.3.1076; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SABATINI DD, 1995, METABOLIC BASIS INHE, P459; Sanjay A, 1998, J BIOL CHEM, V273, P26094, DOI 10.1074/jbc.273.40.26094; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; TANG BL, 1992, J BIOL CHEM, V267, P10122; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335	53	42	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3984	3990		10.1074/jbc.275.6.3984	http://dx.doi.org/10.1074/jbc.275.6.3984			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660554	hybrid			2022-12-25	WOS:000085288800038
J	Meyer, GA; Radsak, KD				Meyer, GA; Radsak, KD			Identification of a novel signal sequence that targets transmembrane proteins to the nuclear envelope inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMIN-B-RECEPTOR; VIRUS GLYCOPROTEIN-GB; HUMAN CYTOMEGALOVIRUS; INTRACELLULAR-TRANSPORT; PORE COMPLEX; FUNCTIONAL-ORGANIZATION; DOMAIN; CELLS; SUFFICIENT; BINDING	Herpesvirus maturation requires translocation of glycoprotein B homologue from the endoplasmic reticulum to the inner nuclear membrane. Glycoprotein B of human cytomegalovirus was used in this context as a model protein. To identify a specific signal sequence within human cytomegalovirus glycoprotein B acting in a modular fashion, coding sequences were recombined with reporter proteins. Immunofluorescence and cell fractionation demonstrated that a short sequence element within the cytoplasmic tail of human cytomegalovirus glycoprotein B was sufficient to translocate the membrane protein CD8 to the inner nuclear membrane. This carboxyl-terminal sequence had no detectable nuclear localization signal activity for soluble beta-Galactosidase and could not be substituted by the nuclear localization signal of SV40 T antigen. For glycoprotein B of herpes simplex virus, a carboxyl-terminal element with comparable properties was found. Further experiments showed that the amino acid sequence DRLRHR of human cytomegalovirus glycoprotein B (amino acids 885-890) was sufficient for nuclear envelope translocation. Single residue mutations revealed that the arginine residues in positions 4 and 6 of the DRLRHR sequence were essential for its function. These results support the view that transmembrane protein transport to the inner nuclear membrane is controlled by a mechanism different from that of soluble proteins.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany	Philipps University Marburg	Radsak, KD (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.	radsak@mailer.uni-marburg.de						AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; AKEY CW, 1995, J MOL BIOL, V248, P273, DOI 10.1016/S0022-2836(95)80050-6; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; Bogner E, 1997, J GEN VIROL, V78, P1647, DOI 10.1099/0022-1317-78-7-1647; Bold S, 1996, J GEN VIROL, V77, P2297, DOI 10.1099/0022-1317-77-9-2297; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; COMPTON T, 1984, J VIROL, V49, P594, DOI 10.1128/JVI.49.2.594-597.1984; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; EISHUBINGER AM, 1991, INTERVIROLOGY, V32, P351, DOI 10.1159/000150219; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; FURUKAWA K, 1995, EMBO J, V14, P1626, DOI 10.1002/j.1460-2075.1995.tb07151.x; Furukawa K, 1998, J BIOL CHEM, V273, P4213, DOI 10.1074/jbc.273.7.4213; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GILBERT R, 1994, J VIROL, V68, P2272, DOI 10.1128/JVI.68.4.2272-2285.1994; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; GONG M, 1990, J VIROL, V64, P1507, DOI 10.1128/JVI.64.4.1507-1516.1990; GRAHAM J, 1984, CENTRIFUGATION PRACT, P219; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; QUALTIERE LF, 1979, INT J CANCER, V23, P808, DOI 10.1002/ijc.2910230612; RADSAK K, 1990, VIROLOGY, V177, P515, DOI 10.1016/0042-6822(90)90516-T; RASILE L, 1993, J VIROL, V67, P4856, DOI 10.1128/JVI.67.8.4856-4866.1993; RAVIPRAKASH K, 1990, J BIOL CHEM, V265, P1777; REIS B, 1993, J GEN VIROL, V74, P1371, DOI 10.1099/0022-1317-74-7-1371; Roizman B, 1996, FIELDS VIROLOGY, P2231; Rolls MM, 1999, J CELL BIOL, V146, P29, DOI 10.1083/jcb.146.1.29; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SMITH S, 1993, J CELL BIOL, V120, P631, DOI 10.1083/jcb.120.3.631; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; SPAETE RR, 1988, VIROLOGY, V167, P207, DOI 10.1016/0042-6822(88)90071-2; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; WOZNIAK RW, 1992, J CELL BIOL, V119, P1441, DOI 10.1083/jcb.119.6.1441; YE Q, 1994, J BIOL CHEM, V269, P11306	41	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3857	3866		10.1074/jbc.275.6.3857	http://dx.doi.org/10.1074/jbc.275.6.3857			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660537	hybrid			2022-12-25	WOS:000085288800021
J	Galvagni, F; Oliviero, S				Galvagni, F; Oliviero, S			Utrophin transcription is activated by an intronic enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; MDX MICE; FUNCTIONAL-ANALYSIS; SKELETAL-MUSCLE; EXPRESSION; GENE; PROMOTER; PROTEIN; INDUCTION; MODEL	The utrophin gene codes for a large cytoskeletal protein closely related to dystrophin. Its transcription is driven by a TATA-less promoter. Here we analyzed 40 kilobases of the 5' end region of the utrophin gene searching for new utrophin regulatory elements in muscle cells. By transient transfection of utrophin genomic fragments in front of a reporter gene, we identified a new enhancer that maps downstream of the transcription start site within the second intron and co-localizes with a DNase I-hypersensitive site. By deletion analysis it was mapped to a sequence of 128 base pairs that retains the whole activity. Linker scanning mutagenesis showed that most of the enhancer sequence is essential for its transcriptional activity. Binding analysis with nuclear cell extracts demonstrated that the enhancer regulatory elements, identified by mutagenesis, are protected from DNase I digestion. Because utrophin can functionally substitute dystrophin, the identification and characterization of new regulatory elements provide new targets for possible therapies of Duchenne muscular dystrophy aiming at the up-regulation of the utrophin expression in muscle cells.	Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy	University of Siena	Oliviero, S (corresponding author), Univ Siena, Dipartimento Biol Mol, Via Fiorentina 1, I-53100 Siena, Italy.		Galvagni, Federico/F-9186-2013; oliviero, salvatore/R-6657-2019	oliviero, salvatore/0000-0002-3405-765X	Telethon [970] Funding Source: Medline	Telethon(Fondazione Telethon)		Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Dennis CL, 1996, NUCLEIC ACIDS RES, V24, P1646, DOI 10.1093/nar/24.9.1646; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Galvagni F, 1998, J BIOL CHEM, V273, P33708, DOI 10.1074/jbc.273.50.33708; Galvagni F, 1997, MOL CELL BIOL, V17, P1731, DOI 10.1128/MCB.17.3.1731; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Gramolini AO, 1998, J BIOL CHEM, V273, P736, DOI 10.1074/jbc.273.2.736; Gramolini AO, 1997, J BIOL CHEM, V272, P8117, DOI 10.1074/jbc.272.13.8117; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; GRAMOLINI AO, 1999, NUCLEIC ACIDS RES, V98, P1; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; OLIVIERO S, 1987, EMBO J, V6, P1905, DOI 10.1002/j.1460-2075.1987.tb02450.x; PEARCE M, 1993, HUM MOL GENET, V2, P1765, DOI 10.1093/hmg/2.11.1765; SCHOFIELD J, 1993, DEV DYNAM, V198, P254, DOI 10.1002/aja.1001980403; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TIJAN R, 1994, CELL, V77, P5; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0	24	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3168	3172		10.1074/jbc.275.5.3168	http://dx.doi.org/10.1074/jbc.275.5.3168			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652301	hybrid			2022-12-25	WOS:000085146500023
J	Viriyakosol, S; Mathison, JC; Tobias, PS; Kirkland, TN				Viriyakosol, S; Mathison, JC; Tobias, PS; Kirkland, TN			Structure-function analysis of CD14 as a soluble receptor for lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; LPS BINDING-PROTEIN; BACTERIAL LIPOPOLYSACCHARIDE; MEMBRANE CD14; CELLS; ACTIVATION; ENDOTOXIN; IDENTIFICATION; RECOGNITION; COMPLEXES	CD14 is a glycophosphatidylinositol-linked protein expressed by myeloid cells and also circulates as a plasma protein lacking the glycophosphatidylinositol anchor. Both membrane and soluble CD14 function to enhance activation of cells by lipopolysaccharide (LPS), which we refer to as receptor function. We have previously reported the LPS binding and cell activation functions of a group of five deletion mutants of CD14 (Viriyakosol, S., and Kirkland, T.N. (1995) J. Biol. Chem. 270, 361-368). We have now studied the functional impact of these mutations on soluble CD14. We found that some deletions that abrogated LPS binding in membrane CD14 have no effect on LPS binding in soluble CD14. In fact, some of the soluble CD14 deletion mutants bound LPS with an apparent higher affinity than wild-type CD14. Furthermore, we found that all five deletions essentially ablated soluble CD14 LPS receptor function, whereas only two of the deletions completely destroyed membrane CD14 LPS receptor function. Some of the mutants were able to compete with wild-type CD14 in soluble CD14-dependent assays of cellular activation. We concluded that the soluble and membrane forms of CD14 have different structural determinants for LPS receptor function.	Univ Calif San Diego, Sch Med, Vet Affairs San Diego Healthcare Syst, Dept Pathol,Infect Dis Sect, San Diego, CA 92161 USA; Univ Calif San Diego, Sch Med, Vet Affairs San Diego Healthcare Syst, Dept Med, San Diego, CA 92161 USA; Scripps Res Inst, La Jolla, CA 92037 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Scripps Research Institute	Kirkland, TN (corresponding author), Univ Calif San Diego, Sch Med, Vet Affairs San Diego Healthcare Syst, Dept Pathol,Infect Dis Sect, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.		Kirkland, Theo/ADK-9674-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM37696] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; DESCH CE, 1989, LYMPHOKINE RES, V8, P141; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; ESPEVIK T, 1993, EUR J IMMUNOL, V23, P255, DOI 10.1002/eji.1830230140; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; HAZIOT A, 1988, J IMMUNOL, V141, P547; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hogan LH, 1995, J BIOL CHEM, V270, P30725, DOI 10.1074/jbc.270.51.30725; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; JUAN TSC, 1995, J BIOL CHEM, V270, P17237, DOI 10.1074/jbc.270.29.17237; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KIRIKAE T, 1993, J IMMUNOL, V151, P2742; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; KUSUNOKI T, 1995, J EXP MED, V182, P1673, DOI 10.1084/jem.182.6.1673; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; PETERSON PK, 1995, INFECT IMMUN, V63, P1598, DOI 10.1128/IAI.63.4.1598-1602.1995; PUGIN J, 1993, J EXP MED, V178, P2193, DOI 10.1084/jem.178.6.2193; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; Sellati TJ, 1998, J IMMUNOL, V160, P5455; Shapiro RA, 1997, INFECT IMMUN, V65, P293, DOI 10.1128/IAI.65.1.293-297.1997; SIRIYAKOSOL S, 1995, CLIN INFECT DIS   S2, V21, P190; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; ULEVITCH RJ, 1981, J CLIN INVEST, V67, P827, DOI 10.1172/JCI110100; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Viriyakosol S, 1996, INFECT IMMUN, V64, P653, DOI 10.1128/IAI.64.2.653-656.1996; Wang PY, 1998, J BIOL CHEM, V273, P24309, DOI 10.1074/jbc.273.38.24309; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J IMMUNOL, V158, P3925	36	48	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3144	3149		10.1074/jbc.275.5.3144	http://dx.doi.org/10.1074/jbc.275.5.3144			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652298	hybrid			2022-12-25	WOS:000085146500020
J	Yang, CR; Wilson-Van Patten, C; Planchon, SM; Wuerzberger-Davis, SM; Davis, TW; Cuthill, S; Miyamoto, S; Boothman, DA				Yang, CR; Wilson-Van Patten, C; Planchon, SM; Wuerzberger-Davis, SM; Davis, TW; Cuthill, S; Miyamoto, S; Boothman, DA			Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation	FASEB JOURNAL			English	Article						PLDR; Sp1; retinoblastoma control protein; NF-kappa B; p53; ionizing radiation; genomic instability; aneuploid/polyploid; apoptosis	DEPENDENT PROTEIN-KINASE; RETINOBLASTOMA GENE-PRODUCT; BETA-LAPACHONE; DNA-BINDING; RB PROTEIN; SP1-MEDIATED TRANSCRIPTION; PLASMINOGEN-ACTIVATOR; NUCLEAR-LOCALIZATION; TOPOISOMERASE-I; MAMMALIAN-CELLS	Regulation of transcriptional responses in growth-arrested human cells under conditions that promote potentially lethal damage repair after ionizing radiation (TR) is poorly understood. Sp1/retinoblastoma control protein (RCP) DNA binding increased within 30 min and peaked at 2-4 h after IR (450-600 cGy) in confluent radioresistant human malignant melanoma (U1-Mel) cells. Increased phosphorylation of Spl directly corresponded to Sp1/RCP binding and immediate-early gene induction, whereas pRb remained hypophosphorylated. Transfection of U1-Mel cells with the human papillomavirus E7 gene abrogated Sp1/RCP induction and G(0)/G(1) cell cycle checkpoint arrest responses, increased apoptosis and radiosensitivity, and augmented genetic instability (i.e., increased polyploidy cells) after IR. Increased NF-KB DNA binding in U1-Mel cells after LR treatment lasted much longer (i.e., >20 h). U1-Mel cells overexpressing dominant-negative I kappa R alpha S32/36A mutant protein were significantly more resistant to IR exposure and retained both G(2)/M and G(0)/G(1) cell cycle checkpoint responses without significant genetic instability (i.e., polyploid cell populations were not observed). Nuclear p53 protein levels and DNA binding activity increased only after high doses of IR (>1200 cGy). Disruption of p53 responses in U1-Mel cells by E6 transfection also abrogated G(0)/G(1) cell cycle checkpoint arrest responses and increased polyploidy after IR, but did not alter radiosensitivity. These data suggest that abrogation of individual components of this coordinate IR-activated transcription factor response may lead to divergent alterations in cell cycle checkpoints, genomic instability, apoptosis, and survival. Such coordinate transcription factor activation in human cancer cells is reminiscent of prokaryotic SOS responses, and further elucidation of these events should shed light on the initial molecular events in the chromosome instability phenotype.	Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Response, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Lab Mol Stress Response, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Comprehens Canc Ctr, Lab Mol Stress Response, Cleveland, OH 44106 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53792 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53792 USA; DeRoche Discovery Welwyn, Welwyn Garden City AL7 3AY, Herts, England	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Roche Holding	Boothman, DA (corresponding author), Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Response, 10900 Euclid Ave,BRB 326, Cleveland, OH 44106 USA.		Boothman, David/Q-7776-2019; Planchon, Sarah/A-5731-2009		NCI NIH HHS [CA-78530, CA-EY67995, R01 CA078530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067995, R01CA078530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1999, MOL CELL BIOL, V19, P1961; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Bakker TR, 1999, INT J CANCER, V80, P320; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; BOOTHMAN DA, 1994, CANCER RES, V54, P4618; BOOTHMAN DA, 1989, CANCER RES, V49, P605; BOOTHMAN DA, 1994, RADIAT RES, V138, pS68, DOI 10.2307/3578765; Boothman DA, 1997, STEM CELLS, V15, P27; BOOTHMAN DA, 1989, CANCER RES, V49, P2871; BOOTHMAN DA, 1987, CANCER RES, V47, P5361; BOOTHMAN DA, 1992, INT J RADIAT ONCOL, V24, P939, DOI 10.1016/0360-3016(92)90478-Z; BOOTHMAN DA, 1991, CANCER RES, V51, P5587; BOOTHMAN DA, 1993, P NATL ACAD SCI USA, V90, P7200, DOI 10.1073/pnas.90.15.7200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fujimoto M, 1997, DNA Res, V4, P151, DOI 10.1093/dnares/4.2.151; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GOODRICH DW, 1992, NATURE, V360, P6403; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALLAHAN DE, 1991, INT J RADIAT ONCOL, V21, P1677, DOI 10.1016/0360-3016(91)90352-5; HALLAHAN DE, 1992, INT J RADIAT ONCOL, V22, P829; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jung M, 1997, CANCER RES, V57, P24; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Ludwig DL, 1997, GENE, V199, P181, DOI 10.1016/S0378-1119(97)00366-1; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROBBINS PD, 1991, NATURE, V351, P6325; RUBIN P, 1993, CLIN ONCOLOGY MULTID, V306, P72; SAHIJDAK WM, 1994, RADIAT RES, V138, pS47, DOI 10.2307/3578760; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SUMMERS WC, 1985, CANCER SURV, V4, P517; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; UEDA A, 1994, J IMMUNOL, V153, P2052; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WEICHSELBAUM RR, 1985, P NATL ACAD SCI USA, V82, P4732, DOI 10.1073/pnas.82.14.4732; WEICHSELBAUM RR, 1992, INT J RADIAT ONCOL, V24, P565, DOI 10.1016/0360-3016(92)91075-X; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU RL, 1994, J BIOL CHEM, V269, P28450; Wuerzberger SM, 1998, CANCER RES, V58, P1876	62	70	72	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					379	390		10.1096/fasebj.14.2.379	http://dx.doi.org/10.1096/fasebj.14.2.379			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657994				2022-12-25	WOS:000085184800017
J	Burke, A; Lawson, JA; Meagher, EA; Rokach, J; FitzGerald, GA				Burke, A; Lawson, JA; Meagher, EA; Rokach, J; FitzGerald, GA			Specific analysis in plasma and urine of 2,3-dinor-5,6-dihydro-isoprostane F-2 alpha-III, a metabolite of isoprostane F-2 alpha-III and an oxidation product of gamma-linolenic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED LIPID-PEROXIDATION; STRESS IN-VIVO; OXIDANT STRESS; 8-ISO-PROSTAGLANDIN F2-ALPHA; CORONARY REPERFUSION; GENERATION; HUMANS; DISEASE; NONCYCLOOXYGENASE; F-2-ISOPROSTANES	F-2-isoprostanes (iPs) are free radical-catalyzed isomers of prostaglandin F-2 alpha. Circulating and urinary iPs have been used as indices of lipid peroxidation in vivo. Utilizing an O-18-labeled homologous internal standard, we developed a gas chromatography/mass spectrometry assay for the 2,3-dinor-5,6 dihydro (dinor-dihydro) metabolite of iPF(2 alpha)-III. Although urinary excretion of iPF(2 alpha)-III reflects systemic lipid peroxidation, the metabolite is more abundant (median of 877 (range of 351-1831) versus 174 (range of 56-321) pg/mg of creatinine; p < 0.01) than the parent iP in urine and can be measured in plasma. Metabolite analysis may be preferable in plasma due to the abundance of arachidonic acid as a source of ex vivo lipid peroxidation. Also, iPF(2 alpha)-III may be formed in blood samples in a cyclooxygenase-dependent manner by platelets ex vivo. By contrast, the metabolite is not formed by aggregated platelets (0.71 +/- 0.08 versus 0.65 +/- 0.09 pg/ml). Although the metabolite/parent ratio is altered in cirrhosis, urinary dinor-dihydro-iPF(2 alpha)-III is elevated and increases further during reperfusion following orthoptic liver transplantation. In addition to its formation as an iPF(2) metabolite, analysis of gamma-linolenic acid autooxidation products and the compound present in freeze-thawed plasma suggests that gamma-linolenic acid may also be an important source of dinor-dihydro-iPF(2 alpha)-III.	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	University of Pennsylvania; Florida Institute of Technology; Florida Institute of Technology	FitzGerald, GA (corresponding author), Univ Penn, Ctr Expt Therapeut, 816 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.upenn.edu	FitzGerald, Garret A/A-4222-2010	Meagher, Emma/0000-0003-1841-4570; Rokach, Joshu/0000-0003-1814-7505	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000040] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061364] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00040] Funding Source: Medline; NHLBI NIH HHS [HL 61364] Funding Source: Medline; NIDDK NIH HHS [DK 44730] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aleynik SI, 1998, ALCOHOL CLIN EXP RES, V22, P192, DOI 10.1097/00000374-199802000-00026; Basu S, 1998, FEBS LETT, V428, P32, DOI 10.1016/S0014-5793(98)00481-5; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CATELLA F, 1986, P NATL ACAD SCI USA, V83, P5861, DOI 10.1073/pnas.83.16.5861; Chiabrando C, 1999, J BIOL CHEM, V274, P1313, DOI 10.1074/jbc.274.3.1313; Davi G, 1999, CIRCULATION, V99, P224; Delanty N, 1997, CIRCULATION, V95, P2492, DOI 10.1161/01.CIR.95.11.2492; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3824, DOI 10.1073/pnas.71.10.3824; HARRISON KA, 1995, J BIOL CHEM, V270, P17273, DOI 10.1074/jbc.270.29.17273; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; Lawson JA, 1998, J BIOL CHEM, V273, P29295, DOI 10.1074/jbc.273.45.29295; Leo MA, 1997, AM J GASTROENTEROL, V92, P2069; LLOBATESTELLES M, 1989, ANALYST, V114, P597, DOI 10.1039/an9891400597; Meagher EA, 1999, J CLIN INVEST, V104, P805, DOI 10.1172/JCI5584; Morrow JD, 1996, J BIOL CHEM, V271, P23185, DOI 10.1074/jbc.271.38.23185; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Morrow JD, 1999, ANAL BIOCHEM, V269, P326, DOI 10.1006/abio.1999.4008; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; Nourooz-Zadeh J, 1999, J NEUROCHEM, V72, P734, DOI 10.1046/j.1471-4159.1999.0720734.x; Parchmann S, 1998, J BIOL CHEM, V273, P32650, DOI 10.1074/jbc.273.49.32650; PICKETT WC, 1981, ANAL BIOCHEM, V111, P115, DOI 10.1016/0003-2697(81)90237-2; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735; Pratico D, 1998, AM J RESP CRIT CARE, V158, P1709, DOI 10.1164/ajrccm.158.6.9709066; Pratico D, 1998, J INVEST MED, V46, P51; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Reilly M, 1996, CIRCULATION, V94, P19, DOI 10.1161/01.CIR.94.1.19; Reilly MP, 1998, CIRCULATION, V98, P2822, DOI 10.1161/01.CIR.98.25.2822; Reilly MP, 1997, CIRCULATION, V96, P3314; Roberts LJ, 1996, J BIOL CHEM, V271, P20617, DOI 10.1074/jbc.271.34.20617; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P853, DOI 10.1016/S0090-6980(97)00184-6; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P823, DOI 10.1016/S0090-6980(97)00183-4; WANG ZY, 1995, J PHARMACOL EXP THER, V275, P94; Witztum JL, 1998, CURR OPIN LIPIDOL, V9, P441, DOI 10.1097/00041433-199810000-00008	37	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2499	2504		10.1074/jbc.275.4.2499	http://dx.doi.org/10.1074/jbc.275.4.2499			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644705	hybrid			2022-12-25	WOS:000085128000037
J	Schumacher, MA; Moff, I; Sudanagunta, SP; Levine, JD				Schumacher, MA; Moff, I; Sudanagunta, SP; Levine, JD			Molecular cloning of an N-terminal splice variant of the capsaicin receptor - Loss of N-terminal domain suggests functional divergence among capsaicin receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGEMINAL GANGLION NEURONS; EXPRESS SUBSTANCE-P; RAT SENSORY NEURONS; CATION CHANNEL; ACTIVATED CURRENT; CELLS; DESENSITIZATION; RESINIFERATOXIN; TRANSDUCTION; ELEGANS	Recently a cDNA clone, vanilloid receptor subtype-1 (VR1), was isolated and found to encode an ion channel that is activated by both capsaicin, the pain producing compound in chili peppers, and by noxious thermal stimuli. Subsequently, two related cDNAs have been isolated, a stretch inactivating channel with mechanosensitive properties and a vanilloid receptor-like protein that is responsive to high temperatures (52-53 degrees C). Here, we report the isolation of a vanilloid receptor 5'-splice variant (VR.5'sv) which differs from VR1 by elimination of the majority of the intracellular N-terminal domain and ankyrin repeat elements. Both VR.5'sv and VR1 mRNA were shown to be expressed in tissues reportedly responsive to capsaicin including dorsal root ganglion, brain, and peripheral blood mononuclear cells. Functional expression of VR.5'sv in Xenopus oocytes and mammalian cells showed no sensitivity to capsaicin, the potent vanilloid resiniferatoxin, hydrogen ions (pH 6.2), or noxious thermal stimuli (50 degrees C). Since VR.5'sv is otherwise identical to VR1 throughout its transmembrane spanning domains and C-terminal region, these results support the hypothesis that the N-terminal intracellular domain is essential for the formation of functional receptors activated by vanilloid compounds and noxious thermal stimuli.	Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Schumacher, MA (corresponding author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021647, R01NS038737] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38737-01, NS21647] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Acs G, 1997, J NEUROSCI, V17, P5622; Biro T, 1998, BLOOD, V91, P1332, DOI 10.1182/blood.V91.4.1332; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BUCK SH, 1986, PHARMACOL REV, V38, P179; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; Colbert HA, 1997, J NEUROSCI, V17, P8259; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; Ho WZ, 1997, J IMMUNOL, V159, P5654; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; HORI T, 1988, NEUROPHARMACOLOGY, V27, P135, DOI 10.1016/0028-3908(88)90162-1; Jung J, 1999, J NEUROSCI, V19, P529; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; Lai JP, 1998, J NEUROIMMUNOL, V86, P80, DOI 10.1016/S0165-5728(98)00025-3; Liu L, 1998, NEUROSCIENCE, V84, P569, DOI 10.1016/S0306-4522(97)00523-X; LIU L, 1994, P NATL ACAD SCI USA, V91, P738, DOI 10.1073/pnas.91.2.738; Liu L, 1996, J NEUROPHYSIOL, V75, P1503, DOI 10.1152/jn.1996.75.4.1503; Macica CM, 1998, AM J PHYSIOL-RENAL, V274, pF175, DOI 10.1152/ajprenal.1998.274.1.F175; Morales MJ, 1996, P NATL ACAD SCI USA, V93, P15119, DOI 10.1073/pnas.93.26.15119; Oh U, 1996, J NEUROSCI, V16, P1659; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Petersen M, 1996, NEUROSCIENCE, V75, P495, DOI 10.1016/0306-4522(96)00259-X; Reichling DB, 1997, P NATL ACAD SCI USA, V94, P7006, DOI 10.1073/pnas.94.13.7006; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; VRAY B, 1994, J IMMUNOL METHODS, V174, P53, DOI 10.1016/0022-1759(94)90009-4; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Winter J, 1998, NEUROSCI LETT, V241, P21, DOI 10.1016/S0304-3940(97)00978-6; WOOD JN, 1988, J NEUROSCI, V8, P3208; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	35	110	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2756	2762		10.1074/jbc.275.4.2756	http://dx.doi.org/10.1074/jbc.275.4.2756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644739	hybrid			2022-12-25	WOS:000085128000071
J	Ueda, H; Itoh, H; Yamauchi, J; Morishita, R; Kaziro, Y; Kato, K; Asano, T				Ueda, H; Itoh, H; Yamauchi, J; Morishita, R; Kaziro, Y; Kato, K; Asano, T			G protein beta gamma subunits induce stress fiber formation and focal adhesion assembly in a Rho-dependent manner in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; COUPLED RECEPTORS; SIGNALING PATHWAY; TYROSINE KINASE; JUN KINASE; EXPRESSION; ACTIVATION; 3-KINASE-GAMMA; G-ALPHA(12); STIMULATION	In fibroblasts, the G protein alpha subunits G alpha(12) and G alpha(13) stimulate Rho-dependent stress fiber formation and focal adhesion assembly, whereas G protein beta gamma subunits instead exert a disruptive influence. We show here that the latter can, however, stimulate the formation of stress fibers and focal adhesions in epithelial-like HeLa cells. Transient expression of beta(1) with gamma(2), gamma(5), gamma(7), and gamma(12) in quiescent HeLa cells induced stress fiber formation and focal adhesion assembly as did expression of the constitutively active G alpha(12). Co-expression of beta gamma with G alpha(i2) and the C-terminal fragment of the beta-adrenergic receptor kinase, both of which are known to bind and sequester free beta gamma, blocked beta gamma-induced stress fiber and focal adhesion formation. Inhibition was also noted with co-expression of a dominant negative mutant of Rho. Botulinum C3 exoenzyme, which ADP-ribosylates and inactivates Rho, and a Rho-associated protein kinase inhibitor, Y-27632, similarly inhibited beta gamma-induced stress fiber and focal adhesion assembly. These results indicate that G protein beta gamma subunits regulate Rho-dependent actin polymerization in HeLa cells.	Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 4800392, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Asano, T (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 4800392, Japan.							BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Coso OA, 1996, J BIOL CHEM, V271, P3963; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MORISHITA R, 1988, EUR J BIOCHEM, V174, P87, DOI 10.1111/j.1432-1033.1988.tb14066.x; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; NOBES CD, 1995, J CELL SCI, V108, P225; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; Ueda H, 1997, J CELL SCI, V110, P1503; Ueda H, 1999, J BIOL CHEM, V274, P12124, DOI 10.1074/jbc.274.17.12124; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; YAMAUCHI J, 1995, BIOCHEM BIOPH RES CO, V214, P694, DOI 10.1006/bbrc.1995.2341; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	29	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2098	2102		10.1074/jbc.275.3.2098	http://dx.doi.org/10.1074/jbc.275.3.2098			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636914	hybrid			2022-12-25	WOS:000084940000077
J	D'Errico, M; Calcagnile, A; Canzona, F; Didona, B; Posteraro, P; Cavalieri, R; Corona, R; Vorechovsky, I; Nardo, T; Stefanini, M; Dogliotti, E				D'Errico, M; Calcagnile, A; Canzona, F; Didona, B; Posteraro, P; Cavalieri, R; Corona, R; Vorechovsky, I; Nardo, T; Stefanini, M; Dogliotti, E			UV mutation signature in tumor suppressor genes involved in skin carcinogenesis in xeroderma pigmentosum patients	ONCOGENE			English	Article						skin cancer; XP; p53; PATCHED; UV light	BASAL-CELL CARCINOMAS; HUMAN HOMOLOG; P53 MUTATIONS; SONIC HEDGEHOG; NEVUS SYNDROME; PATCHED GENE; CANCER; REPAIR; SPECTRA; PTCH	Molecular analysis of p53 and patched (PTCH), two candidate tumor suppressor genes for non-melanocytic skin cancer, was performed in skin tumors from six patients affected by the cancer-prone disease xeroderma pigmentosum (XP), UV-specific p53 mutations were detected at a frequency of 38-50% in all the tumor types analysed, including melanomas, Additional analysis of PTCH mutations in the subset of eight basal call carcinomas (BCC) revealed a very high mutation frequency of this gene (90%) which exceeded that detected in the p53 gene in the same tumors (38%), PTCH mutations were predominantly UV-specific C > T transitions, This mutation pattern is different from that reported in BCC from normal donors where PTCH mutation frequency is 27% and mutations are frequently deletions and insertions. These findings suggest that PTCH mutations represent an earlier event in BCC development than p53 alterations and that the inability of XP patients to repair UV-induced PTCH mutations might significantly contribute to the early and frequent appearance of BCC observed in these patients.	Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy; Ist Dermopat Immacolata, I-00167 Rome, Italy; Karolinska Inst, Dept Biosci Novum, Ctr Nutr & Toxicol, S-14157 Huddinge, Sweden; CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituto Dermopatico dell'Immacolata (IDI); Karolinska Institutet; Consiglio Nazionale delle Ricerche (CNR)	Dogliotti, E (corresponding author), Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, Viale Regina Elens 299, I-00161 Rome, Italy.			Didona, Biagio/0000-0001-6635-0490				Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; Bodak N, 1999, P NATL ACAD SCI USA, V96, P5117, DOI 10.1073/pnas.96.9.5117; Chidambaram A, 1996, CANCER RES, V56, P4599; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DErrico M, 1997, CANCER RES, V57, P747; Dogliotti E, 1998, RECENT RES CANCER, V154, P97; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; Eklund LK, 1998, MOL CARCINOGEN, V21, P87, DOI 10.1002/(SICI)1098-2744(199802)21:2<87::AID-MC2>3.0.CO;2-L; Gailani MR, 1997, JNCI-J NATL CANCER I, V89, P1103, DOI 10.1093/jnci/89.15.1103; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Giglia G, 1998, CANCER RES, V58, P4402; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McGregor WG, 1999, MOL CELL BIOL, V19, P147; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; Papp T, 1996, J CANCER RES CLIN, V122, P541, DOI 10.1007/BF01213550; STEFANINI M, 1993, CARCINOGENESIS, V14, P1101, DOI 10.1093/carcin/14.6.1101; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Unden AB, 1996, CANCER RES, V56, P4562; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Wicking C, 1997, AM J HUM GENET, V60, P21; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	28	45	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					463	467		10.1038/sj.onc.1203313	http://dx.doi.org/10.1038/sj.onc.1203313			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656695				2022-12-25	WOS:000084873700018
J	Kapoor, M; Hamm, R; Yan, W; Taya, Y; Lozano, G				Kapoor, M; Hamm, R; Yan, W; Taya, Y; Lozano, G			Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation	ONCOGENE			English	Article						phosphorylation; DNA binding; UV radiation	TUMOR-SUPPRESSOR PROTEIN-P53; DNA-BINDING; ULTRAVIOLET-RADIATION; GAMMA-RADIATION; KINASE; DAMAGE; TERMINUS; IDENTIFICATION; ACETYLATION; SERINE-389	The activity of the tumor suppressor p53 is induced in response to DNA-damaging agents such as UV and gamma radiation. Phosphorylation is one of the key regulatory steps for activating p53 function. Recent reports have shown that p53 is phosphorylated at both serines 15 and 392 in response to UV radiation, Phosphorylation at serine 15 prevents the binding of HDM2, a negative regulator of p53. Phosphorylation at serine 392 induces the DNA-binding function of p53, We examined the requirement for phosphorylation at both serines and show that both these modifications occur on the same molecule of p53, In vitro assays demonstrate that phosphorylation at either one of these sites is not sufficient to yield an active p53. Phosphorylation by DNA-PK, that modifies serines 15 and 37, inhibits HDM2 binding to p53 but does not induce the DNA-binding activity of p53, Phosphorylation at serine 392, on the other hand, stimulates the DNA-binding ability of p53 but does not make it immune to binding and inhibition by HDM2, Thus, our results demonstrate that multiple sites need to be modified to yield a functional p53.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan	University of Texas System; UTMD Anderson Cancer Center; National Cancer Center - Japan	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA047296, R29CA047296] Funding Source: NIH RePORTER; NCI NIH HHS [CA47296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mayo LD, 1997, CANCER RES, V57, P5013; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Shaw P, 1996, ONCOGENE, V12, P921; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	33	72	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					358	364		10.1038/sj.onc.1203300	http://dx.doi.org/10.1038/sj.onc.1203300			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656682				2022-12-25	WOS:000084873700005
J	Senga, T; Miyazaki, K; Machida, K; Iwata, H; Matsuda, S; Nakashima, I; Hamaguchi, M				Senga, T; Miyazaki, K; Machida, K; Iwata, H; Matsuda, S; Nakashima, I; Hamaguchi, M			Clustered cysteine residues in the kinase domain of v-Src: critical role for protein stability, cell transformation and sensitivity to herbimycin A	ONCOGENE			English	Article						v-Src; temperature sensitive; cysteine; herbimycin A; protein stability	ROUS-SARCOMA VIRUS; TYROSINE KINASE; C-SRC; PHOSPHORYLATION; P60SRC; GENE; INACTIVATION; INHIBITION; PP60C-SRC; MECHANISM	We have previously reported the activation of Src by mercuric chloride based on the sulfhydryl modification, To evaluate the significance of cysteine residues in v-Src, we replaced each cysteine to alanine by oligonucleotide-directed mutagenesis and examined its effect on cell transformation. Of ten cysteine residues scattered over v-Src, four cysteines clustered in kinase domain, Cys483, Cys487, Cys496 and Cys498, were important for protein stability and cell transformation, whereas those in SH2 domain were dispensable. A single mutation in Cys498 yielded suppression of kinase activity and a temperature-sensitivity in anchorage independent growth, Double mutation either in Cys483/Cys487 or in Cys496/ Cys498 yielded clear temperature-sensitivity in cell transformation and in stability of Src protein. Instability of Src protein was magnified by quadruple mutation in the cysteines, which decreased the half-life of Src to be less than one quarter of that of wild-type. In addition, both Cys483/Cyr487 and Cys496/Cys498 kinases became resistant to in vitro inactivation by herbimycin A, which directly inactivates v-Src in addition to its effect on HSP90, Taken together, our results strongly suggest that the cysteine clustered motif of v-Src are critical for protein stability, cell transformation and in vitro inactivation by herbimycin A.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.							BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; FUKAZAWA H, 1990, BIOCHEM BIOPH RES CO, V173, P276, DOI 10.1016/S0006-291X(05)81053-8; FUKAZAWA H, 1994, FEBS LETT, V340, P155, DOI 10.1016/0014-5793(94)80127-4; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARONEY AC, 1992, ONCOGENE, V7, P1207; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Pu MY, 1996, ONCOGENE, V13, P2615; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIMPSON RB, 1961, J AM CHEM SOC, V83, P4711, DOI 10.1021/ja01484a005; STRICKS W, 1953, J AM CHEM SOC, V75, P5673, DOI 10.1021/ja01118a060; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	35	50	53	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					273	279		10.1038/sj.onc.1203296	http://dx.doi.org/10.1038/sj.onc.1203296			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645006				2022-12-25	WOS:000084844400013
J	Weber, CK; Slupsky, JR; Herrmann, C; Schuler, M; Rapp, UR; Block, C				Weber, CK; Slupsky, JR; Herrmann, C; Schuler, M; Rapp, UR; Block, C			Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes	ONCOGENE			English	Article						Ras; Raf; mitogenic signaling	COMPLETE CODING SEQUENCE; PROTEIN-KINASE; A-RAF; PLASMA-MEMBRANE; BIOCHEMICAL-PROPERTIES; B-RAF; ACTIVATION; BINDING; DOMAIN; EXPRESSION	In the mitogenic signaling cascade interaction of Ras with Raf represents a critical step for the regulation of cell growth and differentiation. The major effector of Ras, the serine/threonine kinase Raf exists as three isoforms with different tissue distributions. We demonstrate that transient transfection of oncogenic Ha-Ras leads to a preferential activation of endogenous c-Raf-l in HEK 293 cells as opposed to A-Raf, In vitro binding studies using purified Ras binding domains of Raf as well as in vivo bindings tests with full length molecules reveals significantly lower binding affinities of A-Raf to Ha-Ras as compared to other Raf isoforms, The Ras-binding interface of c-Raf differs from A-Raf by a conservative Arg to Lys exchange at residue 59 or 22 respectively. Mutational analysis reveals that this residue represents a point of isozyme discrimination: c-Raf-R59K binds Ha-Ras weaker than the wildtype, likewise A-Raf-K22R increases its affinity to Ha-Ras in vivo and in vitro. Differential binding affinities are reflected in downstream signaling. Immunecomplex kinase assays reveal that Ha-Ras mediated Raf activation is decreased for c-Raf-R59K and increased for A-Raf-K22R when compared to the respective wildtype forms. Thus our observations introduce a new level of isoform discrimination in Ras/ Raf signaling asa functional consequence of conservative amino acid exchange in the Ras binding domains.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Max Planck Inst Mol Physiol, Abt Strukt Biol, D-44026 Dortmund, Germany	University of Wurzburg; Max Planck Society	Weber, CK (corresponding author), Univ Ulm, Innere Med Abt 1, D-89070 Ulm, Germany.		Slupsky, Joseph/H-2843-2019	Slupsky, Joseph/0000-0002-7410-9004				BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CRAVCHIK A, 1993, GENE, V137, P139, DOI 10.1016/0378-1119(93)90262-2; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jaitner BK, 1997, J BIOL CHEM, V272, P29927, DOI 10.1074/jbc.272.47.29927; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHN J, 1988, J BIOL CHEM, V263, P11792; Kerkhoff E, 1998, CANCER RES, V58, P1636; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MELNICK MB, 1993, DEVELOPMENT, V118, P127; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; RAPP UR, 1988, ONCOGENE HDB; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SLUPSKY JR, 1998, CELL GROWTH ONCOGENE; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STORM SM, 1990, ONCOGENE, V5, P345; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	37	57	63	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					169	176		10.1038/sj.onc.1203261	http://dx.doi.org/10.1038/sj.onc.1203261			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644994				2022-12-25	WOS:000084844400001
J	Nakajima, H; Nakajima, HO; Soonpaa, MH; Jing, SL; Field, LJ				Nakajima, H; Nakajima, HO; Soonpaa, MH; Jing, SL; Field, LJ			Heritable lympho-epithelial thymoma resulting from a transgene insertional mutation	ONCOGENE			English	Article						cancer; lymphoma; insertional mutagenesis; transgenic mice	THYMIC HYPERPLASIA; INSITU HYBRIDIZATION; MICE; ENLARGEMENT; GENES; RATS	Thymoma is the most common tumor of the anterior-superior mediastinum. We have identified a line of transgenic mice which spontaneously and heritably develop thymomas at a very high penetrance. The available data suggest that thymoma formation in these mice results as a consequence of transgene insertional mutagenesis, Immune histologic analyses indicate that the thymomas are of epithelial cell origin. Survival studies indicate that tumor progression is more aggressive in females as compared to males (73.9 vs 41.7% mortality at 20 weeks of age, respectively), Fluorescent in situ hybridizations have localized the transgene integration site to the F2-G region of mouse chromosome 2. Translocation encompassing the syntenic region in humans has been implicated in lympho-epithelial thymoma. These animals may constitute a useful resource for the identification of gene(s) which participate in thymoma progression, as well as a model system for screening anti-thymoma therapeutic agents.	Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Field, LJ (corresponding author), Herman B Wells Ctr Pediat Res, 702 Barnhill Dr,Room 2600, Indianapolis, IN 46202 USA.							BATTIFORA H, 1980, HUM PATHOL, V11, P635, DOI 10.1016/S0046-8177(80)80074-8; BLOOM W, 1986, AFS TXB HISTOLOGY; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; DEMINATTI MM, 1994, ANN GENET-PARIS, V37, P72; FENG GS, 1994, ONCOGENE, V9, P1545; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GULICK J, 1991, J BIOL CHEM, V266, P9180; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Hogan B, 1994, MANIPULATING MOUSE E; LEWIS JE, 1987, CANCER, V60, P2727, DOI 10.1002/1097-0142(19871201)60:11<2727::AID-CNCR2820601125>3.0.CO;2-D; MATANI A, 1973, ARCH PATHOL, V95, P90; MATSUYAMA M, 1988, JPN J CANCER RES, V79, P1031, DOI 10.1111/j.1349-7006.1988.tb00070.x; MOLL J, 1992, EUR J IMMUNOL, V22, P1587, DOI 10.1002/eji.1830220636; MURAKUMO Y, 1993, JPN J CANCER RES, V84, P838, DOI 10.1111/j.1349-7006.1993.tb02054.x; Murakumo Y, 1996, MAMM GENOME, V7, P505, DOI 10.1007/s003359900152; REDDY VB, 1978, SCIENCE, V200, P494, DOI 10.1126/science.205947; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Sambrook J., 1989, MOL CLONING; Seiki K, 1997, ARCH HISTOL CYTOL, V60, P29, DOI 10.1679/aohc.60.29	21	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					32	38		10.1038/sj.onc.1203266	http://dx.doi.org/10.1038/sj.onc.1203266			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644977				2022-12-25	WOS:000084844300004
J	Gilbert, M; Brisson, JR; Karwaski, MF; Michniewicz, J; Cunningham, AM; Wu, YY; Young, NM; Wakarchuk, WW				Gilbert, M; Brisson, JR; Karwaski, MF; Michniewicz, J; Cunningham, AM; Wu, YY; Young, NM; Wakarchuk, WW			Biosynthesis of ganglioside mimics in Campylobacter jejuni OH4384 - Identification of the glycosyltransferase genes, enzymatic synthesis of model compounds, and characterization of nanomole amounts by 600-MHz H-1 and C-13 NMR analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUILLAIN-BARRE-SYNDROME; NEISSERIA-MENINGITIDIS; MOLECULAR MIMICRY; HOST STRUCTURES; LIPOPOLYSACCHARIDES; RESIDUES; ALPHA-2,3-SIALYLTRANSFERASE; POLYSACCHARIDE; SEROTYPE-O-19; SEROSTRAIN	We have applied two strategies for the cloning of four genes responsible for the biosynthesis of the GT1a ganglioside mimic in the lipooligosaccharide (LOS) of a bacterial pathogen, Campylobacter jejuni OH4384, which has been associated with Guillain-Barre syndrome. We first cloned a gene encoding an alpha-2,3-sialyltransferase (cst-I) using an activity screening strategy. We then used nucleotide sequence information from the recently completed sequence from C.jejuni NCTC 11168 to amplify a region involved in LOS biosynthesis from C, jejuni OH4384, The LOS biosynthesis locus from C, jejuni OH4384 is 11.47 kilobase pairs and encodes 13 partial or complete open reading frames, while the corresponding locus in C,jejuni NCTC 11168 spans 13.49 kilobase pairs and contains 15 open reading frames, indicating a different organization between these two strains. Potential glycosyltransferase genes were cloned individually, expressed in Escherichia coli, and assayed using synthetic fluorescent oligosaccharides as accepters. We identified genes encoding a beta-1,4-N-acetylgalactosaminyl-transferase (cgtA), a beta-1,3-galactosyltransferase (cgtB), and a bifunctional sialyltransferase (cst-II), which transfers sialic acid to 0-3 of galactose and to 0-8 of a sialic acid that is linked alpha-2,3 to a galactose, The linkage specificity of each identified glycosyltransferase was confirmed by NMR analysis at 600 MHz on nanomole amounts of model compounds synthesized in vitro. Using a gradient inverse broadband nano-NMR probe, sequence information could be obtained by detection of (3)J(C,H) correlations across the glycosidic bond. The role of cgtA and csf-II in the synthesis of the GT1a mimic in C,jejuni OH4384 were confirmed by comparing their sequence and activity with corresponding homologues in two related C,jejuni strains that express shorter ganglioside mimics in their LOS.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Wakarchuk, WW (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	warren.wakarchuk@nrc.ca	Wakarchuk, Warren/Q-9514-2017; Wakarchuk, Warren/AAO-2774-2020	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Gilbert, Michel/0000-0002-0204-4408				ASPINALL GO, 1992, J BACTERIOL, V174, P1324, DOI 10.1128/jb.174.4.1324-1332.1992; ASPINALL GO, 1994, BIOCHEMISTRY-US, V33, P250, DOI 10.1021/bi00167a033; ASPINALL GO, 1994, INFECT IMMUN, V62, P2122, DOI 10.1128/IAI.62.5.2122-2125.1994; ASPINALL GO, 1994, BIOCHEMISTRY-US, V33, P241, DOI 10.1021/bi00167a032; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; Brisson JR, 1997, BIOCHEMISTRY-US, V36, P3278, DOI 10.1021/bi961819l; Chester MA, 1998, EUR J BIOCHEM, V257, P293; Fry BN, 1998, MICROBIOL-SGM, V144, P2049, DOI 10.1099/00221287-144-8-2049; Gilbert M, 1997, EUR J BIOCHEM, V249, P187, DOI 10.1111/j.1432-1033.1997.t01-1-00187.x; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; Gilbert M, 1998, NAT BIOTECHNOL, V16, P769, DOI 10.1038/nbt0898-769; Ketley JM, 1997, MICROBIOL-UK, V143, P5, DOI 10.1099/00221287-143-1-5; Klena JD, 1998, GENE, V222, P177, DOI 10.1016/S0378-1119(98)00501-0; KUROKI S, 1993, ANN NEUROL, V33, P243, DOI 10.1002/ana.410330304; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; MICHON F, 1987, BIOCHEMISTRY-US, V26, P8399, DOI 10.1021/bi00399a055; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Moran AP, 1996, J ENDOTOXIN RES, V3, P521, DOI 10.1177/096805199600300611; PARELLA T, 1995, J MAGN RESON SER A, V112, P241, DOI 10.1006/jmra.1995.1038; PAVLIAK V, 1993, J BIOL CHEM, V268, P14146; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; SABESAN S, 1984, CAN J CHEM, V62, P1034, DOI 10.1139/v84-172; SABESAN S, 1986, J AM CHEM SOC, V108, P2068, DOI 10.1021/ja00268a056; Salloway S, 1996, INFECT IMMUN, V64, P2945, DOI 10.1128/IAI.64.8.2945-2949.1996; SKIRROW MB, 1977, BRIT MED J, V2, P9, DOI 10.1136/bmj.2.6078.9; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wakarchuk W, 1996, J BIOL CHEM, V271, P19166, DOI 10.1074/jbc.271.32.19166; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; Wakarchuk WW, 1998, PROTEIN ENG, V11, P295, DOI 10.1093/protein/11.4.295; Wood AC, 1999, MICROBIOL-UK, V145, P379, DOI 10.1099/13500872-145-2-379	31	218	235	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3896	3906		10.1074/jbc.275.6.3896	http://dx.doi.org/10.1074/jbc.275.6.3896			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660542	hybrid			2022-12-25	WOS:000085288800026
J	Sharma, KK; Kumar, RS; Kumar, GS; Quinn, PT				Sharma, KK; Kumar, RS; Kumar, GS; Quinn, PT			Synthesis and characterization of a peptide identified as a functional element in alpha A-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; HEAT-SHOCK-PROTEIN; B-CRYSTALLIN; MOLECULAR CHAPERONE; 1,1'-BI(4-ANILINO)NAPHTHALENE-5,5'-DISULFONIC ACID; TERMINAL DOMAIN; LENS; BINDING; GROEL; TISSUES	Eye lens alpha-crystallin is a member of the small heat shock protein (sHSP) family and forms large multimeric structures. Earlier studies have shown that it can act like a molecular chaperone and form a stable complex with partially unfolded proteins, We have observed that prior binding of the hydrophobic protein melittin to alpha-crystallin diminishes its chaperone-like activity toward denaturing alcohol dehydrogenase, suggesting the presence of mutually exclusive sites for these proteins in alpha-crystallin, To investigate the mechanism of the interaction between alpha-crystallin and substrate proteins, we determined the melittin-binding sites in alpha-crystallin by cross-linking studies. Localization of melittin-binding sites in alpha-crystallin resulted in the identification of RTLGPFYPSR and FVIFLDVKHFSPEDLTVK of alpha A-crystallin and FSVNLDVK of alpha B-crystallin as the chaperone sites. Of these sites, FVIFLDVKHFSPEDLTVK and FSVNLDVK were identified earlier as 1,1'-bi(4-anilino) naphthalene-5,5'-disulfonic acid (bis-ANS)-binding hydrophobic sites. Here we also report the synthesis and characterization of the peptide, KFVIFLDVKHFSPEDLTVK, having the melittin as well as bis-ANS-binding sequence of alpha A-crystallin. We show that this peptide has characteristics similar to that of alpha A-crystallin by in vitro thermal aggregation assay, gel filtration study, CD spectroscopy, and bis-ANS interaction studies. The peptide sequence corresponds to the beta 3 and beta 4 region present in the cu-crystallin domain of sHSP 16.5. We hypothesize that the alpha-crystallin domain in other sHSPs may have a similar function and would likely possess the anti-aggregation property even when separated from the native protein.	Univ Missouri, Dept Ophthalmol, Mason Eye Inst, Columbia, MO 65212 USA; Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Sharma, KK (corresponding author), Univ Missouri, Dept Ophthalmol, Mason Eye Inst, Columbia, MO 65212 USA.		Kumar, Dr Suresh/HHZ-2615-2022; KUMAR, P. SURESH/AAT-8951-2020; Kumar, Gopinatha Suresh/W-1461-2019	Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604; 	NATIONAL EYE INSTITUTE [R01EY011981] Funding Source: NIH RePORTER; NEI NIH HHS [EY11981] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bloemendal M, 1999, BBA-PROTEIN STRUCT M, V1432, P234, DOI 10.1016/S0167-4838(99)00107-7; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Brazil BT, 1997, J BIOL CHEM, V272, P5105, DOI 10.1074/jbc.272.8.5105; BYER CF, 1973, NATURE-NEW BIOL, V241, P78; Carver JA, 1996, EXP EYE RES, V63, P639, DOI 10.1006/exer.1996.0158; Clark JI, 1996, P NATL ACAD SCI USA, V93, P15185, DOI 10.1073/pnas.93.26.15185; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GESELOWITZ DA, 1995, BIOCONJUGATE CHEM, V6, P502, DOI 10.1021/bc00034a021; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; Lindner RA, 1998, EUR J BIOCHEM, V258, P170, DOI 10.1046/j.1432-1327.1998.2580170.x; Mchaourab HS, 1999, INVEST OPHTH VIS SCI, V40, pS300; MERCK KB, 1993, MOL BIOL REP, V18, P209, DOI 10.1007/BF01674432; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; RAMAN B, 1994, J BIOL CHEM, V269, P27264; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; RAO PV, 1994, J BIOL CHEM, V269, P13266; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; Smith JB, 1996, EXP EYE RES, V63, P125, DOI 10.1006/exer.1996.0100; Smulders RHPH, 1997, FEBS LETT, V409, P101, DOI 10.1016/S0014-5793(97)00498-5; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; TAKEMOTO L, 1993, BIOCHEM J, V294, P435, DOI 10.1042/bj2940435; TAKEMOTO L, 1994, CURR EYE RES, V13, P35, DOI 10.3109/02713689409042396; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; WANG KY, 1994, J BIOL CHEM, V269, P13601; YANG JT, 1986, METHOD ENZYMOL, V130, P208	43	195	212	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3767	3771		10.1074/jbc.275.6.3767	http://dx.doi.org/10.1074/jbc.275.6.3767			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660525	hybrid			2022-12-25	WOS:000085288800009
J	Yakhnin, AV; Trimble, JJ; Chiaro, CR; Babitzke, P				Yakhnin, AV; Trimble, JJ; Chiaro, CR; Babitzke, P			Effects of mutations in the L-tryptophan binding pocket of the trp RNA-binding attenuation protein of Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ATTENUATION; LEADER RNA; OPERON; TRAP; EXPRESSION; BIOSYNTHESIS; MTRB	The Bacillus subtilis tryptophan biosynthetic genes are regulated by the trp RNA-binding attenuation protein (TRAP), Cooperative binding of L-tryptophan activates TRAP so that it can bind to RNA. The crystal structure revealed that L-tryptophan forms nine hydrogen bonds with various amino acid residues of TRAP, We performed site-directed mutagenesis to determine the importance of several of these hydrogen bonds in TRAP activation. We tested both alanine substitutions as well as substitutions more closely related to the natural amino acid at appropriate positions. Tryptophan binding mutations were identified in vivo having unchanged, reduced, or completely eliminated repression activity. Several of the in vivo defective TRAP mutants exhibited reduced affinity for tryptophan in vitro but did not interfere with RNA binding at saturating tryptophan concentrations. However, a 10-fold decrease in TRAP affinity for tryptophan led to an almost complete loss of regulation, whereas increased TRAP affinity for tryptophan had little or no effect on the in vivo regulatory activity of TRAP. One hydrogen bond was found to be dispensable for TRAP activity, whereas two others appear to be essential for TRAP function, Another mutant protein exhibited tryptophan-independent RNA binding activity. We also found that trp leader RNA increases the affinity of TRAP for tryptophan.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Babitzke, P (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.		Babitzke, Paul/AAL-3048-2020	Babitzke, Paul/0000-0003-2481-1062	NIGMS NIH HHS [R01 GM052840, GM52840] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052840] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; BABITZKE P, 1995, J BIOL CHEM, V270, P12452, DOI 10.1074/jbc.270.21.12452; BABITZKE P, 1992, J BACTERIOL, V174, P2059, DOI 10.1128/JB.174.7.2059-2064.1992; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; Babitzke P, 1997, MOL MICROBIOL, V26, P1, DOI 10.1046/j.1365-2958.1997.5541915.x; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; Miller J.H., 1972, EXPT MOL GENETICS; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; Sudershana S, 1999, J BACTERIOL, V181, P5742, DOI 10.1128/JB.181.18.5742-5749.1999; SULLIVAN MA, 1984, GENE, V29, P21, DOI 10.1016/0378-1119(84)90161-6; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149	17	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4519	4524		10.1074/jbc.275.6.4519	http://dx.doi.org/10.1074/jbc.275.6.4519			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660627	hybrid			2022-12-25	WOS:000085288800111
J	Gerrish, K; Grannon, M; Shih, D; Henderson, E; Stoffel, M; Wright, CVE; Stein, R				Gerrish, K; Grannon, M; Shih, D; Henderson, E; Stoffel, M; Wright, CVE; Stein, R			Pancreatic beta cell-specific transcription of the pdx-1 gene - The role of conserved upstream control regions and their hepatic nuclear factor 3 beta sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE; HOMEODOMAIN PROTEIN; HOMEOBOX FACTOR; HYPERSENSITIVE SITES; MOUSE EMBRYO; ISLET CELLS; YOUNG MODY1; EXPRESSION; ACTIVATION; ENDODERM	To identify potential transactivators of pdx-1, we sequenced approximately 4.5 kilobases of the 5' promoter region of the human and chicken homologs, assuming that sequences conserved with the mouse gene would contain critical cis-regulatory elements. The sequences associated with hypersensitive site 1 (HSS1) represented the principal area of homology within which three conserved subdomains were apparent: area I (-2694 to -2561 base pairs (bp)), area II (-2139 to -1958 bp), and area III (-1879 to -1799 bp), The identities between the mouse and chicken/human genes are very high, ranging from 78 to 89%, although only areas I and III are present within this region in chicken. Pancreatic beta cell-selective expression was shown to be controlled by mouse and human area I or area II, but not area III, from an analysis of pdx-1-driven reporter activity in transfected beta- and non-beta cells. Mutational and functional analyses of conserved hepatic nuclear factor 3 (HNF3)-like sites located within area I and area II demonstrated that activation by these regions was mediated by HNF3 beta, To determine if a similar regulatory relationship might exist within the context of the endogenous gene, pdx-1 expression was measured in embryonic stem cells in which one or both alleles of HNF3 beta were inactivated, pdx-1 mRNA levels induced upon differentiation to embryoid bodies were down-regulated in homozygous null HNF3 beta cells. Together, these results suggest that the conserved sequences represented by areas I and II define the binding sites for factors such as HNF3 beta, which control islet beta cell-selective expression of the pdx-1 gene.	Rockefeller Univ, Lab Metabol Dis, New York, NY 10021 USA; Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA	Rockefeller University; Vanderbilt University; Vanderbilt University	Stein, R (corresponding author), Rockefeller Univ, Lab Metabol Dis, 1230 York Ave, New York, NY 10021 USA.		Gannon, Maureen A/F-9060-2012	Stoffel, Markus/0000-0003-1304-5817	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050203] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD 28062] Funding Source: Medline; NIDDK NIH HHS [DK 42502, R01 DK50203] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BrethertonWatt D, 1996, BIOCHEM J, V313, P495, DOI 10.1042/bj3130495; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUZ Y, 1995, DEVELOPMENT, V121, P11; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; Inoue H, 1996, DIABETES, V45, P789, DOI 10.2337/diabetes.45.6.789; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Kim SK, 1997, DEVELOPMENT, V124, P4243; Larsson LI, 1996, MECH DEVELOP, V60, P175, DOI 10.1016/S0925-4773(96)00609-0; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; MARTI E, 1995, DEVELOPMENT, V121, P2537; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; Petersen HV, 1998, FEBS LETT, V431, P362, DOI 10.1016/S0014-5793(98)00776-5; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Rawdon BB, 1998, MICROSC RES TECHNIQ, V43, P292, DOI 10.1002/(SICI)1097-0029(19981115)43:4<292::AID-JEMT3>3.0.CO;2-X; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Samadani U, 1996, MOL CELL BIOL, V16, P6273; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; Sharma S, 1996, J BIOL CHEM, V271, P2294, DOI 10.1074/jbc.271.4.2294; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Watada H, 1996, BIOCHEM BIOPH RES CO, V229, P746, DOI 10.1006/bbrc.1996.1875; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Zaret KS, 1996, ANNU REV PHYSIOL, V58, P231, DOI 10.1146/annurev.physiol.58.1.231	55	127	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3485	3492		10.1074/jbc.275.5.3485	http://dx.doi.org/10.1074/jbc.275.5.3485			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652343	hybrid			2022-12-25	WOS:000085146500065
J	Kokai-Kun, JF; Melton-Celsa, AR; O'Brien, AD				Kokai-Kun, JF; Melton-Celsa, AR; O'Brien, AD			Elastase in intestinal mucus enhances the cytotoxicity of Shiga toxin type 2d	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI STRAINS; PROTEOLYTIC ACTIVATION; POLYACRYLAMIDE GELS; BACTERIAL TOXINS; SHIGELLA TOXIN; PROTEINS; MOUSE; IDENTIFICATION; CELLS; GENES	Shiga toxin variant type 2d (Stx2d) produced by some strains of Shiga toxin-producing Escherichia coli is composed of an enzymatically active A subunit and a B (binding) pentamer, The cytotoxicity of Stx2d is increased (activated) 10-1000-fold for Vero cells when the toxin is incubated with mucus obtained from the small intestine of mice. In this study we isolated an Stx2d activator and identified it as a mouse elastase with strong homology to human elastase IIIB, Moreover, commercially available porcine pancreatic elastase preparations also activated Stx2d cytotoxicity although with a lower specific activity than isolated mouse elastase. Elastase directly nicked the Stx2d A subunit to A(1) and A(2), an event that did not correlate with activation. However, elastase also reduced the size and changed the isoelectric point of the A(2) peptide, as determined by SDS-polyacrylamide gel electrophoresis and two-dimensional electrophoresis followed by Western immunoblot analysis. This elastase-mediated size and charge shift in the A(2) peptide of Stx2d occurred concurrently with activation of the toxin, Both the reduction in size of the Stx2d A(2) peptide by incubation with elastase as well as the associated activation of Stx2d cytotoxicity were fully inhibited by elastatinal, an elastase-specific inhibitor.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	O'Brien, AD (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bride Rd, Bethesda, MD 20814 USA.				NIAID NIH HHS [AI20148-16] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020148, R22AI020148, R01AI020148] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALLARD J, 1993, MOL MICROBIOL, V10, P627, DOI 10.1111/j.1365-2958.1993.tb00934.x; DEAN EA, 1990, INFECT IMMUN, V58, P4030, DOI 10.1128/IAI.58.12.4030-4035.1990; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; FRASER ME, 1994, NAT STRUCT BIOL, V1, P59, DOI 10.1038/nsb0194-59; GENTRY MK, 1980, J CLIN MICROBIOL, V12, P361, DOI 10.1128/JCM.12.3.361-366.1980; GORDON VM, 1994, INFECT IMMUN, V62, P333, DOI 10.1128/IAI.62.2.333-340.1994; GORDON VM, 1995, INFECT IMMUN, V63, P82, DOI 10.1128/IAI.63.1.82-87.1995; GRANUM PE, 1981, BIOCHIM BIOPHYS ACTA, V668, P325, DOI 10.1016/0005-2795(81)90165-3; GRANUM PE, 1991, TOXICON, V29, P445; IRVINE JW, 1993, FEMS MICROBIOL LETT, V110, P113, DOI 10.1111/j.1574-6968.1993.tb06304.x; ITO H, 1990, MICROB PATHOGENESIS, V8, P47, DOI 10.1016/0882-4010(90)90007-D; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; Kaper J.B, 1998, ESCHERICHIA COLI O15; KokaiKun JF, 1997, INFECT IMMUN, V65, P1014, DOI 10.1128/IAI.65.3.1014-1022.1997; KONGMUANG U, 1988, FEMS MICROBIOL LETT, V56, P105, DOI 10.1016/0378-1097(88)90135-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARGMAN C, 1976, BIOCHEMISTRY-US, V15, P2491, DOI 10.1021/bi00656a036; Lea N, 1999, MICROBIOL-UK, V145, P999, DOI 10.1099/13500872-145-5-999; LINDGREN SW, 1993, INFECT IMMUN, V61, P3832, DOI 10.1128/IAI.61.9.3832-3842.1993; LINDGREN SW, 1994, INFECT IMMUN, V62, P623, DOI 10.1128/IAI.62.2.623-631.1994; LOUIE M, 1994, EPIDEMIOL INFECT, V112, P449, DOI 10.1017/S0950268800051153; MeltonCelsa AR, 1996, INFECT IMMUN, V64, P1569, DOI 10.1128/IAI.64.5.1569-1576.1996; MELTONCELSA AR, 1998, BACTERIAL PROTEIN S, V29, P192; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OGATA M, 1992, J BIOL CHEM, V267, P25396; SCHMITT CK, 1991, INFECT IMMUN, V59, P1065, DOI 10.1128/IAI.59.3.1065-1073.1991; SHEN W, 1987, BIOCHEMISTRY-US, V26, P3447, DOI 10.1021/bi00386a030; Shotton D. M., 1970, METHOD ENZYMOL, V19, P113, DOI 10.1016/0076-6879(70)19009-4; STEVENSON BJ, 1986, NUCLEIC ACIDS RES, V14, P8307, DOI 10.1093/nar/14.21.8307; SZIEGOLEIT A, 1985, EUR J BIOCHEM, V151, P595, DOI 10.1111/j.1432-1033.1985.tb09145.x; TANI T, 1988, J BIOL CHEM, V263, P1231; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Umezawa H, 1976, Methods Enzymol, V45, P678; WADOLKOWSKI EA, 1990, INFECT IMMUN, V58, P3959, DOI 10.1128/IAI.58.12.3959-3965.1990	36	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3713	3721		10.1074/jbc.275.5.3713	http://dx.doi.org/10.1074/jbc.275.5.3713			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652371	hybrid			2022-12-25	WOS:000085146500093
J	Tasanen, K; Eble, JA; Aumailley, M; Schumann, H; Baetge, J; Tu, H; Bruckner, P; Bruckner-Tuderman, L				Tasanen, K; Eble, JA; Aumailley, M; Schumann, H; Baetge, J; Tu, H; Bruckner, P; Bruckner-Tuderman, L			Collagen XVII is destabilized by a glycine substitution mutation in the cell adhesion domain Col15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULLOUS PEMPHIGOID ANTIGEN; JUNCTIONAL EPIDERMOLYSIS-BULLOSA; BETA-4 INTEGRIN SUBUNIT; EXTRACELLULAR-MATRIX; DENATURED COLLAGEN; BP180 ECTODOMAIN; TRIPLE-HELIX; AUTOANTIBODIES; KERATINOCYTES; PROCOLLAGEN	Collagen XVII is a hemidesmosomal transmembrane molecule important for epithelial adhesion in the skin. It exists in two forms, as a full-length protein and as a soluble ectodomain that is shed from the keratinocyte surface by furin-mediated proteolysis. To obtain information on the conformation and the functions of this unusual collagen, its largest collagenous domain, Col15, was expressed in a eukaryotic episomal expression system and purified by DEAE and fast protein liquid- Mono S chromatography. The protein was triple-helical (T-m of 26.5 degrees C) when produced in cultures containing ascorbic acid. When the vitamin supply was limited, the 4-hydroxyproline content was reduced from 74 to 9%, which, in turn, resulted in a drastic reduction of the stability of the triple helix. The glycine substitution mutation G627V associated with junctional epidermolysis bullosa, a human blistering shin disease, also had a striking effect on thermal stability of rCol15 causing partial unfolding already at 4 degrees C, Col15 promoted cell adhesion of epithelial and fibroblastic cell lines with a beta 1 integrin-mediated mechanism. In concert with this, in acquired autoimmune blistering skin diseases, circulating IgG and IgA autoantibodies were found to target rCol15r.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Munster, Dept Physiol Chem, D-48149 Munster, Germany; Univ Oulu, Dept Dermatol, SF-90220 Oulu, Finland; Univ Oulu, Dept Med Biochem, SF-90220 Oulu, Finland; Univ Cologne, Dept Biochem, D-50931 Cologne, Germany	University of Munster; University of Munster; University of Oulu; University of Oulu; University of Cologne	Bruckner-Tuderman, L (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 56, D-48149 Munster, Germany.		Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611; Tasanen, Kaisa/0000-0001-8056-5949				Aho S, 1998, BIOCHEM BIOPH RES CO, V243, P694, DOI 10.1006/bbrc.1998.8162; Arnold WV, 1998, J BIOL CHEM, V273, P31822, DOI 10.1074/jbc.273.48.31822; AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; Balding SD, 1997, BIOCHEMISTRY-US, V36, P8821, DOI 10.1021/bi970675n; Balding SD, 1996, J INVEST DERMATOL, V106, P141, DOI 10.1111/1523-1747.ep12329728; Borradori L, 1997, J CELL BIOL, V136, P1333, DOI 10.1083/jcb.136.6.1333; Borradori L, 1998, EXP CELL RES, V239, P463, DOI 10.1006/excr.1997.3923; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BRUCKNERTUDERMA.L, 2000, CONNECTIVE TISSUE IT; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; Floeth M, 1998, J INVEST DERMATOL, V111, P528, DOI 10.1046/j.1523-1747.1998.00325.x; GAMMON WR, 1992, J AM ACAD DERMATOL, V27, P79; Gatalica B, 1997, AM J HUM GENET, V60, P352; Ghohestani RF, 1997, J INVEST DERMATOL, V108, P854, DOI 10.1111/1523-1747.ep12292581; GIUDICE GJ, 1993, J IMMUNOL, V151, P5742; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; Haase C, 1998, J INVEST DERMATOL, V110, P282, DOI 10.1046/j.1523-1747.1998.00126.x; Hammami-Hauasli N, 1998, J BIOL CHEM, V273, P19228, DOI 10.1074/jbc.273.30.19228; Hirako Y, 1998, J BIOL CHEM, V273, P9711, DOI 10.1074/jbc.273.16.9711; Hirako Y, 1996, J BIOL CHEM, V271, P13739, DOI 10.1074/jbc.271.23.13739; Hopkinson SB, 1998, J INVEST DERMATOL, V111, P1015, DOI 10.1046/j.1523-1747.1998.00452.x; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; McGrath JA, 1996, AM J PATHOL, V148, P1787; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; Nakatani C, 1998, BRIT J DERMATOL, V139, P365; Nie ZX, 1999, J INVEST DERMATOL, V112, P254, DOI 10.1046/j.1523-1747.1999.00501.x; Pas HH, 1997, J INVEST DERMATOL, V108, P423, DOI 10.1111/1523-1747.ep12289703; Perriard J, 1999, J INVEST DERMATOL, V112, P141, DOI 10.1046/j.1523-1747.1999.00497.x; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; PIEZ KA, 1970, BIOCHEMISTRY-US, V9, P4129, DOI 10.1021/bi00823a015; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Pulkkinen L, 1998, EXP DERMATOL, V7, P46, DOI 10.1111/j.1600-0625.1998.tb00304.x; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Schumann H, 1997, AM J HUM GENET, V60, P1344, DOI 10.1086/515463; SCHUMANN H, 2000, IN PRESS AM J PATHOL; STANLEY JR, 1995, J EXP MED, V181, P1, DOI 10.1084/jem.181.1.1; TUCKWELL DS, 1994, J CELL SCI, V107, P993; Zafarullah K, 1997, MATRIX BIOL, V16, P245, DOI 10.1016/S0945-053X(97)90013-5; Zillikens D, 1997, J INVEST DERMATOL, V109, P573, DOI 10.1111/1523-1747.ep12337492; Zone JJ, 1998, J INVEST DERMATOL, V110, P207, DOI 10.1046/j.1523-1747.1998.00129.x	51	48	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3093	3099		10.1074/jbc.275.5.3093	http://dx.doi.org/10.1074/jbc.275.5.3093			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652291	hybrid			2022-12-25	WOS:000085146500013
J	Wessler, S; Hocker, M; Fischer, W; Wang, TC; Rosewicz, S; Haas, R; Wiedenmann, B; Meyer, TF; Naumann, M				Wessler, S; Hocker, M; Fischer, W; Wang, TC; Rosewicz, S; Haas, R; Wiedenmann, B; Meyer, TF; Naumann, M			Helicobacter pylori activates the histidine decarboxylase promoter through a mitogen-activated protein kinase pathway independent of pathogenicity island-encoded virulence factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROCHROMAFFIN-LIKE CELLS; NF-KAPPA-B; PHORBOL 12-MYRISTATE 13-ACETATE; GASTRIC EPITHELIAL-CELLS; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; ISCHEMIA-REPERFUSION; HISTAMINE SYNTHESIS; CANCER CELLS; INFECTION	Helicobacter pylori infection of the gastric mucosa is accompanied by an activated histamine metabolism. Histamine plays a central role in the regulation of gastric acid secretion and is involved in the pathogenesis of gastroduodenal ulcerations. Histidine decarboxylase (HDC) is the rate-limiting enzyme for histamine production, and its activity is regulated through transcriptional mechanisms. The present study investigated the effect of H. pylori infection on the transcriptional activity of the human HDC (hHDC) promoter in a gastric epithelial cell line (AGS) and analyzed the underlying molecular mechanisms. Our studies demonstrate that H, pylori infection potently transactivated the hHDC promoter. The H. pylori-responsive element of the hHDC gene was mapped to the sequence +1 to +27 base pairs, which shows no homology to known cis-acting elements and also functions as a gastrin-responsive element. H. pylori regulates the activity of this element via a Raf-1/MEK/ERK pathway, which was activated in a Ras-independent manner. Furthermore, we found that H. pylori-induced transactivation of the hHDC promoter was independent of the cag pathogenicity island and the vacuolating cytotoxin A gene and therefore may be exerted through (a) new virulence factor(s), A better understanding of H. pylori-directed hHDC transcription can provide novel insights into the molecular mechanisms of H, pylori-dependent gene regulation in gastric epithelial cells and may lead to new therapeutic approaches.	Max Planck Inst Infektionsbiol, Mol Biol Abt, D-10117 Berlin, Germany; Humboldt Univ, Klinikum Charite, Med Klink Schwerpunkt Gastroenterol & Hepatol, D-1086 Berlin, Germany; Max Von Pettenkofer Inst Med Mikrobiol & Hyg, Abt Bakteriol, D-80336 Munich, Germany; Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Naumann, M (corresponding author), Max Planck Inst Infektionsbiol, Mol Biol Abt, Monbijoustr 2, D-10117 Berlin, Germany.		Wessler, Silja/C-6309-2015; Naumann, Michael/B-5285-2011; Meyer, Thomas F. F/J-2485-2013	Wessler, Silja/0000-0001-7011-6162; Naumann, Michael/0000-0002-8060-2313; Meyer, Thomas F. F/0000-0002-6120-8679; Wiedenmann, Bertram/0000-0002-7890-2552				Aihara M, 1997, INFECT IMMUN, V65, P3218, DOI 10.1128/IAI.65.8.3218-3224.1997; ANDRE F, 1985, GASTROENTEROLOGY, V88, P452, DOI 10.1016/0016-5085(85)90506-2; Asahara M, 1996, GASTROENTEROLOGY, V111, P45, DOI 10.1053/gast.1996.v111.pm8698224; BECHI P, 1996, AM J GASTROENTEROL, V91, P2339; Ben-Hamida A, 1998, INFLAMM RES, V47, P193, DOI 10.1007/s000110050317; Ben-Hamida A, 1998, DIGEST DIS SCI, V43, P126, DOI 10.1023/A:1018888423882; Bodger K, 1998, BRIT MED BULL, V54, P139; BOUCLIER M, 1983, EUR J PHARMACOL, V90, P129, DOI 10.1016/0014-2999(83)90224-8; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Chan EC, 1996, FEBS LETT, V399, P127, DOI 10.1016/S0014-5793(96)01304-X; Chang CS, 1999, GASTROENTEROLOGY, V117, P82, DOI 10.1016/S0016-5085(99)70553-6; CHEN D, 1994, GASTROENTEROLOGY, V107, P18, DOI 10.1016/0016-5085(94)90056-6; Covacci A, 1998, CURR OPIN MICROBIOL, V1, P96, DOI 10.1016/S1369-5274(98)80148-3; Cover TL, 1999, GASTROENTEROLOGY, V117, P257, DOI 10.1016/S0016-5085(99)70575-5; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIMALINE R, 1991, FEBS LETT, V281, P20, DOI 10.1016/0014-5793(91)80348-7; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; FIGURA N, 1987, J CLIN GASTROENTEROL, V25, P149; FUJIMOTO K, 1992, J CLIN INVEST, V89, P126, DOI 10.1172/JCI115552; Glocker E, 1998, INFECT IMMUN, V66, P2346, DOI 10.1128/IAI.66.5.2346-2348.1998; Hocker M, 1997, J BIOL CHEM, V272, P27015, DOI 10.1074/jbc.272.43.27015; Hocker M, 1998, J BIOL CHEM, V273, P23046, DOI 10.1074/jbc.273.36.23046; Hocker M, 1996, AM J PHYSIOL-GASTR L, V270, pG619, DOI 10.1152/ajpgi.1996.270.4.G619; Hocker M, 1996, YALE J BIOL MED, V69, P21; HOLLANDE F, 1994, AM J PHYSIOL, V266, pG395, DOI 10.1152/ajpgi.1994.266.3.G395; KAHLSON G, 1972, EXPERIENTIA, V28, P993, DOI 10.1007/BF01918636; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Kidd M, 1997, GASTROENTEROLOGY, V113, P1110, DOI 10.1053/gast.1997.v113.pm9322505; KULUSHI S, 1996, GASTROENTEROLOGY, V110, P452; Malfertheiner P, 1997, DIGESTION, V58, P17, DOI 10.1159/000201517; MARAZOVA K, 1993, AGENTS ACTIONS, V38, pC300; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; McGowan CC, 1996, GASTROENTEROLOGY, V110, P926, DOI 10.1053/gast.1996.v110.pm8608904; Megraud F, 1997, J GASTROENTEROL, V32, P278, DOI 10.1007/BF02936383; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Modlin IM, 1996, GASTROENTEROLOGY, V111, P783, DOI 10.1053/gast.1996.v111.agast961110783; Naumann M, 1998, J EXP MED, V188, P1277, DOI 10.1084/jem.188.7.1277; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Nedrud JG, 1997, CURR OPIN GASTROEN, V13, P71, DOI 10.1097/00001574-199701000-00013; Pai R, 1998, AM J PATHOL, V152, P1617; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Peek RM, 1997, AM J MED, V102, P200, DOI 10.1016/S0002-9343(96)00273-2; PRINZ C, 1993, GASTROENTEROLOGY, V105, P449, DOI 10.1016/0016-5085(93)90719-S; Raychowdhury R, 1999, J BIOL CHEM, V274, P20961, DOI 10.1074/jbc.274.30.20961; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Schubert ML, 1996, CURR OPIN GASTROEN, V12, P493, DOI 10.1097/00001574-199611000-00002; Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595; Sharma SA, 1998, J IMMUNOL, V160, P2401; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; TILLY BC, 1990, J CELL BIOL, V110, P1211, DOI 10.1083/jcb.110.4.1211; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TSUNADA S, 1994, GASTROENTEROLOGY, V107, P1297, DOI 10.1016/0016-5085(94)90530-4; Zhang ZS, 1996, J BIOL CHEM, V271, P14188, DOI 10.1074/jbc.271.24.14188	56	64	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3629	3636		10.1074/jbc.275.5.3629	http://dx.doi.org/10.1074/jbc.275.5.3629			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652359	Green Published, hybrid			2022-12-25	WOS:000085146500081
J	Hirao, K; Hata, Y; Yao, I; Deguchi, M; Kawabe, H; Mizoguchi, A; Takai, Y				Hirao, K; Hata, Y; Yao, I; Deguchi, M; Kawabe, H; Mizoguchi, A; Takai, Y			Three isoforms of synaptic scaffolding molecule and their characterization - Multimerization between the isoforms and their interaction with N-methyl-D-aspartate receptors and SAP90/PSD-95-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY; PDZ DOMAIN; RAT-BRAIN; PSD-95; LOCALIZATION; RECOGNITION; FAMILY; SAP90	The synaptic scaffolding molecule (S-SCAM) has been identified as a protein interacting with SAP90/PSD-95-associated protein (SAPAP) (also called guanylate kinase-associated protein/hDLG-associated protein). S-SCAM;I has six PDZ (we have numbered them PDZ-0 to -5), two WV, and one guanylate kinase (GK) domains and interacts with N-methyl-D-aspartate (NMDA) receptor via PDZ-5 and SAPAP via the GIC domain. me have identified here shorter isoforms of S-SCAM that start at the 164th or 224th methionine, and we renamed the original one, S-SCAM alpha, the middle one, S-SCAM beta, and the shortest one, SSCAM-gamma. S-SCAM beta and -gamma have five PDZ (PDZ-1 to -5), two WW, and one GK domains. S-SCAM alpha interacted with S-SCAM beta and -gamma through the region containing PDZ-4 and -5. The region containing both of PDZ-4 and -5 is sufficient for the clustering of NMDA receptors and forms a dimer in gel filtration, suggesting that S-SCAM forms multimers via the interaction between the C-terminal PDZ domains and assembles NMDA receptors into clusters. S-SCAM beta P and -gamma also interacted with SAPAP, suggesting that the N-terminal region of the GH domain is not necessary for the interaction. Finally, we have identified the interaction of the PDZ domains of S-SCAM with the GK domain of PSD-95/SAP90. S-SCAM PSD-95/SAP90, and SAPAP are colocalized at least in some part in brain. Therefore, S-SCAM, PSD-95/SAP90, and SA-PAP may form a complex in vivo.	JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan; Tokyo Med & Dent Univ, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan; Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Kyoto Univ, Grad Sch, Dept Anat & Neurobiol, Kyoto 6068315, Japan	Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU); Osaka University; Kyoto University	Takai, Y (corresponding author), JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, 2-2-10 Murotani, Kobe, Hyogo 6512241, Japan.	ytakai@molbio.med.osak-u.ac.jp	Kawabe, Hiroshi/U-7325-2018	Kawabe, Hiroshi/0000-0001-5650-8696				Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1998, J NEUROSCI, V18, P8805; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Ide N, 1999, BIOCHEM BIOPH RES CO, V256, P456, DOI 10.1006/bbrc.1999.0364; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SRIVASTAVA S, 1998, NEURON, V22, P179; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463	26	57	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2966	2972		10.1074/jbc.275.4.2966	http://dx.doi.org/10.1074/jbc.275.4.2966			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644767	hybrid			2022-12-25	WOS:000085128000099
J	Lei, BF; Wei, CJ; Tu, SC				Lei, BF; Wei, CJ; Tu, SC			Action mechanism of antitubercular isoniazid - Activation mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALASE-PEROXIDASE GENE; DRUG-RESISTANT TUBERCULOSIS; PURIFICATION; MUTATIONS; TARGET	Activation of the antitubercular isoniazid (INH) by the Mycobacterium tuberculosis KatG produces an inhibitor for enoyl reductase (InhA). The mechanism for INH activation remains poorly understood, and the inhibitor has never been isolated. We have purified the InhA-inhibitor complex generated in the M. tuberculosis KatG-catalyzed INH activation. The complex exhibited a 278-nm absorption peak and a shoulder around 326 nn with a characteristic A(326)/A(278) ratio of 0.16. The complex was devoid of enoyl reductase activity. The inhibitor noncovalently binds to InhA with a K-d < 0.4 nM and can be dissociated from denatured InhA for chromatographic isolation. The free inhibitor showed absorption peaks at 326 (epsilon(326) 6900 M-1 cm(-1)) and 260 nm (epsilon(260) 27,000 M-1 cm(-1)). The inactive complex can be reconstituted from InhA and the isolated inhibitor. The InhA inhibitor from the KatG-catalyzed INH activation was identical to that from a slow, KatG-independent, Mn2+-mediated reaction based on high pressure liquid chromatography analysis and absorption and mass spectral characteristics. By monitoring the formation of the InhA-inhibitor complex, we have found that manganese is not essential to the INH activation by M. tuberculosis KatG. Furthermore, the formation of the InhA inhibitor in the KatG reaction was independent of InhA.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ Houston, Dept Chem, Houston, TX 77204 USA	University of Houston System; University of Houston; University of Houston System; University of Houston	Tu, SC (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.			Lei, Benfang Lei/0000-0001-8133-6021	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025953] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25953] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTAMIRANO M, 1994, J INFECT DIS, V169, P162; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BERNSTEIN J, 1952, AM REV TUBERC PULM, V65, P357; BIFANI P, 1909, JAMA-J AM MED ASSOC, V275, P452; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; Falk J. E., 1964, PORPHYRINS METALLOPO, P804; FASSEL VA, 1974, ANAL CHEM, V46, P1110, DOI 10.1021/ac60349a722; FOX HH, 1952, SCIENCE, V116, P129, DOI 10.1126/science.116.3006.129; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOLDMAN P, 1961, J BIOL CHEM, V236, P2620; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HILDEBRANDT AG, 1975, ARCH BIOCHEM BIOPHYS, V171, P385, DOI 10.1016/0003-9861(75)90047-8; HOLDINESS MR, 1984, CLIN PHARMACOKINET, V9, P511, DOI 10.2165/00003088-198409060-00003; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; LOEWEN PC, 1990, BIOCHEM CELL BIOL, V68, P1037, DOI 10.1139/o90-153; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magliozzo RS, 1997, J BIOL CHEM, V272, P8867; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; Mdluli K, 1996, J INFECT DIS, V174, P1085, DOI 10.1093/infdis/174.5.1085; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265; PANSY F, 1952, AM REV TUBERC PULM, V65, P761; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Wengenack NL, 1998, BIOCHEMISTRY-US, V37, P15825, DOI 10.1021/bi982023k; WINDER F G, 1970, Journal of General Microbiology, V63, P41; Zabinski RF, 1997, J AM CHEM SOC, V119, P2331, DOI 10.1021/ja9639731; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	30	183	188	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2520	2526		10.1074/jbc.275.4.2520	http://dx.doi.org/10.1074/jbc.275.4.2520			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644708	hybrid			2022-12-25	WOS:000085128000040
J	Meagher, JL; Olson, ST; Gettins, PGW				Meagher, JL; Olson, ST; Gettins, PGW			Critical role of the linker region between helix D and strand 2A in heparin activation of antithrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; REACTIVE CENTER; PROTEINASE REACTIONS; BINDING SITE; HINGE REGION; FACTOR-XA; MECHANISM; PENTASACCHARIDE; ACCELERATION; RECOGNITION	The binding of pentasaccharide heparin to antithrombin induces a conformational change that is transmitted to the reactive center loop and increases the rate of inhibition of factor Xa by similar to 300-fold, The mechanism of such transmission is not known. To test the role of residues 134-137, which link helix D to beta-sheet A, in this signal transduction, we created variant antithrombins in which we removed amino acids 134-137 stepwise and cumulatively. Although the deletions did not compromise the fundamental ability of antithrombin to bind to heparin or to inhibit target proteinases thrombin and factor Xa, they did largely decouple conformational changes in the heparin-binding site from conformational activation of the reactive center loop. Because the variant with only Ala(134) removed was as compromised as variants with larger deletions, yet the variant with Ser(137) removed was normal, we concluded that the length of the linker is less important than the precise interrelationship between residues in this region and other residues involved in conformational activation of antithrombin.	Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA.				NHLBI NIH HHS [HL49234, HL39888] Funding Source: Medline; NIDDK NIH HHS [T32 DK07789] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049234, R01HL049234, R37HL039888, R01HL039888, R29HL039888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007789] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; GETTINS P, 1992, J BIOL CHEM, V267, P21946; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P65; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1998, BIOCHEMISTRY-US, V37, P3272, DOI 10.1021/bi972182o; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; LANCHANTIN GF, 1973, J BIOL CHEM, V248, P5956; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; Meagher JL, 1996, J BIOL CHEM, V271, P29353, DOI 10.1074/jbc.271.46.29353; Meagher JL, 1998, J BIOL CHEM, V273, P23283, DOI 10.1074/jbc.273.36.23283; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; Zettlmeissl G, 1988, Behring Inst Mitt, P26	25	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2698	2704		10.1074/jbc.275.4.2698	http://dx.doi.org/10.1074/jbc.275.4.2698			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644732	hybrid			2022-12-25	WOS:000085128000064
J	Swanson, DJ; Adachi, M; Lewis, EJ				Swanson, DJ; Adachi, M; Lewis, EJ			The homeodomain protein Arix promotes protein kinase A-dependent activation of the dopamine beta-hydroxylase promoter through multiple elements and interaction with the coactivator cAMP-response element-binding protein-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER BIOSYNTHETIC GENES; CBP-INDUCED STIMULATION; TRANSCRIPTION FACTOR; TYROSINE-HYDROXYLASE; MAMMALIAN-CELLS; CYCLIC-AMP; EXPRESSION; CREB; PHOX2A; DNA	The differentiation and maintenance of a neurotransmitter phenotype is guided by the interaction of exogenous cues with intrinsic genetic machinery. For the noradrenergic phenotype, these influences combine to activate the expression of the catecholaminergic biosynthetic enzymes tyrosine hydroxylase and dopamine beta-hydroxylase (DBH). in this study, we evaluate the molecular mechanisms by which the transcription factor Arix/Phox2a contributes to DBH gene transcription. We have evaluated the contribution of individual homeodomain binding sites in the rat DBH promoter region and find that all are essential for both basal and cAMP-dependent protein kinase A (PKA)-stimulated transcription. Using mammalian one-hybrid and two-hybrid systems, we demonstrate that recruitment of Arix to the positions of homeodomain core recognition sites 1 and 2 at -153 to -166 of the DBH gene restores complete responsiveness of the promoter to PHA in SHSY-5Y neuroblastoma and HepG2 hepatoma cells. Intracellular Arix-Arix interactions are evident and may contribute to the interdependence of homeodomain binding sites. Analysis of functional domains of Arix reveals an N-terminal activation domain and a C-terminal repression domain. The N terminus of Arix contains an amino acid moth similar to a region in Brachyury and Pax9 transcription factors. The N terminal activation domain of Arix interacts with the transcriptional co-activator, cAMP-response element-binding protein-binding protein, which potentiates transcription from the DBH promoter in a PEA-dependent manner, The present study supports the hypothesis that the paired-like homeodomain protein, Arix, acts as a critical phenotype-specific regulator of the DBH promoter by serving as an integrator of signal-dependent transcription activators within the network of the general transcription machinery.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Lewis, EJ (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, L224, Portland, OR 97201 USA.		Adachi, Megumi/M-7746-2017	Adachi, Megumi/0000-0003-3404-6640	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038696, R01GM038696] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38696] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ausbel F.M., 1995, CURRENT PROTOCOLS MO; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BISSOTTO S, 1996, J BIOL CHEM, V271, P17746; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Conlon FL, 1996, DEVELOPMENT, V122, P2427; Cruzalegui FH, 1999, EMBO J, V18, P1335, DOI 10.1093/emboj/18.5.1335; ERNSBERGER U, 1995, MECH DEVELOP, V52, P125, DOI 10.1016/0925-4773(95)00396-I; Ghee M, 1998, MOL BRAIN RES, V55, P101, DOI 10.1016/S0169-328X(97)00370-7; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Goridis C, 1999, CURR OPIN NEUROBIOL, V9, P47, DOI 10.1016/S0959-4388(99)80006-3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROVES AK, 1995, DEVELOPMENT, V121, P887; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim HS, 1998, J NEUROSCI, V18, P8247; KISPERT A, 1995, EMBO J, V14, P4763, DOI 10.1002/j.1460-2075.1995.tb00158.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; Lo LC, 1998, DEVELOPMENT, V125, P609; Lo LC, 1999, NEURON, V22, P693, DOI 10.1016/S0896-6273(00)80729-1; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Nornes S, 1996, J BIOL CHEM, V271, P26914, DOI 10.1074/jbc.271.43.26914; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; Simon KJ, 1997, MOL CELL BIOL, V17, P6653, DOI 10.1128/MCB.17.11.6653; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Swanson DJ, 1997, J BIOL CHEM, V272, P27382, DOI 10.1074/jbc.272.43.27382; Swanson DJ, 1998, J BIOL CHEM, V273, P24065, DOI 10.1074/jbc.273.37.24065; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; TIJAN R, 1994, CELL, V77, P5; Yang CY, 1998, J NEUROCHEM, V71, P1813; Yokoyama M, 1999, GENOMICS, V59, P40, DOI 10.1006/geno.1999.5845; Yokoyama M, 1996, DNA Res, V3, P311, DOI 10.1093/dnares/3.5.311; Zellmer E, 1995, J NEUROSCI, V15, P8109	46	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2911	2923		10.1074/jbc.275.4.2911	http://dx.doi.org/10.1074/jbc.275.4.2911			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644760	hybrid			2022-12-25	WOS:000085128000092
J	Thomas, WG; Qian, HW; Chang, CS; Karnik, S				Thomas, WG; Qian, HW; Chang, CS; Karnik, S			Agonist-induced phosphorylation of the angiotensin II (AT(1A)) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CONSTITUTIVE ACTIVATION; BETA(2)-ADRENERGIC RECEPTOR; DESENSITIZATION; INTERNALIZATION; BINDING; ENDOCYTOSIS; RHODOPSIN; MUTATION; ASN(111)	G protein coupled receptors are thought to isomerize between distinct inactive and active conformations, an idea supported by receptor mutations that induce constitutive (agonist-independent) activation. The agonist-promoted active state initiates signaling and, presumably, is then phosphorylated and internalized to terminate the signal. In this study, we examined the phosphorylation and internalization of wild type and constitutively active mutants (N111A and N111G) of the type 1 (AT(1A)) angiotensin II receptor. Cells expressing these receptors were stimulated with angiotensin II (Ang-II) and [Sar(1),Ile(4),Ile(8)]AngII, an analog that only activates signaling through the constitutive receptors, Wild type AT(1A) receptors displayed a basal level of phosphorylation, which was stimulated by AngII, Unexpectedly, the constitutively active AT(1A) receptors did not exhibit an increase in basal phosphorylation nor was phosphorylation enhanced by AngII stimulation. Phosphorylation of the constitutively active receptors was unaffected by pretreatment with the non-peptide AT(1A) receptor inverse agonist, EXP3174, and was not stimulated by the selective ligand, [Sar(1),Ile(4),Ile(8)]AngII. Paradoxically, [Sar(1),Ile(4),Ile(8)]AngII produced a robust (similar to 85% of AngII), dose-dependent phosphorylation of the wild type AT(1A) receptor at sites in the carboxyl terminus similar to those phosphorylated by AngII, Moreover, internalization of both wild type and constitutive receptors was induced by AngII, but not [Sar(1),Ile(4),Ile(8)]AngII, providing a differentiation between the phosphorylated and internalized states. These data suggest that the AT(1A) receptor can attain a conformation for phosphorylation without going through the conformation required for inositol phosphate signaling and provide evidence for a transition of the receptor through multiple states, each associated with separate stages of receptor activation and regulation. Separate transition states may be a common paradigm for G protein-coupled receptors.	Baker Med Res Inst, Mol Endocrinol Lab, Melbourne, Vic 8008, Australia; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	Baker Heart and Diabetes Institute; Cleveland Clinic Foundation	Thomas, WG (corresponding author), Baker Med Res Inst, Mol Endocrinol Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	walter.thomas@baker.edu.au	Karnik, Sadashiva/Y-2477-2019; Thomas, Walter/I-2208-2015	Karnik, Sadashiva/0000-0003-0746-2753; Thomas, Walter/0000-0003-0685-2952	NHLBI NIH HHS [R01 HL057470, HL-5648, R01 HL064845] Funding Source: Medline; PHS HHS [EI 994078] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BOULAY G, 1994, ENDOCRINOLOGY, V135, P2130, DOI 10.1210/en.135.5.2130; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P256, DOI 10.1016/S0165-6147(00)89037-9; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; Leff P, 1997, TRENDS PHARMACOL SCI, V18, P355, DOI 10.1016/S0165-6147(97)90664-7; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; Negishi M, 1996, FEBS LETT, V386, P165, DOI 10.1016/0014-5793(96)00354-7; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; Pauwels PJ, 1998, MOL NEUROBIOL, V17, P109, DOI 10.1007/BF02802027; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Perez DM, 1996, MOL PHARMACOL, V49, P112; PIURA S, 1999, J BIOL CHEM, V274, P7103; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; Qian HW, 1999, BIOCHEM J, V343, P637, DOI 10.1042/0264-6021:3430637; Quitterer U, 1996, BIOCHEMISTRY-US, V35, P13368, DOI 10.1021/bi961163w; REN Q, 1993, J BIOL CHEM, V268, P16483; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; Scaramellini C, 1998, ANN NY ACAD SCI, V861, P97; Smith RD, 1998, MOL PHARMACOL, V54, P935, DOI 10.1124/mol.54.6.935; Surya A, 1998, TRENDS PHARMACOL SCI, V19, P243; SWILLENS S, 1992, TRENDS PHARMACOL SCI, V13, P430, DOI 10.1016/0165-6147(92)90139-W; Thomas WG, 1998, MOL ENDOCRINOL, V12, P1513, DOI 10.1210/me.12.10.1513; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; Thomas WG, 1996, CLIN EXP PHARMACOL P, V23, pS74, DOI 10.1111/j.1440-1681.1996.tb02817.x; WESTPHAL RS, 1995, MOL PHARMACOL, V48, P200; Zuscik MJ, 1998, J BIOL CHEM, V273, P3401, DOI 10.1074/jbc.273.6.3401	37	86	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2893	2900		10.1074/jbc.275.4.2893	http://dx.doi.org/10.1074/jbc.275.4.2893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644757	hybrid			2022-12-25	WOS:000085128000089
J	Ernst, OP; Meyer, CK; Marin, EP; Henklein, P; Fu, WY; Sakmar, TP; Hofmann, KP				Ernst, OP; Meyer, CK; Marin, EP; Henklein, P; Fu, WY; Sakmar, TP; Hofmann, KP			Mutation of the fourth cytoplasmic loop of rhodopsin affects binding of transducin and peptides derived from the carboxyl-terminal sequences of transducin alpha and gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; BOVINE RHODOPSIN; SCHIFF-BASE; METARHODOPSIN-II; SIGNALING STATE; PROTON UPTAKE; ACTIVATION; RECEPTOR; MUTANTS; PALMITOYLATION	The role of the putative fourth cytoplasmic loop of rhodopsin in the binding and catalytic activation of the heterotrimeric G protein, transducin (G(t)), is not well defined. We developed a novel assay to measure the ability of G(t), or G(t)-derived peptides, to inhibit the photoregeneration of rhodopsin from its active metarhodopsin II state. We show that a peptide corresponding to residues 340-350 of the alpha subunit of G(t), or a cysteinyl-thioetherfarnesyl peptide corresponding to residues 50-71 of the gamma subunit of G(t), are able to interact with metarhodopsin II and inhibit its photoconversion to rhodopsin. Alteration of the amino acid sequence of either peptide, or removal of the farnesyl group from the gamma-derived peptide, prevents inhibition. Mutation of the amino-terminal region of the fourth cytoplasmic loop of rhodopsin affects interaction with G(t), (Marin, E, P,, Krishna, A G;., Zvyaga T, A, Isele, J., Siebert, F,, and Sakmar, T. P. (2000) J. Biol Chem. 275, 1930-1936), Here, we provide evidence that this segment of rhodopsin interacts with the carboxyl-terminal peptide of the cu subunit of G(t). We propose that the amino-terminal region of the fourth cytoplasmic loop of rhodopsin is part of the binding site for the carboxyl terminus of the alpha subunit of G(t) and plays a role in the regulation of beta gamma subunit binding.	Rockefeller Univ, Howard Hughes Med Inst, Biochem & Mol Biol Lab, New York, NY 10021 USA; Humboldt Univ, Inst Med Phys & Biophys, Fak Med, D-10098 Berlin, Germany; Humboldt Univ, Inst Biochem, Fak Med, D-10098 Berlin, Germany	Howard Hughes Medical Institute; Rockefeller University; Humboldt University of Berlin; Humboldt University of Berlin	Hofmann, KP (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Biochem & Mol Biol Lab, Box 284,1230 York Ave, New York, NY 10021 USA.	klaus_peter.hofmann@charite.de	Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NIGMS NIH HHS [GM07739, GM07982] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7931, DOI 10.1021/bi9900121; ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; ARNIS S, 1994, J BIOL CHEM, V269, P23879; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; DEGRIP WJ, 1982, METHOD ENZYMOL, V81, P197; EMEIS D, 1981, FEBS LETT, V136, P201, DOI 10.1016/0014-5793(81)80618-7; ERNST OP, 2000, IN PRESS METHODS ENZ; Fahmy K, 1998, BIOPHYS J, V75, P1306, DOI 10.1016/S0006-3495(98)74049-4; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Han M, 1998, BIOCHEMISTRY-US, V37, P538, DOI 10.1021/bi972060w; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; HOFMANN KP, 1999, RHODOPSINS PHOTOTRAN, P158; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; Kim JM, 1997, P NATL ACAD SCI USA, V94, P14273, DOI 10.1073/pnas.94.26.14273; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; Nishimura S, 1998, BIOCHEMISTRY-US, V37, P15816, DOI 10.1021/bi981451n; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PAPAC DI, 1992, J BIOL CHEM, V267, P16889; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHLEICHER A, 1987, J MEMBRANE BIOL, V95, P271, DOI 10.1007/BF01869489; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	42	145	151	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1937	1943		10.1074/jbc.275.3.1937	http://dx.doi.org/10.1074/jbc.275.3.1937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636895	hybrid			2022-12-25	WOS:000084940000058
J	Roy, G; Horton, JK; Roy, R; Denning, T; Mitra, S; Boldogh, I				Roy, G; Horton, JK; Roy, R; Denning, T; Mitra, S; Boldogh, I			Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins	ONCOGENE			English	Article						drug resistance; apoptosis; alkylating drugs; pro- and anti-apoptotic proteins; bcl-2 family	GENE O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; BASE EXCISION-REPAIR; APURINIC/APYRIMIDINIC ENDONUCLEASE; CYTOCHROME-C; DNA; BCL-2; MITOCHONDRIA; RECOGNITION; EXPRESSION; ACTIVATION	In a systematic study to elucidate the involvement of pro-and anti-apoptotic proteins in alkylating drug resistance of tumor cells, we utilized the A2780(100) line, that was selected by repeated exposure of A2780 cell line (human ovarian carcinoma line) to chlorambucil (CBL), A2780(100) was 5-10-fold more resistant to nitrogen mustards (IC,, of 50-60 mu M) and other DNA crosslinking agents, e,g,, cisplatin, and also to DNA topoisomerase inhibitor etoposide (ETO) than A2780. CEL (125 mu M) induced extensive apoptosis in A2780 associated with mitochondrial damage but not in A2780(100). No significant differences were observed between A2780 and A2780(100) cells in the basal levels, or the enhanced levels in some cases after CBL treatment, of DNA repair proteins involved in repair of alkyl base adducts or in repair of DNA crosslinks or double strand break repair. However, the basal levels of anti-apoptotic proteins Bcl-x(L), and Mcl-1 were 4-8-fold higher in A2780(100) than in A2780 neither of which expressed Bcl-2, In contrast, the levels of pro-apoptotic Bas and Bak were 3-5-fold higher in the CBL-treated A2780 but not in A2780(100). ETO (5 mu M) induced apoptosis in A2780 without altering the levels of Bax and Bak in these cells. lit the same time, neither ol expression of Bcl-x(L), in A2780, nor its antisense expression in A2780(100), and nor overexpression of Bas in A2780(100), significantly affected drug sensitivity of either line. Our results suggest that a change in an early step in DNA damage processing which affects intracellular signaling, such as enhanced DNA double-strand break repair, could be the primary cause for development of resistance in A2780(100) cells to drugs which induce DNA crosslinks or double strand-breaks.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Route 1079, Galveston, TX 77555 USA.		Denning, Timothy/F-2271-2011	Denning, Timothy/0000-0002-1072-7444	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES007572] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07572, ES06676] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Begleiter A, 1996, LEUKEMIA LYMPHOMA, V23, P187, DOI 10.3109/10428199609054821; Boldogh I, 1998, CANCER RES, V58, P3950; Bresnahan WA, 1997, VIROLOGY, V231, P239, DOI 10.1006/viro.1997.8489; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Chen KH, 1998, NUCLEIC ACIDS RES, V26, P2001, DOI 10.1093/nar/26.8.2001; Chen ZF, 1998, J PHARMACOL EXP THER, V285, P608; COLVIN OM, 1993, ADV ENZYME REGUL, V33, P19; Decaudin D, 1997, CANCER RES, V57, P62; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hazra TK, 1997, BIOCHEMISTRY-US, V36, P5769, DOI 10.1021/bi963085i; Horton JK, 1999, BIOCHEM PHARMACOL, V58, P693, DOI 10.1016/S0006-2952(99)00142-2; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; KAMESAKI S, 1993, CANCER RES, V53, P4251; KOHN KW, 1966, J MOL BIOL, V19, P266, DOI 10.1016/S0022-2836(66)80004-9; Krokan HE, 1997, BIOCHEM J, V325, P1; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Stahelin BJ, 1998, J CLIN PATHOL-MOL PA, V51, P204; Tano K, 1997, J BIOL CHEM, V272, P13250, DOI 10.1074/jbc.272.20.13250; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	33	21	23	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					141	150		10.1038/sj.onc.1203318	http://dx.doi.org/10.1038/sj.onc.1203318			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644989				2022-12-25	WOS:000084844300016
J	Filoteo, AG; Enyedi, A; Verma, AK; Elwess, NL; Penniston, JT				Filoteo, AG; Enyedi, A; Verma, AK; Elwess, NL; Penniston, JT			Plasma membrane Ca2+ pump isoform 3f is weakly stimulated by calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; SKELETAL-MUSCLE; CALCIUM-PUMP; KINASE; ATPASE; 4B; CA2+-ATPASE; ANTIBODIES; REGION; BRAIN	Isoform 3f of the plasma membrane Ca2+ pump is a major isoform of this pump in rat skeletal muscle. It has an unusual structure, with a short carboxyl-terminal regulatory region of only 33 residues when compared with the 77 to 124 residues found in the other isoforms, Also, whereas the regulatory regions of the other iso forms, downstream of the alternative splice, consist of two homologous groups, the sequence of 3f is not related to either group. A synthetic peptide representing the calmodulin binding domain of isoform 3f had a much lower calmodulin affinity (with a K-d of 15 nM) than the corresponding peptide of isoform 2b (K-d value was 0.2 nM). The characteristics of this domain were further studied by making chimeras of the 3f regulatory region with the catalytic core of isoform 4 and by making the full-length isoform 3f, Both constructs bound to calmodulin-Sepharose. The chimera was fully active without calmodulin, showing no stimulation of activity when calmodulin was added. The full-length isoform 3f was slightly activated by calmodulin, These data show that the regulatory region of isoform 3f is only a weak autoinhibitor of the enzyme, in contrast to the properties of all the other isoforms studied so far, Rather, this isoform is a special-purpose, constitutively active form of the enzyme, expressed primarily in skeletal muscle and as a minor isoform in brain.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Natl Inst Haematol & Immunol, H-1113 Budapest, Hungary	Mayo Clinic	Penniston, JT (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.		Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835, R01GM055514] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28835, GM55514] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURK SE, 1992, J BIOL CHEM, V267, P19683; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Caride AJ, 1999, J BIOL CHEM, V274, P35227, DOI 10.1074/jbc.274.49.35227; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1993, J BIOL CHEM, V268, P17120; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; Enyedi A, 1997, J BIOL CHEM, V272, P27525, DOI 10.1074/jbc.272.44.27525; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; Filoteo AG, 1997, J BIOL CHEM, V272, P23741, DOI 10.1074/jbc.272.38.23741; GRAF E, 1980, ARCH BIOCHEM BIOPHYS, V203, P719, DOI 10.1016/0003-9861(80)90231-3; GREEB J, 1989, J BIOL CHEM, V264, P18569; KEETON TP, 1993, J BIOL CHEM, V268, P2740; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; LINDBERG O, 1956, METHODS BIOCHEMICAL, P1; MCCORMICK DJ, 1987, J IMMUNOL, V139, P2615; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; REDDY LG, 1999, BIOPHYS, V76, P99012; SEILER S, 1982, J BIOL CHEM, V257, P13862; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; Verma AK, 1996, J BIOL CHEM, V271, P3714; Verma AK, 1999, J BIOL CHEM, V274, P527, DOI 10.1074/jbc.274.1.527; VERMA AK, 1994, J BIOL CHEM, V269, P1687	28	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4323	4328		10.1074/jbc.275.6.4323	http://dx.doi.org/10.1074/jbc.275.6.4323			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660601	hybrid			2022-12-25	WOS:000085288800085
J	Fong, AM; Erickson, HP; Zachariah, JP; Poon, S; Schamberg, NJ; Imai, T; Patel, DD				Fong, AM; Erickson, HP; Zachariah, JP; Poon, S; Schamberg, NJ; Imai, T; Patel, DD			Ultrastructure and function of the fractalkine mucin domain in CX3C chemokine domain presentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN GLYCOPROTEIN LIGAND-1; EPIDERMAL GROWTH-FACTOR; P-SELECTIN; ADHESION; CX(3)CR1; RECEPTOR; IDENTIFICATION; ENDOTHELIUM; ACTIVATION; LEUKOCYTES	Fractalkine (FKN), a CX3C chemokine/mucin hybrid molecule on endothelium, functions as an adhesion molecule to capture and induce firm adhesion of a subset of leukocytes in a selectin- and integrin-independent manner. We hypothesized that the FKN mucin domain may be important for its function in adhesion, and tested the ability of secreted alkaline phosphatase (SEAP) fusion proteins containing the entire extracellular region (FKN-SEAP), the chemokine domain (CX3C-SEAP), or the mucin domain (mucin-SEAP) to support firm adhesion under now. CX3C-SEAP induced suboptimal firm adhesion of resting peripheral blood mononuclear cells, compared with FKN-SEAP, and mucin-SEAP induced no firm adhesion. CX3C-SEAP and FKN-SEAP bound to CX(3)CR1 with similar affinities. By electron microscopy, fractalkine was 29 nm in length with a long stalk (mucin domain), and a globular head (CX3C). To test the function of the mucin domain, a chimeric protein replacing the mucin domain with a rod-like segment of E-selectin was constructed. This chimeric protein gave the same adhesion of peripheral blood mononuclear cells as intact FKN, both when immobilized on glass and when expressed on the cell surface. This implies that the function of the mucin domain is to provide a stalk, extending the chemokine domain away from the endothelial cell surface to present it to flowing leukocytes.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Kinki Univ, Sch Med, Dept Microbiol, Sayama, Osaka 5898511, Japan	Duke University; Duke University; Kindai University (Kinki University)	Patel, DD (corresponding author), Duke Univ, Med Ctr, Dept Med, 223 Med Sci Res Bldg,Box 3258, Durham, NC 27710 USA.				NATIONAL CANCER INSTITUTE [R01CA047056, R37CA047056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039162] Funding Source: NIH RePORTER; NCI NIH HHS [CA47056] Funding Source: Medline; NIAMS NIH HHS [AR39162] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Feng LL, 1999, KIDNEY INT, V56, P612, DOI 10.1046/j.1523-1755.1999.00604.x; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HONDA S, 1994, J IMMUNOL, V152, P4026; Hoylaerts MF, 1997, J BIOL CHEM, V272, P22781, DOI 10.1074/jbc.272.36.22781; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; LEY K, 1995, J IMMUNOL, V155, P525; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; MCEVER RP, 1997, J CLIN INVEST, V100, P97; Mehta P, 1997, BLOOD, V90, P2381, DOI 10.1182/blood.V90.6.2381.2381_2381_2389; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Nishiyori A, 1998, FEBS LETT, V429, P167, DOI 10.1016/S0014-5793(98)00583-3; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Tu LL, 1996, J IMMUNOL, V157, P3995; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229	31	71	79	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3781	3786		10.1074/jbc.275.6.3781	http://dx.doi.org/10.1074/jbc.275.6.3781			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660527	hybrid			2022-12-25	WOS:000085288800011
J	Pignol, D; Ayvazian, L; Kerfelec, B; Timmins, P; Crenon, I; Hermoso, J; Fontecilla-Camps, JC; Chapus, C				Pignol, D; Ayvazian, L; Kerfelec, B; Timmins, P; Crenon, I; Hermoso, J; Fontecilla-Camps, JC; Chapus, C			Critical role of micelles in pancreatic lipase activation revealed by small angle neutron scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-SALT; TAURODEOXYCHOLATE MICELLES; CRYSTAL-STRUCTURE; HORSE COLIPASE; CO-LIPASE; PORCINE; COMPLEX; DETERGENTS; ADSORPTION; VESICLES	In the duodenum, pancreatic lipase (PL) develops its activity on triglycerides by binding to the bile-emulsified oil droplets in the presence of its protein cofactor pancreatic colipase (PC), The neutron crystal structure of a PC-PL-micelle complex (Hermoso, J,, Pignol, D,, Penel, S,, Roth, M,, Chapus, C,, and Fontecilla-Camps, J, C, (1997) EMBO J, 16, 5531-5536) has suggested that the stabilization of the enzyme in its active conformation and its adsorption to the emulsified oil droplets are mediated by a preformed lipase-colipase-micelle complex. Here, we correlate the ability of different amphypathic compounds to activate FL, with their association with PC-FL in solution, The method of small angle neutron scattering with D2O/H2O contrast variation was used to characterize a solution containing PC-FL complex and taurodeoxycholate micelles, The resulting radius of gyration (56 Angstrom) and the match point of the solution indicate the formation of a ternary complex that is similar to the one observed in the neutron crystal structure. In addition, we show that either bile salts, lysophospholipids, or nonionic detergents that form micelles with radii of gyration ranging from 13 to 26 Angstrom are able to bind to the PC-FL complex, whereas smaller micelles or nonmicellar compounds are not. This further supports the notion of a micelle size-dependent affinity process for lipase activation in vivo.	CNRS, CNR, Inst Biol Struct Jean Pierre Ebel, Cristallog & Cristallogenese Prot Lab, F-38027 Grenoble 1, France; UPR 9036 CNRS, Lab Bioenerget & Ingn Prot, F-13402 Marseille, France; Inst Max Von Laue Paul Langevin, Large Scale Struct Grp, F-38042 Grenoble, France; CSIC, Inst Rocasolano, Grp Cristalog Macromol & Biol Estruct, E-28006 Madrid, Spain	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Institut Laue-Langevin (ILL); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Fontecilla-Camps, JC (corresponding author), CNRS, CNR, Inst Biol Struct Jean Pierre Ebel, Cristallog & Cristallogenese Prot Lab, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.		Hermoso, Juan/J-3433-2012	Hermoso, Juan/0000-0002-1862-8950; PIGNOL, David/0000-0002-8070-0319				BORGSTRO.B, 1973, EUR J BIOCHEM, V37, P60, DOI 10.1111/j.1432-1033.1973.tb02957.x; BOURNE Y, 1994, J MOL BIOL, V238, P709, DOI 10.1006/jmbi.1994.1331; CANIONI P, 1981, BIOCHIM BIOPHYS ACTA, V670, P305, DOI 10.1016/0005-2795(81)90101-X; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; CHAPUS C, 1975, FEBS LETT, V58, P155, DOI 10.1016/0014-5793(75)80247-X; CHAPUS C, 1981, EUR J BIOCHEM, V115, P99; CHARLES M, 1975, EUR J BIOCHEM, V58, P555, DOI 10.1111/j.1432-1033.1975.tb02405.x; CHARLES M, 1980, J MOL BIOL, V139, P297, DOI 10.1016/0022-2836(80)90132-1; DONNER J, 1976, BIOCHEMISTRY-US, V15, P5413, DOI 10.1021/bi00669a031; EGELHAAF SU, 1994, J PHYS CHEM-US, V98, P8560, DOI 10.1021/j100085a041; EGLOFF MP, 1995, BIOCHEMISTRY-US, V34, P2571; GHOSH R, 1981, 81GH29T ILL; GRANON S, 1986, BIOCHIM BIOPHYS ACTA, V671, P54; Hermoso J, 1997, EMBO J, V16, P5531, DOI 10.1093/emboj/16.18.5531; Hermoso J, 1996, J BIOL CHEM, V271, P18007, DOI 10.1074/jbc.271.30.18007; HOFMANN AF, 1967, ANNU REV MED, V18, P333, DOI 10.1146/annurev.me.18.020167.002001; IBEL K, 1976, J APPL CRYSTALLOGR, V9, P296, DOI 10.1107/S0021889876011394; JACROT B, 1976, REP PROG PHYS, V39, P911, DOI 10.1088/0034-4885/39/10/001; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LOMBARDO D, 1989, J MOL BIOL, V205, P259, DOI 10.1016/0022-2836(89)90380-X; MCINTYRE JC, 1990, BIOCHEMISTRY-US, V29, P2092, DOI 10.1021/bi00460a019; MCINTYRE JC, 1987, BIOCHEM J, V245, P821, DOI 10.1042/bj2450821; PATTON JS, 1978, J BIOL CHEM, V253, P4195; PEDERSEN JS, 1995, J PHYS CHEM-US, V99, P1299, DOI 10.1021/j100004a033; SARI H, 1978, FEBS LETT, V95, P229, DOI 10.1016/0014-5793(78)81000-X; SARI H, 1975, BIOCHIMIE, V57, P1045, DOI 10.1016/S0300-9084(75)80360-9; SMALL DM, 1968, J AM OIL CHEM SOC, V45, P108, DOI 10.1007/BF02915334; TIMMINS P, 1994, BIOPHYS CHEM, V53, P27, DOI 10.1016/0301-4622(94)00073-5; VANDERMEERS A, 1975, FEBS LETT, V49, P334, DOI 10.1016/0014-5793(75)80779-4; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; VANTILBEURGH H, 1993, NATURE, V362, P812; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	32	42	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4220	4224		10.1074/jbc.275.6.4220	http://dx.doi.org/10.1074/jbc.275.6.4220			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660587	Green Published, hybrid			2022-12-25	WOS:000085288800071
J	Schneider, H; Guerette, B; Guntermann, C; Rudd, CE				Schneider, H; Guerette, B; Guntermann, C; Rudd, CE			Resting lymphocyte kinase (Rlk/Txk) targets lymphoid adaptor SLP-76 in the cooperative activation of interleukin-2 transcription in T-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; X-LINKED AGAMMAGLOBULINEMIA; ANTIGEN-RECEPTOR; SRC FAMILY; THYMOCYTE DEVELOPMENT; GENETIC-EVIDENCE; MICE LACKING; PHOSPHORYLATION; ZAP-70; ITK	Blk/Txk is a T-cell-specific member of the Btk/Tec family of tyrosine kinases, whereas SLP-76 is a lymphoid adaptor that is essential for pre-TcR and mature TcR signaling, Although Rlk deficient T-cells show partial defects in T-cell proliferation, Rlk can complement ITK-/- cells with multiple defects in TcR initiated early events and interleukin (IL)-2 production. A key question is the nature of the target of Rlk responsible for bridging the TcR with the activation of IL-2 transcription. In this study, we identify a pathway in which Rlk phosphorylates SLP-76 leading to the phosphorylation of PLC gamma 1, activation of ERKs, and the synergistic up-regulation of TcR-driven IL-2 NFAT/AP-1 transcription, Rlk phosphorylated the N-terminal region of SLP-76, a region that has been previously shown to serve as a target for ZAP-70. Loss of N-terminal YESP/YEPP sites of SLP-76 or the Rlk kinase activity attenuated cooperativity between Rlk and SLP-76. These observations support a model where the TcR can utilize Rlk (as well as ZAP-70) in the phosphorylation of key sites in SLP-76 leading to the up-regulation of Th1 preferred cytokine IL-2.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Rudd, CE (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.	christopher_rudd@dfci.harvard.edu	Rudd, Christopher E/ABF-7259-2021; Rudd, Christopher E/GOH-2021-2022	Rudd, Christopher E/0000-0001-5295-9019				Bachmann MF, 1997, J VIROL, V71, P7253, DOI 10.1128/JVI.71.10.7253-7257.1997; Calvo CR, 1997, J EXP MED, V186, P1645, DOI 10.1084/jem.186.10.1645; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Cheng AM, 1997, CURR OPIN IMMUNOL, V9, P528, DOI 10.1016/S0952-7915(97)80106-9; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Debnath J, 1999, MOL CELL BIOL, V19, P1498; DESIDERIO S, 1994, CHEM IMMUNOL, V59, P191; Fang N, 1996, J IMMUNOL, V157, P3769; Gibson S, 1996, J IMMUNOL, V156, P2716; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; Heyeck SD, 1997, J BIOL CHEM, V272, P25401, DOI 10.1074/jbc.272.40.25401; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Liao XC, 1997, J EXP MED, V186, P221, DOI 10.1084/jem.186.2.221; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Peterson EJ, 1998, CURR OPIN IMMUNOL, V10, P337, DOI 10.1016/S0952-7915(98)80173-8; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Schneider H, 1998, BIOCHEM BIOPH RES CO, V252, P14, DOI 10.1006/bbrc.1998.9559; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SOMMERS CL, 1995, ONCOGENE, V11, P245; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; WEISS DR, 1994, CELL, V71, P649; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1	43	50	53	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3835	3840		10.1074/jbc.275.6.3835	http://dx.doi.org/10.1074/jbc.275.6.3835			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660534	hybrid			2022-12-25	WOS:000085288800018
J	Dolmer, K; Huang, W; Gettins, PGW				Dolmer, K; Huang, W; Gettins, PGW			NMR solution structure of complement-like repeat CR3 from the low density lipoprotein receptor-related protein - Evidence for specific binding to the receptor binding domain of human alpha(2)-macroglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH REPEAT; 3-DIMENSIONAL STRUCTURE; ALPHA-2-MACROGLOBULIN RECEPTOR; SCAVENGER RECEPTORS; APOLIPOPROTEIN-E; CHEMICAL-SHIFTS; COMPLEXES; LRP; MODULE; SITE	We have used NMR methods to determine the structure of the calcium complex of complement-like repeat 3 (CR3) from the low density lipoprotein receptor-related protein (LRP) and to examine its specific interaction with the receptor binding domain of human alpha(2)-macroglobulin. CR3 is one of eight related repeats that constitute a major ligand binding region of LRP. The structure is very similar in overall fold to homologous complement-like repeat CR8 from LRP and complement-like repeats LB1, LB2, and LB5 from the low density lipoprotein receptor and contains a short two-strand antiparallel beta-sheet, a one turn alpha-helix, and a high affinity calcium site with coordination from four carboxyls and two backbone carbonyls, The surface electrostatics and topography are, however, quite distinct from each of these other repeats. Two-dimensional H-1,N-15-heteronuclear single quantum coherence spectra provide evidence for a specific, though relatively weak (K-d similar to 140 mu M), interaction between CR3 and human alpha 2-macroglobulin receptor binding domain that involves a contiguous patch of surface residues in the central region of CR3. This specific interaction is consistent with a mode of LRP binding to ligands that uses contributions from more than one domain to generate a wide array of different binding sites, each with overall high affinity.	Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Biol, M-C 536,1853 W Polk St, Chicago, IL 60612 USA.		Dolmer, Klavs/G-5512-2012	Dolmer, Klavs/0000-0001-7359-360X	NIGMS NIH HHS [GM54414] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Biekofsky RR, 1998, BIOCHEMISTRY-US, V37, P7617, DOI 10.1021/bi9800449; CASE DA, 1997, AMBER 5; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; Dolmer K, 1998, BIOCHEMISTRY-US, V37, P17016, DOI 10.1021/bi982022s; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; Huang W, 2000, J BIOL CHEM, V275, P1089, DOI 10.1074/jbc.275.2.1089; Huang W, 1999, J BIOL CHEM, V274, P14130, DOI 10.1074/jbc.274.20.14130; Jenner L, 1998, STRUCTURE, V6, P595, DOI 10.1016/S0969-2126(98)00061-6; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Nielsen KL, 1996, J BIOL CHEM, V271, P12909, DOI 10.1074/jbc.271.22.12909; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; Storm D, 1997, J BIOL CHEM, V272, P31043, DOI 10.1074/jbc.272.49.31043; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISHART DS, 1994, METHOD ENZYMOL, V239, P363	27	48	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3264	3269		10.1074/jbc.275.5.3264	http://dx.doi.org/10.1074/jbc.275.5.3264			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652313	hybrid			2022-12-25	WOS:000085146500035
J	Vallorosi, CJ; Day, KC; Zhao, X; Rashid, MG; Rubin, MA; Johnson, KR; Wheelock, MJ; Day, ML				Vallorosi, CJ; Day, KC; Zhao, X; Rashid, MG; Rubin, MA; Johnson, KR; Wheelock, MJ; Day, ML			Truncation of the beta-catenin binding domain of E-cadherin precedes epithelial apoptosis during prostate and mammary involution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-ADHESION MOLECULES; RAT VENTRAL PROSTATE; CANCER-CELLS; CYTOPLASMIC DOMAIN; CARCINOMA-CELLS; GROWTH-FACTORS; N-CADHERIN; ACTIVATION; MEMBRANE	A potential target of hormone action during prostate and mammary involution is the intercellular junction of adjacent secretory epithelium. This is supported by the long-standing observation that one of the first visible stages of prostate and mammary involution is the disruption of interepithelial adhesion prior to the onset of apoptosis, In a previous study addressing this aspect of involution, we acquired compelling evidence indicating that the disruption of E-cadherin-dependent adhesion initiates apoptotic programs during prostate and mammary involution. In cultured prostate and mammary epithelial cells, inhibition of E-cadherin-dependent aggregation resulted in cell death following apoptotic stimuli. Loss of cell-cell adhesion in the nonaggregated population appeared to result from the rapid truncation within the cytosolic domain of the mature, 120-kDa species of E-cadherin (E-cad(120)). Immunoprecipitations from cell culture and involuting mammary gland demonstrated that this truncation removed the beta-catenin binding domain from the cytoplasmic tail of E-cadherin, resulting in a non beta-catenin binding, membrane-bound 97-kDa species (E-cad(97)) and a free cytoplasmic 35-kDa form (E-cad(34)) that is bound to beta-catenin, Examination of E-cadherin expression and cellular distribution during prostate and mammary involution revealed a dramatic reduction in junctional membrane staining that correlated with a similar reduction in E-cad(120) and accumulation of E-cad(97) and E-cad(35). The observation that E-cadherin was truncated during involution suggested that hormone depletion activated the same apoptotic pathway in vivo as observed in vitro. Based on these findings, we hypothesize that truncation of E-cadherin results in the loss of beta-catenin binding and cellular dissociation that may signal epithelial apoptosis during prostate and mammary involution, Thus, E-cadherin may be central to homeostatic regulation in these tissues by coordinating adhesion-dependent survival and dissociation-induced apoptosis.	Univ Michigan, Dept Surg, Div Urol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Toledo, Dept Biol, Toledo, OH 43606 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Ohio; University of Toledo	Day, ML (corresponding author), Box 0944,Rm 6219 CGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mday@umich.edu		Rubin, Mark/0000-0002-8321-9950	NATIONAL CANCER INSTITUTE [P50CA069568] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA69568] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Amar LS, 1998, CELL ADHES COMMUN, V5, P1, DOI 10.3109/15419069809005594; Ansonoff MA, 1998, ENDOCRINOLOGY, V139, P3050, DOI 10.1210/en.139.7.3050; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; CHIANG L, 1982, BIOCHEM INT, V4, P161; Colin IM, 1998, ENDOCRINOLOGY, V139, P3796, DOI 10.1210/en.139.9.3796; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P515; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; FABRE M, 1993, J CELL SCI, V106, P513; Fabre S, 1996, MOL CELL ENDOCRINOL, V124, P79, DOI 10.1016/S0303-7207(96)03931-7; Fishman DD, 1998, INT J ONCOL, V12, P181; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GUENETTE RS, 1994, J MOL ENDOCRINOL, V12, P47, DOI 10.1677/jme.0.0120047; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; Ilyas M, 1997, J PATHOL, V182, P128; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; KATAYAMA M, 1994, INT J ONCOL, V5, P1049; LEWIS JE, 1994, J CELL SCI, V107, P3615; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Marino M, 1998, BIOCHEM BIOPH RES CO, V245, P254, DOI 10.1006/bbrc.1998.8413; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nieman MT, 1999, J CELL SCI, V112, P1621; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; RENNIE PS, 1984, BIOCHEM J, V221, P171, DOI 10.1042/bj2210171; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SHEU HM, 1989, EXP CELL RES, V185, P176, DOI 10.1016/0014-4827(89)90047-5; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; SKOUDY A, 1995, FEBS LETT, V374, P415, DOI 10.1016/0014-5793(95)01167-D; St Croix Brad, 1997, Current Opinion in Oncology, V9, P549; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Sylvia VL, 1998, J CELL PHYSIOL, V176, P435, DOI 10.1002/(SICI)1097-4652(199808)176:2<435::AID-JCP22>3.0.CO;2-0; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; Werb Z, 1996, BRAZ J MED BIOL RES, V29, P1087; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; WILSON MJ, 1995, ARCH ANDROLOGY, V35, P119, DOI 10.3109/01485019508987862; WILSON MJ, 1991, BIOL REPROD, V44, P776, DOI 10.1095/biolreprod44.5.776; WINKEL GK, 1990, DEV BIOL, V138, P1, DOI 10.1016/0012-1606(90)90171-E; Wu JC, 1996, BIOCHEM BIOPH RES CO, V225, P733, DOI 10.1006/bbrc.1996.1243; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	56	82	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3328	3334		10.1074/jbc.275.5.3328	http://dx.doi.org/10.1074/jbc.275.5.3328			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652321	hybrid			2022-12-25	WOS:000085146500043
J	Kawasaki, K; Akashi, S; Shimazu, R; Yoshida, T; Miyake, K; Nishijima, M				Kawasaki, K; Akashi, S; Shimazu, R; Yoshida, T; Miyake, K; Nishijima, M			Mouse toll-like receptor 4 center dot MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by taxol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MURINE MACROPHAGES; BACTERIAL LIPOPOLYSACCHARIDE; TYROSINE PHOSPHORYLATION; ENDOTOXIN ANTAGONIST; DROSOPHILA TOLL; NITRIC-OXIDE; KAPPA-B; PROTEIN; ACTIVATION	Taxol, an antitumor agent derived from a plant, mimics the action of lipopolysaccharide (LPS) in mice but not in humans, Although Taxol is structurally unrelated to LPS, Taxol and LPS are presumed to share a receptor or signaling molecule, The LPS-mimetic activity of Taxol is not observed in LPS-hyporesponsive C3H/HeJ mice, which possess a point mutation in Toll-like receptor 4 (TLR4); therefore, TLR4 appears to be involved in both Taxol and LPS signaling. In addition, TLR4 was recently shown to physically associate with MD-2, a molecule that confers LPS responsiveness on TLR4. To determine whether TLR4 MD-2 complex mediates a Taxol-induced signal, we constructed transformants of the mouse pro-B cell line, Ba/F3, expressing mouse TLR4 alone, both mouse TLR4 and mouse MD-2, and both mouse MD-2 and mouse TLR4 lacking the cytoplasmic portion, and then examined whether Taxol induced NF kappa B activation in these transfectants, Noticeable NF kappa B activation by Taxol was detected in Ba/F3 expressing mouse TLR4 and mouse MD-2 but not in the other transfectants. Coexpression of human TLR4 and human MD-2 did not confer Taxol responsiveness on Ba/F3 cells, suggesting that the TLR4 MD-2 complex is responsible for the species specificity with respect to Taxol responsiveness. Furthermore, Taxol-induced NF kappa B activation via TLR4 MD-2 was blocked by an LPS antagonist that blocks LPS-induced NF kappa B activation via TLR4 MD-2. These results demonstrated that coexpression of mouse TLR4 and mouse MD-2 is required for Taxol responsiveness and that the TLR4.MD-2 complex is the shared molecule in Taxol and LPS signal transduction in mice.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjyuku Ku, Tokyo 1628640, Japan; Saga Med Sch, Dept Immunol, Saga 8498501, Japan	National Institute of Infectious Diseases (NIID); Saga University	Nishijima, M (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjyuku Ku, Toyama 1-23-1, Tokyo 1628640, Japan.							ALLEN JN, 1993, J LAB CLIN MED, V122, P374; Bhat N, 1999, J IMMUNOL, V162, P7335; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; DING A, 1993, J IMMUNOL, V151, P5596; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; Fenton MJ, 1998, J LEUKOCYTE BIOL, V64, P25, DOI 10.1002/jlb.64.1.25; Hoshino K, 1999, J IMMUNOL, V162, P3749; KIRIKAE F, 1995, INFECT IMMUN, V63, P486, DOI 10.1128/IAI.63.2.486-497.1995; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Lee LF, 1996, CANCER RES, V56, P1303; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; MANTHEY CL, 1993, J EXP MED, V178, P695, DOI 10.1084/jem.178.2.695; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; MIYAKE K, 1995, J IMMUNOL, V154, P3333; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Perera PY, 1996, INFECT IMMUN, V64, P878, DOI 10.1128/IAI.64.3.878-884.1996; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; QURESHI N, 1991, INFECT IMMUN, V59, P441, DOI 10.1128/IAI.59.1.441-444.1991; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Soejima K, 1996, AM J RESP CRIT CARE, V154, P900, DOI 10.1164/ajrccm.154.4.8887583; WANG SC, 1994, SURGERY, V116, P339; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Yamamoto H, 1997, BIOCHEM J, V325, P223, DOI 10.1042/bj3250223	32	287	307	7	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2251	2254		10.1074/jbc.275.4.2251	http://dx.doi.org/10.1074/jbc.275.4.2251			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644670	hybrid			2022-12-25	WOS:000085128000002
J	Porter, M; Schindler, T; Kuriyan, J; Miller, WT				Porter, M; Schindler, T; Kuriyan, J; Miller, WT			Reciprocal regulation of Hck activity by phosphorylation of Tyr(527) and Tyr(416) - Effect of introducing a high affinity intramolecular SH2 ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; C-SRC ACTIVITY; INTERMOLECULAR AUTOPHOSPHORYLATION; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; NEF PROTEIN; BINDING; FAMILY; ACTIVATION; PEPTIDES	The Src family tyrosine kinase Hck possesses two phosphorylation sites,Tyr(527) and Tyr(416), that affect the catalytic activity in opposite ways. When phosphorylated, Tyr(527) and residues C-terminal to it are involved in an inhibitory intramolecular interaction with the SH2 domain. However, this sequence does not conform to the sequence of the high affinity SH2 ligand, pYEEI, We mutated this sequence to YEEI and show that this mutant form of Hck cannot be activated by exogenous SH2 ligands. The SH3 domain of Hck is also involved in an inhibitory interaction with the catalytic domain. The SH3 ligand Nef binds to and activates YEEI-Hck mutant in a similar manner to wild-type Hck, indicating that disrupting the SH3 interaction overrides the strengthened SH2 interaction. The other phosphorylation site, Tyr(416), is the autophosphorylation site in the activation loop. Phosphorylation of Tyr(416) is required for Hck activation. We mutated this residue to alanine and characterized its catalytic activity. The Y416A mutant shows a higher K-m value for peptide and a lower V-max than autophosphorylated wild-type Hck. We also present evidence for cross-talk between the activation loop and the intramolecular binding of the SH2 and SH3 domains.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	miller@physiology.pnb.sunysb.edu			NCI NIH HHS [CA58530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058530, R29CA058530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; Bradshaw JM, 1998, BIOCHEMISTRY-US, V37, P9083, DOI 10.1021/bi973147k; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; FERRACINI R, 1990, ONCOGENE RES, V5, P205; GARCIA P, 1993, J BIOL CHEM, V268, P25146; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; LAW DA, 1992, MOL IMMUNOL, V29, P917, DOI 10.1016/0161-5890(92)90130-P; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIU XQ, 1993, ONCOGENE, V8, P1119; Mayer BJ, 1997, CURR BIOL, V7, pR295, DOI 10.1016/S0960-9822(06)00141-2; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nguyen JT, 1997, NAT STRUCT BIOL, V4, P256, DOI 10.1038/nsb0497-256; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Weijland A, 1996, EUR J BIOCHEM, V240, P756, DOI 10.1111/j.1432-1033.1996.0756h.x; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; XU B, 1995, J BIOL CHEM, V270, P29825; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	99	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2721	2726		10.1074/jbc.275.4.2721	http://dx.doi.org/10.1074/jbc.275.4.2721			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644735	hybrid, Green Submitted			2022-12-25	WOS:000085128000067
J	Villain, M; Jackson, PL; Manion, MK; Dong, WJ; Su, ZC; Fassina, G; Johnson, TM; Sakai, TT; Krishna, NR; Blalock, JE				Villain, M; Jackson, PL; Manion, MK; Dong, WJ; Su, ZC; Fassina, G; Johnson, TM; Sakai, TT; Krishna, NR; Blalock, JE			De novo design of peptides targeted to the EF hands of calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANTI-IDIOTYPIC ANTIBODIES; MONOCLONAL ANTIIDIOTYPIC ANTIBODIES; AUTOIMMUNE MYASTHENIA-GRAVIS; COMPLEMENTARY PEPTIDES; ACETYLCHOLINE-RECEPTOR; PROTEOLYTIC FRAGMENTS; MOLECULAR RECOGNITION; GENETIC ALGORITHM	This report describes the use of the concept of inversion of hyrdropathy patterns to the de novo design of peptides targeted to a predetermined site on a protein. Eight- and la-residue peptides were constructed with the EF hands or Ca2+-coordinating sites of calmodulin as their anticipated points of interaction. These peptides, but not unrelated peptides nor those with the same amino acid composition but a scrambled sequence, interacted with the two carboxyl-terminal Ca2+-binding sites of calmodulin as well as the EF hands of troponin C. The interactions resulted in a conformational change whereby the 8-mer peptide-calmodulin complex could activate phosphodiesterase in the absence of Ca2+. In contrast, the la-mer peptide-calmodulin complex did not activate phosphodiesterase but rather inhibited activation by Ca2+. This inhibition could be overcome by high levels of Ca2+. Thus, it would appear that the afore-mentioned concept can be used to make peptide agonists and antagonists that are targeted to predetermined sites on proteins such as calmodulin.	Univ Alabama Birmingham, Dept Phys & Biophys, Sch Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Ctr Canc, Sch Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Phys & Biophys, Sch Dent, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Sch Dent, Ctr Canc, Birmingham, AL 35294 USA; Tecnogen, I-81015 Piana Di Monte Verna, CE, Italy	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Blalock, JE (corresponding author), Univ Alabama Birmingham, Dept Phys & Biophys, Sch Med, Birmingham, AL 35294 USA.	Blalock@physiology.uab.edu	Fassina, Giorgio/I-7127-2012	Fassina, Giorgio/0000-0003-1845-2657; Blalock, J. Edwin/0000-0001-5303-8123	NCI NIH HHS [CA13148] Funding Source: Medline; NIMH NIH HHS [MH52527] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSSON A, 1983, BIOCHEMISTRY-US, V22, P2309, DOI 10.1021/bi00279a001; ARAGA S, 1993, P NATL ACAD SCI USA, V90, P8747, DOI 10.1073/pnas.90.18.8747; Araga S, 1996, J IMMUNOL, V157, P386; BARANYI L, 1995, NAT MED, V1, P894, DOI 10.1038/nm0995-894; BLALOCK JE, 1990, TRENDS BIOTECHNOL, V8, P140, DOI 10.1016/0167-7799(90)90159-U; BLALOCK JE, 1995, NAT MED, V1, P876, DOI 10.1038/nm0995-876; BLALOCK JE, 1989, METHOD ENZYMOL, V178, P63; BLALOCK JE, 1981, BIOCHEM BIOPH RES CO, V101, P472, DOI 10.1016/0006-291X(81)91284-5; BLALOCK JE, 1986, BIOCHEM J, V234, P679, DOI 10.1042/bj2340679; Blalock JE, 1999, CELL MOL LIFE SCI, V55, P513, DOI 10.1007/s000180050309; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOQUET D, 1995, MOL IMMUNOL, V32, P303, DOI 10.1016/0161-5890(95)00012-4; BOROVSKY D, 1994, FASEB J, V8, P350, DOI 10.1096/fasebj.8.3.7908271; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; Browne JP, 1997, BIOCHEMISTRY-US, V36, P9550, DOI 10.1021/bi970460d; CADAY CG, 1985, J BIOL CHEM, V260, P5985; CHABBERT M, 1991, BIOCHEMISTRY-US, V30, P7615, DOI 10.1021/bi00244a034; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DEMAILLE JG, 1982, CALCIUM CELL FUNCTIO, V2, P111; Dery O, 1997, J NEUROIMMUNOL, V76, P1, DOI 10.1016/S0165-5728(97)00026-X; DILL KA, 1995, PROTEIN SCI, V4, P561; DILLON J, 1991, P NATL ACAD SCI USA, V88, P9726, DOI 10.1073/pnas.88.21.9726; Dong WJ, 1997, J BIOL CHEM, V272, P19229, DOI 10.1074/jbc.272.31.19229; Dong WJ, 1997, BIOPHYS J, V72, P850, DOI 10.1016/S0006-3495(97)78719-8; FASSINA G, 1989, J BIOL CHEM, V264, P11252; FASSINA G, 1992, ARCH BIOCHEM BIOPHYS, V296, P137, DOI 10.1016/0003-9861(92)90555-B; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; GHISO J, 1990, P NATL ACAD SCI USA, V87, P1288, DOI 10.1073/pnas.87.4.1288; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; Henikoff JG, 1999, NUCLEIC ACIDS RES, V27, P226, DOI 10.1093/nar/27.1.226; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HIRATSUKA T, 1982, J BIOL CHEM, V257, P13354; JANKOV BP, 1994, 23 EUR PEPT S EUR PE, P324; JARPE MA, 1994, PEPTIDES DESIGN SYNT, P165; Johnson H M, 1994, Immunomethods, V5, P167, DOI 10.1006/immu.1994.1051; JOHNSON JD, 1987, ANAL BIOCHEM, V162, P291, DOI 10.1016/0003-2697(87)90039-X; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KILHOFFER MC, 1992, BIOCHEMISTRY-US, V31, P8098, DOI 10.1021/bi00149a046; KILHOFFER MC, 1988, J BIOL CHEM, V263, P17023; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KINCAID RL, 1986, P NATL ACAD SCI USA, V83, P1193, DOI 10.1073/pnas.83.5.1193; LENTZ TL, 1984, SCIENCE, V226, P847, DOI 10.1126/science.6494916; LI CH, 1982, BIOCHEM ACTION HORM, P1; Maier C C, 1994, Immunomethods, V5, P107, DOI 10.1006/immu.1994.1044; Martins VR, 1997, NAT MED, V3, P1376, DOI 10.1038/nm1297-1376; McGuigan J E, 1994, Immunomethods, V5, P158, DOI 10.1006/immu.1994.1050; Mulchahey JJ, 1999, CELL MOL LIFE SCI, V55, P653, DOI 10.1007/s000180050321; NAGY GM, 1991, 73 ANN END SOC M, P209; OGATA C, 1987, NATURE, V328, P739, DOI 10.1038/328739a0; OMICHINSKI JG, 1988, PROT SOC M SAN DIE S, V321, P58; PALLA E, 1993, J BIOL CHEM, V268, P13486; PASCUAL D W, 1989, Peptide Research, V2, P207; RADDING W, 1992, J AUTONOM NERV SYST, V40, P161, DOI 10.1016/0165-1838(92)90027-E; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Riddle DS, 1997, NAT STRUCT BIOL, V4, P805, DOI 10.1038/nsb1097-805; RUIZOPAZO N, 1995, NAT MED, V1, P1074, DOI 10.1038/nm1095-1074; SMITH LR, 1987, J IMMUNOL, V138, P7; THULIN E, 1970, P NATL ACAD SCI USA, V71, P1862; TORRES BA, 1990, J NEUROIMMUNOL, V27, P191, DOI 10.1016/0165-5728(90)90069-Y; VOGEL HJ, 1983, FEBS LETT, V157, P241, DOI 10.1016/0014-5793(83)80554-7; VOGEL HJ, 1994, CELL BIOL, V72, P357; Weigent D A, 1994, Immunomethods, V5, P91, DOI 10.1006/immu.1994.1042; WHITAKER JN, 1989, J NEUROIMMUNOL, V22, P157, DOI 10.1016/0165-5728(89)90047-7; WOODY WR, 1985, PEPTIDE, P15; Zhou S R, 1994, Immunomethods, V5, P136, DOI 10.1006/immu.1994.1048; ZHOU SR, 1994, J IMMUNOL, V153, P2340; ZHOU SR, 1993, J IMMUNOL, V150, P1629; ZHOU SR, 1994, CLIN IMMUNOL IMMUNOP, V70, P251, DOI 10.1006/clin.1994.1037	70	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2676	2685		10.1074/jbc.275.4.2676	http://dx.doi.org/10.1074/jbc.275.4.2676			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644729	hybrid			2022-12-25	WOS:000085128000061
J	Potter, MD; Nicchitta, CV				Potter, MD; Nicchitta, CV			Ribosome-independent regulation of translocon composition and Sec61 alpha conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL SEQUENCE RECOGNITION; PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; ROUGH MICROSOMES; DIFFERENTIAL SOLUBILIZATION; TOPOGENIC SEQUENCE; APOLIPOPROTEIN-B; BINDING-ACTIVITY; BOUND RIBOSOMES	In this study, the contributions of membrane-bound ribosomes to the regulation of endoplasmic reticulum translocon composition and Sec61 alpha conformation were examined. Following solubilization of rough microsomes (RM) with digitonin, ribosomes co-sedimented in complexes containing the translocon proteins Sec61 alpha, ribophorin I, and TRAP alpha, and endoplasmic reticulum phospholipids. Complexes of similar composition were identified in digitonin extracts of ribosome-free membranes, indicating that the ribosome does not define the composition of the digitonin-soluble translocon, Whereas in digitonin solution a highly electrostatic ribosome-translocon junction is observed, no stable interactions between ribosomes and Sec61 alpha, ribophorin I, or TRAP alpha were observed following solubilization of RM with lipid derived detergents at physiological salt concentrations. Sec61 alpha was found to exist in at least two conformational states, as defined by mild proteolysis, A protease-resistant form was observed in RM and detergent-solubilized RM. Removal of peripheral proteins and ribosomes markedly enhanced the sensitivity of Sec61 alpha to proteolysis, yet the readdition of inactive ribosomes to salt-washed membranes yielded only modest reductions in protease sensitivity, Addition of sublytic concentrations of detergents to salt-washed RM markedly decreased the protease sensitivity of Sec61 alpha, indicating that a protease-resistant conformation of Sec61 alpha can be conferred in a ribosome-independent manner.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.				NIDDK NIH HHS [DK47897] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047897] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aveldano MI, 1995, ARCH BIOCHEM BIOPHYS, V324, P331, DOI 10.1006/abbi.1995.0046; BANERJEE P, 1995, CHEM PHYS LIPIDS, V77, P65, DOI 10.1016/0009-3084(95)02455-R; BANERJEE P, 1993, INDIAN J BIOCHEM BIO, V30, P358; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; Chevet E, 1999, EMBO J, V18, P3655, DOI 10.1093/emboj/18.13.3655; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; COLLINS PG, 1991, J CELL BIOL, V114, P639, DOI 10.1083/jcb.114.4.639; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; GABRIEL NE, 1986, BIOCHEMISTRY-US, V25, P2812, DOI 10.1021/bi00358a012; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; ICHIMURA T, 1992, FEBS LETT, V296, P7, DOI 10.1016/0014-5793(92)80391-S; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KAIHOVAARA P, 1991, BIOCHEMISTRY-US, V30, P8380, DOI 10.1021/bi00098a015; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; KESSI J, 1994, BIOCHEMISTRY-US, V33, P10825, DOI 10.1021/bi00201a033; KIRKPATRICK FH, 1974, BIOCHIM BIOPHYS ACTA, V345, P154, DOI 10.1016/0005-2736(74)90254-5; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MANS RJ, 1961, ARCH BIOCHEM BIOPHYS, V94, P48, DOI 10.1016/0003-9861(61)90009-1; MARTIN TE, 1969, J MOL BIOL, V43, P135, DOI 10.1016/0022-2836(69)90084-9; MAZER NA, 1980, BIOCHEMISTRY-US, V19, P601, DOI 10.1021/bi00545a001; Mothes W, 1998, J CELL BIOL, V142, P355, DOI 10.1083/jcb.142.2.355; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; NUNNARI JM, 1991, NATURE, V352, P638, DOI 10.1038/352638a0; PALADE GE, 1955, J BIOPHYS BIOCHEM CY, V1, P59, DOI 10.1083/jcb.1.1.59; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SABATINI DD, 1966, J MOL BIOL, V19, P503, DOI 10.1016/S0022-2836(66)80019-0; SAVITZ AJ, 1993, J CELL BIOL, V120, P853, DOI 10.1083/jcb.120.4.853; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; Savitz AJ, 1997, J BIOL CHEM, V272, P13140, DOI 10.1074/jbc.272.20.13140; Shivanna BD, 1997, BIOCHEM J, V325, P533, DOI 10.1042/bj3250533; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SMALL DM, 1969, BIOCHIM BIOPHYS ACTA, V176, P178, DOI 10.1016/0005-2760(69)90086-1; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931	48	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2037	2045		10.1074/jbc.275.3.2037	http://dx.doi.org/10.1074/jbc.275.3.2037			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636907	hybrid			2022-12-25	WOS:000084940000070
J	Summy, JM; Guappone, AC; Sudol, M; Flynn, DC				Summy, JM; Guappone, AC; Sudol, M; Flynn, DC			The SH3 and SH2 domains are capable of directing specificity in protein interactions between the non-receptor tyrosine kinases cSrc and cYes	ONCOGENE			English	Article						Src; Yes; SH3; SH2; tyrosine phosphorylation	HUMAN-COLON-CARCINOMA; SRC FAMILY KINASES; C-SRC; BINDING-SPECIFICITY; COMPLEX-FORMATION; GENE-PRODUCT; YES; ASSOCIATION; ACTIVATION; CELLS	The c-src and eyes proto-oncogenes encode 60 000 and 62 000 Dalton non-receptor tyrosine kinases of the Src family, pp60(c-src) and pp62(c-yes), respectively. These kinases are over 80% homologous outside of their unique amino termini, yet several studies suggest that differences exist in the regulation, activation, and function of cSrc and c Yes. The determinants of specificity in signaling between these proteins, however, remain unclear, In order to investigate the roles of the Src Homology (SH) 3 and 2 domains in mediating signaling specificity between cSrc and cYes, chimeras were created in which the SH3 and/or SH2 domains of cSrc or the fully activated variant Src(527F) were replaced by the corresponding domains of cYes. These constructs were used to assess the effects of the Yes SH3 and SH2 domains on the ability of Src to form stable complexes with and induce tyrosine phosphorylation of Src SH3 and SH2 domain binding partners in vivo. Both the Yes SH3 and SH2 domains were found to alter the capacity of Src to form stable associations with heterologous proteins. The Yes SH3 domain was unable to affinity absorb the Src SN3/SH2 binding partner AFAP-110 from COS-1 cell lysates, and chimeric constructs of Src(527F) containing the cYes SH3 domain were unable to efficiently coimmunoprecipitate with AFAP-110 from chicken embryo fibroblasts. Interactions with the Src SH2 domain binding partner pp130cas were unaffected, Additionally only chimeras containing the cYes SH2 domain were able to co-immunoprecipitate with an unidentified 87 kDa tyrosine-phosphorylated protein. These results indicate that the SH3 and SH2 domains are capable of directing specificity in substrate binding between Src and Yes, suggesting potential mechanisms for generating specificity in signaling between these two highly related non-receptor tyrosine kinases.	W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol & Immunol, Morgantown, WV 26506 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	West Virginia University; West Virginia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Flynn, DC (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, POB 9300, Morgantown, WV 26506 USA.				NCI NIH HHS [CA60731, CA45757, CA01605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060731, R29CA045757, R01CA060731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Fuhrer DK, 1996, EXP HEMATOL, V24, P195; Fuhrer DK, 1996, BIOCHEM BIOPH RES CO, V224, P289, DOI 10.1006/bbrc.1996.1023; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; GUAPPONE AC, 1996, METH CELL SCI, V18, P1; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Luton F, 1999, MOL CELL, V4, P627, DOI 10.1016/S1097-2765(00)80213-0; Marchetti D, 1998, ONCOGENE, V16, P3253, DOI 10.1038/sj.onc.1201877; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; PARK J, 1995, MOL CELL BIOL, V15, P2374; PARK JS, 1993, ONCOGENE, V8, P2627; PENA SV, 1995, GASTROENTEROLOGY, V108, P117, DOI 10.1016/0016-5085(95)90015-2; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; Sicilia RJ, 1998, J BIOL CHEM, V273, P16756, DOI 10.1074/jbc.273.27.16756; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; SUDOL M, 1994, ONCOGENE, V9, P2145; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tsygankova OM, 1998, J CELL BIOCHEM, V69, P63, DOI 10.1002/(SICI)1097-4644(19980401)69:1<63::AID-JCB7>3.0.CO;2-T; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; ZHAO YH, 1993, MOL CELL BIOL, V13, P7507, DOI 10.1128/MCB.13.12.7507; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	25	25	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2000	19	1					155	160		10.1038/sj.onc.1203265	http://dx.doi.org/10.1038/sj.onc.1203265			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644991				2022-12-25	WOS:000084844300018
J	Na, SQ; Li, BY; Grewal, IS; Enslen, H; Davis, RJ; Hanke, JH; Flavell, RA				Na, SQ; Li, BY; Grewal, IS; Enslen, H; Davis, RJ; Hanke, JH; Flavell, RA			Expression of activated CDC42 induces T cell apoptosis in thymus and peripheral lymph organs via different pathways	ONCOGENE			English	Article						apoptosis; thymus; T cells; CDC42; Fas; Fas ligand	PROTEIN-KINASE ACTIVATION; NEGATIVE SELECTION; SIGNALING PATHWAY; TRANSGENIC MICE; GTPASE CDC42; FAS LIGAND; IN-VIVO; LYMPHOCYTES; RHO; DEATH	CDC42, a Ras-related small GTP binding protein, is involved in diverse cellular functions in lymphocytes. We generated transgenic mice expressing constitutively active murine CDC42 (Q61L) under the control of the human CD2 promoter. Transgenic mice showed smaller thymi with a dramatic reduction of CD4(+)CD8(+), CD4(+) and CD8(+) thymocytes and with increase of CD4(-)CD8(-) thymocytes at CD25(-)CD44(+) and CD25(+) stage. A high percentage of the transgenic thymocytes were apoptotic, explaining the reduction of cellularity and size of the thymus, Mature T cells (TCR alpha beta(+)) in peripheral lymph organs, spleen and lymph node, were also dramatically reduced, and exhibited massive apoptosis, Expression of Fas and Fas ligand on both thymocytes and peripheral T cells was upregulated in transgenic mice, but the increased apoptosis in the thymus was independent of Fas (CD95), whereas peripheral spleen and lymph node T cell apoptosis was Fas dependent. Thus, activated CDC42 triggers distinct apoptotic pathways in thymocytes and peripheral T cells.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Pfizer; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Flavell, RA (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, POB 20811, New Haven, CT 06520 USA.		Enslen, Hervé/M-3400-2017; Enslen, Hervé/AAH-4492-2021	Enslen, Hervé/0000-0001-9741-5293; Enslen, Hervé/0000-0001-9741-5293; Grewal, Iqbal S/0000-0002-4775-055X	NCI NIH HHS [CA72009, CA65861] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072009, R01CA065861] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; ALAN A, 1997, J EXP MED, V186, P1503; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Avraham A, 1998, EUR J IMMUNOL, V28, P2320, DOI 10.1002/(SICI)1521-4141(199808)28:08<2320::AID-IMMU2320>3.0.CO;2-K; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Faris M, 1998, J IMMUNOL, V160, P134; Galandrini R, 1997, IMMUNITY, V7, P163, DOI 10.1016/S1074-7613(00)80519-1; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GODFREY DI, 1993, J IMMUNOL, V150, P4244; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOGAN B, 1986, MANIPULATING MOUSE E, P217; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; Kaga S, 1998, J IMMUNOL, V160, P4182; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; LINETTE GP, 1994, CURR OPIN CELL BIOL, V6, P809, DOI 10.1016/0955-0674(94)90049-3; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mehal WZ, 1998, J IMMUNOL, V161, P1686; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moorman JP, 1996, J IMMUNOL, V156, P4146; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; vonFreedenJeffry U, 1997, IMMUNITY, V7, P147, DOI 10.1016/S1074-7613(00)80517-8; WEBB SR, 1994, J IMMUNOL, V152, P586; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	49	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7966	7974		10.1038/sj.onc.1203122	http://dx.doi.org/10.1038/sj.onc.1203122			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637507				2022-12-25	WOS:000084634600005
J	Graham, DE; Bock, CL; Schalk-Hihi, C; Lu, ZCJ; Markham, GD				Graham, DE; Bock, CL; Schalk-Hihi, C; Lu, ZCJ; Markham, GD			Identification of a highly diverged class of S-adenosylmethionine synthetases in the archaea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; MASS-SPECTROMETRY; RAT-LIVER; 2 FORMS; PURIFICATION; YEAST; METHYLATION; ACTIVATION; METABOLISM; SEQUENCE	S-Adenosylmethionine is the primary alkylating agent in all known organisms. ATP:L-methionine S-adenosyl-transferase (MAT) catalyzes the only known biosynthetic: route to this central metabolite. Although the amino acid sequence of MAT is strongly conserved among bacteria and eukarya, no homologs have been recognized in the completed genome sequences of any archaea, In this study, MAT has been purified to homogeneity from the archaeon Methanococcus jannaschii, and the gene encoding it has been identified by mass spectrometry. The peptide mass map identifies the gene encoding MAT as MJ1208, a hypothetical open reading frame, The gene was cloned in Escherichia coli, and expressed enzyme has been purified and characterized. This protein has only 22 and 23% sequence identity to the E, coli and human enzymes, respectively, whereas those are 59% identical to each other. The few identical residues include the majority of those constituting the polar active site residues. Each complete archaeal genome sequence contains a homolog of this archaeal-type MAT. Surprisingly, three bacterial genomes encode both the archaeal and eukaryal/bacterial types of MAT. This identification of a second major class of MAT emphasizes the long evolutionary history of the archaeal lineage and the structural diversity found even in crucial metabolic enzymes.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	Fox Chase Cancer Center; University of Illinois System; University of Illinois Urbana-Champaign	Graham, DE (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Graham, David E/F-8578-2010	Graham, David E/0000-0001-8968-7344	NCI NIH HHS [CA06927] Funding Source: Medline; NIGMS NIH HHS [GM31186] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CANTONI GL, 1953, J BIOL CHEM, V204, P403; CHIANG PK, 1977, J BIOL CHEM, V252, P4506; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; CHIFFLET S, 1986, ANAL BIOCHEM, V168, P1; DANIELS L, 1986, APPL ENVIRON MICROB, V51, P703, DOI 10.1128/AEM.51.4.703-709.1986; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; Hanzelka BL, 1996, J BACTERIOL, V178, P5291, DOI 10.1128/jb.178.17.5291-5294.1996; HOFFMAN JL, 1983, METHOD ENZYMOL, V94, P223; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; Jermiin LS, 1997, MOL BIOL EVOL, V14, P1296, DOI 10.1093/oxfordjournals.molbev.a025739; KOTB M, 1985, J BIOL CHEM, V260, P3923; Maidak BL, 1999, NUCLEIC ACIDS RES, V27, P171, DOI 10.1093/nar/27.1.171; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MCQUENEY MS, 1995, J BIOL CHEM, V270, P18277, DOI 10.1074/jbc.270.31.18277; Mudd S. H., 1973, ENZYMES, V8, P121; Mukhopadhyay B, 1999, APPL ENVIRON MICROB, V65, P5059; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; PEGG AE, 1988, CANCER RES, V48, P759; PORCELLI M, 1988, EUR J BIOCHEM, V177, P273, DOI 10.1111/j.1432-1033.1988.tb14373.x; RECZKOWSKI RS, 1995, J BIOL CHEM, V270, P18484, DOI 10.1074/jbc.270.31.18484; Schroder G, 1997, PLANT MOL BIOL, V33, P211, DOI 10.1023/A:1005711720930; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Taylor JC, 1999, J BIOL CHEM, V274, P32909, DOI 10.1074/jbc.274.46.32909; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; USDIN E, 1982, BIOCH S ADENOSYLMETH; Xu HM, 1999, NAT STRUCT BIOL, V6, P750; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	37	44	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4055	4059		10.1074/jbc.275.6.4055	http://dx.doi.org/10.1074/jbc.275.6.4055			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660563	hybrid			2022-12-25	WOS:000085288800047
J	Makise, M; Mima, S; Tsuchiya, T; Mizushima, T				Makise, M; Mima, S; Tsuchiya, T; Mizushima, T			Identification of amino acids involved in the functional interaction between DnaA protein and acidic phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTATIONAL ANALYSIS; ESCHERICHIA-COLI CHROMOSOME; UNSATURATED FATTY-ACIDS; ATP-BINDING; IN-VITRO; INITIATION PROTEIN; REPLICATION; MUTANTS; CARDIOLIPIN; HYDROLYSIS	DnaA protein, the initiator of chromosomal DNA replication in Escherichia coli, seems to be regulated through its binding to acidic phospholipids, such as cardiolipin. In our previous paper (Hase, M., Yoshimi, T,Ishikawa, Y., Ohba, A., Guo, L., Mima, S., Makise, M., Yamaguchi, Y., Tsuchiya, T., and Mizushima, T, (1998) J, Biol, Chem. 273, 28651-28656), we found that mutant DnaA protein (DnaA431), in which three basic amino acids (Arg(360), Arg(364) and Lys(372)) were mutated to acidic amino acids showed a decreased ability to interact with cardiolipin in vitro, suggesting that DnaA protein binds to cardiolipin through an ionic interaction. In this study, we construct three mutant dnaA genes each with a single mutation and examined the function of the mutant proteins in vitro and in vivo. All mutant proteins maintained activities for DNA replication and ATP binding, A mutant protein in which Lys(372) was mutated to Glu showed the weakest interaction with cardiolipin among these three mutant proteins. Thus, Lys(372) seems to play an important role in the interaction between DnaA protein and acidic phospholipids. Plasmid complementation analyses revealed that all these mutant proteins, including DnaA431 could function as an initiator for chromosomal DNA replication in vivo.	Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan; Japan Sci & Technol Corp, PRESTO, Okayama 7008530, Japan	Okayama University; Japan Science & Technology Agency (JST)	Mizushima, T (corresponding author), Okayama Univ, Fac Pharmaceut Sci, 1-1-1 Tsushima Naka, Okayama 7008530, Japan.	mizushima@pheasant.pharm.okayama-u.ac.jp						Carr KM, 1996, MOL MICROBIOL, V20, P1307, DOI 10.1111/j.1365-2958.1996.tb02649.x; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; Garner J, 1998, J BIOL CHEM, V273, P5167, DOI 10.1074/jbc.273.9.5167; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; Hase M, 1998, J BIOL CHEM, V273, P28651, DOI 10.1074/jbc.273.44.28651; Hase M, 1998, J BIOCHEM-TOKYO, V123, P680; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kurokawa K, 1998, BIOCHEM BIOPH RES CO, V243, P90, DOI 10.1006/bbrc.1997.8069; LARK KG, 1969, J MOL BIOL, V42, P221, DOI 10.1016/0022-2836(69)90039-4; Mizushima T, 1997, EMBO J, V16, P3724, DOI 10.1093/emboj/16.12.3724; Mizushima T, 1998, J BIOL CHEM, V273, P20847, DOI 10.1074/jbc.273.33.20847; Mizushima T, 1996, J BIOL CHEM, V271, P3633; Mizushima T, 1996, J BIOL CHEM, V271, P25178, DOI 10.1074/jbc.271.41.25178; Mizushima T, 1997, J BIOL CHEM, V272, P21195, DOI 10.1074/jbc.272.34.21195; Mizushima T, 1996, MOL GEN GENET, V252, P212, DOI 10.1007/BF02173222; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SHINPUKU T, 1995, BIOCHEM BIOPH RES CO, V212, P84, DOI 10.1006/bbrc.1995.1939; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; Suzuki E, 1998, BIOL PHARM BULL, V21, P657; Suzuki E, 1998, MOL MICROBIOL, V28, P95, DOI 10.1046/j.1365-2958.1998.00777.x; WEIMING X, 1995, P NATL ACAD SCI USA, P783; Yamaguchi Y, 1999, BIOCHEM J, V340, P433, DOI 10.1042/0264-6021:3400433; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	28	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4513	4518		10.1074/jbc.275.6.4513	http://dx.doi.org/10.1074/jbc.275.6.4513			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660626	hybrid			2022-12-25	WOS:000085288800110
J	Pecheur, EI; Martin, I; Bienvenue, A; Ruysschaert, JM; Hoekstra, D				Pecheur, EI; Martin, I; Bienvenue, A; Ruysschaert, JM; Hoekstra, D			Protein-induced fusion can be modulated by target membrane lipids through a structural switch at the level of the fusion peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL EXTREMITY; BIOLOGICAL-MEMBRANES; SECONDARY STRUCTURE; FTIR SPECTROSCOPY; HEMAGGLUTININ; COMPLEX; PHOSPHATIDYLETHANOLAMINE; CONFORMATION; MECHANISMS; BILAYER	Regulatory features of protein-induced membrane fusion are largely unclear, particularly at the level of the fusion peptide. Fusion peptides being part of larger protein complexes, such investigations are met with technical limitations. Here, we show that the fusion activity of influenza virus or Golgi membranes is strongly inhibited by minor amounts of (lyso)lipids when present in the target membrane but not when inserted into the viral or Golgi membrane itself. To investigate the underlying mechanism, we employ a membrane-anchored peptide system and show that fusion is similarly regulated by these lipids when inserted into the target but not when present in the peptide-containing membrane, Peptide-induced fusion is regulated by a reversible switch of secondary structure from a fusion-permissive alpha-helix to a nonfusogenic beta-sheet. The "on/off" activation of this switch is governed by minor amounts of (lyso)-phospholipids in targets, causing a drop in cu-helix and a dramatic increase in beta-sheet contents. Concomitantly, fusion is inhibited, due to impaired peptide insertion into the target membrane. Our observations in biological fusion systems together with the model studies suggest that distinct lipids in target membranes provide a means for regulating membrane fusion by causing a reversible secondary structure switch of the fusion peptides.	Univ Groningen, Dept Physiol Chem, NL-9713 AV Groningen, Netherlands; Free Univ Brussels, Chim Phys Macromol Interfaces Lab, B-1050 Brussels, Belgium; Univ Montpellier 2, UMR 5539, CNRS, Dept Biol Sante, F-34095 Montpellier, France	University of Groningen; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Hoekstra, D (corresponding author), Univ Groningen, Dept Physiol Chem, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.			Pecheur, Eve/0000-0002-8613-862X				Bogdanov M, 1998, EMBO J, V17, P5255, DOI 10.1093/emboj/17.18.5255; Canaves JM, 1998, J BIOL CHEM, V273, P34214, DOI 10.1074/jbc.273.51.34214; Chernomordik L, 1996, CHEM PHYS LIPIDS, V81, P203, DOI 10.1016/0009-3084(96)02583-2; CHERNOMORDIK L, 1995, J VIROL, V69, P3049, DOI 10.1128/JVI.69.5.3049-3058.1995; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; Chernomordik LV, 1997, J CELL BIOL, V136, P81, DOI 10.1083/jcb.136.1.81; DEJONGH HHJ, 1995, BIOCHEMISTRY-US, V34, P172, DOI 10.1021/bi00001a021; deJongh HHJ, 1996, ANAL BIOCHEM, V242, P95, DOI 10.1006/abio.1996.0434; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; EPAND RM, 1995, BIOPOLYMERS, V37, P319, DOI 10.1002/bip.360370504; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GOORMAGHTIGH E, 1997, DETERMINATION SOLUBL, V23, P329; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; Hunter GW, 1999, BIOCHEMISTRY-US, V38, P4604, DOI 10.1021/bi982392g; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Kiyota T, 1996, BIOCHEMISTRY-US, V35, P13196, DOI 10.1021/bi961289t; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Lindblom G, 1998, CURR OPIN COLLOID IN, V3, P499, DOI 10.1016/S1359-0294(98)80024-1; LUNEBERG J, 1995, J BIOL CHEM, V270, P27606; Martin I, 1998, EUR J BIOCHEM, V258, P150, DOI 10.1046/j.1432-1327.1998.2580150.x; Martin I, 1996, J VIROL, V70, P298, DOI 10.1128/JVI.70.1.298-304.1996; Martin I, 1999, BIOCHEMISTRY-US, V38, P9337, DOI 10.1021/bi9829534; McIntosh TJ, 1999, BIOPHYS J, V76, P2090, DOI 10.1016/S0006-3495(99)77365-0; Myles DG, 1997, BIOL REPROD, V56, P320, DOI 10.1095/biolreprod56.2.320; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; NOVICK SL, 1988, P NATL ACAD SCI USA, V85, P7433, DOI 10.1073/pnas.85.20.7433; Otter-Nilsson M, 1999, EMBO J, V18, P2074, DOI 10.1093/emboj/18.8.2074; PAK CC, 1994, J BIOL CHEM, V269, P14614; Pecheur EI, 1997, BIOCHEMISTRY-US, V36, P3773, DOI 10.1021/bi9622128; Pecheur EI, 1999, J MEMBRANE BIOL, V167, P1, DOI 10.1007/s002329900466; Pecheur EI, 1999, BIOCHEMISTRY-US, V38, P364, DOI 10.1021/bi981389u; Pecheur EI, 1998, BIOCHEMISTRY-US, V37, P2361, DOI 10.1021/bi972697f; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Siegel DP, 1997, BIOPHYS J, V73, P3089, DOI 10.1016/S0006-3495(97)78336-X; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TATULIAN SA, 1995, EMBO J, V14, P5514, DOI 10.1002/j.1460-2075.1995.tb00238.x; VANDEENEN LLM, 1965, PROG CHEM FATS OTHER, V8; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Yun CH, 1997, J BIOL CHEM, V272, P19725, DOI 10.1074/jbc.272.32.19725	41	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3936	3942		10.1074/jbc.275.6.3936	http://dx.doi.org/10.1074/jbc.275.6.3936			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660547	hybrid			2022-12-25	WOS:000085288800031
J	Thommesen, L; Norsett, K; Sandvik, AK; Hofsli, E; Laegreid, A				Thommesen, L; Norsett, K; Sandvik, AK; Hofsli, E; Laegreid, A			Regulation of inducible cAMP early repressor expression by gastrin and cholecystokinin in the pancreatic cell line AR42J	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVATION; NERVE GROWTH-FACTOR; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PHOSPHOLIPASE-C; B RECEPTORS; TYROSINE PHOSPHORYLATION; INDUCED TRANSCRIPTION; CREB PHOSPHORYLATION; RESPONSIVE-ELEMENT	The CREM gene encodes both activators and repressors of cAMP-induced transcription. Inducible cAMP early repressor (ICER) isoforms are generated upon activation of an alternative, intronic promoter within the CREM gene. ICER is proposed to down-regulate both its own expression and the expression of other genes that contain cAMP-responsive elements such as a number of growth factors. Thus, ICER has been postulated to play a role in proliferation and differentiation. Here we show that ICER gene expression is induced by gastrin, cholecystokinin (CCK), and epidermal growth factor in AR42J cells. The time course of gastrin- and CCK-mediated ICER induction is rapid and transient, similar to forskolin- and phorbol la-myristate 13-acetate-induced ICER expression. The specific CCK-B receptor antagonist L740,093 blocks the gastrin but not the CCK response, indicating that both the CCK-B and the CCK-A receptor can mediate ICER gene activation. Noteworthy, CREB is constitutively phosphorylated at Ser-133 in AR42J cells, and ICER induction proceeds in the absence of increased CREB Ser(P)-133. Gastrin-mediated ICER induction was not reduced in the presence of the protein kinase A inhibitor H-89, indicating a protein kinase A-independent mechanism. This is the first report on ICER inducibility via G(q)/G(11) protein-coupled receptors.	Norwegian Univ Sci & Technol, Dept Physiol & Biomed Engn, N-7489 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Laegreid, A (corresponding author), Norwegian Univ Sci & Technol, Dept Physiol & Biomed Engn, Med Tekn Senter, N-7005 Trondheim, Norway.	astridl@medisin.ntnu.no						BERTRAND V, 1994, INT J CANCER, V56, P427, DOI 10.1002/ijc.2910560324; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bodor J, 1996, P NATL ACAD SCI USA, V93, P3536, DOI 10.1073/pnas.93.8.3536; Bodor J, 1998, J BIOL CHEM, V273, P9544, DOI 10.1074/jbc.273.16.9544; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BRENNA E, 1992, GUT, V33, P1303, DOI 10.1136/gut.33.10.1303; CHRISTOPHE J, 1994, AM J PHYSIOL, V266, pG963, DOI 10.1152/ajpgi.1994.266.6.G963; Dabrowski A, 1997, DIGESTION, V58, P361, DOI 10.1159/000201466; Dabrowski A, 1997, AM J PHYSIOL-CELL PH, V273, pC1472, DOI 10.1152/ajpcell.1997.273.5.C1472; Daulhac L, 1997, BIOCHEM J, V325, P383, DOI 10.1042/bj3250383; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; Dethloff LA, 1999, FOOD CHEM TOXICOL, V37, P105, DOI 10.1016/S0278-6915(98)00119-7; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; Houpt TA, 1997, BRAIN RES, V751, P143, DOI 10.1016/S0006-8993(96)01413-8; ISHIZUKA J, 1994, CANCER RES, V54, P2129; Korf HW, 1996, NATURWISSENSCHAFTEN, V83, P535; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; LAEGREID A, 1995, J BIOL CHEM, V270, P25418, DOI 10.1074/jbc.270.43.25418; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LALLI E, 1994, J BIOL CHEM, V269, P17359; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MARINO CR, 1993, FEBS LETT, V316, P48, DOI 10.1016/0014-5793(93)81734-H; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Monaco L, 1997, ONCOGENE, V15, P2493, DOI 10.1038/sj.onc.1201636; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; PATEL S, 1994, MOL PHARMACOL, V46, P943; PIIPER A, 1997, AM J PHYSIOL, V272, P135; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Ruchaud S, 1997, ONCOGENE, V15, P827, DOI 10.1038/sj.onc.1201248; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDVIK AK, 1991, AM J PHYSIOL, V260, pG925, DOI 10.1152/ajpgi.1991.260.6.G925; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SCEMAMA JL, 1989, AM J PHYSIOL, V256, pG846, DOI 10.1152/ajpgi.1989.256.5.G846; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Seva C, 1996, FEBS LETT, V378, P74, DOI 10.1016/0014-5793(95)01414-4; SEVA C, 1994, REGUL PEPTIDES, V52, P31, DOI 10.1016/0167-0115(94)90018-3; Seva C, 1997, BIOCHEM BIOPH RES CO, V238, P202, DOI 10.1006/bbrc.1997.7163; SEVA C, 1990, CANCER RES, V50, P5829; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; TANIGUCHI T, 1994, ONCOGENE, V9, P861; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; TODISCO A, 1995, J BIOL CHEM, V270, P28337; Todisco A, 1997, AM J PHYSIOL-GASTR L, V273, pG891, DOI 10.1152/ajpgi.1997.273.4.G891; WALDUM HL, 1995, DIGEST DIS, V13, P25, DOI 10.1159/000171484; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423; Wang HL, 1997, J NEUROCHEM, V68, P1728; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	64	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4244	4250		10.1074/jbc.275.6.4244	http://dx.doi.org/10.1074/jbc.275.6.4244			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660591	hybrid			2022-12-25	WOS:000085288800075
J	Hauser, M; Donhardt, AM; Barnes, D; Naider, F; Becker, JM				Hauser, M; Donhardt, AM; Barnes, D; Naider, F; Becker, JM			Enkephalins are transported by a novel eukaryotic peptide uptake system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; CENTRAL-NERVOUS-SYSTEM; SACCHAROMYCES-CEREVISIAE; YEAST; <D-PENICILLAMINE(2,5)>ENKEPHALIN; FAMILY; GENE	We have identified an oligopeptide transporter in the yeast Saccharomyces cerevisiae which mediates the uptake of tetra- and pentapeptides, including the endogenous opioids leucine enkephalin (Tyr-Gly-Gly-Phe-Leu) and methionine enkephalin (Tyr-Gly-Gly-Phe-Met). The transporter is encoded by the gene OPT1. Yeast expressing OPT1 can utilize enkephalins to satisfy amino acid auxotrophic requirements for growth. The transport of radiolabeled leucine enkephalin exhibits saturable kinetics, with a K-m of 310 mu M. Transport activity is optimum at acidic pH and sensitive to reagents which uncouple oxidative phosphorylation, suggesting an energy dependence on the proton gradient. Growth, transport, and chromatographic data indicate that leucine enkephalin is not hydrolyzed in the extracellular medium and as such is translocated intact across the cell membrane. The system is specific for tetra- and pentapeptides and can be inhibited by the opioid receptor antagonists naloxone and naltrexone. To date, this is the first example of a eukaryotic transport system which can use enkephalins as a substrate, opening the possibility that a homologue exists in higher eukaryotes.	Univ Tennessee, Dept Microbiol & Biochem Mol & Cellular Biol, Knoxville, TN 37996 USA; CUNY Coll Staten Isl, Dept Chem, Staten Isl, NY 10314 USA	University of Tennessee System; University of Tennessee Knoxville; City University of New York (CUNY) System; College of Staten Island (CUNY)	Becker, JM (corresponding author), Univ Tennessee, Dept Microbiol, M409 Walters Life Sci, Knoxville, TN 37996 USA.	jbecker@utk.edu			NIGMS NIH HHS [GM22087, GM22086] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM022086, R01GM022087, R56GM022087, R01GM022086] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKS WA, 1986, AM J PHYSIOL, V251, pE477, DOI 10.1152/ajpendo.1986.251.4.E477; Banks WA, 1997, ALCOHOL, V14, P237, DOI 10.1016/S0741-8329(96)00148-6; BANKS WA, 1990, AM J PHYSIOL, V259, pE1, DOI 10.1152/ajpendo.1990.259.1.E1; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BECKER JM, 1977, ARCH BIOCHEM BIOPHYS, V178, P245, DOI 10.1016/0003-9861(77)90189-8; BECKER JM, 1995, PEPTIDE BASED DRUG D, P369; Blakely RD, 1998, BIOL PSYCHIAT, V44, P169, DOI 10.1016/S0006-3223(98)00124-3; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; Brachmann CB, 1998, YEAST, V14, P115; Chen CP, 1997, J PHARMACOL EXP THER, V283, P1151; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Egleton RD, 1999, J PHARM SCI-US, V88, P392, DOI 10.1021/js980410+; Egleton RD, 1998, J PHARM SCI-US, V87, P1433, DOI 10.1021/js980062b; Fei YJ, 1998, PROG NUCLEIC ACID RE, V58, P239; Fiori A, 1997, P NATL ACAD SCI USA, V94, P9469, DOI 10.1073/pnas.94.17.9469; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; HAGTING A, 1994, J BIOL CHEM, V269, P11391; Lubkowitz MA, 1998, MOL MICROBIOL, V28, P729, DOI 10.1046/j.1365-2958.1998.00827.x; Lubkowitz MA, 1997, MICROBIOL-UK, V143, P387, DOI 10.1099/00221287-143-2-387; MCNICHOLAS LF, 1984, DRUGS, V27, P81, DOI 10.2165/00003495-198427010-00004; Plotkin SR, 1997, J NEUROSCI RES, V48, P273; Roman G, 1998, AM J PHYSIOL-CELL PH, V275, pC857, DOI 10.1152/ajpcell.1998.275.3.C857; SLOKOVIC BV, 1989, J NEUROCHEM, V53, P1333; STEINER HY, 1995, MOL MICROBIOL, V16, P825, DOI 10.1111/j.1365-2958.1995.tb02310.x; Thomas SA, 1997, J PHARMACOL EXP THER, V280, P1235; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Williams SA, 1996, J NEUROCHEM, V66, P1289	28	66	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3037	3041		10.1074/jbc.275.5.3037	http://dx.doi.org/10.1074/jbc.275.5.3037			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652283	hybrid			2022-12-25	WOS:000085146500005
J	Dupont, G; Tordjmann, T; Clair, C; Swillens, S; Claret, M; Combettes, L				Dupont, G; Tordjmann, T; Clair, C; Swillens, S; Claret, M; Combettes, L			Mechanism of receptor-oriented intercellular calcium wave propagation in hepatocytes	FASEB JOURNAL			English	Article						liver; phase wave; gap junctions; inositol 1,4,5-triphosphate	REGULATORY CA2+-BINDING SITES; INOSITOL 1,4,5-TRISPHOSPHATE; RAT HEPATOCYTES; CA2+ WAVES; PERMEATION PATHWAY; GAP-JUNCTIONS; OSCILLATIONS; MODEL; CELLS; LIVER	Intercellular calcium signals are propagated in multicellular hepatocyte systems as well as in the intact liver, The stimulation of connected hepatocytes by glycogenolytic agonists induces reproducible sequences of intracellular calcium concentration increases, resulting in unidirectional intercellular calcium waves. Hepatocytes are characterized by a gradient of vasopressin binding sites from the periportal to perivenous areas of the cell plate in hepatic lobules, Also, coordination of calcium signals between neighboring cells requires the presence of the agonist at each cell surface as well as gap junction permeability, We present a model based on the junctional coupling of several hepatocytes differing in sensitivity to the agonist and thus in the intrinsic period of calcium oscillations. In this model, each hepatocyte displays repetitive calcium spikes with a slight phase shift with respect to neighboring cells, giving rise to a phase wave. The orientation of the apparent calcium wave is imposed by the direction of the gradient of hormonal sensitivity. Calcium spikes are coordinated by the diffusion across junctions of small amounts of inositol 1,4,5-trisphosphate (InsP(3)), Theoretical predictions from this model are confirmed experimentally. Thus, major physiological insights may be gained from this model for coordination and spatial orientation of intercellular signals.	Univ Paris 11, Unite Rech U442, Inst Natl Rech Sci Sante, F-91405 Orsay, France; Free Univ Brussels, Fac Sci CP231, B-1050 Brussels, Belgium; Free Univ Brussels, IRIBHN, Fac Med, B-1050 Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Combettes, L (corresponding author), Univ Paris 11, Unite Rech U442, Inst Natl Rech Sci Sante, Ba 443, F-91405 Orsay, France.	laurent.combettes@ibaic.u-psud.fr	Tordjmann, Thierry/K-4706-2013; Combettes, Laurent/L-1842-2013	Combettes, Laurent/0000-0002-1376-4574				ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bird GSJ, 1997, CELL CALCIUM, V21, P253, DOI 10.1016/S0143-4160(97)90049-X; Charles AC, 1996, MOL CELL NEUROSCI, V7, P337, DOI 10.1006/mcne.1996.0025; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; COMBETTES L, 1994, BIOCHEM J, V304, P585, DOI 10.1042/bj3040585; DAndrea P, 1997, FEBS LETT, V400, P58, DOI 10.1016/S0014-5793(96)01356-7; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; Dufour JF, 1997, J BIOL CHEM, V272, P2675, DOI 10.1074/jbc.272.5.2675; Dupont G, 1997, CELL CALCIUM, V22, P321, DOI 10.1016/S0143-4160(97)90017-8; Dupont G, 1996, BIOPHYS J, V71, P1714, DOI 10.1016/S0006-3495(96)79373-6; GAUTAM A, 1987, HEPATOLOGY, V7, P216, DOI 10.1002/hep.1840070203; Goldbeter A., 1996, BIOCH OSCILLATIONS C; HANSEN M, 1993, J CELL SCI, V106, P995; HANSEN M, 1995, J CELL SCI, V108, P2583; JAFRI MS, 1994, P NATL ACAD SCI USA, V91, P9485, DOI 10.1073/pnas.91.20.9485; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; Keener J., 1999, MATH PHYSL; Lindqvist SM, 1998, GASTROENTEROLOGY, V115, P1131, DOI 10.1016/S0016-5085(98)70084-8; LOESSBERG PA, 1993, J BIOL CHEM, V268, P19769; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MOTTA PM, 1988, BIOPATHOLOGY LIVER U; Murray J. D., 1989, MATH BIOL, DOI DOI 10.1007/978-3-662-08539-4; Nathanson M H, 1996, Prog Liver Dis, V14, P1; NATHANSON MH, 1995, AM J PHYSIOL-GASTR L, V269, pG167, DOI 10.1152/ajpgi.1995.269.1.G167; NATHANSON MH, 1992, MOL BIOL CELL, V3, P113, DOI 10.1091/mbc.3.1.113; OSTROWSKI NL, 1993, ENDOCRINOLOGY, V133, P1849, DOI 10.1210/en.133.4.1849; RENARD D, 1987, BIOCHEM J, V243, P391, DOI 10.1042/bj2430391; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; Sanderson MJ, 1996, NEWS PHYSIOL SCI, V11, P262, DOI 10.1152/physiologyonline.1996.11.6.262; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; Sneyd J, 1998, BIOPHYS CHEM, V72, P101, DOI 10.1016/S0301-4622(98)00126-4; SNEYD J, 1995, AM J PHYSIOL-CELL PH, V268, pC1537, DOI 10.1152/ajpcell.1995.268.6.C1537; Spray David C., 1994, P951; SWILLENS S, 1994, P NATL ACAD SCI USA, V91, P10074, DOI 10.1073/pnas.91.21.10074; Tang YH, 1996, BIOPHYS J, V70, P246, DOI 10.1016/S0006-3495(96)79567-X; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Tordjmann T, 1998, EMBO J, V17, P4695, DOI 10.1093/emboj/17.16.4695; Tordjmann T, 1997, EMBO J, V16, P5398, DOI 10.1093/emboj/16.17.5398; Tordjmann T, 1996, GASTROENTEROLOGY, V111, P1343, DOI 10.1053/gast.1996.v111.pm8898649; Venance L, 1997, J NEUROSCI, V17, P1981; Wilkins M, 1998, J THEOR BIOL, V191, P299, DOI 10.1006/jtbi.1997.0585; Yule DI, 1996, AM J PHYSIOL-CELL PH, V271, pC1285, DOI 10.1152/ajpcell.1996.271.4.C1285	45	72	76	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					279	289		10.1096/fasebj.14.2.279	http://dx.doi.org/10.1096/fasebj.14.2.279			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657984				2022-12-25	WOS:000085184800007
J	Graff, JR; Gabrielson, E; Fujii, H; Baylin, SB; Herman, JG				Graff, JR; Gabrielson, E; Fujii, H; Baylin, SB; Herman, JG			Methylation patterns of the E-cadherin 5 ' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVASION-SUPPRESSOR FUNCTION; CARCINOMA IN-SITU; CANCER CELL-LINES; BREAST-CANCER; CHROMATIN STRUCTURE; DNA METHYLATION; TRANSCRIPTION FACTORS; TUMOR-CELLS; NUDE-MICE; GENE	Metastatic progression of most common epithelial tumors involves a heterogeneous, transient loss of expression of the homotypic cell adhesion protein, E-cadherin, rather than the uniform loss of a functional protein resulting from coding region mutation. Indeed, whereas E-cadherin loss may promote invasion, reexpression may facilitate cell survival within metastatic deposits. The mechanisms underlying such plasticity are unclear. We now show that the heterogeneous loss of E-cadherin expression in primary human breast cancers reflects a heterogeneous pattern of promoter region methylation, which begins early prior to invasion. In cultured human tumor cells, such heterogeneous methylation is dynamic, varying from allele to allele and shifting in relation to the tumor microenvironment. Following invasion in vitro which favors diminished E-cadherin expression, the density of promoter methylation markedly increased. When these cells were cultured as spheroids, which requires homotypic cell adhesion, promoter methylation decreased dramatically, and E-cadherin was reexpressed, These data show that the methylation associated with E-cadherin loss in human breast cancer is heterogeneous and unstable and suggest that such epigenetic plasticity may contribute to the dynamic, phenotypic heterogeneity that drives metastatic progression.	Johns Hopkins Univ, Ctr Comprehens Canc, Baltimore, MD 21231 USA; Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University	Graff, JR (corresponding author), Eli Lilly & Co, Lilly Res Labs, Lilly Corp Ctr, Drop Code 0546, Indianapolis, IN 46285 USA.	graff_jeremy@lilly.com						Bachman KE, 1999, CANCER RES, V59, P798; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Baylin SB, 1998, ADV CANCER RES, V72, P141; BECKER KF, 1994, CANCER RES, V54, P3845; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BOGHAERT ER, 1991, INT J CANCER, V47, P610, DOI 10.1002/ijc.2910470422; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; Fujii H, 1996, CANCER RES, V56, P5260; Graff JR, 1998, CANCER RES, V58, P2063; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; HEPPNER GH, 1984, CANCER RES, V44, P2259; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ingram M, 1997, IN VITRO CELL DEV-AN, V33, P459; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Jones PA, 1996, CANCER RES, V56, P2463; Kanai Y, 1997, INT J CANCER, V71, P355; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Lapidus RG, 1998, CANCER RES, V58, P2515; LING V, 1984, J CELL PHYSIOL, P99; Liteplo R G, 1985, Basic Life Sci, V33, P285; MAREEL M, 1995, CANCER DETECT PREV, V19, P451; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; Matsuo K, 1998, EMBO J, V17, P1446, DOI 10.1093/emboj/17.5.1446; MOLL R, 1993, AM J PATHOL, V143, P1731; NICOLSON GL, 1987, CANCER RES, V47, P1473; OKA H, 1993, CANCER RES, V53, P1696; PASSANITI A, 1992, INT J CANCER, V51, P318, DOI 10.1002/ijc.2910510224; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; St Croix Brad, 1997, Current Opinion in Oncology, V9, P549; StCroix B, 1996, NAT MED, V2, P1204; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TALMADGE JE, 1982, SCIENCE, V217, P361, DOI 10.1126/science.6953592; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; VANDENBOSSCHE GMR, 1994, INT J CANCER, V57, P73, DOI 10.1002/ijc.2910570114; VandenBroecke C, 1996, CLIN EXP METASTAS, V14, P282, DOI 10.1007/BF00053902; Vermeulen S, 1996, PATHOL RES PRACT, V192, P694, DOI 10.1016/S0344-0338(96)80091-4; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Vos CBJ, 1997, BRIT J CANCER, V76, P1131, DOI 10.1038/bjc.1997.523; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	55	306	321	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2727	2732		10.1074/jbc.275.4.2727	http://dx.doi.org/10.1074/jbc.275.4.2727			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644736	hybrid			2022-12-25	WOS:000085128000068
J	Zhou, TH; Ling, K; Guo, J; Zhou, H; Wu, YL; Jing, Q; Ma, L; Pei, G				Zhou, TH; Ling, K; Guo, J; Zhou, H; Wu, YL; Jing, Q; Ma, L; Pei, G			Identification of a human brain-specific isoform of mammalian STE20-like kinase 3 that is regulated by cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL CENTER KINASE; BETA-GAMMA-SUBUNITS; N-TERMINAL KINASE; OPIOID RECEPTOR; MAP KINASE; PATHWAY; ACTIVATION; FAMILY; CLONING; CASCADE	A novel isoform of mammalian STE20-like kinase 3 (MST3) with a different 5' coding region from MST3, termed MST3b, was identified by searching through expressed sequence tag data base and obtained by rapid amplification of cDNA 5'-ends, MST3b was assigned to the long arm of human chromosome 13, D13S159-D13S280, by use of the National Center for Biotechnology Information sequence-tagged sites data base. Reverse transcription-polymerase chain reaction and Northern blot analysis with a probe derived from 5' distinct sequence of MST3b revealed that the expression of MST3b mRNA is restricted to the brain, in contrast to ubiquitous distribution of MST3 transcript. Western analysis confirmed the brain-specific expression of MST3b protein. In situ hybridization of rat brain sections with a MST3b-specific probe indicated that MST3b is widely expressed in different brain regions, with especially high expression in hippocampus and cerebral cortex. When expressed in human embryonic kidney 293 (HEK293) cells, MST3b effectively phosphorylated myelin basic protein, as well as undergoing autophosphorylation, Interestingly, expression of MST3, but not MST3b, in HEK293 cells was able to activate the endogenous p42/44 mitogen-activated protein kinase (MAPK) up to 4-fold, whereas neither isoform activated p38 MAPK under the same conditions. Further experiments demonstrated that MST3b, but not MST3, was effectively phosphorylated by activation of cyclic AMP-dependent protein kinase (PKA) in both in vivo and in vitro assays. The mutation of Thr-18 into Ala in MST3b (T18A), a putative PHA phosphorylation site that is absent in MST3, abolished its phosphorylation by PKA, Consequently, expression of the T18A mutant in HEK293 cells led to partial activation of p42/44 MAPK, indicating that MST3b is under the regulation of PKA, Taken together, our data provide evidence that the two isoforms of STE20-like kinase 3 are differentially distributed and regulated.	Chinese Acad Sci, Shanghai Inst Cell Biol, Shanghai 200031, Peoples R China; Shanghai Med Univ, Natl Lab Med Neurobiol, Shanghai 200032, Peoples R China; Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University	Pei, G (corresponding author), Chinese Acad Sci, Shanghai Inst Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	gangpei@sunm.shcnc.ac.cn	zhou, tianhua/K-4908-2013; Ma, Lan/B-9295-2009	zhou, tianhua/0000-0002-1791-2124; Ma, Lan/0000-0001-9034-5472				Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BOGUSKI MS, 1994, SCIENCE, V265, P1993, DOI 10.1126/science.8091218; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Cayanis E, 1998, GENOMICS, V47, P26, DOI 10.1006/geno.1997.5087; Cheng ZJ, 1998, J BIOL CHEM, V273, P24328, DOI 10.1074/jbc.273.38.24328; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; FAURE M, 1994, J BIOL CHEM, V269, P7851; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; GRANT AL, 1997, MOL BIOL NEURON, P67; Guthrie CR, 1997, J BIOL CHEM, V272, P29560, DOI 10.1074/jbc.272.47.29560; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Jing Q, 1999, CIRC RES, V84, P831; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lou LG, 1999, MOL PHARMACOL, V55, P557; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEI G, 1995, MOL PHARMACOL, V48, P173; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Schuler GD, 1997, GENOME RES, V7, P541, DOI 10.1101/gr.7.5.541; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118	51	38	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2513	2519		10.1074/jbc.275.4.2513	http://dx.doi.org/10.1074/jbc.275.4.2513			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644707	hybrid			2022-12-25	WOS:000085128000039
J	Fuglsang, CC; Berka, RM; Wahleithner, JA; Kauppinen, S; Shuster, JR; Rasmussen, G; Halkier, T; Dalboge, H; Henrissat, B				Fuglsang, CC; Berka, RM; Wahleithner, JA; Kauppinen, S; Shuster, JR; Rasmussen, G; Halkier, T; Dalboge, H; Henrissat, B			Biochemical analysis of recombinant fungal mutanases - A new family of alpha 1,3-glucanases with novel carbohydrate-binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BASED CLASSIFICATION; GLYCOSYL HYDROLASES; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-ORYZAE; EXPRESSION; ACID; GENE; CLONING; PURIFICATION; SIMILARITIES	Nucleotide sequence analysis shows that Trichoderma harzianum and Penicillium purpurogenum alpha 1,3-glucanases (mutanases) have homologous primary structures (53% amino acid sequence identity), and are composed of two distinct domains: a NH2-terminal catalytic domain and a putative COOH-terminal polysaccharide-binding domain separated by a O-glycosylated Pro-Ser-Thr-rich linker peptide. Each mutanase was expressed in Aspergillus oryzae host under the transcriptional control of a strong cu-amylase gene promoter. The purified recombinant mutanases show a pH optimum in the range from pH 3.5 to 4.5 and a temperature optimum around 50-55 degrees C at pH 5.5. Also, they exhibit strong binding to insoluble mutan with K-D around 0.11 and 0.13 mu M at pH 7 for the P. purpurogenum and T. harzianum mutanases, respectively. Partial hydrolysis showed that the COOH-terminal domain of the T. harzianum mutanase binds to mutan, The catalytic domains and the binding domains were assigned to a new family of glycoside hydrolases and to a new family of carbohydrate-binding domains, respectively.	Novo Nordisk AS, Novo Allee, DK-2880 Bagsvaerd, Denmark; Novo Nordisk Biotech Inc, Davis, CA 95616 USA; CNRS, INF1, F-13402 Marseille, France	Novo Nordisk; Novo Nordisk; Centre National de la Recherche Scientifique (CNRS)	Fuglsang, CC (corresponding author), Novo Nordisk AS, Novo Allee, DK-2880 Bagsvaerd, Denmark.	ccf@novo.dk	Henrissat, Bernard/J-2475-2012	Henrissat, Bernard/0000-0002-3434-8588				AIZO M, 1992, Patent No. 1992058889; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Berka RM, 1998, APPL ENVIRON MICROB, V64, P4423; Berka RM, 1997, APPL ENVIRON MICROB, V63, P3151, DOI 10.1128/AEM.63.8.3151-3157.1997; BOEL E, 1984, EMBO J, V3, P1097, DOI 10.1002/j.1460-2075.1984.tb01935.x; BOTHWELL MK, 1995, BIORESOURCE TECHNOL, V53, P21, DOI 10.1016/0960-8524(95)00046-H; BRODY H, 1998, Patent No. 9811203; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTENSEN T, 1988, BIO-TECHNOL, V6, P1419, DOI 10.1038/nbt1288-1419; COUTINHO PM, 1994, PROTEIN ENG, V7, P393, DOI 10.1093/protein/7.3.393; DALESSIO JM, 1992, FOCUS, V14, P76; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davis R., 1980, ADV BACTERIAL GENETI; Draborg H, 1995, BIOCHEM MOL BIOL INT, V36, P781; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEBLER J, 1992, J BIOL CHEM, V267, P12559; GIESECKE H, 1992, J VIROL METHODS, V38, P47, DOI 10.1016/0166-0934(92)90168-D; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GINSBURG I, 1982, MICROBIOLOGY, P292; GUGGENHEIM B, 1972, J DENT RES, V51, P394, DOI 10.1177/00220345720510022701; GUGGENHEIM B, 1970, Helvetica Odontologica Acta, V14, P89; GUGGENHEIM B, 1980, CARIES RES, V14, P128, DOI 10.1159/000260447; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; HAMADA S, 1980, MICROBIOL REV, V44, P331, DOI 10.1128/MMBR.44.2.331-384.1980; HASEGAWA S, 1969, J BIOL CHEM, V244, P5460; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KELSTRUP J, 1978, SCAND J DENT RES, V86, P93; KOFOD LV, 1994, J BIOL CHEM, V269, P29182; Matsuda S, 1997, J FERMENT BIOENG, V83, P593, DOI 10.1016/S0922-338X(97)81143-9; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; OPPERMANN RV, 1979, SCAND J DENT RES, V87, P302; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIGGAARDANDERSEN M, 1991, P NATL ACAD SCI USA, V88, P4114, DOI 10.1073/pnas.88.10.4114; Straubinger B., 1992, FUNGAL GENET NEWSLET, V39, P82; TAKEHARA T, 1981, J BACTERIOL, V145, P729, DOI 10.1128/JB.145.2.729-735.1981; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; Tsuchiya R, 1998, J DENT RES, V77, P971; VANARSDELL JN, 1987, BIO-TECHNOL, V5, P60, DOI 10.1038/nbt0187-60; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Warren RAJ, 1996, ANNU REV MICROBIOL, V50, P183, DOI 10.1146/annurev.micro.50.1.183	46	59	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2009	2018		10.1074/jbc.275.3.2009	http://dx.doi.org/10.1074/jbc.275.3.2009			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636904	hybrid			2022-12-25	WOS:000084940000067
J	Sandy, P; Gostissa, M; Fogal, V; De Cecco, L; Szalay, K; Rooney, RJ; Schneider, C; Del Sal, G				Sandy, P; Gostissa, M; Fogal, V; De Cecco, L; Szalay, K; Rooney, RJ; Schneider, C; Del Sal, G			p53 is involved in the p120E4F-mediated growth arrest	ONCOGENE			English	Article						E4F; p53; growth suppression; transcriptional repression	TRANSCRIPTION FACTOR E4F; DNA-BINDING ACTIVITY; WILD-TYPE P53; NUCLEAR-LOCALIZATION; PROTEIN; IDENTIFICATION; CELLS; GENE; MODULATION; EXPRESSION	Control of cell growth and division by the p53 tumor suppressor protein requires its abilities to transactivate and repress specific target genes and to associate in complex with other proteins. Here we demonstrate that p53 binds to the E1A-regulated transcription factor p120E4F, a transcriptional repressor of the adenovirus E4 promoter. The interaction involves carboxy-terminal half of p120E4F and sequences located at the end of the sequence-specific DNA-binding domain of p53, Ectopic expression of p120E4F leads to a block of cell proliferation in several human and murine cell lines and this effect requires the association with wild-type (wt) p53, Although p120E4F can also bind to mutant p53, the growth suppression induced by overexpression of the protein is severely reduced in a cell line that contains mutant p53. These data suggest that p120E4F may represent an important element within the complex network of p53 checkpoint functions.	Consorzio Interuniv Biotecnol, Lab Nazl, I-34012 Trieste, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34012 Trieste, Italy; Univ Udine, Dipartimento Sci & Technol Biomed, I-33100 Udine, Italy; Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA	University of Trieste; University of Udine; Duke University	Del Sal, G (corresponding author), Consorzio Interuniv Biotecnol, Lab Nazl, Padriciano 99,AREA Sci Pk, I-34012 Trieste, Italy.		De Cecco, Loris/K-7036-2016	De Cecco, Loris/0000-0002-7066-473X; DEL SAL, GIANNINO/0000-0003-2185-6003				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; FOGNANI C, 1993, EMBO J, V12, P1985; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Muller H, 1997, MOL CELL BIOL, V17, P5508; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; PAVIETICH NP, 1993, GENE DEV, V7, P2556; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; Rooney RJ, 1998, MAMM GENOME, V9, P320, DOI 10.1007/s003359900758; Rooney RJ, 1998, NUCLEIC ACIDS RES, V26, P1681, DOI 10.1093/nar/26.7.1681; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Saccone S, 1998, CYTOGENET CELL GENET, V82, P99, DOI 10.1159/000015075; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TARUNINA M, 1993, ONCOGENE, V8, P3165; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	40	39	44	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					188	199		10.1038/sj.onc.1203250	http://dx.doi.org/10.1038/sj.onc.1203250			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644996				2022-12-25	WOS:000084844400003
J	Baasiri, RA; Glasser, SR; Steffen, DL; Wheeler, DA				Baasiri, RA; Glasser, SR; Steffen, DL; Wheeler, DA			The Breast Cancer Gene Database: a collaborative information resource	ONCOGENE			English	Article						electronic publishing; breast cancer; database; information retrieval		The Breast Cancer Gene Database (BCGD) is a compendium of molecular genetic data relating to genes involved in breast cancer, and which is freely available via the World Wide Web. The data in BCGD is extracted from the published biomedical research literature and stored as a collection of 'Facts', which in turn are collected into topical categories organized by gene, This organization facilitates quick searches and rapid retrievals of specific data such as gene characteristics, functions and role in oncogenesis, and is an important factor allowing for continuous updates, BCGD can be searched either by gene name or keyword, Data is deposited and retrieved from the database through a set of interactive Web forms, making it both platform-independent and universally accessible in facilitating worldwide collaborative authoring of the database. Data in BCGD is linked to other on-line resources such as Entrez, GeneCards and On-Line Mendelian Inheritance in Man, BCGD is located at http://mbcr.bcm.tmc.edu/ ermb/bcgd/bcgd.html.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Biomed Comp Inc, Houston, TX 77005 USA	Baylor College of Medicine	Wheeler, DA (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Wheeler, David A/M-9740-2018	Wheeler, David A/0000-0002-9056-6299	NCI NIH HHS [CA70532] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA070532] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; Barker WC, 1999, NUCLEIC ACIDS RES, V27, P39, DOI 10.1093/nar/27.1.39; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; Blake JA, 1999, NUCLEIC ACIDS RES, V27, P95, DOI 10.1093/nar/27.1.95; BUHLE EL, 1994, J AM MED INFORM ASSN, P103; Kuska B, 1996, J NATL CANCER I, V88, P1801, DOI 10.1093/jnci/88.24.1801; OHKAWA H, 1995, ISMB, V3, P259; Rebhan M, 1998, BIOINFORMATICS, V14, P656, DOI 10.1093/bioinformatics/14.8.656; Stoesser G, 1999, NUCLEIC ACIDS RES, V27, P18, DOI 10.1093/nar/27.1.18; Tateno Y, 1997, NUCLEIC ACIDS RES, V25, P14, DOI 10.1093/nar/25.1.14	10	39	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 23	1999	18	56					7958	7965		10.1038/sj.onc.1203335	http://dx.doi.org/10.1038/sj.onc.1203335			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637506				2022-12-25	WOS:000084634600004
J	Muller-Newen, G; Kuster, A; Wijdenes, J; Schaper, F; Heinrich, PC				Muller-Newen, G; Kuster, A; Wijdenes, J; Schaper, F; Heinrich, PC			Studies on the interleukin-6-type cytokine signal transducer gp130 reveal a novel mechanism of receptor activation by monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; COMPLEX; IL-6; EXPRESSION; BINDING; CLONING; ASSOCIATION; FAMILY; SITES; DIMERIZATION	The transmembrane glycoprotein gp130 belongs to the family of hematopoietic cytokine receptors. It represents the common signal transducing receptor component of the so called interleukin-6-type cytokines. For several cytokine receptors including gp130 it has been shown that receptor activation cannot only be achieved by the natural ligand but also by single monoclonal antibodies raised against the receptor ectodomain. These findings have been interpreted in a way that dimerization of cytokine receptors is sufficient for receptor activation, Here we show that the recently described gp130-activating antibody B-S12 actually consists of two different monoclonal antibodies. By subcloning of B-S12 the monoclonal antibodies B-S12-A5 and B-S12-G7 were obtained. The individual antibodies are biologically inactive, in combination they exert B-Sla-like activity on hepatoma cells. On Ba/F3 cells stably transfected with gp130 a combination of B-S12-G7 with another monoclonal gp130 antibody, B-P8, is required to stimulate proliferation. Using gp130 deletion mutants we show that all three antibodies map to domains 2 and 3 of gp130 which constitute the cytokine binding module. The individual antibodies inhibit activation of the signal transducer by interleukin-6 and interfere with binding of interleukin-6 to gp130, Interestingly, the combination of B-S12-G7 and a Fab fragment of B-PS retains biological activity. We conclude from our data that (i) the monoclonal antibodies activate gp130 by mimicking the natural ligand and (ii) enforcement of gp130 dimerization is not sufficient for receptor activation but additional conformational requirements have to be fulfilled.	Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany; DIACLONE, F-25020 Besancon, France	RWTH Aachen University	Muller-Newen, G (corresponding author), Rhein Westfal TH Aachen, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	mueller-newen@RWTH-Aachen.de	Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; Autissier P, 1997, EUR J IMMUNOL, V27, P794, DOI 10.1002/eji.1830270331; Ballinger MD, 1998, NAT STRUCT BIOL, V5, P938, DOI 10.1038/2911; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Fourcin M, 1996, J BIOL CHEM, V271, P11756, DOI 10.1074/jbc.271.20.11756; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Grotzinger J, 1997, PROTEINS, V27, P96; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; HORSTEN U, 1995, FEBS LETT, V360, P43, DOI 10.1016/0014-5793(95)00053-C; Kernebeck T, 1999, PROTEIN SCI, V8, P5; Kurth I, 1999, J IMMUNOL, V162, P1480; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WIJDENES J, 1991, MOL IMMUNOL, V28, P1183, DOI 10.1016/0161-5890(91)90004-4; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YIN TG, 1993, J IMMUNOL, V151, P2555; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	44	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4579	4586		10.1074/jbc.275.7.4579	http://dx.doi.org/10.1074/jbc.275.7.4579			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671483	hybrid			2022-12-25	WOS:000085378200009
J	Hu, QH; Maity, SN				Hu, QH; Maity, SN			Stable expression of a dominant negative mutant of CCAAT binding factor/NF-Y in mouse fibroblast cells resulting in retardation of cell growth and inhibition of transcription of various cellular genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; FACTOR CBF; NF-Y; SUBUNIT INTERACTION; FUNCTIONAL DOMAINS; MAMMALIAN-CELLS; MESSENGER-RNA; HISTONE FOLD; YEAST HAP5; B-SUBUNIT	The heterotrimeric CCAAT-binding factor CBF specifically interacts with the CCAAT motif present in the proximal promoters of numerous mammalian genes. To understand the in vivo function of CBF, a dominant negative mutant of CBF-B subunit that inhibits DNA binding of wild type CBF was stably expressed in mouse fibroblast cells under control of tetracycline-responsive promoter. Expression of the mutant CBF-B but not the wild-type CBF-B resulted in retardation of fibroblast cell growth. The analysis of cell growth using bromode-oxyuridine labeling showed that expression of the mutant CBF-B decreased the number of cells entering into S phase, and also delayed induction of S phase in the quiescent cells after serum stimulation, thus indicating that the inhibition of CBF binding prolonged the progression of S phase in fibroblasts. These results provide direct evidence for the first time that CBF is an important regulator of fibroblast growth. The inhibition of CBF binding reduced expression of various cellular genes including the alpha 2(1) collagen, E2F1, and topoisomerase II alpha genes which promoters contain the CEF-binding site. This result implied that expression of many other genes which promoters contain CBF-binding site was also decreased by the inhibition of CBF binding, and that the decreased expression of multiple cellular genes possibly caused the retardation of fibroblast cell growth.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Maity, SN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Maity, Sankar/0000-0002-2387-6545	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043660] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NIAMS NIH HHS [AR43660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI N, 1992, NUCLEIC ACIDS RES, V20, P5297, DOI 10.1093/nar/20.20.5297; Adachi N, 1997, BIOCHEM BIOPH RES CO, V230, P105, DOI 10.1006/bbrc.1996.5893; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen HX, 1998, GENETICS, V148, P123; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hasegawa T, 1996, NUCLEIC ACIDS RES, V24, P3253, DOI 10.1093/nar/24.16.3253; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Kim IS, 1996, MOL CELL BIOL, V16, P4003; LALANNE JL, 1987, NUCLEIC ACIDS RES, V15, P4990, DOI 10.1093/nar/15.12.4990; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liang SG, 1998, J BIOL CHEM, V273, P31590, DOI 10.1074/jbc.273.47.31590; Lotan T, 1998, CELL, V93, P1195, DOI 10.1016/S0092-8674(00)81463-4; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P8286; Maity SN, 1996, METHOD ENZYMOL, V273, P217; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MAITY SN, 1998, TRENDS BIOCHEM SCI, V18, P459; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; McNabb DS, 1997, MOL CELL BIOL, V17, P7008, DOI 10.1128/MCB.17.12.7008; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; Niederreither K, 1995, MATRIX BIOL, V14, P705, DOI 10.1016/S0945-053X(05)80013-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; TATE EH, 1983, CYTOMETRY, V4, P211, DOI 10.1002/cyto.990040304; TULCHINSKY EM, 1990, GENE, V87, P219, DOI 10.1016/0378-1119(90)90305-B; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	45	61	63	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4435	4444		10.1074/jbc.275.6.4435	http://dx.doi.org/10.1074/jbc.275.6.4435			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660616	hybrid			2022-12-25	WOS:000085288800100
J	Jakubowski, H				Jakubowski, H			Calcium-dependent human serum homocysteine thiolactone hydrolase - A protective mechanism against protein N-homocysteinylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AMINO-ACIDS; PROOFREADING INVIVO; ESCHERICHIA-COLI; PARAOXONASE; PLASMA; LIPOPROTEINS; SELECTION; FAILURE; HEART	Homocysteine thiolactone is formed in all cell types studied thus far as a result of editing reactions of some aminoacyl-tRNA synthetases. Because inadvertent reactions of thiolactone with proteins are potentially harmful, the ability to detoxify homocysteine thiolactone is essential for biological integrity. This work shows that a single specific enzyme, present in mammalian but not in avian sera, hydrolyzes thiolactone to homocysteine. Human serum thiolactonase, a 45-kDa protein component of high density lipoprotein, requires calcium for activity and stability and is inhibited by isoleucine and penicillamine, Substrate specificity studies suggest that homocysteine thiolactone is a likely natural substrate of this enzyme. However, thiolactonase also hydrolyzes nonnatural substrates, such as phenyl acetate, p-nitrophenyl acetate, and the organophospate paraoxon, N-terminal amino acid sequence of pure thiolactonase is identical with that of human paraoxonase. These and other data indicate that paraoxonase, an organophosphate-detoxifying enzyme whose natural substrate and function remained unknown up to now, is in fact homocysteine thiolactonase. By detoxifying homocysteine thiolactone, the thiolactonase/paraoxonase would protect proteins against homocysteinylation, a potential contributing factor to atherosclerosis.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave, Newark, NJ 07103 USA.		Jakubowski, Hieronim/AAA-6834-2019; Jakubowski, Hieronim/A-2510-2017	Jakubowski, Hieronim/0000-0001-5845-4409				ANDERSON RF, 1974, INT J RADIAT PHYS CH, V6, P33, DOI 10.1016/0020-7055(74)90033-3; Baernstein HD, 1934, J BIOL CHEM, V106, P451; BURSTEIN M, 1970, J LIPID RES, V11, P583; DONAHUE S, 1974, AM J PATHOL, V77, P167; DUDMAN NPB, 1991, ARTERIOSCLER THROMB, V11, P663, DOI 10.1161/01.ATV.11.3.663; Ferguson E, 1998, J LIPID RES, V39, P925; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1250, DOI 10.1021/bi00574a021; GAN KN, 1991, DRUG METAB DISPOS, V19, P100; Gardemann A, 1999, EUR HEART J, V20, P584, DOI 10.1053/euhj.1998.1340; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; HASSETT C, 1991, BIOCHEMISTRY-US, V30, P10141, DOI 10.1021/bi00106a010; Heinecke JW, 1998, AM J HUM GENET, V62, P20, DOI 10.1086/301691; Jakubowski H, 1996, BIOCHEMISTRY-US, V35, P8252, DOI 10.1021/bi960344v; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 1999, BIOCHEMISTRY-US, V38, P8088, DOI 10.1021/bi990629i; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1995, J BIOL CHEM, V270, P17672, DOI 10.1074/jbc.270.30.17672; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1990, P NATL ACAD SCI USA, V87, P4504, DOI 10.1073/pnas.87.12.4504; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Jakubowski H, 1997, BIOCHEMISTRY-US, V36, P11077, DOI 10.1021/bi970589n; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; JAKUBOWSKI H, 2000, HOMOCYSTEINE HLTH DI; JAKUBOWSKI H, 2000, IN PRESS ENCY LIFE S; JAKUBOWSKI H, 1993, FEBS LETT, V317, P593; Liu GM, 1997, J BIOL CHEM, V272, P32370, DOI 10.1074/jbc.272.51.32370; Mackness B, 1998, GEN PHARMACOL-VASC S, V31, P329, DOI 10.1016/S0306-3623(98)00028-7; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; MUDD SH, 1989, RES COMMUN CHEM PATH, V63, P297; Rosenquist TH, 1996, P NATL ACAD SCI USA, V93, P15227, DOI 10.1073/pnas.93.26.15227; RUDEL LL, 1974, BIOCHEM J, V139, P89, DOI 10.1042/bj1390089; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; SKOVBY F, 1984, J BIOL CHEM, V259, P588; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; VANAERTES LA, 1993, TOXICOL IN VITRO, V6, P743	36	327	337	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3957	3962		10.1074/jbc.275.6.3957	http://dx.doi.org/10.1074/jbc.275.6.3957			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660550	hybrid			2022-12-25	WOS:000085288800034
J	Mousseau, DD; Banville, D; L'Abbe, D; Bouchard, P; Shen, SH				Mousseau, DD; Banville, D; L'Abbe, D; Bouchard, P; Shen, SH			PILR alpha, a novel immunoreceptor tyrosine-based inhibitory motif-bearing protein, recruits SHP-1 upon tyrosine phosphorylation and is paired with the truncated counterpart PILR beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PROTEIN; HEMATOPOIETIC-CELLS; PHOSPHATASE PTP1C; SH2 DOMAINS; RECEPTOR; ACTIVATION; ASSOCIATION; BINDING; GENE; MACROPHAGES	SHP-1-mediated dephosphorylation of protein tyrosine residues is central to the regulation of several cell signaling pathways, the specificity of which is dictated by the intrinsic affinity of SH2 domains for the flanking sequences of phosphotyrosine residues. By using a modified yeast two-hybrid system and SHP-1 as bait, we have cloned a human cDNA, PILR alpha, encoding a 303-amino acid immunoglobulin-like transmembrane receptor bearing two cytoplasmic tyrosines positioned within an immunoreceptor tyrosine-based inhibitory motif, Substrate trapping in combination with pervanadate treatment of 293T cells confirms that PILR alpha associates with SHP-1 in vivo upon tyrosine phosphorylation. Mutation of the tyrosine residues in PILR alpha indicates the pivotal role of the Tyr-269 residue in recruiting SHP-1; Surface plasmon resonance analysis further suggests that the association between PILR alpha-Tyr-269 and SHP-1 is mediated primarily via the amino-terminal SH2 domain of the latter. Polymerase chain reaction amplification of cDNA in combination with genomic sequence analysis revealed a second gene, PILR beta, coding for a putative activating receptor as suggested by a truncated cytoplasmic tail and a charged lysine residue in its transmembrane region. The PILR alpha and PILR beta genes are localized to chromosome 7 which is in contrast with the mapping of known members of the inhibitory receptor superfamil.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada	National Research Council Canada; McGill University	Shen, SH (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.							Adachi M, 1996, CELL, V85, P15; Berg KL, 1998, ONCOGENE, V17, P2535, DOI 10.1038/sj.onc.1202203; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; Bruhns P, 1999, J IMMUNOL, V162, P3168; Burshtyn DN, 1997, TRENDS CELL BIOL, V7, P473, DOI 10.1016/S0962-8924(97)01167-7; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Burshtyn DN, 1999, J IMMUNOL, V162, P897; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Keegan K, 1996, ONCOGENE, V12, P1537; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; Kuroiwa A, 1998, J BIOL CHEM, V273, P1070, DOI 10.1074/jbc.273.2.1070; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; Olcese L, 1996, J IMMUNOL, V156, P4531; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tangye SG, 1999, J IMMUNOL, V162, P6981; Taylor LS, 1999, BLOOD, V94, P1790, DOI 10.1182/blood.V94.5.1790.417k16_1790_1796; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vely F, 1997, J IMMUNOL, V159, P2075; Vely F, 1997, EUR J IMMUNOL, V27, P3010, DOI 10.1002/eji.1830271138; Wagtmann N, 1995, IMMUNITY, V3, P801, DOI 10.1016/1074-7613(95)90069-1; Wang LL, 1999, J IMMUNOL, V162, P1318; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687	40	78	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4467	4474		10.1074/jbc.275.6.4467	http://dx.doi.org/10.1074/jbc.275.6.4467			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660620	hybrid			2022-12-25	WOS:000085288800104
J	Nolan, DP; Jackson, DG; Biggs, MJ; Brabazon, ED; Pays, A; Van Laethem, F; Paturiaux-Hanocq, F; Elliot, JF; Voorheis, HP; Pays, E				Nolan, DP; Jackson, DG; Biggs, MJ; Brabazon, ED; Pays, A; Van Laethem, F; Paturiaux-Hanocq, F; Elliot, JF; Voorheis, HP; Pays, E			Characterization of a novel alanine-rich protein located in surface microdomains in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; BLOOD-STREAM FORMS; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; ACIDIC REPETITIVE PROTEIN; AFRICAN TRYPANOSOMES; CELL-SURFACE; TRANSFERRIN RECEPTOR; SECONDARY STRUCTURE; PROCYCLIC FORMS; CROSS-LINKING	Heterologous expression in COS cells followed by orientation-specific polymerase chain reaction to select and amplify cDNAs encoding surface proteins in Trypanosoma brucei resulted in the isolation of a cDNA (similar to 1.4 kilobase) which encodes an acidic, alanine-rich polypeptide that is expressed only in bloodstream forms of the parasite and has been termed bloodstream stage alanine-rich protein (BARP). Analysis of the amino acid sequence predicted the presence of a typical NH2-terminal leader sequence as well as a COOH-terminal hydrophobic extension with the potential to be replaced by a glycosylphosphatidylinositol anchor. A search of existing protein sequences revealed partial homology between BARP and the major surface antigen of procyclic forms of Trypanosoma congolense. BARP migrated as a complex, heterogeneous series of bands on Western blots with an apparent molecular mass (similar to 50-70 kDa) significantly higher than predicted from the amino acid sequence (similar to 26 kDa). Confocal microscopy demonstrated that BARP was present in small discrete spots that were distributed over the entire cellular surface. Detergent extraction experiments revealed that BARP was recovered in the detergent-insoluble, glycolipid-enriched fraction. These data suggested that BARP may be sequestered in Lipid rafts.	Free Univ Brussels, Mol Parasitol Lab, Inst Mol Biol & Med, B-6041 Gosselies, Belgium; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England; Univ Alberta, Dept Med Microbiol & Infect Dis, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Immunol, Edmonton, AB T6G 2H7, Canada; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland	University of Oxford; University of Alberta; University of Alberta; Trinity College Dublin	Nolan, DP (corresponding author), Free Univ Brussels, Mol Parasitol Lab, Inst Mol Biol & Med, 12 Rue Prof Jeener & Brachet, B-6041 Gosselies, Belgium.	dnolan@dbm.ulb.ac.be		, david/0000-0002-4133-9364; Nolan, Derek/0000-0002-3742-4304				BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; Bastin P, 1996, MOL BIOCHEM PARASIT, V76, P43, DOI 10.1016/0166-6851(95)02537-5; BAYNE RAL, 1993, MOL BIOCHEM PARASIT, V61, P295, DOI 10.1016/0166-6851(93)90075-9; BEECROFT RP, 1993, MOL BIOCHEM PARASIT, V61, P285, DOI 10.1016/0166-6851(93)90074-8; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BRINGAUD F, 1993, MOL CELL BIOL, V13, P1146, DOI 10.1128/MCB.13.2.1146; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUN R, 1979, ACTA TROP, V36, P289; Carrington M, 1996, MOL BIOCHEM PARASIT, V81, P119, DOI 10.1016/0166-6851(96)02706-5; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERGUSON MAJ, 1993, BIOCHEM J, V291, P51, DOI 10.1042/bj2910051; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; JACKSON DG, 1993, J BIOL CHEM, V268, P1894; JACKSON DG, 1990, BIOCHEM SOC T, V18, P1032, DOI 10.1042/bst0181032; JACKSON DG, 1993, J BIOL CHEM, V268, P8085; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Kubler E, 1996, J BIOL CHEM, V271, P32975, DOI 10.1074/jbc.271.51.32975; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; Mehlert A, 1998, MOL BIOCHEM PARASIT, V91, P145, DOI 10.1016/S0166-6851(97)00187-4; MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333; Nolan DP, 1997, J BIOL CHEM, V272, P29212, DOI 10.1074/jbc.272.46.29212; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; OVERATH P, 1994, PARASITOL TODAY, V10, P53, DOI 10.1016/0169-4758(94)90393-X; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PaturiauxHanocq F, 1997, BIOCHEM J, V324, P885, DOI 10.1042/bj3240885; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; PAYS E, 1980, NUCLEIC ACIDS RES, V8, P5965, DOI 10.1093/nar/8.24.5965; PAYS E, 1988, ANNU REV GENET, V22, P107, DOI 10.1146/annurev.ge.22.120188.000543; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; RODITI I, 1990, PARASITOL TODAY, V6, P79, DOI 10.1016/0169-4758(90)90216-Q; ROLIN S, 1990, EXP PARASITOL, V71, P350, DOI 10.1016/0014-4894(90)90041-A; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Salmon D, 1997, EMBO J, V16, P7272, DOI 10.1093/emboj/16.24.7272; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wu M, 1997, J MEMBRANE BIOL, V159, P137, DOI 10.1007/s002329900277; Xiao Z, 1997, MOL BIOL CELL, V8, P855, DOI 10.1091/mbc.8.5.855; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang XQ, 1997, BIOCHEM J, V323, P197, DOI 10.1042/bj3230197; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	59	52	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4072	4080		10.1074/jbc.275.6.4072	http://dx.doi.org/10.1074/jbc.275.6.4072			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660566	hybrid			2022-12-25	WOS:000085288800050
J	Vorobiov, D; Bera, AK; Keren-Raifman, T; Barzilai, R; Dascal, N				Vorobiov, D; Bera, AK; Keren-Raifman, T; Barzilai, R; Dascal, N			Coupling of the muscarinic m2 receptor to G protein-activated K+ channels via G alpha(z) and a Receptor-G alpha(z) fusion protein - Fusion between the receptor and G alpha(z) eliminates catalytic (collision) coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; GUANINE-NUCLEOTIDE-BINDING; SIGNAL-TRANSDUCTION; XENOPUS-OOCYTES; PERTUSSIS-TOXIN; ALPHA-SUBUNIT; POTASSIUM CHANNEL; ACETYLCHOLINE-RECEPTOR; MOLECULAR-PROPERTIES; EXPRESSION	G protein-activated K+ channel (GIRK), which is activated by the Gp, subunit of heterotrimeric G proteins, and muscarinic m2 receptor (m2R) were coexpressed in Xenopus oocytes, Acetylcholine evoked a K+ current, I-ACh, via the endogenous pertussis toxin (PTX)-sensitive G(z), proteins. Activation of I-ACh was accelerated by increasing the expression of m2R, suggesting a collision coupling mechanism in which one receptor catalytically activates several G proteins. Coexpression of the alpha subunit of the PTX-insensitive G protein G(z), G(alpha z), induced a slowly activating PTX-insensitive I-ACh, whose activation kinetics were also compatible with the collision coupling mechanism. When GIRK was coexpressed with an m2R.G alpha(z) fusion protein (tandem), in which the C terminus of m2R was tethered to the N terminus of G(alpha z), part of IACh Was still eliminated by PTX. Thus, the m2R of the tandem activates the tethered Ga, but also the nontethered G(i/o) proteins. After PTX treatment, the speed of activation of the m2R.G alpha(z)-mediated response did not depend on the expression level of m2R.G alpha(z), and was faster than when m2R and Ga, were coexpressed as separate proteins. These results demonstrate that fusing the receptor and the G alpha strengthens their coupling, support the collision-coupling mechanism between m2R and the G proteins, and suggest a noncatalytic (stoichiometric) coupling between the G: protein and GIRK in this model system.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Dascal, N (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.		Dascal, Nathan/O-3915-2015	Dascal, Nathan/0000-0002-5397-4146; Bera, Amal Kanti/0000-0003-0362-5578	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056260] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56260] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEALS CR, 1987, P NATL ACAD SCI USA, V84, P7886, DOI 10.1073/pnas.84.22.7886; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; Carr IC, 1998, FEBS LETT, V428, P17, DOI 10.1016/S0014-5793(98)00476-1; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FU MLX, 1994, RECEPTOR CHANNEL, V2, P121; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Ho IHM, 1999, J BIOL CHEM, V274, P8639, DOI 10.1074/jbc.274.13.8639; Ho MKC, 1998, BIOL SIGNAL RECEPT, V7, P80; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Ikeda SR, 1999, ADV SEC MESS PHOSPH, V33, P131; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Jeong SW, 1998, NEURON, V21, P1201, DOI 10.1016/S0896-6273(00)80636-4; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; Kostenis E, 1999, LIFE SCI, V64, P355, DOI 10.1016/S0024-3205(98)00574-8; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; Lamb TD, 1996, P NATL ACAD SCI USA, V93, P566, DOI 10.1073/pnas.93.2.566; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LEVITZKI A, 1993, LIFE SCI, V52, P2093, DOI 10.1016/0024-3205(93)90724-H; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; Medici R, 1997, EMBO J, V16, P7241, DOI 10.1093/emboj/16.24.7241; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; Sautel M, 1998, FEBS LETT, V436, P46, DOI 10.1016/S0014-5793(98)01094-1; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; Sodickson DL, 1998, J NEUROSCI, V18, P8153; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; Vorobiov D, 1998, PFLUG ARCH EUR J PHY, V436, P56, DOI 10.1007/s004240050604; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Wise A, 1997, J BIOL CHEM, V272, P24673, DOI 10.1074/jbc.272.39.24673; Yamada M, 1998, PHARMACOL REV, V50, P723	51	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4166	4170		10.1074/jbc.275.6.4166	http://dx.doi.org/10.1074/jbc.275.6.4166			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660578	hybrid			2022-12-25	WOS:000085288800062
J	Bradford, AP; Brodsky, KS; Diamond, SE; Kuhn, LC; Liu, YM; Gutierrez-Hartmann, A				Bradford, AP; Brodsky, KS; Diamond, SE; Kuhn, LC; Liu, YM; Gutierrez-Hartmann, A			The Pit-1 homeodomain and beta-domain interact with Ets-1 and modulate synergistic activation of the rat prolactin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GHF-1; ANTERIOR-PITUITARY DEVELOPMENT; GROWTH-HORMONE PROMOTER; RETINOIC ACID RECEPTORS; GENE-EXPRESSION; DNA-BINDING; SIGNAL-TRANSDUCTION; RESPONSE ELEMENTS; CELL PHENOTYPES; THYROID-HORMONE	Pit-1/GHF-1 is a pituitary-specific, POU homeodomain transcription factor required for development of somatotroph, lactotroph, and thyrotroph cell lineages and regulation of the temporal and spatial expression of the growth hormone, prolactin (PRL), and thyrotropin-beta genes. Synergistic interaction of Pit-1 with a member of the Ets family of transcription factors, Ets-1, has been shown to be an important mechanism regulating basal and Ras-induced lactotroph-specific rat (r) PRL promoter activity. Pit-1 beta/GHF-2, an alternatively spliced isoform containing a 26-amino acid insert (beta-domain) within its transcription-activation domain, physically interacts with Ets-l but fails to synergize. By using a series of Pit-1 internal-deletion constructs in a transient transfection protocol to reconstitute rPRL promoter activity in HeLa cells, we have determined that the functional and physical interaction of Pit-1 and Ets-1 is mediated via the POU homeodomain, which is common to both Pit-1 and Pit-1 beta. Although the Pit-1 homeodomain is both necessary and sufficient for direct binding to Ets-1 in a DNA-independent manner, an additional interaction surface was mapped to the beta-domain, specific to the Pit-1 beta isoform, Thus, the unique transcriptional properties of Pit-1 and Pit-1 beta on the rPRL promoter may be due to the formation of functionally distinct complexes of these two Pit-1 isoforms with Ets-1.	Univ Colorado, Hlth Sci Ctr, Dept Obstet & Gynecol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Bradford, AP (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Obstet & Gynecol, 4200 E 9th Ave,B-198, Denver, CO 80262 USA.		Gutierrez-Hartmann, Arthur/F-1295-2011		NCI NIH HHS [P30 CA46934] Funding Source: Medline; NIDDK NIH HHS [DK 46868, DK 53496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053496, R56DK046868, R01DK046868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; Castillo AI, 1999, MOL ENDOCRINOL, V13, P1141, DOI 10.1210/me.13.7.1141; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; Castillo AI, 1997, ENDOCRINOLOGY, V138, P5442, DOI 10.1210/en.138.12.5442; Chang W, 1996, J BIOL CHEM, V271, P17733, DOI 10.1074/jbc.271.30.17733; Chuang FM, 1997, MOL ENDOCRINOL, V11, P1332, DOI 10.1210/me.11.9.1332; CONRAD KE, 1992, ONCOGENE, V7, P1279; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Day RN, 1998, MOL ENDOCRINOL, V12, P1410, DOI 10.1210/me.12.9.1410; de la Hoya M, 1998, CELL MOL LIFE SCI, V54, P1059, DOI 10.1007/s000180050234; Diamond SE, 1999, MOL ENDOCRINOL, V13, P228, DOI 10.1210/me.13.2.228; Diamond SE, 1996, J BIOL CHEM, V271, P28925, DOI 10.1074/jbc.271.46.28925; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; FISCHBERG DJ, 1994, MOL ENDOCRINOL, V8, P1566, DOI 10.1210/me.8.11.1566; Gaiddon C, 1999, MOL ENDOCRINOL, V13, P742, DOI 10.1210/me.13.5.742; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GUTIERREZHARTMANN A, 1994, MOL ENDOCRINOL, V8, P1447, DOI 10.1210/me.8.11.1447; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jiang YH, 1996, J BIOL CHEM, V271, P10723, DOI 10.1074/jbc.271.18.10723; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LIANG J, 1995, J BIOL CHEM, V270, P25520, DOI 10.1074/jbc.270.43.25520; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MORRIS AE, 1992, NUCLEIC ACIDS RES, V20, P1355, DOI 10.1093/nar/20.6.1355; NOWAKOWSKI BE, 1994, MOL ENDOCRINOL, V8, P1742, DOI 10.1210/me.8.12.1742; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; Palomino T, 1998, FASEB J, V12, P1201, DOI 10.1096/fasebj.12.12.1201; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sanchez-Pacheco A, 1998, FEBS LETT, V422, P103, DOI 10.1016/S0014-5793(97)01609-8; Schaufele F, 1996, J BIOL CHEM, V271, P21484, DOI 10.1074/jbc.271.35.21484; Schweppe RE, 1997, J BIOL CHEM, V272, P30852, DOI 10.1074/jbc.272.49.30852; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; Tolon RM, 1998, J BIOL CHEM, V273, P26652, DOI 10.1074/jbc.273.41.26652; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; Wang YH, 1999, MOL ENDOCRINOL, V13, P1094, DOI 10.1210/me.13.7.1094; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P251; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268	64	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3100	3106		10.1074/jbc.275.5.3100	http://dx.doi.org/10.1074/jbc.275.5.3100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652292	hybrid			2022-12-25	WOS:000085146500014
J	Choi, J; Liu, RM; Kundu, RK; Sangiorgi, F; Wu, WC; Maxson, R; Forman, HJ				Choi, J; Liu, RM; Kundu, RK; Sangiorgi, F; Wu, WC; Maxson, R; Forman, HJ			Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; NF-KAPPA-B; PERFORMANCE LIQUID-CHROMATOGRAPHY; HIV-INFECTED PATIENTS; EPITHELIAL L2 CELLS; OXIDATIVE STRESS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; RAT; ACTIVATION	Human immunodeficiency virus (HIV) progressively depletes GSH content in humans. Although the accumulated evidence suggests a role of decreased GSH in the pathogenesis of HIV, significant controversy remains concerning the mechanism of GSH depletion, especially in regard to envisioning appropriate therapeutic strategies to help compensate for such decreased antioxidant capacity. Tat, a transactivator encoded by HIV, is sufficient to cause GSH depletion in vitro and is implicated in AIDS-associated Kaposi's sarcoma and B cell lymphoma. In this study, we report a decrease in GSH biosynthesis with Tat, using HIV-1 Tat transgenic (Tat+) mice. A significant decline in the total intracellular GSH content in liver and erythrocytes of Tat+ mice was accompanied by decreased gamma-glutamylcysteine synthetase regulatory subunit mRNA and protein content, which resulted in an increased sensitivity of gamma-glutamylcysteine synthetase to feedback inhibition by GSH, Further study revealed a significant reduction in the activity of GSH synthetase in liver of Tat+ mice, which was linearly associated with their GSH content. Therefore, Tat appears to decrease GSH in vivo, at least partially, through modulation of GSH biosynthetic enzymes.	Univ Alabama Birmingham, Sch Publ Hlth, Dept Environm Hlth Sci, Birmingham, AL 35294 USA; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Norris Hosp, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Res Inst, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA 90089 USA	University of Alabama System; University of Alabama Birmingham; University of Southern California; University of Southern California; University of Southern California	Forman, HJ (corresponding author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Environm Hlth Sci, 1665 Univ Blvd,Ryals 317, Birmingham, AL 35294 USA.	hforman@uab.edu		Forman, Henry Jay/0000-0001-5838-2791	NIEHS NIH HHS [ES05511] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES005511, R01ES005511] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JD, 1983, J PHARMACOL EXP THER, V227, P749; ANDERSON ME, 1980, BIOCHEM BIOPH RES CO, V96, P848, DOI 10.1016/0006-291X(80)91433-3; Barbaro G, 1996, AM J GASTROENTEROL, V91, P2569; BUHL R, 1989, LANCET, V2, P1294; Chang ML, 1997, MOL CHEM NEUROPATHOL, V30, P187, DOI 10.1007/BF02815097; Chen LH, 1996, CHEM-BIOL INTERACT, V99, P17, DOI 10.1016/0009-2797(95)03657-1; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; Choi J, 1997, BIOCHEM PHARMACOL, V53, P987, DOI 10.1016/S0006-2952(96)00867-2; DEBIEU D, 1987, CLIN CHIM ACTA, V170, P161, DOI 10.1016/0009-8981(87)90124-0; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; DEQUAY B, 1992, AIDS, V6, P815, DOI 10.1097/00002030-199208000-00008; Dobmeyer TS, 1997, FREE RADICAL BIO MED, V22, P775, DOI 10.1016/S0891-5849(96)00403-0; ECK HP, 1991, LANCET, V338, P346, DOI 10.1016/0140-6736(91)90482-5; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FAVIER A, 1994, CHEM-BIOL INTERACT, V91, P165, DOI 10.1016/0009-2797(94)90037-X; FLORES SC, 1993, P NATL ACAD SCI USA, V90, P7632, DOI 10.1073/pnas.90.16.7632; Garaci E, 1997, J LEUKOCYTE BIOL, V62, P54, DOI 10.1002/jlb.62.1.54; GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51; HAMILOS DL, 1985, J IMMUNOL, V135, P2740; Helbling B, 1996, EUR J CLIN INVEST, V26, P38, DOI 10.1046/j.1365-2362.1996.88237.x; Herzenberg LA, 1997, P NATL ACAD SCI USA, V94, P1967, DOI 10.1073/pnas.94.5.1967; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; ISHII Y, 1992, J CLIN INVEST, V89, P794, DOI 10.1172/JCI115658; Jahoor F, 1999, AM J PHYSIOL-ENDOC M, V276, pE205, DOI 10.1152/ajpendo.1999.276.1.E205; JARSTRAND C, 1994, CHEM-BIOL INTERACT, V91, P141, DOI 10.1016/0009-2797(94)90034-5; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; Kameoka M, 1996, AIDS RES HUM RETROV, V12, P1635, DOI 10.1089/aid.1996.12.1635; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; KUMAR S, 1992, BIOCHEM INT, V26, P469; KUMAR S, 1994, FOLIA MICROBIOL, V39, P571, DOI 10.1007/BF02814111; Kundu RK, 1999, BLOOD, V94, P275, DOI 10.1182/blood.V94.1.275.413a30_275_282; LAUTERBURG BH, 1984, HEPATOLOGY, V4, P586, DOI 10.1002/hep.1840040402; Liu RM, 1998, AM J PHYSIOL-LUNG C, V275, pL861, DOI 10.1152/ajplung.1998.275.5.L861; LOGUERCIO C, 1992, SCAND J CLIN LAB INV, V52, P207, DOI 10.3109/00365519209088787; Luo JL, 1998, AM J PHYSIOL-ENDOC M, V275, pE359, DOI 10.1152/ajpendo.1998.275.2.E359; MARIN E, 1993, ACTA PHYSIOL SCAND, V147, P369, DOI 10.1111/j.1748-1716.1993.tb09513.x; Marmor M, 1997, AIDS, V11, P1389, DOI 10.1097/00002030-199711000-00014; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; NARDI G, 1990, J CHROMATOGR-BIOMED, V530, P122, DOI 10.1016/S0378-4347(00)82310-5; ORLOWSKI M, 1975, EUR J BIOCHEM, V53, P581, DOI 10.1111/j.1432-1033.1975.tb04101.x; PACE GW, 1995, FREE RADICAL BIO MED, V19, P523, DOI 10.1016/0891-5849(95)00047-2; Pacht ER, 1997, CHEST, V112, P785, DOI 10.1378/chest.112.3.785; Palamara AT, 1996, AIDS RES HUM RETROV, V12, P1537, DOI 10.1089/aid.1996.12.1537; Prakash O, 1997, ARCH BIOCHEM BIOPHYS, V343, P173, DOI 10.1006/abbi.1997.0168; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; ROSENBLATT JD, 1995, CURR TOP MICROBIOL, V193, P25; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SANDSTROM PA, 1993, AIDS RES HUM RETROV, V9, P1107, DOI 10.1089/aid.1993.9.1107; SAPPEY C, 1994, CLIN CHIM ACTA, V230, P35, DOI 10.1016/0009-8981(94)90086-8; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SETHNA SS, 1983, CURR EYE RES, V2, P735, DOI 10.3109/02713688209020005; SHI MM, 1994, J BIOL CHEM, V269, P26512; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Sun Y, 1997, FEBS LETT, V408, P16, DOI 10.1016/S0014-5793(97)00380-3; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; TATEISHI N, 1974, J BIOCHEM, V75, P93, DOI 10.1093/oxfordjournals.jbchem.a130387; VANDERVEN AJM, 1994, J ANTIMICROB CHEMOTH, V34, P1, DOI 10.1093/jac/34.1.1; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Willmore WG, 1997, AM J PHYSIOL-REG I, V273, pR219, DOI 10.1152/ajpregu.1997.273.1.R219; WITSCHI A, 1995, AIDS RES HUM RETROV, V11, P141, DOI 10.1089/aid.1995.11.141; XIE PY, 1991, OPHTHALMIC RES, V23, P133, DOI 10.1159/000267112; YAN CC, 1995, J CHROMATOGR B, V672, P217, DOI 10.1016/0378-4347(95)00226-9; [No title captured]	68	133	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3693	3698		10.1074/jbc.275.5.3693	http://dx.doi.org/10.1074/jbc.275.5.3693			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652368	hybrid			2022-12-25	WOS:000085146500090
J	Glover, BP; McHenry, CS				Glover, BP; McHenry, CS			The DnaX-binding subunits delta ' and psi are bound to gamma and not tau in the DNA polymerase III holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; ESCHERICHIA-COLI; SLIDING CLAMPS; EPSILON-SUBUNIT; LAGGING-STRAND; CROSS-LINKERS; BETA-SUBUNIT; PROTEIN; COMPLEX; IDENTIFICATION	The DnaX complex subassembly of the DNA polymerase III holoenzyme is comprised of the DnaX proteins tau and gamma and the auxiliary subunits delta, delta, chi and Psi,which together load the beta processivity factor onto primed DNA in an ATP-dependent reaction. delta' and Psi bind directly to DnaX whereas delta and chi bind to delta' and Psi, respectively (Onrust, R., Finkelstein, J., Naktinis, V., Turner, J., Fang, L., and O'Donnell, M. (1995) J. Biol. Chem. 270, 13348-13357), Until now, it has been unclear which DnaX protein, tau or gamma, in holoenzyme binds the auxiliary subunits delta, delta' chi,and Psi. Treatment of purified holoenzyme with the homobifunctional cross-linker bis(sulfo-succinimidyl)suberate produces covalently cross-linked gamma-delta' and gamma-Psi complexes identified by Western blot analysis. Immunodetection of cross-linked species with anti-delta' and anti-Psi, antibodies revealed that no tau-delta' or tau-Psi cross-links had formed, suggesting that the delta' and Psi subunits reside only on gamma within holoenzyme.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McHenry, CS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.				NIGMS NIH HHS [GM 35695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archibald K, 1998, NEUROPHARMACOLOGY, V37, P1345, DOI 10.1016/S0028-3908(98)00135-X; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; CARTER JR, 1992, J BACTERIOL, V174, P7013, DOI 10.1128/JB.174.21.7013-7025.1992; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; FAY PJ, 1981, J BIOL CHEM, V256, P976; FLOWER AM, 1991, J MOL BIOL, V220, P649, DOI 10.1016/0022-2836(91)90107-H; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; HORIUCHI T, 1978, MOL GEN GENET, V163, P277, DOI 10.1007/BF00271956; HURWITZ J, 1974, P NATL ACAD SCI USA, V71, P6, DOI 10.1073/pnas.71.1.6; JENNINGS ML, 1995, BIOCHEMISTRY-US, V34, P3588, DOI 10.1021/bi00011a013; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Jordan JA, 1996, BBA-GEN SUBJECTS, V1291, P27, DOI 10.1016/0304-4165(96)00040-2; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; McDermott AM, 1996, BIOCHEM J, V317, P119, DOI 10.1042/bj3170119; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MOK M, 1987, J BIOL CHEM, V262, P16644; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	43	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3017	3020		10.1074/jbc.275.5.3017	http://dx.doi.org/10.1074/jbc.275.5.3017			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652279	hybrid			2022-12-25	WOS:000085146500001
J	Rezaie, AR				Rezaie, AR			Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR SUBSTRATE RECOGNITION; BLOOD-COAGULATION FACTOR; PROTEIN-C ACTIVATION; ANTITHROMBIN-III; PROTHROMBINASE COMPLEX; CONFORMATIONAL CHANGE; ENZYME SPECIFICITY; ACTIVE-SITE; THROMBIN; ACCELERATION	recently demonstrated that a template mechanism makes a significant contribution to the heparin-accelerated inactivation of factor Xa (FXa) by antithrombin at physiologic Ca2+, suggesting that FXa has a potential heparin-binding site. Structural data indicate that 7 of the 11 basic residues of the heparin-binding exosite of thrombin are conserved at similar three-dimensional locations in FXa, These residues, Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) were substituted with Ala in separate constructs in Gla domainless forms. It was found that all derivatives cleave Spectrozyme FXa with similar catalytic efficiencies. Antithrombin inactivated FXa derivatives with a similar second-order association rate constant (k(2)) in both the absence and presence of pentasaccharide, In the presence of heparin, however, k(2) with certain mutants were impaired up to 25-fold. Moreover, these mutants bound to heparin-Sepharose with lower affinities. Heparin concentration dependence of the inactivation revealed that only the template portion of the cofactor effect of heparin was affected by the mutagenesis. The order of importance of these residues for binding heparin was as follows: Arg240 > Lys(236) > Lys(169) > Arg(165) > Lys(96) > Arg(93) greater than or equal to Arg(125). Interestingly, further study suggested that certain basic residues of this site, particularly Arg(165) and Lys(169), play key roles in factor Va and/or prothrombin recognition by FXa in prothrombinase.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NHLBI NIH HHS [R01 HL 62565] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062565] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; ELLIS V, 1986, BIOCHEM J, V238, P329, DOI 10.1042/bj2380329; ELLIS V, 1986, BIOCHEM J, V233, P161, DOI 10.1042/bj2330161; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GRIFFITH MJ, 1982, THROMB RES, V25, P245, DOI 10.1016/0049-3848(82)90244-4; He XH, 1997, BIOCHEMISTRY-US, V36, P8969, DOI 10.1021/bi9704717; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JORDAN RE, 1980, J BIOL CHEM, V255, P81; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; LANE DA, 1992, BLOOD COAGUL FIBRIN, V3, P315, DOI 10.1097/00001721-199206000-00012; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1991, J BIOL CHEM, V266, P2453; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1995, J BIOL CHEM, V270, P16176, DOI 10.1074/jbc.270.27.16176; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; Rezaie AR, 1996, BIOCHEMISTRY-US, V35, P1918, DOI 10.1021/bi952065y; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEN P, 1989, J BIOL CHEM, V264, P10002; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; YE J, 1994, J BIOL CHEM, V269, P17965	39	104	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3320	3327		10.1074/jbc.275.5.3320	http://dx.doi.org/10.1074/jbc.275.5.3320			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652320	hybrid			2022-12-25	WOS:000085146500042
J	Weixel, KM; Bradbury, NA				Weixel, KM; Bradbury, NA			The carboxyl terminus of the cystic fibrosis transmembrane conductance regulator binds to AP-2 clathrin adaptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR INTERNALIZATION; DI-LEUCINE MOTIF; CHLORIDE CHANNELS; AMINO-ACID; ENDOCYTOSIS; CFTR; TYROSINE; PROTEIN; SIGNAL; SEQUENCE	The cystic fibrosis transmembrane conductance regulator (CFTR) undergoes rapid and efficient endocytosis. Since functionally active CFTR is found in purified clathrin-coated vesicles isolated from both cultured epithelial cells and intact epithelial tissues, we investigated the molecular mechanisms whereby CFTR could enter such endocytic clathrin-coated vesicles. In vivo cross-linking and in vitro pull-down assays show that full-length CFTR binds to the endocytic adaptor complex AP-2. Fusion proteins containing the carboxyl terminus of CFTR (amino acids 1404-1480) were also able to bind AP-2 but did not bind the Golgi-specific adaptor complex AP-1, Substitution of an alanine residue for tyrosine at position 1424 significantly reduced the ability of AP-2 to bind the carboxyl terminus of CFTR; however, mutation to a phenylalanine residue (an amino acid found at position 1424 in dogfish CFTR) did not perturb AP-2 binding. Secondary structure predictions suggest that Tyr(1424) is present in a beta-turn conformation, a conformation disrupted by alanine but not phenylalanine. Together, these data suggest that the carboxyl terminus of CFTR contains a tyrosine-based internalization signal that interacts with the endocytic adaptor complex AP-2 to facilitate efficient entry of CFTR into clathrin-coated vesicles.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Cyst Fibrosis Res Ctr, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Bradbury, NA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Cyst Fibrosis Res Ctr, 3500 Terrace St, Pittsburgh, PA 15261 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047850] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47850] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BIWERSI J, 1994, AM J PHYSIOL, V266, pC149, DOI 10.1152/ajpcell.1994.266.1.C149; Boge M, 1998, J BIOL CHEM, V273, P15773, DOI 10.1074/jbc.273.25.15773; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; Bradbury NA, 1999, AM J PHYSIOL-LUNG C, V276, pL659, DOI 10.1152/ajplung.1999.276.4.L659; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COHN JA, 1994, CYSTIC FIBROSIS CURR, V2, P173; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; Lukacs GL, 1997, BIOCHEM J, V328, P353; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Orzech E, 1999, J BIOL CHEM, V274, P2201, DOI 10.1074/jbc.274.4.2201; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; PRINCE LS, 1993, AM J PHYSIOL, V264, pC491, DOI 10.1152/ajpcell.1993.264.2.C491; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WEBSTER P, 1994, AM J PHYSIOL, V267, pC340, DOI 10.1152/ajpcell.1994.267.2.C340	37	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3655	3660		10.1074/jbc.275.5.3655	http://dx.doi.org/10.1074/jbc.275.5.3655			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652362	hybrid			2022-12-25	WOS:000085146500084
J	Fabbrini, MS; Carpani, D; Soria, MR; Ceriotti, A				Fabbrini, MS; Carpani, D; Soria, MR; Ceriotti, A			Cytosolic immunization allows the expression of preATF-saporin chimeric toxin in eukaryotic cells	FASEB JOURNAL			English	Article						ribosome-inactivating proteins; urokinase receptor; urokinase amino-terminal fragment; intracellular immunization; anti-cancer therapy	RIBOSOME-INACTIVATING PROTEINS; UROKINASE-PLASMINOGEN-ACTIVATOR; XENOPUS OOCYTES; SAPONARIA-OFFICINALIS; ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; MESSENGER-RNAS; KILLER-CELLS; WILD-TYPE; RECEPTOR	In this work, we have devised an intracellular immunization strategy for the expression in high amounts of ATF-saporin, a targeted chimeric toxin constituted by the ATF receptor binding domain of human urokinase and the plant ribosome-inactivating protein saporin, which has been shown to be highly cytotoxic to target cells. This strategy may allow the production of highly toxic secretory proteins in eukaryotic cells, avoiding cell suicide caused by autointoxication. The procedure consists of equipping host cells with cytosolic neutralizing antibodies directed toward the toxic domain of the heterologous polypeptide, We show that this intracellular immunization is essential for the synthesis of correctly folded, biologically active ATF-SAP in the high amounts needed to investigate its in vivo antimetastatic potential. Such a strategy should be generally useful for the production of toxic molecules of therapeutic value whose folding and maturation require transit through the eukaryotic secretory pathway.	Ist Sci San Raffaele, Dibit Dept Biol & Technol Res, I-20132 Milan, Italy; CNR, Ist Biointesi Vegetali, I-20133 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR)	Fabbrini, MS (corresponding author), Ist Sci San Raffaele, Dibit Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.	fabbrini.serena@hsr.it	Ceriotti, Aldo/A-1448-2016	Ceriotti, Aldo/0000-0002-8230-8863				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BENATTI L, 1989, EUR J BIOCHEM, V183, P465, DOI 10.1111/j.1432-1033.1989.tb14951.x; BIOCCA S, 1994, BIO-TECHNOL, V12, P396, DOI 10.1038/nbt0494-396; BLASI F, 1998, BIOCHIM BIOPHYS ACTA, V1423, pR35; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRANDAZZA A, 1991, J BIOTECHNOL, V20, P201, DOI 10.1016/0168-1656(91)90228-N; CARZANIGA R, 1994, PLANTA, V194, P461, DOI 10.1007/BF00714457; CAVALLARO U, 1993, J BIOL CHEM, V268, P23186; CAVALLARO U, 1995, EUR J BIOCHEM, V232, P165, DOI 10.1111/j.1432-1033.1995.tb20795.x; Ceriotti A, 1995, Methods Mol Biol, V37, P151; CERIOTTI A, 1991, EUR J BIOCHEM, V202, P959, DOI 10.1111/j.1432-1033.1991.tb16456.x; Ceriotti A, 1995, METHOD CELL BIOL, V50, P295, DOI 10.1016/S0091-679X(08)61038-9; Chen SY, 1997, NATURE, V385, P78, DOI 10.1038/385078a0; CORTI A, 1989, THROMB HAEMOSTASIS, V62, P934; ENDO Y, 1988, BIOCHEM BIOPH RES CO, V150, P1032, DOI 10.1016/0006-291X(88)90733-4; Fabbrini MS, 1997, FASEB J, V11, P1169, DOI 10.1096/fasebj.11.13.9367352; Fabbrini MS, 1997, BIOCHEM J, V322, P719, DOI 10.1042/bj3220719; FABBRINI MS, 1993, P NATL ACAD SCI USA, V90, P3923, DOI 10.1073/pnas.90.9.3923; Fitzgerald D, 1996, SEMIN CANCER BIOL, V7, P87, DOI 10.1006/scbi.1996.0013; Flavell DJ, 1998, CURR TOP MICROBIOL, V234, P57; Frigerio L, 1998, J BIOL CHEM, V273, P14194, DOI 10.1074/jbc.273.23.14194; Galili G, 1995, METHOD CELL BIOL, V50, P497, DOI 10.1016/S0091-679X(08)61053-5; HUR Y, 1995, P NATL ACAD SCI USA, V92, P8448, DOI 10.1073/pnas.92.18.8448; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; LEITZGEN K, 1998, CHEMTRACTS BIOCH MOL, V11, P423; Lord JM, 1998, J CELL BIOL, V140, P733; Mantyh PW, 1997, SCIENCE, V278, P275, DOI 10.1126/science.278.5336.275; MAY MJ, 1989, EMBO J, V8, P301, DOI 10.1002/j.1460-2075.1989.tb03377.x; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; OLSON D, 1992, J BIOL CHEM, V267, P9129; Pai LH, 1996, NAT MED, V2, P350, DOI 10.1038/nm0396-350; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; Pastan I, 1997, BBA-REV CANCER, V1333, pC1, DOI 10.1016/S0304-419X(97)00021-8; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; RICHTER JD, 1981, CELL, V27, P183, DOI 10.1016/0092-8674(81)90372-X; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Sambrook T, 1989, MOL CLONING LAB MANU; SANTORO C, 1986, NUCLEIC ACIDS RES, V14, P2863, DOI 10.1093/nar/14.7.2863; SAXENA SK, 1989, J BIOL CHEM, V264, P596; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; Williams MD, 1998, PROTEIN EXPRES PURIF, V13, P210, DOI 10.1006/prep.1998.0900; Yang AG, 1997, NAT BIOTECHNOL, V15, P46, DOI 10.1038/nbt0197-46	47	22	24	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					391	398		10.1096/fasebj.14.2.391	http://dx.doi.org/10.1096/fasebj.14.2.391			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657995				2022-12-25	WOS:000085184800018
J	Yoon, SS; Nakamura, H; Carroll, NM; Bode, BP; Chiocca, EA; Tanabe, KK				Yoon, SS; Nakamura, H; Carroll, NM; Bode, BP; Chiocca, EA; Tanabe, KK			An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma	FASEB JOURNAL			English	Article						HSV1; gene therapy; ribonucleotide reductase	EXPERIMENTAL BRAIN-TUMORS; THYMIDINE KINASE GENE; RIBONUCLEOTIDE REDUCTASE; ANTITUMOR-ACTIVITY; MALIGNANT GLIOMAS; VIRAL MUTANT; HEPATITIS-B; P53 STATUS; REPLICATION; THERAPY	Viruses used for gene therapy are usually genetically modified to deliver therapeutic transgenes and prevent viral replication. in contrast, replication-competent viruses may be used for cancer therapy because replication of some viruses within cancer cells can result in their destruction (oncolysis). Viral ribonucleotide reductase expression is defective in the HSV1 mutant hrR3, Cellular ribonucleotide reductase, which is scarce in normal liver and abundant in liver metastases, can substitute for its viral counterpart to allow hrR3 replication in infected cells. Two or three log orders more of hrR3 virions are produced from infection of colon carcinoma cells than from infection of normal hepatocytes in viral replication assays. This viral replication is oncolytic, A single intravascular administration of hrR3 into immune-competent mice bearing diffuse Liver metastases dramatically reduces tumor burden. hrR3-mediated tumor inhibition is equivalent in immune-competent and immune-incompetent mice, suggesting that viral oncolysis and not the host immune response is the primary mechanism of tumor destruction. HSV1-mediated oncolysis of diffuse liver metastases is effective in mice preimmunized against HSV1, These results indicate that replication-competent HSV1 mutants hold significant promise as cancer therapeutic agents.	Massachusetts Gen Hosp, Div Surg Oncol, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Tanabe, KK (corresponding author), Massachusetts Gen Hosp, Div Surg Oncol, Dept Surg, Cox 626,100 Blossom St, Boston, MA 02114 USA.				NCI NIH HHS [CA71345, CA60011, CA64454] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA071345, R29CA064454] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALZARINI J, 1993, J BIOL CHEM, V268, P6332; Becker TM, 1996, SEX TRANSM DIS, V23, P138, DOI 10.1097/00007435-199603000-00009; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BOVIATSIS EJ, 1994, CANCER RES, V54, P5745; BOVIATSIS EJ, 1994, GENE THER, V1, P323; BREAKEFIELD XO, 1991, NEW BIOL, V3, P203; BREAKEFIELD XO, 1995, INTERNET BOOK GENE T, P41; Carroll NM, 1997, J SURG RES, V69, P413, DOI 10.1006/jsre.1997.5089; Carroll NM, 1996, ANN SURG, V224, P323, DOI 10.1097/00000658-199609000-00008; Chase M, 1998, NAT BIOTECHNOL, V16, P444, DOI 10.1038/nbt0598-444; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DELUCA NA, 1985, J VIROL, V56, P558, DOI 10.1128/JVI.56.2.558-570.1985; Dranoff G, 1998, J CLIN ONCOL, V16, P2548, DOI 10.1200/JCO.1998.16.7.2548; ENZMINGER WD, 1983, SEMIN ONCOL, V10, P176; GIAVAZZI R, 1986, J NATL CANCER I, V77, P1303; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Herrlinger U, 1998, GENE THER, V5, P809, DOI 10.1038/sj.gt.3300643; Higgins GM, 1931, ARCH PATHOL, V12, P186; JOHNSON PA, 1992, MOL BRAIN RES, V12, P95, DOI 10.1016/0169-328X(92)90072-J; JOHNSON PA, 1992, J VIROL, V66, P2952, DOI 10.1128/JVI.66.5.2952-2965.1992; JOLLY D, 1995, INTERNET BOOK GENE T, P3; Kirn D, 1998, NAT MED, V4, P1341, DOI 10.1038/3902; LELIE PN, 1987, J MED VIROL, V23, P297, DOI 10.1002/jmv.1890230313; LI AP, 1992, J TISSUE CULT METHOD, V14, P139; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; MINETA T, 1994, CANCER RES, V54, P3963; MORRISON LA, 1994, J VIROL, V68, P689, DOI 10.1128/JVI.68.2.689-696.1994; NIDERHUBER JE, 1993, CANC PRINICIPLES PRA, P2201; PAGANO JS, 1981, MED MICROBIOLOGY INF, P541; READ GS, 1983, J VIROL, V46, P498, DOI 10.1128/JVI.46.2.498-512.1983; RICE SA, 1993, J VIROL, V67, P1778, DOI 10.1128/JVI.67.4.1778-1787.1993; Roizman B, 1996, FIELDS VIROLOGY, P2231; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Toda M, 1999, HUM GENE THER, V10, P385, DOI 10.1089/10430349950018832; Toda M, 1998, J IMMUNOL, V160, P4457; WEISS L, 1986, J PATHOL, V150, P195, DOI 10.1002/path.1711500308; Yoon SS, 1998, ANN SURG, V228, P366, DOI 10.1097/00000658-199809000-00009	44	98	108	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					301	311		10.1096/fasebj.14.2.301	http://dx.doi.org/10.1096/fasebj.14.2.301			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657986				2022-12-25	WOS:000085184800009
J	Bradsher, J; Coin, F; Egly, JM				Bradsher, J; Coin, F; Egly, JM			Distinct roles for the helicases of TFIIH in transcript initiation and promoter escape	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CDK-ACTIVATING KINASE; PIGMENTOSUM GROUP-D; DNA-REPAIR; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; PREINITIATION COMPLEX; BASAL TRANSCRIPTION; TERMINAL DOMAIN; GENE	To provide an explanation of some clinical features observed within rare xeroderma pigmentosum (XP) patients and to further define the role of XPB, XPD, and cdk7, the three enzymatic subunits of TFIIH, in the transcription reaction, we have examined two defined enzymatic steps: phosphodiester bond formation and promoter escape, me provide evidence that the XPB helicase plays a dominant role in initiation, whereas the XPD helicase plays a minor contributing role in this step. The cyclin-activating kinase subcomplex of TFIIH improves the efficiency of initiation, but this involves only the structural contributions of cyclin-activating kinase rather than enzymatic activity. We demonstrate that XPB patient-derived mutants in TFIIH suffer from defects in initiation. Moreover, mutant analysis shows that in addition to its crucial role in initiation, the XPB helicase plays a critical enzymatic role in the promoter escape, whereas XPD plays an important structural role in the promoter escape process. Finally, using patient-derived mutations in TFIIH, we demonstrate deficiencies in promoter escape for both mutants of the class that suffer from combined xeroderma pigmentosum/Cockayne's syndrome.	ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, CU De Strasbour, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Egly, JM (corresponding author), ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 163, F-67404 Illkirch Graffenstaden, CU De Strasbour, France.	egly@igbmc.u-strasbg.fr	Coin, Frédéric/F-5925-2013	Coin, Frédéric/0000-0002-5620-8519	NIGMS NIH HHS [1 F32 GM20174-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020174] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, J BIOL CHEM, V272, P28175, DOI 10.1074/jbc.272.45.28175; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GERARD M, 1991, J BIOL CHEM, V266, P20940; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; MIYAMOTO NG, 1984, NUCLEIC ACIDS RES, V12, P8779, DOI 10.1093/nar/12.23.8779; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, J BIOL CHEM, V269, P9826; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TAKAYAMA K, 1995, CANCER RES, V55, P5656; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; Weeda G, 1997, AM J HUM GENET, V60, P320; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U	38	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2532	2538		10.1074/jbc.275.4.2532	http://dx.doi.org/10.1074/jbc.275.4.2532			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644710	hybrid			2022-12-25	WOS:000085128000042
J	Miyamoto, T; Fox, JC				Miyamoto, T; Fox, JC			Autocrine signaling through Ras prevents apoptosis in vascular smooth muscle cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR; C-MYC; GENE-TRANSFER; INHIBITION; EFFECTORS; RECEPTOR; TRANSDUCTION; STIMULATION	Vascular smooth muscle cell (SMC) apoptosis contributes to physiological and pathological vascular remodeling, Autocrine fibroblast growth factor (FGF) signaling promotes survival in SMC in vitro. Interruption of autocrine FGF signaling results in apoptosis that can be rescued by other growth factors such as PDGF (platelet-derived growth factor) or EGF (epidermal, growth factor). Such heterologous growth factor rescue is prevented by pharmacological inhibition of MAPK, implicating signaling through Ras in mediating survival. This study was designed to test the hypothesis that signaling through Ras is both necessary and sufficient to mediate SMC survival in vitro. Recombinant adenoviruses encoding dominant-negative (Ras(N17)) and constitutively active (Ras(L61)) mutants of Ras were used. Ras(N17) blocks growth factor-mediated MAPK activation and can itself induce SMC apoptosis. Ras(N17) is synergistic with inhibition of autocrine FGF signaling in triggering apoptosis and prevents heterologous growth factor rescue. Conversely, Ras(L61) prevents apoptosis resulting from inhibition of autocrine FGF signaling. Rescue by Ras(L61) can be partially prevented by pharmacological inhibition of MEK or phosphatidylinositol 3-kinase, two downstream effecters of Ras. These results suggest that Ras signaling is both necessary and sufficient to mediate survival in SMC in vitro. Further work is required to determine how these signaling events are regulated in the context of vascular remodeling in vivo.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Fox, JC (corresponding author), SmithKline Beecham Pharmaceut, 51 N 39th St, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [HL02939] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002939] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ai WD, 1999, FEBS LETT, V456, P196, DOI 10.1016/S0014-5793(99)00949-7; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Fox JC, 1996, J BIOL CHEM, V271, P12578, DOI 10.1074/jbc.271.21.12578; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Hafizi S, 1999, CLIN EXP PHARMACOL P, V26, P511, DOI 10.1046/j.1440-1681.1999.03071.x; Hanna AK, 1997, J VASC SURG, V25, P320, DOI 10.1016/S0741-5214(97)70353-7; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miyamoto T, 1998, J CELL PHYSIOL, V177, P58, DOI 10.1002/(SICI)1097-4652(199810)177:1<58::AID-JCP6>3.0.CO;2-D; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Neschis DG, 1998, J VASC SURG, V27, P126, DOI 10.1016/S0741-5214(98)70299-X; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; Rose L, 1998, DEV GROWTH DIFFER, V40, P231; Stang S, 1997, MOL CELL BIOL, V17, P3047, DOI 10.1128/MCB.17.6.3047; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Wang XHS, 1996, J BIOL CHEM, V271, P31607; YANG YP, 1993, P NATL ACAD SCI USA, V90, P4601, DOI 10.1073/pnas.90.10.4601; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	31	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2825	2830		10.1074/jbc.275.4.2825	http://dx.doi.org/10.1074/jbc.275.4.2825			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644748	hybrid			2022-12-25	WOS:000085128000080
J	Foster, DB; Shen, LH; Kelly, J; Thibault, P; Van Eyk, JE; Mak, AS				Foster, DB; Shen, LH; Kelly, J; Thibault, P; Van Eyk, JE; Mak, AS			Phosphorylation of caldesmon by p21-activated kinase - Implications for the Ca2+ sensitivity of smooth muscle contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATPASE ACTIVITY; MYOSIN SUBFRAGMENT-1; CALMODULIN-BINDING; HEAVY-MEROMYOSIN; RHO-KINASE; ACTIN; PROTEIN; SITES; ACTIVATION; IDENTIFICATION	We have previously shown that pal-activated kinase, PAK, induces Ca2+-independent contraction of Triton-skinned smooth muscle with concomitant increase in phosphorylation of caldesmon and desmin but not myosin-regulatory light chain (Van Eyk, J, E,, Arrell, D, K,, Foster, D, B., Strauss, J, D,, Heinonen, T, Y,, Furmaniak-Kazmierczak, E,, Cote, G. P,, and Mak, A. S, (1998) J, Biol, Chem. 273, 23433-23439), In this study, we provide biochemical evidence implicating a role for PAK in Ca2+-independent contraction of smooth muscle via phosphorylation of caldesmon, Mass spectroscopy data show that stoichiometric phosphorylation occurs at Ser(657) and Ser(687) abutting the calmodulin-binding sites A and B of chicken gizzard caldesmon, respectively. Phosphorylation of Ser(657) and Ser(687) has an important functional impact on caldesmon, PAK-phosphorylation reduces binding of caldesmon to calmodulin by about 10-fold whereas binding of calmodulin to caldesmon partially inhibits PAK phosphorylation, Phosphorylated caldesmon displays a modest reduction in affinity for actin-tropomyosin but is significantly less effective in inhibiting actin-activated S1 ATPase activity in the presence of tropomyosin, We conclude that PAK-phosphorylation of caldesmon at the calmodulin-binding sites modulates caldesmon inhibition of actin-myosin ATPase activity and may, in concert with the actions of Rho-kinase, contribute to the regulation of Ca2+ sensitivity of smooth muscle contraction.	Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Natl Res Council Canada, Ottawa, ON K1A 0R6, Canada	Queens University - Canada; Queens University - Canada; National Research Council Canada	Van Eyk, JE (corresponding author), Queens Univ, Dept Physiol, 4th Floor,Botterell Hall, Kingston, ON K7L 3N6, Canada.		Foster, D. Brian/S-9108-2019; Foster, D. Brian/C-6350-2009	Foster, D. Brian/0000-0002-9290-9590; Foster, D. Brian/0000-0002-9290-9590; Thibault, Pierre/0000-0001-5993-0331				ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Chacko S, 1987, Prog Clin Biol Res, V245, P143; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Graether SP, 1997, BIOCHEMISTRY-US, V36, P364, DOI 10.1021/bi962008k; GREENE LE, 1983, BIOCHEMISTRY-US, V22, P530, DOI 10.1021/bi00272a002; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; IKEBE M, 1990, J BIOL CHEM, V265, P17607; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Krymsky MA, 1999, FEBS LETT, V452, P254, DOI 10.1016/S0014-5793(99)00641-9; LASH JA, 1986, J BIOL CHEM, V261, P6155; MANI RS, 1992, BIOCHEMISTRY-US, V31, P11896, DOI 10.1021/bi00162a031; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1996, BIOCH SMOOTH MUSCLE, P77; NGAI PK, 1984, J BIOL CHEM, V259, P3656; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Pfitzer G, 1998, ACTA PHYSIOL SCAND, V164, P449, DOI 10.1111/j.1365-201X.1998.tb10698.x; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SUTHERLAND C, 1994, J MUSCLE RES CELL M, V15, P440, DOI 10.1007/BF00122118; TANAKA T, 1990, EUR J BIOCHEM, V188, P495, DOI 10.1111/j.1432-1033.1990.tb15427.x; Tuazon PT, 1998, BIOCHEMISTRY-US, V37, P17024, DOI 10.1021/bi982103o; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; VanEyk JE, 1997, J BIOL CHEM, V272, P10529; VELAZ L, 1990, J BIOL CHEM, V265, P2929; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WATSON MH, 1990, J BIOL CHEM, V265, P18860; Zhou N, 1997, BIOCHEMISTRY-US, V36, P2817, DOI 10.1021/bi9625713	40	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1959	1965		10.1074/jbc.275.3.1959	http://dx.doi.org/10.1074/jbc.275.3.1959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636898	hybrid			2022-12-25	WOS:000084940000061
J	Seo, B; Choy, EW; Maudsley, S; Miller, WE; Wilson, BA; Luttrell, LM				Seo, B; Choy, EW; Maudsley, S; Miller, WE; Wilson, BA; Luttrell, LM			Pasteurella multocida toxin stimulates mitogen-activated protein kinase via G(q)/(11)-dependent transactivation of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; COUPLED RECEPTORS; TYROSINE PHOSPHORYLATION; POTENT MITOGEN; EGF RECEPTOR; DERMONECROTIC TOXIN; DISTINCT PATHWAYS; SIGNALING PATHWAY; ESCHERICHIA-COLI; ION-CHANNEL	The dermatonecrotic toxin produced by Pasteurella multocida is one of the most potent mitogenic substances known for fibroblasts in vitro. Exposure to recombinant P. multocida toxin (rPMT) causes phospholipase C-mediated hydrolysis of inositol phospholipids, calcium mobilization, and activation of protein kinase C via a poorly characterized mechanism involving G(q/11) family heterotrimeric G proteins. To determine whether the regulation of G protein pathways contributes to the mitogenic effects of rPMT, we have examined the mechanism whereby rPMT stimulates the Erk mitogen-activated protein kinase cascade in cultured HEK-293 cells. Treatment with rPMT resulted in a dose and time-dependent increase in Erk 1/2 phosphorylation that paralleled its stimulation of inositol phospholipid hydrolysis. Both rPMT- and alpha-thrombin receptor- stimulated Erk phosphorylation were selectively blocked by cellular expression of two peptide inhibitors of G(q/11) signaling, the dominant negative mutant G protein-coupled receptor kinase, GRK2(K220R), and the G alpha(q) carboxyl-terminal peptide, G alpha(q)-(305359). Like alpha-thrombin receptor-mediated Erk activation, the effect of rPMT was insensitive to the protein kinase C inhibitor GF109203X, but was blocked by the epidermal growth factor receptor-specific tyrphostin, AG1478 and by dominant negative mutants of mSos1 and Ha-Ras, These data indicate that rPMT employs G(q/11) family heterotrimeric G proteins to induce Ras-dependent Erk activation via protein kinase C-independent "transactivation" of the epidermal growth factor receptor.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	Duke University; University of Illinois System; University of Illinois Urbana-Champaign	Luttrell, LM (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3821, Durham, NC 27710 USA.		Maudsley, Stuart/AAV-9929-2021; Maudsley, Stuart/Q-4782-2019	Maudsley, Stuart/0000-0002-1868-184X; Luttrell, Louis/0000-0003-2805-6949	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038396, R01AI038396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002352, R56DK055524, R01DK055524] Funding Source: NIH RePORTER; NIAID NIH HHS [R29 AI038396, AI38396] Funding Source: Medline; NIDDK NIH HHS [DK02352, DK55524] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BUYS WECM, 1990, NUCLEIC ACIDS RES, V18, P2815, DOI 10.1093/nar/18.9.2815; Carter G R, 1967, Adv Vet Sci, V11, P321; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Diviani D, 1996, J BIOL CHEM, V271, P5049; DUDET LI, 1996, INFECT IMMUN, V66, P5636; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FALBO V, 1993, INFECT IMMUN, V61, P4909, DOI 10.1128/IAI.61.11.4909-4914.1993; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LAX AJ, 1990, FEBS LETT, V277, P59, DOI 10.1016/0014-5793(90)80809-W; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Mullan PB, 1996, INFECT IMMUN, V64, P959, DOI 10.1128/IAI.64.3.959-965.1996; MURPHY AC, 1992, J BIOL CHEM, V267, P25296; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; PETTIT RK, 1993, LAB INVEST, V69, P94; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; STADDON JM, 1991, J BIOL CHEM, V266, P4840; STADDON JM, 1990, J BIOL CHEM, V265, P11841; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wilson BA, 1999, INFECT IMMUN, V67, P80, DOI 10.1128/IAI.67.1.80-87.1999; Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	42	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2239	2245		10.1074/jbc.275.3.2239	http://dx.doi.org/10.1074/jbc.275.3.2239			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636931	hybrid			2022-12-25	WOS:000084940000094
J	Witte, S; Villalba, M; Bi, K; Liu, YH; Isakov, N; Altman, A				Witte, S; Villalba, M; Bi, K; Liu, YH; Isakov, N; Altman, A			Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappa B pathways by PICOT, a novel protein kinase C-interacting protein with a thioredoxin homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKC-THETA; T-CELLS; SIGNAL-TRANSDUCTION; INNATE IMMUNITY; BINDING-PROTEIN; ACTIVATION; FAMILY; AP-1; LYMPHOCYTES; ASSOCIATION	Protein kinase C-theta (PKC theta) is a Ca2+-independent PKC isoform that is selectively expressed in T lymphocytes (and muscle), and is thought to play an important role in T cell receptor-induced activation. To gain a better understanding of the function and regulation of PRC theta, we have employed the yeast two-hybrid system to identify PKC theta-interacting proteins. We report the isolation and characterization of a cDNA encoding a novel 335-amino acid (37.5-kDa) PKC theta-interacting protein termed PICOT (for (P) under bar KC-(i) under bar nteracting (c) under bar ousin (o) under bar f (t) under bar hioredoxin). PICOT is expressed in various tissues, including in T cells, where it colocalizes with PKC theta. PICOT displays an N-terminal thioredoxin homology domain, which is required for the interaction with PKC, Comparison of the unique C-terminal region of PICOT with expressed sequence tag data bases revealed two tandem repeats of a novel domain that is highly conserved from plants to mammals. Transient overexpression of full-length PICOT (but not its N- or C-terminal fragments) in T cells inhibited the activation of c-Jun N-terminal kinase (but not extracellular signal-regulated kinase), and the transcription factors AP-1 or NF-kappa B. These findings suggest that PICOT and its evolutionary conserved homologues may interact with PKC-related kinases in multiple organisms and, second, that it plays a role in regulating the function of the thioredoxin system.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; Ben Gurion Univ Negev, Dept Microbiol, IL-84105 Beer Sheva, Israel	La Jolla Institute for Immunology; Ben Gurion University	Altman, A (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		ISAKOV, NOAH/F-1659-2012; villalba, martin/N-7123-2017; villalba, martin/AAG-2604-2020	villalba, martin/0000-0002-4385-4888; villalba, martin/0000-0002-4385-4888; Isakov, Noah/0000-0002-1412-0957	NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NCI NIH HHS [CA35299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAIER G, 1993, J BIOL CHEM, V268, P4997; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; GOLEMIS EA, 1997, PROTOCOLS MOL BIOL, V3; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1997, NEW ENGL J MED, V336, P1066; Kruse M, 1996, J MOL EVOL, V43, P374; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Meller N, 1998, STEM CELLS, V16, P178, DOI 10.1002/stem.160178; Meller N, 1996, MOL CELL BIOL, V16, P5782; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; POWIS G, 1994, ONCOL RES, V6, P539; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Sokolova M, 1997, FEBS LETT, V400, P201, DOI 10.1016/S0014-5793(96)01380-4; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Subramaniam R, 1997, PLANT CELL, V9, P653, DOI 10.1105/tpc.9.4.653; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; Witte S, 1997, J BIOL CHEM, V272, P22243, DOI 10.1074/jbc.272.35.22243	39	152	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1902	1909		10.1074/jbc.275.3.1902	http://dx.doi.org/10.1074/jbc.275.3.1902			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636891	hybrid			2022-12-25	WOS:000084940000054
J	Nikolopoulos, SN; Spengler, BA; Kisselbach, K; Evans, AE; Biedler, JL; Ross, RA				Nikolopoulos, SN; Spengler, BA; Kisselbach, K; Evans, AE; Biedler, JL; Ross, RA			The human non-muscle alpha-actinin protein encoded by the ACTN4 gene suppresses tumorigenicity of human neuroblastoma cells	ONCOGENE			English	Article						alpha-actinin; chromosome #4; tumor suppression; human neuroblastoma	NEURO-BLASTOMA CELLS; RAS-TRANSFORMED FIBROBLASTS; SIGNALING PATHWAYS; CYTOPLASMIC DOMAIN; BETA-CATENIN; EXPRESSION; ADHESION; CDNA; CYTOSKELETAL; GROWTH	alpha-Actinins are actin-binding proteins important in organization of the cytoskeleton and in cell adhesion. We have cloned and characterized a cDNA from human neuroblastoma cell variants which encodes the second non-muscle alpha-actinin isoform designated ACTN4 (actinin-4), mRNA encoded by the ACTN4 gene, mapped to chromosome 4, is abundant in non-tumorigenic, substrate-adherent human neuroblastoma cell variants but absent or only weakly expressed in malignant, poorly substrate-adherent neuroblasts, It is also present in many adherent tumor cell lines of diverse tissue origins. Cell lines typically co-express ACTN4 and ACTN1, a second non-muscle alpha-actinin gene. Expression is correlated with substrate adhesivity, Analysis of deduced amino acid sequences suggests that the two isoforms may differ in function and in regulation by calcium. Moreover, ACTN4 exhibits tumor suppressor activity. Stable clones containing increased levels of alpha-actinin, isolated from highly malignant neuroblastoma stem cells [BE(2)-C] after transfection with a full-length ACTN4 cDNA, show decreased anchorage-independent growth ability, loss of tumorigenicity in nude mice, and decreased expression of the N-myc proto-oncogene.	Fordham Univ, Dept Biol Sci, Neurobiol Lab, Bronx, NY 10458 USA; Childrens Hosp Philadelphia, Div Oncol, Abramson Pediat Res Ctr, Philadelphia, PA 19104 USA	Fordham University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Ross, RA (corresponding author), Fordham Univ, Dept Biol Sci, Neurobiol Lab, 441 E Fordham Road, Bronx, NY 10458 USA.							Akamatsu H, 1996, CANCER RES, V56, P4541; BARON MD, 1987, J BIOL CHEM, V262, P2558; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; BURN P, 1985, NATURE, V314, P469, DOI 10.1038/314469a0; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; Chan YM, 1998, BIOCHEM BIOPH RES CO, V248, P134, DOI 10.1006/bbrc.1998.8920; CICCARONE V, 1989, CANCER RES, V49, P219; Dosaka-Akita H, 1998, CANCER RES, V58, P322; EBASHI S, 1964, NATURE, V203, P645, DOI 10.1038/203645a0; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GEIGER B, 1992, COLD SPRING HARB SYM, V57, P631, DOI 10.1101/SQB.1992.057.01.069; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Han X, 1997, BIOCHEMISTRY-US, V36, P10364, DOI 10.1021/bi962929v; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; IMAMURA M, 1994, EUR J BIOCHEM, V223, P395, DOI 10.1111/j.1432-1033.1994.tb19006.x; IMAMURA M, 1992, J BIOL CHEM, V267, P25927; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kretsinger R H, 1980, Ann N Y Acad Sci, V356, P14, DOI 10.1111/j.1749-6632.1980.tb29594.x; LANDON F, 1985, EUR J BIOCHEM, V153, P231, DOI 10.1111/j.1432-1033.1985.tb09291.x; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; Nikolopoulos S. N., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P510; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PAVALKO FM, 1991, J CELL BIOL, V114, P481, DOI 10.1083/jcb.114.3.481; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHULTHEISS T, 1992, P NATL ACAD SCI USA, V89, P9282, DOI 10.1073/pnas.89.19.9282; Spengler BA, 1997, ONCOL RES, V9, P467; SPENGLER BA, 1994, P AM ASSOC CANC RES, V35, P302; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; TANAKA M, 1995, CANCER RES, V55, P3228; Travers H, 1996, CELL GROWTH DIFFER, V7, P1353; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	59	63	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					380	386		10.1038/sj.onc.1203310	http://dx.doi.org/10.1038/sj.onc.1203310			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656685				2022-12-25	WOS:000084873700008
J	Morimoto, AM; Tomlinson, MG; Nakatani, K; Bolen, JB; Roth, RA; Herbst, R				Morimoto, AM; Tomlinson, MG; Nakatani, K; Bolen, JB; Roth, RA; Herbst, R			The MMAC1 tumor suppressor phosphatase inhibits phospholipase C and integrin-linked kinase-activity	ONCOGENE			English	Article						MMAC1; PTEN; TEP1; ILK; PLC	PROTEIN-KINASE; SIGNAL-TRANSDUCTION; GLIOBLASTOMA CELLS; GERMLINE MUTATIONS; PTEN; GENE; GROWTH; GAMMA; DOMAIN; ACTIVATION	Loss of the tumor suppressor MMAC1 has been shown to be involved in breast, prostate and brain cancer, Consistent with its identification as a tumor suppressor, expression of MMAC1 has been demonstrated to reduce cell proliferation, tumorigenicity, and motility as well as affect cell-cell and cell-matrix interactions of malignant human glioma cells. Subsequently, MMAC1 was shown to have lipid phosphatase activity towards PIP, and protein phosphatase activity against focal adhesion kinase (FAK), The lipid phosphatase activity of MMAC1 results in decreased activation of the PIP3- dependent, anti-apoptotic kinase, AKT. It is thought that this inhibition of AKT culminates with reduced glioma cell proliferation, In contrast, MMAC1's effects on cell motility, cell-cell and cell-matrix interactions are thought to be due to its protein phosphatase activity towards FAK, However, recent studies suggest that the lipid phosphatase activity of MMAC1 correlates with its ability to be a tumor suppressor. The high rate of mutation of MMAC1 in late stage metastatic tumors suggests that effects of MMAC1 on motility, cell-cell and cell-matrix interactions are due to its tumor suppressor activity, Therefore the Lipid phosplratase activity of MMAC1 may affect PIP, dependent signaling pathways and result in reduced motility and altered cell-cell and cell-matrix interactions. We demonstrate here that expression of MMAC1 in human glioma cells reduced intracellular levels of inositol trisphosphate and inhibited extracellular Ca2+ influx, suggesting that MMAC1 affects the phospholipase C signaling pathway, In addition, we show that MMAC1 expression inhibits integrin-linked kinase activity. Furthermore, we show that these effects require the catalytic activity of MMAC1. Our data thus provide a link of MMAC1 to PIP, dependent signaling pathways that regulate cell-matrix and cell-cell interactions as well as motility. Lastly, we demonstrate that AKT3, an isoform of AKT highly expressed in the brain, is also a target for MMAC1 repression. These data suggest an important role for AKT3 in glioblastoma multiforme, We therefore propose that repression of multiple PIP, dependent signaling pathways may be required for MMAC1 to act as a tumor suppressor.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signalling, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Hoechst Marion Roussel, Dept Oncol, Bridgewater, NJ 08807 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University	Herbst, R (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signalling, 901 Calif Ave, Palo Alto, CA 94304 USA.			Tomlinson, Michael/0000-0002-1189-0091				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Baltuch GH, 1996, BRAIN RES, V710, P143, DOI 10.1016/0006-8993(95)01395-4; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Cheney IW, 1998, CANCER RES, V58, P2331; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Khoshyomn S, 1999, NEUROSURGERY, V44, P568, DOI 10.1097/00006123-199903000-00073; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki M, 1998, J VESTIBUL RES-EQUIL, V8, P169, DOI 10.1016/S0957-4271(97)00003-7; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Turner T, 1997, CLIN CANCER RES, V3, P2275; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	38	43	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					200	209		10.1038/sj.onc.1203288	http://dx.doi.org/10.1038/sj.onc.1203288			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644997				2022-12-25	WOS:000084844400004
J	Fueyo, J; Gomez-Manzano, C; Alemany, R; Lee, PSY; McDonnell, TJ; Mitlianga, P; Shi, YX; Levin, VA; Yung, WKA; Kyritsis, AP				Fueyo, J; Gomez-Manzano, C; Alemany, R; Lee, PSY; McDonnell, TJ; Mitlianga, P; Shi, YX; Levin, VA; Yung, WKA; Kyritsis, AP			A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo	ONCOGENE			English	Article						oncolytic virus; gene therapy; Rb; E2F; E1A	GENE-TRANSFER; CANCER-CELLS; BRAIN-TUMORS; P53 GENE; IN-VIVO; GROWTH; TRANSFORMATION; REPLICATION; APOPTOSIS; PROTEINS	Effective anti cancer strategies necessitate the use of agents that target tumor cells rather than normal tissues, In this study, we constructed a tumor-selective adenovirus, Delta 24, that carries a 24-bp deletion in the E1A region responsible for binding Rb protein. Immunoprecipitation analyses verified that this deletion rendered Delta 24 unable to bind the Rb protein. However, titration experiments in 293 cells demonstrated that the Delta 24 adenovirus could replicate in and Iyse cancer cells with great efficiency. Lysis of most human glioma cells was observed within 10-14 days after infection with Delta 24 at 10 PFU/cell. In vivo, a single dose of the Delta 24 virus induced a 66.3% inhibition (P<0.005) and multiple injections, an 83.8% inhibition (P<0.01) of tumor growth in nude mice. However, normal fibroblasts or cancer cells with restored Rb activity were resistant to the Delta 24 adenovirus. These results suggest that the E1A-mutant Delta 24 adenovirus may be clinically and therapeutically useful against gliomas and possibly other cancers with disrupted Rb pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Box 100,1515 Holcombe Blvd, Houston, TX 77030 USA.		Mitlianga, Paraskevi/AAU-1541-2020	Mitlianga, Paraskevi/0000-0003-3145-5596; Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335				Alemany R, 1997, J VIROL METHODS, V68, P147, DOI 10.1016/S0166-0934(97)00129-8; Alemany R, 1996, CANCER GENE THER, V3, P296; Andreansky S, 1997, CANCER RES, V57, P1502; ARAP W, 1995, CANCER RES, V55, P1351; Attia M, 1996, CANCER RES, V126, P1787; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Chase M, 1998, NAT BIOTECHNOL, V16, P444, DOI 10.1038/nbt0598-444; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; Costello JF, 1996, CANCER RES, V56, P2405; Costello JF, 1997, CANCER RES, V57, P1250; DYSON N, 1992, CANCER SURV, V12, P161; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323; Fueyo J, 1998, NEUROLOGY, V50, P1307, DOI 10.1212/WNL.50.5.1307; Fueyo J, 1996, ONCOGENE, V12, P103; Fueyo J, 1996, ONCOGENE, V13, P1615; Fueyo J, 1998, NEUROLOGY, V51, P1250, DOI 10.1212/WNL.51.5.1250; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; Furnari FB, 1995, CANCER SURV, V25, P233; GomezManzano C, 1997, J NATL CANCER I, V89, P1036, DOI 10.1093/jnci/89.14.1036; GomezManzano C, 1996, CANCER RES, V56, P694; GOMEZMANZANO C, 1998, GENE TRANSFER THERAP, P201; HAMER AJ, 1993, J PEDIATR ORTHOP B, V2, P159, DOI 10.1097/01202412-199302020-00012; Hay JG, 1999, HUM GENE THER, V10, P579, DOI 10.1089/10430349950018652; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; HIRVONEN HE, 1994, BRIT J CANCER, V69, P16, DOI 10.1038/bjc.1994.3; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JEN J, 1994, CANCER RES, V54, P6353; Kirn D, 1998, NAT MED, V4, P1341, DOI 10.1038/3902; Kyritsis AP, 1996, ONCOGENE, V12, P63; Kyritsis AP, 1996, MOL CARCINOGEN, V15, P1; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; NEVINS JR, 1992, SCIENCE, V258, P424; Puumalainen AM, 1998, HUM GENE THER, V9, P1769, DOI 10.1089/hum.1998.9.12-1769; Ridgway PJ, 1997, VIROLOGY, V237, P404, DOI 10.1006/viro.1997.8782; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Ueki K, 1996, CANCER RES, V56, P150; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988	48	593	648	3	45	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					2	12		10.1038/sj.onc.1203251	http://dx.doi.org/10.1038/sj.onc.1203251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644974				2022-12-25	WOS:000084844300001
J	Chiarugi, P; Cirri, P; Taddei, L; Giannoni, E; Camici, G; Manao, G; Raugei, G; Ramponi, G				Chiarugi, P; Cirri, P; Taddei, L; Giannoni, E; Camici, G; Manao, G; Raugei, G; Ramponi, G			The low M-r protein-tyrosine phosphatase is involved in Rho-mediated cytoskeleton rearrangement after integrin and platelet-derived growth factor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; ACTIN CYTOSKELETON; C-SRC; PHOSPHORYLATION; ADHESION; EXPRESSION; ANCHORAGE; ACTIVATION; RECEPTOR; E-CDK2	The low molecular weight protein-tyrosine phosphatase (LMW-PTP) is an enzyme that is involved in the early events of platelet-derived growth factor (PDGF) receptor signal transduction, In fact, LMW-PTP is able to specifically bind and dephosphorylate activated PDGF receptor, thus modulating PDGF-induced mitogenesis. In particular, LMW-PTP is involved in pathways that regulate the transcription of the immediately early genes myc and fos in response to growth factor stimulation. Recently, we have found that LMW-PTP exists constitutively in cytosolic and cytoskeleton-associated localization and that, after PDGF stimulation, c-Src is able to bind and phosphorylate LMW-PTP only in the cytoskeleton-associated fraction. As a consequence of its phosphorylation, LMW-PTP increases its catalytic activity about 20-fold, In this study, our interest was to investigate the role of LMW-PTP phosphorylation in cellular response to PDGF stimulation, To address this issue, we have transfected in NIH-3T3 cells a mutant form of LMW-PTP in which the c-Src phosphorylation sites (Tyr(131) and Tyr(132)) were mutated to alanine, We have established that LMW-PTP phosphorylation by c-Src after PDGF treatment strongly influences both cell adhesion and migration. In addition, we have discovered a new LMW-PTP substrate localized in the cytoskeleton that becomes tyrosine-phosphorylated after PDGF treatment: p190Rho-GAP, Hence, LMW-PTP plays multiple roles in PDGF receptor-mediated mitogenesis, since it can bind and dephosphorylate PDGF receptor, and, at the same time, the cytoskeleton-associated LMW-PTP, through the regulation of the p190Rho-GAP phosphorylation state, controls the cytoskeleton rearrangement in response to PDGF stimulation.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Florence	Ramponi, G (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	raugei@cesit1.unifi.it	Chiarugi, Paola/CDD-7988-2022; Giannoni, Elisa/AAE-2092-2020; Camici, Giovanni/H-1631-2018	Chiarugi, Paola/0000-0001-7655-2969; raugei, giovanni/0000-0003-1294-786X; Giannoni, Elisa/0000-0001-7136-1098; Camici, Giovanni/0000-0002-0523-0695				Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bucciantini M, 1999, FEBS LETT, V456, P73, DOI 10.1016/S0014-5793(99)00828-5; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Cirri P, 1998, J BIOL CHEM, V273, P32522, DOI 10.1074/jbc.273.49.32522; CIRRI P, 1993, BIOCHIM BIOPHYS ACTA, V1161, P216, DOI 10.1016/0167-4838(93)90216-E; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Fincham VJ, 1999, J CELL SCI, V112, P947; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Vincent S, 1999, EUR J CELL BIOL, V78, P539, DOI 10.1016/S0171-9335(99)80019-3; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	31	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4640	4646		10.1074/jbc.275.7.4640	http://dx.doi.org/10.1074/jbc.275.7.4640			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671492	hybrid			2022-12-25	WOS:000085378200018
J	Klatt, AR; Nitsche, DP; Kobbe, B; Morgelin, M; Paulsson, M; Wagener, R				Klatt, AR; Nitsche, DP; Kobbe, B; Morgelin, M; Paulsson, M; Wagener, R			Molecular structure and tissue distribution of matrilin-3, a filament-forming extracellular matrix protein expressed during skeletal development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; CARTILAGE; MODULE; MEMBER; FAMILY	Matrilin-3 is a recently identified member of the superfamily of proteins containing von Willebrand factor Ih-like domains and is able to form hetero-oligomers with matrilin-1 (cartilage matrix protein) via a C-terminal coiled coil domain. Full-length matrilin-3 and a fragment lacking the assembly domain were expressed in 293-EBNA cells, purified, and subjected to biochemical characterization. Recombinantly expressed full-length matrilin-3 occurs as monomers, dimers, trimers, and tetramers, as detected by electron microscopy and SDS-polyacrylamide gel electrophoresis, whereas matrilin-3, purified from fetal calf cartilage, forms homotetramers as well as hetero-oligomers of variable stoichiometry with matrilin-1, In the matrix formed by cultured chondrosarcoma cells, matrilin-3 is found in a filamentous, collagen-dependent network connecting cells and in a collagen-independent pericellular network. Affinity-purified antibodies detect matrilin-3 expression in a variety of mouse cartilaginous tissues, such as sternum, articular, and epiphyseal cartilage, and in the cartilage anlage of developing bones. It is found both inside the lacunae and in the interterritorial matrix of the resting, proliferating, hypertrophic, and calcified cartilage zones, whereas the expression is lower in the superficial articular cartilage. In trachea and in costal cartilage of adult mice, an expression was seen in the perichondrium. Furthermore, matrilin-3 is found in bone, and its expression is, therefore, not restricted to chondroblasts and chondrocytes.	Univ Cologne, Inst Biochem, Fac Med, D-50931 Cologne, Germany; Univ Lund, Dept Cell & Mol Biol, S-22100 Lund, Sweden	University of Cologne; Lund University	Wagener, R (corresponding author), Univ Cologne, Inst Biochem, Fac Med, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.							Aszodi A, 1996, EUR J BIOCHEM, V236, P970, DOI 10.1111/j.1432-1033.1996.00970.x; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; Belluoccio D, 1998, GENOMICS, V53, P391, DOI 10.1006/geno.1998.5519; Belluoccio D, 1997, FEBS LETT, V415, P212, DOI 10.1016/S0014-5793(97)01126-5; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; Chen Q, 1999, MOL BIOL CELL, V10, P2149, DOI 10.1091/mbc.10.7.2149; Deak F, 1999, MATRIX BIOL, V18, P55, DOI 10.1016/S0945-053X(98)00006-7; Deak F, 1997, J BIOL CHEM, V272, P9268; DEBLOCK M, 1993, ANAL BIOCHEM, V215, P86, DOI 10.1006/abio.1993.1558; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; HAUSER N, 1994, J BIOL CHEM, V269, P25747; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; PAULSSON M, 1982, BIOCHEM J, V207, P207, DOI 10.1042/bj2070207; PAULSSON M, 1984, BIOCHEM J, V221, P623, DOI 10.1042/bj2210623; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; Wagener R, 1997, FEBS LETT, V413, P129, DOI 10.1016/S0014-5793(97)00895-8; Wagener R, 1998, FEBS LETT, V436, P123, DOI 10.1016/S0014-5793(98)01111-9; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; Wu JJ, 1998, J BIOL CHEM, V273, P17433, DOI 10.1074/jbc.273.28.17433	24	110	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3999	4006		10.1074/jbc.275.6.3999	http://dx.doi.org/10.1074/jbc.275.6.3999			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660556	hybrid			2022-12-25	WOS:000085288800040
J	Lynch, J; Suh, ER; Silberg, DG; Rulyak, S; Blanchard, N; Traber, PG				Lynch, J; Suh, ER; Silberg, DG; Rulyak, S; Blanchard, N; Traber, PG			The caudal-related homeodomain protein Cdx1 inhibits proliferation of intestinal epithelial cells by down-regulation of D-type cyclins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; HOMEOBOX GENE-EXPRESSION; TRANSCRIPTION; DIFFERENTIATION; ACTIVATION; PROMOTERS; SEQUENCE; ELEMENTS; CDX-2/3; BINDING	Gdx1 is a homeodomain transcription factor that regulates intestine-specific gene expression. Experimental evidence suggests that Cdx1 may be involved in cell cycle regulation, but its role is ill defined and the mechanisms have not been explored. We used stable transfection of inducible constructs and transient expression with a replication-deficient adenovirus to induce Cdx1 expression in rat IEC6 cells, a non-transformed intestinal epithelial cell line that does not express Cdx1 protein. Expression of Cdx1 markedly reduced proliferation of IEC6 cells with accumulation of cells in the G(0)/G(1) phase of the cell cycle. Cell cycle arrest was accompanied by an increase in the hypophosphorylated forms of the retinoblastoma protein (pRb) and the pRb-related p130 protein. Protein levels of multiple cyclin-dependent kinase inhibitors were either unchanged (p16, p18, p21, p27, and p57) or were not detected (p15 and p19), Most significantly, levels of cyclins D1 and D2 were markedly diminished with Cdx1 expression, but not cyclins D3, E, or the G(1) kinases, Additionally, cyclin-dependent kinase-4 activity was decreased in association with decreased cyclin D protein, We conclude that Cdx1 regulates intestinal epithelial cell proliferation by inhibiting progression through G(0)/G(1), most likely via modulation of cyclin D1 and D2 protein levels.	Univ Penn, Div Gastroenterol, Dept Med & Genet, Philadelphia, PA 19104 USA	University of Pennsylvania	Traber, PG (corresponding author), Hosp Univ Penn, 3400 Spruce St,100 Centrex, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK049210, P30DK050306, T32DK007066] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK49210, T32-DK07066, P30-DK50306] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; BONNER CA, 1995, GENOMICS, V28, P206, DOI 10.1006/geno.1995.1132; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; BRENT R, 1997, SHORT PROTOCOLS MOL; BURGLIN TR, 1994, COMPREHENSIVE CLASSI; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; Duluc I, 1997, J CELL SCI, V110, P1317; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EE HC, 1995, AM J PATHOL, V147, P586; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GERTZENBERG RH, 1994, J CELL BIOCHEM, V55, P22; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; JAMES R, 1991, J BIOL CHEM, V266, P3246; JAMES R, 1994, J BIOL CHEM, V269, P15229; Jin TR, 1996, MOL CELL BIOL, V16, P19; Jin TR, 1997, MOL ENDOCRINOL, V11, P203, DOI 10.1210/me.11.2.203; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; Lambert M, 1996, EUR J BIOCHEM, V236, P778, DOI 10.1111/j.1432-1033.1996.00778.x; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; MEYER BI, 1993, DEVELOPMENT, V117, P191; PETERSON MG, 1988, EUR J BIOCHEM, V174, P417, DOI 10.1111/j.1432-1033.1988.tb14114.x; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; Trinh KY, 1999, J BIOL CHEM, V274, P6011, DOI 10.1074/jbc.274.9.6011; TROELSEN JT, 1994, FEBS LETT, V342, P297, DOI 10.1016/0014-5793(94)80520-2; TROELSEN JT, 1992, J BIOL CHEM, V267, P20407; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; Yang D, 1998, GASTROENTEROLOGY, V114, pA707, DOI 10.1016/S0016-5085(98)82902-8	38	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4499	4506		10.1074/jbc.275.6.4499	http://dx.doi.org/10.1074/jbc.275.6.4499			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660624	hybrid			2022-12-25	WOS:000085288800108
J	Katayama, A; Fujita, N; Ishihama, A				Katayama, A; Fujita, N; Ishihama, A			Mapping of subunit-subunit contact surfaces on the beta ' subunit of Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL ASSEMBLY DOMAIN; ALPHA-SUBUNIT; FUNCTIONAL MAP; NUCLEOTIDE-SEQUENCE; ACTIVE-CENTER; BINDING; TRANSCRIPTION; PROTEIN; REGION; BETA'-SUBUNIT	The RNA polymerase core enzyme of Escherichia coli with the catalytic activity of RNA polymerization is assembled sequentially under the order: 2 alpha-->alpha(2)-->alpha(2)beta-->alpha(2)beta beta'. The core enzyme gains the activities of promoter recognition and transcription initiation after binding the sigma subunit, The subunit-subunit contact surfaces of beta' subunit (1407 residues) were analyzed by testing complex formation between various beta' fragments and either the alpha(2)beta complex or the sigma(70) subunit. Results indicate that two regions, one central region between residues 515 and 842 and the other COOH-terminal proximal region downstream from residue 1141, are involved in binding the alpha(2)beta complex; and the NH2-terminal proximal region between residues 201 and 345 plays a major role in binding the sigma(70) subunit. However, both alpha(2)beta binding sites have weak activity of the sigma(70) subunit; likewise, the sigma(70) subunit-contact surface has weak binding activity of the alpha(2)beta complex. The sites involved in the catalytic function of RNA polymerization are all located within two spacer regions sandwiched between these three subunit-subunit contact surfaces.	Grad Univ Adv Studies, Natl Inst Genet, Dept Mol Genet, Shizuoka 4118540, Japan; Grad Univ Adv Studies, Sch Life Sci, Shizuoka 4118540, Japan	Graduate University for Advanced Studies - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan	Ishihama, A (corresponding author), Grad Univ Adv Studies, Natl Inst Genet, Dept Mol Genet, Shizuoka 4118540, Japan.							Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; AZUMA Y, 1991, NUCLEIC ACIDS RES, V19, P461, DOI 10.1093/nar/19.3.461; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; Christie GE, 1996, J BACTERIOL, V178, P6991, DOI 10.1128/jb.178.23.6991-6993.1996; CLERGET M, 1995, J MOL BIOL, V248, P768, DOI 10.1006/jmbi.1995.0259; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; Fujita N, 1996, METHOD ENZYMOL, V273, P121; FUKUDA R, 1974, J MOL BIOL, V87, P523, DOI 10.1016/0022-2836(74)90102-8; GLASS RE, 1986, MOL GEN GENET, V203, P492, DOI 10.1007/BF00422075; Greiner DP, 1996, P NATL ACAD SCI USA, V93, P71, DOI 10.1073/pnas.93.1.71; HAYWARD RS, 1991, J MOL BIOL, V221, P23, DOI 10.1016/0022-2836(91)80197-3; HU J, 1990, P NATL ACAD SCI USA, V87, P1531, DOI 10.1073/pnas.87.4.1531; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; IGLOI GL, 1990, MOL GEN GENET, V221, P379, DOI 10.1007/BF00259403; ISHIHAMA A, 1972, BIOCHEMISTRY-US, V11, P1250, DOI 10.1021/bi00757a021; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1987, PROTEINS, V2, P42, DOI 10.1002/prot.340020106; Ishihama A, 1981, Adv Biophys, V14, P1; Ishihama A., 1997, NUCL ACIDS MOL BIOL, V11, P53; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; Jeon YH, 1997, J MOL BIOL, V267, P953, DOI 10.1006/jmbi.1997.0902; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KIMURA M, 1995, J MOL BIOL, V248, P756, DOI 10.1006/jmbi.1995.0258; KIMURA M, 1994, J MOL BIOL, V242, P107, DOI 10.1006/jmbi.1994.1562; KIMURA M, 1995, J MOL BIOL, V254, P342, DOI 10.1006/jmbi.1995.0621; Kimura M, 1996, GENES CELLS, V1, P517, DOI 10.1046/j.1365-2443.1996.d01-258.x; LUO JY, 1992, J BIOL CHEM, V267, P18175; Luo JY, 1996, GENES CELLS, V1, P819, DOI 10.1046/j.1365-2443.1996.700269.x; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; Miller A, 1997, SCIENCE, V275, P1655, DOI 10.1126/science.275.5306.1655; Miyake R, 1998, BIOCHEMISTRY-US, V37, P1344, DOI 10.1021/bi9723313; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; NEGISHI T, 1995, J MOL BIOL, V248, P723, DOI 10.1006/jmbi.1995.0254; Nomura T, 1999, BIOCHEMISTRY-US, V38, P1346, DOI 10.1021/bi982381n; OVCHINNIKOV YA, 1982, NUCLEIC ACIDS RES, V10, P4035, DOI 10.1093/nar/10.13.4035; Owens JT, 1998, P NATL ACAD SCI USA, V95, P6021, DOI 10.1073/pnas.95.11.6021; PUHLER G, 1989, NUCLEIC ACIDS RES, V17, P4517, DOI 10.1093/nar/17.12.4517; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; SHIMADA H, 1990, MOL GEN GENET, V221, P395, DOI 10.1007/BF00259404; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; Zakharova N, 1998, J BIOL CHEM, V273, P24912, DOI 10.1074/jbc.273.38.24912; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; Zhang GY, 1998, SCIENCE, V281, P262, DOI 10.1126/science.281.5374.262	46	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3583	3592		10.1074/jbc.275.5.3583	http://dx.doi.org/10.1074/jbc.275.5.3583			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652354	hybrid			2022-12-25	WOS:000085146500076
J	Lyman, SD; Escobar, S; Rousseau, AM; Armstrong, A; Fanslow, WC				Lyman, SD; Escobar, S; Rousseau, AM; Armstrong, A; Fanslow, WC			Identification of CD7 as a cognate of the human K12 (SECTM1) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELL; COLONY-STIMULATING FACTOR; MOLECULAR-CLONING; MONOCLONAL-ANTIBODIES; EXTRACELLULAR DOMAIN; CELIAC-DISEASE; CROSS-LINKING; GROWTH-FACTOR; ANTIGEN CD7; EXPRESSION	CD7 is a 40-kDa protein found primarily on T, NK, and pre-B cells; the function of the CD7 protein in the immune system is largely unknown. The K12 (SECTM1) protein was originally identified by its location just up-stream of the CD7 locus, The K12 gene encodes a transmembrane protein of unknown function. In order to clone a Kla-binding protein, we generated a soluble version of the human K12 protein by fusing its extracellular domain to the Fc portion of human IgG(1). Flow cytometry experiments showed that the K12-Fc fusion protein bound at high levels to both human T and NK cells. Precipitation experiments using K12-Fc on S-35-radiolabeled NK cells lysates indicated that the K12 cognate was an approximately 40-kDa protein. A human peripheral blood T cell cDNA expression library was screened with the K12-Fc protein, and two independent, positive cDNA clones were identified and sequenced. Both cDNAs encoded the same protein, which was CD7, Thus, K12 and CD7 are cognate proteins that are located next to each other on human chromosome 17q25. Additionally, we have cloned the gene encoding the mouse homologue of K12, shown that it maps near the mouse CD7 gene on chromosome 11, and established that the mouse K12 protein binds to mouse, but not human, CD7. Mouse K12-Fc inhibited in a dose-dependent manner concanavalin A-induced proliferation, but not anti-TcR alpha/beta induced proliferation, of mouse lymph node T cells, Human K12-Fc stimulated the up-regulation of CD25, CD54, and CD69 on human NK cells in vitro.	Immunex Res & Dev Corp, Seattle, WA 98101 USA		Lyman, SD (corresponding author), Immunex Res & Dev Corp, 51 Univ St, Seattle, WA 98101 USA.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; BARCENA A, 1995, LEUKEMIA LYMPHOMA, V17, P1; Baum W, 1996, BRIT J HAEMATOL, V95, P327, DOI 10.1046/j.1365-2141.1996.d01-1900.x; Bonilla FA, 1997, INT IMMUNOL, V9, P1875, DOI 10.1093/intimm/9.12.1875; CARREL S, 1991, EUR J IMMUNOL, V21, P1195, DOI 10.1002/eji.1830210515; CARRERA AC, 1988, J IMMUNOL, V141, P1919; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; Eiras P, 1998, CYTOMETRY, V34, P95, DOI 10.1002/(SICI)1097-0320(19980415)34:2<95::AID-CYTO6>3.0.CO;2-B; Flaherty L, 1998, MAMM GENOME, V9, P417, DOI 10.1007/s003359900788; Flavell DJ, 1997, BRIT J CANCER, V75, P1035, DOI 10.1038/bjc.1997.177; Frankel AE, 1997, LEUKEMIA LYMPHOMA, V26, P287, DOI 10.3109/10428199709051778; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; Haynes B F, 1990, Semin Immunol, V2, P67; HAYNES BF, 1981, IMMUNOL REV, V57, P127, DOI 10.1111/j.1600-065X.1981.tb00445.x; HAYNES BF, 1989, IMMUNOL TODAY, V10, P87, DOI 10.1016/0167-5699(89)90232-6; Hou ZC, 1996, BLOOD, V88, P124; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JUNG LKL, 1986, J CLIN INVEST, V77, P940, DOI 10.1172/JCI112393; JUNG LKL, 1992, CELL IMMUNOL, V141, P189, DOI 10.1016/0008-8749(92)90138-F; LAZAROVITS AI, 1993, J IMMUNOL, V150, P5163; LAZAROVITS AI, 1988, TRANSPLANT P, V20, P1253; Lee DM, 1996, INT IMMUNOL, V8, P1195, DOI 10.1093/intimm/8.8.1195; Lee DM, 1998, J IMMUNOL, V160, P5749; LEE DM, 1994, IMMUNOGENETICS, V39, P289, DOI 10.1007/BF00188794; Leta E, 1996, CELL IMMUNOL, V173, P15, DOI 10.1006/cimm.1996.0247; LETA E, 1995, CELL IMMUNOL, V165, P101, DOI 10.1006/cimm.1995.1192; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OSADA S, 1988, CYTOGENET CELL GENET, V47, P8, DOI 10.1159/000132494; Pauza ME, 1997, J IMMUNOL, V158, P3259; RABINOWICH H, 1994, J IMMUNOL, V152, P517; RABINOWICH H, 1994, J IMMUNOL, V153, P3504; SATO AI, 1994, J IMMUNOL, V152, P5142; SCHANBERG LE, 1995, J IMMUNOL, V155, P2407; Sempowski GD, 1999, J EXP MED, V189, P1011, DOI 10.1084/jem.189.6.1011; SHIMIZU Y, 1992, J EXP MED, V175, P577, DOI 10.1084/jem.175.2.577; Slentz-Kesler KA, 1998, GENOMICS, V47, P327, DOI 10.1006/geno.1997.5151; SPENCER J, 1989, GUT, V30, P339, DOI 10.1136/gut.30.3.339; YOSHIKAWA K, 1993, IMMUNOGENETICS, V37, P114, DOI 10.1007/BF00216834; YOSHIKAWA K, 1995, IMMUNOGENETICS, V41, P159, DOI 10.1007/BF00182331; YOSHIKAWA K, 1991, IMMUNOGENETICS, V33, P352, DOI 10.1007/BF00216694	45	27	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3431	3437		10.1074/jbc.275.5.3431	http://dx.doi.org/10.1074/jbc.275.5.3431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652336	hybrid			2022-12-25	WOS:000085146500058
J	Rehling, P; Skaletz-Rorowski, A; Girzalsky, W; Voorn-Brouwer, T; Franse, MM; Distel, B; Veenhuis, M; Kunau, WH; Erdmann, R				Rehling, P; Skaletz-Rorowski, A; Girzalsky, W; Voorn-Brouwer, T; Franse, MM; Distel, B; Veenhuis, M; Kunau, WH; Erdmann, R			Pex8p, an intraperoxisomal peroxin of Saccharomyces cerevisiae required for protein transport into peroxisomes binds the PTS1 receptor Pex5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI SHUTTLE VECTORS; TARGETING SIGNAL; 3-OXOACYL-COA THIOLASE; HANSENULA-POLYMORPHA; RESTRICTION SITES; PICHIA-PASTORIS; MATRIX PROTEINS; GENE ENCODES; IMPORT; YEAST	We report the characterization of ScPex8p, which is essential for peroxisomal biogenesis in Saccharomyces cerevisiae, Cells lacking Pex8p are characterized by the presence of peroxisomal membrane ghosts and mislocalization of peroxisomal matrix proteins of the PTS1 and PTS2 variety to the cytosol, Pex8p is tightly associated with the lumenal face of the peroxisomal membrane, Consistent with its intraperoxisomal localization, Pex8p contains a peroxisomal targeting signal 1, and it interacts with the PTS1 receptor Pex5p. However, the Pex5p/Pex8p association is also observed upon deletion of the PTS1 of Pex8p, suggesting that Pex8p contains a second binding site for Pex5p. The pex8 Delta mutant phenotype and the observed PTS1-independent interaction with the PTSI receptor suggest that Pex8p is involved in protein import into the peroxisomal matrix. In pex8 Delta cells, the PTS1 and PTS2 receptor still associate with membrane bound components of the protein import machinery, supporting the assumption that the Pex8p function in protein translocation follows the docking event.	Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, Div Cellular & Mol Medl, La Jolla, CA 92093 USA; Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands; Univ Groningen, Ctr Biol, Electron Microscopy Lab, NL-9751 NN Haren, Netherlands	Free University of Berlin; Ruhr University Bochum; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen	Erdmann, R (corresponding author), Free Univ Berlin, Inst Biochem, Thielallee 63, D-14195 Berlin, Germany.							Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Blobel F, 1996, EUR J BIOCHEM, V240, P468, DOI 10.1111/j.1432-1033.1996.0468h.x; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; BUTT TR, 1984, P NATL ACAD SCI-BIOL, V81, P3332, DOI 10.1073/pnas.81.11.3332; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CRANE DI, 1994, J BIOL CHEM, V269, P21835; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Elgersma Y, 1996, BBA-REV BIOMEMBRANES, V1286, P269, DOI 10.1016/S0304-4157(96)00012-3; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; ERDMANN R, 1994, YEAST, V10, P1173, DOI 10.1002/yea.320100905; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Erdmann R, 1997, TRENDS CELL BIOL, V7, P400, DOI 10.1016/S0962-8924(97)01126-4; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Geraghty MT, 1999, P NATL ACAD SCI USA, V96, P2937, DOI 10.1073/pnas.96.6.2937; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; HARLOW E, 1988, ANTIBODIES, P451; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LIU H, 1995, J BIOL CHEM, V270, P10940, DOI 10.1074/jbc.270.18.10940; Maniatis T., 1982, MOL CLONING LAB MANU; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Rehling P, 1996, ANN NY ACAD SCI, V804, P34, DOI 10.1111/j.1749-6632.1996.tb18606.x; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith JJ, 1997, MOL CELL BIOL, V17, P2511, DOI 10.1128/MCB.17.5.2511; Subramani S, 1996, CURR OPIN CELL BIOL, V8, P513, DOI 10.1016/S0955-0674(96)80029-9; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Subramani S, 1996, J BIOL CHEM, V271, P32483, DOI 10.1074/jbc.271.51.32483; Tabak HF, 1995, COLD SPRING HARB SYM, V60, P649, DOI 10.1101/SQB.1995.060.01.069; vanderKlei IJ, 1996, ANN NY ACAD SCI, V804, P47; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737	61	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3593	3602		10.1074/jbc.275.5.3593	http://dx.doi.org/10.1074/jbc.275.5.3593			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652355	Green Published, hybrid			2022-12-25	WOS:000085146500077
J	Romey, MC; Pallares-Ruiz, N; Mange, A; Mettling, C; Peytavi, R; Demaille, J; Claustres, M				Romey, MC; Pallares-Ruiz, N; Mange, A; Mettling, C; Peytavi, R; Demaille, J; Claustres, M			A naturally occurring sequence variation that creates a YY1 element is associated with increased cystic fibrosis transmembrane conductance regulator gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; DNA-BINDING ACTIVITY; PROMOTER REGION; 5'-FLANKING REGION; ADENOVIRUS E1A; CFTR GENE; IDENTIFICATION; TRANSCRIPTION; PROTEIN; SITE	We have identified previously a novel complex mutant allele in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in a patient affected with cystic fibrosis (CF), This allele contained a mutation in CFTR exon II known to cause CF (S549R(T>G)), associated with the first alteration described so far in the minimal CFTR promoter region (-102T>A), Studies on genotype-phenotype correlations revealed striking differences between patients carrying mutation (S549R(T>G)) alone, who had a severe disease, and patients carrying the complex allele (-102(T>A) + S549R(T > G)), who exhibited milder forms of CF. We thus postulated that the sequence change (-102T>A) may attenuate the effects of the severe (S549R(T>G)) mutation through regulation of CFTR expression, Analysis of transiently transfected cell lines with wild-type and -102A variant human CFTR-directed luciferase reporter genes demonstrates that constructs containing the -102A variant (which creates a Yin Yang 1 (YY1) core element) increases CFTR expression significantly. Electrophoretic mobility shift. assays indicate that the -102 site is located in a region of multiple DNA-protein interactions and that the -102A allele recruits specifically an additional nuclear protein related to YY1, The finding that the YY1-binding allele causes a significant increase in CFTR expression in vitro may allow a better understanding of the milder phenotype observed in patients who carry a severe CF mutation within the same gene.	Univ Montpellier, Ctr Spitalier, Inst Biol, Mol Genet Lab, F-34060 Montpellier, France; Inst Biol, Virol Lab, F-34060 Montpellier, France; CNRS, Lab Biol Encephalopathies Spongiformes Transmissi, Montpellier 5, France; CNRS, Lab Virol Mol & Transfert Gene, Inst Genet Humaine Unite Propre Rech 1142, Montpellier 5, France	Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Claustres, M (corresponding author), Univ Montpellier, Ctr Spitalier, Inst Biol, Mol Genet Lab, F-34060 Montpellier, France.		Mange, Alain/U-1157-2017; ROMEY-CHATELAIN, Marie-Catherine/A-9623-2008	Mange, Alain/0000-0002-1566-9407; Mettling, Clement/0000-0002-4963-2928				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BIENVENU T, 1995, HUM GENET, V95, P698; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; CHOU JL, 1991, J BIOL CHEM, V266, P24471; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Griesenbeck J, 1999, FEBS LETT, V443, P20, DOI 10.1016/S0014-5793(98)01671-8; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HARRIS A, 1991, DEVELOPMENT, V113, P305; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; Ishiguro H, 1998, J BIOL CHEM, V273, P21941, DOI 10.1074/jbc.273.34.21941; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; Kim JC, 1998, J BIOL CHEM, V273, P26130, DOI 10.1074/jbc.273.40.26130; Kim JS, 1996, NUCLEIC ACIDS RES, V24, P4341, DOI 10.1093/nar/24.21.4341; Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649; KOH J, 1993, J BIOL CHEM, V268, P15912; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; Matthews RP, 1996, J BIOL CHEM, V271, P31869, DOI 10.1074/jbc.271.50.31869; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Romey MC, 1999, HUM GENET, V105, P145, DOI 10.1007/s004390051077; Romey MC, 1999, J MED GENET, V36, P263; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Rutter JL, 1998, CANCER RES, V58, P5321; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Smith AN, 1996, J BIOL CHEM, V271, P9947, DOI 10.1074/jbc.271.17.9947; SMITH AN, 1995, BIOCHEM BIOPH RES CO, V211, P274, DOI 10.1006/bbrc.1995.1807; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; TREZISE AEO, 1993, HUM MOL GENET, V2, P213, DOI 10.1093/hmg/2.3.213; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; Verlingue C, 1998, J MED GENET, V35, P137, DOI 10.1136/jmg.35.2.137; Vuillaumier S, 1997, MOL BIOL EVOL, V14, P372, DOI 10.1093/oxfordjournals.molbev.a025773; Vuillaumier S, 1997, BIOCHEM J, V327, P651, DOI 10.1042/bj3270651; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	53	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3561	3567		10.1074/jbc.275.5.3561	http://dx.doi.org/10.1074/jbc.275.5.3561			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652351	hybrid			2022-12-25	WOS:000085146500073
J	Rosenfeldt, H; Grinnell, F				Rosenfeldt, H; Grinnell, F			Fibroblast quiescence and the disruption of ERK signaling in mechanically unloaded collagen matrices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; PROTEIN-KINASE-C; MAP-KINASE; IN-VITRO; GROWTH-CONTROL; ACTIVATION; PROLIFERATION; CONTRACTION; PDGF; FOS	Fibroblasts in mechanically unloaded collagen matrices had low levels of DNA synthesis compared with cells in mechanically loaded matrices. Under the former conditions, the cellular ERK signaling pathway appeared to be disrupted. Also, pharmacologic inhibition of ERK signaling blocked DNA synthesis by fibroblasts in mechanically loaded matrices. These results were consistent with the idea that mechanoregulation of fibroblast DNA synthesis in collagen matrices occurs at the level of the ERK signaling pathway.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Grinnell, F (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NIAMS NIH HHS [AR41940] Funding Source: Medline; NIGMS NIH HHS [GM31321] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031321, R01GM031321] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; Desmouliere A, 1996, MOL CELLULAR BIOL WO, P391; EASTWOOD M, 1994, BBA-GEN SUBJECTS, V1201, P186, DOI 10.1016/0304-4165(94)90040-X; Fluck J, 1998, J INVEST DERMATOL, V110, P153, DOI 10.1046/j.1523-1747.1998.00095.x; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; Lin TH, 1997, J BIOL CHEM, V272, P8849; LIN YC, 1993, J CELL BIOL, V122, P663, DOI 10.1083/jcb.122.3.663; Lin YC, 1998, EXP CELL RES, V240, P377, DOI 10.1006/excr.1998.4013; MARQUARDT B, 1994, ONCOGENE, V9, P3213; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; NAKAGAWA S, 1989, EXP CELL RES, V182, P572, DOI 10.1016/0014-4827(89)90260-7; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rosenfeldt H, 1998, MOL CELL BIOL, V18, P2659, DOI 10.1128/MCB.18.5.2659; Sambrook J., 2002, MOL CLONING LAB MANU; SARBER R, 1981, MECH AGEING DEV, V17, P107, DOI 10.1016/0047-6374(81)90077-4; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; SINGER II, 1984, J CELL BIOL, V98, P2091, DOI 10.1083/jcb.98.6.2091; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273; [No title captured]	46	74	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3088	3092		10.1074/jbc.275.5.3088	http://dx.doi.org/10.1074/jbc.275.5.3088			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652290	hybrid			2022-12-25	WOS:000085146500012
J	Foster, LC; Wiesel, P; Huggins, GS; Panares, R; Chin, MT; Pellacani, A; Perrella, MA				Foster, LC; Wiesel, P; Huggins, GS; Panares, R; Chin, MT; Pellacani, A; Perrella, MA			Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1 beta in vascular smooth muscle cells	FASEB JOURNAL			English	Article						inflammation; gene transcription; adhesion molecule; arteriosclerosis	INTERCELLULAR-ADHESION MOLECULE-1; EPIDERMAL GROWTH-FACTOR; NF-KAPPA-B; TRANSCRIPTION FACTORS; CHROMOSOMAL-PROTEINS; METASTATIC BEHAVIOR; HYALURONAN-BINDING; ENDOTHELIAL-CELLS; GLYCOPROTEIN CD44; DNA-BINDING	CD44 is a multifunctional cell adhesion molecule that participates in pathological states such as inflammation and tumorigenesis. CD44 is induced on vascular smooth muscle cells after arterial wall injury and may mediate their proliferation and migration into the neointima during arteriosclerosis. We have demonstrated elsewhere that the proinflammatory cytokine interleukin (IL)-1 beta upregulates CD44 mRNA and protein expression in cultured rat aortic smooth muscle cells (RASMC) by increasing gene transcription. By transient transfection of 5'-deletion constructs into RASMC, we show in the present study that a conserved AP-1 site 110 base pairs from the transcription start site of the mouse CD44 promoter is important for basal activity, Mutation of the AP-1 site significantly reduced induction of promoter activity by IL-1 beta, and electrophoretic mobility shift assays demonstrated that Fos and c-Jun were present in the CD44 AP-1 binding complex after IL-1 beta stimulation, in addition, cotransfection of the architectural transcription factor high mobility group (HMG)-I(Y) protein with c-Fos and c-Jun markedly increased trans-activation of the CD44 promoter, Taken together, our studies demonstrate that AP-1 proteins are a central regulatory component used by IL-1 beta to modulate expression of CD44 during an inflammatory response in vascular smooth muscle cells and that transcription of CD44 by AP-1 proteins is enhanced by HMG-1(Y).	Brigham & Womens Hosp, Program Dev Cardiovasc Biol, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Program Dev Cardiovasc Biol, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiac Unit, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Perrella, MA (corresponding author), Brigham & Womens Hosp, Program Dev Cardiovasc Biol, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	perrella@cvlab.harvard.edu			NHLBI NIH HHS [HL03745, HL60788, HL03194] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLINTON SK, 1991, AM J PATHOL, V138, P1005; CLINTON SK, 1992, ARCH PATHOL LAB MED, V116, P1292; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COUFFINHAL T, 1994, CIRC RES, V74, P225, DOI 10.1161/01.RES.74.2.225; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Fedele M, 1996, CANCER RES, V56, P1896; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Fitzgerald K, 1997, BIOCHEM SOC T, V25, pS185, DOI 10.1042/bst025185s; Foster LC, 1998, J BIOL CHEM, V273, P20341, DOI 10.1074/jbc.273.32.20341; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GIACHELLI CM, 1995, ANN NY ACAD SCI, V760, P109, DOI 10.1111/j.1749-6632.1995.tb44624.x; GIANCOTTI V, 1993, EUR J BIOCHEM, V213, P825, DOI 10.1111/j.1432-1033.1993.tb17825.x; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HERRLICH P, 1993, PEZ FDN SYM, V4, P265; HOFMANN M, 1993, CANCER RES, V53, P1516; Holth LT, 1997, DNA CELL BIOL, V16, P1299, DOI 10.1089/dna.1997.16.1299; IKEDA U, 1993, ATHEROSCLEROSIS, V104, P61, DOI 10.1016/0021-9150(93)90176-U; Jain M, 1996, J CLIN INVEST, V97, P596, DOI 10.1172/JCI118455; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Levesque MC, 1996, J IMMUNOL, V156, P1557; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; MIANO JM, 1993, AM J PATHOL, V142, P715; MOYER CF, 1991, AM J PATHOL, V138, P951; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; NILSSON J, 1993, CARDIOVASC RES, V27, P1184, DOI 10.1093/cvr/27.7.1184; NOMOTO A, 1988, ATHEROSCLEROSIS, V72, P213, DOI 10.1016/0021-9150(88)90083-4; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Pellacani A, 1999, J BIOL CHEM, V274, P1525, DOI 10.1074/jbc.274.3.1525; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Perrella MA, 1999, J BIOL CHEM, V274, P9045, DOI 10.1074/jbc.274.13.9045; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; REEVES R, 1990, J BIOL CHEM, V265, P8573; Riessen R, 1996, CIRCULATION, V93, P1141, DOI 10.1161/01.CIR.93.6.1141; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; ROSS R, 1995, MOL CARDIOVASCULAR M, P11; RUDY W, 1993, CANCER RES, V53, P1262; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; WANG XK, 1994, CARDIOVASC RES, V28, P1808, DOI 10.1093/cvr/28.12.1808; WARNER SJC, 1987, J EXP MED, V165, P1316, DOI 10.1084/jem.165.5.1316; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WEGNER M, 1990, BIOCHEM BIOPH RES CO, V166, P1110, DOI 10.1016/0006-291X(90)90981-R; Weiss JM, 1998, J INVEST DERMATOL, V111, P227, DOI 10.1046/j.1523-1747.1998.00286.x; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; YANG-YEN H-F, 1990, New Biologist, V2, P351; Ye L, 1997, CIRC RES, V81, P289, DOI 10.1161/01.RES.81.3.289; Yet SF, 1998, J BIOL CHEM, V273, P10530, DOI 10.1074/jbc.273.17.10530; Zhang M, 1996, CLIN EXP METASTAS, V14, P268; Zhang M, 1997, J BIOL CHEM, V272, P14139, DOI 10.1074/jbc.272.22.14139	66	47	53	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					368	378		10.1096/fasebj.14.2.368	http://dx.doi.org/10.1096/fasebj.14.2.368			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657993				2022-12-25	WOS:000085184800016
J	Farrar, JD; Smith, JD; Murphy, TL; Murphy, KM				Farrar, JD; Smith, JD; Murphy, TL; Murphy, KM			Recruitment of Stat4 to the human interferon-alpha/beta receptor requires activated Stat2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; IFN-ALPHA; PHENOTYPE DEVELOPMENT; T-CELLS; GAMMA; IL-12; PROTEIN; CLONING; TH1; LYMPHOCYTES	Stat4 activation is involved in differentiation of type 1 helper (Th1) T cells. Although State is activated by interleukin (IL)-12 in both human and murine T cells, State is activated by interferon (IFN)-alpha only in human, but not murine, CD4+ T cells. This species-specific difference in cytokine activation of State underlies critical differences in Th1 development in response to cytokines and is important to the interpretation of murine models of immunopathogenesis. Here, we sought to determine the mechanism of Stat4 recruitment and activation by the human IFN-alpha receptor. Analysis of phosphopeptide binding analysis suggests that State does not interact directly with tyrosine-phosphorylated amino acid residues within the cytoplasmic domains of either of the subunits of the IFN-alpha receptor complex. Expression of murine State in the Stat1-deficient U3A and the Stat2-deficient U6A cell lines shows that IFN-alpha-induced State phosphorylation requires the presence of activated Stat2 but not Stat1. Thus, in contrast to the direct recruitment of Stat4 by the IL-12 receptor, Stat4 activation by the human IFN-alpha receptor occurs through indirect recruitment by intermediates involving Stat2.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Ctr Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Murphy, KM (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave, St Louis, MO 63110 USA.	murphy@immunology.wustl.edu			NCI NIH HHS [CA09547] Funding Source: Medline; NIAID NIH HHS [AIDK39676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BRINKMANN V, 1993, J EXP MED, V178, P1655, DOI 10.1084/jem.178.5.1655; Cho SS, 1996, J IMMUNOL, V157, P4781; COHEN B, 1995, MOL CELL BIOL, V15, P4208; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; Cook JR, 1996, J BIOL CHEM, V271, P13448, DOI 10.1074/jbc.271.23.13448; Dumler I, 1999, J BIOL CHEM, V274, P24059, DOI 10.1074/jbc.274.34.24059; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Guler ML, 1997, J IMMUNOL, V159, P1767; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kim SH, 1997, GENE, V196, P279, DOI 10.1016/S0378-1119(97)00240-0; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Naeger LK, 1999, J BIOL CHEM, V274, P1875, DOI 10.1074/jbc.274.4.1875; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Owczarek CM, 1997, J BIOL CHEM, V272, P23865, DOI 10.1074/jbc.272.38.23865; PARRONCHI P, 1992, J IMMUNOL, V149, P2977; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; Ranganath S, 1998, J IMMUNOL, V161, P3822; Rogge L, 1998, J IMMUNOL, V161, P6567; SOH JM, 1994, J BIOL CHEM, V269, P18102; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; Wenner CA, 1996, J IMMUNOL, V156, P1442; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459	38	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2693	2697		10.1074/jbc.275.4.2693	http://dx.doi.org/10.1074/jbc.275.4.2693			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644731	hybrid			2022-12-25	WOS:000085128000063
J	Habuchi, H; Tanaka, M; Habuchi, O; Yoshida, K; Suzuki, H; Ban, K; Kimata, K				Habuchi, H; Tanaka, M; Habuchi, O; Yoshida, K; Suzuki, H; Ban, K; Kimata, K			The occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HAMSTER OVARY CELLS; MOLECULAR-CLONING; DEACETYLASE/N-SULFOTRANSFERASE; CARCINOMA-CELLS; BINDING SEQUENCE; CDNA CLONING; BIOSYNTHESIS; EXPRESSION; PROTEOGLYCANS	We previously cloned heparan sulfate 6-O-sulfotransferase (HS6ST) (Habuchi, H., Kobayashi, M., and Kimata, K. (1998) J. Biol. Chem. 273, 9208-9213). In this study, we report the cloning and characterization of three mouse isoforms of HS6ST, a mouse homologue to the original human HS6ST (HS6ST-1) and two novel HS6STs (HS6ST-2 and HS6ST-3). The cDNAs have been obtained from mouse brain cDNA library by cross-hybridization with human HS6ST cDNA The three cDNAs contained single open reading frames that predicted type II transmembrane proteins composed of 401, 506, and 470 amino acid residues, respectively. Amino acid sequence of HS6ST-1 was 51 and 57% identical to those of HS6ST-2 and HS6ST-3, respectively. HS6ST-2 and HS6ST-3 had the 50% identity. Overexpression of each isoform in COS-7 cells resulted in about 10-fold increase of HS6ST activity, The three isoforms purified with anti-FLAG antibody affinity column transferred sulfate to heparan sulfate and heparin but not to other glycosaminoglycans. Each isoform showed different specificity toward the isomeric hexuronic acid adjacent to the targeted N-sulfoglucosamine; HS6ST-1 appeared to prefer the iduronosyl N-sulfoglucosamine while HS6ST-2 had a different preference, depending upon the substrate concentrations, and HS6ST-3 acted on either substrate. Northern analysis showed that the expression of each message in various tissues was characteristic to the respective isoform. HS6ST-1 was expressed strongly in liver, and HS6ST-2 was expressed mainly in brain and spleen. In contrast, HS6ST-3 was expressed rather ubiquitously. These results suggest that the expression of these isoforms may be regulated in tissue specific manners and that each isoform may be involved in the synthesis of heparan sulfates with tissue-specific structures and functions.	Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 4488542, Japan; Seikagaku Corp, Tokyo 1030023, Japan	Aichi Medical University; Aichi University Education; Seikagaku Corporation	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan.							Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BERNFIELD M, 1992, ANN REV CELL BIOL, V8, P369; Binari RC, 1997, DEVELOPMENT, V124, P2623; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; Brickman YG, 1998, GLYCOBIOLOGY, V8, P463, DOI 10.1093/glycob/8.5.463; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; LIND T, 1993, J BIOL CHEM, V268, P20705; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl B, 1997, J BIOL CHEM, V272, P26091, DOI 10.1074/jbc.272.42.26091; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Rostand KS, 1997, INFECT IMMUN, V65, P1; Salmivirta M, 1998, GLYCOBIOLOGY, V8, P1029, DOI 10.1093/glycob/8.10.1029; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; Stickens D, 1998, NAT GENET, V19, P110, DOI 10.1038/458; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998	77	185	199	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2859	2868		10.1074/jbc.275.4.2859	http://dx.doi.org/10.1074/jbc.275.4.2859			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644753	hybrid			2022-12-25	WOS:000085128000085
J	Hirohashi, T; Suzuki, H; Takikawa, H; Sugiyama, Y				Hirohashi, T; Suzuki, H; Takikawa, H; Sugiyama, Y			ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION TRANSPORTER; PRIMARY ACTIVE-TRANSPORT; CONJUGATE EXPORT PUMP; CANALICULAR MEMBRANE; BILIARY-SECRETION; CMOAT MRP2; LIVER; EXPRESSION; ACIDS; GENE	We have previously shown that cloned rat multidrug resistance-associated protein 3 (Mrp3) has the ability to transport organic anions such as 17 beta-estradiol 17-beta-D-glucuronide (E(2)17 beta G) and has a different substrate specificity from MRP1 and MRP2 in that glutathione conjugates are poor substrates for Mrp3 (Hirohashi, T,, Suzuki, H., and Sugiyama, Y, (1999) J, Biol. Chem. 274, 15181-15185). In the present study, the involvement of Mrp3 in the transport of endogenous bile salts was investigated using membrane vesicles from LLC-PK1 cells transfected with rat Mrp3 cDNA The ATP-dependent uptake of [H-3]taurocholate (TC), [C-14]glycocholate (GC), [H-3]taurochenodeoxycholate-3-sulfate (TCDC-S), and [H-3]taurolithocholate-3-sulfate (TLC-S) was markedly stimulated by Mrp3 transfection in LLC-PK1 cells. The extent of Mrp3-mediated transport of bile salts was in the order, TLC-S > TCDC-S > TC > GC. The K-m and V-max values for the uptake of TC and TLC-S were K-m = 15.9 +/- 4.9 mu M and V-max = 50.1 +/- 9.3 pmol/min/mg of protein and K-m = 3.06 +/- 0.57 mu M and V-max = 161.9 +/- 21.7 pmol/min/mg of protein, respectively. At 55 nM [H-3]E(2)17 beta G and 1.2 mu M [H-3]TC, the apparent K-m values for ATP were 1.36 and 0.66 mM, respectively, TC, GC, and TCDC-S inhibited the transport of [H-3]E(2)17 beta G and [H-3]TC to the same extent with an apparent IC50 of similar to 10 mu M. TLC-S inhibited the uptake of [H-3]E(2)17 beta G and [H-3]TC most potently (IC50 of similar to 1 mu M) among the bile salts examined, whereas cholate weakly inhibited the uptake (IC50 similar to 75 mu M). Although TC and GC are transported by bile salt export pump/sister of P-glycoprotein, but not by MRP2, and TCDC-S and TLC-S are transported by MRP2, but not by bile salt export pump/sister of P-glycoprotein, it was found that Mrp3 accepts all these bile salts as substrates, This information, together with the finding that MRP3 is extensively expressed on the basolateral membrane of human cholangiocytes, suggests that MRP3/Mrp3 plays a significant role in the cholehepatic circulation of bile salts.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Teikyo Univ, Sch Med, Dept Med, Itabashi Ku, Tokyo 1730003, Japan	University of Tokyo; Teikyo University	Suzuki, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	suzuki@seizai.f.u-tokyo.ac.jp						Akita H, 1999, HEPATOLOGY, V30, p530A; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui YH, 1999, MOL PHARMACOL, V55, P929; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Gartung C, 1996, GASTROENTEROLOGY, V110, P199, DOI 10.1053/gast.1996.v110.pm8536857; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Hirohashi T, 1998, MOL PHARMACOL, V53, P1068; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; Ishikawa T, 1997, BIOSCIENCE REP, V17, P189, DOI 10.1023/A:1027385513483; Ito K, 1998, J BIOL CHEM, V273, P1684, DOI 10.1074/jbc.273.3.1684; Jedlitschky G, 1996, CANCER RES, V56, P988; Keppler D, 1997, FASEB J, V11, P509, DOI 10.1096/fasebj.11.7.9212074; Kinoshita S, 1998, PHARMACEUT RES, V15, P1851, DOI 10.1023/A:1011953906065; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kool M, 1997, CANCER RES, V57, P3537; KUIPERS F, 1989, J LIPID RES, V30, P1835; KUIPERS F, 1988, J CLIN INVEST, V81, P1593, DOI 10.1172/JCI113493; Lazaridis KN, 1997, J CLIN INVEST, V100, P2714, DOI 10.1172/JCI119816; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Love MW, 1998, CURR OPIN LIPIDOL, V9, P225, DOI 10.1097/00041433-199806000-00007; Madon J, 1997, FEBS LETT, V406, P75, DOI 10.1016/S0014-5793(97)00245-7; MULLER M, 1991, J BIOL CHEM, V266, P18920; Muller M, 1998, J HEPATOL, V28, P344, DOI 10.1016/0168-8278(88)80024-2; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; MURATA N, 1983, STEROIDS, V42, P575, DOI 10.1016/0039-128X(83)90121-6; Niinuma K, 1997, J PHARMACOL EXP THER, V282, P866; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OGAWA K, 2000, IN PRESS AM J PHYSL; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; Suzuki H, 1998, SEMIN LIVER DIS, V18, P359, DOI 10.1055/s-2007-1007170; TAKIKAWA H, 1991, HEPATOLOGY, V14, P352, DOI 10.1002/hep.1840140223; van Aubel RAMH, 1998, MOL PHARMACOL, V53, P1062; WEINBERG SL, 1986, J CLIN INVEST, V78, P44, DOI 10.1172/JCI112571; YOON YB, 1986, GASTROENTEROLOGY, V90, P837, DOI 10.1016/0016-5085(86)90859-0; Zhang J, 1997, J LABELLED COMPD RAD, V39, P159	41	269	276	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2905	2910		10.1074/jbc.275.4.2905	http://dx.doi.org/10.1074/jbc.275.4.2905			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644759	hybrid			2022-12-25	WOS:000085128000091
J	Ritz, D; Patel, H; Doan, B; Zheng, M; Aring;slund, F; Storz, G; Beckwith, J				Ritz, D; Patel, H; Doan, B; Zheng, M; Aring;slund, F; Storz, G; Beckwith, J			Thioredoxin 2 is involved in the oxidative stress response in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; DISULFIDE BOND FORMATION; SALMONELLA-TYPHIMURIUM; TRANSCRIPTION FACTOR; MUTANT THIOREDOXINS; EXPRESSION; GLUTAREDOXIN; ACTIVATION; CYTOPLASM; SEQUENCE	Two genes encoding thioredoxin are found on the Escherichia coli genome. Both of them are capable of reducing protein disulfide bonds in vivo and in vitro. The catalytic site contains a Cys-X-1-X-2-Cys motif in a so-called thioredoxin fold. Thioredoxin 2 has two additional pairs of cysteines in a non-conserved N-terminal domain. This domain does not appear to be important for the function of thioredoxin 2 in donating electrons to ribonucleotide reductase, 3'-phosphoadenylsulfate-reductase, or the periplasmic disulfide isomerase DsbC. Our results suggests that the two thioredoxins are equivalent for most of the in vivo functions that were tested. On the other hand, transcriptional regulation is different. The expression of trxC is regulated by the transcriptional activator OxyR in response to oxidative stress. Oxidized OxyR binds directly to the trxC promoter and induces its expression in response to elevated hydrogen peroxide levels or the disruption of one or several of the cytoplasmic redox pathways. Mutants lacking thioredoxins 1 and 2 are more resistant to high levels of hydrogen peroxide, whereas they are more sensitive to diamide, a disulfide bond-inducing agent.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; NICHHD, NIH, Cell Biol & Metab Branch, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Beckwith, J (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.	Jon_Beckwith@hms.harvard.edu		Storz, Gisela/0000-0001-6698-1241	NIGMS NIH HHS [GM41883] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041883] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Aslund F, 1999, J BACTERIOL, V181, P1375; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; Fetrow JS, 1998, J MOL BIOL, V282, P703, DOI 10.1006/jmbi.1998.2061; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; GUZMAN LM, 1992, J BACTERIOL, V174, P7716, DOI 10.1128/JB.174.23.7717-7728.1992; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HUBER HE, 1986, J BIOL CHEM, V261, P5006; Iwata S, 1997, J IMMUNOL, V158, P3108; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; KLECKNER N, 1991, METHOD ENZYMOL, V204, P139; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; MOSKOVITZ J, 1995, J BACTERIOL, V177, P502, DOI 10.1128/jb.177.3.502-507.1995; Mouaheb N, 1998, P NATL ACAD SCI USA, V95, P3312, DOI 10.1073/pnas.95.6.3312; O'Toole GA, 1998, MOL MICROBIOL, V28, P449, DOI 10.1046/j.1365-2958.1998.00797.x; Poole LB, 1996, BIOCHEMISTRY-US, V35, P65, DOI 10.1021/bi951888k; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; RUSSEL M, 1985, P NATL ACAD SCI USA, V82, P29, DOI 10.1073/pnas.82.1.29; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SCHULZEOSTHOFF K, 1995, METHOD ENZYMOL, V252, P253; SINGER M, 1989, MICROBIOL REV, V53, P1; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; STORZ G, 1994, METHOD ENZYMOL, V234, P217; Takemoto T, 1998, FREE RADICAL BIO MED, V24, P556, DOI 10.1016/S0891-5849(97)00287-6; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zheng M, 1999, J BACTERIOL, V181, P4639, DOI 10.1128/JB.181.15.4639-4643.1999	36	116	124	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2505	2512		10.1074/jbc.275.4.2505	http://dx.doi.org/10.1074/jbc.275.4.2505			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644706	hybrid			2022-12-25	WOS:000085128000038
J	Saika, S; Shiraishi, A; Saika, S; Liu, CY; Funderburgh, JL; Kao, CWC; Converse, RL; Kao, WWY				Saika, S; Shiraishi, A; Saika, S; Liu, CY; Funderburgh, JL; Kao, CWC; Converse, RL; Kao, WWY			Role of lumican in the corneal epithelium during wound healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; COLLAGENASE EXPRESSION; GLYCOPROTEIN-SYNTHESIS; TARGETED DISRUPTION; ENDOTHELIAL-CELLS; SKIN FRAGILITY; SHEET MOVEMENT; MOUSE LUMICAN; SMOOTH-MUSCLE; DECORIN	Lumican regulates collagenous matrix assembly as a keratan sulfate proteoglycan in the cornea and is also present in the connective tissues of other organs and embryonic corneal stroma as a glycoprotein. in normal unwounded cornea, lumican is expressed by stromal keratocytes. Our data show that injured mouse corneal epithelium ectopically and transiently expresses lumican during the early phase of wound healing, suggesting a potential lumican functionality unrelated to regulation of collagen fibrillogenesis, e.g. modulation of epithelial cell adhesion or migration. An anti-lumican antibody was found to retard corneal epithelial wound healing in cultured mouse eyes. Healing of a corneal epithelial injury in Lum(-/-) mice was significantly delayed compared with Lum(+/-) mice. These observations indicate that lumican expressed in injured epithelium may modulate cell behavior such as adhesion or migration, thus contributing to corneal epithelial wound healing.	Univ Cincinnati, Med Ctr, Dept Ophthalmol, Cincinnati, OH 45267 USA; Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15213 USA	University System of Ohio; University of Cincinnati; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kao, WWY (corresponding author), Univ Cincinnati, Med Ctr, Dept Ophthalmol, Hlth Profess Bldg,Suite 350,ML0527,Eden & Bethesd, Cincinnati, OH 45267 USA.			Liu, Chia-yang/0000-0002-8398-5516	NATIONAL EYE INSTITUTE [R01EY011845, R01EY009368, R01EY010556] Funding Source: NIH RePORTER; NEI NIH HHS [EY11845, EY10556, R01 EY010556, R01 EY009368-08, EY09368, R01 EY011845, R01 EY009368] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Brown DL, 1997, SURGERY, V121, P372, DOI 10.1016/S0039-6060(97)90306-8; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Delorenzi NJ, 1996, INT J BIOL MACROMOL, V19, P15, DOI 10.1016/0141-8130(96)01094-X; Fullwood NJ, 1996, INVEST OPHTH VIS SCI, V37, P1256; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; FUNDERBURGH JL, 1995, INVEST OPHTH VIS SCI, V36, P2296; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Funderburgh JL, 1998, INVEST OPHTH VIS SCI, V39, P1957; Funderburgh JL, 1997, INVEST OPHTH VIS SCI, V38, P1159; GIPSON IK, 1984, DEV BIOL, V101, P212, DOI 10.1016/0012-1606(84)90131-3; GIPSON IK, 1982, DEV BIOL, V92, P259, DOI 10.1016/0012-1606(82)90170-1; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; ISHIZAKI M, 1993, INVEST OPHTH VIS SCI, V34, P3320; JARVELAINEN HT, 1992, EXP CELL RES, V203, P395, DOI 10.1016/0014-4827(92)90013-X; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; Kao WWY, 1996, INVEST OPHTH VIS SCI, V37, P2572; Kao WWY, 1998, INVEST OPHTH VIS SCI, V39, P502; Liu CY, 1998, J BIOL CHEM, V273, P22584, DOI 10.1074/jbc.273.35.22584; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Moyer PD, 1996, DIFFERENTIATION, V60, P31, DOI 10.1046/j.1432-0436.1996.6010031.x; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; Saika S, 1998, CURR EYE RES, V17, P1049, DOI 10.1076/ceyr.17.11.1049.5227; SCHRECENGOST PK, 1992, ARCH BIOCHEM BIOPHYS, V292, P54, DOI 10.1016/0003-9861(92)90050-7; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; Smith RS, 1996, INVEST OPHTH VIS SCI, V37, P397; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; Wilson SE, 1997, J REFRACT SURG, V13, P171; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306; YU FSX, 1995, INVEST OPHTH VIS SCI, V36, P1997; Yu FSX, 1998, INVEST OPHTH VIS SCI, V39, P710; ZIESKE JD, 1989, J CELL BIOL, V109, P571, DOI 10.1083/jcb.109.2.571	45	202	206	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2607	2612		10.1074/jbc.275.4.2607	http://dx.doi.org/10.1074/jbc.275.4.2607			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644720	Green Accepted, hybrid			2022-12-25	WOS:000085128000052
J	Skovronsky, DM; Moore, DB; Milla, ME; Doms, RW; Lee, VMY				Skovronsky, DM; Moore, DB; Milla, ME; Doms, RW; Lee, VMY			Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; FAMILIAL ALZHEIMERS-DISEASE; NT2N CELLS; DISINTEGRIN; NEURONS; METALLOPROTEINASE; ACCUMULATION; COMPARTMENT; CATABOLISM; MATURATION	The release of amyloidogenic amyloid-beta peptide (A beta) from amgloid-beta precursor protein (APP) requires cleavage by beta- and gamma-secretases. in contrast, alpha-secretase cleaves APP within the A beta sequence and precludes amyloidogenesis. Regulated and unregulated alpha-secretase activities have been reported, and the fraction of cellular alpha-secretase activity regulated by protein kinase C (PKC) has been attributed to the ADAM (a disintegrin and metalloproaease) family members TACE and ADAM-10. Although unregulated alpha-secretase cleavage of APP has been shown to occur at the cell surface, we sought to identify the intracellular site of PEG-regulated alpha-secretase APP cleavage. To accomplish this, we measured levels of secreted ectodomains and C-terminal fragments of APP generated by alpha-secretase (sAPP alpha) (C83) versus beta-secretase (sAPP beta) (C99) and secreted A beta in cultured cells treated with PEC and inhibitors of TACE/ ADAM-10. We found that PKC stimulation increased sAPP alpha but decreased sAPP beta levels by altering the competition between alpha- versus beta-secretase for APP within the same organelle rather than by perturbing APP trafficking. Moreover, data implicating the trans-Golgi network (TGN) as a major site for beta-secretase activity prompted us to hypothesize that PEG-regulated alpha-secretase(s) also reside in this organelle, To test this hypothesis, we performed studies demonstrating proteolytically mature TACE intracellularly, and we also showed that regulated alpha-secretase APP cleavage occurs in the TGN using an APP mutant construct targeted specifically to the TGN, By detecting regulated alpha-secretase APP cleavage in the TGN by TACE/ADAM-10, we reveal ADAM activity in a novel location. Finally, the competition between TACE/ADAM-10 and beta-secretase for intracellular APP cleavage may represent a novel target for the discovery of new therapeutic agents to treat Alzheimer's disease.	Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Lee, VMY (corresponding author), HUP, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Maloney 3, Philadelphia, PA 19104 USA.							Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Forman MS, 1997, J BIOL CHEM, V272, P32247, DOI 10.1074/jbc.272.51.32247; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; HAASS C, 1995, J BIOL CHEM, V270, P6186, DOI 10.1074/jbc.270.11.6186; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Jolly-Tornetta C, 1998, J BIOL CHEM, V273, P14015, DOI 10.1074/jbc.273.22.14015; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Mills J, 1997, J NEUROSCI, V17, P9415; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1997, MOL GENETIC BASIS NE, P601; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SUZUKI N, 1994, AM J PATHOL, V145, P452; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748	34	282	306	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2568	2575		10.1074/jbc.275.4.2568	http://dx.doi.org/10.1074/jbc.275.4.2568			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644715	hybrid			2022-12-25	WOS:000085128000047
J	Tsujimoto, S; Bean, AJ				Tsujimoto, S; Bean, AJ			Distinct protein domains are responsible for the interaction of Hrs-2 with SNAP-25 - The role of Hrs-2 in 7 S complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; MEMBRANE-FUSION; CLOSTRIDIAL NEUROTOXINS; COILED COILS; SNARE; SYNTAXIN; IDENTIFICATION; SPECIFICITY; EXOCYTOSIS; ACTIVATION	Regulated secretion of neurotransmitter at the synapse is likely to be mediated by dynamic protein interactions involving components of the vesicle (vesicle-associated membrane protein; VAMP) and plasma membrane (syntaxin and synaptosomal associated protein of 25 kDa (SNAP-25)) along with additional molecules that allow for the regulation of this process. Recombinant Hrs-2 interacts with SNAP-25 in a calcium-dependent manner (they dissociate at elevated calcium levels) and inhibits neurotransmitter release. Thus, Hrs-a has been hypothesized to serve a negative regulatory role in secretion through its interaction with SNAP-25. In this report, we show that Hrs-2 and SNAP-25 interact directly through specific coiled-coil domains in each protein. The presence of syntaxin enhances the binding of Hrs-2 to SNAP-25. Moreover, while both Hrs-2 and VAMP can separately bind to SNAP-25, they cannot bind simultaneously. Additionally, the presence of Hrs-2 reduces the incorporation of VAMP into the syntaxin SNAP-25.VAMP (7 S) complex. These findings suggest that Hrs-2 may modulate exocytosis by regulating the assembly of a protein complex implicated in membrane fusion.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA; Univ Texas, Sch Med, WM Keck Ctr Neurobiol Learning & Memory, Houston, TX 77030 USA	University of Texas System; University of Texas System	Bean, AJ (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, 6431 Fannin St,Rm 7-208, Houston, TX 77030 USA.				NIMH NIH HHS [MH058920] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058920] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hao JC, 1997, J NEUROSCI, V17, P1596; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; KUFFLER SW, 1984, NEURON BRAIN; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Robinson LJ, 1998, CURR OPIN CELL BIOL, V10, P483, DOI 10.1016/S0955-0674(98)80063-X; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tsujimoto S, 1999, EUR J NEUROSCI, V11, P3047, DOI 10.1046/j.1460-9568.1999.00716.x; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X	28	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2938	2942		10.1074/jbc.275.4.2938	http://dx.doi.org/10.1074/jbc.275.4.2938			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644763	hybrid			2022-12-25	WOS:000085128000095
J	Jensen, LH; Nitiss, KC; Rose, A; Dong, JW; Zhou, JF; Hu, T; Osheroff, N; Jensen, PB; Sehested, M; Nitiss, JL				Jensen, LH; Nitiss, KC; Rose, A; Dong, JW; Zhou, JF; Hu, T; Osheroff, N; Jensen, PB; Sehested, M; Nitiss, JL			A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE; SACCHAROMYCES-CEREVISIAE; YEAST-CELLS; CONFERS RESISTANCE; COVALENT COMPLEXES; EUKARYOTIC CELLS; PROTEIN CLAMP; ETOPOSIDE; INHIBITORS; ENZYME	Bisdioxopiperazines are a unique class of topoisomerase II inhibitors that lock topoisomerase II at a point in the enzyme reaction cycle where the enzyme forms a closed clamp around DNA, We examined cell killing by ICRF-187 and ICRF-193 in yeast cells expressing human topoisomerase II alpha (htop-II alpha). Expression of htop-II alpha in yeast cells sensitizes them to both ICRF-187 and ICRF-193, compared with cells expressing yeast topoisomerase II. ICRF 193 is still able to exert growth inhibition in the presence of genes encoding both ICRF-193-resistant and ICRF-193-sensitive htop-II alpha enzymes, indicating that sensitivity to bisdioxopiperazines is dominant. Killing by ICRF-193 occurs more rapidly, than the killing in yeast cells due to a temperature-sensitive yeast topoisomerase II incubated at the non-permissive temperature. These results are reminiscent of a top-II poison such as etoposide, However, the killing caused by ICRF-193 and ICRF-187 is not enhanced by mutations in the RAD52 pathway. The levels of drug-induced DNA cleavage observed with htop-II alpha in vitro is insufficient to explain the sensitivity induced by this enzyme in yeast cells. Finally, arrest of cells in G(1) does not protect cells from ICRF-193 lethality, a result inconsistent with killing mechanisms due to catalytic inhibition of top-II or stabilization of a cleavable complex. We suggest that the observed pattern of cell killing is most consistent with a poisoning of htop-II by ICRF-193 by a novel mechanism. The accumulation of closed clamp conformations of htop-II induced by ICRF-193 that are trapped on DNA might interfere with transcription, or other DNA metabolic processes, resulting in cell death.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38018 USA; Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark; Duke Univ, Sch Med, Dept Biochem, Durham, NC 27710 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	St Jude Children's Research Hospital; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Duke University; Vanderbilt University; Vanderbilt University	Nitiss, JL (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38018 USA.	john.nitiss@stjude.org	Nitiss, John/E-9974-2010	Nitiss, John/0000-0002-1013-4972	NATIONAL CANCER INSTITUTE [R01CA052814, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA52814] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chang S, 1998, J BIOL CHEM, V273, P19822, DOI 10.1074/jbc.273.31.19822; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHEN M, 1995, CANCER RES, V55, P1509; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, CANCER RES, V49, P2578; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; ELSEA SH, 1992, J BIOL CHEM, V267, P13150; ENG WK, 1988, MOL PHARMACOL, V34, P755; Fortune JM, 1998, J BIOL CHEM, V273, P17643, DOI 10.1074/jbc.273.28.17643; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; Hsiung Y, 1996, CANCER RES, V56, P91; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; HSU SM, 1990, METHOD ENZYMOL, V184, P357; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; ISHIDA R, 1995, CANCER RES, V55, P2299; ISHIMI Y, 1995, J MOL BIOL, V247, P835, DOI 10.1006/jmbi.1995.0183; JANNATIPOUR M, 1993, J BIOL CHEM, V268, P18586; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; JENSEN PB, 1991, CANCER RES, V51, P5093; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; LEONG MML, 1990, METHOD ENZYMOL, V184, P442; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU YX, 1994, CANCER RES, V54, P2943; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; NITISS J, 1991, DNA TOPOISOMERASES C, P77; Nitiss JL, 1997, CANCER RES, V57, P4564; NITISS JL, 1993, CANCER RES, V53, P89; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Nitiss JL, 1998, BIOCHEMISTRY-US, V37, P3078, DOI 10.1021/bi9723257; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; NITISS JL, 1992, CANCER RES, V52, P4467; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; ROCA J, 1995, TRENDS BIOCHEM SCI, V20, P156, DOI 10.1016/S0968-0004(00)88993-8; Sehested M, 1996, BIOCHEM PHARMACOL, V51, P879, DOI 10.1016/0006-2952(95)02241-4; Sehested M, 1998, CANCER RES, V58, P1460; Snapka RM, 1996, BIOCHEM PHARMACOL, V52, P543, DOI 10.1016/0006-2952(96)00305-X; Tennyson RB, 1997, BIOCHEMISTRY-US, V36, P6107, DOI 10.1021/bi970152f; van Hille B, 1998, CANCER CHEMOTH PHARM, V42, P345, DOI 10.1007/s002800050828; Vassetzky YS, 1996, BRIT J CANCER, V73, P1201, DOI 10.1038/bjc.1996.231; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; [No title captured]	51	80	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2137	2146		10.1074/jbc.275.3.2137	http://dx.doi.org/10.1074/jbc.275.3.2137			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636919	hybrid			2022-12-25	WOS:000084940000082
J	Cha, SH; Sekine, T; Kusuhara, H; Yu, E; Kim, JY; Kim, DK; Sugiyama, Y; Kanai, Y; Endou, H				Cha, SH; Sekine, T; Kusuhara, H; Yu, E; Kim, JY; Kim, DK; Sugiyama, Y; Kanai, Y; Endou, H			Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION TRANSPORTER; RAT-KIDNEY; FUNCTIONAL EXPRESSION; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; PROTEIN; BRAIN; LIVER; IDENTIFICATION; MECHANISMS	A cDNA encoding a novel multispecific organic anion transporter, OAT4, was isolated from a human kidney cDNA library, The OAT4 cDNA consisted of 2210 base pairs that encoded a 550-amino acid residue protein with 12 putative membrane-spanning domains. The amino acid sequence of OAT4 showed 38 to 44% identity to those of other members of the OAT family. Northern blot analysis revealed that OAT4 mRNA is abundantly expressed in the placenta as well as in the kidney. When expressed in Xenopus oocytes, OAT4 mediated the high affinity transport of estrone sulfate (K-m = 1.01 mu M) and dehydroepiandrosterone sulfate (K-m = 0.63 mu M) in a sodium-independent manner. OAT4 also mediated the transport of ochratoxin A. OAT4-mediated transport of estrone Sulfate was inhibited by several sulfate conjugates, such as p-nitrophenyl sulfate, alpha-naphthyl sulfate, beta-estradiol sulfate, and 4-methylumbelliferyl sulfate. By contrast, glucuronide conjugates showed little or no inhibitory effect on the OAT4-mediated transport of estrone sulfate. OAT4 interacted with chemically heterogeneous anionic compounds, such as nonsteroidal antiinflammatory drugs, diuretics, sulfobromophthalein, penicillin G, and bile salts, whereas tetraethylammonium, an organic cation, did not. OAT4 is the first member of the multispecific organic anion transporter family, which is expressed abundantly in the placenta. OAT4 might be responsible for the elimination and detoxification of harmful anionic substances from the fetus.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Mitaka, Tokyo 1818611, Japan; Univ Tokyo, Dept Biopharmaceut, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Kyorin University; University of Tokyo	Endou, H (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.							Allikmets R, 1998, CANCER RES, V58, P5337; Angeletti RH, 1997, P NATL ACAD SCI USA, V94, P283, DOI 10.1073/pnas.94.1.283; Apiwattanakul N, 1999, MOL PHARMACOL, V55, P847; Beaulieu E, 1997, BIOCHEM J, V326, P539, DOI 10.1042/bj3260539; Bradbury MWB, 1979, CONCEPT BLOOD BRAIN; BRANCHAUD CL, 1983, J CLIN ENDOCR METAB, V56, P761, DOI 10.1210/jcem-56-4-761; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Jariyawat S, 1999, J PHARMACOL EXP THER, V290, P672; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Kuze K, 1999, J BIOL CHEM, V274, P1519, DOI 10.1074/jbc.274.3.1519; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Lu R, 1999, AM J PHYSIOL-RENAL, V276, pF295, DOI 10.1152/ajprenal.1999.276.2.F295; Matthews JC, 1998, AM J PHYSIOL-CELL PH, V274, pC603, DOI 10.1152/ajpcell.1998.274.3.C603; Moller J. V., 1983, PHARMACOL REV, V34, P315; Morgan DJ, 1997, CLIN EXP PHARMACOL P, V24, P869, DOI 10.1111/j.1440-1681.1997.tb02707.x; Mori K, 1997, FEBS LETT, V417, P371, DOI 10.1016/S0014-5793(97)01325-2; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; Pardridge WM., 1991, PEPTIDE DRUG DELIVER; PETZINGER E, 1994, REV PHYSIOL BIOCH P, V123, P47, DOI 10.1007/BFb0030903; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Race JE, 1999, BIOCHEM BIOPH RES CO, V255, P508, DOI 10.1006/bbrc.1998.9978; Rapoport SI, 1976, BLOOD BRAIN BARRIER; Schomig E, 1998, FEBS LETT, V425, P79, DOI 10.1016/S0014-5793(98)00203-8; SCHUETZ JD, 1993, J CLIN INVEST, V92, P1018, DOI 10.1172/JCI116607; Sekine T, 1998, FEBS LETT, V429, P179, DOI 10.1016/S0014-5793(98)00585-7; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; SHIN BC, 1997, ENDOCRINOLOGY, V138, P3397; SIMONSON GD, 1994, J CELL SCI, V107, P1065; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Tojo A, 1999, J AM SOC NEPHROL, V10, P464; Tsuda M, 1999, J PHARMACOL EXP THER, V289, P1301; ULLRICH KJ, 1993, CLIN INVESTIGATOR, V71, P843; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879	44	329	340	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4507	4512		10.1074/jbc.275.6.4507	http://dx.doi.org/10.1074/jbc.275.6.4507			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660625	hybrid			2022-12-25	WOS:000085288800109
J	Falnes, PO; Ariansen, S; Sandvig, K; Olsnes, S				Falnes, PO; Ariansen, S; Sandvig, K; Olsnes, S			Requirement for prolonged action in the cytosol for optimal protein synthesis inhibition by diphtheria toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; A-FRAGMENT; LOW PH; INTRACELLULAR STABILITY; ENTRY; CELLS; MOLECULE; TRANSLOCATION; RIBOSYLATION	Diphtheria toxin A-fragment enters the cytosol of target cells, where it inhibits protein synthesis by catalyzing ADP-ribosylation of elongation factor 2 (EF-2). We have here analyzed toxin-induced protein synthesis inhibition in single cells by autoradiography and compared it with inhibition of protein synthesis in the whole cell culture. The data show that half-maximal protein synthesis inhibition in the whole cell population after a-short incubation time is achieved by partially inhibiting protein synthesis in basically all the cells, while half-maximal protein synthesis inhibition after a long incubation time is due to a complete protein synthesis block in about half the cells in the population. We have also compared stable and unstable A-fragment mutants with respect to the kinetics of cell intoxication. While the toxicity of the stable mutants increased with time, the unstable mutants showed a similar toxicity at early and late time points. When studying the kinetics of cell intoxication by toxins with short cytosolic half-life, we could not detect any recovery of protein synthesis at late time points when all the mutant A-fragments should be degraded. This indicates that the ADP-ribosylation of EF-2 cannot be reversed by an endogenous activity in the cells. The data indicate that entry of toxin into a cell is not associated with an immediate block in protein synthesis, and that prolonged action of single A-fragment molecules in the cytosol is sufficient to obtain complete protein synthesis inhibition at low toxin concentrations.	Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway	University of Oslo	Olsnes, S (corresponding author), Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway.		Falnes, Pål Ø./AAA-4581-2020	Falnes, Pal/0000-0001-8114-6025				CARROLL SF, 1986, BIOCHEMISTRY-US, V25, P2425, DOI 10.1021/bi00357a019; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; Falnes PO, 1998, EMBO J, V17, P615, DOI 10.1093/emboj/17.2.615; FALNES PO, 1995, BIOCHEMISTRY-US, V34, P11152, DOI 10.1021/bi00035a021; FALNES PO, 1994, J BIOL CHEM, V269, P8402; FENDRICK JL, 1992, EUR J BIOCHEM, V205, P25, DOI 10.1111/j.1432-1033.1992.tb16748.x; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HONJO T, 1971, J BIOL CHEM, V246, P4251; HUDSON TH, 1985, J BIOL CHEM, V260, P2675; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; LEE H, 1984, P NATL ACAD SCI-BIOL, V81, P2703, DOI 10.1073/pnas.81.9.2703; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 1995, COLD SPRING HARB SYM, V60, P461, DOI 10.1101/SQB.1995.060.01.051; YAMAIZUMI M, 1982, P NATL ACAD SCI-BIOL, V79, P461, DOI 10.1073/pnas.79.2.461; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5	24	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4363	4368		10.1074/jbc.275.6.4363	http://dx.doi.org/10.1074/jbc.275.6.4363			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660606	hybrid			2022-12-25	WOS:000085288800090
J	Hall, SK; Armstrong, DL				Hall, SK; Armstrong, DL			Conditional and unconditional inhibition of calcium-activated potassium channels by reversible protein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNEL; THYROTROPIN-RELEASING-HORMONE; VASOACTIVE INTESTINAL PEPTIDE; KINASE-A; BETA-SUBUNIT; CYCLIC-AMP; DIFFERENTIAL MODULATION; HIPPOCAMPAL-NEURONS; LARGE-CONDUCTANCE; PHOSPHATASE 2A	Large conductance, calcium-activated potassium channels (BKCa or maxi-K) are important determinants of membrane excitability in many cell types. We used patch clamp techniques to study the biochemical regulatiom of native BKCa channel proteins by endogenous Ser/Thr-directed protein kinases and phosphatases in cell-free membrane patches from rat pituitary tumor cells (GE(4)C(1)). When protein kinase activity was blocked by removing ATP, endogenous protein phosphatases slowly increased BKCa channel activity approximately 3-fold. Dephosphorylated channels could be activated fully by physiological increases in cytoplasmic calcium or membrane depolarization. In contrast, endogenous protein kinases inhibited BKCa channel activity at two functionally distinct sites. A closely associated, cAMP-dependent protein kinase rapidly reduced channel activity in a conditional manner that could be overcome completely by increasing cytoplasmic free calcium 3-fold or 20 mV further depolarization. Phosphorylation at a pharmacologically distinct site inhibited channel activity unconditionally by reducing availability to approximately half that of maximum at all physiological calcium and voltages. Conditional versus unconditional inhibition of BKCa channel activity through different protein kinases provides cells with a powerful computational mechanism for regulating membrane excitability.	Cardiff Univ, Cardiff Sch Biosci, Physiol Unit, Cardiff CF10 3US, S Glam, Wales; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	Cardiff University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hall, SK (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Physiol Unit, POB 911,Museum Ave, Cardiff CF10 3US, S Glam, Wales.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080043, ZIAES080043] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADLER EM, 1991, J NEUROSCI, V11, P1496; ALKON DL, 1986, BIOCHEM BIOPH RES CO, V134, P1245, DOI 10.1016/0006-291X(86)90384-0; ARMSTRONG DL, 1992, TRENDS NEUROSCI, V15, P403, DOI 10.1016/0166-2236(92)90192-B; ARMSTRONG DL, 1999, ADV 2 MESSENGER PHOS, V33; BARROS F, 1993, FEBS LETT, V336, P433, DOI 10.1016/0014-5793(93)80851-K; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIELEFELDT K, 1994, J PHYSIOL-LONDON, V475, P241, DOI 10.1113/jphysiol.1994.sp020065; BYERLY L, 1984, J PHYSIOL-LONDON, V352, P637, DOI 10.1113/jphysiol.1984.sp015314; CARL A, 1991, AM J PHYSIOL, V261, pC387, DOI 10.1152/ajpcell.1991.261.2.C387; DORNER D, 1988, J NEUROSCI, V8, P4069; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LECHLEITER JD, 1988, NEURON, V1, P227, DOI 10.1016/0896-6273(88)90143-2; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P221, DOI 10.1113/jphysiol.1986.sp016006; MARTY A, 1985, J PHYSIOL-LONDON, V367, P117, DOI 10.1113/jphysiol.1985.sp015817; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; MEERA P, 1995, AM J PHYSIOL-CELL PH, V269, pC312, DOI 10.1152/ajpcell.1995.269.2.C312; Nara M, 1998, J BIOL CHEM, V273, P14920, DOI 10.1074/jbc.273.24.14920; Navaratnam DS, 1997, NEURON, V19, P1077, DOI 10.1016/S0896-6273(00)80398-0; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; Pedarzani P, 1995, J NEUROPHYSIOL, V74, P2749, DOI 10.1152/jn.1995.74.6.2749; PEREZ G, 1994, AM J PHYSIOL, V266, pC1459, DOI 10.1152/ajpcell.1994.266.5.C1459; Ramanathan K, 1999, SCIENCE, V283, P215, DOI 10.1126/science.283.5399.215; REINHART PH, 1991, J NEUROSCI, V11, P1627; REINHART PH, 1995, J NEUROSCI, V15, P4572; Rosenblatt KP, 1997, NEURON, V19, P1061, DOI 10.1016/S0896-6273(00)80397-9; Sakmann B., 1995, SINGLE CHANNEL RECOR; Shipston MJ, 1996, J PHYSIOL-LONDON, V493, P665, DOI 10.1113/jphysiol.1996.sp021413; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; SIMASKO SM, 1991, ENDOCRINOLOGY, V128, P2015, DOI 10.1210/endo-128-4-2015; Smith MA, 1998, J PHYSIOL-LONDON, V513, P733, DOI 10.1111/j.1469-7793.1998.733ba.x; Stockand JD, 1996, AM J PHYSIOL-CELL PH, V271, pC1669, DOI 10.1152/ajpcell.1996.271.5.C1669; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; TORRES GE, 1995, MOL PHARMACOL, V47, P191; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; YAJIMA Y, 1986, J BIOL CHEM, V261, P2684; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760	46	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3749	3754		10.1074/jbc.275.6.3749	http://dx.doi.org/10.1074/jbc.275.6.3749			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660522	hybrid			2022-12-25	WOS:000085288800006
J	Mason, JM; Beattie, BK; Liu, QR; Dumont, DJ; Barber, DL				Mason, JM; Beattie, BK; Liu, QR; Dumont, DJ; Barber, DL			The SH2 inositol 5-phosphatase Ship1 is recruited in an SH2-dependent manner to the erythropoietin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; STAT5 ACTIVATION; POLYPHOSPHATE 5-PHOSPHATASE; PHOSPHATASE SHIP; PHOSPHATIDYLINOSITOL 3-KINASE; ERYTHROID PROGENITORS; INTRACELLULAR DOMAIN; HUMAN ERYTHROBLASTS; MULTIPLE CYTOKINES; MOLECULAR-CLONING	Ship1 ((S) under bar H2 (i) under bar nositol 5-(p) under bar hosphatase (1) under bar) has been shown to be a target of tyrosine phosphorylation downstream of cytokine and immunoregulatory receptors. In addition to its catalytic activity on phosphatidylinositol substrates, it can serve as an adaptor protein in binding Shc and Grb2. Erythropoietin (EPO), the primary regulator of erythropoiesis, has been shown to activate the tyrosine phosphorylation of Shc, resulting in recruitment of Grb2, However, the mechanism by which the erythropoietin receptor (EPO-R) recruits Shc remains unknown. EPO activates the tyrosine phosphorylation of Ship1, resulting in the interdependent recruitment of Shc and Grb2, Ship1 is recruited to the EPO-R in an SH2-dependent manner. Utilizing a panel of EPO-R deletion and tyrosine mutants, we have discovered remarkable redundancy in Ship1 recruitment. EPO-R Tyr(401) appears to be a major site of Ship1 binding; however, Tyr(429) and Tyr(431) can also serve to recruit Ship1, In addition, we have shown that EPO stimulates the formation of a ternary complex consisting of Ship1, Shc, and Grb2. Ship1 may modulate several discrete signal transduction pathways. EPO-dependent activation of ERK1/2 and protein kinase B (PKB)/Akt was examined utilizing a panel of EPO-R deletion mutants. Activation of ERK1/2 was observed in EPO-R Delta 99, which retains only the most proximal tyrosine, Tyr(343). In contrast, EPO-dependent PKB activation was observed in EPO-R Delta 43, but not in EPO-R Delta 99. It appears that EPO-dependent PKB activation is downstream of a region that indirectly couples to phosphatidylinositol 3-kinase.	Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Amgen Inst, Toronto, ON M5G 2G1, Canada; Sunnybrook & Womens Hlth Sci Ctr, Div Canc Biol, Toronto, ON M4N 3MS, Canada; Toronto Gen Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Barber, DL (corresponding author), Ontario Canc Inst, Div Cellular & Mol Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Barber, Dwayne/0000-0001-5528-8150				Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; BARBER DL, 1994, MOL CELL BIOL, V14, P2257, DOI 10.1128/MCB.14.4.2257; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Bergelson S, 1998, J BIOL CHEM, V273, P2396, DOI 10.1074/jbc.273.4.2396; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; CHEUNG JY, 1992, J CLIN INVEST, V90, P1850, DOI 10.1172/JCI116061; Coffer PJ, 1998, BIOCHEM J, V335, P1; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; Furukawa T., 1996, Blood, V88, p145A; Geier SJ, 1997, BLOOD, V89, P1876, DOI 10.1182/blood.V89.6.1876; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HUANG LW, 1995, ONCOGENE, V11, P2097; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Kralovics R, 1997, BLOOD, V90, P2057, DOI 10.1182/blood.V90.5.2057; Kralovics R., 1995, Blood, V86, p18A; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu Q, 1997, GENOMICS, V39, P109, DOI 10.1006/geno.1996.4374; Liu QR, 1998, BLOOD, V91, P2753, DOI 10.1182/blood.V91.8.2753.2753_2753_2759; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MILLER BA, 1989, BLOOD, V73, P1188; MILLER BA, 1994, CELL CALCIUM, V16, P481, DOI 10.1016/0143-4160(94)90078-7; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Odai H, 1997, BLOOD, V89, P2745, DOI 10.1182/blood.V89.8.2745; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Zamorano J, 1998, J IMMUNOL, V161, P859; ZHU H, 1994, J BIOL CHEM, V269, P29943	56	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4398	4406		10.1074/jbc.275.6.4398	http://dx.doi.org/10.1074/jbc.275.6.4398			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660611	hybrid			2022-12-25	WOS:000085288800095
J	Sharma, R; Rensing, C; Rosen, BP; Mitra, B				Sharma, R; Rensing, C; Rosen, BP; Mitra, B			The ATP hydrolytic activity of purified ZntA, a Pb(II)/Cd(II)/Zn(II)-translocating ATPase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; COPPER-TRANSPORTING ATPASE; WILSON DISEASE GENE; MEMBRANE-VESICLES; ENTEROCOCCUS-HIRAE; MENKES DISEASE; ENCODES; RECONSTITUTION; PURIFICATION; SEQUENCE	ZntA, a soft metal-translocating P1-type ATPase from Escherichia coli, confers resistance to Pb(II), Cd(II), and Zn(II). ZntA was expressed as a histidyl-tagged protein, solubilized from membranes with Triton X-100, and purified to homogeneity, The soft metal-dependent ATP hydrolysis activity of purified ZntA was characterized. The activity was specific for Pb(II), Cd(II), Zn(II), and Hg(II), with the highest activity obtained when the metals were present as thiolate complexes of cysteine or glutathione. The maximal ATPase activity of ZntA was similar to 3 mu mol/(mg.min) obtained with the Pb(II)-thiolate complex. In the absence of thiolates, Cd(II) inhibits ZntA above pH 6, whereas the Cd(II)-thiolate complexes stimulate activity, suggesting that a metal-thiolate complex is the true substrate in vivo. These results are consistent with the physiological role of ZntA as mediator of resistance to toxic concentrations of the divalent soft metals, Pb(PI), Cd(II), and Zn(II), by ATP-dependent efflux. Our results confirm that ZntA is the first Pb(II)-dependent ATPase discovered to date.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Mitra, B (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.		Rensing, Christopher/D-3947-2011; Sharma, Rakesh/F-4859-2012	Rensing, Christopher/0000-0002-5012-7953; Sharma, Rakesh/0000-0003-3320-4491; Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054102, R01GM055425, R37GM055425] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54102, GM18973, GM55425] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; DAWSON RMC, 1969, DATA BIOMEDICAL RES; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Fedosova NU, 1998, BIOCHEMISTRY-US, V37, P13634, DOI 10.1021/bi980703h; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; GE ZM, 1995, MOL MICROBIOL, V15, P97, DOI 10.1111/j.1365-2958.1995.tb02224.x; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hunter GW, 1999, BIOCHEMISTRY-US, V38, P4604, DOI 10.1021/bi982392g; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KANAMARU K, 1994, MOL MICROBIOL, V13, P369, DOI 10.1111/j.1365-2958.1994.tb00430.x; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Morrison J F, 1979, Methods Enzymol, V63, P257; PHUNG LT, 1994, P NATL ACAD SCI USA, V91, P9651, DOI 10.1073/pnas.91.20.9651; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rensing C, 1998, BIOCHEM CELL BIOL, V76, P787, DOI 10.1139/bcb-76-5-787; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Rensing C, 1998, J BIOL CHEM, V273, P32614, DOI 10.1074/jbc.273.49.32614; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; SIGEL H, 1987, EUR J BIOCHEM, V165, P65, DOI 10.1111/j.1432-1033.1987.tb11194.x; Solioz M, 1997, FEBS LETT, V412, P165, DOI 10.1016/S0014-5793(97)00770-9; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; Takeda K, 1999, J MEMBRANE BIOL, V170, P13, DOI 10.1007/s002329900533; TSAI KJ, 1992, J BACTERIOL, V174, P116, DOI 10.1128/jb.174.1.116-121.1992; TSAI KJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P267, DOI 10.1006/abbi.1993.1421; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WylerDuda P, 1996, FEBS LETT, V399, P143, DOI 10.1016/S0014-5793(96)01306-3	33	177	188	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					3873	3878		10.1074/jbc.275.6.3873	http://dx.doi.org/10.1074/jbc.275.6.3873			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660539	hybrid			2022-12-25	WOS:000085288800023
J	Lopez, S; Peiretti, F; Bonardo, B; Juhan-Vague, I; Nalbone, G				Lopez, S; Peiretti, F; Bonardo, B; Juhan-Vague, I; Nalbone, G			Tumor necrosis factor alpha up-regulates in an autocrine manner the synthesis of plasminogen activator inhibitor type-1 during induction of monocytic differentiation of human HL-60 leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED IMMUNOSORBENT-ASSAY; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR-BETA; PROTEIN-KINASE-C; ENDOTHELIAL-CELLS; GENE-EXPRESSION; PHORBOL ESTER; MACROPHAGE DIFFERENTIATION; UROKINASE RECEPTOR; VITRONECTIN	Tumor necrosis factor-alpha (TNF alpha) critically regulates several cellular functions during monocyte/macrophage differentiation. We therefore investigated during the phorbol ester (phorbol 12-myristate 13-acetate (PMA))-nduced monocyte/macrophage differentiation of the human HL-60 leukemia cells, if TNF alpha contributed to plasminogen activator inhibitor type-1 (PAI-1) synthesis that is initiated by a protein kinase CP-extracellular signal-regulated kinase a-dependent pathway (Lopez, S,, Peiretti, F., Morange, P., Laouar, A., Fossat, C., Bonardo, B., Huberman, E., Juhan-Vague, I., and Nalbone, G. (1999) Thromb, Haemostasis 81, 415-422), Following PMA treatment, the level of TNFa mRNA strongly increased and appeared earlier than PAI-1 mRNk. An anti-TNF alpha antibody significantly inhibited the PMAnduced PAI-1NA and protein levels. The recombinant human TNFa, which is inactive on native HL-60 cells in terms of PAI-1 synthesis, optimally potentiates it once HL-60 cells are committed into the differentiation process. The use of 1) the HL-525 cell line, a clone issued from HL-60 cells rendered resistant to PMA-induced differentiation, and 2) the transforming growth factory beta-1/vitamin 113 differentiative mixture confirmed the relationships between the induction of differentiation and the potency of TNF alpha to up-regulate PAI-1 synthesis. In conclusion, we showed that during the induction of monocyte/macrophage differentiation, TNF alpha and PAI-1 gene expressions are activated and that synthesized TNF alpha up-regulates and prolongs, in an autocrine manner, the synthesis of PAI-1.	Fac Med Marseille, Hematol Lab, EPI 9936, INSERM, F-13385 Marseille 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Nalbone, G (corresponding author), Fac Med Marseille, Hematol Lab, EPI 9936, INSERM, 27 Bd Jean Moulin, F-13385 Marseille 5, France.	Gilles.Nalbone@medecine.univ-mrs.fr	LOPEZ, SOPHIE/R-1917-2016; Peiretti, Franck/GLV-3378-2022; peiretti, franck/L-2718-2017	LOPEZ, SOPHIE/0000-0002-5009-5533; Peiretti, Franck/0000-0001-7198-0534; peiretti, franck/0000-0001-7198-0534				AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; Allaire E, 1998, CIRCULATION, V98, P249, DOI 10.1161/01.CIR.98.3.249; Arts J, 1999, ARTERIOSCL THROM VAS, V19, P39, DOI 10.1161/01.ATV.19.1.39; Bacharach E, 1998, BLOOD, V92, P939, DOI 10.1182/blood.V92.3.939.415k28_939_945; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CAO XM, 1992, J BIOL CHEM, V267, P1345; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; CHOMIKI N, 1994, THROMB HAEMOSTASIS, V72, P44; CIAMBRONE GJ, 1990, J CELL BIOL, V111, P2183, DOI 10.1083/jcb.111.5.2183; Colli S, 1999, THROMB HAEMOSTASIS, V81, P576; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DECLERCK PJ, 1988, BLOOD, V71, P220; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Glick D, 1996, FEBS LETT, V394, P237, DOI 10.1016/0014-5793(96)00958-1; GRUNEIRO AJ, 1995, FIBRINOLYSIS, V9, P71, DOI 10.1016/S0268-9499(95)80067-0; HOMMA Y, 1986, P NATL ACAD SCI USA, V83, P7316, DOI 10.1073/pnas.83.19.7316; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; JuhanVague I, 1996, CIRCULATION, V94, P2057, DOI 10.1161/01.CIR.94.9.2057; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KIM MY, 1991, J BIOL CHEM, V266, P484; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Kumar A, 1998, ONCOGENE, V17, P913, DOI 10.1038/sj.onc.1201998; Laouar A, 1999, J IMMUNOL, V162, P407; Lee E, 1996, CIRC RES, V78, P44, DOI 10.1161/01.RES.78.1.44; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Lopez S, 1999, THROMB HAEMOSTASIS, V81, P415, DOI 10.1055/s-0037-1614488; LUND LR, 1988, MOL CELL ENDOCRINOL, V60, P43, DOI 10.1016/0303-7207(88)90118-9; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; PADRO T, 1995, ARTERIOSCL THROM VAS, V15, P893, DOI 10.1161/01.ATV.15.7.893; Peiretti F, 1996, BLOOD, V87, P162; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RITCHIE H, 1995, BLOOD, V86, P3428, DOI 10.1182/blood.V86.9.3428.bloodjournal8693428; Robbie LA, 1996, ARTERIOSCL THROM VAS, V16, P539, DOI 10.1161/01.ATV.16.4.539; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; SCHNEIDERMAN J, 1992, P NATL ACAD SCI USA, V89, P6998, DOI 10.1073/pnas.89.15.6998; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; Sobel BE, 1998, CIRCULATION, V97, P2213, DOI 10.1161/01.CIR.97.22.2213; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; TIPPING PG, 1993, AM J PATHOL, V143, P875; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; VANHINSBERGH VWM, 1988, BLOOD, V72, P1467; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WINZEN R, 1992, J IMMUNOL, V148, P3454; WOHLWEND A, 1987, J EXP MED, V165, P320, DOI 10.1084/jem.165.2.320; Xie B, 1998, J BIOL CHEM, V273, P11583, DOI 10.1074/jbc.273.19.11583; YANG KD, 1994, BLOOD, V83, P490	53	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3081	3087		10.1074/jbc.275.5.3081	http://dx.doi.org/10.1074/jbc.275.5.3081			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652289	hybrid			2022-12-25	WOS:000085146500011
J	Ohashi, K; Nagata, K; Maekawa, M; Ishizaki, T; Narumiya, S; Mizuno, K				Ohashi, K; Nagata, K; Maekawa, M; Ishizaki, T; Narumiya, S; Mizuno, K			Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ACTIN DYNAMICS; ZINC-FINGER; FOCAL ADHESIONS; IDENTIFICATION; REORGANIZATION; CYTOSKELETON; FAMILY; COFILIN; MOTIFS	LIM-kinase 1 (LIMK1) phosphorylates cofilin, an actin-depolymerizing factor, and regulates actin cytoskeletal reorganization. LIMK1 is activated by the small GTPase Rho and its downstream protein kinase ROCK. We now report the site of phosphorylation of LIMK1 by ROCK. In vitro kinase reaction revealed that the active forms of ROCK phosphorylated LIMK1 on the threonine residue and markedly increased its cofilin-phosphorylating activity. A LIMK1 mutant (T508A) with replacement of Thr-508 within the activation loop of the kinase domain by alanine was neither phosphorylated nor activated by ROCK. Replacement of Thr-508 by serine changed the ROCK-catalyzed phosphorylation residue from threonine to serine. A LIMK1 mutant with replacement of Thr-508 by two glutamates increased the kinase activity about a-fold but was not further activated by ROCK. In addition, wild-type LIMK1, but not its T508A mutant, was activated by co-expression with ROCK in cultured cells. These results suggest that ROCK activates LIMK1 in vitro and in vivo by phosphorylation at Thr-508. Together with the recent finding that PAI(I, a downstream effector of Rac, also activates LIMK1 by phosphorylation at Thr-508, these results suggest that activation of LIMK1 is one of the common targets for Rho and Rac to reorganize the actin cytoskeleton.	Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan	Tohoku University; Kyoto University	Mizuno, K (corresponding author), Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan.	kmizuno@biology.tohoku.ac.jp	Ohashi, Kazumasa/U-7028-2019; Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X; 				AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Leung T, 1996, MOL CELL BIOL, V16, P5313; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MIZUNO K, 1994, ONCOGENE, V9, P1605; Nagata K, 1999, BIOCHEM J, V343, P99, DOI 10.1042/0264-6021:3430099; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NUNOUE K, 1995, ONCOGENE, V11, P701; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Toshima J, 1999, J BIOL CHEM, V274, P12171, DOI 10.1074/jbc.274.17.12171; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	30	397	406	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3577	3582		10.1074/jbc.275.5.3577	http://dx.doi.org/10.1074/jbc.275.5.3577			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652353	hybrid			2022-12-25	WOS:000085146500075
J	Himpel, S; Tegge, W; Frank, R; Leder, S; Joost, HG; Becker, W				Himpel, S; Tegge, W; Frank, R; Leder, S; Joost, HG; Becker, W			Specificity determinants of substrate recognition by the protein kinase DYRK1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; SYNDROME CRITICAL REGION; DOWN-SYNDROME; PHOSPHORYLASE-KINASE; HUMAN HOMOLOG; CELLULOSE MEMBRANES; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; SPOT-SYNTHESIS; IDENTIFICATION	DYRK1A is a dual-specificity protein kinase that is thought to be involved in brain development. We identified a single phosphorylated amino acid residue in the DYRK substrate histone H3 (threonine 45) by mass spectrometry, phosphoamino acid analysis, and protein sequencing. Exchange of threonine 45 for alanine abolished phosphorylation of histone H3 by DYRK1A and by the related kinases DYRK1B, DYRK2, and DYRK3 but not by CLK8, In order to define the consensus sequence for the substrate specificity of DYRK1A, a library of 300 peptides was designed in variation of the H3 phosphorylation site. Evaluation of the phosphate incorporation into these peptides identified DYRK1A as a proline-directed kinase with a phosphorylation consensus sequence (RPX(S/T)P) similar to that of ERK2 (PX(S/T)P). A peptide designed after the optimal substrate sequence (DYRKtide) was efficiently phosphorylated by DYRK1A (K-m = 35 mu m) but not by ERK2, Both ERK2 and DYRK1A phosphorylated myelin basic protein, whereas only ERK2, but not DYRK1A phosphorylated the mitogen-activated protein kinase substrate ELK-1, This marked difference in substrate specificity between DYRK1A and ERK2 can be explained by the requirement for an arginine at the P -3 site of DYRK substrates and its presumed interaction with aspartate 247 conserved in all DYRKs.	Rhein Westfal TH Aachen, Fak Med, Inst Pharmakol & Toxikol, D-52057 Aachen, Germany; AG Mol Erkennung, GBF, D-38124 Braunschweig, Germany	RWTH Aachen University; Helmholtz Association; Helmholtz-Center for Infection Research	Becker, W (corresponding author), Rhein Westfal TH Aachen, Fak Med, Inst Pharmakol & Toxikol, Wendlingweg 2, D-52057 Aachen, Germany.	walter.becker@post.rwth-aachen.de	Becker, Walter/B-8889-2008; Joost, Hans-Georg/J-4462-2013	Becker, Walter/0000-0002-0347-4768; Joost, Hans-Georg/0000-0002-5860-606X				Bahler J, 1998, GENE DEV, V12, P1356, DOI 10.1101/gad.12.9.1356; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Becker W, 1996, BBA-MOL CELL RES, V1312, P63, DOI 10.1016/0167-4889(96)00036-5; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dostmann WRG, 1999, PHARMACOL THERAPEUT, V82, P373, DOI 10.1016/S0163-7258(98)00063-1; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; Gross T, 1997, NUCLEIC ACIDS RES, V25, P1028, DOI 10.1093/nar/25.5.1028; Guimera J, 1996, HUM MOL GENET, V5, P1305, DOI 10.1093/hmg/5.9.1305; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Himpel S, 1999, ANAL BIOCHEM, V274, P138, DOI 10.1006/abio.1999.4205; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Leder S, 1999, BIOCHEM BIOPH RES CO, V254, P474, DOI 10.1006/bbrc.1998.9967; Lee K, 1996, J BIOL CHEM, V271, P27299, DOI 10.1074/jbc.271.44.27299; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; LUO KX, 1995, P NATL ACAD SCI USA, V92, P11761, DOI 10.1073/pnas.92.25.11761; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nigg E A, 1991, Semin Cell Biol, V2, P261; Ohira M, 1997, GENOME RES, V7, P47, DOI 10.1101/gr.7.1.47; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith DJ, 1997, NAT GENET, V16, P28, DOI 10.1038/ng0597-28; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Souza GM, 1998, DEVELOPMENT, V125, P2291; TEGGE W, 1995, BIOCHEMISTRY-US, V34, P10569, DOI 10.1021/bi00033a032; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toomik R, 1996, PEPTIDE RES, V9, P6; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X; WOODGETT J, 1995, PROTEIN KINASE FACTS, P231; WU JZ, 1994, BIOCHEMISTRY-US, V33, P14825, DOI 10.1021/bi00253a022; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; YUAN CJ, 1993, J BIOL CHEM, V268, P17683; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	61	177	184	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2431	2438		10.1074/jbc.275.4.2431	http://dx.doi.org/10.1074/jbc.275.4.2431			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644696	hybrid			2022-12-25	WOS:000085128000028
J	Irie, Y; Yamagata, K; Gan, YH; Miyamoto, K; Do, E; Kuo, CH; Taira, E; Miki, N				Irie, Y; Yamagata, K; Gan, YH; Miyamoto, K; Do, E; Kuo, CH; Taira, E; Miki, N			Molecular cloning and characterization of amida, a novel protein which interacts with a neuron-specific immediate early gene product arc, contains novel nuclear localization signals, and causes cell death in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY-REGULATED GENE; SYNAPTIC ACTIVITY; BRAIN NEURONS; GROWTH-FACTOR; APOPTOSIS; EXPRESSION; DENDRITES; ENCODES; LONG	Amida was isolated by the yeast two-hybrid system as a novel protein which associated with Are, a non-transcriptional immediate early gene specific to the brain. Amida was confirmed to be associated with Are in vitro and in vivo. Amida shows no homology to known proteins. Amida is ubiquitously expressed, although it is abundant in the brain. A transfection study revealed that Amida was localized in the nucleus and after 72 h the transfected cells underwent apoptosis, Furthermore, we found two nuclear localization signals and a domain needed for interacting with Are was encompassed by two nuclear localization signals. Co-transfection experiment with Amida and Are suggested that Amida transported Are into the nucleus and negatively regulated Amida-induced cell death. These results indicate that Are together with Amida may modulate cell death in the brain.	Osaka Univ, Sch Med, Dept Pharmacol, Suita, Osaka 5650871, Japan; Tokyo Metropolitan Inst Neurosci, Dept Mol Neurobiol, Fuchu, Tokyo 1830042, Japan	Osaka University; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Miki, N (corresponding author), Osaka Univ, Sch Med, Dept Pharmacol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Akins PT, 1996, STROKE, V27, P1682, DOI 10.1161/01.STR.27.9.1682; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DU F, 1995, J NEUROSCI, V15, P6301; FADDIS BT, 1997, J NEUROSCI, V17, P941; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; Gould E, 1993, Curr Opin Neurobiol, V3, P676, DOI 10.1016/0959-4388(93)90138-O; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; KOZAK M, 1987, J MOL BIOL, V12, P3919; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LINK W, 1995, P NATL ACAD SCI USA, V92, P5832; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; MESNER PW, 1995, J NEUROSCI, V15, P7357; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; Pouli AE, 1998, BIOCHEM J, V331, P669, DOI 10.1042/bj3310669; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WORLEY PF, 1990, COLD SH Q B, V55, P213, DOI 10.1101/SQB.1990.055.01.023; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yamagata K, 1994, Learn Mem, V1, P140; Yoon Y, 1998, J CELL BIOL, V140, P779, DOI 10.1083/jcb.140.4.779	26	39	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2647	2653		10.1074/jbc.275.4.2647	http://dx.doi.org/10.1074/jbc.275.4.2647			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644725	hybrid			2022-12-25	WOS:000085128000057
J	Shenkman, M; Ehrlich, M; Lederkremer, GZ				Shenkman, M; Ehrlich, M; Lederkremer, GZ			Masking of an endoplasmic reticulum retention signal by its presence in the two subunits of the asialoglycoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-GOLGI DEGRADATION; SURFACE EXPRESSION; GENE-TRANSFER; CELL-SURFACE; H2 SUBUNIT; DOMAIN; FATE; ER; DIMERIZATION; ASSOCIATION	Human asialoglycoprotein receptor HI and H2b subunits assemble into a hetero-oligomer that travels to the cell surface. The H2a variant on the other hand is a precursor of a cleaved soluble form that is secreted. Uncleaved H2a precursor molecules cannot exit the endoplasmic reticulum (ER), a lumenal juxtamembrane pentapeptide being responsible for their retention. Insertion of this pentapeptide into H1 (H1i5) causes its complete ER retention but not fast degradation as happens to H2a. Cotransfection of H2a elicited, by heterodimerization, the Golgi processing of H1i5 and its surface expression. This occurred to a much lesser extent by cotransfection of H2b. Likewise, coexpression of H1i5 and not HI stabilized H2a and caused its export to the cell surface. Homodimerization of molecules containing the pentapeptide did not cancel the retention. Thus, only when the pentapeptide is present in both subunits is the ER retention efficiently abrogated. The results show the unexpected finding that identical ER retention signals present in two associated chains can mask and cancel each other's effect. This could have important implications as similar abrogation of ER retention of other proteins could eventually be obtained by engineering and coexpressing an associated protein containing the same retention signal.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Lederkremer, GZ (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.			Lederkremer, Gerardo/0000-0002-9857-7152; Ehrlich, Marcelo/0000-0002-2352-1808				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; Ayalon-Soffer M, 1999, FEBS LETT, V460, P112, DOI 10.1016/S0014-5793(99)01321-6; Bider MD, 1996, J BIOL CHEM, V271, P31996, DOI 10.1074/jbc.271.50.31996; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cocquerel L, 1999, J VIROL, V73, P2641, DOI 10.1128/JVI.73.4.2641-2649.1999; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HENNECKE S, 1993, J BIOL CHEM, V268, P26607; KEREM A, 1993, J BIOL CHEM, V268, P180; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Marambaud P, 1998, MOL MED, V4, P147, DOI 10.1007/BF03401912; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naim HY, 1996, EUR J CELL BIOL, V70, P198; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; PARDI R, 1995, J IMMUNOL, V155, P1252; Shenkman M, 1997, P NATL ACAD SCI USA, V94, P11363, DOI 10.1073/pnas.94.21.11363; SOLHEIM JC, 1995, EUR J IMMUNOL, V25, P3011, DOI 10.1002/eji.1830251104; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Tolchinsky S, 1996, J BIOL CHEM, V271, P14496, DOI 10.1074/jbc.271.24.14496; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WILEMAN T, 1993, J CELL BIOL, V122, P67, DOI 10.1083/jcb.122.1.67; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735	34	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2845	2851		10.1074/jbc.275.4.2845	http://dx.doi.org/10.1074/jbc.275.4.2845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644751	hybrid			2022-12-25	WOS:000085128000083
J	Vogel, K; Cabaniols, JP; Roche, PA				Vogel, K; Cabaniols, JP; Roche, PA			Targeting of SNAP-25 to membranes is mediated by its association with the target SNARE syntaxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; AXONAL-TRANSPORT; SYNAPTIC VESICLES; PALMITOYLATION; COMPLEX; PALMITOYLTRANSFERASE; MYRISTOYLATION; SYNAPTOBREVIN; INSERTION; MACHINERY	The docking and fusion of synaptic vesicles with the presynaptic plasma membrane require the interaction of the vesicle-associated membrane protein VAMP with the plasma membrane proteins syntaxin and SNAP-25, Both of these proteins behave as integral membrane proteins, although they are unusual in that they insert into membranes post-translationally. Whereas VAMP and syntaxin possess hydrophobic transmembrane domains, SNAP-25 does not, and it is widely believed that SNAP-25 traffics to and inserts into membranes by posttranslational palmitoylation. In pulse-chase biosynthesis studies, we now show that SNAP-25 and syntaxin rapidly bind to each other while still in the cytosol of neuroendocrine and transfected heterologous cells. Cell fractionation studies revealed that cytosolic SNAP-25 .syntaxin complexes then traffic to and insert into membranes. Furthermore, the association of SNAP-25 with membranes is dramatically enhanced by syntaxin, and the transmembrane domain of syntaxin is essential for this effect. Surprisingly, despite the importance of the SNAP-25 palmitoylation domain for membrane anchoring at steady state, removal of this domain did not inhibit the initial association of newly synthesized SNAP-25 with membranes in the presence of syntaxin. These data demonstrate that the initial attachment of newly synthesized SNAP-25 to membranes is a consequence of its association with syntaxin and that it is only after syntaxin-mediated membrane tethering that SNAP-25 is palmitoylated.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roche, PA (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10,Rm 4B36, Bethesda, MD 20892 USA.			Roche, Paul/0000-0002-8949-9172				Anderson HA, 1998, J IMMUNOL, V160, P4850; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; Gonzalo S, 1999, J BIOL CHEM, V274, P21313, DOI 10.1074/jbc.274.30.21313; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; HESS DT, 1992, J NEUROSCI, V12, P4634; JANTTI J, 1994, J CELL SCI, V107, P3623; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; Lane SR, 1997, J NEUROCHEM, V69, P1864; Li JY, 1996, EUR J CELL BIOL, V70, P12; Liu L, 1996, J BIOL CHEM, V271, P23269, DOI 10.1074/jbc.271.38.23269; Low SH, 1998, J BIOL CHEM, V273, P3422, DOI 10.1074/jbc.273.6.3422; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; Shiff G, 1997, J NEUROSCI RES, V48, P313; SOLIMENA M, 1994, J CELL BIOL, V126, P331, DOI 10.1083/jcb.126.2.331; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; SUDHOF TC, 1993, CELL, V75, P1; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wong SH, 1999, MOL BIOL CELL, V10, P119, DOI 10.1091/mbc.10.1.119	33	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2959	2965		10.1074/jbc.275.4.2959	http://dx.doi.org/10.1074/jbc.275.4.2959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644766	hybrid			2022-12-25	WOS:000085128000098
J	Zhang, J; Sanguinetti, MC; Kwiecinski, H; Ptacek, LJ				Zhang, J; Sanguinetti, MC; Kwiecinski, H; Ptacek, LJ			Mechanism of inverted activation of ClC-1 channels caused by a novel myotonia congenita mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CHLORIDE CHANNEL; VARIABLE PENETRANCE; VOLTAGE-DEPENDENCE; THOMSEN DISEASE; DOMINANT; BECKER; GENE; CONDUCTANCE; DELETION; ACIDS	The voltage-gated chloride channel ClC-1 is the major contributor of membrane conductance in skeletal muscle and has been associated with the inherited muscular disorder myotonia congenita. Here, we report a novel mutation identified in a recessive myotonia congenita family, This mutation, Gly-499 to Arg (G499R) is located in the putative transmembrane domain 10 of the ClC-1 protein. In contrast to normal ClC-1 channels that deactivate upon hyperpolarization, functional expression of G499R ClC-1 yielded a hyperpolarization-activated chloride current when measured in the presence of a high (134 mM) intracellular chloride concentration. Current was abolished when measured with a physiological chloride transmembrane gradient. Electrophysiological analysis of other Gly-499 mutants (G499K, G499Q, and G499E) suggests that the positive charge introduced by the G499R mutation may be responsible for this unique gating behavior. To further explore the function of domain 10, we mutated two charged residues near Gly-499 of ClC-1. Functional analyses of R496Q, R496Q/G499R, R496K, and E500Q mutant channels suggest that the charged residues in domain 10 are important for normal channel function. Study of these mutants may shed further light on the structure and voltage-gating of this channel.	Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Neurol, Salt Lake City, UT 84112 USA; Univ Utah, Program Neurosci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Med Acad Warsaw, Dept Neurol, PL-02097 Warsaw, Poland	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Ptacek, LJ (corresponding author), Univ Utah, Howard Hughes Med Inst, Bldg 533,Rm 4420,15N 2030 E, Salt Lake City, UT 84112 USA.	ptacek@genetics.utah.edu	Sanguinetti, Michael/AAN-2615-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00064] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABDALLA JA, 1992, AM J HUM GENET, V51, P579; BRYANT SH, 1971, J PHYSIOL-LONDON, V219, P367, DOI 10.1113/jphysiol.1971.sp009667; Chen TY, 1996, J GEN PHYSIOL, V108, P237, DOI 10.1085/jgp.108.4.237; Fahlke C, 1997, P NATL ACAD SCI USA, V94, P2729, DOI 10.1073/pnas.94.6.2729; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; Fahlke C, 1997, J GEN PHYSIOL, V110, P551, DOI 10.1085/jgp.110.5.551; Fahlke C, 1996, BIOPHYS J, V71, P695, DOI 10.1016/S0006-3495(96)79269-X; FAHLKE C, 1995, NEURON, V15, P463, DOI 10.1016/0896-6273(95)90050-0; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; FURMAN RE, 1978, ANN NEUROL, V4, P357, DOI 10.1002/ana.410040411; GEORGE AL, 1994, HUM MOL GENET, V3, P2071; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEINE R, 1994, HUM MOL GENET, V3, P1123, DOI 10.1093/hmg/3.7.1123; Jentsch T J, 1993, Curr Opin Neurobiol, V3, P316, DOI 10.1016/0959-4388(93)90123-G; JENTSCH TJ, 1993, ANN NY ACAD SCI, V707, P285, DOI 10.1111/j.1749-6632.1993.tb38059.x; KOCH MC, 1993, J MED GENET, V30, P914, DOI 10.1136/jmg.30.11.914; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Koty PP, 1996, NEUROLOGY, V47, P963, DOI 10.1212/WNL.47.4.963; Kubisch C, 1998, HUM MOL GENET, V7, P1753, DOI 10.1093/hmg/7.11.1753; KWIECINSKI H, 1981, CRC CR REV TOXICOL, V8, P279, DOI 10.3109/10408448109089901; KWIECINSKI H, 1988, MUSCLE NERVE, V11, P576, DOI 10.1002/mus.880110609; LEHMANNHORN F, 1995, HUM MOL GENET, V4, P1397, DOI 10.1093/hmg/4.8.1397; LORENZ C, 1994, HUM MOL GENET, V3, P941, DOI 10.1093/hmg/3.6.941; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Mailander V, 1996, AM J HUM GENET, V58, P317; MEYERKLEINE C, 1994, HUM MOL GENET, V3, P1015, DOI 10.1093/hmg/3.6.1015; MEYERKLEINE C, 1995, AM J HUM GENET, V57, P1325; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; PALADE PT, 1977, J GEN PHYSIOL, V69, P325, DOI 10.1085/jgp.69.3.325; Plassart-Schiess E, 1998, NEUROLOGY, V50, P1176, DOI 10.1212/WNL.50.4.1176; Pusch M, 1996, J GEN PHYSIOL, V108, P233, DOI 10.1085/jgp.108.4.233; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Pusch M, 1999, J PHYSIOL-LONDON, V515, P341, DOI 10.1111/j.1469-7793.1999.341ac.x; RUDEL R, 1985, PHYSIOL REV, V65, P310, DOI 10.1152/physrev.1985.65.2.310; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; Thomsen, 1876, ARCH PSYCHIAT NERVEN, V6, P702, DOI DOI 10.1007/BF02164912; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Zhang J, 1996, NEUROLOGY, V47, P993, DOI 10.1212/WNL.47.4.993	44	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2999	3005		10.1074/jbc.275.4.2999	http://dx.doi.org/10.1074/jbc.275.4.2999			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644771	hybrid			2022-12-25	WOS:000085128000103
J	Imatani, A; Callahan, R				Imatani, A; Callahan, R			Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines	ONCOGENE			English	Article						NOTCH-4/INT-3; activated gene product; human	MAMMARY EPITHELIAL-CELLS; SPLIT COMPLEX GENES; TRUNCATED INT3 GENE; NOTCH-GENE; NEOPLASTIC TRANSFORMATION; DROSOPHILA NOTCH; MAMMALIAN NOTCH; HUMAN HOMOLOG; C-MYC; DIFFERENTIATION	Ectopic expression of the intracellular domain of NOTCH-4/INT-3 leads to tumorigenesis in the mouse mammary gland. This results from a gain-of-function mutation. To evaluate gain-of-function NOTCH-4/INT-3 activity in human cancers we have surveyed human breast, lung, and colon carcinoma tissue culture cell lines for evidence of increased NOTCH-4/INT-3 RNA expression. High levels of a 1.8 Kb NOTCH-4/INT-3 RNA species are detected in normal human testis but not in other tissues where a 6.5 Kb species is prevalent. Transformed human cancer cell lines express the 1.8 Kb NOTCH-4/INT-3 RNA species. We show that this RNA species encodes a truncated form of the NOTCH-4/INT3 intracellular domain (ICD), This novel NOTCH-4/ INT-3 protein includes the CDC10 repeats and amino acid residues C-terminal to them, but is missing the CBF-1 binding region of the NOTCH-4/INT-3 ICD, This suggests that it has a different mode of action, Furthermore, we show that a transgene which expresses the 1.8 Kb NOTCH-4/INT-3 RNA species in the 'normal' human mammary epithelial cell line MCF-10A enables these cells to grow in soft agar.	NCI, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Callahan, R (corresponding author), NCI, Tumor Immunol & Biol Lab, NIH, Bldg 10,Room 5B50, Bethesda, MD 20892 USA.							Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Hardy J, 1999, NATURE, V398, P466, DOI 10.1038/18979; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Jolicoeur P, 1998, BIOCHEM SOC SYMP, P159; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Matsuno K, 1997, DEVELOPMENT, V124, P4265; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; SARKAR NH, 1994, VIROLOGY, V203, P52, DOI 10.1006/viro.1994.1454; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Shawber C, 1996, DEVELOPMENT, V122, P3765; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SMITHIES O, 1981, CELL, V26, P345, DOI 10.1016/0092-8674(81)90203-8; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096	38	87	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					223	231		10.1038/sj.onc.1203295	http://dx.doi.org/10.1038/sj.onc.1203295			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645000				2022-12-25	WOS:000084844400007
J	Weterman, MAJ; von Groningen, JJM; Jansen, A; van Kessel, AG				Weterman, MAJ; von Groningen, JJM; Jansen, A; van Kessel, AG			Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins	ONCOGENE			English	Article						TFE3; PRCC; renal cell carcinoma; t(X;1) translocation	HELIX-LOOP-HELIX; HEAVY-CHAIN GENE; ACTIVATION DOMAINS; TRANSLOCATION X-1; PROLINE-RICH; DNA-BINDING; TRANSCRIPTION; ENHANCER; IDENTIFICATION; EXPRESSION	The papillary renal cell carcinoma-associated t(X;1)(p11;q21) leads to fusion of the transcription factor TFE3 gene on the X-chromosome to a novel gene, PRCC, on chromosome 1, As a result, two putative fusion proteins are formed: PRCCTFE3, which contains all known domains for DNA binding, dimerization, and transactivation of the TFE3 protein, and the reciprocal product TFE3PRCC, Upon transfection into COS cells, both wild type and fusion proteins were found to be located in the nucleus, When comparing the transactivating capacities of these (fusion) proteins, significant differences were noted. PRCCTFE3 acted as a threefold better transactivator than wild type TFE3 both in a TFE3-specific and in a general (Zebra) reporter assay. In addition, PRCC and the two fusion proteins were found to he potent transactivators in the Zebra reporter assay. We propose that, as a result of the (X;1) translocation, fusion of the N-terminal PRCC sequences to TFE3 alters the transactivation capacity of the transcription factor thus leading to aberrant gene regulation and, ultimately, tumor formation.	Univ Nijmegen Hosp, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Weterman, MAJ (corresponding author), Univ Nijmegen Hosp, Dept Human Genet 417, POB 9101, NL-6500 HB Nijmegen, Netherlands.		van Kessel, Ad Geurts/A-2810-2010					ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; Askovic S, 1997, BIOTECHNIQUES, V22, P948, DOI 10.2144/97225rr02; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dijkhuizen T, 1998, CANCER GENET CYTOGEN, V104, P74; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rogaia D, 1997, CANCER RES, V57, P799; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; TONK V, 1995, CANCER GENET CYTOGEN, V81, P72, DOI 10.1016/S0165-4608(94)00195-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 1996, CYTOGENET CELL GENET, V75, P2, DOI 10.1159/000134444	30	61	62	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					69	74		10.1038/sj.onc.1203255	http://dx.doi.org/10.1038/sj.onc.1203255			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644981				2022-12-25	WOS:000084844300008
J	Williams, E; Williams, G; Gour, BJ; Blaschuk, OW; Doherty, P				Williams, E; Williams, G; Gour, BJ; Blaschuk, OW; Doherty, P			A novel family of cyclic peptide antagonists suggests that N-cadherin specificity is determined by amino acids that flank the HAV motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; NEURITE OUTGROWTH; CAM; IDENTIFICATION; LOCALIZATION; MAINTENANCE; NEURONS; CANCER; L1	The classical cadherins (e.g. N-, E-, and P-cadherin) are well established homophilic adhesion molecules; however, the mechanism that governs cadherin specificity remains contentious. The classical cadherins contain an evolutionarily conserved His-Ala-Val (HAV) sequence, and linear peptides harboring this motif are capable of inhibiting a variety of cadherin-dependent processes. We now demonstrate that short cyclic HAV peptides can inhibit N-cadherin function. Interestingly, the nature of the amino acids that flank the HAV motif determine both the activity and specificity of the peptides. For example, when the HAV motif is flanked by a single aspartic acid, which mimics the natural HAVD sequence of N-cadherin, the peptide becomes a much more effective inhibitor of N-cadherin function. In contrast, when the HAV motif is flanked by a single serine, which mimics the natural HAVS sequence of E-cadherin, it loses its ability to inhibit the N-cadherin response. Our results demonstrate that subtle changes in the amino acids that flank the HAV motif can account for cadherin specificity and that small cyclic peptides can inhibit cadherin function. An emerging role for cadherins in a number of pathological processes suggests that the cyclic peptides reported in this study might be developed as therapeutic agents.	Kings Coll London, Mol Neurobiol Grp, Guys Kings & St Thomas Sch Med, London SE1 9RT, England; McGill Univ, Dept Surg, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada	University of London; King's College London; McGill University; McGill University	Doherty, P (corresponding author), Kings Coll London, Mol Neurobiol Grp, Guys Kings & St Thomas Sch Med, 4th Floor,New Hunts House,Guys Campus,London Brid, London SE1 9RT, England.	patrick.doherty@kcl.ac.uk	Doherty, Patrick/A-8752-2008; Williams, Gareth/B-3202-2010	Williams, Gareth/0000-0001-9205-4943; Doherty, Patrick/0000-0002-0407-5689				ALEXANDER JS, 1993, J CELL PHYSIOL, V156, P610, DOI 10.1002/jcp.1041560321; Blaschuk O W, 1994, Can J Oncol, V4, P291; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BLASCHUK OW, 1990, J MOL BIOL, V211, P679, DOI 10.1016/0022-2836(90)90065-T; CHEN Z, 1994, ALGEBRA C, V1, P1; CHUAH MI, 1991, DEV BRAIN RES, V60, P123, DOI 10.1016/0165-3806(91)90040-P; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; KCH AW, 1999, CURR OPIN STRUC BIOL, V9, P275; MEGE RM, 1992, J CELL SCI, V103, P897; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MIYATANI S, 1989, SCIENCE, V245, P631, DOI 10.1126/science.2762814; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NEWTON SC, 1993, DEV DYNAM, V197, P1, DOI 10.1002/aja.1001970102; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; Peluso JJ, 1996, ENDOCRINOLOGY, V137, P1196, DOI 10.1210/en.137.4.1196; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Rubin Lee L., 1992, Current Opinion in Cell Biology, V4, P830, DOI 10.1016/0955-0674(92)90107-N; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; STEWART JM, 1969, SOLID PHASE PEPTIDE; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, J CELL BIOL, V124, P1029, DOI 10.1083/jcb.124.6.1029; WILLIAMS EJ, 1992, J CELL BIOL, V119, P883, DOI 10.1083/jcb.119.4.883; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774	34	131	140	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4007	4012		10.1074/jbc.275.6.4007	http://dx.doi.org/10.1074/jbc.275.6.4007			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660557	hybrid			2022-12-25	WOS:000085288800041
J	Couture, M; Stuehr, DJ; Rousseau, DL				Couture, M; Stuehr, DJ; Rousseau, DL			The ferrous dioxygen complex of the oxygenase domain of neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; MACROPHAGE NO SYNTHASE; HYDROXY-L-ARGININE; LOW-TEMPERATURE; BIDOMAIN STRUCTURE; CRYSTAL-STRUCTURE; THIOLATE LIGAND; BINDING DOMAINS; SUBSTRATE; TETRAHYDROBIOPTERIN	The mechanisms by which nitric-oxide synthases (NOSs) bind and activate oxygen at their P450-type heme active site in order to synthesize nitric oxide from the substrate L-arginine are mostly unknown. To obtain information concerning the structure and properties of the first oxygenated intermediate of the enzymatic cycle, we have used a rapid continuous flow mixer and resonance Raman spectroscopy to generate and identify the ferrous dioxygen complex of the oxygenase domain of nNOS (Fe2+O2 nNOSoxy), We detect a line at 1135 cm(-1) in the resonance Raman spectrum of the intermediate formed from 0.6 to 3.0 ms after the rapid mixing of the ferrous enzyme with oxygen that is shifted to 1068 cm(-1) with O-18(2). This line is assigned as the O-O stretching mode (upsilon(O-O)) of the oxygenated complex of nNOSoxy. Rapid mixing experiments performed with nNOSoxy saturated with L-arginine or N-omega-hydroxy-L-arginine, in the presence or absence of (6R)-5,6,7,8-tetrahydro-L-biopterin, reveal that the upsilon(O-O) line is insensitive to the presence of the substrate and the pterin. The optical spectrum of this ferrous dioxygen species, with a Soret band wavelength maximum at 430 nm, confirms the identification of the previously reported oxygenated complexes generated by stopped flow techniques.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA	Yeshiva University; Albert Einstein College of Medicine; Cleveland Clinic Foundation	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.		Couture, Manon/F-8326-2015	Couture, Manon/0000-0001-8296-8055	NIGMS NIH HHS [GM51491, GM54812, GM54806] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491, R01GM054806, R01GM054812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ALBEN JO, 1978, FOURIER TRANSFORM IN, P607; BANGCHAROENPAURPONG O, 1986, J BIOL CHEM, V261, P8089; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BONFILS C, 1979, BIOCHEM BIOPH RES CO, V88, P1301, DOI 10.1016/0006-291X(79)91122-7; BUDYKA MF, 1981, BIOCHEM BIOPH RES CO, V101, P615, DOI 10.1016/0006-291X(81)91303-6; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHOTTARD G, 1984, INORG CHEM, V23, P4557, DOI 10.1021/ic00194a030; Clague MJ, 1997, BIOCHEMISTRY-US, V36, P14465, DOI 10.1021/bi971024u; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; EDWARDS SL, 1990, J BIOL CHEM, V265, P2588; EGAWA T, 1991, J BIOL CHEM, V266, P10246; EISENSTEIN L, 1977, BIOCHEM BIOPH RES CO, V77, P1377, DOI 10.1016/S0006-291X(77)80131-9; Fan BC, 1997, BIOCHEMISTRY-US, V36, P12660, DOI 10.1021/bi9715369; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; HU SZ, 1991, J AM CHEM SOC, V113, P4815, DOI 10.1021/ja00013a016; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; KERR EA, 1985, J BIOL CHEM, V260, P8360; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; LAMBEIR AM, 1985, EUR J BIOCHEM, V147, P93, DOI 10.1111/j.1432-1033.1985.tb08723.x; LARROQUE C, 1980, FEBS LETT, V115, P175, DOI 10.1016/0014-5793(80)81161-6; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Macdonald IDG, 1999, J AM CHEM SOC, V121, P376, DOI 10.1021/ja9810383; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; NAKAJIMA R, 1985, BIOCHEM BIOPH RES CO, V128, P1, DOI 10.1016/0006-291X(85)91635-3; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V149, P197, DOI 10.1016/0003-9861(72)90315-3; PRONIEWICZ LM, 1990, J AM CHEM SOC, V112, P675, DOI 10.1021/ja00158a028; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SONO M, 1985, J BIOL CHEM, V260, P5530; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; TUCKEY RC, 1982, J BIOL CHEM, V257, P9309; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1994, J BIOL CHEM, V269, P28500	54	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3201	3205		10.1074/jbc.275.5.3201	http://dx.doi.org/10.1074/jbc.275.5.3201			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652305	hybrid			2022-12-25	WOS:000085146500027
J	Ostrowski, J; Schullery, DS; Denisenko, ON; Higaki, Y; Watts, J; Aebersold, R; Stempka, L; Gschwendt, M; Bomsztyk, K				Ostrowski, J; Schullery, DS; Denisenko, ON; Higaki, Y; Watts, J; Aebersold, R; Stempka, L; Gschwendt, M; Bomsztyk, K			Role of tyrosine phosphorylation in the regulation of the interaction of heterogenous nuclear ribonucleoprotein K protein with its protein and RNA partners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HNRNP-K; T-CELL; MESSENGER-RNA; TRANSCRIPTIONAL REPRESSOR; VAV PROTOONCOGENE; ANTIGEN RECEPTOR; IN-VITRO; KINASE-C; ACTIVATION; IDENTIFICATION	The heterogeneous nuclear ribonucleoprotein K protein recruits a diversity of molecular partners and may act as a docking platform involved in such processes as transcription, RNA processing, and translation. We show that K protein is tyrosine-phosphorylated in vitro by Src and Lck. Treatment with H2O2/Na3VO4, which induces oxidative stress, stimulated tyrosine phosphorylation of K protein in cultured cells and in intact livers. Tyrosine phosphorylation increased binding of Lck and the proto-oncoprotein Vav to K protein in vitro, Oxidative stress increased the association of K protein with Lck and Vav, suggesting that tyrosine phosphorylation regulates the ability of K protein to recruit these effecters in vivo, Translation-based assay showed that K protein is constitutively bound to many mRNAs in vivo. Native immunoprecipitated K protein-mRNA complexes were disrupted by tyrosine phosphorylation, suggesting that the in vine binding of K protein to mRNA may be responsive to the extracellular signals that activate tyrosine kinases, This study shows that tyrosine phosphorylation of K protein regulates K protein-protein and K protein-RNA interactions, These data are consistent with a model in which functional interaction of K protein is responsive to changes in the extracellular environment, Acting as a docking platform, K protein may bridge signal transduction pathways to sites of nucleic acid-dependent process such as transcription, RNA processing, and translation.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; German Canc Res Ctr, D-69120 Heidelberg, Germany; Maria Sklodowska Curie Mem Canc Ctr, Med Ctr Postgrad Educ, Dept Gastroenterol, PL-02781 Warsaw, Poland; Inst Oncol, PL-02781 Warsaw, Poland	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Helmholtz Association; German Cancer Research Center (DKFZ); Centre of Postgraduate Medical Education - Poland; Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology	Bomsztyk, K (corresponding author), Univ Washington, Dept Med, Box 356521, Seattle, WA 98195 USA.			Ostrowski, Jerzy/0000-0003-1363-3766	NIAID NIH HHS [AI41109] Funding Source: Medline; NIDDK NIH HHS [DK45978] Funding Source: Medline; NIGMS NIH HHS [GM45134] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045978, R01DK045978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045134] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAST A, 1989, PHARM WEEKBLAD, V11, P199, DOI 10.1007/BF01959411; Bijlmakers MJJE, 1999, J CELL BIOL, V145, P457, DOI 10.1083/jcb.145.3.457; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Emkey R, 1997, J BIOL CHEM, V272, P31172, DOI 10.1074/jbc.272.49.31172; FEUERBACH D, 1995, J BIOL CHEM, V270, P25949, DOI 10.1074/jbc.270.43.25949; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HOBERT O, 1994, J BIOL CHEM, V269, P20225; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; MAA MC, 1994, MOL CELL BIOL, V14, P5466, DOI 10.1128/MCB.14.8.5466; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Ostrowski J, 1998, ONCOGENE, V16, P1223, DOI 10.1038/sj.onc.1201624; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; ROSENBERGER U, 1996, EUR J CELL BIOL S42, V69, P288; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; WANG JYJ, 1994, TRENDS BIOCHEM SCI, V19, P373, DOI 10.1016/0968-0004(94)90114-7; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; WATTS JD, 1992, J BIOL CHEM, V267, P901; Watts JD, 1996, FEBS LETT, V398, P217, DOI 10.1016/S0014-5793(96)01241-0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	53	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3619	3628		10.1074/jbc.275.5.3619	http://dx.doi.org/10.1074/jbc.275.5.3619			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652358	hybrid			2022-12-25	WOS:000085146500080
J	Bailly, K; Soulet, F; Leroy, D; Amalric, F; Bouche, G				Bailly, K; Soulet, F; Leroy, D; Amalric, F; Bouche, G			Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor	FASEB JOURNAL			English	Article						FGF-2; mitogenicity; signaling pathway; activation; CK2	CASEIN KINASE-II; NIH 3T3 CELLS; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; RECEPTOR-BINDING; FGF RECEPTOR-1; FACTOR MUTANT; ENDOTHELIAL-CELLS; PROTEIN-KINASES; TYROSINE KINASE	FGF-2 exerts its pleiotropic effects on cell growth and differentiation by interacting with specific cell surface receptors. In addition, exogenously added FGF-2 is translocated from outside the cell to the nucleus during G1-S transition. In this study, we show that a single point mutation in FGF-2 (substitution of residue serine 117 by alanine) is sufficient to drastically reduce its mitogenic activity without affecting its differentiation properties. The FGF-2(S117A) mutant binds to and activates tyrosine kinase receptors and induces MAPK and p70S6K activation as strongly as the wild-type FGF-2. We demonstrate that this mutant enters NIH3T3 cells, is translocated to the nucleus, and is phosphorylated similar to the wild-type growth factor. This suggests that FGF-2 mitogenic activity may require, in addition to signaling through cell surface receptors and nuclear translocation, activation of nuclear targets. We have previously shown that, in vitro, FGF-2 directly stimulates the activity of the casein kinase 2 (CK2), a ubiquitous serine/threonine kinase involved in the control of cell proliferation. We report that, in vivo, FGF-2(WT) transiently interacts with CK2 and stimulates its activity in the nucleus during G1-S transition in NIH3T3 cells. In contrast, the FGF-2(S117A) mutant fails to interact with CK2. Thus, our results show that FGF-2 mitogenic and differentiation activities can be dissociated by a single point mutation and that CK2 may be a new nuclear effector involved in FGF-2 mitogenic activity.	CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse 4, France; INSERM, Commiss Energie Atom Biochim Regulat Cellulairs E, U244 CEN, F-38054 Grenoble, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bouche, G (corresponding author), CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse 4, France.							ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOUCHE G, 1994, CELL MOL BIOL RES, V40, P547; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; Ginisty H, 1999, J CELL SCI, V112, P761; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kilkenny DM, 1996, ENDOCRINOLOGY, V137, P5078, DOI 10.1210/en.137.11.5078; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klingenberg O, 1998, J BIOL CHEM, V273, P11164, DOI 10.1074/jbc.273.18.11164; Kudla AJ, 1998, J CELL BIOL, V142, P241, DOI 10.1083/jcb.142.1.241; Lam K, 1998, J BIOMOL STRUCT DYN, V15, P1009, DOI 10.1080/07391102.1998.10508997; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEROY D, 1995, J BIOL CHEM, V270, P17400, DOI 10.1074/jbc.270.29.17400; LI LY, 1994, BIOCHEMISTRY-US, V33, P10999, DOI 10.1021/bi00202a020; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LORENZ P, 1994, CELL MOL BIOL RES, V40, P519; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Mehta VB, 1998, J BIOL CHEM, V273, P4197, DOI 10.1074/jbc.273.7.4197; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; MOY FJ, 1995, J BIOMOL NMR, V6, P245; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; OLSON MOJ, 1990, EUKARYOTIC NUCLEUS M, V2, P520; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; STACHOWIAK MK, 1996, MOL BIOL CELL, V7, P1290; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0; VILGRAIN I, 1993, FEBS LETT, V331, P228, DOI 10.1016/0014-5793(93)80342-R; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	67	67	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					333	344		10.1096/fasebj.14.2.333	http://dx.doi.org/10.1096/fasebj.14.2.333			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657989				2022-12-25	WOS:000085184800012
J	Cheng, ZJ; Zhao, J; Sun, Y; Hu, W; Wu, YL; Cen, B; Wu, GX; Pei, G				Cheng, ZJ; Zhao, J; Sun, Y; Hu, W; Wu, YL; Cen, B; Wu, GX; Pei, G			beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LEUKOCYTE CHEMOATTRACTANT RECEPTORS; HIV-1 ENTRY; KINASE ACTIVATION; TROPIC HIV-1; DESENSITIZATION; INFECTION; CLONING; LIGAND; SDF-1	The chemokine receptor CXCR4 has recently been shown to be a co-receptor involved in the entry of human immunodeficiency virus type 1 into target cells. This study shows that coexpression of beta-arrestin with CXCR4 in human embryonic kidney 293 cells attenuated chemokine-stimulated G protein activation and inhibition of cAMP production. Truncation of the C-terminal 34 amino acids of CXCR4 (CXCR4-T) abolished the effects of beta-arrestin on CXCR4/G protein signaling, indicating the functional interaction of the receptor C terminus with beta-arrestin. On the other hand, receptor internalization and the subsequent activation of extracellular signal-regulated kinases were significantly promoted by coexpression of beta-arrestin with CXCR4, whereas the C-terminal truncation of CXCR4 did not affect this regulation of beta-arrestin, suggesting that beta-arrestin can functionally interact with CXCR4 with or without the C terminus. Moreover, beta(2)V54D, the dominant inhibitory mutant of beta-arrestin 2, exerted no effects on CXCR4/G protein signaling, but strongly influenced receptor internalization and extracellular signal-regulated kinase activation. Further cross-linking experiments demonstrated that beta-arrestin as well. as beta(2)V54D could physically contact both CXCR4. and CXCR4-T. Glutathione S-transferase pub-down assay showed that beta-arrestin was able to bind efficiently In vitro to both the third intracellular loop and the 34-amino acid C terminus of CXCR4. Taken together, our data clearly establish that beta-arrestin can effectively regulate different functions of CXCR4 and that this is mediated through its distinct interactions with the C terminus and other regions including the third loop of CXCR4.	Chinese Acad Sci, Shanghai Inst Cell Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Pei, G (corresponding author), Chinese Acad Sci, Shanghai Inst Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.		Zhao, Jian/E-2008-2019	Zhao, Jian/0000-0002-8862-0591				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Barlic J, 1999, J BIOL CHEM, V274, P16287, DOI 10.1074/jbc.274.23.16287; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; CHEN CY, 1993, J BIOL CHEM, V268, P7825; Cheng ZJ, 1997, NEUROREPORT, V8, P1913, DOI 10.1097/00001756-199705260-00024; Cheng ZJ, 1998, J BIOL CHEM, V273, P24328, DOI 10.1074/jbc.273.38.24328; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; HAGA K, 1994, J BIOL CHEM, V269, P12594; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Ling K, 1999, P NATL ACAD SCI USA, V96, P7922, DOI 10.1073/pnas.96.14.7922; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MOCHIZUKI M, 1985, INVEST OPHTH VIS SCI, V26, P226; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PARRUTI G, 1993, J RECEPTOR RES, V13, P95, DOI 10.3109/10799899309073648; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; Power CA, 1996, TRENDS PHARMACOL SCI, V17, P209, DOI 10.1016/0165-6147(96)10019-5; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Tarasova NI, 1998, J BIOL CHEM, V273, P15883, DOI 10.1074/jbc.273.26.15883; Ueda H, 1997, J BIOL CHEM, V272, P24966, DOI 10.1074/jbc.272.40.24966; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zhao J, 1999, J EXP MED, V190, P101, DOI 10.1084/jem.190.1.101	45	172	183	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2479	2485		10.1074/jbc.275.4.2479	http://dx.doi.org/10.1074/jbc.275.4.2479			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644702	hybrid			2022-12-25	WOS:000085128000034
J	Kumar, D; Whiteside, TL; Kasid, U				Kumar, D; Whiteside, TL; Kasid, U			Identification of a novel tumor necrosis factor-alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of Fas-associated death domain-like interleukin-1 beta-converting enzyme-inhibitory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SQUAMOUS CARCINOMA; CELL-CARCINOMA; IONIZING-RADIATION; MEDIATED APOPTOSIS; CD95 FAS/APO-1; FLOW-CYTOMETRY; TNF-ALPHA; EXPRESSION; FLICE; RECEPTORS	We report here the isolation and characterization of a novel tumor necrosis factor-alpha (TNF-alpha)-inducible gene, SCC-S2, Based on the nucleotide sequence, the SCC-SP open reading frame contains a sequence in the amino terminus that shows a significant homology to death effector domain II of cell death regulatory protein, Fas-associated death domain-like interleukin-1 beta-converting enzyme-inhibitory protein (FLIP). Unlike FLIP, the SCC-SS open reading frame contains only one death effector domain and lacks the carboxyl-terminal caspase-like homology domain, raising the possibility that SCC-S2 may be a novel member of the FLIP family. SCC-S2 mRNA expression is found in most normal tissues and malignant cells. The steady state level of SCC-S2 mRNA is significantly induced by TNF-a in different tumor cells (TNF-alpha at 20 ng/ml for 3 h: A549, similar to 2-9-fold; SKOV-3, similar to 3-fold; PCI-04A, similar to 3-6-fold), TNF-alpha treatment (100 ng/ml, 4 h) of HeLa cells transiently transfected with FLAG epitope-tagged SCC-S2 cDNA or expression vector alone led to an increase in the number of apoptotic cells as compared with the untreated counterpart. Interestingly, however, SCC-S2 transfectants revealed a significant decrease in the number of apoptotic cells as compared with the vector transfectants (p < 0.001). These data implicate a role of SCC-S2 as a negative mediator of apoptosis in certain cell, types.	Georgetown Univ, Lombardi Canc Ctr, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA; Georgetown Univ, Lombardi Canc Ctr, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Univ Pittsburgh, Sch Med, Pittsburgh Canc Inst, Dept Pathol, Pittsburgh, PA 15261 USA	Georgetown University; Georgetown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Kasid, U (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Med Ctr, Dept Radiat Med, E208,Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	kasidu@gunet.georgetown.edu			NCI NIH HHS [CA74175, CA68322, P30-CA51008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA068322, P01CA074175, P30CA051008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chiou SK, 1998, VIROLOGY, V244, P108, DOI 10.1006/viro.1998.9077; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; EARL PL, 1986, P NATL ACAD SCI USA, V83, P3659, DOI 10.1073/pnas.83.11.3659; Gokhale PC, 1999, ANTISENSE NUCLEIC A, V9, P191, DOI 10.1089/oli.1.1999.9.191; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Griffith TS, 1998, J IMMUNOL, V161, P2833; HAN SK, 1994, AM J RESP CELL MOL, V11, P270, DOI 10.1165/ajrcmb.11.3.8086165; HEO DS, 1989, CANCER RES, V49, P5167; Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431; Hu MC, 1997, VIROLOGY, V227, P295, DOI 10.1006/viro.1996.8349; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; IRMIER M, 1997, NATURE, V388, P190; Kasid U, 1997, MOL CELL BIOCHEM, V173, P193; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; Kasid Usha, 1998, P85; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kissil JL, 1999, EMBO J, V18, P353, DOI 10.1093/emboj/18.2.353; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MORIMOTO H, 1991, J IMMUNOL, V147, P2609; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; ODA T, 1993, BIOCHEM BIOPH RES CO, V193, P897, DOI 10.1006/bbrc.1993.1710; Patel S, 1998, ACTA ONCOL, V37, P475, DOI 10.1080/028418698430430; Patel S, 1997, ORAL ONCOL, V33, P197, DOI 10.1016/S0964-1955(96)00065-6; Patel S, 1997, MOL MED, V3, P674, DOI 10.1007/BF03401706; SACCHI M, 1991, ARCH OTOLARYNGOL, V117, P321; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; Weiss R A, 1998, J Natl Cancer Inst Monogr, P51; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795	43	107	121	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2973	2978		10.1074/jbc.275.4.2973	http://dx.doi.org/10.1074/jbc.275.4.2973			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644768	hybrid			2022-12-25	WOS:000085128000100
J	Lesa, GM; Seemann, J; Shorter, J; Vandekerckhove, J; Warren, G				Lesa, GM; Seemann, J; Shorter, J; Vandekerckhove, J; Warren, G			The amino-terminal domain of the Golgi protein Giantin interacts directly with the vesicle-tethering protein p115	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL MEMBRANE-PROTEIN; CELL-FREE SYSTEM; ENDOPLASMIC-RETICULUM; COATED VESICLES; TRANSPORT VESICLES; HELA-CELLS; CIS-GOLGI; VESICULAR TRANSPORT; MITOTIC CONDITIONS; ENDOSOME FUNCTION	Giantin is thought to form a complex with p115 and Golgi matrix protein 130, which is involved in the reassembly of Golgi cisternae and stacks at the end of mitosis. The complex is involved in the tethering of coat protomer I vesicles to Golgi membranes and the initial stacking of reforming cisternae, Here we show that the NH2-terminal 15% of Giantin suffices to bind p115 in vitro and in vivo and to block cell-free Golgi reassembly. Because Giantin is a long, rod-like protein anchored to the membrane by its extreme COOH terminus, these results support the idea of a long, flexible tether linking vesicles and cisternae.	Imperial Canc Res Fund, Cell Biol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Mol Neuropathobiol Lab, London WC2A 3PX, England; State Univ Ghent VIB, Dept Biochem, B-9000 Ghent, Belgium; State Univ Ghent VIB, Dept Med Prot Res, B-9000 Ghent, Belgium	Cancer Research UK; Cancer Research UK; Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Warren, G (corresponding author), Imperial Canc Res Fund, Cell Biol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	graham.warren@yale.edu	Shorter, James/ABE-7307-2020; Shorter, James/E-8207-2011	Shorter, James/0000-0001-5269-8533; 				Allen PG, 1999, BIOESSAYS, V21, P451, DOI 10.1002/(SICI)1521-1878(199906)21:6<451::AID-BIES1>3.0.CO;2-B; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; Barr FA, 1996, SEMIN CELL DEV BIOL, V7, P505, DOI 10.1006/scdb.1996.0063; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Clague MJ, 1999, CURR BIOL, V9, pR258, DOI 10.1016/S0960-9822(99)80158-4; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERNANDEZPATRON C, 1995, ANAL BIOCHEM, V224, P203, DOI 10.1006/abio.1995.1031; Gaynor EC, 1998, BBA-MOL CELL RES, V1404, P33, DOI 10.1016/S0167-4889(98)00045-7; Gevaert K, 1998, ELECTROPHORESIS, V19, P909, DOI 10.1002/elps.1150190606; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; Griffin PR, 1995, RAPID COMMUN MASS SP, V9, P1546, DOI 10.1002/rcm.1290091515; Harborth J, 1999, EMBO J, V18, P1689, DOI 10.1093/emboj/18.6.1689; HEINS S, 1994, CURR OPIN CELL BIOL, V6, P25, DOI 10.1016/0955-0674(94)90112-0; Hui N, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P46; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kim DW, 1999, MOL BIOL CELL, V10, P3317, DOI 10.1091/mbc.10.10.3317; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Shorter J, 1999, J CELL BIOL, V146, P57, DOI 10.1083/jcb.146.1.57; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Sohda M, 1998, J BIOL CHEM, V273, P5385, DOI 10.1074/jbc.273.9.5385; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1995, TRENDS CELL BIOL, V5, P413, DOI 10.1016/S0962-8924(00)89094-7; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WEBER K, 1969, J BIOL CHEM, V244, P4406; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; WHITNEY JA, 1995, CELL, V83, P703; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9; Yamakawa H, 1996, J STRUCT BIOL, V116, P356, DOI 10.1006/jsbi.1996.0053; Yuan L, 1996, EXP CELL RES, V229, P272, DOI 10.1006/excr.1996.0371	71	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2831	2836		10.1074/jbc.275.4.2831	http://dx.doi.org/10.1074/jbc.275.4.2831			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644749	Green Submitted, hybrid			2022-12-25	WOS:000085128000081
J	Saas, J; Ziegelbauer, K; von Haeseler, A; Fast, B; Boshart, M				Saas, J; Ziegelbauer, K; von Haeseler, A; Fast, B; Boshart, M			A developmentally regulated aconitase related to iron-regulatory protein-1 is localized in the cytoplasm and in the mitochondrion of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; ELEMENT-BINDING-PROTEIN; ETIOLATED PUMPKIN COTYLEDONS; HIGHER-PLANT CELLS; IN-VITRO IMPORT; SULFUR CLUSTERS; DIHYDROLIPOAMIDE DEHYDROGENASE; AFRICAN TRYPANOSOMES; CYTOSOLIC ACONITASE; MUTATIONAL ANALYSIS	Mitochondrial energy metabolism and Krebs cycle activities are development-ally regulated in the life cycle of the protozoan parasite Typanosoma brucei. Here we report cloning of a T. brucei aconitase gene that is closely related to mammalian iron-regulatory protein 1 (IRP-1) and plant aconitases. Kinetic analysis of purified recombinant TbACO expressed in Escherichia coli resulted in a K-m (isocitrate) of 3 +/- 0.4 mM, similar to aconitases of other organisms. This was unexpected since an arginine conserved in the aconitase protein family and crucial for substrate positioning in the catalytic center and for activity of pig mitochondrial aconitase (Zheng, L., Kennedy, M. C., Beinert, H., and Zalkin, H. (1992) J. Biol. Chem. 267, 7895-7903) is substituted by leucine in the TbACO sequence. Expression of the 98-kDa TbACO was shown to be lowest in the slender bloodstream stage of the parasite, 8-fold elevated in the stumpy stage, and increased a further 4-fold in the procyclic stage. The differential expression of TbACO protein contrasted with only minor changes in TbACO mRNA, indicating translational or post-translational mechanisms of regulation, Whereas animal cells express two distinct compartmentalized aconitases, mitochondrial aconitase and cytoplasmic aconitase/IRP-1, TbACO accounts for total aconitase activity in trypanosomes, By cell fractionation and immunofluorescence microscopy, we show that native as well as a transfected epitope-tagged TbACO localizes in both the mitochondrion (30%) and in the cytoplasm (70%), Together with phylogenetic reconstructions of the aconitase family, this suggests that animal IRPs have evolved from a multicompartmentalized ancestral aconitase, The possible functions of a cytoplasmic aconitase in trypanosomes are discussed.	FU Berlin, Inst Mol Biol & Biochem, AG Mol Zellbiol, D-12203 Berlin, Germany; FU Berlin, Inst Infect Med, D-12203 Berlin, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Max Planck Inst Biol, D-7400 Tubingen, Germany; Max Planck Inst Evolutionary Anthropol, Leipzig, Germany	Free University of Berlin; Free University of Berlin; Max Planck Society; Max Planck Society; Max Planck Society	Boshart, M (corresponding author), FU Berlin, Inst Mol Biol & Biochem, AG Mol Zellbiol, Hindenburgdamm 27, D-12203 Berlin, Germany.	boshart@ukbf.fu-berlin.de	Boshart, Michael/A-2700-2011; von Haeseler, Arndt/HCI-9958-2022	Boshart, Michael/0000-0002-5070-2663; von Haeseler, Arndt/0000-0002-3366-4458				Alen C, 1999, P NATL ACAD SCI USA, V96, P10412, DOI 10.1073/pnas.96.18.10412; Anderson SA, 1998, EXP PARASITOL, V89, P63, DOI 10.1006/expr.1998.4260; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; BLUM JJ, 1994, J BIOENERG BIOMEMBR, V26, P147, DOI 10.1007/BF00763063; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BROUQUISSE R, 1987, PLANT PHYSIOL, V84, P1402, DOI 10.1104/pp.84.4.1402; BRUN R, 1979, ACTA TROP, V36, P289; BRUN R, 1981, Z PARASITENKD, V66, P17, DOI 10.1007/BF00941941; CARRUTHERS VB, 1993, NUCLEIC ACIDS RES, V21, P2537, DOI 10.1093/nar/21.10.2537; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; CLAYTON C, 1995, MICROBIOL REV, V59, P325, DOI 10.1128/MMBR.59.3.325-344.1995; Clayton CE, 1996, PARASITOL TODAY, V12, P465, DOI 10.1016/S0169-4758(96)10073-9; COURTOISVERNIQUET F, 1993, BIOCHEM J, V294, P103, DOI 10.1042/bj2940103; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; DEBELLIS L, 1993, PHYSIOL PLANTARUM, V88, P485, DOI 10.1111/j.1399-3054.1993.tb01363.x; DEBELLIS L, 1995, PLANTA, V195, P464, DOI 10.1007/BF00202606; ELSE AJ, 1994, MOL BIOCHEM PARASIT, V64, P233, DOI 10.1016/0166-6851(93)00016-3; ELSE AJ, 1993, EUR J BIOCHEM, V212, P423, DOI 10.1111/j.1432-1033.1993.tb17678.x; Escher CL, 1997, BIOL CHEM, V378, P803; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; Fast B, 1999, BIOCHEM J, V342, P691, DOI 10.1042/0264-6021:3420691; Frishman D, 1996, EUR J BIOCHEM, V239, P197, DOI 10.1111/j.1432-1033.1996.0197u.x; GALE M, 1994, J BIOL CHEM, V269, P31659; GANGLOFF SP, 1990, MOL CELL BIOL, V10, P3551, DOI 10.1128/MCB.10.7.3551; GLUSKER JP, 1971, ENZYMES, V5, P413; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Gruer MJ, 1997, TRENDS BIOCHEM SCI, V22, P3, DOI 10.1016/S0968-0004(96)10069-4; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; Hauser R, 1996, J CELL SCI, V109, P517; Hausler T, 1997, EUR J CELL BIOL, V73, P240; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; HAYASHI M, 1995, PLANT CELL PHYSIOL, V36, P669; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HENSON CP, 1967, J BIOL CHEM, V242, P3833; Hentze MW, 1996, TRENDS BIOCHEM SCI, V21, P282, DOI 10.1016/S0968-0004(96)20019-2; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Hotz HR, 1997, NUCLEIC ACIDS RES, V25, P3017, DOI 10.1093/nar/25.15.3017; Irvin SD, 1998, J MOL EVOL, V46, P401, DOI 10.1007/PL00006319; JACKMAN SA, 1990, EUR J BIOCHEM, V193, P91, DOI 10.1111/j.1432-1033.1990.tb19308.x; JORDANOV J, 1992, J BIOL CHEM, V267, P16775; KEEGAN FP, 1993, J EUKARYOT MICROBIOL, V40, P730, DOI 10.1111/j.1550-7408.1993.tb04467.x; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LAUBLE H, 1995, PROTEINS, V22, P1, DOI 10.1002/prot.340220102; Matthews KR, 1997, J CELL SCI, V110, P2609; MENGAUD JM, 1993, J BACTERIOL, V175, P5666, DOI 10.1128/JB.175.17.5666-5676.1993; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; MIZOBUCHI M, 1992, BIOTECHNIQUES, V12, P350; Murakami K, 1997, BIOCHEM MOL BIOL INT, V41, P481; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; OVERATH P, 1986, EUR J BIOCHEM, V160, P175, DOI 10.1111/j.1432-1033.1986.tb09955.x; PEYRET P, 1995, J BIOL CHEM, V270, P8131, DOI 10.1074/jbc.270.14.8131; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; PRIEST JW, 1994, MOL BIOCHEM PARASIT, V65, P291, DOI 10.1016/0166-6851(94)90080-9; Priest JW, 1996, J BIOL CHEM, V271, P20060, DOI 10.1074/jbc.271.33.20060; PRIEST JW, 1995, BBA-MOL CELL RES, V1269, P201, DOI 10.1016/0167-4889(95)00154-6; PRIEST JW, 1993, BIOCHIM BIOPHYS ACTA, V1144, P229, DOI 10.1016/0005-2728(93)90178-I; PRIEST JW, 1994, J BIOENERG BIOMEMBR, V26, P179, DOI 10.1007/BF00763067; PURNELLE B, 1994, YEAST, V10, P1235, DOI 10.1002/yea.320100912; Reuner B, 1997, MOL BIOCHEM PARASIT, V90, P269, DOI 10.1016/S0166-6851(97)00160-6; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; SCHULZ I, 1990, METHOD ENZYMOL, V192, P280; Schurch N, 1997, MOL BIOCHEM PARASIT, V89, P109, DOI 10.1016/S0166-6851(97)00107-2; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; Steverding D, 1998, PARASITOL RES, V84, P59, DOI 10.1007/s004360050357; Strimmer K, 1997, MOL BIOL EVOL, V14, P210, DOI 10.1093/oxfordjournals.molbev.a025756; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; THEIL EC, 1994, BIOCHEM J, V304, P1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TORRI AF, 1993, MOL BIOCHEM PARASIT, V57, P305, DOI 10.1016/0166-6851(93)90206-D; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tyler KM, 1997, P ROY SOC B-BIOL SCI, V264, P1481, DOI 10.1098/rspb.1997.0205; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; Vassella E, 1996, MOL BIOCHEM PARASIT, V82, P91, DOI 10.1016/0166-6851(96)02727-2; Vassella E, 1997, MOL BIOCHEM PARASIT, V90, P381, DOI 10.1016/S0166-6851(97)00171-0; Vassella E, 1997, J CELL SCI, V110, P2661; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643; VICKERMAN K, 1965, NATURE, V208, P762, DOI 10.1038/208762a0; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; VILLAREJO MR, 1974, J BACTERIOL, V120, P466, DOI 10.1128/JB.120.1.466-474.1974; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; YANG ZH, 1994, J MOL EVOL, V39, P306, DOI 10.1007/BF00160154; ZHANG JW, 1993, MOL BIOL CELL, V4, P1351, DOI 10.1091/mbc.4.12.1351; ZHENG L, 1992, J BIOL CHEM, V267, P7895; ZHENG LM, 1990, J BIOL CHEM, V265, P2814; ZHOU YH, 1995, PLANT MOL BIOL, V28, P635, DOI 10.1007/BF00021189	108	72	72	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2745	2755		10.1074/jbc.275.4.2745	http://dx.doi.org/10.1074/jbc.275.4.2745			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644738	hybrid, Green Published			2022-12-25	WOS:000085128000070
J	Suzuki, H; Chiba, T; Suzuki, T; Fujita, T; Ikenoue, T; Omata, M; Furuichi, K; Shikama, H; Tanaka, K				Suzuki, H; Chiba, T; Suzuki, T; Fujita, T; Ikenoue, T; Omata, M; Furuichi, K; Shikama, H; Tanaka, K			Homodimer of two F-box proteins beta TrCP1 or beta TrCP2 binds to I kappa B alpha for signal-dependent ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; PROTEASOME PATHWAY; PROTEOLYSIS; DEGRADATION; COMPLEX; ACTIVATION; KINASE; SYSTEM; LIGASE	We found previously that overexpression of an F-box protein beta TrCP1 and the structurally related beta TrCP2 augments ubiquitination of phosphorylated I kappa B alpha (pI kappa B alpha) induced by tumor necrosis factor-alpha (TNF-alpha), but the relationship of the two homologous beta TrCP proteins remains unknown. Herein we reveal that deletion mutants of beta TrCP1 and beta TrCP2 lacking the F-box domain suppressed ubiquitination and destruction of pI kappa B alpha as well as transcriptional activation of NF-kappa B, The ectopically expressed beta TrCP1 and beta TrCP2 formed both homodimer and heterodimer complexes without displaying the trimer complex. Dimerization of beta TrCP1 and/or beta TrCP2 takes place at their conserved NH2-terminal regions, termed a "D-domain" (for dimerization domain), located upstream of the F-box domain. The D-domain was necessary and sufficient for the dimer formation. Intriguingly, the beta TrCP homodimer, but not the heterodimer, was selectively recruited to pI kappa B alpha induced by TNF-alpha. These results indicate that not only beta TrCP1 but also beta TrCP2 participates in the ubiquitination- dependent destruction of I kappa B alpha by forming SCFbeta TrCP1-beta TrCP1 and SCFbeta TrCP2-beta TrCP2 ubiquitin-ligase complexes.	Japan Sci & Technol Corp, Tokyo Metropolitan Inst Med Sci, Core Res Evolut Sci & Technol, Bunkyo Ku, Tokyo 1138613, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan; Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan	Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science; Astellas Pharmaceuticals; University of Tokyo	Tanaka, K (corresponding author), Japan Sci & Technol Corp, Tokyo Metropolitan Inst Med Sci, Core Res Evolut Sci & Technol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.			Suzuki, Toshiaki/0000-0002-0650-6251				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kominami K, 1998, GENES CELLS, V3, P721, DOI 10.1046/j.1365-2443.1998.00225.x; KOMINAMI K, 1975, GENE DEV, V1115, P97; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Lagna G, 1999, MECH DEVELOP, V80, P101, DOI 10.1016/S0925-4773(98)00208-1; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Maekawa H, 1998, CURR GENET, V33, P29, DOI 10.1007/s002940050305; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P121, DOI 10.1006/bbrc.1999.0296; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wolf DA, 1999, CURR BIOL, V9, P373, DOI 10.1016/S0960-9822(99)80165-1; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	47	107	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2877	2884		10.1074/jbc.275.4.2877	http://dx.doi.org/10.1074/jbc.275.4.2877			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644755	hybrid			2022-12-25	WOS:000085128000087
J	Toure, BB; Munzer, JS; Basak, A; Benjannet, S; Rochemont, J; Lazure, C; Chretien, M; Seidah, NG				Toure, BB; Munzer, JS; Basak, A; Benjannet, S; Rochemont, J; Lazure, C; Chretien, M; Seidah, NG			Biosynthesis and enzymatic characterization of human SKI-1/S1P and the processing of its inhibitory prosegment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROPROTEIN CONVERTASES; LIVING CELLS; CLEAVAGE; PEPTIDES; INVOLVEMENT; MECHANISM; PROTEINS; BINDING; CALCIUM	Biochemical and enzymatic characterization of the novel human subtilase hSKI-1 was carried out in various cell lines. Within the endoplasmic reticulum of LoVo cells, proSKI-1 is converted to SKI-1 by processing of its prosegment into 26-, 24-, 14-, 10-, and 8-kDa products, some of which remain tightly associated with the enzyme. N-terminal sequencing and mass spectrometric analysis were used to map the cleavage sites of the most abundant fragments, which were confirmed by synthetic peptide processing. To characterize its in vitro enzymatic properties, we generated a secreted form of SKI-1. Our data demonstrate that SKI-1 is a Ca2+-dependent proteinase exhibiting optimal cleavage at pH 6.5. We present evidence that SKI-1 processes peptides mimicking the cleavage sites of the SKI-1 prosegment, pro-brain-derived neurotrophic factor, and the sterol regulatory element-binding protein SREBP-2. Among the candidate peptides encompassing sections of the SKI-1 prosegment, the RSLK137-,and RRLL186-containing peptides were best cleaved by this enzyme. Mutagenesis of the latter peptide allowed us to develop an efficiently processed SKI-I substrate and to assess the importance of several P and P' residues. Finally, we demonstrate that, in vitro, recombinant prosegments of SKI-1 inhibit its activity with apparent inhibitor constants of 100-200 nM.	Clin Res Inst Montreal, Biochem Lab, Montreal, PQ H2W 1R7, Canada; Clin Res Inst Montreal, Lab Mol Neuroendocrinol, Montreal, PQ H2W 1R7, Canada; Clin Res Inst Montreal, Lab Struct & Metab Neuropeptides, Prot Engn Network, Ctr Excellence, Montreal, PQ H2W 1R7, Canada; Univ Ottawa, Prot Chem Ctr, Loeb Hlth Res Inst, Ottawa Hosp, Ottawa, ON K1Y 4K9, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute	Seidah, NG (corresponding author), Clin Res Inst Montreal, Biochem Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	seidahn@ircm.qc.ca	Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Basak A, 1997, J PEPT RES, V49, P596; Basak A, 1995, J Pept Sci, V1, P385, DOI 10.1002/psc.310010606; Benjannet S, 1998, FEBS LETT, V428, P37, DOI 10.1016/S0014-5793(98)00480-3; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; BURBACH JPH, 1986, EUR J BIOCHEM, V156, P137, DOI 10.1111/j.1432-1033.1986.tb09558.x; Cheng D, 1999, J BIOL CHEM, V274, P22805, DOI 10.1074/jbc.274.32.22805; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; GRAM H, 1994, BIO-TECHNOL, V12, P1017, DOI 10.1038/nbt1094-1017; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUDSON P, 1981, NATURE, V291, P127, DOI 10.1038/291127a0; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; KENDALL JM, 1994, ANAL BIOCHEM, V221, P173, DOI 10.1006/abio.1994.1394; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Lei YH, 1999, DNA CELL BIOL, V18, P175, DOI 10.1089/104454999315565; LING N, 1976, P NATL ACAD SCI USA, V73, P3042; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; MALIDE D, 1995, J HISTOCHEM CYTOCHEM, V43, P11, DOI 10.1177/43.1.7822759; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; RITTENHOUSE J, 1984, ANAL BIOCHEM, V138, P442, DOI 10.1016/0003-2697(84)90836-4; Rovere C, 1999, J BIOL CHEM, V274, P12461, DOI 10.1074/jbc.274.18.12461; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; SEIDAH NG, 1998, MOL B INT U, V2, P49; Siezen RJ, 1997, PROTEIN SCI, V6, P501; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913	39	76	79	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	2000	275	4					2349	2358		10.1074/jbc.275.4.2349	http://dx.doi.org/10.1074/jbc.275.4.2349			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	280XA	10644685	hybrid			2022-12-25	WOS:000085128000017
J	Marcus, NY; Perlmutter, DH				Marcus, NY; Perlmutter, DH			Glucosidase and mannosidase inhibitors mediate increased secretion of mutant alpha 1 antitrypsin Z	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; HUMAN ALPHA(1)-ANTITRYPSIN; SACCHAROMYCES-CEREVISIAE; LIVER-DISEASE; DEGRADATION; CALNEXIN; GLYCOSYLATION; GLYCOPROTEIN; CASTANOSPERMINE; DEFICIENCY	It is now well known that the addition and trimming of oligosaccharide side chains during post-translational modification play an important role in determining the fate of secretory, membrane, and lysosomal glycoproteins, Recent studies have suggested that trimming of oligosaccharide side chains also plays a role in the degradation of misfolded glycoproteins as a part of the quality control mechanism of the endoplasmic reticulum (ER), In this study, we examined the effect of several inhibitors of carbohydrate processing on the fate of the misfolded secretory protein alpha 1 antitrypsin Z. Retention of this misfolded glycoprotein in the ER of liver cells in the classical form of alpha 1 antitrypsin (alpha 1-AT) deficiency is associated with severe liver injury and hepatocellular carcinoma and lack of its secretion is associated with destructive lung disease/emphysema. The results show marked alterations in the fate of alpha 1 antitrypsin Z (alpha 1-ATZ), Indeed, one glucosidase inhibitor, castanospermine (CST), and two mannosidase inhibitors, kifunensine (RIF) and deoxymannojirimycin (DMJ), mediate marked increases in secretion of alpha 1-ATZ by distinct mechanisms. The effects of these inhibitors on secretion have interesting implications for our understanding of the quality control apparatus of the ER, These inhibitors may also constitute models for development of additional drugs for chemoprophylaxis of liver injury and emphysema in patients with alpha 1-AT deficiency.	Washington Univ, St Louis Childrens Hosp, Dept Pediat, Sch Med,Div Gastroenterol & Nutr, St Louis, MO 63110 USA; Washington Univ, St Louis Childrens Hosp, Dept Cell Biol & Physiol, Sch Med,Div Gastroenterol & Nutr, St Louis, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Perlmutter, DH (corresponding author), Washington Univ, St Louis Childrens Hosp, Dept Pediat, Sch Med,Div Gastroenterol & Nutr, 1 Childrens Pl,Box 8116, St Louis, MO 63110 USA.	perlmutter@kids.wustl.edu			NHLBI NIH HHS [HL37884] Funding Source: Medline; NICHD NIH HHS [T32 HD07409] Funding Source: Medline; NIDDK NIH HHS [DK52526] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL037884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATHURST IC, 1984, FEBS LETT, V177, P179, DOI 10.1016/0014-5793(84)81279-X; BURROWS JAJ, 2000, IN PRESS P NATL ACAD; Campbell EJ, 1999, J CLIN INVEST, V104, P337, DOI 10.1172/JCI6092; GROSS V, 1986, BIOCHEM J, V236, P853, DOI 10.1042/bj2360853; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; JACOB GS, 1995, CURR OPIN STRUC BIOL, V5, P605, DOI 10.1016/0959-440X(95)80051-4; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Kang HA, 1998, YEAST, V14, P371, DOI 10.1002/(SICI)1097-0061(19980315)14:4<371::AID-YEA231>3.3.CO;2-T; KANG MS, 1995, GLYCOBIOLOGY, V5, P147, DOI 10.1093/glycob/5.1.147; Karaivanova VK, 1998, GLYCOBIOLOGY, V8, P725, DOI 10.1093/glycob/8.7.725; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Kwon KS, 1997, BBA-GEN SUBJECTS, V1335, P265, DOI 10.1016/S0304-4165(96)00143-2; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; OGUSHI F, 1987, J CLIN INVEST, V80, P1366, DOI 10.1172/JCI113214; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Teckman JH, 1996, HEPATOLOGY, V24, P1504, DOI 10.1002/hep.510240635; TECKMAN JH, 1999, IN PRESS AM J PHYSL; Verhoeven AJM, 1999, BIOCHEM J, V337, P133, DOI 10.1042/0264-6021:3370133; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943	31	55	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1987	1992		10.1074/jbc.275.3.1987	http://dx.doi.org/10.1074/jbc.275.3.1987			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636901	hybrid			2022-12-25	WOS:000084940000064
J	Noda, A; Toma-Aiba, Y; Fujiwara, Y				Noda, A; Toma-Aiba, Y; Fujiwara, Y			A unique, short sequence determines p53 gene basal and UV-inducible expression in normal human cells	ONCOGENE			English	Article						p53; UV; X-ray; stress response; transcription; promoter	DEPENDENT PROTEIN-KINASE; CELLULAR TUMOR-ANTIGEN; KAPPA-B ACTIVATION; RNA POLYMERASE-II; DNA-DAMAGE; NUCLEAR ACCUMULATION; IONIZING-RADIATION; GLIOBLASTOMA CELLS; TRANSCRIPTION; GROWTH	The p53 tumor suppressor protein plays a central role in the cellular defence against agents which cause genetic damage. The induction and activation of p53 upon stress has been shown at post-transcription level by multiple mechanisms, while the regulatory role of p53 gene transcription is still poorly understood. Here we show that the causative mechanisms underlying this activation are attributed in part to the promoter function of p53, In various normal human cells, p53 gene expression is induced transcriptionally by ultraviolet (UV) but not X-ray irradiation. We determined that, by p53 promoter dissection, the 21 bp element (PE21) responsible for this UV activation resides adjacent to, and upstream to the putative NF kappa B binding site. Moreover, the PE21 sequence,vas found to be a primary determinant for human p53 gene basal expression carrying bi-directional transcriptional initiation activity, which controls the initiation of RNA synthesis about 50 bases downstream, indicating that the sequence plays a critical role in both basal and inducible transcription. Finally, we detected the putative PE21 binding factor(s) in nuclear extracts from non-irradiated and irradiated cells, Since the PE21 sequence does not show any homologies to the conventional TATA or GC box, or to an 'initiatior', all of which determine the initiation site for transcription, the PE21 sequence appears to be a new class in eukaryotic promoter elements. Our results indicate that the mechanism of PE21-directed p53 mRNA transcription has an important role in the cellular stress response as well as tumor suppression.	Kobe Univ, Sch Med, Dept Radiat Biophys & Genet, Chuo Ku, Kobe, Hyogo 6500017, Japan; Meiji Cell Technol Ctr, Odawara 250, Japan	Kobe University; Meiji Holdings Co., Ltd.	Noda, A (corresponding author), Kobe Univ, Sch Med, Dept Radiat Biophys & Genet, Chuo Ku, 7-5-1 Kusunokicho, Kobe, Hyogo 6500017, Japan.			Noda, Asao/0000-0002-9029-9813				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHODOSH LA, 1991, CURRENT PROTOCOLS MO, V2; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FORNACE AJ, 1982, MUTAT RES, V94, P263, DOI 10.1016/0027-5107(82)90290-1; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FRITSCHE M, 1993, ONCOGENE, V8, P307; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JAYARAMAN L, 1997, GENE DEV, V11, P588; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MALZMAN W, 1984, MOL CELL BIOL, V4, P1689; MCKNIGHT SL, 1984, CELL, V37, P253, DOI 10.1016/0092-8674(84)90321-0; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MONSNER J, 1995, EMBO J, V14, P4442; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PORTER MB, 1990, J CELL PHYSIOL, V142, P425, DOI 10.1002/jcp.1041420228; Rathmell WK, 1997, CANCER RES, V57, P68; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID P, 1991, DEVELOPMENT, V113, P857; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; SUN XG, 1995, MOL CELL BIOL, V15, P4489; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU HY, 1994, J BIOL CHEM, V269, P20067; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; XU LC, 1991, NUCLEIC ACIDS RES, V19, P6699, DOI 10.1093/nar/19.24.6699; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	56	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					21	31		10.1038/sj.onc.1203230	http://dx.doi.org/10.1038/sj.onc.1203230			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644976				2022-12-25	WOS:000084844300003
J	Hell, K; Tzagoloff, A; Neupert, W; Stuart, RA				Hell, K; Tzagoloff, A; Neupert, W; Stuart, RA			Identification of Cox20p, a novel protein involved in the maturation and assembly of cytochrome oxidase subunit 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-MEMBRANE SYSTEM; SACCHAROMYCES-CEREVISIAE; C-OXIDASE; NUCLEAR GENE; INTERMEMBRANE SPACE; N-TERMINI; PET GENES; YEAST; EXPRESSION; CLONING	We have identified Cox20p, a 23.8-kDa protein of the mitochondrial inner membrane that is involved in the biogenesis of the yeast cytochrome oxidase complex. Cytochrome oxidase subunit 2 (Cox2p) accumulates as a precursor in cox20 mutants, suggesting a defect in bio genesis of this mitochondrially encoded protein. The inability of cox20 mutants to process the subunit 2 precursor (pCox2p) is not due to impaired export of the protein across the inner membrane or to an inactive Imp1p/Imp2p peptidase. Rather, Cox20p specifically binds the newly synthesized pCox2p, a step required to present the exported pCox2p as a substrate to the Imp1p peptidase, All of the endogenous pCox2p accumulated in an Delta imp1 mutant, and a small fraction of Cox2p in wild type yeast, is detected in a complex with Cox20p, Following maturation Cox2p remained associated with Cox20p, prior to assembling into the cytochrome oxidase complex. We propose that Cox20p acts as a membrane-bound chaperone necessary for cleavage of pCox2p and for interaction of the mature protein with other subunits of cytochrome oxidase in a later step of the assembly process.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of Munich; Columbia University	Stuart, RA (corresponding author), Marquette Univ, Dept Biol, Milwaukee, WI 53201 USA.	rosemary.stuart@marquette.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050187, GM50187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BISSON R, 1982, J BIOL CHEM, V257, P6716; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CAPALDI RA, 1990, ARCH BIOCHEM BIOPHYS, V280, P252, DOI 10.1016/0003-9861(90)90327-U; Church C, 1996, J BIOL CHEM, V271, P18499, DOI 10.1074/jbc.271.31.18499; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; Douglas M, 1979, Methods Enzymol, V56, P58; Esser K, 1996, MOL GEN GENET, V252, P437, DOI 10.1007/s004380050248; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GRIVELL LA, 1995, CRIT REV BIOCHEM MOL, V30, P121, DOI 10.3109/10409239509085141; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; Harlow E, 1988, ANTIBODIES LABORATOR, P521; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; HERRMANN JM, 1995, J BIOL CHEM, V270, P27079, DOI 10.1074/jbc.270.45.27079; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CM, 1999, J BIOL CHEM, V274, P20937, DOI 10.1074/jbc.274.30.20937; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON TL, 1973, J BIOL CHEM, V248, P1346; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MCEWEN JE, 1985, J BACTERIOL, V161, P831, DOI 10.1128/JB.161.3.831-835.1985; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; Meyer W, 1997, BIOL CHEM, V378, P1373, DOI 10.1515/bchm.1997.378.11.1373; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Poyton Robert O., 1992, Trends in Cell Biology, V2, P369, DOI 10.1016/0962-8924(92)90049-S; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SEVARINO KA, 1980, P NATL ACAD SCI-BIOL, V77, P142, DOI 10.1073/pnas.77.1.142; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x	58	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2000	275	7					4571	4578		10.1074/jbc.275.7.4571	http://dx.doi.org/10.1074/jbc.275.7.4571			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	285FC	10671482	hybrid			2022-12-25	WOS:000085378200008
J	Angelo, RG; Rubin, CS				Angelo, RG; Rubin, CS			Characterization of structural features that mediate the tethering of Caenorhabditis elegans protein kinase A to a novel A kinase anchor protein - Insights into the anchoring of PKAI isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; AFFINITY BINDING-PROTEIN; A-KINASE; II-BETA; MOLECULAR CHARACTERIZATION; CA2+ CHANNELS; C-ELEGANS; EXPRESSION; CLONING; CELLS	Caenorhabditis elegans protein kinase A (PKAI(CE)) is tethered to organelles in vivo. A unique A kinase anchor protein (AKAP(CE)) avidly binds the RI-like regulatory subunits (R-CE) of PKAI(CE) and stringently discriminates against RII alpha and RII beta subunits, the preferred ligands for classical AKAPs, We elucidated structural features that stabilize AKAP(CE).R-CE complexes and confer atypical R isoform specificity on the anchor protein. Three large aliphatic amino acids (Leu(236), Ile(248), and Leu(252)) in the tethering domain of AKAP(CE) (residues 236-255) are crucial for ligation of R-CE. Their side chains apparently generate a precisely configured hydrophobic binding pocket that accommodates an apolar surface on RCE dimers, Basic residues (His(254)-Arg(255)-Lys(256)) at the C terminus of the tethering site set an upper limit on affinity for R-CE. A central dipeptide (phe(243)-Ser(244)) contributes critical and distinctive properties of the tethering site. Ser(244) is essential for selective binding of R-CE and exclusion of RII isoforms, The aromatic hydrophobic character of phe(243) ensures maximal R-CE binding activity, thereby supporting a "gatekeeper" function of Ser(244). Substitution of phe(243)-Ser(244) With Leu-Val generated an RII-specific AKAP. R-CE and RII subunits contain similar dimerization domains. AKAP-binding domains of R-CE (residues 23-47) and RII differ markedly in size, amino acid sequence, and docking specificity. Four hydrophobic residues (Cys(23), Val(27), Ile(32), and Cys(44)) in R-CE are crucial for avid binding with AKAP(CE), whereas side chains from Leu(20), Leu(35), Val(36), Ile(40), and Ile(41) have little impact on complex formation. Tyr(26) is embedded in the docking domain, but its aromatic ring is required for R-CE-R-CE dimerization. Residues 236-255 in AKAP(CE) also constitute a binding site for mammalian RI alpha. RI alpha (PKAI alpha) is tightly sequestered by AKAP(CE) in vitro (K-D = similar to 10 10 nM) and in the environment of intact cells. The tethering domain of AKAP(CE) provides a molecular module for manipulating intracellular localization of RI and elucidating functions of anchored PKAI in eukaryotes.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rubin, CS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, 1300 Morris Pk Ave,F-229, Bronx, NY 10461 USA.				NIGMS NIH HHS [GM07620, GM57660] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057660] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; Banky P, 1998, J BIOL CHEM, V273, P35048, DOI 10.1074/jbc.273.52.35048; BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BUBIS J, 1987, J BIOL CHEM, V262, P14961; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DURGERIAN S, 1989, J BIOL CHEM, V264, P9807; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; GROSS RE, 1990, J BIOL CHEM, V265, P6896; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Han JD, 1997, J BIOL CHEM, V272, P26611, DOI 10.1074/jbc.272.42.26611; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; ImaizumiScherrer T, 1996, J CELL BIOL, V134, P1241, DOI 10.1083/jcb.134.5.1241; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; LAND M, 1994, J BIOL CHEM, V269, P9234; Leon DA, 1997, J BIOL CHEM, V272, P28431, DOI 10.1074/jbc.272.45.28431; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; Li Z, 1999, J BIOL CHEM, V274, P27191, DOI 10.1074/jbc.274.38.27191; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LU XY, 1990, J BIOL CHEM, V265, P3293; Miki E, 1998, J BIOL CHEM, V273, P34384, DOI 10.1074/jbc.273.51.34384; Miki K, 1999, J BIOL CHEM, V274, P29057, DOI 10.1074/jbc.274.41.29057; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moos J, 1998, MOL REPROD DEV, V50, P79, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;79::AID-MRD10&gt;3.0.CO;2-T; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; Rossi EA, 1999, J BIOL CHEM, V274, P27201, DOI 10.1074/jbc.274.38.27201; RUBIN CS, 1973, P NATL ACAD SCI USA, V70, P3735, DOI 10.1073/pnas.70.12.3735; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858	58	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4351	4362		10.1074/jbc.275.6.4351	http://dx.doi.org/10.1074/jbc.275.6.4351			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660605	hybrid			2022-12-25	WOS:000085288800089
J	Bhaskar, V; Valentine, SA; Courey, AJ				Bhaskar, V; Valentine, SA; Courey, AJ			A functional interaction between dorsal and components of the Smt3 conjugation machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; UBIQUITIN-LIKE PROTEIN; DROSOPHILA EMBRYO; TRANSCRIPTION FACTORS; DORSOVENTRAL PATTERN; SIGNAL-TRANSDUCTION; NUCLEAR IMPORT; ENZYME; GRADIENT; GENE	To identify proteins that regulate the function of Dorsal, a Drosophila Rel family transcription factor, we employed a yeast two-hybrid screen to search for genes encoding Dorsal-interacting proteins. Six genes were identified, including two that encode previously known Dorsal-interacting proteins (Twist and Cactus), three that encode novel proteins, and one that encodes Drosophila Ubc9 (DmUbc9), a protein thought to conjugate the ubiquitin-like polypeptide Smt3 to protein substrates, We have found that DmUbc9 binds and conjugates Drosophila Smt3 (DmSmt3) to Dorsal. in cultured cells, DmUbc9 was found to relieve inhibition of Dorsal nuclear uptake by Cactus, allowing Dorsal to enter the nucleus and activate transcription. The effect of DmUbc9 on Dorsal activity was potentiated by the overexpression of DmSmt3, We have also identified a DmSmt3-activating enzyme, DmSAE1/DmSAE2 and found that it further potentiates Dorsal-mediated activation.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Courey, AJ (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM07185, GM44522] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUREY AJ, 1995, BBA-GENE STRUCT EXPR, V1261, P1, DOI 10.1016/0167-4781(94)00234-T; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Drier EA, 1997, SEMIN CANCER BIOL, V8, P83, DOI 10.1006/scbi.1997.0059; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Epps JL, 1998, CURR BIOL, V8, P1277, DOI 10.1016/S0960-9822(07)00538-6; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GIESLER R, 1992, CELL, V71, P613; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; Govind S, 1996, MOL CELL BIOL, V16, P1103; Huang HW, 1998, BIOCHEM MOL BIOL INT, V46, P775; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; ISODA K, 1992, GENE DEV, V6, P619, DOI 10.1101/gad.6.4.619; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Joanisse DR, 1998, BIOCHEM BIOPH RES CO, V244, P102, DOI 10.1006/bbrc.1998.8214; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Loveys DA, 1997, GENE, V201, P169, DOI 10.1016/S0378-1119(97)00444-7; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NORRIS JL, 1995, GENE DEV, V9, P358, DOI 10.1101/gad.9.3.358; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Qi FX, 1998, VIRUS RES, V57, P1, DOI 10.1016/S0168-1702(98)00073-2; RAY RP, 1991, DEVELOPMENT, V113, P35; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saltzman A, 1998, FEBS LETT, V425, P431, DOI 10.1016/S0014-5793(98)00287-7; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shirokawa JM, 1997, MOL CELL BIOL, V17, P3345, DOI 10.1128/MCB.17.6.3345; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Yang J, 1997, P NATL ACAD SCI USA, V94, P14524, DOI 10.1073/pnas.94.26.14524	47	84	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4033	4040		10.1074/jbc.275.6.4033	http://dx.doi.org/10.1074/jbc.275.6.4033			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660560	hybrid			2022-12-25	WOS:000085288800044
J	Brenneisen, P; Wenk, J; Wlaschek, M; Krieg, T; Scharffetter-Kochanek, K				Brenneisen, P; Wenk, J; Wlaschek, M; Krieg, T; Scharffetter-Kochanek, K			Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; SKIN IN-VIVO; GROWTH-FACTOR; MATRIX-METALLOPROTEINASES; ATAXIA-TELANGIECTASIA; GEL-ELECTROPHORESIS; PYRIMIDINE DIMERS; RADICAL FORMATION; OZONE DEPLETION; GENE-EXPRESSION	Ultraviolet B (UVB) irradiation has been shown to stimulate the expression of matrix-degrading metalloproteinases via generation of DNA damage and/or reactive oxygen species. Matrix-degrading metalloproteinases promote UVB-triggered detrimental long term effects like cancer formation and premature skin aging. Here, we were interested in identifying components of the signal transduction pathway that causally link UVB-mediated DNA damage and induction of matrix-degrading metalloproteinase (MMP)-1/interstitial collagenase and MMP-3/stromelysin-1 in human dermal fibroblasts in vitro. The activity of p70 ribosomal S6 kinase, a downstream target of the FK506-binding protein- 12/rapamycin-associated protein kinase (FRAP) kinase (RAFT1, mTOR), was identified to be 4.8 +/- 0.8-fold, and MMP-1 and MMP-3 protein levels 2.4- and 11.5-fold increased upon UVB irradiation compared with mock-irradiated controls, The FRAP kinase inhibitor rapamycin and the DNA repair inhibitor aphidicolin significantly suppressed the UVB-mediated increase in p70 ribosomal S6 kinase activity by 50-65% and MMP-1 and MMP-3 protein levels by 34-68% and 42-88% compared with UVB-irradiated fibroblasts, By contrast, the interleukin-1 beta-mediated increase in MMP-1 and MMP-3 protein levels could not be suppressed by rapamycin, Collectively, our data suggest that the FRAP-controlled p70 ribosomal S6 kinase is an essential component of a DNA damage-dependent, but not of the interleukin-1/cell membrane receptor-dependent signaling.	Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany	University of Cologne	Scharffetter-Kochanek, K (corresponding author), Univ Cologne, Dept Dermatol, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	karin.scharffetter@uni-koeln.de		Scharffetter-Kochanek, Karin/0000-0002-9655-685X				Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; Ahrens C, 1997, P NATL ACAD SCI USA, V94, P6837, DOI 10.1073/pnas.94.13.6837; ALTMEYER A, 1993, CYTOKINE, V5, P133, DOI 10.1016/1043-4666(93)90052-7; Anderson R.R., 1993, CLIN PHOTOMEDICINE, P19; ANGEL P, 1985, J CELL BIOCHEM, V29, P351, DOI 10.1002/jcb.240290408; Averbeck D, 1998, PHOTOCHEM PHOTOBIOL, V68, P289, DOI 10.1111/j.1751-1097.1998.tb09683.x; BAYREUTHER K, 1992, ARCH GERONTOL GERIAT, P47, DOI 10.1016/S0167-4943(05)80006-8; Blattner C, 1998, ONCOGENE, V16, P2827, DOI 10.1038/sj.onc.1201827; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Brenneisen P, 1996, PHOTOCHEM PHOTOBIOL, V64, P649, DOI 10.1111/j.1751-1097.1996.tb03119.x; Brenneisen P, 1998, J BIOL CHEM, V273, P5279, DOI 10.1074/jbc.273.9.5279; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CLINGEN PH, 1995, PHOTOCHEM PHOTOBIOL, V61, P163, DOI 10.1111/j.1751-1097.1995.tb03955.x; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; CRAWFORD HC, 1994, INVAS METAST, V14, P234; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DARR D, 1994, J INVEST DERMATOL, V102, P671, DOI 10.1111/1523-1747.ep12374036; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Drouin R, 1997, PHOTOCHEM PHOTOBIOL, V66, P719, DOI 10.1111/j.1751-1097.1997.tb03213.x; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; Fisher GJ, 1999, PHOTOCHEM PHOTOBIOL, V69, P154, DOI 10.1111/j.1751-1097.1999.tb03268.x; FLEISCHMAJER R, 1981, J INVEST DERMATOL, V76, P400, DOI 10.1111/1523-1747.ep12520933; FREEMAN SE, 1986, ANAL BIOCHEM, V158, P119, DOI 10.1016/0003-2697(86)90599-3; GILCHREST BA, 1989, J AM ACAD DERMATOL, V21, P610, DOI 10.1016/S0190-9622(89)70227-9; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HANAWALT PC, 1991, MUTAT RES, V247, P203, DOI 10.1016/0027-5107(91)90016-H; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; Herrmann G, 1993, Exp Dermatol, V2, P92, DOI 10.1111/j.1600-0625.1993.tb00015.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hjertvik M, 1998, MUTAT RES-DNA REPAIR, V407, P87, DOI 10.1016/S0921-8777(97)00062-1; ITO K, 1992, BIOCHEMISTRY-US, V31, P11606, DOI 10.1021/bi00161a046; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JURKIEWICZ BA, 1994, PHOTOCHEM PHOTOBIOL, V59, P1, DOI 10.1111/j.1751-1097.1994.tb04993.x; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KEYSE SM, 1993, CANC BIOL, V4, P19; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kleijn M, 1996, FEBS LETT, V396, P165, DOI 10.1016/0014-5793(96)01097-6; KOIVUKANGAS V, 1994, ACTA DERM-VENEREOL, V74, P279; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAJMUDAR G, 1994, MOL CARCINOGEN, V9, P17, DOI 10.1002/mc.2940090105; MASAKI H, 1995, BIOCHEM BIOPH RES CO, V206, P474, DOI 10.1006/bbrc.1995.1067; MATSUNAGA T, 1993, PHOTOCHEM PHOTOBIOL, V57, P934, DOI 10.1111/j.1751-1097.1993.tb02952.x; Mount DW, 1996, NATURE, V383, P763, DOI 10.1038/383763a0; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; Perez S., 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P453; Petit-Frere C, 1998, J INVEST DERMATOL, V111, P354, DOI 10.1038/sj.jid.5602962; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RYDBERG B, 1994, RADIAT RES, V139, P133, DOI 10.2307/3578657; Sawamura D, 1996, ARCH DERMATOL RES, V288, P628, DOI 10.1007/s004030050115; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; Slaper H, 1996, NATURE, V384, P256, DOI 10.1038/384256a0; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEWART MJ, 1994, BIOESSAYS, V16, P809, DOI 10.1002/bies.950161107; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; SUTHERLAND JC, 1991, BIOTECHNIQUES, V10, P492; Tedesco AC, 1997, BRAZ J MED BIOL RES, V30, P561, DOI 10.1590/S0100-879X1997000500002; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1993, J BIOL CHEM, V268, P12062; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Yarosh D, 1999, PHOTOCHEM PHOTOBIOL, V69, p44S; Yarosh Daniel B., 1998, Photochemistry and Photobiology, V67, p59S	84	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4336	4344		10.1074/jbc.275.6.4336	http://dx.doi.org/10.1074/jbc.275.6.4336			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660603	hybrid			2022-12-25	WOS:000085288800087
J	Saphire, ACS; Guan, TL; Schirmer, EC; Nemerow, GR; Gerace, L				Saphire, ACS; Guan, TL; Schirmer, EC; Nemerow, GR; Gerace, L			Nuclear import adenovirus DNA in vitro involves the nuclear protein import pathway and hsc70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-70; PORE COMPLEX; TRANSPORT; CELLS; INHIBITION; RECEPTOR; RAN/TC4; REQUIRES; SIGNALS; ENTRY	Adenovirus, a respiratory virus with a double-stranded DNA genome, replicates in the nuclei of mammalian cells. We have developed a cytosol-dependent in vitro assay utilizing adenovirus nucleocapsids to examine the requirements for adenovirus docking to the nuclear pore complex and for DNA import into the nucleus. Our assay reveals that adenovirus DNA import is blocked by a competitive excess of classical protein nuclear localization sequences and other inhibitors of nuclear protein import and indicates that this process is dependent on hsc70, Previous work revealed that the hexon (coat) protein of adenovirus is the only major protein on the surface of the adenovirus nucleocapsid that docks at the nuclear pore complex. This, together with our finding that in vitro nuclear import of hexon is inhibited by an excess of classical nuclear localization sequences, suggests a role for the hexon protein in adenovirus DNA import. However, recombinant transport factors that are sufficient for hexon import in permeabilized cells do not support DNA import, indicating that there are other as yet unidentified factors required for this process.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Gerace, L (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd,IMM 10, La Jolla, CA 92037 USA.	lgerace@scripps.edu		Schirmer, Eric/0000-0003-2635-1338	NHLBI NIH HHS [HL54352] Funding Source: Medline; NIGMS NIH HHS [GM41955] Funding Source: Medline; PHS HHS [EI38948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041955] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CEPKO CL, 1982, CELL, V31, P407, DOI 10.1016/0092-8674(82)90134-9; Clarkson WD, 1997, J MOL BIOL, V272, P716, DOI 10.1006/jmbi.1997.1255; DALES S, 1973, VIROLOGY, V56, P465, DOI 10.1016/0042-6822(73)90050-0; Dingwall C, 1998, METHOD CELL BIOL, V53, P517; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; Greber UF, 1997, EMBO J, V16, P5998, DOI 10.1093/emboj/16.19.5998; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; GUAN TL, 1995, MOL BIOL CELL, V6, P1591, DOI 10.1091/mbc.6.11.1591; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Kann M, 1997, J VIROL, V71, P1310, DOI 10.1128/JVI.71.2.1310-1316.1997; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LAVER WG, 1969, VIROLOGY, V39, P599, DOI 10.1016/0042-6822(69)90111-1; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NIEWIAROWSKA J, 1992, EXP CELL RES, V201, P408, DOI 10.1016/0014-4827(92)90290-O; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; ONEILL RE, 1995, J BIOL CHEM, V270, P22701, DOI 10.1074/jbc.270.39.22701; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PATTERSON S, 1986, VACCINE, V4, P79, DOI 10.1016/0264-410X(86)90042-3; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; PUVIONDUTILLEUL F, 1995, MICROSC RES TECHNIQ, V31, P22, DOI 10.1002/jemt.1070310104; Robbins PD, 1998, TRENDS BIOTECHNOL, V16, P35, DOI 10.1016/S0167-7799(97)01137-2; Shenk Thomas, 1996, P979; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; STANDIFORD DM, 1992, J CELL BIOL, V118, P991, DOI 10.1083/jcb.118.5.991; STEWART PL, 1993, EMBO J, V12, P2589, DOI 10.1002/j.1460-2075.1993.tb05919.x; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; WARIS M, 1987, J CHROMATOGR, V397, P321, DOI 10.1016/S0021-9673(01)85015-9; WICKHAM TJ, 1994, J CELL BIOL, V127, P257, DOI 10.1083/jcb.127.1.257; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YAMADA M, 1993, J VIROL, V67, P119, DOI 10.1128/JVI.67.1.119-130.1993; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	40	113	116	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	2000	275	6					4298	4304		10.1074/jbc.275.6.4298	http://dx.doi.org/10.1074/jbc.275.6.4298			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	283RJ	10660598	hybrid			2022-12-25	WOS:000085288800082
J	Ghanouni, P; Schambye, H; Seifert, R; Lee, TW; Rasmussen, SGF; Gether, U; Kobilka, BK				Ghanouni, P; Schambye, H; Seifert, R; Lee, TW; Rasmussen, SGF; Gether, U; Kobilka, BK			The effect of pH on beta(2) adrenoceptor function - Evidence for protonation-dependent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CARBOXYLIC-ACID GROUP; CONSTITUTIVE ACTIVATION; CONFORMATIONAL-CHANGES; TRANSMEMBRANE HELICES; METARHODOPSIN-II; FUSION PROTEIN; AMINO-ACID; RHODOPSIN; G(S)ALPHA	The transition of rhodopsin from the inactive to the active state is associated with proton uptake at Glu(134) (1), and recent mutagenesis studies suggest that protonation of the homologous amino acid in the alpha(1B) adrenergic receptor (Asp(142)) may be involved in its mechanism of activation (2). To further explore the role of protonation in G protein-coupled receptor activation, we examined the effects of pH on the rate of ligand-induced conformational change and on receptor-mediated G protein activation for the beta(2) adrenergic receptor (beta(2)AR). The rate of agonist-induced change in the fluorescence of NBD-labeled, purified beta(2)AR was 2-fold greater at pH 6.5 than at pH 8, even though agonist affinity was lower at pH 6.5, This biophysical analysis was corroborated by functional studies; basal (agonist-independent) activation of G alpha(8) by the beta(2)AR was greater at pH 6.5 compared with pH 8.0. Taken together, these results provide evidence that protonation increases basal activity by destabilizing the inactive state of the receptor. In addition, we found that the pH sensitivity of beta(2)AR activation is not abrogated by mutation of Asp(130), which is homologous to the highly conserved acidic amino acids that link protonation to activation of rhodopsin (Glu(134)) and the alpha(1B) adrenergic receptor (Asp(142)).	Stanford Univ, Sch Med, Beckman Ctr, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA; Univ Copenhagen, Panum Inst, Inst Med Physiol 125, Dept Cellular Physiol, DK-2200 Copenhagen, Denmark	Howard Hughes Medical Institute; Stanford University; Stanford University; University of Copenhagen	Kobilka, BK (corresponding author), Stanford Univ, Sch Med, Beckman Ctr, Howard Hughes Med Inst, B-157, Stanford, CA 94305 USA.		Seifert, Roland/G-3189-2013	Gether, Ulrik/0000-0002-0020-3807; Rasmussen, Soren/0000-0002-1853-1841; Kobilka, Brian/0000-0001-5958-3990	NIGMS NIH HHS [5T32GM07365] Funding Source: Medline; NINDS NIH HHS [NS28471] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028471, R01NS028471] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARNIS S, 1994, J BIOL CHEM, V269, P23879; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; CHUNG FZ, 1988, J BIOL CHEM, V263, P4052; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; Kim JM, 1997, P NATL ACAD SCI USA, V94, P14273, DOI 10.1073/pnas.94.26.14273; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; WEITZ CJ, 1992, NEURON, V8, P465, DOI 10.1016/0896-6273(92)90274-H; Wenzel-Seifert K, 1998, BIOCHEM J, V334, P519, DOI 10.1042/bj3340519; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	29	89	92	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3121	3127		10.1074/jbc.275.5.3121	http://dx.doi.org/10.1074/jbc.275.5.3121			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652295	Green Submitted, hybrid			2022-12-25	WOS:000085146500017
J	Halbleib, CM; Zhang, YP; Ludden, PW				Halbleib, CM; Zhang, YP; Ludden, PW			Regulation of dinitrogenase reductase ADP-ribosyltransferase and dinitrogenase reductase-activating glycohydrolase by a redox-dependent conformational change of nitrogenase Fe protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM-IRON PROTEIN; AZOTOBACTER-VINELANDII NITROGENASE; BACTERIUM RHODOSPIRILLUM-RUBRUM; KLEBSIELLA-PNEUMONIAE; ELECTRON-TRANSFER; SWITCH-OFF; POSTTRANSLATIONAL REGULATION; AZOSPIRILLUM-BRASILENSE; NUCLEOTIDE-BINDING; METAL CENTERS	The nitrogenase-regulating enzymes dinitrogenase reductase ADP-ribosyltransferase (DRAT) and dinitrogenase reductase-activating glycohydrolase (DRAG), from Rhodospirillum rubrum, were shown to be sensitive to the redox status of the [Fe4S4](1+/2+) cluster of nitrogenase Fe protein from R, rubrum or Azotobacter vinelandii, DRAG had <2% activity with oxidized R. rubrum Fe protein relative to activity with reduced Fe protein, The activity of DRAG with oxygen-denatured Fe protein or a low molecular weight substrate, N-alpha-dansyl-N-omega-(1,N-6-etheno-ADP-ribosyl) arginine methyl ester, was independent of redox potential. The redox midpoint potential of DRAG activation of Fe protein was -430 mV versus standard hydrogen electrode, coinciding with the midpoint potential of the [Fe4S4] cluster from R, rubrum Fe protein. DRAT was found to have a specificity opposite that of DRAG, exhibiting low (<2%) activity with 87% reduced R, rubrum Fe protein relative to activity with fully oxidized Fe protein. A mutant of R. rubrum in which the rate of oxidation of Fe protein was substantially decreased had a markedly slower rate of ADP-ribosylation in vivo in response to 10 mw NH4Cl or darkness stimulus. It is concluded that the redox state of Fe protein plays a significant role in regulation of the activities of DRAT and DRAG in vivo.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Ctr Study Nitrogen Fixat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ludden@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349, R01GM054910] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 T32 GM08349, GM54910] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; ASHBY GA, 1987, BIOCHEM J, V246, P455, DOI 10.1042/bj2460455; FITZMAURICE WP, 1989, MOL GEN GENET, V218, P340, DOI 10.1007/BF00331287; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Grunwald SK, 1997, J BACTERIOL, V179, P3277, DOI 10.1128/jb.179.10.3277-3283.1997; GRUNWALD SK, 1995, J BACTERIOL, V177, P628, DOI 10.1128/jb.177.3.628-635.1995; HAGEMAN RV, 1980, BIOCHEMISTRY-US, V19, P2333, DOI 10.1021/bi00552a009; Halbleib CM, 1999, ARCH MICROBIOL, V172, P51, DOI 10.1007/s002030050739; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; Johnson JL, 1996, BIOCHEMISTRY-US, V35, P11336, DOI 10.1021/bi952581o; KANEMOTO RH, 1984, J BACTERIOL, V158, P713, DOI 10.1128/JB.158.2.713-720.1984; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; Lanzilotta WN, 1997, BIOCHEMISTRY-US, V36, P12976, DOI 10.1021/bi9715371; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; Lanzilotta WN, 1998, BIOCHEMISTRY-US, V37, P399, DOI 10.1021/bi971681m; LIANG JH, 1991, J BACTERIOL, V173, P6903, DOI 10.1128/jb.173.21.6903-6909.1991; LJONES T, 1972, BIOCHIM BIOPHYS ACTA, V275, P93, DOI 10.1016/0005-2728(72)90027-8; LOWE DJ, 1993, BIOCHEM J, V292, P93, DOI 10.1042/bj2920093; LOWERY RG, 1986, J BACTERIOL, V166, P513, DOI 10.1128/jb.166.2.513-518.1986; LOWERY RG, 1989, BIOCHEMISTRY-US, V28, P4956, DOI 10.1021/bi00438a008; LOWERY RG, 1988, J BIOL CHEM, V263, P16714; LUDDEN PW, 1989, CURR TOP CELL REGUL, V30, P23; LUDDEN PW, 1989, J BACTERIOL, V171, P5210, DOI 10.1128/jb.171.9.5210-5211.1989; LUDDEN PW, 1978, BIOCHEM J, V175, P251, DOI 10.1042/bj1750251; LUDDEN PW, 1976, SCIENCE, V194, P424, DOI 10.1126/science.824729; Miller RW, 1998, BIOCHEM J, V334, P601, DOI 10.1042/bj3340601; NIELSEN GM, 1994, BIOCHEM J, V302, P801, DOI 10.1042/bj3020801; NORDLUND S, 1984, BIOCHIM BIOPHYS ACTA, V791, P21, DOI 10.1016/0167-4838(84)90276-0; Noren A, 1997, BIOCHEM J, V322, P829, DOI 10.1042/bj3220829; NOREN A, 1994, FEBS LETT, V356, P43, DOI 10.1016/0014-5793(94)01233-4; ORMEROD JG, 1961, ARCH BIOCHEM BIOPHYS, V94, P449, DOI 10.1016/0003-9861(61)90073-X; PAUL TD, 1984, BIOCHEM J, V224, P961, DOI 10.1042/bj2240961; PETERS JW, 1995, J BIOL CHEM, V270, P27007, DOI 10.1074/jbc.270.45.27007; POPE MR, 1985, P NATL ACAD SCI USA, V82, P3173, DOI 10.1073/pnas.82.10.3173; POPE MR, 1986, J BIOL CHEM, V261, P104; POPE MR, 1985, BIOCHEMISTRY-US, V24, P2374, DOI 10.1021/bi00330a037; POPE MR, 1987, ANAL BIOCHEM, V160, P68, DOI 10.1016/0003-2697(87)90615-4; PRESTON GG, 1982, BIOCHEM J, V205, P489, DOI 10.1042/bj2050489; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; SAARI LL, 1984, J BIOL CHEM, V259, P5502; SAARI LL, 1986, J BIOL CHEM, V261, P4973; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SIMPSON FB, 1984, SCIENCE, V224, P1095, DOI 10.1126/science.6585956; STEPHENS PJ, 1979, P NATL ACAD SCI USA, V76, P2585, DOI 10.1073/pnas.76.6.2585; STEWART WDP, 1967, P NATL ACAD SCI USA, V58, P2071, DOI 10.1073/pnas.58.5.2071; THORNELEY RNF, 1988, BIOCHEM J, V253, P587, DOI 10.1042/bj2530587; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; ZHANG YP, 1993, J BACTERIOL, V175, P6781, DOI 10.1128/jb.175.21.6781-6788.1993; ZHANG YP, 1994, J BACTERIOL, V176, P5780, DOI 10.1128/JB.176.18.5780-5787.1994; ZUMFT WG, 1974, EUR J BIOCHEM, V46, P525, DOI 10.1111/j.1432-1033.1974.tb03646.x	55	22	22	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3493	3500		10.1074/jbc.275.5.3493	http://dx.doi.org/10.1074/jbc.275.5.3493			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652344	hybrid			2022-12-25	WOS:000085146500066
J	Lam, EWF; Glassford, J; Banerji, L; Thomas, NSB; Sicinski, P; Klaus, GGB				Lam, EWF; Glassford, J; Banerji, L; Thomas, NSB; Sicinski, P; Klaus, GGB			Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; DEPENDENT KINASES; E2F; PROLIFERATION; FAMILY; D1; TRANSCRIPTION; ACCUMULATION	Cyclin D2 is the only D-type cyclin expressed in mature mouse B-lymphocytes, and its expression is associated with retinoblastoma protein (pRB) and pRB-related protein phosphorylation and induction of E2F activity, as B-cells enter the cell cycle following stimulation via surface IgM and/or CD40. Cyclin D-dependent kinase activity is required for cell proliferation, yet cyclin D2(-/-) mice have normal levels of mature B-lymphocytes. Here we show that B-lymphocytes from cyclin D2(-/-) mice can proliferate in response to anti-IgM and anti-CD40, but the time taken to enter S-phase is longer than for the corresponding cyclin D2(+/+) cells. This is due to the compensatory induction of cyclin D3, but not cyclin D1, which causes pRb phosphorylation on CDK4-specific sites. This is the first demonstration that loss of a D-type cyclin causes specific expression and functional compensation by another member of the family in vivo and provides a rationale for the presence of mature B-lymphocytes in cyclin D2(-/-) mice.	Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, St Marys, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sect Virol & Cell Biol, London W2 1PG, England; UCL Royal Free & Univ Coll Med Sch, Dept Haematol, London WC1E 6HX, England; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; University of London; University College London; UCL Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; MRC National Institute for Medical Research	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.	eric.lam@ic.ac.uk	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576				BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Claudio PP, 1996, CANCER RES, V56, P2003; Craxton A, 1998, J IMMUNOL, V161, P3225; DellaRagione F, 1997, BIOCHEM BIOPH RES CO, V231, P73, DOI 10.1006/bbrc.1997.5938; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; Desrivieres S, 1997, J BIOL CHEM, V272, P2470; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; HATAKEYAMA M, 1994, COLD SPRING HARB SYM, V59, P1; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Iida S, 1992, Nihon Rinsho, V50, P1374; JOHNSON DG, 1995, ONCOGENE, V11, P1685; Johnson-Leger C, 1998, J IMMUNOL, V161, P4618; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Klaus G G, 1997, Int Rev Immunol, V15, P5, DOI 10.3109/08830189709068169; Kouskoff V, 1998, J EXP MED, V188, P1453, DOI 10.1084/jem.188.8.1453; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 1999, EUR J IMMUNOL, V29, P3380, DOI 10.1002/(SICI)1521-4141(199910)29:10<3380::AID-IMMU3380>3.0.CO;2-C; Lam EWF, 1998, J BIOL CHEM, V273, P10051, DOI 10.1074/jbc.273.16.10051; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; Schilizzi BM, 1997, IMMUNOLOGY, V92, P346, DOI 10.1046/j.1365-2567.1997.d01-2341.x; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Solvason N, 1996, J EXP MED, V184, P407, DOI 10.1084/jem.184.2.407; TAM SW, 1994, ONCOGENE, V9, P2663; Tanguay DA, 1999, J EXP MED, V189, P1685, DOI 10.1084/jem.189.11.1685; van der Sman J, 1999, J BIOL CHEM, V274, P12009, DOI 10.1074/jbc.274.17.12009; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	45	106	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3479	3484		10.1074/jbc.275.5.3479	http://dx.doi.org/10.1074/jbc.275.5.3479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652342	hybrid			2022-12-25	WOS:000085146500064
J	Pardali, E; Xie, XQ; Tsapogas, P; Itoh, S; Arvanitidis, K; Heldin, CH; ten Dijke, P; Grundstrom, T; Sideras, P				Pardali, E; Xie, XQ; Tsapogas, P; Itoh, S; Arvanitidis, K; Heldin, CH; ten Dijke, P; Grundstrom, T; Sideras, P			Smad and AML proteins synergistically confer transforming growth factor beta 1 responsiveness to human germ-line IgA genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; HEAVY-CHAIN GENES; HUMAN B-CELLS; CLEIDOCRANIAL DYSPLASIA; INDUCED TRANSCRIPTION; BONE; ACTIVATION; PROMOTER; ENHANCER; CBFA1	Transcription of germ-line immunoglobulin heavy chain genes conditions them to participate in isotype switch recombination, Transforming growth factor-beta 1 (TGF-beta 1) stimulates promoter elements located upstream of the IgA1 and IgA2 switch regions, designated I alpha 1 and I alpha 2, and contributes to the development of IgA responses. We demonstrate that intracellular Smad proteins mediate activation of the I alpha 1 promoter by TGF-beta. TGF-beta type 1 receptor (ALK-5), activin type IB receptor (ALK-4), and the "orphan" ALK-7 trans-activate the I alpha 1 promoter, thus raising the possibility that other members of the TGF-beta superfamily can also modulate IgA synthesis. Smads physically interact with the AML family of transcription factors and cooperate with them to activate the I alpha 1 promoter. The I alpha 1 element provides a canape of interspersed high and low affinity sites for Smad and AML factors, some of which are indispensable for TGF-beta responsiveness. While AML Smad complexes are formed in the cytoplasm of DG75 and K562 cells constitutively, only after TGF-beta receptor activation, novel Smad3.Smad4.AML complexes are detected in nuclear extracts by EMSA with I alpha 1 promoter-derived probes. Considering the wide range of biological phenomena that AMLs and Smads regulate, the physical/ functional interplay between them has implications that extend beyond the regulation of class switching to IgA.	AstraZeneca R&D, Dept Inflammat Pharmacol, S-22100 Lund, Sweden; Umea Univ, Div Tumor Biol, Dept Cell & Mol Biol, S-90187 Umea, Sweden; Biomed Ctr, Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	AstraZeneca; Umea University; Ludwig Institute for Cancer Research	Sideras, P (corresponding author), AstraZeneca R&D, Dept Inflammat Pharmacol, S-22100 Lund, Sweden.	Paschalis.Sideras@cmb.umu.se	Tsapogas, Panagiotis/AAN-2465-2020; Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Arvanitidis, Konstantinos/0000-0003-0639-2474; Itoh, Susumu/0000-0002-7967-0730; Tsapogas, Panagiotis/0000-0002-9450-2604; Sideras, Paschalis/0000-0003-0701-1258				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dzierzak E, 1998, IMMUNOL TODAY, V19, P228, DOI 10.1016/S0167-5699(98)01258-4; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; HONJO T, 1978, P NATL ACAD SCI USA, V75, P2140, DOI 10.1073/pnas.75.5.2140; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KITANI A, 1993, J IMMUNOL, V151, P3478; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LIN YCA, 1992, J IMMUNOL, V149, P2914; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NILSSON L, 1995, INT IMMUNOL, V7, P1191, DOI 10.1093/intimm/7.8.1191; NILSSON L, 1991, INT IMMUNOL, V3, P1107, DOI 10.1093/intimm/3.11.1107; NILSSON L, 1993, INT IMMUNOL, V5, P271; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; Ryden M, 1996, J BIOL CHEM, V271, P30603, DOI 10.1074/jbc.271.48.30603; Shi MJ, 1998, J IMMUNOL, V161, P6751; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Snapper CM, 1997, IMMUNITY, V6, P217, DOI 10.1016/S1074-7613(00)80324-6; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; VANVLASSELAER P, 1992, J IMMUNOL, V148, P2062; Visser JA, 1998, MOL CELL ENDOCRINOL, V146, P7, DOI 10.1016/S0303-7207(98)00198-1; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wilson PA, 1997, DEVELOPMENT, V124, P3177; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	55	131	137	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3552	3560		10.1074/jbc.275.5.3552	http://dx.doi.org/10.1074/jbc.275.5.3552			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652350	hybrid			2022-12-25	WOS:000085146500072
J	Suzuki, E; Nagata, D; Yoshizumi, M; Kakoki, M; Goto, A; Omata, M; Hirata, Y				Suzuki, E; Nagata, D; Yoshizumi, M; Kakoki, M; Goto, A; Omata, M; Hirata, Y			Reentry into the cell cycle of contact-inhibited vascular endothelial cells by a phosphatase inhibitor - Possible involvement of extracellular signal-regulated kinase and phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR-BETA; DEPENDENT KINASES; CDK INHIBITOR; ARRESTED FIBROBLASTS; POTENTIAL MEDIATOR; DOWN-REGULATION; G(1) PHASE; P27(KIP1); EXPRESSION	Vascular endothelial cells are unique in that they exit from the cell cycle when they come into contact with each other. Although the phenomenon is called "contact inhibition," little is known about the cellular mechanisms involved. Here we show that the phosphatase inhibitor sodium orthovanadate (SOV) induced the reentry of contact-inhibited human umbilical vascular endothelial cells (HUVECs) into the cell cycle and that reentry was associated with activation of the extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI 3-K)/Akt pathways. SOV stimulated [H-3]thymidine uptake of contact-inhibited HUVECs in a time- and dose-dependent manner. SOV-induced increase in [SH]thymidine uptake was significantly inhibited by the mitogen-activated protein kinase kinase inhibitor PD98059 and by the PI 3-K inhibitor LY294002, SOV also stimulated the expression of cyclin D1, cyclin E, and cyclin A, and the activity of CDK2 kinase, whereas it decreased the expression of p27(kip1). In marked contrast, growth media alone did not induce these changes. Furthermore, these SOV-induced changes were abolished by pretreatment with PD98059 and LY294002, SOV stimulated phosphorylation of ERK and Akt in contact-inhibited HUVECs, while growth media alone did not. This phosphorylation was associated with inhibition of phosphatase activity in the cells. Finally, overexpression of high cell density-enhanced protein tyrosine phosphatase 1 inhibited c-fos and cyclin A promoter activity. Taken together, our results suggest that in contact-inhibited HUVECs, increased phosphatase activity suppressed the ERK and PI 3-K/Akt pathways, resulting in exit from the cell cycle by down-regulation of cyclin D1, cyclin E, and cyclin A and by upregulation of p27(kip1).	Univ Tokyo, Fac Med, Dept Internal Med 2, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Dept Geriatr, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo	Suzuki, E (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 2, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Kato A, 1997, J BIOL CHEM, V272, P8065, DOI 10.1074/jbc.272.12.8065; Keane MM, 1996, CANCER RES, V56, P4236; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kosaka C, 1996, AM J PHYSIOL-CELL PH, V270, pC170, DOI 10.1152/ajpcell.1996.270.1.C170; Kuramochi S, 1996, FEBS LETT, V378, P7, DOI 10.1016/0014-5793(95)01415-2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Suzuki E, 1999, CIRC RES, V84, P611, DOI 10.1161/01.RES.84.5.611; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Vinals F, 1999, MOL CELL BIOL, V19, P2763; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZHOU W, 1993, J BIOL CHEM, V268, P23041	46	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	2000	275	5					3637	3644		10.1074/jbc.275.5.3637	http://dx.doi.org/10.1074/jbc.275.5.3637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	281FD	10652360	hybrid			2022-12-25	WOS:000085146500082
J	Bunnell, SC; Diehn, M; Yaffe, MB; Findell, PR; Cantley, LC; Berg, LJ				Bunnell, SC; Diehn, M; Yaffe, MB; Findell, PR; Cantley, LC; Berg, LJ			Biochemical interactions integrating Itk with the T cell receptor-initiated signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; ACTIVATED PROTEIN-KINASE; ENRICHED MEMBRANE DOMAINS; ANTIGEN RECEPTOR; SRC-FAMILY; MEDIATED ACTIVATION; GENETIC-EVIDENCE; SH3 DOMAIN; PHOSPHORYLATION	Itk, a Tec family tyrosine kinase, acts downstream of Lck and phosphatidylinositol S'-kinase to facilitate T cell receptor (TCR)-dependent calcium influxes and increases in extracellular-regulated kinase activity. Here we demonstrate interactions between Itk and crucial components of TCR-dependent signaling pathways. First, the inositide-binding pocket of the Itk pleckstrin homology domain directs the constitutive association of Itk with buoyant membranes that are the primary site of TCR activation and are enriched in both Lck and LAT. This association is required for the transphosphorylation of Itk. Second, the Itk proline-rich region binds to Grb2 and LAT. Third, the Itk Src homology (SH3) 3 and SH2 domains interact cooperatively with Syk-phosphorylated SLP-76. Notably, SLP-76 contains a predicted binding motif for the Itk SH2 domain and binds to full-length Itk In vitro. Finally, we show that kinase-inactive Itk can antagonize the SLP-76-dependent activation of NF-AT. The inhibition of NF-AT activation depends on the Itk pleckstrin homology domain, proline-rich region, and SH2 domain. Together, these observations suggest that multivalent interactions recruit Itk to LAT-nucleated signaling complexes and facilitate the activation of LAT-associated phospholipase C gamma 1 by Itk.	Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA; Harvard Univ, Inst Med, Div Signal Transduct, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Roche Biosci, Palo Alto, CA 94034 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Beth Israel Deaconess Medical Center; Roche Holding	Berg, LJ (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA.	Leslie.Berg@umassmed.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Bunnell, Stephen/0000-0001-6887-0828	NHLBI NIH HHS [HL03601] Funding Source: Medline; NIAID NIH HHS [AI32494] Funding Source: Medline; NIGMS NIH HHS [GM56203] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; Arni S, 1996, BIOCHEM BIOPH RES CO, V225, P801, DOI 10.1006/bbrc.1996.1254; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Cerny J, 1996, EUR J IMMUNOL, V26, P2335, DOI 10.1002/eji.1830261010; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Fang N, 1996, J IMMUNOL, V157, P3769; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; Gibson S, 1996, J IMMUNOL, V156, P2716; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Heyeck SD, 1997, J BIOL CHEM, V272, P25401, DOI 10.1074/jbc.272.40.25401; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Mano H, 1996, FASEB J, V10, P637, DOI 10.1096/fasebj.10.5.8621063; Marengere LEM, 1997, J IMMUNOL, V159, P3220; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Nisitani S, 1999, P NATL ACAD SCI USA, V96, P2221, DOI 10.1073/pnas.96.5.2221; Pacini S, 1998, J BIOL CHEM, V273, P20487, DOI 10.1074/jbc.273.32.20487; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Pelosi M, 1999, J BIOL CHEM, V274, P14229, DOI 10.1074/jbc.274.20.14229; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Wunderlich L, 1999, EUR J IMMUNOL, V29, P1068, DOI 10.1002/(SICI)1521-4141(199904)29:04<1068::AID-IMMU1068>3.0.CO;2-P; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; YAFFE MB, 1999, IN PRESS METHODS ENZ; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	86	210	217	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					2219	2230		10.1074/jbc.275.3.2219	http://dx.doi.org/10.1074/jbc.275.3.2219			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636929	hybrid			2022-12-25	WOS:000084940000092
J	Tomita, A; Towatari, M; Tsuzuki, S; Hayakawa, F; Kosugi, H; Tamai, K; Miyazaki, T; Kinoshita, T; Saito, H				Tomita, A; Towatari, M; Tsuzuki, S; Hayakawa, F; Kosugi, H; Tamai, K; Miyazaki, T; Kinoshita, T; Saito, H			c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300	ONCOGENE			English	Article						c-Myb; p300; GCN5; acetylation; bromodomain	NEGATIVE REGULATORY DOMAIN; GENE V-MYB; HISTONE ACETYLTRANSFERASES; DNA-BINDING; PHOSPHORYLATION SITE; B-MYB; CBP; PROTOONCOGENE; EXPRESSION; TRANSACTIVATION	Transcription factor c-Myb plays important roles in cell survival and differentiation in immature hematopoietic cells, Here we demonstrate that c-Myb is acetylated at the carboxyl-terminal conserved domain by histone acetyltransferase p300 both in vitro and in vivo. The acetylation sites in Pho have been located at the lysine residues of the conserved domain (K471, K480, K485) by the use of the mutant Myb (Myb-KAmut), in which all three lysine residues are substituted into alanine. Electrophoretic mobility shift assay reveals that Myb-KAmut shows higher DNA binding activity than wild type c-Myb and that acetylation of c-Myb in vitro by p300 causes dramatic increase in DNA binding activity, Accordingly, transactivation activity of both mim-1 and CD34 promoters by Myb-KAmut is higher than that driven by wild type c-Myb. Furthermore, the bromodomain of p300, in addition to the histone acetyltransferase (HAT) domain, is required for effective acetylation of Myb, and hGCN5 is revealed to be a factor acetyltransferase for c-Myb in vitro. We present a new manner of post-translational modification of the c-Myb protein and the potential significance of the acetylation in c-Myb.	Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Med & Biol Labs Co Ltd, Nagano, Japan; CycLex Inc, Nagano, Japan	Nagoya University	Towatari, M (corresponding author), Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Tsurumai Cho 65, Nagoya, Aichi 4668550, Japan.		Tamai, Katsuyuki/F-4743-2013; Hayakawa, Fumihiko/I-7288-2014	Tamai, Katsuyuki/0000-0003-4094-3911; Tsuzuki, Shinobu/0000-0002-3209-3550				AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BURN TC, 1992, BLOOD, V80, P3051; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; Gonda TJ, 1998, INT J BIOCHEM CELL B, V30, P547, DOI 10.1016/S1357-2725(98)00003-X; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HU YL, 1991, ONCOGENE, V6, P1549; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Liu L, 1999, MOL CELL BIOL, V19, P1202; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Nakahara Y, 1999, INT J HEMATOL, V69, P237; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; NESS SA, 1989, CELL, V59, P115; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tanaka Y, 1997, FEBS LETT, V413, P162, DOI 10.1016/S0014-5793(97)00900-9; TASHIRO S, 1995, ONCOGENE, V10, P1699; Tomita A, 1998, LEUKEMIA, V12, P1422, DOI 10.1038/sj.leu.2401113; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	44	103	103	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					444	451		10.1038/sj.onc.1203329	http://dx.doi.org/10.1038/sj.onc.1203329			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656693				2022-12-25	WOS:000084873700016
J	Nakagawa, H; Koyama, K; Murata, Y; Morito, M; Akiyama, T; Nakamura, Y				Nakagawa, H; Koyama, K; Murata, Y; Morito, M; Akiyama, T; Nakamura, Y			EB3, a novel member of the EB1 family preferentially expressed in the central nervous system, binds to a CNS-specific APC homologue	ONCOGENE			English	Article						APC; APCL; EB1; EB3; microtubules; central nervous system	TUMOR-SUPPRESSOR PROTEIN; GENE; CHROMOSOME-5Q21; IDENTIFICATION; MUTATIONS; FAP	APCL, a homologue of the adenomatous polyposis coli (APC) tumor suppressor, can deplete cytoplasmic betacatenin like APC, However, as its biological function remains unclear, we have been using a yeast two-hybrid system to search for proteins that associate with its carboxyl region. Among several cDNA clones we isolated from a fetal-brain cDNA library as candidates, six included an identical sequence with significant homology to EB1, a protein known to bind to APC, The full-length cDNA of this novel homologue of EB1, named EB3, encoded a protein of 282 amino acids with 54% identity to EB1, and it was expressed preferentially in brain tissue on Northern blots. Confocal microscopy demonstrated that exogenous EB3, like EB1, is associated with the cytoplasmic microtubule network, Moreover, in these experiments EB3 and APCL appeared together in the perinucleus and the cytoplasmic microtubule network. Since APCL is also expressed highly and specifically in the central nervous system, APCL;EB3 interaction may be specific to the CNS, possibly involving stability and/or extension of microtubules during neuritogenesis.	Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Sch Med, Div Clin Genet, Biomed Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Ongone Res, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Surg 2, Osaka 5650871, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Dept Human Genome Anal, Tokyo 1708544, Japan	University of Tokyo; Osaka University; Osaka University; Osaka University; Japanese Foundation for Cancer Research	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.			Murata, Yoji/0000-0002-9576-7030				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; BHAT RV, 1994, J NEUROSCI, V14, P3059; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Laurent-Puig P, 1998, NUCLEIC ACIDS RES, V26, P269, DOI 10.1093/nar/26.1.269; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MINEMATSU S, 1995, P NATL ACAD SCI USA, V92, P3046; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Nakagawa H, 1998, CANCER RES, V58, P5176; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972	19	83	89	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					210	216		10.1038/sj.onc.1203308	http://dx.doi.org/10.1038/sj.onc.1203308			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644998				2022-12-25	WOS:000084844400005
J	Perissi, V; Menini, N; Cottone, E; Capello, D; Sacco, M; Montaldo, F; De Bortoli, M				Perissi, V; Menini, N; Cottone, E; Capello, D; Sacco, M; Montaldo, F; De Bortoli, M			AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen	ONCOGENE			English	Article						ERBB2; oestrogen repression; AP-2; ER	BREAST-CANCER CELLS; ESTROGEN-RECEPTOR; PROTEIN EXPRESSION; MAMMARY-CARCINOMA; GROWTH; AP2; OVEREXPRESSION; AMPLIFICATION; SUPPRESSION; MECHANISMS	Transcription of the ERBB2 oncogene is repressed by oestrogen in human breast cancer cells. We show that a 218 bp fragment of the human ERBB2 gene promoter is responsive to oestrogen in transient transfection in ZR75.1 and SKBR.3 cells when the oestrogen receptor is expressed. Deletion analysis of this fragment shows that a sequence located at the 5' end, which is known to mediate ERBB2 overexpression in breast cancer, is also responsible for the oestrogen response. This sequence binds AP-2 transcription factors and appears functionally identical to an element of the oestrogen-dependent enhancer described in the first intron of human ERBB2, We observed that oestrogen treatment down-regulates expression of AP-2 proteins but does not affect the DNA binding activity of AP-2. Constitutive expression of AP-2 beta or AP-2 gamma, but not AP-2 alpha, abrogates the estrogenic repression. Our results demonstrate that AP-2 transcription factors are implicated in the oestrogenic regulation of ERBB2 gene expression and suggest a complex interplay involving the different AP-2 isoforms and other unidentified factors.	Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Univ Turin, Dept Anim & Human Biol, I-10124 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	De Bortoli, M (corresponding author), Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.		Capello, Daniela/J-4110-2012; De Bortoli, Michele/B-5418-2013	Capello, Daniela/0000-0001-9157-8753; De Bortoli, Michele/0000-0002-6666-9052; Perissi, Valentina/0000-0002-3716-0003				ANTONIOTTI S, 1992, EUR J CANCER, V28A, P318, DOI 10.1016/S0959-8049(05)80045-0; ANTONIOTTI S, 1994, BRIT J CANCER, V70, P1095, DOI 10.1038/bjc.1994.454; Bates NP, 1997, J MAMMARY GLAND BIOL, V2, P153, DOI 10.1023/A:1026303814855; Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; Benson LQ, 1999, J BIOL CHEM, V274, P28794, DOI 10.1074/jbc.274.40.28794; Bisgrove DA, 1999, DEV DYNAM, V214, P195, DOI 10.1002/(SICI)1097-0177(199903)214:3<195::AID-AJA3>3.0.CO;2-8; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; DATI C, 1990, ONCOGENE, V5, P1001; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DRUEGE PM, 1986, NUCLEIC ACIDS RES, V14, P9329, DOI 10.1093/nar/14.23.9329; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; Kannan F, 1999, MOL CELL BIOL, V19, P899; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; READ LD, 1990, CANCER RES, V50, P3947; RUSSEL KS, 1992, CANCER RES, V50, P3947; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Turner BC, 1998, CANCER RES, V58, P5466; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; WARRI AM, 1991, INT J CANCER, V49, P616, DOI 10.1002/ijc.2910490425; WHITE MRA, 1992, ONCOGENE, V7, P677; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	38	56	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					280	288		10.1038/sj.onc.1203303	http://dx.doi.org/10.1038/sj.onc.1203303			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645007				2022-12-25	WOS:000084844400014
J	Gonin, S; Diaz-Latoud, C; Richard, MJ; Ursini, MV; Imbo, A; Manero, F; Arrigo, AP				Gonin, S; Diaz-Latoud, C; Richard, MJ; Ursini, MV; Imbo, A; Manero, F; Arrigo, AP			p53/T-antigen complex disruption in T-antigen transformed NIH3T3 fibroblasts exposed to oxidative stress: correlation with the appearance of a Fas/APO-1/CD95 dependent, caspase independent, necrotic pathway	ONCOGENE			English	Article						T-antigen; oxidative stress; necrosis; p53; Fas	FAS-MEDIATED APOPTOSIS; LARGE TUMOR-ANTIGEN; APO-1/FAS RECEPTOR/LIGAND SYSTEM; DRUG-INDUCED APOPTOSIS; KAPPA-B ACTIVATION; DNA-DAMAGE; GLUTATHIONE-PEROXIDASE; LIGAND EXPRESSION; 3T3 FIBROBLASTS; HEAT-SHOCK	Simian Virus 40 Large T-antigen expressed in NIH3T3 cells increases p53 level and interacts with this tumor suppressor to form large nuclear complexes, We show here that T-antigen sensitizes NIH3T3 cells to loa doses of the oxidative stress inducer menadione, This oxidant increased p53 accumulation and disrupted p53/T-antigen interaction, but not T-antigen/pRb, T-antigen/Hsc70 and p53/Hsc70 complexes; a phenomenon inhibited by the anti-oxidant N-acetyl-cysteine. Analysis of several p53 downstream gene products revealed that the level of Fas receptor, which was sharply reduced by T-antigen expression, was drastically increased in response to menadione treatment. Menadione also induced a T-antigen dependent cleavage of Fas ligand. Analysis performed with Fas receptor antagonist antibody and metalloproteinases inhibitor revealed that menadione triggers a Fas-dependent death of a fraction of T-antigen expressing cells, This Fas pathway does not activate caspase 8 or 3, probably because of the inhibition induced by T-antigen, and leads to a necrotic cell death which contributes at least in part to the hypersensitivity of T-antigen transformed cells to oxidative stress.	Univ Lyon 1, CNRS UMR 5534, Ctr Genet Mol & Cellulaire, Villeurbanne, France; Ctr Hosp Univ, Biochim Lab C, Grenoble, France; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Arrigo, AP (corresponding author), Univ Lyon 1, CNRS UMR 5534, Ctr Genet Mol & Cellulaire, Villeurbanne, France.							ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; AEBI H, 1984, METHOD ENZYMOL, V105, P121; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; BRAVARD A, 1993, CARCINOGENESIS, V14, P21, DOI 10.1093/carcin/14.1.21; Butler LM, 1998, BRIT J CANCER, V77, P1454, DOI 10.1038/bjc.1998.239; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eguchi Y, 1997, CANCER RES, V57, P1835; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FABREJONCA N, 1995, EUR J BIOCHEM, V232, P118, DOI 10.1111/j.1432-1033.1995.tb20789.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fenton RG, 1998, CANCER RES, V58, P3391; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gonin S, 1997, CELL STRESS CHAPERON, V2, P238, DOI 10.1379/1466-1268(1997)002<0238:TBTAAO>2.3.CO;2; Green DR, 1998, NATURE, V396, P629, DOI 10.1038/25248; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAINAUT P, 1995, ONCOGENE, V10, P27; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; KHANDJIAN EW, 1995, ONCOGENE, V10, P359; KLAUSING K, 1994, CUR TOP MICROBIOL IM, V144, P31; Koike M, 1996, CANCER LETT, V108, P185, DOI 10.1016/S0304-3835(96)04408-4; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Kristjuhan A, 1998, ONCOGENE, V16, P2413, DOI 10.1038/sj.onc.1201749; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MIYASHITA T, 1995, CELL, V80, P293; Moorwood K, 1996, EXP CELL RES, V223, P308, DOI 10.1006/excr.1996.0086; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Paley EL, 1996, CARCINOGENESIS, V17, P939, DOI 10.1093/carcin/17.5.939; Parat MO, 1997, BIOL TRACE ELEM RES, V60, P187, DOI 10.1007/BF02784439; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; ROUQUET N, 1995, ONCOGENE, V11, P1061; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Sompayrac L, 1997, VIROLOGY, V233, P130, DOI 10.1006/viro.1997.8610; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; von Reyher U, 1998, CANCER RES, V58, P526; Wendel A, 1981, Methods Enzymol, V77, P325; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	66	20	20	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 23	1999	18	56					8011	8023		10.1038/sj.onc.1203319	http://dx.doi.org/10.1038/sj.onc.1203319			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637512				2022-12-25	WOS:000084634600010
